FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Elfiky, AA
AF Elfiky, Abdo A.
TI Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
SO LIFE SCIENCES
LA English
DT Article
DE Wuhan coronavirus; COVID-19; RdRp; Docking; Structural bioinformatics;
   Sofosbuvir; Nucleotide inhibitors
ID HEPATITIS-C; ANTIVIRAL ACTIVITY; PLUS RIBAVIRIN; POLYMERASE; SOFOSBUVIR;
   DOCKING; VIRUS; IDX-184; DRUGS; OPTIMIZATION
AB Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today > 2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for > 8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).
   Materials and methods: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.
   Key findings: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
   Significance: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
C1 [Elfiky, Abdo A.] Cairo Univ, Fac Sci, Biophys Dept, Giza, Egypt.
   [Elfiky, Abdo A.] Univ Al Jouf, Coll Appl Med Sci, Sakakah, Saudi Arabia.
RP Elfiky, AA (corresponding author), Cairo Univ, Fac Sci, Biophys Dept, Giza, Egypt.
EM abdo@sci.cu.edu.eg
RI Mohamed, Abdo/H-3595-2019; Ribeiro, Nuno/AAH-2299-2020
OI Mohamed, Abdo/0000-0003-4600-6240; 
CR Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Cretton-Scott E, 2008, J HEPATOL, V48, pS220, DOI 10.1016/S0168-8278(08)60590-5
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2018, SAR QSAR ENVIRON RES, V29, P409, DOI 10.1080/1062936X.2018.1454981
   Elfiky A.A., 2016, SOFTWARE TECHNIQUES, P197
   Elfiky A.A., 2020, FUTURE VIROLOGY
   Elfiky A.A.I., 2020, ANTI SARS ANTI HCV D
   Elfiky AA, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116958
   Elfiky AA, 2019, MED CHEM, V15, P130, DOI 10.2174/1573406414666181015152511
   Elfiky AA, 2017, FUTURE VIROL, V12, P720, DOI 10.2217/fvl-2017-0081
   Elfiky AA, 2018, J MED VIROL, V90, P13, DOI 10.1002/jmv.24934
   Elfiky AA, 2017, FUTURE VIROL, V12, P339, DOI 10.2217/fvl-2017-0027
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Elfiky AA, 2016, MED CHEM RES, V25, P1005, DOI 10.1007/s00044-016-1533-y
   Elfiky AA, 2015, J COMPUT THEOR NANOS, V12, P376, DOI 10.1166/jctn.2015.3739
   Elfiky AA, 2013, PROTEIN J, V32, P75, DOI 10.1007/s10930-013-9462-9
   Ezat Ahmed A., 2019, VirusDisease, V30, P207, DOI 10.1007/s13337-019-00516-7
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   Hemida MG, 2019, ONE HEALTH-AMSTERDAM, V8, DOI 10.1016/j.onehlt.2019.100102
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ibrahim I.M., 2020, J INFECT
   Ibrahim I.M.A., 2020, COVID 19 SPIKE HOST
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lam AM, 2012, ANTIMICROB AGENTS CH, V56, P3359, DOI 10.1128/AAC.00054-12
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Leach A. R., 2001, MOL MODELLING PRINCI
   LII JH, 1989, J AM CHEM SOC, V111, P8576, DOI 10.1021/ja00205a003
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Markland W, 2000, ANTIMICROB AGENTS CH, V44, P859, DOI 10.1128/AAC.44.4.859-866.2000
   McQuaid T, 2015, J CLIN TRANSL HEPATO, V3, P27, DOI 10.14218/JCTH.2014.00041
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Murakami E, 2010, J BIOL CHEM, V285, P34337, DOI 10.1074/jbc.M110.161802
   Organization W.H., 2019, CLIN MAN SEV AC RESP
   Organization WH, 2016, MIDDL E RESP SYNDR C
   Parr J., 2020, PNEUMONIA CHINA LACK
   Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Summers KL, 2012, BIOCHEM BIOPH RES CO, V425, P485, DOI 10.1016/j.bbrc.2012.07.141
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang M, 2020, SOL RRL, V4, DOI 10.1002/solr.202000013
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Watts A, 2020, J TRAVEL MED
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   World Health Organization, 2020, LAB TEST HUM SUSP CA
   World Health Organization, 2020, INF PREV CONTR HLTH
   World Health Organization (WHO), 2020, SURV CAS DEF HUM INF
   Yang L., 2020, CHINA CONFIRMS HUMAN
   Yang PL, 2011, CURR OPIN VIROL, V1, P607, DOI 10.1016/j.coviro.2011.10.019
   Zhou XJ, 2011, ANTIMICROB AGENTS CH, V55, P76, DOI 10.1128/AAC.01101-10
NR 61
TC 147
Z9 154
U1 21
U2 86
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD MAY 1
PY 2020
VL 248
AR 117477
DI 10.1016/j.lfs.2020.117477
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LB2LN
UT WOS:000524467100025
PM 32119961
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Gordon, DE
   Jang, GM
   Bouhaddou, M
   Xu, JW
   Obernier, K
   White, KM
   O'Meara, MJ
   Rezelj, VV
   Guo, JFZ
   Swaney, DL
   Tummino, TA
   Huttenhain, R
   Kaake, RM
   Richards, AL
   Tutuncuoglu, B
   Foussard, H
   Batra, J
   Haas, K
   Modak, M
   Kim, M
   Haas, P
   Polacco, BJ
   Braberg, H
   Fabius, JM
   Eckhardt, M
   Soucheray, M
   Bennett, MJ
   Cakir, M
   McGregor, MJ
   Li, QY
   Meyer, B
   Roesch, F
   Vallet, T
   Mac Kain, A
   Miorin, L
   Moreno, E
   Naing, ZZC
   Zhou, Y
   Peng, SM
   Shi, Y
   Zhang, ZY
   Shen, WQ
   Kirby, IT
   Melnyk, JE
   Chorba, JS
   Lou, KV
   Dai, SZA
   Barrio-Hernandez, I
   Memon, D
   Hernandez-Armenta, C
   Lyu, J
   Mathy, CJP
   Perica, T
   Pilla, KB
   Ganesan, SJ
   Saltzberg, DJ
   Rakesh, R
   Liu, X
   Rosenthal, SB
   Calviello, L
   Venkataramanan, S
   Liboy-Lugo, J
   Lin, YZ
   Huang, XP
   Liu, YF
   Wankowicz, SA
   Bohn, M
   Safari, M
   Ugur, FS
   Koh, C
   Savar, NS
   Tran, QD
   Shengjuler, D
   Fletcher, SJ
   O'Neal, MC
   Cai, YM
   Chang, JCJ
   Broadhurst, DJ
   Klippsten, S
   Sharp, PP
   Wenzell, NA
   Kuzuoglu-Ozturk, D
   Wang, HY
   Trenker, R
   Young, JM
   Cavero, DA
   Hiatt, J
   Roth, TL
   Rathore, U
   Subramanian, A
   Noack, J
   Hubert, M
   Stroud, RM
   Frankel, AD
   Rosenberg, OS
   Verba, KA
   Agard, DA
   Ott, M
   Emerman, M
   Jura, N
   von Zastrow, M
   Verdin, E
   Ashworth, A
   Schwartz, O
   D'Enfert, C
   Mukherjee, S
   Jacobson, M
   Malik, HS
   Fujimori, DG
   Ideker, T
   Craik, CS
   Floor, SN
   Fraser, JS
   Gross, JD
   Sali, A
   Roth, BL
   Ruggero, D
   Taunton, J
   Kortemme, T
   Beltrao, P
   Vignuzzi, M
   Garcia-Sastre, A
   Shokat, KM
   Shoichet, BK
   Krogan, NJ
AF Gordon, David E.
   Jang, Gwendolyn M.
   Bouhaddou, Mehdi
   Xu, Jiewei
   Obernier, Kirsten
   White, Kris M.
   O'Meara, Matthew J.
   Rezelj, Veronica V.
   Guo, Jeffrey Z.
   Swaney, Danielle L.
   Tummino, Tia A.
   Huttenhain, Ruth
   Kaake, Robyn M.
   Richards, Alicia L.
   Tutuncuoglu, Beril
   Foussard, Helene
   Batra, Jyoti
   Haas, Kelsey
   Modak, Maya
   Kim, Minkyu
   Haas, Paige
   Polacco, Benjamin J.
   Braberg, Hannes
   Fabius, Jacqueline M.
   Eckhardt, Manon
   Soucheray, Margaret
   Bennett, Melanie J.
   Cakir, Merve
   McGregor, Michael J.
   Li, Qiongyu
   Meyer, Bjoern
   Roesch, Ferdinand
   Vallet, Thomas
   Mac Kain, Alice
   Miorin, Lisa
   Moreno, Elena
   Naing, Zun Zar Chi
   Zhou, Yuan
   Peng, Shiming
   Shi, Ying
   Zhang, Ziyang
   Shen, Wenqi
   Kirby, Ilsa T.
   Melnyk, James E.
   Chorba, John S.
   Lou, Kevin
   Dai, Shizhong A.
   Barrio-Hernandez, Inigo
   Memon, Danish
   Hernandez-Armenta, Claudia
   Lyu, Jiankun
   Mathy, Christopher J. P.
   Perica, Tina
   Pilla, Kala Bharath
   Ganesan, Sai J.
   Saltzberg, Daniel J.
   Rakesh, Ramachandran
   Liu, Xi
   Rosenthal, Sara B.
   Calviello, Lorenzo
   Venkataramanan, Srivats
   Liboy-Lugo, Jose
   Lin, Yizhu
   Huang, Xi-Ping
   Liu, YongFeng
   Wankowicz, Stephanie A.
   Bohn, Markus
   Safari, Maliheh
   Ugur, Fatima S.
   Koh, Cassandra
   Savar, Nastaran Sadat
   Tran, Quang Dinh
   Shengjuler, Djoshkun
   Fletcher, Sabrina J.
   O'Neal, Michael C.
   Cai, Yiming
   Chang, Jason C. J.
   Broadhurst, David J.
   Klippsten, Saker
   Sharp, Phillip P.
   Wenzell, Nicole A.
   Kuzuoglu-Ozturk, Duygu
   Wang, Hao-Yuan
   Trenker, Raphael
   Young, Janet M.
   Cavero, Devin A.
   Hiatt, Joseph
   Roth, Theodore L.
   Rathore, Ujjwal
   Subramanian, Advait
   Noack, Julia
   Hubert, Mathieu
   Stroud, Robert M.
   Frankel, Alan D.
   Rosenberg, Oren S.
   Verba, Kliment A.
   Agard, David A.
   Ott, Melanie
   Emerman, Michael
   Jura, Natalia
   von Zastrow, Mark
   Verdin, Eric
   Ashworth, Alan
   Schwartz, Olivier
   D'Enfert, Christophe
   Mukherjee, Shaeri
   Jacobson, Matt
   Malik, Harmit S.
   Fujimori, Danica G.
   Ideker, Trey
   Craik, Charles S.
   Floor, Stephen N.
   Fraser, James S.
   Gross, John D.
   Sali, Andrej
   Roth, Bryan L.
   Ruggero, Davide
   Taunton, Jack
   Kortemme, Tanja
   Beltrao, Pedro
   Vignuzzi, Marco
   Garcia-Sastre, Adolfo
   Shokat, Kevan M.
   Shoichet, Brian K.
   Krogan, Nevan J.
TI A SARS-CoV-2 protein interaction map reveals targets for drug
   repurposing
SO NATURE
LA English
DT Article
ID CORONAVIRUS REPLICATION; NETWORK; VIRUS; IDENTIFICATION; MECHANISMS;
   INHIBITOR; DISCOVERY; SOFTWARE; DENGUE; MODEL
AB A human-SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.
   A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption(1,2). There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.
C1 QBI COVID 19 Res Grp QCRG, San Francisco, CA USA.
   [Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Broadhurst, David J.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Mukherjee, Shaeri; Jacobson, Matt; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.] Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94143 USA.
   [Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; Guo, Jeffrey Z.; Swaney, Danielle L.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Ott, Melanie; Krogan, Nevan J.] J David Gladstone Inst, San Francisco, CA USA.
   [Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Guo, Jeffrey Z.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Ugur, Fatima S.; Sharp, Phillip P.; Wenzell, Nicole A.; Wang, Hao-Yuan; Jura, Natalia; von Zastrow, Mark; Fujimori, Danica G.; Ruggero, Davide; Taunton, Jack; Shokat, Kevan M.; Krogan, Nevan J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
   [White, Kris M.; Garcia-Sastre, Adolfo; Krogan, Nevan J.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [White, Kris M.; Rezelj, Veronica V.; Koh, Cassandra; Schwartz, Olivier; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [O'Meara, Matthew J.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.] Inst Pasteur, CNRS UMR 3569, Viral Populat & Pathogenesis Unit, Paris, France.
   [Tummino, Tia A.; Peng, Shiming; Lyu, Jiankun; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Verba, Kliment A.; Jacobson, Matt; Fujimori, Danica G.; Gross, John D.; Sali, Andrej; Shoichet, Brian K.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
   [Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Shokat, Kevan M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.
   [Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Beltrao, Pedro] European Bioinformat Inst, European Mol Biol Lab EMBL, Wellcome Genome Campus, Cambridge, England.
   [Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Wankowicz, Stephanie A.; Fraser, James S.; Sali, Andrej; Kortemme, Tanja] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Mathy, Christopher J. P.; Kortemme, Tanja] Univ Calif San Francisco, UC Berkeley UCSF Grad Program Bioengn, San Francisco, CA 94143 USA.
   [Rosenthal, Sara B.] Univ Calif San Diego, Dept Med, Ctr Computat Biol & Bioinformat, San Diego, CA 92103 USA.
   [Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping] Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.
   [Liu, YongFeng; Roth, Bryan L.] Univ N Carolina, Chapel Hill Sch Med, Dept Pharmacol, Chapel Hill, NC USA.
   [Wankowicz, Stephanie A.] Univ Calif San Francisco, Biophys Grad Program, San Francisco, CA 94143 USA.
   [Stroud, Robert M.; Frankel, Alan D.; Agard, David A.; Floor, Stephen N.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   [O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker] Zoic Labs, Culver City, CA USA.
   [Kuzuoglu-Ozturk, Duygu; Craik, Charles S.; Floor, Stephen N.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Kuzuoglu-Ozturk, Duygu; Ruggero, Davide] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
   [Trenker, Raphael; Jura, Natalia] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
   [Young, Janet M.; Malik, Harmit S.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98104 USA.
   [Cavero, Devin A.; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Mukherjee, Shaeri] Univ Calif San Francisco, Dept Microbiol & Immunol, George William Hooper Fdn, San Francisco, CA 98104 USA.
   [Hiatt, Joseph; Roth, Theodore L.; Hubert, Mathieu] Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94143 USA.
   Inst Pasteur, Virus & Immun Unit, Paris, France.
   [Rosenberg, Oren S.; Ott, Melanie; Verdin, Eric] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Emerman, Michael] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.
   [von Zastrow, Mark] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
   [Rosenberg, Oren S.; Verdin, Eric; Ashworth, Alan] Buck Inst Res Aging, Novato, CA USA.
   [D'Enfert, Christophe] Inst Pasteur, Direct Sci, Paris, France.
   [Garcia-Sastre, Adolfo] Univ Calif San Diego, Dept Med, Div Genet, San Diego, CA 92103 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
RP Vignuzzi, M (corresponding author), QBI COVID 19 Res Grp QCRG, San Francisco, CA USA.; Shokat, KM; Shoichet, BK; Krogan, NJ (corresponding author), Univ Calif San Francisco, Quantitat Biosci Inst QBI, San Francisco, CA 94143 USA.; Vignuzzi, M; Shokat, KM; Krogan, NJ (corresponding author), J David Gladstone Inst, San Francisco, CA USA.; Vignuzzi, M (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.; Krogan, NJ (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.; Shokat, KM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.; Garcia-Sastre, A; Krogan, NJ (corresponding author), Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA.; Garcia-Sastre, A (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
EM marco.vignuzzi@pasteur.fr; Adolfo.Garcia-Sastre@mssm.edu;
   Kevan.Shokat@ucsf.edu; shoichet@cgl.ucsf.edu; nevan.krogan@ucsf.edu
RI shi, ying/R-4974-2019; Gordon, David/ABF-1817-2020; Roth,
   Bryan/ABE-7032-2020; Batra, Jyoti/ABI-2086-2020; Liu,
   Yongfeng/ABG-1361-2020; Savar, Nastaran Sadat/F-9420-2014
OI Roth, Bryan/0000-0002-0561-6520; Liu, Yongfeng/0000-0002-8649-7892;
   Hernandez-Armenta, Claudia/0000-0003-1510-1253; Trenker,
   Raphael/0000-0003-1748-0517; Mac Kain, Alice/0000-0002-5218-6690; Guo,
   Jeffrey/0000-0003-2857-9870; Calviello, Lorenzo/0000-0002-5600-0988;
   Melnyk, James/0000-0003-1915-8089; Mathy,
   Christopher/0000-0002-5546-9733; Barrio-Hernandez,
   Inigo/0000-0002-5686-0451; Zhang, Ziyang/0000-0003-0541-7211; Meyer,
   Bjorn/0000-0002-7903-5710; Perica, Tina/0000-0003-3152-8425; Wang,
   Haoyuan/0000-0001-8490-8793; Cakir, Merve/0000-0003-1803-5693;
   Shengjuler, Djoshkun/0000-0002-6286-9727; Gordon,
   David/0000-0001-7954-0306; O'Meara, Matthew/0000-0002-3128-5331;
   Ganesan, Sai/0000-0002-8335-2866; Moreno, Elena/0000-0002-2301-4558;
   Kuzuoglu Ozturk, Duygu/0000-0003-1737-5020; Savar, Nastaran
   Sadat/0000-0003-2509-2127; Shen, Wenqi/0000-0002-8657-4931; Rosenthal,
   Sara Brin/0000-0002-6548-9658
FU Howard Hughes Medical InstituteHoward Hughes Medical Institute Funding
   Source: Medline; NCI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01 CA221969, F30 CA239476, F32 CA236347, F32 CA239333,
   R01 CA244550] Funding Source: Medline; NHGRI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Human Genome Research Institute (NHGRI) [R01 HG009979]
   Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [K08 HL124068] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [P01 AI063302, R01 AI122747,
   HHSN272201400008C, U19 AI135972, U19 AI135990, P50 AI150476, R01
   AI120694, R01 AI143292] Funding Source: Medline; NIGMS NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [T32 GM067547, F32 GM133144, R35 GM122481, T32 GM064337] Funding
   Source: Medline; NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1F32CA236347-01,
   1R01CA244550] Funding Source: Medline
CR Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z
   Armstrong JF, 2020, NUCLEIC ACIDS RES, V48, pD1006, DOI 10.1093/nar/gkz951
   Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257
   Besnard J, 2012, NATURE, V492, P215, DOI 10.1038/nature11691
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Carelli JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10222
   Cencic R, 2011, J VIROL, V85, P6381, DOI 10.1128/JVI.00078-11
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chaudhury S, 2010, BIOINFORMATICS, V26, P689, DOI 10.1093/bioinformatics/btq007
   Chiva C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189209
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Deutsch EW, 2017, NUCLEIC ACIDS RES, V45, pD1100, DOI 10.1093/nar/gkw936
   Dewe JM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00214-17
   Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332
   Eckhardt M, 2020, NAT REV GENET, V21, P339, DOI 10.1038/s41576-020-0212-5
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8
   Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074
   Giurgiu M, 2019, NUCLEIC ACIDS RES, V47, pD559, DOI 10.1093/nar/gky973
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Heaton NS, 2016, IMMUNITY, V44, P46, DOI 10.1016/j.immuni.2015.12.017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang XP, 2010, ASSAY DRUG DEV TECHN, V8, P727, DOI 10.1089/adt.2010.0331
   Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043
   Ivanov P, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032813
   Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719
   Jimenez-Morales D., 2020, ARTMS ANAL R TOOLS M
   Joosten RP, 2014, IUCRJ, V1, P213, DOI 10.1107/S2052252514009324
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kondo T, 2012, BIOCHEM BIOPH RES CO, V422, P501, DOI 10.1016/j.bbrc.2012.05.028
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Li MH, 2019, NAT MICROBIOL, V4, P985, DOI 10.1038/s41564-019-0375-z
   Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014
   Mahon C, 2014, BIOMOLECULES, V4, P897, DOI 10.3390/biom4040897
   Marazzi I, 2012, NATURE, V483, P428, DOI 10.1038/nature10892
   Mitsuda T, 2011, BIOCHEM BIOPH RES CO, V415, P519, DOI 10.1016/j.bbrc.2011.10.113
   Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010
   Mysinger MM, 2010, J CHEM INF MODEL, V50, P1561, DOI 10.1021/ci100214a
   Nakagawa K, 2016, ADV VIRUS RES, V96, P165, DOI 10.1016/bs.aivir.2016.08.001
   Nakagawa K, 2018, J VIROL, V92, DOI 10.1128/JVI.00902-18
   Paton J., 2020, BLOOMBERG NEWS
   Penn BH, 2018, MOL CELL, V71, P637, DOI 10.1016/j.molcel.2018.07.010
   Prussia A, 2011, INT J MOL SCI, V12, P4027, DOI 10.3390/ijms12064027
   Quan BL, 2014, P NATL ACAD SCI USA, V111, P9127, DOI 10.1073/pnas.1409076111
   Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reineke LC, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00596-16
   Ren J, 2008, PROTEIN ENG DES SEL, V21, P639, DOI 10.1093/protein/gzn039
   Riva L, 2020, PREPRINT, DOI 10.1101/2020.04.16.044016v1
   Schmidt HR, 2018, NAT STRUCT MOL BIOL, V25, P981, DOI 10.1038/s41594-018-0137-2
   Shah PS, 2018, CELL, V175, P1931, DOI 10.1016/j.cell.2018.11.028
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Si L., 2020, PREPRINT, DOI 10.1101/2020.04.13.039917v1
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Slaine PD, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120388
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Spicka I, 2019, ANN HEMATOL, V98, P2139, DOI 10.1007/s00277-019-03739-2
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Teo GC, 2014, J PROTEOMICS, V100, P37, DOI 10.1016/j.jprot.2013.10.023
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Thompson PA, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2698
   Timms RT, 2019, SCIENCE, V365, P45, DOI 10.1126/science.aaw4912
   Verschueren Erik, 2015, Curr Protoc Bioinformatics, V49, DOI 10.1002/0471250953.bi0819s49
   Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DX, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188503
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie YW, 2016, SCI REP-UK, V6, DOI 10.1038/srep33350
   Xu PF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1448-9
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 85
TC 366
Z9 370
U1 56
U2 72
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 16
PY 2020
VL 583
IS 7816
BP 459
EP +
DI 10.1038/s41586-020-2286-9
EA APR 2020
PG 30
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MK4AA
UT WOS:000546557400001
PM 32353859
OA Bronze, Green Accepted
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Wang, L
   Zhang, Y
   Zhang, SY
AF Wang, Lun
   Zhang, Yang
   Zhang, Shuyang
TI Cardiovascular Impairment in COVID-19: Learning From Current Options for
   Cardiovascular Anti-Inflammatory Therapy
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE Coronavirus Disease 2019; cardiovascular impairment; inflammation;
   cardiovascular diseases; cardiovascular anti-inflammatory therapy
ID CHRONIC HEART-FAILURE; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS;
   DOUBLE-BLIND; AUTOIMMUNE MYOCARDITIS; INFLAMMATORY RESPONSE; PROTEASE
   INHIBITORS; CRUCIAL ROLE; TOCILIZUMAB; CARDIOMYOPATHY
AB In December 2019, Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, occurred in China and has currently led to a global pandemic. In addition to respiratory involvement, COVID-19 was also associated with significant multiple organ dysfunction syndrome (MODS). Cardiovascular impairment has been observed and is now drawing growing attention. Cardiovascular protective strategies are urgent and of great significance to the overall prognosis of COVID-19 patients. Direct viral infection, cytokine storm, and aggravation of existing cardiovascular diseases were recognized as possible mechanisms of cardiovascular impairment in COVID-19. Hyperactivated inflammation plays an important role in all three mechanisms and is considered to be fundamental in the development of cardiovascular impairment and MODS in COVID-19. Therefore, in addition to conventional cardiovascular treatment, anti-inflammatory therapy is a reasonable strategy for severe cases to further enhance cardiovascular protection and potentially mitigate MODS. We reviewed the inflammatory features and current promising treatments of COVID-19 as well as cardiovascular anti-inflammatory therapies that have been verified in previous clinical trials with positive outcomes. We believe that targeting the central pathway (IL-1 beta, TNF-alpha, IL-6), balancing the Th1 and Th2 response, and administering long-term anti-inflammatory therapy might be promising prospects to reduce cardiovascular impairment and even MODS during the acute and recovery phases of COVID-19. The cardiovascular anti-inflammatory therapies might be of great application value to the management of COVID-19 patients and we further propose an algorithm for the selection of anti-inflammatory therapy for COVID-19 patients with or at high risk of cardiovascular impairment. We recommend to take the experiences in cardiovascular anti-inflammatory therapy as references in the management of COVID-19 and conduct related clinical trials, while the clinical translation of novel treatments from preclinical studies or in vitro drug screening should proceed with caution due to unguaranteed efficacy and safety profiles.
C1 [Wang, Lun; Zhang, Yang; Zhang, Shuyang] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
RP Zhang, SY (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
EM shuyangzhang103@nrdrs.org
CR Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   Bacchiega BC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005038
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen F, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P301, DOI 10.3760/cma.j.issn.0254-6450.2020.03.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2018, CIRCULATION, V138, P2559, DOI 10.1161/CIRCULATIONAHA.118.033890
   Chinese Society of Cardiology of Chinese Medical Association Editorial Board of Chinese Journal of cardiovascular disease, 2020, CHIN J CARDIOL, V48, pE001
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Chung ES, 2003, CIRCULATION, V107, P3133, DOI 10.1161/01.CIR.0000077913.60364.D2
   ClinicalTrials.gov, STUD TOC COMP ET PAR
   Cooper LT, 2009, NEW ENGL J MED, V360, P1526, DOI 10.1056/NEJMra0800028
   Cunningham MW, 2001, AM J PATHOL, V159, P5, DOI 10.1016/S0002-9440(10)61665-3
   DeBerge M, 2017, CIRC RES, V121, P930, DOI 10.1161/CIRCRESAHA.117.311327
   Dick SA, 2016, CIRC RES, V119, P159, DOI 10.1161/CIRCRESAHA.116.308030
   England BR, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1036
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Everett BM, 2019, CIRCULATION, V139, P1289, DOI 10.1161/CIRCULATIONAHA.118.038010
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Frangogiannis NG, 2000, J IMMUNOL, V165, P2798, DOI 10.4049/jimmunol.165.5.2798
   Frangogiannis NG, 2014, NAT REV CARDIOL, V11, P255, DOI 10.1038/nrcardio.2014.28
   Frangogiannis NG, 2012, CIRC RES, V110, P159, DOI 10.1161/CIRCRESAHA.111.243162
   Frustaci A, 2009, EUR HEART J, V30, P1995, DOI 10.1093/eurheartj/ehp249
   Gabay C, 2016, ANN RHEUM DIS, V75, P1806, DOI 10.1136/annrheumdis-2015-207872
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gibson PG, 2017, LANCET, V390, P659, DOI 10.1016/S0140-6736(17)31281-3
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hartman O, 2017, EUR HEART J-CARD PHA, V3, P92, DOI 10.1093/ehjcvp/pvw035
   Hill A, 2009, HIV CLIN TRIALS, V10, P1, DOI [10.1310/hct1001-001, 10.1310/hct1001-1]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung YM, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13095
   Ikonomidis I, 2014, CIRC-CARDIOVASC IMAG, V7, P619, DOI 10.1161/CIRCIMAGING.113.001193
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kalogeris T, 2017, COMPR PHYSIOL, V7, P113, DOI 10.1002/cphy.c160006
   Kavanaugh A, 2013, ANN RHEUM DIS, V72, P674
   Kawai C, 1999, CIRCULATION, V99, P1091, DOI 10.1161/01.CIR.99.8.1091
   Kleveland O, 2016, EUR HEART J, V37, P2406, DOI 10.1093/eurheartj/ehw171
   Kobayashi H, 2018, J RHEUMATOL, V45, P1620, DOI 10.3899/jrheum.180065
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuhl U, 1996, HEART, V75, P295, DOI 10.1136/hrt.75.3.295
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lazzerini PE, 2015, ARTHRIT CARE RES, V67, P332, DOI 10.1002/acr.22455
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Matsumori A, 1996, CURR OPIN CARDIOL, V11, P302, DOI 10.1097/00001573-199605000-00011
   Mohammad Madjid SDS, 2020, ACC CLIN B CARDIAC I
   Monzavi SM, 2018, INFLAMMOPHARMACOLOGY, V26, P1175, DOI 10.1007/s10787-018-0512-y
   National Health Commission of the People's Republic of China, DIAGN TREATM PLAN NO
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Nidorf SM, 2013, J AM COLL CARDIOL, V61, P404, DOI 10.1016/j.jacc.2012.10.027
   Okura Y, 1997, J MOL CELL CARDIOL, V29, P491, DOI 10.1006/jmcc.1996.0293
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426
   Patel AN, 2016, LANCET, V387, P2412, DOI 10.1016/S0140-6736(16)30137-4
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203
   Roubille C, 2015, ANN RHEUM DIS, V74, P480, DOI 10.1136/annrheumdis-2014-206624
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Setoguchi S, 2008, AM HEART J, V156, P336, DOI 10.1016/j.ahj.2008.02.025
   Shiraishi M, 2016, J CLIN INVEST, V126, P2151, DOI 10.1172/JCI85782
   Soubrier M, 2017, RHEUMATOL THER, V4, P133, DOI 10.1007/s40744-016-0049-8
   Strauer BE, 2010, EUR J HEART FAIL, V12, P721, DOI 10.1093/eurjhf/hfq095
   Tanaka T, 2010, EXPERT REV CLIN IMMU, V6, P843, DOI [10.1586/eci.10.70, 10.1586/ECI.10.70]
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Torre-Amione G, 2008, LANCET, V371, P228, DOI 10.1016/S0140-6736(08)60134-8
   Tsiodras S, 2000, ARCH INTERN MED, V160, P2050, DOI 10.1001/archinte.160.13.2050
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Watanabe K, 2001, CIRCULATION, V104, P1098, DOI 10.1161/hc3501.096190
   Westman PC, 2016, J AM COLL CARDIOL, V67, P2050, DOI 10.1016/j.jacc.2016.01.073
   Wojnicz R, 2001, CIRCULATION, V104, P39, DOI 10.1161/01.CIR.104.1.39
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan XX, 2013, J MOL CELL CARDIOL, V62, P24, DOI 10.1016/j.yjmcc.2013.04.023
   Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 81
TC 5
Z9 5
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD APR 30
PY 2020
VL 7
AR 78
DI 10.3389/fcvm.2020.00078
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LS2VF
UT WOS:000536246300001
PM 32426374
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shivarov, V
   Petrov, PK
   Pashov, AD
AF Shivarov, Velizar
   Petrov, Peter K.
   Pashov, Anastas D.
TI Potential SARS-CoV-2 Preimmune IgM Epitopes
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; epitope; mimotope; B cell precursors; IgM
ID PROTEIN EPITOPES; SPIKE PROTEIN; CORE-PROTEIN; ANTIBODIES
AB While studying the human public IgM igome as represented by a library of 224,087 linear mimotopes, three exact matches to peptides in the proteins of SARS-CoV-2 were found: two in the open reading frame 1ab and one in the spike protein. Joining the efforts to fast track SARS-CoV-2 vaccine development, here we describe briefly these potential epitopes in comparison to mimotopes representing peptides of SARS-CoV, HCoV 229E and OC43.
C1 [Shivarov, Velizar] Sofiamed Univ Hosp, Lab Clin Immunol, Sofia, Bulgaria.
   [Shivarov, Velizar] Sofiamed Univ Hosp, Dept Clin Hematol, Sofia, Bulgaria.
   [Shivarov, Velizar] Sofia Univ, Fac Biol, Sofia, Bulgaria.
   [Petrov, Peter K.] Bulgarian Acad Sci BAS, Inst Math & Informat, Dept Anal Geometry & Topol, Sofia, Bulgaria.
   [Pashov, Anastas D.] Bulgarian Acad Sci BAS, Dept Immunol, Steph Angeloff Inst Microbiol, Sofia, Bulgaria.
RP Pashov, AD (corresponding author), Bulgarian Acad Sci BAS, Dept Immunol, Steph Angeloff Inst Microbiol, Sofia, Bulgaria.
EM a_pashov@microbio.bas.bg
OI Pashov, Anastas/0000-0002-6033-3566
FU Bulgarian Fund for Scientific Research Grant [D01-11/2016]
FX This work was funded partially by the Bulgarian Fund for Scientific
   Research Grant D01-11/2016.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Baumgarth N, 2005, SPRINGER SEMIN IMMUN, V26, P347, DOI 10.1007/s00281-004-0182-2
   Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271
   Baumgarth N, 2000, IMMUNOL REV, V176, P171
   BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155
   BURCHELL J, 1987, CANCER RES, V47, P5476
   Cao Z, 2013, ASIAN J ANDROL, V15, P742, DOI 10.1038/aja.2013.79
   Felder M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-129
   Grifoni A., 2020, CANDIDATE TARGETS IM, DOI [10.1101/2020.02.12.946087, DOI 10.1101/2020.02.12.946087]
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Hong S, 2018, IMMUNITY, V49, P695, DOI 10.1016/j.immuni.2018.08.012
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Pashov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02796
   Petrakou E, 1998, TUMOR BIOL, V19, P21, DOI 10.1159/000056501
   Popi AF, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00138
   SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang JB, 2009, INT IMMUNOL, V21, P63, DOI 10.1093/intimm/dxn124
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou DP, 2018, MOLECULES, V23, DOI 10.3390/molecules23061326
NR 23
TC 1
Z9 1
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 30
PY 2020
VL 11
AR 932
DI 10.3389/fimmu.2020.00932
PG 5
WC Immunology
SC Immunology
GA LR2WC
UT WOS:000535554900001
PM 32425955
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Enayatkhani, M
   Hasaniazad, M
   Faezi, S
   Guklani, H
   Davoodian, P
   Ahmadi, N
   Einakian, MA
   Karmostaji, A
   Ahmadi, K
AF Enayatkhani, Maryam
   Hasaniazad, Mehdi
   Faezi, Sobhan
   Guklani, Hamed
   Davoodian, Parivash
   Ahmadi, Nahid
   Einakian, Mohammad Ali
   Karmostaji, Afsaneh
   Ahmadi, Khadijeh
TI Reverse vaccinology approach to design a novel multi-epitope vaccine
   candidate against COVID-19: an in silico study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; Vaccine; Epitope; Immunoinformatics
ID FAST INTERACTION REFINEMENT; PARTICLE MESH EWALD; NUCLEOCAPSID PROTEIN;
   SARS; CORONAVIRUS; PREDICTION; ANTIBODIES; NEUTRALIZATION; FIREDOCK;
   IMMUNITY
AB At present, novel Coronavirus (2019-nCoV, the causative agent of COVID-19) has caused worldwide social and economic disruption. The disturbing statistics of this infection promoted us to develop an effective vaccine candidate against the COVID-19. In this study, bioinformatics approaches were employed to design and introduce a novel multi-epitope vaccine against 2019-nCoV that can potentially trigger both CD4+ and CD8+ T-cell immune responses and investigated its biological activities by computational tools. Three known antigenic proteins (Nucleocapsid, ORF3a, and Membrane protein, hereafter called NOM) from the virus were selected and analyzed for prediction of the potential immunogenic B and T-cell epitopes and then validated using bioinformatics tools. Based on in silico analysis, we have constructed a multi-epitope vaccine candidate (NOM) with five rich-epitopes domain including highly scored T and B-cell epitopes. After predicting and evaluating of the third structure of the protein candidate, the best 3 D predicted model was applied for docking studies with Toll-like receptor 4 (TLR4) and HLA-A*11:01. In the next step, molecular dynamics (MD) simulation was used to evaluate the stability of the designed fusion protein with TLR4 and HLA-A*11:01 receptors. MD studies demonstrated that the NOM-TLR4 and NOM-HLA-A*11:01 docked models were stable during simulation time. In silico evaluation showed that the designed chimeric protein could simultaneously elicit humoral and cell-mediated immune responses. Communicated by Ramaswamy H. Sarma
C1 [Enayatkhani, Maryam; Hasaniazad, Mehdi; Guklani, Hamed; Davoodian, Parivash; Karmostaji, Afsaneh; Ahmadi, Khadijeh] Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Infect & Trop Dis Res Ctr, Bandar Abbas, Iran.
   [Faezi, Sobhan] Guilan Univ Med Sci, Sch Paramed, Med Biotechnol Res Ctr, Rasht, Iran.
   [Ahmadi, Nahid] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmaceut Chem, Tehran, Iran.
   [Einakian, Mohammad Ali] Hormozgan Univ Med Sci, Food Hlth Res Ctr, Bandar Abbas, Iran.
RP Ahmadi, K (corresponding author), Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Infect & Trop Dis Res Ctr, Bandar Abbas, Iran.
EM khadijeh_6482@yahoo.com
RI Faezi, Sobhan/M-5803-2019; Karmostaji, Afsaneh/AAW-1977-2020; Ahmadi,
   Khadijeh/AAE-5003-2020
OI Faezi, Sobhan/0000-0002-4611-9985; Karmostaji,
   Afsaneh/0000-0002-0634-3288; Ahmadi, Khadijeh/0000-0003-4669-0708;
   Enayatkhani, Maryam/0000-0002-5887-6975
FU Hormozgan University of Medical Sciences [HUMS-REC.1398.647]; Bandar
   Abbas, Iran
FX This work was supported by the Hormozgan University of Medical Sciences
   under Grant [number: HUMS-REC.1398.647], Bandar Abbas, Iran.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Al-Tawfiq JA, 2014, TRAVEL MED INFECT DI, V12, P422, DOI 10.1016/j.tmaid.2014.06.007
   Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chiarella P, 2009, RECENT PAT ANTI-CANC, V4, P227, DOI 10.2174/157489209789206922
   Cong YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06062-w
   Culshaw A, 2017, NAT IMMUNOL, V18, P1228, DOI 10.1038/ni.3850
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Deming D, 2007, PLOS MED, V4, P397, DOI 10.1371/journal.pmed.0040080
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Heymann DL, 2020, LANCET, V395, P469, DOI 10.1016/S0140-6736(20)30184-7
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002
   Kloczkowski A, 2002, PROTEINS, V49, P154, DOI 10.1002/prot.10181
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   KRAUS D, 2014, MED WRIT, V23, P25, DOI DOI 10.1179/2047480613Z.000000000181
   Kruiswijk C, 2020, HUM VACC IMMUNOTHER, V16, P277, DOI 10.1080/21645515.2019.1703453
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   신웅희, 2014, Biodesign, V2, P1
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Lim Y.X., 2016, DISEASES, V4, P26, DOI DOI 10.3390/DISEASES4030026
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Liu X, 2004, CLIN DIAGN LAB IMMUN, V11, P227, DOI 10.1128/CDLI.11.1.227-228.2004
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   McBride R, 2012, VIRUSES-BASEL, V4, P2902, DOI 10.3390/v4112902
   Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313
   Oberholser K, 2010, BIOCHEM MOL BIOL EDU, V38, P430, DOI 10.1002/bmb.20457
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Organization WH, 2020, COR DIS 2019 COVID 1, P45
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Reche Pedro A., 2007, V409, P185, DOI 10.1007/978-1-60327-118-9_13
   Reynolds CR, 2018, J MOL BIOL, V430, P2244, DOI 10.1016/j.jmb.2018.01.013
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Testa JS, 2012, FUTURE VIROL, V7, P1077, DOI 10.2217/FVL.12.108
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wieser A, 2010, INFECT IMMUN, V78, P3432, DOI 10.1128/IAI.00174-10
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zheng JZ, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050112
NR 61
TC 59
Z9 59
U1 17
U2 31
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1756411
EA APR 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM3VV
UT WOS:000532179800001
PM 32295479
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhavoronkov, A
AF Zhavoronkov, Alex
TI Geroprotective and senoremediative strategies to reduce the comorbidity,
   infection rates, severity, and lethality in gerophilic and gerolavic
   infections
SO AGING-US
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; sirolimus; rapalog
ID ANTIAGING DRUG TODAY; EXTENDS LIFE-SPAN; IMMUNE FUNCTION; RAPAMYCIN;
   INFLUENZA; SIROLIMUS; CANCER; TOR; SENESCENCE; TARGET
AB The recently identified SARS-CoV-2 betacoronavirus responsible for the COVID-19 pandemic has uncovered the age-associated vulnerability in the burden of disease and put aging research in the spotlight. The limited data available indicates that COVID-19 should be referred to as a gerolavic (from Greek, Oros "old man" and epilavis, "harmful") infection because the infection rates, severity, and lethality are substantially higher in the population aged 60 and older. This is primarily due to comorbidity but may be partially due to immunosenescence, decreased immune function in the elderly, and general loss of function, fitness, and increased frailty associated with aging. Immunosenescence is a major factor affecting vaccination response, as well as the severity and lethality of infectious diseases. While vaccination reduces infection rates, and therapeutic interventions reduce the severity and lethality of infections, these interventions have limitations. Previous studies showed that postulated geroprotectors, such as sirolimus (rapamycin) and its close derivative rapalog everolimus (RAD001), decreased infection rates in a small sample of elderly patients. This article presents a review of the limited literature available on geroprotective and senoremediative interventions that may be investigated to decrease the disease burden of gerolavic infections. This article also highlights a need for rigorous clinical validation of deep aging clocks as surrogate markers of biological age. These could be used to assess the need for, and efficacy of, geroprotective and senoremediative interventions and provide better protection for elderly populations from gerolavic infections. This article does not represent medical advice and the medications described are not yet licensed or recommended as immune system boosters, as they have not undergone clinical evaluation for this purpose.
C1 [Zhavoronkov, Alex] Hong Kong Sci & Technol Pk HKSTP, Insilico Med, Tai Po, Hong Kong, Peoples R China.
   [Zhavoronkov, Alex] Biogerontol Res Fdn, London, England.
RP Zhavoronkov, A (corresponding author), Hong Kong Sci & Technol Pk HKSTP, Insilico Med, Tai Po, Hong Kong, Peoples R China.; Zhavoronkov, A (corresponding author), Biogerontol Res Fdn, London, England.
EM alex@insilico.com
CR Aliper A, 2017, AGING-US, V9, P2245, DOI 10.18632/aging.101319
   Aliper A, 2016, AGING-US, V8, P2127, DOI 10.18632/aging.101047
   Amici SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01593
   Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486
   Anisimov VN, 2010, AM J PATHOL, V176, P2092, DOI 10.2353/ajpath.2010.091050
   Aspinall R, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0111-6
   Bak S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02953
   Barardo D, 2017, AGING CELL, V16, P594, DOI 10.1111/acel.12585
   Barnes PJ, 2015, EUR RESPIR J, V45, P790, DOI 10.1183/09031936.00229714
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Beier UH, 2011, MOL CELL BIOL, V31, P1022, DOI 10.1128/MCB.01206-10
   Blagosklonny MV, 2008, CANCER BIOL THER, V7, P1520, DOI 10.4161/cbt.7.10.6663
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288
   Blagosklonny MV, 2015, ONCOTARGET, V6, P19405, DOI 10.18632/oncotarget.3740
   Blagosklonny MV, 2009, AGING-US, V1, P281, DOI 10.18632/aging.100034
   Bravo-San Pedro JM, 2013, AGING-US, V5, P793, DOI 10.18632/aging.100619
   Brunner S, 2011, AGEING RES REV, V10, P362, DOI 10.1016/j.arr.2010.08.003
   Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267
   Calimport SRG, 2019, SCIENCE, V366, P576, DOI 10.1126/science.aay7319
   Campistol JM, 2006, J AM SOC NEPHROL, V17, P581, DOI 10.1681/ASN.2005090993
   Centers for Disease Control, EST INFL ILLN MED VI
   Centers for Disease Control and Prevention, 2020, INFL ANT MED CLIN SU
   Chow EJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2491-9
   ClinicalTrials.gov, 2020, EFF RTB101 ILL ASS R
   Comas M, 2012, AGING-US, V4, P715, DOI 10.18632/aging.100496
   Cortese Franco, 2018, Oncotarget, V9, P14692, DOI 10.18632/oncotarget.24461
   Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9
   de Cabo R, 2019, NEW ENGL J MED, V381, P2541, DOI 10.1056/NEJMra1905136
   de Zoeten EF, 2010, GASTROENTEROLOGY, V138, P583, DOI 10.1053/j.gastro.2009.10.037
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Dolopikou CF, 2020, EUR J NUTR, V59, P505, DOI 10.1007/s00394-019-01919-4
   Duggal NA, 2019, NAT REV IMMUNOL, V19, P563, DOI 10.1038/s41577-019-0177-9
   Elhassan YS, 2019, CELL REP, V28, P1717, DOI 10.1016/j.celrep.2019.07.043
   Euvrard S, 2012, NEW ENGL J MED, V367, P329, DOI 10.1056/NEJMoa1204166
   Evelyne B, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20216
   Fahy GM, 2019, AGING CELL, V18, DOI 10.1111/acel.13028
   Ferrer IR, 2011, AM J TRANSPLANT, V11, P654, DOI 10.1111/j.1600-6143.2011.03473.x
   Flores KG, 1999, J CLIN INVEST, V104, P1031, DOI 10.1172/JCI7558
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Fulop T, 2010, BIOGERONTOLOGY, V11, P547, DOI 10.1007/s10522-010-9287-2
   Fulop T, 2019, HEALTHY AGEING LONG, V10, P231, DOI 10.1007/978-3-030-24970-0_15
   Galkin F, 2018, BIORXIV, P1, DOI [10.1101/507780., DOI 10.1101/507780]
   Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676
   Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Guerra SG, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1173-4
   Guerrero A, 2019, NAT METAB, V1, P1074, DOI 10.1038/s42255-019-0122-z
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Heneghan CJ, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2547
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Insilico Medicine, 2020, INS MED PUBL MOL STR
   Jefferson T, 2014, BMJ-BRIT MED J, V348, P2545, DOI DOI 10.1136/BMJ.G2545
   Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059
   Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969
   Kline KA, 2016, CURR OPIN MICROBIOL, V29, P63, DOI 10.1016/j.mib.2015.11.003
   Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2
   Leontieva OV, 2015, ONCOTARGET, V6, P23238, DOI 10.18632/oncotarget.4836
   Leontieva OV, 2014, AGING-US, V6, P1010, DOI 10.18632/aging.100714
   Levast B, 2014, VACCINES-BASEL, V2, P297, DOI 10.3390/vaccines2020297
   Levitt M., ANAL CORONAVIRUS 201
   Li Darrick K, 2019, Methods Mol Biol, V1911, P3, DOI 10.1007/978-1-4939-8976-8_1
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mamoshina P, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00242
   Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564
   Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892
   Martens CR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03421-7
   Mayor S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6360
   Mendelsohn AR, 2019, REJUV RES, V22, P261, DOI 10.1089/rej.2019.2218
   Meyer KC, 2004, AGEING RES REV, V3, P55, DOI 10.1016/j.arr.2003.07.002
   Mizumoto K., 2020, ESTIMATING ASYMPTOMA, DOI [10.1101/2020.02.20.20025866, DOI 10.1101/2020.02.20.20025866]
   Monto AS, 2004, CLIN INFECT DIS, V39, P459, DOI 10.1086/422646
   Moskalev A, 2015, AGING-US, V7, P616, DOI 10.18632/aging.100799
   Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446
   Ozaki KS, 2005, INT IMMUNOPHARMACOL, V5, P103, DOI 10.1016/j.intimp.2004.09.008
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   Peters PH, 2001, J AM GERIATR SOC, V49, P1025, DOI 10.1046/j.1532-5415.2001.49204.x
   Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406
   Putin E, 2016, AGING-US, V8, P1021, DOI 10.18632/aging.100968
   Ritchie H., 2018, CAUSES DEATH OUR WOR
   Robida-Stubbs S, 2012, CELL METAB, V15, P713, DOI 10.1016/j.cmet.2012.04.007
   Robson C, 2019, AUST PRESCR, V42, P51, DOI 10.18773/austprescr.2019.013
   Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x
   Scialo F, 2015, CELL CYCLE, V14, P2949, DOI 10.1080/15384101.2015.1071745
   Somerville VS, 2016, ADV NUTR, V7, P488, DOI 10.3945/an.115.010538
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Templeman I, 2020, P NUTR SOC, V79, P76, DOI 10.1017/S0029665119000636
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Turner AP, 2011, AM J TRANSPLANT, V11, P613, DOI 10.1111/j.1600-6143.2010.03407.x
   Uddin GM, 2016, FRONT PHARMACOL, V7, DOI [10.13389/fphar.2016.00258, 10.3389/fphar.2016.00258]
   Wei XC, 2020, J CLIN PHARMACOL, V60, P768, DOI 10.1002/jcph.1576
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   Yoshikawa TT, 2000, CLIN INFECT DIS, V30, P931, DOI 10.1086/313792
   Zhang R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024268
   Zhavoronkov A, 2020, POTENTIAL COVID 2019, V2, DOI [10.26434/chemrxiv.11829102.v2, DOI 10.26434/CHEMRXIV.11829102.V2, 10.26434/chemrxiv.11829102.v2.]
   Zhavoronkov A, 2019, NAT BIOTECHNOL, V37, P1038, DOI 10.1038/s41587-019-0224-x
   Zhavoronkov A, 2019, TRENDS PHARMACOL SCI, V40, P546, DOI 10.1016/j.tips.2019.05.004
   Zhavoronkov A, 2019, AGEING RES REV, V49, P49, DOI 10.1016/j.arr.2018.11.003
   Zhavoronkov A, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00017
   Zhavoronkov A, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00326
   Zhavoronkov A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00049
   Zhavoronkov A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022597
   Zhavoronkov A, 2015, ONCOTARGET, V6, P45010, DOI 10.18632/oncotarget.6878
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 111
TC 21
Z9 22
U1 12
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD APR 30
PY 2020
VL 12
IS 8
BP 6492
EP 6510
DI 10.18632/aging.102988
PG 19
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA LK5DW
UT WOS:000530887200002
PM 32229705
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sargiacomo, C
   Sotgia, F
   Lisanti, MP
AF Sargiacomo, Camillo
   Sotgia, Federica
   Lisanti, Michael P.
TI COVID-19 and chronological aging: senolytics and other anti-aging drugs
   for the treatment or prevention of corona virus infection?
SO AGING-US
LA English
DT Article
DE COVID-19; corona virus; aging; senescence; senolytic drug therapy;
   prevention; viral replication; drug repurposing; antibiotic;
   Azithromycin; Hydroxy-chloroquine; Rapamycin; Doxycycline; Quercetin
ID RESPIRATORY SYNDROME-CORONAVIRUS; IMMUNE-RESPONSES; AZITHROMYCIN
AB COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.
C1 [Sargiacomo, Camillo; Sotgia, Federica; Lisanti, Michael P.] Univ Salford, Sch Sci Engn & Environm See, Translat Med, Manchester, England.
RP Sargiacomo, C; Sotgia, F (corresponding author), Univ Salford, Sch Sci Engn & Environm See, Translat Med, Manchester, England.
EM fsotgia@gmail.com; michaelp.lisanti@gmail.com
OI Sotgia, Federica/0000-0003-2826-4529; Lisanti,
   Michael/0000-0003-2034-1382
FU Lunella Biotech, Inc.
FX The Lisanti/Sotgia Laboratory is supported by research grant funding,
   provided by Lunella Biotech, Inc.
CR Baas T, 2008, J VIROL, V82, P9465, DOI 10.1128/JVI.00489-08
   Blagosklonny MV, 2019, AGING-US, V11, P8048, DOI 10.18632/aging.102355
   Blagosklonny MV, 2018, CELL CYCLE, V17, P2655, DOI 10.1080/15384101.2018.1554781
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Cavalcante MB, 2020, AGING-US, V12, P2711, DOI 10.18632/aging.102772
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Fredeking Terry M, 2015, Recent Pat Antiinfect Drug Discov, V10, P51
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guy JL, 2008, EXP PHYSIOL, V93, P579, DOI 10.1113/expphysiol.2007.040139
   Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188
   Khemais-Benkhiat S, 2016, J GERONTOL A-BIOL, V71, P1581, DOI 10.1093/gerona/glv213
   Kim J, 2020, J MICROBIOL BIOTECHN, V30, P427, DOI 10.4014/jmb.1910.10055
   Kim KM, 2017, GENE DEV, V31, P1529, DOI 10.1101/gad.302570.117
   Kleine-Weber H, 2020, EMERG MICROBES INFEC, V9, P155, DOI 10.1080/22221751.2020.1713705
   Kurz DJ, 2000, J CELL SCI, V113, P3613
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Mah W, 2017, AM J PATHOL, V187, P1717, DOI 10.1016/j.ajpath.2017.04.017
   Mosquera RA, 2018, PEDIATR PULM, V53, P567, DOI 10.1002/ppul.23956
   Ozsvari B, 2018, AGING-US, V10, P3294, DOI 10.18632/aging.101633
   Peiris-Pages M, 2019, AGING-US, V11, P4801, DOI 10.18632/aging.102054
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Roy J, 2002, ANTIMICROB AGENTS CH, V46, P3447, DOI 10.1128/AAC.46.11.3447-3455.2002
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Song JT, 2020, BIOCHEM BIOPH RES CO, V525, P812, DOI 10.1016/j.bbrc.2020.02.151
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tang F, 2017, ONCOL LETT, V14, P5211, DOI 10.3892/ol.2017.6813
   Tishler M, 1999, ANN RHEUM DIS, V58, P253, DOI 10.1136/ard.58.4.253
   van Doremalen N, 2014, J VIROL, V88, P9220, DOI 10.1128/JVI.00676-14
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 48
Z9 48
U1 16
U2 31
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD APR 30
PY 2020
VL 12
IS 8
BP 6511
EP 6517
DI 10.18632/aging.103001
PG 7
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA LK5DW
UT WOS:000530887200003
PM 32229706
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, PY
   Cai, Z
   Wu, WB
   Peng, L
   Li, YF
   Chen, CM
   Chen, L
   Li, JM
   Cao, ML
   Feng, SY
   Jiang, X
   Yuan, J
   Liu, YX
   Yang, L
   Wang, FX
AF Zhang, Peiyan
   Cai, Zhao
   Wu, Weibo
   Peng, Ling
   Li, Yinfeng
   Chen, Chuming
   Chen, Li
   Li, Jianming
   Cao, Mengli
   Feng, Shiyan
   Jiang, Xiao
   Yuan, Jing
   Liu, Yingxia
   Yang, Liang
   Wang, Fuxiang
TI The novel coronavirus (COVID-19) pneumonia with negative detection of
   viral ribonucleic acid from nasopharyngeal swabs: a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus; COVID-19; Pneumonia; Tracheoscopy; Bronchoalveolar-lavage
   fluid
AB Background The novel coronavirus disease 2019 (COVID-19) outbreak started in Wuhan, Hubei, China since Dec 2019 and cases of infection have been continuously reported in various countries. It is now clear that the SARS-COV-2 coronavirus is transmissible from human to human. Nucleic acid detection is considered as the gold standard for the diagnosis of COVID-19. In this case report, we describe our experience in detection of SARS-COV-2 from a confirmed patient using nucleic acid test of bronchoalveolar-lavage fluid (BALF) samples but not nasopharyngeal swabs. Case presentation We present a case of severely ill SARS-COV-2 infected 46-year-old man with fever, coughing and chest tightness. We performed viral detection using his BALF samples and imaging method (CT) for confirmation. The patient received combination of interferonalfa-1b and ribavirin, lopinavir and ritonavir for antiviral treatment at different stages. Other medication was also given to him in combination for anti-inflammation, intestinal microbial regulation, phlegm elimination, liver protection and pulmonary fibrosis prevention purposes. We provided oxygen supply to him using BIPAP ventilator and high-flow humidification oxygen therapy instrument to facilitate respiration. The patient was cured and discharged. Conclusion This case report described an effective supportive medication scheme to treat SARS-COV-2 infected patient and emphasized the necessity of detection of the viral genome using BALF samples and its significance in the diagnosis and prognosis of the disease.
C1 [Zhang, Peiyan; Wu, Weibo; Peng, Ling; Li, Yinfeng; Chen, Chuming; Chen, Li; Li, Jianming; Cao, Mengli; Feng, Shiyan; Jiang, Xiao; Yuan, Jing; Liu, Yingxia; Wang, Fuxiang] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp Affiliated 2, Shenzhen, Guangdong, Peoples R China.
   [Cai, Zhao; Yang, Liang] Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.
RP Wang, FX (corresponding author), Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp Affiliated 2, Shenzhen, Guangdong, Peoples R China.; Yang, L (corresponding author), Southern Univ Sci & Technol, Sch Med, Shenzhen 518055, Guangdong, Peoples R China.
EM yangl@sustech.edu.cn; 13927486077@163.com
RI Yang, Liang/C-8487-2011
OI Yang, Liang/0000-0002-2362-0128
FU National Science and Technology Major Project [2017ZX10103011]; Chinese
   Ministry of Education Changjiang Scholar Program [Q2018288]
FX This work is supported by National Science and Technology Major Project
   (2017ZX10103011). LY is supported by the Chinese Ministry of Education
   Changjiang Scholar Program (Q2018288). The funders contributed to the
   clinical patient care and management, and data analysis.
CR [Anonymous], 2020, COR DIS 2019 COVID 1
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lam T.T.Y., 2020, IDENTIFICATION 2019
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Yang Yang M, 2020, EVALUATING ACCURACY, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhang YF, 2020, DIGEST DIS SCI, DOI 10.1007/s10620-020-06488-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 11
TC 3
Z9 3
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 30
PY 2020
VL 20
IS 1
AR 317
DI 10.1186/s12879-020-05045-z
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA LJ6FP
UT WOS:000530259200001
PM 32354369
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lacour, T
   Semaan, C
   Genet, T
   Ivanes, F
AF Lacour, Thibaud
   Semaan, Carl
   Genet, Thibaud
   Ivanes, Fabrice
TI Insights for increased risk of failed fibrinolytic therapy and stent
   thrombosis associated with COVID-19 in ST-segment elevation myocardial
   infarction patients
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article; Early Access
DE acute myocardial infarction; antithrombotic treatment; viral infection
AB Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis.
C1 [Lacour, Thibaud; Semaan, Carl; Genet, Thibaud; Ivanes, Fabrice] Ctr Hosp Reg Univ Tours, Serv Cardiol, F-37044 Tours 9, France.
   [Semaan, Carl; Ivanes, Fabrice] Univ Tours, Fac Med, Tours, France.
RP Ivanes, F (corresponding author), Ctr Hosp Reg Univ Tours, Serv Cardiol, F-37044 Tours 9, France.
EM fabrice.ivanes@univ-tours.fr
CR Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x
   Moser M, 1999, CIRCULATION, V100, P1858, DOI 10.1161/01.CIR.100.18.1858
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 10
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
DI 10.1002/ccd.28948
EA APR 2020
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LI6SZ
UT WOS:000529614400001
PM 32352633
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Oberemok, VV
   Laikova, KV
   Yurchenko, KA
   Fomochkina, II
   Kubyshkin, AV
AF Oberemok, Volodymyr V.
   Laikova, Kateryna, V
   Yurchenko, Kseniya A.
   Fomochkina, Irina I.
   Kubyshkin, Anatolii, V
TI SARS-CoV-2 will continue to circulate in the human population: an
   opinion from the point of view of the virus-host relationship
SO INFLAMMATION RESEARCH
LA English
DT Article
DE SARS-CoV-2; Virus-host relationship system; Pandemic
ID HUMAN CORONAVIRUS NL63; INFECTION; CHILDREN; PROTECTION; MECHANISMS;
   COVID-19; DISEASE; ORIGIN; SARS
AB At the population level, the virus-host relationship is not set up to end with the complete elimination of either or both. Pathogen-resistant individuals will always remain in the host population. In turn, the virus can never completely eliminate the host population, because evolutionarily such an event is a dead end for the virus as an obligate intracellular parasite. A certain existential balance exists in the virus-host relationship. Against this backdrop, viral epidemics and pandemics only become manifest and egregious to human beings when tens and hundreds of thousands of people die and the question emerges what caused the high mortality peaks on the death chart. The answer seems clear; the emerging strain of the virus is new to the host population, and new mutations of the virus and natural selection will lead to a survival of only genetically resistant individuals in a host population. The dangers inherent to a novel virus are due to new features generally inthe molecular structure of proteins, which enable the virus to infect the cells of the host organism more intensively, dramatically challenging host immunity, and thus be transmitted more readily in the host population. In this article, we will concentrate on the facts currently available about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused COVID-19 (coronavirus disease 2019) pandemic and try to predict its development and consequences based on the virus-host relationship. In fact, only two scenarios will occur simultaneously in the very near future: people who are genetically resistant to the virus will get sick, recover, and develop immunity, while people who are sensitive to the virus will need drugs and vaccines, which will have to be researched and developed if they are to recover. If the pandemic does not stop, in a few decades it is anticipated that SARS-CoV-2 will become as safe as the four non-severe acute respiratory syndrome human coronaviruses (HCoV-NL63, HCoV-HKU1, HCoV-OC43, and HCoV-229E) currently circulating but causing low mortality in the human population.
C1 [Oberemok, Volodymyr V.; Laikova, Kateryna, V; Yurchenko, Kseniya A.; Fomochkina, Irina I.; Kubyshkin, Anatolii, V] VI Vernadsky Crimean Fed Univ, Simferopol, Russia.
RP Kubyshkin, AV (corresponding author), VI Vernadsky Crimean Fed Univ, Simferopol, Russia.
EM kubyshkin_av@mail.ru
RI Yurchenko, Kseniya/ABA-5778-2020; Kubyshkin, Anatolii/AAU-1822-2020;
   Kubyshkin, Anatoliy/L-9262-2013
OI Yurchenko, Kseniya/0000-0002-0284-7059; Kubyshkin,
   Anatoliy/0000-0002-1309-4005
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2010, B WORLD HEALTH ORGAN, V88, P1, DOI [10.2471/BLT.10.041010, DOI 10.2471/BLT.10.041010]
   Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301
   Choi EH, 2006, CLIN INFECT DIS, V43, P585, DOI 10.1086/506350
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289
   Esper F, 2006, EMERG INFECT DIS, V12, P775, DOI 10.3201/eid1205.051316
   Fazakerley JK, 1993, ADV VIRUS RES, DOI [10.10116/S0065-3527(08)60087-1, DOI 10.10116/S0065-3527(08)60087-1]
   GERNA G, 1984, MICROBIOLOGICA, V7, P315
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li B, 2020, MSPHERE, V5, DOI [10.1128/mSphere.00170-20, 10.1128/mSphere.00807-19]
   Li H, 2016, ANTIVIR RES, V130, P19, DOI 10.1016/j.antiviral.2016.03.003
   Liu SL, 2020, EMERG MICROBES INFEC, V9, P505, DOI 10.1080/22221751.2020.1733440
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Pyrc K, 2006, J MOL BIOL, V364, P964, DOI 10.1016/j.jmb.2006.09.074
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   STRASSBURG MA, 1982, AM J INFECT CONTROL, V10, P53, DOI 10.1016/0196-6553(82)90003-7
   Takano T, 2014, ANTIVIR THER, V19, P645, DOI 10.3851/IMP2735
   Tang X, 2020, NATL SCI REV, DOI [10.1186/s40779-020-00240-0, DOI 10.1186/S40779-020-00240-0]
   Trujillo JA, 2014, J IMMUNOL, V192, P5245, DOI 10.4049/jimmunol.1400111
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang XW, 2005, ARCH VIROL, V150, P1, DOI 10.1007/s00705-004-0413-9
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 41
TC 4
Z9 5
U1 2
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD JUL
PY 2020
VL 69
IS 7
BP 635
EP 640
DI 10.1007/s00011-020-01352-y
EA APR 2020
PG 6
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA LS5II
UT WOS:000529580300001
PM 32350571
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lu, DW
   Sang, L
   Du, SH
   Li, T
   Chang, YG
   Yang, XA
AF Lu, Dawei
   Sang, Lin
   Du, Shihua
   Li, Tao
   Chang, Yange
   Yang, Xiu-An
TI Asymptomatic COVID-19 infection in late pregnancy indicated no vertical
   transmission
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE asymptomatic COVID-19 infection; intrauterine infection; late pregnancy;
   vertical transmission
AB This study is to investigate the clinical characteristics of late pregnancy with asymptomatic 2019 novel coronavirus disease (COVID-19) infection, evaluate the outcome of maternal and fetal prognosis, and identify the evidence of intrauterine vertical transmission. A 22-years-old pregnant woman with asymptomatic COVID-19 infection who was admitted to our hospital on 11 February 2020 was enrolled in this study. Clinical data including laboratory test results and chest computed tomography (CT) scanning were collected and reviewed. Diagnosis of late pregnancy with asymptomatic COVID-19 infection was made. Lumbar anesthesia for cesarean section was performed and a female baby was delivered uneventfully, with the Apgar score of 9 to 10 points. Three times of COVID-19 nucleic acid test for the baby was negative after delivery. The puerpera returned to normal after the operation and two times of throat swab COVID-19 nucleic acid test were all negative after antiviral therapy. We reported an asymptomatic COVID-19 pregnant woman with detailed clinical information and our result indicated that for late pregnant women with asymptomatic COVID-19 infection, there might be no intrauterine infection caused by vertical transmission.
C1 [Lu, Dawei; Sang, Lin; Du, Shihua; Li, Tao] Anhui Med Univ, 2 Peoples Hosp Hefei City, Dept Obstet & Gynecol, Hefei, Peoples R China.
   [Chang, Yange; Yang, Xiu-An] Chengde Med Univ, Sch Basic Med Sci, Dept Biochem, Chengde, Peoples R China.
RP Yang, XA (corresponding author), Chengde Med Univ, Sch Basic Med Sci, Anyuan Rd, Chengde 067000, Peoples R China.
EM yangxiuan07@mails.ucas.edu.cn
RI Yang, Xiu‐An/AAP-3699-2020
OI Yang, Xiu-An/0000-0002-3485-0172
FU Scientific and Technological Research Projects of Hebei Higher Education
   [ZD2019084]; Initial Scientific Research Fund for High-Level Talents of
   Chengde Medical University [201901]
FX Scientific and Technological Research Projects of Hebei Higher
   Education, Grant/Award Number: ZD2019084; Initial Scientific Research
   Fund for High-Level Talents of Chengde Medical University, Grant/Award
   Number: 201901
CR Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Cossarizza A, 2020, CYTOM PART A, V97, P340, DOI 10.1002/cyto.a.24002
   Hong B, 2020, CHIN J OBSTET GYNECO, V55, P73
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Muthu V, 2019, J CRIT CARE, V50, P207, DOI 10.1016/j.jcrc.2018.12.006
   Ramsey PS, 2001, OBSTET GYN CLIN N AM, V28, P553, DOI 10.1016/S0889-8545(05)70217-5
   Schwartz DA, 2020, ARCH PATHOL LAB MED
   Wang X, 2020, CLIN INFECT DIS
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Zhang L, 2020, ZHONGHUA FU CHAN KE, V55, pE009
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 12
TC 20
Z9 21
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1660
EP 1664
DI 10.1002/jmv.25927
EA APR 2020
PG 5
WC Virology
SC Virology
GA NA8CG
UT WOS:000529602200001
PM 32330313
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kim, YC
   Dema, B
   Reyes-Sandoval, A
AF Kim, Young Chan
   Dema, Barbara
   Reyes-Sandoval, Arturo
TI COVID-19 vaccines: breaking record times to first-in-human trials
SO NPJ VACCINES
LA English
DT Article
ID ZIKA VIRUS; CORONAVIRUS; PNEUMONIA; OUTBREAK; ISLAND; FEVER
AB The twenty-first century has come with a new era in vaccinology, in which recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic.
C1 [Kim, Young Chan; Dema, Barbara; Reyes-Sandoval, Arturo] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.
RP Reyes-Sandoval, A (corresponding author), Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England.
EM arturo.reyes@ndm.ox.ac.uk
OI Kim, Young Chan/0000-0003-2847-9407
FU Department of Health and Social Care using UK Aid [16/107/05]
FX This research is funded by the Department of Health and Social Care
   using UK Aid funding and is managed by the NIHR, project 16/107/05. The
   views expressed in this publication are those of the author(s) and not
   necessarily those of the Department of Health and Social Care.
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   Ashburn PM, 2004, J INFECT DIS, V189, P1747
   Bhurani V, 2018, INT REV IMMUNOL, V37, P249, DOI 10.1080/08830185.2018.1471479
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   FDA News, 2020, FDA NEWS
   FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   HARRISON VR, 1971, J IMMUNOL, V107, P643
   PATTYN S, 1977, LANCET, V1, P573
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Rosling L, 2003, BRIT MED J, V326, P416, DOI 10.1136/bmj.326.7386.416
   ROSS R. W., 1956, JOUR HYG, V54, P177
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   Sergon K, 2008, AM J TROP MED HYG, V78, P333, DOI 10.4269/ajtmh.2008.78.333
   Simpson D I, 1967, East Afr Med J, V44, P86
   Vitelli A, 2017, EXPERT REV VACCINES, V16, P1241, DOI 10.1080/14760584.2017.1394842
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, 2020, WHO COVID 19 DASHBOA
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 25
TC 19
Z9 19
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD APR 30
PY 2020
VL 5
IS 1
AR 34
DI 10.1038/s41541-020-0188-3
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LI7XH
UT WOS:000529693200001
PM 32377399
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Teoh, JYC
   Roupret, M
   Shariat, SF
   Herrmann, T
AF Teoh, Jeremy Y. C.
   Roupret, Morgan
   Shariat, Shahrokh F.
   Herrmann, Thomas
TI Intravesical therapy for bladder cancer in the pandemic of Covid-19
SO WORLD JOURNAL OF UROLOGY
LA English
DT Letter; Early Access
ID CALMETTE-GUERIN; CHEMOTHERAPY; CARCINOMA
C1 [Teoh, Jeremy Y. C.] Chinese Univ Hong Kong, SH Ho Urol Ctr, Dept Surg, Hong Kong, Peoples R China.
   [Roupret, Morgan] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Predicit Oncouro,GRC 5, Paris 75013, France.
   [Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, Vienna, Austria.
   [Shariat, Shahrokh F.] IM Sechenov First Moscow State Med Univ, Inst Urol & Reprod Hlth, Moscow, Russia.
   [Shariat, Shahrokh F.] Weill Cornell Med Coll, Dept Urol, New York, NY USA.
   [Shariat, Shahrokh F.] Univ Texas Southwestern, Dept Urol, Dallas, TX USA.
   [Shariat, Shahrokh F.] Charles Univ Prague, Dept Urol, Prague, Czech Republic.
   [Herrmann, Thomas] Spital Thurgau AG, Dept Urol, Frauenfeld, Switzerland.
   [Herrmann, Thomas] Hanover Med Sch MHH, Dept Urol, Hannover, Germany.
RP Herrmann, T (corresponding author), Spital Thurgau AG, Dept Urol, Frauenfeld, Switzerland.; Herrmann, T (corresponding author), Hanover Med Sch MHH, Dept Urol, Hannover, Germany.
EM thomas.herrmann@stgag.ch
RI Teoh, Jeremy Yuen Chun/H-5184-2016
OI Teoh, Jeremy Yuen Chun/0000-0002-9361-2342; Roupret,
   Morgan/0000-0001-8440-7075
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Bohle A, 2004, UROLOGY, V63, P682, DOI 10.1016/j.urology.2003.11.049
   Cumberbatch MGK, 2018, EUR UROL, V74, P784, DOI 10.1016/j.eururo.2018.09.001
   GUDARU K, 2019, J ENDOLUMINAL ENDOUR, V2, pE20, DOI DOI 10.22374/JELEU.V2I2.44
   Hegarty P, 2020, BCG VACCINATION MAY
   Huncharek M, 2001, ANTICANCER RES, V21, P765
   Oddens J, 2013, EUR UROL, V63, P462, DOI 10.1016/j.eururo.2012.10.039
   Oke J., 2020, GLOBAL COVID 19 CASE
   Sylvester RJ, 2008, EUR UROL, V53, P709, DOI 10.1016/j.eururo.2008.01.015
   Zlotta AR, 2000, EUR UROL, V37, P470, DOI 10.1159/000020170
NR 10
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03218-8
EA APR 2020
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA LJ0EW
UT WOS:000529848700002
PM 32356225
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ackerman, CM
   Myhrvold, C
   Thakku, SG
   Freije, CA
   Metsky, HC
   Yang, DK
   Ye, SH
   Boehm, CK
   Kosoko-Thoroddsen, TSF
   Kehe, J
   Nguyen, TG
   Carter, A
   Kulesa, A
   Barnes, JR
   Dugan, VG
   Hung, DT
   Blainey, PC
   Sabeti, PC
AF Ackerman, Cheri M.
   Myhrvold, Cameron
   Thakku, Sri Gowtham
   Freije, Catherine A.
   Metsky, Hayden C.
   Yang, David K.
   Ye, Simon H.
   Boehm, Chloe K.
   Kosoko-Thoroddsen, Tinna-Solveig F.
   Kehe, Jared
   Nguyen, Tien G.
   Carter, Amber
   Kulesa, Anthony
   Barnes, John R.
   Dugan, Vivien G.
   Hung, Deborah T.
   Blainey, Paul C.
   Sabeti, Pardis C.
TI Massively multiplexed nucleic acid detection with Cas13
SO NATURE
LA English
DT Article
ID DIAGNOSTICS; ARRAYS
AB The great majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3)while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanolitre droplets containing CRISPR-based nucleic acid detection reagents(7)self-organize in a microwell array(8)to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of more than 4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with at least 10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. The intrinsic multiplexing and throughput capabilities of CARMEN make it practical to scale, as miniaturization decreases reagent cost per test by more than 300-fold. Scalable, highly multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11).
C1 [Ackerman, Cheri M.; Myhrvold, Cameron; Thakku, Sri Gowtham; Freije, Catherine A.; Metsky, Hayden C.; Yang, David K.; Ye, Simon H.; Boehm, Chloe K.; Kosoko-Thoroddsen, Tinna-Solveig F.; Kehe, Jared; Nguyen, Tien G.; Carter, Amber; Kulesa, Anthony; Hung, Deborah T.; Blainey, Paul C.; Sabeti, Pardis C.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Ackerman, Cheri M.; Kehe, Jared; Kulesa, Anthony; Blainey, Paul C.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Myhrvold, Cameron; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
   [Thakku, Sri Gowtham; Ye, Simon H.] Harvard Med Sch, Div Hlth Sci & Technol, Cambridge, MA 02115 USA.
   [Thakku, Sri Gowtham; Ye, Simon H.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Freije, Catherine A.] Harvard Med Sch, PhD Program Virol, Div Med Sci, Boston, MA 02115 USA.
   [Metsky, Hayden C.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Barnes, John R.; Dugan, Vivien G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Hung, Deborah T.] Massachusetts Gen Hosp, Mol Biol Dept, Boston, MA 02114 USA.
   [Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
   [Blainey, Paul C.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD USA.
   [Sabeti, Pardis C.] Harvard TH Chan Sch Publ Hearth, Dept Immunol & Infect Dis, Boston, MA USA.
RP Myhrvold, C; Blainey, PC (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Blainey, PC (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Myhrvold, C (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.; Blainey, PC (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM cmyhrvol@broadinstitute.org; pblainey@broadinstitute.org
OI Yang, David/0000-0002-9972-3035; Myhrvold, Cameron/0000-0002-8971-184X;
   Metsky, Hayden/0000-0002-8871-2349
FU Defense Advanced Research Projects Agency (DARPA)United States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [D18AC00006]; Howard Hughes Medical InstituteHoward Hughes Medical
   Institute; Koch Institute for Integrative Cancer Research Bridge
   Project, an MIT Deshpande Center Innovation Award; Merkin Institute for
   Transformative Technologies in Healthcare; Burroughs Wellcome Fund CASI
   AwardBurroughs Wellcome Fund; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [F32CA236425]
FX We thank J. Gootenberg, O. Abudayyeh, E. Spady and Sabeti and Blainey
   lab members for discussions and feedback on the manuscript, and Boca
   Biolistics for support with patient samples. Funding was provided by
   Defense Advanced Research Projects Agency (DARPA) grant D18AC00006, the
   Howard Hughes Medical Institute, the Koch Institute for Integrative
   Cancer Research Bridge Project, an MIT Deshpande Center Innovation
   Award, the Merkin Institute for Transformative Technologies in
   Healthcare and a Burroughs Wellcome Fund CASI Award (to P.C.B.). C.M.A.
   was supported by NIH grant F32CA236425. The views, opinions and/or
   findings expressed should not be interpreted as representing the
   official views or policies of the Department of Defense, NIH or the US
   government. This study has been approved for public release;
   distribution is unlimited.
CR Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573
   Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170
   Bosch I, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan1589
   Briese T, 2015, MBIO, V6, DOI 10.1128/mBio.01491-15
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Chen JS, 2018, SCIENCE, V360, P436, DOI 10.1126/science.aar6245
   Chertow DS, 2018, SCIENCE, V360, P381, DOI 10.1126/science.aat4982
   Du Y, 2017, ANGEW CHEM INT EDIT, V56, P992, DOI 10.1002/anie.201609108
   Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023
   East-Seletsky A, 2016, NATURE, V538, P270, DOI 10.1038/nature19802
   Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179
   Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321
   Gupta RK, 2018, LANCET INFECT DIS, V18, P346, DOI [10.1016/S1473-3099(17)30702-8, 10.1016/s1473-3099(17)30702-8]
   Hassibi A, 2018, NAT BIOTECHNOL, V36, P738, DOI 10.1038/nbt.4179
   Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182
   Ismagilov RF, 2001, ANAL CHEM, V73, P5207, DOI 10.1021/ac010502a
   Jackman RJ, 1998, ANAL CHEM, V70, P2280, DOI 10.1021/ac971295a
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kehe J, 2019, P NATL ACAD SCI USA, V116, P12804, DOI 10.1073/pnas.1900102116
   Kocak DD, 2018, NATURE, V557, P168, DOI 10.1038/d41586-018-04975-8
   Kulesa A, 2018, P NATL ACAD SCI USA, V115, P6685, DOI 10.1073/pnas.1802233115
   Li H, 2013, ALIGNING SEQUENCE RE
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Matranga CB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0519-7
   Metsky HC, 2020, BIORXIV, DOI [10.1101/2020.02.26.967026, DOI 10.1101/2020.02.26.967026, 10.1101/2020.02.26.967026.]
   Myhrvold C, 2018, SCIENCE, V360, P444, DOI 10.1126/science.aas8836
   Palacios G, 2007, EMERG INFECT DIS, V13, P73, DOI 10.3201/eid1301.060837
   Popowitch EB, 2013, J CLIN MICROBIOL, V51, P1528, DOI 10.1128/JCM.03368-12
   Quake S., 2018, SOLVING TYRANNY PIPE
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Wensing AM, 2017, TOP ANTIVIR MED, V24, P132
NR 35
TC 23
Z9 23
U1 56
U2 70
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN
PY 2020
VL 582
IS 7811
BP 277
EP +
DI 10.1038/s41586-020-2279-8
EA APR 2020
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MB6FF
UT WOS:000539181700001
PM 32349121
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Boopathi, S
   Poma, AB
   Kolandaivel, P
AF Boopathi, Subramanian
   Poma, Adolfo B.
   Kolandaivel, Ponmalai
TI Novel 2019 coronavirus structure, mechanism of action, antiviral drug
   promises and rule out against its treatment
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus; computational simulation; coronavirus Spike; ACE2 receptor;
   antiviral drugs; COVID-19
ID MAIN PROTEASE; ION CHANNELS; SARS; SPIKE; CHLOROQUINE; INHIBITORS;
   AZITHROMYCIN; BINDING; DESIGN
AB In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19.
C1 [Boopathi, Subramanian] Univ Talca, Ctr Bioinformat & Simulac Mol CBSM, 1 Poniente 1141, Talca 3460000, Chile.
   [Poma, Adolfo B.] Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, Pawinskiego 5B, PL-02106 Warsaw, Poland.
   [Kolandaivel, Ponmalai] Periyar Univ, Salem, Tamil Nadu, India.
RP Boopathi, S (corresponding author), Univ Talca, Ctr Bioinformat & Simulac Mol CBSM, 1 Poniente 1141, Talca 3460000, Chile.; Poma, AB (corresponding author), Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, Pawinskiego 5B, PL-02106 Warsaw, Poland.; Kolandaivel, P (corresponding author), Periyar Univ, Salem, Tamil Nadu, India.
EM boopathialzheimer@outlook.com; apoma@ippt.pan.pl; ponkvel@hotmail.com
RI Boopathi, Subramanian/AAP-7497-2020; Poma, Adolfo/AAA-5145-2020
OI Boopathi, Subramanian/0000-0002-9249-1112; Poma,
   Adolfo/0000-0002-8875-3220
FU National Science Centre, PolandNational Science Center, PolandNational
   Science Centre, Poland [2017/26/D/NZ1/00466]
FX This work was supported by the National Science Centre, Poland, under
   Grant number 2017/26/D/NZ1/00466.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, COR COVID 19 GLOB CA
   [Anonymous], 2020, COVID 19 FEATURED CO
   Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896
   Baden L. R., 2020, NEW ENGLAND J MED, DOI 10.1056/NEJMe2005477
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Bostrom J, 2018, NAT REV DRUG DISCOV, V17, P709, DOI 10.1038/nrd.2018.116
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Desease Control and Prevention, 2005, CTR DIS CONTR PREV F
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gupta M. K., 2020, J BIOMOLECULAR STRUC, DOI 10.1080/07391102.2020.1751300
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jin Z., 2020, BIORXIV
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Koenig KL, 2015, WEST J EMERG MED, V16, P619, DOI 10.5811/westjem.2015.7.27915
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lissenberg A, 2005, J VIROL, V79, P15054, DOI 10.1128/JVI.79.24.15054-15063.2005
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Sarma P., 2020, J BIOMOLECULAR STRUC
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Song HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang FH, 2017, J MED CHEM, V60, P3212, DOI 10.1021/acs.jmedchem.7b00103
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Q, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-99
   WHO, 2019, MIDDL E RESP SYNDR C
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   World Health Organization, DIR GEN REM MED BRIE
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 66
TC 73
Z9 73
U1 22
U2 45
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1758788
EA APR 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM3LR
UT WOS:000532152900001
PM 32306836
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Sanchez, TH
   Zlotorzynska, M
   Rai, M
   Baral, SD
AF Sanchez, Travis H.
   Zlotorzynska, Maria
   Rai, Mona
   Baral, Stefan D.
TI Characterizing the Impact of COVID-19 on Men Who Have Sex with Men
   Across the United States in April, 2020
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Coronavirus; COVID-19; MSM; Gay; HIV
AB The COVID-19 pandemic is reinforcing health inequities among vulnerable populations, including men who have sex with men (MSM). We conducted a rapid online survey (April 2 to April 13, 2020) of COVID-19 related impacts on the sexual health of 1051 US MSM. Many participants had adverse impacts to general wellbeing, social interactions, money, food, drug use and alcohol consumption. Half had fewer sex partners and most had no change in condom access or use. Some reported challenges in accessing HIV testing, prevention and treatment services. Compared to older MSM, those 15-24 years were more likely to report economic and service impacts. While additional studies of COVID-19 epidemiology among MSM are needed, there is already evidence of emerging interruptions to HIV-related services. Scalable remote solutions such as telehealth and mailed testing and prevention supplies may be urgently needed to avert increased HIV incidence among MSM during the COVID-19 pandemic era.
C1 [Sanchez, Travis H.; Zlotorzynska, Maria; Rai, Mona] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Baral, Stefan D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Sanchez, TH (corresponding author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
EM Travis.Sanchez@emory.edu
OI sanchez, travis/0000-0003-1133-4762
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30AI050409,
   R01MH110358]
FX The study was funded by a grant from the National Institutes of Health
   [Grant No. P30AI050409 and R01MH110358].
CR Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Centers for Disease Control and Prevention, 2019, EST HIV INC PREV US, V24
   Centers for Disease Control and Prevention, 2020, COVIDVIEW WEEKL SURV
   Centers for Disease Control and Prevention, 2019, SEL NAT HIV PREV CAR
   Chiasson MA, 2005, ARCH SEX BEHAV, V34, P527, DOI 10.1007/s10508-005-6278-5
   HIV Medical Association, 2020, COVID 19 SPEC CONS P
   Johns Hopkins Center for Systems Science and Engineering, 2020, COR COVID 19 GLOB GA
   Kates J., 2020, STAY AT HOME ORDERS
   Kochhar R., 2020, YOUNG WORKERS HARD H
   Sanchez TH, 2018, AIDS BEHAV, V22, P2413, DOI 10.1007/s10461-018-2168-4
   Sanchez Travis Howard, 2015, JMIR Public Health Surveill, V1, pe3, DOI 10.2196/publichealth.4314
   Thorbecke C, 2020, 66000000 MORE AM FIL
   White House, 2020, 30 DAYS SLOW SPREAD
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
NR 14
TC 24
Z9 25
U1 4
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2020
VL 24
IS 7
BP 2024
EP 2032
DI 10.1007/s10461-020-02894-2
EA APR 2020
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA MB5LE
UT WOS:000529842100002
PM 32350773
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Uno, Y
AF Uno, Yoshiharu
TI Camostat mesilate therapy for COVID-19
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Letter
ID CORONAVIRUS
C1 [Uno, Yoshiharu] Off Uno Column, 419-2 Yota,Onoe Cho, Kakogawa, Hyogo, Japan.
RP Uno, Y (corresponding author), Off Uno Column, 419-2 Yota,Onoe Cho, Kakogawa, Hyogo, Japan.
EM yoshiharu333@hotmail.com
CR Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ota S, 2016, RESPIR MED CASE REP, V19, P21, DOI 10.1016/j.rmcr.2016.06.005
   Rabaan AA, 2017, EXPERT REV RESP MED, V11, P901, DOI 10.1080/17476348.2017.1367288
   Sato T, 1992, J CLIN THERAP MED, V8, P1877
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 5
TC 19
Z9 19
U1 0
U2 1
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1577
EP 1578
DI 10.1007/s11739-020-02345-9
EA APR 2020
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000529459600001
PM 32347443
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU van den Broek, MPH
   Mohlmann, JE
   Abeln, BGS
   Liebregts, M
   van Dijk, VF
   van de Garde, EMW
AF van den Broek, M. P. H.
   Mohlmann, J. E.
   Abeln, B. G. S.
   Liebregts, M.
   van Dijk, V. F.
   van de Garde, E. M. W.
TI Chloroquine-induced QTc prolongation in COVID-19 patients
SO NETHERLANDS HEART JOURNAL
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2; Chloroquine; QT prolongation;
   Electrocardiogram
ID ANTIMALARIAL
AB Background In the battle against the SARS-CoV-2 pandemic, chloroquine has emerged as a new potential therapeutic option for the treatment of infected patients. A safety consideration for the application of chloroquine is its QTc-prolonging potential. Thus far, no data are available on the QTc-prolonging potential of chloroquine in COVID-19 patients. Objective To assess the degree of chloroquine-induced QTc prolongation in hospitalised COVID-19 patients. Methods A baseline electrocardiogram (ECG) and ECGs recorded during chloroquine treatment were retrospectively collected in patients suspected of having COVID-19. The QTc interval was calculated by computerised and manual interpretation. Baseline and follow-up QTc intervals were compared using the paired samples t-test. Results A total of 95 patients had a baseline ECG recording and at least one ECG recording during chloroquine therapy. Chloroquine treatment resulted in a mean QTc prolongation of 35 & x202f;ms (95% CI 28-43 & x202f;ms) using computerised interpretation and 34 & x202f;ms (95% CI 25-43 & x202f;ms) using manual interpretation. No torsade de pointes was observed during chloroquine treatment. After manual review, 22 patients (23%) had a QTc interval exceeding 500 & x202f;ms during chloroquine treatment. None of these patients had a prolonged QTc interval prior to the initiation of chloroquine treatment. Conclusions Chloroquine significantly prolongs the QTc interval in a clinically relevant matter. This highlights the need for ECG monitoring when prescribing chloroquine to COVID-19 patients.
C1 [van den Broek, M. P. H.; Mohlmann, J. E.; van de Garde, E. M. W.] St Antonius Hosp, Dept Clin Pharm, Utrecht, Netherlands.
   [Abeln, B. G. S.; Liebregts, M.; van Dijk, V. F.] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands.
   [van de Garde, E. M. W.] Univ Utrecht, Dept Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.
RP van den Broek, MPH (corresponding author), St Antonius Hosp, Dept Clin Pharm, Utrecht, Netherlands.
EM mp.van.den.broek@antoniusziekenhuis.nl
CR Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI 10.1016/j.jacc.2010.01.001
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4
   Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006
   Olafuyi O, 2019, J PHARM SCI-US, V108, P661, DOI 10.1016/j.xphs.2018.10.056
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 9
TC 27
Z9 28
U1 1
U2 4
PU BOHN STAFLEU VAN LOGHUM BV
PI HOUTEN
PA POSTBUS 246, 3990 GA HOUTEN, NETHERLANDS
SN 1568-5888
EI 1876-6250
J9 NETH HEART J
JI Neth. Heart J.
PD JUL
PY 2020
VL 28
IS 7-8
BP 406
EP 409
DI 10.1007/s12471-020-01429-7
EA APR 2020
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA MP0XT
UT WOS:000529577700001
PM 32350818
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Mugheddu, C
   Dell'Antonia, M
   Sanna, S
   Agosta, D
   Atzori, L
   Rongioletti, F
AF Mugheddu, Cristina
   Dell'Antonia, Massimo
   Sanna, Silvia
   Agosta, Daniele
   Atzori, Laura
   Rongioletti, Franco
TI Successful guselkumab treatment in a psoriatic patient affected with
   Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE Cornelia de Lange syndrome; COVID-19; guselkumab; intellectual
   disability; psoriasis
AB Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.
C1 [Mugheddu, Cristina; Dell'Antonia, Massimo; Sanna, Silvia; Agosta, Daniele; Atzori, Laura; Rongioletti, Franco] Univ Cagliari, Dermatol Clin, Dept Med Sci & Publ Hlth, Cagliari, Italy.
RP Atzori, L (corresponding author), Clin Dermatol, Via Osped 54, I-09124 Cagliari, Italy.
EM atzoril@unica.it
OI Dell'Antonia, Massimo/0000-0003-0250-5750
CR Augustin M, 2011, DERMATOLOGY, V222, P363, DOI 10.1159/000329026
   Boyle MI, 2015, CLIN GENET, V88, P1, DOI 10.1111/cge.12499
   Kouris A, 2017, Psychiatriki, V28, P54, DOI 10.22365/jpsych.2017.281.54
   Nogueira Miguel, 2019, Drugs Context, V8, P212594, DOI 10.7573/dic.212594
   Pie J, 2016, AM J MED GENET C, V172, P198, DOI 10.1002/ajmg.c.31501
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Zaghloul SS, 2004, ARCH DERMATOL, V140, P408, DOI 10.1001/archderm.140.4.408
NR 7
TC 2
Z9 2
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13433
DI 10.1111/dth.13433
EA APR 2020
PG 3
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000529215400001
PM 32306513
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Molloy, EJ
AF Molloy, Eleanor J.
TI The Doctor's Dilemma: lessons from GB Shaw in a modern pandemic COVID-19
SO PEDIATRIC RESEARCH
LA English
DT Article; Early Access
ID SEPSIS
AB In the current COVID 19 pandemic, the only treatments are supportive as no definitive pharmacological intervention is available. The heterogeneity of the immune response in different patient groups is clear with less severe illness in children. Understanding these disparities is particularly important as severely affected patients with COVID19 cannot always be predicted before they experience a cytokine storm and multiorgan dysfunction. Over 100 years ago, the concept of individualised immunotherapy was introduced by Sir Almroth Wright and immortalised in GB Shaw's play The Doctor's Dilemma. Shaw's play The Doctor's Dilemma explores the issues of private medical practice, equality of health care delivery, rationing of scarce resources (intensive care) and high-risk therapies. The play also describes the dilemma of rationing of resources and selecting the correct patient for new experimental therapies. Immunological theories of the time are now reflected in current understanding of inflammatory responses in sepsis and immunomodulation during the COVID19 pandemic.
C1 [Molloy, Eleanor J.] Univ Dublin, Trinity Coll, Paediat, Dublin, Ireland.
   [Molloy, Eleanor J.] Trinity Coll Dublin, Trinity Translat Med Inst TTMI, Dublin, Ireland.
   [Molloy, Eleanor J.] Trinity Coll Dublin, Trinity Res Childhood Ctr TRICC, Dublin, Ireland.
   [Molloy, Eleanor J.] Childrens Hosp Ireland CHI Tallaght & Crumlin, Paediat & Neonatol, Dublin, Ireland.
   [Molloy, Eleanor J.] Coombe Women & Infants Univ Hosp, Dublin, Ireland.
RP Molloy, EJ (corresponding author), Univ Dublin, Trinity Coll, Paediat, Dublin, Ireland.; Molloy, EJ (corresponding author), Trinity Coll Dublin, Trinity Translat Med Inst TTMI, Dublin, Ireland.; Molloy, EJ (corresponding author), Trinity Coll Dublin, Trinity Res Childhood Ctr TRICC, Dublin, Ireland.; Molloy, EJ (corresponding author), Childrens Hosp Ireland CHI Tallaght & Crumlin, Paediat & Neonatol, Dublin, Ireland.; Molloy, EJ (corresponding author), Coombe Women & Infants Univ Hosp, Dublin, Ireland.
EM eleanor.molloy@tcd.ie
RI Molloy, Eleanor/I-3435-2019
OI Molloy, Eleanor/0000-0001-6798-2158
FU Health Research Board, Ireland
FX This work was supported by Health Research Board, Ireland.
CR Ashare A, 2005, AM J PHYSIOL-LUNG C, V288, pL633, DOI 10.1152/ajplung.00231.2004
   Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010
   Brown K, 2004, A FLEMING ANTIBIOTIC
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chinese Clinical Trial Registry, 2020, MULT RAND CONTR TRIA
   Colebrook L., 1954, A WRIGHT PROVOCATIVE
   Dunn PM, 2008, ARCH DIS CHILD-FETAL, V93, pF246, DOI 10.1136/adc.2006.104448
   Dunnill M., 2000, PLATO PRAED STREET L
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Haveman JW, 1999, NETH J MED, V55, P132, DOI 10.1016/S0300-2977(98)00156-9
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Molloy EJ, 2020, PEDIATR RES, V88, P2, DOI 10.1038/s41390-020-0850-5
   Osuchowski MF, 2009, CRIT CARE MED, V37, P1567, DOI 10.1097/CCM.0b013e31819df06b
   Panacek EA, 2004, CRIT CARE MED, V32, P2173, DOI 10.1097/01.CCM.0000145229.59014.6c
   Shaw G. B, 1941, DOCTORS DILEMMA PREF
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
NR 17
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
DI 10.1038/s41390-020-0927-1
EA APR 2020
PG 3
WC Pediatrics
SC Pediatrics
GA LL7TG
UT WOS:000531758500001
PM 32344425
OA Bronze
DA 2021-01-01
ER

PT J
AU Seo, G
   Lee, G
   Kim, MJ
   Baek, SH
   Choi, M
   Ku, KB
   Lee, CS
   Jun, S
   Park, D
   Kim, HG
   Kim, SJ
   Lee, JO
   Kim, BT
   Park, EC
   Kim, SI
AF Seo, Giwan
   Lee, Geonhee
   Kim, Mi Jeong
   Baek, Seung-Hwa
   Choi, Minsuk
   Ku, Keun Bon
   Lee, Chang-Seop
   Jun, Sangmi
   Park, Daeui
   Kim, Hong Gi
   Kim, Seong-Jun
   Lee, Jeong-O
   Kim, Bum Tae
   Park, Edmond Changkyun
   Kim, Seung Il
TI Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human
   Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based
   Biosensor
SO ACS NANO
LA English
DT Article
DE FET; biosensor; COVID-19; SARS-CoV-2; 2019-nCoV
ID GRAPHENE; SARS
AB Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect the SARSCoV-2 spike protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 X 10(1) pfu/mL) and clinical samples (LOD: 2.42 X 10(2) copies/mL). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling.
C1 [Seo, Giwan; Kim, Mi Jeong; Park, Edmond Changkyun; Kim, Seung Il] Korea Basic Sci Inst, Res Ctr Bioconvergence Anal, Cheongju 28119, South Korea.
   [Seo, Giwan; Kim, Mi Jeong; Baek, Seung-Hwa; Choi, Minsuk; Ku, Keun Bon; Jun, Sangmi; Park, Daeui; Kim, Hong Gi; Kim, Seong-Jun; Kim, Bum Tae; Park, Edmond Changkyun; Kim, Seung Il] Korea Res Inst Chem Technol, Ctr Convergent Res Emerging Virus Infect, Daejeon 34114, South Korea.
   [Park, Edmond Changkyun; Kim, Seung Il] Univ Sci & Technol UST, Dept Bioanal Sci, Daejeon 34113, South Korea.
   [Lee, Geonhee; Lee, Jeong-O] Korea Res Inst Chem Technol, Adv Mat Div, Daejeon 34114, South Korea.
   [Baek, Seung-Hwa; Park, Daeui] Korea Inst Toxicol, Dept Predict Toxicol, Daejeon 34114, South Korea.
   [Lee, Chang-Seop] Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju 54986, South Korea.
   [Lee, Chang-Seop] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Jeonju 54907, South Korea.
   [Jun, Sangmi] Korea Basic Sci Inst, Ctr Res Equipment, Cheongju 28119, South Korea.
RP Park, EC; Kim, SI (corresponding author), Korea Basic Sci Inst, Res Ctr Bioconvergence Anal, Cheongju 28119, South Korea.; Park, EC; Kim, SI (corresponding author), Korea Res Inst Chem Technol, Ctr Convergent Res Emerging Virus Infect, Daejeon 34114, South Korea.; Park, EC; Kim, SI (corresponding author), Univ Sci & Technol UST, Dept Bioanal Sci, Daejeon 34113, South Korea.
EM edpark@kbsi.re.kr; ksi@kbsi.re.kr
OI SEO, GIWAN/0000-0002-8734-6199; Park, Daeui/0000-0002-9452-5849
FU National Research Council of Science and Technology (NST) - Ministry of
   Science and ICT, Republic of Korea [CRC-16-01-KRICT]; Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea
   [HI20C0033, HI20C0363]
FX This work was supported by National Research Council of Science and
   Technology (NST) funded by the Ministry of Science and ICT, Republic of
   Korea (Grant No. CRC-16-01-KRICT), and Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare, Republic of Korea (Grant
   Nos. HI20C0033 and HI20C0363).
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Choi Y, 2016, ADV MATER, V28, P3742, DOI 10.1002/adma.201506450
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Janissen R, 2017, NANO LETT, V17, P5938, DOI 10.1021/acs.nanolett.7b01803
   Jung YJ, 2020, COMP ANAL PRIMER PRO, DOI [10.1101/2020.02.25.964775, DOI 10.1101/2020.02.25.964775]
   Lei YM, 2017, BIOSENS BIOELECTRON, V91, P1, DOI 10.1016/j.bios.2016.12.018
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu JY, 2013, J MATER CHEM C, V1, P1713, DOI 10.1039/c3tc00191a
   Liu JX, 2019, NANO LETT, V19, P1437, DOI 10.1021/acs.nanolett.8b03818
   Liu YP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6461
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   SINGH N, 2012, ISRN CONDENS MATTER, V2012
   Teng F, 2018, ADV MATER, V30, DOI 10.1002/adma.201706262
   Tian X., 2020, SCIENCE, V9, P382
   World Health Organization, 2019, NOV COR 2019 NCOV SI
   World Health Organization, COR DIS COVID 19 TEC
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu GF, 2017, APPL SURF SCI, V425, P713, DOI 10.1016/j.apsusc.2017.07.048
   Zhou L, 2017, BIOSENS BIOELECTRON, V87, P701, DOI 10.1016/j.bios.2016.09.025
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 25
TC 100
Z9 100
U1 67
U2 113
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD APR 28
PY 2020
VL 14
IS 4
BP 5135
EP 5142
DI 10.1021/acsnano.0c02823
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA LJ0WV
UT WOS:000529895500128
PM 32293168
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Duan, K
   Liu, BD
   Li, CS
   Zhang, HJ
   Yu, T
   Qu, JM
   Zhou, M
   Chen, L
   Meng, SL
   Hu, Y
   Peng, C
   Yuan, MC
   Huang, JY
   Wang, ZJ
   Yu, JH
   Gao, XX
   Wang, D
   Yu, XQ
   Li, L
   Zhang, JY
   Wu, X
   Li, B
   Xu, YP
   Chen, W
   Peng, Y
   Hu, YQ
   Lin, LZ
   Liu, XF
   Huang, SH
   Zhou, ZJ
   Zhang, LH
   Wang, Y
   Zhang, Z
   Deng, K
   Xia, ZW
   Gong, Q
   Zhang, W
   Zheng, XB
   Liu, Y
   Yang, HC
   Zhou, DB
   Yu, D
   Hou, JF
   Shi, ZL
   Chen, SJ
   Chen, Z
   Zhang, XX
   Yang, XM
AF Duan, Kai
   Liu, Bende
   Li, Cesheng
   Zhang, Huajun
   Yu, Ting
   Qu, Jieming
   Zhou, Min
   Chen, Li
   Meng, Shengli
   Hu, Yong
   Peng, Cheng
   Yuan, Mingchao
   Huang, Jinyan
   Wang, Zejun
   Yu, Jianhong
   Gao, Xiaoxiao
   Wang, Dan
   Yu, Xiaoqi
   Li, Li
   Zhang, Jiayou
   Wu, Xiao
   Li, Bei
   Xu, Yanping
   Chen, Wei
   Peng, Yan
   Hu, Yeqin
   Lin, Lianzhen
   Liu, Xuefei
   Huang, Shihe
   Zhou, Zhijun
   Zhang, Lianghao
   Wang, Yue
   Zhang, Zhi
   Deng, Kun
   Xia, Zhiwu
   Gong, Qin
   Zhang, Wei
   Zheng, Xiaobei
   Liu, Ying
   Yang, Huichuan
   Zhou, Dongbo
   Yu, Ding
   Hou, Jifeng
   Shi, Zhengli
   Chen, Saijuan
   Chen, Zhu
   Zhang, Xinxin
   Yang, Xiaoming
TI Effectiveness of convalescent plasma therapy in severe COVID-19 patients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE COVID-19; convalescent plasma; treatment outcome; pilot project
ID EBOLA-VIRUS DISEASE; RESPIRATORY SYNDROME; CORONAVIRUS; INFLUENZA;
   ANTIBODIES; INFECTION; PNEUMONIA
AB Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary end-point was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 x 10(9)/L vs. 0.76 x 10(9)/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
C1 [Duan, Kai; Yang, Huichuan; Zhou, Dongbo; Yu, Ding; Yang, Xiaoming] China Natl Biotec Grp Co Ltd, Beijing 100029, Peoples R China.
   [Duan, Kai; Meng, Shengli; Wang, Zejun; Li, Li; Zhang, Jiayou; Chen, Wei; Hu, Yeqin; Huang, Shihe; Zhang, Lianghao; Zhang, Zhi; Xia, Zhiwu; Yang, Xiaoming] Wuhan Inst Biol Prod Co Ltd, Natl Engn Technol Res Ctr Combined Vaccines, Wuhan 430207, Peoples R China.
   [Liu, Bende] First Peoples Hosp Jiangxia Dist, Wuhan 430200, Peoples R China.
   [Li, Cesheng; Hu, Yong; Yu, Jianhong; Wu, Xiao; Peng, Yan; Lin, Lianzhen; Zhou, Zhijun; Wang, Yue; Deng, Kun; Gong, Qin; Zhang, Wei; Zheng, Xiaobei; Liu, Ying] Sinopharm Wuhan Plasma Derived Biotherapies Co Lt, Wuhan 430207, Peoples R China.
   [Zhang, Huajun; Peng, Cheng; Gao, Xiaoxiao; Li, Bei; Shi, Zhengli] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Key Lab Special Pathogens, Wuhan 430071, Peoples R China.
   [Yu, Ting] WuHan Jinyintan Hosp, Wuhan 430023, Peoples R China.
   [Qu, Jieming; Zhou, Min; Xu, Yanping; Liu, Xuefei] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Resp & Crit Care Med, Sch Med, Shanghai 200025, Peoples R China.
   [Qu, Jieming; Zhou, Min; Xu, Yanping; Liu, Xuefei] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med, Sch Med, Shanghai 200025, Peoples R China.
   [Qu, Jieming; Zhou, Min; Xu, Yanping; Liu, Xuefei] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Resp Dis, Sch Med, Shanghai 200025, Peoples R China.
   [Chen, Li] Shanghai Jiao Tong Univ, Ruijin Hosp North, Clin Res Ctr, Dept Gastroenterol,Sch Med, Shanghai 200018, Peoples R China.
   [Yuan, Mingchao; Wang, Dan] Wuhan Blood Ctr, Wuhan 430030, Peoples R China.
   [Huang, Jinyan; Chen, Saijuan; Chen, Zhu] Shanghai Jiao Tong Univ, State Key Lab Med Genom, Shanghai Inst Hematol, Natl Res Ctr Translat Med,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
   [Yu, Xiaoqi; Zhang, Xinxin] Shanghai Jiao Tong Univ, Res Lab Clin Virol, Ruijin Hosp, Natl Res Ctr Translat Med,Sch Med, Shanghai 200025, Peoples R China.
   [Yu, Xiaoqi; Zhang, Xinxin] Shanghai Jiao Tong Univ, Res Lab Clin Virol, Ruijin Hosp North, Natl Res Ctr Translat Med,Sch Med, Shanghai 200025, Peoples R China.
   [Hou, Jifeng] Natl Inst Food & Drug Control China, Beijing 102629, Peoples R China.
RP Yang, XM (corresponding author), China Natl Biotec Grp Co Ltd, Beijing 100029, Peoples R China.; Yang, XM (corresponding author), Wuhan Inst Biol Prod Co Ltd, Natl Engn Technol Res Ctr Combined Vaccines, Wuhan 430207, Peoples R China.; Chen, Z (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Med Genom, Shanghai Inst Hematol, Natl Res Ctr Translat Med,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.; Zhang, XX (corresponding author), Shanghai Jiao Tong Univ, Res Lab Clin Virol, Ruijin Hosp, Natl Res Ctr Translat Med,Sch Med, Shanghai 200025, Peoples R China.; Zhang, XX (corresponding author), Shanghai Jiao Tong Univ, Res Lab Clin Virol, Ruijin Hosp North, Natl Res Ctr Translat Med,Sch Med, Shanghai 200025, Peoples R China.
EM zchen@stn.sh.cn; zhangx@shsmu.edu.cn; yangxiaoming@sinopharm.com
OI Yang, Xiaoming/0000-0002-2481-555X; chen, li/0000-0001-8492-1963
FU Key projects of the Ministry of Science and Technology China
   "Preparation of specific plasma and specific globulin from patients with
   a recovery period of COVID-19 infection" [2020YFC0841800]; Shanghai
   Guangci Translational Medicine Development Foundation
FX This study was funded by Key projects of the Ministry of Science and
   Technology China "Preparation of specific plasma and specific globulin
   from patients with a recovery period of COVID-19 infection" (Project
   2020YFC0841800). This work was also supported by Shanghai Guangci
   Translational Medicine Development Foundation. We thank all patients and
   donors involved in this study.
CR Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Benson AB, 2009, BRIT J HAEMATOL, V147, P431, DOI 10.1111/j.1365-2141.2009.07840.x
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Eickmann M, 2018, TRANSFUSION, V58, P2202, DOI 10.1111/trf.14652
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kong L K, 2006, Hong Kong Med J, V12, P489
   Lee P. I., J MICROBIOL IMMUNOL
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mora-Rillo M, 2015, LANCET RESP MED, V3, P554, DOI 10.1016/S2213-2600(15)00180-0
   National Health Commission of China, GUID DIAGN TREATM NO
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   WHO, COR DIS COVID 19 PAN
   Wong V. W. S., 2003, Hong Kong Medical Journal, V9, P199
   World Health Organization, CLIN MAN SEV AC RESP
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 31
TC 435
Z9 441
U1 19
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 28
PY 2020
VL 117
IS 17
BP 9490
EP 9496
DI 10.1073/pnas.2004168117
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LJ3WV
UT WOS:000530099500052
PM 32253318
OA Other Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Brunello, A
   Zagonel, V
AF Brunello, Antonella
   Zagonel, Vittorina
TI Caring for Patients with Advanced Stage Cancer at the Time of COVID-19
SO ONCOLOGIST
LA English
DT Letter
AB This letter to the editor alerts oncologists to the importance of accurately defining benefit-risk ratio during the COVID-19 pandemic for patients with advanced-stage cancer treated with chemotherapy after failure of first-line and second-line therapy.
C1 [Brunello, Antonella; Zagonel, Vittorina] IRCCS, Ist Oncol Veneto, Dept Oncol, Med Oncol Unit 1, Padua, Italy.
RP Brunello, A (corresponding author), IRCCS, Ist Oncol Veneto, Dept Oncol, Med Oncol Unit 1, Padua, Italy.
EM antonella.brunello@iov.veneto.it
RI Brunello, Antonella/F-4224-2014; zagonel, vittorina/F-4226-2014
OI Brunello, Antonella/0000-0003-2583-5226; zagonel,
   vittorina/0000-0002-0829-2525
CR [Anonymous], AG SEX EX COND COVID
   El Ramahi R, 2019, J ONCOL PRACT, V15, P177, DOI 10.1200/JOP.18.00567
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Schnipper LE, 2012, J CLIN ONCOL, V30, P1715, DOI 10.1200/JCO.2012.42.8375
   Simmons CPL, 2017, J PAIN SYMPTOM MANAG, V53, P962, DOI 10.1016/j.jpainsymman.2016.12.330
NR 5
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUL
PY 2020
VL 25
IS 7
BP E1131
EP E1131
DI 10.1634/theoncologist.2020-0230
EA APR 2020
PG 1
WC Oncology
SC Oncology
GA MI6PW
UT WOS:000529044100001
PM 32307803
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chen, QQ
   Zheng, ZC
   Zhang, C
   Zhang, XJ
   Wu, HJ
   Wang, JD
   Wang, SW
   Zheng, C
AF Chen, Qingqing
   Zheng, Zhencang
   Zhang, Chao
   Zhang, Xijiang
   Wu, Huijuan
   Wang, Jingdong
   Wang, Shuwei
   Zheng, Cheng
TI Clinical characteristics of 145 patients with corona virus disease 2019
   (COVID-19) in Taizhou, Zhejiang, China
SO INFECTION
LA English
DT Article
DE Corona virus disease 2019; COVID-19; SARS-CoV-2; Clinical
   characteristics; Epidemiology; Treatment; Outcomes
ID PNEUMONIA; WUHAN
AB Objective The aim of this study was to investigate the clinical characteristics of Corona Virus Disease 2019 in Taizhou, China. Methods A single center retrospective observational study was performed between Jan 1, 2020 and Mar 11, 2020 at Taizhou Public Health Medical Center, Zhejiang, China. All patients with confirmed Corona Virus Disease 2019 were enrolled, and their clinical data were gathered by reviewing electronic medical records. Outcomes of severely ill patients and non-severely ill patients were compared. Results Of 145 hospitalized patients with COVID-19, the average age was 47.5 years old (standard deviation, 14.6) and 54.5% were men. Hypertension was the most common comorbidity (15.2%), followed by diabetes mellitus (9.7%). Common symptoms included dry cough (81.4%), fever (75.2%), anorexia (42.8%), fatigue (40.7%), chest tightness (32.4%), diarrhea (26.9%) and dizziness (20%). According to imaging examination, 79.3% patients showed bilateral pneumonia, 18.6% showed unilateral pneumonia, 61.4% showed ground-glass opacity, and 2.1% showed no abnormal result. Compared with non-severely ill patients, severely ill patients were older (mean, years, 52.8 vs. 45.3, p < 0.01), had a higher proportion of diabetes mellitus (16.3% vs. 6.9%, p = 0.08), had a higher body mass index (mean, 24.78 vs. 23.20, p = 0.02) and were more likely to have fever (90.7% vs. 68.6%, p = 0.01), anorexia (60.5% vs. 35.3%, p = 0.01), chest tightness (60.5% vs.20.6%, p < 0.01) and dyspnea (7.0% vs. 0%, p = 0.03). Of the 43 severely ill patients, 6 (14%) received high-flow nasal cannula oxygen therapy, and 1 (2.3%) received invasive mechanical ventilation. Conclusions Older patients or patients with comorbidities such as obesity or diabetes mellitus were more likely to have severe condition. Treatments of COVID-19 is still experimental and more clinical trials are needed.
C1 [Chen, Qingqing; Zheng, Zhencang; Zhang, Chao; Wang, Jingdong; Wang, Shuwei] Enze Hosp, Dept Crit Care Med, Taizhou Enze Med Ctr Grp, Taizhou 318050, Zhejiang, Peoples R China.
   [Zhang, Xijiang; Zheng, Cheng] Taizhou Municipal Hosp, Dept Crit Care Med, Taizhou 318000, Zhejiang, Peoples R China.
   [Wu, Huijuan] Luqiao Hosp, Dept Crit Care Med, Taizhou Enze Med Ctr Grp, Taizhou 318050, Zhejiang, Peoples R China.
RP Zheng, C (corresponding author), Taizhou Municipal Hosp, Dept Crit Care Med, Taizhou 318000, Zhejiang, Peoples R China.
EM dr.zhengcheng@foxmail.com
RI ; Quevedo-Teruel, Oscar/O-7714-2018
OI Mesa, Francisco/0000-0001-8943-9068; Quevedo-Teruel,
   Oscar/0000-0002-4900-4788; Chen, Qingkun/0000-0002-8003-3149; CHEN,
   QIAN/0000-0002-5899-9342; Zheng, Cheng/0000-0002-9472-1807
FU Medical Health Science and Technology Project of Zhejiang Provincial
   Health Commission [2019KY781]
FX This work was supported in part by grants from the Medical Health
   Science and Technology Project of Zhejiang Provincial Health Commission
   (No. 2019KY781, XJ Zhang).
CR [Anonymous], 2019, REP CLUST PNEUM UNK
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   National Health Commission of People's Republic of China, DIAGN TREATM PNEUM C
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, COR DIS COVID 2019 S
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wuhan Municipal Health Commission, 2020, REP NOV COR INF PNEU
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 24
TC 46
Z9 46
U1 4
U2 20
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD AUG
PY 2020
VL 48
IS 4
BP 543
EP 551
DI 10.1007/s15010-020-01432-5
EA APR 2020
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA MU2BA
UT WOS:000529129500001
PM 32342479
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Wang, Y
   Jiang, WW
   He, Q
   Wang, C
   Wang, BJ
   Zhou, P
   Dong, NG
   Tong, QX
AF Wang, Yin
   Jiang, Weiwei
   He, Qi
   Wang, Cheng
   Wang, Baoju
   Zhou, Pan
   Dong, Nianguo
   Tong, Qiaoxia
TI A retrospective cohort study of methylprednisolone therapy in severe
   patients with COVID-19 pneumonia
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Letter
C1 [Wang, Yin; Dong, Nianguo] Huazhong Univ Sci & Technol, Union Hosp, Dept Cardiovasc Surg, Tongji Med Coll, Wuhan 43000, Peoples R China.
   [Jiang, Weiwei; He, Qi] Huazhong Univ Sci & Technol, Union Hosp, Dept Gastroenterol, Tongji Med Coll, Wuhan 43000, Peoples R China.
   [Wang, Cheng] Huazhong Univ Sci & Technol, Union Hosp, Dept Rheumatol, Tongji Med Coll, Wuhan 43000, Peoples R China.
   [Wang, Baoju; Tong, Qiaoxia] Huazhong Univ Sci & Technol, Union Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan 43000, Peoples R China.
   [Zhou, Pan] Huazhong Univ Sci & Technol, Union Hosp, Dept Hand Surg, Tongji Med Coll, Wuhan 43000, Peoples R China.
RP Dong, NG (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Cardiovasc Surg, Tongji Med Coll, Wuhan 43000, Peoples R China.; Tong, QX (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan 43000, Peoples R China.
EM dongnianguo63@gmail.com; 2013xh0859@hust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81700317]
FX We acknowledge the National Natural Science Foundation of China for the
   financial support (NO.81700317).
CR Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 5
TC 33
Z9 33
U1 3
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD APR 28
PY 2020
VL 5
IS 1
AR 57
DI 10.1038/s41392-020-0158-2
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LH9IH
UT WOS:000529096300001
PM 32341331
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gossling, S
   Scott, D
   Hall, CM
AF Gossling, Stefan
   Scott, Daniel
   Hall, C. Michael
TI Pandemics, tourism and global change: a rapid assessment of COVID-19
SO JOURNAL OF SUSTAINABLE TOURISM
LA English
DT Article
DE Global change; COVID-19; pandemic; crisis; travel restrictions; tourism
   demand; resilience
ID MACROECONOMIC IMPACT; BIODIVERSITY LOSS; 1918 INFLUENZA; HEALTH; TRAVEL;
   GLOBALIZATION; INTERVENTIONS; URBANIZATION; CONSEQUENCES; MORTALITY
AB The novel coronavirus (COVID-19) is challenging the world. With no vaccine and limited medical capacity to treat the disease, nonpharmaceutical interventions (NPI) are the main strategy to contain the pandemic. Unprecedented global travel restrictions and stay-at-home orders are causing the most severe disruption of the global economy since World War II. With international travel bans affecting over 90% of the world population and wide-spread restrictions on public gatherings and community mobility, tourism largely ceased in March 2020. Early evidence on impacts on air travel, cruises, and accommodations have been devastating. While highly uncertain, early projections from UNWTO for 2020 suggest international arrivals could decline by 20 to 30% relative to 2019. Tourism is especially susceptible to measures to counteract pandemics because of restricted mobility and social distancing. The paper compares the impacts of COVID-19 to previous epidemic/pandemics and other types of global crises and explores how the pandemic may change society, the economy, and tourism. It discusses why COVID-19 is an analogue to the ongoing climate crisis, and why there is a need to question the volume growth tourism model advocated by UNWTO, ICAO, CLIA, WTTC and other tourism organizations.
C1 [Gossling, Stefan] Western Norway Res Inst, Sogndal, Norway.
   [Gossling, Stefan] Lund Univ, Serv Management & Serv Studies, Helsingborg, Sweden.
   [Gossling, Stefan] Linnaeus Univ, Sch Business & Econ, Kalmar, Sweden.
   [Scott, Daniel] Univ Waterloo, Dept Geog & Environm Management, Waterloo, ON, Canada.
   [Scott, Daniel] Univ Surrey, Sch Hospitality & Tourism Management, Guildford, Surrey, England.
   [Hall, C. Michael] Univ Canterbury, Dept Management Mkt & Entrepreneurship, Christchurch, New Zealand.
RP Gossling, S (corresponding author), Western Norway Res Inst, Sogndal, Norway.; Gossling, S (corresponding author), Lund Univ, Serv Management & Serv Studies, Helsingborg, Sweden.; Gossling, S (corresponding author), Linnaeus Univ, Sch Business & Econ, Kalmar, Sweden.
EM stefan.gossling@lnu.se
RI , Polly/AAX-2742-2020; Hall, Colin Michael/C-1439-2010
OI Gossling, Stefan/0000-0003-0505-9207; Scott, Daniel/0000-0001-7825-9301;
   Hall, Colin Michael/0000-0002-7734-4587
CR Air New Zealand, 2020, COVID 19 FAQS
   Airports Council International, 2020, IMP COVID 19 AIRP BU
   Al-Tawfiq JA, 2014, TRAVEL MED INFECT DI, V12, P422, DOI 10.1016/j.tmaid.2014.06.007
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, COMMUNICATION
   [Anonymous], 2020, BUSINESS INSIDER
   [Anonymous], 2020, NAT COR RESP ROAD MA
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Baldwin R., 2020, EC TIME COVID 19, P1
   Banister D, 2004, TRANSPORT REV, V24, P611, DOI 10.1080/0144164042000206060
   Barlow J, 2016, NATURE, V535, P144, DOI 10.1038/nature18326
   Barry M., 2004, J TRANSL MED, V2, DOI [10.1186/1479-5876-2-3, DOI 10.1186/1479-5876-2-3]
   Berry M, 2015, VIRUSES-BASEL, V7, P996, DOI 10.3390/v7030996
   Bloom DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00549
   Bloomberg, 2020, BRENT CRUD
   Browne A, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/tav002
   Burkle F.M., 2006, J INT AFF, V59, P231
   Burns A., 2006, EVALUATING EC CONSEQ
   Byerly CR, 2010, PUBLIC HEALTH REP, V125, P82
   Carbon Brief, 2020, AIRLINES LOBBY REWRI
   Chowell G, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0196-0
   CNN, 2020, CNN
   Cohen SA, 2018, TRANSPORT RES D-TR E, V61, P406, DOI 10.1016/j.trd.2017.01.004
   Coker RJ, 2011, LANCET, V377, P599, DOI 10.1016/S0140-6736(10)62004-1
   Conde Nast Traveller, 2020, COR HAS EMPT TOUR AT
   Cordesmeyer M., 2011, CRUISE SECTOR CHALLE, P127
   Dodds R., 2019, OVERTOURISM ISSUES R
   DOWNS A, 1972, PUBLIC INTEREST, P38
   Euractiv, 2020, COR HIT CARM URG EU
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Fan VY, 2018, B WORLD HEALTH ORGAN, V96, P129, DOI 10.2471/BLT.17.199588
   Fauci AS, 2012, NEW ENGL J MED, V366, P454, DOI 10.1056/NEJMra1108296
   FCO (The Foreign & Commonwealth Office), 2020, FOR SECR ADV ALL BRI
   Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795
   FlightRadar24, 2020, FLIGHTRADAR24
   Forbes, 2020, FORBES
   Garrett T. A., 2008, EC EFFECTS 1918 INFL, DOI [10.20955/r.90.74-94, DOI 10.20955/R.90.74-94]
   Gossling S, 2002, GLOBAL ENVIRON CHANG, V12, P283, DOI 10.1016/S0959-3780(02)00044-4
   Gossling S., 2020, CURRENT ISSUES TOURI, DOI [10.1080/13683500.2020.1749244, DOI 10.1080/13683500.2020.1749244]
   Gossling S, 2016, J SUSTAIN TOUR, V24, P527, DOI 10.1080/09669582.2015.1085869
   Greger M, 2007, CRIT REV MICROBIOL, V33, P243, DOI 10.1080/10408410701647594
   GWPF, 2020, SOS EU URG PUT EC SU
   Hall C. M., 2002, Current Issues in Tourism, V5, P458, DOI 10.1080/13683500208667935
   Hall C.M., 2013, SUSTAINABLE CULINARY
   Hall C.M., 2020, HDB GLOBALISATION TO, P114
   Hall CM, 2019, J SUSTAIN TOUR, V27, P1044, DOI 10.1080/09669582.2018.1560456
   Hall CM, 2005, CONTEMP GEOGR LEIS T, P142
   Hall CM, 2009, ANATOLIA, V20, P46, DOI 10.1080/13032917.2009.10518894
   Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104
   Holtenius Jonas, 2014, Infection Ecology & Epidemiology, V4, P21528, DOI 10.3402/iee.v4.21528
   Hon KL, 2013, TRAVEL MED INFECT DI, V11, P285, DOI 10.1016/j.tmaid.2013.06.005
   Hopkins J, 2020, CORONAVIRUS COVID 19
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IATA, 2019, CHALL YEAR IMPR EXP
   IATA, 2018, EC PERF AIRL IND
   IATA Economics, 2020, COVID 19 UPD IMP ASS
   International SOS Security Services, 2020, COR DIS COVID 19 PAN
   International SOS Security Services, 2020, TRAV RESTR FLIGHT OP
   Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022
   Jonas O., 2014, PANDEMIC RISK
   Keogh-Brown MR, 2010, HEALTH ECON, V19, P1345, DOI 10.1002/hec.1554
   Keogh-Brown MR, 2010, EUR J HEALTH ECON, V11, P543, DOI 10.1007/s10198-009-0210-1
   Khan K, 2009, NEW ENGL J MED, V361, P212, DOI 10.1056/NEJMc0904559
   Killingray David, 2003, CARIBBEAN Q, V49, P30
   Kopnina H, 2020, EURO-MEDITERR J ENVI, V5, DOI 10.1007/s41207-019-0139-4
   Kristiansen IS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-48
   Labonte R, 2011, ANNU REV PUBL HEALTH, V32, P263, DOI 10.1146/annurev-publhealth-031210-101225
   Lade SJ, 2020, NAT SUSTAIN, V3, P119, DOI 10.1038/s41893-019-0454-4
   Lee CC, 2011, TOURISM MANAGE, V32, P1421, DOI 10.1016/j.tourman.2010.12.009
   Lenton TM, 2019, NATURE, V575, P592, DOI 10.1038/d41586-019-03595-0
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Mallapaty Smriti, 2020, Nature, V580, P18, DOI 10.1038/d41586-020-00885-w
   Maphanga P.M., 2019, AFRICAN J HOSPITALIT, V8
   Markel H, 2007, JAMA-J AM MED ASSOC, V298, P644, DOI 10.1001/jama.298.6.644
   Markel H, 2006, EMERG INFECT DIS, V12, P1961
   McKercher B, 2004, ANN TOURISM RES, V31, P716, DOI 10.1016/j.annals.2003.11.002
   McKibbin W. J., 2006, GLOBAL MACROECONOMIC
   McKibbin Warwick, 2020, 192020 CAMA AUSTR NA
   McKinsey and Company, 2020, CAUT OPT CHIN CONS B
   McKinsey and Company, 2020, NEAR TERM IMP COR WO
   McKinsey and Company, 2020, GLOB SURV CONS SENT
   Moriarty LF, 2020, MMWR-MORBID MORTAL W, V69, P347, DOI 10.15585/mmwr.mm6912e3
   National Academies of Sciences Engineering and Medicine, 2018, UND EC MICR THREATS
   National Academies of Sciences Engineering and Medicine; Health and Medicine Division; Board on Global Health; Committee on Global Health and the Future of the United States, 2017, GLOB HLTH FUT ROL US
   NHO Reiseliv, 2020, KOR AN REIS
   Nicolaides C, 2020, RISK ANAL, V40, P723, DOI 10.1111/risa.13438
   Novelli M, 2018, ANN TOURISM RES, V70, P76, DOI 10.1016/j.annals.2018.03.006
   OECD, 2012, LIV DIS PREV CONTR C, DOI [10.1787/9789264178762-en, DOI 10.1787/9789264178762-EN]
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068
   Page S., 2007, J BUS CONTIN EMER PL, V1, P167
   Peasah SK, 2013, VACCINE, V31, P5339, DOI 10.1016/j.vaccine.2013.09.013
   Petersen E, 2016, INT J INFECT DIS, V44, P11, DOI 10.1016/j.ijid.2016.02.001
   Piketty T, 2015, AM ECON REV, V105, P48, DOI 10.1257/aer.p20151060
   Pongsiri MJ, 2009, BIOSCIENCE, V59, P945, DOI 10.1525/bio.2009.59.11.6
   Prager F, 2017, RISK ANAL, V37, P4, DOI 10.1111/risa.12625
   Rassy D, 2013, HEALTH ECON, V22, P824, DOI 10.1002/hec.2862
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Schmidt CW, 2016, ENVIRON HEALTH PERSP, V124, pA157, DOI 10.1289/ehp.124-A157
   Schouten G, 2012, ECOL ECON, V83, P42, DOI 10.1016/j.ecolecon.2012.08.007
   Scott D, 2019, ANN TOURISM RES, V77, P49, DOI 10.1016/j.annals.2019.05.007
   Scott D, 2015, TOUR RECREAT RES, V40, P269, DOI 10.1080/02508281.2015.1075739
   Seraphin H, 2018, J DESTIN MARK MANAGE, V9, P374, DOI 10.1016/j.jdmm.2018.01.011
   Simple Flying, 2020, UN COULD FOLL AM EAR
   Siu A, 2004, ASIAN ECON PAP, V3, P62, DOI DOI 10.1162/1535351041747996
   Stay Grounded, 2020, SAVEPEOPLENOTPLANES
   Stay Grounded, 2020, NO UNC AIRL BAIL TAK
   STR, 2020, US HOT REVPAR FOR DR
   STR. (, 2020, COVID 19 HOT IND IMP
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   The World Bank, 2012, PEOPL PATH OUR PLAN, V2
   The World Bank, 2020, AIR TRANSP PASS CARR
   UNWTO, 2020, COVID 19 UNWTO CALLS
   UNWTO (United Nations World Tourism Organisation), 2020, INT TOUR ARR COULD F
   US Bureau of Labor Statistics, 2020, NONF PAYR EMPL FALLS
   Veterinaires sans Frontieres (VSF) Suisse, 2018, LIV DIS SURV EARL WA
   Viboud C, 2012, LANCET INFECT DIS, V12, P651, DOI 10.1016/S1473-3099(12)70152-4
   World Bank, 2020, INT TOUR NUMB ARR
   Wu T, 2017, AMBIO, V46, P18, DOI 10.1007/s13280-016-0809-2
NR 118
TC 156
Z9 156
U1 152
U2 199
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0966-9582
EI 1747-7646
J9 J SUSTAIN TOUR
JI J. Sustain. Tour.
PD OCT 13
PY 2020
VL 29
IS 1
BP 1
EP 20
DI 10.1080/09669582.2020.1758708
EA APR 2020
PG 20
WC Green & Sustainable Science & Technology; Hospitality, Leisure, Sport &
   Tourism
SC Science & Technology - Other Topics; Social Sciences - Other Topics
GA OD0BP
UT WOS:000532557100001
OA Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Ali, FR
   Al-Niaimi, F
AF Ali, Faisal R.
   Al-Niaimi, Firas
TI Noncutaneous considerations of COVID-19 for dermatology practices
SO JOURNAL OF COSMETIC DERMATOLOGY
LA English
DT Letter
DE Coronavirus; COVID-19; dermatology; teledermatology
AB COVID-19 presents many pressing challenges to the global dermatological community and our patients with ongoing skin needs, which must be considered by every dermatology provider. Many of these are logistical and administrative, distinct from physical manifestations, and could be summarized by the acronym COVID (Consultations, Operations, Videoconferencing, Immunosuppressive medications, Drug and equipment shortages). While the pandemic may represent a threat to many parts of our existence, dermatologists can help the patients we care for by considering noncutaneous implications of COVID-19 upon our practice.
C1 [Ali, Faisal R.] Vernova Healthcare Community Interest Co, Macclesfield SK11 6JL, Cheshire, England.
   [Al-Niaimi, Firas] 152 Harley St, London, England.
RP Ali, FR (corresponding author), Vernova Healthcare Community Interest Co, Macclesfield SK11 6JL, Cheshire, England.
EM f.r.ali.01@cantab.net
OI Ali, Faisal/0000-0002-8588-791X
CR Ali FR, 2011, NATURE, V475, P455, DOI 10.1038/475455d
   Shah P, 2020, J AM ACAD DERMATOL, V82, pE203, DOI 10.1016/j.jaad.2020.03.056
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1473-2130
EI 1473-2165
J9 J COSMET DERMATOL-US
JI J. Cosmet. Dermatol.
PD JUL
PY 2020
VL 19
IS 7
BP 1544
EP 1544
DI 10.1111/jocd.13444
EA APR 2020
PG 1
WC Dermatology
SC Dermatology
GA LZ4YE
UT WOS:000528812700001
PM 32298514
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Schulze-Koops, H
   Holle, J
   Moosig, F
   Specker, C
   Aries, P
   Burmester, G
   Fiehn, C
   Hoyer, B
   Krause, A
   Leipe, J
   Lorenz, HM
   Schneider, M
   Sewerin, P
   Voormann, A
   Wager, U
   Kruger, K
   Iking-Konert, C
AF Schulze-Koops, H.
   Holle, J.
   Moosig, F.
   Specker, C.
   Aries, P.
   Burmester, G.
   Fiehn, C.
   Hoyer, B.
   Krause, A.
   Leipe, J.
   Lorenz, H. -M.
   Schneider, M.
   Sewerin, P.
   Voormann, A.
   Wager, U.
   Krueger, K.
   Iking-Konert, C.
CA Kommission Pharmakotherapie
TI Current guidance of the German Society of Rheumatology for the care of
   patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE SARS-CoV-2; COVID-19; Therapy Management; Recommendations; Inflammatory
   diseases
AB In the current SARS-CoV-2 pandemic there are many questions regarding the safe treatment of patients with inflammatory rheumatic diseases. Many of these questions cannot yet be answered on an evidence-based basis and this does not make patient care easy. The German Society for Rheumatology (DGRh) hopes that these initial recommendations will provide support for specific issues in the care of patients with inflammatory rheumatic diseases in view of the current threat posed by SARS-CoV-2. In order to take advantage of the dynamic worldwide gain in knowledge for our patients, the recommendations will be updated regularly. The updated versions of the recommendations are deposited on the homepage of the DGRh.
C1 [Schulze-Koops, H.; Specker, C.; Krause, A.; Lorenz, H. -M.; Voormann, A.; Wager, U.] Deutsch Gesell Rheumatol eV, Berlin, Germany.
   [Schulze-Koops, H.] Ludwig Maximilians Univ Munchen, Med Klin 4, Sekt Rheumatol & Klin Immunol, Pettenkoferstr 8a, Munich, Germany.
   [Holle, J.] Rheumazentrum Schleswig Holstein Mitte, Neumunster, Germany.
   [Specker, C.] Kliniken Essen Mitte, Klin Rheumatol & Klin Immunol, Essen, Germany.
   [Aries, P.] Rheumatol Struenseehaus, Hamburg, Germany.
   [Burmester, G.] Charite Univ Med Berlin, Klin Rheumatol & Klin Immunol, Berlin, Germany.
   [Burmester, G.] Freie Univ, Berlin, Germany.
   [Burmester, G.] Humboldt Univ, Berlin, Germany.
   [Fiehn, C.] Med Ctr Baden Baden, Baden, Switzerland.
   [Fiehn, C.] ViDia Kliniken Karlsruhe, Praxis Rheumatol & Klin Immunol, Baden, Switzerland.
   [Hoyer, B.] Univ Krankenhaus Schleswig, Med Klin 1, Abteilung Rheumatol, Holstein Campus Kiel, Kiel, Germany.
   [Krause, A.] Immanuel Krankenhaus Berlin, Abteilung Rheumatol Osteol & Klin Immunol, Berlin, Germany.
   [Leipe, J.] Univ Kransenhaus Mannheim, Med Klin 5, Abt Rheumatol, Mannheim, Germany.
   [Lorenz, H. -M.] Univ Klinikum Heidelberg, Med Klin 5, Abt Rheumatol, Heidelberg, Germany.
   [Schneider, M.; Sewerin, P.] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Poliklin Funkt Bereich & Hiller Forschungszentrum, Dusseldorf, Germany.
   [Wager, U.] Univ Klinikum Leipzig, Klin & Poliklin Endokrinol Nephrol, Rheumatol, Abt Rheumatol, Leipzig, Germany.
   [Krueger, K.] Kommiss Pharmakotherapie DGRh eV, Rheumatol Praxiszentrum, St Bonifatius Str 5, D-81541 Munich, Germany.
   [Iking-Konert, C.] Univ Klinikum Hamburg Eppendorf, Sekt Rheumatol, Med Klin & Poliklin 3, Hamburg, Germany.
RP Schulze-Koops, H (corresponding author), Ludwig Maximilians Univ Munchen, Med Klin 4, Sekt Rheumatol & Klin Immunol, Pettenkoferstr 8a, Munich, Germany.; Kruger, K (corresponding author), Kommiss Pharmakotherapie DGRh eV, Rheumatol Praxiszentrum, St Bonifatius Str 5, D-81541 Munich, Germany.
EM Hendrik.Schulze-Koops@med.uni-muenchen.de;
   Klaus.Krueger@med.uni-muenchen.de
RI Aries, Peer/AAE-6166-2020; Burmester, Gerd R./AAY-7514-2020
NR 0
TC 7
Z9 5
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD MAY
PY 2020
VL 79
IS 4
SI SI
BP 385
EP 388
DI 10.1007/s00393-020-00799-y
EA APR 2020
PG 4
WC Rheumatology
SC Rheumatology
GA LK4DG
UT WOS:000528966300001
PM 32342184
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Singh, AG
   Deodhar, J
   Chaturvedi, P
AF Singh, Arjun Gurmeet
   Deodhar, Jayita
   Chaturvedi, Pankaj
TI Navigating the impact of COVID-19 on palliative care for head and neck
   cancer
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE coronavirus; COVID-19; head neck; palliative care; pandemic
AB Health care services are being confronted by a daily dilemma of who can receive critical care and who cannot. In a palliative care clinic, this apprehension gets exemplified, as these patients have limited life expectancy. The head and neck region further makes things critical, as it comprises of all the sites through which the SARS-CoV-2 can be transmitted. This document strives to define the ways in which the head and neck cancer services can contribute to better patient care in a triage context. Practical steps suggested are protective equipment use, ensuring access to critical drugs (such as opioids), greater use of telemedicine consultations, discussing advance care plans, and embracing the role of a wider community support.
C1 [Singh, Arjun Gurmeet; Chaturvedi, Pankaj] Tata Mem Ctr & HBNI, Dept Head & Neck Oncol, Mumbai, Maharashtra, India.
   [Deodhar, Jayita] Tata Mem Ctr & HBNI, Dept Palliat Med, Mumbai, Maharashtra, India.
RP Chaturvedi, P (corresponding author), Tata Mem Ctr & HBNI, Dept Head & Neck Oncol, Mumbai, Maharashtra, India.
EM chaturvedi.pankaj@gmail.com
OI Singh, Arjun/0000-0002-8119-8439
CR al CPH, TRACH PROT COVID 19
   Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], 2020, GUARDIAN
   [Anonymous], CRUC MED PROT COR CO
   Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581
   Connor S, 2014, GLOBAL ATLAS PALLIAT
   Lawson BJ, 2008, J PALLIAT CARE, V24, P247, DOI 10.1177/082585970802400404
NR 7
TC 4
Z9 4
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUN
PY 2020
VL 42
IS 6
BP 1144
EP 1146
DI 10.1002/hed.26211
EA APR 2020
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA LU5GY
UT WOS:000528687000001
PM 32338809
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ranasinghe, V
   Mady, LJ
   Kim, S
   Ferris, RL
   Duvvuri, U
   Johnson, JT
   Solari, MG
   Sridharan, S
   Kubik, M
AF Ranasinghe, Viran
   Mady, Leila J.
   Kim, Seungwon
   Ferris, Robert L.
   Duvvuri, Umamaheswar
   Johnson, Jonas T.
   Solari, Mario G.
   Sridharan, Shaum
   Kubik, Mark
TI Major head and neck reconstruction during the COVID-19 pandemic: The
   University of Pittsburgh approach
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
   NECK
LA English
DT Article
DE coronavirus; COVID-19; head and neck reconstruction; microvascular
AB The 2019 novel coronavirus (COVID-19) pandemic has created significant challenges to the delivery of care for patients with advanced head and neck cancer requiring multimodality therapy. Performing major head and neck ablative surgery and reconstruction is a particular concern given the extended duration and aerosolizing nature of these cases. In this manuscript, we describe our surgical approach to provide timely reconstructive care and minimize infectious risk to the providers, patients, and families.
C1 [Ranasinghe, Viran; Mady, Leila J.; Kim, Seungwon; Ferris, Robert L.; Duvvuri, Umamaheswar; Johnson, Jonas T.; Solari, Mario G.; Sridharan, Shaum; Kubik, Mark] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA USA.
   [Solari, Mario G.; Sridharan, Shaum; Kubik, Mark] Univ Pittsburgh, Med Ctr, Dept Plast Surg, Pittsburgh, PA USA.
RP Kubik, M (corresponding author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Inst Eye & Ear, Suite 500 200 Lothrop St, Pittsburgh, PA 15213 USA.
EM kubikmw2@upmc.edu
RI Duvvuri, Umamaheswar/AAN-7973-2020
OI Duvvuri, Umamaheswar/0000-0003-1968-3756; Ferris,
   Robert/0000-0001-6605-2071
CR Cai TY, 2020, HEAD NECK-J SCI SPEC, V42, P476, DOI 10.1002/hed.26028
   Hanasono MM, 2013, LARYNGOSCOPE, V123, P597, DOI 10.1002/lary.23717
   Hanasono MM, 2010, PLAST RECONSTR SURG, V125, P1413, DOI 10.1097/PRS.0b013e3181d62aef
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Ong JJY, 2020, HEADACHE, V60, P864, DOI 10.1111/head.13811
   Patel UA, 2017, JAMA OTOLARYNGOL, V143, P803, DOI 10.1001/jamaoto.2017.0304
   Rebmann T, 2013, AM J INFECT CONTROL, V41, P1218, DOI 10.1016/j.ajic.2013.02.017
   Shnayder Y, 2015, JAMA FACIAL PLAST SU, V17, P367, DOI 10.1001/jamafacial.2015.0825
   Vargas M, 2020, HEAD NECK-J SCI SPEC, V42, P1278, DOI 10.1002/hed.26163
   Vukkadala N, 2020, LARYNGOSCOPE, V130, P2537, DOI 10.1002/lary.28672
NR 10
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
EI 1097-0347
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD JUN
PY 2020
VL 42
IS 6
BP 1243
EP 1247
DI 10.1002/hed.26207
EA APR 2020
PG 5
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA LU5GY
UT WOS:000528689600001
PM 32338790
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tang, N
   Bai, H
   Chen, X
   Gong, JL
   Li, DJ
   Sun, ZY
AF Tang, Ning
   Bai, Huan
   Chen, Xing
   Gong, Jiale
   Li, Dengju
   Sun, Ziyong
TI Anticoagulant treatment is associated with decreased mortality in severe
   coronavirus disease 2019 patients with coagulopathy
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE coagulopathy; coronavirus disease 2019; D-dimer; low molecular weight
   heparin; sepsis
ID DISSEMINATED INTRAVASCULAR COAGULATION; SEPTIC SHOCK; SEPSIS;
   THROMBOEMBOLISM; GUIDELINES; THERAPY
AB Background A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.
   Methods Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result.
   Results There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score >= 4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017).
   Conclusions Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.
C1 [Tang, Ning; Bai, Huan; Chen, Xing; Gong, Jiale; Sun, Ziyong] Huazhong Univ Sci & Technol, Dept Clin Lab, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   [Li, Dengju] Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
RP Sun, ZY (corresponding author), Huazhong Univ Sci & Technol, Dept Clin Lab, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
EM 499388475@qq.com
FU National Mega Project on Major Infectious Disease Prevention of China
   [2017ZX10103005-007]
FX National Mega Project on Major Infectious Disease Prevention of China,
   Grant/Award Number: 2017ZX10103005-007
CR Aikawa N, 2011, SHOCK, V35, P349, DOI 10.1097/SHK.0b013e318204c019
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2014, J THROMB HAEMOST, V12, P1010, DOI 10.1111/jth.12596
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Iba T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017046
   Levi M, 2017, THROMB RES, V149, P38, DOI 10.1016/j.thromres.2016.11.007
   Liu XL, 2014, EXP THER MED, V7, P604, DOI 10.3892/etm.2013.1466
   Luo W, 2020, CLIN PATHOLOGY CRITI, DOI DOI 10.1016/S1473-3099(20)30086-4
   Menter DG, 2017, CANCER METAST REV, V36, P199, DOI 10.1007/s10555-017-9682-0
   National Health Commission of China, 2020, DIANG TREAT PLAN NOV
   Nishida O, 2018, ACUTE MED SURG, V5, P3, DOI 10.1002/ams2.322
   Poterucha TJ, 2017, THROMB HAEMOSTASIS, V117, P437, DOI 10.1160/TH16-08-0620
   Schmitt FCF, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0499-6
   Shanghai Novel Coronavirus Disease Clinical Treatment Expert Group, 2020, CHIN J INFECT DIS, P38, DOI [10.3760/cma.j.issn.1000-6680.2020.0016, DOI 10.3760/CMA.J.ISSN.1000-6680.2020.0016]
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stein PD, 2004, AM J MED, V116, P435, DOI 10.1016/j.amjmed.2003.11.020
   Sun HM, 2009, BLOOD, V113, P1358, DOI 10.1182/blood-2008-07-170506
   Umemura Y, 2016, J THROMB HAEMOST, V14, P518, DOI 10.1111/jth.13230
   Venclauskas L, 2018, EUR J ANAESTH, V35, P134, DOI 10.1097/EJA.0000000000000706
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   WHO, 2020, CLIN MAN SEV AC RESP
   Zakai NA, 2011, J THROMB HAEMOST, V9, P1877, DOI 10.1111/j.1538-7836.2011.04443.x
NR 26
TC 166
Z9 184
U1 24
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD MAY
PY 2020
VL 18
IS 5
BP 1094
EP 1099
DI 10.1111/jth.14817
EA APR 2020
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA LI2ER
UT WOS:000528704600001
PM 32220112
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Al-Shamsi, HO
   Alhazzani, W
   Alhuraiji, A
   Coomes, EA
   Chemaly, RF
   Almuhanna, M
   Wolff, RA
   Ibrahim, NK
   Chua, MLK
   Hotte, SJ
   Meyers, BM
   Elfiki, T
   Curigliano, G
   Eng, C
   Grothey, A
   Xie, CH
AF Al-Shamsi, Humaid O.
   Alhazzani, Waleed
   Alhuraiji, Ahmad
   Coomes, Eric A.
   Chemaly, Roy F.
   Almuhanna, Meshari
   Wolff, Robert A.
   Ibrahim, Nuhad K.
   Chua, Melvin L. K.
   Hotte, Sebastien J.
   Meyers, Brandon M.
   Elfiki, Tarek
   Curigliano, Giuseppe
   Eng, Cathy
   Grothey, Axel
   Xie, Conghua
TI A Practical Approach to the Management of Cancer Patients During the
   Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International
   Collaborative Group
SO ONCOLOGIST
LA English
DT Article
DE Coronavirus; COVID-19; Influenza; Neoplasm; Pandemic; SARS-CoV-2
ID RESPIRATORY VIRAL-INFECTIONS; VIRUS; CHEMOTHERAPY; IMPACT; DIAGNOSIS
AB The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches.
   Implications for Practice The main management strategies for treating cancer patients during the COVID-19 epidemic include clear communication and education about hand hygiene, infection control measures, high-risk exposure, and the signs and symptoms of COVID-19. Consideration of risk and benefit for active intervention in the cancer population must be individualized. Postponing elective surgery or adjuvant chemotherapy for cancer patients with low risk of progression should be considered on a case-by-case basis. Minimizing outpatient visits can help to mitigate exposure and possible further transmission. Telemedicine may be used to support patients to minimize number of visits and risk of exposure. More research is needed to better understand SARS-CoV-2 virology and epidemiology.
C1 [Al-Shamsi, Humaid O.] Alzahra Hosp Dubai, Med Oncol Dept, Dubai, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Univ Sharjah, Dept Med, Sharjah, U Arab Emirates.
   [Al-Shamsi, Humaid O.] Emirates Oncol Soc, Dubai, U Arab Emirates.
   [Alhazzani, Waleed] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Alhazzani, Waleed] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Alhuraiji, Ahmad] Kuwait Canc Control Ctr, Dept Hematol, Kuwait, Kuwait.
   [Coomes, Eric A.] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada.
   [Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA.
   [Wolff, Robert A.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
   [Ibrahim, Nuhad K.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Almuhanna, Meshari] Min Sheng Gen Hosp, Taoyuan, Taiwan.
   [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Radiat Oncol, Singapore, Singapore.
   [Chua, Melvin L. K.] Natl Canc Ctr Singapore, Div Med Sci, Singapore, Singapore.
   [Chua, Melvin L. K.] Duke NUS Med Sch, Oncol Acad Program, Singapore, Singapore.
   [Chua, Melvin L. K.] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Singapore.
   [Hotte, Sebastien J.; Meyers, Brandon M.] McMaster Univ, Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada.
   [Elfiki, Tarek] Windsor Reg Canc Ctr, Windsor, ON, Canada.
   [Elfiki, Tarek] Univ Western Ontario, Schulich Sch Med, Dept Oncol, London, ON, Canada.
   [Curigliano, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
   [Curigliano, Giuseppe] Univ Milan, Div Early Drug Dev Innovat Therapy, Milan, Italy.
   [Curigliano, Giuseppe] European Inst Oncol, Milan, Italy.
   [Curigliano, Giuseppe] Univ Milan, IRCCS, Milan, Italy.
   [Eng, Cathy] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   [Grothey, Axel] Univ Tennessee, West Canc Ctr, Memphis, TN USA.
   [Xie, Conghua] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Peoples R China.
RP Al-Shamsi, HO (corresponding author), Univ Sharjah, Sharjah, U Arab Emirates.
EM Humaid.Al-Shamsi@medportal.ca
RI Chua, Melvin LK/ABG-6045-2020; Curigliano, Giuseppe/D-3371-2018
OI Chua, Melvin LK/0000-0002-1648-1473; Curigliano,
   Giuseppe/0000-0003-1781-2518; Reis, AlessanRSS/0000-0001-8486-7469; Eng,
   Cathy/0000-0003-2335-0612; Al-Shamsi, Humaid O./0000-0003-3819-0500
FU Khalifa Foundation, Abu Dhabi, United Arab Emirates; Roche
   Pharmaceuticals Middle East FZCO, Dubai, United Arab Emirates; National
   Medical Research CouncilMedical Research Council UK (MRC)
   [CSA/0027/2018]; Health Commission of Hubei Province [WJ2019H002]
FX Funding for this study was provided by the Khalifa Foundation, Abu
   Dhabi, United Arab Emirates and by Roche Pharmaceuticals Middle East
   FZCO, Dubai, United Arab Emirates to Humaid O. Al-Shamsi. Melvin L.K.
   Chua received funding from the National Medical Research Council
   Clinician-Scientist Award (CSA/0027/2018). Conghua Xie received funding
   from the Health Commission of Hubei Province Scientific Research Project
   (WJ2019H002). We express special appreciation to Ms. Fatma Al Falasi for
   her help with the illustration of the figures in this article.
CR Adams JG, 2020, JAMA
   Alpert A, 2019, CLIN PHARMACOL THER, V106, P415, DOI 10.1002/cpt.1390
   American College of Surgeons, REC PRIOR TREATM TRI
   American College of Surgeons, COVID 19 GUID TRIAG
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, CLIN GUIDE MANAGEMEN
   [Anonymous], VOX
   [Anonymous], CBC NEWS
   ASTRO, COVID 19 REC RAD ONC
   Battershill P M, 2006, Curr Oncol, V13, P119
   Blaschke AJ, 2011, J CLIN VIROL, V52, P210, DOI 10.1016/j.jcv.2011.07.015
   Bos ACRK, 2015, EUR J CANCER, V51, P2553, DOI 10.1016/j.ejca.2015.08.016
   Busta ER, 2017, NTEGRATING CLIN RES
   Campbell AP, 2015, CLIN INFECT DIS, V61, P192, DOI 10.1093/cid/civ272
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, INT CLIN GUID MAN PA
   Centers for DiseaseControl and Prevention, INT INF PREV CONTR R
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chemaly RF, 2014, CLIN INFECT DIS, V59, pS344, DOI 10.1093/cid/ciu623
   Chen YM, 2004, LUNG CANCER-J IASLC, V45, P39, DOI 10.1016/j.lungcan.2004.01.002
   Coronavirus disease COVID-19: EBMT recommendations (update march 23 2020), 2020, COR DIS COVID 19 EBM
   Dignan FL, 2016, BRIT J HAEMATOL, V173, P380, DOI 10.1111/bjh.14027
   Dignani Maria Cecilia, 2014, F1000Res, V3, P221, DOI 10.12688/f1000research.5251.1
   European Centre for Disease Prevention and Control, OUTBR NOV COR DIS 20
   Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6
   Guan WJ, 2020, N ENGL J MED
   Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844
   Hofheinz RD, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70116-X
   Lee I, 2007, DRUGS, V67, P1411, DOI 10.2165/00003495-200767100-00004
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mansfield SA, 2017, BREAST J, V23, P444, DOI 10.1111/tbj.12758
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Mukherjee R K, 2003, Australas Radiol, V47, P143, DOI 10.1046/j.0004-8461.2003.01165.x
   Nishiura H, 2020, INT J INFECT DIS
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, ZHONGHUA LIU XING BI, V41, P145
   Numico G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120827
   Ohrmalm L, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-340
   Onder G, 2020, JAMA
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Repici A, 2020, GASTROINTEST ENDOSC
   Shereen Nabhani-Gebara, 2019, Br J Community Nurs, V24, P482, DOI 10.12968/bjcn.2019.24.10.482
   Sim SA, 2018, BIOL BLOOD MARROW TR, V24, P1490, DOI 10.1016/j.bbmt.2018.03.004
   Sirintrapun S Joseph, 2018, Am Soc Clin Oncol Educ Book, V38, P540, DOI 10.1200/EDBK_200141
   Steinkuller F, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy053
   Stukel TA, 2008, MED CARE, V46, P991, DOI 10.1097/MLR.0b013e3181792525
   Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1
   The Cancer Letter, WHAT EXP ONC RESP CO
   The New York Times Coronavirus Map, NY TIMES
   U.S. Food & Drug Administration, COR COVID 19 UPD BLO
   U.S. Food & Drug Administration, FDA STAT COR COVID 1
   US Food and Drug Administration, FDA DRUG SHORT
   van Doremalen N, 2020, N ENGL J MED
   Ventola C Lee, 2011, P T, V36, P740
   Warr J, 2013, J ONCOL PRACT, V9, pE182, DOI 10.1200/JOP.2012.000719
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   WHO, COR DIS COVID 19 PAN
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, 2011, MAINT SAF AD BLOOD S
   World Health Organization, 2020, DIS OUTBR NEWS NOV C
   Worldometer, COVID 19 COR PAND
   Yang L., 2020, ZHONGHUA ZHONG LIU Z, V42, pE006
   Yu J, 2020, JAMA ONCOL
   Zou XC, 2017, CLIN COLORECTAL CANC, V16, pE123, DOI 10.1016/j.clcc.2017.01.009
NR 66
TC 127
Z9 130
U1 37
U2 51
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUN
PY 2020
VL 25
IS 6
BP E936
EP E945
DI 10.1634/theoncologist.2020-0213
EA APR 2020
PG 10
WC Oncology
SC Oncology
GA LW8TY
UT WOS:000528737400001
PM 32243668
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, SY
   Li, L
   Shen, AZ
   Chen, YW
   Qi, ZG
AF Zhang, Shengyu
   Li, Lei
   Shen, Aizong
   Chen, Yongwu
   Qi, Zhigang
TI Rational Use of Tocilizumab in the Treatment of Novel Coronavirus
   Pneumonia
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article
ID CYTOKINE RELEASE SYNDROME; T-CELL THERAPY
AB Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that & x2053; 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and "Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)" in China, so as to provide reference for the treatment of COVID-19.
C1 [Zhang, Shengyu; Shen, Aizong; Chen, Yongwu] Univ Sci & Technol China, Affiliated Hosp 1, Dept Pharm, Hefei 230001, Anhui, Peoples R China.
   [Li, Lei] Univ Sci & Technol China, Affiliated Hosp 1, Infect Dept, Hefei 230001, Anhui, Peoples R China.
   [Qi, Zhigang] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Pharm, Wuxi 214023, Jiangsu, Peoples R China.
RP Qi, ZG (corresponding author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Pharm, Wuxi 214023, Jiangsu, Peoples R China.
EM qizhigang058518@163.com
FU Wuxi Medical and Health Guidance Plan for scientific and technological
   development [NZ2019004]
FX The preparation of this review was supported by Wuxi Medical and Health
   Guidance Plan for scientific and technological development [Grant
   numbers NZ2019004].
CR Braun GS, 2016, J AM SOC NEPHROL, V27, P132, DOI 10.1681/ASN.2014111147
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Fei ZhiYong, 2019, Chinese Journal of Nosocomiology, V29, P380
   Ferfar Y, 2016, AUTOIMMUN REV, V15, P544, DOI 10.1016/j.autrev.2016.02.012
   FERRARA JLM, 1993, TRANSPLANT P, V25, P1216
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   General Office of the National Health Committee of China, 2020, CHIN TRAD CHIN MED A
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Liao H, 2019, Zhonghua Nei Ke Za Zhi, V58, P444, DOI 10.3760/cma.j.issn.0578-1426.2019.06.009
   Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/ 2020.02.16.20023671, DOI 10.1101/2020.02.16.20023671, 10.1101/2020.02.16.20023671]
   Ma YePing, 2019, Chinese Journal of Nosocomiology, V29, P1007
   Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866
   Nakaoka Y, 2018, ANN RHEUM DIS, V77, P348, DOI 10.1136/annrheumdis-2017-211878
   Rose-John S, 2017, CLIN PHARMACOL THER, V102, P591, DOI 10.1002/cpt.782
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Samson M, 2018, EUR J INTERN MED, V57, P96, DOI 10.1016/j.ejim.2018.06.008
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   The first affiliated hospital of university of science and technology, 2020, 1 AFFILIATED HOSP U
   The U.S. Food and Drug Administration, INF ACTEMRA TOC
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu K.J., 2020, ZHEJIANG DA XUE XUE
   Xu X, 2020, EFFECTIVE TREATMENT
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4
   Zhai Hu, 2018, Tianjin Medical Journal, V46, P952
   Zhang J.W., 2020, ZHONGGUO YAO XUE ZA
   [张艳丽 Zhang Yanli], 2015, [生命科学, Chinese Bulletin of Life Sciences], V27, P554
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
NR 35
TC 39
Z9 40
U1 3
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-2563
EI 1179-1918
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PD JUN
PY 2020
VL 40
IS 6
BP 511
EP 518
DI 10.1007/s40261-020-00917-3
EA APR 2020
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LQ1YW
UT WOS:000529073200001
PM 32337664
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shanthanna, H
   Strand, NH
   Provenzano, DA
   Lobo, CA
   Eldabe, S
   Bhatia, A
   Wegener, J
   Curtis, K
   Cohen, SP
   Narouze, S
AF Shanthanna, H.
   Strand, N. H.
   Provenzano, D. A.
   Lobo, C. A.
   Eldabe, S.
   Bhatia, A.
   Wegener, J.
   Curtis, K.
   Cohen, S. P.
   Narouze, S.
TI Caring for patients with pain during the COVID-19 pandemic: consensus
   recommendations from an international expert panel
SO ANAESTHESIA
LA English
DT Article
DE chronic pain; COVID-19; opioids; recommendations; steroids
ID EPIDURAL STEROID INJECTIONS; QUALITY-OF-LIFE; OPIOID THERAPY;
   UNITED-STATES; MANAGEMENT; IMMUNE; RISK; POPULATION; PREVALENCE;
   PREVENTION
AB Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result, all elective surgical procedures, outpatient procedures and patient visits, including pain management services, have been postponed or cancelled. This has affected the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies.
C1 [Shanthanna, H.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Strand, N. H.] Mayo Clin, Div Pain Med, Alix Sch Med, Phoenix, AZ USA.
   [Provenzano, D. A.] Pain Diagnost & Intervent Care, Sewickley, PA USA.
   [Lobo, C. A.] Hosp Forcas Armadas, Dept Anaesthesiol, Polo Porto, Portugal.
   [Eldabe, S.] James Cook Univ Hosp, Dept Pain Med, Middlesbrough, Cleveland, England.
   [Bhatia, A.] Univ Toronto, Dept Anesthesia & Pain Med, Comprehens Integrated Pain Program Intervent Pain, Toronto, ON, Canada.
   [Bhatia, A.] Toronto Western Hosp, Toronto, ON, Canada.
   [Wegener, J.] Sint Maartenskliniek, Dept Anesthesiol, Nijmegen, Netherlands.
   [Curtis, K.] Toronto Western Hosp, Dept Anesthesia & Pain Med, Comprehens Integrated Pain Program, Intervent Pain Serv, Toronto, ON, Canada.
   [Cohen, S. P.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Neurol & Phys Med & Rehabil, Baltimore, MD USA.
   [Narouze, S.] Northeast Ohio Med Univ, Cuyahoga Falls, OH USA.
   [Narouze, S.] Western Reserve Hosp, Ctr Pain Med, Cuyahoga Falls, OH USA.
RP Shanthanna, H (corresponding author), McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
EM shanthh@mcmaster.ca
FU Canadian Anesthesia Research Foundation through the Career Scientist
   Award, 2018-2020; Avanos; MedtronicMedtronic; Nevro; Stimgenics;
   AbbottAbbott Laboratories; National Institute of Health Research
   (NIHR)National Institute for Health Research (NIHR); MIRROR; U.S.
   Department of DefenseUnited States Department of Defense; Uniformed
   Services University; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA
FX HS is supported by the Canadian Anesthesia Research Foundation through
   the Career Scientist Award, 2018-2020. DP has consulted for Avanos,
   Boston Scientific, Medtronic, Nevro, and Esteve. He has received
   research support from Avanos, Medtronic, Nevro, Stimgenics, and Abbott.
   SE has received consulting fees from Mainstay Medical, Medtronic and
   Saluda Medical. His department has received research funding from The
   National Institute of Health Research (NIHR), Nevro and Medtronic. SC is
   supported by grants from MIRROR, U.S. Department of Defense, Uniformed
   Services University, and the National Institutes of Health. No other
   external funding or competing interests declared.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   American Society of Regional Anesthesiology, 2020, REC CHRON PAIN PRACT
   [Anonymous], 2009, Med Lett Drugs Ther, V51, P64
   [Anonymous], 2020, COVID 19 GUID TRIAG
   [Anonymous], COVID 19 INF PAG
   Arteta J, 2016, PAIN MED, V17, P295, DOI 10.1111/pme.12886
   Ballester JMS, 2018, SURGERY, V163, P672, DOI 10.1016/j.surg.2017.08.015
   Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2
   Bluthenthal RN, 2020, DRUG ALCOHOL DEPEN, V211, DOI 10.1016/j.drugalcdep.2020.107932
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Breivik H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1229
   Brennan F, 2016, PAIN MED, V17, P1785, DOI 10.1093/pm/pnw222
   Buhrman Monica, 2016, Internet Interv, V4, P17, DOI 10.1016/j.invent.2015.12.001
   Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363
   Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495-199600525-00004
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559
   Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820
   COVI G, 1984, INT J CLIN PHARM RES, V4, P47
   Darnall BD, 2017, PAIN MED, V18, P1413, DOI 10.1093/pm/pnw166
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Deer TR, 2017, NEUROMODULATION, V20, P31, DOI 10.1111/ner.12565
   Devan H, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13080
   Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1
   Dublin S, 2011, J AM GERIATR SOC, V59, P1899, DOI 10.1111/j.1532-5415.2011.03586.x
   Eccleston C, 2020, PAIN, V161, P889, DOI 10.1097/j.pain.0000000000001885
   Edwards L, 2014, J MED INTERNET RES, V16, P154, DOI 10.2196/jmir.3257
   European Medicines Agency, 2020, EMA GIV ADV US NONST
   Faculty of Pain Medicine, 2020, FPM RESP REL SAF STE
   Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364
   Fayaz A, 2016, SCAND J PAIN, V13, P76, DOI 10.1016/j.sjpain.2016.06.005
   Food and Drug Administration, 2020, FDA ADV PAT US NONST
   Food and Drug Administration Communication, 2018, US CAUT IMPL PUMPS I
   Franchi S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02914
   Friedly JL, 2018, PAIN, V159, P876, DOI 10.1097/j.pain.0000000000001158
   Gabay E, 2004, PAIN, V110, P354, DOI 10.1016/j.pain.2004.04.021
   Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009
   Griffith JF, 2011, SEMIN MUSCULOSKEL R, V15, P554, DOI 10.1055/s-0031-1293500
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Habib G, 2014, J INVEST MED, V62, P621, DOI 10.2310/JIM.0000000000000048
   Herndon CM, 2007, PHARMACOTHERAPY, V27, P745, DOI 10.1592/phco.27.5.745
   Ho KY, 2018, J PAIN RES, V11, P1937, DOI 10.2147/JPR.S168188
   Lee HMD, 2016, J MED TOXICOL, V12, P134, DOI 10.1007/s13181-015-0505-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu MM, 2017, ANESTHESIOLOGY, V127, P166, DOI 10.1097/ALN.0000000000001659
   Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700
   Mellon RD, 1998, J NEUROIMMUNOL, V83, P19, DOI 10.1016/S0165-5728(97)00217-8
   Melzack R, 2001, J Dent Educ, V65, P1378
   Mills SEE, 2019, BRIT J ANAESTH, V123, pE273, DOI 10.1016/j.bja.2019.03.023
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nah SY, 2018, PAIN PHYSICIAN, V21, pE435
   Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002
   Parker L, 2014, FAM PRACT, V31, P557, DOI 10.1093/fampra/cmu035
   Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Porter S, NHS STAFF RECEIVE FR
   Provenzano DA, 2014, CURR MED RES OPIN, V30, P2051, DOI 10.1185/03007995.2014.921610
   Quinten C, 2009, LANCET ONCOL, V10, P865, DOI 10.1016/S1470-2045(09)70200-1
   Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234
   Rhodin A, 2010, CLIN J PAIN, V26, P374, DOI 10.1097/AJP.0b013e3181d1059d
   Sacerdote P, 2006, PALLIATIVE MED, V20, pS9, DOI 10.1191/0269216306pm1124oa
   Shanthanna H, 2018, BENEFIT ADDING STERO
   Shanthanna H, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0190-z
   Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444
   Smith J, 2019, PAIN MED, V20, P2385, DOI 10.1093/pm/pnz208
   Sytsma Terin T, 2018, Mayo Clin Proc Innov Qual Outcomes, V2, P194, DOI 10.1016/j.mayocpiqo.2018.01.005
   Toronto Academic Pain Medicine Institute, PAIN U ONL
   US Department of Health and Human Services, 2020, NOT ENF DISCR TEL RE
   Van Boxem K, 2019, PAIN PRACT, V19, P61, DOI 10.1111/papr.12709
   Webster F, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1010-6
   Wiese AD, 2016, ARTHRITIS RHEUMATOL, V68, P323, DOI 10.1002/art.39462
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 72
TC 39
Z9 40
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD JUL
PY 2020
VL 75
IS 7
BP 935
EP 944
DI 10.1111/anae.15076
EA APR 2020
PG 10
WC Anesthesiology
SC Anesthesiology
GA LT2QY
UT WOS:000528450000001
PM 32259288
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ebrahimi, SA
AF Ebrahimi, Soltan A.
TI Noscapine, a possible drug candidate for attenuation of cytokine release
   associated with SARS-CoV-2
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE ACE2; SARS-CoV-2
ID CONVERTING ENZYME; ACE2; CORONAVIRUS; AXIS
AB Successful treatment of viral infections has proven to be huge challenge for modern medicine with the most effective approach being prior vaccination. The problem with vaccination is the time it takes to develop an effective vaccine, validate its safety and manufacture it in large quantities. Facing Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we simply do not have the time to develop the vaccine before thousands of people die. Therefore, any treatment which can decrease the severe symptoms due to lung damage may help attenuate mortality rates. Inactivation of ACE2 during virus fusion into the host cell may be one of the underlying reasons for intense immunological reaction seen in the lung tissue. This overreaction is probably mediated through the bradykinin receptor activation. Noscapine, a medication used for the treatment of cough, has been shown to inhibit bradykinin enhanced cough response in man. As it is already marketed in a number of countries as a cough medicine, even for children, a suitable formulation with all the required licenses is available that can be rapidly utilized in preliminary trials.
C1 [Ebrahimi, Soltan A.] Iran Univ Med Sci, Dept Pharmacol, Tehran, Iran.
RP Ebrahimi, SA (corresponding author), Iran Univ Med Sci, Dept Pharmacol, Tehran, Iran.
EM ebrahimi.sa@iums.ac.ir
CR Amrani Y, 1997, AM J PHYSIOL-LUNG C, V273, pL1020
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Ebrahimi S. A., 2003, Acta Physiologica Hungarica, V90, P147, DOI 10.1556/APhysiol.90.2003.2.7
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023710
   Mahmoudian M, 2003, EUR J CLIN PHARMACOL, V59, P579, DOI 10.1007/s00228-003-0676-1
   Mahmoudian M, 2015, IRAN J NEUROL, V14, P12
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mooraki A, 2005, NEPHROLOGY, V10, P348, DOI 10.1111/j.1440-1797.2005.00429.x
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Patel SK, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00227
   Pedersen S. F., 2020, J CLIN INVEST, V13
   Qian X, 2016, TUBERCULOSIS, V101, pS109, DOI 10.1016/j.tube.2016.09.022
   Sen EF, 2011, BRIT J CLIN PHARMACO, V71, P943, DOI 10.1111/j.1365-2125.2010.03860.x
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Vahabzadeh G, 2015, PHARMACOL REP, V67, P281, DOI 10.1016/j.pharep.2014.10.011
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Yoshikawa N, 2009, J VIROL, V83, P5451, DOI 10.1128/JVI.02272-08
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 23
TC 3
Z9 3
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD NOV
PY 2020
VL 81
IS 7
BP 765
EP 767
DI 10.1002/ddr.21676
EA APR 2020
PG 3
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OP0AZ
UT WOS:000528510800001
PM 32337769
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, Q
   Wang, YK
   Qi, CS
   Shen, L
   Li, J
AF Zhang, Qi
   Wang, Yakun
   Qi, Changsong
   Shen, Lin
   Li, Jian
TI Response to "Comments on 'Zhang et al: Clinical trial analysis of
   2019-nCoV therapy registered in China'"
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
C1 [Zhang, Qi; Wang, Yakun; Qi, Changsong; Shen, Lin; Li, Jian] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China.
RP Li, J (corresponding author), Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Fucheng Rd 52, Beijing 100142, Peoples R China.
EM oncogene@163.com
CR Ge PC, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-1612-z
   Yang Y, 2020, J MED VIROL
NR 2
TC 13
Z9 14
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2020
VL 92
IS 7
BP 713
EP 713
DI 10.1002/jmv.25803
EA APR 2020
PG 1
WC Virology
SC Virology
GA LW4RW
UT WOS:000528227100001
PM 32232977
OA Bronze
DA 2021-01-01
ER

PT J
AU Pu, T
   Ding, C
   Li, YD
   Liu, XJ
   Li, HW
   Duan, JM
   Zhang, H
   Bi, YW
   Cun, W
AF Pu, Tao
   Ding, Chen
   Li, Yadong
   Liu, Xiaojuan
   Li, Haiwei
   Duan, Jinmei
   Zhang, Heng
   Bi, Yanwei
   Cun, Wei
TI Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by
   pseudoviral particles
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE infectivity; neutralization; pseudoviral particles; SARS-CoV-2
ID PNEUMONIA
AB Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans in late 2019, it has rapidly spread worldwide. To identify the biological characteristics of SARS-CoV-2 in a normal laboratory environment (biosafety level 2 [BSL-2]), a lentiviral-based nucleocapsid was used to carry the spike protein of SARS-CoV-2 onto the surface of pseudoviral particles as a surrogate model to evaluate the infective characterization of SARS-CoV-2. This study indicated that SARS-CoV-2 has extensive tissue tropism for humans and may infect monkeys and tree shrews but not rodents. More importantly, the use of pseudoviral particles in this study allows rapid assessment of neutralizing antibodies in serum in a BSL-2 laboratory. This study will provide a quick and easy tool for evaluating neutralizing antibodies in the serum of recovering patients and assessing the potency of candidate vaccines.
C1 [Pu, Tao; Ding, Chen; Li, Yadong; Liu, Xiaojuan; Li, Haiwei; Duan, Jinmei; Zhang, Heng; Bi, Yanwei; Cun, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Beijing, Peoples R China.
   [Pu, Tao; Ding, Chen; Li, Yadong; Liu, Xiaojuan; Li, Haiwei; Duan, Jinmei; Zhang, Heng; Bi, Yanwei; Cun, Wei] Yunnan Key Lab Vaccine Res & Dev Severe Infect De, Kunming, Yunnan, Peoples R China.
RP Cun, W (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Beijing, Peoples R China.
EM cun@imbcams.com.cn
FU CAMS Initiative for Innovative Medicine [2016-I2M-1-019,
   2016-I2M-1-013]; Talent development project [D2017003]; National Science
   and Technology Major Projects [2018ZX10101001-002, 2018ZX09738003-007];
   Major Science and Technology Projects of Yunnan Province [2019ZF001];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81971947]
FX CAMS Initiative for Innovative Medicine, Grant/Award Numbers:
   2016-I2M-1-019, 2016-I2M-1-013; Talent development project, Grant/Award
   Number: D2017003; National Science and Technology Major Projects,
   Grant/Award Numbers: 2018ZX10101001-002, 2018ZX09738003-007; Major
   Science and Technology Projects of Yunnan Province, Grant/Award Number:
   2019ZF001; National Natural Science Foundation of China, Grant/Award
   Number: 81971947
CR [Anonymous], 2020, LAB TEAM SUCC IS VIR
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Guan W-J, 2020, NEW ENGL J MED
   Huang X, 2000, CHINESE J BIOL
   Ksiazek T, 2003, NEW ENGL J MED, V348, P348
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Liu Xin, 2011, CHINESE MED BIOTECHN, V6, P4
   Ning-zhu HU, 2005, CHINESE J BIOL, V18, P50
   Walls A.C., 2020, CELL
   WHO, 2020, PNEUM UNKN CAUS CHIN
   World Health Organization (WHO), 2020, SIT REP
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao K., 2020, ISOLATION CHARACTERI, DOI [10.1101/2020.02.17.951335, DOI 10.1101/2020.02.17.951335]
   Xin L, 2020, CHINESE J BIOINFORMA
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhen L., 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212v2, DOI 10.1101/2020.02.08.20021212V2]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 20
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1609
EP 1614
DI 10.1002/jmv.25865
EA APR 2020
PG 6
WC Virology
SC Virology
GA NA8CG
UT WOS:000528226800001
PM 32275081
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lei, CH
   Qian, KW
   Li, T
   Zhang, S
   Fu, WY
   Ding, M
   Hu, S
AF Lei, Changhai
   Qian, Kewen
   Li, Tian
   Zhang, Sheng
   Fu, Wenyan
   Ding, Min
   Hu, Shi
TI Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant
   ACE2-Ig
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; CORONAVIRUS; FIBROSIS; RECEPTOR
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.
C1 [Lei, Changhai; Qian, Kewen; Li, Tian; Hu, Shi] Second Mil Med Univ, Coll Basic Med Sci, Dept Biophys, Shanghai 200433, Peoples R China.
   [Lei, Changhai; Qian, Kewen; Li, Tian; Hu, Shi] Second Mil Med Univ, Dept Biophys, Team SMMU China Int Genetically Engn Machine iGEM, Shanghai 200433, Peoples R China.
   [Zhang, Sheng] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, Shanghai 200011, Peoples R China.
   [Fu, Wenyan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Assisted Reprod, Shanghai 200011, Peoples R China.
   [Ding, Min] Pharchoice Therapeut Inc, Shanghai 201406, Peoples R China.
RP Hu, S (corresponding author), Second Mil Med Univ, Coll Basic Med Sci, Dept Biophys, Shanghai 200433, Peoples R China.; Hu, S (corresponding author), Second Mil Med Univ, Dept Biophys, Team SMMU China Int Genetically Engn Machine iGEM, Shanghai 200433, Peoples R China.
EM hus@smmu.edu.cn
RI Hu, Shi/ABF-4231-2020; Hu, Shi/A-2140-2015
OI Hu, Shi/0000-0002-7905-4284
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041012, 81773261, 31970882, 81903140,
   81602690]; Shanghai Rising-Star Program [19QA1411400]; Shanghai Sailing
   Program [19YF1438600]
FX We thank J Xu for critical support for the research. This study was
   supported by the National Natural Science Foundation of China (grant
   nos. 82041012, 81773261, 31970882, 81903140, and 81602690), the Shanghai
   Rising-Star Program (grant no. 19QA1411400), and the Shanghai Sailing
   Program (19YF1438600).
CR Chen LJ, 2016, PEPTIDES, V79, P49, DOI 10.1016/j.peptides.2016.03.008
   Collins P, 2016, HAEMOPHILIA, V22, P487, DOI 10.1111/hae.13013
   Elased KM, 2006, HYPERTENSION, V47, P1010, DOI 10.1161/01.HYP.0000215588.38536.30
   Fu W., 2019, PREPRINT, DOI [10.1101/819243v1, DOI 10.1101/819243V1]
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   He YX, 2005, VIROLOGY, V334, P74, DOI 10.1016/j.virol.2005.01.034
   Hu S, 2013, J BIOL CHEM, V288, P27059, DOI 10.1074/jbc.M113.491530
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huentelman MJ, 2005, EXP PHYSIOL, V90, P783, DOI 10.1113/expphysiol.2005.031096
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu P, 2018, KIDNEY INT, V94, P114, DOI 10.1016/j.kint.2018.01.029
   Liu SW, 2019, CLIN IMMUNOL, V203, P72, DOI 10.1016/j.clim.2019.04.007
   Rice GI, 2006, HYPERTENSION, V48, P914, DOI 10.1161/01.HYP.0000244543.91937.79
   Romero C, 2015, NAT REV ENDOCRINOL, V11, P242, DOI 10.1038/nrendo.2015.6
   Shapiro A, 2013, EXPERT OPIN BIOL TH, V13, P1287, DOI 10.1517/14712598.2013.819339
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wysocki J, 2017, KIDNEY INT, V91, P1336, DOI 10.1016/j.kint.2016.09.032
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Zhong JC, 2011, HYPERTENSION, V57, P314, DOI 10.1161/HYPERTENSIONAHA.110.164244
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 30
TC 58
Z9 59
U1 6
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR 24
PY 2020
VL 11
IS 1
AR 2070
DI 10.1038/s41467-020-16048-4
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MY8BK
UT WOS:000558640500001
PM 32332765
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Elmezayen, AD
   Al-Obaidi, A
   Sahin, AT
   Yelekci, K
AF Elmezayen, Ammar D.
   Al-Obaidi, Anas
   Sahin, Alp Tegin
   Yelekci, Kemal
TI Drug repurposing for coronavirus (COVID-19): in silico screening of
   known drugs against coronavirus 3CL hydrolase and protease enzymes
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; structure-based virtual screening; homology modeling; ADMET;
   MD simulation; MM-PBSA
ID SPIKE PROTEIN; INHIBITORS; WEB; ACTIVATION; INFLUENZA; BINDING; TMPRSS2;
   TOOL
AB In December 2019, COVID-19 epidemic was described in Wuhan, China, and the infection has spread widely affecting hundreds of thousands. Herein, an effort was made to identify commercially available drugs in order to repurpose them against coronavirus by the means of structure-based virtual screening. In addition, ZINC15 library was used to identify novel leads against main proteases. Human TMPRSS2 3D structure was first generated using homology modeling approach. Our molecular docking study showed four potential inhibitors against Mpro enzyme, two available drugs (Talampicillin and Lurasidone) and two novel drug-like compounds (ZINC000000702323 and ZINC000012481889). Moreover, four promising inhibitors were identified against TMPRSS2; Rubitecan and Loprazolam drugs, and compounds ZINC000015988935 and ZINC000103558522. ADMET profile showed that the hits from our study are safe and drug-like compounds. Furthermore, molecular dynamic (MD) simulation and binding free energy calculation using the MM-PBSA method was performed to calculate the interaction energy of the top-ranked drugs. Communicated by Ramaswamy H. Sarma
C1 [Elmezayen, Ammar D.; Al-Obaidi, Anas; Sahin, Alp Tegin; Yelekci, Kemal] Kadir Has Univ, Fac Engn & Nat Sci, Dept Bioinformat & Genet, Istanbul, Turkey.
RP Yelekci, K (corresponding author), Kadir Has Univ, Fac Engn & Nat Sci, Dept Bioinformat & Genet, Istanbul, Turkey.
EM yelekci@khas.edu.tr
RI Alobaidi, Anas/AAU-4056-2020; Elmezayen, Ammar/AAU-1143-2020; Yelekci,
   Kemal/B-1431-2019
OI Alobaidi, Anas/0000-0002-6089-8188; Elmezayen,
   Ammar/0000-0002-2926-7070; Yelekci, Kemal/0000-0002-0052-4926
CR Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Boonstra S, 2016, J PHYS CHEM B, V120, P3692, DOI 10.1021/acs.jpcb.6b01316
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   CLARK BG, 1986, DRUGS, V31, P500, DOI 10.2165/00003495-198631060-00003
   Clark JW, 2006, EXPERT OPIN INV DRUG, V15, P71, DOI 10.1517/13543784.15.1.71
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Corponi F, 2019, EUR NEUROPSYCHOPHARM, V29, P971, DOI 10.1016/j.euroneuro.2019.06.008
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kyrieleis OJP, 2007, FEBS J, V274, P2148, DOI 10.1111/j.1742-4658.2007.05756.x
   Laporte M, 2017, CURR OPIN VIROL, V24, P16, DOI 10.1016/j.coviro.2017.03.018
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu H, 2016, BIOINFORMATICS, V32, P2216, DOI 10.1093/bioinformatics/btw215
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sielaff F, 2011, BIOORG MED CHEM LETT, V21, P4860, DOI 10.1016/j.bmcl.2011.06.033
   Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vyas VK, 2012, INDIAN J PHARM SCI, V74, P1, DOI 10.4103/0250-474X.102537
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Worldometer, 2020, COR UPD LIV 1 790 82
   Xiang ZX, 2006, CURR PROTEIN PEPT SC, V7, P217, DOI 10.2174/138920306777452312
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Zhou JW, 2019, FASEB J, V33, P14575, DOI 10.1096/fj.201901624RR
NR 38
TC 92
Z9 92
U1 19
U2 32
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1758791
EA APR 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LM0XR
UT WOS:000531977000001
PM 32306862
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Borba, MGS
   Val, FFA
   Sampaio, VS
   Alexandre, MAA
   Melo, GC
   Brito, M
   Mourao, MPG
   Brito-Sousa, JD
   Baia-da-Silva, D
   Guerra, MVF
   Hajjar, LA
   Pinto, RC
   Balieiro, AAS
   Pacheco, AGF
   Santos, JDO
   Naveca, FG
   Xavier, MS
   Siqueira, AM
   Schwarzbold, A
   Croda, J
   Nogueira, ML
   Romero, GAS
   Bassat, Q
   Fontes, CJ
   Albuquerque, BC
   Daniel-Ribeiro, CT
   Monteiro, WM
   Lacerda, MVG
AF Borba, Mayla Gabriela Silva
   Val, Fernando Fonseca Almeida
   Sampaio, Vanderson Souza
   Alexandre, Marcia Almeida Araujo
   Melo, Gisely Cardoso
   Brito, Marcelo
   Mourao, Maria Paula Gomes
   Brito-Sousa, Jose Diego
   Baia-da-Silva, Djane
   Guerra, Marcus Vinitius Farias
   Hajjar, Ludhmila Abrahao
   Pinto, Rosemary Costa
   Balieiro, Antonio Alcirley Silva
   Pacheco, Antonio Guilherme Fonseca
   Santos, James Dean Oliveira, Jr.
   Naveca, Felipe Gomes
   Xavier, Mariana Simao
   Siqueira, Andre Machado
   Schwarzbold, Alexandre
   Croda, Julio
   Nogueira, Mauricio Lacerda
   Romero, Gustavo Adolfo Sierra
   Bassat, Quique
   Fontes, Cor Jesus
   Albuquerque, Bernardino Claudio
   Daniel-Ribeiro, Claudio-Tadeu
   Monteiro, Wuelton Marcelo
   Lacerda, Marcus Vinicius Guimaraes
CA CloroCovid 19 Team
TI Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive
   Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome
   Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID IN-VITRO; HYDROXYCHLOROQUINE; COVID-19
AB Importance There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug. Objective To evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19. Design, Setting, and Participants This parallel, double-masked, randomized, phase IIb clinical trial with 81 adult patients who were hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon. Interventions Patients were allocated to receive high-dosage CQ (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days). Main Outcomes and Measures Primary outcome was reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group. Data presented here refer primarily to safety and lethality outcomes during treatment on day 13. Secondary end points included participant clinical status, laboratory examinations, and electrocardiogram results. Outcomes will be presented to day 28. Viral respiratory secretion RNA detection was performed on days 0 and 4. Results Out of a predefined sample size of 440 patients, 81 were enrolled (41 [50.6%] to high-dosage group and 40 [49.4%] to low-dosage group). Enrolled patients had a mean (SD) age of 51.1 (13.9) years, and most (60 [75.3%]) were men. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group. Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%). Conclusions and Relevance The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19.
C1 [Borba, Mayla Gabriela Silva; Val, Fernando Fonseca Almeida; Sampaio, Vanderson Souza; Alexandre, Marcia Almeida Araujo; Melo, Gisely Cardoso; Brito, Marcelo; Mourao, Maria Paula Gomes; Brito-Sousa, Jose Diego; Baia-da-Silva, Djane; Guerra, Marcus Vinitius Farias; Monteiro, Wuelton Marcelo; Lacerda, Marcus Vinicius Guimaraes] Fundacao Med Trop Dr Heitor Vieira Dourado, Av Pedro Teixeira,25 Dom Pedro, BR-69040000 Manaus, Amazonas, Brazil.
   [Borba, Mayla Gabriela Silva; Val, Fernando Fonseca Almeida; Sampaio, Vanderson Souza; Melo, Gisely Cardoso; Brito, Marcelo; Mourao, Maria Paula Gomes; Brito-Sousa, Jose Diego; Baia-da-Silva, Djane; Monteiro, Wuelton Marcelo; Lacerda, Marcus Vinicius Guimaraes] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Sampaio, Vanderson Souza; Pinto, Rosemary Costa] Fundacao Vigilancia Saude Amazonas, Manaus, Amazonas, Brazil.
   [Hajjar, Ludhmila Abrahao] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Balieiro, Antonio Alcirley Silva; Naveca, Felipe Gomes; Lacerda, Marcus Vinicius Guimaraes] Fiocruz Amazonas, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Pacheco, Antonio Guilherme Fonseca] Fiocruz MS, Programa Comp Cient, Rio De Janeiro, Brazil.
   [Santos, James Dean Oliveira, Jr.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Xavier, Mariana Simao; Siqueira, Andre Machado] Inst Nacl Infectol Carlos Chagas Fiocruz, Rio De Janeiro, Brazil.
   [Schwarzbold, Alexandre] Univ Fed Santa Maria, Santa Maria, RS, Brazil.
   [Croda, Julio] Univ Fed Mato Grosso Do Sul, Fac Med, Campo Grande, MS, Brazil.
   [Croda, Julio] Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose Do Rio Preto, Sao Paulo, Brazil.
   [Romero, Gustavo Adolfo Sierra] Univ Brasilia, Brasilia, DF, Brazil.
   [Bassat, Quique] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona, Spain.
   [Bassat, Quique] Ctr Invest Saude Manhica, Maputo, Mozambique.
   [Bassat, Quique] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain.
   [Bassat, Quique] Univ Barcelona, Hosp St Joan Deu, Pediat Dept, Pediat Infect Dis Unit, Barcelona, Spain.
   [Bassat, Quique] Consorcio Invest Biomed Red Epidemiol & Salud Pub, Madrid, Spain.
   [Fontes, Cor Jesus] Univ Fed Mato Grosso, Cuiaba, Mato Grosso, Brazil.
   [Albuquerque, Bernardino Claudio] Univ Fed Amazonas, Fac Med, Manaus, Amazonas, Brazil.
   [Daniel-Ribeiro, Claudio-Tadeu] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Lacerda, MVG (corresponding author), Fundacao Med Trop Dr Heitor Vieira Dourado, Av Pedro Teixeira,25 Dom Pedro, BR-69040000 Manaus, Amazonas, Brazil.
EM marcuslacerda.br@gmail.com
RI Nogueira, Mauricio L/B-7599-2012; Sampaio, Vanderson/AAQ-1418-2020;
   Bassat, Quique/P-2341-2016; Pacheco, Antonio Guilherme/E-6378-2013
OI Nogueira, Mauricio L/0000-0003-1102-2419; Sampaio,
   Vanderson/0000-0001-7307-8851; Bassat, Quique/0000-0003-0875-7596;
   Pacheco, Antonio Guilherme/0000-0003-3095-1774; Val,
   Fernando/0000-0001-9995-0249; Brito-Sousa, Jose
   Diego/0000-0003-1659-3763; Santos, James/0000-0002-0627-6126
FU Coordination for the Improvement of Higher Education Personnel; Spanish
   Ministry of Science and Innovation through Centro de Excelencia Severo
   Ochoa 2019-2023 Program [CEX2018-000806-S]; Generalitat de Catalunya
   through the Centres de Recerca de Catalunya Program; Government of
   Mozambique; Spanish Agency for International Development; Fundacao de
   Amparo a Pesquisa do Estado do Amazonas; Government of the Amazonas
   State; Farmanguinhos (Fiocruz); Superintendencia da Zona Franca de
   Manaus; Brazilian Senate
FX Many members of the CloroCovid-19 Team are funded by Fundacao de Amparo
   a Pesquisa do Estado do Amazonas and Coordination for the Improvement of
   Higher Education Personnel. ISGlobal receives support from the Spanish
   Ministry of Science and Innovation through Centro de Excelencia Severo
   Ochoa 20192023 Program (grant, CEX2018-000806-S) and from Generalitat de
   Catalunya through the Centres de Recerca de Catalunya Program. Centro de
   Investigacao em Saude de Manhica is supported by the Government of
   Mozambique and the Spanish Agency for International Development. This
   study was funded by the Government of the Amazonas State, Farmanguinhos
   (Fiocruz), Superintendencia da Zona Franca de Manaus, Coordination for
   the Improvement of Higher Education Personnel, Fundacao de Amparo a
   Pesquisa do Estado do Amazonas, and federal funds facilitated by the
   Brazilian Senate.
CR Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chorin E, 2020, QT INTERVAL PATIENTS
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   INGLOT AD, 1969, J GEN VIROL, V4, P203, DOI 10.1099/0022-1317-4-2-203
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Kazi M.S., 2013, J OPHTHALMOL, V20, P89
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Ling ZK, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108956
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Mavrikakis I, 2003, OPHTHALMOLOGY, V110, P1321, DOI 10.1016/S0161-6420(03)00409-3
   MILLER DK, 1981, P NATL ACAD SCI-BIOL, V78, P3605, DOI 10.1073/pnas.78.6.3605
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Nti AA, 2019, RETINA-J RET VIT DIS, V39, P502, DOI 10.1097/IAE.0000000000002027
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613
   Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18
   Science Direct, CHLOR RET
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Silva JA, 2007, CLIN EXP RHEUMATOL, V25, P795
   US Centers for Disease Control and Prevention, CDC 2019 NOV COR 201
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 268
Z9 274
U1 19
U2 29
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD APR 24
PY 2020
VL 3
IS 4
AR e208857
DI 10.1001/jamanetworkopen.2020.8857
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA LJ1VI
UT WOS:000529959400001
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Dominguez, A
   Velasquez, SA
   David, MA
AF Dominguez, Angela
   Velasquez, Sergio Andres
   David, Mario Alejandro
TI Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Letter
ID OXIDATIVE STRESS; LASER THERAPY; ERYTHROCYTES
C1 [Dominguez, Angela; Velasquez, Sergio Andres; David, Mario Alejandro] Unicoc, Dept Orthodont, Cl 13N 3N-13, Cali 760036, CO, Colombia.
RP Dominguez, A (corresponding author), Unicoc, Dept Orthodont, Cl 13N 3N-13, Cali 760036, CO, Colombia.
EM angela.dominguezc@gmail.com
OI Dominguez, Angela/0000-0002-6434-1969
CR Fisher-Wellman K, 2009, OXID MED CELL LONGEV, V2, P43, DOI 10.4161/oxim.2.1.7732
   Fujimaki Y, 2003, J CLIN LASER MED SUR, V21, P165, DOI 10.1089/104454703321895635
   INOUE K, 1989, LASER SURG MED, V9, P271, DOI 10.1002/lsm.1900090310
   Kutko II, 1996, ZH NEVROPATOL PSIKH, V96, P34
   Milic VD, 2009, TOXICOL MECH METHOD, V19, P24, DOI 10.1080/01612840802203098
   Pandey KB, 2010, OXID MED CELL LONGEV, V3, P2, DOI 10.4161/oxim.3.1.10476
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Szymczyszyn A, 2016, LASER MED SCI, V31, P1301, DOI 10.1007/s10103-016-1971-2
   Thais-Meneguzzo D., 2018, LOW LEVEL LIGHT THER, P319
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
NR 10
TC 4
Z9 4
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578-5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD MAY 1
PY 2020
VL 38
IS 5
BP 258
EP 259
DI 10.1089/photob.2020.4870
EA APR 2020
PG 2
WC Surgery
SC Surgery
GA LO8AN
UT WOS:000529404800001
PM 32330404
OA Bronze
DA 2021-01-01
ER

PT J
AU Tanriverdi, O
AF Tanriverdi, Ozgur
TI Lymphopenia that may develop in patients treated with temozolomide and
   immune control check-point inhibitor may be a high risk for mortality
   during the COVID-19 outbreak
SO MEDICAL ONCOLOGY
LA English
DT Letter
DE COVID; 19; Lymphopenia; Mortality; Cancer patients
AB As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
C1 [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Dept Med Oncol, Fac Med, Mugla, Turkey.
   [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Grad Sch Nat & Appl Sci, Dept Mol Biol & Genet, Mugla, Turkey.
   [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Educ & Res Hosp, Grad Sch Hlth Sci, Kotekli Mah Kemoterapi Merkezi, Marmaris Yolu Uzeri, TR-48000 Mugla, Turkey.
RP Tanriverdi, O (corresponding author), Mugla Sitki Kocman Univ, Dept Med Oncol, Fac Med, Mugla, Turkey.; Tanriverdi, O (corresponding author), Mugla Sitki Kocman Univ, Grad Sch Nat & Appl Sci, Dept Mol Biol & Genet, Mugla, Turkey.; Tanriverdi, O (corresponding author), Mugla Sitki Kocman Univ, Educ & Res Hosp, Grad Sch Hlth Sci, Kotekli Mah Kemoterapi Merkezi, Marmaris Yolu Uzeri, TR-48000 Mugla, Turkey.
EM mugla.medicaloncology@gmail.com
RI Tanriverdi, Ozgur/M-2172-2015
CR Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Mendez JS, 2016, J NEURO-ONCOL, V127, P329, DOI 10.1007/s11060-015-2037-1
NR 3
TC 1
Z9 1
U1 1
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD APR 24
PY 2020
VL 37
IS 6
AR 51
DI 10.1007/s12032-020-01376-8
PG 2
WC Oncology
SC Oncology
GA LG8ZI
UT WOS:000528381400001
PM 32333196
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rajabally, YA
   Goedee, HS
   Attarian, S
   Hartung, HP
AF Rajabally, Yusuf A.
   Goedee, H. Stephan
   Attarian, Shahram
   Hartung, Hans-Peter
TI Management challenges for chronic dysimmune neuropathies during the
   COVID-19 pandemic
SO MUSCLE & NERVE
LA English
DT Article
DE chronic inflammatory demyelinating polyneuropathy; COVID-19; dysimmune;
   multifocal motor neuropathy; pandemic; paraproteinemic neuropathy
ID INFLAMMATORY DEMYELINATING POLYNEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY;
   INTRAVENOUS IMMUNOGLOBULIN; SUBCUTANEOUS IMMUNOGLOBULIN;
   DIAGNOSTIC-CRITERIA; DISABILITY SCALE; TERM; POLYRADICULONEUROPATHY;
   INFECTIONS; THERAPY
AB Since March 2020, the COVID-19 pandemic has led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions.
C1 [Rajabally, Yusuf A.] Univ Hosp Birmingham, Inflammatory Neuropathy Clin, Birmingham, W Midlands, England.
   [Rajabally, Yusuf A.] Aston Univ, Aston Med Sch, Birmingham B4 7ET, W Midlands, England.
   [Goedee, H. Stephan] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
   [Attarian, Shahram] CHU Timone, Reference Ctr Neuromuscular Dis & ALS, 264 Rue St Pierre, F-13385 Marseille, France.
   [Attarian, Shahram] Aix Marseille Univ, GMGF, INSERM, Marseille, France.
   [Hartung, Hans-Peter] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany.
   [Hartung, Hans-Peter] Heinrich Heine Univ, Ctr Neurol & Neuropsychiat, LVR Klinikum, Dusseldorf, Germany.
RP Rajabally, YA (corresponding author), Aston Univ, Aston Med Sch, Birmingham B4 7ET, W Midlands, England.
EM y.rajabally@aston.ac.uk
FU LFB; CSL Behring; Baxter; Prinses Beatrix Spierfonds [W.OR14.08,
   W.OR17-21]; Shire/Baxalta.S.A.; PfizerPfizer
FX Y.A.R. has received speaker/consultancy honoraria from CSL Behring, LFB,
   Grifols, BPL, Octapharma, and Kedrion, has received educational
   sponsorships from LFB, CSL Behring and Baxter and has obtained research
   grants from CSL Behring and LFB; H.S.G. has received research grants
   from Prinses Beatrix Spierfonds (W.OR14.08 and W.OR17-21), and received
   speaker fee/travel grants from Shire/Baxalta.S.A. has received
   speaker/consultancy honoraria from LFB, Alnylam, Akcea, Pfizer,
   Pharnext, Sanofi, and Biogen, has received educational sponsorships from
   LFB, and has obtained research grants from and LFB and Pfizer. H.P.H.
   received fees for serving on steering committees and advisory boards
   from CSL Behring, LFB, Octapharma, Roche, UCB
CR AANEM, 2020, GUID MAN NCS EMG TES
   Allen JA, 2015, NEUROLOGY, V85, P498, DOI 10.1212/WNL.0000000000001833
   Beadon K, 2018, CURR OPIN NEUROL, V31, P559, DOI 10.1097/WCO.0000000000000605
   Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cocito D, 2016, J NEUROL NEUROSUR PS, V87, P791, DOI 10.1136/jnnp-2014-310280
   Draak THP, 2016, EUR J NEUROL, V23, P1248, DOI 10.1111/ene.13025
   Dureault A, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008846
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Graham RC, 2006, J NEUROL NEUROSUR PS, V77, P973, DOI 10.1136/jnnp.2005.081547
   Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088
   Iijima M, 2005, NEUROLOGY, V64, P1471, DOI 10.1212/01.WNL.0000158680.89323.F8
   Keith P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2836-4
   Klein BC, 2020, NEUROLOGY, V94, P903, DOI 10.1212/WNL.0000000000009494
   Koski CL, 2009, J NEUROL SCI, V277, P1, DOI 10.1016/j.jns.2008.11.015
   Leger JM, 2008, J NEUROL NEUROSUR PS, V79, P93, DOI 10.1136/jnnp.2007.121756
   Lunn MPT, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002827.pub3, 10.1002/14651858.CD002827.pub4]
   Magy L, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/450391
   Mahdi-Rogers M, 2014, EUR J NEUROL, V21, P28, DOI 10.1111/ene.12190
   Matsumura-Kimoto Y, 2016, BIOL BLOOD MARROW TR, V22, P1102, DOI 10.1016/j.bbmt.2016.02.020
   Muley SA, 2020, MUSCLE NERVE, V61, P575, DOI 10.1002/mus.26804
   Nobile-Orazio E, 2012, LANCET NEUROL, V11, P493, DOI 10.1016/S1474-4422(12)70093-5
   Oaklander AL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010369.pub2
   Querol L, 2017, NAT REV NEUROL, V13, P533, DOI 10.1038/nrneurol.2017.84
   Rajabally YA, 2019, NEURODEGENER DIS MAN, V9, P259, DOI 10.2217/nmt-2019-0009
   Rajabally YA, 2017, NEURODEGENER DIS MAN, V7, P331, DOI 10.2217/nmt-2017-0017
   Rajabally YA, 2015, MUSCLE NERVE, V51, P657, DOI 10.1002/mus.24554
   Rajabally YA, 2009, MUSCLE NERVE, V39, P432, DOI 10.1002/mus.21206
   Reusken CB, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.12.2000334
   Shimizu S, 2020, JMIR RES PROTOC, V9, DOI 10.2196/17117
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Thery-Casari C, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102505
   Van den Bergh PYK, 2010, EUR J NEUROL, V17, P356, DOI 10.1111/j.1468-1331.2009.02930.x
   van Nes SI, 2011, NEUROLOGY, V76, P337, DOI 10.1212/WNL.0b013e318208824b
   van Schaik IN, 2018, LANCET NEUROL, V17, P35, DOI 10.1016/S1474-4422(17)30378-2
   van Schaik IN, 2010, LANCET NEUROL, V9, P245, DOI 10.1016/S1474-4422(10)70021-1
   Vanhoutte EK, 2015, J PERIPHER NERV SYST, V20, P296, DOI 10.1111/jns.12141
   Vanhoutte EK, 2012, BRAIN, V135, P1639, DOI 10.1093/brain/awr318
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu JH, 2019, CAN MED ASSOC J, V191, pE680, DOI 10.1503/cmaj.190178
   Yu R, 2017, J AM MED DIR ASSOC, V18, DOI 10.1016/j.jamda.2017.03.006
NR 42
TC 9
Z9 9
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL
PY 2020
VL 62
IS 1
BP 34
EP 40
DI 10.1002/mus.26896
EA APR 2020
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LY1IN
UT WOS:000528003600001
PM 32311114
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, LL
   Lin, DZ
   Sun, XYY
   Curth, U
   Drosten, C
   Sauerhering, L
   Becker, S
   Rox, K
   Hilgenfeld, R
AF Zhang, Linlin
   Lin, Daizong
   Sun, Xinyuanyuan
   Curth, Ute
   Drosten, Christian
   Sauerhering, Lucie
   Becker, Stephan
   Rox, Katharina
   Hilgenfeld, Rolf
TI Crystal structure of SARS-CoV-2 main protease provides a basis for
   design of improved alpha-ketoamide inhibitors
SO SCIENCE
LA English
DT Article
ID 3C PROTEASE; M-PRO; SARS; ULTRACENTRIFUGATION; BINDING; DIMER
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M-pro, also called 3CL(pro)) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M-pro and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 Mpro. The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.
C1 [Zhang, Linlin; Lin, Daizong; Sun, Xinyuanyuan; Hilgenfeld, Rolf] Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, D-23562 Lubeck, Germany.
   [Zhang, Linlin; Sun, Xinyuanyuan; Hilgenfeld, Rolf] Univ Lubeck, German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, D-23562 Lubeck, Germany.
   [Lin, Daizong] Changchun Discovery Sci Ltd, 789 Shunda Rd, Changchun 130012, Jilin, Peoples R China.
   [Curth, Ute] Hannover Med Sch, Inst Biophys Chem, D-30625 Hannover, Germany.
   [Drosten, Christian] Charite Univ Med Berlin, Inst Virol, D-10117 Berlin, Germany.
   [Sauerhering, Lucie; Becker, Stephan] Univ Marburg, Inst Virol, D-35043 Marburg, Germany.
   [Sauerhering, Lucie; Becker, Stephan] Univ Marburg, German Ctr Infect Res DZIF, Marburg Giessen Langen Site, D-35043 Marburg, Germany.
   [Rox, Katharina] Helmholtz Ctr Infect Res HZI, Dept Chem Biol, D-38124 Braunschweig, Germany.
   [Rox, Katharina] Helmholtz Ctr Infect Res, German Ctr Infect Res DZIF, Hannover Braunschweig Site, D-38124 Braunschweig, Germany.
RP Hilgenfeld, R (corresponding author), Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, D-23562 Lubeck, Germany.; Hilgenfeld, R (corresponding author), Univ Lubeck, German Ctr Infect Res DZIF, Hamburg Lubeck Borstel Riems Site, D-23562 Lubeck, Germany.
EM rolf.hilgenfeld@uni-luebeck.de
OI Hilgenfeld, Rolf/0000-0001-8850-2977; Sun,
   Xinyuanyuan/0000-0002-2761-2862; Rox, Katharina/0000-0002-8020-1384
FU German Center for Infection Research (DZIF) [TTU01, 8011801806, TTU09,
   8004709710]
FX We thank the German Center for Infection Research (DZIF) for financial
   support (projects TTU01, grant 8011801806, and TTU09, grant 8004709710).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Brautigam CA, 2015, METHOD ENZYMOL, V562, P109, DOI 10.1016/bs.mie.2015.05.001
   Brown Patrick H, 2008, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1815s81
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dragovich PS, 1999, BIOORGAN MED CHEM, V7, P589, DOI 10.1016/S0968-0896(99)00005-X
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hsu WC, 2005, J BIOL CHEM, V280, P22741, DOI 10.1074/jbc.M502556200
   Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]
   Kratochwil NA, 2002, BIOCHEM PHARMACOL, V64, P1355, DOI 10.1016/S0006-2952(02)01074-2
   Krug M, 2012, J APPL CRYSTALLOGR, V45, P568, DOI 10.1107/S0021889812011715
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1
   Lebedev AA, 2012, ACTA CRYSTALLOGR D, V68, P431, DOI 10.1107/S090744491200251X
   Lim LZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101941
   Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014
   Mueller U, 2012, J SYNCHROTRON RADIAT, V19, P442, DOI 10.1107/S0909049512006395
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Shi JH, 2006, FEBS J, V273, P1035, DOI 10.1111/j.1742-4658.2006.05130.x
   Tan JZ, 2013, J VIROL, V87, P4339, DOI 10.1128/JVI.01123-12
   Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012
   Tian QP, 2001, TETRAHEDRON LETT, V42, P6807, DOI 10.1016/S0040-4039(01)01416-2
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang L, 2020, MED CHEM RES, V29, P575, DOI 10.1007/s00044-020-02509-4
   Zhang L, 2020, STRUCT CONCRETE, V21, P1612, DOI 10.1002/suco.201900550
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu L., 2012, CRYSTAL STRUCTURE SA
   Zhu LL, 2011, ANTIVIR RES, V92, P204, DOI 10.1016/j.antiviral.2011.08.001
NR 43
TC 370
Z9 379
U1 44
U2 128
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD APR 24
PY 2020
VL 368
IS 6489
BP 409
EP +
DI 10.1126/science.abb3405
PG 47
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LH0XH
UT WOS:000528513300041
PM 32198291
OA Green Published, Other Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Azizy, A
   Fayaz, M
   Agirbasli, M
AF Azizy, Abdulmunir
   Fayaz, Mujtaba
   Agirbasli, Mehmet
TI Do Not Forget Afghanistan in Times of COVID-19: Telemedicine and the
   Internet of Things to Strengthen Planetary Health Systems
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
DE COVID-19; pandemic; telemedicine; Internet of Things; planetary health;
   Afghanistan
AB Health care does not always take place in a setting of peace, prosperity, and social order, a point that is often overlooked in quotidian medical practice. This has become most evident with the current COVID-19 pandemic by the new coronavirus that is wreaking havoc across the planet. Health care providers are facing unprecedented challenges to intervene on numerous nonlinear uncertainties in science and society as the pandemic evolves. In Afghanistan, health care delivery is already a major crosscutting challenge. Although efforts to rebuild the health care systems in Afghanistan have been made (Acerra et al.), both acute and chronic illnesses remain as major medical and critical governance gaps to be remedied. In addition, health care facilities and medical equipment are not adequate in the country. There is a need for medical and scientific expertise to clinically and sociologically contextualize and interpret diagnostic tests as well as drugs and vaccines that will be deployed in the coming months as part of the planetary collective response to the COVID-19 pandemic. In a time of pandemic and facing a novel infectious pathogen, health care workers are in need of planetary scale consultation and support. Even creating a small consultation network using mobile applications might offer improved health outcomes. The Internet of Things and digital health ought to be considered in concert with telemedicine as part of an effective pandemic response.
C1 [Azizy, Abdulmunir] Serat Hosp, Dept Pediat, Kabul, Afghanistan.
   [Azizy, Abdulmunir; Fayaz, Mujtaba] Acibadem Maslak Hosp, Dept Med, Esenler Mah Turna Sokak 10,D 17, TR-34457 Istanbul, Turkey.
   [Agirbasli, Mehmet] Medeniyet Univ, Dept Cardiol, Sch Med, Istanbul, Turkey.
RP Azizy, A (corresponding author), Acibadem Maslak Hosp, Dept Med, Esenler Mah Turna Sokak 10,D 17, TR-34457 Istanbul, Turkey.
EM munir.azizy@gmail.com
CR Acerra JR, 2009, INT J EMERG MED, V2, P77, DOI 10.1007/s12245-009-0106-y
   Calton B, 2020, J PAIN SYMPTOM MANAG
   Ozdemir V, 2019, OMICS, V23, P623, DOI 10.1089/omi.2019.0175
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Peeri NC, 2020, INT J EPIDEMIOL
   Reichert C, 2019, ZDNET
   Sarewitz D., 2016, NEW ATLANTIS, V49, P4
   Sclove R, 2020, DIGIT GOV RES PRACT, P5
   Thunberg G., 2019, GUARDIAN
   WHO, 2020, 75 WHO
   World Health Organization, 2016, AFGH COUNTR PROF
NR 11
TC 4
Z9 5
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD JUN 1
PY 2020
VL 24
IS 6
BP 311
EP 313
DI 10.1089/omi.2020.0053
EA APR 2020
PG 3
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA LV5US
UT WOS:000529423700001
PM 32324451
OA Bronze
DA 2021-01-01
ER

PT J
AU Choy, EH
   De Benedetti, F
   Takeuchi, T
   Hashizume, M
   John, MR
   Kishimoto, T
AF Choy, Ernest H.
   De Benedetti, Fabrizio
   Takeuchi, Tsutomu
   Hashizume, Misato
   John, Markus R.
   Kishimoto, Tadamitsu
TI Translating IL-6 biology into effective treatments
SO NATURE REVIEWS RHEUMATOLOGY
LA English
DT Article
ID JUVENILE IDIOPATHIC ARTHRITIS; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY;
   MODIFYING ANTIRHEUMATIC DRUGS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   NECROSIS-FACTOR-ALPHA; LONG-TERM SAFETY; ACTIVE RHEUMATOID-ARTHRITIS;
   GIANT-CELL ARTERITIS; OPEN-LABEL EXTENSION; DOUBLE-BLIND
AB In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and cytokine release syndrome. Targeting this pathway has also identified avenues for potential expansion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumonia. To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling, including the successes and challenges and with an emphasis on rheumatic diseases.
   In this Perspective article, the authors recount the earliest stages of translational research into IL-6 biology and the subsequent development of therapeutic IL-6 pathway inhibitors for the treatment of autoimmune rheumatic diseases and potentially numerous other indications.
C1 [Choy, Ernest H.] Cardiff Univ, CREATE Ctr, Div Infect & Immun, Cardiff, England.
   [De Benedetti, Fabrizio] Osped Pediat Bambino Gesu, Div Rheumatol, Rome, Italy.
   [De Benedetti, Fabrizio] Osped Pediat Bambino Gesu, Lab ImmunoRheumatol, Rome, Italy.
   [Takeuchi, Tsutomu] Keio Univ, Dept Internal Med, Div Rheumatol, Sch Med, Tokyo, Japan.
   [Hashizume, Misato] Chugai Pharmaceut Co Ltd, Tokyo, Japan.
   [John, Markus R.] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
   [Kishimoto, Tadamitsu] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, Lab Immune Regulat, Osaka, Japan.
RP Choy, EH (corresponding author), Cardiff Univ, CREATE Ctr, Div Infect & Immun, Cardiff, England.
EM ChoyEH@Cardiff.ac.uk
RI de benedetti, fabrizio/J-9577-2018; Takeuchi, Tsutomu/L-2327-2013
OI de benedetti, fabrizio/0000-0001-8749-8232; Choy,
   Ernest/0000-0003-4459-8609; Takeuchi, Tsutomu/0000-0003-1111-8218
CR Albrecht K, 2014, RHEUMATOL INT, V34, P1, DOI 10.1007/s00296-013-2848-3
   Aletaha D, 2017, LANCET, V389, P1206, DOI 10.1016/S0140-6736(17)30401-4
   Ambarus C, 2012, CURR OPIN RHEUMATOL, V24, P351, DOI 10.1097/BOR.0b013e3283534df4
   Atreya R, 2000, NAT MED, V6, P583
   BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685
   BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392
   BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904
   Bharucha KN, 2018, J RHEUMATOL, V45, P1173, DOI 10.3899/jrheum.170326
   Boyapati A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1132-9
   Brunner HI, 2015, ANN RHEUM DIS, V74, P1110, DOI 10.1136/annrheumdis-2014-205351
   Burmester GR, 2017, ANN RHEUM DIS, V76, P1279, DOI 10.1136/annrheumdis-2016-210561
   Burmester GR, 2017, ANN RHEUM DIS, V76, P1078, DOI 10.1136/annrheumdis-2016-210297
   Burmester GR, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210310
   Burmester GR, 2016, ANN RHEUM DIS, V75, P1081, DOI 10.1136/annrheumdis-2015-207628
   Burmester GR, 2016, ANN RHEUM DIS, V75, P68, DOI 10.1136/annrheumdis-2015-207281
   Cazzola M, 1996, BLOOD, V87, P4824, DOI 10.1182/blood.V87.11.4824.bloodjournal87114824
   Choy EHS, 2002, ARTHRITIS RHEUM-US, V46, P3143, DOI 10.1002/art.10623
   Choy E, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2018-000798
   Curtis JR, 2015, SEMIN ARTHRITIS RHEU, V44, P381, DOI 10.1016/j.semarthrit.2014.07.006
   DASGUPTA B, 1990, BRIT J RHEUMATOL, V29, P456
   Davis MC, 2008, BRAIN BEHAV IMMUN, V22, P24, DOI 10.1016/j.bbi.2007.06.013
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   De Benedetti F, 2015, ARTHRITIS RHEUMATOL, V67, P840, DOI 10.1002/art.38984
   De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802
   De Lauretis A, 2013, J RHEUMATOL, V40, P435, DOI 10.3899/jrheum.120725
   DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207
   DEBENEDETTI F, 1994, J CLIN INVEST, V93, P2114, DOI 10.1172/JCI117206
   DEBENEDETTI F, 1991, ARTHRITIS RHEUM, V34, P1158, DOI 10.1002/art.1780340912
   Dejaco C, 2017, NAT REV RHEUMATOL, V13, P578, DOI 10.1038/nrrheum.2017.142
   Devauchelle-Pensec V, 2016, ANN RHEUM DIS, V75, P1506, DOI 10.1136/annrheumdis-2015-208742
   Dougados M, 2014, ANN RHEUM DIS, V73, P803, DOI 10.1136/annrheumdis-2013-204761
   Dougados M, 2013, ANN RHEUM DIS, V72, P43, DOI 10.1136/annrheumdis-2011-201282
   Duarte C, 2017, ACTA REUMATOL PORT, V42, P112
   Dutch Association for Rheumatology, 2009, NVR STANDP TOC VERKL
   Edwards CJ, 2018, RHEUMATOLOGY, V57, P84, DOI 10.1093/rheumatology/kex358
   Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932
   Emery P, 2019, RHEUMATOLOGY, V58, P849, DOI 10.1093/rheumatology/key361
   European Medicines Agency, 2017, SAR SUMM PROD CHAR E
   European Medicines Agency, 2018, TOC SUMM PROD CHAR E
   FDA, 2017, FDA SUMM MIN ARTHR A
   Finzel S, 2019, ANN RHEUM DIS, V78, P1186, DOI 10.1136/annrheumdis-2018-214894
   Fioravanti A, 2019, CLIN EXP RHEUMATOL, V37, P293
   Flaig T, 2016, J CLIN PHARM THER, V41, P718, DOI 10.1111/jcpt.12456
   Fleischmann R, 2017, ARTHRITIS RHEUMATOL, V69, P277, DOI 10.1002/art.39944
   Fonseca JE, 2011, ACTA REUMATOL PORT, V36, P385
   Fujimoto M, 2008, ARTHRITIS RHEUM-US, V58, P3710, DOI 10.1002/art.24126
   Gabay C, 2016, ANN RHEUM DIS, V75, P1806, DOI 10.1136/annrheumdis-2015-207872
   Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0
   Garbers C, 2018, NAT REV DRUG DISCOV, V17, P395, DOI 10.1038/nrd.2018.45
   Garcia-Vicuna R, 2017, REUMATOL CLIN, V13, P127, DOI 10.1016/j.reuma.2016.10.002
   Gaujoux-Viala C, 2014, JOINT BONE SPINE, V81, P287, DOI 10.1016/j.jbspin.2014.05.002
   Genentech, 2019, TOC PACK INS US
   Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2968, DOI 10.1002/art.23940
   Genovese MC, 2017, ARTHRITIS RHEUMATOL, V69, P1751, DOI 10.1002/art.40176
   Genovese MC, 2014, ANN RHEUM DIS, V73, P1607, DOI 10.1136/annrheumdis-2013-204760
   Genovese MC, 2013, J RHEUMATOL, V40, P768, DOI 10.3899/jrheum.120687
   GORDON C, 1991, CLIN EXP IMMUNOL, V86, P145
   GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927
   Gron KL, 2019, ANN RHEUM DIS, V78, P320, DOI 10.1136/annrheumdis-2018-214326
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921
   GURRAM M, 1994, ANN ALLERGY, V73, P493
   Hashizume M, 2015, INT REV IMMUNOL, V34, P265, DOI 10.3109/08830185.2014.938325
   Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644
   HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7
   Hinze C, 2015, NAT REV RHEUMATOL, V11, P290, DOI 10.1038/nrrheum.2014.212
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   HIROHATA S, 1990, ARTHRITIS RHEUM, V33, P644, DOI 10.1002/art.1780330506
   Hoeltzenbein M, 2016, SEMIN ARTHRITIS RHEU, V46, P238, DOI 10.1016/j.semarthrit.2016.05.004
   Hoshino T, 1998, J RHEUMATOL, V25, P396
   Hosokawa T, 1999, J GASTROEN HEPATOL, V14, P987, DOI 10.1046/j.1440-1746.1999.01989.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Illei GG, 2010, ARTHRITIS RHEUM-US, V62, P542, DOI 10.1002/art.27221
   Imagawa T, 2012, MOD RHEUMATOL, V22, P109, DOI 10.1007/s10165-011-0481-0
   Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Jones G, 2010, ANN RHEUM DIS, V69, P88, DOI 10.1136/ard.2008.105197
   Jones G, 2017, J RHEUMATOL, V44, P142, DOI 10.3899/jrheum.160287
   Kadono T, 1998, J RHEUMATOL, V25, P296, DOI 10.1016/S0923-1811(98)84143-1
   Kaneko Y, 2018, ANN RHEUM DIS, V77, P1720, DOI 10.1136/annrheumdis-2018-213920
   Kaneko Y, 2018, ANN RHEUM DIS, V77, P1268, DOI 10.1136/annrheumdis-2018-213416
   Kaneko Y, 2016, ANN RHEUM DIS, V75, P1917, DOI 10.1136/annrheumdis-2015-208426
   Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026
   Katsume A, 2002, CYTOKINE, V20, P304, DOI 10.1006/cyto.2002.2012
   Kavanaugh A, 2013, ANN RHEUM DIS, V72, P674
   KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0
   KHANNA D, 2018, ARTHRITIS RHEUMAT S9, V70
   Khanna D, 2016, LANCET, V387, P2630, DOI 10.1016/S0140-6736(16)00232-4
   Kim ESH, 2018, HEART, V104, P558, DOI 10.1136/heartjnl-2016-310848
   Kim SC, 2018, SEMIN ARTHRITIS RHEU, V48, P399, DOI 10.1016/j.semarthrit.2018.03.012
   Kim SC, 2017, ARTHRITIS RHEUMATOL, V69, P1154, DOI 10.1002/art.40084
   KISHIMOTO T, 1973, J IMMUNOL, V111, P1194
   Kitaba S, 2012, AM J PATHOL, V180, P165, DOI 10.1016/j.ajpath.2011.09.013
   Kivitz A, 2016, RHEUMATOL THER, V3, P291, DOI 10.1007/s40744-016-0043-1
   Koike T, 2014, J RHEUMATOL, V41, P15, DOI 10.3899/jrheum.130466
   Koike T, 2011, ANN RHEUM DIS, V70, P2148, DOI 10.1136/ard.2011.151092
   Kremer JM, 2016, CLIN EXP RHEUMATOL, V34, P625
   Kremer JM, 2018, ARTHRITIS RHEUMATOL, V70, P1200, DOI 10.1002/art.40493
   Kremer JM, 2011, ARTHRITIS RHEUM-US, V63, P609, DOI 10.1002/art.30158
   Lally L, 2016, ARTHRITIS RHEUMATOL, V68, P2550, DOI 10.1002/art.39740
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   LU ZY, 1995, BLOOD, V86, P3123
   Macchioni P, 2013, SEMIN ARTHRITIS RHEU, V43, P113, DOI 10.1016/j.semarthrit.2013.01.003
   Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033
   Mease PJ, 2016, ARTHRITIS RHEUMATOL, V68, P2163, DOI 10.1002/art.39700
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   MEYERS FJ, 1991, CANCER-AM CANCER SOC, V67, P2087, DOI 10.1002/1097-0142(19910415)67:8<2087::AID-CNCR2820670814>3.0.CO;2-R
   Mihara M, 2005, INT IMMUNOPHARMACOL, V5, P1731, DOI 10.1016/j.intimp.2005.05.010
   MIHARA M, 1990, INT ARCH ALLER A IMM, V93, P89, DOI 10.1159/000235285
   MITSUYAMA K, 1995, GUT, V36, P45, DOI 10.1136/gut.36.1.45
   Monemi S, 2016, RHEUMATOL THER, V3, P337, DOI 10.1007/s40744-016-0037-z
   Morel J, 2017, RHEUMATOLOGY, V56, P1746, DOI 10.1093/rheumatology/kex238
   Moreland LW, 2009, SEMIN ARTHRITIS RHEU, V39, P132, DOI 10.1016/j.semarthrit.2008.08.003
   Nakaoka Y, 2018, ANN RHEUM DIS, V77, P348, DOI 10.1136/annrheumdis-2017-211878
   National Institute for Health and Care Excellence, 2016, AD ET INFL CERT PEG
   Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447
   Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303
   Nishimoto N, 2009, ANN RHEUM DIS, V68, P1580, DOI 10.1136/ard.2008.092866
   Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602
   Nishimoto N, 2000, BLOOD, V95, P56, DOI 10.1182/blood.V95.1.56
   Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21
   Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064
   Noris M, 1999, CIRCULATION, V100, P55, DOI 10.1161/01.CIR.100.1.55
   Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222
   Opoka-Winiarska V, 2018, CLIN RHEUMATOL, V37, P1807, DOI 10.1007/s10067-018-4071-9
   Papalopoulos I, 2018, CLIN EXP RHEUMATOL, V36, P102
   Pardeo M, 2019, J RHEUMATOL, V46, P1117, DOI 10.3899/jrheum.180795
   Partsch G, 1997, J RHEUMATOL, V24, P518
   Pignatti P, 2001, J RHEUMATOL, V28, P1670
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x
   Ranganathan V, 2017, NAT REV RHEUMATOL, V13, P359, DOI 10.1038/nrrheum.2017.56
   Ravelli A, 2007, LANCET, V369, P767, DOI 10.1016/S0140-6736(07)60363-8
   RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0
   Rovin BH, 2016, ARTHRITIS RHEUMATOL, V68, P2174, DOI 10.1002/art.39722
   Rubbert-Roth A, 2018, RHEUMATOL THER, V5, P21, DOI 10.1007/s40744-018-0102-x
   Rutherford AI, 2018, ANN RHEUM DIS, V77, P905, DOI 10.1136/annrheumdis-2017-212825
   Sakai R, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0583-8
   San-Miguel J, 2014, BLOOD, V123, P4136, DOI 10.1182/blood-2013-12-546374
   Sanofi, 2018, SAR PACK INS US
   SATO K, 1993, CANCER RES, V53, P851
   Scher JU, 2019, NAT REV RHEUMATOL, V15, P153, DOI 10.1038/s41584-019-0175-0
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Shima Y, 2010, RHEUMATOLOGY, V49, P2408, DOI 10.1093/rheumatology/keq275
   Shirota Y, 2013, ANN RHEUM DIS, V72, P118, DOI 10.1136/annrheumdis-2012-201310
   Sieper J, 2015, ANN RHEUM DIS, V74, P1051, DOI 10.1136/annrheumdis-2013-204963
   Sieper J, 2014, ANN RHEUM DIS, V73, P95, DOI 10.1136/annrheumdis-2013-203559
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis-2019-216655
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Strand V, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2017-000496
   SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547
   Swedish Rheumatological Association, 2011, GUID PHARM MAN RHEUM
   Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.3.CO;2-G
   Takeuchi T, 2017, ANN RHEUM DIS, V76, P2001, DOI 10.1136/annrheumdis-2017-211328
   Takeuchi T, 2011, RHEUMATOLOGY, V50, P1908, DOI 10.1093/rheumatology/ker221
   TANAKA Y, 1988, J IMMUNOL, V141, P3043
   Taylor PC, 2018, ANN RHEUM DIS, V77, P658, DOI 10.1136/annrheumdis-2017-212496
   Teitsma XM, 2018, ANN RHEUM DIS, V77, P1261, DOI 10.1136/annrheumdis-2018-213035
   Teitsma XM, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1108-9
   Tsunenari T, 1997, BLOOD, V90, P2437
   van Kuijk AWR, 2006, ANN RHEUM DIS, V65, P1551, DOI 10.1136/ard.2005.050963
   van Rhee F, 2014, LANCET ONCOL, V15, P966, DOI 10.1016/S1470-2045(14)70319-5
   VANDELOO FAJ, 1995, ARTHRITIS RHEUM, V38, P164
   Villiger PM, 2016, LANCET, V387, P1921, DOI 10.1016/S0140-6736(16)00560-2
   WAAGE A, 1989, CLIN IMMUNOL IMMUNOP, V50, P394, DOI 10.1016/0090-1229(89)90146-3
   Wallace DJ, 2017, ANN RHEUM DIS, V76, P534, DOI 10.1136/annrheumdis-2016-209668
   WENDLING D, 1993, J RHEUMATOL, V20, P259
   Woo P, 2005, ARTHRITIS RES THER, V7, pR1281, DOI 10.1186/ar1826
   Yamamoto K, 2015, J RHEUMATOL, V42, P1368, DOI 10.3899/jrheum.141210
   YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
   Yokota S, 2005, ARTHRITIS RHEUM, V52, P818, DOI 10.1002/art.20944
   Yokota S, 2016, ANN RHEUM DIS, V75, P1654, DOI 10.1136/annrheumdis-2015-207818
   Yokota S, 2014, J RHEUMATOL, V41, P759, DOI 10.3899/jrheum.130690
   Yokota S, 2013, ANN RHEUM DIS, V72, P627, DOI 10.1136/annrheumdis-2012-202310
   YOSHIZAKI K, 1989, BLOOD, V74, P1360
NR 177
TC 18
Z9 20
U1 5
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4790
EI 1759-4804
J9 NAT REV RHEUMATOL
JI Nat. Rev. Rheumatol.
PD JUN
PY 2020
VL 16
IS 6
BP 335
EP 345
DI 10.1038/s41584-020-0419-z
EA APR 2020
PG 11
WC Rheumatology
SC Rheumatology
GA LR9IW
UT WOS:000528511900001
PM 32327746
OA Bronze, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Yang, CL
   Qiu, X
   Fan, HR
   Jiang, M
   Lao, XJ
   Zeng, YK
   Zhang, ZM
AF Yang, Chenglei
   Qiu, Xue
   Fan, Haoran
   Jiang, Mei
   Lao, Xiaojie
   Zeng, Yukeng
   Zhang, Zhiming
TI Coronavirus disease 2019: reassembly attack of coronavirus
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH
LA English
DT Article; Early Access
DE COVID-19; sars-CoV-2; epidemiology
ID TO-HUMAN TRANSMISSION; GLOBAL HEALTH; 2019-NCOV; OUTBREAK; WUHAN; SARS;
   MERS
AB There have been three major global outbreaks of acute respiratory disease caused by coronavirus in the last two decades. The ongoing Coronavirus Disease 2019 (COVID-19) first emerged in Wuhan, China, is the most dangerous, which spread to 163 countries and 6 continents and caused a major public health emergency worldwide. The outbreak is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) originated from bats, which spreads rapidly from human to human. As of 17 March 2020, there have been 179,112 confirmed cases and 7426 deaths worldwide, with a mortality rate of 4.1%. There is currently no effective treatment or approved vaccine, so isolating the source of infection and blocking the routes of transmission is important. In this article, we summarized the worldwide epidemic trend of COVID-19 and discussed its epidemiological characteristics, prevention and control measures. We hope this article could provide experience and help for global epidemic prevention and control.
C1 [Yang, Chenglei; Zhang, Zhiming] Guangxi Med Univ, Dept Hepatobiliary Surg, Canc Hosp, Nanning, Guangxi, Peoples R China.
   [Qiu, Xue; Fan, Haoran; Jiang, Mei; Zeng, Yukeng] Guangxi Med Univ, Clin Med Sch 1, Nanning, Guangxi, Peoples R China.
   [Lao, Xiaojie] Guangxi Med Univ, Dept Infect Dis, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
RP Zhang, ZM (corresponding author), 71 Hedi Rd,Bldg 106, Nanning 530021, Guangxi, Peoples R China.
EM z450211@yeah.net
CR Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen Y., 2020, PREPRINTS, P1, DOI [10.20944/preprints202002.0258.v2, DOI 10.20944/PREPRINTS202002.0258.V2]
   Christian MD, 2004, CLIN INFECT DIS, V38, P1420, DOI 10.1086/420743
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo X, 2020, LONG TERM PERSISTENC
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XG, 2020, J MED VIROL, V92, P448, DOI 10.1002/jmv.25693
   Lin QY, 2018, STAT METHODS MED RES, V27, P1968, DOI 10.1177/0962280217746442
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Liu P, ARE PANGOLINS INTERM
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Lu H, 2020, DESCRIPTIVE STUDY IM, V2020
   Peiris J, 2004, NAT MED, V89, P551
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Read JM, NOVEL CORONAVIRUS 20
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Silverstein WK, 2020, LANCET, V395, P734, DOI 10.1016/S0140-6736(20)30370-6
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tian H, 2020, EARLY EVALUATION WUH
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang J, 2020, ACE2 EXPRESSION COLO
   Wilson ME, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa015
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xiao K, 2020, ISOLATION CHARACTERI
   Yang Y, 2020, EPIDEMIOLOGICAL CLIN
   Yang ZF, 2020, J THORAC DIS, V12, P165, DOI 10.21037/jtd.2020.02.64
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu WB, DECODING EVOLUTION T
   Zhang C., 2020, ORIGIN TIME EPIDEMIC
   Zhang H, 2020, DIGESTIVE SYSTEM IS
   Zhang RQ, 2020, TRANSMISSION EPIDEMI
   Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2020, OPHTHALMOLOGIC EVIDE
NR 49
TC 2
Z9 2
U1 1
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0960-3123
EI 1369-1619
J9 INT J ENVIRON HEAL R
JI Int. J. Environ. Health Res.
DI 10.1080/09603123.2020.1747602
EA APR 2020
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA LG5XS
UT WOS:000528173800001
PM 32316751
DA 2021-01-01
ER

PT J
AU Sang, P
   Tian, SH
   Meng, ZH
   Yang, LQ
AF Sang, Peng
   Tian, Shu-Hui
   Meng, Zhao-Hui
   Yang, Li-Quan
TI Anti-HIV drug repurposing against SARS-CoV-2
SO RSC ADVANCES
LA English
DT Article
ID GENERAL FORCE-FIELD; BIOLOGICAL EVALUATION; MAIN PROTEASE; SARS;
   INHIBITORS; INSIGHTS; DOCKING
AB A novel severe acute respiratory syndrome human coronavirus (SARS HCoV) was identified from respiratory illness patients (named SARS-CoV-2 by ICTV) in December 2019 and has recently emerged as a serious threat to world public health. However, no approved drugs have been found to effectively inhibit the virus. Since it has been reported that HIV protease inhibitors can be used as anti-SARS drugs by targeting SARS-CoV-1 3CLpro, we chose six approved anti-HIV drugs and investigated their binding interactions with 3CLpro to evaluate their potential to become clinical drugs for the new coronavirus pneumonia (COVID-19) caused by SARS-CoV-2 infection. The molecular docking results indicate that the 3CLpro of SARS-CoV-2 has a higher binding affinity for all the studied inhibitors than does SARS-CoV-1. Two docking complexes (indinavir and darunavir) with high docking scores were further subjected to MM-PBSA binding free energy calculations to detail the molecular interactions between these two protease inhibitors and SARS HCoV 3CLpro. Our results show that, among the inhibitors tested, darunavir has the highest binding affinity with SARS-CoV-2 and SARS-CoV-1 3CLpro, indicating that it may have the potential to be used as an anti-COVID-19 clinical drug. The mechanism behind the increased binding affinity of HIV protease inhibitors toward SARS-CoV-2 3CLpro (as compared to SARS-CoV-1) was investigated by MD simulations. Our study provides insight into the possible role of structural flexibility during interactions between SARS HCoV 3CLpro and inhibitors and sheds light on structure-based design of anti-COVID-19 drugs targeting SARS-CoV-2 3CLpro.
C1 [Sang, Peng; Tian, Shu-Hui; Yang, Li-Quan] Dali Univ, Coll Agr & Biol Sci, Dali, Peoples R China.
   [Meng, Zhao-Hui] Kunming Med Univ, Dept Cardiol, NHC Key Lab Drug Addict Med, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China.
RP Yang, LQ (corresponding author), Dali Univ, Coll Agr & Biol Sci, Dali, Peoples R China.; Meng, ZH (corresponding author), Kunming Med Univ, Dept Cardiol, NHC Key Lab Drug Addict Med, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China.
EM zhhmeng@aliyun.com; ylqbioinfo@gmail.com
OI , sang/0000-0002-8556-2461
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31860243, 31960198, 31660015, 81860074];
   Yunnan Applied Basic Research Projects [2017FH001-032, 2017FB024]
FX This study was funded by the National Natural Sciences Foundation of
   China (31860243, 31960198 and 31660015, 81860074) and Yunnan Applied
   Basic Research Projects (2017FH001-032 and 2017FB024). We greatly
   acknowledge the help of Roger DuBois in revising the manuscript.
CR [Anonymous], PYMOL MOL GRAPHICS S
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Bond CS, 2009, ACTA CRYSTALLOGR D, V65, P510, DOI 10.1107/S0907444909007835
   Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082080
   Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kokkinidis M, 2012, ADV PROTEIN CHEM STR, V87, P181, DOI 10.1016/B978-0-12-398312-1.00007-X
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee CC, 2007, FEBS LETT, V581, P5454, DOI 10.1016/j.febslet.2007.10.048
   Liu SQ, 2011, J MOL MODEL, V17, P289, DOI 10.1007/s00894-010-0724-6
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Reddy AD, 2003, B KOR CHEM SOC, V24, P899
   Sang P, 2017, J BIOMOL STRUCT DYN, V35, P2441, DOI 10.1080/07391102.2016.1222967
   Sang P, 2017, COMPUT BIOL CHEM, V67, P141, DOI 10.1016/j.compbiolchem.2016.12.015
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Wang L, 2017, EUR J MED CHEM, V137, P450, DOI 10.1016/j.ejmech.2017.05.045
   Wu RJ, 2019, EUR J MED CHEM, V162, P348, DOI 10.1016/j.ejmech.2018.11.005
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
   Zhang XW, 2004, BIOORGAN MED CHEM, V12, P2517, DOI 10.1016/j.bmc.2004.03.035
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 17
Z9 17
U1 2
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD APR 22
PY 2020
VL 10
IS 27
BP 15775
EP 15783
DI 10.1039/d0ra01899f
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA LK2WB
UT WOS:000530721700015
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Pachetti, M
   Marini, B
   Benedetti, F
   Giudici, F
   Mauro, E
   Storici, P
   Masciovecchio, C
   Angeletti, S
   Ciccozzi, M
   Gallo, RC
   Zella, D
   Ippodrino, R
AF Pachetti, Maria
   Marini, Bruna
   Benedetti, Francesca
   Giudici, Fabiola
   Mauro, Elisabetta
   Storici, Paola
   Masciovecchio, Claudio
   Angeletti, Silvia
   Ciccozzi, Massimo
   Gallo, Robert C.
   Zella, Davide
   Ippodrino, Rudy
TI Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA
   polymerase variant
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Mutation; Drug resistance; RdRp; Europe;
   RNA-dependent-RNA-polymerase; Pneumonia; Viral mutagenesis
ID REPLICATION; RIBAVIRIN; VIRUS
AB Background SARS-CoV-2 is a RNA coronavirus responsible for the pandemic of the Severe Acute Respiratory Syndrome (COVID-19). RNA viruses are characterized by a high mutation rate, up to a million times higher than that of their hosts. Virus mutagenic capability depends upon several factors, including the fidelity of viral enzymes that replicate nucleic acids, as SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Mutation rate drives viral evolution and genome variability, thereby enabling viruses to escape host immunity and to develop drug resistance. Methods We analyzed 220 genomic sequences from the GISAID database derived from patients infected by SARS-CoV-2 worldwide from December 2019 to mid-March 2020. SARS-CoV-2 reference genome was obtained from the GenBank database. Genomes alignment was performed using Clustal Omega. Mann-Whitney and Fisher-Exact tests were used to assess statistical significance. Results We characterized 8 novel recurrent mutations of SARS-CoV-2, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403 and 28881. Mutations in 2891, 3036, 14408, 23403 and 28881 positions are predominantly observed in Europe, whereas those located at positions 17746, 17857 and 18060 are exclusively present in North America. We noticed for the first time a silent mutation in RdRp gene in England (UK) on February 9th, 2020 while a different mutation in RdRp changing its amino acid composition emerged on February 20th, 2020 in Italy (Lombardy). Viruses with RdRp mutation have a median of 3 point mutations [range: 2-5], otherwise they have a median of 1 mutation [range: 0-3] (p value < 0.001). Conclusions These findings suggest that the virus is evolving and European, North American and Asian strains might coexist, each of them characterized by a different mutation pattern. The contribution of the mutated RdRp to this phenomenon needs to be investigated. To date, several drugs targeting RdRp enzymes are being employed for SARS-CoV-2 infection treatment. Some of them have a predicted binding moiety in a SARS-CoV-2 RdRp hydrophobic cleft, which is adjacent to the 14408 mutation we identified. Consequently, it is important to study and characterize SARS-CoV-2 RdRp mutation in order to assess possible drug-resistance viral phenotypes. It is also important to recognize whether the presence of some mutations might correlate with different SARS-CoV-2 mortality rates.
C1 [Pachetti, Maria; Storici, Paola; Masciovecchio, Claudio] Elettra Sincrotrone Trieste Area Sci Pk, Trieste, Italy.
   [Pachetti, Maria] Univ Trieste, Dept Phys, Via Valerio 2, Trieste, Italy.
   [Giudici, Fabiola] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
   [Marini, Bruna; Mauro, Elisabetta; Ippodrino, Rudy] Ulisse BioMed Area Sci Pk, Trieste, Italy.
   [Benedetti, Francesca; Zella, Davide] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Inst Human Virol, Baltimore, MD 21201 USA.
   [Angeletti, Silvia; Ciccozzi, Massimo] Univ Biomed Campus, Med Stat & Mol Epidemiol Unit, Rome, Italy.
   [Gallo, Robert C.] Univ Maryland, Sch Med, Dept Med, Inst Human Virol, Baltimore, MD 21201 USA.
   [Gallo, Robert C.; Zella, Davide] Global Virus Network, Baltimore, MD 21201 USA.
RP Ippodrino, R (corresponding author), Ulisse BioMed Area Sci Pk, Trieste, Italy.; Zella, D (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Inst Human Virol, Baltimore, MD 21201 USA.; Zella, D (corresponding author), Global Virus Network, Baltimore, MD 21201 USA.
EM DZella@ihv.umaryland.edu; r.ippodrino@ulissebiomed.com
RI ZELLA, DAVIDE/AAC-7630-2020; Benedetti, Francesca/AAU-3879-2020;
   Giudici, Fabiola/R-8426-2016; GIUDICI, FABIOLA/AAJ-4919-2020
OI ZELLA, DAVIDE/0000-0001-5576-5770; Benedetti,
   Francesca/0000-0001-8720-090X; Giudici, Fabiola/0000-0002-4160-3479;
   GIUDICI, FABIOLA/0000-0002-4160-3479; storici,
   paola/0000-0002-2590-3332; Pachetti, Maria/0000-0002-1307-7475
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Domingo E, 2000, VIROLOGY, V270, P251, DOI 10.1006/viro.2000.0320
   Domingo E, 2002, J VIROL, V76, P463, DOI 10.1128/JVI.76.1.463-465.2002
   Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Jia HX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01945
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim SY, 2017, OPEN FORUM INFECT DI, DOI [DOI 10.1093/ofid/ofx162.129, 10.1093/ofid/ofx162.129]
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Najjar M, 2015, CELL REP, V10, P1850, DOI 10.1016/j.celrep.2015.02.052
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100
   Ruan Z., 2020, PREPRINTS, DOI [10.20944/preprints202003.0024.v1, DOI 10.20944/PREPRINTS202003.0024.V1]
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 34
TC 94
Z9 96
U1 14
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD APR 22
PY 2020
VL 18
IS 1
AR 179
DI 10.1186/s12967-020-02344-6
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LJ4IU
UT WOS:000530130800001
PM 32321524
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Suba, Z
AF Suba, Zsuzsanna
TI Prevention and Therapy of COVID-19 via Exogenous Estrogen Treatment for
   Both Male and Female Patients; An Opinion Paper
SO JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
LA English
DT Article
ID PLASMACYTOID DENDRITIC CELLS; ACUTE RESPIRATORY SYNDROME; BREAST-CANCER;
   RISK-FACTORS; POSTMENOPAUSAL WOMEN; INSULIN-RESISTANCE; IN-VIVO;
   RECEPTOR; INFLUENZA; INFECTION
AB The presented work summarizes the results of studies underlining the crucial role of estrogen receptor (ER) signaling in both innate and adaptive immune responses as well as in tissue repairing processes during respiratory virus infection. Experimental studies justify that among respiratory virus infected mice, a weaker ER signaling leads to increased morbidity and mortality in both males and females. In animal experiments, estrogen treatment silences the inflammatory reactions and decreases virus titers leading to improved survival rate; it seems to be an ideal prevention and therapy against COVID-19. We should overcome the widespread reluctance to estrogen therapy as we have a unique estrogen formula; conjugated estrogens, or conjugated equine estrogens available under the brand name of Premarin deriving from natural sources. Premarin can exert similar ER upregulative and gene repairing power like endogenous estrogen without any risk for adverse reactions. Premarin is capable of stopping the COVID-19 pandemic.
C1 [Suba, Zsuzsanna] Natl Inst Oncol, Dept Mol Pathol, Rath Gyorgy Str 7-9, H-1122 Budapest, Hungary.
RP Suba, Z (corresponding author), Natl Inst Oncol, Dept Mol Pathol, Rath Gyorgy Str 7-9, H-1122 Budapest, Hungary.
EM subazdr@gmail.com
CR Al-Baadani AM, 2019, ANN THORAC MED, V14, P179, DOI 10.4103/atm.ATM_179_18
   Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2020, WALL STREET J S 0402
   [Anonymous], 1984, NIH CONSENSUS STATE, V5, P1
   Barros RPA, 2006, TRENDS MOL MED, V12, P425, DOI 10.1016/j.molmed.2006.07.004
   Begley Sharon, 2020, HLTH WHO IS GETTING
   Bennink HJTC, 2017, MATURITAS, V95, P11, DOI 10.1016/j.maturitas.2016.10.010
   Bloomgarden ZT, 2005, DIABETES CARE, V28, P1821, DOI 10.2337/diacare.28.7.1821
   Brohet RM, 2007, J CLIN ONCOL, V25, P3831, DOI 10.1200/JCO.2007.11.1179
   Calippe B, 2008, J IMMUNOL, V180, P7980, DOI 10.4049/jimmunol.180.12.7980
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chlebowski RT, 2019, SAN ANT BREAST CANC
   COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Dolle JM, 2009, CANCER EPIDEM BIOMAR, V18, P1157, DOI 10.1158/1055-9965.EPI-08-1005
   EDITORS' PICK Forbes Healthcare, 2020, SEX DOES MATTER IT C
   Goritzka M, 2015, J EXP MED, V212, P699, DOI 10.1084/jem.20140825
   Gorski SA, 2012, CURR OPIN VIROL, V2, P233, DOI 10.1016/j.coviro.2012.04.006
   Guan W, 2020, COMORBIDITY ITS IMPA
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y
   Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729
   Hilakivi-Clarke L, 2013, J MAMMARY GLAND BIOL, V18, P25, DOI 10.1007/s10911-013-9274-8
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Hulme KD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00861
   Igarashi H, 2001, P NATL ACAD SCI USA, V98, P15131, DOI 10.1073/pnas.011513098
   Kadel S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01653
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Keselman A, 2017, J IMMUNOL, V199, P1573, DOI 10.4049/jimmunol.1601975
   Klein SL, 2012, J LEUKOCYTE BIOL, V92, P67, DOI 10.1189/jlb.0811427
   Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Laffont S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01069
   Laffont S, 2014, J IMMUNOL, V193, P5444, DOI 10.4049/jimmunol.1303400
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840
   Ma HY, 2010, CANCER RES, V70, P575, DOI 10.1158/0008-5472.CAN-09-3460
   Maggi A, 2011, BBA-MOL BASIS DIS, V1812, P1054, DOI 10.1016/j.bbadis.2011.05.001
   Mauvais-Jarvis F, 2017, ENDOCR REV, V38, P173, DOI 10.1210/er.2016-1146
   McMichael TM, 2020, MMWR-MORBID MORTAL W, V69, P339, DOI 10.15585/mmwr.mm6912e1
   MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028
   MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689
   Murphy AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005539
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Omer SB, 2020, JAMA-J AM MED ASSOC, V323, P1767, DOI 10.1001/jama.2020.5788
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Peretz J, 2016, AM J PHYSIOL-LUNG C, V310, pL415, DOI 10.1152/ajplung.00398.2015
   Petitti DB, 2012, NEW ENGL J MED, V366, P2316, DOI 10.1056/NEJMe1204769
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Rabin Roni Caryn, 2020, NEW YORK TIMES  0407
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Rettew JA, 2008, BIOL REPROD, V78, P432, DOI 10.1095/biolreprod.107.063545
   Robinson DP, 2014, J VIROL, V88, P4711, DOI 10.1128/JVI.02081-13
   Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149
   Seillet C, 2012, BLOOD, V119, P454, DOI 10.1182/blood-2011-08-371831
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Shim GJ, 2004, P NATL ACAD SCI USA, V101, P12628, DOI 10.1073/pnas.0405099101
   Shim GJ, 2004, P NATL ACAD SCI USA, V101, P1720, DOI 10.1073/pnas.0307915100
   Shim GJ, 2003, P NATL ACAD SCI USA, V100, P6694, DOI 10.1073/pnas.0731830100
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Spinelli J, 2009, INT SAN ANT BREAST C
   STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703
   Stefanick ML, 2005, AM J MED S12B, V118, P6473
   Suba Z., 2019, TOPICS ANTICANCER RE, V8, P44, DOI DOI 10.2174/9789811404382119080005
   Suba Z, 2007, PATHOL ONCOL RES, V13, P195, DOI 10.1007/BF02893499
   Suba Z, 2018, RECENT PAT ANTI-CANC, V13, P428, DOI 10.2174/1574892813666180720123732
   Suba Z, 2017, RECENT PAT ANTI-CANC, V12, P136, DOI 10.2174/1574892812666170227110842
   Suba Z, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S84437
   Suba Z, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.1000272
   Suba Z, 2014, DRUG DES DEV THER, V8, P1381, DOI 10.2147/DDDT.S70570
   Suba Z, 2014, ONCOTARGETS THER, V7, P147, DOI 10.2147/OTT.S52600
   Suba Z, 2013, RECENT PAT ANTI-CANC, V8, P154
   Suba Zsuzsanna, 2009, Orvosi Hetilap, V150, P1155, DOI 10.1556/OH.2009.28646
   Vanderschueren D, J CLIN ENDOCRIN META, V85, P3024
   vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yoo JK, 2013, J ALLERGY CLIN IMMUN, V132, P1263, DOI 10.1016/j.jaci.2013.06.006
NR 82
TC 24
Z9 24
U1 1
U2 1
PU CANADIAN SOC PHARMACEUTICAL SCIENCES
PI EDMONTON
PA 3118 DENTISTRY-PHARMACY CENTRE UNIV ALBERTA CAMPUS, EDMONTON, ALBERTA
   T6G2N8, CANADA
SN 1482-1826
J9 J PHARM PHARM SCI
JI J. Pharm. Pharm. Sci.
PD APR 22
PY 2020
VL 23
BP 75
EP 85
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LI4EE
UT WOS:000529437900001
PM 32324533
OA DOAJ Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Harrison, EA
   Wu, JW
AF Harrison, Emily A.
   Wu, Julia W.
TI Vaccine confidence in the time of COVID-19
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Vaccine hesitancy; Vaccine confidence; COVID-19; Vaccine safety
   regulation; Culture; Historical
ID PUBLIC-HEALTH; MODERNIZATION; TUBERCULOSIS; MEASLES
AB In the early months of the COVID-19 epidemic, some have wondered if the force of this global experience will solve the problem of vaccine refusal that has vexed and preoccupied the global public health community for the last several decades. Drawing on historical and epidemiological analyses, we critique contemporary approaches to reducing vaccine hesitancy and articulate our notion of vaccine confidence as an expanded way of conceptualizing the problem and how to respond to it. Intervening on the rush of vaccine optimism we see pervading present discourse around the COVID-19 epidemic, we call for a re-imagination of the culture of public health and the meaning of vaccine safety regulations. Public confidence in vaccination programs depends on the work they do for the community-social, political, and moral as well as biological. The concept of public health and its programs must be broader than the delivery of the vaccine technology itself. The narrative work and policy actions entailed in actualizing such changes will, we expect, be essential in achieving a true vaccine confidence, however the public reacts to the specific vaccine that may be developed for COVID-19.
C1 [Harrison, Emily A.; Wu, Julia W.] Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
   [Harrison, Emily A.] Harvard Univ GSAS, Dept Hist Sci, Cambridge, MA 02138 USA.
RP Harrison, EA (corresponding author), Harvard Univ, Dept Epidemiol, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.; Harrison, EA (corresponding author), Harvard Univ GSAS, Dept Hist Sci, Cambridge, MA 02138 USA.
EM harrison@post.harvard.edu
OI Wu, Julia Wei/0000-0002-1320-4788
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Angwenyi V, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-65
   [Anonymous], 2006, NAT STRAT PAND INFL
   Benecke O, 2019, GLOBAL PEDIAT HLTH, V6, P1
   Bhattacharya Sanjoy, 2005, FRACTURED STATES SMA
   Bill & Melinda Gates Foundation, 2020, GOALK REP 2018
   Brandt AM, 2015, COMMUNICATION    SEP
   CDC, 2019, FLU VACC COV US 2018
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241
   Centers for Disease Control and Prevention (CDC), 2020, MEASL RUB CAS OUTBR
   Colgrove J, 2005, AM J PUBLIC HEALTH, V95, P571, DOI 10.2105/AJPH.2004.055145
   Conis E, 2015, VACCINE NATION AM CH
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   Dreze J., 2002, INDIA DEV PARTICIPAT
   Enria L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3799-x
   Fitzpatrick Michael, 2006, J ROY SOC MED, V99, P156, DOI [10.1258/jrsm.99.3, DOI 10.1258/JRSM.99.3.156]
   Fox R, 1990, SOCIAL SCI PERSPECTI
   Freeman P, 1997, PUBLIC HEALTH REP, V112, P21
   FROST WH, 1995, AM J EPIDEMIOL, V141, P4, DOI 10.1093/oxfordjournals.aje.a117343
   Gates B, 2020, NEJM
   Hammonds EM, 1999, CHILDHOODS DEADLY SC
   Kahan DM, 2010, LAW HUMAN BEHAV, V34, P501, DOI 10.1007/s10979-009-9201-0
   Koh HK, 2020, JAMA-J AM MED ASSOC, V323, P914, DOI 10.1001/jama.2020.1372
   Larson HJ, 2019, SCIENCE, V364, P105, DOI 10.1126/science.aax6172
   Larson HJ, 2013, JAMA INTERN MED, V173, P1393, DOI 10.1001/jamainternmed.2013.7191
   MacMahon B, 1960, EPIDEMIOLOGIC METHOD
   Marks HM, 1997, PROGR EXPT SCI THERA
   McMillen CW, 2010, COMP STUD SOC HIST, V52, P180, DOI 10.1017/S0010417509990375
   MEADE T, 1986, J SOC HIST, V20, P301, DOI 10.1353/jsh/20.2.301
   Mol A, 2008, LOGIC CARE HLTH PROB
   NEEDELL JD, 1987, HISPANIC AM HIST REV, V67, P233, DOI 10.2307/2515023
   Nuzzo J, 2019, PREPAREDNESS HIGH IM
   Paul JR, ORIGINAL TEXT ADDRES
   Piot P, 2019, NATURE
   Portnoy A, 2019, LANCET GLOB HEALTH, V7, pE472, DOI 10.1016/S2214-109X(18)30537-0
   Robbins A, 2012, J PUBLIC HEALTH POL, V33, P387, DOI 10.1057/jphp.2012.37
   Robert A, 2019, LANCET
   ROSENBERG CE, 1977, PERSPECT BIOL MED, V20, P485
   ROSENBERG CE, 1989, DAEDALUS-US, V118, P1
   Steelfisher GK, 2019, HARVARD VACCINATION
   US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, 2019, CRIMS CONT 2019 FUNC
   Walloch K. L., 2015, ANTIVACCINE HERESY J
   Warner John Harley, 1986, THERAPEUTIC PERSPECT
   WHO, 2019, VACC SAF NET
   WHO, 2005, 64 WORLD HLTH ASS PR
   WHO-China, 2020, REP WHO CHIN JOINT M, P16
   Wilson R, 2015, HPV VACCINATION JAPA
   World Health Organization, 2020, 10 THREATS GLOB HLTH
   World Health Organization, 2020, NEW MEASL SURV DAT 2
   Yang LJ, 2019, EUR J EPIDEMIOL, V34, P893, DOI 10.1007/s10654-019-00574-7
NR 50
TC 16
Z9 15
U1 15
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD APR
PY 2020
VL 35
IS 4
BP 325
EP 330
DI 10.1007/s10654-020-00634-3
EA APR 2020
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LI7TK
UT WOS:000528087600001
PM 32318915
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sadeghipour, P
   Talasaz, AH
   Eslami, V
   Gerayeli, B
   Vojdanparast, M
   Sedaghat, M
   Moosavi, AF
   Alipour-Parsa, S
   Aminian, B
   Firouzi, A
   Ghafari, S
   Ghasemi, M
   Saleh, DK
   Khosravi, A
   Kojuri, J
   Noohi, F
   Pourhosseini, H
   Salarifar, M
   Salehi, MR
   Sezavar, H
   Shabestari, M
   Soleimani, A
   Tabarsi, P
   Parsa, AFZ
   Abdi, S
AF Sadeghipour, Parham
   Talasaz, Azita H.
   Eslami, Vahid
   Gerayeli, Babak
   Vojdanparast, Mohammad
   Sedaghat, Mojtaba
   Moosavi, Abouzar Fakhr
   Alipour-Parsa, Saeed
   Aminian, Bahram
   Firouzi, Ata
   Ghafari, Samad
   Ghasemi, Massoud
   Saleh, Davood Kazemi
   Khosravi, Alireza
   Kojuri, Javad
   Noohi, Feridoun
   Pourhosseini, Hamid
   Salarifar, Mojtaba
   Salehi, Mohamad Reza
   Sezavar, Hashem
   Shabestari, Mahmoud
   Soleimani, Abbas
   Tabarsi, Payam
   Parsa, Amir Farhang Zand
   Abdi, Seifollah
TI Management of ST-segment-elevation myocardial infarction during the
   coronavirus disease 2019 (COVID-19) outbreak: Iranian"247" National
   Committee's position paper on primary percutaneous coronary intervention
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article; Early Access
DE acute myocardial infarction; STEMI; percutaneous coronary intervention;
   thrombolytic therapy
ID TASK-FORCE; GUIDELINE; THERAPY
AB World Health Organization has designated coronavirus disease 2019 (COVID-19) as a pandemic. During the past several weeks, a considerable burden has been imposed on the Iranian's healthcare system. The present document reviewed the latest evidence and expert opinion regarding the management of ST-segment-elevation myocardial infarction during the outbreak of COVID-19 and outlines a practical algorithm for it.
C1 [Sadeghipour, Parham; Firouzi, Ata; Noohi, Feridoun; Abdi, Seifollah] Iran Univ Med Sci, Cardiovasc Intervent Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Vali Asr Ave, Tehran 1996911101, Iran.
   [Talasaz, Azita H.; Pourhosseini, Hamid; Salarifar, Mojtaba] Univ Tehran Med Sci, Tehran Heart Ctr, Tehran, Iran.
   [Eslami, Vahid; Alipour-Parsa, Saeed] Shahid Beheshti Univ Med Sci, Modares Hosp, Tehran, Iran.
   [Gerayeli, Babak; Ghasemi, Massoud; Parsa, Amir Farhang Zand] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Dept Cardiol, Tehran, Iran.
   [Vojdanparast, Mohammad; Shabestari, Mahmoud] Mashhad Univ Med Sci, Imam Reza Hosp, Atherosclerosis Prevent Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Sedaghat, Mojtaba] Univ Tehran Med Sci, Dept Community Med, Fac Med, Tehran, Iran.
   [Moosavi, Abouzar Fakhr] Guilan Univ Med Sci, Heshmat Hosp, Rasht, Iran.
   [Aminian, Bahram; Kojuri, Javad] Shiraz Univ Med Sci, Shiraz, Iran.
   [Ghafari, Samad] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz, Iran.
   [Saleh, Davood Kazemi] Bahman Hosp, Tehran, Iran.
   [Khosravi, Alireza] Isfahan Univ Med Sci, Cardiovasc Res Inst, Hypertens Res Ctr, Esfahan, Iran.
   [Salehi, Mohamad Reza] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Dept Infect Dis, Tehran, Iran.
   [Sezavar, Hashem] Iran Univ Med Sci, Rasoul E Akram Hosp, Dept Cardiovasc Med, Tehran, Iran.
   [Soleimani, Abbas] Univ Tehran Med Sci, Sina Hosp, Tehran, Iran.
   [Tabarsi, Payam] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Dept Infect Dis, Tehran, Iran.
RP Abdi, S (corresponding author), Iran Univ Med Sci, Cardiovasc Intervent Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Vali Asr Ave, Tehran 1996911101, Iran.
EM sayfabdi@yahoo.com
RI Sadeghipour, Parham/H-9836-2017; Khosravi, Alireza/B-7453-2018
OI Sadeghipour, Parham/0000-0001-9602-0513; Khosravi,
   Alireza/0000-0003-0736-2090
CR Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA
   American College of Cardiology, 2020, COVID 19 CLIN GUID C
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, GUID PREP WORKPL COV
   APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Europian Society of Cardiology, 2020, AC COR SYNDR COVID 1
   Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x
   Giguere P, 2019, CAN J CARDIOL, V35, P326, DOI 10.1016/j.cjca.2018.12.020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Iranian Ministry of Health, 2020, 3 IR MIN HLTH
   Makris M, 2013, BRIT J HAEMATOL, V160, P35, DOI 10.1111/bjh.12107
   McCarthy CP, 2017, EUR HEART J, V38, P3488, DOI 10.1093/eurheartj/ehx531
   O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6
   Resuscitation Council of United Kingdom, 2020, RES COUNC UK STAT CO
   Society for Cardiovascular Angiography and Interventions, 2020, EV PAND COVID 19 INT
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Van de Werf F, 2006, LANCET, V367, P569, DOI 10.1016/S0140-6736(06)68147-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 3
Z9 3
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
DI 10.1002/ccd.28889
EA APR 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LF4TA
UT WOS:000527410800001
PM 32320138
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Emameh, RZ
   Nosrati, H
   Taheri, RA
AF Zolfaghari Emameh, Reza
   Nosrati, Hassan
   Taheri, Ramezan Ali
TI Combination of Biodata Mining and Computational Modelling in
   Identification and Characterization of ORF1ab Polyprotein of SARS-CoV-2
   Isolated from Oronasopharynx of an Iranian Patient
SO BIOLOGICAL PROCEDURES ONLINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; ORF1ab; nsp1; Biodata mining; Protein Modelling
ID RESPIRATORY SYNDROME-CORONAVIRUS; RECEPTOR-BINDING DOMAIN; DIPEPTIDYL
   PEPTIDASE 4; T-CELL RESPONSES; MERS-COV; SPIKE PROTEIN;
   IMMUNE-RESPONSES; MOUSE MODEL; NEUTRALIZING ANTIBODIES; TRANSGENIC MICE
AB Background Coronavirus disease 2019 (COVID-19) is an emerging zoonotic viral infection, which was started in Wuhan, China, in December 2019 and transmitted to other countries worldwide as a pandemic outbreak. Iran is one of the top ranked countries in the tables of COVID-19-infected and -mortality cases that make the Iranian patients as the potential targets for diversity of studies including epidemiology, biomedical, biodata, and viral proteins computational modelling studies. Results In this study, we applied bioinformatic biodata mining methods to detect CDS and protein sequences of ORF1ab polyprotein of SARS-CoV-2 isolated from oronasopharynx of an Iranian patient. Then through the computational modelling and antigenicity prediction approaches, the identified polyprotein sequence was analyzed. The results revealed that the identified ORF1ab polyprotein belongs to a part of nonstructural protein 1 (nsp1) with the high antigenicity residues in a glycine-proline or hydrophobic amino acid rich domain. Conclusions The results revealed that nsp1 as a virulence factor and crucial agent in spreading of the COVID-19 among the society can be a potential target for the future epidemiology, drug, and vaccine studies.
C1 [Zolfaghari Emameh, Reza] NIGEB, Dept Energy & Environm Biotechnol, Tehran 14965161, Iran.
   [Nosrati, Hassan] Tarbiat Modares Univ, Dept Mat Engn, Tehran, Iran.
   [Taheri, Ramezan Ali] Baqiyatallah Univ Med Sci, Nanobiotechnol Res Ctr, Tehran, Iran.
RP Emameh, RZ (corresponding author), NIGEB, Dept Energy & Environm Biotechnol, Tehran 14965161, Iran.
EM zolfaghari@nigeb.ac.ir
RI Nosrati, Hassan/AAS-9972-2020
OI Nosrati, Hassan/0000-0003-1509-9819; Zolfaghari Emameh,
   Reza/0000-0002-3253-7844
FU National Institute of Genetic Engineering and Biotechnology (NIGEB) of
   the Islamic Republic of Iran
FX To perform this study, RZE received a research grant support from the
   National Institute of Genetic Engineering and Biotechnology (NIGEB) of
   the Islamic Republic of Iran.
CR Adney DR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030212
   Adney DR, 2014, EMERG INFECT DIS, V20, P1999, DOI 10.3201/eid2012.141280
   Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Ahmadzadeh J, 2019, INT J GEN MED, V12, P305, DOI 10.2147/IJGM.S215396
   Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bodmer BS, 2018, VIROLOGY, V521, P99, DOI 10.1016/j.virol.2018.05.028
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Chi H, 2017, VACCINE, V35, P2069, DOI 10.1016/j.vaccine.2017.02.063
   Cockrell AS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.226
   Coleman CM, 2017, VACCINE, V35, P1586, DOI 10.1016/j.vaccine.2017.02.012
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Connor RF, 2007, TRENDS MICROBIOL, V15, P51, DOI 10.1016/j.tim.2006.12.005
   Dalla Valle L, 2010, J ANAT, V216, P356, DOI 10.1111/j.1469-7580.2009.01192.x
   Deng Y, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0056-7
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Emameh RZ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1415-7
   Emameh RZ, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-403
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Fan CF, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090448
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Goodsell DS, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002140
   Guo XJ, 2015, IMMUNOLOGY, V145, P476, DOI 10.1111/imm.12462
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jung SY, 2018, VACCINE, V36, P3468, DOI 10.1016/j.vaccine.2018.04.082
   Kim E, 2014, VACCINE, V32, P5975, DOI 10.1016/j.vaccine.2014.08.058
   Kim Tae Yun, 2001, Korean Journal of Parasitology, V39, P57, DOI 10.3347/kjp.2001.39.1.57
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Lan JM, 2018, VIROL SIN, V33, P453, DOI 10.1007/s12250-018-0064-8
   Lan JM, 2017, VACCINE, V35, P10, DOI 10.1016/j.vaccine.2016.11.064
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lan JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112602
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007
   Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086
   Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004
   Malczyk AH, 2015, J VIROL, V89, P11654, DOI 10.1128/JVI.01815-15
   Menachery VD, 2017, MSPHERE, V2
   Munster VJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0029-1
   Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462
   Nyon MP, 2018, VACCINE, V36, P1853, DOI 10.1016/j.vaccine.2018.02.065
   Oostra M, 2008, J VIROL, V82, P12392, DOI 10.1128/JVI.01219-08
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Plant EP, 2008, FRONT BIOSCI-LANDMRK, V13, P4873, DOI 10.2741/3046
   Plant EP, 2013, VIRUSES-BASEL, V5, P279, DOI 10.3390/v5010279
   Prescott J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00205
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rose AS, 2018, BIOINFORMATICS, V34, P3755, DOI 10.1093/bioinformatics/bty419
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Song F, 2013, J VIROL, V87, P11950, DOI 10.1128/JVI.01672-13
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sun Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051633
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Tchernychev B, 1997, P NATL ACAD SCI USA, V94, P6335, DOI 10.1073/pnas.94.12.6335
   Thompson RN, 2020, J CLIN MED, V9
   Veit S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120718
   Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15
   Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang LH, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.140
   Wang YX, 2017, HUM VACC IMMUNOTHER, V13, P153, DOI 10.1080/21645515.2016.1225637
   Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16
   Yarawsky AE, 2017, J MOL BIOL, V429, P261, DOI 10.1016/j.jmb.2016.11.017
   Yeung ML, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.4, 10.1038/nmicrobiol.2016.4]
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Yu P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172093
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zheng J, 2018, VIROLOGY, V513, P65, DOI 10.1016/j.virol.2017.10.003
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 80
TC 2
Z9 2
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1480-9222
J9 BIOL PROCED ONLINE
JI Biol. Proced. Online
PD APR 21
PY 2020
VL 22
IS 1
AR 8
DI 10.1186/s12575-020-00121-9
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA LI1TI
UT WOS:000529266700001
PM 32336957
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Moshayedi, P
   Ryan, TE
   Mejia, LLP
   Nour, M
   Liebeskind, DS
AF Moshayedi, Pouria
   Ryan, Timothy E.
   Mejia, Lucido Luciano Ponce
   Nour, May
   Liebeskind, David S.
TI Triage of Acute Ischemic Stroke in Confirmed COVID-19: Large Vessel
   Occlusion Associated With Coronavirus Infection
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE COVID-19; stroke-diagnosis; therapy; large vessel occlusion (LVO);
   disease transmission; triage
AB The outbreak of COVID-19 has posed a significant challenge to global healthcare. Acute stroke care requires rapid bedside attendance, imaging, and intervention. However, for acute stroke patients who have a diagnosis of or are under investigation for COVID-19, the concern for nosocomial transmission moderates operational procedures for acute stroke care. We present our experience with an in-hospital stroke code called on a COVID-19-positive patient with a left middle cerebral artery syndrome and the challenges faced for timely examination, imaging, and decision to intervene. The outlook for the ongoing COVID-19 pandemic necessitates the development of protocols to sustain timely and effective acute stroke care while mitigating healthcare-associated transmission.
C1 [Moshayedi, Pouria; Ryan, Timothy E.; Nour, May; Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
   [Mejia, Lucido Luciano Ponce; Nour, May] Univ Calif Los Angeles, Dept Intervent Neuroradiol, Los Angeles, CA USA.
RP Liebeskind, DS (corresponding author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
EM dliebeskind@mednet.ucla.edu
OI Moshayedi, Pouria/0000-0003-1713-4681
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Guan LL, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00352-2020
   Hui DS, 2015, CHEST, V147, P1336, DOI 10.1378/chest.14-1934
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Mirza SK, 2015, RADIOGRAPHICS, V35, P1231, DOI 10.1148/rg.2015140034
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 7
TC 17
Z9 17
U1 3
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD APR 21
PY 2020
VL 11
AR 353
DI 10.3389/fneur.2020.00353
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA LL5OG
UT WOS:000531606900001
PM 32373061
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kochanczyk, M
   Grabowski, F
   Lipniacki, T
AF Kochanczyk, Marek
   Grabowski, Frederic
   Lipniacki, Tomasz
TI Dynamics of COVID-19 pandemic at constant and time-dependent contact
   rates
SO MATHEMATICAL MODELLING OF NATURAL PHENOMENA
LA English
DT Article
DE basic reproduction number; novel coronavirus
AB We constructed a simple Susceptible{Exposed{Infectious{Removed model of the spread of COVID-19. The model is parametrised only by the average incubation period, , and two rate parameters: contact rate, fi, and exclusion rate, . The rates depend on nontherapeutic interventions and determine the basic reproduction number, R0 = fi=, and, together with , the daily multiplication coefficient in the early exponential phase, . Initial R0 determines the reduction of fi required to contain the spread of the epidemic. We demonstrate that introduction of a cascade of multiple exposed states enables the model to reproduce the distributions of the incubation period and the serial interval reported by epidemiologists. Using the model, we consider a hypothetical scenario in which fi is modulated solely by anticipated changes of social behaviours: first, fi decreases in response to a surge of daily new cases, pressuring people to self-isolate, and then, over longer time scale, fi increases as people gradually accept the risk. In this scenario, initial abrupt epidemic spread is followed by a plateau and slow regression, which, although economically and socially devastating, grants time to develop and deploy vaccine or at least limit daily cases to a manageable number.
C1 [Kochanczyk, Marek; Lipniacki, Tomasz] Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, PL-02106 Warsaw, Poland.
   [Grabowski, Frederic] Univ Warsaw, Fac Math Informat & Mech, PL-02097 Warsaw, Poland.
RP Lipniacki, T (corresponding author), Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, PL-02106 Warsaw, Poland.
EM tlipnia@ippt.pan.pl
OI Grabowski, Frederic/0000-0003-4070-9500; Lipniacki,
   Tomasz/0000-0002-3488-2561
FU National Science Centre (Poland)National Science Center, PolandNational
   Science Centre, Poland [2018/29/B/NZ2/00668]
FX This study was supported by the National Science Centre (Poland) grant
   2018/29/B/NZ2/00668.
CR ANDERSON R M, 1991
   [Anonymous], 2020, NOVEL CORONAVIRUS CO
   [Anonymous], 2020, COVID 19 COMMUNITY M
   [Anonymous], 2020, MANY TESTS COVID 19
   [Anonymous], 2020, MATH NOTEBOOK
   CAPASSO V, 1978, MATH BIOSCI, V42, P43, DOI 10.1016/0025-5564(78)90006-8
   Funk S, 2010, J R SOC INTERFACE, V7, P1247, DOI 10.1098/rsif.2010.0142
   Goh G., 2020, EPIDEMIC CALCULATOR
   Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lauer SA, 2020, INCUBATION PERIOD 20, DOI [10.1101/2020.02.02.20020016, DOI 10.1101/2020.02.02.20020016]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Perra N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023084
   Riou J, 2020, ADJUSTED AGE SPECIFI, P2020, DOI [10.1101/2020.03.04.20031104, DOI 10.1101/2020.03.04.20031104]
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Wang X., 2020, EFFECTS CHINESE STRA, DOI [10.1101/2020.03.10.20032755, DOI 10.1101/2020.03.10.20032755]
NR 20
TC 7
Z9 7
U1 5
U2 10
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0973-5348
EI 1760-6101
J9 MATH MODEL NAT PHENO
JI Math. Model. Nat. Phenom.
PD APR 21
PY 2020
VL 15
AR 28
DI 10.1051/mmnp/2020011
PG 12
WC Mathematical & Computational Biology; Mathematics, Applied; Mathematics,
   Interdisciplinary Applications
SC Mathematical & Computational Biology; Mathematics
GA LH6UJ
UT WOS:000528920600002
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Krause, NM
   Freiling, I
   Beets, B
   Brossard, D
AF Krause, Nicole M.
   Freiling, Isabelle
   Beets, Becca
   Brossard, Dominique
TI Fact-checking as risk communication: the multi-layered risk of
   misinformation in times of COVID-19
SO JOURNAL OF RISK RESEARCH
LA English
DT Article
DE Risk communication; misinformation; trust; uncertainty
ID VALUE PREDISPOSITIONS; PUBLIC TRUST; NANOTECHNOLOGY; PERCEPTIONS;
   VACCINE; SCIENCE; ONLINE; MEDIA
AB The emergence of the 2019 novel coronavirus has led to more than a pandemic-indeed, COVID-19 is spawning myriad other concerns as it rapidly marches around the globe. One of these concerns is a surge of misinformation, which we argue should be viewed as a risk in its own right, and to which insights from decades of risk communication research must be applied. Further, when the subject of misinformation is itself a risk, as in the case of COVID-19, we argue for the utility of viewing the problem as a multi-layered risk communication problem. In such circumstances, misinformation functions as a meta-risk that interacts with and complicates publics' perceptions of the original risk. Therefore, as the COVID-19 "misinfodemic" intensifies, risk communication research should inform the efforts of key risk communicators. To this end, we discuss the implications of risk research for efforts to fact-check COVID-19 misinformation and offer practical recommendations.
C1 [Krause, Nicole M.; Freiling, Isabelle; Beets, Becca; Brossard, Dominique] Univ Wisconsin, Dept Life Sci Commun, Hiram Smith Hall,1545 Observ Dr, Madison, WI 53706 USA.
   [Freiling, Isabelle] Univ Munster, Trust & Commun Digitized World, DFG Res Training Grp, Munster, Germany.
   [Brossard, Dominique] Morgridge Inst Res, Madison, WI USA.
RP Krause, NM (corresponding author), Univ Wisconsin, Dept Life Sci Commun, Hiram Smith Hall,1545 Observ Dr, Madison, WI 53706 USA.
EM nmkrause@wisc.edu
RI Freiling, Isabelle/AAW-6732-2020
OI Freiling, Isabelle/0000-0002-6046-4005; Beets,
   Becca/0000-0002-3323-1281; Brossard, Dominique/0000-0002-9188-8388;
   Krause, Nicole/0000-0003-0550-9546
CR Brandtzaeg PB, 2017, COMMUN ACM, V60, P65, DOI 10.1145/3122803
   Brennan J. S., 2020, TYPES SOURCES CLAIMS
   Brossard D, 2007, INT J PUBLIC OPIN R, V19, P24, DOI 10.1093/ijpor/edl003
   Centers for Disease Control and Prevention, 2020, STOP SPREAD RUM 2020
   Covello VT, 2001, J URBAN HEALTH, V78, P382, DOI 10.1093/jurban/78.2.382
   Frenkel S., 2020, NY TIMES
   Gitlin T., 2020, MEDIUM          0403
   Graves L., 2016, DECIDING WHATS TRUE
   Hanitzsch T, 2018, INT J PRESS/POLIT, V23, P3, DOI 10.1177/1940161217740695
   Hansson SO, 2010, J RISK RES, V13, P231, DOI 10.1080/13669870903126226
   Ho SS, 2011, SCI COMMUN, V33, P167, DOI 10.1177/1075547010380386
   Ju Y, 2015, J HEALTH COMMUN, V20, P879, DOI 10.1080/10810730.2015.1018602
   KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185
   Kaiser Family Foundation, 2020, KFF COR POLL MARCH 2
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kim J, 2014, RISK ANAL, V34, P965, DOI 10.1111/risa.12141
   KUNDA Z, 1990, PSYCHOL BULL, V108, P480, DOI 10.1037/0033-2909.108.3.480
   Kuznia R., 2020, CNN COM
   Newman Nic, 2019, REUTERS I DIGITAL NE
   Offit PA, 2003, VACCINE, V22, P1, DOI 10.1016/S0264-410X(03)00532-2
   Pew Research Center, 2019, REP FAR MOR LIK DEM
   Pew Research Center, 2020, EXPL DAT
   Pew Research Center, 2019, MAN AM SAY MAD NEWS
   RAYNER S, 1992, SOCIAL THEORIES OF RISK, P83
   RENN O, 1992, SOCIAL THEORIES OF RISK, P53
   Requarth T., 2020, SLATE
   Sandman P., 1987, EPA J, V13, P21, DOI DOI 10.1177/0893318988002002006
   Scheufele DA, 2019, P NATL ACAD SCI USA, V116, P7662, DOI 10.1073/pnas.1805871115
   Scheufele DA, 2013, P NATL ACAD SCI USA, V110, P14040, DOI 10.1073/pnas.1213275110
   Service RF, 2020, SCIENCE, V368, P119, DOI 10.1126/science.368.6487.119
   Siegrist M, 2000, RISK ANAL, V20, P195, DOI 10.1111/0272-4332.202020
   Slovic P., 1992, SOCIAL THEORIES RISK, P117
   Southwell BG, 2018, MISINFORMATION MASS
   Trumbo CW, 2002, J COMMUN, V52, P367, DOI 10.1093/joc/52.2.367
   Tufekci Z., 2020, ATLANTIC
   van der Bles AM, 2020, P NATL ACAD SCI USA, V117, P7672, DOI 10.1073/pnas.1913678117
   Waldrop T., 2020, CNN COM
   World Health Organization, 2020, COR DIS COVID 19 ADV
   World Health Organization, 2020, NOV COR 2019 NCOV SI
NR 39
TC 15
Z9 15
U1 9
U2 32
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1366-9877
EI 1466-4461
J9 J RISK RES
JI J. Risk Res.
PD AUG 2
PY 2020
VL 23
IS 7-8
BP 1052
EP 1059
DI 10.1080/13669877.2020.1756385
EA APR 2020
PG 8
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA PB6YF
UT WOS:000528361900001
OA Bronze
DA 2021-01-01
ER

PT J
AU Iwasaki, A
   Yang, YX
AF Iwasaki, Akiko
   Yang, Yexin
TI The potential danger of suboptimal antibody responses in COVID-19
SO NATURE REVIEWS IMMUNOLOGY
LA English
DT Article; Early Access
ID SARS-COV; INFECTION; VACCINE; NEUTRALIZATION; PROTEIN; CELLS; MICE
AB Here, Iwasaki and Yang highlight the potential dangers of inducing suboptimal antibody responses to SARS-CoV-2. They stress the need for proper safety evaluation of candidate vaccines for COVID-19.
   There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.
C1 [Iwasaki, Akiko; Yang, Yexin] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.
   [Iwasaki, Akiko] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Iwasaki, A (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.; Iwasaki, A (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM akiko.iwasaki@yale.edu
CR Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jiang H-w, 2020, GLOBAL PROFILING SAR, DOI [10.1101/2020.03.20.20039495, DOI 10.1101/2020.03.20.20039495]
   Lee N, 2006, J CLIN VIROL, V35, P179, DOI 10.1016/j.jcv.2005.07.005
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Yuan FF, 2005, TISSUE ANTIGENS, V66, P291, DOI 10.1111/j.1399-0039.2005.00476.x
NR 18
TC 114
Z9 113
U1 24
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1733
EI 1474-1741
J9 NAT REV IMMUNOL
JI Nat. Rev. Immunol.
DI 10.1038/s41577-020-0321-6
EA APR 2020
PG 3
WC Immunology
SC Immunology
GA LG4LM
UT WOS:000528074400001
PM 32317716
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Abdelhafiz, AS
   Mohammed, Z
   Ibrahim, ME
   Ziady, HH
   Alorabi, M
   Ayyad, M
   Sultan, EA
AF Abdelhafiz, Ahmed Samir
   Mohammed, Zeinab
   Ibrahim, Maha Emad
   Ziady, Hany H.
   Alorabi, Mohamed
   Ayyad, Mohamed
   Sultan, Eman A.
TI Knowledge, Perceptions, and Attitude of Egyptians Towards the Novel
   Coronavirus Disease (COVID-19)
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE COVID-19; Egypt; Knowledge; Perceptions; Attitude
ID EPIDEMIC
AB Coronavirus disease 2019 (COVID-19) has been recognized as a pandemic by the World Health Organization. Global efforts have been exerted to prevent the spreading of the disease through political decisions together with personal behaviors, which depend on awareness of the public. The goal of this study is to assess the knowledge, perceptions and attitude of the Egyptian public towards the COVID-19 disease. We conducted a cross-sectional survey about these points, which was distributed among adult Egyptians. Five hundred and fifty nine persons completed the survey. The mean knowledge score was 16.39 out of 23, gained mainly though social media (66.9%), and the internet (58.3%). Knowledge was significantly lower among older, less educated, lower income participants, and rural residents. Most participants (86.9%) were concerned about the risk of infection. While 37.6% thought that their salary will be continued if they become isolated, 68.5% believed that it should be continued during this period. About 73.0% were looking forward to get the vaccine when available. In general, participants had a good knowledge about the disease and a positive attitude towards protective measures. This knowledge is gained mainly through novel media channels, which have pros and cons. Although the government has taken major steps to educate the public and limit the spread of the disease, more effort is needed to educate and support the lower economic strata. If a vaccine or a treatment is approved, we recommend a government control over its use to preserve the rights of the vulnerable and needy groups.
C1 [Abdelhafiz, Ahmed Samir] Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Kasr Al Aini St,Fom Elkhalig Sq, Cairo 11796, Egypt.
   [Mohammed, Zeinab] Beni Suef Univ, Dept Publ Hlth & Community Med, Fac Med, Bani Suwayf, Egypt.
   [Ibrahim, Maha Emad] Suez Canal Univ, Dept Phys Med Rheumatol & Rehabil, Fac Med, Ismailia, Egypt.
   [Ziady, Hany H.; Sultan, Eman A.] Alexandria Univ, Dept Community Med, Fac Med, Alexandria, Egypt.
   [Alorabi, Mohamed] Ain Shams Univ, Dept Clin Oncol, Fac Med, Cairo, Egypt.
   [Ayyad, Mohamed] Cairo Univ, Natl Canc Inst, Dept Surg Oncol, Cairo, Egypt.
RP Abdelhafiz, AS (corresponding author), Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Kasr Al Aini St,Fom Elkhalig Sq, Cairo 11796, Egypt.
EM ahmed.samir@nci.cu.edu.eg
RI Ibrahim, Maha/AAL-7141-2020; Alorabi, Mohamed/AAT-7223-2020; Sultan,
   Eman/AAU-3977-2020; Abdelhafiz, Ahmed Samir/AAU-6439-2020; Alorabi,
   Mohamed/C-1450-2019
OI Ibrahim, Maha/0000-0003-2577-1111; Alorabi, Mohamed/0000-0002-3706-6332;
   Sultan, Eman/0000-0002-9801-0607; Abdelhafiz, Ahmed
   Samir/0000-0003-4564-8073; Alorabi, Mohamed/0000-0002-3706-6332; Reis,
   AlessanRSS/0000-0001-8486-7469
CR Abdelhafiz AS, 2017, BIOPRESERV BIOBANK, V15, P350, DOI 10.1089/bio.2016.0111
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, Q A SMOKING COVID 19
   [Anonymous], 2020, RECOMMENDATION REGAR
   [Anonymous], 2020, EGYPT SHUTS SCH U 2
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, EGYPTIAN GOVT ANTIVI
   [Anonymous], 2020, MED SYNDICATE IS INV
   [Anonymous], 2020, EGYPITAN PM
   [Anonymous], 2020, PREPRINT UNCANNY SIM
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Cascella M, 2020, STATPEARLS
   Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Haseltine WA, 2020, NEW ENGL J MED, V382, P1081, DOI 10.1056/NEJMp1915818
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung LS, 2003, J ROY SOC MED, V96, P374, DOI 10.1258/jrsm.96.8.374
   Kabbash IA, 2018, ENVIRON SCI POLLUT R, V25, P30755, DOI 10.1007/s11356-016-7848-x
   Lemeshow S., 1990, ADEQUACY SAMPLE SIZE
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mostafa A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023496
   Sedyaningsih ER, 2008, ANN ACAD MED SINGAP, V37, P482
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Waked I, 2020, NEW ENGL J MED, V382, P1166, DOI 10.1056/NEJMsr1912628
   World Health Organization, 2020, WHO Q A CORONAVIRUSE
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
NR 29
TC 33
Z9 33
U1 10
U2 28
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0094-5145
EI 1573-3610
J9 J COMMUN HEALTH
JI J. Community Health
PD OCT
PY 2020
VL 45
IS 5
BP 881
EP 890
DI 10.1007/s10900-020-00827-7
EA APR 2020
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA NA9NC
UT WOS:000528135100001
PM 32318986
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Choudhury, R
   Barrett, CD
   Moore, HB
   Moore, EE
   McIntyre, RC
   Moore, PK
   Talmor, DS
   Nydam, TL
   Yaffe, MB
AF Choudhury, Rashikh
   Barrett, Christopher D.
   Moore, Hunter B.
   Moore, Ernest E.
   McIntyre, Robert C.
   Moore, Peter K.
   Talmor, Daniel S.
   Nydam, Trevor L.
   Yaffe, Michael B.
TI Salvage use of tissue plasminogen activator (tPA) in the setting of
   acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a
   Markov decision analysis
SO WORLD JOURNAL OF EMERGENCY SURGERY
LA English
DT Letter
DE COVID-19; Acute respiratory distress syndrome (ARDS); Tissue plasminogen
   activator (tPA); Pulmonary failure; Fibrinolysis; Markov
ID CARE
AB Background COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO2/FiO(2) (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS). It is unclear to what extent tPA may impact population-based survival during the current US COVID-19 pandemic. Methods A decision analytic Markov state transition model was created to simulate the life critically ill COVID-19 patients as they transitioned to either recovery or death. Two patient groups were simulated (50,000 patients in each group); (1) Patients received tPA immediately upon diagnosis of ARDS and (2) patients received standard therapy for ARDS. Base case critically ill COVID-19 patients were defined as having a refractory PaO2/FiO(2) of < 60 mmHg (salvage use criteria). Transition from severe to moderate to mild ARDS, recovery, and death were estimated. Markov model parameters were extracted from existing ARDS/COVID-19 literature. Results The use of tPA was associated with reduced mortality (47.6% [tTPA] vs. 71.0% [no tPA]) for base case patients. When extrapolated to the projected COVID-19 eligible for salvage use tPA in the USA, peak mortality (deaths/100,000 patients) was reduced for both optimal social distancing (70.5 [tPA] vs. 75.0 [no tPA]) and no social distancing (158.7 [tPA] vs. 168.8 [no tPA]) scenarios. Conclusions Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic.
C1 [Choudhury, Rashikh; Moore, Hunter B.; Moore, Ernest E.; McIntyre, Robert C.; Nydam, Trevor L.] Univ Colorado, Dept Surg, Div Transplant Surg, Denver, CO 80202 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Dept Biol, Ctr Precis Canc Med, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Acute Care Surg Trauma & Surg Crit Care, Dept Surg, Boston, MA 02115 USA.
   [Moore, Ernest E.] Ernest Moore Shock Trauma Ctr Denver Hlth, Dept Surg, Denver, CO USA.
   [Moore, Peter K.] Univ Colorado, Dept Med, Denver, CO USA.
   [Talmor, Daniel S.] Harvard Med Sch, Dept Anesthesia Crit Care & Pain Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
RP Yaffe, MB (corresponding author), MIT, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Yaffe, MB (corresponding author), MIT, Dept Biol, Ctr Precis Canc Med, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.; Yaffe, MB (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Acute Care Surg Trauma & Surg Crit Care, Dept Surg, Boston, MA 02115 USA.
EM myaffe@mit.edu
OI Choudhury, Rashikh/0000-0003-3325-3090
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [UM1-HL120877, F32HL134244,
   L30-GM120751]; DoD Peer Reviewed Medical Research Program
   [W81XWH-16-1-0464]
FX This work was supported by NIH Grants UM1-HL120877 (EEM, MBY),
   F32HL134244 (CDB), and L30-GM120751 (CDB); and DoD Peer Reviewed Medical
   Research Program, Contract Number W81XWH-16-1-0464 (MBY).
CR Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bromberger B, 2014, J GASTROINTEST SURG, V18, P321, DOI 10.1007/s11605-013-2298-y
   Califf RM, 1996, CIRCULATION, V94, P1233, DOI 10.1161/01.CIR.94.6.1233
   Choudhury RA, 2019, J GASTROINTESTINAL S
   Choudhury RA, 2014, J GASTROINTEST SURG, V18, P2074, DOI 10.1007/s11605-014-2653-7
   Choudhury RA, 2014, SURG OBES RELAT DIS, V10, P79, DOI 10.1016/j.soard.2013.04.016
   Ferguson Neil M, 2020, IMPACT NONPHARMACEUT
   Glover MJ, 2018, MED DECIS MAKING, V38, P439, DOI 10.1177/0272989X17753380
   Han H, 2020, CLIN CHEM LAB MED
   Hardaway RM, 2001, AM SURGEON, V67, P377
   Jennifer H, 2020, EMERGING INFECT DIS, V26
   Moore HB, 2020, J TRAUMA ACUTE CARE
   Naugler WE, 2010, LIVER TRANSPLANT, V16, P1186, DOI 10.1002/lt.22129
   Remuzzi A., LANCET, DOI 10.1016%2Fs0140-6736%2820%2930627-9
   Remuzzi A, 2020, LANCET
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI [10.1016/j.tmaid.2020.101623, DOI 10.1016/J.TMAID.2020.101623]
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Tang N., 2020, J THROMB HAEMOST
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 19
TC 11
Z9 11
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-7922
J9 WORLD J EMERG SURG
JI World J. Emerg. Surg.
PD APR 20
PY 2020
VL 15
IS 1
AR 29
DI 10.1186/s13017-020-00305-4
PG 6
WC Emergency Medicine; Surgery
SC Emergency Medicine; Surgery
GA LJ0ZE
UT WOS:000529901600001
PM 32312290
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Song, JC
   Wang, G
   Zhang, W
   Zhang, Y
   Li, WQ
   Zhou, Z
AF Song, Jing-Chun
   Wang, Gang
   Zhang, Wei
   Zhang, Yang
   Li, Wei-Qin
   Zhou, Zhou
CA Chinese Soc Thrombosis Haemostasis
TI Chinese expert consensus on diagnosis and treatment of coagulation
   dysfunction in COVID-19
SO MILITARY MEDICAL RESEARCH
LA English
DT Article
DE COVID-19; Severe; Coagulation dysfunction; Diagnosis; Treatment
ID HEPARIN-INDUCED THROMBOCYTOPENIA; DISSEMINATED INTRAVASCULAR
   COAGULATION; CRITICALLY-ILL PATIENTS; AMERICAN SOCIETY; SCORING SYSTEM;
   GUIDELINES; MANAGEMENT; HEMODILUTION; HEMOSTASIS; THROMBOSIS
AB Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.
C1 [Song, Jing-Chun] Chinese PLA, Dept Crit Care Med, Hosp 908, Joint Logist Support Forces, Nanchang 330002, Jiangxi, Peoples R China.
   [Wang, Gang] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Crit Care Med, Xian 710001, Peoples R China.
   [Zhang, Wei] Chinese PLA, Dept Emergency Med, Hosp 900, Joint Logist Support Forces, Fuzhou 350000, Peoples R China.
   [Zhang, Yang; Zhou, Zhou] Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Dept Lab Med, Beijing 100037, Peoples R China.
   [Li, Wei-Qin] Chinese PLA, Gen Hosp Eastern Theater Command, Dept Crit Care Med, Nanjing 210002, Peoples R China.
RP Song, JC (corresponding author), Chinese PLA, Dept Crit Care Med, Hosp 908, Joint Logist Support Forces, Nanchang 330002, Jiangxi, Peoples R China.; Zhou, Z (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Dept Lab Med, Beijing 100037, Peoples R China.; Li, WQ (corresponding author), Chinese PLA, Gen Hosp Eastern Theater Command, Dept Crit Care Med, Nanjing 210002, Peoples R China.
EM songjingchun@126.com; liweiqindr@vip.163.com; fwcomd@126.com
RI Song, Jingchun/O-7563-2015
OI Song, Jingchun/0000-0001-5869-5077
CR Akhoundi A, 2015, BLOOD PURIFICAT, V39, P333, DOI 10.1159/000380903
   Alizadehasl Azin, 2015, Res Cardiovasc Med, V4, pe28086, DOI 10.5812/cardiovascmed.28086v2
   [Anonymous], 2019, NAT BIOTECHNOL, V37, P1, DOI DOI 10.3760/CMA.J.ISSN.1000-6680.2019.01.001
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Chinese Research Hospital Association of Critical Care Medicine, 2020, CHIN CRIT CARE MED, V1, P32, DOI [10.3760/cma.j.cn121430-20200218-00001, DOI 10.3760/CMA.J.CN121430-20200218-00001]
   Choi JH, 2019, ANN CARDIOTHORAC SUR, V8, P19, DOI 10.21037/acs.2018.12.02
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Coats TJ, 2006, EMERG MED J, V23, P846, DOI 10.1136/emj.2006.036574
   Committee of Critical Care Medicine Chinese Association of Chest Physician Chinese Medical Doctor Association, 2019, Zhonghua Jie He He Hu Xi Za Zhi, V42, P660, DOI 10.3760/cma.j.issn.1001-0939.2019.09.006
   Committee of Extracorporeal Life Support of Chinese Medical Association, 2018, CHIN MED J, V98, P886
   Cuker A, 2018, BLOOD ADV, V2, P3360, DOI 10.1182/bloodadvances.2018024489
   Cvirn G, 2010, CLIN LAB, V56, P585
   Deng XP, 2018, J SOU CHIN NATL I DE, V20, P476, DOI [10.3969/j.issn.1672-271X.2018.05.006, DOI 10.3969/J.ISSN.1672-271X.2018.05.006]
   DING Y, 2020, PSYCHOL REP 0415
   Emergency Medicine Branch of Chinese Medical Education Association Cardio Cerebrovascular Group of Emergency Medicine Branch of Chinese Medical Association Emergency Expert Consensus Group of Acute Thrombotic Diseases, 2019, CHIN EMERG MED, V39, P501, DOI [10.3969/j.issn.1002-1949.2019.06.001, DOI 10.3969/J.ISSN.1002-1949.2019.06.001]
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Expert Group on Novel Coronavirus Disease Clinical Treatment in Shanghai, 2020, CHIN J INFECT DIS, V1, P38, DOI [10.3760/cma.j.issn.1000-6680.2020.0016, DOI 10.3760/CMA.J.ISSN.1000-6680.2020.0016]
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Guru PK, 2016, NEPHRON, V133, P175, DOI 10.1159/000447543
   Hadem J, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-24
   Hansson EC, 2014, BRIT J ANAESTH, V112, P570, DOI 10.1093/bja/aet339
   Hartmann J, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10020118
   Hermann A, 2019, ARTIF ORGANS, V43, P1077, DOI 10.1111/aor.13514
   Holme PA, 2018, HAEMOPHILIA, V24, P24, DOI 10.1111/hae.13331
   Holmes CE, 2009, J THROMB THROMBOLYS, V27, P406, DOI 10.1007/s11239-008-0228-8
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Liebrecht LK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207147
   Liu HQ, 2019, CLIN J MED OFFIC, V47, P387
   Nanchal R, 2020, CRIT CARE MED, V48, pE173, DOI 10.1097/CCM.0000000000004192
   National Health Commission of the PRC, 2018, TRANSF WHOL BLOOD BL
   National Infectious Diseases Clinical Medicine Center National Laboratory of Infectious Diseases Diagnosis and Treatment, 2020, CHIN J CLIN INFECT D, V13, pE003
   Newland A, 2019, HEMATOLOGY, V24, P679, DOI 10.1080/16078454.2019.1662200
   Orfeo T, 2018, MIL MED, V183, P175, DOI 10.1093/milmed/usx180
   Oudemans-van Straaten HM, 2015, SEMIN THROMB HEMOST, V41, P91, DOI 10.1055/s-0034-1398384
   Peng HT, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7020539
   Peterson K, 2013, J PEDIATR NURS, V28, P85, DOI 10.1016/j.pedn.2012.10.006
   Putzu A, 2019, ANESTHESIOLOGY, V131, P580, DOI 10.1097/ALN.0000000000002820
   Ronco C, 2019, BLOOD PURIFICAT, V48, P99, DOI 10.1159/000490694
   Schwartz J, 2016, J CLIN APHERESIS, V31, P149, DOI 10.1002/jca.21470
   Scott KJ, 2019, J CLIN ANESTH, V58, P39, DOI 10.1016/j.jclinane.2019.04.032
   Squizzato A, 2016, THROMB HAEMOSTASIS, V115, P896, DOI 10.1160/TH15-09-0740
   Steiger T, 2019, ARTIF ORGANS, V43, P1065, DOI 10.1111/aor.13513
   Stettler GR, 2018, J TRAUMA ACUTE CARE, V85, P734, DOI 10.1097/TA.0000000000002037
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Thrombosis and Hemostasis group Hematology Society Chinese Medical Association, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P978
   Thrombosis and Hemostasis Group Hematology Society of Chinese Medical Association, 2017, Zhonghua Xue Ye Xue Za Zhi, V38, P361, DOI 10.3760/cma.j.issn.0253-2727.2017.05.001
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Vayne C, 2019, THROMB HAEMOSTASIS, V119, P1138, DOI 10.1055/s-0039-1688827
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Warkentin TE, 2011, J THROMB HAEMOST, V9, P2498, DOI 10.1111/j.1538-7836.2011.04536.x
   Warkentin TE, 2016, THROMB HAEMOSTASIS, V116, P813, DOI 10.1160/TH16-06-0435
   Waters JH, 2014, BRIT J ANAESTH, V113, P3, DOI 10.1093/bja/aeu379
   Wesley B, 2019, J ORTHOP TRAUMA, DOI [10.1097/BOT.0000000000001714, DOI 10.1097/B0T.0000000000001714]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09190-5
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XH, 2020, CHIN MED J, V1, P100, DOI [10.3760/cma.j.cn112137-20200224-00420, DOI 10.3760/CMA.J.CN112137-20200224-00420]
   Zeng QB, 2019, CHIN J TRANSFUS, V32, P1004
   Zhang ZL, 2016, J HUAZHONG U SCI-MED, V36, P614, DOI 10.1007/s11596-016-1634-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 64
TC 36
Z9 37
U1 4
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-7467
EI 2054-9369
J9 MILITARY MED RES
JI MILITARY MED. RES.
PD APR 20
PY 2020
VL 7
IS 1
AR 19
DI 10.1186/s40779-020-00247-7
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA LH6SA
UT WOS:000528913800001
PM 32307014
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Tillu, G
   Chaturvedi, S
   Chopra, A
   Patwardhan, B
AF Tillu, Girish
   Chaturvedi, Sarika
   Chopra, Arvind
   Patwardhan, Bhushan
TI Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; ASHWAGANDHA; DRUGS
C1 [Tillu, Girish; Patwardhan, Bhushan] Savitribai Phule Pune Univ, Interdisciplinary Sch Hlth Sci, AYUSH Ctr Excellence, Ctr Complementary & Integrat Hlth, Pune, Maharashtra, India.
   [Chaturvedi, Sarika] Dr DY Patil Vidyapeeth DPU, Pune, Maharashtra, India.
   [Chopra, Arvind] Ctr Rheumat Dis, Pune, Maharashtra, India.
RP Patwardhan, B (corresponding author), Savitribai Phule Pune Univ, Interdisciplinary Sch Hlth Sci, AYUSH Ctr Excellence, Ctr Complementary & Integrat Hlth, Pune, Maharashtra, India.
EM bpatwardhan@gmail.com
RI Patwardhan, Bhushan/F-1583-2011
OI Patwardhan, Bhushan/0000-0003-3918-2609
CR Abbott DJ, 2001, AM J RHINOL, V15, P41, DOI 10.2500/105065801781329464
   Abel AN, 2013, J ALTERN COMPLEM MED, V19, P185, DOI 10.1089/acm.2011.0516
   Acharya Y., 1992, CHARAKA SAMHITA
   Acharya YT, 2003, SHRI DALHANACHARAYA, P761
   Agarwal A, 2009, ANESTH ANALG, V109, P77, DOI 10.1213/ane.0b013e3181a6ad47
   Agarwal R, 1999, J ETHNOPHARMACOL, V67, P27, DOI 10.1016/S0378-8741(99)00065-3
   Amruthesh Sunita, 2008, Indian J Dent Res, V19, P52
   Balasubramani SP, 2011, CHIN J INTEGR MED, V17, P88, DOI 10.1007/s11655-011-0659-5
   Bani S, 2006, J ETHNOPHARMACOL, V107, P107, DOI 10.1016/j.jep.2006.02.016
   Chandran S, 2018, J AYURVEDA INTEGR ME, V9, P136, DOI 10.1016/j.jaim.2017.10.008
   Chopra A, 2010, J Ayurveda Integr Med, V1, P243, DOI 10.4103/0975-9476.74423
   Chopra A, 2012, CLIN RHEUMATOL, V31, P259, DOI 10.1007/s10067-011-1809-z
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Cyranoski David, 2020, Nature, DOI 10.1038/d41586-020-00938-0
   Diwanay S, 2004, J ETHNOPHARMACOL, V90, P49, DOI 10.1016/j.jep.2003.09.023
   Fan W, 2020, RESEARCHGATE, DOI [10.13140/RG.2.2.31786.98248, DOI 10.13140/RG.2.2.31786.98248]
   Johnsen J, 2001, ARCH OTOLARYNGOL, V127, P1353, DOI 10.1001/archotol.127.11.1353
   Kaminsky DA, 2017, J ALTERN COMPLEM MED, V23, P696, DOI 10.1089/acm.2017.0102
   King D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006821.pub3
   Maxwell Lizzie, 2015, WMJ, V114, P100
   Ministry of AYUSH Government of India, AYURV IMM BOOST MEAS
   Morgan N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100903
   Muktibodhananda S, 2012, HATHA YOGO PRADIPIKA, P202
   Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001
   Papp ME, 2017, EUR J PHYS REHAB MED, V53, P447, DOI 10.23736/S1973-9087.16.04374-4
   Paradkar H, 2003, ASHTANGA HRUDAYA VAG, P287
   Patwardhan B, 2008, J ALTERN COMPLEM MED, V14, P571, DOI 10.1089/acm.2007.0515
   Saggam A, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112759
   SAKETKHOO K, 1978, CHEST, V74, P408, DOI 10.1378/chest.74.4.408
   Shanbhag Vagish Kumar L, 2017, J Tradit Complement Med, V7, P106, DOI 10.1016/j.jtcme.2016.05.004
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shrungeswara AH, 2019, J AYURVEDA INTEGR ME, V10, P222, DOI 10.1016/j.jaim.2017.08.003
   Singh N, 2011, AFR J TRADIT COMPLEM, V8, P208, DOI 10.4314/ajtcam.v8i5S.9
   Sumantran VN, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/306346
   Thatte U, 2015, INDIAN J MED RES, V142, P53, DOI 10.4103/0971-5916.162099
   Vanka A, 2001, Indian J Dent Res, V12, P133
   Vathanophas Vannipa, 2019, Asian Pac J Allergy Immunol, DOI 10.12932/AP-090818-0393
   Vinjamury S.P., 2012, EVIDENCE BASED PRACT, P113
   Weeks J., 2020, COVID 19 NCCIH DIREC
   Weeks J, 2020, J ALTERN COMPLEM MED, V26, P256, DOI 10.1089/acm.2020.29083.jjw
   World Health Organization, 2020, LAB US MED COVID 19
   World Health Organization, 2020, WHO SOL CLIN TRIAL C
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 43
TC 15
Z9 16
U1 3
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY 1
PY 2020
VL 26
IS 5
BP 360
EP 364
DI 10.1089/acm.2020.0129
EA APR 2020
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LM3QX
UT WOS:000527808800001
PM 32310670
OA Bronze
DA 2021-01-01
ER

PT J
AU Aminian, A
   Kermansaravi, M
   Azizi, S
   Alibeigi, P
   Safamanesh, S
   Mousavimaleki, A
   Rezaei, MT
   Faridi, M
   Mokhber, S
   Pazouki, A
   Safari, S
AF Aminian, Ali
   Kermansaravi, Mohammad
   Azizi, Shahriar
   Alibeigi, Peyman
   Safamanesh, Sina
   Mousavimaleki, Ali
   Rezaei, Mohammad Taghi
   Faridi, Maziar
   Mokhber, Somayeh
   Pazouki, Abdolreza
   Safari, Saeed
TI Bariatric Surgical Practice During the Initial Phase of COVID-19
   Outbreak
SO OBESITY SURGERY
LA English
DT Article
DE Bariatric surgery; Gastric bypass; Complications; COVID-19; Coronavirus;
   Pneumonia
AB There is no data on patients with severe obesity who developed coronavirus disease 2019 (COVID-19) after bariatric surgery. Four gastric bypass operations, performed in a 2-week period between Feb 24 and March 4, 2020, in Tehran, Iran, were complicated with COVID-19. The mean age and body mass index were 46 +/- 12 years and 49 +/- 3 kg/m(2). Patients developed their symptoms (fever, cough, dyspnea, and fatigue) 1, 2, 4, and 14 days after surgery. One patient had unnoticed anosmia 2 days before surgery. Three patients were readmitted in hospital. All 4 patients were treated with hydroxychloroquine. In two patients who required admission in intensive care unit, other off-label therapies including antiretroviral and immunosuppressive agents were also administered. All patients survived. In conclusion, COVID-19 can complicate the postoperative course of patients after bariatric surgery. Correct diagnosis and management in the postoperative setting would be challenging. Timing of infection after surgery in our series would raise the possibility of hospital transmission of COVID-19: from asymptomatic patients at the time of bariatric surgery to the healthcare workers versus acquiring the COVID-19 infection by non-infected patients in the perioperative period.
C1 [Aminian, Ali] Cleveland Clin, Dept Gen Surg, Bariatr & Metab Inst, 9500 Euclid Ave,Desk M61, Cleveland, OH 44195 USA.
   [Kermansaravi, Mohammad; Mousavimaleki, Ali; Mokhber, Somayeh; Pazouki, Abdolreza] Iran Univ Med Sci, Minimally Invas Surg Res Ctr, Rasool E Akram Hosp, Tehran, Iran.
   [Azizi, Shahriar] Erfan Niayesh Hosp, Tehran, Iran.
   [Alibeigi, Peyman; Rezaei, Mohammad Taghi] Mehrad Hosp, Tehran, Iran.
   [Safamanesh, Sina; Faridi, Maziar] Iranmehr Hosp, Tehran, Iran.
   [Safari, Saeed] Iran Univ Med Sci, Firoozgar Gen Hosp, Tehran, Iran.
RP Aminian, A (corresponding author), Cleveland Clin, Dept Gen Surg, Bariatr & Metab Inst, 9500 Euclid Ave,Desk M61, Cleveland, OH 44195 USA.
EM aminiaa@ccf.org
RI ; Kermansaravi, Mohammad/G-1154-2017
OI safari, saeed/0000-0001-6127-6359; Kermansaravi,
   Mohammad/0000-0001-8978-9359
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Aminian A, 2015, DIABETES OBES METAB, V17, P198, DOI 10.1111/dom.12405
   Aminian A, 2020, ANN SURG, V272, pE27, DOI 10.1097/SLA.0000000000003925
   Daigle CR, 2018, SURG OBES RELAT DIS, V14, P652, DOI 10.1016/j.soard.2018.01.008
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 10
TC 18
Z9 18
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0960-8923
EI 1708-0428
J9 OBES SURG
JI Obes. Surg.
PD SEP
PY 2020
VL 30
IS 9
BP 3624
EP 3627
DI 10.1007/s11695-020-04617-x
EA APR 2020
PG 4
WC Surgery
SC Surgery
GA MO8RR
UT WOS:000527899000003
PM 32314249
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Bajaj, A
   Purohit, HJ
AF Bajaj, Abhay
   Purohit, Hemant J.
TI Understanding SARS-CoV-2: Genetic Diversity, Transmission and Cure in
   Human
SO INDIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2 genome; Genetic diversity; Phylogeny; Gut microbiome; Drug
   development
ID GUT MICROBIOME
AB As the SARS-CoV-2 virus race around the world across the different population, there needs to be a consolidated effort to understand the divergence of demographically distributed strains. The emerging trends in SARS-CoV-2 genome data show specific mutation and genetic diversity, which could provide the basis to develop a cocktail of vaccine and may also be used to develop the region-specific diagnostic tool, thus decreasing the chances of testing failures in fields. Since the transmission of SARS-CoV-2 is subject to the extent of human interaction, the insights from the correlation of genetic diversity with epidemiological parameter would give paramount information to tackle this transmission. Previously, studies have also correlated the epidemiological data with gut microbiome and its role in immunomodulation for maintaining health status, and such information could be generated from recovered individuals from different demographic regions. It will help in designing a probiotic-based diet for modulation of the gut microbiome, and that could be another plausible prophylactic treatment option. The genomics data suggest that a specific variant of SARS-CoV-2 gets enriched with the specific demographic region. Overall, demographic data suggests that host influences mutation and expression of the virus. Hence, the experiences from the clinical intervention for that region should be considered in control and treatment strategies.
C1 [Bajaj, Abhay; Purohit, Hemant J.] CSIR NEERI, Environm Biotechnol & Genom Div, Nagpur 440020, Maharashtra, India.
RP Purohit, HJ (corresponding author), CSIR NEERI, Environm Biotechnol & Genom Div, Nagpur 440020, Maharashtra, India.
EM hj_purohit@neeri.res.in
FU CSIR-National Environmental Engineering Research Institute (CSIR-NEERI)
FX Authors are thankful to the Director, CSIR-National Environmental
   Engineering Research Institute (CSIR-NEERI) for his support. The
   manuscript is checked by Knowledge Resource Center, CSIR-NEERI, Nagpur,
   India and assigned KRC No. CSIR-NEERI/KRC/2020/MARCH/EBGD/2.
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   [Anonymous], 2020, ICELAND SCI FOUND 40
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Global Initiative on Sharing All Influenza Data, 2020, GENOMIC EPIDEMIOLOGY
   Jakkula MK, 2018, PROCEEDINGS OF THE 2018 IEEE INTERNATIONAL CONFERENCE ON COMMUNICATION AND SIGNAL PROCESSING (ICCSP), P1000, DOI 10.1109/ICCSP.2018.8524507
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maji A, 2018, ENVIRON MICROBIOL, V20, P402, DOI 10.1111/1462-2920.14015
   Galdeano CM, 2019, ANN NUTR METAB, V74, P115, DOI 10.1159/000496426
   Ngwa CJ, 2015, TRENDS PARASITOL, V31, P2, DOI 10.1016/j.pt.2014.11.006
   Patra A, 2020, OSF, DOI [10.17605/osf.io/y8uac, DOI 10.17605/OSF.IO/Y8UAC]
   Purohit HJ, 2018, INDIAN J MICROBIOL, V58, P3, DOI 10.1007/s12088-017-0697-6
   Sardar R, 2020, COMP ANAL SAR COV2 G, DOI [10.1101/2020.03.21.001586, DOI 10.1101/2020.03.21.001586]
   Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Tang X, 2020, NATL SCI REV, DOI [10.1093/nsr/nwaa036/5775463, DOI 10.1093/NSR/NWAA036/5775463]
   Verma H, 2008, INDIAN J MED MICROBI, V26, P322
   Villarino NF, 2016, P NATL ACAD SCI USA, V113, P2235, DOI 10.1073/pnas.1504887113
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Worldometer, 2020, COR CAS
   Yadav Pragya D, 2020, Indian J Med Res, V151, P200, DOI 10.4103/ijmr.IJMR_663_20
NR 22
TC 5
Z9 6
U1 5
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0046-8991
EI 0973-7715
J9 INDIAN J MICROBIOL
JI Indian J. Microbiol.
PD SEP
PY 2020
VL 60
IS 3
BP 398
EP 401
DI 10.1007/s12088-020-00869-4
EA APR 2020
PG 4
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA ME5LT
UT WOS:000527512900002
PM 32317810
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Song, J
   Kang, S
   Choi, SW
   Seo, KW
   Lee, S
   So, MW
   Lim, DH
AF Song, Jehun
   Kang, Seongmin
   Choi, Seung Won
   Seo, Kwang Won
   Lee, Sunggun
   So, Min Wook
   Lim, Doo-Ho
TI Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a
   patient with rheumatoid arthritis receiving conventional
   disease-modifying antirheumatic drugs
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Coronavirus; COVID-19; Pneumonia; Rheumatoid arthritis;
   Disease-modifying antirheumatic drugs
ID INFECTIONS
AB In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
C1 [Song, Jehun; Kang, Seongmin; Choi, Seung Won; Lim, Doo-Ho] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Rheumatol,Dept Internal Med, 877 Bangeojinsunhwan Doro, Ulsan 44033, South Korea.
   [Seo, Kwang Won] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Ulsan, South Korea.
   [Lee, Sunggun] Inje Univ, Haeundae Paik Hosp, Coll Med, Div Rheumatol,Dept Internal Med, Busan, South Korea.
   [So, Min Wook] Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Rheumatol, Yangsan, South Korea.
RP Lim, DH (corresponding author), Univ Ulsan, Ulsan Univ Hosp, Coll Med, Div Rheumatol,Dept Internal Med, 877 Bangeojinsunhwan Doro, Ulsan 44033, South Korea.
EM dlaengh@hanmail.net
OI Lee, Sunggun/0000-0003-3640-9185; Lim, Doo-Ho/0000-0002-8012-7364
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Atzeni F, 2017, CURR OPIN RHEUMATOL, V29, P323, DOI 10.1097/BOR.0000000000000389
   Blum CA, 2015, LANCET, V385, P1511, DOI 10.1016/S0140-6736(14)62447-8
   Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158
   Cascella M, 2020, FEATURES EVALUATION
   Gasparyan AY, 2011, RHEUMATOL INT, V31, P1409, DOI 10.1007/s00296-011-1999-3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203
   Ledingham J, 2017, RHEUMATOLOGY, V56, P2257, DOI 10.1093/rheumatology/kex389
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Shale Matt, 2010, Therap Adv Gastroenterol, V3, P173, DOI 10.1177/1756283X10366368
   Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
NR 20
TC 9
Z9 9
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD JUN
PY 2020
VL 40
IS 6
BP 991
EP 995
DI 10.1007/s00296-020-04584-7
EA APR 2020
PG 5
WC Rheumatology
SC Rheumatology
GA LI7TB
UT WOS:000527473800001
PM 32314010
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ulrich, H
   Pillat, MM
AF Ulrich, Henning
   Pillat, Micheli M.
TI CD147 as a Target for COVID-19 Treatment: Suggested Effects of
   Azithromycin and Stem Cell Engagement
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE SARS-CoV-2; Lung stem cells; Coronavirus; Cellular therapy; Asthma;
   Diabetes mellitus; Invasion; Anti-viral responses; Basigin; EMMPRIN
ID RESIDENT FIBROBLASTS; PULMONARY-FIBROSIS; EXPRESSION; INVASION; BASIGIN;
   DRUGS
AB The expressive number of deaths and confirmed cases of SARS-CoV-2 call for an urgent demand of effective and available drugs for COVID-19 treatment. CD147, a receptor on host cells, is a novel route for SARS-CoV-2 invasion. Thus, drugs that interfere in the spike protein/CD147 interaction or CD147 expression may inhibit viral invasion and dissemination among other cells, including in progenitor/stem cells. Studies suggest beneficial effects of azithromycin in reducing viral load of hospitalized patients, possibly interfering with ligand/CD147 receptor interactions; however, its possible effects on SARS-CoV-2 invasion has not yet been evaluated. In addition to the possible effect in invasion, azithromycin decreases the expression of some metalloproteinases (downstream to CD147), induces anti-viral responses in primary human bronchial epithelial infected with rhinovirus, decreasing viral replication and release. Moreover, resident lung progenitor/stem are extensively differentiated into myofibroblasts during pulmonary fibrosis, a complication observed in COVID-19 patients. This process, and the possible direct viral invasion of progenitor/stem cells via CD147 or ACE2, could result in the decline of these cellular stocks and failing lung repair. Clinical tests with allogeneic MSCs from healthy individuals are underway to enhance endogenous lung repair and suppress inflammation.
C1 [Ulrich, Henning] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, SP, Brazil.
   [Pillat, Micheli M.] Fed Univ Santa Maria RS, Hlth Sci Ctr, Dept Microbiol & Parasitol, Ave Roraima 1000, BR-97105900 Santa Maria, RS, Brazil.
RP Pillat, MM (corresponding author), Fed Univ Santa Maria RS, Hlth Sci Ctr, Dept Microbiol & Parasitol, Ave Roraima 1000, BR-97105900 Santa Maria, RS, Brazil.
EM mmpillat@gmail.com
RI Pillat, Micheli/AAW-3423-2020
OI Pillat, Micheli/0000-0002-6753-6083
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Federal University of Santa Maria (UFSM), RS, Brazil; Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo [Sao Paulo Research
   Foundation (FAPESP)]Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2018/08426-0]; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Federal University of Santa Maria
   (UFSM), RS, Brazil. HU acknowledges grant support by Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo [Sao Paulo Research Foundation
   (FAPESP) Project No. 2018/08426-0] and CNPq.
CR Aguai ZH, 2007, PEDIATR RES, DOI [10.1203/PDR.0b013e318142582d, DOI 10.1203/PDR.0B013E318142582D]
   Amati E, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-017-0755-3
   Bao W, 2010, AM J PHYSIOL-CELL PH, V299, pC1212, DOI 10.1152/ajpcell.00228.2010
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Bouwman JJM, 2004, J LAB CLIN MED, V144, P18, DOI 10.1016/j.lab.2004.03.012
   Crosnier C, 2011, NATURE, V480, P534, DOI 10.1038/nature10606
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   El Agha E, 2017, CELL STEM CELL, V21, P166, DOI 10.1016/j.stem.2017.07.011
   Emingil G, 2008, J PERIODONTOL, V79, P469, DOI [10.1902/jop.2008.070165, 10.1902/jop.2008.070165 ]
   Moheimani F, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0851-7
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Guillot S, 2006, EXP LUNG RES, V32, P81, DOI 10.1080/01902140600710512
   Higashi Kiyoshi, 2015, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V34, P7, DOI 10.1089/mab.2014.0075
   Hoyles RK, 2011, AM J RESP CRIT CARE, V183, P249, DOI 10.1164/rccm.201002-0279OC
   Hung C, 2013, AM J RESP CRIT CARE, V188, P820, DOI 10.1164/rccm.201212-2297OC
   Jun D, 2011, STEM CELLS, V29, P725, DOI 10.1002/stem.604
   Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103
   Kobayashi Y, 2013, J PHARMACOL EXP THER, V345, P76, DOI 10.1124/jpet.112.200733
   Kong LM, 2014, CANCER RES, V74, P3764, DOI 10.1158/0008-5472.CAN-13-3555
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Li XP, 2008, AM J PHYSIOL-LUNG C, V295, pL178, DOI 10.1152/ajplung.00009.2008
   Li XP, 2003, AM J PHYSIOL-LUNG C, V284, pL501, DOI 10.1152/ajplung.00273.2002
   Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Marriott S, 2014, AM J PHYSIOL-CELL PH, V307, pC684, DOI 10.1152/ajpcell.00114.2014
   Mattos W, 2002, CHEST, V122, P1543, DOI 10.1378/chest.122.5.1543
   Muralidharan V, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0185-6
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108
   Singh S, 2014, ANTIMICROB AGENTS CH, V58, P4657, DOI 10.1128/AAC.02141-13
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Toole BP, 2020, ANAT REC, V303, P1573, DOI 10.1002/ar.24147
   Vandooren J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174853
   Verleden SE, 2011, TRANSPL IMMUNOL, V25, P159, DOI 10.1016/j.trim.2011.06.006
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang S, 2017, TUMOR BIOL, DOI [10.1177/1010428317718192, DOI 10.1177/1010428317718192]
   Wilson DW, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0162-0
   Xie T, 2016, J CLIN INVEST, V126, P3626, DOI 10.1172/JCI89968
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zenonos ZA, 2015, J EXP MED, V212, P1145, DOI 10.1084/jem.20150032
NR 43
TC 60
Z9 65
U1 6
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JUN
PY 2020
VL 16
IS 3
BP 434
EP 440
DI 10.1007/s12015-020-09976-7
EA APR 2020
PG 7
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA LR9PX
UT WOS:000527520800001
PM 32307653
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rubin, GA
   Biviano, A
   Dizon, J
   Yarmohammadi, H
   Ehlert, F
   Saluja, D
   Rubin, DA
   Morrow, JP
   Waase, M
   Berman, J
   Kushnir, A
   Abrams, MP
   Garan, H
   Wan, ELY
AF Rubin, Geoffrey A.
   Biviano, Angelo
   Dizon, Jose
   Yarmohammadi, Hirad
   Ehlert, Frederick
   Saluja, Deepak
   Rubin, David A.
   Morrow, John P.
   Waase, Marc
   Berman, Jeremy
   Kushnir, Alexander
   Abrams, Mark P.
   Garan, Hasan
   Wan, Elaine Y.
TI Performance of electrophysiology procedures at an academic medical
   center amidst the 2020 coronavirus (COVID-19) pandemic
SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
LA English
DT Article
DE coronavirus; COVID-19; electrophysiology laboratory; pandemic
AB A global coronavirus (COVID-19) pandemic occurred at the start of 2020 and is already responsible for more than 74 000 deaths worldwide, just over 100 years after the influenza pandemic of 1918. At the center of the crisis is the highly infectious and deadly SARS-CoV-2, which has altered everything from individual daily lives to the global economy and our collective consciousness. Aside from the pulmonary manifestations of disease, there are likely to be several electrophysiologic (EP) sequelae of COVID-19 infection and its treatment, due to consequences of myocarditis and the use of QT-prolonging drugs. Most crucially, the surge in COVID-19 positive patients that have already overwhelmed the New York City hospital system requires conservation of hospital resources including personal protective equipment (PPE), reassignment of personnel, and reorganization of institutions, including the EP laboratory. In this proposal, we detail the specific protocol changes that our EP department has adopted during the COVID-19 pandemic, including performance of only urgent/emergent procedures, after hours/7-day per week laboratory operation, single attending-only cases to preserve PPE, appropriate use of PPE, telemedicine and video chat follow-up appointments, and daily conferences to collectively manage the clinical and ethical dilemmas to come. We discuss also discuss how we perform EP procedures on presumed COVID positive and COVID tested positive patients to highlight issues that others in the EP community may soon face in their own institution as the virus continues to spread nationally and internationally.
C1 [Rubin, Geoffrey A.; Biviano, Angelo; Dizon, Jose; Yarmohammadi, Hirad; Ehlert, Frederick; Saluja, Deepak; Rubin, David A.; Morrow, John P.; Waase, Marc; Berman, Jeremy; Kushnir, Alexander; Abrams, Mark P.; Garan, Hasan; Wan, Elaine Y.] Columbia Univ, Dept Med, Div Cardiol, Vagelos Coll Phys & Surg, New York, NY USA.
RP Wan, ELY (corresponding author), 622 W168 St,PH 3 Ctr, New York, NY 10032 USA.
EM eyw2003@cumc.columbia.edu
CR [Anonymous], 2020, HLTH INFORM PRIVACY
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ilmarinen T, 2012, EUR ARCH OTO-RHINO-L, V269, P2367, DOI 10.1007/s00405-012-2049-9
   Lakkireddy DR, 2020, CIRCULATION
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   O'Laughlin JP, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/4626279
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 10
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-3873
EI 1540-8167
J9 J CARDIOVASC ELECTR
JI J. Cardiovasc. Electrophysiol.
PD JUN
PY 2020
VL 31
IS 6
BP 1249
EP 1254
DI 10.1111/jce.14493
EA APR 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LT3HW
UT WOS:000527079700001
PM 32281214
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Smit, C
   Peeters, MYM
   van den Anker, JN
   Knibbe, CAJ
AF Smit, Cornelis
   Peeters, Mariska Y. M.
   van den Anker, John N.
   Knibbe, Catherijne A. J.
TI Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic
   and Safety Properties
SO CLINICAL PHARMACOKINETICS
LA English
DT Article
ID POPULATION PHARMACOKINETICS; DISPOSITION; PHARMACODYNAMICS; ELIMINATION;
   METABOLISM; KINETICS; CHILDREN; MALARIA; PLASMA; DESETHYLCHLOROQUINE
AB Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 mu mol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children.
C1 [Smit, Cornelis; van den Anker, John N.] Univ Basel, Pediat Pharmacol & Pharmacometr Res Ctr, Childrens Hosp, Basel, Switzerland.
   [Smit, Cornelis; Knibbe, Catherijne A. J.] Leiden Univ, Leiden Acad Ctr Drug Res, Dept Syst Biomed & Pharmacol, Leiden, Netherlands.
   [Peeters, Mariska Y. M.; Knibbe, Catherijne A. J.] St Antonius Hosp, Dept Clin Pharm, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.
   [van den Anker, John N.] Childrens Natl Hosp, Div Clin Pharmacol, Washington, DC USA.
RP Knibbe, CAJ (corresponding author), Leiden Univ, Leiden Acad Ctr Drug Res, Dept Syst Biomed & Pharmacol, Leiden, Netherlands.; Knibbe, CAJ (corresponding author), St Antonius Hosp, Dept Clin Pharm, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.
EM c.knibbe@antoniusziekenhuis.nl
RI Smit, Cornelis/AAK-8756-2020
OI Smit, Cornelis/0000-0002-1357-9248; Knibbe, Catherijne Annette
   Jantine/0000-0001-9893-4415; van den Anker, Johannes/0000-0003-0571-7492
CR ADELUSI SA, 1982, BRIT J CLIN PHARMACO, V14, P483, DOI 10.1111/j.1365-2125.1982.tb02016.x
   ADELUSI SA, 1982, GEN PHARMACOL, V13, P433, DOI 10.1016/0306-3623(82)90110-0
   AKINTONWA A, 1986, THER DRUG MONIT, V8, P285, DOI 10.1097/00007691-198609000-00008
   Alliance Pharmaceuticals, SUMM PROD CHAR AV
   BERGQVIST Y, 1983, J CHROMATOGR, V272, P137, DOI 10.1016/S0378-4347(00)86110-1
   BERLINER RW, 1948, J CLIN INVEST, V27, P98, DOI 10.1172/JCI101980
   BRITTON WJ, 1978, MED J AUSTRALIA, V2, P407, DOI 10.5694/j.1326-5377.1978.tb76816.x
   Brocks DR, 2003, CLIN PHARMACOKINET, V42, P1359, DOI 10.2165/00003088-200342150-00004
   CANN HM, 1961, PEDIATRICS, V27, P95
   Charoenchokthavee W, 2016, BREAST CANCER-TARGET, V8, P149, DOI 10.2147/BCTT.S105563
   Clark I.A., 2006, MALARIA J, V5, P1, DOI DOI 10.1186/1475-2875-5-1
   COLLEE GG, 1992, INTENS CARE MED, V18, P170, DOI 10.1007/BF01709241
   DAHER A, 2019, MALARIA J, V18, P1, DOI DOI 10.1186/s12936-018-2635-4
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Dutch Working Party on Antibiotic Policy (Stichting Werkgroep Antibiotica Beleid SWAB), MED BEH BIJ PAT MET
   EDWARDS G, 1988, BRIT J CLIN PHARMACO, V25, P477, DOI 10.1111/j.1365-2125.1988.tb03332.x
   ESSIEN EE, 1986, J PHARM PHARMACOL, V38, P543, DOI 10.1111/j.2042-7158.1986.tb04635.x
   FINIELZ P, 1993, NEPHRON, V65, P333, DOI 10.1159/000187506
   FRISKHOLMBERG M, 1983, EUR J CLIN PHARMACOL, V24, P837, DOI 10.1007/BF00607097
   FRISKHOLMBERG M, 1984, EUR J CLIN PHARMACOL, V26, P521, DOI 10.1007/BF00542151
   FRISKHOLMBERG M, 1979, CLIN PHARMACOL THER, V25, P345
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   GUSTAFSSON LL, 1983, LANCET, V1, P126
   GUSTAFSSON LL, 1983, CLIN PHARMACOL THER, V34, P383, DOI 10.1038/clpt.1983.183
   GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x
   GUSTAFSSON LL, 1987, BRIT J CLIN PHARMACO, V24, P221, DOI 10.1111/j.1365-2125.1987.tb03165.x
   Han YS, 2019, J MED VIROL, V91, P1182, DOI 10.1002/jmv.25440
   Hoglund R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1181-1
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   JAEGER A, 1987, MED TOXICOL ADV DRUG, V2, P242, DOI 10.1007/BF03259868
   KELLY JC, 1990, ANN EMERG MED, V19, P47, DOI 10.1016/S0196-0644(05)82141-9
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Khan FY, 2019, J FAM COMMUNITY MED, V26, P232, DOI 10.4103/jfcm.JFCM_78_19
   Kim KA, 2003, ARCH PHARM RES, V26, P631, DOI 10.1007/BF02976712
   Knibbe CAJ, 2015, ANNU REV PHARMACOL, V55, P149, DOI 10.1146/annurev-pharmtox-010814-124354
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   MARKOWITZ HA, 1964, JAMA-J AM MED ASSOC, V189, P950
   McLeay SC, 2012, CLIN PHARMACOKINET, V51, P319, DOI 10.2165/11598930-000000000-00000
   Moser JAS, 2019, INFLUENZA OTHER RESP, V13, P3, DOI 10.1111/irv.12618
   Mouton JW, 2008, J ANTIMICROB CHEMOTH, V61, P235, DOI 10.1093/jac/dkm476
   Muller M, 2004, ANTIMICROB AGENTS CH, V48, P1441, DOI 10.1128/AAC.48.5.1441-1453.2004
   NAMPOORY MRN, 1992, NEPHRON, V62, P108
   NIX DE, 1991, ANTIMICROB AGENTS CH, V35, P1953, DOI 10.1128/AAC.35.10.1953
   Obua C, 2008, BRIT J CLIN PHARMACO, V65, P493, DOI 10.1111/j.1365-2125.2007.03050.x
   PUSSARD E, 1991, ANTIMICROB AGENTS CH, V35, P406, DOI 10.1128/AAC.35.3.406
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Roberts DJ, 2013, EXPERT OPIN DRUG MET, V9, P1067, DOI 10.1517/17425255.2013.799137
   Sahin S, 2008, PHARM RES-DORDR, V25, P2869, DOI 10.1007/s11095-008-9787-9
   Salako LA, 2005, AFR J MED MED SCI, V13, P177
   Smit C, 2018, EXPERT OPIN DRUG MET, V14, P275, DOI 10.1080/17425255.2018.1440287
   STEAD AH, 1983, HUM TOXICOL, V2, P437, DOI 10.1177/096032718300200301
   STIFF G, 1991, POSTGRAD MED J, V67, P678, DOI 10.1136/pgmj.67.789.678
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   TULPULE A, 1982, EUR J CLIN PHARMACOL, V23, P271, DOI 10.1007/BF00547567
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Ursing J, 2016, J INFECT DIS, V213, P1315, DOI 10.1093/infdis/jiv590
   VALLEE E, 1992, ANTIMICROB AGENTS CH, V36, P1412, DOI 10.1128/AAC.36.7.1412
   van Kralingen S, 2011, CLIN PHARMACOKINET, V50, P739, DOI 10.2165/11592890-000000000-00000
   Vet NJ, 2016, AM J RESP CRIT CARE, V194, P58, DOI 10.1164/rccm.201510-2114OC
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WALKER O, 1983, BRIT J CLIN PHARMACO, V16, P701, DOI 10.1111/j.1365-2125.1983.tb02244.x
   WALKER O, 1987, BRIT J CLIN PHARMACO, V23, P295, DOI 10.1111/j.1365-2125.1987.tb03048.x
   WALKER O, 1983, BRIT J CLIN PHARMACO, V15, P375, DOI 10.1111/j.1365-2125.1983.tb01513.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHITE NJ, 1987, J INFECT DIS, V155, P192, DOI 10.1093/infdis/155.2.192
   Woosley RL, QTDRUGS LIST
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   ZHAO Q, 2014, MALARIA J, V13, P1, DOI DOI 10.1186/1475-2875-13-1
NR 69
TC 14
Z9 15
U1 4
U2 11
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0312-5963
EI 1179-1926
J9 CLIN PHARMACOKINET
JI Clin. Pharmacokinet.
PD JUN
PY 2020
VL 59
IS 6
BP 659
EP 669
DI 10.1007/s40262-020-00891-1
EA APR 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LX9LV
UT WOS:000528073000001
PM 32306288
OA Other Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Khan, RJ
   Jha, RK
   Amera, GM
   Jain, M
   Singh, E
   Pathak, A
   Singh, RP
   Muthukumaran, J
   Singh, AK
AF Khan, Rameez Jabeer
   Jha, Rajat Kumar
   Amera, Gizachew Muluneh
   Jain, Monika
   Singh, Ekampreet
   Pathak, Amita
   Singh, Rashmi Prabha
   Muthukumaran, Jayaraman
   Singh, Amit Kumar
TI Targeting SARS-CoV-2: a systematic drug repurposing approach to identify
   promising inhibitors against 3C-like proteinase and 2 '-O-ribose
   methyltransferase
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Drug repurposing; SARS-CoV-2; 3C-like proteinase; 2 '-O-ribose
   methyltransferase; docking; MD simulation
ID HIV-1 INFECTION; DOUBLE-BLIND; DOLUTEGRAVIR; STEREOCHEMISTRY;
   RALTEGRAVIR; ATTENUATION; COMBINATION; ACCURACY; DYNAMICS; DOCKING
AB The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has resulted in an unprecedented number of infected people. The highly contagious nature of this virus makes it imperative for us to identify promising inhibitors from pre-existing antiviral drugs. Two druggable targets, namely 3C-like proteinase (3CLpro) and 2 '-O-ribose methyltransferase (2 '-O-MTase) were selected in this study due to their indispensable nature in the viral life cycle. 3CLpro is a cysteine protease responsible for the proteolysis of replicase polyproteins resulting in the formation of various functional proteins, whereas 2 '-O-MTase methylates the ribose 2 '-O position of the first and second nucleotide of viral mRNA, which sequesters it from the host immune system. The selected drug target proteins were screened against an in-house library of 123 antiviral drugs. Two promising drug molecules were identified for each protein based on their estimated free energy of binding (Delta G), the orientation of drug molecules in the active site and the interacting residues. The selected protein-drug complexes were then subjected to MD simulation, which consists of various structural parameters to equivalently reflect their physiological state. From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (Delta G = -9.8 kcal/mol) & Raltegravir (Delta G = -7.8 kcal/mol) for 3CLpro and Dolutegravir (Delta G = -9.4 kcal/mol) and Bictegravir (Delta G = -8.4 kcal/mol) for 2 '-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2.
C1 [Khan, Rameez Jabeer; Jha, Rajat Kumar; Amera, Gizachew Muluneh; Jain, Monika; Singh, Ekampreet; Muthukumaran, Jayaraman; Singh, Amit Kumar] Sharda Univ, Sch Engn & Technol, Dept Biotechnol, Greater Noida, UP, India.
   [Pathak, Amita] Indian Inst Technol, Dept Chem, New Delhi, India.
   [Singh, Rashmi Prabha] IILM Coll Engn Technol, Dept Biotechnol, Greater Noida, UP, India.
RP Muthukumaran, J; Singh, AK (corresponding author), Sharda Univ, Sch Engn & Technol, Dept Biotechnol, Greater Noida, UP, India.
EM j.muthukumaran@sharda.ac.in; amitk.singh@sharda.ac.in
RI ; MUTHUKUMARAN, JAYARAMAN/M-1509-2013
OI Jha, Rajat Kumar/0000-0002-8557-4219; MUTHUKUMARAN,
   JAYARAMAN/0000-0002-0953-1196
FU College of Natural Science, Wollo University, Dessie, Ethiopia
FX Dr. Amit Kumar Singh thanks the Department of Science and Technology
   (DST) and Indian National Science Academy (INSA), New Delhi, India.
   Gizachew Muluneh Amera thanks the College of Natural Science, Wollo
   University, Dessie, Ethiopia for the sponsorship. The authors also thank
   to Supercomputing Facility for Bioinformatics & Computational Biology,
   IIT Delhi.
CR Abraham M., 2014, GROMACS USER MANUAL, V5, P1
   Ambure P, 2019, J BIOMOL STRUCT DYN, V37, P1282, DOI 10.1080/07391102.2018.1456975
   Amera GM, 2020, J BIOMOL STRUCT DYN, V38, P5230, DOI 10.1080/07391102.2019.1700167
   Amera GM, 2019, INFORM MED UNLOCKED, V16, P100216, DOI [DOI 10.1016/J.IMU.2019.100216, 10.1016/j.imu.2019.100216]
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, COR COVID 19 GLOB CA
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Carrion AF, 2014, EXPERT OPIN PHARMACO, V15, P711, DOI 10.1517/14656566.2014.889116
   Centers for Disease Control and Prevention, 2020, SEV OUTC PAT COR DIS
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chiu SW, 2009, J PHYS CHEM B, V113, P2748, DOI 10.1021/jp807056c
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Feld JJ, 2016, J HEPATOL, V64, P301, DOI 10.1016/j.jhep.2015.10.005
   Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375
   Hospital Adam, 2015, Adv Appl Bioinform Chem, V8, P37, DOI 10.2147/AABC.S70333
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Lugari A, 2010, J BIOL CHEM, V285, P33230, DOI 10.1074/jbc.M110.120014
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Madhav N, 2017, DIS CONTROL PRIORITI
   Marklund EG, 2019, CURR OPIN STRUC BIOL, V54, P50, DOI 10.1016/j.sbi.2018.12.011
   Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c
   Menachery VD, 2014, VIRUS RES, V194, P191, DOI 10.1016/j.virusres.2014.09.009
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   Micheletti C, 2013, PHYS LIFE REV, V10, P1, DOI 10.1016/j.plrev.2012.10.009
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Sax PE, 2017, LANCET, V390, P2073, DOI [10.1016/s0140-6736(17)32340-1, 10.1016/S0140-6736(17)32340-1]
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sulkowski MS, 2015, JAMA-J AM MED ASSOC, V313, P1223, DOI 10.1001/jama.2015.1328
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   UCLA MBI, STRUCT AN VER SERV
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2019, MIDDL E RESP SYNDR C
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organisation, 2020, STAT 2 M INT HLTH RE
   World Health Organization, 2020, NAM COR DIS COVID 19
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 24
Z9 24
U1 2
U2 23
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1753577
EA APR 2020
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LF7LN
UT WOS:000527598700001
PM 32266873
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Chen, WH
   Hotez, PJ
   Bottazzi, ME
AF Chen, Wen-Hsiang
   Hotez, Peter J.
   Bottazzi, Maria Elena
TI Potential for developing a SARS-CoV receptor-binding domain (RBD)
   recombinant protein as a heterologous human vaccine against coronavirus
   infectious disease (COVID)-19
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE Heterologous vaccine; receptor-binding domain; subunit vaccine;
   coronavirus; COVID-19; SARS; SARS-CoV-2
ID HUMAN MONOCLONAL-ANTIBODY; SPIKE PROTEIN; STRUCTURAL BASIS;
   NEUTRALIZATION
AB A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel (R), induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.
C1 [Chen, Wen-Hsiang; Hotez, Peter J.; Bottazzi, Maria Elena] Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Dev, Dept Pediat, Houston, TX 77030 USA.
   [Chen, Wen-Hsiang; Hotez, Peter J.; Bottazzi, Maria Elena] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA.
   [Hotez, Peter J.; Bottazzi, Maria Elena] Baylor Coll Med, Mol Virol & Microbiol, Houston, TX 77030 USA.
RP Chen, WH; Bottazzi, ME (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Dev, Dept Pediat, Houston, TX 77030 USA.
EM Wen-Hsiang.Chen@bcm.edu; bottazzi@bcm.edu
RI Chen, Wen-Hsiang/AAB-9097-2020
CR Bian C, 2009, VIROLOGY, V383, P39, DOI 10.1016/j.virol.2008.09.029
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Hoffmann M, 2020, CELL
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   WHO, 2020, WHO DIR GEN REM MED
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zeng LP, 2017, SCI CHINA LIFE SCI, V60, P1399, DOI 10.1007/s11427-017-9189-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 22
TC 16
Z9 16
U1 11
U2 38
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD JUN 2
PY 2020
VL 16
IS 6
BP 1239
EP 1242
DI 10.1080/21645515.2020.1740560
EA APR 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA ME3YS
UT WOS:000527167100001
PM 32298218
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, RCH
AF Zhao, Robert Chunhua
TI Stem Cell-Based Therapy for Coronavirus Disease 2019
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE COVID-19; transplantation; clinical trial
ID REGULATORY DENDRITIC CELLS; INDUCE; GENERATION
AB The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.
C1 [Zhao, Robert Chunhua] Shanghai Univ, Sch Life Sci, Dept Cell Biol, 99 Shangda Rd, Shanghai 20444, Peoples R China.
RP Zhao, RCH (corresponding author), Shanghai Univ, Sch Life Sci, Dept Cell Biol, 99 Shangda Rd, Shanghai 20444, Peoples R China.
EM zhaochunhua@vip.126.com
FU National Key Research and Development Program of China [2016YFA0101000]
FX This work was funded in part by the National Key Research and
   Development Program of China (2016YFA0101000).
CR Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo H, 2002, CHINA J MOD MED, V12, P1
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Leng ZK, 2020, J MED VIROL, V92, P1715, DOI 10.1002/jmv.25779
   Liu XX, 2015, J IMMUNOL, V194, P4298, DOI 10.4049/jimmunol.1402641
   Liu XX, 2012, J IMMUNOL, V189, P1182, DOI 10.4049/jimmunol.1102996
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Health Commission and National Administration of Traditional Chinese Medicine, 2020, CHINESE MED J, V133, pE027
   Omer SB, 2020, JAMA-J AM MED ASSOC, V323, P1767, DOI 10.1001/jama.2020.5788
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang B, 2009, BLOOD, V113, P46, DOI 10.1182/blood-2008-04-154138
NR 15
TC 12
Z9 12
U1 2
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JUN 1
PY 2020
VL 29
IS 11
BP 679
EP 681
DI 10.1089/scd.2020.0071
EA APR 2020
PG 3
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA LT0OG
UT WOS:000528393400001
PM 32292113
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Han, YN
   Feng, ZW
   Sun, LN
   Ren, XX
   Wang, H
   Xue, YM
   Wang, Y
   Fang, Y
AF Han, Ya-nan
   Feng, Zhan-wei
   Sun, Li-na
   Ren, Xiao-Xia
   Wang, Hua
   Xue, Yong-ming
   Wang, Yi
   Fang, Ying
TI A comparative-descriptive analysis of clinical characteristics in
   2019-coronavirus-infected children and adults
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 2019 novel coronavirus; clinical manifestations; comparative analysis;
   differences between children and adults; laboratory parameters
ID LOPINAVIR/RITONAVIR; CORONAVIRUS; PNEUMONIA
AB Acute respiratory disease caused by 2019 novel coronavirus (2019-nCoV) has rapidly spread throughout China. Children and adults show a different clinical course. The purpose of the current study is to comparatively analyze the clinical characteristics of 2019-nCoV infection in children and adults and to explore the possible causes for the discrepancies present. The medical records of 25 adults and 7 children confirmed cases of 2019-2019-nCoV acute respiratory diseases were reviewed retrospectively. All children were family clusters. The total adult patients were differentiated into the local residents of Wuhan, a history of travel to Wuhan and direct contact with people from Wuhan. The numbers were 14 (56%), 10 (40%), and 1 (4%), respectively. The median incubation period of children and adults was 5 days (ranged, 3-12 days) and 4 days (ranged, 2-12 days), respectively. Diarrhoea and/or vomiting (57.1%) were demic by World Health Organiza more common in children, whereas for adults it was myalgia or fatigue (52%). On admission, the percentage of children having pneumonia (5%, 71.4%) was roughly the same as adults (20%, 80%). A total of 20% of adults had leucopoenia, but leukocytosis was more frequently in children (28.6%, P=.014). A higher number of children had elevated creatine kinase isoenzyme (57.1% vs 4%, P=.004). Antiviral therapy was given to all adult patients but to none of the children. In summary, knowledge of these differences between children and adults will not only be helpful for the clinical diagnosis of 2019-nCoV disease, but also for a future discussion on age-specific coronavirus infection.
C1 [Han, Ya-nan; Sun, Li-na; Ren, Xiao-Xia; Wang, Hua; Fang, Ying] Xian Childrens Hosp, Dept Gastroenterol, Xian 710003, Peoples R China.
   [Feng, Zhan-wei] Xian Childrens Hosp, Dept Resp Med, Xian, Peoples R China.
   [Xue, Yong-ming] Xian Eighth Hosp, Dept Radiol, Xian, Peoples R China.
   [Wang, Yi] Xian Childrens Hosp, Dept NICU, Xian 710003, Peoples R China.
RP Fang, Y (corresponding author), Xian Childrens Hosp, Dept Gastroenterol, Xian 710003, Peoples R China.; Wang, Y (corresponding author), Xian Childrens Hosp, Dept NICU, Xian 710003, Peoples R China.
EM wangyichengxian@163.com; 970910576@qq.com
CR [Anonymous], NAT REC DIAGN TREATM
   Chen F, 2020, ZHONGHUA ER KE ZA ZH, V58, pE005
   Chen H., 2020, PROFILING ACE2 EXPRE, DOI [10.1101/2020.02.15.20023457, DOI 10.1101/2020.02.15.20023457]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Naoumkina M, 2020, MOL BREEDING, V40, DOI 10.1007/s11032-020-01111-1
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Su B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01472
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI [10.1093/jtm/taaa02, DOI 10.1093/JTM/TAAA02]
   Yang HN, 2020, CLIN CARDIOL, V43, P450, DOI 10.1002/clc.23341
   Zeng LK, 2020, ZHONGHUA ER KE ZA ZH, V58, pE9
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu WB, 2020, J MED VIROL, V92, P1525, DOI 10.1002/jmv.25763
NR 21
TC 31
Z9 34
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1596
EP 1602
DI 10.1002/jmv.25835
EA APR 2020
PG 7
WC Virology
SC Virology
GA NA8CG
UT WOS:000526672500001
PM 32249943
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Walls, AC
   Park, YJ
   Tortorici, MA
   Wall, A
   McGuire, AT
   Veesler, D
AF Walls, Alexandra C.
   Park, Young-Jun
   Tortorici, M. Alejandra
   Wall, Abigail
   McGuire, Andrew T.
   Veesler, David
TI Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
   Glycoprotein
SO CELL
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; HUMAN MONOCLONAL-ANTIBODY; CRYO-EM
   STRUCTURE; SYNDROME SARS CORONAVIRUS; TO-HUMAN TRANSMISSION; MERS-COV;
   BAT CORONAVIRUS; POTENT NEUTRALIZATION; MOLECULAR EVOLUTION; RECEPTOR
   USAGE
AB The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S-1/S-2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.
C1 [Walls, Alexandra C.; Park, Young-Jun; Tortorici, M. Alejandra; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Tortorici, M. Alejandra] Inst Pasteur, F-75015 Paris, France.
   [Tortorici, M. Alejandra] CNRS, UMR 3569, Unite Virol Struct, F-75015 Paris, France.
   [Wall, Abigail; McGuire, Andrew T.] Fred Hutchinson Canc Res Ctr, Vaccines & Infect Dis Div, Seattle, WA 98195 USA.
   [McGuire, Andrew T.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
RP Veesler, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM dveesler@uw.edu
OI Tortorici, M. Alejandra/0000-0002-2260-2577
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM120553];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700059C]; Pew Biomedical Scholars Award; Burroughs Wellcome
   FundBurroughs Wellcome Fund; Washington Research Foundation; Pasteur
   Institute; University of Washington Arnold and Mabel Beckman cryoEM
   center
FX This study was supported by the National Institute of General Medical
   Sciences (R01GM120553 to D.V.), the National Institute of Allergy and
   Infectious Diseases (HHSN272201700059C to D.V.), a Pew Biomedical
   Scholars Award (D.V.), an Investigators in the Pathogenesis of
   Infectious Disease Award from the Burroughs Wellcome Fund (D.V.), the
   University of Washington Arnold and Mabel Beckman cryoEM center, the
   Washington Research Foundation, and the Pasteur Institute (M.A.T.). We
   are grateful to Lynda Stuart for sharing the full-length hACE2 plasmid,
   to Gary Whittaker for the MLV pseudotyping system, and to Ning Zheng for
   providing access to the Octet device.
CR Agirre J, 2015, NAT STRUCT MOL BIOL, V22, P833, DOI 10.1038/nsmb.3115
   Anthony SJ, 2017, MBIO, V8, DOI [10.1128/mBio.00373-17, 10.1128/mbio.00373-17]
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brown A, 2015, ACTA CRYSTALLOGR D, V71, P136, DOI 10.1107/S1399004714021683
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Frenz B, 2019, STRUCTURE, V27, P134, DOI 10.1016/j.str.2018.09.006
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   He JF, 2004, SCIENCE, V303, P1666, DOI 10.1126/science.1092002
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hoffmann M., 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31]
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang C, 2020, CLIN FEATURES PATIEN
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Kan B, 2005, J VIROL, V79, P11892, DOI 10.1128/JVI.79.18.11892-11900.2005
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Millet J, 2016, BIO-PROTOCOL, V6, pe2035
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rossen JWA, 1998, J VIROL, V72, P497, DOI 10.1128/JVI.72.1.497-503.1998
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Steinhauer DA, 1999, VIROLOGY, V258, P1, DOI 10.1006/viro.1999.9716
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526
   Walls A, 2017, PROTEIN SCI, V26, P113, DOI 10.1002/pro.3048
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Wang QH, 2014, CELL HOST MICROBE, V16, P328, DOI 10.1016/j.chom.2014.08.009
   Wang RYR, 2016, ELIFE, V5, DOI 10.7554/eLife.17219
   Wong AHM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01706-x
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xiong XL, 2018, J VIROL, V92
   Yang XL, 2016, J VIROL, V90, P3253, DOI 10.1128/JVI.02582-15
   Yang Y, 2015, J VIROL, V89, P9119, DOI 10.1128/JVI.01279-15
   Yang Y, 2014, P NATL ACAD SCI USA, V111, P12516, DOI 10.1073/pnas.1405889111
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 99
TC 1104
Z9 1121
U1 131
U2 249
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 16
PY 2020
VL 181
IS 2
BP 281
EP +
DI 10.1016/j.cell.2020.02.058
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LD7BL
UT WOS:000526184900012
PM 32155444
OA Bronze, Green Accepted, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Lee, SA
AF Lee, Sherman A.
TI Coronavirus anxiety scale: A brief mental health screener for COVID-19
   related anxiety
SO DEATH STUDIES
LA English
DT Article; Early Access
ID ACUTE RESPIRATORY SYNDROME; PSYCHOLOGICAL IMPACT; TONIC IMMOBILITY;
   EPIDEMIC; OUTBREAK; DISORDER; CHINA; SARS
AB Mental health concerns of people impacted by the coronavirus pandemic have not been adequately addressed. The objective of this study was to develop and evaluate the properties of the Coronavirus Anxiety Scale (CAS), which is a brief mental health screener to identify probable cases of dysfunctional anxiety associated with the COVID-19 crisis. This 5-item scale, which was based on 775 adults with anxiety over the coronavirus, demonstrated solid reliability and validity. Elevated CAS scores were found to be associated with coronavirus diagnosis, impairment, alcohol/drug coping, negative religious coping, extreme hopelessness, suicidal ideation, as well as attitudes toward President Trump and Chinese products. The CAS discriminates well between persons with and without dysfunctional anxiety using an optimized cut score of >= 9 (90% sensitivity and 85% specificity). These results support the CAS as an efficient and valid tool for clinical research and practice.
C1 [Lee, Sherman A.] Christopher Newport Univ, Dept Psychol, 1 Ave,Arts, Newport News, VA 23606 USA.
RP Lee, SA (corresponding author), Christopher Newport Univ, Dept Psychol, 1 Ave,Arts, Newport News, VA 23606 USA.
EM sherman.lee@cnu.edu
CR American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Axelrod J., 2020, CORONAVIRUS MAY INFE
   Balaratnasingam S, 2006, CURR OPIN PSYCHIATR, V19, P171, DOI 10.1097/01.yco.0000214343.59872.7a
   Barger P., 2011, IND ORG PSYCHOL, V49, P11, DOI DOI 10.1145/1809400.1809422
   Barlow D. H., 1991, PSYCHOL INQ, V2, P58, DOI [10.1207/s15327965pli0201_15, DOI 10.1207/S15327965PLI0201_15]
   Bergkvist L, 2007, J MARKETING RES, V44, P175, DOI 10.1509/jmkr.44.2.175
   Brown T.A., 2015, CONFIRMATORY FACTOR
   Byrne B. M., 2001, STRUCTURAL EQUATION
   Chong MY, 2004, BRIT J PSYCHIAT, V185, P127, DOI 10.1192/bjp.185.2.127
   Cosmides L., 2000, HDB EMOTIONS, P91, DOI DOI 10.1007/978-94-007-1951-4
   Ekman P., 2003, EMOTIONS REVEALED RE
   FORD JK, 1986, PERS PSYCHOL, V39, P291, DOI 10.1111/j.1744-6570.1986.tb00583.x
   Joslyn MR, 2018, RES POLITICS, V5, DOI 10.1177/2053168018794060
   Jost JT, 2017, SOC COGNITION, V35, P324, DOI 10.1521/soco.2017.35.4.324
   KEIL R, 2006, TOPIA, V16, P23
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Marx BP, 2008, CLIN PSYCHOL-SCI PR, V15, P74, DOI 10.1111/j.1468-2850.2008.00112.x
   Moller A, 2017, ACTA OBSTET GYN SCAN, V96, P932, DOI 10.1111/aogs.13174
   Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461
   Ohman A., 2000, HDB EMOTIONS, P573
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Tabachnick B. G., 2001, USING MULTIVARIATE S
   Thompson B. A., 2004, EXPLORATORY CONFIRMA
   Van Dam NT, 2013, ANXIETY STRESS COPIN, V26, P70, DOI 10.1080/10615806.2011.631525
   WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Yip PSF, 2010, CRISIS, V31, P86, DOI 10.1027/0227-5910/a000015
NR 31
TC 67
Z9 69
U1 16
U2 50
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0748-1187
EI 1091-7683
J9 DEATH STUD
JI Death Stud.
DI 10.1080/07481187.2020.1748481
EA APR 2020
PG 9
WC Psychology, Multidisciplinary; Social Issues; Social Sciences,
   Biomedical
SC Psychology; Social Issues; Biomedical Social Sciences
GA LF1HH
UT WOS:000527176000001
PM 33349159
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Schwartz, RA
   Janniger, CK
AF Schwartz, Robert A.
   Janniger, Camila K.
TI Generalized pustular figurate erythema: A newly delineated severe
   cutaneous drug reaction linked with hydroxychloroquine
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE acute generalized exanthematous pustulosis; coronavirus; COVID-19; DRESS
   syndrome; drug rash; erythema multiforme; figurate erythema;
   hydroxychloroquine; SARS-2; SARS-CoV-2; Stevens-Johnson syndrome; Sweet
   syndrome; toxic epidermal necrolysis; urticaria
ID EXANTHEMATOUS PUSTULOSIS; AGEP
AB A severe cutaneous drug reaction resembling acute generalized exanthematous pustulosis resulting from ingestion of hydroxychloroquine has been documented. It is distinguishable by its longer incubation period, more varied morphology with initially urticarial and later targetoid and arcuate plaques, recalcitrance to therapy and longer duration. Given the anticipated surge in the use of hydroxychloroquine due to its reported benefits in those with coronavirus disease 2019, specific recognition of this entity is pivotal. We delineate it as generalized pustular figurate erythema.
C1 [Schwartz, Robert A.; Janniger, Camila K.] Rutgers New Jersey Med Sch, Newark, NJ 07103 USA.
RP Schwartz, RA (corresponding author), Rutgers New Jersey Med Sch, Dermatol, 185 South Orange Ave, Newark, NJ 07103 USA.
EM roschwar@cal.berkeley.edu
OI Schwartz, Robert/0000-0003-3036-3825
CR Bodard Q, 2020, REV MED INTERNE, V41, P289, DOI 10.1016/j.revmed.2019.08.010
   Castner NB, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12660
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Copaescu AM, 2020, ALLERGY ASTHMA CL IM, V16, DOI 10.1186/s13223-020-0407-5
   Dmochowski M, 1999, CLIN DERMATOL, P1
   Duan YJ, 2020, FA YI XUE ZA ZHI, V36, DOI [10.12116/j.issn.1004-5619.2020.02.001, DOI 10.12116/J.ISSN.1004-5619.2020.02.001]
   Duman H, 2017, AN BRAS DERMATOL, V92, P404, DOI 10.1590/abd1806-4841.20175561
   Falcone LM, 2018, NEUTROPHILIC DERMATO, P259
   Girijala RL, 2019, J DRUGS DERMATOL, V18, P207
   Hoegler KM, 2018, J EUR ACAD DERMATOL, V32, P1645, DOI 10.1111/jdv.14949
   Husain Z, 2013, J AM ACAD DERMATOL, V68, DOI 10.1016/j.jaad.2013.01.032
   Islamoglu ZGK, 2019, CLIN CASE REP, V7, P1721, DOI 10.1002/ccr3.2352
   Jadotte YT, 2012, J AM ACAD DERMATOL, V66, P187, DOI 10.1016/j.jaad.2011.09.039
   Lateef A, 2009, CLIN RHEUMATOL, V28, P1449, DOI 10.1007/s10067-009-1262-4
   Manzo Ciro, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6040111
   Matsuda-Hirose H, 2020, J DERMATOL, V47, pE53, DOI 10.1111/1346-8138.15185
   Mercogliano C, 2018, J COMMUNITY HOSP INT, V8, P360, DOI 10.1080/20009666.2018.1547089
   Miteva L, 2020, ACTA DERM-VENEREOL, V18, P267
   Park JJ, 2010, ANN DERMATOL, V22, P102, DOI 10.5021/ad.2010.22.1.102
   Patel S, 2020, AM J CLIN DERMATOL, V21, P393, DOI 10.1007/s40257-020-00505-3
   Pearson KC, 2016, CUTIS, V97, P212
   Schwartz RA, 2013, J AM ACAD DERMATOL, V69, DOI 10.1016/j.jaad.2013.05.002
   Sidoroff A, 2007, BRIT J DERMATOL, V157, P989, DOI 10.1111/j.1365-2133.2007.08156.x
   Szatkowski J, 2015, J AM ACAD DERMATOL, V73, P843, DOI 10.1016/j.jaad.2015.07.017
   Yalcin B, 2015, ANN DERMATOL, V27, P431, DOI 10.5021/ad.2015.27.4.431
NR 25
TC 21
Z9 21
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD MAY
PY 2020
VL 33
IS 3
AR e13380
DI 10.1111/dth.13380
EA APR 2020
PG 3
WC Dermatology
SC Dermatology
GA OS5AD
UT WOS:000526561600001
PM 32253799
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Brownstone, ND
   Thibodeaux, QG
   Reddy, VD
   Myers, BA
   Chan, SHY
   Bhutani, T
   Liao, WS
AF Brownstone, Nicholas D.
   Thibodeaux, Quinn G.
   Reddy, Vidhatha D.
   Myers, Bridget A.
   Chan, Stephanie Y.
   Bhutani, Tina
   Liao, Wilson
TI Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis:
   Infection Risk and Patient Counseling in Uncertain Times
SO DERMATOLOGY AND THERAPY
LA English
DT Article; Early Access
DE Biologics; Coronavirus; COVID-19; Infection; Pandemic; Psoriasis;
   SARS-CoV-2
ID PLACEBO-CONTROLLED TRIAL; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY;
   RANDOMIZED CONTROLLED-TRIAL; TO-SEVERE PSORIASIS; PHASE-III;
   DOUBLE-BLIND; PLAQUE PSORIASIS; EFFICACY; SAFETY; MODERATE
AB With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.
C1 [Brownstone, Nicholas D.; Thibodeaux, Quinn G.; Reddy, Vidhatha D.; Myers, Bridget A.; Chan, Stephanie Y.; Bhutani, Tina; Liao, Wilson] Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, Dept Dermatol, San Francisco, CA 94143 USA.
RP Liao, WS (corresponding author), Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, Dept Dermatol, San Francisco, CA 94143 USA.
EM wilson.liao@ucsf.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5U01AI119125];
   Abbvie; AmgenAmgen; JanssenJohnson & Johnson USAJanssen Biotech Inc;
   NovartisNovartis; Regeneron; Sanofi; TRex Bio
FX Nicholas Brownstone, Quinn Thibodeaux, Vidhatha Reddy, Bridget Myers,
   and Stephanie Chan have nothing to disclose. Wilson Liao is editorial
   board member of the journal and is funded in part by grants from the
   National Institutes of Health (5U01AI119125) and Abbvie, Amgen, Janssen,
   Novartis, Regeneron, Sanofi, and TRex Bio. Tina Bhutani is currently an
   investigator for Celgene, Janssen, Merck, and Regeneron. She has served
   as an advisor for Abbvie, Lilly, and Pfizer.
CR Blauvelt A, 2015, BRIT J DERMATOL, V172, P484, DOI 10.1111/bjd.13348
   Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P405, DOI 10.1016/j.jaad.2016.11.041
   Gooderham Melinda, 2018, Curr Probl Dermatol, V53, P15, DOI 10.1159/000478074
   Gordon KB, 2016, NEW ENGL J MED, V375, P345, DOI 10.1056/NEJMoa1512711
   Gordon KB, 2018, LANCET, V392, P650, DOI 10.1016/S0140-6736(18)31713-6
   Gottlieb AB, 2018, J AM ACAD DERMATOL, V79, P302, DOI 10.1016/j.jaad.2018.04.012
   Langley R, 2019, J AM ACAD DERMATOL, V81, pAB52
   Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258
   Lebwohl M, 2018, J AM ACAD DERMATOL, V79, P266, DOI 10.1016/j.jaad.2018.04.013
   Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409
   Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4
   Menter A, 2008, J AM ACAD DERMATOL, V58, P106, DOI 10.1016/j.jaad.2007.09.010
   Menter MDA, 2007, J AM ACAD DERMATOL, V56, pe1, DOI [10.1016/j.jaad.2006.07.017, DOI 10.1016/J.JAAD.2006.07.017]
   Ortonne JP, 2009, BRIT J DERMATOL, V161, P1190, DOI 10.1111/j.1365-2133.2009.09238.x
   Papp KA, 2018, BRIT J DERMATOL, V179, P320, DOI 10.1111/bjd.16464
   Papp KA, 2016, BRIT J DERMATOL, V175, P273, DOI 10.1111/bjd.14493
   Papp KA, 2005, BRIT J DERMATOL, V152, P1304, DOI 10.1111/j.1365-2133.2005.06688.x
   Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6
   Paul C, 2015, J EUR ACAD DERMATOL, V29, P1082, DOI 10.1111/jdv.12751
   Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6
   Reich K, 2012, BRIT J DERMATOL, V167, P180, DOI 10.1111/j.1365-2133.2012.10941.x
   Reich K, 2017, J AM ACAD DERMATOL, V76, P418, DOI 10.1016/j.jaad.2016.11.042
   Reich K, 2017, LANCET, V390, P276, DOI 10.1016/S0140-6736(17)31279-5
   Saurat JH, 2008, BRIT J DERMATOL, V158, P558, DOI 10.1111/j.1365-2133.2007.08315.x
   Tyring S, 2007, ARCH DERMATOL, V143, P719, DOI 10.1001/archderm.143.6.719
   WHO, REP WHO CHIN JOINT M
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 6
Z9 6
U1 0
U2 64
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 2193-8210
EI 2190-9172
J9 DERMATOLOGY THER
JI Dermatol. Ther.
DI 10.1007/s13555-020-00377-9
EA APR 2020
PG 11
WC Dermatology
SC Dermatology
GA LD8NC
UT WOS:000526283400001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tatara, AM
AF Tatara, Alexander M.
TI Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE tissue engineering; biomaterials; pandemic; coronavirus; viral
ID MONOCLONAL-ANTIBODY; SARS CORONAVIRUS; CONTROLLED-RELEASE; ORAL
   DELIVERY; INFLUENZA-A; IN-VIVO; VACCINE; BIOMATERIALS; SYSTEM; CELLS
AB In light of the current novel coronavirus (COVID-19) pandemic, as well as other viral outbreaks in the 21st century, there is a dire need for new diagnostic and therapeutic strategies to combat infectious diseases worldwide. As a convergence science, tissue engineering has traditionally focused on the application of engineering principles to biological systems, collaboration across disciplines, and rapid translation of technologies from the benchtop to the bedside. Given these strengths, tissue engineers are particularly well suited to apply their skill set to the current crisis and viral outbreaks in general. This work introduces the basics of virology and epidemiology for tissue engineers, and highlights important developments in the field of tissue engineering relevant to the current pandemic, including in vitro model systems, vaccine technology, and small-molecule drug delivery. COVID-19 serves as a call to arms for scientists across all disciplines, and tissue engineers are well trained to be leaders and contributors in this time of need.
   Impact statement
   Given the steep mortality caused by the recent novel coronavirus (COVID-19) pandemic, there is clear need for advances in diagnostics and therapeutics for viral outbreaks. Tissue engineering has the potential for critical impact on clinical outcomes in viral outbreaks. Tissue engineers, if mobilized, could play key roles as leaders in the outbreak, given their ability to apply engineering principles to biological processes, experience in collaborative environments, and penchant for technological translation from benchtop to bedside. In this work, three areas pioneered by tissue engineers that could be applied to the current COVID-19 crisis and future viral outbreaks are highlighted.
C1 [Tatara, Alexander M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
RP Tatara, AM (corresponding author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA.
EM atatara@partners.org
CR Abramson A, 2019, SCIENCE, V363, P611, DOI 10.1126/science.aau2277
   Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   Ali Omar A, 2011, Biomatter, V1, P66, DOI 10.4161/biom.1.1.16277
   Ali OA, 2011, PHARM RES-DORDR, V28, P1074, DOI 10.1007/s11095-010-0361-x
   Ali OA, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000359
   Barry MA, 2016, HUM VACC IMMUNOTHER, V12, P976, DOI 10.1080/21645515.2015.1119346
   Bell DM, 2004, EMERG INFECT DIS, V10, P1900, DOI 10.3201/eid1011.040729
   Bhowmick R, 2018, TISSUE ENG PT A, V24, P1468, DOI [10.1089/ten.TEA.2017.0449, 10.1089/ten.tea.2017.0449]
   Chang C, 2016, J AUTOIMMUN, V68, P1, DOI 10.1016/j.jaut.2016.02.006
   Chatterjee S., 2020, UNDERSTANDING NATURE
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen X, 2016, BIOMACROMOLECULES, V17, P1205, DOI 10.1021/acs.biomac.6b00027
   Chen YJ, 2014, BIOMATERIALS, V35, P10058, DOI 10.1016/j.biomaterials.2014.09.003
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub6
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fehring V, 2014, MOL THER, V22, P811, DOI 10.1038/mt.2013.291
   Feng GZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061135
   Fong ELS, 2016, BIOMATERIALS, V77, P164, DOI 10.1016/j.biomaterials.2015.10.059
   Fong ELS, 2012, ADV MATER, V24, P4995, DOI 10.1002/adma.201201762
   Gardner JK, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110304
   Gause KT, 2016, ADV FUNCT MATER, V26, P7526, DOI 10.1002/adfm.201603563
   Gautret P., 2020, INT J ANTIMICROB AG, DOI [10.1016/ijantimicag.2020.105949, DOI 10.1016/IJANTIMICAG.2020.105949]
   Gomes MF, 2014, PLOS CURR, P6
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Honko AN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06179-y
   Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249
   Jeon S., 2020, IDENTIFICATION ANTIV, DOI [10.1101/ 2020.03.20.999730., DOI 10.1101/2020.03.20.999730, 10.1101/2020.03.20.999730.]
   Jiang T, 2014, BIOMATERIALS, V35, P2365, DOI 10.1016/j.biomaterials.2013.11.073
   Johansen LM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5597
   Jones KS, 2008, BIOTECHNOL PROGR, V24, P807, DOI 10.1002/btpr.10
   Kaselitz TB, 2019, INFECT DIS CLIN PRAC, V27, P328, DOI 10.1097/IPC.0000000000000777
   Khademhosseini A, 2016, NAT PROTOC, V11, P1775, DOI 10.1038/nprot.2016.123
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Kim J, 2015, NAT BIOTECHNOL, V33, P64, DOI 10.1038/nbt.3071
   Kim YS, 2019, TISSUE ENG PT A, V25, P1, DOI [10.1089/ten.tea.2018.0138, 10.1089/ten.TEA.2018.0138]
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280
   Li WA, 2016, BIOMATERIALS, V83, P249, DOI 10.1016/j.biomaterials.2016.01.026
   Li XJ, 2012, INT J PHARMACEUT, V433, P79, DOI 10.1016/j.ijpharm.2012.04.081
   Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Luo XZ, 2015, ANGEW CHEM INT EDIT, V54, P14531, DOI 10.1002/anie.201507928
   Mansilla E, 2010, CANCER BIOTHER RADIO, V25, P97, DOI 10.1089/cbr.2009.0655
   Mazzocchi A, 2019, APPL PHYS REV, V6, DOI 10.1063/1.5056188
   Miller AJ, 2017, PHYSIOLOGY, V32, P246, DOI 10.1152/physiol.00041.2016
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nichols JE, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt368
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Poole PJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002733.pub2
   Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Sanchez-Guzman D, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119308
   Schwegmann-Wessels C, 2006, GLYCOCONJUGATE J, V23, P51, DOI 10.1007/s10719-006-5437-9
   Schweizer D, 2013, J CONTROL RELEASE, V172, P975, DOI 10.1016/j.jconrel.2013.10.010
   Simovic S, 2014, MATER LETT, V130, P210, DOI 10.1016/j.matlet.2014.05.110
   Suderman MT, 2006, NASATP2006213723
   Super M., 2020, MODULAR BIOMATERIALS, DOI [10.1101/2020.02.25/964601, DOI 10.1101/2020.02.25/964601]
   Tatara A.M., 2015, TRANSLATIONAL REGENE, P141
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Veiseh O, 2015, NAT MATER, V14, P643, DOI [10.1038/NMAT4290, 10.1038/nmat4290]
   Vishwakarma A, 2016, TRENDS BIOTECHNOL, V34, P470, DOI 10.1016/j.tibtech.2016.03.009
   Wang QY, 2018, BIOMATERIALS, V160, P107, DOI 10.1016/j.biomaterials.2018.01.022
   WHO, 2020, COR DIS COVID 19 PAN
   Wu YB, 2012, BIOMATERIALS, V33, P2351, DOI 10.1016/j.biomaterials.2011.11.068
   Xie J, 2020, DEV EXTERNAL VALIDAT, DOI [10.1101/2020.03.28.20045997, DOI 10.1101/2020.03.28.20045997]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao WJ, 2013, MOL PHARMACEUT, V10, P2904, DOI 10.1021/mp4000053
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng BJ, 2004, ANTIVIR THER, V9, P365
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Ziegler C, 2020, CELL, DOI [10.2139/ssrn.3555145, DOI 10.2139/SSRN.3555145]
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 79
TC 3
Z9 4
U1 1
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAY 1
PY 2020
VL 26
IS 9-10
BP 468
EP 474
DI 10.1089/ten.tea.2020.0094
EA APR 2020
PG 7
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
SC Cell Biology; Engineering; Materials Science
GA LO3LK
UT WOS:000526966600001
PM 32272857
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Yu, Y
   Shi, QL
   Chen, H
AF Yu, Yang
   Shi, Qianling
   Chen, Hao
TI Comments on Zhang et al: Clinical trial analysis of 2019-nCoV therapy
   registered in China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter
C1 [Yu, Yang; Chen, Hao] Lanzhou Univ, Hosp 2, Dept Tumor Surg, 80 Cuiying Gate,Linxia Rd, Lanzhou 730030, Peoples R China.
   [Yu, Yang] Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China.
   [Shi, Qianling] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China.
   [Shi, Qianling] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China.
RP Chen, H (corresponding author), Lanzhou Univ, Hosp 2, Dept Tumor Surg, 80 Cuiying Gate,Linxia Rd, Lanzhou 730030, Peoples R China.
EM ery_chenh@lzu.edu.cn
OI Yu, Yang/0000-0002-2409-3681
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670594, 81470791, 81376597]; Key Project
   of Science and Technology in Gansu province [19ZD2WA001]
FX This work was supported by National Natural Science Foundation of China
   (81670594, 81470791, 81376597), and Key Project of Science and
   Technology in Gansu province (19ZD2WA001). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Chen F, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P301, DOI 10.3760/cma.j.issn.0254-6450.2020.03.004
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18
   Zhang Q, 2020, J MED VIROL, V92, P713, DOI 10.1002/jmv.25803
NR 6
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2020
VL 92
IS 7
BP 711
EP 712
DI 10.1002/jmv.25806
EA APR 2020
PG 2
WC Virology
SC Virology
GA LW4RW
UT WOS:000525819300001
PM 32239514
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Luo, P
   Liu, Y
   Qiu, L
   Liu, XL
   Liu, D
   Li, J
AF Luo, Pan
   Liu, Yi
   Qiu, Lin
   Liu, Xiulan
   Liu, Dong
   Li, Juan
TI Tocilizumab treatment in COVID-19: A single center experience
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE COVID-19; cytokine storms; interleukin-6; SARS-CoV-2; Tocilizumab
ID CORONAVIRUS PNEUMONIA
AB Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6), emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after TCZ therapy and clinical outcome in the 15 COVID-19 patients were retrospectively assessed. Totally 15 patients with COVID-19 were included in this study. Two of them were moderately ill, six were seriously ill and seven were critically ill. The TCZ was used in combination with methylprednisolone in eight patients. Five patients received the TCZ administration twice or more. Although TCZ treatment ameliorated the increased CRP in all patients rapidly, for the four critically ill patients who received an only single dose of TCZ, three of them (No. 1, 2, and 3) still dead and the CRP level in the rest one patient (No. 7) failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further spiked firstly and then decreased after TCZ therapy in 10 patients. A persistent and dramatic increase of IL-6 was observed in these four patients who failed treatment. TCZ appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for these critically ill patients with elevated IL-6, the repeated dose of the TCZ is recommended.
C1 [Luo, Pan; Liu, Yi; Qiu, Lin; Liu, Xiulan; Liu, Dong; Li, Juan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
RP Liu, D; Li, J (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
EM l_d2069@163.com; lijuan@tjh.tjmu.edu.cn
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chiaretti A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/495848
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaur S, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115327
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 8
TC 380
Z9 386
U1 41
U2 66
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2020
VL 92
IS 7
BP 814
EP 818
DI 10.1002/jmv.25801
EA APR 2020
PG 5
WC Virology
SC Virology
GA LW4RW
UT WOS:000525799000001
PM 32693685
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Muralidharan, N
   Sakthivel, R
   Velmurugan, D
   Gromiha, MM
AF Muralidharan, Nisha
   Sakthivel, R.
   Velmurugan, D.
   Gromiha, M. Michael
TI Computational studies of drug repurposing and synergism of lopinavir,
   oseltamivir and ritonavir binding with SARS-CoV-2 protease against
   COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Letter; Early Access
ID REVEALS
C1 [Muralidharan, Nisha; Sakthivel, R.; Gromiha, M. Michael] Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai, Tamil Nadu, India.
   [Velmurugan, D.] SRM Inst Sci & Technol, Dept Biotechnol, Sch Bioengn, Chennai, Tamil Nadu, India.
RP Gromiha, MM (corresponding author), Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai, Tamil Nadu, India.
EM gromiha@iitm.ac.in
RI Ramasamy, Sakthivel/AAU-7918-2020
FU Department of Biotechnology, Government of IndiaDepartment of
   Biotechnology (DBT) India
FX The work is partially supported by the Department of Biotechnology,
   Government of India to MMG.
CR Accelrys, 2018, ACC DISC STUD
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Case DA, 2016, AMBER, V2016
   Chen H, 2006, J BIOL CHEM, V281, P13894, DOI 10.1074/jbc.M510745200
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Hodos RA, 2016, WIRES SYST BIOL MED, V8, P186, DOI 10.1002/wsbm.1337
   Li Y., 2020, THERAPEUTIC DRUGS TA, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Shanmugam A., 2020, CURRENT TOPICS MED C
   Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Turner P., 2005, XMGRACE VERSION 5 1
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhao Qi, 2013, Recent Pat Antiinfect Drug Discov, V8, P150
NR 23
TC 123
Z9 123
U1 6
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1752802
EA APR 2020
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA LF1CX
UT WOS:000527164600001
PM 32248766
DA 2021-01-01
ER

PT J
AU Kluge, S
   Janssens, U
   Welte, T
   Weber-Carstens, S
   Marx, G
   Karagiannidis, C
AF Kluge, Stefan
   Janssens, Uwe
   Welte, Tobias
   Weber-Carstens, Steffen
   Marx, Gernot
   Karagiannidis, Christian
TI German recommendations for critically ill patients with COVID-19
SO MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN
LA English
DT Article; Early Access
DE COVID-19; Coronavirus; Acute respiratory failure; ARDS; High-flow nasal
   cannula
AB Since December 2019, a novel coronavirus (severe acute respiratory syndrome-coronavirus 2, SARS-CoV-2) has rapidly spread around the world resulting in an acute respiratory illness pandemic. The majority of patients presents with mild symptoms of coronavirus disease 2019 (COVID-19). However, about 5% become critically ill and require intensive care treatment. Acute hypoxemic failure with severe dyspnea and an increased respiratory rate (>30/min) usually leads to ICU admission. At that point, bilateral pulmonary infiltrates are typically seen. Patients often develop a severe acute respiratory distress syndrome (ARDS). To date there is no specific treatment available-the main goal of supportive therapy is to ascertain adequate oxygenation. Early intubation and repeated prone positioning are key elements in treating hypoxemic COVID-19 patients. Strict adherence to basic infection control measures (including hand hygiene) and use of personal protection equipment (PPE) are essential in the care of patients. Procedures that lead to formation of aerosols should be avoided where possible and carried out with utmost precaution.
C1 [Kluge, Stefan; Janssens, Uwe; Karagiannidis, Christian] German Soc Med Intens Care & Emergency Med, Berlin, Germany.
   [Kluge, Stefan; Janssens, Uwe; Marx, Gernot; Karagiannidis, Christian] Deutsch Interdisziplinare Vereinigung Intens & No, German Interdisciplinary Assoc Crit Care & Emerge, Berlin, Germany.
   [Welte, Tobias] Deutsch Gesell Pneumol & Beatmungsmed DGP, German Resp Soc, Berlin, Germany.
   [Weber-Carstens, Steffen; Marx, Gernot] German Soc Anaesthesiol & Intens Care Med, Nurnberg, Germany.
   [Kluge, Stefan; Janssens, Uwe; Welte, Tobias; Weber-Carstens, Steffen; Marx, Gernot; Karagiannidis, Christian] ARDS Network Germany, Berlin, Germany.
   [Kluge, Stefan] Univ Med Ctr Hamburg Eppendorf, Dept Intens Care, Martinistr 52, D-20246 Hamburg, Germany.
RP Kluge, S (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Intens Care, Martinistr 52, D-20246 Hamburg, Germany.
EM skluge@uke.de
CR [Anonymous], 2020, EMP ROB KOCH I HYG
   Arabi YM, 2020, INTENS CARE MED, V46, P833, DOI 10.1007/s00134-020-05955-1
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Brunkhorst FM, 2020, MED KLIN-INTENSIVMED, V115, P178, DOI 10.1007/s00063-020-00671-6
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Fichtner F, 2019, RESPIRATION, V98, P357, DOI 10.1159/000502157
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Liao XL, 2020, INTENS CARE MED, V46, P357, DOI 10.1007/s00134-020-05954-2
   University of Liverpool, 2020, COVID 19 DRUG INT
   World Health Organization, 2020, CLIN SEV AC RESP INF
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 17
TC 7
Z9 8
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2193-6218
EI 2193-6226
J9 MED KLIN-INTENSIVMED
JI Med. Klin.-Intensivmed Notfallmed.
DI 10.1007/s00063-020-00689-w
EA APR 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LD9WM
UT WOS:000526376000002
PM 32291505
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, Z
   Bai, H
   Duan, JC
   Wang, J
AF Zhao, Zhe
   Bai, Hua
   Duan, Jianchun
   Wang, Jie
TI Recommendations of individualized medical treatment and common adverse
   events management for lung cancer patients during the outbreak of
   COVID-19 epidemic
SO THORACIC CANCER
LA English
DT Article
DE COVID-19; lung neoplasms; therapeutics
ID TARGETED THERAPY; CHEMOTHERAPY; COMBINATION; NAUSEA
AB Since its outbreak in December 2019 in China, the novel coronavirus disease (COVID-19) has rapidly spread and affected several countries. It has resulted in a difficult situation for cancer patients owing to the risks of the epidemic situation outbreak as well as cancer. Patients with cancer are more likely than the general population to contract COVID-19 because of the systemic immunosuppressive status caused by malignant diseases or anticancer treatment. Lung cancer has the highest morbidity and mortality in China and the world. Most patients with lung cancer are smokers with poor underlying lung conditions and low immunity, thus it is vital to protect them from epidemic diseases during cancer treatment. It is necessary to provide individualized medical treatment and management of treatment-related adverse events for patients with lung cancer based on patients' conditions and regional epidemic patterns.
C1 [Zhao, Zhe; Bai, Hua; Duan, Jianchun; Wang, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, 17 Pan Jia Yuan S Ln, Beijing 100021, Peoples R China.
RP Wang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, 17 Pan Jia Yuan S Ln, Beijing 100021, Peoples R China.
EM zlhuxi@163.com
RI Duan, Jianchun/AAM-5765-2020
FU National key research and development project [2019YFC1315700]; National
   Natural Sciences Foundation Key Program [81630071]; CAMS Innovation Fund
   for Medical Sciences [CIFMS 2016-I2M-3-008]; Aiyou foundation
   [KY201701]; Ministry of Education Innovation Team development project
   [IRT-17R10]; CAMS Key Laboratory of translational research on lung
   cancer [2018PT31035]
FX This work was supported by the National key research and development
   project 2019YFC1315700; the National Natural Sciences Foundation Key
   Program (81630071); CAMS Innovation Fund for Medical Sciences (CIFMS
   2016-I2M-3-008); Aiyou foundation (KY201701), Ministry of Education
   Innovation Team development project (IRT-17R10), and CAMS Key Laboratory
   of translational research on lung cancer (2018PT31035).
CR Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561
   Binder D, 2011, CANCER CHEMOTH PHARM, V68, P1575, DOI 10.1007/s00280-011-1648-2
   CARLISLE PS, 1993, INFECT CONT HOSP EP, V14, P320, DOI 10.1086/646750
   Dadkhah Behrouz, 2019, J Caring Sci, V8, P165, DOI 10.15171/jcs.2019.024
   Dai WC, 2020, CAN ASSOC RADIOL J, V4
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Hoffner B, 2020, CANCER TREAT REV, V85, DOI 10.1016/j.ctrv.2020.101979
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Karagozoglu S, 2013, J CLIN NURS, V22, P39, DOI 10.1111/jocn.12030
   Lai ChihCheng, 2020, International Journal of Antimicrobial Agents, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li JX, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419890020
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu MT, 2019, THORAC CANCER, V10, P1868, DOI 10.1111/1759-7714.13162
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019
   Qiang HP, 2020, J CANCER RES CLIN, V146, P631, DOI 10.1007/s00432-020-03129-6
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Rubin Eric J, 2020, N Engl J Med, V382, pe19, DOI 10.1056/NEJMe2004244
   Salazar MC, 2017, JAMA ONCOL, V3, P610, DOI 10.1001/jamaoncol.2016.5829
   Santini FC, 2018, CANCER J, V24, P15, DOI 10.1097/PPO.0000000000000300
   Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Sgambato A, 2018, EXPERT REV ANTICANC, V18, P71, DOI 10.1080/14737140.2018.1412260
   Simard S, 2013, J CANCER SURVIV, V7, P300, DOI 10.1007/s11764-013-0272-z
   Sun XY, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5701-6
   Villanueva N, 2018, THER ADV RESPIR DIS, V12, DOI 10.1177/1753466618794133
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang YY, 2019, AM J CANCER RES, V9, P619
   Wargo JA, 2015, SEMIN ONCOL, V42, P601, DOI 10.1053/j.seminoncol.2015.05.007
   Yuan JH, 2020, J MOD ONCOL, V28, P1
   Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5
NR 32
TC 6
Z9 6
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-7706
EI 1759-7714
J9 THORAC CANCER
JI Thorac. Cancer
PD JUN
PY 2020
VL 11
IS 6
BP 1752
EP 1757
DI 10.1111/1759-7714.13424
EA APR 2020
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA LS9CP
UT WOS:000525834000001
PM 32291968
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gupta, MK
   Vemula, S
   Donde, R
   Gouda, G
   Behera, L
   Vadde, R
AF Gupta, Manoj Kumar
   Vemula, Sarojamma
   Donde, Ravindra
   Gouda, Gayatri
   Behera, Lambodar
   Vadde, Ramakrishna
TI In-silicoapproaches to detect inhibitors of the human severe acute
   respiratory syndrome coronavirus envelope protein ion channel
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronaviruses; severe acute respiratory syndrome; docking; modeling;
   molecular dynamics
ID MOUSE HEPATITIS-VIRUS; RESISTANCE; BILAYER
AB Recent outbreak of Coronavirus disease (COVID-19) pandemic around the world is associated with 'severe acute respiratory syndrome' (SARS-CoV2) in humans. SARS-CoV2 is an enveloped virus and E proteins present in them are reported to form ion channels, which is mainly associated with pathogenesis. Thus, there is always a quest to inhibit these ion channels, which in turn may help in controlling diseases caused by SARS-CoV2 in humans. Considering this, in the present study, authors employed computational approaches for studying the structure as well as function of the human 'SARS-CoV2 E' protein as well as its interaction with various phytochemicals. Result obtained revealed that alpha-helix and loops present in this protein experience random movement under optimal condition, which in turn modulate ion channel activity; thereby aiding the pathogenesis caused via SARS-CoV2 in human and other vertebrates. However, after binding with Belachinal, Macaflavanone E, and Vibsanol B, the random motion of the human 'SARS-CoV2 E' protein gets reduced, this, in turn, inhibits the function of the 'SARS-CoV2 E' protein. It is pertinent to note that two amino acids, namely VAL25 and PHE26, play a key role while interacting with these three phytochemicals. As these three phytochemicals, namely, Belachinal, Macaflavanone E & Vibsanol B, have passed the ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) property as well as 'Lipinski's Rule of 5s', they may be utilized as drugs in controlling disease caused via SARS-COV2, after further investigation. Communicated by Ramaswamy H. Sarma
C1 [Gupta, Manoj Kumar; Vadde, Ramakrishna] Yogi Vemana Univ, Dept Biotechnol & Bioinformat, Kadapa 516005, Andhra Pradesh, India.
   [Vemula, Sarojamma] Govt Med Coll, Dept Microbiol, Anantapur, Andhra Pradesh, India.
   [Donde, Ravindra; Gouda, Gayatri; Behera, Lambodar] ICAR Natl Rice Res Inst, Cuttack, Odisha, India.
RP Vadde, R (corresponding author), Yogi Vemana Univ, Dept Biotechnol & Bioinformat, Kadapa 516005, Andhra Pradesh, India.
EM vrkrishna70@gmail.com
OI Ramakrishna, Vadde/0000-0002-5223-7208
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3
   Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512
   Biovia D.S., 2017, DISCOVERY STUDIO VIS
   Curtis KM, 2002, J VIROL, V76, P1422, DOI 10.1128/JVI.76.3.1422-1434.2002
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-28
   Donde R, 2019, AMINO ACIDS, V51, P839, DOI 10.1007/s00726-019-02727-0
   Fischer F, 1998, J VIROL, V72, P7885, DOI 10.1128/JVI.72.10.7885-7894.1998
   Gouda G, 2020, J BIOMOL STRUCT DYN, V38, P1158, DOI 10.1080/07391102.2019.1597771
   Gupta M. K., 2019, NOVO ASSEMBLY CHARAC, DOI [10.1101/844639, 10.1101/844639., DOI 10.1101/844639]
   Gupta MK, 2019, CURR DRUG METAB, V20, P977, DOI 10.2174/1389200220666191007153238
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1733666
   Gupta MK, 2019, J BIOMOL STRUCT DYN, V37, P1649, DOI 10.1080/07391102.2018.1462737
   Gupta MK, 2019, J MOL GRAPH MODEL, V88, P209, DOI 10.1016/j.jmgm.2019.01.018
   Gupta MK, 2020, J BIOMOL STRUCT DYN, V38, P137, DOI 10.1080/07391102.2019.1567391
   Gupta MK, 2019, J CELL BIOCHEM, V120, P10323, DOI 10.1002/jcb.28316
   KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   LIN YC, 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1155/2013/736386
   Mehrnejad F, 2008, J BIOMOL STRUCT DYN, V26, P255, DOI 10.1080/07391102.2008.10507241
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Ramphul K, 2020, CUREUS, V12, DOI 10.7759/cureus.7276
   Rani YG, 2019, J BIOMOL STRUCT DYN, V37, P1189, DOI 10.1080/07391102.2018.1453378
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Tandon G, 2015, J BIOMOL STRUCT DYN, V33, P2180, DOI 10.1080/07391102.2014.996187
   Teponno RB, 2016, NAT PROD REP, V33, P1044, DOI 10.1039/c6np00021e
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Verdia-Baguena C, 2013, BBA-BIOMEMBRANES, V1828, P2026, DOI 10.1016/j.bbamem.2013.05.008
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Westerbeck JW, 2019, J VIROL, V93, DOI [10.1128/JVI.00015-19, 10.1128/jvi.00015-19]
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wolf MG, 2010, J COMPUT CHEM, V31, P2169, DOI 10.1002/jcc.21507
NR 43
TC 73
Z9 74
U1 3
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1751300
EA APR 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NA5JG
UT WOS:000559852100001
PM 32238078
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Li, XQ
   Zhang, CB
   Liu, LY
   Gu, MJ
AF Li, Xiangqi
   Zhang, Chaobao
   Liu, Lianyong
   Gu, Mingjun
TI Existing bitter medicines for fighting 2019-nCoV-associated infectious
   diseases
SO FASEB JOURNAL
LA English
DT Article
DE 2019-nCoV; coronavirus; COVID-19; cytokine storm; infectious disease;
   type 2 taste receptors (TAS2Rs)
ID TASTE RECEPTORS; CHEMOSENSORY CELLS; TYPE-2 IMMUNITY; 2019-NCOV; T2R38;
   CHLOROQUINE; EXPRESSION; ACTIVATE; HEALTH; VIRUS
AB The sudden outbreak of COVID-19 has led to more than seven thousand deaths. Unfortunately, there are no specific drugs available to cure this disease. Type 2 taste receptors (TAS2Rs) may play an important role in host defense mechanisms. Based on the idea of host-directed therapy (HDT), we performed a negative co-expression analysis using big data of 60 000 Affymetrix expression arrays and 5000 TCGA data sets to determine the functions of TAS2R10, which can be activated by numerous bitter substances. Excitingly, we found that the main functions of TAS2R10 involved controlling infectious diseases caused by bacteria, viruses, and parasites, suggesting that TAS2R10 is a key trigger of host defense pathways. To quickly guide the clinical treatment of 2019-nCoV, we searched currently available drugs that are agonists of TAS2Rs. We identified many cheap, available, and safe medicines, such as diphenidol, quinine, chloroquine, artemisinin, chlorpheniramine, yohimbine, and dextromethorphan, which may target the most common symptoms caused by 2019-nCoV. We suggest that a cocktail-like recipe of existing bitter drugs may help doctors to fight this catastrophic disease and that the general public may drink or eat bitter substances, such as coffee, tea, or bitter vegetables, to reduce the risk of infection.
C1 [Li, Xiangqi; Gu, Mingjun] Second Mil Med Univ, Shanghai Gongli Hosp, Dept Endocrinol, Shanghai 200135, Peoples R China.
   [Zhang, Chaobao] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci, Univ Chinese Acad Sci,State Key Lab Mol Biol, Shanghai, Peoples R China.
   [Liu, Lianyong] Punan Hosp Pudong New Dist, Dept Endocrinol, Shanghai, Peoples R China.
RP Li, XQ (corresponding author), Second Mil Med Univ, Shanghai Gongli Hosp, Dept Endocrinol, Shanghai 200135, Peoples R China.
EM lixq@sibs.ac.cn
FU Pudong Health and Family Planning Commission of Shanghai [PWZxk2017-07,
   PWZzk2017-29, PWRI2018-02]; Pudong New Area Science and Technology
   Commission [PKJ2019-Y21]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019M651615, 2018229]
FX Pudong Health and Family Planning Commission of Shanghai, Grant/Award
   Number: PWZxk2017-07, PWZzk2017-29 and PWRI2018-02; Pudong New Area
   Science and Technology Commission, Grant/Award Number: PKJ2019-Y21;
   China Postdoctoral Science Foundation, Grant/Award Number: 2019M651615
   and 2018229
CR An J, 2017, ANNU REV MED, V68, P317, DOI 10.1146/annurev-med-043015-123453
   Avau B, 2016, ACTA PHYSIOL, V216, P407, DOI 10.1111/apha.12621
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13209
   Behrens M, 2013, SEMIN CELL DEV BIOL, V24, P215, DOI 10.1016/j.semcdb.2012.08.006
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Bortolotti M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00486
   Brockhoff A, 2007, J AGR FOOD CHEM, V55, P6236, DOI 10.1021/jf070503p
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen M, 2018, HUM GENOMICS, V12, DOI 10.1186/s40246-018-0133-y
   Chen YW, 2013, NEUROSCI LETT, V552, P62, DOI 10.1016/j.neulet.2013.07.030
   Clark AA, 2012, FASEB J, V26, P4827, DOI 10.1096/fj.12-215087
   Cohen NA, 2017, LARYNGOSCOPE, V127, P44, DOI 10.1002/lary.26198
   Elewa H, 2017, EUR J DRUG METAB PH, V42, P745, DOI 10.1007/s13318-016-0399-1
   Grassin-Delyle S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01267
   Guo CH, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0273-8
   Hatzimouratidis K, 2005, DRUGS, V65, P1621, DOI 10.2165/00003495-200565120-00003
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648
   Huang C., 2020, CHINA LANCET
   Jing FM, 2013, J PHARM PHARMACOL, V65, P847, DOI 10.1111/jphp.12041
   Kohl S, 2013, J AGR FOOD CHEM, V61, P53, DOI 10.1021/jf303146h
   Lee E E, 2001, Am J Clin Dermatol, V2, P27, DOI 10.2165/00128071-200102010-00005
   Lee RJ, 2015, CELL MOL LIFE SCI, V72, P217, DOI 10.1007/s00018-014-1736-7
   Lee RJ, 2014, AM J RHINOL ALLERGY, V28, P366, DOI 10.2500/ajra.2014.28.4077
   Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094
   Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240
   Lei WW, 2018, P NATL ACAD SCI USA, V115, P5552, DOI 10.1073/pnas.1720758115
   Levit A, 2014, FASEB J, V28, P1181, DOI 10.1096/fj.13-242594
   Li DY, 2014, MOL BIOL EVOL, V31, P303, DOI 10.1093/molbev/mst219
   Liyanage CR, 2014, BMJ CASE REP, V2014, pbcr2014204424
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu P, 2017, J GEN PHYSIOL, V149, P181, DOI 10.1085/jgp.201611637
   Luo XC, 2019, P NATL ACAD SCI USA, V116, P5564, DOI 10.1073/pnas.1812901116
   Meyerhof W, 2005, REV PHYSIOL BIOCH P, V154, P37, DOI 10.1007/s10254-005-0041-0
   Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092
   Nguyen L, 2016, PHARMACOL THERAPEUT, V159, P1, DOI 10.1016/j.pharmthera.2016.01.016
   Oritani S, 2017, HUM CELL, V30, P106, DOI 10.1007/s13577-016-0151-9
   Parry J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m351
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Quezada SM, 2018, EXPERT REV GASTROENT, V12, P1183, DOI 10.1080/17474124.2018.1545574
   Rao M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00962
   Savarin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03022
   Seo Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176851
   Sharifi-Rad M, 2018, PHYTOTHER RES, V32, P2131, DOI 10.1002/ptr.6157
   Shimokawa T, 2020, EUR J PHARMACOL, V871, DOI 10.1016/j.ejphar.2020.172917
   Sloan Victor S, 2019, Drugs Real World Outcomes, V6, P47, DOI 10.1007/s40801-019-0152-6
   Tekin HG, 2015, TURK PEDIATR ARSIVI, V50, P248, DOI 10.5152/TurkPediatriArs.2015.1360
   Tran HTT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02949
   Vliegenthart R, 2018, ARCH DIS CHILD-FETAL, V103, pF523, DOI 10.1136/archdischild-2017-313556
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong JP, 2017, FUTURE MED CHEM, V9, P169, DOI 10.4155/fmc-2016-0181
   Yang CC, 1998, J TOXICOL-CLIN TOXIC, V36, P33, DOI 10.3109/15563659809162581
   Zhang L, 2015, FORENSIC SCI MED PAT, V11, P570, DOI 10.1007/s12024-015-9709-1
   Zhang T, 2020, SCI CHINA LIFE SCI, V63, P737, DOI 10.1007/s11427-019-9550-4
   Zheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12505-x
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 60
TC 11
Z9 11
U1 4
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2020
VL 34
IS 5
BP 6008
EP 6016
DI 10.1096/fj.202000502
EA APR 2020
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA LL1OX
UT WOS:000526117200001
PM 32281695
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ahn, JY
   Sohn, Y
   Lee, SH
   Cho, Y
   Hyun, JH
   Baek, YJ
   Jeong, SJ
   Kim, JH
   Ku, NS
   Yeom, JS
   Roh, J
   Ahn, MY
   Chin, BS
   Kim, YS
   Lee, H
   Yong, D
   Kim, HO
   Kim, S
   Choi, JY
AF Ahn, Jin Young
   Sohn, Yujin
   Lee, Su Hwan
   Cho, Yunsuk
   Hyun, Jong Hoon
   Baek, Yae Jee
   Jeong, Su Jin
   Kim, Jung Ho
   Ku, Nam Su
   Yeom, Joon-Sup
   Roh, Juhye
   Ahn, Mi Young
   Chin, Bum Sik
   Kim, Young Sam
   Lee, Hyukmin
   Yong, Dongeun
   Kim, Hyun Ok
   Kim, Sinyoung
   Choi, Jun Yong
TI Use of Convalescent Plasma Therapy in Two COVID-19 Patients With Acute
   Respiratory Distress Syndrome in Korea
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Treatment; Convalescent Plasma
ID CORTICOSTEROID TREATMENT
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 not yet has established its treatment, but convalescent plasma has been expected to increase survival rates as in the case with other emerging viral infections. We describe two cases of COVID-19 treated with convalescent plasma infusion. Both patients presented severe pneumonia with acute respiratory distress syndrome and showed a favorable outcome after the use of convalescent plasma in addition to systemic corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma therapy for COVID-19 in Korea.
C1 [Ahn, Jin Young; Sohn, Yujin; Lee, Su Hwan; Cho, Yunsuk; Hyun, Jong Hoon; Baek, Yae Jee; Jeong, Su Jin; Kim, Jung Ho; Ku, Nam Su; Yeom, Joon-Sup; Kim, Young Sam; Choi, Jun Yong] Yonsei Univ, Coll Med, Severance Hosp, Dept Internal Med, Seoul, South Korea.
   [Roh, Juhye; Lee, Hyukmin; Yong, Dongeun; Kim, Hyun Ok; Kim, Sinyoung] Yonsei Univ, Coll Med, Severance Hosp, Dept Lab Med, Seoul, South Korea.
   [Ahn, Mi Young] Seoul Med Ctr, Dept Internal Med, Seoul, South Korea.
   [Chin, Bum Sik] Natl Med Ctr, Dept Internal Med, Seoul, South Korea.
RP Choi, JY (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, 50 Yonsei Ro, Seoul 002, South Korea.; Choi, JY (corresponding author), Yonsei Univ, Coll Med, AIDS Res Inst, 50 Yonsei Ro, Seoul 002, South Korea.; Kim, S (corresponding author), Yonsei Univ, Coll Med, Dept Lab Med, 50 Yonsei Ro, Seoul 03722, South Korea.
EM sykim@yuhs.ac; seran@yuhs.ac
RI Yeom, Joon Sup/AAV-1290-2020; Yeom, Joon Sup/Q-5559-2019
OI Yeom, Joon Sup/0000-0001-8940-7170; Kim, Young Sam/0000-0001-9656-8482;
   Baek, YaeJee/0000-0003-0994-4940; Kim, Sinyoung/0000-0002-2609-8945;
   Lee, Su Hwan/0000-0002-3487-2574; Hyun, JongHoon/0000-0002-9621-0250;
   Lee, Hyukmin/0000-0002-8523-4126; Jeong, Su Jin/0000-0003-4025-4542;
   Kim, Jung Ho/0000-0002-5033-3482; dongeun, yong/0000-0002-1225-8477;
   Ahn, Jin Young/0000-0002-3740-2826; Ku, Nam Su/0000-0002-9717-4327;
   Choi, Jun Yong/0000-0002-2775-3315; Cho, Yunsuk/0000-0002-6089-876X;
   Kim, Hyun Ok/0000-0002-4964-1963
FU HIV (Korea HIV/AIDS Cohort Study) [2019-ER510100]; Ministry of Health &
   Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of
   Korea [HI14C1324]
FX This study was supported by research grants for deriving the major
   clinical and epidemiological indicators of people with HIV (Korea
   HIV/AIDS Cohort Study, 2019-ER510100), and a grant from the Ministry of
   Health & Welfare, Republic of Korea (grant No. HI14C1324).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Choe PG, 2017, EMERG INFECT DIS, V23, P1079, DOI 10.3201/eid2307.170310
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hanley B., 2020, J CLIN PATHOL
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Liu Y., 2020, LANCET INFECT DIS
   Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Public Health, TREATM MERS COV INF
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Wong V. W. S., 2003, Hong Kong Medical Journal, V9, P199
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 20
TC 89
Z9 92
U1 3
U2 9
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD APR 13
PY 2020
VL 35
IS 14
AR e149
DI 10.3346/jkms.2020.35.e149
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LD6AN
UT WOS:000526111800007
PM 32281317
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Rossi, JJ
   Rossi, D
AF Rossi, John J.
   Rossi, Daniel
TI Oligonucleotides and the COVID-19 Pandemic: A Perspective
SO NUCLEIC ACID THERAPEUTICS
LA English
DT Article
DE coronavirus; virus-host interactions; chemistry optimization
AB The present global health emergency involving the emergence and rapid spread of a novel coronavirus has prompted the world scientific community to consider how it can help to fight this growing viral pandemic. With few safe and effective drugs available to combat this threat to humanity and the normal functioning of our society, the oligonucleotide research community is uniquely positioned to apply its technology and expertise to help alleviate the crisis, thanks to its capacity for rational drug design, swift development cycles, and pursuing targets undruggable by conventional treatment strategies.
C1 [Rossi, John J.] Beckman Res Inst City Hope, Dept Mol & Cellular Biol, 1500 East Duarte Rd, Duarte, CA 91010 USA.
   [Rossi, Daniel] ISTAT Therapeut, Monrovia, CA USA.
RP Rossi, JJ (corresponding author), Beckman Res Inst City Hope, Dept Mol & Cellular Biol, 1500 East Duarte Rd, Duarte, CA 91010 USA.
EM jrossi@coh.org
FU Division Of Mathematical SciencesNational Science Foundation (NSF)NSF -
   Directorate for Mathematical & Physical Sciences (MPS) [1839351] Funding
   Source: National Science Foundation
CR Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Zhong YX, 2012, VIRUSES-BASEL, V4, P980, DOI 10.3390/v4060980
NR 2
TC 5
Z9 5
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2159-3337
EI 2159-3345
J9 NUCLEIC ACID THER
JI Nucl. Acid Ther.
PD JUN 1
PY 2020
VL 30
IS 3
BP 129
EP 132
DI 10.1089/nat.2020.0868
EA APR 2020
PG 4
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine,
   Research & Experimental
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research &
   Experimental Medicine
GA LR1FS
UT WOS:000526628200001
PM 32297843
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, SA
   Zia, K
   Ashraf, S
   Uddin, R
   Ul-Haq, Z
AF Khan, Salman Ali
   Zia, Komal
   Ashraf, Sajda
   Uddin, Reaz
   Ul-Haq, Zaheer
TI Identification of chymotrypsin-like protease inhibitors of
   SARS-CoV-2viaintegrated computational approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE 3CL(pro); drug repurposing; MD simulation; remdesivir; SARS-CoV-2;
   virtual screening; corona virus
ID DRUG DESIGN; CORONAVIRUS; INSIGHTS; BINDING
AB Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery. Communicated by Ramaswamy H. Sarma
C1 [Khan, Salman Ali; Zia, Komal; Ashraf, Sajda; Uddin, Reaz; Ul-Haq, Zaheer] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.
   [Ul-Haq, Zaheer] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem & Biol Sci, Karachi, Pakistan.
RP Ul-Haq, Z (corresponding author), Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.
EM zaheer.qasmi@iccs.edu
RI Uddin, Reaz/I-5673-2017; Ul-Haq, Zaheer/AAE-1628-2020; ,
   sajda/C-9791-2018
OI Uddin, Reaz/0000-0002-9928-4482; Ul-Haq, Zaheer/0000-0002-8530-8711;
   Ullah, Imdad/0000-0002-8188-2601; khan, sami/0000-0001-7004-9393; ,
   sajda/0000-0003-4378-2754; Khan, Salman Ali/0000-0001-5307-5151
CR Anand K, 2005, BIRK ADV INFECT DIS, P173
   Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Case D., 2018, AMBER 2018
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin Z, STRUCTURE MPRO 1 COV, DOI DOI 10.1101/2020.02.26.964882V2
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Labute P, 2009, PROTEINS, V75, P187, DOI 10.1002/prot.22234
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Racine J, 2006, J APPL ECONOMET, V21, P133, DOI 10.1002/jae.885
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   WHO, 2020, NAM COR DIS COV 19 V
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 37
TC 95
Z9 96
U1 5
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1751298
EA APR 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA MZ0XO
UT WOS:000558846800001
PM 32238094
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Zeng, JH
   Liu, YX
   Yuan, J
   Wang, FX
   Wu, WB
   Li, JX
   Wang, LF
   Gao, H
   Wang, Y
   Dong, CF
   Li, YJ
   Xie, XJ
   Feng, C
   Liu, L
AF Zeng, Jia-Hui
   Liu, Ying-Xia
   Yuan, Jing
   Wang, Fu-Xiang
   Wu, Wei-Bo
   Li, Jin-Xiu
   Wang, Li-Fei
   Gao, Hong
   Wang, Yao
   Dong, Chang-Feng
   Li, Yi-Jun
   Xie, Xiao-Juan
   Feng, Cheng
   Liu, Lei
TI First case of COVID-19 complicated with fulminant myocarditis: a case
   report and insights
SO INFECTION
LA English
DT Article
DE COVID-19; Coronavirus; Fulminant myocarditis; Infection;
   Echocardiography
ID CYTOKINE STORM; INFECTIONS
AB Background Coronavirus disease 2019 (COVID-19) has been demonstrated to be the cause of pneumonia. Nevertheless, it has not been reported as the cause of acute myocarditis or fulminant myocarditis. Case presentation A 63-year-old male was admitted with pneumonia and cardiac symptoms. He was genetically confirmed as having COVID-19 according to sputum testing on the day of admission. He also had elevated troponin I (Trop I) level (up to 11.37 g/L) and diffuse myocardial dyskinesia along with a decreased left ventricular ejection fraction (LVEF) on echocardiography. The highest level of interleukin-6 was 272.40 pg/ml. Bedside chest radiographs showed typical ground-glass changes indicative of viral pneumonia. Laboratory test results for viruses that cause myocarditis were all negative. The patient conformed to the diagnostic criteria of the Chinese expert consensus statement for fulminant myocarditis. After receiving antiviral therapy and mechanical life support, Trop I was reduced to 0.10 g/L, and interleukin-6 was reduced to 7.63 pg/mL. Moreover, the LVEF of the patient gradually recovered to 68%. The patient died of aggravation of secondary infection on the 33rd day of hospitalization. Conclusion COVID-19 patients may develop severe cardiac complications such as myocarditis and heart failure. This is the first report of COVID-19 complicated with fulminant myocarditis. The mechanism of cardiac pathology caused by COVID-19 needs further study.
C1 [Zeng, Jia-Hui; Wang, Yao; Dong, Chang-Feng; Li, Yi-Jun; Xie, Xiao-Juan; Feng, Cheng] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Med Ultrason, Natl Clin Res Ctr Infect Dis,State Key Discipline, 29 Bulan Rd, Shenzhen 518112, Peoples R China.
   [Liu, Ying-Xia; Liu, Lei] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
   [Yuan, Jing; Wang, Fu-Xiang; Wu, Wei-Bo] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Infect Dis, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
   [Li, Jin-Xiu] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Intens Care Unit, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
   [Wang, Li-Fei] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Radiol, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
   [Gao, Hong] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Cardiol, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
RP Feng, C (corresponding author), Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2,Dept Med Ultrason, Natl Clin Res Ctr Infect Dis,State Key Discipline, 29 Bulan Rd, Shenzhen 518112, Peoples R China.; Liu, L (corresponding author), Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Hosp 2, Natl Clin Res Ctr Infect Dis,State Key Discipline, Shenzhen, Peoples R China.
EM chaosheng-01@szsy.sustech.edu.cn; liulei3322@aliyun.com
OI Yuan, Jing/0000-0002-8937-9568
CR Alhogbani T, 2016, ANN SAUDI MED, V36, P78, DOI 10.5144/0256-4947.2016.78
   Blackburn R, 2018, CLIN INFECT DIS, V67, P8, DOI 10.1093/cid/cix1144
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   EDWARDS S, 1992, J INFECT DIS, V165, P134, DOI 10.1093/infdis/165.1.134
   Han Yun, 2003, J Tradit Chin Med, V23, P214
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Sawamura A, 2018, CIRC J, V82, P2089, DOI 10.1253/circj.CJ-18-0136
   Wang DW, 2019, SCI CHINA LIFE SCI, V62, P187, DOI 10.1007/s11427-018-9385-3
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2016, ANESTH ANALG, V122, P373, DOI 10.1213/ANE.0000000000001048
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 113
Z9 116
U1 3
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
PD OCT
PY 2020
VL 48
IS 5
BP 773
EP 777
DI 10.1007/s15010-020-01424-5
EA APR 2020
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NT0QS
UT WOS:000539134900001
PM 32277408
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Gordon, CJ
   Tchesnokov, EP
   Feng, JY
   Porter, DP
   Gotte, M
AF Gordon, Calvin J.
   Tchesnokov, Egor P.
   Feng, Joy Y.
   Porter, Danielle P.
   Gotte, Matthias
TI The antiviral compound remdesivir potently inhibits RNA-dependent RNA
   polymerase from Middle East respiratory syndrome coronavirus
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE plus-stranded RNA virus; viral polymerase; drug development; enzyme
   inhibitor; nucleoside; nucleotide analog; coronavirus; positive-sense
   RNA virus; Ebola virus (EBOV); Middle East respiratory syndrome
   coronavirus (MERS?CoV); SARS?CoV-2; remdesivir; antiviral drug; RNA
   chain termination; RNA-dependent RNA polymerase (RdRp); viral replicase
ID EBOLA-VIRUS; GS-5734; REPLICATION; EXCISION
AB Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome?coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome?CoV and Middle East respiratory syndrome (MERS?CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS?CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS?CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3??5? exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.
C1 [Gordon, Calvin J.; Tchesnokov, Egor P.; Gotte, Matthias] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
   [Gotte, Matthias] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB T6G 2E1, Canada.
   [Feng, Joy Y.; Porter, Danielle P.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA.
RP Gotte, M (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
EM gotte@ualberta.ca
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [159507]; Alberta Ministry of Economic Development,
   Trade and Tourism by the Major Innovation Fund Program for the AMR-One
   Health Consortium; Gilead SciencesGilead Sciences
FX This study was supported by Canadian Institutes of Health Research Grant
   159507 (to M. G.) and a grant from the Alberta Ministry of Economic
   Development, Trade and Tourism by the Major Innovation Fund Program for
   the AMR-One Health Consortium (to M. G.). M. G. has previously received
   funding from Gilead Sciences in support for the study of EBOV RdRp
   inhibition by RDV.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036
   Bieniossek Christoph, 2008, Curr Protoc Protein Sci, VChapter 5, DOI 10.1002/0471140864.ps0520s51
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deval J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004995
   Dulin D, 2017, CELL REP, V21, P1063, DOI 10.1016/j.celrep.2017.10.005
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   Jordan PC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006889
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Muhlberger E, 1999, J VIROL, V73, P2333
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Noton SL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002980
   POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tchesnokov EP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22328-3
   Tchesnokov EP, 2008, J BIOL CHEM, V283, P34218, DOI 10.1074/jbc.M806797200
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
NR 26
TC 190
Z9 193
U1 19
U2 52
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 10
PY 2020
VL 295
IS 15
BP 4773
EP 4779
DI 10.1074/jbc.AC120.013056
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA LE7FC
UT WOS:000526887000002
PM 32094225
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Misra, DP
   Agarwal, V
   Gasparyan, AY
   Zimba, O
AF Misra, Durga Prasanna
   Agarwal, Vikas
   Gasparyan, Armen Yuri
   Zimba, Olena
TI Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and
   potential therapeutic targets
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE COVID-19; Epidemiology; Hydroxychloroquine; Hypothesis; Immunity;
   Pathogenesis; Vaccines; Vitamin D
ID 2019-NCOV; CHLOROQUINE; HYDROXYCHLOROQUINE
AB The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.
C1 [Misra, Durga Prasanna; Agarwal, Vikas] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, Uttar Pradesh, India.
   [Gasparyan, Armen Yuri] Dudley Grp NHS Fdn Trust Teaching Trust, Dept Rheumatol & Res & Dev, Russells Hall Hosp, Dudley, W Midlands, England.
   [Zimba, Olena] Danylo Halytsky Lviv Natl Med Univ, Dept Internal Med 2, Lvov, Ukraine.
RP Misra, DP (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, Uttar Pradesh, India.
EM durgapmisra@gmail.com
RI Zimba, Olena/Q-4031-2017; Gasparyan, Armen Yuri/C-9174-2009
OI Zimba, Olena/0000-0002-4188-8486; Gasparyan, Armen
   Yuri/0000-0001-8749-6018
CR Andreasen V, 2008, J INFECT DIS, V197, P270, DOI 10.1086/524065
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Clerkin Kevin J, 2020, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120.046941, DOI 10.1161/CIRCULATIOAHA.120.046941]
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Biancatelli RMLC, 2020, EXPERT REV ANTI-INFE, V18, P99, DOI 10.1080/14787210.2020.1706483
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Day M, 2020, COVID 19 EUROPEAN DR, V368, pm1168, DOI [10.1136/bmj.m1168, DOI 10.1136/BMJ.M1168]
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Goncalves-Mendes N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00065
   Grant W.B., 2020, VITAMIN D SUPPLEMENT, DOI [10.20944/preprints202003.0235.v1, DOI 10.20944/PREPRINTS202003.0235.V1]
   Grant WB, 2020, EUR J CLIN NUTR, V74, P366, DOI 10.1038/s41430-020-0564-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Hindawi SI, 2018, TRANSFUSION, V58, P52, DOI 10.1111/trf.14422
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Kwon Ki Tae, 2020, J Korean Med Sci, V35, pe123, DOI 10.3346/jkms.2020.35.e123
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Mason JW, 2017, J ANTIMICROB CHEMOTH, V72, P1272, DOI 10.1093/jac/dkw591
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ramos-Casals M, 2020, ANN RHEUM DIS, V79, P3, DOI 10.1136/annrheumdis-2019-216114
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu X., 2020, CHINAXIV20200300026
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
NR 50
TC 59
Z9 60
U1 13
U2 67
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JUL
PY 2020
VL 39
IS 7
BP 2055
EP 2062
DI 10.1007/s10067-020-05073-9
EA APR 2020
PG 8
WC Rheumatology
SC Rheumatology
GA LY1IL
UT WOS:000524963800001
PM 32277367
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sampangi-Ramaiah, MH
   Vishwakarma, R
   Shaanker, RU
AF Sampangi-Ramaiah, Megha Hastantram
   Vishwakarma, Ram
   Shaanker, R. Uma
TI Molecular docking analysis of selected natural products from plants for
   inhibition of SARS-CoV-2 main protease
SO CURRENT SCIENCE
LA English
DT Article
DE Affinity/binding energy; COVID-19 protease; drug discovery; ligands;
   natural products
ID HEDERAGENIN; PROTEINS
AB In this article, we report results of a molecular docking analysis of commonly occurring natural product compounds against COVID-19 6LU7 and 6Y2E proteases. Our results show that several of these compounds have binding affinity against both the COVID-19 proteases, and compare well with a known anti-HIV drug, Saquinavir. Many of the compounds form an integral component of many cuisines, both Indian as well as others. We propose that some of these compounds could be easily and quickly positioned to hold fort against the COVID-19 virus, until of course newer therapies are discovered and detailed studies are taken to empirically validate some of the compounds for their ability to inhibit the virus.
C1 [Sampangi-Ramaiah, Megha Hastantram; Shaanker, R. Uma] Univ Agr Sci, Sch Ecol & Conservat, Gkvk 560065, Bengaluru, India.
   [Vishwakarma, Ram] CSIR, Indian Inst Integrat Med, Jammu 180001, India.
   [Shaanker, R. Uma] Univ Agr Sci, Dept Crop Physiol, Gkvk 560065, Bengaluru, India.
RP Shaanker, RU (corresponding author), Univ Agr Sci, Sch Ecol & Conservat, Gkvk 560065, Bengaluru, India.; Shaanker, RU (corresponding author), Univ Agr Sci, Dept Crop Physiol, Gkvk 560065, Bengaluru, India.
EM umashaanker@gmail.com
RI Sampangi-Ramaiah, Megha H/AAV-1084-2020
OI Sampangi-Ramaiah, Megha H/0000-0002-9057-2170
FU DBT grant on 'Chemical Ecology of the North East Region (NER) of India:
   A collaborative programme Linking NER and Bangalore Researchers'
   [DBT-NER/Agri/24/2013]; ICAR Emeritus Scientist Grant; Council for
   Scientific and Industrial Research, Government of IndiaCouncil of
   Scientific & Industrial Research (CSIR) - India
FX M.H.S. is supported by a DBT grant on 'Chemical Ecology of the North
   East Region (NER) of India: A collaborative programme Linking NER and
   Bangalore Researchers' (DBT-NER/Agri/24/2013). R.U.S. is supported by an
   ICAR Emeritus Scientist Grant. R.V. is supported by the Council for
   Scientific and Industrial Research, Government of India.
CR [Anonymous], 2020, NAT PLANTS, V6, P177, DOI 10.1038/s41477-020-0628-0
   CESKA O, 1988, PHYTOCHEMISTRY, V27, P2083, DOI 10.1016/0031-9422(88)80101-8
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Ishtiyaq A., 2019, J DRUG DELIV THERAP, V9, P765
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Khwaza V, 2018, MOLECULES, V23, DOI 10.3390/molecules23092300
   Kumari A., 2019, INT J PHARM SCI DRUG, V11, P376
   Lin JH, 2020, PHYTOTHER RES, V34, P2053, DOI 10.1002/ptr.6669
   Liu X., 2020, CRYSTAL STRUCTURE 20
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007
   Shityakov Sergey, 2014, Adv Appl Bioinform Chem, V7, P23, DOI 10.2147/AABC.S63749
   Tian M, 2008, BIOTECHNOL BIOPROC E, V13, P671, DOI 10.1007/s12257-008-0019-2
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wu AG, 2017, PHARMACOL RES, V115, P25, DOI 10.1016/j.phrs.2016.11.002
   Wu Canrong, 2020, ACTA PHARM SIN B
   Zeng J, 2018, RSC ADV, V8, P24188, DOI 10.1039/c8ra03666g
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 20
TC 9
Z9 9
U1 2
U2 40
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD APR 10
PY 2020
VL 118
IS 7
BP 1087
EP 1092
DI 10.18520/cs/v118/i7/1087-1092
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LA8LM
UT WOS:000524193400022
DA 2021-01-01
ER

PT J
AU Jin, ZM
   Du, XY
   Xu, YC
   Deng, YQ
   Liu, MQ
   Zhao, Y
   Zhang, B
   Li, XF
   Zhang, LK
   Peng, C
   Duan, YK
   Yu, J
   Wang, L
   Yang, KL
   Liu, FJ
   Jiang, RD
   Yang, XL
   You, T
   Liu, XC
   Yang, XN
   Bai, F
   Liu, H
   Liu, X
   Guddat, LW
   Xu, WQ
   Xiao, GF
   Qin, CF
   Shi, ZL
   Jiang, HL
   Rao, ZH
   Yang, HT
AF Jin, Zhenming
   Du, Xiaoyu
   Xu, Yechun
   Deng, Yongqiang
   Liu, Meiqin
   Zhao, Yao
   Zhang, Bing
   Li, Xiaofeng
   Zhang, Leike
   Peng, Chao
   Duan, Yinkai
   Yu, Jing
   Wang, Lin
   Yang, Kailin
   Liu, Fengjiang
   Jiang, Rendi
   Yang, Xinglou
   You, Tian
   Liu, Xiaoce
   Yang, Xiuna
   Bai, Fang
   Liu, Hong
   Liu, Xiang
   Guddat, Luke W.
   Xu, Wenqing
   Xiao, Gengfu
   Qin, Chengfeng
   Shi, Zhengli
   Jiang, Hualiang
   Rao, Zihe
   Yang, Haitao
TI Structure of M-pro from SARS-CoV-2 and discovery of its inhibitors
SO NATURE
LA English
DT Article
ID RESPIRATORY SYNDROME-CORONAVIRUS; VIRUS MAIN PROTEASE; SARS; PROTEINASE;
   EBSELEN; SPECIFICITIES; PREVENTION; DOCKING; COMPLEX; BINDING
AB A programme of structure-assisted drug design and high-throughput screening identifies six compounds that inhibit the main protease of SARS-CoV-2, demonstrating the ability of this strategy to isolate drug leads with clinical potential.
   A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the aetiological agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19)(1-4). Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited. Here we describe the results of a programme that aimed to rapidly discover lead compounds for clinical use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening. This programme focused on identifying drug leads that target main protease (M-pro) of SARS-CoV-2: M-pro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2(5,6). We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then determined the crystal structure of M-pro of SARS-CoV-2 in complex with this compound. Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compounds-including approved drugs, drug candidates in clinical trials and other pharmacologically active compounds-as inhibitors of M-pro. Six of these compounds inhibited M-pro, showing half-maximal inhibitory concentration values that ranged from 0.67 to 21.4 mu M. One of these compounds (ebselen) also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.
C1 [Jin, Zhenming; Zhao, Yao; Zhang, Bing; Duan, Yinkai; Yu, Jing; Wang, Lin; Liu, Fengjiang; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Xu, Wenqing; Jiang, Hualiang; Rao, Zihe; Yang, Haitao] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.
   [Jin, Zhenming; Zhao, Yao; Zhang, Bing; Duan, Yinkai; Yu, Jing; Wang, Lin; Liu, Fengjiang; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Xu, Wenqing; Jiang, Hualiang; Rao, Zihe; Yang, Haitao] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.
   [Jin, Zhenming; Du, Xiaoyu; Rao, Zihe] Tsinghua Univ, Sch Life Sci, Struct Biol Lab, Beijing, Peoples R China.
   [Jin, Zhenming; Du, Xiaoyu; Rao, Zihe] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Xu, Yechun; Liu, Hong; Jiang, Hualiang] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai, Peoples R China.
   [Deng, Yongqiang; Li, Xiaofeng; Qin, Chengfeng] Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Liu, Meiqin; Zhang, Leike; Jiang, Rendi; Yang, Xinglou; Xiao, Gengfu; Shi, Zhengli] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, CAS Key Lab Special Pathogens, Wuhan, Peoples R China.
   [Peng, Chao; Xu, Wenqing] Chinese Acad Sci, Shanghai Adv Res Inst, Zhangjiang Lab, Natl Facil Prot Sci Shanghai, Shanghai, Peoples R China.
   [Yang, Kailin] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA.
   [Liu, Xiang; Rao, Zihe] Nankai Univ, State Key Lab Med Chem Biol, Frontiers Sci Ctr Cell Response, Coll Life Sci,Coll Pharm, Tianjin, Peoples R China.
   [Guddat, Luke W.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
RP Jiang, HL; Rao, ZH; Yang, HT (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China.; Jiang, HL; Rao, ZH; Yang, HT (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.; Rao, ZH (corresponding author), Tsinghua Univ, Sch Life Sci, Struct Biol Lab, Beijing, Peoples R China.; Rao, ZH (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Jiang, HL (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai, Peoples R China.; Rao, ZH (corresponding author), Nankai Univ, State Key Lab Med Chem Biol, Frontiers Sci Ctr Cell Response, Coll Life Sci,Coll Pharm, Tianjin, Peoples R China.
EM hljiang@simm.ac.cn; raozh@mail.tsinghua.edu.cn;
   yanght@shanghaitech.edu.cn
RI Qin, Cheng-Feng/I-6839-2019; yang, xinglou/AAW-6969-2020; Yang,
   Kailin/L-2205-2013
OI Qin, Cheng-Feng/0000-0002-0632-2807; Liu, Fengjiang/0000-0002-9400-308X;
   Jin, Zhenming/0000-0001-6448-820X; Du, Xiaoyu/0000-0002-8415-8686; You,
   Tian/0000-0003-0555-6916; Yang, Xiuna/0000-0003-3443-9815; Yang,
   Kailin/0000-0001-5968-6738; YU, Xiang/0000-0003-4053-7876
FU National Key R&D Program of China [2017YFC0840300, 2020YFA0707500];
   Project of International Cooperation and Exchanges NSFC [81520108019];
   Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [20431900200];
   Department of Science and Technology of Guangxi Zhuang Autonomous Region
   [2020AB40007]
FX We thank Y. Lei and J. Kong from High Throughput Platform and staff from
   Analytical Chemistry Platform at the Shanghai Institute for Advanced
   Immunochemical Studies for their technical support; the National Centre
   for Protein Science Shanghai and The Molecular and Cell Biology Core
   Facility of the School of Life Science and Technology, ShanghaiTech
   University for use of their instrumentation and technical assistance; Z.
   Liu and H. Su for discussion; and the staff from beamlines BL17U1,
   BL18U1 and BL19U1 at the Shanghai Synchrotron Radiation Facility. This
   work was supported by grants from National Key R&D Program of China
   (grant no. 2017YFC0840300 to Z.R. and no. 2020YFA0707500), Project of
   International Cooperation and Exchanges NSFC (grant no. 81520108019 to
   Z.R.), Science and Technology Commission of Shanghai Municipality (grant
   no. 20431900200) and Department of Science and Technology of Guangxi
   Zhuang Autonomous Region (grant no. 2020AB40007).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Aulner N, 2019, TRENDS PARASITOL, V35, P559, DOI 10.1016/j.pt.2019.05.004
   Bai F, 2013, P NATL ACAD SCI USA, V110, P4273, DOI 10.1073/pnas.1301814110
   Chen LL, 2005, J VIROL, V79, P7095, DOI 10.1128/JVI.79.11.7095-7103.2005
   Cui W, 2019, BIOCHEM BIOPH RES CO, V511, P794, DOI 10.1016/j.bbrc.2019.02.105
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Kil J, 2017, LANCET, V390, P969, DOI 10.1016/S0140-6736(17)31791-9
   Lee CC, 2009, J BIOL CHEM, V284, P7646, DOI 10.1074/jbc.M807947200
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu XF, 2011, J CHEM INF MODEL, V51, P2372, DOI 10.1021/ci200060s
   Lynch Eric, 2009, Seminars in Hearing, V30, P47, DOI 10.1055/s-0028-1111106
   Masaki C, 2016, PSYCHOPHARMACOLOGY, V233, P2655, DOI 10.1007/s00213-016-4319-5
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Potterton L, 2018, ACTA CRYSTALLOGR D, V74, P68, DOI 10.1107/S2059798317016035
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Renson M, 1982, US patent, V4, P352, Patent No. 19824352799
   RUBIN B, 1965, P SOC EXP BIOL MED, V119, P438
   Singh N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2320
   St John SE, 2015, BIOORGAN MED CHEM, V23, P6036, DOI 10.1016/j.bmc.2015.06.039
   Wang FH, 2017, J MED CHEM, V60, P3212, DOI 10.1021/acs.jmedchem.7b00103
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang FH, 2016, J VIROL, V90, P1910, DOI 10.1128/JVI.02685-15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QM, 1997, ANAL BIOCHEM, V252, P238, DOI 10.1006/abio.1997.2315
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yang H, 2005, PLOS BIOL, V3, pe324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhao Q, 2008, J VIROL, V82, P8647, DOI 10.1128/JVI.00298-08
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 373
Z9 383
U1 89
U2 139
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN
PY 2020
VL 582
IS 7811
BP 289
EP +
DI 10.1038/s41586-020-2223-y
EA APR 2020
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MB8KL
UT WOS:000537932300001
PM 32272481
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Di Lorenzo, G
   Di Trolio, R
AF Di Lorenzo, Giuseppe
   Di Trolio, Rossella
TI Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and
   Proposed Remedial Measures
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE coronavirus; causes and management; lung disease; potential drugs;
   prevention
C1 [Di Lorenzo, Giuseppe] Andrea Tortora Hosp, Med Oncol, ASL Salerno, Pagani, Italy.
   [Di Lorenzo, Giuseppe] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy.
   [Di Trolio, Rossella] Ist Nazl Tumori IRCCS Fdn G Pascale, Unit Melanoma Canc Immunotherapy & Dev Therapeut, Naples, Italy.
RP Di Lorenzo, G (corresponding author), Andrea Tortora Hosp, Med Oncol, ASL Salerno, Pagani, Italy.; Di Lorenzo, G (corresponding author), Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy.
EM dilorengiuseppe@gmail.com
RI Di Lorenzo, Giuseppe/AAR-9799-2020
OI Di Lorenzo, Giuseppe/0000-0001-7414-1568
CR Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
NR 3
TC 11
Z9 11
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD APR 9
PY 2020
VL 7
AR 140
DI 10.3389/fmed.2020.00140
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LJ0MZ
UT WOS:000529869800001
PM 32328496
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Buonomo, B
AF Buonomo, Bruno
TI Effects of information-dependent vaccination behavior on coronavirus
   outbreak: insights from a SIRI model
SO RICERCHE DI MATEMATICA
LA English
DT Article
DE Epidemic model; Coronavirus; Reinfection; Vaccine; Information
ID INFECTIOUS-DISEASES; RATIONAL EXEMPTION; EPIDEMIC MODEL; REINFECTION;
   DYNAMICS
AB A mathematical model is proposed to assess the effects of a vaccine on the time evolution of a coronavirus outbreak. The model has the basic structure of SIRI compartments (susceptible-infectious-recovered-infectious) and is implemented by taking into account of the behavioral changes of individuals in response to the available information on the status of the disease in the community. We found that the cumulative incidence may be significantly reduced when the information coverage is high enough and/or the information delay is short, especially when the reinfection rate is high enough to sustain the presence of the disease in the community. This analysis is inspired by the ongoing outbreak of a respiratory illness caused by the novel coronavirus COVID-19.
C1 [Buonomo, Bruno] Univ Naples Federico II, Dept Math & Applicat, Via Cintia, I-80126 Naples, Italy.
RP Buonomo, B (corresponding author), Univ Naples Federico II, Dept Math & Applicat, Via Cintia, I-80126 Naples, Italy.
EM buonomo@unina.it
FU Italian National Group for the Mathematical Physics (GNFM) of National
   Institute for Advanced Mathematics (INdAM)
FX This work has been performed under the auspices of the Italian National
   Group for the Mathematical Physics (GNFM) of National Institute for
   Advanced Mathematics (INdAM).
CR Agenzia Nazionale Stampa Associata, MASCH SOLD OUT FARM
   Anastassopoulou C., DATA BASED ANAL MODE, DOI [10.1101/2020.02.11.20022186v1, DOI 10.1101/2020.02.11.20022186V1.FULL.PDF]
   ANDERSON R M, 1991
   Brauer F., 2008, LECT NOTES MATH MATH, V1945
   Buonomo B, 2013, J MATH ANAL APPL, V404, P385, DOI 10.1016/j.jmaa.2013.02.063
   Buonomo B, 2012, APPL MATH LETT, V25, P1056, DOI 10.1016/j.aml.2012.03.016
   Buonomo B, 2008, MATH BIOSCI, V216, P9, DOI 10.1016/j.mbs.2008.07.011
   Buonomo B, 2019, MATH COMPUT SIMULAT, V162, P97, DOI 10.1016/j.matcom.2019.01.005
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   CAPASSO V, 1993, MATH STRUCTURES EPID
   d'Onofrio A, 2007, MATH MODEL NAT PHENO, V2, P26, DOI 10.1051/mmnp:2008009
   d'Onofrio A, 2016, MATH STAT MODELING E, P341, DOI DOI 10.1007/978-3-319-40413-4_21
   d'Onofrio A, 2007, THEOR POPUL BIOL, V71, P301, DOI 10.1016/j.tpb.2007.01.001
   d'Onofrio A, 2011, J THEOR BIOL, V273, P63, DOI 10.1016/j.jtbi.2010.12.029
   d'Onofrio A, 2009, J THEOR BIOL, V256, P473, DOI 10.1016/j.jtbi.2008.10.005
   D'Onofrio A, 2008, MATH MED BIOL, V25, P337, DOI 10.1093/imammb/dqn019
   Danchin A., 2020, NEW TRANSMISSION ROU, DOI [10.1101/2020.02.14.20022939v1, DOI 10.1101/2020.02.14.20022939V1]
   Gomes MGM, 2004, J THEOR BIOL, V228, P539, DOI 10.1016/j.jtbi.2004.02.015
   ISAACS D, 1983, ARCH DIS CHILD, V58, P500, DOI 10.1136/adc.58.7.500
   Katriel G, 2010, MATH BIOSCI, V228, P153, DOI 10.1016/j.mbs.2010.09.003
   Keeling M. J., 2008, MODELING INFECT DIS
   Kumar A, 2019, MATH COMPUT SIMULAT, V157, P77, DOI 10.1016/j.matcom.2018.09.024
   MacDonald N, 2008, BIOL DELAY SYSTEMS L
   Manfredi P, 2013, MODELING INTERPLAY H
   Martcheva M., 2015, TEXTS APPL MATH
   Martins J, 2017, B MATH BIOL, V79, P853, DOI 10.1007/s11538-017-0257-6
   Nakata Y, 2019, MATH BIOSCI ENG, V16, P813, DOI 10.3934/mbe.2019038
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI DOI 10.1101/2020.01.23.20018549V1.FULL.PDF
   Wang Z, 2016, PHYS REP, V664, P1, DOI 10.1016/j.physrep.2016.10.006
   WHO, MIDDL E RESP SYNDR C
   World Health Organization, DIR GEN REM MED BRIE
   World Health Organization, CUM NUMB REP PROB CA
   World Health Organization, NOV COR 2019 NCOV
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Zhu LH, 2019, PHYS SCRIPTA, V94, DOI 10.1088/1402-4896/ab2f04
NR 35
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0035-5038
EI 1827-3491
J9 RIC MAT
JI Ric. Mat.
PD NOV
PY 2020
VL 69
IS 2
SI SI
BP 483
EP 499
DI 10.1007/s11587-020-00506-8
EA APR 2020
PG 17
WC Mathematics, Applied; Mathematics
SC Mathematics
GA OU7WC
UT WOS:000525298600001
OA Bronze
DA 2021-01-01
ER

PT J
AU Goren, A
   McCoy, J
   Wambier, CG
   Vano-Galvan, S
   Shapiro, J
   Dhurat, R
   Washenik, K
   Lotti, T
AF Goren, Andy
   McCoy, John
   Wambier, Carlos G.
   Vano-Galvan, Sergio
   Shapiro, Jerry
   Dhurat, Rachita
   Washenik, Kenneth
   Lotti, Torello
TI What does androgenetic alopecia have to do with COVID-19? An insight
   into a potential new therapy
SO DERMATOLOGIC THERAPY
LA English
DT Letter
ID PULMONARY SURFACTANT; RECEPTOR; EXPRESSION; LUNG
C1 [Goren, Andy; McCoy, John] Appl Biol Inc, Irvine, CA USA.
   [Wambier, Carlos G.] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
   [Vano-Galvan, Sergio] Univ Alcala De Henares, IRYCIS, Ramon & Cajal Hosp, Trichol Unit,Dept Dermatol, Madrid, Spain.
   [Shapiro, Jerry; Washenik, Kenneth] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA.
   [Dhurat, Rachita] LTM Med Coll & Hosp Sion, Dept Dermatol, Mumbai, Maharashtra, India.
   [Washenik, Kenneth] Bosley Med Grp, Beverly Hills, CA USA.
   [Lotti, Torello] Univ Rome G Marconi, Dept Dermatol & Venereol, Rome, Italy.
RP Wambier, CG (corresponding author), Rhode Isl Hosp, 593 Eddy St,APC,10th Floor, Providence, RI 02903 USA.
EM carlos_wambier@brown.edu
RI Wambier, Carlos/H-4281-2012
OI Wambier, Carlos/0000-0002-4636-4489; Vano-Galvan,
   Sergio/0000-0003-2773-7494
CR Dalpiaz PLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127515
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   KASHON ML, 1995, BIOL REPROD, V52, P1198, DOI 10.1095/biolreprod52.5.1198
   Lin BY, 1999, CANCER RES, V59, P4180
   McCrohon JA, 2000, CIRCULATION, V101, P224, DOI 10.1161/01.CIR.101.3.224
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   NIELSEN HC, 1982, J CLIN INVEST, V69, P611, DOI 10.1172/JCI110488
   NIELSEN HC, 1985, J CLIN INVEST, V76, P177, DOI 10.1172/JCI111943
   Qiu Y, 2020, MICROBES INFECT, V22, P221, DOI 10.1016/j.micinf.2020.03.003
   ROEHRBORN CG, 1987, J CLIN INVEST, V79, P44, DOI 10.1172/JCI112805
   Sawaya ME, 1997, J INVEST DERMATOL, V109, P296, DOI 10.1111/1523-1747.ep12335779
   Seleit I, 2016, SKIN PHARMACOL PHYS, V29, P178, DOI 10.1159/000446662
   Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006
   TORDAY JS, 1981, AM REV RESPIR DIS, V123, P205
NR 17
TC 14
Z9 14
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL
PY 2020
VL 33
IS 4
AR e13365
DI 10.1111/dth.13365
EA APR 2020
PG 2
WC Dermatology
SC Dermatology
GA NL4WM
UT WOS:000564905100001
PM 32237190
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Grifoni, A
   Sidney, J
   Zhang, Y
   Scheuermann, RH
   Peters, B
   Sette, A
AF Grifoni, Alba
   Sidney, John
   Zhang, Yun
   Scheuermann, Richard H.
   Peters, Bjoern
   Sette, Alessandro
TI A Sequence Homology and Bioinformatic Approach Can Predict Candidate
   Targets for Immune Responses to SARS-CoV-2
SO CELL HOST & MICROBE
LA English
DT Article
ID SYNTHETIC PEPTIDES; CELL EPITOPES; SARS; SPIKE; PROTEINS; DATABASE
AB Effective countermeasures against the recent emergence and rapid expansion of the 2019 novel coronavirus (SARS-CoV-2) require the development of data and tools to understand and monitor its spread and immune responses to it. However, little information is available about the targets of immune responses to SARS-CoV-2. We used the Immune Epitope Database and Analysis Resource (IEDB) to catalog available data related to other coronaviruses. This includes SARS-CoV, which has high sequence similarity to SARS-CoV-2 and is the best-characterized coronavirus in terms of epitope responses. We identified multiple specific regions in SARS-CoV-2 that have high homology to the SARS-CoV virus. Parallel bioinformatic predictions identified a priori potential B and T cell epitopes for SARS-CoV-2. The independent identification of the same regions using two approaches reflects the high probability that these regions are promising targets for immune recognition of SARS-CoV-2. These predictions can facilitate effective vaccine design against this virus of high priority.
C1 [Grifoni, Alba; Sidney, John; Scheuermann, Richard H.; Peters, Bjoern; Sette, Alessandro] La Jolla Inst Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
   [Zhang, Yun; Scheuermann, Richard H.] J Craig Venter Inst, La Jolla, CA 92037 USA.
   [Scheuermann, Richard H.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92093 USA.
   [Peters, Bjoern; Sette, Alessandro] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA.
RP Sette, A (corresponding author), La Jolla Inst Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.; Sette, A (corresponding author), Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA.
EM alex@lji.org
OI Zhang, Yun/0000-0002-1180-275X
FU NIH-NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [75N9301900065, 75N93019C00001];
   NIHNIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [75N93019C00076]
FX We thank Erica Ollmann Saphire, Sharon Schendel, and Mitchell Kronenberg
   for critical reading of the manuscript and numerous helpful suggestions.
   We also thank Jason McLellan and Barney Graham for early access to the
   PDB structure of the SARS-2 spike glycoprotein. Support for the work
   included funding provided through NIH-NIAID contracts 75N9301900065
   (A.S.) and 75N93019C00001 (A.S. and B.P.). Additional support was
   provided by NIHNIAID contract 75N93019C00076 (Y.Z. and R.H.S.).
CR Antunes RD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193382
   Pro SC, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/763461
   Cheung Y K, 2008, Hong Kong Med J, V14 Suppl 4, P27
   Cheung YK, 2007, VACCINE, V25, P6070, DOI 10.1016/j.vaccine.2007.05.025
   Chow SCS, 2006, J CLIN PATHOL, V59, P468, DOI 10.1136/jcp.2005.029868
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452
   Dhanda SK, 2018, BIOINFORMATICS, V34, P3931, DOI 10.1093/bioinformatics/bty463
   Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090
   Grifoni A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01309
   Guo JP, 2004, VIROLOGY, V324, P251, DOI 10.1016/j.virol.2004.04.017
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kohyama S, 2009, ANTIVIR RES, V84, P168, DOI 10.1016/j.antiviral.2009.09.004
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2015, J IMMUNOL, V194, P6164, DOI 10.4049/jimmunol.1403074
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Sette A, 2008, IMMUNITY, V28, P847, DOI 10.1016/j.immuni.2008.04.018
   Shichijo S, 2004, TISSUE ANTIGENS, V64, P600, DOI 10.1111/j.1399-0039.2004.00314.x
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Tian Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02125
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yang JB, 2009, INT IMMUNOL, V21, P63, DOI 10.1093/intimm/dxn124
   Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254
NR 38
TC 146
Z9 148
U1 12
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD APR 8
PY 2020
VL 27
IS 4
BP 671
EP +
DI 10.1016/j.chom.2020.03.002
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA LD0PO
UT WOS:000525735600020
PM 32183941
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Carr, AC
AF Carr, Anitra C.
TI A new clinical trial to test high-dose vitamin C in patients with
   COVID-19
SO CRITICAL CARE
LA English
DT Letter
C1 [Carr, Anitra C.] Univ Otago, Dept Pathol & Biomed Sci, POB 4345, Christchurch 8140, New Zealand.
RP Carr, AC (corresponding author), Univ Otago, Dept Pathol & Biomed Sci, POB 4345, Christchurch 8140, New Zealand.
EM anitra.carr@otago.ac.nz
FU Health Research Council of New Zealand Sir Charles Hercus Health
   Research Fellowship
FX ACC is the recipient of a Health Research Council of New Zealand Sir
   Charles Hercus Health Research Fellowship.
CR Carr AC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1891-y
   Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
   Kim WY, 2018, J CRIT CARE, V47, P211, DOI 10.1016/j.jcrc.2018.07.004
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 5
TC 45
Z9 46
U1 4
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD APR 7
PY 2020
VL 24
IS 1
AR 133
DI 10.1186/s13054-020-02851-4
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA LD8DV
UT WOS:000526259200001
PM 32264963
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, ES
   Chin, BS
   Kang, CK
   Kim, NJ
   Kang, YM
   Choi, JP
   Oh, DH
   Kim, JH
   Koh, B
   Kim, SE
   Yun, NR
   Lee, JH
   Kim, JY
   Kim, Y
   Bang, JH
   Song, KH
   Kim, HB
   Chung, KH
   Oh, MD
AF Kim, Eu Suk
   Chin, Bum Sik
   Kang, Chang Kyung
   Kim, Nam Joong
   Kang, Yu Min
   Choi, Jae-Phil
   Oh, Dong Hyun
   Kim, Jeong-Han
   Koh, Boram
   Kim, Seong Eun
   Yun, Na Ra
   Lee, Jae-Hoon
   Kim, Jin Yong
   Kim, Yeonjae
   Bang, Ji Hwan
   Song, Kyoung-Ho
   Kim, Hong Bin
   Chung, Ki-Hyun
   Oh, Myoung-don
CA Korea Natl Comm Clinical Managemen
TI Clinical Course and Outcomes of Patients with Severe Acute Respiratory
   Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28
   Patients from the Korean Cohort Study on COVID-19
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Viral Pneumonia; Prognosis; Cohort Study; Republic
   of Korea
ID VIRAL LOAD; PNEUMONIA; OUTBREAK
AB Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pneumonia emerged in Wuhan, China in December 2019. In this retrospective multicenter study, we investigated the clinical course and outcomes of novel coronavirus disease 2019 (COVID-19) from early cases in Republic of Korea.
   Methods: All of the cases confirmed by real time polymerase chain reaction were enrolled from the 1st to the 28th patient nationwide. Clinical data were collected and analyzed for changes in clinical severity including laboratory, radiological, and virologic dynamics during the progression of illness.
   Results: The median age was 40 years (range, 20-73 years) and 15 (53.6%) patients were male. The most common symptoms were cough (28.6 0 /0) and sore throat (28.6%), followed by fever (25.0%). Diarrhea was not common (10.7 0 /0). Two patients had no symptoms. Initial chest X-ray (CXR) showed infiltration in 46.4% of the patients, but computed tomography scan confirmed pneumonia in 88.9% (16/18) of the patients. Six patients (21.4%) required supplemental oxygen therapy, but no one needed mechanical ventilation. Lymphopenia was more common in severe cases. Higher level of C-reactive protein and worsening of chest radiographic score was observed during the 5-7 day period after symptom onset. Viral shedding was high from day 1 of illness, especially from the tipper respiratory tract (URT).
   Conclusion: The prodromal symptoms of COVID-19 were mild and most patients did not have limitations of daily activity. Viral shedding from URT was high from the prodromal phase. Radiological pneumonia was common from the early days of illness, but it was frequently not evident in simple CXR. These findings could be plausible explanations for the easy and rapid spread of SARS-CoV-2 in the community.
C1 [Kim, Eu Suk; Song, Kyoung-Ho; Kim, Hong Bin] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea.
   [Chin, Bum Sik; Kim, Yeonjae] Natl Med Ctr, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Kang, Chang Kyung; Kim, Nam Joong; Oh, Myoung-don] Seoul Natl Univ, Dept Internal Med, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea.
   [Kang, Yu Min] Myongji Hosp, Dept Infect Dis, Goyang, South Korea.
   [Choi, Jae-Phil; Oh, Dong Hyun] Seoul Med Ctr, Dept Internal Med, Seoul, South Korea.
   [Kim, Jeong-Han] Armed Forces Capital Hosp, Dept Internal Med, Div Infect Dis, Seongnam, South Korea.
   [Koh, Boram] Ansung Hosp, Dept Internal Med, Gyeonggi Prov Med Ctr, Anseong, South Korea.
   [Kim, Seong Eun] Chonnam Natl Univ, Dept Infect Dis, Med Sch, Gwangju, South Korea.
   [Yun, Na Ra] Chosun Univ, Coll Med, Dept Internal Med, Gwangju, South Korea.
   [Lee, Jae-Hoon] Wonkwang Univ, Dept Internal Med, Sch Med, Iksan, South Korea.
   [Kim, Jin Yong] Incheon Med Ctr, Dept Internal Med, Div Infect Dis, Incheon, South Korea.
   [Bang, Ji Hwan] Seoul Natl Univ, Div Infect Dis, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea.
   [Chung, Ki-Hyun] Natl Med Ctr, Dept Pediat, Seoul, South Korea.
RP Oh, MD (corresponding author), Seoul Natl Univ, Dept Internal Med, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea.
EM mdohmd@snu.ac.kr
RI Oh, Dong Hyun/AAO-8832-2020
OI Oh, Dong Hyun/0000-0002-9990-6042; Kim, Seong Eun/0000-0003-0162-6155;
   Chin, Bum Sik/0000-0003-3021-1434; Choi, jae-phil/0000-0003-4805-7930;
   Kang, Chang Kyung/0000-0003-1952-072X; Kang, Yu Min/0000-0002-4368-9878
FU National Health Promotion Fund [2740-309-320-01]; Ministry of Health and
   WelfareMinistry of Health, Labour and Welfare, Japan
FX This study was supported by National Health Promotion Fund
   (#2740-309-320-01) of Ministry of Health and Welfare.
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   COVID-19 National Emergency Response Center Epidemiology and Case Management Team Korea Centers for Disease Control and Prevention, 2020, Osong Public Health Res Perspect, V11, P8, DOI 10.24171/j.phrp.2020.11.1.03
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Seo JH, 2020, MATER RES LETT, V8, P123, DOI 10.1080/21663831.2020.1718231
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, GLOB COVID 19 CLIN C
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 24
TC 65
Z9 67
U1 4
U2 16
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD APR 6
PY 2020
VL 35
IS 13
AR e142
DI 10.3346/jkms.2020.35.e142
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA LA0QF
UT WOS:000523661000008
PM 32242348
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Canarutto, D
   Priolo, A
   Russo, G
   Pitea, M
   Vigone, MC
   Barera, G
AF Canarutto, Daniele
   Priolo, Alessio
   Russo, Gianni
   Pitea, Marco
   Vigone, Maria Cristina
   Barera, Graziano
TI COVID-19 infection in a paucisymptomatic infant: Raising the index of
   suspicion in epidemic settings
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE coronavirus; coronavirus disease 19; COVID-19; epidemic; epidemiology;
   infant; paediatric; SARS-CoV-2; severe acute respiratory syndrome
   coronavirus 2; viral infections
AB Few children have been reported to have been affected by novel coronavirus disease 2019 (COVID-19); it is unclear whether children are less likely to be infected or rather display fewer symptoms. We present the case of a 32-day-old boy infected by COVID-19 that presented with an upper air way infection which resolved spontaneously and did not require any therapy. We argue that in epidemic settings children presenting with any mild symptom potentially attributable to COVID-19 should be considered contagious until proven otherwise, and that management must be guided by clinical conditions.
C1 [Canarutto, Daniele; Priolo, Alessio] Univ Vita Salute San Raffaele, Fac Med & Surg, Via Olgettina 58, I-20132 Milan, Italy.
   [Canarutto, Daniele] IRCCS San Raffaele Sci Inst, Pediat Immunohematol Unit, Milan, Italy.
   [Canarutto, Daniele] IRCCS San Raffaele Sci Inst, BMT Program, Milan, Italy.
   [Russo, Gianni; Pitea, Marco; Vigone, Maria Cristina; Barera, Graziano] IRCCS San Raffaele Sci Inst, Dept Paediat, Milan, Italy.
RP Canarutto, D (corresponding author), Univ Vita Salute San Raffaele, Fac Med & Surg, Via Olgettina 58, I-20132 Milan, Italy.
EM d.canarutto@gmail.com
RI barera, graziano/AAN-5041-2020
OI , Daniele/0000-0001-6999-8479
CR Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Liu W, 2020, P I MECH ENG C-J MEC, V234, P1689, DOI 10.1177/0954406219899691
   Wu Z, 2020, JAMA
   Xia W, 2020, PEDIAT PULMONOL
   Zhou F., 2020, LANCET
NR 5
TC 10
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD JUN
PY 2020
VL 55
IS 6
BP E4
EP E5
DI 10.1002/ppul.24754
EA APR 2020
PG 2
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA LL1MB
UT WOS:000523700700001
PM 32250049
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Luzi, L
   Radaelli, MG
AF Luzi, Livio
   Radaelli, Maria Grazia
TI Influenza and obesity: its odd relationship and the lessons for COVID-19
   pandemic
SO ACTA DIABETOLOGICA
LA English
DT Article
DE Obese subjects; COVID-19; Influenza; Immune-modulation
ID HUMAN ADENOVIRUS-36; METABOLIC SYNDROME; VIRUS; INFLAMMATION; EXERCISE;
   RECEPTOR; TRENDS; MICE
AB Aims Analyze the relationship between obesity and influenza. Methods Basal hormone milieu, defective response of both innate and adaptive immune system and sedentariness are major determinants in the severity of influenza viral infection in obese patients. Being overweight not only increases the risk of infection and of complications for the single obese person, but a large prevalence of obese individuals within the population might increase the chance of appearance of more virulent viral strain, prolongs the virus shedding throughout the total population and eventually might increase overall mortality rate of an influenza pandemic. Results Waiting for the development of a vaccination against COVID-19, isolation of positive cases and social distancing are the primary interventions. Nonetheless, evidence from previous influenza pandemics suggests the following interventions aimed at improving immune response: (1) lose weight with a mild caloric restriction; (2) include AMPK activators and PPAR gamma activators in the drug treatment for obesity associated with diabetes; and (3) practice mild-to-moderate physical exercise. Conclusions Due to prolonged viral shedding, quarantine in obese subjects should likely be longer than normal weight individuals.
C1 [Luzi, Livio; Radaelli, Maria Grazia] IRCCS MultiMed, Dept Endocrinol Nutr & Metab Dis, Milan, Italy.
   [Luzi, Livio] Univ Milan, Dept Biomed Sci & Hlth, Milan, Italy.
RP Luzi, L (corresponding author), IRCCS MultiMed, Dept Endocrinol Nutr & Metab Dis, Milan, Italy.
EM livio.luzi@multimedica.it
FU Italian Ministry of Health-Ricerca Corrente-IRCCS Multimedica
FX We thank Ms. K. Biasi for English language revision. This work was
   supported by Italian Ministry of Health-Ricerca Corrente-IRCCS
   Multimedica.
CR Ahn SY, 2015, ENVIRON TOXICOL PHAR, V40, P924, DOI 10.1016/j.etap.2015.09.020
   Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207
   Atkinson RL, 2005, INT J OBESITY, V29, P281, DOI 10.1038/sj.ijo.0802830
   Caspard H, 2018, DIABETES OBES METAB, V20, P667, DOI 10.1111/dom.13143
   Codella R, 2015, EUR REV MED PHARMACO, V19, P3709
   Constantin-Teodosiu D, 2013, DIABETES METAB J, V37, P301, DOI 10.4093/dmj.2013.37.5.301
   Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/ERI.11.56, 10.1586/eri.11.56]
   Diaz A, 2017, VACCINE, V35, P2694, DOI 10.1016/j.vaccine.2017.03.078
   Hagman E, 2019, ACTA DIABETOL, V56, P219, DOI 10.1007/s00592-018-01285-3
   Honce R, 2020, MBIO, V11, DOI 10.1128/mBio.03341-19
   Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071
   Karlsson EA, 2016, MBIO, V7, DOI 10.1128/mBio.01144-16
   Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354
   Lee AM, 2017, ACTA DIABETOL, V54, P373, DOI 10.1007/s00592-016-0958-6
   Maier HE, 2018, J INFECT DIS, V218, P1378, DOI 10.1093/infdis/jiy370
   Milano Cities Changing Diabetes Atlas, 2020, DIAB TIP 2 OB AR MIL
   Morgan OW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009694
   Moseley CE, 2010, INFLUENZA OTHER RESP, V4, P307, DOI 10.1111/j.1750-2659.2010.00155.x
   Moser JAS, 2019, INFLUENZA OTHER RESP, V13, P3, DOI 10.1111/irv.12618
   Na HN, 2012, J INFECT DIS, V205, P914, DOI 10.1093/infdis/jir864
   O'Brien KB, 2012, J INFECT DIS, V205, P252, DOI 10.1093/infdis/jir729
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101
   Pasarica M, 2006, OBESITY, V14, P1905, DOI 10.1038/oby.2006.222
   Reidy PT, 2019, ACTA PHYSIOL, V226, DOI 10.1111/apha.13251
   Richard C, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000379
   Ritter JB, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-61
   Roser M, 2020, CORONAVIRUS DIS COVI
   Senesi P, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/8274689
   Short KR, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00343
   Spreghini N, 2019, ACTA DIABETOL, V56, P955, DOI 10.1007/s00592-019-01303-y
   Vangipuram SD, 2007, INT J OBESITY, V31, P87, DOI 10.1038/sj.ijo.0803366
   Vangipuram SD, 2004, OBES RES, V12, P770, DOI 10.1038/oby.2004.93
   Warren KJ, 2015, PLOS ONE, V25, P1
   Wong GCL, 2019, EXERC IMMUNOL REV, V25, P48
   Xue KS, 2017, ELIFE, V6, DOI [10.7554/elife.26875, 10.7554/eLife.26875]
   Yamane K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098032
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yang L, 2013, PREV MED, V56, P118, DOI 10.1016/j.ypmed.2012.11.017
   Zhang AJX, 2013, J INFECT DIS, V207, P1270, DOI 10.1093/infdis/jit031
   Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008
   Zheng QS, 2015, CELL PHYSIOL BIOCHEM, V37, P735, DOI 10.1159/000430391
NR 42
TC 75
Z9 76
U1 7
U2 28
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0940-5429
EI 1432-5233
J9 ACTA DIABETOL
JI Acta Diabetol.
PD JUN
PY 2020
VL 57
IS 6
BP 759
EP 764
DI 10.1007/s00592-020-01522-8
EA APR 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA LN1TP
UT WOS:000523578300001
PM 32249357
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Bardazzi, F
   Loi, C
   Sacchelli, L
   Di Altobrando, A
AF Bardazzi, Federico
   Loi, Camilla
   Sacchelli, Lidia
   Di Altobrando, Ambra
TI Biologic therapy for psoriasis during the covid-19 outbreak is not a
   choice
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Letter; Early Access
ID INFECTION; PATIENT
C1 [Bardazzi, Federico; Loi, Camilla; Sacchelli, Lidia; Di Altobrando, Ambra] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
RP Di Altobrando, A (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
EM ambra.dialtobrando@studio.unibo.it
OI Di Altobrando, Ambra/0000-0003-3236-8822
CR American Academy of Dermatology Association, GUID US BIOL AG COVI
   Bardazzi F, 2017, ACTA DERM-VENEREOL, V97, P989, DOI 10.2340/00015555-2698
   Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Deodhar A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1882-2
   Italian Group for the study of Inflammatory Bowel Disease, AVV PAZ CON MICI
   Kaushik SB, 2019, J AM ACAD DERMATOL, V80, P43, DOI 10.1016/j.jaad.2018.06.056
   Kling MC, 2010, ARCH DERMATOL, V146, P651, DOI 10.1001/archdermatol.2010.96
   Magnano M, 2017, DERMATOL THER, V30, DOI 10.1111/dth.12476
   Menter A, 2019, J AM ACAD DERMATOL, V80, P1029, DOI 10.1016/j.jaad.2018.11.057
   Odorici G, 2019, J EUR ACAD DERMATOL, V33, pE453, DOI 10.1111/jdv.15775
   Riassunto delle caratteristiche del prodotto, 2019, RIASSUNTO CARATTERIS
   Serrato VA, 2013, CLIN RHEUMATOL, V32, pS21, DOI 10.1007/s10067-010-1415-5
   SIDeMaST, 2020, INF COR VAD PAZ AFF
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 16
TC 10
Z9 11
U1 2
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1749545
EA APR 2020
PG 2
WC Dermatology
SC Dermatology
GA LA0UN
UT WOS:000523672200001
PM 32248724
DA 2021-01-01
ER

PT J
AU Land, WG
AF Land, Walter Gottlieb
TI Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of
   Caution
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Article
ID MYOCARDIAL-INFARCTION; MOLECULAR-PATTERNS; RESOLVIN D1; MACROPHAGE
   POLARIZATION; POSTINJURY INFLAMMATION; PROMOTE RESOLUTION; INNATE
   IMMUNITY; EMERGING ROLE; DANGER; MEDIATORS
AB This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.
C1 [Land, Walter Gottlieb] Univ Strasbourg, Lab Excellence Transplantex, INSERM UMR S1109, Mol ImmunoRheumatol, Strasbourg, France.
   [Land, Walter Gottlieb] German Acad Transplantat Med, Munich, Germany.
RP Land, WG (corresponding author), Univ Strasbourg, Lab Excellence Transplantex, INSERM UMR S1109, Mol ImmunoRheumatol, Strasbourg, France.; Land, WG (corresponding author), German Acad Transplantat Med, Munich, Germany.
EM land.w.damps@gmail.com
OI Land, Walter Gottlieb/0000-0002-0090-0629
CR Ahn J, 2018, CANCER CELL, V33, P862, DOI 10.1016/j.ccell.2018.03.027
   Andersson U, 2018, EXPERT OPIN THER TAR, V22, P263, DOI 10.1080/14728222.2018.1439924
   Ansari J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041211
   Brennan EP, 2019, CLIN SCI, V133, P2121, DOI 10.1042/CS20190067
   Bresnick Anne R, 2018, Biophys Rev, V10, P1617, DOI 10.1007/s12551-018-0471-y
   Chiurchiu V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7483
   Conte MS, 2018, J CLIN INVEST, V128, P3727, DOI 10.1172/JCI97947
   Dalli J, 2017, MOL ASPECTS MED, V58, P12, DOI 10.1016/j.mam.2017.03.007
   Dalli J, 2017, CRIT CARE MED, V45, P58, DOI 10.1097/CCM.0000000000002014
   Dalli J, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0001-2014
   Dalli J, 2013, FASEB J, V27, P2573, DOI 10.1096/fj.13-227728
   Dalli J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01940
   Dalli J, 2012, BLOOD, V120, pE60, DOI 10.1182/blood-2012-04-423525
   Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968
   Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247
   Dubois C, 2019, SCI REP, P9
   Fosshaug LE, 2019, EBIOMEDICINE, V46, P264, DOI 10.1016/j.ebiom.2019.07.024
   Frangogiannis NG, 2019, MOL ASPECTS MED, V65, P70, DOI 10.1016/j.mam.2018.07.001
   Frangogiannis NG, 2012, CIRC RES, V110, P159, DOI 10.1161/CIRCRESAHA.111.243162
   Fukami A, 2009, METABOLISM, V58, P1688, DOI 10.1016/j.metabol.2009.05.024
   Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588
   Garg AD, 2015, INT J DEV BIOL, V59, P131, DOI 10.1387/ijdb.150061pa
   Garg AD, 2013, BIOFACTORS, V39, P355, DOI 10.1002/biof.1125
   Garg AD, 2012, ONCOIMMUNOLOGY, V1, P786, DOI 10.4161/onci.19750
   Gashaw I, 2012, DRUG DISCOV TODAY, V17, pS24, DOI 10.1016/j.drudis.2011.12.008
   Gong XJ, 2015, EUR REV MED PHARMACO, V19, P2221
   Gruda MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191676
   Halade GV, 2019, ADV EXP MED BIOL, V1161, P45, DOI 10.1007/978-3-030-21735-8_6
   Hayashi T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02619
   He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026
   Heil M, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00578
   Herova M, 2015, J IMMUNOL, V194, P2330, DOI 10.4049/jimmunol.1402166
   Imming P, 2006, NAT REV DRUG DISCOV, V5, P821, DOI 10.1038/nrd2132
   Khodarev NN, 2019, INT REV CEL MOL BIO, V344, P31, DOI 10.1016/bs.ircmb.2018.08.005
   Kooij G, 2019, HAEMATOLOGICA, DOI 10.3324/haematol.2019.219519
   Krenning G, 2010, J CELL PHYSIOL, V225, P631, DOI 10.1002/jcp.22322
   Krishnamoorthy N, 2015, J IMMUNOL, V194, P863, DOI 10.4049/jimmunol.1402534
   Kutzner L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00169
   Kytikova O, 2019, MED MDPI AG
   Lacerda JZ, 2018, FRONT PHARMACOL, V2018, P9
   Lamparello AJ, 2019, J INTERN MED, V286, P2, DOI 10.1111/joim.12874
   LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010
   Land W, 2003, TRANSPLANT REV, P67, DOI [10.1016/S0955-470X(02)00009-5, DOI 10.1016/S0955-470X(02)00009-5]
   Land WG, 2016, AM J TRANSPLANT, V16, P3322, DOI 10.1111/ajt.14012
   Land WG, 2013, ELSE KRONER FRESEN S, V4, P24, DOI 10.1159/000346531
   Land WG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00349
   Land WG, 2012, TRANSPLANT REV-ORLAN, V26, P73, DOI 10.1016/j.trre.2011.02.003
   Land WG, 2012, TRANSPLANT REV-ORLAN, V26, P88, DOI 10.1016/j.trre.2011.07.001
   Land WG, 2018, DAMAGE ASSOCIATED MO
   Leuti A, 2019, OXID MED CELL LONGEV, V2019, P1
   Li Y, 2011, ONCOGENE, V30, P3887, DOI 10.1038/onc.2011.112
   Liaudet Lucas, 2013, Front Biosci (Schol Ed), V5, P86
   Lioy PJ, 2013, ENVIRON HEALTH PERSP, V121, P405, DOI 10.1289/ehp.1206170
   Lundback P, 2016, HEPATOLOGY, V64, P1699, DOI 10.1002/hep.28736
   Luo BW, 2016, J NEUROSCI, V36, P9590, DOI 10.1523/JNEUROSCI.0020-16.2016
   Machado MG, 2020, FASEB J, V34, P2749, DOI 10.1096/fj.201902172R
   Manrai AK, 2017, ANNU REV PUBL HEALTH, V38, P279, DOI 10.1146/annurev-publhealth-082516-012737
   Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Matzinger P, 2012, EXPERT REV CLIN IMMU, V8, P311, DOI [10.1586/eci.12.21, 10.1586/ECI.12.21]
   McIlroy DJ, 2018, J TRAUMA ACUTE CARE, V85, P354, DOI 10.1097/TA.0000000000001919
   Meddeb R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41593-4
   Nanini HF, 2018, WORLD J GASTROENTERO, V24, P4622, DOI 10.3748/wjg.v24.i41.4622
   Powell BS, 2015, CLIN EXP VACCINE RES, V4, P23, DOI 10.7774/cevr.2015.4.1.23
   Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577
   Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603
   Recchiuti A, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00252
   Relja B, 2020, EUR J TRAUMA EMERG S, V46, P751, DOI 10.1007/s00068-019-01235-w
   Rischpler C, 2016, Q J NUCL MED MOL IM, V60, P236
   Rius B, 2014, FASEB J, V28, P836, DOI 10.1096/fj.13-235614
   Rosenberg JH, 2017, MOL CELL BIOCHEM, V434, P171, DOI 10.1007/s11010-017-3047-4
   Rothammer A, 2019, RADIAT ONCOL, P14
   Sauaia A, 2017, CRIT CARE CLIN, V33, P167, DOI 10.1016/j.ccc.2016.08.006
   Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05800-6
   Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943
   Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]
   Shah MH, 2020, CARDIOVASC DRUG THER, V34, P123, DOI 10.1007/s10557-020-06946-6
   Shinde AV, 2014, J MOL CELL CARDIOL, V70, P74, DOI 10.1016/j.yjmcc.2013.11.015
   Tajbakhsh A, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106134
   Talman V, 2016, CELL TISSUE RES, V365, P563, DOI 10.1007/s00441-016-2431-9
   Tang YT, 2016, ANTIOXID REDOX SIGN, V24, P620, DOI 10.1089/ars.2015.6409
   Titos E, 2011, J IMMUNOL, V187, P5408, DOI 10.4049/jimmunol.1100225
   Tsai WH, 2013, J CHIN MED ASSOC, V76, P486, DOI 10.1016/j.jcma.2013.05.004
   Uppal K, 2016, CHEM RES TOXICOL, V29, P1956, DOI 10.1021/acs.chemrestox.6b00179
   van den Borne SWM, 2010, NAT REV CARDIOL, V7, P30, DOI 10.1038/nrcardio.2009.199
   van Hout GPJ, 2016, EXPERT OPIN THER TAR, V20, P223, DOI 10.1517/14728222.2016.1088005
   VanPatten S, 2018, J MED CHEM, V61, P5093, DOI 10.1021/acs.jmedchem.7b01136
   Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031
   Vijayakumar EC, 2019, CURR DRUG TARGETS, V20, P1474, DOI 10.2174/1389450120666190618125100
   Wang G, 2020, NAT COMMUN NATURE RE, V2020, P11
   Wang L, 2015, CORONARY ARTERY DIS, V26, P296, DOI 10.1097/MCA.0000000000000231
   Wiesmann M, 1998, CLIN CHEM, V44, P1056
   Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055
   Wilson SH, 2006, ENVIRON HEALTH PERSP, V114, pA398, DOI 10.1289/ehp.114-a398
   Wong WE, 2018, PROC FRONT EDUC CONF
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Yin P, 2019, FRONT CELL NEUROSCI, V2019, P13
   Zheng CJ, 2006, PHARMACOL REV, V58, P259, DOI 10.1124/pr.58.2.4
NR 98
TC 3
Z9 3
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PD JUN
PY 2020
VL 24
IS 3
BP 251
EP 262
DI 10.1007/s40291-020-00460-z
EA APR 2020
PG 12
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA LT4QW
UT WOS:000524198800001
PM 32248387
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Szperka, CL
   Ailani, J
   Barmherzig, R
   Klein, BC
   Minen, MT
   Singh, RBH
   Shapiro, RE
AF Szperka, Christina L.
   Ailani, Jessica
   Barmherzig, Rebecca
   Klein, Brad C.
   Minen, Mia T.
   Singh, Rashmi B. Halker
   Shapiro, Robert E.
TI Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to
   Insurers
SO HEADACHE
LA English
DT Article
DE migraine; COVID-19; treatment; telemedicine
ID DOUBLE-BLIND; RANDOMIZED-TRIAL; PROPHYLACTIC TREATMENT; PREVENTIVE
   TREATMENT; AMERICAN ACADEMY; RESCUE THERAPY; NASAL SPRAY; EFFICACY;
   PLACEBO; HEADACHE
AB Objective To outline strategies for the treatment of migraine which do not require in-person visits to clinic or the emergency department, and to describe ways that health insurance companies can remove barriers to quality care for migraine.
   Background COVID-19 is a global pandemic causing widespread infections and death. To control the spread of infection we are called to observe "social distancing" and we have been asked to postpone any procedures which are not essential. Since procedural therapies are a mainstay of headache care, the inability to do procedures could negatively affect our patients with migraine. In this manuscript we review alternative therapies, with particular attention to those which may be contra-indicated in the setting of COVID-19 infection.
   Design/Results The manuscript reviews the use of telemedicine visits and acute, bridge, and preventive therapies for migraine. We focus on evidence-based treatment where possible, but also describe "real world" strategies which may be tried. In each section we call out areas where changes to rules from commercial health insurance companies would facilitate better migraine care.
   Conclusions Our common goal as health care providers is to maximize the health and safety of our patients. Successful management of migraine with avoidance of in-person clinic and emergency department visits further benefits the current urgent societal goal of maintaining social distance to contain the COVID-19 pandemic.
C1 [Szperka, Christina L.; Barmherzig, Rebecca] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.
   [Szperka, Christina L.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
   [Szperka, Christina L.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Ailani, Jessica] Medstar Georgetown Univ Hosp, Dept Neurol, Washington, DC USA.
   [Klein, Brad C.] Abington Neurol Associates Ltd, Abington, PA USA.
   [Klein, Brad C.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
   [Minen, Mia T.] NYU Langone Hlth, Dept Neurol, New York, NY USA.
   [Minen, Mia T.] NYU Langone Hlth, Dept Populat Hlth, New York, NY USA.
   [Singh, Rashmi B. Halker] Mayo Clin, Dept Neurol, Phoenix, AZ USA.
   [Shapiro, Robert E.] Univ Vermont, Larner Coll Med, Dept Neurol Sci, Burlington, VA USA.
RP Szperka, CL (corresponding author), CHOP Neurol, 10th Floor,CTRB,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM szperka@email.chop.edu
FU NCCIH NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Complementary &
   Alternative Medicine [K23 AT009706] Funding Source: Medline; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [K23 NS102521] Funding Source: Medline
CR Ashina M, 2020, CEPHALALGIA, V40, P241, DOI 10.1177/0333102420905132
   Bhambri R, 2015, INT J GEN MED, V8, P27, DOI 10.2147/IJGM.S73673
   Bigal ME, 2002, J EMERG MED, V23, P141, DOI 10.1016/S0736-4679(02)00502-4
   Bozkurt B, HFSA ACC AHA STATEME
   Brandes JL, 2009, CEPHALALGIA, V29, P1133, DOI 10.1111/j.1468-2982.2009.01840.x
   Burch RC, 2019, NEUROL CLIN, V37, P631, DOI 10.1016/j.ncl.2019.06.001
   Chou DE, 2019, CEPHALALGIA, V39, P3, DOI 10.1177/0333102418811573
   Chung JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/891348
   Detke HC, 2018, NEUROLOGY, V91, pE2211, DOI 10.1212/WNL.0000000000006640
   Dodick DW, 2019, NEW ENGL J MED, V381, P2230, DOI 10.1056/NEJMoa1813049
   Dodick DW, 2019, CEPHALALGIA, V39, P1075, DOI 10.1177/0333102419858355
   Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853
   Dodick DW, 2018, CEPHALALGIA, V38, P1026, DOI 10.1177/0333102418759786
   Dorosch T, 2019, CURR PAIN HEADACHE R, V23, DOI 10.1007/s11916-019-0823-8
   Duffy S, 2018, NEW ENGL J MED, V378, P104, DOI 10.1056/NEJMp1710735
   Ebrahimi-Monfared M, 2017, RESTOR NEUROL NEUROS, V35, P385, DOI 10.3233/RNN-160704
   Bermejo PE, 2009, CLIN NEUROPHARMACOL, V32, P103, DOI 10.1097/WNF.0b013e318170577f
   Food and Drug Administration, FDA ADV PAT US NONST
   Goadsby PJ, 2019, BRAIN, V142, P1894, DOI 10.1093/brain/awz134
   Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848
   Goncalves AL, 2016, J NEUROL NEUROSUR PS, V87, P1127, DOI 10.1136/jnnp-2016-313458
   Halker RB, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0397-2
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   HOFFERT M, 1995, HEADACHE, V35, P177
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Jackson JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130733
   JONES EB, 1994, ANN EMERG MED, V24, P237, DOI 10.1016/S0196-0644(94)70135-0
   Kelley NE, 2012, HEADACHE, V52, P467, DOI 10.1111/j.1526-4610.2012.02097.x
   Kelley NE, 2012, HEADACHE, V52, P292, DOI 10.1111/j.1526-4610.2011.02070.x
   Kuca B, 2018, NEUROLOGY, V91, pE2222, DOI 10.1212/WNL.0000000000006641
   Lacktman NM, 50 STATE SURVEY TELE
   Lipton RB, 2019, NEW ENGL J MED, V381, P142, DOI 10.1056/NEJMoa1811090
   Lipton RB, 2010, LANCET NEUROL, V9, P373, DOI 10.1016/S1474-4422(10)70054-5
   Maizels Morris, 1999, Headache, V39, P543, DOI 10.1046/j.1526-4610.1999.3908543.x
   Mannix LK, 2007, HEADACHE, V47, P1037, DOI 10.1111/j.1526-4610.2007.00855.x
   Marmura MJ, 2015, HEADACHE, V55, P3, DOI 10.1111/head.12499
   MATHEW NT, 1995, ARCH NEUROL-CHICAGO, V52, P281, DOI 10.1001/archneur.1995.00540270077022
   McCormack PL, 2005, PHARMACOECONOMICS, V23, P1283, DOI 10.2165/00019053-200523120-00011
   Mohammadianinejad SE, 2011, CLIN NEUROPHARMACOL, V34, P174, DOI 10.1097/WNF.0b013e318225140c
   Muller KI, 2017, CEPHALALGIA, V37, P855, DOI 10.1177/0333102416654885
   Muller KI, 2017, NEUROLOGY, V89, P153, DOI 10.1212/WNL.0000000000004085
   Qubty W, 2018, NEUROLOGY, V90, pE1702, DOI 10.1212/WNL.0000000000005482
   Rao AS, 2016, HEADACHE, V56, P331, DOI 10.1111/head.12767
   Robbins MS, 2016, HEADACHE, V56, P240, DOI 10.1111/head.12729
   Schmidt M, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3426
   Schrader H, 2001, BMJ-BRIT MED J, V322, P19, DOI 10.1136/bmj.322.7277.19
   Schuh-Hofer S, 2007, EUR J NEUROL, V14, P701, DOI 10.1111/j.1468-1331.2007.01764.x
   Sheftell FD, 1999, HEADACHE, V39, P506, DOI 10.1046/j.1526-4610.1999.3907506.x
   Silberstein SD, 2012, NEUROLOGY, V78, P1337, DOI 10.1212/WNL.0b013e3182535d20
   Silberstein SD, 2017, NEW ENGL J MED, V377, P2113, DOI 10.1056/NEJMoa1709038
   Simpson DM, 2016, NEUROLOGY, V86, P1818, DOI 10.1212/WNL.0000000000002560
   Singh RBH, 2019, HEADACHE, V59, P33, DOI 10.1111/head.13586
   Skljarevski V, 2018, CEPHALALGIA, V38, P1442, DOI 10.1177/0333102418779543
   Stauffer VL, 2018, JAMA NEUROL, V75, P1080, DOI 10.1001/jamaneurol.2018.1212
   Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI 10.1016/S1474-4422(18)30322-3
   Sussman M, 2018, CEPHALALGIA, V38, P1644, DOI 10.1177/0333102418796842
   Szperka CL, 2017, AM HEAD SOC 59 ANN S
   Tassorelli C, 2018, NEUROLOGY, V91, pE364, DOI 10.1212/WNL.0000000000005857
   Tepper S, 2017, LANCET NEUROL, V16, P425, DOI 10.1016/S1474-4422(17)30083-2
   Tronvik E, 2003, JAMA-J AM MED ASSOC, V289, P65, DOI 10.1001/jama.289.1.65
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   Wootton R, 2012, J TELEMED TELECARE, V18, P211, DOI 10.1258/jtt.2012.120219
   World Health Organization, 2020, COULD IB WORS DIS PE
   Yarnitsky D, 2019, HEADACHE, V59, P1240, DOI 10.1111/head.13551
NR 64
TC 20
Z9 21
U1 0
U2 70
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD MAY
PY 2020
VL 60
IS 5
BP 833
EP 842
DI 10.1111/head.13810
EA APR 2020
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA LH1HJ
UT WOS:000523235300001
PM 32227596
OA Green Published, Bronze, Green Accepted
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Dong, YH
   Wang, LP
   Burgner, DP
   Miller, JE
   Song, Y
   Ren, X
   Li, ZJ
   Xing, Y
   Ma, J
   Sawyer, SM
   Patton, GC
AF Dong, Yanhui
   Wang, Liping
   Burgner, David P.
   Miller, Jessica E.
   Song, Yi
   Ren, Xiang
   Li, Zhongjie
   Xing, Yi
   Ma, Jun
   Sawyer, Susan M.
   Patton, George C.
TI Infectious diseases in children and adolescents in China: analysis of
   national surveillance data from 2008 to 2017
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID HEPATITIS-B; SYSTEMATIC ANALYSIS; SCARLET FEVER; GLOBAL BURDEN;
   MORTALITY; PREVALENCE; TUBERCULOSIS; EPIDEMIC; HEALTH; TRENDS
AB OBJECTIVES
   To outline which infectious diseases in the precovid-19 era persist in children and adolescents in China and to describe recent trends and variations by age, sex, season, and province.
   DESIGN
   National surveillance studies, 2008-17.
   SETTING
   31 provinces in mainland China.
   PARTICIPANTS
   4 959 790 Chinese students aged 6 to 22 years with a diagnosis of any of 44 notifiable infectious diseases. The diseases were categorised into seven groups: quarantinable; vaccine preventable; gastrointestinal and enteroviral; vectorborne; zoonotic; bacterial; and sexually transmitted and bloodborne.
   MAIN OUTCOME MEASURES
   Diagnosis of, and deaths from, 44 notifiable infectious diseases.
   RESULTS
   From 2008 to 2017, 44 notifiable infectious diseases were diagnosed in 4 959 790 participants (3 045 905 males, 1 913 885 females) and there were 2532 deaths (1663 males, 869 females). The leading causes of death among infectious diseases shifted from rabies and tuberculosis to HIV/AIDS, particularly in males. Mortality from infectious diseases decreased steadily from 0.21 per 100 000 population in 2008 to 0.07 per 100 000 in 2017. Quarantinable conditions with high mortality have effectively disappeared. The incidence of notifiable infectious diseases in children and adolescents decreased from 280 per 100 000 in 2008 to 162 per 100 000 in 2015, but rose again to 242 per 100 000 in 2017, largely related to mumps and seasonal influenza. Excluding mumps and influenza, the incidence of vaccine preventable diseases fell from 96 per 100 000 in 2008 to 7 per 100 000 in 2017. The incidence of gastrointestinal and enterovirus diseases remained constant, but typhoid, paratyphoid, and dysentery continued to decline. Vectorborne diseases all declined, with a particularly noticeable reduction in malaria. Zoonotic infections remained at low incidence, but there were still unpredictable outbreaks, such as pandemic A/H1N1 2009 influenza. Tuberculosis remained the most common bacterial infection, although cases of scarlet fever doubled between 2008 and 2017. Sexually transmitted diseases and bloodborne infections increased significantly, particularly from 2011 to 2017, among which HIV/AIDS increased fivefold, particularly in males. Difference was noticeable between regions, with children and adolescents in western China continuing to carry a disproportionate burden from infectious diseases.
   CONCLUSION
   China's success in infectious disease control in the pre-covid-19 era was notable, with deaths due to infectious diseases in children and adolescents aged 6-22 years becoming rare. Many challenges remain around reducing regional inequalities, scaling-up of vaccination, prevention of further escalation of HIV/AIDS, renewed efforts for persisting diseases, and undertaking early and effective response to highly transmissible seasonal and unpredictable diseases such as that caused by the novel SARS-CoV-2 virus.
C1 [Dong, Yanhui; Song, Yi; Xing, Yi; Ma, Jun] Peking Univ, Inst Child & Adolescent Hlth, Sch Publ Hlth, Beijing 100191, Peoples R China.
   [Dong, Yanhui; Song, Yi; Xing, Yi; Ma, Jun] Natl Hlth Commiss Key Lab Reprod Hlth, Beijing 100191, Peoples R China.
   [Wang, Liping; Ren, Xiang; Li, Zhongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis Control & Prevent, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China.
   [Burgner, David P.; Miller, Jessica E.; Sawyer, Susan M.; Patton, George C.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Burgner, David P.; Miller, Jessica E.; Sawyer, Susan M.; Patton, George C.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Sawyer, Susan M.; Patton, George C.] Royal Childrens Hosp, Ctr Adolescent Hlth, Parkville, Vic, Australia.
RP Ma, J (corresponding author), Peking Univ, Inst Child & Adolescent Hlth, Sch Publ Hlth, Beijing 100191, Peoples R China.; Ma, J (corresponding author), Natl Hlth Commiss Key Lab Reprod Hlth, Beijing 100191, Peoples R China.
EM majunt@bjmu.edu.cn
RI Patton, George C/B-5246-2013
OI Patton, George C/0000-0001-5039-8326; Dong, Yanhui/0000-0003-2519-3200
FU China Ministry of Science and TechnologyMinistry of Science and
   Technology, China [2018ZX10713001]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [91846302,
   81673192]; China Scholarship CouncilChina Scholarship Council
   [201806010592]; Innovation Fund for Outstanding Doctoral Candidates of
   Peking University Health Science Centre
FX This study was supported by the China Ministry of Science and Technology
   (grant 2018ZX10713001 to LW), National Natural Science Foundation of
   China (grant 91846302 to LW and YX, and grant 81673192 to JM, and China
   Scholarship Council to YD (201806010592) as well as Innovation Fund for
   Outstanding Doctoral Candidates of Peking University Health Science
   Centre to YD. The funder of the study had no role in study design, data
   collection, data analysis, data interpretation, or writing of the
   report.
CR Alirol E, 2011, LANCET INFECT DIS, V11, P131, DOI 10.1016/S1473-3099(10)70223-1
   [Anonymous], 2018, GLOB TUB REP 2018
   [Anonymous], 2019, JOINP REGR PROGR VER
   Azzopardi PS, 2019, LANCET, V393, P1101, DOI 10.1016/S0140-6736(18)32427-9
   Chatenoud L, 2016, INT J CANCER, V138, P833, DOI 10.1002/ijc.29833
   Chen SQ, 2018, LANCET, V391, P1572, DOI 10.1016/S0140-6736(18)30499-9
   Cui AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169561
   Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477
   Guo CC, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00317
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135068
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jiao WW, 2015, TUBERCULOSIS, V95, P315, DOI 10.1016/j.tube.2015.02.041
   John Ulrich, 2015, BMC Res Notes, V8, P822, DOI 10.1186/s13104-015-1808-2
   Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q
   Koye DN, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-398
   Lamagni T, 2018, LANCET INFECT DIS, V18, P180, DOI 10.1016/S1473-3099(17)30693-X
   Li GQ, 2019, SCIENCE, V364, P711, DOI 10.1126/science.aay0799
   Li Z, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3245-0
   Li ZJ, 2017, LANCET INFECT DIS, V17, P1113, DOI 10.1016/S1473-3099(17)30579-0
   Liang XF, 2013, VACCINE, V31, pJ21, DOI 10.1016/j.vaccine.2013.08.012
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Liu YH, 2018, LANCET INFECT DIS, V18, P903, DOI 10.1016/S1473-3099(18)30231-7
   Ministry of Education of the Peoples Republic of China, 2018, ED STAT DAT CHIN STU
   Ministry of Health; Ministry of Finance, 2008, PLANS EXP NAT IMM PR
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   National Center for AIDS/ATD Control and Prevention, 2019, COR MESS AIDS PREV C
   National Health and Family Planning Commission and Ministry of Education of China, 2015, NOT EST EP NOT SYST
   National Health and Family Planning Commission of China, 2013, NOT NAT HLTH FAM PLA
   National Health Commission of China, 2015, ACT PLAN CHIN MAL EL
   National Health Commission of China, 2018, STAT B CHIN HLTH DEV
   National Health Commission of China, 2016, NOT EL MAL WORK PROG
   National Health Commission of the Peoples Republic of China, 2019, NOT NEW PROGR AIDS P
   Organization WH, 2018, WORLD HLTH STAT 2018
   Pan JH, 2019, EMERG INFECT DIS, V25, P1589, DOI 10.3201/eid2508.181212
   Park DW, 2017, EMERG INFECT DIS, V23, P658, DOI 10.3201/eid2304.160773
   Rea F, 2017, EPIDEMIOL BIOSTAT PU, V14
   Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Snow KJ, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02352-2017
   Tang WM, 2018, LANCET HIV, V5, pE611, DOI 10.1016/S2352-3018(18)30244-3
   UNESCO, 2018, INT TECHN GUID SEX E
   Wang LH, 2014, INT J INFECT DIS, V25, P122, DOI 10.1016/j.ijid.2014.04.016
   Wang LX, 2014, LANCET, V383, P2057, DOI 10.1016/S0140-6736(13)62639-2
   Wang LD, 2008, LANCET, V372, P1793, DOI 10.1016/S0140-6736(08)61358-6
   Wang LD, 2008, LANCET, V372, P1598, DOI 10.1016/S0140-6736(08)61365-3
   WHO, 2017, HEP E FACT SHEET
   Yang SG, 2017, LANCET INFECT DIS, V17, P716, DOI 10.1016/S1473-3099(17)30227-X
   Zhang HL, 2017, INT J HEALTH PLAN M, V32, P329, DOI 10.1002/hpm.2434
   Zhang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031076
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhang QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042830
   Zhang Sheng-Nian, 2002, Environ Health Prev Med, V7, P132, DOI 10.1265/ehpm.2002.132
   Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1
   Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6
NR 56
TC 0
Z9 0
U1 4
U2 18
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD APR 2
PY 2020
VL 369
AR m1043
DI 10.1136/bmj.m1043
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA LA2EV
UT WOS:000523766900001
PM 32241761
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Mummudi, N
   Tibdewal, A
   Ghosh-Laskar, S
   Agarwal, JP
AF Mummudi, Naveen
   Tibdewal, Anil
   Ghosh-Laskar, Sarbani
   Agarwal, Jai Prakash
TI COVID-19 pandemic: Radiotherapy precautions and preparedness
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Cancer; corona virus; COVID-19; radiotherapy
ID RADIATION-THERAPY; CANCER; DISASTER
AB The novel coronavirus (COVID-19) pandemic has disrupted healthcare delivery across the globe. Cancer patients are at a higher risk of acquiring this infection due to their immunosuppressed state. Timely care of patients while ensuring safety of healthcare workers is need of the hour. We list few precautionary measures that can be taken at all radiotherapy centres, during the pandemic to curb and combat the spread of this disease.
C1 [Mummudi, Naveen; Tibdewal, Anil; Ghosh-Laskar, Sarbani; Agarwal, Jai Prakash] Homi Bhabha Natl Inst, Dept Radiat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India.
RP Agarwal, JP (corresponding author), Homi Bhabha Natl Inst, Dept Radiat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India.
EM agarwaljp@tmc.gov.in
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], COR COVID 19 CANC TR
   [Anonymous], 2020, OV COVID 19 RAP GUID
   [Anonymous], COVID 19 REC INF
   [Anonymous], 2006, CAN PHA CLIN CAR GUI
   Battershill P M, 2006, Curr Oncol, V13, P119
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Dinh T-KT, 2020, ADV RAD ONCOL, DOI [10.1016/j.adro.2020.03.007, DOI 10.1016/J.ADRO.2020.03.007.]
   ESTRO, ESTRO NEWS
   Filippi AR, 2020, INT J RADIAT ONCOL, V107, P597, DOI 10.1016/j.ijrobp.2020.03.007
   Gay HA, 2019, PRACT RADIAT ONCOL, V9, P305, DOI 10.1016/j.prro.2019.03.007
   Krengli M, 2020, ADV RAD ONCOL, DOI [10.1016/j.adro.2020.03.003, DOI 10.1016/J.ADRO.2020.03.003.]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mathew AS, 2017, INDIAN J CANCER, V54, P241, DOI 10.4103/0019-509X.219599
   Ozaki A, 2018, INT J RADIAT ONCOL, V100, P845, DOI 10.1016/j.ijrobp.2017.12.285
   Papachristofilou A, 2020, ADV RADIAT ONCOL, V5, P577, DOI 10.1016/j.adro.2020.03.012
   Rivera A, 2020, ADV RADIAT ONCOL, V5, P538, DOI 10.1016/j.adro.2020.03.006
   Roach MC, 2018, INT J RADIAT ONCOL, V100, P836, DOI 10.1016/j.ijrobp.2017.11.001
   Simcock R, 2020, CLIN TRANSL RAD ONCO, V22, P55, DOI 10.1016/j.ctro.2020.03.009
   Udwadia Zarir F, 2020, Med J Armed Forces India, V76, P128, DOI 10.1016/j.mjafi.2020.03.009
   Wu S, 2020, ADV RADIAT ONCOL, V5, P531, DOI 10.1016/j.adro.2020.03.004
   Yom SS, 2018, INT J RADIAT ONCOL, V100, P838, DOI 10.1016/j.ijrobp.2017.12.008
   Yom SS, 2018, INT J RADIAT ONCOL, V100, P832, DOI 10.1016/j.ijrobp.2017.12.001
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD APR-JUN
PY 2020
VL 16
IS 3
BP 634
EP 637
DI 10.4103/jcrt.JCRT_405_20
PG 4
WC Oncology
SC Oncology
GA OL5UJ
UT WOS:000585404400036
PM 32719280
OA Bronze
DA 2021-01-01
ER

PT J
AU Talapatra, K
   Gupta, M
   Singh, K
   Giri, GV
   Vashistha, R
AF Talapatra, Kaustav
   Gupta, Manoj
   Singh, Kishore
   Giri, G. V.
   Vashistha, Rajesh
TI An advisory by the association of radiation oncologists of India for
   radiation therapy patients and staff among COVID 19 pandemic
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Advisory; COVID; radiotherapy
AB Covid19 has become a major public health problem in India and the rest of the world. The dramatic rise in the incidence of COVID 19 cases has severely challenged our healthcare system and forced us to work with limited infrastructure, resources, and workforce. However, even in this time of adversity, we as oncologists cannot neglect the seriousness of cancer care and the utmost attention it requires for the timely management of our patients. Hence, the Association of Radiation Oncologists of India has come up with an advisory for radiation therapy keeping in mind such aspects.
C1 [Talapatra, Kaustav] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Dept Radiat Oncol, Mumbai, Maharashtra, India.
   [Gupta, Manoj] All India Inst Med Sci, Dept Radiat Oncol, Rishikesh, Uttarakhand, India.
   [Singh, Kishore] Maulana Azad Med Coll, Dept Radiat Oncol, New Delhi, India.
   [Giri, G. V.] Sri Shankara Canc Hosp & Res Ctr, Dept Radiat Oncol, Bengaluru, Karnataka, India.
   [Vashistha, Rajesh] Max Superspecial Hosp, Dept Radiat Oncol, Bhatinda, Punjab, India.
RP Talapatra, K (corresponding author), Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Dept Radiat Oncol, Mumbai, Maharashtra, India.
EM kaustee@gmail.com
CR [Anonymous], 2020, CLIN GUID MAN CANC P
   Brunt AM, 2018, INT J RADIAT ONCOL, V102, P1603, DOI 10.1016/j.ijrobp.2018.08.049
   Brunt AM, 2016, RADIOTHER ONCOL, V120, P114, DOI 10.1016/j.radonc.2016.02.027
   Patil V, 2020, CANC RES STAT TREAT, V3, P15
   Tchelebi LT, 2020, RADIOTHER ONCOL, V148, P194, DOI 10.1016/j.radonc.2020.04.010
   Zaorsky NG, 2020, PROSTATE CANC RADIOT, DOI [10.1016/j.adro.2020.03.010, DOI 10.1016/J.ADRO.2020.03.010.D0I:10.1016/J.ADR0.2020.03.010]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD APR-JUN
PY 2020
VL 16
IS 3
BP 638
EP 640
DI 10.4103/jcrt.JCRT_687_20
PG 3
WC Oncology
SC Oncology
GA OL5UJ
UT WOS:000585404400037
PM 32719281
OA Bronze
DA 2021-01-01
ER

PT J
AU Jacob, JJ
   Vasudevan, K
   Veeraraghavan, B
   Iyadurai, R
   Gunasekaran, K
AF Jacob, Jobin John
   Vasudevan, Karthick
   Veeraraghavan, Balaji
   Iyadurai, Ramya
   Gunasekaran, Karthik
TI Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in
   India and vaccine impact
SO INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE COVID-19; evolution; India; severe acute respiratory syndrome
   coronavirus 2; transmission; vaccine
AB Recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent containment procedures have impacted the world as never seen before. Therefore, there is considerable curiosity about the genome evolution related to the origin, transmission and vaccine impact of this virus. We have analysed genome sequences of SARS-CoV-2 isolated from Indian patients to gain an in-depth understanding of genomic evolution and transmission in India. Phylogenetic analysis and mutation profiling revealed major lineages being evolved by characteristic mutations. As the mutation frequency in spike protein is comparatively lesser, the candidate vaccines expected to have wide coverage worldwide including India.
C1 [Jacob, Jobin John; Vasudevan, Karthick] Christian Med Coll & Hosp, Dept Clin Microbiol, Div Mol Biol & Translat Bioinformat, Vellore, Tamil Nadu, India.
   [Veeraraghavan, Balaji] Christian Med Coll & Hosp, Hilda Lazarus Core Res Chair, Vellore, Tamil Nadu, India.
   [Iyadurai, Ramya; Gunasekaran, Karthik] Christian Med Coll & Hosp, Dept Gen Med, Unit 5, Vellore, Tamil Nadu, India.
RP Gunasekaran, K (corresponding author), Christian Med Coll & Hosp, Dept Gen Med, Unit 5, Vellore, Tamil Nadu, India.
EM karthikgunasekaran@yahoo.com
RI vasudevan, karthick/ABH-7205-2020
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Banu S, 2020, BIORXIV
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Boni MF, 2020, BIORXIV
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Koyama T, 2020, IDENTIFICATION LOW P
   Li X., 2020, SCI ADV
   Liu P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008421
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Rajendrakumar AL, 2020, EPIDEMIC LANDSCAPE F
   Somers E.C., TOCILIZUMAB TREATMEN
   Williamson B.N., 2020, BIORXIV
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0255-0857
EI 1998-3646
J9 INDIAN J MED MICROBI
JI Indian J. Med. Microbiol.
PD APR-JUN
PY 2020
VL 38
IS 2
BP 210
EP 212
DI 10.4103/ijmm.IJMM_20_303
PG 3
WC Immunology
SC Immunology
GA NO3YQ
UT WOS:000569422500012
PM 32883935
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Papachristodoulou, E
   Kakoullis, L
   Parperis, K
   Panos, G
AF Papachristodoulou, Eleni
   Kakoullis, Loukas
   Parperis, Konstantinos
   Panos, George
TI Long-term and herd immunity against SARS-CoV-2: implications from
   current and past knowledge
SO PATHOGENS AND DISEASE
LA English
DT Article
DE COVID-19; antibodies; pandemic; outbreak; coronavirus; quarantine
AB Effective herd immunity against SARS-CoV-2 will be determined on many factors: the percentage of the immune population, the length and effectiveness of the immune response and the stability of the viral epitopes. The required percentage of immune individuals has been estimated to be 50-66% of the population which, given the current infection rates, will take long to be achieved. Furthermore, data from SARS-CoV suggest that the duration of immunity may not be sufficiently significant, while the immunity response against SARS-CoV-2 may not be efficiently effective in all patients, as relapses have already been reported. In addition, the development of mutant strains, which has already been documented, can cause the reemergence of the epidemic. In conclusion, the development of an effective vaccine is an urgent necessity, as long-term natural immunity to SARS-CoV-2 may not be sufficient for the control of the current and future outbreaks.
C1 [Papachristodoulou, Eleni; Parperis, Konstantinos; Panos, George] Univ Cyprus, Dept Internal Med, Med Sch, Nicosia, Cyprus.
   [Kakoullis, Loukas] Nicosia Gen Hosp, Dept Internal Med, Nicosia, Cyprus.
   [Kakoullis, Loukas] Univ Patras, Dept Resp Med, Gen Hosp, Patras, Greece.
   [Parperis, Konstantinos] Univ Arizona, Dept Med, Div Rheumatol, Coll Med, Phoenix, AZ USA.
   [Panos, George] Univ Patras, Dept Internal Med, Sect Infect Dis, Gen Hosp, Patras, Greece.
RP Panos, G (corresponding author), Univ Patras, Patras Univ Gen Hosp, Dept Internal Med & Infect Dis, Sch Med, Patras, Greece.; Panos, G (corresponding author), Univ Cyprus, Nicosia Gen Hosp, Dept Internal Med, Med Sch, Nicosia, Cyprus.
EM george.panos.frcp@gmail.com
RI Papachristodoulou, Eleni/ABI-6313-2020
CR Biswas AK, 2020, MEAT QUALITY ANALYSIS: ADVANCED EVALUATION METHODS, TECHNIQUES, AND TECHNOLOGIES, P1, DOI 10.1016/C2018-0-01364-X
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027
   La Maestra S, 2020, J MED VIROL, V92, P1956, DOI 10.1002/jmv.25908
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li X, 2020, PALEONTOL RES, V24, P89, DOI 10.2517/2019PR015
   Mallory ML, 2018, J ALLERGY CLIN IMMUN, V142, P64, DOI 10.1016/j.jaci.2018.05.007
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Syal K, 2020, J MED VIROL, V92, P1380, DOI 10.1002/jmv.25870
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Wang MJ, 2020, J VIROL, V94, DOI 10.1128/JVI.00567-20
   Wissel Benjamin D, 2020, J Am Med Inform Assoc, V27, P1121, DOI 10.1093/jamia/ocaa071
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Zhao J, 2020, CLIN INFECT DIS, DOI [DOI 10.1093/CID/CIAA344/5812996, 10.1093/cid/ciaa34 4/5812996]
NR 17
TC 3
Z9 3
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2049-632X
J9 PATHOG DIS
JI Pathog. Dis.
PD APR
PY 2020
VL 78
IS 3
AR ftaa025
DI 10.1093/femspd/ftaa025
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NJ3DW
UT WOS:000565929200006
PM 32510562
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hill, A
   Wang, JZ
   Levi, J
   Heath, K
   Fortunak, J
AF Hill, Andrew
   Wang, Junzheng
   Levi, Jacob
   Heath, Katie
   Fortunak, Joseph
TI Minimum costs to manufacture new treatments for COVID-19
SO JOURNAL OF VIRUS ERADICATION
LA English
DT Article
DE SARS-CoV2; COVID-19; drug prices; access to medicines
AB Introduction: 'Repurposing' existing drugs to treat COVID-19 is vital to reducing mortality and controlling the pandemic. Several promising drugs have been identified and are in various stages of clinical trials globally. If efficacy of these drugs is demonstrated, rapid, mass availability at an affordable cost would be essential to ensuring equity and access especially amongst low- and middle-income economies.
   Methods: Minimum costs of production were estimated from the costs of active pharmaceutical ingredients using established methodology, which had good predictive accuracy for medicines for hepatitis C and HIV amongst others. Data were extracted from global export shipment records or analysis of the route of chemical synthesis. The estimated costs were compared with list prices from a range of countries where pricing data were available.
   Results: Minimum estimated costs of production were US $0.93/day for remdesivir, $1.45/day for favipiravir, $0.08/day for hydroxychloroquine, $0.02/day for chloroquine, $0.10/day for azithromycin, $0.28/day for lopinavir/ritonavir, $0.39/day for sofosbuvir/daclatasvir and $1.09/day for pirfenidone. Costs of production ranged between $0.30 and $31 per treatment course (10-28 days). Current prices of these drugs were far higher than the costs of production, particularly in the US.
   Conclusions: Should repurposed drugs demonstrate efficacy against COVID-19, they could be manufactured profitably at very low costs, for much less than current list prices. Estimations for the minimum production costs can strengthen price negotiations and help ensure affordable access to vital treatment for COVID-19 at low prices globally.
C1 [Hill, Andrew] Univ Liverpool, Dept Translat Med, 70 Pembroke Pl, Liverpool L69 3GF, Merseyside, England.
   [Wang, Junzheng; Levi, Jacob] Imperial Coll London, Fac Med, London, England.
   [Heath, Katie] Burnet Inst, Melbourne, Vic, Australia.
   [Fortunak, Joseph] Howard Univ, Chem & Pharmaceut Sci, Washington, DC 20059 USA.
RP Hill, A (corresponding author), Univ Liverpool, Dept Translat Med, 70 Pembroke Pl, Liverpool L69 3GF, Merseyside, England.
EM microhaart@aol.com
OI Wang, Junzheng/0000-0002-7635-9461
FU International Treatment Preparedness Coalition (ITPC) as part of the
   Unitaid
FX AH received funding from the International Treatment Preparedness
   Coalition (ITPC) as part of the Unitaid-supported project `Affordable
   medicines for developing countries'.
CR [Anonymous], ACT 400 MG 20 ML LOC
   [Anonymous], 2017, COMM FRAM BIOL MED I
   [Anonymous], 2020, SINA NEWS       0223
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Biodiscover, FAV TREATM COVID 19
   Bollu RB, 2017, Patent No. 122139
   BrazilianHealth Regulatory Agency, DRUG PRIC LISTS
   Cao B, 2020, NEW ENGL J MED, V382
   Chatterjee P, 2020, LANCET, V395, P675, DOI 10.1016/S0140-6736(20)30459-1
   Chen C, 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432.]
   Chen J., 2020, J ZHEJIANG U MED SCI, V49
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Dean EB, 2020, HEALTH SERV RES, V55, P883, DOI 10.1111/1475-6773.13283
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   G Global Fund for AI DS TB and Malaria, RES REP 2019
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gotham D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027780
   Grillon C, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25060
   Guo Q, 2019, CHEM PAP, V73, P1043, DOI 10.1007/s11696-018-0654-9
   Hayden FG, 2019, CURR OPIN INFECT DIS, V32, P176, DOI 10.1097/QCO.0000000000000532
   Hill AM, 2019, AM ASS STUD LIV DIS
   Hill A, 2016, J VIRUS ERAD, V2, P28
   Hill A, 2014, CLIN INFECT DIS, V58, P928, DOI 10.1093/cid/ciu012
   Hill AM, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000571
   Iran Registry of Clinical Trials, 2020, IDENTIFIER IRC IRCT2
   Laplante S, 2018, PHARMACOECON-OPEN, V2, P325, DOI 10.1007/s41669-017-0055-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu FL, 2017, CHEM PAP, V71, P2153, DOI 10.1007/s11696-017-0208-6
   MedEx, COMPR ONL MED IND BA
   Medindia, DRUG PRIC ALL BRAND
   Ministry of Health Malaysia, PHARM SERV PROGR CON
   Molina JM, 2020, MED MALADIES INFECT, DOI [10.1016/j.medmal.2020.03.006, DOI 10.1016/J.MEDMAL.2020.03.006.]
   Mycenax Biotech Inc, LUSINEX TOC MYC IN H
   N National Institute for Health and Care Excellence, 2020, BRIT NATL FORMULARY
   National Center for Biotechnology Information, PubChem Database: Patent=, Patent No. [US9724360, 9724360]
   PEPFAR, 2019, US PRES EM PLAN AI D
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Smolen JS, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000900
   Sweden Dental and Pharmaceutical Benefits Agency, DRUG DAT
   The Global Fund, PRIC REF REP 2013 PR
   US Department of Veterans Affairs, 2020, OFF PROC ACQ LOG PHA
   Vardanyan RS, 2006, SYNTHESIS OF ESSENTIAL DRUGS, P559, DOI 10.1016/B978-044452166-8/50037-6
   World Intellectual Property Office, Patent No. [[Patent] WO2005/062723 A2, 062723]
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 48
TC 7
Z9 8
U1 1
U2 2
PU MEDISCRIPT LTD
PI LONDON
PA 1 MOUNTVIEW CT, 310 FRIERN BARNET LN, LONDON, N20 0LD, ENGLAND
SN 2055-6640
EI 2055-6659
J9 J VIRUS ERAD
JI J. Virus Erad.
PD APR
PY 2020
VL 6
IS 2
BP 61
EP 69
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA MX6PJ
UT WOS:000557843100004
PM 32405423
DA 2021-01-01
ER

PT J
AU Appel, S
   Kaidar-Person, O
   Lawrence, YR
   Ben-Ayun, M
   Katzman, T
   Bar, J
   Mansano, A
   Symon, Z
AF Appel, Sarit
   Kaidar-Person, Orit
   Lawrence, Yaacov Richard
   Ben-Ayun, Maoz
   Katzman, Tamar
   Bar, Jair
   Mansano, Anat
   Symon, Zvi
TI The Coronavirus Pandemic in Israel: Implications for Radiation Oncology
   Departments
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE coronavirus pandemic; COVID-19; radiation therapy; oncologic treatment;
   preparation of healthcare system
ID PNEUMONITIS; CANCER
C1 [Appel, Sarit; Kaidar-Person, Orit; Lawrence, Yaacov Richard; Ben-Ayun, Maoz; Katzman, Tamar; Mansano, Anat; Symon, Zvi] Tel Aviv Univ, Affiliated Sackler Fac Med, Sheba Med Ctr, Dept Radiat Oncol & 2Inst Oncol, Tel Aviv, Israel.
   [Bar, Jair] Tel Aviv Univ, Affiliated Sackler Fac Med, Sheba Med Ctr, Inst Oncol, Tel Aviv, Israel.
RP Appel, S (corresponding author), Sheba Med Ctr, Dept Radiat Oncol, IL-52621 Tel Hashomer, Israel.
EM sarit.appel@sheba.health.gov.il
OI lawrence, yaacov/0000-0002-9959-2485
CR Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jain V, 2018, CANCERS, V10, DOI 10.3390/cancers10070222
   Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005
   Nishino M, 2016, CLIN CANCER RES, V22, P6051, DOI 10.1158/1078-0432.CCR-16-1320
   Xu Yan, 2020, Zhongguo Fei Ai Za Zhi, V23, P136, DOI 10.3779/j.issn.1009-3419.2020.03.02
   Yang L., 2020, ZHONGHUA ZHONG LIU Z, V42, pE006
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 8
TC 2
Z9 2
U1 0
U2 0
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISR MED ASSOC J
JI Isr. Med. Assoc. J.
PD APR
PY 2020
VL 22
IS 4
BP 211
EP 213
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA MT0AO
UT WOS:000554633600002
PM 32286020
DA 2021-01-01
ER

PT J
AU Vanden Eynde, JJ
AF Vanden Eynde, Jean Jacques
TI COVID-19: A Brief Overview of the Discovery Clinical Trial
SO PHARMACEUTICALS
LA English
DT Article
DE chloroquine; COVID-19; hydroxychloroquine; lopinavir; ritonavir;
   remdesivir; repurposing; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; INTERFERON-BETA; SARS-CORONAVIRUS;
   REMDESIVIR; HYDROXYCHLOROQUINE; INHIBITORS; EFFICACY; MODEL
AB The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.
C1 [Vanden Eynde, Jean Jacques] Univ Mons UMONS, Dept Organ Chem FS, B-7000 Mons, Belgium.
RP Vanden Eynde, JJ (corresponding author), Univ Mons UMONS, Dept Organ Chem FS, B-7000 Mons, Belgium.
EM jean-jacques.vandeneynde@ex.umons.ac.be
OI Vanden Eynde, Jean Jacques/0000-0003-4770-4104
CR Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chakraborty S., 2020, WHY REPURPOSING HIV, DOI [10.31219/osf.io/ax98f, DOI 10.31219/OSF.IO/AX98F]
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Council on Foundations, CALL ACT PHIL COMM C
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   FDA, REQ EM US AUTH
   FINBLOOM DS, 1985, J RHEUMATOL, V12, P692
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Live Science, HUSB WIF POIS THEMS
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Spiegel M, 2004, J CLIN VIROL, V30, P211, DOI 10.1016/j.jcv.2003.11.013
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   The Bill and Melinda Gates Foundation, 3 WEEKS 2 DRUG TRIAL
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, UN FDN PARTN LAUNCH
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 7
Z9 7
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD APR
PY 2020
VL 13
IS 4
AR 65
DI 10.3390/ph13040065
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LP0YJ
UT WOS:000534047200023
PM 32290348
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, N
   Jie, ZJ
AF Li, Na
   Jie, Zhijun
TI The application of corticosteroids in COVID-19: A two-edged sword
SO JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
LA English
DT Article
DE COVID-19; corticosteroid; cytokine storm
ID SARS; THERAPY; WUHAN
AB COVID-19 has become a global pandemic and requires the whole world to respond together. There is no specific antiviral treatment recommended at present for COVID-19. The patients must receive the supportive care to help relieve the symptoms and ensure appropriate infection control. Whether or not to use corticosteroids clinically caused controversy. This article has summarized previous researches about the using of corticosteroids in other viral pneumonia, related clinical data in COVID-19, and recommendations in Chinese guideline.
C1 [Li, Na; Jie, Zhijun] Fudan Univ, Shanghai Peoples Hosp 5, Dept Pulm & Crit Care Med, Shanghai 200240, Peoples R China.
   [Jie, Zhijun] Fudan Univ, Ctr Community Based Hlth Res, Shanghai, Peoples R China.
RP Jie, ZJ (corresponding author), Fudan Univ, Shanghai Peoples Hosp 5, Dept Pulm & Crit Care Med, Shanghai 200240, Peoples R China.
EM jiezjlxh@163.com
FU Key Research of Shanghai Fifth People's Hospital [2019WYZD03]
FX This study was supported by Key Research of Shanghai Fifth People's
   Hospital (2019WYZD03).
CR Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004
   [Anonymous], 86 WHO
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Feng Y, 2020, AM J RESP CRIT CARE
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu Y, 2020, SCI PROGRESS-UK, V103, DOI 10.1177/0036850419898659
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Health Commission of the People's Republic of China, 2020, GUID DIAGN TREATM CO
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang J, 2020, TREATMENT OUTCOMES P, DOI 10.2139/ssrn.3546060
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   WHO, MIDDL E RESP SYNDR C
   WHO, SUMM PROB SARS CAS O
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 35
TC 0
Z9 0
U1 0
U2 0
PU SCIENDO
PI WARSAW
PA BOGUMILA ZUGA 32A, WARSAW, MAZOVIA, POLAND
SN 2450-131X
EI 2224-4018
J9 J TRANSL INTERN MED
JI J. TRANSL. INTERN. MED.
PD APR-JUN
PY 2020
VL 8
IS 2
BP 66
EP 70
DI 10.2478/jtim-2020-0011
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN9WX
UT WOS:000551190900003
PM 32983928
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gyula, B
   Adam, B
   Attila, C
   Attila, F
   Akos, J
   Istvan, K
   Zoltan, Z
AF Gyula, Balka
   Adam, Balint
   Attila, Csagola
   Attila, Farsang
   Akos, Jerzsele
   Istvan, Kiss
   Zoltan, Zadori
TI Vaccine developments and pharmacological treatment options against
   SARS-CoV-2 infection and the control of coronaviruses in domestic
   animals Literature review
SO MAGYAR ALLATORVOSOK LAPJA
LA Hungarian
DT Article
ID PORCINE EPIDEMIC DIARRHEA; ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING
   DOMAIN; PERITONITIS VIRUS; MOLECULAR CHARACTERIZATION; NEUTRALIZING
   ANTIBODIES; ENTERIC CORONAVIRUS; CELLULAR-IMMUNITY; BRONCHITIS VIRUS;
   SPIKE PROTEIN
AB In their second review, the authors summarise the knowledge on the most important coronaviral diseases of the domestic animals and their respective vaccination control strategies. They specify the benefits and limitations of the available vaccines in the case of the three most important coronaviral diseases: avian infectious bronchitis, feline infectious peritonitis (FIP) and porcine epidemic diarrhea. They describe the similarities between the vasculitis observed in the granulomatous form of FIP and in the Kawasaki syndrome that has recently been described in children affected by COVID-19. In the next part they show the most important ongoing vaccine developments against SARS-CoV-2, the general properties of the inactivated, subunit, vector, nucleic acid, and modified live virus based vaccinations and the results published to date regarding the new, pandemic coronavirus. In the final part they present the most relevant targets of the pharmacological treatments, the most important drug developments and the treatment protocols that are being tested and published so far.
C1 [Gyula, Balka] Allatorvostud Egyet, Patol Tanszek, Istvan U 2, H-1078 Budapest, Hungary.
   [Adam, Balint] Nemzeti Elelmiszerlanc Biztonsagi Hivatal, Allategeszsegugyi Diagnosztikai Igazgatosag, Budapest, Hungary.
   [Attila, Csagola; Attila, Farsang; Istvan, Kiss] Ceva Phylaxia, Budapest, Hungary.
   [Akos, Jerzsele] Allatorvostud Egyet, Gyogyszertani & Meregtani Tanszek, Budapest, Hungary.
   [Zoltan, Zadori] Agr Tud Kutatokozpont, Allatorvostud Kutatoint, Budapest, Hungary.
RP Gyula, B (corresponding author), Allatorvostud Egyet, Patol Tanszek, Istvan U 2, H-1078 Budapest, Hungary.
EM balka.gyula@univet.hu
CR Addie D, 2020, J FELINE MED SURG, V22, P350, DOI 10.1177/1098612X19848167
   Addie D, 2009, J FELINE MED SURG, V11, P594, DOI 10.1016/j.jfms.2009.05.008
   Al-Salama ZT, 2019, DRUGS, V79, P99, DOI 10.1007/s40265-018-1046-8
   Alharbi NK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52730-4
   [Anonymous], 2012, LIVERTOX CLIN RES IN
   Ayudhya SNN, 2012, TRANSBOUND EMERG DIS, V59, P9, DOI 10.1111/j.1865-1682.2011.01309.x
   Balint A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088758
   Balint A, 2014, VET MICROBIOL, V169, P154, DOI 10.1016/j.vetmic.2013.10.015
   Balint A, 2012, J VIROL, V86, P6258, DOI 10.1128/JVI.00189-12
   Balka G, 2020, MAGY ALLATORVOSOK, V142, P259
   Benyeda J., 1977, Magyar Allatorvosok, V32, P99
   Benyeda Z, 2010, J COMP PATHOL, V143, P276, DOI 10.1016/j.jcpa.2010.04.007
   Benyeda Z, 2009, AVIAN PATHOL, V38, P449, DOI 10.1080/03079450903349196
   Boileau MJ, 2010, VET CLIN N AM-FOOD A, V26, P123, DOI 10.1016/j.cvfa.2009.10.003
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Bru T, 2017, AVIAN PATHOL, V46, P52, DOI 10.1080/03079457.2016.1203393
   Buonavoglia C, 2006, EMERG INFECT DIS, V12, P492, DOI 10.3201/eid1203.050839
   Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Carvajal A, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/s40813-015-0007-9
   Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198
   CHASEY D, 1978, RES VET SCI, V25, P255, DOI 10.1016/S0034-5288(18)32994-1
   Chen C, FAVIPIRAVIR VERSUS A
   CHEN J, 2009, J VIRAL, V84, P1289
   CHEN JF, 2010, SWINE IND SCI, V12, P51
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   CRAWFORD K, 2015, ANN P AM ASS SWIN VE, P212
   Dalmo RA, 2018, J FISH DIS, V41, P1, DOI 10.1111/jfd.12727
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   Dastjerdi A, 2015, EMERG INFECT DIS, V21, P2235, DOI 10.3201/eid2112.150272
   De Groot-Mijnes JDF, 2005, J VIROL, V79, P1036, DOI 10.1128/JVI.79.2.1036-1044.2005
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DEBOUCK P, 1980, AM J VET RES, V41, P219
   DEBOUCK P, 1982, P 7 INT PIG VET C, P53
   Decaro N, 2008, VET MICROBIOL, V132, P221, DOI 10.1016/j.vetmic.2008.06.007
   Decaro N, 2010, EMERG INFECT DIS, V16, P41, DOI 10.3201/eid1601.090726
   Dedeurwaerder A, 2013, VET MICROBIOL, V162, P447, DOI 10.1016/j.vetmic.2012.10.032
   DERZSY D, 1966, MAGY ALLATORV LAPJA, V21, P194
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Du L, 2013, PLOS ONE
   Ellis S, 2018, J VIROL, V92, DOI 10.1128/JVI.01473-18
   Emberi Eroforrasok Miniszteriuma, 2020, 2020 EVB AZ KOR SARS
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Eriksson Klara Kristin, 2008, V454, P237, DOI 10.1007/978-1-59745-181-9_18
   Erles K, 2003, VIROLOGY, V310, P216, DOI 10.1016/S0042-6822(03)00160-0
   Fast E, 2020, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484]
   FOLEGATTI P. M, 2020, LANCET INFECT DIS
   FUJIWARA H, 1986, ACTA PATHOL JAPON, V36, P857
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerdts V, 2017, VET MICROBIOL, V206, P45, DOI 10.1016/j.vetmic.2016.11.029
   Graham RL, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0175-7
   GREIN J, NEW ENGL J MED
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Habibi M, 2017, ACTA VIROL, V61, P150, DOI 10.4149/av_2017_02_04
   Haijema BJ, 2004, J VIROL, V78, P3863, DOI 10.1128/JVI.78.8.3863-3871.2004
   HAYASHI T, 1978, JPN J VET SCI, V40, P207
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang YW, 2013, MBIO, V4, DOI 10.1128/mBio.00737-13
   J LOHMER L. R. L., APPROVED DOSE IVERME
   Jackwood MW, 2012, INFECT GENET EVOL, V12, P1305, DOI 10.1016/j.meegid.2012.05.003
   Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Johnson MA, 2003, VACCINE, V21, P2730, DOI 10.1016/S0264-410X(03)00227-5
   Karimi V, 2019, TROP ANIM HEALTH PRO, V51, P629, DOI 10.1007/s11250-018-1730-4
   Keidar S, 2007, NEPHROL DIAL TRANSPL, V22, P597, DOI 10.1093/ndt/gfl632
   Kipar A, 2005, VET PATHOL, V42, P321, DOI 10.1354/vp.42-3-321
   Kiss I, 2004, J FELINE MED SURG, V6, P89, DOI 10.1016/j.jfms.2003.08.009
   Koch T., 2020, LANCET INFECT DIS
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Kweon CH, 1999, VACCINE, V17, P2546, DOI 10.1016/S0264-410X(99)00059-6
   Lakatos B, 2013, MAGY ALLATORVOSOK, V135, P41
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   LAW P. K., 2020, OPEN J REGENERATIVE, V9, P1
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Li WT, 2012, EMERG INFECT DIS, V18, P1350, DOI 10.3201/eid1808.120002
   LIAN N, 2020, CLIN MICROBIOL INFEC
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ma CQ, 2014, VACCINE, V32, P2100, DOI 10.1016/j.vaccine.2014.02.004
   Ma S.Q, 1995, CHIN ANIM INFECT DIS, V6, P23
   MA SQ, 1994, CHIN ANIM INFECT DIS, V2, P15
   MAGAGNOLI I.-, 2020, OUTCOMES HYDROXYCHLO
   Makadiya N, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0512-8
   Malbon AJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121144
   Martelli R, 2008, VET REC, V162, P307
   Martins A, 2018, J PAEDIATR CHILD H, V54, P1371, DOI 10.1111/jpc.14102
   MEHRA M. R, 2020, LANCET, DOI [10.1016/50140-6736(20)31180-6, DOI 10.1016/50140-6736(20)31180-6]
   Mesquita JR, 2015, TRANSBOUND EMERG DIS, V62, P586, DOI 10.1111/tbed.12409
   Mogler MA, 2014, ANN P AM ASS SWIN VE, P63
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Morein B, 2004, ADV DRUG DELIVER REV, V56, P1367, DOI 10.1016/j.addr.2004.02.004
   Myint AM, 2009, METAB BRAIN DIS, V24, P55, DOI 10.1007/s11011-008-9114-5
   Nagy B, 1996, ACTA VET HUNG, V44, P9
   Niederwerder MC, 2018, TRANSBOUND EMERG DIS, V65, P660, DOI 10.1111/tbed.12823
   OLDHAM I., 1972, PIG FARMING S, P72
   Paltrinieri S, 1998, VET IMMUNOL IMMUNOP, V65, P205, DOI 10.1016/S0165-2427(98)00155-X
   PEDERSEN NC, 1984, AM J VET RES, V45, P2580
   Pedersen NC, 2019, J FELINE MED SURG, V21, P271, DOI 10.1177/1098612X19825701
   Pedersen NC, 2009, VIRUSES-BASEL, V1, P166, DOI 10.3390/v1020166
   Pensaert MB, 2016, VIRUS RES, V226, P1, DOI 10.1016/j.virusres.2016.05.030
   PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606
   PIJPERS A, 1993, VET REC, V132, P129, DOI 10.1136/vr.132.6.129
   Pratelli A, 2004, VET MICROBIOL, V99, P43, DOI 10.1016/j.vetmic.2003.07.009
   Pritchard GC, 1999, VET REC, V144, P616
   QINGXIAN C, 2020, ENGINEERING BEIJING, P2020
   Quinlan BD, 2020, SARS COV 2 RECEPTOR, DOI 10.036418
   Quinteros JA, 2016, VET MICROBIOL, V197, P27, DOI 10.1016/j.vetmic.2016.11.003
   RAPP-GABRIELSON V. J, 2014, N AM PRRS S
   Rivera-Figueroa EI, 2020, INDIAN PEDIAT
   Rossi G, 2011, VET MICROBIOL, V150, P248, DOI 10.1016/j.vetmic.2011.02.004
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sato T, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0940-8
   Sato T, 2011, VIRUS GENES, V43, P72, DOI 10.1007/s11262-011-0617-5
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Schmidt R, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0082-4
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006
   Shin YW, 2019, J MICROBIOL BIOTECHN, V29, P651, DOI 10.4014/jmb.1812.12024
   Shirato K, 2016, J GEN VIROL, V97, P2528, DOI 10.1099/jgv.0.000563
   Song DS, 2007, RES VET SCI, V82, P134, DOI 10.1016/j.rvsc.2006.03.007
   Song D, 2015, CLIN EXP VACCINE RES, V4, P166, DOI 10.7774/cevr.2015.4.2.166
   Stadler J, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0454-1
   Steinrigl A, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0624-1
   Stower Hannah, 2020, Nat Med, V26, P465, DOI 10.1038/s41591-020-0849-9
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Sun RQ, 2012, EMERG INFECT DIS, V18, P161, DOI 10.3201/eid1801.111259
   Suzuki T, 2002, AM J RESP CRIT CARE, V165, P1113, DOI 10.1164/ajrccm.165.8.2103094
   TAKAHASHI K, 1983, JPN J VET SCI, V45, P829
   Takano T, 2014, VACCINE, V32, P1834, DOI 10.1016/j.vaccine.2014.01.074
   Thor SW, 2011, VIRUSES-BASEL, V3, P1777, DOI 10.3390/v3091777
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Tian YF, 2013, VIRUSES-BASEL, V5, P1991, DOI 10.3390/v5081991
   Tong Y, 1999, CHIN J PREV VET MED, V21, P406
   TONG YE, 1998, CHIN ANIM INFECT DIS, V20, P329
   TOPLAK I, 2016, GENOME ANNOUNC, V4
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Tsioris K, 2015, INTEGR BIOL-UK, V7, P1587, DOI [10.1039/c5ib00169b, 10.1039/C5IB00169B]
   Tuboly T, 1996, MAGY ALLATORVOSOK, V51, P361
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Valko A, 2019, ACTA VET HUNG, V67, P307, DOI 10.1556/004.2019.031
   Valko A, 2017, ACTA VET HUNG, V65, P253, DOI 10.1556/004.2017.025
   VARGA J, 1999, HAZIALLATOK FERTOZO, P481
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017
   Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang D, 2016, VIRUS RES, V226, P7, DOI 10.1016/j.virusres.2016.05.026
   Wang JB, 2013, EMERG INFECT DIS, V19, P2048, DOI 10.3201/eid1912.121088
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Williamson BN, 2020, CLIN BENEFIT REMDESI
   WOLFE LG, 1966, PATHOL VET, V3, P255, DOI 10.1177/030098586600300309
   WOOD EN, 1977, VET REC, V100, P243, DOI 10.1136/vr.100.12.243
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu JY, 2019, EMERG MICROBES INFEC, V8, P841, DOI 10.1080/22221751.2019.1624482
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Yao X, 2020, CLIN INFECT DIS
   Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zuniga S, 2016, VIRUS RES, V226, P142, DOI 10.1016/j.virusres.2016.07.003
NR 168
TC 0
Z9 0
U1 6
U2 6
PU MEZOGAZDA KIADO KFT
PI BUDAPEST
PA PO BOX 16, 1631 BUDAPEST, HUNGARY
SN 0025-004X
J9 MAGY ALLATORVOSOK
JI Magy. Allatorv. Lapja
PD APR
PY 2020
VL 142
IS 4
BP 323
EP 348
PG 26
WC Veterinary Sciences
SC Veterinary Sciences
GA MK6YF
UT WOS:000548930800001
DA 2021-01-01
ER

PT J
AU Huang, ZX
   Zhao, S
   Xu, L
   Chen, JX
   Lin, W
   Zeng, HJ
   Chen, ZX
   Du, L
   Shi, YJ
   Zhang, N
   Song, B
AF Huang, Zixing
   Zhao, Shuang
   Xu, Lin
   Chen, Jianxin
   Lin, Wei
   Zeng, Hanjiang
   Chen, Zhixia
   Du, Liang
   Shi, Yujun
   Zhang, Na
   Song, Bin
TI Imaging features and mechanisms of novel coronavirus pneumonia
   (COVID-19) Study Protocol Clinical Trial (SPIRIT Compliant)
SO MEDICINE
LA English
DT Article
DE computer tomography; disease coronavirus disease 2019; multicenter
   study; prospective observational study; severe acute respiratory
   syndrome coronavirus 2
ID CHEST CT
AB Introduction: A novel coronavirus, tentatively designated as 2019 Novel Coronavirus (2019-nCoV), now called severe acute respiratory syndrome coronavirus 2, emerged in Wuhan, China, at the end of 2019 and which continues to expand. On February 11, 2020, the World Health Organization (WHO) named the disease coronavirus disease 2019 (COVID-19). On February 28, WHO increased our assessment of the risk of spread and the risk of impact of COVID-19 to very high at a global level. The COVID-19 poses significant threats to international health. Computed tomography (CT) has been an important imaging modality in assisting in the diagnosis and management of patients withCOVID-19. Some retrospective imaging studies have reported chest CT findings of COVID-19 in the past 2 months, suggesting that several CT findings may be characteristic. To our knowledge, there has been no prospective multicentre imaging study of COVID-19 to date. We proposed a hypothesis: There are some specific CT features on Chest CT of COVID-19 patients. And the mechanism of these CT features is explicable based on pathological findings. Objective: To investigate the specific CT features of COVID-19 and the formation mechanism of these CT features. Method: This study is a prospective multicenter observational study. We will recruit 100 patients with COVID-19 at 55 hospitals. All patients undergo chest CT examination with the same scan protocol. The distribution and morphology of lesions on chest CT, clinical data will be recorded. A number of patients will be pathologically examined after permission is granted. The data of these three aspects will be analyzed synthetically. Discussion: This study will help us to identify the chest CT features of COVID-19 and its mechanism. Ethics and dissemination: This retrospective study was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (No. 2020-140). Written informed consent will be obtained from all study participants prior to enrollment in the study. To protect privacy of participants, all private information were kept anonymous. The results will be published in a peer-reviewed journal and will be disseminated electronically and in print regardless of results.
C1 [Huang, Zixing; Zhao, Shuang; Zeng, Hanjiang; Chen, Zhixia; Song, Bin] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610041, Peoples R China.
   [Xu, Lin] Danzhou Cent Hosp, Dept Radiol, Danzhou, Peoples R China.
   [Chen, Jianxin] Sichuan Univ, West China Guangan Hosp, Dept Radiol, Guangan, Peoples R China.
   [Lin, Wei] Sichuan Univ, Peoples Hosp 1, Dept Radiol, Chengdu, Peoples R China.
   [Du, Liang] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Peoples R China.
   [Shi, Yujun] Sichuan Univ, West China Hosp, Lab Pathol, Chengdu, Peoples R China.
   [Zhang, Na] Publ Hlth Clin Ctr, Dept Radiol, Chengdu 610041, Peoples R China.
RP Song, B (corresponding author), Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610041, Peoples R China.; Zhang, N (corresponding author), Publ Hlth Clin Ctr, Dept Radiol, Chengdu 610041, Peoples R China.
EM 147841845@qq.com; songlab_radiology@163.com
RI Song, Bin/AAD-3670-2020
OI Huang, Zixing/0000-0001-7967-5948
FU Scientific and Technological Project of 2019-nCoV, West China Hospital
   of Sichuan University [HX-2019-nCoV-24]
FX This work was funded by the Scientific and Technological Project of
   2019-nCoV, West China Hospital of Sichuan University (Grant number:
   HX-2019-nCoV-24).
CR Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Duan YN, 2020, RADIOLOGY, V295, P21, DOI 10.1148/radiol.2020200323
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hosseiny M, 2020, AM J ROENTGENOL, V214, P1078, DOI 10.2214/AJR.20.22969
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   National Health Commission of the People's Republic of China, MARCH 7 DAIL BRIEF N
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   World Health Organization, COR DIS COVID 2019 S
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou SC, 2020, AM J ROENTGENOL, V214, P1287, DOI 10.2214/AJR.20.22975
NR 17
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR
PY 2020
VL 99
IS 16
AR e19900
DI 10.1097/MD.0000000000019900
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA ME5SF
UT WOS:000544714800102
PM 32312018
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pegado, R
   Silva, E
   Lima, INDF
   Gualdi, L
AF Pegado, Rodrigo
   Silva-Filho, Edson
   Lima, Illig Nadinne D. F.
   Gualdi, Lucien
TI Coronavirus disease 2019 (COVID-19) in Brasil: information to physical
   therapists
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE Coronavirus infections; Respiratory distress syndrome, adult;
   Respiratory therapy
ID OUTBREAK
AB The emergence of the Coronavirus Disease 2019 (COVID-19) pandemic shows a rapid increase in cases and deaths. The World Health Organization (WHO) has shown that more than 200.000 confirmed cases have been identified in more than 166 countries/territories. Public health authorities in Brasil have reported 532 confirmed cases by March 19. Approximately 5% of the patients will require intensive care unit treatment with oxygen therapy and mechanical ventilation. Limited data are available about rehabilitation protocols for severe illness and intensive care treatment of COVID-19 increase. Thus, we aim to show current information about COVID-19, describing symptoms and the respiratory management for critical patients and preventive care. Physical therapists and all health care professionals need to recognize the challenges they will face in the coming months.
C1 [Pegado, Rodrigo; Silva-Filho, Edson; Lima, Illig Nadinne D. F.; Gualdi, Lucien] Univ Fed Rio Grande do Norte, Programa Posgrad Ciencias Reabilitacao, Natal, RN, Brazil.
RP Silva, E (corresponding author), Univ Fed Rio Grande do Norte, Fac Ciencias Saude Trairi, R Teodor Bezerra, BR-59200000 Santa Cruz, RN, Brazil.
EM meneses.edson@yahoo.com.br
RI Gualdi, Lucien/ABF-2712-2020
OI Silva Filho, Edson Meneses/0000-0002-0732-5049
CR Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liew MF, 2020, CRIT CARE, V24, DOI [10.1186/s13054-020-2814-x, 10.1186/s13054-020-2828-4]
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Qiu HB, 2020, INTENS CARE MED, V46, P576, DOI 10.1007/s00134-020-05966-y
   Seus TL, 2020, EPIDEMIOLOGIA SERVIC, V28
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 11
TC 0
Z9 0
U1 2
U2 2
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD APR
PY 2020
VL 66
IS 4
BP 498
EP 501
DI 10.1590/1806-9282.66.4.498
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MA3CI
UT WOS:000541794900022
PM 32578785
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Sato, K
   Mano, T
   Iwata, A
   Toda, T
AF Sato, Kenichiro
   Mano, Tatsuo
   Iwata, Atsushi
   Toda, Tatsushi
TI Neuropsychiatric adverse events of chloroquine: a real-world
   pharmacovigilance study using the FDA Adverse Event Reporting System
   (FAERS) database
SO BIOSCIENCE TRENDS
LA English
DT Article
DE COVID-19; chloroquine; adverse events; pharmacovigilance; FAERS;
   real-world data
ID ANTIMALARIAL-DRUG TOXICITY
AB In late March and early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID- 19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019. We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model: exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19.
C1 [Sato, Kenichiro; Mano, Tatsuo; Iwata, Atsushi; Toda, Tatsushi] Univ Tokyo, Grad Sch Med, Dept Neurol, Tokyo, Japan.
   [Iwata, Atsushi] Tokyo Metropolitan Geriatr Med Ctr Hosp, Dept Neurol, Tokyo, Japan.
RP Iwata, A (corresponding author), Tokyo Metropolitan Geriatr Med Ctr Hosp, Dept Neurol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.
EM iwata@m.u-tokyo.ac.jp
RI Iwata, Atsushi/AAH-8924-2019
OI Iwata, Atsushi/0000-0001-7308-5314
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20H03587]
FX This study was performed using the FDA Adverse Event Reporting System
   (FAERS) database that was provided by the FDA. The information, results,
   or interpretation of the current study do not represent any opinion of
   the FDA. This study was supported by JSPS KAKENHI Grant Number 20H03587.
CR Alkadi HO, 2007, CHEMOTHERAPY, V53, P385, DOI 10.1159/000109767
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bogaczewicz A, 2017, PSYCHIATR PSYCHOL KL, V17, P111, DOI 10.15557/PiPK.2017.0012
   Casals M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112653
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   EMA, 2020, EMA170590
   Food and Drug Administration, 2020, COR COVID 19 UPD DAI
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Larsen K, 2000, BIOMETRICS, V56, P909, DOI 10.1111/j.0006-341X.2000.00909.x
   Michel C, 2017, CLIN DRUG INVEST, V37, P415, DOI 10.1007/s40261-017-0503-6
   Nevin RL, 2016, NEUROL THER, V5, P69, DOI 10.1007/s40120-016-0045-5
   Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001
   Sato K, 2019, J NEURO-ONCOL, V145, P1, DOI 10.1007/s11060-019-03273-1
   Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003
   Thomas KH, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-54
   van Puijenbroek EP, 1999, BRIT J CLIN PHARMACO, V47, P689, DOI 10.1046/j.1365-2125.1999.00957.x
   Verity R., 2020, LANCET INFECT DIS
   Yokoyama S, 2020, INT J MED SCI, V17, P471, DOI 10.7150/ijms.39523
NR 18
TC 5
Z9 5
U1 0
U2 0
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD APR
PY 2020
VL 14
IS 2
BP 139
EP 143
DI 10.5582/bst.2020.03082
PG 5
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9JD
UT WOS:000541534200008
PM 32321905
OA Bronze
DA 2021-01-01
ER

PT J
AU Gao, JJ
   Hu, SS
AF Gao, Jianjun
   Hu, Shasha
TI Update on use of chloroquine/hydroxychloroquine to treat coronavirus
   disease 2019 (COVID-19)
SO BIOSCIENCE TRENDS
LA English
DT Article
DE SARS-CoV-2; COVID-19; chloroquine; hydroxychloroquine
AB Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.
C1 [Gao, Jianjun] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Peoples R China.
   [Hu, Shasha] Qingdao Univ, Dept Pathol, Affiliated Hosp, Qingdao, Peoples R China.
RP Gao, JJ (corresponding author), Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Peoples R China.
EM gaojj@qdu.edu.cn
CR [Anonymous], NOT ISS 7 ED GUID CO
   [Anonymous], COVID 19 CHLOR HYDR
   [Anonymous], NOT ISS 6 ED GUID CO
   Chen J, 2020, ZHE JIANG DA XUE XUE
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, MEDITERRANEE INFECT
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang ML, 2020, J CELL MOL MED, V24, P7778, DOI 10.1111/jcmm.15409
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0019
   National Health Commission, AUD TRANSCR NEWS BRI
   National Health Commission, INT 6 ED GUID COVID
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 15
Z9 15
U1 1
U2 6
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD APR
PY 2020
VL 14
IS 2
BP 156
EP 158
DI 10.5582/bst.2020.03072
PG 3
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9JD
UT WOS:000541534200011
PM 32281583
OA Bronze
DA 2021-01-01
ER

PT J
AU Ohe, M
   Shida, H
   Jodo, S
   Kusunoki, Y
   Seki, M
   Furuya, K
   Goudarzi, H
AF Ohe, Masashi
   Shida, Haruki
   Jodo, Satoshi
   Kusunoki, Yoshihiro
   Seki, Masahide
   Furuya, Ken
   Goudarzi, Houman
TI Macrolide treatment for COVID-19: Will this be the way forward?
SO BIOSCIENCE TRENDS
LA English
DT Article
DE COVID-19; SARS-CoV-2; macrolide
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection.
C1 [Ohe, Masashi; Shida, Haruki; Jodo, Satoshi; Kusunoki, Yoshihiro; Seki, Masahide; Furuya, Ken] JCHO Hokkaido Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan.
   [Goudarzi, Houman] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Hokkaido, Japan.
   [Goudarzi, Houman] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
RP Ohe, M (corresponding author), JCHO Hokkaido Hosp, Dept Internal Med, Toyohira Ku, 1-8-3-18 Nakanoshima, Sapporo, Hokkaido 0628618, Japan.
EM oektsp1218@sweet.ocn.ne.jp
CR Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Dayer MR, 2020, ARXIV200304524
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570
NR 6
TC 19
Z9 20
U1 2
U2 7
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD APR
PY 2020
VL 14
IS 2
BP 159
EP 160
DI 10.5582/bst.2020.03058
PG 2
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9JD
UT WOS:000541534200012
PM 32249257
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Calligari, P
   Bobone, S
   Ricci, G
   Bocedi, A
AF Calligari, Paolo
   Bobone, Sara
   Ricci, Giorgio
   Bocedi, Alessio
TI Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions
   with Antiviral Drugs
SO VIRUSES-BASEL
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; viral protease; spike protein;
   antiviral drug; RNA-dependent RNA-polymerase; viral protein N; molecular
   modeling; molecular docking
ID PROTEASE INHIBITORS; CORONAVIRUS; DOCKING; SPIKE; BINDING
AB A new Coronavirus strain, named SARS-CoV-2, suddenly emerged in early December 2019. SARS-CoV-2 resulted in being dramatically infectious, with thousands of people infected. In this scenario, and without effective vaccines available, the importance of an immediate tool to support patients and against viral diffusion becomes evident. In this study, we exploit the molecular docking approach to analyze the affinity between different viral proteins and several inhibitors, originally developed for other viral infections. Our data show that, in some cases, a relevant binding can be detected. These findings support the hypothesis to develop new antiviral agents against COVID-19, on the basis of already established therapies.
C1 [Calligari, Paolo; Bobone, Sara; Ricci, Giorgio; Bocedi, Alessio] Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci 1, I-00133 Rome, Italy.
RP Bocedi, A (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci 1, I-00133 Rome, Italy.
EM paolo.calligari@uniroma2.it; sara.bobone@uniroma2.it;
   riccig@uniroma2.it; bcdlss01@uniroma2.it
RI Calligari, Paolo/AAC-5705-2020
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Ascenzi P, 2008, MOL ASPECTS MED, V29, P151, DOI 10.1016/j.mam.2007.09.005
   Bhatnagar T., 2020, INDIAN J MED RES
   Bobone S, 2017, J VIROL, V91, DOI 10.1128/JVI.00267-17
   Calligari PA, 2012, ACTA CRYSTALLOGR D, V68, P1690, DOI 10.1107/S0907444912039029
   Cao B, 2020, NEW ENGL J MED, V382
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen LL, 2006, J BIOMOL SCREEN, V11, P915, DOI 10.1177/1087057106293295
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cummings MD, 2010, ANGEW CHEM INT EDIT, V49, P1652, DOI 10.1002/anie.200906696
   Deng L, 2020, J INFECTION
   Florea NR, 2003, PHARMACOTHERAPY, V23, P339, DOI 10.1592/phco.23.3.339.32099
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074
   Hofer CT, 2019, BBA-BIOMEMBRANES, V1861, P1123, DOI 10.1016/j.bbamem.2019.03.013
   Kontoyianni M, 2017, METHODS MOL BIOL, V1647, P255, DOI 10.1007/978-1-4939-7201-2_18
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu ZM, 2005, J CHEM INF MODEL, V45, P10, DOI 10.1021/ci049809b
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614, DOI 10.1128/CMR.11.4.614
   Pshenichnaya NY, 2019, TERAPEVT ARKH, V91, P56, DOI 10.26442/00403660.2019.03.000127
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   Tahara SM, 1998, ADV EXP MED BIOL, V440, P313
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu Z., 2020, BIORXIV
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
NR 42
TC 17
Z9 18
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2020
VL 12
IS 4
AR 445
DI 10.3390/v12040445
PG 13
WC Virology
SC Virology
GA LX0IV
UT WOS:000539525300087
PM 32295237
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cava, C
   Bertoli, G
   Castiglioni, I
AF Cava, Claudia
   Bertoli, Gloria
   Castiglioni, Isabella
TI In Silico Discovery of Candidate Drugs against Covid-19
SO VIRUSES-BASEL
LA English
DT Article
DE bioinformatics; covid-19; drugs; gene network
ID VIRUS; CORONAVIRUS; ACE2; MODULATION; RECEPTOR; PROTEIN; KINASE; GENE
AB Previous studies reported that Angiotensin converting enzyme 2 (ACE2) is the main cell receptor of SARS-CoV and SARS-CoV-2. It plays a key role in the access of the virus into the cell to produce the final infection. In the present study we investigated in silico the basic mechanism of ACE2 in the lung and provided evidences for new potentially effective drugs for Covid-19. Specifically, we used the gene expression profiles from public datasets including The Cancer Genome Atlas, Gene Expression Omnibus and Genotype-Tissue Expression, Gene Ontology and pathway enrichment analysis to investigate the main functions of ACE2-correlated genes. We constructed a protein-protein interaction network containing the genes co-expressed with ACE2. Finally, we focused on the genes in the network that are already associated with known drugs and evaluated their role for a potential treatment of Covid-19. Our results demonstrate that the genes correlated with ACE2 are mainly enriched in the sterol biosynthetic process, Aryldialkylphosphatase activity, adenosylhomocysteinase activity, trialkylsulfonium hydrolase activity, acetate-CoA and CoA ligase activity. We identified a network of 193 genes, 222 interactions and 36 potential drugs that could have a crucial role. Among possible interesting drugs for Covid-19 treatment, we found Nimesulide, Fluticasone Propionate, Thiabendazole, Photofrin, Didanosine and Flutamide.
C1 [Cava, Claudia; Bertoli, Gloria] Natl Res Council IBFM CNR, Inst Mol Bioimaging & Physiol, Via F Cervi 93, I-20090 Milan, Italy.
   [Castiglioni, Isabella] Univ Milano Bicocca, Dept Phys Giuseppe Occhialini, Piazza Ateneo Nuovo, I-20126 Milan, Italy.
RP Cava, C; Bertoli, G (corresponding author), Natl Res Council IBFM CNR, Inst Mol Bioimaging & Physiol, Via F Cervi 93, I-20090 Milan, Italy.
EM claudia.cava@ibfm.cnr.it; gloria.bertoli@ibfm.cnr.it;
   isabella.castiglioni@ibfm.cnr.it
RI Cava, Claudia/P-2257-2018; Bertoli, Gloria/J-6559-2016
OI Cava, Claudia/0000-0002-5540-4104; Bertoli, Gloria/0000-0002-5901-4269
CR Abraham R, 2018, P NATL ACAD SCI USA, V115, pE10457, DOI 10.1073/pnas.1812130115
   AlQarni S, 2018, ONCOGENE, V37, P3998, DOI 10.1038/s41388-018-0147-x
   Baliji S, 2010, VIROLOGY, V402, P238, DOI 10.1016/j.virol.2010.03.023
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bhagavan N.V., 2002, MED BIOCH, P331
   Bravata V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041084
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Cava C, 2019, COMPUT MATH METHOD M, V2019, DOI 10.1155/2019/9029351
   Cava C, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1535-2
   Cava C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020274
   Cava C, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1196-1
   Chan SW, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00518
   Chen J., 2020, PREPRINTS
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005074
   Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Dasinger JH, 2016, HYPERTENSION, V67, P1281, DOI 10.1161/HYPERTENSIONAHA.116.07548
   Duygu F, 2011, J CLIN LAB ANAL, V25, P311, DOI 10.1002/jcla.20473
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Esfandiarei M, 2006, CIRC RES, V99, P354, DOI 10.1161/01.RES.0000237022.72726.01
   Fan H-H, 2020, CHIN MED J
   Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gunther S, 2008, NUCLEIC ACIDS RES, V36, pD919, DOI 10.1093/nar/gkm862
   Hoffmann M, 2020, CELL
   Huang L L, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P466, DOI 10.3760/cma.j.cn112338-20200209-00080
   Ioannidis I, 2012, J VIROL, V86, P5422, DOI 10.1128/JVI.06757-11
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   JONES F, 1988, J VIROL, V62, P2701, DOI 10.1128/JVI.62.8.2701-2711.1988
   Kariyawasam HH, 2010, J ASTHMA ALLERGY, V3, P19
   KELLER BT, 1987, MOL PHARMACOL, V31, P485
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Manzoor R, 2014, J BIOL CHEM, V289, P7599, DOI 10.1074/jbc.M113.507798
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Meher G, 2019, J PHYS CHEM B, V123, P10654, DOI 10.1021/acs.jpcb.9b08455
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Mishra JS, 2016, J RENIN-ANGIO-ALDO S, V17, DOI 10.1177/1470320316674875
   Mustafa Sabeena, 2019, Advances in Bioinformatics, V2019, P6815105, DOI 10.1155/2019/6815105
   Nikonova EV, 2012, HUM MOL GENET, V21, P163, DOI 10.1093/hmg/ddr451
   Osseman Q, 2018, J HEPATOL, V68, P441, DOI 10.1016/j.jhep.2017.10.032
   Park DE, 2019, P NATL ACAD SCI USA, V116, P1027, DOI 10.1073/pnas.1818798116
   Perry CM, 1996, DRUGS, V52, P928, DOI 10.2165/00003495-199652060-00014
   Petersen J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003911
   Ren WK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00319
   Staresinic A G, 2000, Expert Opin Pharmacother, V1, P1227, DOI 10.1517/14656566.1.6.1227
   Vaclavikova R, 2015, GENE, V571, P1, DOI 10.1016/j.gene.2015.07.071
   Vaidya B, 2016, J AGR FOOD CHEM, V64, P4416, DOI 10.1021/acs.jafc.6b00148
   VANARMAN GG, 1975, TEX REP BIOL MED, V33, P303
   Vysochan A, 2017, P NATL ACAD SCI USA, V114, pE1528, DOI 10.1073/pnas.1614268114
   Wang Y, 2020, J MED VIROL
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   World Health Organization, 2020, COR DIS 2019 COVID 1
   World Health Organization, 2004, SARS SEV AC RESP SYN
   Wudiri GA, 2014, J VIROL, V88, P13918, DOI 10.1128/JVI.01615-14
   Xu J., 2020, ACS INFECT DIS
   Yang ZG, 2015, INT J MED SCI, V12, P256, DOI 10.7150/ijms.10735
   Zhao DC, 2019, REPROD FERT DEVELOP, V31, P237, DOI 10.1071/RD18178
   ZHENG Y, 2020, ZHONGHUA YU FANG YI, V54, DOI DOI 10.1016/J.YOFTE.2019.102127
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 62
TC 18
Z9 18
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2020
VL 12
IS 4
AR 404
DI 10.3390/v12040404
PG 14
WC Virology
SC Virology
GA LX0IV
UT WOS:000539525300046
PM 32268515
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU He, JH
   Tao, HY
   Yan, YM
   Huang, SY
   Xiao, Y
AF He, Jiahua
   Tao, Huanyu
   Yan, Yumeng
   Huang, Sheng-You
   Xiao, Yi
TI Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2
SO VIRUSES-BASEL
LA English
DT Article
DE coronaviruses; SARS-CoV-2; SARS-CoV; human infection; molecular
   mechanism; protein docking; MD simulations
ID PROTEIN-PROTEIN; CORONAVIRUS; PNEUMONIA; DYNAMICS; SPIKE; CHINA; SARS;
   DOCKING; WUHAN; COV
AB The outbreak of a novel coronavirus, which was later formally named the severe acute respiratory coronavirus 2 (SARS-CoV-2), has caused a worldwide public health crisis. Previous studies showed that SARS-CoV-2 is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to ACE2. Here, we have systematically studied the molecular mechanisms of human infection with SARS-CoV-2 and SARS-CoV by protein-protein docking and MD simulations. It was found that SARS-CoV-2 binds ACE2 with a higher affinity than SARS-CoV, which may partly explain that SARS-CoV-2 is much more infectious than SARS-CoV. In addition, the spike protein of SARS-CoV-2 has a significantly lower free energy than that of SARS-CoV, suggesting that SARS-CoV-2 is more stable and may survive a higher temperature than SARS-CoV. This provides insights into the evolution of SARS-CoV-2 because SARS-like coronaviruses have originated in bats. Our computation also suggested that the RBD-ACE2 binding for SARS-CoV-2 is much more temperature-sensitive than that for SARS-CoV. Thus, it is expected that SARS-CoV-2 would decrease its infection ability much faster than SARS-CoV when the temperature rises. These findings would be beneficial for the disease prevention and drug/vaccine development of SARS-CoV-2.
C1 [He, Jiahua; Tao, Huanyu; Yan, Yumeng; Huang, Sheng-You; Xiao, Yi] Huazhong Univ Sci & Technol, Inst Biophys, Sch Phys, Wuhan 430074, Peoples R China.
RP Huang, SY; Xiao, Y (corresponding author), Huazhong Univ Sci & Technol, Inst Biophys, Sch Phys, Wuhan 430074, Peoples R China.
EM d201880053@hust.edu.cn; d201980099@hust.edu.cn; yanyumeng110@gmail.com;
   huangsy@hust.edu.cn; yxiao@hust.edu.cn
OI Huang, Shengyou/0000-0002-4209-4565
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31670724]; startup grant of Huazhong
   University of Science and Technology
FX This research was funded by the National Natural Science Foundation of
   China (grant No. 31670724) and the startup grant of Huazhong University
   of Science and Technology.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Case D.A., AMBER 2016
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fagre AC, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030215
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SY, 2008, PROTEINS, V72, P557, DOI 10.1002/prot.21949
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020130
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WHO, 70 WHO
   Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan Y., 2020, NAT P
   Yan YM, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3270-y
   Yan YM, 2017, NUCLEIC ACIDS RES, V45, pW365, DOI 10.1093/nar/gkx407
   Yan YM, 2017, PROTEINS, V85, P497, DOI 10.1002/prot.25234
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 52
TC 24
Z9 27
U1 4
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2020
VL 12
IS 4
AR 428
DI 10.3390/v12040428
PG 11
WC Virology
SC Virology
GA LX0IV
UT WOS:000539525300070
PM 32290077
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Srinivasan, S
   Cui, HZ
   Gao, ZY
   Liu, M
   Lu, SB
   Mkandawire, W
   Narykov, O
   Sun, M
   Korkin, D
AF Srinivasan, Suhas
   Cui, Hongzhu
   Gao, Ziyang
   Liu, Ming
   Lu, Senbao
   Mkandawire, Winnie
   Narykov, Oleksandr
   Sun, Mo
   Korkin, Dmitry
TI Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved
   Functional Regions of Viral Proteins
SO VIRUSES-BASEL
LA English
DT Article
DE 2019 novel coronavirus; SARS-CoV-2; 2019-nCoV; COVID-19; structural
   genomics; interactome; protein-protein interactions
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; MERS-COV;
   NEUTRALIZING ANTIBODY; GLOBAL HEALTH; SARS; DISCOVERY; PREDICTION;
   VACCINE
AB During its first two and a half months, the recently emerged 2019 novel coronavirus, SARS-CoV-2, has already infected over one-hundred thousand people worldwide and has taken more than four thousand lives. However, the swiftly spreading virus also caused an unprecedentedly rapid response from the research community facing the unknown health challenge of potentially enormous proportions. Unfortunately, the experimental research to understand the molecular mechanisms behind the viral infection and to design a vaccine or antivirals is costly and takes months to develop. To expedite the advancement of our knowledge, we leveraged data about the related coronaviruses that is readily available in public databases and integrated these data into a single computational pipeline. As a result, we provide comprehensive structural genomics and interactomics roadmaps of SARS-CoV-2 and use this information to infer the possible functional differences and similarities with the related SARS coronavirus. All data are made publicly available to the research community.
C1 [Srinivasan, Suhas; Korkin, Dmitry] Worcester Polytech Inst, Data Sci Program, Worcester, MA 01609 USA.
   [Cui, Hongzhu; Gao, Ziyang; Liu, Ming; Lu, Senbao; Mkandawire, Winnie; Sun, Mo; Korkin, Dmitry] Worcester Polytech Inst, Bioinformat & Computat Biol Program, Worcester, MA 01609 USA.
   [Narykov, Oleksandr; Korkin, Dmitry] Worcester Polytech Inst, Dept Comp Sci, Worcester, MA 01609 USA.
RP Korkin, D (corresponding author), Worcester Polytech Inst, Data Sci Program, Worcester, MA 01609 USA.; Korkin, D (corresponding author), Worcester Polytech Inst, Bioinformat & Computat Biol Program, Worcester, MA 01609 USA.; Korkin, D (corresponding author), Worcester Polytech Inst, Dept Comp Sci, Worcester, MA 01609 USA.
EM ssrinivasan@wpi.edu; hcui2@wpi.edu; zgao@wpi.edu; mliu5@wpi.edu;
   slu3@wpi.edu; wmkandawire@wpi.edu; onarykov@wpi.edu; msun3@wpi.edu;
   dkorkin@wpi.edu
OI Narykov, Oleksandr/0000-0002-3336-0534; Srinivasan,
   Suhas/0000-0001-8309-9648
FU National Science FoundationNational Science Foundation (NSF) [1458267];
   National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [LM012772-01A1]
FX This work was supported by National Science Foundation (1458267) and
   National Institute of Health (LM012772-01A1) to D.K.
CR Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Berman HM, 2003, PROTEIN STRUCTURE: DETERMINATION, ANALYSIS, AND APPLICATIONS FOR DRUG DISCOVERY, P389
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783
   Cavasotto CN, 2008, J MED CHEM, V51, P581, DOI 10.1021/jm070759m
   Cavasotto CN, 2009, DRUG DISCOV TODAY, V14, P676, DOI 10.1016/j.drudis.2009.04.006
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Cheng SS, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002905
   Cho CC, 2016, J BIOL CHEM, V291, P4894, DOI 10.1074/jbc.M115.700542
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Coughlin MM, 2009, VIROLOGY, V394, P39, DOI 10.1016/j.virol.2009.07.028
   Davis FP, 2007, PROTEIN SCI, V16, P2585, DOI 10.1110/ps.073228407
   de Chassey B, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0115-1
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dong N., 2020, BIORXIV
   Durmus S, 2017, FEBS OPEN BIO, V7, P96, DOI 10.1002/2211-5463.12167
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ekins Sean, 2016, F1000Res, V5, P275
   ESWAR N, 2006, CURR PROTOC BIOINFOR, V15
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hoffmann M, 2020, BIORXIV
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lasso G, 2019, CELL, V178, P1526, DOI 10.1016/j.cell.2019.08.005
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113
   Loewenstein Y, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-2-207
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186
   Patel H, 2019, VIROLOGY, V537, P97, DOI 10.1016/j.virol.2019.08.013
   Patel H, 2017, VIROLOGY, V509, P112, DOI 10.1016/j.virol.2017.06.009
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Russell RB, 2004, CURR OPIN STRUC BIOL, V14, P313, DOI 10.1016/j.sbi.2004.04.006
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Serrano P, 2007, J VIROL, V81, P12049, DOI 10.1128/JVI.00969-07
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196
   Shimamoto Y, 2015, BIOORGAN MED CHEM, V23, P876, DOI 10.1016/j.bmc.2014.12.028
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Su D, 2006, J VIROL, V80, P7902, DOI 10.1128/JVI.00483-06
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Sui JH, 2014, J VIROL, V88, P13769, DOI 10.1128/JVI.02232-14
   Vidalain PO, 2010, MICROBES INFECT, V12, P1134, DOI 10.1016/j.micinf.2010.09.001
   Voitenko OS, 2016, BIOINFORMATICS, V32, P685, DOI 10.1093/bioinformatics/btw441
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wan Y, 2020, J VIROL, V94
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wang SQ, 2007, BIOCHEM BIOPH RES CO, V354, P634, DOI 10.1016/j.bbrc.2006.12.235
   Warren SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070687
   Wichapong K, 2010, J MOL RECOGNIT, V23, P283, DOI 10.1002/jmr.977
   Yan L, 2003, FEBS LETT, V554, P257, DOI 10.1016/S0014-5793(03)01115-3
   Yuan YC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14657
   Zhang AD, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1500-8
   Zhang QC, 2012, NATURE, V490, P556, DOI 10.1038/nature11503
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zumla A, 2019, LANCET INFECT DIS, V19, P1054, DOI 10.1016/S1473-3099(19)30477-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 80
TC 40
Z9 42
U1 10
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2020
VL 12
IS 4
AR 360
DI 10.3390/v12040360
PG 17
WC Virology
SC Virology
GA LX0IV
UT WOS:000539525300002
PM 32218151
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU D'Ardes, D
   Boccatonda, A
   Rossi, I
   Guagnano, MT
   Santilli, F
   Cipollone, F
   Bucci, M
AF D'Ardes, Damiano
   Boccatonda, Andrea
   Rossi, Ilaria
   Guagnano, Maria Teresa
   Santilli, Francesca
   Cipollone, Francesco
   Bucci, Marco
TI COVID-19 and RAS: Unravelling an Unclear Relationship
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE RAS; ACE; AT1R; ACE2; COVID-19; SARS-CoV-2
ID ANGIOTENSIN-CONVERTING ENZYME; SARS CORONAVIRUS; FUNCTIONAL RECEPTOR;
   CARDIAC DYSFUNCTION; AT(2) RECEPTORS; BLOOD-PRESSURE; 2 ACE2; RENIN;
   LUNG; SYSTEM
AB The renin-angiotensin system (RAS) plays a main role in regulating blood pressure and electrolyte and liquid balance. Previous evidence suggests that RAS may represent an important target for the treatment of lung pathologies, especially for acute respiratory distress syndrome and chronic fibrotic disease. The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.
C1 [D'Ardes, Damiano; Boccatonda, Andrea; Rossi, Ilaria; Guagnano, Maria Teresa; Santilli, Francesca; Cipollone, Francesco; Bucci, Marco] G DAnnunzio Univ Chieti Pescara, Clin Med Inst, European Ctr Excellence Atherosclerosis Hypertens, I-66100 Chieti, Italy.
RP Santilli, F (corresponding author), G DAnnunzio Univ Chieti Pescara, Clin Med Inst, European Ctr Excellence Atherosclerosis Hypertens, I-66100 Chieti, Italy.
EM 89damiano@gmail.com; andrea.boccatonda@gmail.com;
   rossilaria91@gmail.com; guagnano@unich.it; fra.santilli22@gmail.com;
   francesco.cipollone@unich.it; mbucci@unich.it
OI Maria Teresa, Guagnano/0000-0001-7225-0891; D'Ardes,
   Damiano/0000-0001-5573-4536
CR American College of Cardiology, 2020, J AM COLL CARDIOL, V1, P1
   Bukowska A, 2017, EXP BIOL MED, V242, P1412, DOI 10.1177/1535370217718808
   Carey RM, 2008, TRENDS ENDOCRIN MET, V19, P84, DOI 10.1016/j.tem.2008.01.003
   Chappell MC, 2016, AM J PHYSIOL-HEART C, V310, pH137, DOI 10.1152/ajpheart.00618.2015
   Chappell MC, 2017, J CELL SIGNAL, V2, P134, DOI DOI 10.4172/2576-1471.1000134
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen J., 2020, INDIVIDUAL VARIATION, V3, P191
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Donoghue M, 2003, J MOL CELL CARDIOL, V35, P1043, DOI 10.1016/S0022-2828(03)00177-9
   Ferreira AJ, 2001, HYPERTENSION, V38, P665, DOI 10.1161/01.HYP.38.3.665
   Guang C, 2012, ARCH CARDIOVASC DIS, V105, P373, DOI 10.1016/j.acvd.2012.02.010
   Gupte M, 2012, ARTERIOSCL THROM VAS, V32, P1392, DOI 10.1161/ATVBAHA.112.248559
   Gurley SB, 2006, J CLIN INVEST, V116, P2218, DOI 10.1172/JCI16980
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Jones ES, 2008, PHARMACOL THERAPEUT, V120, P292, DOI 10.1016/j.pharmthera.2008.08.009
   Juillerat-Jeanneret L, 2020, J MED CHEM, V63, P1978, DOI 10.1021/acs.jmedchem.9b01780
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Klein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688
   Klimas J, 2015, J CELL MOL MED, V19, P1965, DOI 10.1111/jcmm.12573
   Komukai K, 2010, FUND CLIN PHARMACOL, V24, P687, DOI 10.1111/j.1472-8206.2010.00854.x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2013, CIRC J, V77, P301, DOI 10.1253/circj.CJ-12-1544
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li YC, 2015, SHOCK, V43, P395, DOI 10.1097/SHK.0000000000000302
   Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086
   Marshall RP, 2004, AM J PHYSIOL-LUNG C, V286, pL156, DOI 10.1152/ajplung.00313.2002
   Masson R, 2009, HYPERTENSION, V53, P694, DOI 10.1161/HYPERTENSIONAHA.108.122333
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Messerli FH, 2018, J AM COLL CARDIOL, V71, P1474, DOI 10.1016/j.jacc.2018.01.058
   MORRELL NW, 1995, AM J PHYSIOL-HEART C, V269, pH1186
   Nakamura K, 2008, HYPERTENS RES, V31, P1953, DOI 10.1291/hypres.31.1953
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Perlot T, 2013, MICROBES INFECT, V15, P866, DOI 10.1016/j.micinf.2013.08.003
   Qian K, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.14.20021535 2020.02.14. 20021535., DOI 10.1101/2020.02.14.20021535, 10.1101/2020.02.14.20021535]
   Raiden S, 2002, J PHARMACOL EXP THER, V303, P45, DOI 10.1124/jpet.102.037382
   Rentzsch B, 2008, HYPERTENSION, V52, P967, DOI 10.1161/HYPERTENSIONAHA.108.114322
   Santos RAS, 2013, J ENDOCRINOL, V216, pR1, DOI 10.1530/JOE-12-0341
   Sarkissian SD, 2008, HYPERTENSION, V51, P712, DOI 10.1161/HYPERTENSIONAHA.107.100693
   Shoemaker R, 2019, BIOL SEX DIFFER, V10, DOI 10.1186/s13293-019-0260-8
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Sun M L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P219, DOI [10.3760/cma.j.issn.1001-0939.2020.0014, 10.3760/cma.j.issn.1001-0939.2020.03.016]
   Tan WSD, 2018, CURR OPIN PHARMACOL, V40, P9, DOI 10.1016/j.coph.2017.12.002
   Wagenaar GTM, 2013, AM J PHYSIOL-LUNG C, V305, pL341, DOI 10.1152/ajplung.00360.2012
   Wosten-van Asperen RM, 2011, J PATHOL, V225, P618, DOI 10.1002/path.2987
   Wosten-van Asperen RM, 2010, AM J PATHOL, V176, P2219, DOI 10.2353/ajpath.2010.090565
   Yamamoto K, 2006, HYPERTENSION, V47, P718, DOI 10.1161/01.HYP.0000205833.89478.5b
   Zambelli Vanessa, 2015, Intensive Care Med Exp, V3, P44, DOI 10.1186/s40635-015-0044-3
   Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 61
TC 17
Z9 17
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2020
VL 21
IS 8
AR 3003
DI 10.3390/ijms21083003
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA LR3AC
UT WOS:000535565300345
PM 32344526
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Narain, T
   Gautam, G
   Seth, A
   Panwar, V
   Rawal, S
   Dhar, P
   Talwar, H
   Singh, A
   Jaipuria, J
   Mittal, A
AF Narain, Tushar
   Gautam, Gagan
   Seth, Amlesh
   Panwar, Vikas
   Rawal, Sudhir
   Dhar, Puneet
   Talwar, Harkirat
   Singh, Amitabh
   Jaipuria, Jiten
   Mittal, Ankur
TI Uro-oncology in times of COVID-19: The available evidence and
   recommendations in the Indian scenario
SO INDIAN JOURNAL OF CANCER
LA English
DT Article
DE Bladder cancer; cancer; COVID-19; kindey cancer; open surgery; penile
   cancer; prostate cancer; robotic surgery; testicular tumor; urooncology
ID INVASIVE BLADDER-CANCER; CARBON-DIOXIDE LASER; RISK; DELAY;
   PAPILLOMAVIRUS; RECURRENCE; OUTCOMES; BIOPSY; PLUME
AB The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphant. An extensive literature search for impact of delay in management of various urological malignancies was carried out. Expert opinions were sought wherever there was paucity of evidence, in order to reach a consensus and come up with recommendations for directing uro-oncology services in the times of COVID-19. The panel recommends deferring treatment of patients with renal cell carcinoma by 3 to 6 months, except for those with ongoing hematuria and/or inferior vena cava thrombus, which warrant immediate surgery. Metastatic renal cell cancers should be started on targeted therapy. Low grade non-muscle invasive bladder cancers can be kept on active surveillance while high risk non-muscle invasive bladder cancers and muscle invasive bladder cancers should be treated within 3 months. Neoadjuvant chemotherapy should be avoided. Management of low and intermediate risk prostate cancer can be deferred for 3 to 6months while high risk prostate cancer patients can be initiated on neoadjuvant androgen deprivation therapy. Patients with testicular tumors should undergo high inguinal orchiectomy and be treated according to stage without delay, with stage I patients being offered surveillance. Penile cancers should undergo penectomy, while clinically negative groins can be kept on surveillance. Neoadjuvant chemotherapy should be avoided and adjuvant therapy should be deferred. We need to tailor our treatment strategies to the prevailing present conditions, so as to fight and defeat both, the SARS-CoV-2 virus and cancer. Protection of health care workers, judicious use of available resources, and a rational and balanced outlook towards different malignancies is the need of the hour.
C1 [Narain, Tushar; Panwar, Vikas; Talwar, Harkirat; Mittal, Ankur] All India Inst Med Sci, Dept Urol, Rishikesh, Uttarakhand, India.
   [Dhar, Puneet] All India Inst Med Sci, Dept Gastrointestinal Surg, Rishikesh, Uttarakhand, India.
   [Gautam, Gagan] Max Super Specialty Hosp, Dept Urooncol, Saket, India.
   [Seth, Amlesh] All India Inst Med Sci, Dept Urol, Rishikesh, India.
   [Rawal, Sudhir; Singh, Amitabh; Jaipuria, Jiten] Rajiv Gandhi Canc Inst & Res Ctr, Dept Urooncol, New Delhi, India.
RP Narain, T (corresponding author), All India Inst Med Sci, Dept Urol, Rishikesh, Uttarakhand, India.
EM aditya.tushar@gmail.com
RI Narain, Tushar Aditya/AAV-4498-2020
OI Narain, Tushar Aditya/0000-0002-9336-0683
CR Abol-Enein H, 2005, EUR UROL, V48, P202, DOI 10.1016/j.eururo.2005.04.006
   Ahmed HU, 2017, LANCET, V389, P815, DOI 10.1016/S0140-6736(16)32401-1
   Babjuk M, 2019, EUR UROL, V76, P639, DOI 10.1016/j.eururo.2019.08.016
   Becker A, 2014, UROL INT, V92, P455, DOI 10.1159/000356175
   Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
   Bhindi B, 2019, EUR UROL, V75, P111, DOI [10.1016/j.eururo.2018.09.016, 10.1016/j.eururo.2018.11.021]
   Bourgade V, 2014, WORLD J UROL, V32, P475, DOI 10.1007/s00345-013-1045-z
   Capizzi PJ, 1998, LASER SURG MED, V23, P172, DOI 10.1002/(SICI)1096-9101(1998)23:3<172::AID-LSM7>3.0.CO;2-M
   Dearnaley D, 2016, LANCET ONCOL, V17, P1047, DOI 10.1016/S1470-2045(16)30102-4
   Fahmy NM, 2006, EUR UROL, V50, P1176, DOI 10.1016/j.eururo.2006.05.046
   Finnbladder N. B. C. S. G., 1999, LANCET, V354, P533, DOI DOI 10.1016/S0140-6736(99)02292-8
   Fizazi K, 2016, EUR UROL, V70, P438, DOI 10.1016/j.eururo.2016.02.035
   Gao W, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0863-z
   GLOSTER HM, 1995, J AM ACAD DERMATOL, V32, P436, DOI 10.1016/0190-9622(95)90065-9
   Hahn AW, 2017, UROL ONCOL-SEMIN ORI, V35, P701, DOI 10.1016/j.urolonc.2017.08.005
   Hensman C, 1998, SURG ENDOSC-ULTRAS, V12, P1017, DOI 10.1007/s004649900771
   Heyns CF, 2010, UROLOGY, V76, pS43, DOI 10.1016/j.urology.2010.03.001
   JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110
   Kwak HD, 2016, OCCUP ENVIRON MED, V73, P857, DOI 10.1136/oemed-2016-103724
   Lammers RJM, 2016, WORLD J UROL, V34, P173, DOI 10.1007/s00345-015-1598-0
   Lee CT, 2006, J UROLOGY, V175, P1262, DOI 10.1016/S0022-5347(05)00644-0
   Li CC, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1737232, 10.1080/10962247.2020.1717675]
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mano R, 2016, UROL ONCOL, V34, P239
   Marcq G, 2019, TRANSL ANDROL UROL, V8, P54, DOI 10.21037/tau.2018.10.20
   Mejean A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA3
   Mottrie A, ERUS EAU ROBOTIC URO
   Prakash G, 2018, J UROLOGY, V199, pE1031
   SAWCHUK WS, 1989, J AM ACAD DERMATOL, V21, P41, DOI 10.1016/S0190-9622(89)70146-8
   Schwartz MJ, 2007, BJU INT, V99, P881, DOI 10.1111/j.1464-410X.2006.06653.x
   Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031
   Trilla A, 2008, CLIN INFECT DIS, V47, P668, DOI 10.1086/590567
   van Rhijn BWG, 2010, EUR UROL, V58, P433, DOI 10.1016/j.eururo.2010.05.043
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zheng MH, 2020, ANN SURG, V272, pE5, DOI 10.1097/SLA.0000000000003924
NR 35
TC 1
Z9 1
U1 3
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-509X
EI 1998-4774
J9 INDIAN J CANCER
JI Indian J. Cancer
PD APR-JUN
PY 2020
VL 57
IS 2
BP 129
EP 138
DI 10.4103/ijc.IJC_356_20
PG 10
WC Oncology
SC Oncology
GA LS9NV
UT WOS:000536706600003
PM 32445315
DA 2021-01-01
ER

PT J
AU Zhou, HM
   Zhang, GC
   Deng, XX
   Jin, BW
   Qiu, Q
   Yan, MH
   Wang, X
   Zheng, X
AF Zhou, Hongmei
   Zhang, Gangcheng
   Deng, Xiaoxian
   Jin, Bowen
   Qiu, Qiu
   Yan, Menghuan
   Wang, Xi
   Zheng, Xuan
TI Understanding the current status of patients with pulmonary hypertension
   during COVID-19 outbreak: a small-scale national survey from China
SO PULMONARY CIRCULATION
LA English
DT Article
DE coronavirus disease 2019 (COVID-19); pulmonary hypertension; medical
   care
ID ARTERIAL-HYPERTENSION; COMBINATION THERAPY
AB Pulmonary hypertension is a chronic disease developing progressively with high mortality. Pulmonary hypertension patients need persistent medical care; however, limited reports focused on them when there was an outbreak of coronavirus disease 2019 in China. This national survey was aimed to evaluate the overall condition of pulmonary hypertension patients during this period. A questionnaire regarding the living condition of pulmonary hypertension patients during coronavirus disease 2019 was designed by pulmonary hypertension diagnostic experts in Wuhan Asia Heart Hospital. Pulmonary hypertension patients and their family members were invited to participate in this survey online. One-hundred twenty pulmonary hypertension patients and 23 family members participated in the survey; 64.8% (n = 87) participants came from Hubei, and others were from 15 other provinces; 98.6% (n = 141) participants were in home quarantine; 65.8% (n = 79) were pulmonary arterial hypertension associated with congenital heart disease; and 76.7% (n = 92) patients proclaimed their heart function was well maintained at class I or II. One (0.8%) patient was confirmed severe acute respiratory syndrome coronavirus 2 infection. Two (1.7%) patients were hospitalized due to heart function worsening. Nearly 70% (n = 100) participants implied shortage in medications during coronavirus disease 2019 outbreak. A total of 24.2% (n = 29) patients indicated that medications were discontinued due to the insufficient supply. Most of the participants stayed optimistic on either coronavirus disease 2019 outbreak or their pulmonary hypertension disease, and 61.7% (n = 74) patients would go to the hospital for follow-up immediately after outbreak. These preliminary data show pulmonary hypertension patients are able to avoid severe disease when they are in home quarantine. Medication supplement is important for pulmonary hypertension patients when their heart function is well maintained. In addition, there might be increasing requirements of medical care for pulmonary hypertension patients after the outbreak.
C1 [Zhou, Hongmei; Zhang, Gangcheng; Deng, Xiaoxian; Jin, Bowen; Qiu, Qiu; Yan, Menghuan; Wang, Xi; Zheng, Xuan] Wuhan Asia Heart Hosp, Congenital Heart Dis Ctr, Wuhan, Peoples R China.
   [Zheng, Xuan] Wuhan Asia Heart Hosp, Lab Mol Cardiol, Wuhan, Peoples R China.
RP Zheng, X (corresponding author), Wuhan Asia Heart Hosp, Congenital Heart Dis Ctr, Lab Mol Cardiol, 753 Jinghan Ave, Wuhan 430022, Hubei, Peoples R China.
EM soniazheng@outlook.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702059]; Hubei Provincial Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [2017CFB256]; Wuhan Youth Medical Elite training program
FX National Natural Science Foundation of China (81702059), Hubei
   Provincial Natural Science Foundation of China (2017CFB256), and 2017
   Wuhan Youth Medical Elite training program to X.Z.
CR Fernandes CJC, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00307-2018
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lajoie AC, 2017, PULM CIRC, V7, P312, DOI 10.1177/2045893217710639
   McGoon MD, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01919-2018
   Narechania S, 2020, J CARDIOVASC PHARM T, V25, P131, DOI 10.1177/1074248419877409
   Preston IR, 2018, J HEART LUNG TRANSPL, V37, P401, DOI 10.1016/j.healun.2017.09.024
   Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212
   Shapiro S, 2017, RESP MED, V126, P84, DOI 10.1016/j.rmed.2017.03.025
   Sitbon O, 2016, EUR RESPIR J, V47, P1727, DOI 10.1183/13993003.02043-2015
   Studer S, 2018, PULM CIRC, V9, DOI 10.1177/2045894018816294
   Wang L, EUR RESP J
   Wright SP, J HEART LUNG TRANSPL
   Yao Y, EUR RESP J
   You RX, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/1015239
   Zhang Gangcheng, 2014, Zhonghua Xin Xue Guan Bing Za Zhi, V42, P1001
   Zhang R, 2011, CHEST, V140, P301, DOI 10.1378/chest.10-2327
   Zhu B, 2012, J CARDIOVASC PHARM, V60, P342, DOI 10.1097/FJC.0b013e318262a793
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 21
TC 2
Z9 2
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD APR
PY 2020
VL 10
IS 2
AR 2045894020924566
DI 10.1177/2045894020924566
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA LT0KW
UT WOS:000536766900001
PM 32523686
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ryan, JJ
   Melendres-Groves, L
   Zamanian, RT
   Oudiz, RJ
   Chakinala, M
   Rosenzweig, EB
   Gomberg-Maitland, M
AF Ryan, John J.
   Melendres-Groves, Lana
   Zamanian, Roham T.
   Oudiz, Ronald J.
   Chakinala, Murali
   Rosenzweig, Erika B.
   Gomberg-Maitland, Mardi
TI Care of patients with pulmonary arterial hypertension during the
   coronavirus (COVID-19) pandemic
SO PULMONARY CIRCULATION
LA English
DT Article
DE pulmonary hypertension; therapeutics; right heart failure; mechanical
   ventilation; clinical trials; prostacyclin
ID HEART-FAILURE; SURVIVAL
AB The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing care and evaluation of pulmonary arterial hypertension patients with "exposure risk" to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.
C1 [Ryan, John J.] Univ Utah, Div Cardiovasc Med, Salt Lake City, UT 84132 USA.
   [Melendres-Groves, Lana] Univ New Mexico, Div Pulm & Crit Care Med, Albuquerque, NM 87131 USA.
   [Zamanian, Roham T.] Stanford Univ, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.
   [Oudiz, Ronald J.] Harbor UCLA Med Ctr, Div Cardiol, Lundquist Inst Biomed Innovat & Res, Torrance, CA 90509 USA.
   [Chakinala, Murali] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Rosenzweig, Erika B.] Columbia Univ Coll Phys & Surg, Div Pediat Cardiol, 630 W 168th St, New York, NY 10032 USA.
   [Gomberg-Maitland, Mardi] George Washington Univ Med & Hlth Sci, Div Cardiovasc Med, Washington, DC USA.
RP Ryan, JJ (corresponding author), Univ Utah Hlth, 30 North 1900 East,Room 4A100, Salt Lake City, UT 84132 USA.
EM john.ryan@hsc.utah.edu
OI Rosenzweig, Erika B./0000-0003-4849-214X
FU Reagan Corporation; Gordon Family; Cushman Family
FX Dr Ryan and his research is supported by funding from The Reagan
   Corporation, The Gordon Family, and The Cushman Family.
CR Benza RL, 2019, CHEST, V156, P323, DOI 10.1016/j.chest.2019.02.004
   Burger CD, 2014, CHEST, V146, P1263, DOI 10.1378/chest.14-0193
   Campo A, 2011, EUR RESPIR J, V38, P359, DOI 10.1183/09031936.00148310
   Chakinala MM, 2016, CARDIOL CLIN, V34, P489, DOI 10.1016/j.ccl.2016.04.008
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haddad F, 2011, CIRC-HEART FAIL, V4, P692, DOI 10.1161/CIRCHEARTFAILURE.110.949933
   HOEPER MM, 2019, EUR RESPIR J, P53
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humbert M, 2010, EUR RESPIR J, V36, P549, DOI 10.1183/09031936.00057010
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Maron BA, 2019, CIRCULATION, V139, P1861, DOI 10.1161/CIRCULATIONAHA.118.037613
   Padang R, 2020, EUR HEART J, V41, P1273, DOI 10.1093/eurheartj/ehaa037
   Pan IZ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00081
   Pandolfi R, 2017, THORAX, V72, P460, DOI 10.1136/thoraxjnl-2015-208067
   Price LC, 2017, THORAX, V72, P396, DOI 10.1136/thoraxjnl-2016-209199
   Ryan JJ, 2014, PULM CIRC, V4, P441, DOI 10.1086/677357
   Simonneau G, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01913-2018
   Sztrymf B, 2010, EUR RESPIR J, V35, P1286, DOI 10.1183/09031936.00070209
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Welt FGP, 2020, J AM COLL CARDIOL, V75, P2372, DOI 10.1016/j.jacc.2020.03.021
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 25
TC 12
Z9 12
U1 2
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2045-8932
EI 2045-8940
J9 PULM CIRC
JI Pulm. Circ.
PD APR
PY 2020
VL 10
IS 2
AR 2045894020920153
DI 10.1177/2045894020920153
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA LR7PI
UT WOS:000535887400001
PM 32426111
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rahimi, F
   Abadi, ATB
AF Rahimi, Farid
   Abadi, Amin Talebi Bezmin
TI Practical Strategies Against the Novel Coronavirus and COVID-19-the
   Imminent Global Threat
SO ARCHIVES OF MEDICAL RESEARCH
LA English
DT Article
DE Coronaviridae; COVID-19; Pandemic; Prevention; WHO; Wuhan
AB The last month of 2019 harbingered the emergence of a viral outbreak that is now a major public threat globally. COVID-19 was first diagnosed and confirmed in a couple of cases with unknown pneumonia; the patients lived in, or travelled to, Wuhan, the capital of China's Hubei province. People now face a complex challenge that deserves urgent intervention by all involved in medical healthcare globally. Conventional antiviral therapies or vaccines are the most referred means of tackling the virus, but we think establishing these ideal management strategies is presently far-fetched. In-house isolation or quarantine of suspected cases to keep hospital admissions manageable and prevent in-hospital spread of the virus, and promoting general awareness about transmission routes are the practical strategies used to tackle the spread of COVID-19. Cases with weakened or compromised immune systems-for example, elderly individuals, young children, and those with preexisting conditions such as diabetes, cancer, hypertension, and chronic respiratory diseases-are particularly more susceptible to COVID-19. Hopefully, cumulative data using whole-genome sequencing of the SARS-CoV-2 genome in parallel with mathematical modeling will help the molecular biologists to understand unknown features of the pathogenesis and epidemiology of COVID-19. (C) 2020 IMSS. Published by Elsevier Inc.
C1 [Rahimi, Farid] Australian Natl Univ, Res Sch Biol, Canberra, ACT, Australia.
   [Abadi, Amin Talebi Bezmin] Tarbiat Modares Univ, Fac Med Sci, Dept Bacteriol, POB 14115-111, Tehran, Iran.
RP Abadi, ATB (corresponding author), Tarbiat Modares Univ, Fac Med Sci, Dept Bacteriol, POB 14115-111, Tehran, Iran.
EM Amin.talebi@modares.ac.ir
RI Rahimi, Farid/E-6522-2018
OI Rahimi, Farid/0000-0002-0920-8188
CR [Anonymous], 2020, CORONAVIRUS DIS 2019
   Duddu P., 2020, CORONAVIRUS COVID 19
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai N., 2020, 2 IMP COLL LOND
   Olena A., 2020, NEWER VACCINE TECHNO
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 8
TC 8
Z9 8
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0188-4409
EI 1873-5487
J9 ARCH MED RES
JI Arch. Med. Res.
PD APR
PY 2020
VL 51
IS 3
BP 280
EP 281
DI 10.1016/j.arcmed.2020.03.005
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LS1GC
UT WOS:000536139200013
PM 32229157
OA Green Published
DA 2021-01-01
ER

PT J
AU Kuupiel, D
   Adu, KM
   Bawontuo, V
   Adogboba, DA
   Drain, PK
   Moshabela, M
   Mashamba-Thompson, TP
AF Kuupiel, Desmond
   Adu, Kwame M.
   Bawontuo, Vitalis
   Adogboba, Duncan A.
   Drain, Paul K.
   Moshabela, Mosa
   Mashamba-Thompson, Tivani P.
TI Geographical Accessibility to Glucose-6-Phosphate Dioxygenase Deficiency
   Point-of-Care Testing for Antenatal Care in Ghana
SO DIAGNOSTICS
LA English
DT Article
DE geographical access; glucose-6-phosphate dioxygenase deficiency;
   point-of-care testing; antenatal care; upper east region; Ghana
ID SULFADOXINE-PYRIMETHAMINE; G6PD DEFICIENCY; MALARIA; HEALTH;
   CHLOROQUINE; EFFICACY; ANEMIA
AB Background: Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency screening test is essential for malaria treatment, control, and elimination programs. G6PD deficient individuals are at high risk of severe hemolysis when given anti-malarial drugs such as primaquine, quinine, other sulphonamide-containing medicines, and chloroquine, which has recently been shown to be potent for the treatment of coronavirus disease (COVID-19). We evaluated the geographical accessibility to POC testing for G6PD deficiency in Ghana, a malaria-endemic country. Methods: We obtained the geographic information of 100 randomly sampled clinics previously included in a cross-sectional survey. We also obtained the geolocated data of all public hospitals providing G6PD deficiency testing services in the region. Using ArcGIS 10.5, we quantified geographical access to G6PD deficiency screening test and identified clinics as well as visualize locations with poor access for targeted improvement. The travel time was estimated using an assumed speed of 20 km per hour. Findings: Of the 100 clinics, 58% were Community-based Health Planning and Services facilities, and 42% were sub-district health centers. The majority (92%) were Ghana Health Service facilities, and the remaining 8% were Christian Health Association of Ghana facilities. Access to G6PD deficiency screening test was varied across the districts, and G6PD deficiency screening test was available in all eight public hospitals. This implies that the health facility-to-population ratio for G6PD deficiency testing service was approximately 1:159,210 (8/1,273,677) population. The spatial analysis quantified the current mean distance to a G6PD deficiency testing service from all locations in the region to be 34 +/- 14 km, and travel time (68 +/- 27 min). The estimated mean distance from a clinic to a district hospital for G6PD deficiency testing services was 15 +/- 11 km, and travel time (46 +/- 33 min). Conclusion: Access to POC testing for G6PD deficiency in Ghana was poor. Given the challenges associated with G6PD deficiency, it would be essential to improve access to G6PD deficiency POC testing to facilitate administration of sulphadoxine-pyrimethamine to pregnant women, full implementation of the malaria control program in Ghana, and treatment of COVID-19 patients with chloroquine in malaria-endemic countries. To enable the World Health Organization include appropriate G6PD POC diagnostic tests in its list of essential in-vitro diagnostics for use in resource-limited settings, we recommend a wider evaluation of available POC diagnostic tests for G6PD deficiency, particularly in malaria-endemic countries.
C1 [Kuupiel, Desmond; Moshabela, Mosa; Mashamba-Thompson, Tivani P.] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Dept Publ Hlth Med, ZA-4041 Durban, South Africa.
   [Kuupiel, Desmond; Bawontuo, Vitalis] Res Sustainable Dev Consult, Sunyani, Ghana.
   [Adu, Kwame M.] Univ Ghana, Dept Geog, Legon, Ghana.
   [Bawontuo, Vitalis] Catholic Univ Coll Ghana, Fac Hlth & Allied Sci, Fiapre, Sunyani, Ghana.
   [Adogboba, Duncan A.] Ghana Hlth Serv, Reg Hlth Directorate, Upper East Region, Bolgatanga, Ghana.
   [Drain, Paul K.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Kuupiel, Desmond; Mashamba-Thompson, Tivani P.] Univ Limpopo, Dept Publ Hlth, Fac Hlth Sci, ZA-0723 Polokwane, South Africa.
RP Kuupiel, D (corresponding author), Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Dept Publ Hlth Med, ZA-4041 Durban, South Africa.; Kuupiel, D (corresponding author), Res Sustainable Dev Consult, Sunyani, Ghana.
EM desmondkuupiel98@hotmail.com; meous007@gmail.com;
   bawontuovitalis@yahoo.com; alemna@gmail.com; pkdrain@uw.edu;
   Moshabela@ukzn.ac.za; Mashamba-Thompson@ukzn.ac.za
RI Kuupiel, Desmond/V-8883-2019
OI Kuupiel, Desmond/0000-0001-7780-1955; Moshabela,
   Mosa/0000-0002-9438-7095; Mashamba-Thompson, Tivani/0000-0002-4193-2416
FU University of KwaZulu-Natal, College of Health Sciences
FX We are thankful to the University of KwaZulu-Natal for providing us with
   essential research resources during this study. The authors would like
   to thank the authorities of the Upper East Regional Health Directorate,
   the District Health Management Teams, and all the rural PHC managers for
   granting us permission to conduct this study. We also thank the
   University of KwaZulu-Natal, College of Health Sciences for providing
   funding for the conduct of this study.
CR Adu-Gyasi D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125796
   Amoako N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112868
   Anderle A, 2018, INT J NEONAT SCREEN, V4, DOI 10.3390/ijns4040034
   [Anonymous], 2012, 2010 POP HOUS CENS S
   Arthur E, 2012, HEALTH ECON REV, V2, DOI 10.1186/2191-1991-2-14
   Baird K, 2015, PATHOG GLOB HEALTH, V109, P93, DOI 10.1179/2047773215Y.0000000016
   Becher H, 2004, B WORLD HEALTH ORGAN, V82, P265
   BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613
   BEUTLER E, 1991, NEW ENGL J MED, V324, P169
   Carter N, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-241
   CHAN TK, 1976, BRIT MED J, V2, P1227, DOI 10.1136/bmj.2.6046.1227
   Dangisso MH, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.29443
   Diallo N, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1751-x
   Ferguson WJ, 2016, INT J HEALTH GEOGR, V15, DOI 10.1186/s12942-016-0037-9
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gething PW, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-991
   Hwang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06447-z
   Kajubi R, 2019, LANCET, V393, P1428, DOI 10.1016/S0140-6736(18)32224-4
   Kost GJ, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00329
   Kost GJ, 2012, POINT CARE, V11, P96
   Kuliszkiewicz-Janus Malgorzata, 2003, Pol Arch Med Wewn, V110, P1327
   Kuupiel D, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040175
   Kuupiel Desmond, 2019, EClinicalMedicine, V13, P74, DOI 10.1016/j.eclinm.2019.06.015
   Kuupiel D, 2019, POINT CARE, V18, P72, DOI 10.1097/POC.0000000000000186
   Kuupiel D, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7052-2
   Kuupiel D, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01236
   Kuupiel D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211498
   Lee J, 2018, BMC COMPLEM ALTERN M, V18, DOI [10.1186/s12906-018-2162-4, 10.1186/s12879-018-3031-y]
   Ley B, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0896-8
   Luzzatto L, 2014, BRIT J HAEMATOL, V164, P469, DOI 10.1111/bjh.12665
   National Malaria Control Programme, 2019, INT PREV TREATM PREG
   Nkhoma ET, 2009, BLOOD CELL MOL DIS, V42, P267, DOI 10.1016/j.bcmd.2008.12.005
   Owusu R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136828
   Owusu-Agyei S, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.19033
   Owusu-Ofori A, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1289-3
   Patel A., 2012, APPL GEOGRAPHIC INFO
   Republic of Ghana, 2009, ANT DRUG POL GHAN AC
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Therrell BL, 2015, SEMIN PERINATOL, V39, P171, DOI 10.1053/j.semperi.2015.03.002
   van Eijk AM, 2019, LANCET INFECT DIS, V19, P546, DOI 10.1016/S1473-3099(18)30732-1
   Vick J.D., 2020, CHLOROQUINE IS NOT H
   White NJ, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-418
   WHO, 2020, COR DIS COVID 19 PAN
   Wilson NO, 2011, AM J TROP MED HYG, V85, P12, DOI 10.4269/ajtmh.2011.10-0512
   World Health Organisation, 2019, WORLD MAL REP 2018 G
   World Health Organisation, 2019, MAL GEN WHO
   World Health Organisation, 2012, SINGL DOS PRIM GAM P
NR 48
TC 3
Z9 3
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD APR
PY 2020
VL 10
IS 4
AR 229
DI 10.3390/diagnostics10040229
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA LP3XB
UT WOS:000534251000064
PM 32316233
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gentile, D
   Patamia, V
   Scala, A
   Sciortino, MT
   Piperno, A
   Rescifina, A
AF Gentile, Davide
   Patamia, Vincenzo
   Scala, Angela
   Sciortino, Maria Teresa
   Piperno, Anna
   Rescifina, Antonio
TI Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine
   Natural Products: A Virtual Screening and Molecular Modeling Study
SO MARINE DRUGS
LA English
DT Article
DE COVID-19; SARS-CoV-2; marine natural product; virtual screening; docking
ID SARS-COV 3CL(PRO); DRUG DISCOVERY; ECKLONIA-CAVA; 3CL PROTEASE;
   CORONAVIRUSES; PARAMETERS; SARGASSUM; PROTEINS; DIECKOL; DESIGN
AB The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M-pro) provides a highly validated pharmacological target for the discovery and design of inhibitors. We identified potent M-pro inhibitors employing computational techniques that entail the screening of a Marine Natural Product (MNP) library. MNP library was screened by a hyphenated pharmacophore model, and molecular docking approaches. Molecular dynamics and re-docking further confirmed the results obtained by structure-based techniques and allowed this study to highlight some crucial aspects. Seventeen potential SARS-CoV-2 M-pro inhibitors have been identified among the natural substances of marine origin. As these compounds were extensively validated by a consensus approach and by molecular dynamics, the likelihood that at least one of these compounds could be bioactive is excellent.
C1 [Gentile, Davide; Patamia, Vincenzo; Rescifina, Antonio] Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.
   [Scala, Angela; Sciortino, Maria Teresa; Piperno, Anna] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Vle F Stagno dAlcontres 31, I-98166 Messina, Italy.
   [Rescifina, Antonio] Consorzio Interuniv Nazl Ric Metodol & Proc Innov, Via E Orabona 4, I-70125 Bari, Italy.
RP Gentile, D; Rescifina, A (corresponding author), Univ Catania, Dept Drug Sci, I-95125 Catania, Italy.; Rescifina, A (corresponding author), Consorzio Interuniv Nazl Ric Metodol & Proc Innov, Via E Orabona 4, I-70125 Bari, Italy.
EM davide.gentile@unict.it; vincenzo.patamia@unict.it; ascala@unime.it;
   mtsciortino@unime.it; apiperno@unime.it; arescifina@unict.it
RI Rescifina, Antonio/E-7412-2012; Piperno, Anna/K-2259-2015; Sciortino,
   Maria Teresa/B-9425-2012
OI Rescifina, Antonio/0000-0001-5039-2151; Scala,
   Angela/0000-0003-2171-9033; Piperno, Anna/0000-0001-6004-5196; Gentile,
   Davide/0000-0003-4494-3855; Sciortino, Maria Teresa/0000-0002-8519-7724
CR ALEMAN C, 1993, J COMPUT CHEM, V14, P799, DOI 10.1002/jcc.540140706
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Artan M, 2008, BIOORGAN MED CHEM, V16, P7921, DOI 10.1016/j.bmc.2008.07.078
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Barf T, 2009, BIOORG MED CHEM LETT, V19, P1745, DOI 10.1016/j.bmcl.2009.01.084
   Bzowka M., 2020, MOL DYNAMICS SIMULAT, DOI [10.1101/2020.02.27.968008, DOI 10.1101/2020.02.27.968008]
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Di Lodovico S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40991-y
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Floresta G, 2019, MAR DRUGS, V17, DOI 10.3390/md17110624
   Floresta G, 2019, MAR DRUGS, V17, DOI 10.3390/md17020113
   Floresta G, 2018, MAR DRUGS, V16, DOI 10.3390/md16100384
   Galimberti M, 2017, RUBBER CHEM TECHNOL, V90, P285, DOI 10.5254/rct.17.82665
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Ghosh AK, 2007, BIOORG MED CHEM LETT, V17, P5876, DOI 10.1016/j.bmcl.2007.08.031
   GLOMBITZA KW, 1995, PHYTOCHEMISTRY, V38, P987, DOI 10.1016/0031-9422(94)00735-C
   Grosser JW, 1996, PLANT CELL REP, V15, P672, DOI 10.1007/BF00231922
   Heo SJ, 2009, TOXICOL IN VITRO, V23, P1123, DOI 10.1016/j.tiv.2009.05.013
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jin Z., 2020, STRUCTURE MPRO COVID, DOI [10.1038/s41586-020-2223-y, DOI 10.1038/S41586-020-2223-Y]
   Kong CS, 2009, FOOD CHEM TOXICOL, V47, P1653, DOI 10.1016/j.fct.2009.04.013
   Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104
   Krieger E, 2006, J MOL GRAPH MODEL, V25, P481, DOI 10.1016/j.jmgm.2006.02.009
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Krieger E, 2012, METHODS MOL BIOL, V819, P405, DOI 10.1007/978-1-61779-465-0_25
   Li Y, 2008, J AGR FOOD CHEM, V56, P12073, DOI 10.1021/jf802732n
   Liu L, 2012, J ETHNOPHARMACOL, V142, P591, DOI 10.1016/j.jep.2012.05.046
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mayer AMS, 2011, COMP BIOCHEM PHYS C, V153, P191, DOI 10.1016/j.cbpc.2010.08.008
   Meng SA, 2017, ONCOTARGET, V8, P19834, DOI 10.18632/oncotarget.15771
   Moharram FA, 2017, PHARMACOGN MAG, V13, pS244, DOI 10.4103/pm.pm_344_16
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Myung CS, 2005, ARCH PHARM RES, V28, P691, DOI 10.1007/BF02969360
   Nakao Y, 1999, J AM CHEM SOC, V121, P2425, DOI 10.1021/ja9831195
   Napoli E, 2018, PHYTOCHEMISTRY, V152, P162, DOI 10.1016/j.phytochem.2018.05.003
   Park JY, 2013, BIOORGAN MED CHEM, V21, P3730, DOI 10.1016/j.bmc.2013.04.026
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Qiao F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160003
   Samet I, 2015, DIFFERENTIATION, V89, P146, DOI 10.1016/j.diff.2015.07.001
   Shie JJ, 2005, BIOORGAN MED CHEM, V13, P5240, DOI 10.1016/j.bmc.2005.05.065
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Stewart JJP, 2004, J MOL MODEL, V10, P155, DOI 10.1007/s00894-004-0183-z
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang YJ, 2017, MAR DRUGS, V15, DOI 10.3390/md15010018
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Yoon NY, 2009, J AGR FOOD CHEM, V57, P4124, DOI 10.1021/jf900006f
   Zhang R, 2008, EUR J PHARMACOL, V591, P114, DOI 10.1016/j.ejphar.2008.06.086
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 56
TC 34
Z9 35
U1 6
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD APR
PY 2020
VL 18
IS 4
AR 225
DI 10.3390/md18040225
PG 19
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA LO8XP
UT WOS:000533909300004
PM 32340389
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Valdenassi, L
   Franzini, M
   Ricevuti, G
   Rinaldi, L
   Galoforo, AC
   Tirelli, U
AF Valdenassi, L.
   Franzini, M.
   Ricevuti, G.
   Rinaldi, L.
   Galoforo, A. C.
   Tirelli, U.
TI Potential mechanisms by which the oxygen-ozone (O-2-O-3) therapy could
   contribute to the treatment against the coronavirus COVID-19
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Letter
ID SOLE TREATMENT; INACTIVATION
C1 [Valdenassi, L.; Franzini, M.; Galoforo, A. C.] Oxygen Ozone Therapy Sci Soc SIOOT, Gorle, BG, Italy.
   [Valdenassi, L.; Franzini, M.; Ricevuti, G.; Galoforo, A. C.; Tirelli, U.] Univ Pavia, Pavia, Italy.
   [Rinaldi, L.] Univ Campania Luigi Vanvitelli, Dept Adv Surg & Med Sci, Naples, Italy.
   [Tirelli, U.] Tirelli Med Grp, Pordenone, Italy.
RP Tirelli, U (corresponding author), Univ Pavia, Pavia, Italy.; Tirelli, U (corresponding author), Tirelli Med Grp, Pordenone, Italy.
EM utirelli@cro.it
OI Galoforo, Antonio Carlo/0000-0003-4982-9808
CR Berretta M, 2017, ONCOTARGET, V8, P24401, DOI 10.18632/oncotarget.14224
   Brie A, 2018, FOOD MICROBIOL, V70, P1, DOI 10.1016/j.fm.2017.08.010
   Jiang HJ, 2019, BIOMED ENVIRON SCI, V32, P324, DOI 10.3967/bes2019.044
   Molinari F, 2014, INT J IMMUNOPATH PH, V27, P379, DOI 10.1177/039463201402700308
   Murray BK, 2008, J VIROL METHODS, V153, P74, DOI 10.1016/j.jviromet.2008.06.004
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Rowen RJ, 2018, MED GAS RES, V8, P121, DOI 10.4103/2045-9912.241078
   Rowen RJ, 2018, MED GAS RES, V8, P67, DOI 10.4103/2045-9912.235139
   Silva RA, 2009, ACTA CIR BRAS, V24, P124, DOI 10.1590/S0102-86502009000200009
   Tirelli U, 2019, EUR REV MED PHARMACO, V23, P1786, DOI 10.26355/eurrev_201902_17141
NR 10
TC 5
Z9 5
U1 1
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4059
EP 4061
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000007
PM 32374009
DA 2021-01-01
ER

PT J
AU Joshi, T
   Joshi, T
   Sharma, P
   Mathpal, S
   Pundir, H
   Bhatt, V
   Chandra, S
AF Joshi, T.
   Joshi, T.
   Sharma, P.
   Mathpal, S.
   Pundir, H.
   Bhatt, V.
   Chandra, S.
TI In silica screening of natural compounds against COVID-19 by targeting
   Mpro and ACE2 using molecular docking
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Molecular docking; Phytochemicals;
   Mpro; ACE2
ID LECTIN; SARS
AB OBJECTIVE: Currently, Coronavirus COVID-19 Is spreading worldwide very rapidly and its control is very difficult because there is no effective vaccine or drugs available in markets. This virus can infect both animals and people and cause illnesses of the respiratory tract. WHO has declared Coronavirus as pandemic and the whole world is fighting against Coronavirus. Globally, more than 199,478 people have been diagnosed with COVID-19. As of March 18, 2020, more than 167 countries have been affected and more than 8000 deaths have been reported. The main country being affected is China followed by Italy, Iran, Spain, France, and the USA.
   MATERIALS AND METHODS: Since there are no effective drugs available against Coronavirus, we conducted virtual screening of phytochemicals to find novel compounds against this virus. Hence, we created a phytochemical library of 318 phytochemicals from 11 plants which have been reported as antiviral, antibacterial and antifungal activity. The phytochemical library was subjected to virtual screening against molecular targets; Main protease (Mpro) and Angiotensin-Converting Enzyme 2 (ACE2).
   RESULTS: Top 10 compounds were selected from each target which had better and significantly low binding energy as compared to the reference molecule.
   CONCLUSIONS: Based on the binding energy score, we suggest that these compounds can be tested against Coronavirus and used to develop effective antiviral drugs.
C1 [Joshi, T.; Mathpal, S.] Kumaun Univ, Dept Biotechnol, Bhimtal Campus, Bhimtal, Uttarakhand, India.
   [Joshi, T.; Chandra, S.] Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
   [Sharma, P.; Pundir, H.] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal, Uttarakhand, India.
   [Bhatt, V.] Sanskar Coll Pharm & Res, Ghaziabad, Uttar Pradesh, India.
RP Chandra, S (corresponding author), Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
EM scjnu@yahoo.co.in
RI Chandra, Subhash/AAN-6789-2020
CR Daisy P, 2011, BIOINFORMATION, V6, P167, DOI 10.6026/97320630006167
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ekowati H, 2017, DRUG DISCOV THER, V11, P329, DOI 10.5582/ddt.2017.01071
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joshi T, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1719200
   Kumar RV, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01460
   Leeson P, 2012, NATURE, V481, P455, DOI 10.1038/481455a
   Nisha CM, 2016, J MOL GRAPH MODEL, V65, P100, DOI 10.1016/j.jmgm.2016.03.001
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Ye XY, 2001, J PROTEIN CHEM, V20, P367, DOI 10.1023/A:1012276619686
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang JJ, 2020, DISCOVERY ANTI SARS
NR 15
TC 13
Z9 14
U1 2
U2 8
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4529
EP 4536
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000061
PM 32373991
DA 2021-01-01
ER

PT J
AU Meo, SA
   Klonoff, DC
   Akram, J
AF Meo, S. A.
   Klonoff, D. C.
   Akram, J.
TI Efficacy of chloroquine and hydroxychloroquine in the treatment of
   COVID-19
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronaviruss; COVID-19; Hydroxychloroquine; Chloroquine; Antiviral
ID DRUG
AB OBJECTIVE: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19, has caused a pandemic which has swiftly involved the entire world and raised great public health concerns. The scientific community is actively exploring treatments that would potentially be effective in combating COVID-19. Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro. In malarial pandemic countries, chloroquine is widely used to treat malaria. In malarial non-pandemic nations, chloroquine is not widely used. Chloroquine and hydroxychloroquine share similar chemical structures and mechanisms of action. The aim of this study was to indirectly investigate the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 by determining the prevalence of COVID-19 in malaria pandemic and non-pandemic nations. We sought evidence to support or refute the hypothesis that these drugs could show efficacy in the treatment of COVID-19.
   MATERIALS AND METHODS: We reviewed in vitro studies. in vivo studies, original studies, clinical trials, and consensus reports, that were conducted to evaluate the antiviral activities of chloroquine and hydroxychloroquine. The studies on "COVID-19 and its allied treatment were found from World Health Organization (WHO). ISI-Web of Science. PubMed, EMBASE, Scopus, Google Scholar, and clinical trial registries. The search was based on keywords: antiviral drugs, chloroquine, hydroxychloroquine. COVID-19, COVID-19 treatment modalities. and coronavirus. In addition, we analyzed the prevalence of COVID-19 in malaria pandemic and non-pandemic countries. The review and analyses were performed on March 28, 2020.
   RESULTS: For this study, we identified a total of 09 published articles: 03 clinical trials with sample size 150: 03 in vitro studies and 03 expert consensus reports. These studies were all suggestive that chloroquine and hydroxychloroquine can successfully treat COVID-19 infections. We found that COVID-19 infections are highly pandemic in countries where malaria is least pandemic and are least pandemic in nations where malaria is highly pandemic.
   CONCLUSIONS: Chloroquine and hydroxychloroquine have antiviral characteristics in vitro. The findings support the hypothesis that these drugs have efficacy in the treatment of COVID-19. People are currently using these drugs for malaria. It is reasonable, given the hypothetical benefit of these two drugs, that they are now being tested in clinical trials to assess their effectiveness to combat this global health crisis.
C1 [Meo, S. A.] King Saud Univ, Dept Physiol, Coll Med, Riyadh, Saudi Arabia.
   [Klonoff, D. C.] Mills Peninsula Med Ctr, Diabet Res Inst, San Mateo, CA USA.
   [Akram, J.] Univ Hlth Sci, Lahore, Pakistan.
RP Meo, SA (corresponding author), King Saud Univ, Dept Physiol, Coll Med, Riyadh, Saudi Arabia.
EM sultanmeo@hotmail.com
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP2019/47]
FX We thank the "Researchers supporting project number (RSP2019/47), King
   Saud University, Riyadh, Saudi Arabia".
CR Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Cortegiani A, 2020, CRIT CARE, V24
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Li Q, 1999, N ENGL J MED, V35
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, MALARIA
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 19
TC 32
Z9 32
U1 6
U2 10
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4539
EP 4547
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000063
PM 32373993
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Paulpandi, M
   Kavithaa, K
   Asaikkutti, A
   Balachandar, V
   Ayyadurai, N
   Arul, N
AF Paulpandi, M.
   Kavithaa, K.
   Asaikkutti, A.
   Balachandar, V.
   Ayyadurai, N.
   Arul, N.
TI Could host cell receptor alteration prevent SARS-CoV-2 viral entry? -
   Hype or hope
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-CoV-2; Receptor modulation; Corona viral control strategy;
   Antivirals; Upper respiratory tract viruses
ID SARS
AB Cell-surface receptors are the inviters of many potent pathogens that can adjust to any kind of circumstance for their existence. Many of these organisms are highly resistant to the currently existing drugs and mutate to new strains with high levels of pathogenesis, posing life-threatening consequences. Owing to such concerns, antiviral strategies are being assessed based on host cell receptor targeting. Many natural compounds with a tendency to strip off the cell surface receptors are under evaluation. Compounds that are non-toxic, patient friendly, and yield a quick output are essential for the current scenario. Drugs targeting the cell surface receptors should, therefore, be developed and standardized for the effective management of SARS-CoV-2 viral infection.
C1 [Paulpandi, M.; Kavithaa, K.; Arul, N.] Bharathiar Univ, Sch Life Sci, Dept Zool, Dis Prote Lab, Coimbatore, TN, India.
   [Asaikkutti, A.] Pondicherry Univ, Sch Life Sci, Dept Biotechnol, Pondicherry, TN, India.
   [Balachandar, V.] Bharathiar Univ, Dept Human Genet & Mol Biol, Human Mol Cytogenet & Stem Cell Lab, Coimbatore, TN, India.
   [Ayyadurai, N.] CSIR Cent Leather Res Inst, Dept Biotechnol, Chennai, TN, India.
RP Paulpandi, M; Arul, N (corresponding author), Bharathiar Univ, Sch Life Sci, Dept Zool, Dis Prote Lab, Coimbatore, TN, India.
EM curlyproteomics@gmail.com; swamyarul@gmail.com
CR Chang A, 2012, J VIROL, V86, P3230, DOI 10.1128/JVI.06706-11
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2
   Kuo LL, 2000, J VIROL, V74, P1393, DOI 10.1128/JVI.74.3.1393-1406.2000
   Matrosovich M, 2003, REV MED VIROL, V13, P85, DOI 10.1002/rmv.372
   Paulpandi M, 2011, J CELL ANIMAL BIOL, V5, P1
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Wan Y, 2020, J VIROL, V94
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 11
TC 1
Z9 1
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4554
EP 4557
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000065
PM 32373994
DA 2021-01-01
ER

PT J
AU Pavone, P
   Ceccarelli, M
   Taibi, R
   La Rocca, G
   Nunnari, G
AF Pavone, P.
   Ceccarelli, M.
   Taibi, R.
   La Rocca, G.
   Nunnari, G.
TI Outbreak of COVID-19 infection in children: fear and serenity
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Children
ID CORONAVIRUS 2019
AB OBJECTIVE: The recent outbreak of SARS-CoV-2 greatly involves the resources of the global healthcare system, as it affects new-borns, adults, and elders. This infection runs in three major stages: a mild cold-like illness. a moderate respiratory syndrome and a severe acute interstitial pneumonia. SARS-CoV-2 infection seems to have a more benign evolution in children. As a matter of fact, low susceptibility and minor aggressivity have been highlighted in most cases. There are currently no effective antiviral drugs treatment for the affected children. No sufficient results have been reached by the use of interferon (IFN), lopinavir/ritonavir, orbidol, and oseltamivir in the treatment of the coronaviruses infection. The aim of this short review is to highlight the differences existing between COVID-19 cases in adults and children.
C1 [Pavone, P.] Univ Catania, Sect Pediat & Child Neuropsychiat, Dept Clin & Expt Med, Catania, Italy.
   [Ceccarelli, M.] Univ Catania, Dept Clin & Expt Med, Infect Dis Unit, Catania, Italy.
   [Taibi, R.] Natl Canc Inst Aviano, Dept Med Oncol A, Aviano, Italy.
   [La Rocca, G.] Enzo Life Sci, Farmingdale, NY USA.
   [Nunnari, G.] Univ Messina, Dept Clin & Expt Med, Infect Dis Unit, Messina, Italy.
RP Nunnari, G (corresponding author), Univ Messina, Dept Clin & Expt Med, Infect Dis Unit, Messina, Italy.
EM gnunnari@unime.it
RI Nunnari, Giuseppe/AAC-1928-2019; La Rocca, Gaspare/AAG-3586-2019;
   Ceccarelli, Manuela/G-6612-2018; Pavone, Piero/H-5097-2019
OI Ceccarelli, Manuela/0000-0001-5987-3576; Pavone,
   Piero/0000-0002-5600-9560; La Rocca, Gaspare/0000-0003-1277-0566
CR [Anonymous], 2020, J KOREAN MED SCI, V35, pe112
   Azhar EI, 2017, ADV EXP MED BIOL, V972, P49, DOI 10.1007/5584_2016_133
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Cao Q, 2020, J FORMOS MED ASSOC, V119, P670, DOI 10.1016/j.jfma.2020.02.009
   Caselli D, 2020, PEDIATRIC REP, V12, P1, DOI 10.4081/pr.2020.8495
   Ceccarelli M, 2020, EUR REV MED PHARMACO, V24, P2781, DOI 10.26355/eurrev_202003_20551
   Cheng AC, 2020, MED J AUSTRALIA, V212, P393, DOI 10.5694/mja2.50530
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P371, DOI 10.1016/j.jmii.2020.02.011
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   WALLS AC, 2020, CELL, DOI [10.10164 ce11.2020.02.058, DOI 10.1016/CELL.2020.02.058]
   Wang GH, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30547-X
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Yang P, 2020, J INFECTION, V80, P684, DOI 10.1016/j.jinf.2020.02.024
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 22
TC 10
Z9 11
U1 63
U2 64
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4572
EP 4575
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000068
PM 32373997
DA 2021-01-01
ER

PT J
AU Li, Y
   He, F
   Zhou, N
   Wei, J
   Ding, ZY
   Wang, LY
   Chen, P
   Guo, SM
   Zhang, BH
   Wan, XN
   Zhu, W
AF Li, Yong
   He, Fan
   Zhou, Ning
   Wei, Jia
   Ding, Zeyang
   Wang, Luyun
   Chen, Peng
   Guo, Shuiming
   Zhang, Binhao
   Wan, Xiaoning
   Zhu, Wei
CA Huazhong Univ Sci Technology
TI Organ function support in patients with coronavirus disease 2019: Tongji
   experience
SO FRONTIERS OF MEDICINE
LA English
DT Article
DE COVID-19; severe and critical type; organ function support
AB Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.
C1 [Li, Yong; He, Fan; Zhou, Ning; Wei, Jia; Ding, Zeyang; Wang, Luyun; Chen, Peng; Guo, Shuiming; Zhang, Binhao; Wan, Xiaoning; Zhu, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Opt Valley Branch, Wuhan, Peoples R China.
   [Li, Yong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Resp & Crit Care Med,Dept Internal Med, Wuhan 430030, Peoples R China.
   [He, Fan; Guo, Shuiming] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol,Dept Internal Med, Wuhan 430030, Peoples R China.
   [Zhou, Ning; Wang, Luyun; Chen, Peng; Wan, Xiaoning] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Cardiol,Dept Internal Med, Wuhan 430030, Peoples R China.
   [Zhou, Ning; Wang, Luyun; Chen, Peng; Wan, Xiaoning] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Genet Diag Ctr, Wuhan 430030, Peoples R China.
   [Zhou, Ning; Wang, Luyun; Chen, Peng; Wan, Xiaoning] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China.
   [Wei, Jia] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430030, Peoples R China.
   [Ding, Zeyang; Zhang, Binhao] Huazhong Univ Sci & Technol, Hepat Surg Ctr, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Peoples R China.
   [Ding, Zeyang; Zhang, Binhao] Huazhong Univ Sci & Technol, Hubei Key Lab HPB Dis, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Peoples R China.
   [Zhu, Wei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency & Crit Care Med, Wuhan 430030, Peoples R China.
RP Zhu, W (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Emergency & Crit Care Med, Wuhan 430030, Peoples R China.
EM tjjzkzw512@163.com
OI Ding, Ze-yang/0000-0001-5826-0970; He, Fan/0000-0002-2487-5827
CR [Anonymous], 2020, CHIN J TUBERC RESP D
   [Anonymous], 2020, DIAGN TREATM PROT NO
   Chen L, 2020, CHIN J TUBERC RESP D
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan XD, 2020, CHIN J CRIT CARE INT, P6
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Han F, 2015, AM J MED SCI, V349, P199, DOI 10.1097/MAJ.0000000000000379
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joannidis M, 2011, CRIT CARE, V15, DOI 10.1186/cc10109
   Liu J., 2020, NEUTROPHIL TO LYMPHO
   Miao HJ, 2019, CRIT CARE MED, V47, pE806, DOI 10.1097/CCM.0000000000003901
   Putzu A, 2017, MINERVA ANESTESIOL, V83, P867, DOI 10.23736/S0375-9393.17.11946-2
   Sun TW, 2020, CHIN CRIT CARE MED, P32
   Wang DW, 2019, SCI CHINA LIFE SCI, V62, P187, DOI 10.1007/s11427-018-9385-3
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Zhao JP, 2020, CHIN J TUBERC RESP D
NR 18
TC 3
Z9 3
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
PD APR
PY 2020
VL 14
IS 2
BP 232
EP 248
DI 10.1007/s11684-020-0774-9
PG 17
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA LN1TA
UT WOS:000532726700015
PM 32405974
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhao, L
   Chen, B
   Huang, YN
   Yang, MX
   Yang, JF
   Zhao, ZH
AF Zhao, Li
   Chen, Bo
   Huang, Ya'nan
   Yang, Minxia
   Yang, Jianfeng
   Zhao, Zhenhua
TI A Dynamic Follow-Up of Pneumonia Caused by Coronavirus Disease 2019
   (COVID-19) on CT Scan
SO IRANIAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE COVID-19; Pneumonia; Tomography
AB Coronavirus disease (COVID-19) broke out in Wuhan, China. It was a highly contagious respiratory disease, the basic reproductive number (RO value) for COVID-19 was reported to be 2.68 with an epidemic doubling time of 6.4 days. In this case report, a 50-yearold man presented with a history of fever and chills. Chest radiographs failed to find any abnormality, and computed tomography (CT) showed ground glass shadow of the upper lobe of the left lung. Real-time polymerase chain reaction (RT-PCR) of the patient's pharyngeal swab was positive for COVID-19 nucleic acid. The course of the disease developed from mild to severe, then improved and recovered. The patient underwent antiviral drugs, low dose of glucocorticoids, symptomatic treatment, and immunoglobulin for human intravenous injection. We report this long time follow-up case of COVID-19.
C1 [Zhao, Li; Chen, Bo; Huang, Ya'nan; Yang, Minxia; Yang, Jianfeng; Zhao, Zhenhua] Shaoxing Univ, Dept Radiol, Shaoxing Peoples Hosp, Affiliated Hosp 1, 568 Zhongxing North Rd, Shaoxing 312000, Peoples R China.
RP Zhao, ZH (corresponding author), Shaoxing Univ, Dept Radiol, Shaoxing Peoples Hosp, Affiliated Hosp 1, 568 Zhongxing North Rd, Shaoxing 312000, Peoples R China.
EM zhao2075@163.com
CR Chaolin H, 2020, LANCET, V395, DOI [10.1016/S0140-6736(20)30183-5-506, 10.1016/S0140-6736(20)30183-5, DOI 10.1016/S0140-6736(20)30183-5-506.]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chest CT, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200241., DOI 10.1148/RADIOL.2020200241]
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yingxia L, 2020, SCI CHINA LIFE SCI, DOI [10.1007/s11427-020-1643-8, DOI 10.1007/S11427-020-1643-8.[PUBMED:32048163]]
NR 6
TC 0
Z9 0
U1 1
U2 1
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 1735-1065
EI 2008-2711
J9 IRAN J RADIOL
JI Iran. J. Radiol.
PD APR
PY 2020
VL 17
IS 2
AR e102847
DI 10.5812/iranjradiol.102847
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA LO3SI
UT WOS:000533549200003
OA Other Gold
DA 2021-01-01
ER

PT J
AU Meng, YF
   Wu, P
   Lu, WR
   Liu, K
   Ma, K
   Huang, L
   Cai, JJ
   Zhang, H
   Qin, Y
   Sun, HY
   Ding, WC
   Gui, LL
   Wu, P
AF Meng, Yifan
   Wu, Ping
   Lu, Wanrong
   Liu, Kui
   Ma, Ke
   Huang, Liang
   Cai, Jiaojiao
   Zhang, Hong
   Qin, Yu
   Sun, Haiying
   Ding, Wencheng
   Gui, Lingli
   Wu, Peng
TI Sex-specific clinical characteristics and prognosis of coronavirus
   disease-19 infection in Wuhan, China: A retrospective study of 168
   severe patients
SO PLOS PATHOGENS
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME
AB Author summary
   Overall, our results highlight sex-specific differences in clinical characteristics and prognosis to COVID-19, which are consistent with the sex-bias observed in other COVID-19 related studies. We also provided more evidence and explored the underlying mechanism with epidemiological analysis. Six candidate laboratory indicators with significant sex differences were considered as potential mediators affecting the prognosis of COVID-19. The age-specific risk distributions of COVID-19 showed a positive correlation between the prognosis and age/ comorbidities, which was significantly affected by sex. We also emphasize that sex is a biological variable that should be considered in the prevention and therapy of COVID-19. It is our hope that these methods may serve as a guide to the clinician in providing timely and specific therapy. Obviously, future studies are warranted to elucidate the different pathways and cellular responses between women and men. The key challenge is how best to use this disparity for providing adequate protection in both males and females.
   To confirm the relationship between sex and the progression of Coronavirus Disease-19 (COVID-19), and its potential mechanism, among severe patients. For this retrospective study, we included 168 consecutive severe patients with pathogen-confirmed COVID-19 who were hospitalized between January 16th and February 4th, 2020, at Tongji Hospital in Wuhan, China. Clinical characteristics, laboratory parameters, and outcomes were compared and analyzed between males and females. In the present study, we analyzed 168 severe patients with COVID-19, including 86 males and 82 females, and 48 patients (28.6%) were diagnosed as critically ill. Of 86 male patients, 12.8% (11/86) died and 75.6% (65/86) were discharged; of 82 female patients, 7.3% (6/82) died and 86.6% (71/82) were discharged. Eleven laboratory parameters showed significant differences between male and female patients, and six of them were higher during the whole clinical course in patients who died than in patients who were discharged. In adjusted logistic regression analysis, males with comorbidities presented a higher risk of being critically ill than males without comorbidities (OR = 3.824, 95% CI = 1.279-11.435). However, this association attenuated to null in female patients (OR = 2.992, 95% CI = 0.937-9.558). A similar sex-specific trend was observed in the relation between age and critically ill conditions. We highlighted sex-specific differences in clinical characteristics and prognosis. Male patients appeared to be more susceptible to age and comorbidities. Sex is an important biological variable that should be considered in the prevention and treatment of COVID-19.
C1 [Meng, Yifan; Wu, Ping; Lu, Wanrong; Qin, Yu; Sun, Haiying; Ding, Wencheng; Wu, Peng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr,Key Lab,Minist Educ, Wuhan, Peoples R China.
   [Liu, Kui] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Resp & Crit Care Med, Tongji Med Coll, Wuhan, Peoples R China.
   [Ma, Ke] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Infect Dis, Tongji Med Coll, Wuhan, Peoples R China.
   [Huang, Liang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China.
   [Cai, Jiaojiao; Zhang, Hong; Qin, Yu; Sun, Haiying; Ding, Wencheng; Wu, Peng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China.
   [Gui, Lingli] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.
RP Wu, P (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr,Key Lab,Minist Educ, Wuhan, Peoples R China.; Wu, P (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China.; Gui, LL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan, Peoples R China.
EM gui_lingli@hotmail.com; pengwu8626@tjh.tjmu.edu.cn
RI Huang, Liang/I-3299-2019
OI Huang, Liang/0000-0002-8370-3232; Meng, Yifan/0000-0002-4673-4603; Ma,
   Ke/0000-0003-1436-3673
FU research-oriented clinician funding program of Tongji Medical College,
   Huazhong University of Science and Technology
FX This work was supported by the research-oriented clinician funding
   program of Tongji Medical College, Huazhong University of Science and
   Technology. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Brosnihan KB, 2008, EXP PHYSIOL, V93, P658, DOI 10.1113/expphysiol.2007.041806
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/ 2020.02.16.20023671, DOI 10.1101/2020.02.16.20023671, 10.1101/2020.02.16.20023671]
   Liu J, 2020, NEUTROPHIL TO LYMPHO, DOI [10.1101/2020.02.10.20021584, DOI 10.1101/2020.02.10.20021584]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y., 2020, LAB DIAGNOSIS MONITO, DOI [10.1101/2020.02.11.20021493, DOI 10.1101/2020.02.11.20021493]
   Yang Y., 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675, DOI 10.1101/2020.02.10.20021675]
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 27
TC 42
Z9 41
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2020
VL 16
IS 4
AR e1008520
DI 10.1371/journal.ppat.1008520
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA LL2DU
UT WOS:000531365400051
PM 32343745
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Guzzi, PH
   Mercatelli, D
   Ceraolo, C
   Giorgi, FM
AF Guzzi, Pietro H.
   Mercatelli, Daniele
   Ceraolo, Carmine
   Giorgi, Federico M.
TI Master Regulator Analysis of the SARS-CoV-2/Human Interactome
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE coronavirus; bioinformatics; gene network analysis; COVID-19; SARS-CoV-2
ID CONVERTING ENZYME 2; CASPASE-DEPENDENT APOPTOSIS; MULTIPLE SEQUENCE
   ALIGNMENT; E3 UBIQUITIN LIGASE; GENE-TRANSCRIPTION; VIRUS-REPLICATION;
   CORONAVIRUS; COMPLEX; SARS; EPIDEMIOLOGY
AB The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. In this paper, we set out to shed light on the SARS-CoV-2/host receptor recognition, a crucial factor for successful virus infection. Based on the current knowledge of the interactome between SARS-CoV-2 and host cell proteins, we performed Master Regulator Analysis to detect which parts of the human interactome are most affected by the infection. We detected, amongst others, affected apoptotic and mitochondrial mechanisms, and a downregulation of the ACE2 protein receptor, notions that can be used to develop specific therapies against this new virus.
C1 [Guzzi, Pietro H.] Univ Catanzaro, Dept Surg & Med Sci, Catanzaro 88100, Italy.
   [Mercatelli, Daniele; Ceraolo, Carmine; Giorgi, Federico M.] Univ Bologna, Dept Pharm & Biotechnol, Bologna 40126, Italy.
RP Giorgi, FM (corresponding author), Univ Bologna, Dept Pharm & Biotechnol, Bologna 40126, Italy.
EM hguzzi@unicz.it; daniele.mercatelli2@unibo.it;
   carmine.ceraolo@studio.unibo.it; federico.giorgi@unibo.it
RI Giorgi, Federico M./AAD-5797-2020
OI Giorgi, Federico M./0000-0002-7325-9908; Mercatelli,
   Daniele/0000-0003-3228-0580
FU CINECACINECA, Italy [HP10CPQJBV, HP10CC5F89]; Italian Ministry of
   University and Research (MIUR)Ministry of Education, Universities and
   Research (MIUR)
FX This research was supported by CINECA, grant numbers HP10CPQJBV and
   HP10CC5F89; this research was also funded by the Italian Ministry of
   University and Research (MIUR).
CR Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593
   Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Bordi L, 2006, ARCH VIROL, V151, P369, DOI 10.1007/s00705-005-0632-8
   Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007
   Burley Stephen K, 2017, Methods Mol Biol, V1607, P627, DOI 10.1007/978-1-4939-7000-1_26
   Caldera Michael, 2017, Current Opinion in Systems Biology, V3, P88, DOI 10.1016/j.coisb.2017.04.015
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Giorgi FM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109569
   Giorgi FM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-553
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   Holding AN, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1698-z
   Jackman SD, 2017, GENOME RES, V27, P768, DOI 10.1101/gr.214346.116
   Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/nmeth.3317, 10.1038/NMETH.3317]
   Kodama Y, 2012, NUCLEIC ACIDS RES, V40, pD54, DOI 10.1093/nar/gkr854
   Kolesnikov N, 2015, NUCLEIC ACIDS RES, V43, pD1113, DOI 10.1093/nar/gku1057
   KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lakshmi BS, 2019, GLOBAL VIROLOGY III: VIROLOGY IN THE 21ST CENTURY, P59, DOI 10.1007/978-3-030-29022-1_3
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267
   Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31
   Lei C., 2020, POTENT NEUTRALIZATIO, DOI [10.1101/2020.02.01.929976, DOI 10.1101/2020.02.01.929976]
   Li C, 2013, ANTIVIR RES, V100, P487, DOI 10.1016/j.antiviral.2013.09.002
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   Liu C, 2001, J VIROL, V75, P6402, DOI 10.1128/JVI.75.14.6402-6409.2001
   Liu P, 2020, ARE PANGOLINS INTERM, DOI [10.1101/2020.02.18.954628, DOI 10.1101/2020.02.18.954628]
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Liu X, 2014, VIRUS RES, V185, P64, DOI 10.1016/j.virusres.2014.03.010
   Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Maruyama T, 2007, CLIN EXP IMMUNOL, V147, P164, DOI 10.1111/j.1365-2249.2006.03249.x
   Mercatelli D, 2020, BIOINFORMATICS, V36, P3916, DOI 10.1093/bioinformatics/btaa223
   Mercatelli D, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194430
   Mercatelli D, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00671
   Munday DC, 2010, PROTEOMICS, V10, P4320, DOI 10.1002/pmic.201000228
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rao VK, 2014, BBA-MOL BASIS DIS, V1842, P1267, DOI 10.1016/j.bbadis.2013.09.003
   Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102
   Reverter A, 2008, BIOINFORMATICS, V24, P2491, DOI 10.1093/bioinformatics/btn482
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Selinger C, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1161
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Sikora D, 2009, VIROLOGY, V390, P71, DOI 10.1016/j.virol.2009.04.022
   Song GH, 2016, NAT IMMUNOL, V17, P1342, DOI 10.1038/ni.3588
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tovar H, 2015, COMPUT BIOL CHEM, V59, P67, DOI 10.1016/j.compbiolchem.2015.08.007
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Vasilevski A, 2012, MOL BIOSYST, V8, P2566, DOI 10.1039/c2mb25096a
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yoshikawa T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008729
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng ZQ, 2018, EUR J CLIN MICROBIOL, V37, P363, DOI 10.1007/s10096-017-3144-z
   Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang ZQ, 2015, ARCH VIROL, V160, P1449, DOI 10.1007/s00705-015-2403-5
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhong YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030191
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 88
TC 32
Z9 32
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2020
VL 9
IS 4
AR 982
DI 10.3390/jcm9040982
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA LL8RF
UT WOS:000531821000089
PM 32244779
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Radovanovic, D
   Rizzi, M
   Pini, S
   Saad, M
   Chiumello, DA
   Santus, P
AF Radovanovic, Dejan
   Rizzi, Maurizio
   Pini, Stefano
   Saad, Marina
   Chiumello, Davide Alberto
   Santus, Pierachille
TI Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients
   with COVID-19: A Management Strategy Proposal
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE continuous positive airway pressure; positive end-expiratory pressure;
   COVID-19; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);
   respiratory failure; helmet; hypoxia; pneumonia
ID POSITIVE AIRWAY PRESSURE; NONINVASIVE VENTILATION; OXYGEN-THERAPY; MASK
AB Since the beginning of March 2020, the coronavirus disease 2019 (COVID-19) pandemic has caused more than 13,000 deaths in Europe, almost 54% of which has occurred in Italy. The Italian healthcare system is experiencing a stressful burden, especially in terms of intensive care assistance. In fact, the main clinical manifestation of COVID-19 patients is represented by an acute hypoxic respiratory failure secondary to bilateral pulmonary infiltrates, that in many cases, results in an acute respiratory distress syndrome and requires an invasive ventilator support. A precocious respiratory support with non-invasive ventilation or high flow oxygen should be avoided to limit the droplets' air-dispersion and the healthcare workers' contamination. The application of a continuous positive airway pressure (CPAP) by means of a helmet can represent an effective alternative to recruit diseased alveolar units and improve hypoxemia. It can also limit the room contamination, improve comfort for the patients, and allow for better clinical assistance with long-term tolerability. However, the initiation of a CPAP is not free from pitfalls. It requires a careful titration and monitoring to avoid a delayed intubation. Here, we discuss the rationale and some important considerations about timing, criteria, and monitoring requirements for patients with COVID-19 respiratory failure requiring a CPAP treatment.
C1 [Radovanovic, Dejan; Rizzi, Maurizio; Pini, Stefano; Saad, Marina; Santus, Pierachille] Univ Milan, Osped L Sacco, ASST Fatebenefratelli Sacco, Dept Biomed & Clin Sci DIBIC,Div Resp Dis, Via GB Grassi 74, I-20157 Milan, Italy.
   [Chiumello, Davide Alberto] Univ Milan, Dipartimento Sci Salute, ASST Santi Paolo & Carlo, SC Anestesia & Rianimaz,Osped San Paolo Polo Univ, Via Antonio Rudini 8, I-20142 Milan, Italy.
   [Chiumello, Davide Alberto] Ctr Ric Coordinata Insufficienza Respiratoria, I-20123 Milan, Italy.
RP Santus, P (corresponding author), Univ Milan, Osped L Sacco, ASST Fatebenefratelli Sacco, Dept Biomed & Clin Sci DIBIC,Div Resp Dis, Via GB Grassi 74, I-20157 Milan, Italy.
EM dejan.radovanovic@asst-fbf-sacco.it; maurizio.rizzi@asst-fbf-sacco.it;
   stefano.pini@unimi.it; marina.saad@icloud.com;
   davide.chiumello@unimi.it; pierachille.santus@unimi.it
OI Radovanovic, Dejan/0000-0002-9013-3418
CR Amatya S, 2017, J PERINATOL, V37, P662, DOI 10.1038/jp.2017.10
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Brambilla AM, 2014, INTENS CARE MED, V40, P942, DOI 10.1007/s00134-014-3325-5
   Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243
   Chiumello D, 2012, MINERVA ANESTESIOL, V78, P1385
   Chiumello D, 2003, INTENS CARE MED, V29, P1671, DOI 10.1007/s00134-003-1825-9
   Chiumello D, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1820-0
   Coppola S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2611-6
   Cosentini R, 2010, CHEST, V138, P114, DOI 10.1378/chest.09-2290
   Crimi C, 2010, EUR RESPIR J, V36, P362, DOI 10.1183/09031936.00123509
   Cunningham D.J.C., 2011, RESP SYSTEM, P475, DOI [DOI 10.1002/CPHY.CP030215, 10.1002/cphy.cp030215]
   EASTON PA, 1986, J APPL PHYSIOL, V61, P906
   Rodriguez AME, 2013, CRIT CARE, V17, DOI 10.1186/cc11875
   Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Milan M, 2011, INTENS CARE MED, V37, P1031, DOI 10.1007/s00134-011-2207-3
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Navalesi P., 2013, PRINCIPLES PRACTICE, P253
   Patroniti N, 2003, INTENS CARE MED, V29, P1680, DOI 10.1007/s00134-003-1931-8
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Racca F, 2005, J APPL PHYSIOL, V99, P1262, DOI 10.1152/japplphysiol.01363.2004
   Radovanovic D, 2016, AM J RESP CRIT CARE, V193
   Richardson Annette, 2006, Intensive Crit Care Nurs, V22, P206, DOI 10.1016/j.iccn.2005.05.007
   Scandroglio M, 2002, Minerva Anestesiol, V68, P475
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Squadrone V, 2005, JAMA-J AM MED ASSOC, V293, P589, DOI 10.1001/jama.293.5.589
   Squadrone V, 2010, INTENS CARE MED, V36, P1666, DOI 10.1007/s00134-010-1934-1
   Taccone P, 2004, CRIT CARE MED, V32, P2090, DOI 10.1097/01.CCM.0000142577.63316.C0
   Tan CW, 2020, AM J HEMATOL, V95, pE156, DOI 10.1002/ajh.25822
   Tang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   WHO, COVID 19 SIT WHO EUR
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 12
Z9 12
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2020
VL 9
IS 4
AR 1191
DI 10.3390/jcm9041191
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LL8RF
UT WOS:000531821000298
PM 32331217
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jiang, YP
   He, SS
   Zhang, C
   Wang, XD
   Chen, X
   Jin, YY
   He, ZB
   Cai, MJ
   Lin, ZM
   Ying, LJ
   Mou, JL
   Zhao, HH
   Lin, RH
   Zhang, S
   Wu, XM
   Chen, HX
   Lv, DQ
AF Jiang, Yongpo
   He, Susu
   Zhang, Chao
   Wang, Xiaodan
   Chen, Xi
   Jin, Yingying
   He, Zebao
   Cai, Minjie
   Lin, Zongmei
   Ying, Lingjun
   Mou, Jianli
   Zhao, Haihong
   Lin, Ronghai
   Zhang, Sheng
   Wu, Xiaomai
   Chen, Haixiao
   Lv, Dongqing
TI Clinical characteristics of 60 discharged cases of 2019 novel
   coronavirus-infected pneumonia in Taizhou, China
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE 2019 novel coronavirus (COVID-19); 2019 novel coronavirus-infection
   pneumonia (COVID-19-infection pneumonia; early treatment; antiviral
AB Background: The number of patients with pneumonia stemming from the 2019 novel coronavirus (COVID-19) infection has increased rapidly. However, the clinical characteristics of discharged patients remain little known. Here, we attempt to describe the clinical characteristics and treatment experiences of discharged cases from Taizhou, China.
   Methods: A total of 60 patients with COVID-19-infected pneumonia who were discharged from Taizhou Enze Medical Center (Group), from January 31, 2020, to February 16, 2020, were included in the analysis. The discharge criteria were based on the New Coronavirus Pneumonia Prevention and Control Program (Fifth Edition, China).
   Results: Of the 60 patients, the median age was 41 years, and 58.3% were male. Only 13.3% of patients were identified as having severe novel coronavirus pneumonia. All patients received combined antiviral treatment on admission, including fl-interferon, lopinavir/tonavir, Abidol and oseltamivir. All patients with severe conditions received gamma globulin and hormone therapy. No patients had endotracheal intubation or died. The median duration from symptom onset to hospitalization was 3 (range, 0-15) days. The median duration of COVID-19 shedding was 14 (range, 5-26) days, and the median duration of hospital stay was 15 (range, 7-23) days.
   Conclusions: Early therapy and comprehensive therapy are key to the outcome for patients with COVID19-in fected pneumonia, especially for those with severe pneumonia.
C1 [Jiang, Yongpo; Zhang, Chao; Jin, Yingying; Cai, Minjie; Lin, Ronghai; Zhang, Sheng] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Crit Care Med, Taizhou 317000, Peoples R China.
   [He, Susu; Chen, Xi; Wu, Xiaomai; Lv, Dongqing] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Resp Med, Taizhou 317000, Peoples R China.
   [Wang, Xiaodan] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Anesthesiol, Taizhou 317000, Peoples R China.
   [He, Zebao; Lin, Zongmei; Ying, Lingjun; Mou, Jianli; Zhao, Haihong] Taizhou Enze Med Ctr Grp Enze Hosp, Taizhou Publ Hlth Ctr, Dept Infect Dis, Taizhou 318050, Peoples R China.
   [Chen, Haixiao] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Orthoped, Taizhou 317000, Peoples R China.
RP Lin, RH; Chen, HX; Lv, DQ (corresponding author), Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, 150 Ximen St, Taizhou 317000, Peoples R China.
EM linrh@enzemed.com; chenhx@enzemed.com; lvdq@enzemed.com
FU Science and Technology Project of Taizhou [1902ky02, 1902ky27]; Natural
   Science Foundation of Zhejiang ProvinceNatural Science Foundation of
   Zhejiang Province [Y20H150029]
FX This work was supported by The Science and Technology Project of Taizhou
   (no. 1902ky02, 1902ky27) and The Natural Science Foundation of Zhejiang
   Province (no. Y20H150029).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kido T, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0597-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Health Commission of China, 2020, NEW COR PNEUM PREV C
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Silverstein WK, 2020, LANCET, V395, P734, DOI 10.1016/S0140-6736(20)30370-6
   Thompson T, 2016, INTENS CARE MED, V42, P921, DOI 10.1007/s00134-016-4255-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, LAB TES 2019 NOV COR
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 3
Z9 3
U1 4
U2 7
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD APR
PY 2020
VL 8
IS 8
AR 547
DI 10.21037/atm.2020.04.20
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA LK5QF
UT WOS:000530920000027
PM 32411770
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Chakraborty, C
   Sharma, AR
   Sharma, G
   Bhattacharya, M
   Lee, SS
AF Chakraborty, C.
   Sharma, A. R.
   Sharma, G.
   Bhattacharya, M.
   Lee, S. S.
TI SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19):
   diagnostic and proposed therapeutic options
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVD-19; SARS-CoV-2; Diagnosis; Proposed therapy
ID CORONAVIRUS OUTBREAK; GLOBAL HEALTH; CHINA; WUHAN; SARS;
   HYDROXYCHLOROQUINE; IDENTIFICATION; CHLOROQUINE; INFECTIONS; INHIBITORS
AB SARS-CoV-2 is responsible for the outbreak of severe respiratory illness (COVID-19) in Wuhan City, China and is now spreading rapidly throughout the world. The prompt outbreak of COVID-19 and its quick spread without any controllable measure defines the severity of the situation. In this crisis, a collective pool of knowledge about the advancement of clinical diagnostic and management for COVID-19 is a prerequisite. Here, we summarize all the available updates on the multidisciplinary approaches for the advancement of diagnosis and proposed therapeutic strategies for COVID-19. Moreover, the review discusses different aspects of the COVID-19, including its epidemiology; incubation period; the general clinical features of patients; the clinical features of intensive care unit (ICU) patients; SARS-CoV-2 infection in the presence of co-morbid diseases and the clinical features of pediatric patients infected with the SARS-CoV-2. Advances in various diagnostic approaches, such as the use of real-time polymerase chain reaction (RTPCR), chest radiography, and computed tomography (CT) imaging; and other modern diagnostic methods, for this infection have been highlighted. However, due to the unavailability of adequate evidence, presently there are no officially approved drugs or vaccines available against SARS-CoV-2. Additionally, we have discussed various therapeutic strategies for COVID-19 under different categories, like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent advancements and strategies for diagnosis and therapy of COVID-19.
C1 [Chakraborty, C.; Sharma, A. R.; Bhattacharya, M.; Lee, S. S.] Hallym Univ, Inst Skeletal Aging & Orthoped Surg, Chuncheon Sacred Heart Hosp, Chuncheon Si, Gangwon Do, South Korea.
   [Sharma, G.] Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea.
   [Chakraborty, C.] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Kolkata, W Bengal, India.
RP Chakraborty, C; Lee, SS (corresponding author), Hallym Univ, Inst Skeletal Aging & Orthoped Surg, Chuncheon Sacred Heart Hosp, Chuncheon Si, Gangwon Do, South Korea.; Chakraborty, C (corresponding author), Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Kolkata, W Bengal, India.
EM drchiranjib@yahoo.com; 123sslee@gmail.com
RI Bhattacharya, Manojit/A-2027-2012
OI Chkraborty, Chiranjib/0000-0002-3958-239X
FU Hallym University Research Fund; Basic Science Research Program through
   the National Research Foundation of Korea (NRF) - Ministry of Education
   [NRF-2017R1A2B4012944]
FX This research was supported by Hallym University Research Fund and by
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education
   (NRF-2017R1A2B4012944).
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Aouadi W, 2017, ANTIVIR RES, V144, P330, DOI 10.1016/j.antiviral.2017.06.021
   Bravo D, 2014, J MED VIROL, V86, P838, DOI 10.1002/jmv.23865
   Cabeca TK, 2012, J CLIN VIROL, V53, P82, DOI 10.1016/j.jcv.2011.09.006
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jiang SB, 2020, CELL MOL IMMUNOL, V17, P554, DOI 10.1038/s41423-020-0372-4
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Join C., 2020, JOIN HANDS FIGHTING
   Kanne JP, 2020, RADIOLOGY, V295, P16, DOI 10.1148/radiol.2020200241
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   McCloskey B, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000254
   Meltzer MI, 2004, EMERG INFECT DIS, V10, P207, DOI 10.3201/eid1002.030426
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Muller H., 1996, CORONAVIRIDAE VIRUSE, P1
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Scholte JBJ, 2014, J CLIN MICROBIOL, V52, P3597, DOI 10.1128/JCM.01494-14
   Sharma G, 2020, PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, 2019, VOL 2A
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Strayer David R., 2014, Infectious Disorders - Drug Targets, V14, P37
   Stupar RM, 2010, P NATL ACAD SCI USA, V107, P21947, DOI 10.1073/pnas.1016809108
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, CLIN MAN AG SEV AC R
   World Health Organization, 2020, LAB TEST 2019 NOV CO
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 53
TC 40
Z9 40
U1 8
U2 12
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 7
BP 4016
EP 4026
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LH4XH
UT WOS:000528789200070
PM 32329877
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ahmad, A
   Rehman, MU
   Alkharfy, KM
AF Ahmad, A.
   Rehman, M. U.
   Alkharfy, K. M.
TI An alternative approach to minimize the risk of coronavirus (Covid-19)
   and similar infections
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; COVID-19; Pandemic; Anti-viral natural products
ID NIGELLA-SATIVA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain that was discovered in 2019 and has not been previously identified in humans. On December 31st 2019 World Health Organization (WHO) was informed of a cluster of cases with pneumonia of unknown origin from Wuhan City, Hubei province of China. The WHO announced in February 2020 that COVID-19 is the official name of the coronavirus diseases. A total of 519,899 confirmed cases with 23,592 deaths linked to this pathogen as on March 27, 2020 have been reported. Due to increasing number of infected people across the continents and huge loss to human life, the WHO has declared the novel COVID-19 outbreak a pandemic. A pandemic is defined as the "worldwide spread" of a new disease. Currently, no COVID-19 specific treatments have been approved by the United States Food and Drug Administration (US FDA). However, the current treatment options include hydroxychloroquine, tocilizumab, remdesivir, lopinavir-ritonavir (Kaletra), and nitazoxanide. In recent past, some natural herbal compounds have demonstrated encouraging anti-viral properties. This article attempted to summarize available information on the reported anti-viral activity of some natural products.
C1 [Ahmad, A.; Rehman, M. U.; Alkharfy, K. M.] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia.
RP Alkharfy, KM (corresponding author), King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia.
EM alkharfy@ksu.edu.sa
RI Rehman, Muneeb U/F-4085-2011
CR Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1
   Al-Bukhari M.I., 1976, COLLECTION AUTHENTIC
   Aldalur I, 2020, BATTERIES SUPERCAPS, V3, P30, DOI 10.1002/batt.201900133
   [Anonymous], 2004, WHO GUID SAF MON HER
   Bennerman BJ, 1983, MED PLANTS PRIMARY H
   Careddu D, 2018, INT J GEN MED, V11, P91, DOI 10.2147/IJGM.S154198
   Cascio A, 2011, CLIN MICROBIOL INFEC, V17, P336, DOI 10.1111/j.1469-0691.2010.03451.x
   Chang JS, 2013, J ETHNOPHARMACOL, V145, P146, DOI 10.1016/j.jep.2012.10.043
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Ekor M, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00177
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Gao Z C, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE001, DOI 10.3760/cma.j.issn.1001-0939.2020.0001
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Lau KM, 2008, J ETHNOPHARMACOL, V118, P79, DOI 10.1016/j.jep.2008.03.018
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lu Q, 2020, J MED VIROL, V92, P564, DOI 10.1002/jmv.25740
   Mahady GB, 2001, J NUTR, V131, p1120S, DOI 10.1093/jn/131.3.1120S
   Mahboubi M, 2018, INTEGR MED RES, V7, P27, DOI 10.1016/j.imr.2018.01.005
   National Health Commission of the People's Republic of China, 2020, HDB PREV TREATM PNEU
   Nii-Trebi NI, 2017, BIOMED RES INT, V2017, P1, DOI 10.1155/2017/5245021
   Roth M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210702
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Salem ML, 2000, INT J IMMUNOPHARMACO, V22, P729, DOI 10.1016/S0192-0561(00)00036-9
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Tavakkoli A, 2017, IRAN J PHARM RES, V16, P2
   Wang KC, 2012, AM J CHINESE MED, V40, P1033, DOI 10.1142/S0192415X12500760
   Witte K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138075
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Yan Jie ML, 2020, CHIN J MICROBIOL IMM, P40
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang Q, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012917
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
NR 38
TC 8
Z9 8
U1 1
U2 13
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 7
BP 4030
EP 4034
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LH4XH
UT WOS:000528789200072
PM 32329879
DA 2021-01-01
ER

PT J
AU Diurno, F
   Numis, FG
   Porta, G
   Cirillo, F
   Maddaluno, S
   Ragozzino, A
   De Negri, P
   Di Gennaro, C
   Pagano, A
   Allegorico, E
   Bressy, L
   Bosso, G
   Ferrara, A
   Serra, C
   Montisci, A
   D'Amico, M
   Lo Morello, SS
   Di Costanzo, G
   Tucci, AG
   Marchetti, P
   Di Vincenzo, U
   Sorrentino, I
   Casciotta, A
   Fusco, M
   Buonerba, C
   Berretta, M
   Ceccarelli, M
   Nunnari, G
   Diessa, Y
   Cicala, S
   Facchini, G
AF Diurno, F.
   Numis, F. G.
   Porta, G.
   Cirillo, F.
   Maddaluno, S.
   Ragozzino, A.
   De Negri, P.
   Di Gennaro, C.
   Pagano, A.
   Allegorico, E.
   Bressy, L.
   Bosso, G.
   Ferrara, A.
   Serra, C.
   Montisci, A.
   D'Amico, M.
   Lo Morello, S. Schiano
   Di Costanzo, G.
   Tucci, A. G.
   Marchetti, P.
   Di Vincenzo, U.
   Sorrentino, I
   Casciotta, A.
   Fusco, M.
   Buonerba, C.
   Berretta, M.
   Ceccarelli, M.
   Nunnari, G.
   Diessa, Y.
   Cicala, S.
   Facchini, G.
TI Eculizumab treatment in patients with COVID-19: preliminary results from
   real life ASL Napoli 2 Nord experience
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; CoVid-19; Treatment; Eculizumab
AB OBJECTIVE: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord.
   PATIENTS AND METHODS: This is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV).
   RESULTS: We treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days.
   CONCLUSIONS: Eculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.
C1 [Diurno, F.; Cirillo, F.; Bressy, L.; Ferrara, A.; Montisci, A.; D'Amico, M.] SM delle Grazie Hosp, Dept Emergency & Crit Care, ASL Napoli Nord 2, Pozzuoli, NA, Italy.
   [Numis, F. G.; Porta, G.; Pagano, A.; Allegorico, E.; Bosso, G.; Serra, C.] SM delle Grazie Hosp, Dept Emergency & Crit Care, ASL Napoli Nord 2, Unit Med & Surg Acceptance & Emergency, Pozzuoli, NA, Italy.
   [Maddaluno, S.; Lo Morello, S. Schiano] SM delle Grazie Hosp, Dept Lab Med, ASL Napoli Nord 2, Unit Lab Clin Pathol, Pozzuoli, NA, Italy.
   [Ragozzino, A.; Di Costanzo, G.; Tucci, A. G.] SM delle Grazie Hosp, Dept Diagnost Imaging, ASL Napoli Nord 2, Pozzuoli, NA, Italy.
   [De Negri, P.; Marchetti, P.] S Giuliano Hosp, Dept Emergency & Crit Care, ASL Napoli Nord 2, Giugliano, NA, Italy.
   [Di Gennaro, C.] A Rizzoli Hosp, Dept Hosp Med, ASL Napoli Nord 2, Unit Internal Med, Ischia, NA, Italy.
   [Di Vincenzo, U.] S Giovanni di Dio Hosp, Dept Emergency & Crit Care, ASL Napoli Nord 2, Frattamaggiore, NA, Italy.
   [Sorrentino, I; Casciotta, A.] SM della Grazie Hosp, Dept Pharm, ASL Napoli Nord 2, Unit Pharm, Pozzuoli, NA, Italy.
   [Fusco, M.] ASL Napoli Nord 2, Dept Pharm, Frattamaggiore, NA, Italy.
   [Buonerba, C.] Zoo Prophylact Inst Southern Italy, Environm & Hlth Operat Unit, Portici, NA, Italy.
   [Berretta, M.] CRO, IRCCS, Ist Nazl Tumori, Dept Med Oncol, Aviano, PN, Italy.
   [Ceccarelli, M.] Univ Catania, Dept Clin & Expt Med, Unit Infect Dis, Catania, Italy.
   [Nunnari, G.] Univ Messina, Dept Clin & Expt Med, Unit Infect Dis, Messina, Italy.
   [Diessa, Y.; Cicala, S.; Facchini, G.] SM della Grazie Hosp, Dept Hosp Med, Unit Med Oncol, ASL Napoli Nord 2, Pozzuoli, NA, Italy.
RP Facchini, G (corresponding author), SM della Grazie Hosp, Dept Hosp Med, Unit Med Oncol, ASL Napoli Nord 2, Pozzuoli, NA, Italy.
EM gaetano.facchini@aslnapoli2nord.it
RI Berretta, Massimiliano/S-5853-2019; Ceccarelli, Manuela/G-6612-2018;
   Nunnari, Giuseppe/AAC-1928-2019; FACCHINI, GAETANO/P-4491-2015
OI Berretta, Massimiliano/0000-0002-9837-9148; Ceccarelli,
   Manuela/0000-0001-5987-3576; Bosso, Giorgio/0000-0002-2759-8343; Pagano,
   Antonio/0000-0003-2322-8457; FACCHINI, GAETANO/0000-0002-7430-001X
CR [Anonymous], EP COVID 19 AGG NAZ
   CDC, 2020, COR DIS 2019 COVID 1
   Ceccarelli M, 2020, EUR REV MED PHARMACO, V24, P2781, DOI 10.26355/eurrev_202003_20551
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   HAMMERSCHMIDT DE, 1980, LANCET, V1, P947
   Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8
   Jodele S, 2020, BLOOD ADV, V4, P1166, DOI 10.1182/bloodadvances.2020001515
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Murphree CR, 2020, J THROMB THROMBOLYS, V49, P602, DOI 10.1007/s11239-020-02094-8
   Nunius C, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01766-0
   Olson SR, 2018, AM J NEPHROL, V48, P96, DOI 10.1159/000492033
   Patel A, 2020, CURR TREAT OPTION NE, V22, DOI 10.1007/s11940-020-0616-8
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Roselli F, 2018, J NEUROTRAUM, V35, P226, DOI 10.1089/neu.2017.5168
   Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 17
TC 87
Z9 92
U1 2
U2 6
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 7
BP 4040
EP 4047
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LH4XH
UT WOS:000528789200074
PM 32329881
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Mejean, A
   Roupret, M
   Rozet, F
   Bensalah, K
   Murez, T
   Game, X
   Rebillard, X
   Mallet, R
   Faix, A
   Mongiat-Artus, P
   Fournier, G
   Neuzillet, Y
AF Mejean, A.
   Roupret, M.
   Rozet, F.
   Bensalah, K.
   Murez, T.
   Game, X.
   Rebillard, X.
   Mallet, R.
   Faix, A.
   Mongiat-Artus, P.
   Fournier, G.
   Neuzillet, Y.
CA Assoc Francaise urologie CCAFU
TI Recommendations CCAFU on the management of cancers of the urogenital
   system during an epidemic with Coronavirus COVID-19
SO PROGRES EN UROLOGIE
LA French
DT Article
DE Prostate cancer; Kidney cancer; Bladder cancer; Testicular cancer;
   Penile cancer; COVID-19
ID CLINICAL-TRIAL; RENAL MASSES; THERAPY; GUIDELINES; DIAGNOSIS; OUTCOMES;
   DELAY
AB Aim. - The French population is facing the COVID-19 pandemic and the health system have been reoriented in emergency for the care of patients with coronavirus. The management of cancers of the urinary and male genital tracts must be adapted to this context.
   Material and method. - An expert opinion documented by a literature review was formulated by the Cancer logy Committee of the French Association of Urology (CCAFU).
   Results. - The medical and surgical management of patients with any cancers of the urinary and male genital tracts must be adapted by modifying the consultation methods, by prioritizing interventions according to the intrinsic prognosis of cancers, taking into account the patient's comorbidi ties. The protection of urologists from COVID-19 must be considered.
   Conclusion. - The CCAFU issues an expert opinion on the measure to be taken to adapt the management of cancers of the male urinary and genital tract to the context of pandemic by COVID-19. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Mejean, A.; Roupret, M.; Rozet, F.; Bensalah, K.; Murez, T.] Com Cancerol Assoc Francaise Urol, 11 Rue Viete, Paris 75017, France.
   [Game, X.; Rebillard, X.; Mallet, R.; Faix, A.; Mongiat-Artus, P.; Fournier, G.; Neuzillet, Y.] Bur Conseil Adm Assoc Francaise Urol, 11 Rue Viete, Paris 75017, France.
RP Neuzillet, Y (corresponding author), Bur Conseil Adm Assoc Francaise Urol, 11 Rue Viete, Paris 75017, France.
EM yneuzillet@afu.fr
RI Bensalah, Karim/ABD-7954-2020
OI Roupret, Morgan/0000-0001-8440-7075
CR Attard G J, 1985, J R Army Med Corps, V131, P140
   Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543
   Boeri L, 2019, EUR UROL ONCOL, V2, P390, DOI 10.1016/j.euo.2018.09.004
   Bourgade V, 2014, WORLD J UROL, V32, P475, DOI 10.1007/s00345-013-1045-z
   Chipollini J, 2017, J UROLOGY, V198, P1347, DOI 10.1016/j.juro.2017.06.076
   D'Amico AV, 2002, CANCER, V95, P281, DOI 10.1002/cncr.10657
   Gao W, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0863-z
   Jimenez-Pacheco A, 2012, ARCH ESP UROL, V65, P542
   Lardas M, 2016, EUR UROL, V70, P265, DOI 10.1016/j.eururo.2015.11.034
   Lu-Yao GL, 2015, EUR UROL, V68, P805, DOI 10.1016/j.eururo.2015.03.021
   McIntosh AG, 2018, EUR UROL, V74, P157, DOI 10.1016/j.eururo.2018.03.011
   Mehrazin R, 2014, J UROLOGY, V192, P659, DOI 10.1016/j.juro.2014.03.038
   Mejean A, 2018, NEW ENGL J MED, V379, P417, DOI 10.1056/NEJMoa1803675
   Mmeje CO, 2018, BJU INT, V122, P89, DOI 10.1111/bju.14211
   MOUL JW, 1990, J UROLOGY, V143, P520, DOI 10.1016/S0022-5347(17)40007-3
   Neuzillet Y, 2012, PROG UROL, V22, P989, DOI 10.1016/j.purol.2012.04.019
   Nouhaud FX, 2018, WORLD J UROL, V36, P1643, DOI 10.1007/s00345-018-2307-6
   Pierorazio PM, 2015, EUR UROL, V68, P408, DOI 10.1016/j.eururo.2015.02.001
   Roupret M, 2018, PROG UROL, V28, pR34, DOI 10.1016/j.purol.2019.01.005
   ROUPRET M, 2018, PROG UROL, V28, pR4, DOI DOI 10.1016/J.PUR0L.2019.01.006
   Rozet F, 2018, PROG UROL, V28, pR81, DOI 10.1016/j.purol.2019.01.007
   Shabbir M, 2014, NAT REV UROL, V11, P702, DOI 10.1038/nrurol.2014.307
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wilt TJ, 2020, EUR UROL, DOI DOI 10.1016/J.EURUR0.2020.02.009
NR 24
TC 9
Z9 11
U1 1
U2 3
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 1166-7087
J9 PROG UROL
JI Prog. Urol.
PD APR
PY 2020
VL 30
IS 5
BP 221
EP 231
DI 10.1016/j.purol.2020.03.009
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA LK2MU
UT WOS:000530695100002
PM 32224294
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Reiner, Z
   Hatamipour, M
   Banach, M
   Pirro, M
   Al-Rasadi, K
   Jamialahmadi, T
   Radenkovic, D
   Montecucco, F
   Sahebkar, A
AF Reiner, Zeljko
   Hatamipour, Mahdi
   Banach, Maciej
   Pirro, Matteo
   Al-Rasadi, Khalid
   Jamialahmadi, Tannaz
   Radenkovic, Dina
   Montecucco, Fabrizio
   Sahebkar, Amirhossein
TI Statins and the COVID-19 main protease: in silico evidence on direct
   interaction
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE COVID-2019; main protease; statins; 6LU7; docking
ID THERAPY; METAANALYSIS
AB Introduction: No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COVID-19 Mpro inhibitors, using a molecular docking study.
   Material and methods: Molecular docking was performed using AutoDock/Vina, a computational docking program. SARS-CoV-2 Mpro was docked with all statins, while antiviral and antiretroviral drugs - favipiravir, nelfinavir, and lopinavir - were used as standards for comparison.
   Results: The binding energies obtained from the docking of 6LU7 with native ligand favipiravir, nelfinavir, lopinavir, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin, and atorvastatin were -6.8, -5.8, -7.9, -7.9, -7.0, -7.7, -6.6, -8.2, -7.4, -7.7, and -6.8 kcal/mol, respectively. The number of hydrogen bonds between statins and amino acid residues of Mpro were 7, 4, and 3 for rosuvastatin, pravastatin, and atorvastatin, respectively, while other statins had two hydrogen bonds.
   Conclusions: These results indicate, based upon the binding energy of pitavastatin, rosuvastatin, lovastatin, and fluvastatin, that statins could be efficient SARS-CoV-2 Mpro inhibitors. This is supported by the fact that the effects of some statins, especially pitavastatin, have a binding energy that is even greater than that of protease or polymerase inhibitors. However, further research is necessary to investigate their potential use as drugs for COVID-19.
C1 [Reiner, Zeljko] Univ Hosp Ctr Zagreb, Dept Internal Med, Zagreb, Croatia.
   [Hatamipour, Mahdi] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Nanotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Hatamipour, Mahdi] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Razavi Khorasan, Iran.
   [Banach, Maciej] Med Univ Lodz, WAM Univ Hosp Lodz, Dept Hypertens, 113 Zeromskiego St, PL-90549 Lodz, Poland.
   [Banach, Maciej] PMMHRI, Lodz, Poland.
   [Pirro, Matteo] Univ Perugia, Dept Med, Unit Internal Med Angiol & Arteriosclerosis Dis, Perugia, Italy.
   [Al-Rasadi, Khalid] Sultan Qaboos Univ Hosp, Dept Clin Biochem, Muscat, Oman.
   [Jamialahmadi, Tannaz] Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran.
   [Jamialahmadi, Tannaz] Mashhad Univ Med Sci, Fac Med, Dept Nutr, Mashhad, Razavi Khorasan, Iran.
   [Radenkovic, Dina] Guys & St Thomas NHS Fdn Trust, London SE1 7EH, England.
   [Montecucco, Fabrizio] Univ Genoa, Dept Internal Med, Clin Internal Med 1, Genoa, Italy.
   [Montecucco, Fabrizio] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy.
   [Montecucco, Fabrizio] IRCCS Osped Policlin San Martino Genoa, Italian Cardiovasc Network, Genoa, Italy.
   [Sahebkar, Amirhossein] FDA, Halal Res Ctr IRI, Tehran, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran.
RP Banach, M (corresponding author), Med Univ Lodz, WAM Univ Hosp Lodz, Dept Hypertens, 113 Zeromskiego St, PL-90549 Lodz, Poland.; Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad 9177948564, Razavi Khorasan, Iran.
EM maciejbanach77@gmail.com; sahebkara@mums.ac.ir
RI Al-Rasadi, Khalid/ABB-7852-2020; Sahebkar, Amirhossein/B-5124-2018;
   Banach, Maciej/A-1271-2009
OI Al-Rasadi, Khalid/0000-0003-0460-1236; Banach,
   Maciej/0000-0001-6690-6874
CR Banach M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0459-4
   Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI 10.1056/NEJMc1312359
   Chrusciel P, 2016, ATHEROSCLEROSIS, V253, P194, DOI 10.1016/j.atherosclerosis.2016.07.897
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fedson DS, 2015, J INFECT DIS, V211, P661, DOI 10.1093/infdis/jiu474
   Gbinigie K, 2020, BJGP OPEN, DOI [10.3399/bjgpopen20X101069, DOI 10.3399/BJGPOPEN20X101069.]
   Jin Z, 2020, BIORXIV, DOI [10.1101/2020.02.26.964882, DOI 10.1101/2020.02.26.964882]
   Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503
   Khaerunnisa S, 2000, POTENTIAL INHIBITOR, P1, DOI 10.20944/preprints202003.0226.v1
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Liu X, 2020, RCSB PROTEIN DATA BA, DOI [10.2210/ pdb6LU7/pdb., DOI 10.2210/PDB6LU7/PDB.]
   Nabavi SF, 2020, ARCH MED SCI, V16, P519, DOI 10.5114/aoms.2020.94504
   Parizadeh SMR, 2011, LIPIDS, V46, P333, DOI 10.1007/s11745-010-3517-x
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Piechota M, 2013, CURR VASC PHARMACOL, V11, P795, DOI 10.2174/1570161111311050018
   Pirro M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010118
   Reiner Z, 2015, NAT REV CARDIOL, V12, P565, DOI 10.1038/nrcardio.2015.92
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Sahebkar A, 2015, THROMB HAEMOSTASIS, V114, P546, DOI 10.1160/TH14-11-0937
   Sahebkar A, 2015, ATHEROSCLEROSIS, V241, P433, DOI 10.1016/j.atherosclerosis.2015.05.022
   Sahebkar A, 2013, CARDIOVASC DRUG THER, V27, P559, DOI 10.1007/s10557-013-6479-4
   Shrivastava-Ranjan P, 2018, MBIO, V9, DOI [10.1128/mBio.00660-18, 10.1128/mbio.00660-18]
   Vuorio A, 2020, J INTERN MED, V287, P746, DOI 10.1111/joim.13070
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.01.27.921627., DOI 10.1101/2020.01.27.921627]
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yende S, 2011, CRIT CARE MED, V39, P1871, DOI 10.1097/CCM.0b013e31821b8290
NR 26
TC 27
Z9 28
U1 2
U2 13
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD APR
PY 2020
VL 16
IS 3
BP 490
EP 496
DI 10.5114/aoms.2020.94655
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LI9SW
UT WOS:000529817100002
PM 32399094
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Azeez, SA
   Alhashim, ZG
   Al Otaibi, WM
   Alsuwat, HS
   Ibrahim, AM
   Almandil, NB
   Borgio, JF
AF Azeez, Sayed Abdul
   Alhashim, Zahra Ghalib
   Al Otaibi, Waad Mohammed
   Alsuwat, Hind Saleh
   Ibrahim, Abdallah M.
   Almandil, Noor B.
   Borgio, J. Francis
TI State-of-the-art tools to identify druggable protein ligand of
   SARS-CoV-2
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; SARS-CoV-2; druggable protein; ligand; nucleocapsid
   phosphoprotein; molecular docking; envelope protein; phylogenetic tree
ID CORONAVIRUS NUCLEOCAPSID PROTEIN; ENVELOPE PROTEIN; GLOBAL HEALTH;
   BINDING; GENERATION; OUTBREAK; SITE
AB Introduction: The SARS-CoV-2 (previously 2019-nCoV) outbreak in Wuhan, China and other parts of the world affects people and spreads coronavirus disease 2019 (COVID-19) through human-to-human contact, with a mortality rate of > 2%. There are no approved drugs or vaccines yet available against SARS-CoV-2.
   Material and methods: State-of-the-art tools based on in-silico methods are a cost-effective initial approach for identifying appropriate ligands against SARS-CoV-2. The present study developed the 3D structure of the envelope and nucleocapsid phosphoprotein of SARS-CoV-2, and molecular docking analysis was done against various ligands.
   Results: The highest log octanol/water partition coefficient, high number of hydrogen bond donors and acceptors, lowest non-bonded interaction energy between the receptor and the ligand, and high binding affinity were considered for the best ligand for the envelope (mycophenolic acid: log P = 3.00; Delta G = -10.2567 kcal/mol; pKi = 7.713 NM) and nucleocapsid phosphoprotein (1-[(2,4-dichlorophenyl)methyl]pyrazole-3,5-dicarboxylic acid: log P = 2.901; Delta G = -12.2112 kcal/mol; pKi = 7.885 mu M) of SARS-CoV-2.
   Conclusions: The study identifies the most potent compounds against the SARS-CoV-2 envelope and nucleocapsid phosphoprotein through state-ofthe-art tools based on an in-silico approach. A combination of these two ligands could be the best option to consider for further detailed studies to develop a drug for treating patients infected with SARS-CoV-2, COVID-19.
C1 [Azeez, Sayed Abdul; Alhashim, Zahra Ghalib; Al Otaibi, Waad Mohammed; Alsuwat, Hind Saleh; Ibrahim, Abdallah M.; Borgio, J. Francis] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Genet Res, Dammam, Saudi Arabia.
   [Alhashim, Zahra Ghalib] Imam Abdulrahman Bin Faisal Univ, Coll Clin Pharm, Dammam, Saudi Arabia.
   [Ibrahim, Abdallah M.] Imam Abdulrahman Bin Faisal Univ, Coll Nursing, Dept Fundamentals Nursing, Dammam, Saudi Arabia.
   [Almandil, Noor B.] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Clin Pharm Res, Dammam, Saudi Arabia.
   [Borgio, J. Francis] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Epidem Dis Res, Dammam, Saudi Arabia.
RP Borgio, JF (corresponding author), Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Genet Res, Dammam, Saudi Arabia.
EM fbalexander@iau.edu.sa
RI Borgio, J Francis/P-5586-2014; Sayed, Abdulazeez/I-6770-2019
OI Borgio, J Francis/0000-0001-7199-1540; Sayed,
   Abdulazeez/0000-0002-9763-9446; Alsuwat, Hind/0000-0001-9773-9765
CR Abdulazeez S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212492
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Boscarino JA, 2008, J VIROL, V82, P2989, DOI 10.1128/JVI.01906-07
   Botta L, 2018, FRONT BIOSCI-LANDMRK, V23, P997, DOI 10.2741/4630
   Cardenas-Conejo Y, 2020, J MED VIROL, V92, P688, DOI 10.1002/jmv.25758
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chemical Computing Group ULC, 2017, MOL OP ENV MOE 09
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Galloux M, 2012, J VIROL, V86, P8375, DOI 10.1128/JVI.00058-12
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Organization W.H., 2019, CLIN MAN SEV AC RESP
   Ouizougun-Oubari M, 2015, J VIROL, V89, P11129, DOI 10.1128/JVI.01612-15
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Stodola JK, 2018, VIROLOGY, V515, P134, DOI 10.1016/j.virol.2017.12.023
   Sungsuwan S, 2020, VIROLOGY, V540, P45, DOI 10.1016/j.virol.2019.11.007
   Surjit M, 2005, J VIROL, V79, P11476, DOI 10.1128/JVI.79.17.11476-11486.2005
   Tran TL, 2007, J GEN VIROL, V88, P196, DOI 10.1099/vir.0.82282-0
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Westerbeck JW, 2019, J VIROL, V93, DOI [10.1128/JVI.00015-19, 10.1128/jvi.00015-19]
   World Health Organization, 2020, NAM COR DIS COVID 19
   Wu F, 2020, BIORXIV, p20200124919183, DOI [10.1101/2020.01.24.919183, DOI 10.1101/2020.01.24.919183]
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 36
TC 1
Z9 1
U1 3
U2 9
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD APR
PY 2020
VL 16
IS 3
BP 497
EP 507
DI 10.5114/aoms.2020.94046
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA LI9SW
UT WOS:000529817100003
PM 32399095
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borgio, JF
   Alsuwat, HS
   Al Otaibi, WM
   Ibrahim, AM
   Almandil, NB
   Al Asoom, LI
   Salahuddin, M
   Kamaraj, B
   AbdulAzeez, S
AF Borgio, J. Francis
   Alsuwat, Hind Saleh
   Al Otaibi, Waad Mohammed
   Ibrahim, Abdallah M.
   Almandil, Noor B.
   Al Asoom, Lubna Ibrahim
   Salahuddin, Mohammed
   Kamaraj, Balu
   AbdulAzeez, Sayed
TI State-of-the-art tools unveil potent drug targets amongst clinically
   approved drugs to inhibit helicase in SARS-CoV-2
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; SARS CoV-2; clinically approved drugs; molecular docking;
   helicase; antiretroviral agents
ID CORONAVIRUS; GENERATION
AB Introduction: The extreme health and economic problems in the world due to the SARS CoV-2 infection have led to an urgent need to identify potential drug targets for treating coronavirus disease 2019 (COVID-19). The present state-of-the-art tool-based screening was targeted to identify drug targets among clinically approved drugs by uncovering SARS-CoV-2 helicase inhibitors through molecular docking analysis.
   Material and methods: Helicase is a vital viral replication enzyme, which unwinds nucleic acids and separates the double-stranded nucleic acids into single-stranded nucleic acids. Hence, the SARS-CoV-2 helicase protein 3D structure was predicted, validated, and used to screen the druggable targets among clinically approved drugs such as protease inhibitor, nucleoside reverse transcriptase inhibitor, and non-nucleoside reverse transcriptase inhibitors, used to treat HIV infection using molecular docking analysis.
   Results: Interaction with SARS-CoV-2 helicase, approved drugs, vapreotide (affinity: - 12.88; S score: -9.84 kcal/mol), and atazanavir (affinity: - 11.28; S score: - 9.32 kcal/mol), approved drugs for treating AIDS-related diarrhoea and HIV infection, respectively, are observed with significantly low binding affinity and MOE score or binding free energy. The functional binding pockets of the clinically approved drugs on SARS CoV-2 helicase protein molecule suggest that vapreotide and atazanavir may interrupt the activities of the SARS-CoV-2 helicase.
   Conclusions: The study suggests that vapreotide may be a choice of drug for wet lab studies to inhibit the infection of SARS CoV-2.
C1 [Borgio, J. Francis; Alsuwat, Hind Saleh; Al Otaibi, Waad Mohammed; Ibrahim, Abdallah M.; AbdulAzeez, Sayed] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Genet Res, Dammam, Saudi Arabia.
   [Borgio, J. Francis] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Epidem Dis Res, Dammam, Saudi Arabia.
   [Ibrahim, Abdallah M.] Imam Abdulrahman Bin Faisal Univ, Coll Nursing, Dept Fundamentals Nursing, Dammam, Saudi Arabia.
   [Almandil, Noor B.] Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Clin Pharm Res, Dammam, Saudi Arabia.
   [Al Asoom, Lubna Ibrahim] Imam Abdulrahman Bin Faisal Univ Dammam, Coll Med, Dept Physiol, Dammam, Saudi Arabia.
   [Salahuddin, Mohammed] Imam Abdulrahman Bin Faisal Univ, IRMC, Anim House Unit, Dammam, Saudi Arabia.
   [Kamaraj, Balu] Imam Abdulrahman Bin Faisal Univ, Coll Appl Med Sci, Dept Neurosci Technol, Jubail Ind City, Saudi Arabia.
RP AbdulAzeez, S (corresponding author), Imam Abdulrahman Bin Faisal Univ, IRMC, Dept Genet Res, Dammam, Saudi Arabia.
EM asayed@iau.edu.sa
RI Sayed, Abdulazeez/I-6770-2019; Kamaraj, Balu/AAE-2852-2019; Borgio, J
   Francis/P-5586-2014; Salahuddin, Dr Mohammed/A-3541-2015
OI Sayed, Abdulazeez/0000-0002-9763-9446; Kamaraj,
   Balu/0000-0002-9747-3984; Borgio, J Francis/0000-0001-7199-1540;
   Alsuwat, Hind/0000-0001-9773-9765; Salahuddin, Dr
   Mohammed/0000-0002-6991-755X
FU Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University,
   Dammam, Saudi Arabia [Covid19-2020-007-IRMC]
FX The authors thank the Dean, Institute for Research and Medical
   Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam,
   Saudi Arabia for her continuous support and encouragement. The authors
   thank Mr. Ranilo. M. Tumbaga, and Mr. Horace T. Pacifico for their
   support and assistance. The project is funded by Deanship of Scientific
   Research (Covid19-2020-007-IRMC), Imam Abdulrahman Bin Faisal
   University, Dammam, Saudi Arabia.
CR Adedeji AO, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00235-16
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Azeez SA, 2020, ARCH MED SCI, V16, P497, DOI 10.5114/aoms.2020.94046
   Chemical Computing Group ULC, 2017, MOL OP ENV MOE 09
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Colonno RJ, 2003, ANTIMICROB AGENTS CH, V47, P1324, DOI 10.1128/AAC.47.4.1324-1333.2003
   Cui Sheng, 2020, Methods Mol Biol, V2099, P69, DOI 10.1007/978-1-0716-0211-9_6
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   GIRARD PM, 1992, AIDS, V6, P715, DOI 10.1097/00002030-199207000-00015
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kemnic TR, 2019, HIV ANTIRETROVIRAL T
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Liu X, 2020, BIORXIV, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100.]
   Organization W.H., 2019, CLIN MAN SEV AC RESP
   Patel PH, 2019, STATPEARLS
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pillaiyar T, 2020, DRUG DISCOV TODAY, DOI [10.1016/j.drudis.2020.01.015, DOI 10.1016/J.DRUDIS.2020.01.015.]
   Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   WHO, 2020, US 675000000 NEED NE
   WHO, 2020, WHO EM PREP RESP PNE
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Xiaoyu W., 2020, CHINA DAILY
NR 32
TC 11
Z9 11
U1 3
U2 10
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD APR
PY 2020
VL 16
IS 3
BP 508
EP 518
DI 10.5114/aoms.2020.94567
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA LI9SW
UT WOS:000529817100004
PM 32399096
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nabavi, SF
   Habtemariam, S
   Clementi, E
   Berindan-Neagoe, I
   Cismaru, CA
   Rasekhian, M
   Banach, M
   Izadi, M
   Bagheri, M
   Bagheri, MS
   Nabavi, SM
AF Nabavi, Seyed Fazel
   Habtemariam, Solomon
   Clementi, Emilio
   Berindan-Neagoe, Ioana
   Cismaru, Cosmin Andrei
   Rasekhian, Mahsa
   Banach, Maciej
   Izadi, Morteza
   Bagheri, Mahdi
   Bagheri, Mohammad Sadegh
   Nabavi, Seyed Mohammad
TI Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson
   tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
AB SARS-CoV-2 is a newly emerging infectious disease, which originated from Wuhan in the Hubei province of China in late December 2019 [1]. Since then, it has rapidly spread all over the world, and at the time of writing this letter, WHO statistics show more than 1,696,588 cases and 105,952 deaths confirmed across the world [2]. Although there is no specific therapy for SARS-CoV-2 infection [3], combination therapy with antiviral and anti-inflammatory drugs accompanied by supportive treatment have been used for SARS-CoV-2 patients [4]. The combination of well-known HIV protease inhibitors, such as ritonavir with lopinavir, has also been a common approach to treat SARS-CoV-2. Insufficient outcome in severe cases is, however, one of the main challenges associated with the current antiviral-based therapy for SARS-CoV-2 [5]. In view of the long period required for novel drug discovery and the desperate need for a prompt response to this pandemic infection, one must resort to repurposing FDA-approved drugs. In this direction, our experience with other close members of coronaviruses such as SARS and MERS has taught us that repurposing the current drugs is a reasonable strategy.
   Abelson tyrosine-protein kinase 2 (Abl2), the imatinib target, was required for efficient SARS-CoV and MERS-CoV replication in vitro [6]. Coleman et al. have shown that the imatinib target Abl2 is indispensable for efficient replication of SARS-CoV and MERS-CoV in vitro.
C1 [Nabavi, Seyed Fazel; Izadi, Morteza; Bagheri, Mahdi; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Tehran, Iran.
   [Habtemariam, Solomon] Univ Greenwich, Pharmacognosy Res Labs, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Habtemariam, Solomon] Univ Greenwich, Herbal Anal Serv, Cent Ave, Chatham ME4 4TB, Kent, England.
   [Clementi, Emilio] E Medea Sci Inst, Bosisio Parini, Italy.
   [Clementi, Emilio] Univ Milan, Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci, Unit Clin Pharmacol, Milan, Italy.
   [Berindan-Neagoe, Ioana; Cismaru, Cosmin Andrei] Iuliu Hatieganu Univ Med & Pharm, Res Ctr funct Gen Biomed & Translat Med, Cluj Napoca, Romania.
   [Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Res Ctr Adv Med Medfuture, Cluj Napoca, Romania.
   [Cismaru, Cosmin Andrei] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Dept Funct Sci Immunol & Allergol, Cluj Napoca, Romania.
   [Rasekhian, Mahsa] Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Hlth Inst, Kermanshah, Iran.
   [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Chair Nephrol & Hypertens, Lodz, Poland.
   [Banach, Maciej] PMMHRI, Lodz, Poland.
   [Bagheri, Mohammad Sadegh] Baqiyatallah Univ Med Sci, Student Res Comm, Tehran, Iran.
RP Nabavi, SM (corresponding author), Baqiyatallah Univ Med Sci, Baqiyatallah Hosp, Tehran, Iran.; Banach, M (corresponding author), Med Univ Lodz, Dept Hypertens, Chair Nephrol & Hypertens, Lodz, Poland.
EM maciejbanach77@gmail.com; Nabavi208@gmail.com
RI Banach, Maciej/A-1271-2009; Cismaru, Cosmin Andrei/AAD-1810-2020;
   Nabavi, Seyed Fazel/A-2223-2010
OI Banach, Maciej/0000-0001-6690-6874; Cismaru, Cosmin
   Andrei/0000-0001-5716-8101; 
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503
   Shin JS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060283
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang L, 2020, INT J ANTIMICROB AG, P105948, DOI DOI 10.1016/J.IJANTIMICAG.2020.105948.
   World Health Organization, 2020, COR DIS 2019 COVID 1
NR 9
TC 4
Z9 4
U1 0
U2 0
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD APR
PY 2020
VL 16
IS 3
BP 519
EP 521
DI 10.5114/aoms.2020.94504
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA LI9SW
UT WOS:000529817100005
PM 32399097
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wu, FQ
   Zhang, WL
   Zhang, LG
   Wang, D
   Wan, YX
AF Wu, Fanqi
   Zhang, Wenli
   Zhang, Longguo
   Wang, Dan
   Wan, Yixin
TI Discontinuation of antiviral drugs may be the reason for recovered
   COVID-19 patients testing positive again
SO BRITISH JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
C1 [Wu, Fanqi; Wan, Yixin] Lanzhou Univ, Dept Resp Med, Hosp 2, Lanzhou, Peoples R China.
   [Zhang, Wenli] Lanzhou Pulm Hosp, Ward 2, Lanzhou, Peoples R China.
   [Zhang, Longguo; Wang, Dan] Lanzhou Univ, Clin Med Sch 2, Lanzhou, Peoples R China.
RP Wan, YX (corresponding author), Lanzhou Univ, Dept Resp Med, Hosp 2, Lanzhou, Peoples R China.
EM Izshwanyixin@163.com
FU Gansu Provincial COVID-19 Science and Technology Major Project, China
FX This work was supported by the Gansu Provincial COVID-19 Science and
   Technology Major Project, China.
CR Foreign Affairs Office of Tianjin Municipal People's Government, 2020, PAT REC COVID 19 TES
   National Health Commission of the People's Republic of China, 2020, GUID VIR NUCL AC TES
   National Health Commission of the People's Republic of China, 2020, CHIN J VIRAL DIS, V10, P88, DOI [10.16505/j.2095-0136.2020.0016, DOI 10.16505/J.2095-0136.2020.0016]
   Xie X, 2020, RADIOLOGY, V2020, P200343, DOI DOI 10.1148/RADIOL.2020200343
NR 4
TC 7
Z9 7
U1 1
U2 2
PU MA HEALTHCARE LTD
PI LONDON
PA ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND
SN 1750-8460
EI 1759-7390
J9 BRIT J HOSP MED
JI Br. J. Hosp. Med.
PD APR
PY 2020
VL 81
IS 4
DI 10.12968/hmed.2020.0156
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA LK0VI
UT WOS:000530577700020
PM 32339007
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sorbera, LA
   Graul, AI
   Dulsat, C
AF Sorbera, L. A.
   Graul, A. I.
   Dulsat, C.
TI Taking aim at a fast-moving target: targets to watch for SARS-CoV-2 and
   COVID-19
SO DRUGS OF THE FUTURE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Coronavirus; Therapeutic targets
ID N-METHYLTRANSFERASE; T-CELLS; CORONAVIRUS; INFECTION; HISTAMINE;
   APOPTOSIS; PROTEIN
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized as a betacoronavirus and recognized as the seventh discrete coronavirus species capable of causing human disease. This new coronavirus causes febrile respiratory illness and on March 11, 2020, was characterized as a global pandemic. Investigators have accelerated the search for a vaccine to prevent infection and for agents to treat it. This article presents those drug targets that (as of March 20, 2020) are currently under active investigation for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.
C1 [Sorbera, L. A.; Graul, A. I.; Dulsat, C.] Clarivate Analyt, Barcelona, Spain.
RP Sorbera, LA (corresponding author), Clarivate Analyt, Barcelona, Spain.
EM lisa.sorbera@clarivate.com
CR Barnes WG, 2002, J NEUROCHEM, V82, P1262, DOI 10.1046/j.1471-4159.2002.01063.x
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cascella M, 2020, FEATURES EVALUATION
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen HJ, 2019, POULTRY SCI, V98, P6367, DOI 10.3382/ps/pez465
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen ZN, 2005, J INFECT DIS, V191, P755, DOI 10.1086/427811
   CONTI P, 2020, J BIOL REGUL HOMEOST, V33, DOI DOI 10.1111/DTH.13191
   Dong SJ, 2020, J MED VIROL, V92, P1542, DOI 10.1002/jmv.25768
   Glass WG, 2003, VIROLOGY, V312, P407, DOI 10.1016/S0042-6822(03)00237-X
   Guegan JP, 2018, FEBS J, V285, P809, DOI 10.1111/febs.14292
   Guo RQ, 2020, ADV ELECTRON MATER, V6, DOI 10.1002/aelm.202000035
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hoffmann M, 2020, CELL
   Hornick EE, 2019, J CLIN INVEST, V129, P2888, DOI 10.1172/JCI124937
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ji HL, 2009, AM J PHYSIOL-LUNG C, V296, pL372, DOI 10.1152/ajplung.90437.2008
   Lin MN, 2020, J CHEM INF MODEL, V60, P162, DOI 10.1021/acs.jcim.9b00746
   Liu C., 2020, ACS CENT SCI
   Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com
   Mahmud-Al-Rafat A, 2019, CYTOKINE, V115, P13, DOI 10.1016/j.cyto.2018.12.008
   Malet H, 2008, ANTIVIR RES, V80, P23, DOI 10.1016/j.antiviral.2008.06.007
   Mizutani T, 2007, ANN NY ACAD SCI, V1102, P86, DOI 10.1196/annals.1408.006
   O'Donnell JA, 2015, J LEUKOCYTE BIOL, V97, P321, DOI 10.1189/jlb.3AB1113-594RR
   Paules C.I., 2020, JAMA
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Wang LW, 2002, BIOCHEM PHARMACOL, V64, P699, DOI 10.1016/S0006-2952(02)01223-6
   Zhang JY, 2020, EMERG MICROBES INFEC, V9, P439, DOI 10.1080/22221751.2020.1722758
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 1
Z9 1
U1 0
U2 8
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD APR
PY 2020
VL 45
IS 4
BP 239
EP 244
DI 10.1358/dof.2020.45.4.3150676
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LI3QA
UT WOS:000529399000003
DA 2021-01-01
ER

PT J
AU Ravikumar, N
   Nallasamy, K
   Bansal, A
   Angurana, SK
   Basavaraja, GV
   Sundaram, M
   Lodha, R
   Gupta, D
   Jayashree, M
AF Ravikumar, Namita
   Nallasamy, Karthi
   Bansal, Arun
   Angurana, Suresh Kumar
   Basavaraja, G. V.
   Sundaram, Manu
   Lodha, Rakesh
   Gupta, Dhiren
   Jayashree, Muralidharan
CA Intensive Care Chapter Indian Acad
TI Novel Coronavirus 2019 (2019-nCoV) Infection: Part I-Preparedness and
   Management in the Pediatric Intensive Care Unit in Resource-limited
   Settings
SO INDIAN PEDIATRICS
LA English
DT Article
DE COVID-19; Guideline; Pandemic; SARI; Treatment
ID PNEUMONIA; WUHAN; CHINA
AB First reported in China, the 2019 novel coronavirus has been spreading across the globe. Till 26 March, 2020, 416,686 cases have been diagnosed and 18,589 have died the world over. The coronavirus disease mainly starts with a respiratory illness and about 5-16% require intensive care management for acute respiratory distress syndrome (ARDS) and multi-organ dysfunction. Children account for about 1-2% of the total cases, and 6% of these fall under severe or critical category requiring pediatric intensive care unit (PICU) care. Diagnosis involves a combination of clinical and epidemiological features with laboratory confirmation. Preparedness strategies for managing this pandemic are the need of the hour, and involve setting up cohort ICUs with isolation rooms. Re-allocation of resources in managing this crisis involves careful planning, halting elective surgeries and training of healthcare workers. Strict adherence to infection control like personal protective equipment and disinfection is the key to contain the disease transmission. Although many therapies have been tried in various regions, there is a lack of strong evidence to recommend anti-virals or immunomodulatory drugs.
C1 [Ravikumar, Namita; Nallasamy, Karthi; Bansal, Arun; Angurana, Suresh Kumar; Jayashree, Muralidharan] Postgrad Inst Med Educ & Res PGIMER, Adv Paediat Ctr, Dept Paediat, Div Pediat Crit Care, Chandigarh, India.
   [Basavaraja, G. V.] Indira Gandhi Inst Child Hlth, Paediat Intens Care Unit, Bangalore, Karnataka, India.
   [Sundaram, Manu] Sidra Med, Div Crit Care Med, Doha, Qatar.
   [Lodha, Rakesh] All India Inst Med Sci, Dept Pediat, New Delhi, India.
   [Gupta, Dhiren] Sir Ganga Ram Hosp, Pediat Intens Care Unit, New Delhi, India.
RP Bansal, A (corresponding author), Postgrad Inst Med Educ & Res, Dept Pediat, Adv Pediat Ctr, Chandigarh, India.
EM drarunbansal@gmail.com
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, INSTR US
   [Anonymous], 2020, ADV US MASKS COMM HO
   [Anonymous], 2019, CORONAVIRUS DIS
   [Anonymous], 2020, COVID 19 GUID VERS 1
   [Anonymous], WHO2019NCOVCLINICAL2
   [Anonymous], 2020, REC EMP US HYDR CHLO
   [Anonymous], 2020, PRESS REL FAST TRACK
   [Anonymous], 2020, LAB TEST COR DIS 201
   Cao B, 2020, NEW ENGL J MED
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen L, 2020, LANCET INFECT DIS
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Dong C.-F., 2020, 1 CASE COVID 19 INFE
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grasselli G, 2020, JAMA
   Han SW, 2020, CANCER MED-US, V9, P6667, DOI 10.1002/cam4.3289
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Hu Qi DongMo YX, 2020, PEDIATRICS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Indian Council of Medical Research, 2020, REV STRAT COVID19 TE
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Lee P-I, 2020, JMICROBIOL IMMUNOL I
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu X, 2020, NEW ENGLAND J MED
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Murthy S, 2020, JAMA
   Onder G, 2020, JAMA
   Pan F, 2020, TIME COURSE LUNG CHA
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X F, 2020, Zhonghua Er Ke Za Zhi, V58, pE008, DOI 10.3760/cma.j.issn.0578-1310.2020.0008
   Wang YJW, 2020, EARLY LOW DOSE SHORT
   Whyler NCA, 2019, MED J AUSTRALIA, V211, P501, DOI 10.5694/mja2.50416
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia W, 2020, CLIN CT FEATURES PED
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Yoon SH, 2020, KOREAN J RADIOL, V21, P494, DOI 10.3348/kjr.2020.0132
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 46
TC 5
Z9 5
U1 2
U2 7
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD APR
PY 2020
VL 57
IS 4
BP 324
EP 334
DI 10.1007/s13312-020-1785-y
PG 11
WC Pediatrics
SC Pediatrics
GA LH1ZI
UT WOS:000528586900013
PM 32238612
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baron, SA
   Devaux, C
   Colson, P
   Raoult, D
   Rolain, JM
AF Baron, Sophie Alexandra
   Devaux, Christian
   Colson, Philippe
   Raoult, Didier
   Rolain, Jean-Marc
TI Teicoplanin: an alternative drug for the treatment of COVID-19?
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE SARS-CoV-2; Drug repurposing; Teicoplanin; COVID-19
ID ANTIBIOTICS
AB In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Baron, Sophie Alexandra; Colson, Philippe; Raoult, Didier; Rolain, Jean-Marc] Aix Marseille Univ, Fac Med & Pharm, AP HM, IRD,MEPHI, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France.
   [Devaux, Christian] Aix Marseille Univ, Fac Med & Pharm, AP HM, IRD,VITROME, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France.
   [Raoult, Didier; Rolain, Jean-Marc] IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France.
RP Rolain, JM (corresponding author), Aix Marseille Univ, AP HM, IHU Mediterranee Infect, IRD,MEPHI,Fac Med & Pharm, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France.
EM jean-marc.rolain@univ-amu.fr
RI Rolain, Jean-Marc/Y-3788-2019
OI Rolain, Jean-Marc/0000-0002-2402-4467
FU French Government under the 'Investissements d'avenir' (Investments for
   the Future) programmeFrench National Research Agency (ANR) [10-IAHU-03];
   Region Provence Alpes Cote d'AzurRegion Provence-Alpes-Cote d'Azur;
   European funding FEDER PRIMI
FX This work was supported by the French Government under the
   `Investissements d'avenir' (Investments for the Future) programme
   managed by the Agence Nationale de la Recherche (ANR) [reference:
   Mediterranee Infection 10-IAHU-03]. This work was supported by Region
   Provence Alpes Cote d'Azur and European funding FEDER PRIMI.
CR Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Colson P, 2016, INT J ANTIMICROB AG, V48, P349, DOI 10.1016/j.ijantimicag.2016.07.004
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ko W-C, 2020, INT J ANTIMICROB AGE
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Pan T, 2015, PUBLICATION
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 10
TC 69
Z9 70
U1 12
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD APR
PY 2020
VL 55
IS 4
AR 105944
DI 10.1016/j.ijantimicag.2020.105944
PG 2
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA LI2RB
UT WOS:000529330100023
PM 32179150
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Robson, B
AF Robson, B.
TI Computers and viral diseases. Preliminary bioinformatics studies on the
   design of a synthetic vaccine and a preventative peptidomimetic
   antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE 2019-nCoV coronavirus; Wuhan seafood market coronavirus; Bioinformatics;
   Synthetic vaccine; Peptidomimetic; Retroinverso; Q-UEL language;
   Automatic browser
ID UNIVERSAL EXCHANGE; INFERENCE LANGUAGE; DECISION SUPPORT.; EXPERT
   SYSTEM; PROTEIN; WEB; SUGGESTIONS; INHIBITORS; EMODIN
AB This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19. This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities. The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself. However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV. KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry. This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent. The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace. Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described.
C1 [Robson, B.] Ingine Inc, Cleveland, OH 44106 USA.
   [Robson, B.] Dirac Fdn, Witney, Oxon, England.
RP Robson, B (corresponding author), Ingine Inc, Cleveland, OH 44106 USA.
EM barryrobson@ingine.com
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Ali A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37070-z
   Ball J., 1990, CHEM STRUCTURE INFOR, P107
   Barre O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105984
   Belouzard S., P NATL ACAD SCI, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2008, J VIROL, V82, P2580, DOI 10.1128/JVI.02287-07
   Chu Yanyi, 2019, Brief Bioinform, DOI 10.1093/bib/bbz152
   de Lima DP, 1999, QUIM NOVA, V22, P375
   Deckelman S, 2014, COMMUN INF SYST, V14, P135, DOI 10.4310/CIS.2014.v14.n3.a1
   Feng Y, 2010, BRIT J PHARMACOL, V161, P113, DOI 10.1111/j.1476-5381.2010.00826.x
   Figliozzi G.M., 1996, PROTEIN SCI S1, V5, P72
   Fishleigh R. V., 1995, patent, Patent No. [EP00636145A1, 006361451]
   Fishleigh R.V., 1995, Patent, Patent No. [EU0636145, 0636145]
   Fishleigh R. V., 1990, patent Patent, Patent No. [EP00371046A1, 003710461]
   Fishleigh R. V., 1998, patent, Patent No. [US05773572, 05773572]
   FISHLEIGH RV, 1987, FEBS LETT, V214, P219, DOI 10.1016/0014-5793(87)80060-1
   Forni D, 2015, SCI REP-UK, V5, DOI 10.1038/srep14480
   Garnier J., 1989, PREDICTION PROTEIN S, P417, DOI DOI 10.1007/978-1-4613-1571-1_10
   Garnier J., FRT85T0606 INRAEUC
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   HAGLER AT, 1980, SCIENCE, V208, P599, DOI 10.1126/science.7367882
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Kaliamurthi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010063
   Kam YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007870
   Kao DJ, 2009, CHEM BIOL DRUG DES, V74, P33, DOI 10.1111/j.1747-0285.2009.00825.x
   Katz BA, 2004, J MOL BIOL, V344, P527, DOI 10.1016/j.jmb.2004.09.032
   Kaushik AC, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1708796
   Kaushik AC, 2020, INTERDISCIP SCI, V12, P169, DOI 10.1007/s12539-019-00350-x
   Khan Mohammad Yaseen, 2019, J Tradit Complement Med, V9, P73, DOI 10.1016/j.jtcme.2018.02.001
   Lennart M.R., 2017, PLOS ONE, V12
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li JY, 2000, ASIA-PACIFIC CONFERENCE ON ENVIRONMENTAL ELECTROMAGNETICS: CEEM'2000, PROCEEDINGS, P285, DOI 10.1109/CEEM.2000.853950
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Liu I.j., 2013, PLOS ONE, V8
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mehmood A, 2019, CHEM BIOL DRUG DES, V94, P1868, DOI 10.1111/cbdd.13602
   Palatnik-de-Sousa CB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00826
   Rai J, 2019, CHEM BIOL DRUG DES, V93, P724, DOI 10.1111/cbdd.13472
   ROBSON B, 1987, NATURE, V325, P395, DOI 10.1038/325395a0
   Robson B, 2018, COMPUT BIOL MED, V95, P147, DOI 10.1016/j.compbiomed.2018.02.013
   Robson B., 2011, 2011 IEEE 13th International Conference on e-Health Networking, Applications and Services (Healthcom 2011), P173, DOI 10.1109/HEALTH.2011.6026737
   Robson B, 1996, NAT BIOTECHNOL, V14, P892, DOI 10.1038/nbt0796-892
   Robson B, 2002, J PROTEOME RES, V1, P115, DOI 10.1021/pr0155228
   ROBSON B, 1987, J MOL GRAPHICS, V5, P8, DOI 10.1016/0263-7855(87)80038-3
   Robson B., 2013, ADV PHARMACOEPIDEMIO, V1, P6, DOI [10.4172/2167-1052, DOI 10.4172/2167-1052.100012]
   Robson B., 1982, BIOPHYSICS WATER, P66
   Robson B., 1986, APPL BIOTECHNOLOGY, V1, pB9
   Robson B., 2013, INTEL PROP RIGHTS, V1, P108, DOI [10.4172/ipr.1000108, DOI 10.4172/IPR.1000108]
   Robson B., 2012, PHARM TECHNOL DRUG R, V1
   Robson B., 1992, THEORETICAL BIOCH MO, V2, P207
   Robson B., 2016, ZIKA FLU BACK AGAIN
   Robson B., 1998, 6 FOR C MOL NAN
   Robson B., 1998, INTRO PROTEINS PROTE
   Robson B., 2012, DRUG DISCOVERY DEV T, P77
   Robson B., 2013, DRUG DISCOVERY DEV T, P77
   Robson B., 2020, PRELIMINARY BIOINFOR, DOI [10.13140/RG.2.2.18275.09761, DOI 10.13140/RG.2.2.18275.09761]
   Robson B., 1986, CHEM DES AUTOM NEWS, V1, P9
   Robson B, 2020, COMPUT BIOL MED, V117, DOI 10.1016/j.compbiomed.2020.103621
   Robson B, 2019, COMPUT BIOL MED, V112, DOI 10.1016/j.compbiomed.2019.103369
   Robson B, 2019, COMPUT BIOL MED, V108, P382, DOI 10.1016/j.compbiomed.2019.04.005
   Robson B, 2016, COMPUT BIOL MED, V79, P299, DOI 10.1016/j.compbiomed.2016.10.009
   Robson B, 2016, PERS MED, V13, P361, DOI 10.2217/pme-2015-0012
   Robson B, 2016, COMPUT BIOL MED, V73, P71, DOI 10.1016/j.compbiomed.2016.02.010
   Robson B, 2015, IEEE INT C BIOINFORM, P1397, DOI 10.1109/BIBM.2015.7359882
   Robson B, 2015, COMPUT BIOL MED, V66, P82, DOI 10.1016/j.compbiomed.2015.07.015
   Robson B, 2015, COMPUT BIOL MED, V56, P107, DOI 10.1016/j.compbiomed.2014.10.011
   Robson B, 2015, COMPUT BIOL MED, V56, P51, DOI 10.1016/j.compbiomed.2014.10.022
   Robson B, 2014, COMPUT BIOL MED, V51, P183, DOI 10.1016/j.compbiomed.2014.03.014
   Robson B, 2013, COMPUT BIOL MED, V43, P2297, DOI 10.1016/j.compbiomed.2013.09.010
   Robson B, 2011, J COMPUT AID MOL DES, V25, P427, DOI 10.1007/s10822-011-9429-x
   Robson B, 2008, PROG MOL BIOL TRANSL, V84, P161, DOI 10.1016/S0079-6603(08)00405-4
   Sachdeva S, 2017, INT J PEPT RES THER, V23, P49, DOI 10.1007/s10989-016-9534-8
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Smith D., 1998, IBC LIB SERIES
   Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003
   U.S. National Library of Medicine National center for biotechnology information national institutes of health, NAT CTR BIOT INF NAT
   Van Regenmortel MHV, 2009, OPEN VACCINE J, V2, P33, DOI DOI 10.2174/1875035401002010033
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Westphal U., 1986, MONOGRAPHS ENDOCRINO, V27
   Xu ZQ, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20041200
NR 80
TC 31
Z9 31
U1 15
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD APR
PY 2020
VL 119
AR 103670
DI 10.1016/j.compbiomed.2020.103670
PG 19
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA LG2LV
UT WOS:000527939800007
PM 32209231
OA Green Published
DA 2021-01-01
ER

PT J
AU Bein, B
   Bachmann, M
   Huggett, S
   Wegermann, P
AF Bein, Berthold
   Bachmann, Martin
   Huggett, Susanne
   Wegermann, Petra
TI SARS-CoV-2/COVID-19: Recommendations for Diagnosis and Therapy
SO ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE
LA German
DT Article
ID CHLOROQUINE; PNEUMONIA; COVID-19
C1 [Bein, Berthold] Univ Klinikum Schleswig Holstein, Klin Anasthesiol & Operat Intens Med, Campus Kiel, Kiel, Germany.
   [Bein, Berthold] Asklepios Klin St Georg, Klin Anasthesiol Intens Med Notfallmed & Schmerzt, Lohmuhlenstr 5, D-20099 Hamburg, Germany.
   [Bachmann, Martin] Asklepios Klinikum Harburg, Klin Intens Med & Beatmungsmed, Hamburg, Germany.
   [Huggett, Susanne] Hamburger Kliniken, Krankenhaushyg, Hamburg, Germany.
   [Wegermann, Petra] Asklepios Klin Weissenfels, Weissenfels, Germany.
RP Bein, B (corresponding author), Asklepios Klin St Georg, Klin Anasthesiol Intens Med Notfallmed & Schmerzt, Lohmuhlenstr 5, D-20099 Hamburg, Germany.
EM b.bein@asklepios.com
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   AWMF, S3 LEITL INV BEATM E
   Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Bein B, 2019, BEST PRAC RES-CL ANA, V33, P139, DOI 10.1016/j.bpa.2019.05.008
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Center of Disease Control, HEALTHC PROF FREQ AS
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834
   Empfehlung der Kommission fur Krankenhaushygiene und Infektionspravention (KRINKO) beim Robert Koch-Institut, 2015, BUNDESGESUNDHEITSBLA, V58, P1151
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johns Hopkins Coronavirus Resource Center, COR COVID 19 GLOB CA
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Kogelmann K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1662-9
   LeTourneau JL, 2012, CRIT CARE MED, V40, P847, DOI 10.1097/CCM.0b013e318236f60e
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Muller C., WHO RAT DOCH NICHT I
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Reusken CBEM, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.6.2000082
   Robert Koch-Institut-RKI, COR SARS COV 2 HINW
   Robert Koch-Institut-RKI, COR SARS COV 2 OPT M
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   VLAAR AP, 2020, INTENS CARE MED, DOI DOI 10.1007/S00134-020-06022-5
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   2020, LANCET, V395, P922, DOI DOI 10.1016/S2213-2600(20)30066-7
NR 45
TC 9
Z9 9
U1 0
U2 6
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-2661
EI 1439-1074
J9 ANASTH INTENSIV NOTF
JI Anasthesiol. Intensivmed. NotfMed. Schmerzther.
PD APR
PY 2020
VL 55
IS 4
BP 257
EP 265
DI 10.1055/a-1146-8674
PG 9
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA LF6BR
UT WOS:000527503400011
PM 32274773
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Huang, ZY
   Cao, JT
   Yao, YM
   Jin, XJ
   Luo, Z
   Xue, Y
   Zhu, CW
   Song, YN
   Wang, Y
   Zou, YZ
   Qian, JY
   Yu, KH
   Gong, H
   Ge, JB
AF Huang, Zheyong
   Cao, Jiatian
   Yao, Yumeng
   Jin, Xuejuan
   Luo, Zhe
   Xue, Yuan
   Zhu, Chouwen
   Song, Yanan
   Wang, Ying
   Zou, Yunzeng
   Qian, Juying
   Yu, Kaihuan
   Gong, Hui
   Ge, Junbo
TI The effect of RAS blockers on the clinical characteristics of COVID-19
   patients with hypertension
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); hypertension;
   angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system
   blockers (RAS blockers); ACE inhibitors/angiotensin receptor blockers
   (ACEIs/ARBs)
ID CONVERTING ENZYME-INHIBITION; RECEPTOR BLOCKERS; HEART; ELEVATION
AB Background: Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (designated as SARSCoV-2) has become a pandemic worldwide. Based on the current reports, hypertension may be associated with increased risk of sever condition in hospitalized COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) was recently identified to functional receptor of SARS-CoV-2. Previous experimental data revealed ACE2 level was increased following treatment with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Currently doctors concern whether these commonly used renin-angiotensin system (RAS) blockers-ACEIs/ARBs may increase the severity of COVID-19.
   Methods: We extracted data regarding 50 hospitalized hypertension patients with laboratory confirmed COVID-19 in the Renmin Hospital of Wuhan University from Feb 7 to Mar 03, 2020. These patients were grouped into RAS blockers group (Group A, n=20) and non-RAS blockers group (Group B, n=30) according to the basic blood pressure medications. All patients continued to use pre-admission antihypertensive drugs. Clinical severity (symptoms, laboratory and chest CT findings, etc.), clinical course, and short time outcome were analyzed after hospital admission.
   Results: Ten (50%) and seventeen (56.7%) of the Group A and Group B participants were males (P=0.643), and the average age was 52.65 +/- 13.12 and 67.77 +/- 12.84 years (P=0.000), respectively. The blood pressure of both groups was under effective control. There was no significant difference in clinical severity, clinical course and in-hospital mortality between Group A and Group B. Serum cardiac troponin I (cTnI) (P=0.03), and N-terminal (NT)-pro hormone BNP (NT-proBNP) (P=0.04) showed significant lower level in Group A than in Group B. But the patients with more than 0.04ng/mL or elevated NT-proBNP level had no statistical significance between the two groups. In patients over 65 years or under 65 years, cTnI or NTproBNP level showed no difference between the two groups.
   Conclusions: We observed there was no obvious difference in clinical characteristics between RAS blockers and non-RAS blockers groups. These data suggest ACEIs/ARBs may have few effects on increasing the clinical severe conditions of COVID-19.
C1 [Huang, Zheyong; Cao, Jiatian; Jin, Xuejuan; Song, Yanan; Wang, Ying; Zou, Yunzeng; Qian, Juying; Gong, Hui; Ge, Junbo] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, 180 Feng Lin Rd, Shanghai 200032, Peoples R China.
   [Yao, Yumeng] Fudan Univ, Zhongshan Hosp, Dept Infect Dis, Shanghai 200032, Peoples R China.
   [Luo, Zhe; Xue, Yuan] Fudan Univ, Zhongshan Hosp, Dept Crit Med, Shanghai 200032, Peoples R China.
   [Zhu, Chouwen] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai 200032, Peoples R China.
   [Yu, Kaihuan] Wuhan Univ, Renmin Hosp, Dept Hepatobiliary Surg, Wuhan 430200, Peoples R China.
RP Gong, H; Ge, JB (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, 180 Feng Lin Rd, Shanghai 200032, Peoples R China.
EM gonghui2005@fudan.edu.cn; junboge@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81870269]; National Key Research and
   Development Program of China [2018YFC1312703]
FX This study was supported by the National Natural Science Foundation of
   China (81870269) and National Key Research and Development Program of
   China (2018YFC1312703).
CR [Anonymous], 2020, ESH STATEMENT COVID
   Bozkurt B, 2020, HFSA ACC AHA STATEME
   Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260
   Chen Y, 2020, BIOCH BIOPHYS RES CO
   Dzudie A, 2017, CARDIOVASC J AFR, V28, P406
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   General Office of National Health Comission, 2020, DIAGN TREATM NOV COR, P1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keidar S, 2007, CARDIOVASC RES, V73, P463, DOI 10.1016/j.cardiores.2006.09.006
   Kennon S, 2001, J AM COLL CARDIOL, V38, P724, DOI 10.1016/S0735-1097(01)01426-7
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Liu LS, 2019, J GERIATR CARDIOL, V16, P182, DOI 10.11909/j.issn.1671-5411.2019.03.014
   McClendon J, 2014, J CLIN NEUROSCI, V21, P1133, DOI 10.1016/j.jocn.2013.10.019
   Mendoza-Torres Evelyn, 2015, Ther Adv Cardiovasc Dis, V9, P217, DOI 10.1177/1753944715597623
   Muller P, 2013, J CARDIOVASC PHARM T, V18, P87, DOI 10.1177/1074248411434773
   Ocaranza MP, 2014, CLIN SCI, V127, P549, DOI 10.1042/CS20130449
   Schulz Kenneth, 2018, ESSENTIAL CONCEPTS C
   Soto Maira, 2017, Clin Diabetes Endocrinol, V3, P6, DOI 10.1186/s40842-017-0044-1
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang JG, 2011, HYPERTENS RES, V34, P423, DOI 10.1038/hr.2010.259
   Wang Q, 2017, ONCOTARGET, V9, P24601
   Wang XX, 2016, J MOL CELL CARDIOL, V97, P180, DOI 10.1016/j.yjmcc.2016.05.012
   World Health Organization, 2020, 45 WHO
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang Y, 2012, INT J CARDIOL, V155, P482, DOI 10.1016/j.ijcard.2011.12.070
NR 25
TC 18
Z9 19
U1 3
U2 12
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD APR
PY 2020
VL 8
IS 7
AR 430
DI 10.21037/atm.2020.03.229
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA LF4KU
UT WOS:000527389200012
PM 32395474
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kriegmair, MC
   Kowalewski, KF
   Lange, B
   Heininger, A
   Speck, T
   Haas, H
   Michel, MS
AF Kriegmair, M. C.
   Kowalewski, K. F.
   Lange, B.
   Heininger, A.
   Speck, T.
   Haas, H.
   Michel, M. S.
TI Urology in the corona-virus pandemic-a guideline 4/20
SO UROLOGE
LA German
DT Article
DE COVID-19; Prioritization; Patient care; Reallocation; Urgent surgery
ID SURGICAL SMOKE
AB The coronavirus pandemic is a major challenge for healthcare systems worldwide. For urology, the expansion of the health-care structures for the treatment of patients suffering from COVID-19 should be supported as best as possible. At the same time, one should aim to ensure adequate care for urological emergencies and urgent urological treatments as far as possible, even during the pandemic. For this, patients must be prioritized individually, alternative therapy concepts must be considered and regional and supraregional cooperation must be used. Outpatient departments are of great importance in the care, examination and coordination of urological emergencies and urgent treatment. Urological clinics must prepare themselves to perform urgent operations and interventions on SARS-CoV-2-positive patients. Here, the creation of a separate, appropriately equipped emergency operating room to perform operations and interventions on SARS-CoV-2 patients should be considered. Furthermore strictly defined hygiene measures to protect employees in various clinical scenarios should be set up.
C1 [Kriegmair, M. C.; Kowalewski, K. F.; Michel, M. S.] Heidelberg Univ, Univ Med Mannheim, Klin Urol & Urochirurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
   [Lange, B.; Heininger, A.] Heidelberg Univ, Univ Med Mannheim, Krankenhaushyg, Mannheim, Germany.
RP Michel, MS (corresponding author), Heidelberg Univ, Univ Med Mannheim, Klin Urol & Urochirurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Maurice-Stephan.Michel@medma.uni-heidelberg.de
CR Alp E, 2006, J HOSP INFECT, V62, P1, DOI 10.1016/j.jhin.2005.01.014
   American college of surgeons, 2020, GUID TRIAG NON SURG
   Chan MC, 2020, EUR UROL, V78, pE38, DOI 10.1016/j.eururo.2020.03.004
   Exner M, 2020, INFEKTIONSPRAVENTION
   Ficarra V, 2020, MINERVA UROL NEFROL, V72, P369, DOI 10.23736/S0393-2249.20.03846-1
   Kwak HD, 2016, OCCUP ENVIRON MED, V73, P857, DOI 10.1136/oemed-2016-103724
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   RKI, 2020, EMPF RKI HYG NAHM RA
   Robert Koch-Institut, 2020, COVID 19 VERD MA NAH
   WHO, 2020, DIR GEN OP REM MED B
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Zheng MH, 2020, ANN SURG, V272, pE5, DOI 10.1097/SLA.0000000000003924
NR 13
TC 3
Z9 4
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-2592
EI 1433-0563
J9 UROLOGE
JI Urologe
PD APR
PY 2020
VL 59
IS 4
SI SI
BP 442
EP 449
DI 10.1007/s00120-020-01200-1
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA LD4YQ
UT WOS:000526036700007
PM 32296888
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhang, C
AF Zhang, Cici
TI C&EN talks with Sheng Ding, global drug discovery leader
SO CHEMICAL & ENGINEERING NEWS
LA English
DT Article
AB Director of Beijing's Global Health Drug Discovery Institute aims to tackle unmet needs, including finding treatments for COVID-19
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2347
EI 1520-605X
J9 CHEM ENG NEWS
JI Chem. Eng. News
PD APR
PY 2020
VL 98
IS 13
BP 28
EP 29
PG 2
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA LC5ZE
UT WOS:000525409500038
DA 2021-01-01
ER

PT J
AU Andras, V
   Tamas, F
   Andras, F
AF Andras, Varadi
   Tamas, Ferenci
   Andras, Falus
TI The coronavirus-induced COVID-19 pandemic Previous experiences and
   scientific evidences at the end of March, 2020
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE coronavirus; COVID-19; viral pandemics; viral vaccines; testing; RT-PCR;
   reverse transcriptase polymerase chain reaction
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS CORONAVIRUS; IMMUNE-RESPONSES;
   VACCINES; MICE; DNA
AB The COVID-19 epidemic hit everyone, professionals and civilians alike. The possibility of a worldwide pandemic has long been theorized by epidemiologists, infectologists on the one hand, and sociologists and behavioral scientists dealing with communication and social habits on the other. Yet, faced with real-time events, daily infections and mortality statistics, almost everyone feels uninformed or disturbingly inexperienced. This summary aims to provide an overview of the latest scientific evidences. Of course, the incomplete material, compiled in late March 2020, will certainly contain a few elements that likely will be outdated in a few weeks. The authors hope that in the next publication we will all read much better and more hopeful prospects.
C1 [Andras, Varadi] Magyar Tud Acad, Termeszettudomanyi Kutatokozpont, Enzimol Int, Budapest, Hungary.
   [Tamas, Ferenci] Obudai Egyet, Elettani Szabalyozasok Kutatokozpont, Budapest, Hungary.
   [Tamas, Ferenci] Budapesti Corvinus Egyet, Kozgazdasagtudomanyi Kar, Stat Tanszek, Budapest, Hungary.
   [Andras, Falus] Semmelweis Egyet, Altalanos Orvostudomanyi Kar, Sejt & Imunbiol Int, Budapest, Hungary.
   [Andras, Falus] Magyar Tud Acad, Egeszsegneveles Kortarsoktatassal TANTUdSZ Kutato, Budapest, Hungary.
RP Andras, F (corresponding author), Nagyvarad Ter 4, H-1089 Budapest, Hungary.
EM falus.andras@med.semmelweis-univ.hu
CR Ahmed FS, 2020, VIRUSES, V12, pE254
   [Anonymous], 2020, WHO DIR GEN OP REM M
   BioSpace, 2020, COD SER I IND IN COD
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   DeDiego ML, 2008, VIROLOGY, V376, P379, DOI 10.1016/j.virol.2008.03.005
   European Commission, NEW CONTR MAT DEV JR
   Gautret P, 2020, INT J ANTIMICROB AG, DOI [10.1016/j.ijantimicag.105949, DOI 10.1016/J.IJANTIMICAG.105949.[EPUB]
   Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Molina JM, 2020, MED MALADIES INFECT, DOI [10.1016/j.medmal.2020.03.006, DOI 10.1016/J.MEDMAL.2020.03.006.[EPUB]
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Saif LJ, 2004, DEV BIOLOGICALS, V119, P129
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Shen C, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.4783, DOI 10.1001/JAMA.2020.4783.]
   Silverman E., INTENSE CRITICISM GI
   Takacs M., 2010, VOX MED KIADOI KFT
   Tsunetsugu-Yokota Yasuko, 2008, V454, P119, DOI 10.1007/978-1-59745-181-9_11
   U. S. FDA, INV COVID 19 CONV PL
   Wang ZJ, 2005, BIOCHEM BIOPH RES CO, V327, P130, DOI 10.1016/j.bbrc.2004.11.147
   WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5
   Weiss SR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200537
   WHO, US LAB METH SARS DIA
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Zakhartchouk AN, 2005, VACCINE, V23, P4385, DOI 10.1016/j.vaccine.2005.04.011
NR 26
TC 4
Z9 4
U1 0
U2 6
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD APR
PY 2020
VL 161
IS 17
BP 644
EP 651
DI 10.1556/650.2020.31830
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LC4UL
UT WOS:000525321100001
PM 32324356
OA Other Gold
DA 2021-01-01
ER

PT J
AU Akos, F
   Istvan, L
   Marianna, J
   Mariann, B
   Tamas, V
   Gyorgy, K
   Csilla, M
   Bela, F
AF Akos, Fabian
   Istvan, Laszlo
   Marianna, Juhasz
   Mariann, Berhes
   Tamas, Vegh
   Gyorgy, Koszta
   Csilla, Molnar
   Bela, Fulesdi
TI Pharmacological options in treating SARS-CoV-2 infection/COVID-19
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE COVID-19; treatment; drugs
ID LOPINAVIR/RITONAVIR; COVID-19; EFFICACY
AB There is currently no proven effective therapy for COVID-19. Here we discuss the drugs most investigated for the treatment of the disease. All the listed therapies are experimental at this stage. However, due to the severe healthcare effects of the pandemic and the potentially fatal outcome of COVID-19 patients treated in the intensive care units, their off-label use should none-the-less be considered.
C1 [Akos, Fabian; Istvan, Laszlo; Marianna, Juhasz; Mariann, Berhes; Tamas, Vegh; Gyorgy, Koszta; Csilla, Molnar; Bela, Fulesdi] Debreceni Egyet, Orvostudomanyi Kar, Klin Kozpont, Aneszteziol & Intenz Terapias Klin, Debrecen, Hungary.
RP Akos, F (corresponding author), Nagyerdei Krt 98, H-4032 Debrecen, Hungary.
EM fabian.akos@med.unideb.hu
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Cao B., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2001282, DOI 10.1056/NEJM0A2001282]
   Cao W, 2020, OPEN FORUM INFECT DI, DOI [10.1093/ofid/ofaa102, DOI 10.1093/0FID/0FAA102]
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   European Medicines Agency, 2020, EMA GIVES ADV US NON
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   National Institutes of Health National Library of Medicine, 2020, AD COVID 19 TREATM T
   National Institutes of Health National Library of Medicine, 2020, STUD EV SAF ANT ACT
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Surviving Sepsis Campaign, 2020, COVID 19 GUID
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 25
TC 3
Z9 3
U1 1
U2 6
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD APR
PY 2020
VL 161
IS 17
BP 685
EP 688
DI 10.1556/650.2020.31812
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LC4UL
UT WOS:000525321100007
PM 32324361
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mariann, B
   Akos, F
   Istvan, L
   Tamas, V
   Csilla, M
   Bela, F
   Gyorgy, K
AF Mariann, Berhes
   Akos, Fabian
   Istvan, Laszlo
   Tamas, Vegh
   Csilla, Molnar
   Bela, Fulesdi
   Gyorgy, Koszta
TI Organ replacement therapy and life-supporting treatment modalities in
   critically ill COVID-19 patients
SO ORVOSI HETILAP
LA Hungarian
DT Article
DE COVID-19; intensive therapy; CytoSorb; ECMO; inhalational nitric oxide
ID EXTRACORPOREAL MEMBRANE-OXYGENATION
AB In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis - septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities.
C1 [Mariann, Berhes] Debreceni Egyet, Altalanos Orvostudomanyi Kar, Klin Kozpont, Aneszteziol & Intenz Terapias Klin, Debrecen, Hungary.
RP Gyorgy, K (corresponding author), Nagyerdei Krt 98, H-4032 Debrecen, Hungary.
EM gykoszta@yahoo.co.uk
CR Aferetica, 2020, UPD REG POSS US CYTO
   Alberici F, MANAGEMENT PATIENT D
   Attaway AH, 2017, RESP CARE, V62, P1113, DOI 10.4187/respcare.05708
   Bottari Gabriella, 2020, Crit Care Explor, V2, pe0071, DOI 10.1097/CCE.0000000000000071
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Friesecke S, 2017, J ARTIF ORGANS, V20, P252, DOI 10.1007/s10047-017-0967-4
   Gebistorf F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002787.pub3
   Kogelmann K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1662-9
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ronco C, 2020, BLOOD PURIFICAT, V49, P255, DOI [10.1159/000507039, 10.1159/000508125]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schmidt M, 2014, AM J RESP CRIT CARE, V189, P1374, DOI 10.1164/rccm.201311-2023OC
   Trager Karl, 2016, Case Rep Crit Care, V2016, P9852073, DOI 10.1155/2016/9852073
NR 17
TC 1
Z9 1
U1 1
U2 9
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD APR
PY 2020
VL 161
IS 17
BP 704
EP 709
DI 10.1556/650.2020.31813
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA LC4UL
UT WOS:000525321100011
PM 32324366
OA Other Gold
DA 2021-01-01
ER

PT J
AU Wan, SX
   Xiang, Y
   Fang, W
   Zheng, Y
   Li, BQ
   Hu, YJ
   Lang, CH
   Huang, DQ
   Sun, QY
   Xiong, Y
   Huang, X
   Lv, JL
   Luo, YL
   Shen, L
   Yang, HR
   Huang, G
   Yang, RH
AF Wan, Suxin
   Xiang, Yi
   Fang, Wei
   Zheng, Yu
   Li, Boqun
   Hu, Yanjun
   Lang, Chunhui
   Huang, Daoqiu
   Sun, Qiuyan
   Xiong, Yan
   Huang, Xia
   Lv, Jinglong
   Luo, Yaling
   Shen, Li
   Yang, Haoran
   Huang, Gu
   Yang, Ruishan
TI Clinical features and treatment of COVID-19 patients in northeast
   Chongqing
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE clinical features; cognition; COVID-19; northeast Chongqing; treatment
ID ACUTE RESPIRATORY SYNDROME; INFLAMMATORY CYTOKINES
AB The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19.
C1 [Wan, Suxin; Xiang, Yi; Fang, Wei; Li, Boqun; Hu, Yanjun; Lang, Chunhui; Huang, Daoqiu; Sun, Qiuyan; Xiong, Yan; Huang, Xia; Shen, Li; Yang, Haoran; Huang, Gu; Yang, Ruishan] Chongqing Univ Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Pharmaceut Dept, Chongqing 404100, Peoples R China.
   [Xiang, Yi] Chongqing Three Gorges Cent Hosp, Liver Ctr, Yuan Branch, Chongqing, Peoples R China.
   [Zheng, Yu] Chongqing Univ Three Gorges Hosp, Chengdu Univ Tradit Chinese Med,Sichuan Prov & Mi, Key Lab Standardizat Chinese Herbal Med,Key Lab B, Pharm Coll,Minist Educ,Key Lab Systemat Res Dev &, Chengdu 611137, Peoples R China.
   [Lang, Chunhui] Chongqing Three Gorges Cent Hosp, Off Res Affairs, Chongqing, Peoples R China.
   [Xiong, Yan] Chongqing Three Gorges Cent Hosp, Dept Chinese Internal Med, Chongqing, Peoples R China.
   [Huang, Xia] Chongqing Three Gorges Cent Hosp, Crit Care Med, Chongqing, Peoples R China.
   [Lv, Jinglong] Chongqing Three Gorges Cent Hosp, Dept Hematol, Chongqing, Peoples R China.
   [Luo, Yaling] Chongqing Med Univ, Dept Math, Coll Med Informat, Chongqing, Peoples R China.
RP Li, BQ; Hu, YJ (corresponding author), Chongqing Univ Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Pharmaceut Dept, Chongqing 404100, Peoples R China.; Zheng, Y (corresponding author), Chongqing Univ Three Gorges Hosp, Chengdu Univ Tradit Chinese Med,Sichuan Prov & Mi, Key Lab Standardizat Chinese Herbal Med,Key Lab B, Pharm Coll,Minist Educ,Key Lab Systemat Res Dev &, Chengdu 611137, Peoples R China.
EM yuzheng1@cdutcm.edu.cn; 279685211@qq.com; huyanjun@163.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2020CDJYGRH-YJ03]; National
   Social Science Foundation [15BGL191]
FX Fundamental Research Funds for the Central Universities, Grant/Award
   Number: 2020CDJYGRH-YJ03; National Social Science Foundation,
   Grant/Award Number: 15BGL191
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   D Wang, 2020, JAMA
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   General Office of the National Health and Family PlanningCommission, 2020, CHIN J INTEGR MED, V3
   Guan W, 2020, CLIN CHARACTERISTICS
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Muller NL, 2003, AM J ROENTGENOL, V181, P3, DOI 10.2214/ajr.181.1.1810003
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wan S., 2020, CHARACTERISTICS LYMP
   Wang F, 2018, CHINESE PHARMACOL B, V8, P1105
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO, 2020, CLIN MAN SEV AC RESP
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Yu P, 2020, J INFECT DIS
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE007, DOI 10.3760/cma.j.issn.1001-0939.2020.0007
NR 24
TC 234
Z9 235
U1 35
U2 112
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2020
VL 92
IS 7
BP 797
EP 806
DI 10.1002/jmv.25783
EA APR 2020
PG 10
WC Virology
SC Virology
GA LW4RW
UT WOS:000522745700001
PM 32198776
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Huang, JW
   Zhou, XY
   Lu, SJ
   Xu, Y
   Hu, JB
   Huang, ML
   Wang, HF
   Hu, CC
   Li, SG
   Chen, JK
   Wang, Z
   Hu, SH
   Wei, N
AF Huang, Jin-wen
   Zhou, Xiao-yi
   Lu, Shao-jia
   Xu, Yi
   Hu, Jian-bo
   Huang, Man-li
   Wang, Hua-fen
   Hu, Chan-chan
   Li, Shu-guang
   Chen, Jing-kai
   Wang, Zhong
   Hu, Shao-hua
   Wei, Ning
TI Dialectical behavior therapy-based psychological intervention for woman
   in late pregnancy and early postpartum suffering from COVID-19: a case
   report
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Letter
ID MENTAL-HEALTH; RATING-SCALE; DEPRESSION; VALIDATION; DISTRESS; ANXIETY
C1 [Huang, Jin-wen; Zhou, Xiao-yi; Lu, Shao-jia; Xu, Yi; Hu, Jian-bo; Huang, Man-li; Hu, Chan-chan; Li, Shu-guang; Chen, Jing-kai; Wang, Zhong; Hu, Shao-hua; Wei, Ning] Zhejiang Univ, Affiliated Hosp 1, Dept Psychiat, Sch Med, Hangzhou 310003, Peoples R China.
   [Huang, Jin-wen; Zhou, Xiao-yi; Lu, Shao-jia; Xu, Yi; Hu, Jian-bo; Huang, Man-li; Hu, Chan-chan; Li, Shu-guang; Chen, Jing-kai; Wang, Zhong; Hu, Shao-hua; Wei, Ning] Key Lab Mental Disorder Management Zhejiang Prov, Hangzhou 310003, Peoples R China.
   [Huang, Jin-wen; Zhou, Xiao-yi; Lu, Shao-jia; Xu, Yi; Hu, Jian-bo; Huang, Man-li; Hu, Chan-chan; Li, Shu-guang; Chen, Jing-kai; Wang, Zhong; Hu, Shao-hua; Wei, Ning] Zhejiang Engn Ctr Math Mental Hlth, Hangzhou 310003, Peoples R China.
   [Wang, Hua-fen] Zhejiang Univ, Affiliated Hosp 1, Dept Nursing, Sch Med, Hangzhou 310003, Peoples R China.
RP Hu, SH; Wei, N (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Psychiat, Sch Med, Hangzhou 310003, Peoples R China.; Hu, SH; Wei, N (corresponding author), Key Lab Mental Disorder Management Zhejiang Prov, Hangzhou 310003, Peoples R China.; Hu, SH; Wei, N (corresponding author), Zhejiang Engn Ctr Math Mental Hlth, Hangzhou 310003, Peoples R China.
EM dorhushaohua@zju.edu.cn; nwei2011@zju.edu.cn
FU Science and Technology Department of Zhejiang Province [2017C37037];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81801340]; Zhejiang Provincial Natural
   Science Foundation of ChinaNatural Science Foundation of Zhejiang
   Province [LQ18H090001, LQ20 H090016]
FX Project supported by the Science and Technology Department of Zhejiang
   Province (No. 2017C37037), the National Natural Science Foundation of
   China (No. 81801340), and the Zhejiang Provincial Natural Science
   Foundation of China (Nos. LQ18H090001 and LQ20 H090016)
CR Abad C, 2010, J HOSP INFECT, V76, P97, DOI 10.1016/j.jhin.2010.04.027
   Eisner L, 2017, BEHAV THER, V48, P557, DOI 10.1016/j.beth.2016.12.006
   Fassbinder E, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01373
   Forman EM, 2007, BEHAV MODIF, V31, P772, DOI 10.1177/0145445507302202
   Gambina I, 2011, J REPROD INFANT PSYC, V29, P472, DOI 10.1080/02646838.2011.653962
   Gress-Smith JL, 2012, MATERN CHILD HLTH J, V16, P887, DOI 10.1007/s10995-011-0812-y
   Harley R, 2008, J NERV MENT DIS, V196, P136, DOI 10.1097/NMD.0b013e318162aa3f
   Holditch-Davis D, 2015, INFANT BEHAV DEV, V41, P154, DOI 10.1016/j.infbeh.2015.10.004
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Kingston D, 2012, CHILD PSYCHIAT HUM D, V43, P683, DOI 10.1007/s10578-012-0291-4
   Leentjens AFG, 2011, MOVEMENT DISORD, V26, P407, DOI 10.1002/mds.23184
   Leontjevas R, 2009, AM J GERIAT PSYCHIAT, V17, P56, DOI 10.1097/JGP.0b013e31818b4111
   Licht RW, 2005, ACTA PSYCHIAT SCAND, V111, P144, DOI 10.1111/j.1600-0447.2004.00440.x
   Linehan M., 1993, COGNITIVE BEHAV TREA
   Lothes J. E., 2014, PSYCHOL PSYCHOTHER-T, V4, P144, DOI [10.4172/2161-0487.1000144, DOI 10.4172/2161-0487.1000144]
   Song Y, 2015, NURS EDUC TODAY, V35, P86, DOI 10.1016/j.nedt.2014.06.010
   Steil R, 2011, J TRAUMA STRESS, V24, P102, DOI 10.1002/jts.20617
   WHO, 2020, 67 WHO
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Zar M, 2002, CLIN PSYCHOL PSYCHOT, V9, P122, DOI 10.1002/cpp.305
NR 21
TC 2
Z9 2
U1 4
U2 17
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD MAY
PY 2020
VL 21
IS 5
BP 394
EP 399
DI 10.1631/jzus.B2010012
EA APR 2020
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA LQ1TE
UT WOS:000522936100001
PM 32425005
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Caly, L
   Druce, J
   Roberts, J
   Bond, K
   Tran, T
   Kostecki, R
   Yoga, Y
   Naughton, W
   Taiaroa, G
   Seemann, T
   Schultz, MB
   Howden, BP
   Korman, TM
   Lewin, SR
   Williamson, DA
   Catton, MG
AF Caly, Leon
   Druce, Julian
   Roberts, Jason
   Bond, Katherine
   Tran, Thomas
   Kostecki, Renata
   Yoga, Yano
   Naughton, William
   Taiaroa, George
   Seemann, Torsten
   Schultz, Mark B.
   Howden, Benjamin P.
   Korman, Tony M.
   Lewin, Sharon R.
   Williamson, Deborah A.
   Catton, Mike G.
TI Isolation and rapid sharing of the 2019 novel coronavirus (SAR-CoV-2)
   from the first patient diagnosed with COVID-19 in Australia
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
DE Virus diseases; Public health
ID OUTBREAK
AB Objectives To describe the first isolation and sequencing of SARS-CoV-2 in Australia and rapid sharing of the isolate.
   Setting SARS-CoV-2 was isolated from a 58-year-old man from Wuhan, China who arrived in Melbourne on 19 January 2020 and was admitted to the Monash Medical Centre, Melbourne from the emergency department on 24 January 2020 with fever, cough, and progressive dyspnoea.
   Major outcomes Clinical course and laboratory features of the first reported case of COVID-19 (the illness caused by SARS-CoV-2) in Australia; isolation, whole genome sequencing, imaging, and rapid sharing of virus from the patient.
   Results A nasopharyngeal swab and sputum collected when the patient presented to hospital were each positive for SARS-CoV-2 (reverse transcription polymerase chain reaction). Inoculation of Vero/hSLAM cells with material from the nasopharyngeal swab led to the isolation of SARS-CoV-2 virus in culture. Electron microscopy of the supernatant confirmed the presence of virus particles with morphology characteristic of viruses of the family Coronaviridae. Whole genome sequencing of the viral isolate and phylogenetic analysis indicated the isolate exhibited greater than 99.99% sequence identity with other publicly available SARS-CoV-2 genomes. Within 24 hours of isolation, the first Australian SARS-CoV-2 isolate was shared with local and overseas reference laboratories and major North American and European culture collections.
   Conclusions The ability to rapidly identify, propagate, and internationally share our SARS-CoV-2 isolate is an important step in collaborative scientific efforts to deal effectively with this international public health emergency by developing better diagnostic procedures, vaccine candidates, and antiviral agents.
C1 [Caly, Leon; Druce, Julian; Roberts, Jason; Bond, Katherine; Tran, Thomas; Kostecki, Renata; Yoga, Yano; Catton, Mike G.] Melbourne Hlth, Victorian Infect Dis Reference Lab, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
   [Naughton, William; Korman, Tony M.] Monash Med Ctr, Melbourne, Vic, Australia.
   [Taiaroa, George; Lewin, Sharon R.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
   [Taiaroa, George; Lewin, Sharon R.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Lewin, Sharon R.] The Alfred, Melbourne, Vic, Australia.
   [Seemann, Torsten; Schultz, Mark B.; Howden, Benjamin P.; Williamson, Deborah A.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Microbiol Diagnost Unit, Publ Hlth Lab, Melbourne, Vic, Australia.
   [Williamson, Deborah A.] Melbourne Hlth, Melbourne, Vic, Australia.
RP Lewin, SR (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.; Lewin, SR (corresponding author), Royal Melbourne Hosp, Melbourne, Vic, Australia.; Lewin, SR (corresponding author), The Alfred, Melbourne, Vic, Australia.
EM sharon.lewin@unimelb.edu.au
RI Roberts, Jason A/F-6272-2010; Korman, Tony/I-3099-2013
OI Roberts, Jason A/0000-0001-6218-435X; Bond,
   Katherine/0000-0002-4473-9232; Korman, Tony/0000-0002-6155-8353; Lewin,
   Sharon Ruth/0000-0002-0330-8241; Roberts, Jason/0000-0002-9734-9764
FU National Health and Medical Research Council (NHMRC)National Health and
   Medical Research Council of Australia; Australian Partnership for
   Preparedness Research in Infectious Diseases Emergencies (APPRISE), an
   NHMRC; NHMRC Investigator grantNational Health and Medical Research
   Council of Australia
FX Sharon Lewin receives research support from the National Health and
   Medical Research Council (NHMRC). Sharon Lewin and Benjamin Howden are
   NHMRC Practitioner Fellows; Deborah Williamson holds an NHMRC
   Investigator grant. Sharon Lewin and Mike Catton are supported by the
   Australian Partnership for Preparedness Research in Infectious Diseases
   Emergencies (APPRISE), an NHMRC--funded Centre for Research E xcellence.
CR Australian Department of Health, COR COVID 19 HLTH AL
   Chu DKW, 2011, J VIROL, V85, P12815, DOI 10.1128/JVI.05838-11
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kafetzopoulou LE, 2018, EUROSURVEILLANCE, V23, P18, DOI 10.2807/1560-7917.ES.2018.23.50.1800228
   Lewandowski K, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00963-19
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, 53 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 46
Z9 44
U1 5
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD JUN
PY 2020
VL 212
IS 10
BP 459
EP 462
DI 10.5694/mja2.50569
EA APR 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LU9RG
UT WOS:000522883300001
PM 32237278
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Hufert, F
   Spiegel, M
AF Hufert, F.
   Spiegel, M.
TI Coronavirus: from common cold to severe pulmonary failure Chronology of
   a pandemia
SO MONATSSCHRIFT KINDERHEILKUNDE
LA German
DT Article
DE SARS-Coronavirus-2; COVID-19; Epidemiology; Antiviral drugs; Viral
   vaccines
ID ANTIMALARIAL-DRUGS; CHLOROQUINE; REMDESIVIR
AB In December 2019 a new human coronavirus emerged in Wuhan, China, which is known as SARS-CoV-2. The clinical course of the disease known as coronavirus disease 2019 (COVID-19) ranges from mild respiratory symptoms to severe lung failure. The virus is currently rapidly spreading around the world and pushing health systems to the limits of their capacity due to the exponential increase in the number of cases. The origin of SARS-CoV-2 lies in the bat coronavirus pool and has now emerged in the human population due to interspecies transmission. Molecular diagnostic methods have been established in a very short time and a number of clinical studies on the effectiveness of different antiviral drugs are ongoing. The development of a vaccine using different approaches is also under investigation. Considering the high number of cases and mortality rates of up to 9% there is an urgent need for action. This article summarizes the current state of knowledge on human coronaviruses with a strong focus on the current data on SARS-CoV-2. Due to the daily changing level of knowledge, the article reflects the status up to 21 March 2020.
C1 [Hufert, F.; Spiegel, M.] Med Hsch Brandenburg Fontane, Inst Mikrobiol & Virol, BTU Campus Senftenberg,Univ Pl 1, D-01968 Senftenberg, Germany.
RP Hufert, F; Spiegel, M (corresponding author), Med Hsch Brandenburg Fontane, Inst Mikrobiol & Virol, BTU Campus Senftenberg,Univ Pl 1, D-01968 Senftenberg, Germany.
EM Frank.Hufert@mhb-fontane.de; Martin.Spiegel@mhb-fontane.de
CR Abd El Wahed A, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071642, 10.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364]
   Amer HM, 2013, J VIROL METHODS, V193, P337, DOI 10.1016/j.jviromet.2013.06.027
   Benvenuto D, 2020, PATHOG GLOB HEALTH, V114, P64, DOI 10.1080/20477724.2020.1725339
   Callendret B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192312
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Clarke DK, 2020, LANCET INFECT DIS, V20, P455, DOI 10.1016/S1473-3099(19)30614-0
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Durham DP, 2012, J R SOC INTERFACE, V9, P562, DOI 10.1098/rsif.2011.0325
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Feng S, 2020, LANCET RESP MED, pS2213
   Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Heimdal I, 2019, J INFECT DIS, V219, P1198, DOI 10.1093/infdis/jiy646
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   LAAKSONEN AL, 1974, SCAND J RHEUMATOL, V3, P103, DOI 10.3109/03009747409115809
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MACKENZIE AH, 1983, AM J MED, V75, P48, DOI 10.1016/0002-9343(83)90474-6
   MIDGLEY I, 1994, XENOBIOTICA, V24, P79, DOI 10.3109/00498259409043223
   Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218
   Niu JW, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104646
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Smith ER, 2005, J EMERG MED, V28, P437, DOI 10.1016/j.jemermed.2004.12.011
   Spiegel M, 2006, J GEN VIROL, V87, P1953, DOI 10.1099/vir.0.81624-0
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weidmann M, 2004, J CLIN MICROBIOL, V42, P2771, DOI 10.1128/JCM.42.6.2771-2773.2004
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 48
TC 1
Z9 1
U1 1
U2 36
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0026-9298
EI 1433-0474
J9 MONATSSCHR KINDERH
JI Mon.schr. Kinderheilkd.
PD JUN
PY 2020
VL 168
IS 6
SI SI
BP 488
EP 501
DI 10.1007/s00112-020-00910-2
EA APR 2020
PG 14
WC Pediatrics
SC Pediatrics
GA LU0EM
UT WOS:000522939800001
PM 32292213
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, L
   Huang, QH
   Wang, DC
   Ingbar, DH
   Wang, XD
AF Li, Liyang
   Huang, Qihong
   Wang, Diane C.
   Ingbar, David H.
   Wang, Xiangdong
TI Acute lung injury in patients with COVID-19 infection
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE ARDS; COVID-19; lung edema
ID RECEPTOR RECOGNITION; CHINA; ACE2
AB During the 2020 Spring Festival in China, the outbreak of a novel coronavirus, named COVID-19 by WHO, brought on a worldwide panic. According to the clinical data of infected patients, radiologic evidence of lung edema is common and deserves clinical attention. Lung edema is a manifestation of acute lung injury (ALI) and may progress to hypoxemia and potentially acute respiratory distress syndrome (ARDS). Patients diagnosed with ARDS have poorer prognosis and potentially higher mortality. Although no effective treatment is formally approved for COVID-19 infection, support of ventilation with oxygen therapy and sometimes mechanical ventilation is often required. Treatment with systemic and/or local glucocorticoids might be helpful to alleviate the pulmonary inflammation and edema, which may decrease the development and/or consequences of ARDS. In this article, we focus on the lung edema and ALI of patients with this widely transmitted COVID-19 infection in order to provide clinical indications and potential therapeutic targets for clinicians and researchers.
C1 [Li, Liyang; Huang, Qihong; Wang, Xiangdong] Fudan Univ, Zhongshan Hosp, Shanghai Med Sch, Inst Clin Sci, Shanghai, Peoples R China.
   [Wang, Diane C.] Sunshine Coast Univ Hosp, Dept Emergency, Birtinya, Qld, Australia.
   [Ingbar, David H.] Univ Minnesota, Ctr Lung Sci & Hlth, Pulm Allergy Crit Care & Sleep Div, Minneapolis, MN 55455 USA.
   [Wang, Xiangdong] Fudan Univ, Jinshan Hosp, Shanghai Med Sch, Ctr Tumor Diag & Therapy, Shanghai, Peoples R China.
   [Wang, Xiangdong] Shanghai Engn Res Ctr AI Technol Cardiopulm Dis, Shanghai, Peoples R China.
   [Wang, Xiangdong] Shanghai Inst Clin Bioinformat, Shanghai, Peoples R China.
RP Wang, XD (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai Med Sch, Inst Clin Sci, Shanghai, Peoples R China.
EM xdwang@fuccb.com
FU Shanghai Engineering and Technology Center for Artificial Intelligence
   of Lung and Heart Diseases from Zhongshan Hospital; National Nature
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81873409]; National Key Research and Development Programof
   Precision Medicine [2017YFC0909500]; Shanghai Institute of Clinical
   Bioinformatics
FX Operation funding of Shanghai Institute of Clinical Bioinformatics and
   Shanghai Engineering and Technology Center for Artificial Intelligence
   of Lung and Heart Diseases from Zhongshan Hospital; The National Nature
   Science Foundation of China, Grant/Award Number: 81873409; National Key
   Research and Development Programof Precision Medicine, Grant/Award
   Number: 2017YFC0909500
CR Beloncle F, 2018, CURR OPIN CRIT CARE, V24, P10, DOI 10.1097/MCC.0000000000000477
   Biscayart C, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101567
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Fang Y, 2019, QJM-INT J MED, V112, P914, DOI 10.1093/qjmed/hcz206
   Gouda MM, 2018, LUNG, V196, P609, DOI 10.1007/s00408-018-0150-6
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hosseiny M, 2020, AM J ROENTGENOL, V214, P1078, DOI 10.2214/AJR.20.22969
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li WT, 2018, P NATL ACAD SCI USA, V115, pE5135, DOI 10.1073/pnas.1802879115
   Liu Bo, 2019, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2019.07.009
   Lopes-Pacheco M, 2020, CELL BIOL TOXICOL, V36, P83, DOI 10.1007/s10565-019-09493-5
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Matuschak George M, 2010, Mo Med, V107, P252
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013
   Nieman GF, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2051-8
   Shah TG, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0242-9
   Shaw TD, 2019, EXPERT OPIN EMERG DR, V24, P29, DOI 10.1080/14728214.2019.1591369
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Ueki H, 2018, P NATL ACAD SCI USA, V115, pE6622, DOI 10.1073/pnas.1806265115
   Wang Xiangdong, 2007, Expert Rev Respir Med, V1, P149, DOI 10.1586/17476348.1.1.149
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Zhang F, 2020, CLIN TRANSL ONCOL, V22, P1750, DOI 10.1007/s12094-020-02316-8
   Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 34
TC 6
Z9 6
U1 1
U2 23
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD MAR
PY 2020
VL 10
IS 1
BP 20
EP 27
DI 10.1002/ctm2.16
EA MAR 2020
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA MX9MD
UT WOS:000522506100001
PM 32508022
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhu, L
   Xu, XZ
   Ma, K
   Yang, JL
   Guan, HX
   Chen, S
   Chen, ZS
   Chen, G
AF Zhu, Lan
   Xu, Xizhen
   Ma, Ke
   Yang, Junling
   Guan, Hanxiong
   Chen, Song
   Chen, Zhishui
   Chen, Gang
TI Successful recovery of COVID-19 pneumonia in a renal transplant
   recipient with long-term immunosuppression
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE coronavirus; COVID-19; immunosuppression; pneumonia; renal
   transplantation
AB The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia.
C1 [Zhu, Lan; Chen, Song; Chen, Zhishui; Chen, Gang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Organ Transplantat, Wuhan, Peoples R China.
   [Zhu, Lan; Chen, Song; Chen, Zhishui; Chen, Gang] Chinese Acad Med Sci, Minist Publ Hlth, Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.
   [Xu, Xizhen] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China.
   [Ma, Ke] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan, Peoples R China.
   [Yang, Junling] Second Hosp Jilin Univ, Dept Resp Med 2, Changchun, Peoples R China.
   [Guan, Hanxiong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Radiol, Wuhan, Peoples R China.
RP Chen, ZS; Chen, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Organ Transplantat, Wuhan, Peoples R China.; Chen, ZS; Chen, G (corresponding author), Chinese Acad Med Sci, Minist Publ Hlth, Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.
EM zschen@tjh.tjmu.edu.cn; gchen@tjh.tjmu.edu.cn
OI Chen, Gang/0000-0003-0574-9785
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600-6143.2009.02834.x
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kumar D, 2010, LANCET INFECT DIS, V10, P521, DOI 10.1016/S1473-3099(10)70133-X
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 11
TC 130
Z9 132
U1 7
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2020
VL 20
IS 7
BP 1859
EP 1863
DI 10.1111/ajt.15869
EA MAR 2020
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA MD1JV
UT WOS:000522525500001
PM 32181990
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wang, K
   Zhao, W
   Li, J
   Shu, WW
   Duan, J
AF Wang, Ke
   Zhao, Wei
   Li, Ji
   Shu, Weiwei
   Duan, Jun
TI The experience of high-flow nasal cannula in hospitalized patients with
   2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing,
   China
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Coronavirus; Pneumonia; High-flow nasal cannula
AB Background The outbreak of a novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) is currently ongoing in China. Most of the critically ill patients received high-flow nasal cannula (HFNC) oxygen therapy. However, the experience of HFNC in this population is lacking. Methods We retrospectively screened 318 confirmed patients with NCIP in two hospitals of Chongqing, China, from January 1st to March 4th, 2020. Among them, 27 (8.4%) patients experienced severe acute respiratory failure including 17 patients (63%) treated with HFNC as first-line therapy, 9 patients (33%) treated with noninvasive ventilation (NIV) and one patient (4%) treated with invasive ventilation. HFNC failure was defined by the need of NIV or intubation as rescue therapy. Results Of the 17 HFNC patients, 7 (41%) experienced HFNC failure. The HFNC failure rate was 0% (0/6) in patients with PaO2/FiO(2) > 200 mm Hg vs. 63% (7/11) in those with PaO2/FiO(2) <= 200 mm Hg (p = 0.04). Compared with baseline data, the respiratory rate significantly decreased after 1-2 h of HFNC in successful group [median 26 (IQR: 25-29) vs. 23 (22-25), p = 0.03]. However, it did not in the unsuccessful group. After initiation of NIV as rescue therapy among the 7 patients with HFNC failure, PaO2/FiO(2) significantly improved after 1-2 h of NIV [median 172 (150-208) mmHg vs. 114 (IQR: 79-130) under HFNC, p = 0.04]. However, two out of seven (29%) patients with NIV as rescue therapy ultimately received intubation. Among the 27 patients with severe acute respiratory failure, four patients were eventually intubated (15%). Conclusions Our study indicated that HFNC was the most common ventilation support for patients with NCIP. Patients with lower PaO2/FiO(2) were more likely to experience HFNC failure.
C1 [Wang, Ke] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Chongqing 400010, Peoples R China.
   [Zhao, Wei] Chongqing Med Univ, Affiliated Hosp 2, Dept Oncol, Chongqing 400010, Peoples R China.
   [Li, Ji] Chongqing Publ Hlth Med Ctr, Dept Thorac Surg, Chongqing 500106, Peoples R China.
   [Shu, Weiwei] Chongqing Med Univ, Yongchuan Hosp, Dept Crit Care Med, Xuanhua Rd 429, Chongqing 402160, Peoples R China.
   [Duan, Jun] Chongqing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Youyi Rd 1, Chongqing 400016, Peoples R China.
RP Shu, WW (corresponding author), Chongqing Med Univ, Yongchuan Hosp, Dept Crit Care Med, Xuanhua Rd 429, Chongqing 402160, Peoples R China.; Duan, J (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Youyi Rd 1, Chongqing 400016, Peoples R China.
EM shuweiwei361@163.com; duanjun412589@163.com
OI Duan, Jun/0000-0003-1685-0117
FU special project for emergency clinical research on novel coronavirus
   pneumonia in Chongqing Medical University [13]
FX This study was supported by special project for emergency clinical
   research on novel coronavirus pneumonia in Chongqing Medical University
   (No. 13).
CR Branson RD, 1995, RESP CARE EQUIPMENT, P55
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chikata Y, 2016, RESP CARE, V61, P300, DOI 10.4187/respcare.04331
   Cortegiani A, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2473-y
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Kang HYJ, 2020, RESP CARE, V65, P369, DOI 10.4187/respcare.07205
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Silverstein WK, 2020, LANCET, V395, P734, DOI 10.1016/S0140-6736(20)30370-6
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stephan F, 2017, RESP CARE, V62, P1193, DOI 10.4187/respcare.05473
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077
   Zhao HY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1760-8
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 21
TC 37
Z9 38
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD MAR 30
PY 2020
VL 10
IS 1
AR 37
DI 10.1186/s13613-020-00653-z
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA KY2ZD
UT WOS:000522439900001
PM 32232685
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ding, Q
   Lu, PP
   Fan, YH
   Xia, YJ
   Liu, M
AF Ding, Qiang
   Lu, Panpan
   Fan, Yuhui
   Xia, Yujia
   Liu, Mei
TI The clinical characteristics of pneumonia patients coinfected with 2019
   novel coronavirus and influenza virus in Wuhan, China
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE clinical characteristics; coinfection; COVID-19; influenza virus
AB The outbreak of 2019 novel coronavirus (COVID-19) infection emerged in Wuhan, China, in December 2019. Since then the novel coronavirus pneumonia disease has been spreading quickly and many countries and territories have been affected, with major outbreaks in China, South Korea, Italy, and Iran. Influenza virus has been known as a common pathogen in winter and it can cause pneumonia. It was found clinically that very few patients were diagnosed with both COVID-19 and influenza virus. A total of 5 of the 115 patients confirmed with COVID-19 were also diagnosed with influenza virus infection, with three cases being influenza A and two cases being influenza B. In this study, we describe the clinical characteristics of those patients who got infected with COVID-19 as well as influenza virus. Common symptoms at onset of illness included fever (five [100%] patients), cough (five [100%] patients), shortness of breath (five [100%] patients), nasal tampon (three [60%] patients), pharyngalgia (three [60%] patients), myalgia (two [40%] patients), fatigue (two [40%] patients), headache (two [40%] patients), and expectoration (two [40%] patients). The laboratory results showed that compared to the normal values, the patients' lymphocytes were reduced (four [80%] patients), and liver functions alanine aminotransferase and aspartate aminotransferase (two [40%] patients and two [40%] patients) and C-reactive protein (four [80%] patients) were increased when admitted to hospital. They stayed in the hospital for 14, 30, 17, 12, and 19 days (28.4 +/- 7.02), respectively. The main complications for the patients were acute respiratory distress syndrome (one [20%] patients), acute liver injury (three [60%] patients), and diarrhea (two [40%] patients). All patients were given antiviral therapy (including oseltamivir), oxygen inhalation, and antibiotics. Three patients were treated with glucocorticoids including two treated with oral glucocorticoids. One of the five patients had transient hemostatic medication for hemoptysis. Fortunately, all patients did not need intensive care unit and were discharged from the hospital without death. In conclusion, those patients with both COVID-19 and influenza virus infection did not appear to show a more severe condition because based on the laboratory findings, imaging studies, and patient prognosis, they showed similar clinical characteristics as those patients with COVID-19 infection only. However, it is worth noting that the symptoms of nasal tampon and pharyngalgia may be more prone to appear for those coinfection patients.
C1 [Ding, Qiang; Lu, Panpan; Fan, Yuhui; Xia, Yujia; Liu, Mei] Huazhong Univ Sci & Technol, Dept Gastroenterol, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
   [Fan, Yuhui] TUM, Klinikum Rechts Isar, Internal Med 2, Dept Gastroenterol, Munich, Germany.
RP Liu, M (corresponding author), Huazhong Univ Sci & Technol, Dept Gastroenterol, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
EM fliumei@126.com
OI Fan, Yuhui/0000-0001-6398-9803
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572422, 81700515]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81572422, 81700515
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Caini S, 2018, INFLUENZA OTHER RESP, V12, P780, DOI 10.1111/irv.12575
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   General Office of National Health Committee, NOT ISS PROGR DIAGN
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keske S, 2019, J MED VIROL, V91, P958, DOI 10.1002/jmv.25402
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Schoen K, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4592-0
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 93
Z9 94
U1 7
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1549
EP 1555
DI 10.1002/jmv.25781
EA MAR 2020
PG 7
WC Virology
SC Virology
GA NA8CG
UT WOS:000522313900001
PM 32196707
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Sorbello, M
   El-Boghdadly, K
   Di Giacinto, I
   Cataldo, R
   Esposito, C
   Falcetta, S
   Merli, G
   Cortese, G
   Corso, RM
   Bressan, F
   Pintaudi, S
   Greif, R
   Donati, A
   Petrini, F
AF Sorbello, M.
   El-Boghdadly, K.
   Di Giacinto, I
   Cataldo, R.
   Esposito, C.
   Falcetta, S.
   Merli, G.
   Cortese, G.
   Corso, R. M.
   Bressan, F.
   Pintaudi, S.
   Greif, R.
   Donati, A.
   Petrini, F.
CA SIAARTI
   European Airway Management Soc
TI The Italian coronavirus disease 2019 outbreak: recommendations from
   clinical practice
SO ANAESTHESIA
LA English
DT Article
DE COVID-19; critical care; tracheal intubation; ventilation
ID TRACHEAL INTUBATION; GUIDELINES; MANAGEMENT
AB Novel coronavirus 2019 is a single-stranded, ribonucleic acid virus that has led to an international pandemic of coronavirus disease 2019. Clinical data from the Chinese outbreak have been reported, but experiences and recommendations from clinical practice during the Italian outbreak have not. We report the impact of the coronavirus disease 2019 outbreak on regional and national healthcare infrastructure. We also report on recommendations based on clinical experiences of managing patients throughout Italy. In particular, we describe key elements of clinical management, including: safe oxygen therapy; airway management; personal protective equipment; and non-technical aspects of caring for patients diagnosed with coronavirus disease 2019. Only through planning, training and team working will clinicians and healthcare systems be best placed to deal with the many complex implications of this new pandemic.
C1 [Sorbello, M.] AOU Policlin San Marco Univ Hosp, Anesthesia & Intens Care, Catania, Italy.
   [El-Boghdadly, K.] Guys & St Thomas NHS Fdn Trust, Dept Anaesthesia, London, England.
   [Di Giacinto, I] Azienda Osped Univ St Orsola Malpighi Alma Mater, Anesthesia & Intens Care, Anestesia & Terapia Intens Polivalente, Bologna, Italy.
   [Cataldo, R.] Biomed, Anesthesia & Intens Care, Anestesia Terapia Intens eTerapia Dolore, Univ Campus, Rome, Italy.
   [Esposito, C.] Osped Colli, Dipartimento Area Crit Osped Monaldi, Anesthesia & Intens Care, Naples, Italy.
   [Falcetta, S.] Clin Anestesia & Rianimaz Osped Riuniti Ancona, Anesthesia & Intens Care, Ancona, Italy.
   [Merli, G.] Osped Maggiore Crema, Anesthesia & Intens Care, Dipartimento Anestesia & Terapia Intens, Milan, Italy.
   [Cortese, G.] AOU Citta Salute & Sci, Anesthesia & Intens Care, Dipartimento Anestesia Rianimaz Emergenze, Turin, Italy.
   [Corso, R. M.] Osped GB Morgagni & L Pierantoni, Anesthesia & Intens Care, Dipartimento Chirur Anestesia & Rianimaz, Forli, Italy.
   [Bressan, F.] Osped Santo Stefano Prato, Anestesia & Rianimaz, Anesthesia & Intens Care, Prato, Italy.
   [Pintaudi, S.] ARNAS Garibaldi Catania, Anesthesia & Intens Care, Catania, Italy.
   [Pintaudi, S.] ARNAS Garibaldi Catania, Dipartimento Emergenza Anesthesia & Intens Care, Catania, Italy.
   [Greif, R.] Univ Bern, Bern Univ Hosp, Dept Anaesthesiol & Pain Therapy, Bern, Switzerland.
   [Donati, A.] Univ Politecn Marche, Ancona, Italy.
   [Petrini, F.] Univ G dAnnunzio, Osped Chieti, Anesthesia & Intens Care, Dipartimento Med Perioperatoria Dolore Terapia In, Chieti, Italy.
RP Sorbello, M (corresponding author), AOU Policlin San Marco Univ Hosp, Anesthesia & Intens Care, Catania, Italy.
EM maxsorbello@gmail.com
RI El-Boghdadly, Kariem/P-5011-2017; Greif, Robert/O-6392-2016
OI El-Boghdadly, Kariem/0000-0002-9912-717X; Greif,
   Robert/0000-0003-0160-2073
FU MSD Italia; MSD USA; Ambu; Fisher and Paykel Healthcare Ltd.; GE
   Healthcare Ltd.; Baxter Italia
FX The authors wish to thank all their colleagues for their unconditional
   devotion and for providing feedback and information. Wealso acknowledge
   one of the authors who is currently quarantined following testing
   positive for COVID19. MS has received paid consultancy from Teleflex
   Medical, Verathon Medical and DEAS Italia, is a patent coowner (no
   royalties) of DEAS Italia and has received lecture grants and travel
   reimbursements from MSD Italia, MSD USA. ID, SF and GC have received
   lecture grants and travel reimbursements from MSD Italia. GC has also
   received lecture grants and travel reimbursements from Baxter Italia. KE
   is an Editor of Anaesthesia and has received educational funding and
   research support from Ambu, Fisher and Paykel Healthcare Ltd. and GE
   Healthcare Ltd. No external funding or other competing interests
   declared.
CR Agro FE, 2010, MINERVA ANESTESIOL, V76, P684
   Ahmad I, 2020, ANAESTHESIA, V75, P509, DOI 10.1111/anae.14904
   Alhomary M, 2018, ANAESTHESIA, V73, P1151, DOI 10.1111/anae.14299
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   [Anonymous], 2020, GU SERIE GEN
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, BBC NEWS
   Birenbaum A, 2019, JAMA SURG, V154, P9, DOI 10.1001/jamasurg.2018.3577
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   Cabrini L, 2019, ANESTH ANALG, V128, P971, DOI 10.1213/ANE.0000000000004087
   Casey JD, 2019, NEW ENGL J MED, V380, P811, DOI 10.1056/NEJMoa1812405
   Centers for Disease Control and Prevention, 2020, COR
   De Jong A, 2018, CRIT CARE MED, V46, P532, DOI 10.1097/CCM.0000000000002925
   Dipartimento della Protezione Civile, 2020, DAIL UPD COVID19 OUT
   Driver BE, 2018, JAMA-J AM MED ASSOC, V319, P2179, DOI 10.1001/jama.2018.6496
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Higgs A, 2018, BRIT J ANAESTH, V120, P323, DOI 10.1016/j.bja.2017.10.021
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2013, J THORAC DIS, V5, pS122, DOI 10.3978/j.issn.2072-1439.2013.06.18
   Il Tempo, 2020, IL TEMPO
   Istituto Superiore di Sanita, 2020, EP COVID 19
   Jansson M, 2020, INTENS CRIT CARE NUR, V57, DOI 10.1016/j.iccn.2020.102812
   Kamming D, 2003, BRIT J ANAESTH, V90, P715, DOI 10.1093/bja/aeg173
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Leone M, 2020, EUR J ANAESTH, V37, P265, DOI 10.1097/EJA.0000000000001166
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Levy SD, 2016, LANCET, V387, P1867, DOI 10.1016/S0140-6736(16)30245-8
   Li Y, 2005, INDOOR AIR, V15, P83, DOI 10.1111/j.1600-0668.2004.00317.x
   Livingston Edward, 2020, JAMA, DOI 10.1001/jama.2020.2633
   Lowe JJ, 2015, PREHOSP EMERG CARE, V19, P179, DOI 10.3109/10903127.2014.983661
   Lundstrom LH, 2018, BRIT J ANAESTH, V120, P1381, DOI 10.1016/j.bja.2017.11.106
   Mir F, 2017, ANAESTHESIA, V72, P439, DOI 10.1111/anae.13799
   Mouritsen JM, 2020, ANAESTHESIA, V75, P529, DOI 10.1111/anae.14891
   Nimmagadda U, 2017, ANESTH ANALG, V124, P507, DOI 10.1213/ANE.0000000000001589
   Oglesby KJ, 2020, ANAESTHESIA, V75, P149, DOI 10.1111/anae.14818
   Oliveira JESL, 2017, ANN EMERG MED, V70, P483
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peng PWH, 2020, BRIT J ANAESTH, V395, P470, DOI [10.1016/S0140-6736(20)30185-9, DOI 10.1016/S0140-6736(20)30185-9]
   Petrini F, 2005, Minerva Anestesiol, V71, P617
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Protezione Civile, 2020, EM COR RISP NAZ
   Qiu HB, 2020, INTENS CARE MED, V46, P576, DOI 10.1007/s00134-020-05966-y
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   SIAARTI, 2020, RACC ET CLIN AMM TRA
   Solidoro P, 2019, PANMINERVA MED, V61, P367, DOI 10.23736/S0031-0808.18.03565-6
   Sorbello M, 2013, MINERVA ANESTESIOL, V79, P194
   Sorbello M, 2019, INDIAN J ANAESTH, V63, P78, DOI 10.4103/ija.IJA_502_18
   Sorbello M, 2018, EUR J ANAESTH, V35, P811, DOI 10.1097/EJA.0000000000000893
   Sorbello M, 2016, TRENDS ANAESTH CRIT, V6, P1, DOI 10.1016/j.tacc.2015.11.001
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   WHO, 2003, SUMM PROB SARS CAS O
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, RAT US PERS PROT EQ
   Worldometer, 2020, COR COVID 19 MORT RA
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zuo Mingzhang, 2020, Chinese Medical Sciences Journal, V35, P105, DOI 10.24920/003724
NR 58
TC 99
Z9 100
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD JUN
PY 2020
VL 75
IS 6
BP 724
EP 732
DI 10.1111/anae.15049
EA MAR 2020
PG 9
WC Anesthesiology
SC Anesthesiology
GA LK5FS
UT WOS:000522065600001
PM 32221973
OA Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Georgiev, T
AF Georgiev, Tsvetoslav
TI Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Letter
ID CHLOROQUINE
C1 [Georgiev, Tsvetoslav] Med Univ Varna, Univ Hosp St Marina, Clin Rheumatol, 1 Hristo Smirnenski, Varna 9010, Bulgaria.
RP Georgiev, T (corresponding author), Med Univ Varna, Univ Hosp St Marina, Clin Rheumatol, 1 Hristo Smirnenski, Varna 9010, Bulgaria.
EM tsetso@medfaculty.org
RI Georgiev, Tsvetoslav/J-3884-2019
OI Georgiev, Tsvetoslav/0000-0002-1652-4648
CR Chang R., 2020, REPOSITIONING CHLORO, DOI [10.20944/preprints202003.0279.v1, DOI 10.20944/PREPRINTS202003.0279.V1]
   Chen X., 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.20029520, DOI 10.1101/2020.02.29.20029520]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu J, 2020, URBAN RAIL TRANSIT, V6, P1, DOI 10.1007/s40864-019-00117-z
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS 2019 COV 19
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 15
TC 15
Z9 16
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD MAY
PY 2020
VL 40
IS 5
BP 825
EP 826
DI 10.1007/s00296-020-04570-z
EA MAR 2020
PG 2
WC Rheumatology
SC Rheumatology
GA LB3AA
UT WOS:000522859600002
PM 32232552
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Venerito, V
   Lopalco, G
   Iannone, F
AF Venerito, Vincenzo
   Lopalco, Giuseppe
   Iannone, Florenzo
TI COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for
   medication adherence
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Letter
ID INFECTION; RISK
C1 [Venerito, Vincenzo; Lopalco, Giuseppe; Iannone, Florenzo] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Rheumatol Unit, Bari, Italy.
RP Iannone, F (corresponding author), Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Rheumatol Unit, Bari, Italy.
EM florenzo.iannone@uniba.it
OI Iannone, Florenzo/0000-0003-0474-5344; Venerito,
   Vincenzo/0000-0002-2573-5930; Lopalco, Giuseppe/0000-0003-4524-9566
CR Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   Barrett O, 2017, RHEUMATOL INT, V37, P1021, DOI 10.1007/s00296-017-3694-5
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032
   Iannone F, 2014, J RHEUMATOL, V41, P41, DOI 10.3899/jrheum.140101
NR 5
TC 8
Z9 8
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0172-8172
EI 1437-160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD MAY
PY 2020
VL 40
IS 5
BP 827
EP 828
DI 10.1007/s00296-020-04566-9
EA MAR 2020
PG 2
WC Rheumatology
SC Rheumatology
GA LB3AA
UT WOS:000522859600001
PM 32232551
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Dong, SJ
   Sun, JC
   Mao, Z
   Wang, L
   Lu, YL
   Li, JS
AF Dong, Shengjie
   Sun, Jiachen
   Mao, Zhuo
   Wang, Lu
   Lu, Yi-Lin
   Li, Jiesen
TI A guideline for homology modeling of the proteins from newly discovered
   betacoronavirus, 2019 novel coronavirus (2019-nCoV)
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 2019-nCoV; BLAST algorithm; CLUSTAL analysis; coronavirus; homology
   modeling; MERS-CoV; SARS-CoV; sequence alignment
ID SWISS-MODEL; CHINA; BLAST; PNEUMONIA; WUHAN
AB During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design.
C1 [Dong, Shengjie] Guangdong Baiyun Univ, Fac Educ & Sports, Guangzhou, Peoples R China.
   [Sun, Jiachen] Tianjin Univ Commerce, Sch Biotechnol & Food Sci, Tianjin, Peoples R China.
   [Mao, Zhuo] Tianjin Univ, Fac Sci, Inst Adv Mat Phys, Dept Appl Phys,Tianjin Key Lab Low Dimens Mat Phy, Tianjin, Peoples R China.
   [Wang, Lu] Inner Mongolia Univ Sci & Technol, Sch Sci, Baotou, Peoples R China.
   [Lu, Yi-Lin] Bohai Univ, Coll New Energy, Jinzhou 121007, Peoples R China.
   [Li, Jiesen] Foshan Univ, Sch Environm & Chem Engn, Foshan 528000, Peoples R China.
   [Li, Jiesen] Guangzhou Ginpie Technol Co Ltd, Dept Res & Dev, Guangzhou, Peoples R China.
RP Lu, YL (corresponding author), Bohai Univ, Coll New Energy, Jinzhou 121007, Peoples R China.; Li, JS (corresponding author), Foshan Univ, Sch Environm & Chem Engn, Foshan 528000, Peoples R China.
EM yilinlu@tju.edu.cn; 2lgy@163.com
RI lu, yilin/W-7007-2018
OI lu, yilin/0000-0002-9756-7294; Li, Jie-Sen/0000-0002-5230-2874; Mao,
   Zhuo/0000-0001-9012-9825
FU High-Level Talent Start-Up Research Project of Foshan University
   [Gg040934]; Natural Science Foundation of Inner Mongolia [2019MS01013];
   Opening Project of Guangdong Province Key Laboratory of Computational
   Science at the Sun Yat-sen University [2018015]; Project of Inner
   Mongolia University of Science Technology [2017QDL-B14]; Project of
   Guangdong Baiyun University [2017BYKY29]
FX High-Level Talent Start-Up Research Project of Foshan University,
   Grant/Award Number: Gg040934; Natural Science Foundation of Inner
   Mongolia, Grant/Award Number: 2019MS01013; Opening Project of Guangdong
   Province Key Laboratory of Computational Science at the Sun Yat-sen
   University, Grant/Award Number: 2018015; Project of Inner Mongolia
   University of Science & Technology, Grant/Award Number: 2017QDL-B14;
   Project of Guangdong Baiyun University, Grant/Award Number: 2017BYKY29
CR Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Boratyn GM, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-12
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Cohen J, 2020, SCIENCE, DOI [10.1126/science.abb0659, DOI 10.1126/SCIENCE.ABB0659]
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McGinnis S, 2004, NUCLEIC ACIDS RES, V32, pW20, DOI 10.1093/nar/gkh435
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Parodi SM, 2020, JAMA-J AM MED ASSOC, V323, P1441, DOI 10.1001/jama.2020.3882
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Rubin EJ, 2020, NEW ENGL J MED, V382, P866, DOI 10.1056/NEJMe2001329
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Ye J, 2006, NUCLEIC ACIDS RES, V34, pW6, DOI 10.1093/nar/gkl164
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 15
Z9 15
U1 4
U2 71
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2020
VL 92
IS 9
BP 1542
EP 1548
DI 10.1002/jmv.25768
EA MAR 2020
PG 7
WC Virology
SC Virology
GA NA8CG
UT WOS:000522058900001
PM 32181901
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Phadke, M
   Saunik, S
AF Phadke, Mrudula
   Saunik, Sujata
TI COVID-19 treatment by repurposing drugs until the vaccine is in sight
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
AB Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection.
C1 [Phadke, Mrudula; Saunik, Sujata] Maharashtra Univ Hlth Sci, Govt Maharashtra, UNICEF, NHM, Nasik, Maharashtra, India.
   [Saunik, Sujata] Harvard Univ, ICS Govt Mah, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
RP Phadke, M (corresponding author), Maharashtra Univ Hlth Sci, Govt Maharashtra, UNICEF, NHM, Nasik, Maharashtra, India.
EM drmapaa@yahoo.com
OI Saunik, Sujata/0000-0001-6641-0721
CR Fedson DS, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.03
   Hoffmann M., 2020, CELL, DOI [10.1016/j-cell2020.02.052, DOI 10.1016/J-CELL2020.02.052]
   Kruse Robert L, 2020, THERAPEUTIC STRATEGI
   Lellan Mc, 2020, DANIEL WRAPP
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Phadke M., 2020, BMJ-BRIT MED J, V368
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 20
Z9 20
U1 4
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD AUG
PY 2020
VL 81
IS 5
BP 541
EP 543
DI 10.1002/ddr.21666
EA MAR 2020
PG 3
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MT4CW
UT WOS:000522071500001
PM 32227357
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Alhazzani, W
   Moller, MH
   Arabi, YM
   Loeb, M
   Gong, MN
   Fan, E
   Oczkowski, S
   Levy, MM
   Derde, L
   Dzierba, A
   Du, B
   Aboodi, M
   Wunsch, H
   Cecconi, M
   Koh, Y
   Chertow, DS
   Maitland, K
   Alshamsi, F
   Belley-Cote, E
   Greco, M
   Laundy, M
   Morgan, JS
   Kesecioglu, J
   McGeer, A
   Mermel, L
   Mammen, MJ
   Alexander, PE
   Arrington, A
   Centofanti, J
   Citerio, G
   Baw, B
   Memish, ZA
   Hammond, N
   Hayden, FG
   Evans, L
   Rhodes, A
AF Alhazzani, Waleed
   Moller, Morten Hylander
   Arabi, Yaseen M.
   Loeb, Mark
   Gong, Michelle Ng
   Fan, Eddy
   Oczkowski, Simon
   Levy, Mitchell M.
   Derde, Lennie
   Dzierba, Amy
   Du, Bin
   Aboodi, Michael
   Wunsch, Hannah
   Cecconi, Maurizio
   Koh, Younsuck
   Chertow, Daniel S.
   Maitland, Kathryn
   Alshamsi, Fayez
   Belley-Cote, Emilie
   Greco, Massimiliano
   Laundy, Matthew
   Morgan, Jill S.
   Kesecioglu, Jozef
   McGeer, Allison
   Mermel, Leonard
   Mammen, Manoj J.
   Alexander, Paul E.
   Arrington, Amy
   Centofanti, John
   Citerio, Giuseppe
   Baw, Bandar
   Memish, Ziad A.
   Hammond, Naomi
   Hayden, Frederick G.
   Evans, Laura
   Rhodes, Andrew
TI Surviving Sepsis Campaign: guidelines on the management of critically
   ill adults with Coronavirus Disease 2019 (COVID-19)
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Coronavirus; COVID-19; SARS CoV-2; Clinical practice guidelines;
   Critical illness
ID RESPIRATORY-DISTRESS-SYNDROME; CLINICAL-PRACTICE GUIDELINE;
   END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; LOW TIDAL VOLUME;
   CONSERVATIVE OXYGEN-THERAPY; HEALTH-CARE WORKERS; MERS-COV INFECTION;
   FLOW NASAL CANNULA; NONINVASIVE VENTILATION
AB Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. Methods We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. Results The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. Conclusion The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines.
C1 [Alhazzani, Waleed; Loeb, Mark; Oczkowski, Simon; Belley-Cote, Emilie; Baw, Bandar] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Alhazzani, Waleed; Loeb, Mark; Oczkowski, Simon; Alexander, Paul E.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Moller, Morten Hylander] Copenhagen Univ Hosp, Dept Intens Care, Rigshosp, DK-4131 Copenhagen, Denmark.
   [Moller, Morten Hylander] Scandinavian Soc Anaesthesiol & Intens Care Med S, Copenhagen, Denmark.
   [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Intens Care Dept, Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia.
   [Gong, Michelle Ng; Aboodi, Michael] Albert Einstein Coll Med, Div Crit Care Med, Div Pulm Med, Dept Med,Montefiore Healthcare Syst, Bronx, NY 10467 USA.
   [Fan, Eddy] Univ Toronto, Inst Hlth Policy Management & Evaluat, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Levy, Mitchell M.; Mermel, Leonard] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA.
   [Levy, Mitchell M.] Rhode Isl Hosp, Providence, RI USA.
   [Derde, Lennie; Kesecioglu, Jozef] Univ Utrecht, Dept Intens Care Med, Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [Derde, Lennie] Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Dzierba, Amy] Columbia Univ, NewYork Presbyterian Hosp, Dept Pharm, Irving Med Ctr, New York, NY USA.
   [Du, Bin] Peking Union Med Coll Hosp, Med ICU, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.
   [Wunsch, Hannah] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada.
   [Wunsch, Hannah] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada.
   [Wunsch, Hannah] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Cecconi, Maurizio; Greco, Massimiliano] Humanitas Clin & Res Ctr, Dept Anesthesia & Intens Care, Milan, Italy.
   [Cecconi, Maurizio; Greco, Massimiliano] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea.
   [Chertow, Daniel S.] NIAID, Crit Care Med Dept, NIH, Clin Ctr, Baltimore, MD USA.
   [Chertow, Daniel S.] NIAID, Lab Immunoregulat, Baltimore, MD USA.
   [Maitland, Kathryn] Imperial Coll, Fac Med, London, England.
   [Alshamsi, Fayez] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Internal Med, POB 17666, Al Ain, U Arab Emirates.
   [Belley-Cote, Emilie] Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Laundy, Matthew] St Georges Univ Hosp NHS Fdn Trust, Microbiol & Infect Control, London, England.
   [Laundy, Matthew; Rhodes, Andrew] St Georges Univ London, London, England.
   [Morgan, Jill S.] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA.
   [McGeer, Allison] Univ Toronto, Div Infect Dis, Toronto, ON, Canada.
   [Mammen, Manoj J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA.
   [Alexander, Paul E.] GUIDE Res Methods Grp, Hamilton, ON, Canada.
   [Arrington, Amy] Baylor Coll Med, Houston Childrens Hosp, Houston, TX 77030 USA.
   [Centofanti, John] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.
   [Citerio, Giuseppe] Milano Bicocca Univ, Dept Med & Surg, Milan, Italy.
   [Citerio, Giuseppe] Desio & San Gerardo Hosp, ASST Monza, Monza, Italy.
   [Baw, Bandar] King Abdul Aziz Med City, Dept Emergency Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Minist Hlth, Res & Innovat Ctr, King Saud Med City, Riyadh, Saudi Arabia.
   [Hammond, Naomi] George Inst Global Hlth, Crit Care Div, Sydney, NSW, Australia.
   [Hammond, Naomi] UNSW, Sydney, NSW, Australia.
   [Hammond, Naomi] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care, Sydney, NSW, Australia.
   [Hayden, Frederick G.] Univ Virginia, Sch Med, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.
   [Evans, Laura] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA.
   [Rhodes, Andrew] St Georges Univ Hosp NHS Fdn Trust, Adult Crit Care, London, England.
RP Rhodes, A (corresponding author), St Georges Univ London, London, England.; Rhodes, A (corresponding author), St Georges Univ Hosp NHS Fdn Trust, Adult Crit Care, London, England.
EM andrewrhodes@nhs.net
RI Rhodes, Andrew/G-4265-2011; Arabi, Yaseen/ABF-3316-2020; Moller, Morten
   Hylander/AAQ-6891-2020; Cecconi, Maurizio/A-6241-2012
OI Rhodes, Andrew/0000-0002-8737-574X; Arabi, Yaseen/0000-0001-5735-6241;
   Moller, Morten Hylander/0000-0002-6378-9673; Cecconi,
   Maurizio/0000-0002-4376-6538; Derde, Lennie/0000-0002-3577-5629; Mammen,
   Manoj/0000-0003-0343-3234
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Akl EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057132
   Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037
   Alhazzani W, 2018, INTENS CARE MED, V44, P1691, DOI 10.1007/s00134-018-5367-6
   Alhazzani W, 2013, CRIT CARE, V17, DOI 10.1186/cc12557
   Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635
   Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013
   Antequera Martin AM, 2019, COCHRANE DB SYST REV, V7, pCd012247
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431
   Bednarczyk JM, 2017, CRIT CARE MED, V45, P1538, DOI 10.1097/CCM.0000000000002554
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Bentzer P, 2016, JAMA-J AM MED ASSOC, V316, P1298, DOI 10.1001/jama.2016.12310
   Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303
   Biggerstaff M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-480
   Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0
   Bloomfield R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008095.pub2
   Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218
   BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301
   Brochard L, 2014, SEMIN RESP CRIT CARE, V35, P492, DOI 10.1055/s-0034-1383863
   Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Brunner HI, 2015, ANN RHEUM DIS, V74, P1110, DOI 10.1136/annrheumdis-2014-205351
   Cabrini L, 2020, LANCET, V395, P685, DOI 10.1016/S0140-6736(20)30359-7
   Campbell L, 2011, RHEUMATOLOGY, V50, P552, DOI 10.1093/rheumatology/keq343
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Centers for Disease Control and prevention (CDC), 2020, INT GUID COLL HANDL
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan PKS, 2004, EMERG INFECT DIS, V10, P825, DOI 10.3201/eid1005.030682
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2020, DETECTABLE SERUM SAR
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3
   Claesson J, 2016, ACTA ANAESTH SCAND, V60, P697, DOI 10.1111/aas.12713
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cornejo RA, 2013, AM J RESP CRIT CARE, V188, P440, DOI 10.1164/rccm.201207-1279OC
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Esquinas AM, 2014, EUR RESPIR REV, V23, P427, DOI 10.1183/09059180.00009413
   European Centre for Disease Prevention and Control, 2020, SIT UPD WORLDW
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gamino-Arroyo AE, 2019, CLIN INFECT DIS, V69, P1903, DOI 10.1093/cid/ciz100
   Gamper G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003709.pub4
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gebistorf F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002787.pub3
   Geng Z, 2019, CLIN EXP RHEUMATOL, V37, P318
   Genovese MC, 2018, RHEUMATOLOGY, V57, P1423, DOI 10.1093/rheumatology/key121
   Goligher EC, 2018, JAMA-J AM MED ASSOC, V320, P2251, DOI 10.1001/jama.2018.14276
   Goligher EC, 2017, ANN AM THORAC SOC, V14, pS304, DOI 10.1513/AnnalsATS.201704-340OT
   Gozzoli V, 2001, ARCH INTERN MED, V161, P121, DOI 10.1001/archinte.161.1.121
   Griffiths M, 2019, THORAX, V74, P931, DOI 10.1136/thoraxjnl-2018-212885
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LQ, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0631-4
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   HAUPT MT, 1991, CRIT CARE MED, V19, P1339, DOI 10.1097/00003246-199111000-00006
   Hernandez G, 2019, JAMA-J AM MED ASSOC, V321, P654, DOI 10.1001/jama.2019.0071
   Hodgson CL, 2019, AM J RESP CRIT CARE, V200, P1363, DOI 10.1164/rccm.201901-0109OC
   Hodgson CL, 2011, CRIT CARE, V15, DOI 10.1186/cc10249
   Honarmand Hooshyar, 2012, Daru, V20, P12, DOI 10.1186/2008-2231-20-12
   Honarmand K, 2020, CAN J ANESTH, V67, P369, DOI 10.1007/s12630-019-01546-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08528
   Huh JW, 2009, CRIT CARE, V13, DOI 10.1186/cc7725
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Hui DS, 2015, CHEST, V147, P1336, DOI 10.1378/chest.14-1934
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Janz DR, 2015, CRIT CARE MED, V43, P534, DOI 10.1097/CCM.0000000000000718
   Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Kong L K, 2006, Hong Kong Med J, V12, P489
   Lamontagne F, 2020, JAMA-J AM MED ASSOC, V323, P938, DOI 10.1001/jama.2020.0930
   Lamontagne F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3284
   Lamontagne F, 2018, INTENS CARE MED, V44, P12, DOI 10.1007/s00134-017-5016-5
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee JM, 2014, CRIT CARE MED, V42, P1252, DOI 10.1097/CCM.0000000000000122
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Lewis SR, 2017, BRIT J ANAESTH, V119, P369, DOI 10.1093/bja/aex228
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Lewis SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub7
   Lewis SR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011136.pub2
   Lian XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3175047
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Livingston E., 2020, CORONAVIRUS DIS 2019
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   Long Youlin, 2020, J Evid Based Med, V13, P93, DOI 10.1111/jebm.12381
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   MacIntyre CR, 2014, PREV MED, V62, P1, DOI 10.1016/j.ypmed.2014.01.015
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297
   MacLaren G, 2020, JAMA-J AM MED ASSOC, V323, P1245, DOI 10.1001/jama.2020.2342
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549
   McCullers JA, 2013, CLIN MICROBIOL INFEC, V19, P113, DOI 10.1111/1469-0691.12093
   McIntyre WF, 2018, JAMA-J AM MED ASSOC, V319, P1889, DOI 10.1001/jama.2018.4528
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Memis D, 2004, CRIT CARE, V8, pR474, DOI 10.1186/cc2969
   Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646
   Meyhoff TS, 2020, CHEST, V157, P1478, DOI 10.1016/j.chest.2019.11.050
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Moller MH, 2018, ACTA ANAESTH SCAND, V62, P420, DOI 10.1111/aas.13089
   Moller MH, 2016, ACTA ANAESTH SCAND, V60, P1347, DOI 10.1111/aas.12780
   Momattin H, 2013, INT J INFECT DIS, V17, pE792, DOI 10.1016/j.ijid.2013.07.002
   Mora-Arteaga JA, 2015, MED INTENSIVA, V39, P352, DOI [10.1016/j.medine.2014.11.004, 10.1016/j.medin.2014.11.003]
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0019
   Munshi L, 2019, LANCET RESP MED, V7, P163, DOI 10.1016/S2213-2600(18)30452-1
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Murray MJ, 2016, CRIT CARE MED, V44, P2079, DOI 10.1097/CCM.0000000000002027
   Ni YN, 2018, AM J EMERG MED, V36, P226, DOI 10.1016/j.ajem.2017.07.083
   Niven DJ, 2013, J CRIT CARE, V28, P296, DOI 10.1016/j.jcrc.2012.08.015
   Nyren S, 2010, ANESTHESIOLOGY, V112, P682, DOI 10.1097/ALN.0b013e3181cf40c8
   Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC
   Ou XF, 2017, CAN MED ASSOC J, V189, pE260, DOI 10.1503/cmaj.160570
   Pan JZ, 2019, MEDICINE, V98, DOI [10.1097/MD.0000000000014453, 10.1097/md.0000000000014453]
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Qian H, 2010, BUILD SIMUL-CHINA, V3, P215, DOI 10.1007/s12273-010-0005-4
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Ranieri VM, 2020, JAMA-J AM MED ASSOC, V323, P725, DOI 10.1001/jama.2019.22525
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rice TW, 2012, CRIT CARE MED, V40, P1487, DOI 10.1097/CCM.0b013e3182416f23
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Rochwerg B, 2018, CRIT CARE MED, V46, P1411, DOI 10.1097/CCM.0000000000003262
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V45, P50
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell Terrie-Marie, 2018, J Perioper Pract, V28, P322, DOI 10.1177/1750458918788985
   Rygard SL, 2018, INTENS CARE MED, V44, P1003, DOI 10.1007/s00134-018-5197-6
   Schortgen F, 2015, INTENS CARE MED, V41, P1800, DOI 10.1007/s00134-015-3987-7
   Schortgen F, 2012, AM J RESP CRIT CARE, V185, P1088, DOI 10.1164/rccm.201110-1820OC
   Schulman Carl I, 2005, Surg Infect (Larchmt), V6, P369
   Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shieh WJ, 2010, AM J PATHOL, V177, P166, DOI 10.2353/ajpath.2010.100115
   Siemieniuk RAC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4169
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Silversides JA, 2017, INTENS CARE MED, V43, P155, DOI 10.1007/s00134-016-4573-3
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Smith JD, 2016, CAN MED ASSOC J, V188, P567, DOI 10.1503/cmaj.150835
   Stiehm ER, 2013, TRANSFUS MED REV, V27, P171, DOI 10.1016/j.tmrv.2013.05.004
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Tuite AR, 2020, ANN INTERN MED, V172, P567, DOI 10.7326/M20-0358
   Twu SJ, 2003, EMERG INFECT DIS, V9, P718
   Uyeki TM, 2019, CLIN INFECT DIS, V68, P895, DOI 10.1093/cid/ciy874
   van den Boom W, 2020, CHEST, V157, P566, DOI 10.1016/j.chest.2019.09.015
   van der Voort PHJ, 2001, CRIT CARE, V5, P216, DOI 10.1186/cc1026
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vandvik PO, 2018, INTENS CARE MED, V44, P1738, DOI 10.1007/s00134-018-5338-y
   Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS271, DOI 10.1513/AnnalsATS.201704-337OT
   Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS297, DOI 10.1513/AnnalsATS.201704-338OT
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0289-y
   Wang YJW, 2020, EARLY LOW DOSE SHORT
   WHO, 2020, CLIN MAN SEV AC RESP
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
   World Health O, 2020, INF CONS PRIOR CAND, P2020
   World Health Organization, 2019, BOOK INF CONS PRIOR
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Wu Guobao, 1998, Hunan Yike Daxue Xuebao, V23, P57
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu XJ, 2020, EMERG INFECT DIS, V26, P1324, DOI 10.3201/eid2606.200299
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xi XM, 2010, CHINESE MED J-PEKING, V123, P3100, DOI 10.3760/cma.j.issn.0366-6999.2010.21.027
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Xu XP, 2017, CRIT CARE MED, V45, pE727, DOI 10.1097/CCM.0000000000002361
   Yam LYC, 2003, RESPIROLOGY, V8, pS31, DOI 10.1046/j.1440-1843.2003.00521.x
   Yam WC, 2003, J CLIN MICROBIOL, V41, P4521, DOI 10.1128/JCM.41.10.4521-4524.2003
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang YL, 2013, CHINESE MED J-PEKING, V126, P1809, DOI 10.3760/cma.j.issn.0366-6999.20121880
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yasuda H, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015091
   Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7
   Young P, 2015, NEW ENGL J MED, V373, P2215, DOI 10.1056/NEJMoa1508375
   Zayed Y, 2019, RESPIR MED CASE REP, V27, DOI 10.1016/j.rmcr.2019.100855
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 221
TC 537
Z9 555
U1 61
U2 89
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAY
PY 2020
VL 46
IS 5
BP 854
EP 887
DI 10.1007/s00134-020-06022-5
EA MAR 2020
PG 34
WC Critical Care Medicine
SC General & Internal Medicine
GA LK9CU
UT WOS:000522001200001
PM 32224769
OA Bronze, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU FitzGerald, GA
AF FitzGerald, Garret A.
TI Misguided drug advice for COVID-19
SO SCIENCE
LA English
DT Letter
C1 [FitzGerald, Garret A.] Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP FitzGerald, GA (corresponding author), Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM garret@upenn.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL141912] Funding Source: Medline; Chief
   Scientist Office Funding Source: Medline
CR Amici C, 2006, ANTIVIR THER, V11, P1021
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291
   Sander WJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00089
   Schaeuble K, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000072
   Vijay R, 2017, P NATL ACAD SCI USA, V114, pE5444, DOI 10.1073/pnas.1704099114
   Willsher K., 2020, GUARDIAN
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003
NR 11
TC 50
Z9 53
U1 3
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 27
PY 2020
VL 367
IS 6485
BP 1434
EP 1434
DI 10.1126/science.abb8034
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KZ4RP
UT WOS:000523251600021
PM 32198292
OA Bronze
DA 2021-01-01
ER

PT J
AU Ou, XY
   Liu, Y
   Lei, XB
   Li, P
   Mi, D
   Ren, LL
   Guo, L
   Guo, RX
   Chen, T
   Hu, JX
   Xiang, ZC
   Mu, ZX
   Chen, X
   Chen, JY
   Hu, KP
   Jin, Q
   Wang, JW
   Qian, ZH
AF Ou, Xiuyuan
   Liu, Yan
   Lei, Xiaobo
   Li, Pei
   Mi, Dan
   Ren, Lili
   Guo, Li
   Guo, Ruixuan
   Chen, Ting
   Hu, Jiaxin
   Xiang, Zichun
   Mu, Zhixia
   Chen, Xing
   Chen, Jieyong
   Hu, Keping
   Jin, Qi
   Wang, Jianwei
   Qian, Zhaohui
TI Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
   its immune cross-reactivity with SARS-CoV
SO NATURE COMMUNICATIONS
LA English
DT Article
ID RESPIRATORY SYNDROME-CORONAVIRUS; RECEPTOR-BINDING DOMAIN; HOST-CELL
   ENTRY; EBOLA-VIRUS; MERS-COV; FUNCTIONAL RECEPTOR; PROTEIN; ACTIVATION;
   IDENTIFICATION; PNEUMONIA
AB Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002-2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients' sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.
C1 [Ou, Xiuyuan; Liu, Yan; Lei, Xiaobo; Li, Pei; Mi, Dan; Ren, Lili; Guo, Li; Guo, Ruixuan; Chen, Ting; Hu, Jiaxin; Xiang, Zichun; Mu, Zhixia; Jin, Qi; Wang, Jianwei; Qian, Zhaohui] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing 100176, Peoples R China.
   [Chen, Xing; Hu, Keping] Chinese Acad Med Sci CAMS & Peking Union Med Coll, Inst Med Plant Dev IMPLAD, 151 Malianwa Rd North, Beijing 100193, Peoples R China.
   [Chen, Jieyong] Hengshui Third Peoples Hosp, Hebei, Peoples R China.
RP Jin, Q; Wang, JW; Qian, ZH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, NHC Key Lab Syst Biol Pathogens, Beijing 100176, Peoples R China.
EM jinqi@ipbcams.ac.cn; wangjw28@163.com; zqian2013@sina.com
RI Wang, Jianwei/AAW-9499-2020; Wang, Jianwei/W-5916-2019
OI Wang, Jianwei/0000-0002-1116-4559; 
FU Chinese Science and Technology Key Projects [2017ZX0103004]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31670164, 31970171, 81930063]; COVID-19 Emergency Fund
   from CAMS [2020HY320001]; CAMS Innovation Fund for Medical Sciences
   [2016-12M-1-014]
FX This work was supported by grants from Chinese Science and Technology
   Key Projects (2020YFC0841000), National Natural Science Foundation of
   China (31670164 and 31970171 to Z.Q., and 81930063 to J.W.), Chinese
   Science and Technology Key Projects (2017ZX0103004), COVID-19 Emergency
   Fund from CAMS (2020HY320001), and the CAMS Innovation Fund for Medical
   Sciences (2016-12M-1-014 to J.W.)
CR Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bertram S, 2013, J VIROL, V87, P6150, DOI 10.1128/JVI.03372-12
   Bertram S, 2011, J VIROL, V85, P13363, DOI 10.1128/JVI.05300-11
   de Lartigue J, 2009, TRAFFIC, V10, P883, DOI 10.1111/j.1600-0854.2009.00915.x
   Diehl WE, 2016, CELL, V167, P1088, DOI 10.1016/j.cell.2016.10.014
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gunaratne GS, 2018, CELL CALCIUM, V75, P30, DOI 10.1016/j.ceca.2018.08.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XC, 2015, J VIROL, V89, P7202, DOI 10.1128/JVI.00854-15
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   International Committee on Taxonomy of Viruses, 2018, VIRUS TAXONOMY 2018
   Kamps B. S., 2003, SARS REFERENCE
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li P, 2018, J VIROL, V92, DOI 10.1128/JVI.00209-18
   Li P, 2019, TRENDS BIOCHEM SCI, V44, P110, DOI 10.1016/j.tibs.2018.10.006
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Nelson EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005540
   Ou XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15216
   Ou XY, 2016, J VIROL, V90, P5586, DOI 10.1128/JVI.00015-16
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Qian ZH, 2015, J VIROL, V89, P8816, DOI 10.1128/JVI.03737-14
   Qian ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076469
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rutherford AC, 2006, J CELL SCI, V119, P3944, DOI 10.1242/jcs.03153
   Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shirogane Y, 2008, J VIROL, V82, P8942, DOI 10.1128/JVI.00676-08
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013
   Vorou RM, 2007, EPIDEMIOL INFECT, V135, P1231, DOI 10.1017/S0950268807008527
   Wang MK, 2017, CELL HOST MICROBE, V21, P367, DOI 10.1016/j.chom.2017.02.002
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 53
TC 415
Z9 427
U1 61
U2 133
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 27
PY 2020
VL 11
IS 1
AR 1620
DI 10.1038/s41467-020-15562-9
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KY2YM
UT WOS:000522438200001
PM 32221306
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wang, SS
   Zhou, X
   Lin, XG
   Liu, YY
   Wu, JL
   Sharifu, LM
   Hu, XL
   Rong, ZH
   Liu, W
   Luo, XP
   Chen, Z
   Zeng, WJ
   Chen, SH
   Ma, D
   Chen, L
   Feng, L
AF Wang, Shao-shuai
   Zhou, Xuan
   Lin, Xing-guang
   Liu, Yan-yan
   Wu, Jian-li
   Sharifu, Lali Mwamaka
   Hu, Xiao-lin
   Rong, Zhi-hui
   Liu, Wei
   Luo, Xiao-ping
   Chen, Zhuo
   Zeng, Wan-jiang
   Chen, Su-hua
   Ma, Ding
   Chen, Ling
   Feng, Ling
TI Experience of Clinical Management for Pregnant Women and Newborns with
   Novel Coronavirus Pneumonia in Tongji Hospital, China
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; pneumonia; pregnant women; newborn; disease management
AB Based on the New Diagnosis and Treatment Scheme for Novel Coronavirus Infected Pneumonia (Trial Edition 5), combined with our current clinical treatment experience, we recently proposed a revision of the first edition of "Guidance for maternal and fetal management during pneumonia epidemics of novel coronavirus infection in the Wuhan Tongji Hospital". This article focused on the issues of greatest concern of pregnant women including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnostic criteria, inspection precautions, drug treatment options, indications and methods of termination of pregnancy, postpartum fever, breastfeeding considerations, mode of mother-to-child transmission, neonatal isolation and advice on neonatal nursing, to provide valuable experience for better management of SARS-CoV-2 infection in pregnant women and newborns.
C1 [Wang, Shao-shuai; Zhou, Xuan; Lin, Xing-guang; Liu, Yan-yan; Wu, Jian-li; Sharifu, Lali Mwamaka; Zeng, Wan-jiang; Chen, Su-hua; Ma, Ding; Feng, Ling] Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Hu, Xiao-lin; Rong, Zhi-hui; Liu, Wei; Luo, Xiao-ping; Chen, Ling] Huazhong Univ Sci & Technol, Dept Pediat, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Chen, Zhuo] Huazhong Univ Sci & Technol, Dept Tradit Chinese Med, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Peoples R China.
RP Feng, L (corresponding author), Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.; Chen, L (corresponding author), Huazhong Univ Sci & Technol, Dept Pediat, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM colombo2008@sina.com; zhouxuantjh@163.com; 790356760@qq.com;
   fltj007@163.com
RI Ribeiro, Nuno/AAH-2299-2020
CR AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2018, INFECT DIS INFORM, V06, P481
   [Anonymous], 2020, CLIN MANAGEMENT SEVE
   [Anonymous], 2020, QUICK GUIDE DIAGNOSI
   [Anonymous], 2020, GUIDANCE MATERNAL FE
   [Anonymous], 2020, RECOMMENDATIONS MANA
   [Anonymous], 2020, GUIDANCE MATERNAL MA
   [Anonymous], 2020, NEW DIAGNOSIS TREATM
   Centers for Disease Control and Prevention, PREV TRANSM NOV COR
   Chen H, 2020, CLIN CHARACTERISTICS
   Neonatal Physician Branch of Chinese Physician Association Neonatal Health Professional Committee of China Maternal and Child Health Association Perinatal Medical Branch of Chinese Medical Association Editorial Board of Chinese Journal of Perinatal Medicine, 2020, CHIN J PERINATAL MED, V23, P80
   Wang S, 2020, CLIN INFECT DIS OFFI
   World Health Organization, 2020, HOM CAR PAT SUSP NOV
   中国医师协会妇产科医师分会母胎医师专业委员会, 2020, [中华围产医学杂志, Chinese Journal of Perinatal Medicine], V23, P73
NR 13
TC 18
Z9 21
U1 3
U2 33
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096-5230
EI 2523-899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD APR
PY 2020
VL 40
IS 2
BP 285
EP 289
DI 10.1007/s11596-020-2174-4
EA MAR 2020
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA LH5CL
UT WOS:000521874400001
PM 32219626
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Liu, C
   Zhou, QQ
   Li, YZ
   Garner, LV
   Watkins, SP
   Carter, LJ
   Smoot, J
   Gregg, AC
   Daniels, AD
   Jervey, S
   Albaiu, D
AF Liu, Cynthia
   Zhou, Qiongqiong
   Li, Yingzhu
   Garner, Linda, V
   Watkins, Steve P.
   Carter, Linda J.
   Smoot, Jeffrey
   Gregg, Anne C.
   Daniels, Angela D.
   Jervey, Susan
   Albaiu, Dana
TI Research and Development on Therapeutic Agents and Vaccines for COVID-19
   and Related Human Coronavirus Diseases
SO ACS CENTRAL SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SPIKE; VIRUS; GLYCOPROTEIN;
   INHIBITION; PROTEIN; COV
AB Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV. The patent analysis of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.
C1 [Liu, Cynthia; Zhou, Qiongqiong; Li, Yingzhu; Garner, Linda, V; Watkins, Steve P.; Carter, Linda J.; Smoot, Jeffrey; Gregg, Anne C.; Daniels, Angela D.; Jervey, Susan; Albaiu, Dana] CAS, Columbus, OH 43210 USA.
RP Liu, C (corresponding author), CAS, Columbus, OH 43210 USA.
EM cliu@cas.org
CR Alcantara J., 2010, VIRUS ADAPTATION TRE, V2, DOI [https://doi.org/10.2147/VAAT.S12733, DOI 10.2147/VAAT.S12733]
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   De Witt BJ, 2000, EUR J PHARMACOL, V404, P213, DOI 10.1016/S0014-2999(00)00612-9
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guo DY, 2020, VIROL SIN, V35, P253, DOI 10.1007/s12250-020-00204-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Kupferschmidt K, 2020, SCIENCE, V367, P610, DOI 10.1126/science.367.6478.610
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu JW, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104550
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   Mifsud EJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104545
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ning D, 2020, GENOMIC PROTEIN STRU, DOI [20.913368., DOI 10.1101/2020.01.20.913368, 10.1101/2020.01.20.913368]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   World Health Organization, 2020, COR DIS COVID 2019 S
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu YT, 2020, VIROL SIN, V35, P256, DOI 10.1007/s12250-020-00205-6
   Yan BQ, 2019, CURR TOP MED CHEM, V19, P1918, DOI 10.2174/1568026619666190808160241
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zeng J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040371
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 47
TC 213
Z9 220
U1 42
U2 87
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2374-7943
EI 2374-7951
J9 ACS CENTRAL SCI
JI ACS Central Sci.
PD MAR 25
PY 2020
VL 6
IS 3
BP 315
EP 331
DI 10.1021/acscentsci.0c00272
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA KX5RS
UT WOS:000521935600002
PM 32226821
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Ekins, S
   Lane, TR
   Madrid, PB
AF Ekins, Sean
   Lane, Thomas R.
   Madrid, Peter B.
TI Tilorone: a Broad-Spectrum Antiviral Invented in the USA and
   Commercialized in Russia and beyond
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Antiviral; broad spectrum; interferon inducers; respiratory virus
   infections
ID EBOLA-VIRUS; HYDROCHLORIDE; RESISTANCE; ANALOGS; MODELS; ALPHA; CELLS;
   MICE; RNA
AB For the last 50 years we have known of a broad-spectrum agent tilorone dihydrochloride (Tilorone). This is a small-molecule orally bioavailable drug that was originally discovered in the USA and is currently used clinically as an antiviral in Russia and the Ukraine. Over the years there have been numerous clinical and non-clinical reports of its broad spectrum of antiviral activity. More recently we have identified additional promising antiviral activities against Middle East Respiratory Syndrome, Chikungunya, Ebola and Marburg which highlights that this old drug may have other uses against new viruses. This may in turn inform the types of drugs that we need for virus outbreaks such as for the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Tilorone has been long neglected by the west in many respects but it deserves further reassessment in light of current and future needs for broad-spectrum antivirals.
C1 [Ekins, Sean; Lane, Thomas R.] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27695 USA.
   [Madrid, Peter B.] SRI Int, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.
RP Ekins, S (corresponding author), Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27695 USA.
EM sean@collaborationspharma.com
OI Madrid, Peter/0000-0002-4895-5610
FU NIH from NCATS [R21TR001718]; NIH from NIGMS [R44GM122196-02A1]
FX We kindly acknowledge NIH funding: R21TR001718 from NCATS and
   R44GM122196-02A1 from NIGMS (PI -Sean Ekins). Dr. Mindy Davis is
   gratefully acknowledged for assistance with the NIAID virus screening
   capabilities, Task Order number B22. Dr. Luke Mercer and Caleb Goodin
   (Cambrex) are acknowledged for their work on lysosome accumulation
   assays. Dr. Vadim Makarov is kindly acknowledged for discussions on
   Russian antivirals. SE i s founder and owner of Collaborations
   Pharmaceuticals, Inc. TRL is an employee of Collaborations
   Pharmaceuticals, Inc. Collaborations Pharmaceuticals, Inc. has an orphan
   designation on tilorone for use against Ebola and a provisional patent
   submitted for use for Marburg.
CR Anantpadma M, 2019, ACS OMEGA, V4, P2353, DOI 10.1021/acsomega.8b02948
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   CDC, AIDS HIV
   CDC, 2013, INFL FLU
   CDC, HEP B
   CHIZHOV NP, 1990, VOP VIRUSOL+, V35, P411
   Dutta M, 2017, CELL REP, V18, P816, DOI 10.1016/j.celrep.2016.12.069
   Ekins S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00440-20
   Ekins S, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01711-17
   Ekins Sean, 2015, F1000Res, V4, P1091, DOI 10.12688/f1000research.7217.1
   Fleming RW, 1968, US3592819A, Patent No. 3592819
   Furuyama W, 2019, ANNU REV VIROL, V6, P435, DOI 10.1146/annurev-virology-092818-015708
   Gaforio JJ, 2002, CLIN DIAGN LAB IMMUN, V9, P1282, DOI 10.1128/CDLI.9.6.1282-1294.2002
   Garcia-Serradilla M, 2019, VIRUS RES, V264, P22, DOI 10.1016/j.virusres.2019.02.011
   GUPTA DK, 1984, H-S Z PHYSIOL CHEM, V365, P859, DOI 10.1515/bchm2.1984.365.2.859
   HARRINGTON DG, 1981, P SOC EXP BIOL MED, V166, P257
   Holshue ML, 2020, N ENGL J MED
   Karpenko I, 2010, ANTIMICROB AGENTS CH, V54, P2017, DOI 10.1128/AAC.01186-09
   Karpov AV, 2001, ACTA VIROL, V45, P181
   KATZ E, 1976, ANTIMICROB AGENTS CH, V9, P189, DOI 10.1128/AAC.9.1.189
   KATZ E, 1976, J GEN VIROL, V31, P125, DOI 10.1099/0022-1317-31-1-125
   KAUFMAN HE, 1971, P SOC EXP BIOL MED, V137, P357, DOI 10.3181/00379727-137-35576
   Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017
   KRAMER MJ, 1976, ANTIMICROB AGENTS CH, V9, P233, DOI 10.1128/AAC.9.2.233
   KRUEGER RF, 1970, SCIENCE, V169, P1213, DOI 10.1126/science.169.3951.1213
   KUEHNE RW, 1977, ANTIMICROB AGENTS CH, V11, P92, DOI 10.1128/AAC.11.1.92
   Lane TR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007890
   Lane TR, 2020, EFFICACY ORAL UNPUB
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Loginova S. Ya., 2004, Voprosy Virusologii, V49, P8
   LULLMANNRAUCH R, 1995, BIOCHEM PHARMACOL, V49, P1223, DOI 10.1016/0006-2952(95)00042-X
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579
   Martin RE, 2009, SCIENCE, V325, P1680, DOI 10.1126/science.1175667
   MAYER GD, 1970, SCIENCE, V169, P1214, DOI 10.1126/science.169.3951.1214
   Mazzon M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020176
   Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Ratan RR, 2008, ANN NY ACAD SCI, V1147, P383, DOI 10.1196/annals.1427.033
   Salata C, 2017, EXPERT REV ANTI-INFE, V15, P483, DOI 10.1080/14787210.2017.1305888
   Sel'kova EP, 2001, ZH MIKROBIOL EPIDEMI, P42
   Sel'kova EP, 2001, ZH MIKROBIOL EPIDEMI, P31
   Selkova E P, 2001, Antibiot Khimioter, V46, P14
   Selkova EP, 2001, ZH MIKROBIOLOGII EPI, P42
   Semenenko Tatiana A, 2002, Russ J Immunol, V7, P105
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tazulakhova EB, 2001, J INTERF CYTOK RES, V21, P65, DOI 10.1089/107999001750069926
   VARGIN VV, 1977, ACTA VIROL, V21, P114
   VECKENSTEDT A, 1979, ACTA VIROL, V23, P153
   Wang M, 2020, CELL RES, DOI DOI 10.1038/s41422-020-0282-0
   Zakirov I G, 2002, Klin Med (Mosk), V80, P54
   Zhang JR, 2015, MOLECULES, V20, P21458, DOI 10.3390/molecules201219781
   Zholobak N M, 2012, Fiziol Zh, V58, P39
NR 54
TC 11
Z9 11
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAR 25
PY 2020
VL 37
IS 4
DI 10.1007/s11095-020-02799-8
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA KX9PJ
UT WOS:000522207000001
PM 32215760
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU de Wit, E
   Feldmann, F
   Cronin, J
   Jordan, R
   Okumura, A
   Thomas, T
   Scott, D
   Cihlar, T
   Feldmann, H
AF de Wit, Emmie
   Feldmann, Friederike
   Cronin, Jacqueline
   Jordan, Robert
   Okumura, Atsushi
   Thomas, Tina
   Scott, Dana
   Cihlar, Tomas
   Feldmann, Heinz
TI Prophylactic and therapeutic remdesivir (GS-5734) treatment in the
   rhesus macaque model of MERS-CoV infection
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE MERS-CoV; antiviral; animal model; remdesivir; therapy
ID EBOLA-VIRUS; ORGANIZATION; THERAPIES; EFFICACY
AB The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV-induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV.
C1 [de Wit, Emmie; Cronin, Jacqueline; Thomas, Tina; Feldmann, Heinz] NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.
   [Feldmann, Friederike; Scott, Dana] NIAID, Rocky Mt Vet Branch, NIH, Hamilton, MT 59840 USA.
   [Jordan, Robert; Cihlar, Tomas] Gilead Sci, Biol Dept, Foster City, CA 94404 USA.
   [Okumura, Atsushi] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA.
RP de Wit, E (corresponding author), NIAID, Lab Virol, NIH, Hamilton, MT 59840 USA.
EM Emmie.deWit@nih.gov
RI de Wit, Emmie/A-1549-2019; Okumura, Atsushi/E-8012-2015
OI de Wit, Emmie/0000-0002-9763-7758; Okumura, Atsushi/0000-0002-7779-3059
FU Intramural Research Program of NIAID, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID); Biomedical
   Advanced Research and Development Authority, Office of the Assistant
   Secretary for Preparedness and Response, Department of Health and Human
   Services
FX We would like to thank the members of the Rocky Mountain Veterinary
   Branch (Division of Intramural Research [DIR], National Institute of
   Allergy and Infectious Diseases [NIAID], NIH) for their assistance with
   this study, Anita Mora (DIR, NIAID, NIH) for help with figure design,
   and Danielle Porter (Gilead Sciences) for manuscript help. This work was
   supported by the Intramural Research Program of NIAID, NIH, and federal
   funds from the Biomedical Advanced Research and Development Authority,
   Office of the Assistant Secretary for Preparedness and Response,
   Department of Health and Human Services.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Abdely HM, 2019, EMERG INFECT DIS, V25, P753, DOI 10.3201/eid2504.181595
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bin SY, 2016, CLIN INFECT DIS, V62, P755, DOI 10.1093/cid/civ1020
   Brende B, 2017, LANCET, V389, P233, DOI 10.1016/S0140-6736(17)30131-9
   Brining DL, 2010, COMPARATIVE MED, V60, P389
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen Z, 2017, J INFECT DIS, V215, P1807, DOI 10.1093/infdis/jix209
   ClinicalTrials.gov, GS5734 CLINICALTRIAL
   ClinicalTrials.gov, INV THER TREATM PEOP
   Corman VM, 2012, EUROSURVEILLANCE, V17, P3
   de Wit E, 2018, ANTIVIR RES, V156, P64, DOI 10.1016/j.antiviral.2018.06.006
   de Wit E, 2013, P NATL ACAD SCI USA, V110, P16598, DOI 10.1073/pnas.1310744110
   Dornemann J, 2017, J INFECT DIS, V215, P171, DOI 10.1093/infdis/jiw493
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Jacobs M, 2016, LANCET, V388, P498, DOI 10.1016/S0140-6736(16)30386-5
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Modjarrad K, 2016, NAT MED, V22, P701, DOI 10.1038/nm.4131
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Prescott J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00205
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   van Doremalen N, 2017, ANTIVIR RES, V143, P30, DOI 10.1016/j.antiviral.2017.03.025
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHO, COR INF
   World Health Organization, NOV COR 2019 NCOV
NR 29
TC 243
Z9 247
U1 9
U2 42
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 24
PY 2020
VL 117
IS 12
BP 6771
EP 6776
DI 10.1073/pnas.1922083117
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KX4AI
UT WOS:000521821800064
PM 32054787
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ton, AT
   Gentile, F
   Hsing, M
   Ban, FQ
   Cherkasov, A
AF Anh-Tien Ton
   Gentile, Francesco
   Hsing, Michael
   Ban, Fuqiang
   Cherkasov, Artem
TI Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease
   by Deep Docking of 1.3 Billion Compounds
SO MOLECULAR INFORMATICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; deep learning; virtual screening; protease
   inhibitors
ID SARS; DESIGN; DISCOVERY; CORONAVIRUSES; VALIDATION; 3CL(PRO); BIOLOGY
AB The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.
C1 [Anh-Tien Ton; Gentile, Francesco; Hsing, Michael; Ban, Fuqiang; Cherkasov, Artem] Univ British Columbia, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
RP Cherkasov, A (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.
EM acherkasov@prostatecentre.com
OI Gentile, Francesco/0000-0001-8299-1976
FU CIHRCanadian Institutes of Health Research (CIHR) [DC0190GP]; CIHR
   Canadian 2019 Novel Coronavirus (2019-nCoV)Canadian Institutes of Health
   Research (CIHR) [DC0190GP] Funding Source: Medline; NIDCD NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Deafness & Other
   Communication Disorders (NIDCD) [F32 DC000190] Funding Source: Medline
FX This work was funded by the CIHR Canadian 2019 Novel Coronavirus
   (2019-nCoV) Rapid Research grant #DC0190GP.
CR Abuhammad A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2644
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ashtawy HM, 2015, IEEE ACM T COMPUT BI, V12, P335, DOI 10.1109/TCBB.2014.2351824
   Bemis GW, 1996, J MED CHEM, V39, P2887, DOI 10.1021/jm9602928
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   Chaput L, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0167-x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Das PK, 2016, ANTIMICROB AGENTS CH, V60, P7382, DOI 10.1128/AAC.01421-16
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P5684, DOI 10.1016/j.bmcl.2008.08.082
   Ghosh AK, 2006, ANNU REP MED CHEM, V41, P183, DOI 10.1016/S0065-7743(06)41011-3
   Gordon CJ, 2020, J BIOL CHEM
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Lee H, 2014, BIOORGAN MED CHEM, V22, P167, DOI 10.1016/j.bmc.2013.11.041
   Li G., 2020, NAT REV DRUG DISCOV
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Liu X, 2020, SMART MATER STRUCT, V2020, P1
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Lyu J, 2019, NATURE, V566, P224, DOI 10.1038/s41586-019-0917-9
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ragoza M, 2017, J CHEM INF MODEL, V57, P942, DOI 10.1021/acs.jcim.6b00740
   Shah F, 2011, J CHEM INF MODEL, V51, P852, DOI 10.1021/ci200029y
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Torres PHM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184574
   Tuley A, 2018, BIOCHEMISTRY-US, V57, P3326, DOI 10.1021/acs.biochem.8b00315
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Turlington M, 2013, BIOORG MED CHEM LETT, V23, P6172, DOI 10.1016/j.bmcl.2013.08.112
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang H., 2020, DEEP LEARNING BASED
   Zhang HP, 2019, PEERJ, V7, DOI 10.7717/peerj.7362
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 44
TC 83
Z9 84
U1 20
U2 36
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
DI 10.1002/minf.202000028
EA MAR 2020
PG 8
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA NG0TJ
UT WOS:000563700400001
PM 32162456
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Hu, TY
   Frieman, M
   Wolfram, J
AF Hu, Tony Y.
   Frieman, Matthew
   Wolfram, Joy
TI Insights from nanomedicine into chloroquine efficacy against COVID-19
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID CORONAVIRUS; INFECTION; RECEPTOR; ENTRY; CELLS
AB Chloroquine - an approved malaria drug - is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.
C1 [Hu, Tony Y.] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Cellular & Mol Diagnost, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Frieman, Matthew] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Wolfram, Joy] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA.
   [Wolfram, Joy] Mayo Clin, Dept Physiol & Biomed Engn, Jacksonville, FL 32224 USA.
   [Wolfram, Joy] Mayo Clin, Dept Transplantat, Jacksonville, FL 32224 USA.
   [Wolfram, Joy] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA.
RP Hu, TY (corresponding author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, Ctr Cellular & Mol Diagnost, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM tonyhu@tulane.edu; mfrieman@som.umaryland.edu; wolfram.joy@mayo.edu
RI Wolfram, Joy/I-1574-2019
OI Wolfram, Joy/0000-0003-0579-9897; Hu, Tony/0000-0001-7255-5409
FU Department of DefenseUnited States Department of Defense
   [DODW8IXWH1910926]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01HD090927, R01AI122932, R01AI113725, R21AI126361, R21EB026347,
   R21AI52318]
FX We acknowledge funding in the area of namomedicine for infectious
   disease research from the following sources: the Department of Defense
   under award number DODW8IXWH1910926 (T.Y.H.) and the National Institutes
   of Health under award numbers R01HD090927 (T.Y.H.), R01AI122932
   (T.Y.H.), R01AI113725 (T.Y.H.), R21AI126361 (T.Y.H.), R21EB026347
   (T.Y.H.) and R21AI52318 (J.W.). The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the funding agencies.
CR Dowall SD, 2015, J GEN VIROL, V96, P3484, DOI 10.1099/jgv.0.000309
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gentile E, 2013, FUTURE ONCOL, V9, P1849, DOI [10.2217/fon.13.146, 10.2217/FON.13.146]
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Hempelmann E, 2007, PARASITOL RES, V100, P671, DOI 10.1007/s00436-006-0313-x
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Madrid PB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060579
   Miller SE, 2015, DEV CELL, V33, P163, DOI 10.1016/j.devcel.2015.03.002
   Pelt J, 2018, PHARMACOL THERAPEUT, V191, P43, DOI 10.1016/j.pharmthera.2018.06.007
   Roques P, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050268
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wolfram J, 2019, NANO TODAY, V25, P85, DOI 10.1016/j.nantod.2019.02.005
   Wolfram J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14221-2
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 65
Z9 65
U1 18
U2 76
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD APR
PY 2020
VL 15
IS 4
BP 247
EP 249
DI 10.1038/s41565-020-0674-9
EA MAR 2020
PG 3
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA LF4VA
UT WOS:000521522700001
PM 32203437
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Tai, WB
   He, L
   Zhang, XJ
   Pu, J
   Voronin, D
   Jiang, SB
   Zhou, YS
   Du, LY
AF Tai, Wanbo
   He, Lei
   Zhang, Xiujuan
   Pu, Jing
   Voronin, Denis
   Jiang, Shibo
   Zhou, Yusen
   Du, Lanying
TI Characterization of the receptor-binding domain (RBD) of 2019 novel
   coronavirus: implication for development of RBD protein as a viral
   attachment inhibitor and vaccine
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE 2019 novel coronavirus; SARS-CoV-2; spike protein; receptor-binding
   domain; viral inhibitor; cross-neutralization
ID RESPIRATORY SYNDROME CORONAVIRUS; DIPEPTIDYL PEPTIDASE 4; SPIKE PROTEIN;
   MERS-COV; FUNCTIONAL RECEPTOR; S PROTEIN; SARS-COV; TARGET;
   IDENTIFICATION; PNEUMONIA
AB The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.
C1 [Tai, Wanbo; Zhang, Xiujuan; Pu, Jing; Voronin, Denis; Jiang, Shibo; Du, Lanying] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
   [He, Lei; Zhou, Yusen] Beijing Inst Microbiol & Epidemiol, Beijing, Peoples R China.
   [Pu, Jing; Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai, Peoples R China.
RP Jiang, SB; Du, LY (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.; Zhou, YS (corresponding author), Beijing Inst Microbiol & Epidemiol, Beijing, Peoples R China.; Jiang, SB (corresponding author), Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai, Peoples R China.
EM sjiang@nybc.org; yszhou@bmi.ac.cn; ldu@nybc.org
RI Tai, Wanbo/G-3838-2018; Zhang, Xiujuan/AAG-9780-2020
OI Tai, Wanbo/0000-0002-9864-8993; Voronin, Denis/0000-0003-2652-0787
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01AI137472, R01AI139092]; New York
   Blood Center [VIM-NYB616, CFM-NYB595]
FX The authors thank Dr. Fang Li at the University of Minnesota for
   providing 293T cells stably expressing human dipeptidyl peptidase 4.
   This study was supported by the NIH grants (R01AI137472 and R01AI139092)
   and intramural funds of the New York Blood Center (VIM-NYB616 and
   CFM-NYB595).
CR Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Du LY, 2014, J VIROL, V88, P7045, DOI 10.1128/JVI.00433-14
   Du LY, 2013, J VIROL, V87, P9939, DOI 10.1128/JVI.01048-13
   Du LY, 2010, VIRAL IMMUNOL, V23, P211, DOI 10.1089/vim.2009.0090
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Tai WB, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00029
   Tai WB, 2017, J VIROL, V91, DOI 10.1128/JVI.01651-16
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   World Health Organization, 2020, NAM COR DIS COVID 19
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang Y, 2014, P NATL ACAD SCI USA, V111, P12516, DOI 10.1073/pnas.1405889111
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhao GY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-266
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 246
Z9 247
U1 34
U2 107
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD JUN
PY 2020
VL 17
IS 6
BP 613
EP 620
DI 10.1038/s41423-020-0400-4
EA MAR 2020
PG 8
WC Immunology
SC Immunology
GA LZ6WY
UT WOS:000520614400003
PM 32203189
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Wang, DW
   Hu, B
   Hu, C
   Zhu, FF
   Liu, X
   Zhang, J
   Wang, BB
   Xiang, H
   Cheng, ZS
   Xiong, Y
   Zhao, Y
   Li, YR
   Wang, XH
   Peng, ZY
AF Wang, Dawei
   Hu, Bo
   Hu, Chang
   Zhu, Fangfang
   Liu, Xing
   Zhang, Jing
   Wang, Binbin
   Xiang, Hui
   Cheng, Zhenshun
   Xiong, Yong
   Zhao, Yan
   Li, Yirong
   Wang, Xinghuan
   Peng, Zhiyong
TI Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
   Coronavirus-Infected Pneumonia in Wuhan, China
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
AB This single-center case series describes the demographics, symptoms, laboratory and imaging findings, treatment, and clinical course of 138 patients hospitalized with 2019 novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) in Wuhan, China, highlighting presumed human-to-human hospital-associated transmission in many cases.
   Importance In December 2019, novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, China. The number of cases has increased rapidly but information on the clinical characteristics of affected patients is limited. Objective To describe the epidemiological and clinical characteristics of NCIP. Design, Setting, and Participants Retrospective, single-center case series of the 138 consecutive hospitalized patients with confirmed NCIP at Zhongnan Hospital of Wuhan University in Wuhan, China, from January 1 to January 28, 2020; final date of follow-up was February 3, 2020. Exposures Documented NCIP. Main Outcomes and Measures Epidemiological, demographic, clinical, laboratory, radiological, and treatment data were collected and analyzed. Outcomes of critically ill patients and noncritically ill patients were compared. Presumed hospital-related transmission was suspected if a cluster of health professionals or hospitalized patients in the same wards became infected and a possible source of infection could be tracked. Results Of 138 hospitalized patients with NCIP, the median age was 56 years (interquartile range, 42-68; range, 22-92 years) and 75 (54.3%) were men. Hospital-associated transmission was suspected as the presumed mechanism of infection for affected health professionals (40 [29%]) and hospitalized patients (17 [12.3%]). Common symptoms included fever (136 [98.6%]), fatigue (96 [69.6%]), and dry cough (82 [59.4%]). Lymphopenia (lymphocyte count, 0.8 x 10(9)/L [interquartile range {IQR}, 0.6-1.1]) occurred in 97 patients (70.3%), prolonged prothrombin time (13.0 seconds [IQR, 12.3-13.7]) in 80 patients (58%), and elevated lactate dehydrogenase (261 U/L [IQR, 182-403]) in 55 patients (39.9%). Chest computed tomographic scans showed bilateral patchy shadows or ground glass opacity in the lungs of all patients. Most patients received antiviral therapy (oseltamivir, 124 [89.9%]), and many received antibacterial therapy (moxifloxacin, 89 [64.4%]; ceftriaxone, 34 [24.6%]; azithromycin, 25 [18.1%]) and glucocorticoid therapy (62 [44.9%]). Thirty-six patients (26.1%) were transferred to the intensive care unit (ICU) because of complications, including acute respiratory distress syndrome (22 [61.1%]), arrhythmia (16 [44.4%]), and shock (11 [30.6%]). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Patients treated in the ICU (n = 36), compared with patients not treated in the ICU (n = 102), were older (median age, 66 years vs 51 years), were more likely to have underlying comorbidities (26 [72.2%] vs 38 [37.3%]), and were more likely to have dyspnea (23 [63.9%] vs 20 [19.6%]), and anorexia (24 [66.7%] vs 31 [30.4%]). Of the 36 cases in the ICU, 4 (11.1%) received high-flow oxygen therapy, 15 (41.7%) received noninvasive ventilation, and 17 (47.2%) received invasive ventilation (4 were switched to extracorporeal membrane oxygenation). As of February 3, 47 patients (34.1%) were discharged and 6 died (overall mortality, 4.3%), but the remaining patients are still hospitalized. Among those discharged alive (n = 47), the median hospital stay was 10 days (IQR, 7.0-14.0). Conclusions and Relevance In this single-center case series of 138 hospitalized patients with confirmed NCIP in Wuhan, China, presumed hospital-related transmission of 2019-nCoV was suspected in 41% of patients, 26% of patients received ICU care, and mortality was 4.3%.
   Question What are the clinical characteristics of hospitalized patients with 2019 novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) in Wuhan, China? Findings In this single-center case series involving 138 patients with NCIP, 26% of patients required admission to the intensive care unit and 4.3% died. Presumed human-to-human hospital-associated transmission of 2019-nCoV was suspected in 41% of patients. Meaning In this case series in Wuhan, China, NCIP was frequently associated with presumed hospital-related transmission, 26% of patients required intensive care unit treatment, and mortality was 4.3%.
C1 [Wang, Dawei; Hu, Bo; Hu, Chang; Zhu, Fangfang; Liu, Xing; Zhang, Jing; Wang, Binbin; Xiang, Hui; Peng, Zhiyong] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Cheng, Zhenshun] Wuhan Univ, Dept Pulm Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Xiong, Yong] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Zhao, Yan] Wuhan Univ, Dept Emergency Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Li, Yirong] Wuhan Univ, Dept Lab Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
RP Peng, ZY (corresponding author), Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
EM wangxinghuan@whu.edu.cn; pengzy5@hotmail.com
RI Ribeiro, Nuno/AAH-2299-2020; Wang, Xinghuan/U-5388-2017
OI Hu, Chang/0000-0002-5457-6190; xiong, yong/0000-0003-0678-4064; Wang,
   Xinghuan/0000-0003-3497-0024
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81701941, 81772046, 81971816]; Special Project for
   Significant New Drug Research and Development in the Major National
   Science and Technology Projects of China [2020ZX09201007]
FX This work was supported by the National Natural Science Foundation
   (grant 81701941 to Dr D. Wang; grants 81772046 and 81971816 to Dr Peng)
   and the Special Project for Significant New Drug Research and
   Development in the Major National Science and Technology Projects of
   China (2020ZX09201007 to Dr Peng).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, NOV COR 2019 NCOV SI
   Wuhan Municipal Health Commission, 2019, REP CLUST PHEU UNKN
   Wuhan Municipal Health Commission, 2020, REP NOV COR INF PNEU
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 5107
Z9 5312
U1 287
U2 525
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 17
PY 2020
VL 323
IS 11
BP 1061
EP 1069
DI 10.1001/jama.2020.1585
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA KX6DC
UT WOS:000521968800018
PM 32031570
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Yuen, KS
   Ye, ZW
   Fung, SY
   Chan, CP
   Jin, DY
AF Yuen, Kit-San
   Ye, Zi -Wei
   Fung, Sin-Yee
   Chan, Chi-Ping
   Jin, Dong-Yan
TI SARS-CoV-2 and COVID-19: The most important research questions
SO CELL AND BIOSCIENCE
LA English
DT Article
DE SARS-CoV-2; COVID-19; 2019 novel coronavirus (2019-nCoV); Novel
   coronavirus pneumonia (NCP)
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency. Here we highlight nine most important research questions concerning virus transmission, asymptomatic and presymptomatic virus shedding, diagnosis, treatment, vaccine development, origin of virus and viral pathogenesis.
C1 [Yuen, Kit-San; Fung, Sin-Yee; Chan, Chi-Ping; Jin, Dong-Yan] Univ Hong Kong, Sch Biomed Sci, Pokfulam, 3-F Lab Block,21 Sassoon Rd, Hong Kong, Peoples R China.
   [Ye, Zi -Wei] Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
RP Jin, DY (corresponding author), Univ Hong Kong, Sch Biomed Sci, Pokfulam, 3-F Lab Block,21 Sassoon Rd, Hong Kong, Peoples R China.
EM dyjin@hku.hk
RI Jin, Dong-Yan/C-4287-2009
OI Jin, Dong-Yan/0000-0002-2778-3530; Yuen, Kit San/0000-0002-1394-7709;
   Chan, Chi Ping/0000-0001-6876-0864
FU Hong Kong Health and Medical Research Fund [HKM-15-M01]; Hong Kong
   Research Grants CouncilHong Kong Research Grants Council [T11-707/15-R]
FX Coronavirus research in our laboratory was funded by the Hong Kong
   Health and Medical Research Fund (HKM-15-M01) and Hong Kong Research
   Grants Council (T11-707/15-R).
CR Bai Y, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.1585, DOI 10.1001/JAMA.2020.1585]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Heimdal I, 2019, J INFECT DIS, V219, P1198, DOI 10.1093/infdis/jiy646
   Lam TT-Y, 2020, IDENTIFICATION 2019, DOI [10.1101/2020.02.13.945485, 10.1101/2020.02.13.945485., DOI 10.1101/2020.02.13.945485]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 12
TC 127
Z9 130
U1 5
U2 45
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD MAR 16
PY 2020
VL 10
IS 1
AR 40
DI 10.1186/s13578-020-00404-4
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA KX9BI
UT WOS:000522170100002
PM 32190290
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Zhou, YD
   Hou, Y
   Shen, JY
   Huang, Y
   Martin, W
   Cheng, FX
AF Zhou, Yadi
   Hou, Yuan
   Shen, Jiayu
   Huang, Yin
   Martin, William
   Cheng, Feixiong
TI Network-based drug repurposing for novel coronavirus
   2019-nCoV/SARS-CoV-2
SO CELL DISCOVERY
LA English
DT Article
ID SMALL-MOLECULE INHIBITORS; PAPAIN-LIKE PROTEASE; CONVERTING-ENZYME;
   POTENT INHIBITOR; VIRUS; IDENTIFICATION; MELATONIN; SARS; INTERACTS;
   PNEUMONIA
AB Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the "Complementary Exposure" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.
C1 [Zhou, Yadi; Hou, Yuan; Shen, Jiayu; Huang, Yin; Martin, William; Cheng, Feixiong] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA.
   [Cheng, Feixiong] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
RP Cheng, FX (corresponding author), Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA.; Cheng, FX (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44195 USA.
EM chengf@ccf.org
OI Shen, Jia Yu/0000-0002-2279-3502; Martin, William/0000-0003-0616-0462
FU National Heart, Lung, and Blood Institute of the National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K99 HL138272, R00 HL138272]
FX This work was supported by the National Heart, Lung, and Blood Institute
   of the National Institutes of Health (NIH) under Award Number K99
   HL138272 and R00 HL138272 to F.C. The content of this publication does
   not necessarily reflect the views of the Cleveland Clinic.
CR Agarwala R, 2016, NUCLEIC ACIDS RES, V44, pD7, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095, 10.1093/nar/gks1189]
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Avorn J, 2015, NEW ENGL J MED, V372, P1877, DOI 10.1056/NEJMp1500848
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Bedi O, 2016, N-S ARCH PHARMACOL, V389, P695, DOI 10.1007/s00210-016-1252-4
   Biedenkopf N, 2017, ANTIVIR RES, V137, P76, DOI 10.1016/j.antiviral.2016.11.011
   Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045
   Chen HY, 2002, J VIROL, V76, P5233, DOI 10.1128/JVI.76.10.5233-5250.2002
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Xin, 2009, Antivir Chem Chemother, V19, P151
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10744-6
   Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09186-x
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5
   Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006
   Cheng FX, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005074
   Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051
   Cheng FX, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002503
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Chiang CW, 2018, CLIN PHARMACOL THER, V103, P287, DOI 10.1002/cpt.914
   Cong Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194868
   Dai J, 2002, J PINEAL RES, V32, P112, DOI 10.1034/j.1600-079x.2002.1844.x
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Emmott E, 2013, J VIROL, V87, P9486, DOI 10.1128/JVI.00321-13
   Erlandson KM, 2017, CLIN INFECT DIS, V65, P2042, DOI 10.1093/cid/cix645
   Fang J, 2020, NETWORK BASED TRANSL, DOI [10.1101/2020.01.15.20017160, DOI 10.1101/2020.01.15.20017160]
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Fung TS, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0053-0
   Galano A, 2013, J PINEAL RES, V54, P245, DOI 10.1111/jpi.12010
   Garcia CC, 2010, DISCOV MED, V10, P479
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Gebre M, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020055
   Greene JA, 2017, NEW ENGL J MED, V377, P2493, DOI 10.1056/NEJMms1706744
   Gupta A, 2017, RESPIR MED CASE REP, V21, P116, DOI 10.1016/j.rmcr.2017.04.010
   Halder AK, 2018, BRIEF FUNCT GENOMICS, V17, P381, DOI 10.1093/bfgp/elx026
   He SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010286
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Hong M, 2008, VIRAL IMMUNOL, V21, P153, DOI 10.1089/vim.2007.0108
   Johansen LM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005471
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292
   Kim JH, 2013, ASIA PAC ALLERGY, V3, P136, DOI 10.5415/apallergy.2013.3.2.136
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Ko C, 2015, ANTIVIR THER, V20, P835, DOI 10.3851/IMP2965
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085
   Lasso G, 2019, CELL, V178, P1526, DOI 10.1016/j.cell.2019.08.005
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   LEWIS EL, 1992, J GEN VIROL, V73, P3285, DOI 10.1099/0022-1317-73-12-3285
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li QS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004163
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu C, 2020, PHYS REP, V846, P1, DOI 10.1016/j.physrep.2019.12.004
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McNulty S, 2013, J VIROL, V87, P912, DOI 10.1128/JVI.02415-12
   Moskowitz DW, 2004, CURR TOP MED CHEM, V4, P1433
   Muller C, 2018, ANTIVIR RES, V150, P123, DOI 10.1016/j.antiviral.2017.12.010
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Rainsford K. D., 2006, Inflammopharmacology, V14, P2, DOI 10.1007/s10787-006-0002-5
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Seko Y, 2006, CLIN SCI, V110, P379, DOI 10.1042/CS20050299
   Silvestri M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-61
   Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318
   Smith IN, 2019, AM J HUM GENET, V104, P861, DOI 10.1016/j.ajhg.2019.03.009
   Srinivasan V, 2012, RECENT PATENTS ENDOC, V6, P30, DOI 10.2174/187221412799015317
   Stohr S, 2016, GUT, V65, P2017, DOI 10.1136/gutjnl-2014-308971
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Tan DX, 2014, J PINEAL RES, V57, P381, DOI 10.1111/jpi.12186
   Tan X, 2012, NAT BIOTECHNOL, V30, P1125, DOI 10.1038/nbt.2391
   V'kovski P, 2019, ELIFE, V8, DOI 10.7554/eLife.42037
   Wang CH, 2014, CRIT CARE MED, V42, P313, DOI 10.1097/CCM.0b013e3182a2727d
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XJ, 2015, ANTIVIR RES, V120, P140, DOI 10.1016/j.antiviral.2015.06.007
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiao J, 2009, EUR J HEART FAIL, V11, P349, DOI 10.1093/eurjhf/hfp023
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang H, 2016, NUCLEIC ACIDS RES, V44, pD1069, DOI 10.1093/nar/gkv1230
   Yang SP, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00303-18
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zeng XX, 2020, CHEM SCI, V11, P1775, DOI 10.1039/c9sc04336e
   Zeng XX, 2020, BIOINFORMATICS, V36, P2805, DOI 10.1093/bioinformatics/btaa010
   Zeng XX, 2019, BIOINFORMATICS, V35, P5191, DOI 10.1093/bioinformatics/btz418
   Zhao YG, 2016, NATURE, V535, P169, DOI 10.1038/nature18615
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou WB, 2011, BREAST CANCER RES TR, V128, P625, DOI 10.1007/s10549-011-1556-5
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 97
TC 265
Z9 269
U1 19
U2 61
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PD MAR 16
PY 2020
VL 6
IS 1
AR 14
DI 10.1038/s41421-020-0153-3
PG 18
WC Cell Biology
SC Cell Biology
GA KU4SS
UT WOS:000519701100001
PM 32194980
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Wrapp, D
   Wang, NS
   Corbett, KS
   Goldsmith, JA
   Hsieh, CL
   Abiona, O
   Graham, BS
   McLellan, JS
AF Wrapp, Daniel
   Wang, Nianshuang
   Corbett, Kizzmekia S.
   Goldsmith, Jory A.
   Hsieh, Ching-Lin
   Abiona, Olubukola
   Graham, Barney S.
   McLellan, Jason S.
TI Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
SO SCIENCE
LA English
DT Article
ID FUSION PROTEIN; CORONAVIRUS; CLEAVAGE; RECEPTOR; SYSTEM
AB The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.
C1 [Wrapp, Daniel; Wang, Nianshuang; Goldsmith, Jory A.; Hsieh, Ching-Lin; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Corbett, Kizzmekia S.; Abiona, Olubukola; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP McLellan, JS (corresponding author), Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
EM jmclellan@austin.utexas.edu
RI Ribeiro, Nuno/AAH-2299-2020
OI McLellan, Jason/0000-0003-3991-542X; Wrapp, Daniel/0000-0002-0538-9647
FU National Institutes of Health (NIH)/National Institute of Allergy and
   Infectious Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01-AI127521]; NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); University of Texas College of Natural Sciences;
   Cancer Prevention and Research Institute of Texas (CPRIT) [RR160023]
FX This work was supported in part by a National Institutes of Health
   (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)
   grant awarded to J.S.M. (R01-AI127521) and by intramural funding from
   NIAID to B.S.G. The Sauer Structural Biology Laboratory is supported by
   the University of Texas College of Natural Sciences and by award
   RR160023 from the Cancer Prevention and Research Institute of Texas
   (CPRIT).
CR Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Croll TI, 2018, ACTA CRYSTALLOGR D, V74, P519, DOI 10.1107/S2059798318002425
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Grant T, 2018, ELIFE, V7, DOI 10.7554/eLife.35383
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu R., 2020, LANCET
   Lu R., 2020, LANCET, DOI [10.1016/S0140-6736(20)30251-8, DOI 10.1016/S0140-6736(20)30251-8MEDLINE]
   Morin A, 2013, ELIFE, V2, DOI 10.7554/eLife.01456
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Ramirez-Aportela E, 2020, BIOINFORMATICS, V36, P765, DOI 10.1093/bioinformatics/btz671
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Tian X., 2020, BIORXIV, V9, P382
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wan Y., 2020, J VIROL
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wrapp D, 2019, J VIROL, V93, DOI 10.1128/JVI.00923-19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zheng XY, 2020, J CELL MOL MED, V24, P6804, DOI 10.1111/jcmm.15334
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 45
TC 1329
Z9 1406
U1 140
U2 333
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 13
PY 2020
VL 367
IS 6483
BP 1260
EP +
DI 10.1126/science.abb2507
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KU9DP
UT WOS:000520023800044
PM 32511295
OA Other Gold, Green Accepted, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Kaplan, EH
AF Kaplan, Edward H.
TI Containing 2019-nCoV (Wuhan) coronavirus
SO HEALTH CARE MANAGEMENT SCIENCE
LA English
DT Article
DE Coronavirus; Containment; Isolation; Quarantine; Probability modeling
AB The novel coronavirus 2019-nCoV first appeared in December 2019 in Wuhan, China. While most of the initial cases were linked to the Huanan Seafood Wholesale Market, person-to-person transmission has been verified. Given that a vaccine cannot be developed and deployed for at least a year, preventing further transmission relies upon standard principles of containment, two of which are the isolation of known cases and the quarantine of persons believed at high risk of exposure. This note presents probability models for assessing the effectiveness of case isolation and quarantine within a community during the initial phase of an outbreak with illustrations based on early observations from Wuhan.
C1 [Kaplan, Edward H.] Yale Sch Management, Operat Res, 165 Whitney Ave, New Haven, CT 06511 USA.
   [Kaplan, Edward H.] Yale Sch Management, Publ Hlth, 165 Whitney Ave, New Haven, CT 06511 USA.
   [Kaplan, Edward H.] Yale Sch Management, Engn, 165 Whitney Ave, New Haven, CT 06511 USA.
RP Kaplan, EH (corresponding author), Yale Sch Management, Operat Res, 165 Whitney Ave, New Haven, CT 06511 USA.; Kaplan, EH (corresponding author), Yale Sch Management, Publ Hlth, 165 Whitney Ave, New Haven, CT 06511 USA.; Kaplan, EH (corresponding author), Yale Sch Management, Engn, 165 Whitney Ave, New Haven, CT 06511 USA.
EM edward.kaplan@yale.edu
RI Ribeiro, Nuno/AAH-2299-2020
OI Kaplan, Edward/0000-0002-8722-7667
CR ANDERSON R M, 1991
   Becker N. G., 2015, MODELING INFORM INFE
   Borio L, 2020, WALL STREET J
   Britton T, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0670
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Imai N, 2020, 3 LOND IMP COLL
   Kaplan EH, 2003, MATH BIOSCI, V185, P33, DOI 10.1016/S0025-5564(03)00090-7
   Killerby ME, 2020, EMERG INFECT DIS, V26, P191, DOI 10.3201/eid2602.190697
   Kupferschmidt K., 2020, SCIENCE
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Miller SL, 2017, AM J INFECT CONTROL, V45, P652, DOI 10.1016/j.ajic.2017.01.029
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 14
TC 14
Z9 14
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1386-9620
EI 1572-9389
J9 HEALTH CARE MANAG SC
JI Health Care Manag. Sci.
PD SEP
PY 2020
VL 23
IS 3
BP 311
EP 314
DI 10.1007/s10729-020-09504-6
EA MAR 2020
PG 4
WC Health Policy & Services
SC Health Care Sciences & Services
GA MT1AW
UT WOS:000520656400001
PM 32146554
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Shang, WL
   Yang, Y
   Rao, YF
   Rao, XC
AF Shang, Weilong
   Yang, Yi
   Rao, Yifan
   Rao, Xiancai
TI The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
SO NPJ VACCINES
LA English
DT Article
ID SPIKE PROTEIN; SARS-COV; NEUTRALIZATION; IMMUNIZATION
AB The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern. However, no specific antiviral treatments or vaccines are available yet. This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2.
C1 [Shang, Weilong; Yang, Yi; Rao, Yifan; Rao, Xiancai] Third Mil Med Univ, Army Med Univ, Coll Basic Med Sci, Dept Microbiol, Chongqing 400038, Peoples R China.
RP Rao, XC (corresponding author), Third Mil Med Univ, Army Med Univ, Coll Basic Med Sci, Dept Microbiol, Chongqing 400038, Peoples R China.
EM raoxiancai@126.com
FU National Key Biosafety Technology Research and Development Program of
   China [2017YFC1200404-4]; Biosafety Research Program of PLA [17SAZ08]
FX This work was supported by the National Key Biosafety Technology
   Research and Development Program of China (2017YFC1200404-4), and the
   Biosafety Research Program of PLA (17SAZ08).
CR Bukreyev A, 2004, LANCET, V363, P2122, DOI 10.1016/S0140-6736(04)16501-X
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duan YN, 2020, RADIOLOGY, V295, P21, DOI 10.1148/radiol.2020200323
   Eyigun CP, 1998, J VIRAL HEPATITIS, V5, P265, DOI 10.1046/j.1365-2893.1998.00106.x
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   He WQ, 2015, METHODS, V90, P95, DOI 10.1016/j.ymeth.2015.04.037
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   National Health Commission of the People's Republic of China, EP PREV CONTR DYN
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shi SQ, 2006, MOL IMMUNOL, V43, P1791, DOI 10.1016/j.molimm.2005.11.005
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yuan JZ, 2018, NANO LETT, V18, P725, DOI 10.1021/acs.nanolett.7b03893
NR 25
TC 61
Z9 63
U1 3
U2 79
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD MAR 6
PY 2020
VL 5
IS 1
AR 18
DI 10.1038/s41541-020-0170-0
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS5SB
UT WOS:000518367000001
PM 32194995
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lai, THT
   Tang, EWH
   Chau, SKY
   Fung, KSC
   Li, KKW
AF Lai, Tracy H. T.
   Tang, Emily W. H.
   Chau, Sandy K. Y.
   Fung, Kitty S. C.
   Li, Kenneth K. W.
TI Stepping up infection control measures in ophthalmology during the novel
   coronavirus outbreak: an experience from Hong Kong
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; Hong Kong; Infection control; Ophthalmology;
   SARS-CoV-2
AB Purpose Coronavirus disease (COVID-19) has rapidly emerged as a global health threat. The purpose of this article is to share our local experience of stepping up infection control measures in ophthalmology to minimise COVID-19 infection of both healthcare workers and patients. Methods Infection control measures implemented in our ophthalmology clinic are discussed. The measures are based on detailed risk assessment by both local ophthalmologists and infection control experts. Results A three-level hierarchy of control measures was adopted. First, for administrative control, in order to lower patient attendance, text messages with an enquiry phone number were sent to patients to reschedule appointments or arrange drug refill. In order to minimise cross-infection of COVID-19, a triage system was set up to identify patients with fever, respiratory symptoms, acute conjunctivitis or recent travel to outbreak areas and to encourage these individuals to postpone their appointments for at least 14 days. Micro-aerosol generating procedures, such as non-contact tonometry and operations under general anaesthesia were avoided. Nasal endoscopy was avoided as it may provoke sneezing and cause generation of droplets. All elective clinical services were suspended. Infection control training was provided to all clinical staff. Second, for environmental control, to reduce droplet transmission of COVID-19, installation of protective shields on slit lamps, frequent disinfection of equipment, and provision of eye protection to staff were implemented. All staff were advised to measure their own body temperatures before work and promptly report any symptoms of upper respiratory tract infection, vomiting or diarrhoea. Third, universal masking, hand hygiene, and appropriate use of personal protective equipment (PPE) were promoted. Conclusion We hope our initial experience in stepping up infection control measures for COVID-19 infection in ophthalmology can help ophthalmologists globally to prepare for the potential community outbreak or pandemic. In order to minimise transmission of COVID-19, ophthalmologists should work closely with local infection control teams to implement infection control measures that are appropriate for their own clinical settings.
C1 [Lai, Tracy H. T.; Tang, Emily W. H.; Li, Kenneth K. W.] United Christian Hosp, Dept Ophthalmol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China.
   [Lai, Tracy H. T.; Tang, Emily W. H.; Li, Kenneth K. W.] Tseung Kwan O Hosp, Dept Ophthalmol, Tseung Kwan O, 2 Po Ning Path, Hong Kong, Peoples R China.
   [Chau, Sandy K. Y.] Tseung Kwan O Hosp, Dept Pathol, Tseung Kwan O, 2 Po Ning Path, Hong Kong, Peoples R China.
   [Fung, Kitty S. C.] United Christian Hosp, Dept Pathol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China.
RP Li, KKW (corresponding author), United Christian Hosp, Dept Ophthalmol, Kwun Tong, Kowloon, 130 Hip Wo St, Hong Kong, Peoples R China.; Li, KKW (corresponding author), Tseung Kwan O Hosp, Dept Ophthalmol, Tseung Kwan O, 2 Po Ning Path, Hong Kong, Peoples R China.
EM kennethli@rcsed.ac.uk
RI Ribeiro, Nuno/AAH-2299-2020; Li, Kenneth/M-4140-2017
OI Tang, Emily W.H./0000-0002-6885-7882; Li, Kenneth/0000-0001-9440-8063;
   Lai, Tracy/0000-0002-0420-9456
CR [Anonymous], WHAT HAPP EYE EX
   [Anonymous], 2020, AL IMP COR CONT OPHT
   [Anonymous], 2020, SHANGHAI OFFICIALS R
   [Anonymous], 2020, HOSP AUTHORITY ACTIV
   [Anonymous], 2020, CDC TESTS COVID 19
   [Anonymous], 2020, COR KILLS CHIN WHIST
   [Anonymous], 2020, HOW FLU SPREADS
   BRITT JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P225, DOI 10.1001/archopht.1991.01080020071046
   Centers for Diseases Control (CDC), 2020, SYMPT COR DIS 2019
   Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung LS, 2003, J ROY SOC MED, V96, P374, DOI 10.1258/jrsm.96.8.374
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Latest Situation of Coronavirus Disease (COVID-19) in Hong Kong, 2020, LAT SIT COR DIS COVI
   Leung G M, 2009, Hong Kong Med J, V15 Suppl 9, P12
   Loon SC, 2004, BRIT J OPHTHALMOL, V88, P1229, DOI 10.1136/bjo.2003.035931.corr1
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Team TNCPERE, 2020, EP CHAR OUTBR 2019 N, V2020
   The World Health Organization (WHO), 2020, COVID 19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, WHO DIR GEN REM MED
   WHO Region A, 2020, 25 WHO
   World Health Organisation, 2020, 38 WHO
   Zhou Y, 2020, OPHTHALMOLOGIC EVIDE, DOI [10.1101/2020.02.11.20021956, DOI 10.1101/2020.02.11.20021956]
NR 25
TC 107
Z9 110
U1 4
U2 79
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2020
VL 258
IS 5
BP 1049
EP 1055
DI 10.1007/s00417-020-04641-8
EA MAR 2020
PG 7
WC Ophthalmology
SC Ophthalmology
GA LE6JJ
UT WOS:000517698000001
PM 32124000
OA Bronze, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Baruah, V
   Bose, S
AF Baruah, Vargab
   Bose, Sujoy
TI Immunoinformatics-aided identification of T cell and B cell epitopes in
   the surface glycoprotein of 2019-nCoV
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE 2019-nCoV; coronavirus; COVID-19; epitope prediction; immunoinformatics;
   SARS-CoV-2
ID PREDICTION; PROTEIN; EVOLUTION
AB The 2019 novel coronavirus (2019-nCoV) outbreak has caused a large number of deaths with thousands of confirmed cases worldwide, especially in East Asia. This study took an immunoinformatics approach to identify significant cytotoxic T lymphocyte (CTL) and B cell epitopes in the 2019-nCoV surface glycoprotein. Also, interactions between identified CTL epitopes and their corresponding major histocompatibility complex (MHC) class I supertype representatives prevalent in China were studied by molecular dynamics simulations. We identified five CTL epitopes, three sequential B cell epitopes and five discontinuous B cell epitopes in the viral surface glycoprotein. Also, during simulations, the CTL epitopes were observed to be binding MHC class I peptide-binding grooves via multiple contacts, with continuous hydrogen bonds and salt bridge anchors, indicating their potential in generating immune responses. Some of these identified epitopes can be potential candidates for the development of 2019-nCoV vaccines.
C1 [Baruah, Vargab; Bose, Sujoy] Gauhati Univ, Dept Biotechnol, Gauhati 781014, Assam, India.
RP Baruah, V (corresponding author), Gauhati Univ, Dept Biotechnol, Gauhati 781014, Assam, India.
EM vargabbarua@gauhati.ac.in
RI Ribeiro, Nuno/AAH-2299-2020
OI Baruah, Vargab/0000-0002-2882-7785; Bose, Sujoy/0000-0003-3606-958X
CR Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fernando BG, 2016, BIOMED RES INT, V2016, P1
   Francisco RD, 2015, IMMUNOGENETICS, V67, P651, DOI 10.1007/s00251-015-0875-9
   Guest JD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01117
   Huang J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-50
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Ji W, 2019, MOL IMMUNOL, V112, P274, DOI 10.1016/j.molimm.2019.06.005
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   ROGNAN D, 1992, EUR J BIOCHEM, V208, P101, DOI 10.1111/j.1432-1033.1992.tb17163.x
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Salemi M, 2004, J VIROL, V78, P1602, DOI 10.1128/JVI.78.3.1602-1603.2004
   Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292
   World Health Organization, 2020 WHO
   Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702
NR 26
TC 71
Z9 80
U1 10
U2 118
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD MAY
PY 2020
VL 92
IS 5
BP 495
EP 500
DI 10.1002/jmv.25698
EA MAR 2020
PG 6
WC Virology
SC Virology
GA KU3AY
UT WOS:000517679900001
PM 32022276
OA Green Published, Bronze
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Li, SJ
   Wang, YL
   Xue, J
   Zhao, N
   Zhu, TS
AF Li, Sijia
   Wang, Yilin
   Xue, Jia
   Zhao, Nan
   Zhu, Tingshao
TI The Impact of COVID-19 Epidemic Declaration on Psychological
   Consequences: A Study on Active Weibo Users
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE public health emergencies; word frequency analysis; mental health;
   emotion; cognition
ID PERSONALITY; SCALE; SARS
AB COVID-19 (Corona Virus Disease 2019) has significantly resulted in a large number of psychological consequences. The aim of this study is to explore the impacts of COVID-19 on people's mental health, to assist policy makers to develop actionable policies, and help clinical practitioners (e.g., social workers, psychiatrists, and psychologists) provide timely services to affected populations. We sample and analyze the Weibo posts from 17,865 active Weibo users using the approach of Online Ecological Recognition (OER) based on several machine-learning predictive models. We calculated word frequency, scores of emotional indicators (e.g., anxiety, depression, indignation, and Oxford happiness) and cognitive indicators (e.g., social risk judgment and life satisfaction) from the collected data. The sentiment analysis and the paired sample t-test were performed to examine the differences in the same group before and after the declaration of COVID-19 on 20 January, 2020. The results showed that negative emotions (e.g., anxiety, depression and indignation) and sensitivity to social risks increased, while the scores of positive emotions (e.g., Oxford happiness) and life satisfaction decreased. People were concerned more about their health and family, while less about leisure and friends. The results contribute to the knowledge gaps of short-term individual changes in psychological conditions after the outbreak. It may provide references for policy makers to plan and fight against COVID-19 effectively by improving stability of popular feelings and urgently prepare clinical practitioners to deliver corresponding therapy foundations for the risk groups and affected people.
C1 [Li, Sijia; Wang, Yilin; Zhao, Nan; Zhu, Tingshao] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China.
   [Li, Sijia] Univ Chinese Acad Sci, Dept Psychol, Beijing 100049, Peoples R China.
   [Wang, Yilin] Nankai Univ, Dept Psychol, Tianjin 300071, Peoples R China.
   [Xue, Jia] Univ Toronto, Factor Inwentash Fac Social Work, Toronto, ON M5S 1A1, Canada.
RP Zhao, N; Zhu, TS (corresponding author), Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China.
EM lisj@psych.ac.cn; 1613118@mail.nankai.edu.cn; jia.xue@utoronto.ca;
   zhaonan@psych.ac.cn; tszhu@psych.ac.cn
RI Li, Sijia/ABG-1700-2020
OI Wang, Yilin/0000-0003-3710-1123; Zhu, Tingshao/0000-0003-0020-3812
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31700984]
FX This research was funded by National Natural Science Foundation of
   China, grant number 31700984.
CR Ackerman JM, 2009, J EXP SOC PSYCHOL, V45, P478, DOI 10.1016/j.jesp.2008.12.008
   Bibo Hao, 2013, Cross-Cultural Design. Cultural Differences in Everyday Life. 5th International Conference, CCD 2013. Held as Part of HCI International 2013. Proceedings: LNCS 8024, P101, DOI 10.1007/978-3-642-39137-8_12
   Carone DA, 2001, CLIN PSYCHOL REV, V21, P989, DOI 10.1016/S0272-7358(00)00078-7
   Che X.H., 2018, SOCIAL NETWORKS CHIN
   Daniel P.P., 2015, PLOS ONE, V10, P1, DOI [10.1371/journal.pone.0138717, DOI 10.1371/JOURNAL.PONE.0138717]
   DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
   DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13
   Festinger L., 1957, BRIT J PSYCHIAT, V207, P2112, DOI [10.1192/bjp.109.458.164, DOI 10.1192/BJP.109.458.164]
   Gao R., 2013, P 7 ACM C REC SYST, P355, DOI DOI 10.1145/2507157.2507219
   HAN SF, 2017, CHIN NURS RES, V4, P186, DOI DOI 10.1016/J.CNRE.2017.06.005
   Hills P, 2002, PERS INDIV DIFFER, V33, P1073, DOI 10.1016/S0191-8869(01)00213-6
   HOUSTON V, 1994, EUR J SOC PSYCHOL, V24, P279, DOI 10.1002/ejsp.2420240205
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kiecolt-Glaser JK, 2002, ANNU REV PSYCHOL, V53, P83, DOI 10.1146/annurev.psych.53.100901.135217
   Kosinski M, 2015, AM PSYCHOL, V70, P543, DOI 10.1037/a0039210
   LARSEN KS, 1976, J SOC PSYCHOL, V98, P295, DOI 10.1080/00224545.1976.9923404
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095912
   Liu M, 2018, ADV ENG MATER, V2, P1, DOI DOI 10.1177/0886260518757756
   Liu T., 2011, J CHIN INF PROCESS, V6, P53
   Liu XQ, 2015, LECT NOTES COMPUT SC, V8944, P41, DOI 10.1007/978-3-319-15554-8_4
   Maunder R, 2003, CAN MED ASSOC J, V168, P1245
   Milas G, 2013, J INDIVID DIFFER, V34, P203, DOI 10.1027/1614-0001/a000115
   Mortensen CR, 2010, PSYCHOL SCI, V21, P440, DOI 10.1177/0956797610361706
   Navarrete CD, 2007, EVOL HUM BEHAV, V28, P60, DOI 10.1016/j.evolhumbehav.2006.06.002
   Norris FH, 2002, PSYCHIATRY, V65, P240, DOI 10.1521/psyc.65.3.240.20169
   Schaller M., 2007, OXFORD HDB EVOLUTION, P491, DOI DOI 10.1093/OXFORDHB/9780198568308.013.0033
   Schaller M, 2008, J PERS SOC PSYCHOL, V95, P212, DOI 10.1037/0022-3514.95.1.212
   Schaller M, 2006, PSYCHOL INQ, V17, P96
   Schaller M, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0105
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   Tam CWC, 2004, PSYCHOL MED, V34, P1197, DOI 10.1017/S0033291704002247
   Terrizzi JA, 2013, EVOL HUM BEHAV, V34, P99, DOI 10.1016/j.evolhumbehav.2012.10.003
   TZINER A, 1982, SOC BEHAV PERSONAL, V10, P205, DOI 10.2224/sbp.1982.10.2.205
   Wiedemann P M, 1997, Z Arztl Fortbild Qualitatssich, V91, P31
   Youyou Wu, 2017, Psychol Sci, V28, P276, DOI 10.1177/0956797616678187
   Zhao N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157947
NR 36
TC 147
Z9 149
U1 73
U2 102
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAR 2
PY 2020
VL 17
IS 6
AR 2032
DI 10.3390/ijerph17062032
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA LI2VS
UT WOS:000529342300222
PM 32204411
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Myint, A
   Jones, T
AF Myint, Aung
   Jones, Trevor
TI Possible method for the production of a Covid-19 vaccine
SO VETERINARY RECORD
LA English
DT Letter
C1 [Myint, Aung] Livestock Breeding & Vet Dept, Bacterial Vaccine Prod, 111,Sabe Rd,POB 11013, Insein, Myanmar.
RP Myint, A (corresponding author), Livestock Breeding & Vet Dept, Bacterial Vaccine Prod, 111,Sabe Rd,POB 11013, Insein, Myanmar.
EM dr.aungmyint@gmail.com; farmlab@supanet.com
NR 0
TC 3
Z9 3
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD MAR
PY 2020
VL 186
IS 12
BP 388
EP 388
DI 10.1136/vr.m1193
PG 1
WC Veterinary Sciences
SC Veterinary Sciences
GA OS5RX
UT WOS:000590222000018
PM 32221001
OA Bronze
DA 2021-01-01
ER

PT J
AU Kadkhoda, K
AF Kadkhoda, Kamran
TI COVID-19: an Immunopathological View
SO MSPHERE
LA English
DT Article
DE COVID-19; SARS-CoV-2; immunopathology
ID C-REACTIVE PROTEIN; CORONAVIRUS; RECEPTOR; CHILDREN
AB Since its emergence in December 2019, it took only a couple of months for an outbreak of the novel coronavirus disease 2019 (COVID-19) to be declared a pandemic by the World Health Organization (WHO). This along with the highly infectious nature of the disease and the associated mortality call for particular attention to the underlying (immuno)pathomechanism(s). The latter will inform case management and vaccine design. Unravelling these mechanisms can assist basic scientists, laboratory medicine practitioners, clinicians, public health practitioners, funding agencies, and health care policymakers in responding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
C1 [Kadkhoda, Kamran] Cleveland Clin, Immunopathol Lab, Robot J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
RP Kadkhoda, K (corresponding author), Cleveland Clin, Immunopathol Lab, Robot J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
EM kadkhok@ccf.org
CR Anania JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00464
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Batteux F, 1999, EUR CYTOKINE NETW, V10, P509
   Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Choy EH, 2019, RHEUMATOLOGY, V58, P1122, DOI 10.1093/rheumatology/kez002
   Devaraj S, 2013, J CLIN ENDOCR METAB, V98, pE1510, DOI 10.1210/jc.2013-2112
   Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Li M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200478
   Liu DL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0512-1
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nicholls JM, 2006, PLOS MED, V3, P222, DOI 10.1371/journal.pmed.0030027
   Prill MM, 2012, PEDIATR INFECT DIS J, V31, P235, DOI 10.1097/INF.0b013e31823e07fe
   Schlenz H, 2014, INT J OBESITY, V38, pS26, DOI 10.1038/ijo.2014.132
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Tang A, 2020, EMERG INFECT DIS, V26, P1337, DOI 10.3201/eid2606.200301
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   WHO, 2020, REP WHO CHIN JOINT M
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 17
Z9 18
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD MAR-APR
PY 2020
VL 5
IS 2
AR e00344-20
DI 10.1128/mSphere.00344-20
PG 4
WC Microbiology
SC Microbiology
GA MK1JR
UT WOS:000548543100011
PM 32321823
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Batlle, D
   Wysocki, J
   Satchell, K
AF Batlle, Daniel
   Wysocki, Jan
   Satchell, Karla
TI Soluble angiotensin-converting enzyme 2: a potential approach for
   coronavirus infection therapy?
SO CLINICAL SCIENCE
LA English
DT Article
ID FUNCTIONAL RECEPTOR; ACE2; PROTEIN; SPIKE
AB A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.
C1 [Batlle, Daniel; Wysocki, Jan] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Nephrol Hypertens, Chicago, IL 60611 USA.
   [Satchell, Karla] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.
   [Satchell, Karla] Northwestern Univ, Feinberg Sch Med, Ctr Struct Genom Infect Dis, Chicago, IL 60611 USA.
RP Batlle, D (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Nephrol Hypertens, Chicago, IL 60611 USA.
EM d-batlle@northwestern.edu
OI Batlle, Daniel/0000-0002-5878-9046
FU NIAID, NIH, HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201700060C];
   NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [RO1DK104785]
FX The CSGID is funded by NIAID, NIH, HHS [contract number
   HHSN272201700060C]. D.B. is currently funded by NIDDK [grant number
   RO1DK104785].
CR Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Imai Y, 2010, CIRC J, V74, P405, DOI 10.1253/circj.CJ-10-0045
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lei C., 2020, BIORXIV, DOI [10.1101/2020.02.01.929976, DOI 10.1101/2020.02.01.929976]
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Serfozo P, 2020, HYPERTENSION, V75, P173, DOI 10.1161/HYPERTENSIONAHA.119.14071
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wysocki J, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120886
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
NR 13
TC 132
Z9 138
U1 2
U2 8
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD MAR
PY 2020
VL 134
IS 5
BP 543
EP 545
DI 10.1042/CS20200163
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA ME9XO
UT WOS:000545007800002
PM 32167153
OA Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Kowalik, MM
   Trzonkowski, P
   Lasinska-Kowara, M
   Mital, A
   Smiatacz, T
   Jaguszewski, M
AF Kowalik, Maciej M.
   Trzonkowski, Piotr
   Lasinska-Kowara, Magdalena
   Mital, Andrzej
   Smiatacz, Tomasz
   Jaguszewski, Milosz
TI COVID-19-Toward a comprehensive understanding of the disease
SO CARDIOLOGY JOURNAL
LA English
DT Article
DE COVID-19; SARS-CoV-2; epidemiology; immunology; acute respiratory
   distress syndrome; coagulation; therapy
ID TRIGGERED RESOLVIN D3; VIRAL LOAD; CORONAVIRUS; COAGULATION; INFECTION;
   ASSOCIATION; TISSUE; VIRUS; SARS; RISK
AB The evidence on the pathophysiology of the novel coronavirus SARS-CoV-2 infection is rapidly growing. Elucidating why some patients suffering from COVID-19 are getting so sick, while others are not, has become an informal imperative for researchers and clinicians around the globe. The answer to this question would allow rationalizing the fear surrounding this pandemic. Understanding of the pathophysiology of COVID-19 relies on unraveling of interplaying mechanisms, including SARS-CoV-2 virulence, human immune response, and complex inflammatory reactions with coagulation playing a major role. An interplay with bacterial co-infections, as well as the vascular system and microcirculation affected throughout the body should also be examined. More importantly, a comprehensive understanding of pathological mechanisms of COVID-19 will increase the efficacy of therapy and decrease mortality. Herewith, the authors present a combined viewpoint based on the current state of knowledge on COVID-19: beginning from the virus, its transmission, and mechanisms of entry into the human body, through the pathological effects on the cellular level, up to immunological reaction, systemic and organ presentation. Last but not least, currently available and possible future therapeutic and diagnostic options are briefly commented on.
C1 [Kowalik, Maciej M.; Lasinska-Kowara, Magdalena] Med Univ Gdansk, Dept Cardiac Anesthesiol, Ul Smoluchowskiego 17, PL-80217 Gdansk, Poland.
   [Trzonkowski, Piotr] Med Univ Gdansk, Dept Med Immunol, Gdansk, Poland.
   [Mital, Andrzej] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland.
   [Smiatacz, Tomasz] Med Univ Gdansk, Gdansk, Poland.
   [Jaguszewski, Milosz] Med Univ Gdansk, Univ Catheterizat Labs, Dept Cardiol 1, Gdansk, Poland.
RP Kowalik, MM (corresponding author), Med Univ Gdansk, Dept Cardiac Anesthesiol, Ul Smoluchowskiego 17, PL-80217 Gdansk, Poland.
EM mkowalik@gumed.edu.pl
RI Kowalik, Maciej M/C-9247-2014
OI Kowalik, Maciej M/0000-0002-0839-1187; Smiatacz,
   Tomasz/0000-0003-2793-3671
CR Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   [Anonymous], 2020, NAT MED, DOI [10.1038/s41591-020-0877-5, DOI 10.1038/S41591-020-0877-5]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arnardottir HH, 2014, J IMMUNOL, V193, P4235, DOI 10.4049/jimmunol.1401313
   Bellon M, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100289
   Beun R, 2020, INT J LAB HEMATOL, V42, P19, DOI 10.1111/ijlh.13230
   Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC
   Brojakowska A, 2020, J AM COLL CARDIOL, V75, P3085, DOI 10.1016/j.jacc.2020.04.028
   Bruzelius M, 2015, J THROMB HAEMOST, V13, P219, DOI 10.1111/jth.12808
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Ciceri F., 2020, CRIT CARE RESUSC
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Colby JK, 2016, AM J PATHOL, V186, P1801, DOI 10.1016/j.ajpath.2016.03.011
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Coto-Hernandez R, 2020, J THROMB HAEMOST, V18, P1519, DOI 10.1111/jth.14852
   Dalli J, 2013, CHEM BIOL, V20, P188, DOI 10.1016/j.chembiol.2012.11.010
   Danser AH, 2020, HYPERTENSION, DOI [10.1161/HYPERTENSION-AHA.120.15082, DOI 10.1161/HYPERTENSION-AHA.120.15082]
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   de Haan HG, 2012, BLOOD, V120, P656, DOI 10.1182/blood-2011-12-397752
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Drummond GR, 2019, NAT REV IMMUNOL, V19, P517, DOI 10.1038/s41577-019-0160-5
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dukat-Mazurek A, 2017, HUM IMMUNOL, V78, P672, DOI 10.1016/j.humimm.2017.09.005
   Duvall MG, 2016, EUR J PHARMACOL, V785, P144, DOI 10.1016/j.ejphar.2015.11.001
   Dzieciatkowski T, 2020, CARDIOL J, V27, P175, DOI 10.5603/CJ.a2020.0055
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Fang ZX, 2020, J INFECTION, V81, P172, DOI 10.1016/j.jinf.2020.03.013
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Gaete-Argel A, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00336
   Germain M, 2015, AM J HUM GENET, V96, P532, DOI 10.1016/j.ajhg.2015.01.019
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gilead, 2020, GIL INV ANT REMD REC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hohdatsu T, 1998, J VET MED SCI, V60, P49, DOI 10.1292/jvms.60.49
   Hu H, 2020, ACAD EMERG MED, DOI 10.1111/acem.13992
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang J, 2014, ARTERIOSCL THROM VAS, V34, P1093, DOI 10.1161/ATVBAHA.113.302088
   Huang ZY, 2020, CARDIOL J, V27, P171, DOI 10.5603/CJ.a2020.0056
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Isobe Ken-Ichi, 2017, World J Biol Chem, V8, P129, DOI 10.4331/wjbc.v8.i2.129
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Joob B, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620918308
   Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kowalik MM, 2008, ANN NEUROL, V64, P473, DOI 10.1002/ana.21318
   Kowalik Maciej Michal, 2006, Przegl Epidemiol, V60, P273
   Kowalik MM, 2007, J INFECTION, V55, P141, DOI 10.1016/j.jinf.2007.02.002
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lippi G, 2020, J MED VIROL, V92, P1759, DOI 10.1002/jmv.25860
   Maekawa Y, 2007, CIRCULATION, V115, P5, DOI 10.1161/CIRCULATIONAHA.106.670554
   Maffia P, 2019, EUR HEART J, V40, P2492, DOI 10.1093/eurheartj/ehz133
   Mahurkar-Joshi S, 2020, NEUROGASTROENT MOTIL, V32
   Marongiu F, 2020, J THROMB HAEMOST, V18, P1511, DOI 10.1111/jth.14818
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Moore HB, 2020, J TRAUMA ACUTE CARE, V88, P713, DOI 10.1097/TA.0000000000002694
   Mysliwska J, 2006, EUR CYTOKINE NETW, V17, P181, DOI 10.1684/ecn.2006.0035
   Nagata N, 2007, J VIROL, V81, P1848, DOI 10.1128/JVI.01967-06
   Nicola M, 2020, INT J SURG, V77, P206, DOI 10.1016/j.ijsu.2020.04.001
   Nizankowski R, 2020, ZALECENIA COVID 19
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Page MJ, 2020, SEMIN THROMB HEMOST, V46, P302, DOI 10.1055/s-0040-1708827
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Paoli D, 2020, J ENDOCRINOL INVEST, V43, P1819, DOI 10.1007/s40618-020-01261-1
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Patnaik MM, 2008, HAEMOPHILIA, V14, P1229, DOI 10.1111/j.1365-2516.2008.01830.x
   Peng L, 2020, J MED VIROL, V92, P1676, DOI 10.1002/jmv.25936
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Roma-Lavisse C, 2015, DIABETES VASC DIS RE, V12, P279, DOI 10.1177/1479164115582351
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sherwood Edward R, 2004, Best Pract Res Clin Anaesthesiol, V18, P385, DOI 10.1016/S1521-6896(03)00116-2
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Smiatacz T., 2020, EUR J TRANSL CLIN ME
   Streiff MB, 2016, J THROMB THROMBOLYS, V41, P32, DOI 10.1007/s11239-015-1317-0
   Strindhall J, 2007, EXP GERONTOL, V42, P753, DOI 10.1016/j.exger.2007.05.001
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tersalvi G, 2020, J CARD FAIL, DOI [10.1016/j.card-fail.2020.04.009, DOI 10.1016/J.CARD-FAIL.2020.04.009]
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8
   Trzonkowski P., 2009, HDB IMMUNOSENESCENCE, P1455, DOI [10.1007/978-1-4020-9063-9_70., DOI 10.1007/978-1-4020-9063-9_70]
   Trzonkowski P, 2006, CLIN IMMUNOL, V119, P307, DOI 10.1016/j.clim.2006.02.002
   Trzonkowski P, 2010, MECH AGEING DEV, V131, P96, DOI 10.1016/j.mad.2009.12.006
   Trzonkowski P, 2009, BIOGERONTOLOGY, V10, P83, DOI 10.1007/s10522-008-9155-5
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vlieg AV, 2014, CIRC-CARDIOVASC GENE, V7, P806, DOI 10.1161/CIRCGENETICS.114.000682
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Wang M, 2020, J VIROL, DOI [10.1101/2020.03.15.20035204., DOI 10.1101/2020.03.15.20035204]
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Weyand CM, 2016, ANN AM THORAC SOC, V13, pS422, DOI 10.1513/AnnalsATS.201602-095AW
   Williams H, 2017, INT ANGIOL, V36, P145, DOI 10.23736/S0392-9590.16.03661-0
   Wills M, 2011, IMMUN AGEING, V8, DOI 10.1186/1742-4933-8-10
   Wong SH, 2020, J GASTROEN HEPATOL, V35, P744, DOI 10.1111/jgh.15047
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wujtewicz MA, 2020, ANAESTH INTENSIVE TH, V52, P34, DOI 10.5114/ait.2020.93756
   Wypasek E, 2013, ADV CLIN EXP MED, V22, P459
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zielinski M, 2016, J CLIN VIROL, V83, P17, DOI 10.1016/j.jcv.2016.08.290
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 133
TC 7
Z9 7
U1 2
U2 4
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND
SN 1897-5593
EI 1898-018X
J9 CARDIOL J
JI Cardiol. J.
PD MAR
PY 2020
VL 27
IS 2
BP 99
EP 114
DI 10.5603/CJ.a2020.0065
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA LT5KN
UT WOS:000537109600001
PM 32378729
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Harwood, L
AF Harwood, Lori
TI Pandemic Uncertainty: Considerations for Nephrology Nurses
SO NEPHROLOGY NURSING JOURNAL
LA English
DT Article
DE Pandemic; uncertainty; nephrology nurses; dialysis; COVID-19;
   coronavirus
ID APPRAISALS; ANXIETY; H1N1
AB The COVID-19 pandemic is a situation of great magnitude that most of us have not experienced in our lifetime. Pandemics are widespread, affecting many geographical areas, and uncertainty is inherent given the rapidly changing situations. As nurses in dialysis providing a life-sustaining therapy, we are required to provide an essential service during pandemics and need to thrive in the uncertainty. This article offers points for consideration that can assist nephrology nurses in their approach to these uncertain times.
C1 [Harwood, Lori] London Hlth Sci Ctr, Adam Linton Hemodialysis Unit, London, ON, Canada.
RP Harwood, L (corresponding author), London Hlth Sci Ctr, Adam Linton Hemodialysis Unit, London, ON, Canada.
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Lai AYH, 2018, POLICY SOC, V37, P459, DOI 10.1080/14494035.2018.1519979
   MacPhail T., 2010, BEHEMOTH J CIVILISAT, V3, P1866
   Michelle D. S., 2018, J RISK RES, DOI [10.1080/13669877.2018.1459793, DOI 10.1080/13669877.2018.1459793]
   Millar MR, 2014, J HOSP INFECT, V86, P90, DOI 10.1016/j.jhin.2013.11.006
   MISHEL MH, 1981, NURS RES, V30, P258
   Morens DM, 2011, REV MED VIROL, V21, P262, DOI 10.1002/rmv.689
   Neff KD, 2011, SOC PERSONAL PSYCHOL, V5, P1, DOI 10.1111/j.1751-9004.2010.00330.x
   Nohria N., 2020, HARVARD BUSINESS REV
   NORTON RW, 1975, J PERS ASSESS, V39, P607, DOI 10.1207/s15327752jpa3906_11
   Siegrist M, 2014, EUR PSYCHOL, V19, P23, DOI 10.1027/1016-9040/a000169
   Suttie J., 2020, KEEP GREATER GOOD MI
   Taha S, 2014, BRIT J HEALTH PSYCH, V19, P592, DOI 10.1111/bjhp.12058
   Taha SA, 2014, STRESS HEALTH, V30, P149, DOI 10.1002/smi.2505
NR 14
TC 2
Z9 2
U1 4
U2 7
PU JANNETTI PUBLICATIONS, INC
PI PITMAN
PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA
SN 1526-744X
EI 2163-5390
J9 NEPHROL NURS J
JI Nephrol. Nurs. J.
PD MAR-APR
PY 2020
VL 47
IS 2
BP 127
EP 130
DI 10.37526/1526-744X.2020.47.2.127
PG 4
WC Nursing; Urology & Nephrology
SC Nursing; Urology & Nephrology
GA LP5WX
UT WOS:000534389000004
PM 32343086
DA 2021-01-01
ER

PT J
AU Fathi, MB
AF Fathi, Mohammad Bagher
TI The Crystallography of SARS-CoV-2 Suggests Its Deactivation
SO IRANIAN RED CRESCENT MEDICAL JOURNAL
LA English
DT Article
DE Morphology; SARS-CoV-2; COVID-19; Macromolecular Drug Pharmacy
AB Background: The materials science may come to assist pharmacists to fabricate new drugs for coronavirus disease 2019 (COVID-19).
   Objectives: The geometrical structure of elements on the surface of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is analyzed to illustrate some hints about the possible choosing the factors captivating the surface of SARS-CoV-2.
   Methods: The crystallographic classes and their sub-structures can be indicative of practical selection of macromolecules in drug pharmacy.
   Results: The macromolecular structures with hexagonal and its sub-structures are suggested for pharmacists to probe a novel drug for COVID-19.
   Conclusions: Any progress in the field of fabricating macromolecular drugs for COVID-19 is strongly dependent on finding the hexagonal and its sub-structures such as triangular and rhombus geometries.
C1 [Fathi, Mohammad Bagher] Kharazmi Univ, Fac Phys, Condensed Matter Dept, Tehran, Iran.
RP Fathi, MB (corresponding author), Kharazmi Univ, Fac Phys, Condensed Matter Dept, Tehran, Iran.
EM mb.fathi@gmail.com
CR Baron, 1996, MED MICROBIOLOGY
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   SUGIYAMA K, 1981, ARCH VIROL, V67, P241, DOI 10.1007/BF01318134
   The Editors of Encyclopaedia Britannica, 2020, COR
   UIC, 2020, COR DIS 2019 COVID 1
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 7
TC 0
Z9 0
U1 1
U2 3
PU DONOTEDIT-ZAMENPUB
PI TALLINN
PA HARJU MAAKOND, SEPAPAJA TN 6, TALLINN, ESTONIA
SN 2074-1804
EI 2074-1812
J9 IRAN RED CRESCENT ME
JI Iran. Red Crescent Med. J.
PD MAR
PY 2020
VL 22
IS 3
AR e102812
DI 10.5812/ircmj.102812
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA LM6PB
UT WOS:000532370800011
OA Other Gold
DA 2021-01-01
ER

PT J
AU Alakwaa, FM
AF Alakwaa, Fadhl M.
TI Repurposing Didanosine as a Potential Treatment for COVID-19 Using
   Single-Cell RNA Sequencing Data
SO MSYSTEMS
LA English
DT Article
DE COVID-19; drug; repurposing
AB As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pandemic, I developed a bioinformatics pipeline to identify compounds and drug candidates to potentially treat COVID-19. This pipeline is based on publicly available single-cell RNA sequencing (scRNA-seq) data and the drug perturbation database "Library of Integrated Network-Based Cellular Signatures" (LINCS). I developed a ranking score system that prioritizes these drugs or small molecules. The four drugs with the highest total score are didanosine, benzyl-quinazolin-4-yl-amine, camptothecin, and RO-90-7501. In conclusion, I have demonstrated the utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients.
C1 [Alakwaa, Fadhl M.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
RP Alakwaa, FM (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
EM alakwaaf@med.umich.edu
CR Mourad JJ, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0368-x
   Perry CM, 1996, DRUGS, V52, P928, DOI 10.2165/00003495-199652060-00014
   Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Tamari K, 2019, ANTICANCER RES, V39, P4805, DOI 10.21873/anticanres.13665
   Zheng YY, 2020, NAT REV CARDIOL, V17, P313, DOI 10.1038/s41569-020-0369-9
NR 6
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5077
J9 MSYSTEMS
JI mSystems
PD MAR-APR
PY 2020
VL 5
IS 2
AR e00297-20
DI 10.1128/mSystems.00297-20
PG 2
WC Microbiology
SC Microbiology
GA LK7YM
UT WOS:000531077500001
PM 32291351
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, K
   Li, Z
   Wohlford-Lenane, C
   Meyerholz, DK
   Channappanavar, R
   An, D
   Perlman, S
   McCray, PB
   He, B
AF Li, Kun
   Li, Zhuo
   Wohlford-Lenane, Christine
   Meyerholz, David K.
   Channappanavar, Rudragouda
   An, Dong
   Perlman, Stanley
   McCray, Paul B., Jr.
   He, Biao
TI Single-Dose, Intranasal Immunization with Recombinant Parainfluenza
   Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus
   (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
SO MBIO
LA English
DT Article
DE COVID-19; MERS; coronavirus; vaccine
ID INFLUENZA-A VIRUS; DROMEDARY CAMELS; VACCINE; HEMAGGLUTININ; IMMUNITY;
   DOGS; CHALLENGE; OUTBREAK; EFFICACY; RECEPTOR
AB Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5/MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10(4) PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERSMA 6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10(6) PFU UV-inactivated MERSMA 6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.
   IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.
C1 [Li, Kun; Wohlford-Lenane, Christine; Perlman, Stanley; McCray, Paul B., Jr.] Univ Iowa, Dept Pediat, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.
   [Meyerholz, David K.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
   [Channappanavar, Rudragouda; Perlman, Stanley; McCray, Paul B., Jr.] Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.
   [Li, Zhuo; An, Dong; He, Biao] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
RP McCray, PB (corresponding author), Univ Iowa, Dept Pediat, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.; McCray, PB (corresponding author), Univ Iowa, Dept Microbiol & Immunol, Iowa City, IA 52242 USA.; He, B (corresponding author), Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
EM paul-mccray@uiowa.edu; bhe@uga.edu
RI Meyerholz, David/J-8131-2019
OI Meyerholz, David/0000-0003-1552-3253
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P01 AI060699];
   Center for Gene Therapy for Cystic Fibrosis (NIH) [P30 DK-54759]; Cystic
   Fibrosis Foundation; Roy J. Carver Charitable Trust; Fred C. Davison
   Distinguished University Chair in Veterinary Medicine
FX This work is supported by the National Institutes of Health (NIH) grant
   P01 AI060699 and the Cell Morphology Core and Pathology Core, which are
   partially supported by the Center for Gene Therapy for Cystic Fibrosis
   (NIH grant P30 DK-54759), and the Cystic Fibrosis Foundation. P.B.M. is
   supported by the Roy J. Carver Charitable Trust. B.H. is supported by
   the Fred C. Davison Distinguished University Chair in Veterinary
   Medicine.; B.H. is an inventor and holds a patent "Parainfluenza virus
   5-based vaccines," which is owned by the University of Georgia Research
   Foundation (UGARF). CyanVac LLC, which was founded by B.H., has licensed
   the IP from UGARF for the development of PIV5-based vaccines.
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Alharbi NK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52730-4
   Anderson LJ, 2013, SEMIN IMMUNOL, V25, P160, DOI 10.1016/j.smim.2013.04.011
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   AZETAKA M, 1988, JPN J VET SCI, V50, P851
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   BINN LN, 1967, P SOC EXP BIOL MED, V126, P140, DOI 10.3181/00379727-126-32386
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Chan RWY, 2014, LANCET RESP MED, V2, P813, DOI 10.1016/S2213-2600(14)70158-4
   Chen ZH, 2013, J VIROL, V87, P2986, DOI 10.1128/JVI.02886-12
   Chen ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050144
   Cho SY, 2016, LANCET, V388, P994, DOI 10.1016/S0140-6736(16)30623-7
   CORNWELL HJC, 1976, VET REC, V98, P301, DOI 10.1136/vr.98.15.301
   Du LY, 2016, EXPERT REV VACCINES, V15, P1123, DOI 10.1586/14760584.2016.1167603
   Du LY, 2015, EXPERT OPIN BIOL TH, V15, P1647, DOI 10.1517/14712598.2015.1092518
   Fuentes S, 2015, J VIROL, V89, P8193, DOI 10.1128/JVI.00133-15
   Guo XJ, 2015, IMMUNOLOGY, V145, P476, DOI 10.1111/imm.12462
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Hotez PJ, 2014, MICROBES INFECT, V16, P529, DOI 10.1016/j.micinf.2014.05.002
   Jia WX, 2019, EMERG MICROBES INFEC, V8, P760, DOI 10.1080/22221751.2019.1620083
   Kim E, 2014, VACCINE, V32, P5975, DOI 10.1016/j.vaccine.2014.08.058
   Ko SY, 2009, J VIROL, V83, P748, DOI 10.1128/JVI.01811-08
   Lamb R. A, 2001, FIELDS VIROLOGY, P1305
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li K, 2017, P NATL ACAD SCI USA, V114, pE3119, DOI 10.1073/pnas.1619109114
   Li Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120355
   Li Z, 2013, J VIROL, V87, P9604, DOI 10.1128/JVI.01289-13
   Li Z, 2013, J VIROL, V87, P5985, DOI 10.1128/JVI.00120-13
   Li Z, 2013, J VIROL, V87, P354, DOI 10.1128/JVI.02321-12
   Malczyk AH, 2015, J VIROL, V89, P11654, DOI 10.1128/JVI.01815-15
   MCCANDLISH IAP, 1978, VET REC, V102, P298
   Meyerholz DK, 2018, LAB INVEST, V98, P844, DOI 10.1038/s41374-018-0057-0
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   Mooney AJ, 2017, J VIROL, V91, DOI 10.1128/JVI.01579-17
   Mooney AJ, 2013, J VIROL, V87, P363, DOI 10.1128/JVI.02330-12
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Phan SI, 2017, J VIROL, V91, DOI 10.1128/JVI.00559-17
   Phan SI, 2017, J VIROL, V91, DOI 10.1128/JVI.00560-17
   Phan SI, 2014, VACCINE, V32, P3050, DOI 10.1016/j.vaccine.2014.03.049
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   ROSENBERG FJ, 1971, AM J EPIDEMIOL, V94, P147, DOI 10.1093/oxfordjournals.aje.a121307
   Tompkins SM, 2007, VIROLOGY, V362, P139, DOI 10.1016/j.virol.2006.12.005
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15
   Wang D, 2017, J VIROL, V91, DOI 10.1128/JVI.00066-17
   Wernery U, 2015, EMERG INFECT DIS, V21, P1019, DOI 10.3201/eid2106.150038
   Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16
   Yusof MF, 2015, VIRUS GENES, V50, P509, DOI 10.1007/s11262-015-1174-0
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
NR 53
TC 12
Z9 12
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAR-APR
PY 2020
VL 11
IS 2
AR e00554-20
DI 10.1128/mBio.00554-20
PG 12
WC Microbiology
SC Microbiology
GA LK7WC
UT WOS:000531071300065
PM 32265331
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, YX
   Ma, JR
   Wang, SQ
   Zeng, YQ
   Zhou, CY
   Ru, YH
   Zhang, L
   Lu, ZG
   Wu, MH
   Li, H
AF Wang, Y-X
   Ma, J-R
   Wang, S-Q
   Zeng, Y-Q
   Zhou, C-Y
   Ru, Y-H
   Zhang, L.
   Lu, Z-G
   Wu, M-H
   Li, H.
TI Utilizing integrating network pharmacological approaches to investigate
   the potential mechanism of Ma Xing Shi Gan Decoction in treating
   COVID-19
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; 2019 n-CoV; Ma Xing Shi Gan Decoction; Traditional Chinese
   medicine; Integrating network pharmacology
ID NF-KAPPA-B; TRADITIONAL CHINESE MEDICINE; ACUTE LUNG INJURY; MATRIX
   METALLOPROTEINASES; SIGNALING PATHWAYS; CYTOKINE STORM; EXPRESSION;
   QUERCETIN; CORONAVIRUS; INFLAMMATION
AB Beginning in December 2019, coronavirus disease 2019 (COVID-19), due to 2019-nCoV infection, emerged in Wuhan and spread rapidly throughout China and even worldwide. Employing combined therapy of modern medicine and traditional Chinese medicine has been proposed, in which Ma Xing Shi Gan Decoction (MXSGD) was recommended as a basic prescription and applied widely in the clinical treatment of COVID-19. We investigated the underlying mechanism of MXSGD in treating COVID-19 utilizing the approaches of integrating network pharmacology. A total of 97 active ingredients of MXSGD were screened out, and 169 targets were predicted. The protein-protein interaction network exhibited hub targets of MXSGD, such as Heat shock protein 90, RAC-alpha serine/ threonine-protein kinase, Transcription factor AP-1, Mitogen-activated protein kinase 1, Cellular tumor antigen p53, Vascular endothelial growth factor A, and Tumour necrosis factor. Gene Ontology functional enrichment analysis demonstrated that the biological processes altered within the body after taking MXSGD were closely related to the regulation of such processes as the acute inflammatory response, chemokine production, vascular permeability, response to oxygen radicals, ox- idative stress-induced apoptosis, T cell differentiation involved in the immune response, immunoglobulin secretion, and extracellular matrix disassembly. KEGG enrichment analysis indicated that the targets of MXSGD were significantly enriched in inflammation-related pathways, immunomodulation-related pathways, and viral infection-related pathways. The therapeutic mechanisms of MXSGD on COVID-19 may primarily involve the following effects: reducing inflammation, suppressing cytokine storm, protecting the pulmonary alveolar-capillary barrier, alleviating pulmonary edema, regulating the immune response, and decreasing fever.
C1 [Wang, Y-X; Zhang, L.; Wu, M-H; Li, H.] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Neurol, Nanjing, Jiangsu, Peoples R China.
   [Wang, Y-X; Lu, Z-G] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing, Peoples R China.
   [Wang, Y-X] Nanjing Univ Chinese Med, State Key Lab Cultivat Base TCM Qual & Efficacy, Nanjing, Jiangsu, Peoples R China.
   [Ma, J-R] Nanjing Univ Chinese Med, Prov Key Lab Drug Target & Drug Degenerat Dis, Sch Med & Holist Integrat Med, Nanjing, Jiangsu, Peoples R China.
   [Wang, S-Q; Zhou, C-Y] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Respirat, Nanjing, Jiangsu, Peoples R China.
   [Zeng, Y-Q] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Clin Med Sch 1, Nanjing, Jiangsu, Peoples R China.
   [Ru, Y-H] Soochow Univ, Jiangsu Inst Haematol, Natl Clin Res Ctr Haematol Dis, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
RP Wu, MH; Li, H (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Neurol, Nanjing, Jiangsu, Peoples R China.; Lu, ZG (corresponding author), Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing, Peoples R China.
EM amen0614@126.com; mhuawu@yeah.net; mlihui79@gmail.com
RI Ma, Jiarui/AAN-5304-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673412]; National Administration of
   Traditional Chinese Medicine [K2019BZ07]; Jiangsu Province
   Administration of Traditional Chinese Medicine [ZX2016A2]; 333 high
   level talents training project in Jiangsu [BRA2016507]; Social
   Development Program Fund of Jiangsu Province by Jiangsu Science and
   Technology Department [BE2016808]
FX This research was funded by grants from the National Natural Science
   Foundation of China (81673412), the National Administration of
   Traditional Chinese Medicine (K2019BZ07), the Jiangsu Province
   Administration of Traditional Chinese Medicine (ZX2016A2), the 333 high
   level talents training project in Jiangsu (BRA2016507), and the Social
   Development Program Fund of Jiangsu Province by Jiangsu Science and
   Technology Department (BE2016808).
CR Al-Sadi R, 2009, FRONT BIOSCI-LANDMRK, V14, P2765, DOI 10.2741/3413
   Alkharsah KR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061642
   Aoki K, 2005, J PHARMACOL SCI, V98, P327, DOI 10.1254/jphs.SC0050118
   Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481
   Ball M, 2000, NAT GENET, V25, P25
   Bassett M, 2020, EUR J CLIN INVEST, V50
   Bausch D, 2011, ANGIOGENESIS, V14, P235, DOI 10.1007/s10456-011-9207-3
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen LD, 2018, J ETHNOPHARMACOL, V219, P359, DOI 10.1016/j.jep.2017.12.011
   Chen LJ, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/790739
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen XJ, 2012, INT IMMUNOPHARMACOL, V14, P209, DOI 10.1016/j.intimp.2012.07.007
   Chinas NHC, 2020, TIANJIN J TRADITIONA, V1, P1
   Cooks T, 2014, CARCINOGENESIS, V35, P1680, DOI 10.1093/carcin/bgu134
   Davey A, 2011, EUR RESPIR J, V38, P959, DOI 10.1183/09031936.00032111
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106
   Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979
   Eng YS, 2019, MOLECULES, V24, DOI 10.3390/molecules24193505
   Fang YC, 2020, RADIOLOGY, V295, P208, DOI [10.1148/radiol.2020200280, 10.1148/2020200280]
   Ganesan S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-131
   Gao HW, 2018, PHYTOMEDICINE, V38, P145, DOI 10.1016/j.phymed.2017.11.012
   Ge H, 2010, NAT PROD REP, V27, P1758, DOI 10.1039/c0np00005a
   Gralinski LE, 2013, MBIO, V4
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   Gushima Y, 2001, EUR RESPIR J, V18, P827, DOI 10.1183/09031936.01.00049201
   Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061
   Huang C, 2019, LANCET
   Ivanov AI, 2004, FRONT BIOSCI-LANDMRK, V9, P1977, DOI 10.2741/1383
   Kalil AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2539-x
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kim HK, 2007, BIOGERONTOLOGY, V8, P399, DOI 10.1007/s10522-007-9083-9
   Kim W, 2020, TOXINS, V12, DOI 10.3390/toxins12010016
   Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823
   Lan WJ, 2006, BIOMED ENVIRON SCI, V19, P249
   Li X, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165326
   Li XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11017
   Lin L, 2003, AM J CHINESE MED, V31, P821, DOI 10.1142/S0192415X03001521
   Lin L, 2020, ZHONGHUA YI XUE ZA Z, V100, pE001
   Lin LL, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0229-x
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Liu B, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109664
   Liu JJ, 2005, CELL MOL IMMUNOL, V2, P455
   Lu D, 2012, ADV PHARMACOEPIDEM D, V1, P1
   Lu XL, 2017, BIOMED PHARMACOTHER, V85, P658, DOI 10.1016/j.biopha.2016.11.077
   Lupo G, 2019, J CELL MOL MED, V23, P6565, DOI 10.1111/jcmm.14455
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Mazor R, 2013, J BIOL CHEM, V288, P598, DOI 10.1074/jbc.M112.417451
   [苗青 Miao Qing], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P286
   Min YD, 2007, INFLAMM RES, V56, P210, DOI 10.1007/s00011-007-6172-9
   Mlecnik B, 2019, BIOINFORMATICS, V35, P3864, DOI 10.1093/bioinformatics/btz163
   Mlecnik B, 2018, J PROTEOMICS, V171, P2, DOI 10.1016/j.jprot.2017.03.016
   Nah SS, 2008, RHEUMATOLOGY, V47, P425, DOI 10.1093/rheumatology/kem376
   Olave NC, 2010, J CELL BIOCHEM, V111, P720, DOI 10.1002/jcb.22760
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4
   Peng XQ, 2016, INT IMMUNOPHARMACOL, V30, P85, DOI 10.1016/j.intimp.2015.11.029
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rojas-Quintero J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99022
   Roth J, 2014, COMPR PHYSIOL, V4, P1563, DOI 10.1002/cphy.c130033
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shen CS, 2018, BIOMED PHARMACOTHER, V103, P1376, DOI 10.1016/j.biopha.2018.04.174
   SHEN L, 2020, NEW ENGL J MED, DOI DOI 10.1056/NEJM0A2001316
   Song L, 2019, MOL MED REP, V20, P4654, DOI 10.3892/mmr.2019.10698
   Sun J, 2016, SCI REP-UK, V6, DOI 10.1038/srep34328
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tse GMK, 2004, J CLIN PATHOL, V57, P260, DOI 10.1136/jcp.2003.013276
   Vadasz I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00757
   Varshney B, 2011, BIOCHEMISTRY-US, V50, P5419, DOI 10.1021/bi200303r
   Vijayababu MR, 2006, MOL CELL BIOCHEM, V287, P109, DOI 10.1007/s11010-005-9085-3
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031
   Wang HM, 2014, ANN ALLERG ASTHMA IM, V112, P465, DOI 10.1016/j.anai.2014.02.012
   Wang PQ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01288
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang XG, 2014, CHINESE MED J-PEKING, V127, P1344, DOI 10.3760/cma.j.issn.0366-6999.20132029
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep28089
   [王玉光 Wang Yuguang], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P281
   Watanabe R, 2018, CIRC RES, V123, P700, DOI 10.1161/CIRCRESAHA.118.313206
   WHO, 2020, NOV CORN COVID 19 SI
   Woenne EC, 2010, ANTICANCER RES, V30, P703
   Xia WG, 2020, J TRADITIONAL CHINES, V5, P375, DOI DOI 10.13288/j.11-2166/r.2020.05.002
   Xie WL, 2016, LAB INVEST, V96, P526, DOI 10.1038/labinvest.2016.31
   Xu Z, 2020, LANCET RESP MED, V18, pS2213
   Yan YQ, 2018, PHYTOTHER RES, V32, P2560, DOI 10.1002/ptr.6196
   Yang Q, 2013, EVID-BASED COMPL ALT, V2013
   Yu ES, 2008, BIOCHEM PHARMACOL, V76, P70, DOI 10.1016/j.bcp.2008.03.020
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yue Q, 1990, Zhong Xi Yi Jie He Za Zhi, V10, P600
   Yurchenco PD, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004911
   Zhang BM, 2018, CHIN J NAT MEDICINES, V16, P811, DOI 10.1016/S1875-5364(18)30123-7
   Zhang XW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50064-9
   [郑文科 Zheng Wenke], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P277
   Zhong WF, 2017, J FOOD DRUG ANAL, V25, P946, DOI 10.1016/j.jfda.2016.12.007
   Zhong YC, 2016, INTERVIROLOGY, V59, P267, DOI 10.1159/000458726
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 107
TC 9
Z9 9
U1 6
U2 29
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2020
VL 24
IS 6
BP 3360
EP 3384
PG 25
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LC4WF
UT WOS:000525326200060
PM 32271454
DA 2021-01-01
ER

PT J
AU Ye, XT
   Luo, YL
   Xia, SC
   Sun, QF
   Ding, JG
   Zhou, Y
   Chen, W
   Wang, XF
   Zhang, WW
   Du, WJ
   Ruan, ZW
   Hong, L
AF Ye, X-T
   Luo, Y-L
   Xia, S-C
   Sun, Q-F
   Ding, J-G
   Zhou, Y.
   Chen, W.
   Wang, X-F
   Zhang, W-W
   Du, W-J
   Ruan, Z-W
   Hong, L.
TI Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus
   disease 2019
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Clinical trial; Coronavirus; Lopinavir/ritonavir; COVID-19; China
ID RESPIRATORY SYNDROME; SARS; PNEUMONIA; LOPINAVIR
AB OBJECTIVE: The Coronavirus disease 2019 (COVID-19) which outbroke in December 2019 is highly contagious with a low cure rate. In view of this, there is an urgent need to find a more appropriate therapeutic scheme against COVID-19. The study aimed to investigate whether lopinavir/ritonavir (LPV/r) in combination with other pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19.
   PATIENTS AND METHODS: Totally 47 patients with COVID-19 infection who were admitted to Rui'an People's Hospital between January 22 and January 29, 2020 were collected. The patients were divided into the test group and the control group according to whether they had been treated with LPV/r or not during hospitalization. Patients in the test group were treated with LPV/r combined with adjuvant medicine, while those in the control group were just treated with adjuvant medicine. The changes of body temperature, blood routine and blood biochemistry between the two groups were observed and compared.
   RESULTS: Both groups achieved good therapeutic effect with the body temperature of patients decreased gradually from admission to the 10th day of treatment. But the body temperature of patients in the test group decreased faster than that of the control group. Blood routine indexes showed that compared with the control group, the abnormal proportion of white blood cells, lymphocytes and C-reactive protein of the test group could be reduced to some extent. Blood biochemical indexes exhibited that the proportion of patients with abnormal alanine aminotransferase and aspartate aminotransferase in the test group were lower than the control group. The number of days for nCoV-RNA turning negative after treatment was significantly decreased in the test group than that in the control group.
   CONCLUSIONS: Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects. In view of these conclusions, we suggested that the use of LPV/r combined with pneumonia-associated adjuvant drugs in the clinical treatment for patients with COVID-19 should be promoted.
C1 [Ye, X-T; Luo, Y-L; Sun, Q-F; Ding, J-G; Zhou, Y.; Chen, W.; Wang, X-F; Zhang, W-W; Hong, L.] Ruian Peoples Hosp, Dept Infect, Ruian, Peoples R China.
   [Xia, S-C; Du, W-J] Ruian Peoples Hosp, Leading Grp COVID 19, Ruian, Peoples R China.
   [Ruan, Z-W] Ruian Peoples Hosp, Emergency Intens Care Unit, Ruian, Peoples R China.
RP Hong, L (corresponding author), Ruian Peoples Hosp, Dept Infect, Ruian, Peoples R China.; Ruan, ZW (corresponding author), Ruian Peoples Hosp, Emergency Intens Care Unit, Ruian, Peoples R China.
EM rzwdoc1982@163.com; Hong_liang789@163.com
FU Zhejiang Natural Science Foundation: experimental study on the role of
   IL-6-INDUCED exosome pathway in promoting invasion and metastasis of
   hepatocellular carcinoma by omitting microRNA-133a-3p [LY19H160015];
   Medical Science and Technology Project of Zhejiang Province: Study on
   the synergistic lethal effect and molecular mechanism of ALK targeting
   in TP53 mutant intrahepatic Cholangiocarcinoma [2019324310]; Ruian
   Science and Technology Bureau [MS2020023]
FX Zhejiang Natural Science Foundation: experimental study on the role of
   IL-6-INDUCED exosome pathway in promoting invasion and metastasis of
   hepatocellular carcinoma by omitting microRNA-133a-3p LY19H160015.;
   Medical Science and Technology Project of Zhejiang Province: Study on
   the synergistic lethal effect and molecular mechanism of ALK targeting
   in TP53 mutant intrahepatic Cholangiocarcinoma 2019324310.; Ruian
   Science and Technology Bureau (MS2020023).
CR Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Bongiovanni M, 2004, ANTIVIR RES, V62, P53, DOI 10.1016/j.antiviral.2003.12.002
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Sabbatani Sergio, 2003, Infez Med, V11, P18
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wu YC, 2020, J CHIN MED ASSOC, DOI [10.1097/JC- MA.0000000000000270, DOI 10.1097/JC-MA.0000000000000270.[EPUB]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 17
TC 40
Z9 42
U1 5
U2 17
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2020
VL 24
IS 6
BP 3390
EP 3396
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LC4WF
UT WOS:000525326200062
PM 32271456
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Balachandar, V
   Mahalaxmi, I
   Kaavya, J
   Vivekanandhan, G
   Ajithkumar, S
   Arul, N
   Singaravelu, G
   Kumar, NS
   Devi, SM
AF Balachandar, V
   Mahalaxmi, I
   Kaavya, J.
   Vivekanandhan, G.
   Ajithkumar, S.
   Arul, N.
   Singaravelu, G.
   Kumar, N. Senthil
   Devi, S. Mohana
TI COVID-19: emerging protective measures
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19 (Coronavirus disease 2019); Medicinal plant; Respiratory mask;
   Protective measures
AB The COVID-19 (Coronavirus disease 2019) spreads primarily through droplets of saliva or discharge from the nose. COVID-19 is predominantly considered as an unavoidable pandemic, and scientists are very curious about how to provide the best protection to the public before a vaccine can be made available. There is an urge to manufacture a greater number of masks to prevent any aerosol with microbes. Hence, we aim to develop an efficient viral inactivation system by exploiting active compounds from naturally occurring medicinal plants and infusing them into nanofiber-based respiratory masks. Our strategy is to develop fibrous filtration with three-layered masks using the compounds from medicinal plants for viral deactivation. These masks will be beneficial not just to healthcare workers but common citizens as well. In the absence of vaccination, productive masks can be worn to prevent transmission of airborne pathogenic aerosols and control diseases.
C1 [Balachandar, V] Bharathiar Univ, Dept Human Genet & Mol Biol, Human Mol Cytogenet & Stem Cell Lab, Coimbatore, Tamil Nadu, India.
   [Mahalaxmi, I; Kaavya, J.] Avinashilingam Inst Home Sci & Higher Educ Women, Dept Zool, Coimbatore, Tamil Nadu, India.
   [Vivekanandhan, G.] Farmers Bio Fertilizers & Organ, Coimbatore, Tamil Nadu, India.
   [Ajithkumar, S.] Indian Inst Technol Mandi, Sch Basic Sci, Mandi, Himachal Prades, India.
   [Arul, N.] Bharathiar Univ, Dept Zool, Dis Prote Lab, Coimbatore, Tamil Nadu, India.
   [Singaravelu, G.] Thiruvalluvar Univ, Dept Zool, Vellore, Tamil Nadu, India.
   [Kumar, N. Senthil] Mizoram Univ, Dept Biotechnol, Aizawl, Mizoram, India.
   [Devi, S. Mohana] Vis Res Fdn, Dept Genet & Mol Biol, Chennai, Tamil Nadu, India.
RP Balachandar, V (corresponding author), Bharathiar Univ, Dept Human Genet & Mol Biol, Human Mol Cytogenet & Stem Cell Lab, Coimbatore, Tamil Nadu, India.; Devi, SM (corresponding author), Vis Res Fdn, Dept Genet & Mol Biol, Chennai, Tamil Nadu, India.
EM geneticbala@buc.edu.in; geneticmohana@gmail.com
OI Singaravelu, Ganesan/0000-0002-2637-9122
FU Science and Engineering Research Board (SERB) [ECR/2016/001688,
   ECR/2018/000718]; Advanced Level State Biotech Hub, Department of
   Biotechnology (DBT) at Mizoram University [BT/04/NE/2009]
FX This study was funded in part by [Science and Engineering Research Board
   (SERB)], Grant No. [ECR/2016/001688; ECR/2018/000718] and the Advanced
   Level State Biotech Hub, Department of Biotechnology (DBT), Grant No.
   [BT/04/NE/2009 Dt.29.08.2014] at Mizoram University.
CR [Anonymous], 2013, INF PREV CONTR HLTH
   Buonsenso D, 2020, EUR REV MED PHARMACO, V24, P2776, DOI 10.26355/eurrev_202003_20549
   Centers for DiseaseControl and Prevention, INT INF PREV CONTR R
   Coia JE, 2013, J HOSP INFECT, V85, P170, DOI 10.1016/j.jhin.2013.06.020
   Gomathi M, 2020, J AUTISM DEV DISORD, V50, P2740, DOI 10.1007/s10803-020-04381-y
   Kurtz IS, 2018, MATERIALS, V11, DOI 10.3390/ma11071059
   Shankar S, 2015, CARBOHYD POLYM, V117, P468, DOI 10.1016/j.carbpol.2014.10.010
NR 7
TC 13
Z9 13
U1 1
U2 21
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2020
VL 24
IS 6
BP 3422
EP 3425
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LC4WF
UT WOS:000525326200067
PM 32271461
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Ahmed, SF
   Quadeer, AA
   McKay, MR
AF Ahmed, Syed Faraz
   Quadeer, Ahmed A.
   McKay, Matthew R.
TI Preliminary Identification of Potential Vaccine Targets for the COVID-19
   Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
SO VIRUSES-BASEL
LA English
DT Article
DE Coronavirus; 2019-nCoV; 2019 novel coronavirus; SARS-CoV-2; COVID-19;
   SARS-CoV; MERS-CoV; T cell epitopes; B cell epitopes; vaccine
ID ACUTE RESPIRATORY SYNDROME; MULTIPLE SEQUENCE ALIGNMENT; T-CELL
   RESPONSES; NUCLEOCAPSID PROTEIN; SPIKE; NEUTRALIZATION; HIV; IMMUNITY;
   LINKAGE
AB The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.
C1 [Ahmed, Syed Faraz; Quadeer, Ahmed A.; McKay, Matthew R.] Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.
   [McKay, Matthew R.] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Peoples R China.
RP Quadeer, AA; McKay, MR (corresponding author), Hong Kong Univ Sci & Technol, Dept Elect & Comp Engn, Hong Kong, Peoples R China.; McKay, MR (corresponding author), Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Peoples R China.
EM sfahmed@connect.ust.hk; eeaaquadeer@ust.hk.com; m.mckay@ust.hk
RI Quadeer, Ahmed Abdul/AAD-7471-2020; Ahmed, Syed Faraz/K-3879-2012;
   Ribeiro, Nuno/AAH-2299-2020
OI Quadeer, Ahmed Abdul/0000-0002-5295-9067; Ahmed, Syed
   Faraz/0000-0002-6086-0307; 
FU General Research Fund of the Hong Kong Research Grants Council (RGC)
   [16204519]; Hong Kong Ph.D. Fellowship Scheme (HKPFS)
FX We thank all the authors, the originating and submitting laboratories
   (listed in Table S7) for their sequence and metadata shared through
   GISAID, on which this research is based. M.R.M. and A.A.Q. were
   supported by the General Research Fund of the Hong Kong Research Grants
   Council (RGC) [Grant No. 16204519]. S.F.A. was supported by the Hong
   Kong Ph.D. Fellowship Scheme (HKPFS).
CR Ahmed S.F., DATA SOFTWARE CODE R
   Ahmed SF, 2019, BIOINFORMATICS, V35, P3884, DOI 10.1093/bioinformatics/btz524
   Chakraborty AK, 2017, REP PROG PHYS, V80, DOI 10.1088/1361-6633/aa574a
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Dahirel V, 2011, P NATL ACAD SCI USA, V108, P11530, DOI 10.1073/pnas.1105315108
   Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525
   Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6
   Ferguson AL, 2013, IMMUNITY, V38, P606, DOI 10.1016/j.immuni.2012.11.022
   Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972
   Heymann DL, 2020, LANCET, V395, P469, DOI 10.1016/S0140-6736(20)30184-7
   Hoffmann M, 2020, NOVEL CORONAVIRUS 20
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huson DH, 2012, SYST BIOL, V61, P1061, DOI 10.1093/sysbio/sys062
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Letko MC, FUNCTIONAL ASSESSMEN
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Liu X, 2004, CLIN DIAGN LAB IMMUN, V11, P227, DOI 10.1128/CDLI.11.1.227-228.2004
   Liu X, 2020, POTENTIAL INHIBITORS
   Louie RHY, 2018, P NATL ACAD SCI USA, V115, pE564, DOI 10.1073/pnas.1717765115
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mann JK, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003776
   Mirarab S, 2015, J COMPUT BIOL, V22, P377, DOI 10.1089/cmb.2014.0156
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Quadeer AA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14174-2
   Quadeer AA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09819-1
   Quadeer AA, 2014, J VIROL, V88, P7628, DOI 10.1128/JVI.03812-13
   Quadeer AA, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006409
   Ramaiah A, 2020, INSIGHTS CROSS SPECI
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls A.C., 2020, STRUCTURE FUNCTION A, V2020.02.19.956581
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184
   World-Health-Organization Statement on the meeting of the International Health Regulations, 2005, WHO STAT M INT HLTH
   World-Health-Organization Statement on the second meeting of the International Health Regulations, 2005, WHO STAT 2 M INT HLT
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 50
TC 246
Z9 250
U1 46
U2 91
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR
PY 2020
VL 12
IS 3
AR 254
DI 10.3390/v12030254
PG 15
WC Virology
SC Virology
GA LC7BG
UT WOS:000525486800026
PM 32106567
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Yang, GL
   Zhang, HQ
   Yang, YF
AF Yang, Geliang
   Zhang, Huiqing
   Yang, Yufei
TI Challenges and Countermeasures of Integrative Cancer Therapy in the
   Epidemic of COVID-19
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Letter
C1 [Yang, Geliang] Chinese People Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Med Ctr 2, Dept Tradit Chinese Med & Acupuncture, Beijing, Peoples R China.
   [Zhang, Huiqing] Naval Med Univ, Changhai Hosp, Dept Tradit Chinese Med, Shanghai, Peoples R China.
   [Yang, Yufei] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol Diag & Treatment, Beijing, Peoples R China.
RP Zhang, HQ (corresponding author), Naval Med Univ, Changhai Hosp, Dept Tradit Chinese Med, Shanghai, Peoples R China.; Yang, YF (corresponding author), China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol Diag & Treatment, Beijing, Peoples R China.
EM newdew628@aliyun.com; yyf93@vip.sina.com
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   General Office of the National Health Commission of China, 2020, DIAGN TREATM PROT 20
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
NR 3
TC 11
Z9 12
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAR
PY 2020
VL 19
AR 1534735420912811
DI 10.1177/1534735420912811
PG 2
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA LB3CH
UT WOS:000524515000001
PM 32178547
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Contini, C
   Di Nuzzo, M
   Barp, N
   Bonazza, A
   De Giorgio, R
   Tognon, M
   Rubino, S
AF Contini, Carlo
   Di Nuzzo, Mariachiara
   Barp, Nicole
   Bonazza, Aurora
   De Giorgio, Roberto
   Tognon, Mauro
   Rubino, Salvatore
TI The novel zoonotic COVID-19 pandemic: An expected global health concern
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE SARS CoV; MERS CoV; SARS-CoV-2; COVID-19; spillover; drugs
ID RESPIRATORY SYNDROME CORONAVIRUS; SAUDI-ARABIA; SARS; MERS;
   TRANSMISSION; OUTBREAK; PATHOGENESIS; VIRUSES; SYSTEM; COV
AB 18 years ago, in 2002, the world was astonished by the appearance of Severe Acute Respiratory Syndrome (SARS), supported by a zoonotic coronavirus, called SARS-CoV, from the Guangdong Province of southern China. After about 10 years, in 2012, another similar coronavirus triggered the Middle East Respiratory Syndrome (MERS-CoV) in Saudi Arabia. Both caused severe pneumonia killing 774 and 858 people with 8700 cases of confirmed infection for the former, and 2494 for the latter, causing significant economic losses. 8 years later, despite the MERS outbreak remaining in certain parts of the world, at the end of 2019, a new zoonotic coronavirus (SARS-CoV-2) and responsible of coronavirus Disease (COVID-19), arose from Wuhan, Hubei Province, China. It spread rapidly and to date has killed 3,242 persons with more than 81,000 cases of infection in China and causing over 126,000 global cases and 5,414 deaths in 166 other countries around the world, especially Italy. SARS-CoV-2 would seem to have come from a bat, but the intermediate reservoir continues to be unknown. Nonetheless, as for SARS-CoV and MERS CoV, the Spillover effect linked to animal-human promiscuity, human activities including deforestation, illegal bush-trafficking and bushmeat, cannot be excluded. Recently, however, evidence of inter-human only transmission of SARS-CoV-2 has been accumulated and thus, the outbreak seems to be spreading by human-to-human transmission throughout a large part of the world. Herein we will provide with an update on the main features of COVID-19 and suggest possible solutions how to halt the expansion of this novel pandemic.
C1 [Contini, Carlo; Di Nuzzo, Mariachiara; Barp, Nicole; Bonazza, Aurora] Univ Ferrara, Dept Med Sci, Infect Dis & Dermatol Sect, Via Aldo Moro 8, I-44124 Ferrara, Italy.
   [De Giorgio, Roberto] Dept Morphol Surg & Expt Med, Internal Med Unit, Ferrara, Italy.
   [De Giorgio, Roberto] Univ Ferrara, Ferrara, Italy.
   [Tognon, Mauro] Univ Ferrara, Dept Med Sci, Pathol Oncol & Expt Biol Sect, Ferrara, Italy.
   [Rubino, Salvatore] Univ Sassari, Dept Biomed Sci, Microbiol, Sassari, Italy.
RP Contini, C (corresponding author), Univ Ferrara, Dept Med Sci, Infect Dis & Dermatol Sect, Via Aldo Moro 8, I-44124 Ferrara, Italy.
EM cnc@unife.it
OI Contini, Carlo/0000-0001-8809-6470
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Benjamin-Chung J, 2017, INT J EPIDEMIOL, V46, P1251, DOI 10.1093/ije/dyx039
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   BURKS JS, 1980, SCIENCE, V209, P933, DOI 10.1126/science.7403860
   Cao B., 2020, NEW ENGLAND J MED
   Capua I, 2013, VET MICROBIOL, V165, P7, DOI 10.1016/j.vetmic.2013.01.044
   Chen J., 2020, MICROBES INFECT
   Chen L, 2020, LANCET INFECT DIS
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Gallagher J., 2020, BBC NEWS
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Gong Shu-Ran, 2018, Animal Model Exp Med, V1, P125, DOI 10.1002/ame2.12017
   Gordon CJ, 2020, J BIOL CHEM
   Goubar A, 2009, EPIDEMIOL INFECT, V137, P1019, DOI 10.1017/S0950268808001635
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hijawi B, 2013, EMHJ, V19, P1, DOI DOI 10.26719/2013.19.SUPP1.S12
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Kelvin DJ, 2020, J INFECT DEV COUNTR, V14, P1, DOI 10.3855/jidc.12496
   Kuba K, 2010, PHARMACOL THERAPEUT, V128, P119, DOI 10.1016/j.pharmthera.2010.06.003
   Lai AL, 2020, J MED VIROL, V92, P675, DOI 10.1002/jmv.25723
   Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Majumder M, 2020, EARLY TRANSMISSIBILI
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Memish ZA, 2014, INT J INFECT DIS, V23, P63, DOI 10.1016/j.ijid.2014.03.1372
   Meulen V, 1984, ADV EXP MED BIOL, V173, P227
   Milne-Price S, 2014, PATHOG DIS, V71, P119, DOI 10.1111/2049-632X.12166
   Posid JM, 2005, J PUBLIC HEALTH MAN, V11, P208
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Rasmussen SA, 2020, AM J OBSTET GYNECOL
   Reperant LA, 2017, VACCINE, V35, P4470, DOI 10.1016/j.vaccine.2017.04.082
   RESTA S, 1985, SCIENCE, V229, P978, DOI 10.1126/science.2992091
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   She J, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-00271-z
   Song Z, 2019, VIRUSES, V14, P11
   Tam T, 2018, Can Commun Dis Rep, V44, P98
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   World Health Organization, 2020, NOV COR 2019 NCOV TE
   World Health Organization (WHO), 2020, NOV COR JAP EX CHIN
   Wu Z, 2020, JAMA
   Zhai SL, 2020, VET REC, V186, DOI 10.1136/vr.m740
   Zhao SZ, 2020, INT J INFECT DIS, VS1201-9712, P30746
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 65
TC 34
Z9 35
U1 3
U2 16
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD MAR
PY 2020
VL 14
IS 3
BP 254
EP 264
DI 10.3855/jidc.12671
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA KZ4QP
UT WOS:000523249000004
PM 32235085
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU da Rosa, GP
   Ferreira, E
AF Pires da Rosa, G.
   Ferreira, E.
TI Therapies used in rheumatology with relevance to coronavirus disease
   2019
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Letter
C1 [Pires da Rosa, G.] Hosp Lusiadas Porto, Dept Internal Med, Autoimmune Dis Consultat, Porto, Portugal.
   [Pires da Rosa, G.; Ferreira, E.] Univ Porto, Fac Med, Porto, Portugal.
   [Ferreira, E.] Ctr Hosp Univ Sao Joao, Dept Internal Med, Autoimmune Dis Grp, Porto, Portugal.
RP da Rosa, GP (corresponding author), Hosp Lusiadas Porto, Dept Internal Med, Ave Boavista 171, P-4050115 Porto, Portugal.
EM gilbertopiresrosa@gmail.com
OI Pires da Rosa, Gilberto/0000-0003-4919-3053
CR CDC, 2020, INT CLIN GUID MAN PA
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weimer DR, 2020, SPACE WEATHER, V18, DOI 10.1029/2019SW002355
   World Health Organization, CLIN MAN SEV AC RES
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Yao X, 2020, CLIN INFECT DIS
NR 9
TC 4
Z9 4
U1 0
U2 1
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392-856X
EI 1593-098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD MAR-APR
PY 2020
VL 38
IS 2
BP 370
EP 370
PG 1
WC Rheumatology
SC Rheumatology
GA KX5TA
UT WOS:000521941000027
PM 32202241
DA 2021-01-01
ER

PT J
AU Atluri, S
   Manchikanti, L
   Hirsch, JA
AF Atluri, Sairam
   Manchikanti, Laxmaiah
   Hirsch, Joshua A.
TI Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a
   Therapeutic Strategy In Managing Critically Ill COVID-19 Patients: The
   Case for Compassionate Use
SO PAIN PHYSICIAN
LA English
DT Article
DE Coronavirus; COVID-19; cytokine storm; multiorgan failure; expanded
   umbilical cord mesenchymal stem cells
ID LOW-BACK-PAIN; SARS CORONAVIRUS; FUNCTIONAL RECEPTOR; EFFICACY; ACE2;
   TRANSPLANTATION; REMDESIVIR; PNEUMONIA; PEPTIDES; INHIBIT
AB COVID-19 has affected the United States leading to a national emergency with health care and economic impact, propelling the country into a recession with disrupted lifestyles not seen in recent history. COVID-19 is a serious illness leading to multiple deaths in various countries including the United States. Several million Americans satisfy the Center for Disease Control and Prevention (CDC) criteria for being high risk. Unfortunately, the available supply of medical beds and equipment for mechanical ventilation are much less than is projected to be needed. The World Health Organization (WHO) and multiple agencies led by the CDC in the United States have attempted to organize intensive outbreak investigation programs utilizing appropriate preventive measures, evaluation, and treatment.
   The clinical spectrum of COVID-19 varies from asymptomatic forms to conditions encompassing multiorgan and systemic manifestations in terms of septic shock, and multiple organ dysfunction (MOD) syndromes. The presently approved treatments are supportive but not curative for the disease. There are multiple treatments being studied. These include vaccines, medications Remdesivir and hydroxychloroquine and potentially combination therapy. Finally, expanded umbilical cord mesenchymal stem cells or (UC-MSCs) may have a role and are being studied.
   The cure of COVID-19 is essentially dependent on the patients' own immune system. When the immune system is over activated in an attempt to kill the virus, this can lead to the production of a large number of inflammatory factors, resulting in severe cytokine storm. The cytokine storm may induce organ damage followed by the edema, dysfunction of air exchange, acute respiratory distress syndrome (ARDS), acute cardiac injury, and secondary infection, which may lead to death. Thus, at this point, the avoidance of the cytokine storm may be the key for the treatment of HCOV-19 infected patients.
   In China, where there was limited availability of effective modalities to manage COVID-19 several patients were treated with expanded UC-MSCs. Additionally, the Italian College of Anesthesia, Analgesia, Resuscitation and Intensive Care have reported guidelines to treat coronavirus patients with stem cells in the hope of decreasing the number of patients going to the ICU, and, also relatively quickly getting them out of ICU.
   In this manuscript, we describe the urgent need for various solutions, pathogenesis of coronavirus and the clinical evidence for treatment of COVID-19 with stem cells. The limited but emerging evidence regarding UC MSC in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.
   The administration and Coronavirus Task Force might wish to approach the potential of expanded UC-MSCs as an evolutionary therapeutic strategy in managing COVID-19 illness with a 3-pronged approach: If proven safe and effective on a specific and limited basis.
   1. Minimize regulatory burden by all agencies so that critically ill COVID-19 patients will have access regardless of their financial circumstance.
   2. Institute appropriate safeguards to avoid negative consequences from unscrupulous actors.
   3. With proper informed consent from patients or proxy when necessary, and subject to accumulation of data in that cohort, allow the procedure to be initiated in critically ill patients who are not responding to conventional therapies.
C1 [Atluri, Sairam] Tristate Spine Care Inst, Cincinnati, OH USA.
   [Manchikanti, Laxmaiah] Pain Management Ctr Amer, Paducah, KY USA.
   [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Hirsch, Joshua A.] Harvard Med Sch, Boston, MA 02115 USA.
RP Manchikanti, L (corresponding author), 67 Lakeview Dr, Paducah, KY 42001 USA.
EM drlm@thepainmd.com
CR Abraham A, 2020, STEM CELL TRANSL MED, V9, P28, DOI 10.1002/sctm.19-0205
   Aicher RH, 2013, AESTHET SURG J, V33, P452, DOI 10.1177/1090820X13476879
   Alcayaga-Miranda F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00339
   Anderson Jeffrey, 2009, V189, P85, DOI 10.1007/978-3-540-79086-0_4
   [Anonymous], 2020, MEDICALXPRESS B 0317
   [Anonymous], 2017, SEATTLE TIMES
   [Anonymous], 2020, GLOBENEWSWIRE   0317
   [Anonymous], 2020, GULF NEWS
   [Anonymous], COMMUNICATION
   Arentz M, 2020, JAMA
   Arutyunyan I, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6901286
   Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999
   Bartolucci J, 2017, CIRC RES, V121, P1192, DOI 10.1161/CIRCRESAHA.117.310712
   Bauer G, 2018, STEM CELL TRANSL MED, V7, P676, DOI 10.1002/sctm.17-0282
   Behnke J, 2020, J CLIN MED, V3, P9
   Blum N, 2020, TABLET
   Business Wire, 2020, BUSINESS WIRE
   Casadevall A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004717
   Cascella M, 2020, EVALUATION TREATMENT
   Centers for Disease Control and Prevention, INT GUID HEALTHC FAC
   Centers for Disease Control and Prevention, COR  PAND UPD 37 ACE
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, COR COVID 19
   Centers for Disease Control and Prevention, EV TEST PERS COR DIS
   Charo RA, 2018, NEW ENGL J MED, V378, P504, DOI 10.1056/NEJMp1715736
   Chen S, 2020, S CHINA MORNING POST
   Cruz FF, 2020, EXPERT REV RESP MED, V14, P31, DOI 10.1080/17476348.2020.1679628
   D Wang, 2020, JAMA
   Daley GQ, 2017, NEW ENGL J MED, V376, P1075, DOI 10.1056/NEJMe1701379
   Daley GQ, 2012, CELL STEM CELL, V10, P740, DOI 10.1016/j.stem.2012.05.010
   Dasari Venkata Ramesh, 2014, World J Stem Cells, V6, P120, DOI 10.4252/wjsc.v6.i2.120
   Del Rio C, 2020, JAMA
   Dieleman JL, 2020, JAMA-J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734
   Dodd LE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw1049
   Driscoll J, 2019, J GASTROENTEROL, V54, P763, DOI 10.1007/s00535-019-01599-1
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   French Gouvernement, 2020, COM FRANC IS IT SAF
   French Gouvernement, 2020, COR COVID 19
   Frew L, 2011, REPRODUCTION, V141, P725, DOI 10.1530/REP-10-0537
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0106-1
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gostin L.O., 2020, JAMA
   Government of Canada, HLTH CAN POL POS PAP
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hernigou P, 2016, CLIN ORTHOP SURG, V8, P1, DOI 10.4055/cios.2016.8.1.1
   Heydari Z, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020304
   Holly R., 2020, HOME HLTH CARE  0312
   Hu CX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01596-9
   Hu JX, 2013, ENDOCR J, V60, P347
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   IwataYoshikawa N, 2019, J VIROL, V5, P6
   Iyer SS, 2009, PANMINERVA MED, V51, P5
   James S, 2020, BRADY PRESS BRIEFING
   Karakus U, 2019, J VIROL, V94, P4
   Keck Zhen-Yong, 2019, Methods Mol Biol, V1911, P395, DOI 10.1007/978-1-4939-8976-8_27
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Knoepfler P., 2020, WE CANNOT STICK RULE
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li D, 2016, MOL MED REP, V14, P1681, DOI 10.3892/mmr.2016.5416
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liang B., 2020, CLIN REMISSION CRITI
   Litterman Nadia, 2015, F1000Res, V4, P38, DOI 10.12688/f1000research.6120.1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Malarkey MA, 2012, COMMUNICATION
   Malarkey MA, 2012, OWNER MED DIRECTOR Y
   Manchikanti L, 2020, PAIN PHYSICIAN, V23, pE85
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mire CE, 2016, J INFECT DIS, V214, pS367, DOI 10.1093/infdis/jiw333
   Missoum Asmaa, 2020, Curr Urol, V13, P189, DOI 10.1159/000499272
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Murray IR, 2020, BONE JOINT J, V102B, P148, DOI 10.1302/0301-620X.102B2.BJJ-2019-1104.R1
   Nagamura-Inoue Tokiko, 2014, World J Stem Cells, V6, P195, DOI 10.4252/wjsc.v6.i2.195
   Navani A, 2019, PAIN PHYSICIAN, V22, pS1
   Pean CA, 2019, J BONE JOINT SURG AM, V101, DOI 10.2106/JBJS.19.00266
   Piuzzi NS, 2018, J KNEE SURG, V31, P551, DOI 10.1055/s-0037-1604443
   Qian XJ, 2016, STEM CELL TRANSL MED, V5, P1190, DOI 10.5966/sctm.2015-0348
   Riordan NH, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1433-7
   Rosenbaum L., 2020, N ENGL J MED
   Sanapati J, 2018, PAIN PHYSICIAN, V21, P515
   Schneider JJ, 2005, J MOL MED, V83, P587, DOI 10.1007/s00109-005-0657-1
   Schwarz A, 2009, NY TIMES, pA1
   Senturk OI, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201900956
   Shafei AE, 2017, J GENE MED, V19, DOI 10.1002/jgm.2995
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Shin YW, 2019, J MICROBIOL BIOTECHN, V29, P651, DOI 10.4014/jmb.1812.12024
   SIAARTI, 2020, PRO VIT DOL SEMP RAC
   Sutton MT, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5303048
   Thacker TSN, 2020, EC TIMES
   Tipnis S, 2010, IMMUNOL CELL BIOL, V88, P795, DOI 10.1038/icb.2010.47
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trump DJ, 2020, PROCLAMATION DECLARI
   Tsai CH, 2006, CURR PHARM DESIGN, V12, P1339, DOI 10.2174/138161206776361156
   Turner L, 2016, CELL STEM CELL, V19, P154, DOI 10.1016/j.stem.2016.06.007
   U.S. Department of Health and Human Services, 2017, SAM SURG PROC EXC 21
   U.S. Food and Drug Administration, 2017, REG MED ADV THER DES
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss ML, 2006, STEM CELL REV, V2, P155, DOI 10.1007/s12015-006-0022-y
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   World Health Organization (WHO), 2020, SCITECHDAILY    0312
   Wu ZY, 2020, JAMA SURG, V155, P1142, DOI 10.1001/jamasurg.2020.4132
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yamey G., 2020, TIME
   Yao X, 2020, CLIN INFECT DIS
   Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 116
TC 52
Z9 54
U1 24
U2 60
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD MAR-APR
PY 2020
VL 23
IS 2
BP E71
EP E83
PG 13
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA KX3AI
UT WOS:000521753300001
PM 32214286
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Li, JY
   You, Z
   Wang, Q
   Zhou, ZJ
   Qiu, Y
   Luo, R
   Ge, XY
AF Li, Jin-Yan
   You, Zhi
   Wang, Qiong
   Zhou, Zhi-Jian
   Qiu, Ye
   Luo, Rui
   Ge, Xing-Yi
TI The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and
   insights for emerging infectious diseases in the future
SO MICROBES AND INFECTION
LA English
DT Article
DE 2019-nCoV; Pneumonia; ACE2; Spike; SARS-CoV; Bat
ID EAST RESPIRATORY SYNDROME; SARS; CORONAVIRUS; TRANSMISSION; LOPINAVIR;
   CHINA
AB At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV. (C) 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Li, Jin-Yan; You, Zhi; Wang, Qiong; Zhou, Zhi-Jian; Qiu, Ye; Ge, Xing-Yi] Hunan Univ, Coll Biol, Inst Pathogen Biol & Immunol, Hunan Prov Key Lab Med Virol, Changsha 410082, Hunan, Peoples R China.
   [Luo, Rui] Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
   [Luo, Rui] Cooperat Innovat Ctr Sustainable Pig Prod, Key Lab Prevent Vet Med Hubei Prov, Wuhan 430070, Hubei, Peoples R China.
RP Ge, XY (corresponding author), Hunan Univ, Coll Biol, Inst Pathogen Biol & Immunol, Hunan Prov Key Lab Med Virol, Changsha 410082, Hunan, Peoples R China.
EM lijinyan@hnu.edu.cn; YOUZHI@hnu.edu.cn; qw@hnu.edu.cn;
   zjzhou@hnu.edu.cn; qiuye@hnu.edu.cn; luorui@mail.hzau.edu.cn;
   xyge@hnu.edu.cn
RI Ribeiro, Nuno/AAH-2299-2020
FU National Key Research and Development Program of China [2017YFD0500104];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31470260]; Science Fund for Distinguished
   Young Scholars of Hunan ProvinceNational Natural Science Foundation of
   China (NSFC)National Science Fund for Distinguished Young Scholars
   [2019JJ20004]
FX This work was jointly funded by the National Key Research and
   Development Program of China (grant number 2017YFD0500104), National
   Natural Science Foundation of China (31470260), and the Science Fund for
   Distinguished Young Scholars of Hunan Province (grant number
   2019JJ20004).
CR [Anonymous], 2020, 1 CHIN NAT HLTH COMM
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan KH, 2011, ADV VIROL, V2011, DOI 10.1155/2011/734690
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chong YP, 2015, INFECT CHEMOTHER, V47, P212, DOI 10.3947/ic.2015.47.3.212
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kupferschmidt K, 2014, SCIENCE, V343, P1422, DOI 10.1126/science.343.6178.1422
   Letko M, 2020, FUNCTIONAL ASSESSMEN
   Lin QY, 2018, STAT METHODS MED RES, V27, P1968, DOI 10.1177/0962280217746442
   Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tai DYH, 2007, ANN ACAD MED SINGAP, V36, P438
   Tatem AJ, 2006, ADV PARASIT, V62, P293, DOI 10.1016/S0065-308X(05)62009-X
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang M, 2020, CELL RES, DOI DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu Z., 2020, NELFINAVIR WAS PREDI
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang YF, 2020, DIGEST DIS SCI, DOI 10.1007/s10620-020-06488-9
   Zhao Y, 2020, SINGLE CELL RNA EXPR
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 56
Z9 62
U1 6
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD MAR
PY 2020
VL 22
IS 2
SI SI
BP 80
EP 85
DI 10.1016/j.micinf.2020.02.002
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA KU8UJ
UT WOS:000519987000004
PM 32087334
OA Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhang, DH
   Wu, KL
   Zhang, X
   Deng, SQ
   Peng, B
AF Zhang, Deng-hai
   Wu, Kun-lun
   Zhang, Xue
   Deng, Sheng-qiong
   Peng, Bin
TI In silico screening of Chinese herbal medicines with the potential to
   directly inhibit 2019 novel coronavirus
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE 2019-nCoV; Wuhan coronavirus; Drugs; Chinese herbal; Pneumonia; Natural
   compounds; Molecular docking; Network pharmacology
ID PAPAIN-LIKE PROTEASE; SARS-COV 3CL(PRO); ANTIVIRAL ACTIVITIES; DESIGN;
   DERIVATIVES
AB Objective: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia.
   Methods: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb.
   Results: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response.
   Conclusion: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds. (C) 2020 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.
C1 [Zhang, Deng-hai; Zhang, Xue; Peng, Bin] Secondary Mil Med Univ, Shanghai Pudong Gongli Hosp, Shanghai Hlth Commiss Key Lab Artificial Intellig, Sino French Cooperat Cent Lab, Shanghai 200135, Peoples R China.
   [Wu, Kun-lun] Secondary Mil Med Univ, Shanghai Pudong Gongli Hosp, Dept Tradit Chinese Med, Shanghai 200135, Peoples R China.
   [Deng, Sheng-qiong] Secondary Mil Med Univ, Shanghai Pudong Gongli Hosp, Dept Res Affair Management, Shanghai 200135, Peoples R China.
RP Zhang, DH (corresponding author), Secondary Mil Med Univ, Shanghai Pudong Gongli Hosp, Shanghai Hlth Commiss Key Lab Artificial Intellig, Sino French Cooperat Cent Lab, Shanghai 200135, Peoples R China.
EM shanghai_zhang@hotmail.com
FU Shanghai Leading Talent Grants in Medicine [2019LG26]; Shanghai
   Traditional Chinese Medicine Content Construction Innovation Project
   [ZY3-CCCX-3-7001]; Shanghai Gongil Hospital [GLBH2017002]
FX This work is supported by Shanghai Leading Talent Grants in Medicine
   (No. 2019LG26), Shanghai Traditional Chinese Medicine Content
   Construction Innovation Project (No. ZY3-CCCX-3-7001) and Postdoctoral
   Funding of Shanghai Gongil Hospital (No. GLBH2017002).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008
   Hu W, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/5276865
   Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012
   Kesel AJ, 2005, CURR MED CHEM, V12, P2095, DOI 10.2174/0929867054637644
   Kim JY, 2018, INT J ANTIMICROB AG, V52, P730, DOI 10.1016/j.ijantimicag.2018.05.003
   Lai LH, 2006, CURR PHARM DESIGN, V12, P4555, DOI 10.2174/138161206779010396
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu B, 2005, J COMPUT CHEM, V26, P484, DOI 10.1002/jcc.20186
   Mukherjee P, 2011, J CHEM INF MODEL, V51, P1376, DOI 10.1021/ci1004916
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Park JY, 2013, BIOORGAN MED CHEM, V21, P3730, DOI 10.1016/j.bmc.2013.04.026
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Rizvi SMD, 2013, EXCLI J, V12, P831
   Ryu YB, 2010, BIOORG MED CHEM LETT, V20, P1873, DOI 10.1016/j.bmcl.2010.01.152
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Song YH, 2014, BIOL PHARM BULL, V37, P1021, DOI 10.1248/bpb.b14-00026
   Tian H Y, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, pE001, DOI 10.3760/cma.j.issn.0253-9624.2020.0001
   Wang SQ, 2007, AMINO ACIDS, V33, P129, DOI 10.1007/s00726-006-0403-1
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   World Health Organization, 2020, EM COMM REG OUTBR NO
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Zhang WJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00743
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 32
TC 82
Z9 85
U1 7
U2 41
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAR
PY 2020
VL 18
IS 2
BP 152
EP 158
DI 10.1016/j.joim.2020.02.005
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA KU8WN
UT WOS:000519993900006
PM 32113846
OA Green Published, Other Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lai, CC
   Shih, TP
   Ko, WC
   Tang, HJ
   Hsueh, PR
AF Lai, Chih-Cheng
   Shih, Tzu-Ping
   Ko, Wen-Chien
   Tang, Hung-Jen
   Hsueh, Po-Ren
TI Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
   coronavirus disease-2019 (COVID-19): The epidemic and the challenges
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE 2019-nCoV; SARS-CoV-2; COVID-19; China; Epidemic; Remdesivir
ID PNEUMONIA; WUHAN; OUTBREAK; CHINA
AB The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond. (C) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Lai, Chih-Cheng] Kaohsiung Vet Gen Hosp, Dept Internal Med, Tainan Branch, Tainan, Taiwan.
   [Shih, Tzu-Ping] Kaohsiung Vet Gen Hosp, Dept Family Med, Tainan Branch, Tainan, Taiwan.
   [Ko, Wen-Chien] Natl Cheng Kung Univ, Coll Med, Dept Med, Tainan, Taiwan.
   [Tang, Hung-Jen] Chi Mei Med Ctr, Dept Med, Tainan 71004, Taiwan.
   [Hsueh, Po-Ren] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Coll Med, Taipei, Taiwan.
   [Hsueh, Po-Ren] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Coll Med, Taipei, Taiwan.
RP Hsueh, PR (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.; Hsueh, PR (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM hsporen@ntu.edu.tw
RI Ribeiro, Nuno/AAH-2299-2020; Ko, Wen-Chien/ABG-4316-2020
OI Ko, Wen-Chien/0000-0001-7497-149X; HSUEH, PO-REN/0000-0002-7502-9225
CR Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Biscayart C, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101567
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Chou CC, 2019, J MICROBIOL IMMUNOL, V52, P172, DOI 10.1016/j.jmii.2018.11.004
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung HM, 2019, J MICROBIOL IMMUNOL, V52, P233, DOI 10.1016/j.jmii.2018.08.009
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kanne JP, 2020, RADIOLOGY, V295, P16, DOI 10.1148/radiol.2020200241
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lee JY, 2019, J MICROBIOL IMMUNOL, V52, P838, DOI 10.1016/j.jmii.2019.05.014
   Lee Kyoung Hwa, 2019, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2019.05.007
   Lee SH, 2019, J MICROBIOL IMMUNOL, V52, P920, DOI 10.1016/j.jmii.2019.10.009
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin GL, 2019, J MICROBIOL IMMUNOL, V52, P215, DOI 10.1016/j.jmii.2018.07.005
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Ryu S, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020006
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Su IC, 2019, J MICROBIOL IMMUNOL, V52, P365, DOI 10.1016/j.jmii.2018.05.007
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   World Health Organization, NOV COR 2019 NCOV
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yoo JH, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e56
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 48
TC 856
Z9 894
U1 136
U2 297
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD MAR
PY 2020
VL 55
IS 3
AR 105924
DI 10.1016/j.ijantimicag.2020.105924
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA KT2ON
UT WOS:000518855500030
PM 32081636
OA Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Morse, JS
   Lalonde, T
   Xu, SQ
   Liu, WR
AF Morse, Jared S.
   Lalonde, Tyler
   Xu, Shiqing
   Liu, Wenshe Ray
TI Learning from the Past: Possible Urgent Prevention and Treatment Options
   for Severe Acute Respiratory Infections Caused by 2019-nCoV
SO CHEMBIOCHEM
LA English
DT Article
DE antiviral agents; coronavirus; 2019-nCoV; SARS; spike proteins; RdRp;
   3CLpro
ID PAPAIN-LIKE PROTEASE; RECEPTOR-BINDING DOMAIN; SARS-CORONAVIRUS;
   AURINTRICARBOXYLIC ACID; SPIKE PROTEIN; COV; POTENT; IDENTIFICATION;
   RIBAVIRIN; VACCINE
AB With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.
C1 [Morse, Jared S.; Lalonde, Tyler; Xu, Shiqing; Liu, Wenshe Ray] Texas A&M Univ, Dept Chem, Texas A&M Drug Discovery Lab, College Stn, TX 77843 USA.
RP Xu, SQ; Liu, WR (corresponding author), Texas A&M Univ, Dept Chem, Texas A&M Drug Discovery Lab, College Stn, TX 77843 USA.
EM shiqing.xu@tamu.edu; wliu@chem.tamu.edu
RI Ribeiro, Nuno/AAH-2299-2020; Liu, wenshe/O-4425-2014
OI Liu, wenshe/0000-0002-7078-6534
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01GM121584,
   R01GM127575]; Cancer Prevention & Research Institute of Texas
   [RP170797]; Welch FoundationThe Welch Foundation [A1715]
FX Research support in the Texas A&M Drug Discovery Center is provided by
   the National Institutes of Health (grants R01GM121584 and R01GM127575),
   the Cancer Prevention & Research Institute of Texas (grant RP170797),
   and the Welch Foundation (grant A1715). We thank Sunshine Zea Leeuwon
   for providing assistance in designing all the figures.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   [Anonymous], 2019, ANGEW CHEM, V131, P16051
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038
   Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198
   Chen Xin, 2009, Antivir Chem Chemother, V19, P151
   Cheng KW, 2015, ANTIVIR RES, V115, P9, DOI 10.1016/j.antiviral.2014.12.011
   Chiou HE, 2005, CHEST, V128, P263, DOI 10.1378/chest.128.1.263
   CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   GONZALEZ RG, 1979, BIOCHIM BIOPHYS ACTA, V562, P534, DOI 10.1016/0005-2787(79)90116-3
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   He RT, 2004, BIOCHEM BIOPH RES CO, V320, P1199, DOI 10.1016/j.bbrc.2004.06.076
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hipolito CJ, 2012, CURR OPIN CHEM BIOL, V16, P196, DOI 10.1016/j.cbpa.2012.02.014
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2015, J VIROL, V89, P4942, DOI 10.1128/JVI.03688-14
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumar V, 2017, ANTIVIR RES, V141, P101, DOI 10.1016/j.antiviral.2017.02.007
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu W, 2014, BIOORGAN MED CHEM, V22, P292, DOI 10.1016/j.bmc.2013.11.028
   MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W
   Muller MP, 2007, PHARMACOTHERAPY, V27, P494, DOI 10.1592/phco.27.4.494
   Navas-Martin S, 2004, J NEUROVIROL, V10, P75, DOI 10.1080/13550280490280292
   ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411
   Palei S, 2019, CHEMBIOCHEM, V20, P72, DOI 10.1002/cbic.201800552
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Park JY, 2012, BIOL PHARM BULL, V35, P2036, DOI 10.1248/bpb.b12-00623
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Song YH, 2014, BIOL PHARM BULL, V37, P1021, DOI 10.1248/bpb.b14-00026
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Taylor DR, 2006, VACCINE, V24, P863, DOI 10.1016/j.vaccine.2005.08.102
   Wang XSS, 2019, ANGEW CHEM INT EDIT, V58, P15904, DOI 10.1002/anie.201908713
   Xiao WW, 2010, MOL CANCER THER, V9, P2714, DOI 10.1158/1535-7163.MCT-10-0308
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Yap YL, 2005, COMPUT BIOL CHEM, V29, P212, DOI 10.1016/j.compbiolchem.2005.04.006
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 48
TC 168
Z9 188
U1 10
U2 83
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
PD MAR 2
PY 2020
VL 21
IS 5
BP 730
EP 738
DI 10.1002/cbic.202000047
EA FEB 2020
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA KR0RR
UT WOS:000515400100001
PM 32022370
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Lucchese, G
AF Lucchese, Guglielmo
TI Epitopes for a 2019-nCoV vaccine
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
C1 [Lucchese, Guglielmo] Univ Med Greifswald, Dept Neurol, D-17475 Greifswald, Germany.
RP Lucchese, G (corresponding author), Univ Med Greifswald, Dept Neurol, D-17475 Greifswald, Germany.
EM guglielmo.lucchese@uni-greifswald.de
RI Lucchese, Guglielmo/AAL-9860-2020; Ribeiro, Nuno/AAH-2299-2020
OI Lucchese, Guglielmo/0000-0002-1809-6376; 
FU "Gerhard Domagk" research grant - University of Greifswald Medical
   School
FX The author is supported by a "Gerhard Domagk" research grant awarded by
   the University of Greifswald Medical School.
CR Chen CM, 2013, BIOINFORMATICS, V29, P2808, DOI 10.1093/bioinformatics/btt484
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kanduc D, 2008, ADV EXPT MED BIOL, V640
   Patel A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043802
   Richman LP, 2019, CELL SYST, V9, P375, DOI 10.1016/j.cels.2019.08.009
   Vita R, 2010, NUCLEIC ACIDS RES, V38, pD854, DOI 10.1093/nar/gkp1004
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 8
TC 18
Z9 18
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD MAY
PY 2020
VL 17
IS 5
BP 539
EP 540
DI 10.1038/s41423-020-0377-z
EA FEB 2020
PG 2
WC Immunology
SC Immunology
GA LI8BC
UT WOS:000515475700003
PM 32094505
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zumla, A
   Hui, DS
   Azhar, EI
   Memish, ZA
   Maeurer, M
AF Zumla, Alimuddin
   Hui, David S.
   Azhar, Esam I.
   Memish, Ziad A.
   Maeurer, Markus
TI Reducing mortality from 2019-nCoV: host-directed therapies should be an
   option
SO LANCET
LA English
DT Letter
ID ACUTE RESPIRATORY SYNDROME; INFECTIONS
C1 [Zumla, Alimuddin] UCL, Dept Infect, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] Univ Coll London Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Hui, David S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
   [Azhar, Esam I.] King Abdulaziz Univ, Fac Appl Med Sci, King Fahd Med Res Ctr, Special Infect Agents Unit, Jeddah, Saudi Arabia.
   [Azhar, Esam I.] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah, Saudi Arabia.
   [Memish, Ziad A.] Prince Mohamed Bin Abdulaziz Hosp, Dept Med & Res Dept, Infect Dis Div, Minist Hlth, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
   [Maeurer, Markus] Champalimaud Ctr Unknown, Immunotherapy Programme, P-1400038 Lisbon, Portugal.
   [Maeurer, Markus] Johannes Gutenberg Univ Mainz, Med Clin 1, Mainz, Germany.
RP Maeurer, M (corresponding author), Champalimaud Ctr Unknown, Immunotherapy Programme, P-1400038 Lisbon, Portugal.
EM markus.maeurer@fundacaochampalimaud.pt
RI Hui, David SC/O-2754-2015; ZUMLA, Alimuddin/ABA-8208-2020; Azhar,
   Esam/ABI-1044-2020
OI Maeurer, Markus/0000-0002-8436-8077; Zumla, Professor Sir
   Alimuddin/0000-0002-5111-5735; Azhar, Esam/0000-0002-1736-181X
FU European & Developing Countries Clinical Trials Partnership; EU's
   Framework Programme for Research and InnovationEuropean Union (EU);
   National Institutes of Health ResearchUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA; Bill &
   Melinda Gates Foundation - Champalimaud Foundation
FX We declare no competing interests. AZ is coprincipal investigator of the
   Pan-African Network on Emerging and Re-emerging Infections
   (PANDORA-ID-NET), funded by the European & Developing Countries Clinical
   Trials Partnership, supported under Horizon 2020, the EU's Framework
   Programme for Research and Innovation, and a National Institutes of
   Health Research senior investigator. MM is a member of the innate
   immunity advisory group of the Bill & Melinda Gates Foundation, and his
   work is funded by the Champalimaud Foundation.
CR Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Barnard Dale L., 2007, Antiviral Chemistry & Chemotherapy, V18, P125
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   Zumla A, 2015, INT J INFECT DIS, V40, P71, DOI 10.1016/j.ijid.2015.09.005
NR 12
TC 115
Z9 127
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD FEB 22
PY 2020
VL 395
IS 10224
BP E35
EP E36
DI 10.1016/S0140-6736(20)30305-6
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA KN5AJ
UT WOS:000514849400002
PM 32035018
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhou, W
   Liu, YS
   Tian, DD
   Wang, C
   Wang, S
   Cheng, J
   Hu, M
   Fang, MH
   Gao, Y
AF Zhou, Wei
   Liu, Yisi
   Tian, Dongdong
   Wang, Cheng
   Wang, Sa
   Cheng, Jing
   Hu, Ming
   Fang, Minghao
   Gao, Yue
TI Potential benefits of precise corticosteroids therapy for severe
   2019-nCoV pneumonia
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Letter
ID SEPSIS
C1 [Zhou, Wei; Gao, Yue] Beijing Inst Radiat Med, Dept Pharmaceut Sci, Beijing 100850, Peoples R China.
   [Liu, Yisi] Capital Med Univ, Sch Nursing, Beijing 100069, Peoples R China.
   [Tian, Dongdong] Hebei Gen Hosp, Dept Pharm, Shijiazhuang 050000, Hebei, Peoples R China.
   [Wang, Cheng] Chinese PLA, Gen Hosp, Med Ctr 1, Dept Orthoped, Beijing 100853, Peoples R China.
   [Wang, Sa] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Emergency Dept, Hangzhou 310009, Peoples R China.
   [Cheng, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Emergency Surg Dept, Wuhan 430030, Peoples R China.
   [Hu, Ming] Wuhan Pulm Hosp, Intens Care Unit, Wuhan 430030, Peoples R China.
   [Fang, Minghao] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Emergency & Intens Care Unit, Wuhan 430030, Peoples R China.
RP Gao, Y (corresponding author), Beijing Inst Radiat Med, Dept Pharmaceut Sci, Beijing 100850, Peoples R China.; Hu, M (corresponding author), Wuhan Pulm Hosp, Intens Care Unit, Wuhan 430030, Peoples R China.; Fang, MH (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Emergency & Intens Care Unit, Wuhan 430030, Peoples R China.
EM huming74@163.com; fangmh@tjh.tjmu.edu.cn; gaoyue@bmi.ac.cn
RI Ribeiro, Nuno/AAH-2299-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81630102, 81803833]
FX We thank all medical staff working in the Intensive Care Unit of Wuhan
   Pulmonary Hospital for their essential assistance with case collection.
   The authors acknowledge the National Natural Science Foundation of China
   for the financial support (no. 81630102 and no. 81803833).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   BIFFL WL, 1995, AM J SURG, V170, P591, DOI 10.1016/S0002-9610(99)80022-1
   Jiang S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016239
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Marik PE, 2018, J THORAC DIS, V10, pS1070, DOI 10.21037/jtd.2018.04.35
   Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4
   National Health Commission of the People's Republic of China, 2020, 5 TRIAL VERS DIAGN T
   National Health Commission of the People's Republic of China, 2020, NAT HLTH COMM BRIEF
   Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
NR 12
TC 82
Z9 89
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD FEB 21
PY 2020
VL 5
IS 1
AR 18
DI 10.1038/s41392-020-0127-9
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA KR0FH
UT WOS:000517296100001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lu, MM
   Liu, QG
   Wang, XB
   Zhang, JL
   Zhang, X
   Shi, D
   Liu, JB
   Shi, HY
   Chen, JF
   Feng, L
AF Lu, Manman
   Liu, Qiuge
   Wang, Xiaobo
   Zhang, Jialin
   Zhang, Xin
   Shi, Da
   Liu, Jianbo
   Shi, Hongyan
   Chen, Jianfei
   Feng, Li
TI Development of an indirect ELISA for detecting porcine deltacoronavirus
   IgA antibodies
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID TRANSMISSIBLE GASTROENTERITIS VIRUS; RESPIRATORY CORONAVIRUS INFECTIONS;
   EPIDEMIC DIARRHEA VIRUS; LENGTH GENOME SEQUENCE; SPIKE PROTEIN;
   IDENTIFICATION; PIGS; IMMUNITY; SWINE; PREVALENCE
AB Porcine deltacoronavirus (PDCoV) is a novel coronavirus that can cause vomiting and watery diarrhea in pigs and death in piglets. Since PDCoV was first detected in 2009 in Hong Kong, the prevalence of PDCoV has increased in recent years, resulting in serious economic losses to the swine industry. The coronavirus spike (S) protein is an antigen that has been demonstrated to contain epitopes that induce neutralizing antibodies. The presence of serum and milk IgA antibodies against pathogens that replicate primarily on mucosal surfaces is important for mucosal immunity. Here, an indirect anti-PDCoV IgA antibody enzyme-linked immunosorbent assay (PDCoV S1 IgA ELISA) using the purified S1 portion of S protein as the coating antigen was developed to detect PDCoV IgA antibodies in serum and sow's milk. A receiver operating characteristic (ROC) curve analysis showed high specificity and sensitivity of the PDCoV-S1-IgA-ELISA based on samples confirmed by IFA. Anti-PDCoV IgA antibodies in 152 serum samples and 65 milk samples collected from six farms that had experienced diarrhea outbreaks within previous last two years were detected by this assay, and 62.5% of the serum samples and 100% of the milk samples were positive for PDCoV. The indirect ELISA method established in this study will provide a convenient tool for measurement of serum and milk IgA levels against PDCoV in pig herds, rapid detection of PDCoV infection in pigs, and evaluation of the immunogenicity of vaccines.
C1 [Lu, Manman; Liu, Qiuge; Wang, Xiaobo; Zhang, Jialin; Zhang, Xin; Shi, Da; Liu, Jianbo; Shi, Hongyan; Chen, Jianfei; Feng, Li] Chinese Acad Agr Sci, Harbin Vet Res Inst, Div Swine Digest Syst Infect Dis, State Key Lab Vet Biotechnol, Harbin 150069, Peoples R China.
RP Chen, JF; Feng, L (corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, Div Swine Digest Syst Infect Dis, State Key Lab Vet Biotechnol, Harbin 150069, Peoples R China.
EM chenjianfei@caas.cn; fengli@caas.cn
RI Ribeiro, Nuno/AAH-2299-2020
OI Chen, Jianfei/0000-0001-6472-9077
FU National Key Research and Development Program of China [2016YFD0500705];
   Heilongjiang Province Natural Science Foundation of ChinaNatural Science
   Foundation of Heilongjiang Province [C2016065]
FX This study was funded by the National Key Research and Development
   Program of China (2016YFD0500705) and the Heilongjiang Province Natural
   Science Foundation of China (C2016065).
CR ABRAHAM S, 1990, VIROLOGY, V176, P296, DOI 10.1016/0042-6822(90)90257-R
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Chen FZ, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.01284-15
   [陈建飞 Chen Jianfei], 2016, [中国预防兽医学报, Chinase Journal of Preventive Veterinary Medicine], V38, P171
   Chiou HY, 2017, TRANSBOUND EMERG DIS, V64, P157, DOI 10.1111/tbed.12357
   de Arriba ML, 2002, VET IMMUNOL IMMUNOP, V85, P85, DOI 10.1016/S0165-2427(01)00417-2
   DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990
   Elia G, 2010, J VIROL METHODS, V163, P309, DOI 10.1016/j.jviromet.2009.10.015
   Hu H, 2016, ARCH VIROL, V161, P3421, DOI 10.1007/s00705-016-3056-8
   Janetanakit T, 2016, EMERG INFECT DIS, V22, P757, DOI 10.3201/eid2204.151852
   KNUCHEL M, 1992, VET MICROBIOL, V32, P117, DOI 10.1016/0378-1135(92)90100-8
   Lee S, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.01191-14
   Li GW, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00278-14
   Lorsirigool A, 2016, ARCH VIROL, V161, P2909, DOI 10.1007/s00705-016-2983-8
   LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5
   Ma YM, 2016, VET MICROBIOL, V186, P90, DOI 10.1016/j.vetmic.2016.02.004
   Ma YM, 2015, MBIO, V6, DOI 10.1128/mBio.00064-15
   Marthaler D, 2014, EMERG INFECT DIS, V20, P1347, DOI [10.3201/eid2008.14-0526, 10.3201/eid2008.140526]
   Saif LJ, 1996, VET IMMUNOL IMMUNOP, V54, P163, DOI 10.1016/S0165-2427(96)05702-9
   SAIF LJ, 1994, VET IMMUNOL IMMUNOP, V43, P89, DOI 10.1016/0165-2427(94)90124-4
   Salmon H, 2000, ADV EXP MED BIOL, V480, P279
   SIMKINS RA, 1993, AM J VET RES, V54, P254
   Song D, 2015, TRANSBOUND EMERG DIS, V62, P575, DOI 10.1111/tbed.12399
   Su MJ, 2016, J VET MED SCI, V78, P601, DOI 10.1292/jvms.15-0533
   Thachil A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124363
   To TL, 1998, J GEN VIROL, V79, P2661
   Wang YW, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00945-15
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Zhai SL, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0591-6
   Zhang JQ, 2016, VIRUS RES, V226, P71, DOI 10.1016/j.virusres.2016.05.028
NR 30
TC 3
Z9 3
U1 1
U2 15
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD APR
PY 2020
VL 165
IS 4
BP 845
EP 851
DI 10.1007/s00705-020-04541-6
EA FEB 2020
PG 7
WC Virology
SC Virology
GA KZ9SL
UT WOS:000513045100003
PM 32052195
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, YX
   Yang, Y
   Zhang, C
   Huang, FM
   Wang, FX
   Yuan, J
   Wang, ZQ
   Li, JX
   Li, JM
   Feng, C
   Zhang, Z
   Wang, LF
   Peng, L
   Chen, L
   Qin, YH
   Zhao, DD
   Tan, SG
   Yin, L
   Xu, J
   Zhou, CZ
   Jiang, CY
   Liu, L
AF Liu, Yingxia
   Yang, Yang
   Zhang, Cong
   Huang, Fengming
   Wang, Fuxiang
   Yuan, Jing
   Wang, Zhaoqin
   Li, Jinxiu
   Li, Jianming
   Feng, Cheng
   Zhang, Zheng
   Wang, Lifei
   Peng, Ling
   Chen, Li
   Qin, Yuhao
   Zhao, Dandan
   Tan, Shuguang
   Yin, Lu
   Xu, Jun
   Zhou, Congzhao
   Jiang, Chengyu
   Liu, Lei
TI Clinical and biochemical indexes from 2019-nCoV infected patients linked
   to viral loads and lung injury
SO SCIENCE CHINA-LIFE SCIENCES
LA English
DT Article
DE 2019-nCoV; Angiotensin II; ARDS
ID ANGIOTENSIN-CONVERTING ENZYME-2; INHIBITORS; PEPTIDES; PROTECTS
AB The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.
C1 [Liu, Yingxia; Yang, Yang; Wang, Fuxiang; Yuan, Jing; Wang, Zhaoqin; Li, Jinxiu; Li, Jianming; Feng, Cheng; Zhang, Zheng; Wang, Lifei; Peng, Ling; Chen, Li; Liu, Lei] Southern Univ Sci & Technol, Shenzhen Key Lab Pathogen & Immun, State Key Discipline Infect Dis,Shenzhen Peoples, Natl Clin Res Ctr Infect Dis,Hosp Affiliated 1, Shenzhen 518112, Peoples R China.
   [Yang, Yang; Zhou, Congzhao] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Peoples R China.
   [Yang, Yang; Zhou, Congzhao] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China.
   [Zhang, Cong; Huang, Fengming; Qin, Yuhao; Zhao, Dandan; Jiang, Chengyu] Chinese Acad Med Sci, Dept Biochem, Peking Union Med Coll, State Key Lab Med Mol Biol,Inst Basic Med Sci, Beijing 100005, Peoples R China.
   [Tan, Shuguang] Chinese Acad Sci, Inst Microbiol, Beijing 100101, Peoples R China.
   [Yin, Lu; Xu, Jun] Peking Union Med Coll Hosp, Emergence Dept, Beijing 100731, Peoples R China.
RP Liu, YX; Liu, L (corresponding author), Southern Univ Sci & Technol, Shenzhen Key Lab Pathogen & Immun, State Key Discipline Infect Dis,Shenzhen Peoples, Natl Clin Res Ctr Infect Dis,Hosp Affiliated 1, Shenzhen 518112, Peoples R China.; Jiang, CY (corresponding author), Chinese Acad Med Sci, Dept Biochem, Peking Union Med Coll, State Key Lab Med Mol Biol,Inst Basic Med Sci, Beijing 100005, Peoples R China.
EM yingxialiu@hotmail.com; jiang@pumc.edu.cn; liulei3322@aliyun.com
RI Huang, Fengming/AAM-8723-2020; Ribeiro, Nuno/AAH-2299-2020
FU National Science and Technology Major Project [2017ZX10103011,
   2017ZX10204401]; Chinese Academy of Medical Sciences Innovation Fund for
   Medical Sciences [2017-I2M-1-009]; Shenzhen Science and Technology
   Research and Development Project [JCYJ20180504165549581,
   JCYJ20170413141236903]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019T120147]
FX The authors would like to thank a scientist who insists on being
   anonymous. The authors would also like to thank Shunwang Li and Xiaoyun
   Li who helped data analysis and making figures and tables. This work was
   supported by the National Science and Technology Major Project
   (2017ZX10103011 and 2017ZX10204401), Chinese Academy of Medical Sciences
   Innovation Fund for Medical Sciences (2017-I2M-1-009), Shenzhen Science
   and Technology Research and Development Project (JCYJ20180504165549581
   and JCYJ20170413141236903), China Postdoctoral Science Foundation
   (2019T120147).
CR Bi YH, 2019, CLIN INFECT DIS, V68, P1100, DOI 10.1093/cid/ciy681
   Chan JF-W, 2020, LANCET
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Damman K, 2018, JACC-HEART FAIL, V6, P489, DOI 10.1016/j.jchf.2018.02.004
   Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017
   Frohlich H, 2016, AM HEART J, V178, P28, DOI [10.1016/j.ahj.2016.03.024, 10.1016/j.ahj.2076.03.024]
   Guo J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10942
   Huang C, 2020, LANCET
   Huang FM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4595
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Leem AY, 2018, INT J CHRONIC OBSTR, V13, P509, DOI 10.2147/COPD.S148618
   Lin CL, 2004, CHEST, V126, P509, DOI 10.1378/chest.126.2.509
   Lin YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188975
   Mortensen EM, 2012, CLIN INFECT DIS, V55, P1466, DOI 10.1093/cid/cis733
   MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720
   Niu PH, 2018, SCI CHINA LIFE SCI, V61, P1280, DOI 10.1007/s11427-018-9343-8
   Packer M, 2017, LANCET, V389, P1831, DOI 10.1016/S0140-6736(16)30969-2
   Rai AK, 2017, CRIT REV FOOD SCI, V57, P2789, DOI 10.1080/10408398.2015.1068736
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Torres VE, 2014, NEW ENGL J MED, V371, P2267, DOI 10.1056/NEJMoa1402686
   Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan YW, 2015, SCI CHINA LIFE SCI, V58, P208, DOI 10.1007/s11427-015-4814-7
   Yang Y, 2019, J INFECTION, V78, P241, DOI 10.1016/j.jinf.2019.01.005
   Zhu N, 2020, N ENGL J MED
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 30
TC 476
Z9 514
U1 21
U2 39
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7305
EI 1869-1889
J9 SCI CHINA LIFE SCI
JI Sci. China-Life Sci.
PD MAR
PY 2020
VL 63
IS 3
BP 364
EP 374
DI 10.1007/s11427-020-1643-8
EA FEB 2020
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA KU1DB
UT WOS:000518376300004
PM 32048163
OA Green Published, Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Schwartz, DA
   Graham, AL
AF Schwartz, David A.
   Graham, Ashley L.
TI Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV
   (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and
   Other Human Coronavirus Infections
SO VIRUSES-BASEL
LA English
DT Article
DE coronavirus; Middle East respiratory syndrome; severe acute respiratory
   syndrome; SARS-CoV; MERS-CoV; Wuhan coronavirus; 2019-nCoV; SARS-CoV-2;
   COVID-19; pregnancy; maternal mortality; maternal death; pregnancy
   complications; maternal morbidity; pneumonia; epidemic; emerging
   infection; China; Wuhan coronavirus outbreak
ID ACUTE-RESPIRATORY-SYNDROME; OBSTETRIC PATIENTS; NEONATES BORN;
   TRANSMISSION; PNEUMONIA; COV; EPIDEMIC; MOTHERS; GUIDELINES; OUTBREAK
AB In early December 2019 a cluster of cases of pneumonia of unknown cause was identified in Wuhan, a city of 11 million persons in the People's Republic of China. Further investigation revealed these cases to result from infection with a newly identified coronavirus, initially termed 2019-nCoV and subsequently SARS-CoV-2. The infection moved rapidly through China, spread to Thailand and Japan, extended into adjacent countries through infected persons travelling by air, eventually reaching multiple countries and continents. Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human. In the early stages of this epidemic the case fatality rate is estimated to be approximately 2%, with the majority of deaths occurring in special populations. Unfortunately, there is limited experience with coronavirus infections during pregnancy, and it now appears certain that pregnant women have become infected during the present 2019-nCoV epidemic. In order to assess the potential of the Wuhan 2019-nCoV to cause maternal, fetal and neonatal morbidity and other poor obstetrical outcomes, this communication reviews the published data addressing the epidemiological and clinical effects of SARS, MERS, and other coronavirus infections on pregnant women and their infants. Recommendations are also made for the consideration of pregnant women in the design, clinical trials, and implementation of future 2019-nCoV vaccines.
C1 [Schwartz, David A.] Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA.
   [Graham, Ashley L.] Univ Connecticut, Dept Anthropol, Storrs, CT 06269 USA.
RP Schwartz, DA (corresponding author), Augusta Univ, Med Coll Georgia, Augusta, GA 30912 USA.
EM davidalanschwartz@gmail.com; ashley.graham@uconn.edu
RI Ribeiro, Nuno/AAH-2299-2020
OI Schwartz, David/0000-0002-7486-8545; Graham, Ashley/0000-0001-5855-9614
CR Al-Tawfiq JA, 2017, EXPERT REV ANTI-INFE, V15, P269, DOI 10.1080/14787210.2017.1271712
   Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   Alserehi H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1437-y
   Alvarado MG, 2017, ARCH PATHOL LAB MED, V141, P26, DOI 10.5858/arpa.2016-0382-RA
   [Anonymous], 2011, ICTV 9 REPORT
   Assiri A, 2016, CLIN INFECT DIS, V63, P951, DOI 10.1093/cid/ciw412
   BENEDETTI TJ, 1982, AM J OBSTET GYNECOL, V144, P413, DOI 10.1016/0002-9378(82)90246-0
   BERKOWITZ K, 1990, AM J OBSTET GYNECOL, V163, P981, DOI 10.1016/0002-9378(90)91109-P
   CDC, MIDDL E RESP SYNDR M
   Centers for Disease Control and Prevention (CDC), 2015, MIDDL E RESP SYNDR M
   Coalition for Epidemic Preparedness and Innovations, 2020, CEPI FUND 3 PROGR DE
   Cohen J., WUHAN SEAFOOD MARKET
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005
   Gagneur A, 2008, EUR J CLIN MICROBIOL, V27, P863, DOI 10.1007/s10096-008-0505-7
   Gagneur A, 2007, PATHOL BIOL, V55, P525, DOI 10.1016/j.patbio.2007.07.013
   Gillespie T., CORONAVIRUS DOCTORS
   Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06
   Government of Canada, LEARN SARS REN PUBL
   Graham AL, 2019, CURR TROP MED REP, V6, P205, DOI 10.1007/s40475-019-00190-1
   Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002
   Hemida MG, 2017, TRANSBOUND EMERG DIS, V64, P344, DOI 10.1111/tbed.12401
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2017, CLIN CHEST MED, V38, P71, DOI 10.1016/j.ccm.2016.11.007
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hung LS, 2003, J ROY SOC MED, V96, P374, DOI 10.1258/jrsm.96.8.374
   Hunter JC, 2016, EMERG INFECT DIS, V22, P647, DOI 10.3201/eid2204.151615
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Jeong SY, 2017, J KOREAN MED SCI, V32, P1717, DOI 10.3346/jkms.2017.32.10.1717
   Lam CM, 2004, BJOG-INT J OBSTET GY, V111, P771, DOI 10.1111/j.1471-0528.2004.00199.x
   Li AM, 2005, ARCH DIS CHILD-FETAL, V90, pF461, DOI 10.1136/adc.2005.075309
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   MADINGER NE, 1989, AM J OBSTET GYNECOL, V161, P657, DOI 10.1016/0002-9378(89)90373-6
   Malik A, 2016, EMERG INFECT DIS, V22, P515, DOI 10.3201/eid2203.151049
   Maxwell C, 2017, J OBSTET GYNAECOL CA, V39, pE130, DOI 10.1016/j.jogc.2017.04.024
   Maxwell C, 2009, J OBSTET GYNAECOL CA, V31, P358, DOI 10.1016/S1701-2163(16)34155-X
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Ng PC, 2004, BIOL NEONATE, V85, P293, DOI 10.1159/000078174
   Ng PC, 2003, ARCH DIS CHILD-FETAL, V88, pF405, DOI 10.1136/fn.88.5.F405
   Ng WF, 2006, PATHOLOGY, V38, P210, DOI 10.1080/00313020600696280
   NYHAN D, 1983, IRISH MED J, V76, P320
   Oboho IK, 2015, NEW ENGL J MED, V372, P846, DOI 10.1056/NEJMoa1408636
   Oh MD, 2018, KOREAN J INTERN MED, V33, P233, DOI 10.3904/kjim.2018.031
   Payne DC, 2014, J INFECT DIS, V209, P1870, DOI 10.1093/infdis/jiu068
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Peterson M.J., REPORTING INCIDENCE
   Pong W., 2020, BIOCENTURY
   Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634
   Rigby FB, 1996, CLIN OBSTET GYNECOL, V39, P107, DOI 10.1097/00003081-199603000-00011
   Robertson CA, 2004, EMERG INFECT DIS, V10, P345, DOI 10.3201/eid1002.030736
   Sargent I.L., 1992, MED FETUS MOTHER, P317
   Schneider Elizabeth, 2004, AWHONN Lifelines, V8, P122, DOI 10.1177/1091592304265557
   Schwartz DA, 2019, CURR TROP MED REP, V6, P213, DOI 10.1007/s40475-019-00195-w
   Schwartz DA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010038
   Schwartz DA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040081
   Science Media Centre, EXP REACT NEWB BAB T
   Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6
   Shek CC, 2003, PEDIATRICS, V112, pE254, DOI 10.1542/peds.112.4.e254
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Steinbuch Y., CHINESE BABY TESTS P
   Stockman LJ, 2004, EMERG INFECT DIS, V10, P1689, DOI 10.3201/eid1009.040244
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   VISSCHER HC, 1971, AM J OBSTET GYNECOL, V109, P1187, DOI 10.1016/0002-9378(71)90664-8
   Wee S.-L., WHO DECLARES GLOBAL
   WEINBERGER SE, 1980, AM REV RESPIR DIS, V121, P559, DOI 10.1164/arrd.1980.121.3.559
   WHO, MIDDL E RESP SYNDR M
   WHO, 2017, WHO TARG PROD PROF M
   Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019
   Wong SF, 2003, BJOG-INT J OBSTET GY, V110, P641, DOI 10.1046/j.1471-0528.2003.03008.x
   Woodward A., PREGNANT MOTHER INFE
   World Health Organization, CONS DOC EP SEV AC R
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yadav S, 2016, J COMMUNITY HLTH MAN, V3, P41, DOI DOI 10.5958/2394-2770.2016.00014.4
   Yudin MH, 2005, OBSTET GYNECOL, V105, P124, DOI 10.1097/01.AOG.0000151598.49129.de
   Zhang Jian-ping, 2003, Zhonghua Fu Chan Ke Za Zhi, V38, P516
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 78
TC 196
Z9 211
U1 16
U2 48
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD FEB
PY 2020
VL 12
IS 2
AR 194
DI 10.3390/v12020194
PG 16
WC Virology
SC Virology
GA KW6DX
UT WOS:000521256600075
PM 32050635
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lu, HZ
AF Lu, Hongzhou
TI Drug treatment options for the 2019-new coronavirus (2019-nCoV)
SO BIOSCIENCE TRENDS
LA English
DT Article
DE 2019-nCoV; Coronaviruses; pneumonia
ID RESPIRATORY SYNDROME CORONAVIRUS
AB As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), arbidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019-nCoV still need to be further confirmed by clinical experiments.
C1 [Lu, Hongzhou] Fudan Univ, Sci Res Ctr, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.
   [Lu, Hongzhou] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai, Peoples R China.
   [Lu, Hongzhou] Fudan Univ, Dept Infect Dis, Huashan Hosp, Shanghai, Peoples R China.
RP Lu, HZ (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
EM luhongzhou@fudan.edu.cn
RI Ribeiro, Nuno/AAH-2299-2020
FU 13th Five-Year National Science and Technology Major Project from
   Ministry of Science and Technology of the People's Republic of China
   [2017ZX09304027]
FX This research was funded by the 13th Five-Year National Science and
   Technology Major Project from Ministry of Science and Technology of the
   People's Republic of China (Grant No.: 2017ZX09304027).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Bleibtreu A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3223-5
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chow EJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2491-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Imai N, ESTIMATING POTENTIAL
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   National Health Commission of the People's Republic of China, NOT PRINT DISTR DIAG
   National Health Commission of the People's Republic of China, PNEUM EP IT NEW COR
   Pang Y, 2019, J VIS COMMUN IMAGE R, V65, DOI 10.1016/j.jvcir.2019.102676
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 18
TC 291
Z9 307
U1 36
U2 179
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD FEB
PY 2020
VL 14
IS 1
BP 69
EP 71
DI 10.5582/bst.2020.01020
PG 3
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA KU2OR
UT WOS:000519548300011
PM 31996494
OA Bronze
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Gao, JJ
   Tian, ZX
   Yang, X
AF Gao, Jianjun
   Tian, Zhenxue
   Yang, Xu
TI Breakthrough: Chloroquine phosphate has shown apparent efficacy in
   treatment of COVID-19 associated pneumonia in clinical studies
SO BIOSCIENCE TRENDS
LA English
DT Letter
DE COVID-19; SARS-CoV-2; 2019-nCoV; pneumonia; chloroquine
ID DRUG
AB The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.
C1 [Gao, Jianjun] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Shandong, Peoples R China.
   [Tian, Zhenxue; Yang, Xu] Qingdao Municipal Hosp, Dept Pharm, Qingdao, Peoples R China.
RP Gao, JJ (corresponding author), Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Shandong, Peoples R China.
EM gaojj@qdu.edu.cn
RI Ribeiro, Nuno/AAH-2299-2020
CR Lu H., 2020, BIOSCI TRENDS
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Wang M, 2020, CELL RES, DOI DOI 10.1038/s41422-020-0282-0
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
NR 4
TC 799
Z9 818
U1 31
U2 213
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD FEB
PY 2020
VL 14
IS 1
BP 72
EP 73
DI 10.5582/bst.2020.01047
PG 2
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA KU2OR
UT WOS:000519548300012
PM 32074550
OA Bronze
DA 2021-01-01
ER

PT J
AU Xiao, CF
AF Xiao, Chunfeng
TI A Novel Approach of Consultation on 2019 Novel Coronavirus
   (COVID-19)-Related Psychological and Mental Problems: Structured Letter
   Therapy
SO PSYCHIATRY INVESTIGATION
LA English
DT Letter
C1 [Xiao, Chunfeng] Capital Med Univ, Beijing Anding Hosp, Natl Clin Res Ctr Mental Disorder, 5 Ankang Hutong, Beijing 100032, Peoples R China.
   [Xiao, Chunfeng] Capital Med Univ, Beijing Anding Hosp, Beijing Key Lab Mental Disorders, 5 Ankang Hutong, Beijing 100032, Peoples R China.
   [Xiao, Chunfeng] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Beijing, Peoples R China.
RP Xiao, CF (corresponding author), Capital Med Univ, Beijing Anding Hosp, Natl Clin Res Ctr Mental Disorder, 5 Ankang Hutong, Beijing 100032, Peoples R China.; Xiao, CF (corresponding author), Capital Med Univ, Beijing Anding Hosp, Beijing Key Lab Mental Disorders, 5 Ankang Hutong, Beijing 100032, Peoples R China.
EM springwindxiao@163.com
RI Ribeiro, Nuno/AAH-2299-2020
NR 0
TC 51
Z9 53
U1 8
U2 40
PU KOREAN NEUROPSYCHIATRIC ASSOC
PI SEOUL
PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL,
   137-882, SOUTH KOREA
SN 1738-3684
EI 1976-3026
J9 PSYCHIAT INVEST
JI Psychiatry Investig.
PD FEB
PY 2020
VL 17
IS 2
BP 175
EP 176
DI 10.30773/pi.2020.0047
PG 2
WC Psychiatry
SC Psychiatry
GA KQ3DF
UT WOS:000516806500012
PM 32093461
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Alburikan, KA
   Abuelizz, HA
AF Alburikan, Khalid A.
   Abuelizz, Hatem A.
TI Identifying factors and target preventive therapies for Middle East
   Respiratory Syndrome sucsibtable patients
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE Middle East Respiratory Syndrome; MERS-CoV; Diabetes
ID SYNDROME CORONAVIRUS
AB Background: Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.
   Method: We included subjects with suspected MERS-CoV infection and confirmed cases of MERS infection. Subjects were excluded if there were any missing data that prevent the final analysis. Descriptive statistics were used to report demographic data. Percentages and frequencies were used to summarize the categorical variables, while means and standard deviations were calculated for continuous variables. Logistic regression was used to assess the risk of MERS-CoV infection among the suspected cases. A value of p < 0.05 was considered statistically significant.
   Results: A total of 16,189 suspected cases were identified, complete data were analyzed for 3154 to assess factors that are independently associated with MERS-CoV infection. MERS-CoV infection was associated with age (adjusted odds ratio [AOR] = 1.06; 95% CI [1.02-1.098], P-value = 0.004), male gender (AOR = 1.617; 95% CI [1.365-1.77], P-value < 0.001) and diabetes (AOR = 1.68; 95% CI [1.346-1.848], P-value = 0.002. There was no significant association with the other comorbidities. Medication history was not associated with an increase or decrease the likelihood of the infection.
   Conclusions: MERS-Cov infection is more common in male, advanced age and diabetes. No medications were associated with an increase or decrease the likelihood of the infection. This is important to focus on screening and detection to this patient population. (C) 2019 Published by Elsevier B.V. on behalf of King Saud University.
C1 [Alburikan, Khalid A.] King Saud Univ, Coll Pharm, Dept Clincal Pharm, POB 2457, Riyadh 11451, Saudi Arabia.
   [Abuelizz, Hatem A.] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, POB 2457, Riyadh 11451, Saudi Arabia.
RP Abuelizz, HA (corresponding author), King Saud Univ, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia.
EM habuelizz@ksu.edu.sa
FU King Abdulaziz City for Science and Technology (KACST), Target Research
   Program, Middle East Respiratory Syndrome-Corona Virus (MERS-CoV RGP)
   [17-01]
FX This work was supported by King Abdulaziz City for Science and
   Technology (KACST), Target Research Program, Middle East Respiratory
   Syndrome-Corona Virus (MERS-CoV RGP) grant no. 17-01.
CR Aleanizy FS, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2137-3
   [Anonymous], 2019, MIDDLE E RESP SYNDRO
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chen X, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.40
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rivers CM, 2016, AM J EPIDEMIOL, V184, P460, DOI 10.1093/aje/kww013
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 11
TC 3
Z9 3
U1 1
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-0164
EI 2213-7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD FEB
PY 2020
VL 28
IS 2
BP 161
EP 164
DI 10.1016/j.jsps.2019.11.016
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA KH4RD
UT WOS:000510635800002
PM 32042254
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Umar, Y
AF Umar, Yunusa
TI Theoretical studies of the rotational and tautomeric states, electronic
   and spectroscopic properties of favipiravir and its structural
   analogues: a potential drug for the treatment of COVID-19
SO JOURNAL OF TAIBAH UNIVERSITY FOR SCIENCE
LA English
DT Article
DE Favipiravir; potential energy scan; antiviral drugs; tautomerism;
   structural parameters; T705
ID IN-VIVO ACTIVITIES; T-705 FAVIPIRAVIR; CONFORMATIONAL STABILITIES;
   VIBRATIONAL ANALYSIS; VIRUS-INFECTION; DFT; VITRO; BARRIERS; EFFICACY;
   SPECTRA
AB Favipiravir is a broad spectrum antiviral drug that has shown activity against many viruses. Sequel to the recent outbreak of COVID-19, favipiravir is investigated as one of the potential drugs for the treatment of SARS-CoV-2. To augment these efforts, this article reports the rotational isomers, tautomeric states, electronic and spectral properties of favipiravir and its five analogues (Cl, Br, H, CN and CH3) using quantum chemcial code. The enol forms are more stable and the calculated keto-enol relative energies are in the range of 7.86-10.72 kcal/mol in the gas phase and 1.07-3.46 kcal/mol in the solution phase. The relative stabilization of the more polar keto structure in water environment leads to a significant reduction in keto-enol relative energy by 68% for T705, 71% for T705-Cl and T705-Br, 86% for T1105 (H), 88% for T705-CN and 80% for T705-CH3. The density functional theory and time-dependent density functional theory with the 6-311++G(d,p) basis set were used in the computation. The theoretical results were successfully compared with available experimental and theoretical data.
C1 [Umar, Yunusa] Jubail Ind Coll, Dept Chem & Proc Engn Technol, POB 10099, Jubail Ind City 31961, Saudi Arabia.
RP Umar, Y (corresponding author), Jubail Ind Coll, Dept Chem & Proc Engn Technol, POB 10099, Jubail Ind City 31961, Saudi Arabia.
EM umary@jic.edu.sa
CR Abdalla S, 2016, Z PHYS CHEM, V230, P867, DOI 10.1515/zpch-2015-0700
   Abdallah HH, 2016, J SOLUTION CHEM, V45, P1195, DOI 10.1007/s10953-016-0499-1
   Agrawal Umang, 2020, Med J Armed Forces India, V76, P370, DOI 10.1016/j.mjafi.2020.08.004
   Ali I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138861
   Antonov L., 2020, FAVIPIRAVIR TAUTOMER, DOI [10.26434/chemrxiv.12115620.v1, DOI 10.26434/CHEMRXIV.12115620.V1]
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   Chis V, 2005, CHEM PHYS, V316, P153, DOI 10.1016/j.chemphys.2005.05.004
   Crotty S, 2000, NAT MED, V6, P1375
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Furuta Y, 2000, Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both, Patent No. [CA2339272A1, 2339272]
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gowen BB, 2007, ANTIMICROB AGENTS CH, V51, P3168, DOI 10.1128/AAC.00356-07
   Gowen BB, 2010, ANTIVIR RES, V86, P121, DOI 10.1016/j.antiviral.2009.10.015
   Huchting J, 2019, ANTIVIR RES, V167, P1, DOI 10.1016/j.antiviral.2019.04.002
   Huchting J, 2018, J MED CHEM, V61, P6193, DOI 10.1021/acs.jmedchem.8b00617
   Ivanova D, 2015, RSC ADV, V5, P31852, DOI 10.1039/c5ra03653d
   Jamroz MH, 2004, VIBRATIONAL ENERGY D
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Khambholja K, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101710
   Kiso M, 2010, P NATL ACAD SCI USA, V107, P882, DOI 10.1073/pnas.0909603107
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu FL, 2017, CHEM PAP, V71, P2153, DOI 10.1007/s11696-017-0208-6
   Lukose J, 2015, SPECTROCHIM ACTA A, V135, P608, DOI 10.1016/j.saa.2014.07.004
   Lv SZ, 2015, OPT MATER, V42, P220, DOI 10.1016/j.optmat.2015.01.012
   Manolova Y, 2014, SPECTROCHIM ACTA A, V132, P815, DOI 10.1016/j.saa.2014.05.096
   Martin Yvonne Connolly, 2018, Drug Discov Today Technol, V27, P59, DOI 10.1016/j.ddtec.2018.06.006
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Morrey JD, 2008, ANTIVIR RES, V80, P377, DOI 10.1016/j.antiviral.2008.07.009
   Naesens L, 2013, MOL PHARMACOL, V84, P615, DOI 10.1124/mol.113.087247
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Rhyman L, 2018, PHYS SCI REV, V3, DOI 10.1515/psr-2017-0198
   Rocha-Pereira J, 2012, BIOCHEM BIOPH RES CO, V424, P777, DOI 10.1016/j.bbrc.2012.07.034
   Sebastian SHR, 2016, J MOL STRUCT, V1119, P188, DOI 10.1016/j.molstruc.2016.04.088
   Shi FY, 2014, DRUG DISCOV THER, V8, P117, DOI 10.5582/ddt.2014.01028
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Umar Y, 2019, J STRUCT CHEM+, V60, P186, DOI 10.1134/S0022476619020033
   Umar Y, 2016, J STRUCT CHEM+, V57, P1545, DOI 10.1134/S0022476616080084
   Umar Y, 2007, SPECTROCHIM ACTA A, V66, P1133, DOI 10.1016/j.saa.2006.05.026
   Umar Y, 2020, J CHIN CHEM SOC-TAIP, V67, P62, DOI 10.1002/jccs.201900051
   Umar Y, 2019, J THEOR COMPUT CHEM, V18, DOI 10.1142/S0219633619500093
   Umar Y, 2017, J SOLUTION CHEM, V46, P741, DOI 10.1007/s10953-017-0601-3
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhang T, 2017, BIOORG MED CHEM LETT, V27, P2364, DOI 10.1016/j.bmcl.2017.04.028
   [张涛 Zhang Tao], 2013, [中国医药工业杂志, Chinese Journal of Pharmaceuticals], V44, P841
   Zhang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104854
NR 51
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1658-3655
J9 J TAIBAH UNIV SCI
JI J. Taibah Univ. Sci.
PD JAN 1
PY 2020
VL 14
IS 1
BP 1613
EP 1625
DI 10.1080/16583655.2020.1848982
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA PB6DR
UT WOS:000596409800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wilson, SL
   Wiysonge, C
AF Wilson, Steven Lloyd
   Wiysonge, Charles
TI Social media and vaccine hesitancy
SO BMJ GLOBAL HEALTH
LA English
DT Article
DE vaccines
ID DETERMINANTS
AB Background Understanding the threat posed by anti-vaccination efforts on social media is critically important with the forth coming need for world wide COVID-19 vaccination programs. We globally evaluate the effect of social media and online foreign disinformation campaigns on vaccination rates and attitudes towards vaccine safety. Methods Weuse a large-n cross-country regression framework to evaluate the effect ofsocial media on vaccine hesitancy globally. To do so, we operationalize social media usage in two dimensions: the use of it by the public to organize action(using Digital Society Project indicators), and the level of negative lyoriented discourse about vaccines on social media (using a data set of all geocoded tweets in the world from 2018-2019). In addition, we measure the level of foreign-sourced coordinated disinformation operations on social media ineach country (using Digital Society Project indicators). The outcome of vaccine hesitancy is measured in two ways. First, we use polls of what proportion ofthe public per country feels vaccines are unsafe (using Wellcome Global Monitor indicators for 137 countries). Second, we use annual data of actual vaccination rates from the WHO for 166 countries. Results We found the use of social media to organise offline action to be highly predictive of the belief that vaccinations are unsafe, with such beliefs mounting as more organisation occurs on social media. In addition, the prevalence of foreign disinformation is highly statistically and substantively significant in predicting a drop in mean vaccination coverage over time. A 1-point shift upwards in the 5-point disinformation scale is associated with a 2-percentage point drop in mean vaccination coverage year over year. We also found support for the connection of foreign disinformation with negative social media activity about vaccination. The substantive effect of foreign disinformation is to increase the number of negative vaccine tweets by 15% for the median country. Conclusion There is a significant relationship between organisation on social media and public doubts of vaccine safety. In addition, there is a substantial relationship between foreign disinformation campaigns and declining vaccination coverage.
C1 [Wilson, Steven Lloyd] Brandeis Univ, Polit, Waltham, MA 02453 USA.
   [Wiysonge, Charles] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.
RP Wilson, SL (corresponding author), Brandeis Univ, Polit, Waltham, MA 02453 USA.
EM wilson.steven.lloyd@gmail.com
FU European Research CouncilEuropean Research Council (ERC) Funding Source:
   Medline
CR Ache KA, 2008, AM J PREV MED, V35, P389, DOI 10.1016/j.amepre.2008.06.029
   Al-Rfou R, 2020, POLYGLOT
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   Chen YQ, 2014, PROCEEDINGS OF THE 52ND ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS, VOL 2, P383
   Coppedge M, 2020, V DEM COUNTRY YEAR C
   Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22
   Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Evrony A, 2017, HUM VACC IMMUNOTHER, V13, P1475, DOI 10.1080/21645515.2017.1283467
   Fidler D, 2019, DISINFORMATION DIS S
   Hadenius A, 2007, J DEMOCR, V18, P143, DOI 10.1353/jod.2007.0009
   Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003
   Horowitz D. L., 1985, ETHNIC GROUPS CONFLI
   Keelan J, 2007, JAMA-J AM MED ASSOC, V298, P2482, DOI 10.1001/jama.298.21.2482
   Keelan J, 2010, VACCINE, V28, P1535, DOI 10.1016/j.vaccine.2009.11.060
   Kirk K, 2019, FOREIGN POLICY
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   MacKinnon A, 2020, FOREIGN POLICY
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   Mechkova V, 2020, DIGITAL SOC PROJECT
   Mesch GS, 2015, AM J INFECT CONTROL, V43, P1161, DOI 10.1016/j.ajic.2015.06.031
   Mitra T, 2016, 10 INT AAAI C WEB SO
   Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0
   Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3
   Pemstein D, 2020, V DEM WORKING PAPER
   Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406
   Tafuri S, 2014, VACCINE, V32, P4860, DOI 10.1016/j.vaccine.2013.11.006
   Teorell J, 2020, QUALITY GOVT STANDAR
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   UNESCO, HUM DEV DAT 1990 201
   WDI, 2020, WORLD DEV IND
   Wellcome, 2018, WELLC GLOB MON
   WHO, 2019, REP EST VACC COV
   Wilson SL, 2020, GEOCODED TWITTER ARC
   Wilson SL, 2020, SOCIAL MEDIA SOCIAL
NR 38
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2059-7908
J9 BMJ GLOB HEALTH
JI BMJ Glob. Health
PY 2020
VL 5
IS 10
AR e004206
DI 10.1136/bmjgh-2020-004206
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OP4PA
UT WOS:000588062800001
PM 33097547
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sasaki, R
   Hishikawa, N
   Nomura, E
   Omote, Y
   Takemoto, M
   Yamashita, T
   Hatanaka, N
   Higashi, Y
   Abe, K
AF Sasaki, Ryo
   Hishikawa, Nozomi
   Nomura, Emi
   Omote, Yoshio
   Takemoto, Mami
   Yamashita, Toru
   Hatanaka, Noriko
   Higashi, Yasuto
   Abe, Koji
TI Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical
   Course
SO INTERNAL MEDICINE
LA English
DT Article
DE tocilizumab; TCZ; leukoencephalopathy; cognitive dysfunction; COVID-19
AB Tocilizumab (TCZ; Actemra/RoActemra) is an anti-interleukin (IL)-6 receptor antibody for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases and cytokine storms. The present case is a 63-yearold female well-controlled RA patient, who presented with a progressive cognitive impairment after 34 months of TCZ administration. Brain magnetic resonance imaging (MRI) showed leukencephalopathy with a lactic acid peak in magnetic resonance spectroscopy (MRS), a decreased blood flow in single photon emission computed tomography (SPECT), and a decreased accumulation in fluorodeoxyglucose positron emission tomography (FDG-PET). The discontinuation of TCZ improved her cognitive function and brain MRI findings at 3 months after drug cessation. The present case suggests that TCZ may sometimes cause leukoencephalopathy after long-term administration, and thus the early discontinuation of TCZ is recommended to achieve a good prognosis.
C1 [Sasaki, Ryo; Hishikawa, Nozomi; Nomura, Emi; Omote, Yoshio; Takemoto, Mami; Yamashita, Toru; Abe, Koji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol, Okayama, Japan.
   [Hatanaka, Noriko; Higashi, Yasuto] Himeji Cent Hosp, Dept Neurol, Himeji, Hyogo, Japan.
RP Abe, K (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol, Okayama, Japan.
EM pwag680v@okayama-u.ac.jp
FU Japan Agency for Medical Research and DevelopmentJapan Agency for
   Medical Research and Development (AMED) [7211800049, 7211800130,
   7211700121];  [17H0419611];  [15K0931607];  [17H0975609];  [17K1082709]
FX This work was partly supported by a Grant-in-Aid for Scientific Research
   (B) 17H0419611, (C) 15K0931607, 17H0975609, and 17K1082709, and by
   Grants-in-Aid from the Research Committees (Kaji R, Toba K, and Tsuji S)
   from the Japan Agency for Medical Research and Development 7211800049,
   7211800130, and 7211700121.
CR Araki M, 2014, NEUROLOGY, V82, P1302, DOI 10.1212/WNL.0000000000000317
   Biggioggero M, 2019, DRUG DES DEV THER, V13, P57, DOI 10.2147/DDDT.S150580
   Kobayashi K, 2009, INTERNAL MED, V48, P1307, DOI 10.2169/internalmedicine.48.1926
   Kochi S, 1999, EUR J PHARMACOL, V372, P287, DOI 10.1016/S0014-2999(99)00247-2
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Narazaki M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113528
   Nishimoto N, 2000, BLOOD, V95, P56, DOI 10.1182/blood.V95.1.56
   Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1533514, 10.1080/14397595.2018.1546357]
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Yamaguchi Y, 2014, INTERNAL MED, V53, P879, DOI 10.2169/internalmedicine.53.0615
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 11
TC 1
Z9 1
U1 0
U2 0
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2020
VL 59
IS 22
BP 2927
EP 2930
DI 10.2169/internalmedicine.5288-20
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OW3OM
UT WOS:000592800500019
PM 32999229
OA Bronze
DA 2021-01-01
ER

PT J
AU Kurita, T
   Ishida, K
   Muranaka, E
   Sasazawa, H
   Mito, H
   Yano, Y
   Hase, R
AF Kurita, Takashi
   Ishida, Keiko
   Muranaka, Emiri
   Sasazawa, Hiroki
   Mito, Haruki
   Yano, Yudai
   Hase, Ryota
TI A Favipiravir-induced Fever in a Patient with COVID-19
SO INTERNAL MEDICINE
LA English
DT Article
DE drug fever; favipiravir; coronavirus disease 2019
AB We herein report the first case of a fever induced by favipiravir, a potential coronavirus disease 2019 therapeutic drug. An 82-year-old man diagnosed with bilateral pneumonia was transferred to our hospital following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test. He was treated with compassionate use of favipiravir. Both his oxygen demand and fever gradually improved after admission; however, his fever relapsed, and the C-reactive protein (CRP) levels increased on day 7. We diagnosed his fever as being favipiravir-induced. The fever resolved a few days after favipiravir discontinuation, demonstrating the accuracy of the diagnosis. This case revealed that favipiravir can induce a fever.
C1 [Kurita, Takashi; Ishida, Keiko; Muranaka, Emiri; Sasazawa, Hiroki; Mito, Haruki; Yano, Yudai; Hase, Ryota] Japanese Red Cross Narita Hosp, Dept Infect Dis, Narita, Chiba, Japan.
   [Ishida, Keiko; Muranaka, Emiri; Sasazawa, Hiroki; Hase, Ryota] Kameda Med Ctr, Dept Infect Dis, Kamogawa, Chiba, Japan.
RP Kurita, T (corresponding author), Japanese Red Cross Narita Hosp, Dept Infect Dis, Narita, Chiba, Japan.
EM takashi_kurita@med.hokudai.ac.jp
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Cunha BA, 1997, INFECT DIS PRACT, V21, P38
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Grayson ML, 2017, KUCERS USE ANTIBIOTI, P483
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   LIPSKY BA, 1981, JAMA-J AM MED ASSOC, V245, P851, DOI 10.1001/jama.245.8.851
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   MACKOWIAK PA, 1987, ANN INTERN MED, V106, P728, DOI 10.7326/0003-4819-106-5-728
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Patel RA, 2010, PHARMACOTHERAPY, V30, P57, DOI 10.1592/phco.30.1.57
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 14
TC 0
Z9 0
U1 0
U2 0
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2020
VL 59
IS 22
BP 2951
EP 2953
DI 10.2169/internalmedicine.5394-20
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OW3OM
UT WOS:000592800500024
PM 33191372
OA Bronze
DA 2021-01-01
ER

PT J
AU Ardashev, AV
   Ozeroff, O
   Sansalone, R
   Zhelyakov, EG
   Kappato, R
   Snezhitskiy, VA
   Kanorskiy, SG
   Abzaliyeva, SA
   Belenkov, YN
   Karpenko, YI
   Puodzhyukinas, A
   Sayganov, SA
   Santini, L
   Speransa, R
   Yakovleva, MV
   Kolotsey, LV
AF Ardashev, A. V.
   Ozeroff, O.
   Sansalone, R.
   Zhelyakov, E. G.
   Kappato, R.
   Snezhitskiy, V. A.
   Kanorskiy, S. G.
   Abzaliyeva, S. A.
   Belenkov, YU. N.
   Karpenko, YU. I.
   Puodzhyukinas, A.
   Sayganov, S. A.
   Santini, L.
   Speransa, R.
   Yakovleva, M. V.
   Kolotsey, L. V.
TI Recommendations for the Management of COVID 19 Patients Regarding
   Proarrhythmic Effects of Some Current Treatments, Specifically if These
   Patients Suffer From Arrhythmias, and for Those Receiving Antiarrhythmic
   Therapy. Eurasian Arrhythmology Association (EURA), Argentinean Society
   of Arrhythmias (SADEC), European Cardiac Arrhythmia Society (ECAS)
SO KARDIOLOGIYA
LA Russian
DT Article
ID QT INTERVAL PROLONGATION; TORSADES-DE-POINTES; U WAVES; MACROLIDE; RISK
C1 [Ardashev, A. V.; Zhelyakov, E. G.; Belenkov, YU. N.] FSBEI HE Lomonosov Moscow State Univ, Moscow, Russia.
   [Ozeroff, O.; Sansalone, R.; Speransa, R.] Argentine Soc Arrhythmias SADEC, Buenos Aires, DF, Argentina.
   [Kappato, R.] European Arrhythmol Soc ECAS, Marseille, France.
   [Kappato, R.] Humanitas Res Hosp, Milan, Italy.
   [Snezhitskiy, V. A.; Kolotsey, L. V.] EE Grodno State Med Univ, Grodno, BELARUS.
   [Kanorskiy, S. G.] FSBEI HE Kuban State Med Univ, Minist Hlth Russia, Krasnodar, Russia.
   [Abzaliyeva, S. A.] Kazakh Natl Univ named Farabi, Alma Ata, Kazakhstan.
   [Karpenko, YU. I.] Odessa Natl Med Univ, Odessa, Ukraine.
   [Puodzhyukinas, A.] Lithuanian Med Univ Hlth Sci, Klunas Med Acad, Cardiol Clin, Kaunas, Lithuania.
   [Sayganov, S. A.] North Western State Med Univ, Minist Hlth Russia, Fed State Budgetary Educ Inst Higher Educ, St Petersburg, Russia.
   [Santini, L.] Gosiaital Giovanni Batista Grassi, Rome, Italy.
   [Yakovleva, M. V.] Clin Medelent, Moscow, Russia.
   [Ardashev, A. V.; Zhelyakov, E. G.; Snezhitskiy, V. A.; Abzaliyeva, S. A.; Karpenko, YU. I.; Puodzhyukinas, A.; Sayganov, S. A.; Yakovleva, M. V.] Eurasian Arrhythmol Assoc EURA, Moscow, Russia.
RP Ardashev, AV (corresponding author), FSBEI HE Lomonosov Moscow State Univ, Moscow, Russia.
EM ardashev@yahoo.com
CR Albert RK, 2014, AM J RESP CRIT CARE, V189, P1173, DOI 10.1164/rccm.201402-0385CI
   Baciewicz AM, 2013, CURR MED RES OPIN, V29, P1, DOI 10.1185/03007995.2012.747952
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Charbit B, 2008, ANESTHESIOLOGY, V109, P206, DOI 10.1097/ALN.0b013e31817fd8c8
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cornett E, 2017, POSTGRAD MED, V129, P715, DOI 10.1080/00325481.2017.1362938
   Gautret P, 2020, J ANTIMICROB AGENTS, DOI [10.1016/j.ijantimicag.2020.105949, DOI 10.1016/J.IJANTIMICAG.2020.105949]
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hreiche R, 2011, J PHARM SCI-US, V100, P2469, DOI 10.1002/jps.22437
   Kalatsei L.V., 2019, J GRODNO STATE MED U, V17, P99, DOI [10.25298/2221-8785-2019-17-1-99-105, DOI 10.25298/2221-8785-2019-17-1-99-105]
   Kalatsei L.V., 2018, J GRODNO STATE MED U, V16, P533, DOI [10.25298/2221- 8785-2018-16-5-533-541, DOI 10.25298/2221-8785-2018-16-5-533-541]
   Kirchhof P, 2009, J AM COLL CARDIOL, V54, P143, DOI 10.1016/j.jacc.2009.03.043
   Kounas SP, 2005, PACE, V28, P472, DOI 10.1111/j.1540-8159.2005.09348.x
   Labbe L, 2004, THER DRUG MONIT, V26, P492, DOI 10.1097/00007691-200410000-00006
   Lala Anuradha, 2020, medRxiv, DOI 10.1101/2020.04.20.20072702
   Liang T., 2020, HDB COVID 19 PREVENT
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Meid AD, 2017, THER ADV PSYCHOPHARM, V7, P251, DOI 10.1177/2045125317721662
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Rautaharju PM, 2009, J AM COLL CARDIOL, V53, P982, DOI 10.1016/j.jacc.2008.12.014
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   WIENER I, 1981, MT SINAI J MED, V48, P53
   Wright AJ, 2011, CAN MED ASSOC J, V183, P303, DOI 10.1503/cmaj.100702
NR 25
TC 0
Z9 0
U1 0
U2 0
PU RUSSIAN HEART FAILURE SOC
PI MOSCOW
PA 215, 5, BEREGOVOY PROEZD, MOSCOW, 121087, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2020
VL 60
IS 10
BP 4
EP 12
DI 10.18087/cardio.2020.10.n1283
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OW4ZI
UT WOS:000592896300001
PM 33228499
DA 2021-01-01
ER

PT J
AU Gupta, SP
AF Gupta, Satya P.
TI Progress in Studies on Structural and Remedial Aspects of Newly Born
   Coronavirus, SARS-CoV-2
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE 2019-CoV-2; COVID-19; Anti-COVID-19 drugs; Vaccines; Convalescent plasma
   (CP) therapy; Epitopes; Antibodies
ID RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; CONVALESCENT PLASMA;
   SARS-COV; VIRUS; MECHANISMS; RECEPTOR; ENTRY; MERS; ACE2
AB The article highlights an up-to-date progress in studies on structural and the remedial aspects of novel coronavirus 2019-nCoV, renamed as SARS-CoV-2, leading to the disease COVID-19, a pandemic. In general, all CoVs including SARS-CoV-2 are spherical positive single-stranded RNA viruses containing spike (S) protein, envelope (E) protein, nucleocapsid (N) protein, and membrane (M) protein, where S protein has a Receptor-binding Domain (RBD) that mediates the binding to host cell receptor, Angiotensin Converting Enzyme 2 (ACE2). The article details the repurposing of some drugs to be tried for COVID-19 and presents the status of vaccine development so far. Besides drugs and vaccines, the role of Convalescent Plasma (CP) therapy to treat COVID-19 is also discussed.
C1 [Gupta, Satya P.] Meerut Inst Engn & Technol, Dept Pharmaceut Technol, Meerut 250005, Uttar Pradesh, India.
RP Gupta, SP (corresponding author), Meerut Inst Engn & Technol, Dept Pharmaceut Technol, Meerut 250005, Uttar Pradesh, India.
EM spgbits@gamail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Alsaadi EAJ, 2019, FUTURE VIROL, V14, P275, DOI 10.2217/fvl-2018-0144
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Babadaei MMN, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767210
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Batra R, 2020, J PHYS CHEM LETT, V11, P7058, DOI 10.1021/acs.jpclett.0c02278
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Canga AG, 2008, AAPS J, V10, P42, DOI 10.1208/s12248-007-9000-9
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   ClinicalTrials.gov, 2020, AD COVID 19 TREATM T
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Darrell R., 2020, MED COUNTERMEASURES, V2020
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Fahmi M, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104272
   Fast E., 2020, BIORXIV, DOI [10.1101/2020.02.19.955484, DOI 10.1101/2020.02.19.955484DOI]
   FDA, 2020, LETT AUTH EUA VEKL R
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gates B., 2020, 1 MODERN PANDEMIC SC
   Gilead, 2020, GILEAD SCI
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hendaus M.A., 2020, J BIOMOL STRUCT DYN
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Lai AL, 2017, J MOL BIOL, V429, P3875, DOI 10.1016/j.jmb.2017.10.017
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li NN, 2008, P NATL ACAD SCI USA, V105, P4796, DOI 10.1073/pnas.0712051105
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu GQ, 2020, DRUG DES DEV THER, V14, P3429, DOI 10.2147/DDDT.S271754
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lv N., 2020, BIORXIV, P2020
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Mehra M, 2020, LANCET
   Mori M, 2020, EXPERT OPIN THER PAT, V30, P481, DOI 10.1080/13543776.2020.1760838
   Negro F, 2020, SWISS MED WEEKLY, V150
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Oudshoorn D, 2017, MBIO, V8, DOI 10.1128/mBio.01658-17
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Peel M., 2020, COST VACCINATING BIL
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rogers T.F., 2020, BIORXIV
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Schmith V.D., 2020, CLIN PHARM THERAP
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sharun K, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00368-w
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thames AH, 2020, ACS CENTRAL SCI, V6, P1341, DOI 10.1021/acscentsci.0c00644
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Van Beusekom M., 2020, AUTOPSIES COVID 19 P
   van der Hoeven B, 2016, VIRUS RES, V220, P70, DOI 10.1016/j.virusres.2016.04.001
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu X, 2003, NUCLEIC ACIDS RES, V31, P7117, DOI 10.1093/nar/gkg916
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zost S.J., 2020, RAPID ISOLATION PROF
NR 109
TC 0
Z9 0
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2020
VL 20
IS 26
BP 2362
EP 2378
DI 10.2174/1568026620666200922112300
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OS5WR
UT WOS:000590234400002
PM 32962613
DA 2021-01-01
ER

PT J
AU Bassi, GL
   Suen, J
   Barnett, AG
   Corley, A
   Millar, J
   Fanning, J
   Lye, I
   Colombo, S
   Wildi, K
   Livingstone, S
   Abbate, G
   Hinton, S
   Liquet, B
   Shrapnel, S
   Dalton, H
   Fraser, JF
AF Bassi, Gianluigi Li
   Suen, Jacky
   Barnett, Adrian Gerard
   Corley, Amanda
   Millar, Jonathan
   Fanning, Jonathon
   Lye, India
   Colombo, Sebastiano
   Wildi, Karin
   Livingstone, Samantha
   Abbate, Gabriella
   Hinton, Samuel
   Liquet, Benoit
   Shrapnel, Sally
   Dalton, Heidi
   Fraser, John F.
CA COVID-19 Critical Care Consortium
TI Design and rationale of the COVID-19 Critical Care Consortium
   international, multicentre, observational study
SO BMJ OPEN
LA English
DT Article
DE intensive; critical care; respiratory infections; epidemiology; public
   health; epidemiology
AB Introduction There is a paucity of data that can be used to guide the management of critically ill patients with COVID-19. In response, a research and data-sharing collaborative-The COVID-19 Critical Care Consortium-has been assembled to harness the cumulative experience of intensive care units (ICUs) worldwide. The resulting observational study provides a platform to rapidly disseminate detailed data and insights crucial to improving outcomes. Methods and analysis This is an international, multicentre, observational study of patients with confirmed or suspected SARS-CoV-2 infection admitted to ICUs. This is an evolving, open-ended study that commenced on 1 January 2020 and currently includes >350 sites in over 48 countries. The study enrols patients at the time of ICU admission and follows them to the time of death, hospital discharge or 28 days post-ICU admission, whichever occurs last. Key data, collected via an electronic case report form devised in collaboration with the International Severe Acute Respiratory and Emerging Infection Consortium/Short Period Incidence Study of Severe Acute Respiratory Illness networks, include: patient demographic data and risk factors, clinical features, severity of illness and respiratory failure, need for non-invasive and/or mechanical ventilation and/or extracorporeal membrane oxygenation and associated complications, as well as data on adjunctive therapies. Ethics and dissemination Local principal investigators will ensure that the study adheres to all relevant national regulations, and that the necessary approvals are in place before a site may contribute data. In jurisdictions where a waiver of consent is deemed insufficient, prospective, representative or retrospective consent will be obtained, as appropriate. A web-based dashboard has been developed to provide relevant data and descriptive statistics to international collaborators in real-time. It is anticipated that, following study completion, all de-identified data will be made open access.
C1 [Bassi, Gianluigi Li; Suen, Jacky; Corley, Amanda; Fanning, Jonathon; Lye, India; Colombo, Sebastiano; Wildi, Karin; Livingstone, Samantha; Abbate, Gabriella; Fraser, John F.] Prince Charles Hosp, Crit Care Res Grp, Chermside, Qld, Australia.
   [Bassi, Gianluigi Li; Suen, Jacky; Corley, Amanda; Fanning, Jonathon; Lye, India; Colombo, Sebastiano; Wildi, Karin; Livingstone, Samantha; Hinton, Samuel; Fraser, John F.] Univ Queensland, Fac Med, Brisbane, Qld, Australia.
   [Bassi, Gianluigi Li; Fraser, John F.] Queensland Univ Technol, Brisbane, Qld, Australia.
   [Bassi, Gianluigi Li] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain.
   [Barnett, Adrian Gerard] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Millar, Jonathan] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Fanning, Jonathon; Fraser, John F.] UnitingCare Hlth, Crit Care Med, Brisbane, Qld, Australia.
   [Colombo, Sebastiano] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Liquet, Benoit; Shrapnel, Sally] Univ Queensland, Brisbane, Qld, Australia.
   [Liquet, Benoit] Univ Pau & Pays Adour, Pau, France.
   [Dalton, Heidi] Inova Fairfax Med Campus, Falls Church, VA USA.
RP Bassi, GL (corresponding author), Prince Charles Hosp, Crit Care Res Grp, Chermside, Qld, Australia.; Bassi, GL (corresponding author), Univ Queensland, Fac Med, Brisbane, Qld, Australia.; Bassi, GL (corresponding author), Queensland Univ Technol, Brisbane, Qld, Australia.; Bassi, GL (corresponding author), Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain.
EM g.libassi@uq.edu.au
OI Colombo, Sebastiano Maria/0000-0002-9612-5187; Barnett,
   Adrian/0000-0001-6339-0374
FU Common Good, an initiative of the Prince Charles Hospital Foundation;
   Wesley Medical Research, UnitingCare Health
FX This work is supported by the Common Good, an initiative of the Prince
   Charles Hospital Foundation; and, Wesley Medical Research, UnitingCare
   Health.
CR Barrasa H, 2020, ANAESTH CRIT CARE PA, V39, P553, DOI 10.1016/j.accpm.2020.04.001
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Collins GS, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0241-z
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wolkewitz M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5060
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 12
AR e041417
DI 10.1136/bmjopen-2020-041417
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC7MC
UT WOS:000597179800016
PM 33268426
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perera, M
   El Khoury, J
   Chinni, V
   Bolton, D
   Qu, L
   Johnson, P
   Trubiano, J
   McDonald, CF
   Jones, D
   Bellomo, R
   Patel, O
   Ischia, J
AF Perera, Marlon
   El Khoury, John
   Chinni, Vidyasagar
   Bolton, Damien
   Qu, Liang
   Johnson, Paul
   Trubiano, Jason
   McDonald, Christine F.
   Jones, Daryl
   Bellomo, Rinaldo
   Patel, Oneel
   Ischia, Joseph
TI Randomised controlled trial for high-dose intravenous zinc as adjunctive
   therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial
   protocol
SO BMJ OPEN
LA English
DT Article
DE respiratory infections; virology; infectious diseases; public health
ID TRACE-ELEMENT SUPPLEMENTATION; MAJOR BURNS; DOUBLE-BLIND;
   METALLOTHIONEIN; ANTIOXIDANT; ABSORPTION; INFECTION
AB Introduction SARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury-a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of oxygen saturations or requirement of oxygen supplementation. Methods and analysis We designed a double-blind randomised controlled trial of daily HDIVZn (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation (or greatest level of supplemental oxygenation) for non-ventilated patients and worst PaO2/FiO(2) for ventilated patients. Following power calculations, 60 hospitalised patients and 100 ventilated patients will be recruited to demonstrate a 20% difference. The duration of follow-up is up to the point of discharge. Ethics and dissemination Ethical approval was obtained through the independent Human Research Ethics Committee. Participant recruitment will commence in May 2020. Results will be published in peer-reviewed medical journals.
C1 [Perera, Marlon; El Khoury, John; Chinni, Vidyasagar; Bolton, Damien; Qu, Liang; Patel, Oneel; Ischia, Joseph] Austin Hlth, Dept Surg, Heidelberg, Vic, Australia.
   [Johnson, Paul; Trubiano, Jason] Austin Hlth, Infect Dis, Heidelberg, Vic, Australia.
   [McDonald, Christine F.] Austin Hlth, Resp & Sleep Med, Heidelberg, Vic, Australia.
   [Jones, Daryl; Bellomo, Rinaldo] Austin Hlth, Intens Care Unit, Austin Hosp, Heidelberg, Vic, Australia.
   [Jones, Daryl; Bellomo, Rinaldo] Austin Hlth, Dept Med, Heidelberg, Vic, Australia.
RP Perera, M (corresponding author), Austin Hlth, Dept Surg, Heidelberg, Vic, Australia.
EM marlonlperera@gmail.com
RI ; Perera, Marlon/I-8641-2014
OI Trubiano, Jason/0000-0002-5111-6367; Perera, Marlon/0000-0002-1138-6389
CR Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060
   BENNETT JW, 1973, J AGR SCI, V81, P429, DOI 10.1017/S0021859600086469
   Berger MM, 2007, AM J CLIN NUTR, V85, P1293
   Berger MM, 2007, AM J CLIN NUTR, V85, P1301
   Berger MM, 1998, AM J CLIN NUTR, V68, P365
   Bhatnagar S, 2012, LANCET, V379, P2072, DOI 10.1016/S0140-6736(12)60477-2
   BUTTERWORTH BE, 1974, J VIROL, V14, P282, DOI 10.1128/JVI.14.2.282-291.1974
   Castro L, 2001, NUTRITION, V17, P161, DOI 10.1016/S0899-9007(00)00570-0
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Cheung E, 2020, J CLIN EXP HEPATOL, V10, P228, DOI 10.1016/j.jceh.2019.07.006
   Cvijanovich NZ, 2016, JPEN-PARENTER ENTER, V40, P860, DOI 10.1177/0148607115572193
   Donahoe Michael, 2011, Pulm Circ, V1, P192, DOI 10.4103/2045-8932.83454
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Feillet-Coudray C, 2005, AM J CLIN NUTR, V82, P103
   Femiano F, 2005, J ORAL PATHOL MED, V34, P423, DOI 10.1111/j.1600-0714.2005.00327.x
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999
   Frat JP, 2019, LANCET RESP MED, V7, P303, DOI 10.1016/S2213-2600(19)30048-7
   He HY, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2575-6
   HEMPE JM, 1991, J NUTR, V121, P1389
   Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371
   Hulisz Darrell, 2004, J Am Pharm Assoc (2003), V44, P594, DOI 10.1331/1544-3191.44.5.594.Hulisz
   Institute of Medicine Panel on M, 2001, DIET REF INT VIT A V
   Ischia J, 2019, METALLOMICS, V11, P1330, DOI 10.1039/c9mt00079h
   KEYZER JJ, 1983, PHARM WEEKBLAD, V5, P252, DOI 10.1007/BF02332954
   Lachance PA, 2001, NUTRITION, V17, P835, DOI 10.1016/S0899-9007(01)00636-0
   Ledford H, 2020, NATURE, V580, P311, DOI 10.1038/d41586-020-01056-7
   Li Dan, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P449
   Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1
   Mubarak M, 2020, J NEPHROPATHOL, V9, pe21, DOI [10.34172/jnp.2020.21, DOI 10.34172/JNP.2020.21]
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703
   National Cancer Institute, 2017, COMM TERM CRIT ADV E
   O'Kane D, 2018, BIOMETALS, V31, P821, DOI 10.1007/s10534-018-0125-3
   Pennisi MA, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2361-5
   Prasad Ananda S, 2014, Front Nutr, V1, P14, DOI 10.3389/fnut.2014.00014
   Prasad AS, 2014, J TRACE ELEM MED BIO, V28, P364, DOI 10.1016/j.jtemb.2014.07.019
   Rao K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180028
   Ruttkay-Nedecky B, 2013, INT J MOL SCI, V14, P6044, DOI 10.3390/ijms14036044
   Science M, 2012, CAN MED ASSOC J, V184, pE551, DOI 10.1503/cmaj.111990
   Solomons NW, 2011, EUR J CLIN NUTR, V65, P125, DOI 10.1038/ejcn.2010.198
   Stehle P, 2016, EUR J CLIN NUTR, V70, P886, DOI 10.1038/ejcn.2016.53
   Suara RO, 2004, ANTIMICROB AGENTS CH, V48, P783, DOI 10.1128/AAC.48.3.783-790.2004
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Tu H, 2020, J INFECT
   Wang LL, 2018, CLIN RESPIR J, V12, P857, DOI 10.1111/crj.12646
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Weston S, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00203-20
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
   Zhu JY, 2020, J MED VIROL, V92, P891, DOI 10.1002/jmv.25910
NR 49
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 12
AR e040580
DI 10.1136/bmjopen-2020-040580
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC7MC
UT WOS:000597179800002
PM 33268419
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Wilton, A
   Kilich, E
   Chaudhry, Z
   Bell, LCK
   Gahir, J
   Cadman, J
   Lever, RA
   Logan, SA
AF de Wilton, Angus
   Kilich, Eliz
   Chaudhry, Zain
   Bell, Lucy C. K.
   Gahir, Joshua
   Cadman, Jane
   Lever, Robert A.
   Logan, Sarah A.
CA UCLH COVID-19 Response Team
TI Delayed healthcare seeking and prolonged illness in healthcare workers
   during the COVID-19 pandemic: a single-centre observational study
SO BMJ OPEN
LA English
DT Article
DE epidemiology; health policy; human resource management; public health;
   infectious diseases
AB Objectives To describe a cohort of self-isolating healthcare workers (HCWs) with presumed COVID-19. Design A cross-sectional, single-centre study. Setting A large, teaching hospital based in Central London with tertiary infection services. Participants 236 HCWs completed a survey distributed by internal staff email bulletin. 167 were women and 65 men. Measures Information on symptomatology, exposures and health-seeking behaviour were collected from participants by self-report. Results The 236 respondents reported illness compatible with COVID-19 and there was an increase in illness reporting during March 2020 Diagnostic swabs were not routinely performed. Cough (n=179, 75.8%), fever (n=138, 58.5%), breathlessness (n=84, 35.6%) were reported. Anosmia was reported in 42.2%. Fever generally settled within 1 week (n=110/138, 88%). Several respondents remained at home and did not seek formal medical attention despite reporting severe breathlessness and measuring hypoxia (n=5/9, 55.6%). 2 patients required hospital admission but recovered following oxygen therapy. 84 respondents (41.2%) required greater than the obligated 7 days off work and 9 required greater than 3 weeks off. Conclusion There was a significant increase in staff reporting illness compatible with possible COVID-19 during March 2020. Subsequent serology studies at the same hospital study site have confirmed sero-positivity for COVID-19 up to 45% by the end of April 2020 in frontline HCWs. The study revealed a concerning lack of healthcare seeking in respondents with significant red flag symptoms (severe breathlessness, hypoxia). This study also highlighted anosmia as a key symptom of COVID-19 early in the pandemic, prior to this symptom being more widely recognised as a feature of COVID-19.
C1 [de Wilton, Angus; Kilich, Eliz; Chaudhry, Zain; Bell, Lucy C. K.; Gahir, Joshua; Lever, Robert A.; Logan, Sarah A.] Univ Coll London Hosp NHS Fdn Trust, Hosp Trop Dis, Dept Infect Dis, COVID Response Team 19, London, England.
   [Cadman, Jane] Univ Coll London Hosp NHS Fdn Trust, Occupat Hlth, COVID Response Team 19, London, England.
   [Lever, Robert A.] UCL, Div Infect & Immun, London, England.
RP de Wilton, A (corresponding author), Univ Coll London Hosp NHS Fdn Trust, Hosp Trop Dis, Dept Infect Dis, COVID Response Team 19, London, England.
EM angus.dewilton@nhs.net
OI Bell, Lucy/0000-0002-1762-7294
CR Benezit F, 2020, LANCET INFECT DIS, V20, P1014, DOI 10.1016/S1473-3099(20)30297-8
   Collazos JCO, 2020, VENNY 2 1 0
   Committee RE, 2020, REC UCL
   England PH, 2020, STAY HOM GUID HOUS P
   England PH, 2020, COVID 19 MAN EXP HEA
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han YN, 2020, J MED VIROL, V92, P1596, DOI 10.1002/jmv.25835
   Houlihan C, 2020, PANDEMIC PEAK SARS C
   Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488
   Kluytmans M, 2020, INFECT DIS
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Public Health England, 2020, GUID SOC DIST EV UK
   SARS-CoV-2 viral, 2020, SARS COV 2 VIRAL LOA
   Tang YF, 2020, J PAIN SYMPTOM MANAG, V60, pE48, DOI 10.1016/j.jpainsymman.2020.03.039
NR 14
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e040216
DI 10.1136/bmjopen-2020-040216
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PB3HW
UT WOS:000596216900023
PM 33243801
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kirkby, KJ
   Kirkby, NF
   Burnet, NG
   Owen, H
   Mackay, RI
   Crellin, A
   Green, S
AF Kirkby, Karen Joy
   Kirkby, Norman Francis
   Burnet, Neil Gunn
   Owen, Hywel
   Mackay, Ranald Iain
   Crellin, Adrian
   Green, Stuart
TI Heavy charged particle beam therapy and related new radiotherapy
   technologies: The clinical potential, physics and technical developments
   required to deliver benefit for patients with cancer
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID BIOLOGICAL EFFECTIVENESS; PROTON-BEAM; IRRADIATION; RBE
AB In the UK, one in two people will develop cancer during their lifetimes and radiotherapy (RT) plays a key role in effective treatment. High energy proton beam therapy commenced in the UK National Health Service in 2018. Heavier charged particles have potential advantages over protons by delivering more dose in the Bragg peak, with a sharper penumbra, lower oxygen dependence and increased biological effectiveness. However, they also require more costly equipment including larger gantries to deliver the treatment. There are significant uncertainties in the modelling of relative biological effectiveness and the effects of the fragmentation tail which can deliver dose beyond the Bragg peak. These effects need to be carefully considered especially in relation to long-term outcomes.
   In 2019, a group of clinicians, clinical scientists, engineers, physical and life scientists from academia and industry, together with funding agency stakeholders, met to consider how the UK should address new technologies for RT, especially the use of heavier charged particles such as helium and carbon and new modes of delivery such as FLASH and spatially fractionated radiotherapy (SFRT).
   There was unanimous agreement that the UK should develop a facility for heavier charged particle therapy, perhaps constituting a new National Ion Research Centre to enable research using protons and heavier charged particles. Discussion followed on the scale and features, including which ions should be included, from protons through helium, boron, and lithium to carbon, and even oxygen. The consensus view was that any facility intended to treat patients must be located in a hospital setting while providing dedicated research space for physics, preclinical biology and clinical research with beam lines designed for both in vitro and in vivo research. The facility should to be able to investigate and deliver both ultra-high dose rate FLASH RT and SFRT (GRID, minibeams etc.). Discussion included a number of accelerator design options and whether gantries were required. Other potential collaborations might be exploited, including with space agencies, electronics and global communications industries and the nuclear industry.
   In preparation for clinical delivery, there may be opportunities to send patients overseas (for C-12 or He-4 ion therapy) using the model of the National Health Service (NHS) Proton Overseas Programme and to look at potential national clinical trials which include heavier ions, FLASH or SFRT. This could be accomplished under the auspices of NCRI CTRad (National Cancer Research Institute, Clinical and Translational Radiotherapy Research Working Group).
   The initiative should be a community approach, involving all interested parties with a vision that combines discovery science, a translational research capability and a clinical treatment facility. Barriers to the project and ways to overcome them were discussed. Finally, a set of different scenarios of features with different costs and timelines was constructed, with consideration given to the funding environment (prer-Covid-19) and need for cross-funder collaboration.
C1 [Kirkby, Karen Joy; Kirkby, Norman Francis; Burnet, Neil Gunn; Mackay, Ranald Iain] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester Canc Res Ctr, Div Canc Sci, Manchester, Lancs, England.
   [Kirkby, Karen Joy; Kirkby, Norman Francis; Burnet, Neil Gunn; Mackay, Ranald Iain] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England.
   [Kirkby, Karen Joy; Owen, Hywel] Univ Manchester, Cockcroft Inst, Manchester, Lancs, England.
   [Mackay, Ranald Iain] Christie NHS Fdn Trust, Christie Med Phys & Engn, Manchester, Lancs, England.
   [Crellin, Adrian] Leeds Teaching Hosp Trust, Leeds Canc Ctr, NHS England Natl Clin Lead Proton Beam Therapy, Leeds, W Yorkshire, England.
   [Crellin, Adrian] Leeds Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England.
   [Green, Stuart] Univ Hosp Birmingham, Dept Med Phys, Birmingham, Edgbaston, England.
RP Kirkby, KJ (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester Canc Res Ctr, Div Canc Sci, Manchester, Lancs, England.; Kirkby, KJ (corresponding author), Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England.; Kirkby, KJ (corresponding author), Univ Manchester, Cockcroft Inst, Manchester, Lancs, England.
EM karen.kirkby@manchester.ac.uk
RI Kirkby, Karen/M-4725-2015
OI Kirkby, Karen/0000-0002-0901-210X
FU National Institute for Health Research (NIHR) Manchester Biomedical
   Research CentreNational Institute for Health Research (NIHR); Cancer
   Research UKCancer Research UK [C147/A25254, C1994/A28701]; Engineering
   and Physical Sciences Research Council Grand Challenge Network+ in
   Advanced Proton TherapyEngineering & Physical Sciences Research Council
   (EPSRC) [EP/R023220/1]; Science and Technology Facilities Council Global
   Challenge Network+ in Advanced Radiotherapy [ST/N002423/1]; European
   UnionEuropean Union (EU) [730983]
FX We are indebted to Dr Nicholas Henthorn for providing the diagrams used
   in Figure 1 and to Lauren Hewitt for help in preparing the manuscript
   and for facilitating the meeting, to Helena Kondryn and Zoe Lingard for
   alsofacilitating the meeting. KJK,NFK, NGB, and RIMare supported by the
   National Institute for Health Research (NIHR) Manchester Biomedical
   Research Centre. This work was supported by Cancer Research UK via
   funding to the Cancer Research Manchester Centre [C147/A25254] and UK
   RadNet Manchester [C1994/A28701].; We are also grateful to the
   Engineering and Physical Sciences Research Council (EP/R023220/1) Grand
   Challenge Network+ in Advanced Proton Therapy, the Science and
   Technology Facilities Council (ST/N002423/1) Global Challenge Network+
   in Advanced Radiotherapy, the European Union's Horizon 2020 research and
   innovation programme (730983) INSPIRE project for support.
CR Ahmad AS, 2015, BRIT J CANCER, V112, P943, DOI 10.1038/bjc.2014.606
   [Anonymous], 2019, BMJ-BRIT MED J, V313, DOI [10.1259/bjr., 10.1259/bjr.20190873, DOI 10.1259/BJR]
   Billena C, 2019, INT J RADIAT ONCOL, V104, P177, DOI 10.1016/j.ijrobp.2019.01.073
   Bourhis J, 2019, RADIOTHER ONCOL, V139, P11, DOI 10.1016/j.radonc.2019.04.008
   Brualla-Gonzalez L, 2018, MED PHYS, V45, P1771, DOI 10.1002/mp.12816
   Burnet NG, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20190873
   Casiraghi M, 2015, COMPUT MATH METHOD M, DOI 10.1155/2015/908971
   Chaudhary P, 2014, INT J RADIAT ONCOL, V90, P27, DOI 10.1016/j.ijrobp.2014.05.010
   Durante M, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170628
   Eulitz J, 2019, ASSESSMENT CLIN RBE
   FAVAUDON V, 2014, SCI TRANSL MED, V6
   Fossati P, 2018, MED PHYS, V45, pE1096, DOI 10.1002/mp.12506
   Grun R, 2012, PHYS MED BIOL, V57, P7261, DOI 10.1088/0031-9155/57/22/7261
   Harrabi S, 2017, RADIOTHER ONCOL, V123, pS271
   HENDRY JH, 1982, RADIAT RES, V92, P172, DOI 10.2307/3575852
   HENDRY JH, 1979, INT J RADIAT ONCOL, V5, P971, DOI 10.1016/0360-3016(79)90602-3
   Henthorn N, 2019, RSC ADV
   Inaniwa T, 2010, PHYS MED BIOL, V55, P6721, DOI 10.1088/0031-9155/55/22/008
   Indelicato DJ, 2014, ACTA ONCOL, V53, P1298, DOI 10.3109/0284186X.2014.957414
   Ingram S, SCI REPORTS, V2019, P63599
   Jones B, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160116
   Kanai T, 1997, RADIAT RES, V147, P78, DOI 10.2307/3579446
   Kanai T, 1999, INT J RADIAT ONCOL, V44, P201, DOI 10.1016/S0360-3016(98)00544-6
   Kawashiro S, 2018, INT J RADIAT ONCOL, V101, P1212, DOI 10.1016/j.ijrobp.2018.04.057
   Marshall TI, 2016, INT J RADIAT ONCOL, V95, P70, DOI 10.1016/j.ijrobp.2016.02.029
   Montay-Gruel P, 2019, P NATL ACAD SCI USA, V116, P10943, DOI 10.1073/pnas.1901777116
   Montay-Gruel P, 2018, RADIOTHER ONCOL, V129, P582, DOI 10.1016/j.radonc.2018.08.016
   Montay-Gruel P, 2017, RADIOTHER ONCOL, V124, P365, DOI 10.1016/j.radonc.2017.05.003
   Paganetti H, 2014, PHYS MED BIOL, V59, pR419, DOI 10.1088/0031-9155/59/22/R419
   Prezado Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17543-3
   Price J, 2020, CLIN ONCOL-UK, V32, P84, DOI 10.1016/j.clon.2019.09.052
   Rothwell B, 2020, INT J RAD ONCOLOGY B
   Saager M, 2017, RADIOTHER ONCOL, V123, pS273, DOI 10.1016/S0167-8140(17)30957-X
   Schuemann JP, 2019, INT J RADIAT ONCOL, V105, pS230, DOI 10.1016/j.ijrobp.2019.06.329
   Schuler E, 2017, INT J RADIAT ONCOL, V97, P195, DOI 10.1016/j.ijrobp.2016.09.018
   SLATKIN DN, 1992, MED PHYS, V19, P1395, DOI 10.1118/1.596771
   Smith EAK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56258-5
   Tessonnier T, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-017-0944-3
   Tommasino F, 2015, CANCERS, V7, P353, DOI 10.3390/cancers7010353
   Ulrich-Pur F., 2019, 2 ION IM WORKSH
   Underwood T, 2016, INT J RADIAT ONCOL, V95, P56, DOI 10.1016/j.ijrobp.2015.10.006
   van de Water S, 2019, ACTA ONCOL, V58, P1463, DOI 10.1080/0284186X.2019.1627416
   Vozenin MC, 2019, CLIN CANCER RES, V25, P35, DOI 10.1158/1078-0432.CCR-17-3375
   ZEMAN W, 1959, SCIENCE, V130, P1760, DOI 10.1126/science.130.3391.1760-a
NR 44
TC 0
Z9 0
U1 2
U2 2
PU BRITISH INST RADIOLOGY
PI LONDON
PA 48-50 ST JOHN ST, LONDON, ENGLAND
SN 0007-1285
EI 1748-880X
J9 BRIT J RADIOL
JI Br. J. Radiol.
PY 2020
VL 93
IS 1116
AR 20200247
DI 10.1259/bjr.20200247
PG 13
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OW1QB
UT WOS:000592669400009
PM 33021102
DA 2021-01-01
ER

PT J
AU Caballero, A
   Filgueira, LM
   Betancourt, J
   Sanchez, N
   Hidalgo, C
   Ramirez, A
   Martinez, A
   Despaigne, RE
   Escalona, A
   Diaz, H
   Merino, E
   Ortega, LM
   Castillo, U
   Ramos, M
   Saavedra, D
   Garcia, Y
   Lorenzo, G
   Cepeda, M
   Arencibia, M
   Cabrera, L
   Domecq, M
   Estevez, D
   Valenzuela, C
   Lorenzo, P
   Sanchez, L
   Mazorra, Z
   Leon, K
   Crombet, T
AF Caballero, Armando
   Filgueira, Lazaro M.
   Betancourt, Julio
   Sanchez, Naivy
   Hidalgo, Carlos
   Ramirez, Alberto
   Martinez, Alejandro
   Despaigne, Rolando E.
   Escalona, Alberto
   Diaz, Henrry
   Merino, Elio
   Ortega, Lilia M.
   Castillo, Ulises
   Ramos, Mayra
   Saavedra, Danay
   Garcia, Yanelda
   Lorenzo, Geydi
   Cepeda, Meylan
   Arencibia, Maylen
   Cabrera, Leticia
   Domecq, Milagros
   Estevez, Daymys
   Valenzuela, Carmen
   Lorenzo, Patricia
   Sanchez, Lizet
   Mazorra, Zaima
   Leon, Kalet
   Crombet, Tania
TI Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article
DE CD6; COVID-19; cytokine release syndrome; itolizumab; monoclonal
   antibody; SARS-CoV2
ID MONOCLONAL-ANTIBODY; CD6; IOR-T1
AB Objectives. COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T-cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune diseases indicate that it lowers multiple cytokines primarily involving the Th1/Th17 pathway. The primary objective of this study was to assess the impact of itolizumab in arresting the lung function deterioration of COVID-19 patients. Secondary objectives included safety, duration of ventilation, 14-day mortality and evaluation of interleukin 6 concentration. Methods. Patients with confirmed SARS-CoV-2 received itolizumab in combination with other therapies included in the national protocol for COVID-19. Results.Seventy critical, severe or moderate patients were treated with itolizumab in 10 Cuban hospitals. Median age was 68, and 94% had comorbidities. After 72 h, most patients improved the PO2/FiO(2) ratio and reduced FiO(2) requirements. Ventilation time was 8 days for critical and 1 day for severe cases. Ten patients had related adverse events while 3 subjects developed related serious events. In 30 patients, interleukin 6 decreased in individuals with high level and did not change in those with lower concentration. Fourteen-day lethality rate was 4% and 18% for moderate and severe patients, respectively. The proportion of moderate or severe patients with ventilation or death at day 14 was 9.8%. Time to treatment, neurological manifestations and biomarkers such as NLR were significantly associated with higher lethality. Conclusions. The opportune administration of itolizumab might interrupt the hyperinflammatory cascade and prevent COVID-19 morbidity and mortality.
C1 [Caballero, Armando] Arnaldo Milian Castro Univ Hosp, Intens Care Unit, Santa Clara, Cuba.
   [Filgueira, Lazaro M.; Betancourt, Julio; Sanchez, Naivy; Hidalgo, Carlos] Manuel Piti Fajardo Rivero Hosp, Intens Care Unit, Santa Clara, Cuba.
   [Ramirez, Alberto; Martinez, Alejandro] Salvador Allende Hosp, Intens Care Unit, Havana, Cuba.
   [Despaigne, Rolando E.] Joaquin Castillo Hosp, Intens Care Unit, Havana, Cuba.
   [Escalona, Alberto] Faustino Perez Hosp, Intens Care Unit, Matanzas, Cuba.
   [Diaz, Henrry; Merino, Elio] Frank Pais Hosp, Intens Care Unit, Havana, Cuba.
   [Ortega, Lilia M.] Pedro Kouri Inst, Intens Care Unit, Havana, Cuba.
   [Castillo, Ulises] Minist Cuban Hlth, Emergency Dept, Havana, Cuba.
   [Ramos, Mayra; Saavedra, Danay; Garcia, Yanelda; Lorenzo, Geydi; Cepeda, Meylan; Arencibia, Maylen; Cabrera, Leticia; Domecq, Milagros; Estevez, Daymys; Valenzuela, Carmen; Lorenzo, Patricia; Sanchez, Lizet; Mazorra, Zaima; Crombet, Tania] Ctr Mol Immunol CIM, Clin Res Direct, Havana, Cuba.
   [Leon, Kalet] Ctr Mol Immunol CIM, Res Direct, Havana, Cuba.
RP Crombet, T (corresponding author), Ctr Mol Immunol, Ave 216,Esq 15 Atabey Playa,POB 16040, Havana, Cuba.
EM taniac@cim.sld.cu
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Aguiar D, 2020, INT J LEGAL MED, V134, P1271, DOI 10.1007/s00414-020-02318-9
   Aira LE, 2016, MABS-AUSTIN, V8, P187, DOI 10.1080/19420862.2015.1105416
   Aira LE, 2014, MABS-AUSTIN, V6, P782, DOI 10.4161/mabs.28376
   Atal S, 2020, BIODRUGS, V34, P705, DOI 10.1007/s40259-020-00448-5
   Atal S, 2020, PHARM MED, V34, P223, DOI 10.1007/s40290-020-00342-z
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Diaz Y, 2020, GERONTOLOGY, V66, P553, DOI 10.1159/000512210
   Dogra S, 2017, EXPERT OPIN BIOL TH, V17, P395, DOI 10.1080/14712598.2017.1279601
   Dolan RD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16955-5
   Ghnewa YG, 2020, MED KLIN-INTENSIVMED, V115, P10, DOI 10.1007/s00063-020-00683-2
   Grifoni E, 2020, J INFECTION, V81, P466, DOI 10.1016/j.jinf.2020.06.008
   Gubernatorova EO, 2020, CYTOKINE GROWTH F R, V53, P13, DOI 10.1016/j.cytogfr.2020.05.009
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Hermine O, 2020, JAMA INTERN MED, DOI 10.1001/jamainternmed.2020.6820
   Hernandez P, 2016, CURR DRUG TARGETS, V17, P666, DOI 10.2174/1389450117666160201114308
   Krupashankar DS, 2014, J AM ACAD DERMATOL, V71, P484, DOI 10.1016/j.jaad.2014.01.897
   Lippi G, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3989
   Loganathan S, 2020, EXPERT OPIN BIOL TH, V20, P1025, DOI 10.1080/14712598.2020.1798399
   Ma CY, 2019, J CROHNS COLITIS, V13, P510, DOI 10.1093/ecco-jcc/jjy179
   Miossec P, 2020, EUR J RHEUMATOL, V7, pS97, DOI 10.5152/eurjrheum.2020.2062
   OSORIO LM, 1994, CELL IMMUNOL, V154, P123, DOI 10.1006/cimm.1994.1062
   Ponti G, 2020, CRIT REV CL LAB SCI, DOI [10.1080/10408363.2020.1803789, 10.1080/10408363.2020.1770685]
   Poor HD, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.44
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Santos RF, 2016, CURR DRUG TARGETS, V17, P630, DOI 10.2174/1389450116666150531152439
   Steeland S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051442
   Stone John H, 2020, N Engl J Med, V383, P2333, DOI 10.1056/NEJMoa2028836
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2020
VL 9
IS 11
AR e1218
DI 10.1002/cti2.1218
PG 11
WC Immunology
SC Immunology
GA PB7OO
UT WOS:000596506200001
PM 33304584
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Iragorri, N
   Gomez-Restrepo, C
   Barrett, K
   Herrera, S
   Hurtado, I
   Khan, Y
   Mac, S
   Naimark, D
   Pechlivanoglou, P
   Rosselli, D
   Toro, D
   Villamizar, P
   Ximenes, R
   Zapata, H
   Sander, B
AF Iragorri, Nicolas
   Gomez-Restrepo, Carlos
   Barrett, Kali
   Herrera, Socrates
   Hurtado, Isabel
   Khan, Yasin
   Mac, Stephen
   Naimark, David
   Pechlivanoglou, Petros
   Rosselli, Diego
   Toro, Dilian
   Villamizar, Pedro
   Ximenes, Raphael
   Zapata, Helmer
   Sander, Beate
TI COVID-19: Adaptation of a model to predict healthcare resource needs in
   Valle del Cauca, Colombia
SO COLOMBIA MEDICA
LA English
DT Article
DE COVID-19; SARS-CoV-2; healthcare resources; resource constraints; Valle
   del Cauca; Colombia; Global health
AB Background:
   Valle del Cauca is the region with the fourth-highest number of COVID-19 cases in Colombia (>50,000 on September 7, 2020). Due to the lack of anti-COVID-19 therapies, decision-makers require timely and accurate data to estimate the incidence of disease and the availability of hospital resources to contain the pandemic.
   Methods:
   We adapted an existing model to the local context to forecast COVID-19 incidence and hospital resource use assuming different scenarios: (1) the implementation of quarantine from September 1st to October 15th (average daily growth rate of 2%); (2-3) partial restrictions (at 4% and 8% growth rates); and (4) no restrictions, assuming a 10% growth rate. Previous scenarios with predictions from June to August were also presented. We estimated the number of new cases, diagnostic tests required, and the number of available hospital and intensive care unit (ICU) beds (with and without ventilators) for each scenario.
   Results:
   We estimated 67,700 cases by October 15th when assuming the implementation of a quarantine, 80,400 and 101,500 cases when assuming partial restrictions at 4% and 8% infection rates, respectively, and 208,500 with no restrictions. According to different scenarios, the estimated demand for reverse transcription-polymerase chain reaction tests ranged from 202,000 to 1,610,600 between September 1st and October 15th. The model predicted depletion of hospital and ICU beds by September 20th if all restrictions were to be lifted and the infection growth rate increased to 10%.
   Conclusion:
   Slowly lifting social distancing restrictions and reopening the economy is not expected to result in full resource depletion by October if the daily growth rate is maintained below 8%. Increasing the number of available beds provides a safeguard against slightly higher infection rates. Predictive models can be iteratively used to obtain nuanced predictions to aid decision-making
C1 [Iragorri, Nicolas; Barrett, Kali; Khan, Yasin; Mac, Stephen; Naimark, David; Pechlivanoglou, Petros] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Iragorri, Nicolas; Barrett, Kali; Mac, Stephen; Ximenes, Raphael] Univ Hlth Network, Toronto Hlth Econ & Technol Assessment THETA Coll, Toronto, ON, Canada.
   [Gomez-Restrepo, Carlos; Rosselli, Diego] Pontificia Univ Javeriana, Fac Med, Bogota, Colombia.
   [Barrett, Kali; Khan, Yasin] Univ Hlth Network, Toronto, ON, Canada.
   [Barrett, Kali; Khan, Yasin] Univ Thronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Herrera, Socrates; Toro, Dilian] Com Publ Privado Expertos Salud COPESA, Cali, Colombia.
   [Herrera, Socrates; Zapata, Helmer] Ctr Invest Cient Caucaseco, Cali, Colombia.
   [Hurtado, Isabel] Secretaria Dept Salud, Cali, Colombia.
   [Naimark, David] Sunnybrook Med Ctr, Toronto, ON, Canada.
   [Pechlivanoglou, Petros] Hosp Sick Children, Toronto, ON, Canada.
   [Villamizar, Pedro] Pontificia Univ Javeriana, Fac Med, Cali, Colombia.
   [Ximenes, Raphael] Fundacao Getulio Vargas, Escola Matemat Aplicada, Rio De Janeiro, RJ, Brazil.
   [Sander, Beate] Publ Hlth Ontario, Toronto, ON, Canada.
   [Sander, Beate] Inst Clin Evaluat Sci ICES, Toronto, ON, Canada.
RP Iragorri, N (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Iragorri, N (corresponding author), Univ Hlth Network, Toronto Hlth Econ & Technol Assessment THETA Coll, Toronto, ON, Canada.
EM nicolas.iragorri@mail.utoronto.ca
OI Khan, Yasin/0000-0002-0426-1780; Naimark, David/0000-0002-0621-0637;
   Mac, Stephen/0000-0003-4736-1770
CR Barret K, 2020, COVID 19 PREDICTING
   Barrett K, 2020, CAN MED ASSOC J, V192, pE640, DOI 10.1503/cmaj.200715
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Critical Care Services Ontario, 2020, CRIT CAR CAP VENT
   Gobernacion del Valle del Cauca, 2020, LAB HAB
   Instituto Nacional de Salud, 2020, COVID 19 COL REP 14
   Instituto Nacional de Salud, 2020, POS COVID 19 COL
   Ministerio de Salud, 2020, CAP INST PREST SERV
   Ministerio de Salud y Proteccion Social, 2020, COL CONF PRIM CAS CO
   Public Health Agency of Canada, COR DIS 2019 COVID 1
   Registro Especial de Prestadores de Servicios de Salud, 2020, REG ESP PREST SERV S
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 12
TC 0
Z9 0
U1 0
U2 0
PU CORPORACION EDITORA MEDICA VALLE
PI CALI
PA UNIV VALLE, BLDG 118 FACULTY HEALTH, CALLE 4B 36-00, CALI, 00000,
   COLOMBIA
SN 1657-9534
J9 COLOMB MEDICA
JI Colomb. Medica
PY 2020
VL 51
IS 3
AR e204534
DI 10.25100/cm.v51i3.4534
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA PC0XR
UT WOS:000596733900004
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Weber, TK
   Leandro-Merhi, VA
   Rnasconi, I
   de Oliveira, MRM
AF Weber, Thabata Koester
   Leandro-Merhi, Vania Aparecida
   Rnasconi, Isabela
   Marques de Oliveira, Maria Rita
TI Nutritional therapy in hospital care of in-patients with Covid-19:
   evidence, consensus and practice guidelines
SO REVISTA DE NUTRICAO-BRAZILIAN JOURNAL OF NUTRITION
LA English
DT Article
DE Coronavirus infection; Nutritional status; Nutrition therapy
ID CRITICALLY-ILL PATIENTS; ENTERAL NUTRITION; AMERICAN SOCIETY; INADEQUATE
   ENERGY; SUPPORT THERAPY; PATIENT SOCIETY; SCREENING TOOL; MEDICINE SCCM;
   MALNUTRITION; MORTALITY
AB Objective
   The objective of this work was to review papers that deal with nutritional therapy of inpatients with Covid-19 from the beginning of the pandemic. The survey covered the period until the month of September 2020.
   Methods
   This is a review of the indexed literature (Scopus, Pubmed and Lilacs), including area consensus.
   Results
   The review showed that the initial recommendations were based on generic assumptions and, as specific knowledge was being produced, the recommendations became more targeted.
   Conclusion
   In the health crisis generated by Covid-19, in the context of uncertainties related to nutritional care procedures, knowledge and action strategies were generated, coordinated by researchers and health professionals.
C1 [Weber, Thabata Koester; Marques de Oliveira, Maria Rita] Univ Estadual Paulista, Fac Ciencias Farmaceut, Programa Posgrad Alimentos & Nutr, Araraquara, SP, Brazil.
   [Leandro-Merhi, Vania Aparecida] Pontificia Univ Catolica Puc Campinas, Ctr Ciencias Vida, Programa Posgrad Ciencias Saude, Av John Boyd Dunlop S-N, BR-13034685 Campinas, SP, Brazil.
   [Rnasconi, Isabela] Pontificia Univ Catolica Campinas Puc Campinas, Programa Posgrad Ciencias Saude, Ciencias Saude, Campinas, SP, Brazil.
RP Leandro-Merhi, VA (corresponding author), Pontificia Univ Catolica Puc Campinas, Ctr Ciencias Vida, Programa Posgrad Ciencias Saude, Av John Boyd Dunlop S-N, BR-13034685 Campinas, SP, Brazil.
EM vapaleme@gmail.com
FU Universidade Estadual Paulista (Botucatu), Brasil; Pontificia
   Universidade Catolica de Campinas
FX We are grateful for the support of Universidade Estadual Paulista
   (Botucatu), Brasil and Pontificia Universidade Catolica de Campinas.
CR Alvarez-Hernandez J, 2012, NUTR HOSP, V27, P1049, DOI 10.3305/nh.2012.27.4.5986
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Arkin N, 2020, CLIN NUTR, V39, P2327, DOI 10.1016/j.clnu.2020.05.007
   Barazzoni R, 2020, CLIN NUTR, V39, P1631, DOI 10.1016/j.clnu.2020.03.022
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Campos LF, 2020, BRASPEN J, V35, P3
   Caussy C, 2020, LANCET DIABETES ENDO, V8, P562, DOI [10.1016/S2213-8587(20)30160-0, 10.1016/S2213-8587(20)30160-1]
   Caussy C, 2020, OBESITY, V28, P1175, DOI 10.1002/oby.22842
   Cavalcante JR, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000400010, 10.5123/S1679-49742020000400010]
   Chapple LAS, 2020, AUST CRIT CARE, V33, P399, DOI 10.1016/j.aucc.2020.06.002
   Chapple LAS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1177-1
   Conselho Federal de Nutricao (Brasil), 2020, REC CONS FED NUTR BO
   Correia MITD, 2003, CLIN NUTR, V22, P235, DOI 10.1016/S0261-5614(02)00215-7
   de Watteville A, 2020, CLIN NUTR ESPEN, V39, P74, DOI 10.1016/j.clnesp.2020.07.015
   Elia M., 2003, MUST REPORT NUTR SCR
   Gomes F, 2018, CLIN NUTR, V37, P336, DOI 10.1016/j.clnu.2017.06.025
   Gonzalez-Salazar LE, 2020, NUTR HOSP, V37, P622, DOI 10.20960/nh.03180
   Handu Deepa, 2020, J Acad Nutr Diet, DOI 10.1016/j.jand.2020.05.012
   Hasanloei MAV, 2018, CLIN NUTR ESPEN, V23, P162, DOI 10.1016/j.clnesp.2017.10.007
   Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10546
   Hozhabri H, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165648
   Hsu PH, 2018, INT J GERONTOL, V12, P285, DOI 10.1016/j.ijge.2018.03.001
   Ioannidis JPA, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109890
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52
   Jose IB, 2019, NUTR HOSP, V36, P1027, DOI 10.20960/nh.02545
   JOSÉ Isabela Bernasconi, 2018, Arq. Gastroenterol., V55, P283, DOI [10.1590/s0004-2803.201800000-72, 10.1590/S0004-2803.201800000-72]
   Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0
   Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5
   Krznaric Z, 2020, CLIN NUTR, V39, P1983, DOI 10.1016/j.clnu.2020.05.006
   Laviano A, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110834
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P3541, DOI 10.1007/s00405-020-06302-2
   Lee ZY, 2018, CLIN NUTR, V37, P1264, DOI 10.1016/j.clnu.2017.05.013
   Li JL, 2020, AM J MED SCI, V360, P229, DOI 10.1016/j.amjms.2020.05.040
   Li T, 2020, EUR J CLIN NUTR, V74, P871, DOI 10.1038/s41430-020-0642-3
   Lim SL, 2012, CLIN NUTR, V31, P345, DOI 10.1016/j.clnu.2011.11.001
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Martindale R, 2020, JPEN-PARENTER ENTER, V44, P1174, DOI 10.1002/jpen.1930
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Ministerio da Saude (Brasil), 2020, PAIN COR INF VIRT PU
   Organizacao Pan-Americana da Saude, 2020, FOLH INF COVID 19 ES
   Vallejo KP, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1805-z
   Papdimitriou-Olivgeris M, 2020, EUR J INTERN MED, V74, P86, DOI 10.1016/j.ejim.2019.12.022
   Patel JJ, 2020, NUTR CLIN PRACT, V35, P792, DOI 10.1002/ncp.10566
   Peterson SJ, 2010, J AM DIET ASSOC, V110, P427, DOI 10.1016/j.jada.2009.11.020
   Petrilli CM, 2020, FACTORS ASS HOSPITAL, DOI [10.1101/2020.04.08.20057794, DOI 10.1101/2020.04.08.20057794]
   Piovacari SMF, 2020, BRASPEN J, V35, P6
   Romano L, 2020, Eur Rev Med Pharmacol Sci, V24, P4035, DOI 10.26355/eurrev_202004_20874
   Rosenthal MD, 2016, CURR SURG REP, V4, DOI 10.1007/s40137-016-0152-3
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Santana MDMA, 2016, REV NUTR, V29, P645, DOI 10.1590/1678-98652016000500003
   Sigueira-Paese MC, 2016, NUTR HOSP, V33, P522, DOI 10.20960/nh.253
   de Assis MCS, 2016, REV NUTR, V29, P307, DOI 10.1590/1678-98652016000300001
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Stachowska E, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56060289
   Stefan N, 2020, NAT REV ENDOCRINOL, V16, P341, DOI 10.1038/s41574-020-0364-6
   Stratton RJ, 2004, BRIT J NUTR, V92, P799, DOI 10.1079/BJN20041258
   Thibault R, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03159-z
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Tsai JR, 2011, CLIN NUTR, V30, P209, DOI 10.1016/j.clnu.2010.09.003
   Tulunay-Ugur OE, 2018, CLIN GERIATR MED, V34, P183, DOI 10.1016/j.cger.2018.01.007
   Volkert D, 2019, CLIN NUTR, V38, P10, DOI 10.1016/j.clnu.2018.05.024
   White JV, 2012, JPEN-PARENTER ENTER, V36, P275, DOI 10.1177/0148607112440285
NR 63
TC 0
Z9 0
U1 0
U2 0
PU PONTIFICIA UNIVERSIDADE CATOLICA CAMPINAS
PI CAMPINAS
PA NUCLEO EDITORACAO SBI-CCV, CAMPUS II AV JOHN BOYD DUNLOP S-N PREDIO
   ONTOLOGIA JD IPAUSSURAMA, CAMPINAS, SP 13060-904, BRAZIL
SN 1415-5273
J9 REV NUTR
JI Rev. Nutr.
PY 2020
VL 33
AR e200212
DI 10.1590/1678.9865702033e200212
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA PC1TW
UT WOS:000596792800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Genie, MG
   Loria-Rebolledo, LE
   Paranjothy, S
   Powell, D
   Ryan, M
   Sakowsky, RA
   Watson, V
AF Genie, Mesfin G.
   Loria-Rebolledo, Luis Enrique
   Paranjothy, Shantini
   Powell, Daniel
   Ryan, Mandy
   Sakowsky, Ruben Andreas
   Watson, Verity
TI Understanding public preferences and trade-offs for government responses
   during a pandemic: a protocol for a discrete choice experiment in the UK
SO BMJ OPEN
LA English
DT Article
DE COVID-19; health economics; infectious diseases; public health
ID WILLINGNESS
AB Introduction Social distancing and lockdown measures are among the main government responses to the COVID-19 pandemic. These measures aim to limit the COVID-19 infection rate and reduce the mortality rate of COVID-19. Given we are likely to see local lockdowns until a treatment or vaccine for COVID-19 is available, and their effectiveness depends on public acceptability, it is important to understand public preference for government responses. Methods and analysis Using a discrete choice experiment (DCE), this study will investigate the public's preferences for pandemic responses in the UK. Attributes (and levels) are based on: (1) lockdown measures described in policy documents; (2) literature on preferences for lockdown measures and (3) a social media analysis. Attributes include: lockdown type; lockdown length; postponement of usual non-urgent medical care; number of excess deaths; number of infections; impact on household spending and job losses. We will prepilot the DCE using virtual think aloud interviews with respondents recruited via Facebook. We will collect preference data using an online survey of 4000 individuals from across the four UK countries (1000 per country). We will estimate the relative importance of the attributes, and the trade-offs individuals are willing to make between attributes. We will test if respondents' preferences differ based on moral attitudes (using the Moral Foundation Questionnaire), socioeconomic circumstances (age, education, economic insecurity, health status), country of residence and experience of COVID-19. Ethics and dissemination The University of Aberdeen's College Ethics Research Board (CERB) has approved the study (reference: CERB/2020/6/1974). We will seek CERB approval for major changes from the developmental and pilot work. Peer-reviewed papers will be submitted, and results will be presented at public health and health economic conferences nationally and internationally. A lay summary will be published on the Health Economics Research Unit blog.
C1 [Genie, Mesfin G.; Loria-Rebolledo, Luis Enrique; Ryan, Mandy; Sakowsky, Ruben Andreas; Watson, Verity] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
   [Paranjothy, Shantini] Univ Aberdeen, Hlth Data Sci Res Ctr, Aberdeen, Scotland.
   [Powell, Daniel] Univ Aberdeen, Hlth Psychol, Aberdeen, Scotland.
RP Genie, MG (corresponding author), Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
EM mesfin.genie@abdn.ac.uk
OI Paranjothy, Shantini/0000-0002-0528-3121
FU Scottish Government Health and Social Care Directorate; University of
   Aberdeen
FX This project is supported by the Scottish Government Health and Social
   Care Directorate and the University of Aberdeen.
CR Agarwal A, 2011, P WORKSH LANG SOC ME, P30
   AlTakarli NS, 2020, DMJ, V3, P44, DOI [10.1159/000508448, DOI 10.1159/000508448]
   [Anonymous], 2020, TIME
   BBC, 2020, BBC
   Berardi C, 2020, HEALTH POLICY TECHN, V9, P454, DOI 10.1016/j.hlpt.2020.08.019
   Breast Cancer Now, ALM ON MILL WOM UK M
   Burton CD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015689
   CDC, 2020, SOC DIST
   Chetty R., 2020, W27431 NAT BUR EC RE
   Chorus C, 2020, DIABOLIC DILEMMAS CO
   COIBION O., 2020, W27141 NAT BUR EC RE
   Colbourn T, 2020, LANCET PUBLIC HEALTH, V5, pE236, DOI 10.1016/S2468-2667(20)30072-4
   Cook AR, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017355
   Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x
   Fiorillo A, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.35
   Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gavi, HER AR 4 WAYS VIETN
   Graham A, 2020, SOCIUS, V6, DOI [10.1177/2378023120956815, DOI 10.1177/2378023120956815]
   Graham J, 2011, J PERS SOC PSYCHOL, V101, P366, DOI 10.1037/a0021847
   Haidt J., 2007, SOCIAL JUSTICE RES, V20, P98, DOI DOI 10.1007/S11211-007-0034-Z
   Hale T, 2020, OXFORD COVID 19 GOVT
   Henriquez J, 2020, HEALTH POLICY TECHN, V9, P560, DOI 10.1016/j.hlpt.2020.08.013
   Hoekman LM, 2020, HEALTH POLICY TECHN, V9, P613, DOI 10.1016/j.hlpt.2020.08.008
   Hole AR, 2007, HEALTH ECON, V16, P827, DOI 10.1002/hec.1197
   IHME, 2020, COVID 19 PROJ
   Johnson J, 2019, SOC SCI MED, V228, P164, DOI 10.1016/j.socscimed.2019.03.013
   Josephs L, 2020, CNBC NEWS
   Kavaliunas A, 2020, HEALTH POLICY TECHN, V9, P598, DOI 10.1016/j.hlpt.2020.08.009
   LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131
   Liaw SY, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3853
   Louviere J.J., 2000, STATED CHOICE METHOD
   McFadden D, 1974, FRONTIERS ECONOMETRI, P105, DOI DOI 10.1108/EB028592
   McKibbin WJ, 2020, SSRN J, DOI 10.2139/ssrn.3547729
   Meyerowitz-Katz Gideon, 2020, Int J Infect Dis, V101, P138, DOI 10.1016/j.ijid.2020.09.1464
   Nguyen NPT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238830
   NHS Performs, CANC OP
   OECD, 2020, OECD EMPL OUTL 2020
   Qiu Y, 2020, J POPUL ECON, V33, P1127, DOI 10.1007/s00148-020-00778-2
   Reed S, 2020, VALUE HEALTH, V23, P1438, DOI 10.1016/j.jval.2020.07.003
   Rose JM, 2013, TRANSPORTATION, V40, P1021, DOI 10.1007/s11116-013-9451-z
   Ryan M, 2008, ECON NON-MARK GOOD, V11, P1, DOI 10.1007/978-1-4020-5753-3
   Ryan M, 2009, HEALTH ECON, V18, P321, DOI 10.1002/hec.1369
   Sobieralski J. B., 2020, TRANSPORTATION RES I, V5, DOI [10.1016/j.trip.2020.100123., DOI 10.1016/J.TRIP.2020.100123]
   Train KE, 2009, DISCRETE CHOICE METHODS WITH SIMULATION, 2ND EDITION, P1, DOI 10.1017/CBO9780511805271
NR 45
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e043477
DI 10.1136/bmjopen-2020-043477
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA8JT
UT WOS:000595876500015
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marte, JL
   Toney, NJ
   Cordes, L
   Schlom, J
   Donahue, RN
   Gulley, JL
AF Marte, Jennifer L.
   Toney, Nicole J.
   Cordes, Lisa
   Schlom, Jeffrey
   Donahue, Renee N.
   Gulley, James L.
TI Early changes in immune cell subsets with corticosteroids in patients
   with solid tumors: implications for COVID-19 management
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE inflammation mediators; T-lymphocytes; immunomodulation; immunity;
   cellular
ID T-CELLS; ACTIVATION; MECHANISMS; INFECTION; APOPTOSIS; SURVIVAL;
   THERAPY; VIRUS
AB Background The risk-benefit calculation for corticosteroid administration in the management of COVID-19 is complex and urgently requires data to inform the decision. The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with poor prognosis in both COVID-19 and cancer. Investigating NLR as an inflammatory marker and lymphocyte levels as a critical component of antiviral immunity may inform the dilemma of reducing toxic hyperinflammation while still maintaining effective antiviral responses. Methods We performed a retrospective analysis of NLR, absolute neutrophil counts (ANCs) and absolute lymphocyte counts (ALCs) in patients with cancer enrolled in immunotherapy trials who received moderate-dose to high-dose corticosteroids. We compared paired presteroid and available poststeroid initiation values daily during week 1 and again on day 14 using the Wilcoxon signed-rank test. Associated immune subsets by flow cytometry were included where available. Results Patients (n=48) with a variety of solid tumors received prednisone, methylprednisolone, or dexamethasone alone or in combination in doses ranging from 20 to 190 mg/24 hours (prednisone equivalent). The median NLR prior to steroid administration was elevated at 5.0 (range: 0.9-61.2). The corresponding median ANC was 5.1 K/mu L (range: 2.03-22.31 K/mu L) and ALC was 1.03 K/mu L (0.15-2.57 K/mu L). One day after steroid administration, there was a significant transient drop in median ALC to 0.54 K/mu L (p=0.0243), driving an increase in NLR (median 10.8, p=0.0306). Relative lymphopenia persisted through day 14 but was no longer statistically significant. ANC increased steadily over time, becoming significant at day 4 (median: 7.31 K/mu L, p=0.0171) and remaining significantly elevated through day 14. NLR was consistently elevated after steroid initiation, significantly at days 1, 7 (median: 8.2, p=0.0272), and 14 (median: 15.0, p=0.0018). Flow cytometry data from 11 patients showed significant decreases in activated CD4 cells and effector memory CD8 cells. Conclusions The early drop in ALC with persistent lymphopenia as well as the prolonged ANC elevation seen in response to corticosteroid administration are similar to trends associated with increased mortality in several coronavirus studies to include the current SARS-CoV-2 pandemic. The affected subsets are essential for effective antiviral immunity. This may have implications for glucocorticoid therapy for COVID-19.
C1 [Marte, Jennifer L.; Cordes, Lisa; Gulley, James L.] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Toney, Nicole J.; Schlom, Jeffrey; Donahue, Renee N.] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Gulley, JL (corresponding author), NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM gulleyj@mail.nih.gov
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
FU Intramural Research Program of the Center for Cancer Research, National
   Cancer Institute, National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI)
FX This work was supported by the Intramural Research Program of the Center
   for Cancer Research, National Cancer Institute, National Institutes of
   Health, and via CRADAs the NCI has with EMD Serono, Bavarian Nordic,
   Incyte, and ImmunityBio.
CR Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Berhane M, 2019, CLIN LAB, V65, P527, DOI 10.7754/Clin.Lab.2018.180833
   Bertram EM, 2002, EUR J IMMUNOL, V32, P3376, DOI 10.1002/1521-4141(200212)32:12<3376::AID-IMMU3376>3.0.CO;2-Y
   BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen XQ, 2019, WORLD J GASTROENTERO, V25, P4970, DOI 10.3748/wjg.v25.i33.4970
   COX G, 1995, J IMMUNOL, V154, P4719
   Curbelo J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173947
   Donahue RN, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0220-y
   FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304
   Heery CR, 2017, LANCET ONCOL, V18, P587, DOI 10.1016/S1470-2045(17)30239-5
   Huang JP, 2012, BLOOD, V120, P3030, DOI 10.1182/blood-2012-05-427799
   Lepone Lauren M, 2016, J Circ Biomark, V5, P5, DOI 10.5772/62322
   Li Sijia, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa829
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   LIU X, 2016, P IEEE INT C MULT EX, P1, DOI DOI 10.1109/ICME.2016.7553002
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Medscape, 2002, CLIN CHAR COMM US CO
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   News & Events, 2020, LOW COST DEX RED DEA
   O'Connor MA, 2017, VIRAL IMMUNOL, V30, P82, DOI 10.1089/vim.2016.0125
   Olnes MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23002
   R Core Team, 2019, R LANG ENV STAT COMP
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Ronchetti S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124090
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Saini KS, 2020, BRIT J CANCER, V123, P694, DOI 10.1038/s41416-020-0948-x
   SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283
   SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781
   Strauss J, 2018, CLIN CANCER RES, V24, P1287, DOI 10.1158/1078-0432.CCR-17-2653
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Veiga-Parga T, 2013, IMMUNOL REV, V255, P182, DOI 10.1111/imr.12085
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, CLIN MAN SEV AC RESP
   Yang JW, 2015, CLIN MICROBIOL INFEC, V21, P956, DOI 10.1016/j.cmi.2015.06.022
NR 41
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001019
DI 10.1136/jitc-2020-001019
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA PA8LZ
UT WOS:000595882300001
PM 33219091
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Smit, M
   Marinosci, A
   Nicoletti, GJ
   Perneger, T
   Ragozzino, S
   Andrey, DO
   Stoeckle, M
   Jacquerioz, F
   Lebowitz, D
   Agoritsas, T
   Meyer, B
   Spechbach, H
   Salamun, J
   Back, M
   Schaubhut, C
   Fuchs, S
   Decosterd, L
   Battegay, M
   Guessous, I
   Chappuis, F
   Kaiser, L
   Labhardt, ND
   Calmy, A
AF Smit, Mikaela
   Marinosci, Annalisa
   Nicoletti, Giovanni Jacopo
   Perneger, Thomas
   Ragozzino, Silvio
   Andrey, Diego O.
   Stoeckle, Marcel
   Jacquerioz, Frederique
   Lebowitz, Dan
   Agoritsas, Thomas
   Meyer, Benjamin
   Spechbach, Herve
   Salamun, Julien
   Back, Moritz
   Schaubhut, Carla
   Fuchs, Simon
   Decosterd, Laurent
   Battegay, Manuel
   Guessous, Idris
   Chappuis, Francois
   Kaiser, Laurent
   Labhardt, Niklaus D.
   Calmy, Alexandra
TI Efficacy of pragmatic same-day ring prophylaxis for adult individuals
   exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label
   cluster randomised trial
SO BMJ OPEN
LA English
DT Article
DE infectious diseases; epidemiology; preventive medicine; clinical trials;
   COVID-19
AB Introduction Lopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19. Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their efficacy as postexposure ring-prophylaxis among adults exposed to SARS-CoV-2.
   Methods and analysis COPEP is a two-arm open-label cluster-randomised trial conducted in three cantons of Switzerland. Asymptomatic contacts (>= 16 years) of individuals diagnosed with COVID-19 will be randomised (2:1) to either LPV/r (400 mg/100 mg two times per day) for 5 days, or a standard of care arm (no treatment). Asymptomatic individuals may be either SARS-CoV-2 positive or negative. Contacts living in the single household will form a cluster and will be randomised into the same arm. All participants will be followed-up for 21 days and undergo daily monitoring for COVID-19 symptoms. The primary endpoint is 21-day incidence of laboratory-confirmed COVID-19 with >= 1 compatible symptom, analysed in an intention-to-treat (ITT) analysis. The secondary endpoints include the 21-day incidence of COVID-19 as well as SARS-CoV-2 infection in a modified ITT analysis, excluding participants who had a positive SARS-CoV-2 RT-PCR from oropharyngeal swab and/or a positive SARS-CoV-2 IgG serology at baseline. Assuming a 21-day incidence for COVID-19 of 20% among contacts without postexposure chemoprophylaxis, to detect a relative risk reduction of 60% (ie, translating in an absolute reduction from 20% to 8%), with a power of 80%, an alpha of 5%. Accounting for design effect of cluster design of circa 1.1, we plan to enrol 200 participants to the LPV/r arm and 100 to the standard of care arm, 300 participants in total.
   Ethics and dissemination Ethics approval has been granted by the Commission Cantonale d'Ethique de la Recherche, Ethikkommission Nordwest- und Zentralschweiz and Comitato Etico Cantonale (ref 2020-00864) and Swissmedic (2020DR3056). Results from this trial will be disseminated via journal articles and presentations at national and international conferences.
   Registered report identifier CCER 2020-0864.
C1 [Smit, Mikaela; Marinosci, Annalisa; Andrey, Diego O.; Calmy, Alexandra] Geneva Univ Hosp, HIV Unit, Geneva, Switzerland.
   [Smit, Mikaela; Perneger, Thomas; Andrey, Diego O.; Agoritsas, Thomas; Calmy, Alexandra] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Nicoletti, Giovanni Jacopo; Labhardt, Niklaus D.] Swiss Trop & Publ Hlth Inst, Dept Med, Basel, Switzerland.
   [Perneger, Thomas] Geneva Univ Hosp, Div Clin Epidemiol, Geneva, Switzerland.
   [Ragozzino, Silvio; Stoeckle, Marcel; Battegay, Manuel; Labhardt, Niklaus D.] Univ Basel, Dept Infect Dis & Hosp Epidemiol, Basel, Switzerland.
   [Andrey, Diego O.] Geneva Univ Hosp, Diagnost Dept, Div Lab Med, Geneva, Switzerland.
   [Jacquerioz, Frederique; Spechbach, Herve; Salamun, Julien; Guessous, Idris; Chappuis, Francois] Geneva Univ Hosp, Dept Primary Care, Geneva, Switzerland.
   [Lebowitz, Dan] Geneva Univ Hosp, Infect Control Programme, Geneva, Switzerland.
   [Lebowitz, Dan] Direct Gen Sante, Geneva, Switzerland.
   [Agoritsas, Thomas] Geneva Univ Hosp, Dept Med, Geneva, Switzerland.
   [Agoritsas, Thomas] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Meyer, Benjamin] Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland.
   [Back, Moritz; Schaubhut, Carla; Fuchs, Simon] Gesundheitsdept, Basel, Switzerland.
   [Decosterd, Laurent] Univ Lausanne, Lab Clin Pharmacol, Lausanne, Switzerland.
   [Kaiser, Laurent] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland.
   [Kaiser, Laurent] Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland.
RP Smit, M (corresponding author), Geneva Univ Hosp, HIV Unit, Geneva, Switzerland.; Smit, M (corresponding author), Univ Geneva, Fac Med, Geneva, Switzerland.
EM mikaela.smit@hcuge.ch
OI Smit, Mikaela/0000-0001-8530-748X; Labhardt, Niklaus
   Daniel/0000-0003-3599-1791
FU Fondation privee des HUG; Swiss National FundSwiss National Science
   Foundation (SNSF) [33IC30_166819]
FX Fondation privee des HUG (no grant number), Swiss National Fund (project
   number: 33IC30_166819).
CR Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   European AIDS Clinical Society, 2019, GUIDELINES
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Lin CW, 2004, FEBS LETT, V574, P131, DOI 10.1016/j.febslet.2004.08.017
   WHO, ANT THER HIV INF AD
   World Health Organisation (WHO), WHO MOD LISTS ESS ME
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e040110
DI 10.1136/bmjopen-2020-040110
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA5XM
UT WOS:000595708200034
PM 33184083
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tavernier, E
   McNicholas, B
   Pavlov, I
   Roca, O
   Perez, Y
   Laffey, J
   Mirza, S
   Cosgrave, D
   Vines, D
   Frat, JP
   Ehrmann, S
   Li, J
AF Tavernier, Elsa
   McNicholas, Bairbre
   Pavlov, Ivan
   Roca, Oriol
   Perez, Yonatan
   Laffey, John
   Mirza, Sara
   Cosgrave, David
   Vines, David
   Frat, Jean-Pierre
   Ehrmann, Stephan
   Li, Jie
TI Awake prone positioning of hypoxaemic patients with COVID-19: protocol
   for a randomised controlled open-label superiority meta-trial
SO BMJ OPEN
LA English
DT Article
DE adult intensive &amp; critical care; statistics &amp; research methods;
   respiratory infections; international health services; COVID-19
ID CANNULA OXYGEN-THERAPY; NASAL CANNULA; RATIO; ARDS
AB Introduction Prone positioning (PP) is an effective first-line intervention to treat patients with moderate to severe acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation, as it improves gas exchanges and reduces mortality. The use of PP in awake spontaneous breathing patients with ARDS secondary to COVID-19 was reported to improve oxygenation in few retrospective trials with small sample size. High-level evidence of awake PP for hypoxaemic patients with COVID-19 patients is still lacking. Methods and analysis The protocol of this meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled open label superiority trials. This design is particularly adapted to a rapid scientific response in the pandemic setting. It will take place in multiple sites, among others in USA, Canada, Ireland, France and Spain. Patients will be followed up for 28 days. Patients will be randomised to receive whether awake PP and nasal high flow therapy or standard medical treatment and nasal high flow therapy. Primary outcome is defined as the occurrence rate of tracheal intubation or death up to day 28. An interim analysis plan has been set up on aggregated data from the participating research groups. Ethics and dissemination Ethics approvals were obtained in all participating countries. Results of the meta-trial will be submitted for publication in a peer-reviewed journal. Each randomised controlled trial was registered individually, as follows: NCT04325906, NCT04347941, NCT04358939, NCT04395144 and NCT04391140.
C1 [Tavernier, Elsa] CHRU Tours, INSERM 1415, Clin Invest Ctr, Tours, Centre, France.
   [Tavernier, Elsa] INSERM, Methods Patients Ctr Outcomes & Hlth Res, UMR 1246, Nantes, Loire Atlantiqu, France.
   [McNicholas, Bairbre; Laffey, John; Cosgrave, David] Natl Univ Ireland Galway, Sch Med, Dept Anaesthesia & Intens Care Med, Galway, Ireland.
   [McNicholas, Bairbre; Laffey, John; Cosgrave, David] Univ Hosp Galway, Saolta Univ Hosp Grp, Dept Anaesthesia, Galway, Ireland.
   [Pavlov, Ivan] Hop Verdun, Dept Emergency Med, Montreal, PQ, Canada.
   [Roca, Oriol] Vall dHebron Univ Hosp, Vall dHebron Res Inst, Crit Care Dept, Barcelona, Catalunya, Spain.
   [Roca, Oriol] Univ Autonoma Barcelona, Dept Med, Barcelona, Catalunya, Spain.
   [Perez, Yonatan; Ehrmann, Stephan] Univ Tours, Med Intens Reanimat, CIC 1415,CHU Tours, CRICS TriggerSEP,Ctr Etud Pathol Resp,INSERM U110, Tours, Centre, France.
   [Mirza, Sara; Vines, David; Li, Jie] Rush Univ, Dept Cardiopulm Sci, Div Resp Care, Chicago, IL 60612 USA.
   [Frat, Jean-Pierre] CHU Poitiers, Reanimat Med, Poitiers, France.
RP Tavernier, E (corresponding author), CHRU Tours, INSERM 1415, Clin Invest Ctr, Tours, Centre, France.; Tavernier, E (corresponding author), INSERM, Methods Patients Ctr Outcomes & Hlth Res, UMR 1246, Nantes, Loire Atlantiqu, France.
EM elsa.tavernier@univ-tours.fr
OI Tavernier, Elsa/0000-0003-0798-1182
FU OpenAI. (San Francisco, CA, USA); Rice Foundation (Skokie, IL, USA);
   Fisher & Paykel (15 Maurice Paykel Place, East Tamaki, Auckland 2013 New
   Zealand) [PO 480003859]; French ministry of health (Paris, France)
   [API20/T001]
FX This work was supported by OpenAI. (3180 18th St, San Francisco, CA
   94110, USA; no grant number), Rice Foundation (8600 Gross Point Rd,
   Skokie, IL 60077, USA; no grant number), Fisher & Paykel (15 Maurice
   Paykel Place, East Tamaki, Auckland 2013 New Zealand; grant number PO
   480003859) and the French ministry of health (14 Avenue Duquesne, 75 350
   Paris, France; grant number API20/T001).
CR [Anonymous], COR DIS COVID 19 DAS
   Auld SC, 2019, CRIT CARE MED
   Baker K, 2019, EMERG MED AUSTRALAS, DOI 10.1111/1742-6723.13372
   Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994
   Chen W, 2015, CHEST, V148, P1477, DOI 10.1378/chest.15-0169
   Despres C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03001-6
   Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5
   Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   ICNARC, 2020, ICNARC REP COVID 19
   Jennison C., 1999, GROUP SEQUENTIAL MET
   KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029
   Li Jie, 2020, J Crit Care, V60, P140, DOI 10.1016/j.jcrc.2020.07.020
   Li J, 2020, RESP CARE, V65, P545, DOI 10.4187/respcare.07663
   Liu L, 2018, J THORAC DIS, V10, P5394, DOI 10.21037/jtd.2018.08.137
   Nishimura M, 2016, RESP CARE, V61, P529, DOI 10.4187/respcare.04577
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Scaravilli V, 2015, J CRIT CARE, V30, P1390, DOI 10.1016/j.jcrc.2015.07.008
   Scholten EL, 2017, CHEST, V151, P215, DOI 10.1016/j.chest.2016.06.032
   Sun Q, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00650-2
   Tavernier E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158604
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu QH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02991-7
   Zarantonello F, 2020, AM J RESP CRIT CARE, V202, P278, DOI 10.1164/rccm.202003-0775IM
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e041520
DI 10.1136/bmjopen-2020-041520
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA PA5XM
UT WOS:000595708200035
PM 33177145
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cramer, JA
AF Cramer, Jennifer A.
TI "First, Do No Harm": Treed Carefully Where Oral History, Trauma, and
   Current Crises intersect
SO ORAL HISTORY REVIEW
LA English
DT Article
DE Trauma; crisis; therapy; oral history; COVID-19
AB The nature of oral history fieldwork changes when it is conducted during the course of an ongoing, long-term crisis like COVID-19. One must ask what the role of the oral history practitioner is, if any, in crisis events. In what follows, I discuss this and strategies for undertaking COVID-19 projects based on my experience as director for the T. Harry Williams Center for Oral History at Louisiana State University Libraries and on models for crisis-centered oral histories. I also discuss what project managers must take into consideration with regard to the sustainability of crisis oral history projects during our current period of increasing change and political unrest.
C1 [Cramer, Jennifer A.] Oral Hist Assoc, Cincinnati, OH 45203 USA.
RP Cramer, JA (corresponding author), Oral Hist Assoc, Cincinnati, OH 45203 USA.
CR Bostick Joan, 2020, TEMPESTS STORMS ARCH
   Boulanger Ghislaine, 2014, LISTENING EDGE ORAL, P112
   Campisi Elizabeth, 2014, LISTENING EDGE ORAL, P89
   Cave Mark, 2014, LISTENING EDGE ORAL, P3
   Clark Mary Marshall, 2020, ORAL HIST MASTERS PR
   Columbia Center for Oral History Research, 2020, INC REC GRANT NSF CO
   Gilbert D., 2006, STUMBLING HAPPINESS
   Kennelly Tamara, 2014, LISTENING EDGE ORAL, P71
   Kraybill Odelya Gertel, 2019, PSYCHOL TODAY
   Markides K. S., 1990, ORAL HIST REV, V45, P69
   Miller George, 2020, TEMPESTS STORMS ARCH
   Ohio State University's, COV 19 RES FOLKL
   Oral History Society, 2020, ADV REM OR HIST INT
   Ridgley Gwendolyn, 2020, TEMPESTS STORMS ARCH
   U.S. Congress, HR6615 US C
   van der Kolk B., 2014, BODY KEEPS SCORE BRA
   Wheeler Rochelle, 2014, ORAL HIST INTERVIEWS
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0094-0798
EI 1533-8592
J9 ORAL HIST REV
JI Oral Hist. Rev.
PY 2020
VL 47
IS 2
BP 203
EP 213
DI 10.1080/00940798.2020.1793679
PG 11
WC History
SC History
GA OS4QA
UT WOS:000590148300003
OA Bronze
DA 2021-01-01
ER

PT J
AU de Sousa, AFL
   Queiroz, AAFLN
   Lima, SVMA
   Almeida, PD
   de Oliveira, LB
   Chone, JS
   Araujo, TME
   Brignol, SMS
   de Sousa, AR
   Mendes, IAC
   Dias, S
   Fronteira, I
AF Lopes de Sousa, Alvaro Francisco
   Luz Nunes Queiroz, Artur Acelino Francisco
   Melo Almeida Lima, Shirley Veronica
   Almeida, Priscilla Dantas
   de Oliveira, Layze Braz
   Chone, Jeremias Salomao
   Evangelista Araujo, Telma Maria
   Silva Brignol, Sandra Mara
   de Sousa, Anderson Reis
   Costa Mendes, Isabel Amelia
   Dias, Sonia
   Fronteira, Ines
TI Chemsex practice among men who have sex with men (MSM) during social
   isolation from COVID-19: multicentric online survey
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE COVID-19; Sexual Behavior; Men Who Have Sex with Men; HIV; AIDS
ID GAY
AB The aim of this study was to investigate factors associated with sex practice under the effect of drugs (chemsex) among men who have sex with men (MSM) during the period of social isolation in the context of the COVID-19 pandemic. A multicenter online survey was applied to Brazil and Portugal in April 2020 when the two countries were under restrictive health measures due to the pandemic. Participants were recruited with an adaptation of the respondent driven sampling (RDS) method in the online environment. Data were collected using social networks and dating apps for MSM. We used bivariate and multivariate logistic regression to produce crude (OR) and adjusted odds ratios (aOR). In a universe of 2,361 subjects, 920 (38.9%) reported engaging in chemsex practice, which involved casual partners in 95% of the cases. Higher OR of engaging in chemsex were associated with Brazil (aOR = 15.4; 95%CI: 10.7-22.1), not being in social isolation (aOR = 4.9; 95%CI: 2.2-10.9), engaging in casual sex during social distancing (aOR = 52.4; 95%CI: 33.8-81.4), group sex (aOR = 2.9; 95%CI: 2.0-4.4), not presenting any symptom of COVID-19 (aOR = 1.3; 95%CI: 1.1-1.8), not living with the sex partner (aOR = 1.8; 95%CI: 1.2-2.6), and using pre-exposure prophylaxis (aOR = 2.6; 95%CI: 1.8-3.7). The occurrence of chemsex was high, especially in Brazil, where the proposed social distancing did not gain adherence by MSM.
C1 [Lopes de Sousa, Alvaro Francisco; de Oliveira, Layze Braz; Costa Mendes, Isabel Amelia] Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Av Bandeirantes 39011,Campus Univ, BR-14040902 Ribeirao Preto, SP, Brazil.
   [Luz Nunes Queiroz, Artur Acelino Francisco; Almeida, Priscilla Dantas; Evangelista Araujo, Telma Maria] Univ Fed Piaui, Teresina, Brazil.
   [Melo Almeida Lima, Shirley Veronica] Univ Fed Sergipe, Aracaju, Brazil.
   [Chone, Jeremias Salomao; Dias, Sonia; Fronteira, Ines] Univ Nova Lisboa, Inst Higiene & Med Trop, Lisbon, Portugal.
   [Silva Brignol, Sandra Mara] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil.
   [de Sousa, Anderson Reis] Univ Fed Bahia, Escola Enfermagem, Salvador, BA, Brazil.
RP de Sousa, AFL (corresponding author), Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Av Bandeirantes 39011,Campus Univ, BR-14040902 Ribeirao Preto, SP, Brazil.
EM sousa.alvaromd@gmail.com
RI de Sousa, Alvaro Francisco Lopes/C-4505-2016; Queiroz, Artur Acelino
   Francisco Luz Nunes/F-2775-2016; Mendes, Isabel Amelia
   Costa/J-7966-2012; Araujo, Telma Maria Evangelista de/F-5179-2018
OI de Sousa, Alvaro Francisco Lopes/0000-0003-2710-2122; Queiroz, Artur
   Acelino Francisco Luz Nunes/0000-0002-6350-1908; Mendes, Isabel Amelia
   Costa/0000-0002-0704-4319; Araujo, Telma Maria Evangelista
   de/0000-0001-5628-9577; Lima, Shirley/0000-0002-9062-0742; Brignol,
   Sandra/0000-0002-7728-2304; REIS DE SOUSA, ANDERSON/0000-0001-8534-1960
CR Barreto Victor Hugo de Souza, 2019, Mana, V25, P9, DOI 10.1590/1678-49442019v25n1p009
   Berger ZD, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1141
   Bernardes J., 2020, JORNAL USP
   Brennan DJ, 2020, AIDS BEHAV, V30, P1
   Camargo Paola de Oliveira, 2019, Revista Portuguesa de Enfermagem de Saúde Mental, P35, DOI 10.19131/rpesm.0261
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   DeJong CAJ, 2020, BASIC CLIN NEUROSCIE, V11, P163
   Duan YT, 2020, DRUG DISCOV TODAY, V25, P1545, DOI 10.1016/j.drudis.2020.06.018
   Garcia Leila Posenato, 2020, Epidemiol. Serv. Saúde, V29, pe2020222, DOI 10.5123/s1679-49742020000200009
   Hegazi A, 2017, INT J STD AIDS, V28, P362, DOI 10.1177/0956462416651229
   Id YJE, 2019, PLOS ONE, V14
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Queiroz AAFLN, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3970-y
   Queiroz AAFLN, 2018, REV BRAS ENFERM, V71, P1949, DOI 10.1590/0034-7167-2017-0409
   Mohler G, 2020, J CRIM JUST, V68, DOI 10.1016/j.jcrimjus.2020.101692
   O'Halloran C, 2019, INT J DRUG POLICY, V74, P246, DOI 10.1016/j.drugpo.2019.10.007
   Pakianathan M, 2018, HIV MED
   PrEP4All, DEV PREP COVID 19
   Queiroz AAFLN, 2019, BRAZ J INFECT DIS, V23, P298, DOI 10.1016/j.bjid.2019.07.005
   Rocha RP, 2020, ISOLAMENTO SOCIAL DI
   Sanchez TH, 2020, AIDS BEHAV, V24, P2024, DOI 10.1007/s10461-020-02894-2
   Silva RR, 2019, SAUDE COLETIVA, V51, P1920
   Sousa AFL, 2020, CASUAL SEX MSM PERIO, DOI DOI 10.1101/2020.06.07.20113142V2
   Tan RKJ, 2018, INT J DRUG POLICY, V61, P31, DOI 10.1016/j.drugpo.2018.10.002
   Torres TS, 2020, DRUG ALCOHOL DEPEN, V209, DOI 10.1016/j.drugalcdep.2020.107908
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   World Health Organization, 46 WHO
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
NR 29
TC 0
Z9 0
U1 0
U2 0
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2020
VL 36
IS 12
AR e00202420
DI 10.1590/0102-311X00202420
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PA3JZ
UT WOS:000595535400001
PM 33237252
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wang, B
   Lai, JK
   Yan, XY
   Jin, FF
   Yi, B
   An, CX
   Li, YX
   Yao, C
AF Wang, Bin
   Lai, Junkai
   Yan, Xiaoyan
   Jin, Feifei
   Yi, Bin
   An, Caixia
   Li, Yuanxiao
   Yao, Chen
TI COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An
   Overview and Characteristic Analysis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE COVID-19; clinical trials; investigation; intervention; drug; treatment
ID DEXAMETHASONE
AB Objective: This study aims to comprehensively evaluate the characteristics of clinical drug trials to facilitate the collection of evidence for COVID-19 drug treatments.
   Methods: A retrospective analysis of 910 trials retrieved on August 7, 2020.
   Results: A total of 910 registered clinical trials with at least one drug intervention were evaluated. The number of registrations (32.4%, 295) from the United States accounted for nearly one-third of the total and far exceeded that of other countries individually. Furthermore, the peak number of trials were registered in April (34.3%, 312). Over half of the trials (51.2%, 466) are in the recruitment phase, and only 4.2% (38) of the trials have been completed. The median (interquartile range) estimated enrollment is 127 (59, 365). In 39% (355) of trials, the estimated enrollment is less than 100 participants. A total of 94.5% (790) of the trials use randomization in the allocation, 82.7% (753) use a parallel intervention mode, and 52.2% (475) use masking. A total of 287 drug names have been standardized and mapped. "Hydroxychloroquine" is the leading drug among the registered trials (7.47%, 68). Among the main countries contributing to investigations on "hydroxychloroquine", the United States ranks first with 36.76% (25) of the trials.
   Conclusion: The designs of COVID-19 clinical drug trials have greatly improved in terms of the implementation of randomization and, particularly, blinding methods. In terms of drug reuse, the number of drug types has greatly increased, and hundreds of drugs have been used for efficacy screening. The emergence of large-sample registration trials is expected to address the uncertainty regarding the current clinical efficacy of some drugs.
C1 [Wang, Bin; Lai, Junkai; Jin, Feifei; Yao, Chen] Peking Univ First Hosp, Dept Biostat, Beijing, Peoples R China.
   [Yan, Xiaoyan; Yao, Chen] Peking Univ, Clin Res Inst, Beijing, Peoples R China.
   [Yi, Bin; An, Caixia] Gansu Prov Matern & Child Care Hosp, Childrens Emergency Ctr, Lanzhou, Peoples R China.
   [Li, Yuanxiao] Lanzhou Univ, Dept Pediat Gastroenterol, Hosp 2, Lanzhou, Peoples R China.
RP Yao, C (corresponding author), Peking Univ First Hosp, Beijing 100034, Peoples R China.
EM yaochen@hsc.pku.edu.cn
OI Wang, Bin/0000-0003-0012-9835
FU National Science and Technology Key Project [2017ZX10106001003];
   Comprehensive Research on COVID-19 Prevention for Emergency Scientific
   Research Project [GSEBMKT2020YJ03]; Science and Technology Project of
   Lanzhou City [2020SHFZ0041]
FX This study was supported by the National Science and Technology Key
   Project (No. 2017ZX10106001003), Comprehensive Research on COVID-19
   Prevention for Emergency Scientific Research Project (No.
   GSEBMKT2020YJ03), and Science and Technology Project of Lanzhou City
   (No. 2020SHFZ0041).
CR Abrams-Downey A, 2020, EUR UROL FOCUS, V6, P1028, DOI 10.1016/j.euf.2020.05.019
   Acuna-Castroviejo D, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12683
   Alamdari Daryoush Hamidi, 2020, Eur J Pharmacol, V885, P173494, DOI 10.1016/j.ejphar.2020.173494
   Alamdari DH, 2020, ARCH BONE JT SURG-AB, V8, P291, DOI 10.22038/abjs.2020.47745.2349
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Beigel J. H., 2020, N ENGL J MED
   Bischof E, 2020, J CLIN INVEST, V130, P3350, DOI 10.1172/JCI139306
   Boserup B, 2020, ANN MED SURG, V58, P84, DOI 10.1016/j.amsu.2020.08.041
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brotherton H, 2020, LANCET GLOB HEALTH, V8, pE1125, DOI 10.1016/S2214-109X(20)30318-1
   Camargo CA, 2020, FEBS J, V287, P3689, DOI 10.1111/febs.15534
   Dastan F, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106688
   Emamaullee J, 2020, J SURG RES, V256, P76, DOI 10.1016/j.jss.2020.06.049
   Feitosa EL, 2020, INT J MED SCI, V17, P2133, DOI 10.7150/ijms.48053
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Han ZZ, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100425
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Idda ML, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00497
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Karlsen APH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237903
   Kumari Puja, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00226-5
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mathioudakis AG, 2020, AM J RESP CRIT CARE, V202, P635, DOI 10.1164/rccm.202005-1942ED
   McMahon JH, 2020, NEW ENGL J MED, V383, P992, DOI 10.1056/NEJMc2022236
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Merzon E, 2020, FEBS J, V287, P3693, DOI 10.1111/febs.15495
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Nasrallah AA, 2020, J CLIN EPIDEMIOL, V125, P170, DOI 10.1016/j.jclinepi.2020.06.005
   Pan H, 2020, REPURPOSED ANTIVIRAL, V2020
   Rojek AM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01732-5
   Schlesinger Naomi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00225-6
   Sharun K, 2020, INT J SURG, V82, P179, DOI 10.1016/j.ijsu.2020.08.038
   Sher DJ, 2020, INT J RADIAT ONCOL, V108, P333, DOI 10.1016/j.ijrobp.2020.08.001
   Siebenand VS, 2020, PHARM ZTG, V165, P19
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Singh AG, 2020, HEAD NECK-J SCI SPEC, V42, P1516, DOI 10.1002/hed.26223
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Vanden Eynde JJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13010006
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang B, 2020, EUR J INTERN MED, V78, P145, DOI 10.1016/j.ejim.2020.03.016
   Wang B, 2020, CURR MED RES OPIN, V36, P1131, DOI 10.1080/03007995.2020.1771294
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yao Chen, 2018, J Evid Based Med, V11, P3, DOI 10.1111/jebm.12295
   Zhang X, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104927
   Zhang YX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01725-4
NR 52
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2020
VL 14
BP 5097
EP 5108
DI 10.2147/DDDT.S281700
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OZ8RP
UT WOS:000595186800001
PM 33239868
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lopez, RL
   Fernandez, SC
   Perez, LL
   Palacios, AR
   Fernandez-Roldan, MC
   Alonso, EA
   Camacho, IP
   Rodriguez-Bano, J
   Merchante, N
   Olalla, J
   Esteban-Moreno, MA
   Santos, M
   Luque-Pineda, A
   Torre-Cisneros, J
AF Leon Lopez, Rafael
   Carcel Fernandez, Sheila
   Limia Perez, Laura
   Romero Palacios, Alberto
   Concepcion Fernandez-Roldan, Maria
   Aguilar Alonso, Eduardo
   Perez Camacho, Ines
   Rodriguez-Bano, Jesus
   Merchante, Nicolas
   Olalla, Julian
   Angeles Esteban-Moreno, M.
   Santos, Marta
   Luque-Pineda, Antonio
   Torre-Cisneros, Julian
TI Efficacy and safety of early treatment with sarilumab in hospitalised
   adults with COVID-19 presenting cytokine release syndrome (SARICOR
   STUDY): protocol of a phase II, open-label, randomised, multicentre,
   controlled clinical trial
SO BMJ OPEN
LA English
DT Article
AB Introduction About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhibitor) in hospitalised patients with COVID-19, pulmonary infiltrates and a high IL-6 or D-dimer serum level could reduce the progression of ARDS requiring high-flow nasal oxygen or mechanical ventilation (non-invasive or invasive).
   Methods and analysis Phase II, open-label, randomised, multicentre, controlled clinical trial to study the efficacy and safety of the administration of two doses of sarilumab (200 and 400 mg) plus best available therapy (BAT) in hospitalised adults with COVID-19 presenting cytokine release syndrome. This strategy will be compared with a BAT control group. The efficacy and safety will be monitored up to 28 days postadministration. A total of 120 patients will be recruited (40 patients in each arm).
   Ethics and dissemination The clinical trial has been approved by the Research Ethics Committee of the coordinating centre and authorised by the Spanish Agency of Medicines and Medical Products. If the hypothesis is verified, the dissemination of the results could change clinical practice by increasing early administration of sarilumab in adult patients with COVID-19 presenting cytokine release syndrome, thus reducing intensive care unit admissions.
C1 [Leon Lopez, Rafael; Carcel Fernandez, Sheila] Hosp Univ Reina Sofia, Intens Care Unit, Cordoba, Andalucia, Spain.
   [Leon Lopez, Rafael; Carcel Fernandez, Sheila; Limia Perez, Laura; Torre-Cisneros, Julian] IMIBIC, Cordoba, Andalucia, Spain.
   [Limia Perez, Laura; Torre-Cisneros, Julian] Hosp Univ Reina Sofia, Internal Med Unit, Cordoba, Andalucia, Spain.
   [Romero Palacios, Alberto] Hosp Univ Puerto Real, Infect Dis Unit, Puerto Real, Andalucia, Spain.
   [Concepcion Fernandez-Roldan, Maria] Hosp Univ Virgen Nieves, Infect Dis Unit, Granada, Andalucia, Spain.
   [Aguilar Alonso, Eduardo] Hosp Infanta Margarita, Intens Care Unit, Cabra, Andalucia, Spain.
   [Perez Camacho, Ines] Hosp Reg Univ Malaga, Infect Dis Unit, Malaga, Andalucia, Spain.
   [Rodriguez-Bano, Jesus] Hosp Univ Virgen Macarena, Infect Dis Unit, Seville, Andalucia, Spain.
   [Rodriguez-Bano, Jesus] Carlos III Hlth Inst, Spanish Network Res Infect Dis, Madrid, Comunidad De Ma, Spain.
   [Merchante, Nicolas] Hosp Univ Virgen Valme, Infect Dis & Microbiol Unit, Seville, Andalucia, Spain.
   [Olalla, Julian] Hosp Costa Sol, Internal Med Serv, Marbella, Andalucia, Spain.
   [Angeles Esteban-Moreno, M.] Complejo Hosp Torrecardenas, Infect Dis Unit, Almeria, Andalucia, Spain.
   [Santos, Marta] Hosp Univ Jerez de la Frontera, Infect Dis Unit, Jerez de la Frontera, Andalucia, Spain.
   [Luque-Pineda, Antonio] IMIBIC, Clin Trials Unit, Cordoba, Spain.
   [Luque-Pineda, Antonio] Hosp Univ Reina Sofia, Cordoba, Andalucia, Spain.
RP Luque-Pineda, A (corresponding author), IMIBIC, Clin Trials Unit, Cordoba, Spain.; Luque-Pineda, A (corresponding author), Hosp Univ Reina Sofia, Cordoba, Andalucia, Spain.
EM antonio.luque@imibic.org
FU Ministry of Health and Families, Regional Government of Andalusia
   [COVID-0013-2020]
FX COVID-19 Research Programme. Ministry of Health and Families, Regional
   Government of Andalusia. Project code COVID-0013-2020.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], 2020, CANC DISCOV, V10, pOF8
   [Anonymous], 2020, J ULTRASOUND MED, V39, pE17
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Benetti E, 2020, EUR J HUM GENET, V28, P1602, DOI 10.1038/s41431-020-0691-z
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Cheng H, 2020, J MED VIROL, V92, P726, DOI [10.1002/jmv.25785, 10.2112/JCR-SI112-001.1]
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kohler BM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070938
   Laing A.G., 2020, NAT MED
   Li SH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138070
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   Maggi E, 2020, J ALLERGY CLIN IMMUN, V146, P18, DOI 10.1016/j.jaci.2020.05.001
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sinha P, 2020, JAMA INT MED
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R
   Wilson JG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140289
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Zhang XQ, 2020, POSTGRAD MED J, V96, P403, DOI 10.1136/postgradmedj-2020-137935
NR 24
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e039951
DI 10.1136/bmjopen-2020-039951
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OZ7YN
UT WOS:000595137100006
PM 33191263
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lin, LR
   Wang, X
   Ren, JW
   Sun, Y
   Yu, RJ
   Li, KL
   Zheng, LQ
   Yang, JR
AF Lin, Lirong
   Wang, Xiang
   Ren, Jiangwen
   Sun, Yan
   Yu, Rongjie
   Li, Kailong
   Zheng, Luquan
   Yang, Jurong
TI Risk factors and prognosis for COVID-19-induced acute kidney injury: a
   meta-analysis
SO BMJ OPEN
LA English
DT Article
DE nephrology; kidney &amp; urinary tract disorders; acute renal failure
AB Objective To analyse the incidence, risk factors and impact of acute kidney injury (AKI) on the prognosis of patients with COVID-19. Design Meta-analysis. Data sources PubMed, Embase, CNKI and MedRxiv of Systematic Reviews from 1 January 2020 to 15 May 2020. Study selection Studies examining the following demographics and outcomes were included: patients' age; sex; incidence of and risk factors for AKI and their impact on prognosis; COVID-19 disease type and incidence of continuous renal replacement therapy (CRRT) administration during COVID-19 infection. Results A total of 79 research articles, including 49 692 patients with COVID-19, met the systemic evaluation criteria. The mortality rate and incidence of AKI in patients with COVID-19 in China were significantly lower than those in patients with COVID-19 outside China. A significantly higher proportion of patients with COVID-19 from North America were aged >= 65 years and also developed AKI. European patients with COVID-19 had significantly higher mortality and a higher CRRT rate than patients from other regions. Further analysis of the risk factors for COVID-19 combined with AKI showed that age >= 60 years and severe COVID-19 were independent risk factors for AKI, with an OR of 3.53, 95% CI (2.92-4.25) and an OR of 6.07, 95% CI (2.53-14.58), respectively. The CRRT rate in patients with severe COVID-19 was significantly higher than in patients with non-severe COVID-19, with an OR of 6.60, 95% CI (2.83-15.39). The risk of death in patients with COVID-19 and AKI was significantly increased, with an OR of 11.05, 95% CI (9.13-13.36). Conclusion AKI was a common and serious complication of COVID-19. Older age and having severe COVID-19 were independent risk factors for AKI. The risk of in-hospital death was significantly increased in patients with COVID-19 complicated by AKI.
C1 [Lin, Lirong; Sun, Yan; Yu, Rongjie; Li, Kailong; Zheng, Luquan; Yang, Jurong] Chongqing Med Univ, Nephrol, Affiliated Hosp 3, Gener Hosp, Chongqing, Peoples R China.
   [Wang, Xiang] Chongqing Med Univ, Ultrasound, Affiliated Hosp 3, Gener Hosp, Chongqing, Peoples R China.
   [Ren, Jiangwen] Jiulongpo Peoples Hosp Chongqing, Nephrol, Chongqing, Peoples R China.
RP Yang, JR (corresponding author), Chongqing Med Univ, Nephrol, Affiliated Hosp 3, Gener Hosp, Chongqing, Peoples R China.
EM 650230@hospital.cqmu.edu.cn
FU Basic and Frontier Research ProgramProgramme of Chongqing
   [cstc2017jcyjBX0014, cstc2019jscx-msxmX0166]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81770682]
FX This work was supported by the Basic and Frontier Research
   ProgramProgramme of Chongqing (cstc2017jcyjBX0014,
   cstc2019jscx-msxmX0166) and grants from the National Natural Science
   Foundation of China (81770682).
CR Aditi Shastri JW, 2020, DELAYED CLEARANCE SA
   Alexander Gorbalenya E E, 2020, BIORXIV
   Ali H, 2020, RENAL FAILURE, V42, P393, DOI 10.1080/0886022X.2020.1756323
   Bo Diao CW, 2020, HUMAN KIDNEY IS TARG
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Chen Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016867
   China NHCotPsRo, 2020, NOT LAUNCH GUID DIAG
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Daniel Wrapp NW, 2020, BIORXIV
   Hao Zhou WC, 2020, DELAYED PHASE THROMB
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Kun-Long Ma Z-HL, 2020, COVID 19 MYOCARDITIS
   Ling Mao MW, 2020, NEUROLOGICAL MANIFES
   Liu ZZ, 2020, CHRONIC KIDNEY DIS A
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mubarak M, 2020, IMMUNOPATHOL PERSA, V6, DOI 10.34172/ipp.2020.18
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Tang XJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171202
   Uhler C, 2020, NAT REV MOL CELL BIO, V21, P247, DOI 10.1038/s41580-020-0242-z
   Uhler C, 2017, NAT REV MOL CELL BIO, V18, P717, DOI 10.1038/nrm.2017.101
   W ZP Y, 2020, J NEPHROPATHOL, V9, DOI [http://dx.doi.org/10.34172/jnp.2020.37, DOI 10.34172/JNP.2020.37]
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Wu M, 2020, CAUTION KIDNEY DYSFU
   Xin Zhao ZL, 2020, IMPACT CORONAVIRUS D
   Yalameha B, 2020, J NEPHROPHARMACOL, V9, pe22
   Yang L, 2015, LANCET, V386, P1465, DOI 10.1016/S0140-6736(15)00344-X
   Yao X, 2020, CHINESE J PATHOL, V49, pE009
   Yichun Cheng RL, 2020, KIDNEY IMPAIRMENT IS
   Zhixiang Mou XZ, 2020, DANGERS ACUTE KIDNEY
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
   Zununi Vahed S, 2020, IMMUNOPATHOL PERSA, V6, P27, DOI 10.34172/ipp.2020.27
NR 33
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 11
AR e042573
DI 10.1136/bmjopen-2020-042573
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OX7NZ
UT WOS:000593748200010
PM 33172950
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Borges, V
   Isidro, J
   Cortes-Martins, H
   Duarte, S
   Vieira, L
   Leite, R
   Gordo, I
   Caetano, CP
   Nunes, B
   Sa, R
   Oliveira, A
   Guiomar, R
   Gomes, JP
AF Borges, Vitor
   Isidro, Joana
   Cortes-Martins, Helena
   Duarte, Silvia
   Vieira, Luis
   Leite, Ricardo
   Gordo, Isabel
   Caetano, Constantino P.
   Nunes, Baltazar
   Sa, Regina
   Oliveira, Ana
   Guiomar, Raquel
   Gomes, Joao Paulo
CA Portuguese Network SARS-CoV-2 Ge
TI Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; genomic epidemiology; mutation; genetic variant;
   Spike; fusion peptide; D839Y
AB Genomic surveillance of SARS-CoV-2 was rapidly implemented in Portugal by the National Institute of Health in collaboration with a nationwide consortium of >50 hospitals/laboratories. Here, we track the geotemporal spread of a SARS-CoV-2 variant with a mutation (D839Y) in a potential host-interacting region involving the Spike fusion peptide, which is a target motif of anti-viral drugs that plays a key role in SARS-CoV-2 infectivity. The Spike Y839 variant was most likely imported from Italy in mid-late February and massively disseminated in Portugal during the early epidemic, becoming prevalent in the Northern and Central regions of Portugal where it represented 22% and 59% of the sampled genomes, respectively, by 30 April. Based on our high sequencing sampling during the early epidemics [15.5% (1275/8251) and 6.0% (1500/24987) of all confirmed cases until the end of March and April, respectively], we estimate that, between 14 March and 9 April (covering the epidemic exponential phase) the relative frequency of the Spike Y839 variant increased at a rate of 12.1% (6.1%-18.2%, CI 95%) every three days, being potentially associated with 24.8% (20.8-29.7%, CI 95%; 3177-4542 cases, CI 95%) of all COVID-19 cases in Portugal during this period. Our data supports population/epidemiological (founder) effects contributing to the Y839 variant superspread. The potential existence of selective advantage is also discussed, although experimental validation is required. Despite huge differences in genome sampling worldwide, SARS-CoV-2 Spike D839Y has been detected in 13 countries in four continents, supporting the need for close surveillance and functional assays of Spike variants.
C1 [Borges, Vitor; Isidro, Joana; Gomes, Joao Paulo; Portuguese Network SARS-CoV-2 Ge] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Bioinformat Unit, Lisbon, Portugal.
   [Cortes-Martins, Helena] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Reference & Surveillance Unit, Lisbon, Portugal.
   [Duarte, Silvia; Vieira, Luis] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Human Genet, Innovat & Technol Unit, Lisbon, Portugal.
   [Vieira, Luis] Univ Nova Lisboa, Fac Ciencias Med, Nova Med Sch, Ctr Toxicogen & Human Hlth Tox Genet Oncol & Huma, Lisbon, Portugal.
   [Leite, Ricardo; Gordo, Isabel] Inst Gulbenkian Ciencia IGC, Oeiras, Portugal.
   [Caetano, Constantino P.; Nunes, Baltazar] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Epidemiol, Lisbon, Portugal.
   [Nunes, Baltazar] Univ Nova Lisboa, Escola Nacl Saude Publ, Ctr Invest Saude Publ, Lisbon, Portugal.
   [Sa, Regina; Oliveira, Ana] Cent Reg Hlth Adm, Primary Care Cluster Baixo Vouga, Publ Hlth Unit, Aveiro, Portugal.
   [Guiomar, Raquel] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Natl Reference Lab Influenza & Other Resp Viruses, Lisbon, Portugal.
RP Gomes, JP (corresponding author), Natl Inst Hlth Doutor Ricardo Jorge, Dept Infect Dis, Av Padre Cruz, P-1649016 Lisbon, Portugal.
EM j.paulo.gomes@insa.min-saude.pt
RI Leite, Ricardo/B-3389-2008; Veiga, Maria Isabel/H-9922-2018; Sousa,
   Hugo/B-7714-2011; Gordo, Isabel/D-6770-2013; Manageiro, Vera/M-9226-2013
OI Leite, Ricardo/0000-0002-9622-3895; Veiga, Maria
   Isabel/0000-0002-2205-8102; Sousa, Hugo/0000-0001-5795-2131; Gordo,
   Isabel/0000-0003-1622-5143; Borrego, Maria Jose/0000-0002-8604-8800;
   Borges, Vitor/0000-0003-3767-2209; Manageiro, Vera/0000-0001-7729-4199
FU Agencia de Investigacao Clinica e Inovacao Biomedica [234_596874175];
   COMPETE 2020 - Operational Programme for Competitiveness and
   Internationalisation (POCI) [POCI-01-0145FEDER-022184]; Lisboa Portugal
   Regional Operational Programme (Lisboa2020) [POCI-01-0145FEDER-022184];
   Algarve Portugal Regional Operational Programme (CRESC Algarve2020),
   under the PORTUGAL 2020 Partnership Agreement, through the European
   Regional Development Fund (ERDF) [POCI-01-0145FEDER-022184]; Fundacao
   para a Ciencia e a Tecnologia (FCT)Portuguese Foundation for Science and
   Technology [POCI-01-0145FEDER-022184]; Fundacao para a Ciencia e a
   TecnologiaPortuguese Foundation for Science and Technology
FX This study is co-funded by Fundacao para a Ciencia e a Tecnologia and
   Agencia de Investigacao Clinica e Inovacao Biomedica [grant number
   234_596874175] on behalf of the Research 4 COVID-19 call. This work is
   also a result of the GenomePT project [grant number
   POCI-01-0145FEDER-022184], supported by COMPETE 2020 - Operational
   Programme for Competitiveness and Internationalisation (POCI), Lisboa
   Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal
   Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL
   2020 Partnership Agreement, through the European Regional Development
   Fund (ERDF), and by Fundacao para a Ciencia e a Tecnologia (FCT).
CR Alm E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.32.2001410
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Argimon S, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000093
   Borges V, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0555-0
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Cheng Mary Hongying, 2020, Proc Natl Acad Sci U S A, V117, P25254, DOI 10.1073/pnas.2010722117
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lorenzo-Redondo Ramon, 2020, medRxiv, DOI 10.1101/2020.05.19.20107144
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rueca M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091302
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Vishnubhotla R., 2020, GENETIC VARIANTS TMP, DOI [10.1101/2020.06.30.179663, DOI 10.1101/2020.06.30.179663]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 25
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2488
EP 2496
DI 10.1080/22221751.2020.1844552
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OX4QX
UT WOS:000593552200001
PM 33131453
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khurshid, A
   Ahmed, MA
   Aziz, A
   Amin, R
AF Khurshid, A.
   Ahmed, M. Ammar
   Aziz, A.
   Amin, R.
TI Living with Coronavirus (COVID-19): a brief report
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Coronavirus; Pandemic; SARS-CoV-2; Lockdown; Testing;
   Infection; Therapeutics; Diagnosis
ID OUTBREAK
AB The world will never be the same after the current COVID-19 pandemic. We may have to live with the coronavirus for a long time. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has resulted in a major burden on the global health system and economy. This report describes the current COVID-19 landscape and its socioeconomic implications. Despite the concerns for second waves of infection, gradual lifting of lockdown restrictions has occurred worldwide to relieve economic pressures and likely contributes towards possibly surging of outbreak although region wise variation exists due to several other biological factors, such as testing capacity and basic healthcare facilities among susceptible population within that region. Different prediction models have been put forth to forecast the spread of the current outbreak. However, it is challenging to perceive the precise changes happening in the real world as every time dynamics differ same as other epidemics cannot possibly be exactly superimposed to COVID-19. Currently, to decrypt the conundrum for effective antiviral drug against SARS-CoV-2 is in full swing. Due to high rate of mortality and it expeditiously spread is it decisive to understand the biological properties, clinical characteristics, epidemiology, evolution, pathogenesis for vaccine development and pathogenicity studies against the viral curb. Instant diagnostic and adequate therapeutics serve as a major intervention for the management of pandemic containment. Our study aims to analyze the impact of current measures and to suggest appropriate administrative strategic planning rather than to make somewhat authentic prediction in relation to the current scenario. Our predictive analysis analysis study should be helpful against prevention, cure and control of the current outbreak of COVID-19 till the availability of cure or vaccine.
C1 [Khurshid, A.] DOW Univ Hlth Sci, DOW Coll Biotechnol, DOW Res Inst Biotechnol & Biomed Sci, Karachi, Pakistan.
   [Ahmed, M. Ammar] Inst Business Adm, Dept Comp Sci, Karachi, Pakistan.
   [Aziz, A.] Univ Salford, Biomed Res Ctr, Sch Environm & Life Sci, Manchester, Lancs, England.
   [Amin, R.] Univ Hafr Al Batin, Coll Sci, Dept Biol, Hafar Al Batin, Saudi Arabia.
RP Khurshid, A (corresponding author), DOW Univ Hlth Sci, DOW Coll Biotechnol, DOW Res Inst Biotechnol & Biomed Sci, Karachi, Pakistan.; Aziz, A (corresponding author), Univ Salford, Biomed Res Ctr, Sch Environm & Life Sci, Manchester, Lancs, England.; Amin, R (corresponding author), Univ Hafr Al Batin, Coll Sci, Dept Biol, Hafar Al Batin, Saudi Arabia.
EM asma.khurshid@duhs.edu.pk; a.aziz@salford.ac.uk; rashida@uhb.edu.sa
RI Khurshid, Asma/ABH-8346-2020
CR Aghagoli G, 2020, J CARDIAC SURG, V35, P1302, DOI 10.1111/jocs.14538
   [Anonymous], 2020, J PAEDIATR CHILD H, V56, P657
   Arduino PG, 2020, ORAL DIS, DOI 10.1111/odi.13362
   Asadi S, 2020, AEROSOL SCI TECH, V54, P635, DOI 10.1080/02786826.2020.1749229
   Basu-Ray I., 2020, CARDIAC MANIFESTATIO
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Brown H, 2019, GRACE AND PHILOSOPHY: UNDERSTANDING A GRATUITOUS WORLD, P3
   Calderaro A, 2020, INT J INFECT DIS, V96, P387, DOI 10.1016/j.ijid.2020.05.035
   Calvillo-Arguelles Oscar, 2020, JACC CardioOncol, V2, P345, DOI 10.1016/j.jaccao.2020.04.001
   Cascella M, 2020, FEATURES EVALUATION
   Casey K, 2020, AM J EMERG MED, P1
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   CHOWDHURY N, 2020, VIRUSDISEASE, P1, DOI DOI 10.1007/S13337-020-00579-X
   Ciotti M, 2020, J AM COLL CARDIOL, P1
   Columbus Cristie, 2020, Proc (Bayl Univ Med Cent), V33, P209, DOI 10.1080/08998280.2020.1731272
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   De Clercq E, 2019, CHEM-ASIAN J, V14, P3962, DOI 10.1002/asia.201900841
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, P1
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Frater JL, 2020, INT J LAB HEMATOL, V42, P11, DOI 10.1111/ijlh.13229
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hossein-khannazer N, 2020, J MOL MED, V98, P789, DOI 10.1007/s00109-020-01927-6
   Joshua U, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04009
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Leboulanger N, 2020, EUR ANN OTORHINOLARY, V137, P177, DOI 10.1016/j.anorl.2020.04.010
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z
   Li Meng, 2020, Radiol Infect Dis, V7, P51, DOI 10.1016/j.jrid.2020.04.001
   Lian J, 2020, CLIN INFECT DIS, P1
   Lin BY, 2020, OMICS, V24, P231, DOI 10.1089/omi.2020.0047
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma SY, 2020, BURNS, V46, P749, DOI 10.1016/j.burns.2020.03.014
   Macc M, 2020, CHEM PHYS LETT, P1
   Menzella F, 2020, DRUGS CONTEXT, V9, P1
   Mohammadi M, 2020, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-020-01258-3
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Phillip JP, 2020, PREHOSP DISASTER MED, P1
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   van Doremalen N, 2014, EMERG INFECT DIS, V20, P1263, DOI 10.3201/eid2007.140500
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yu L, 2020, CLIN CHEM, P1
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang ZJ, 2020, J INTEGR MED-JIM, V18, P229, DOI 10.1016/j.joim.2020.03.004
   Zheng YL, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104366
   Zhou Y, 2020, CELL CYCLE, V19, P2589, DOI 10.1080/15384101.2020.1804720
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Shudong, 2020, Discoveries (Craiova), V8, pe105, DOI 10.15190/d.2020.2
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 53
TC 0
Z9 0
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 20
BP 10902
EP 10912
DI 10.26355/eurrev_202010_23455
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OL1FI
UT WOS:000585086700081
PM 33155254
DA 2021-01-01
ER

PT J
AU Oliveira, LMD
   Tiyo, BT
   da Silva, LT
   Fonseca, LAM
   Rocha, RC
   dos Santos, VA
   Ceneviva, C
   Bedin, AA
   de Almeida, A
   Duarte, AJD
   Oshiro, TM
AF da Silva Oliveira, Luanda Mara
   Tiyo, Bruna Tiaki
   da Silva, Lais Teodoro
   Marcondes Fonseca, Luiz Augusto
   Rocha, Rosana Coura
   dos Santos, Vera Aparecida
   Ceneviva, Carina
   Bedin, Anderson Aparecido
   de Almeida, Alexandre
   da Silva Duarte, Alberto Jose
   Oshiro, Telma Miyuki
TI Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large
   public university hospital in Sao Paulo, Brazil
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE COVID-19; Anti-SARS-CoV-2 antibodies; Serological inquiry
AB Coronavirus disease 19 (COVID-19) is caused by SARS-Cov-2 and the manifestations of this infection range from an absence of symptoms all the way up to severe disease leading to death. To estimate the prevalence of past infection in a population, the most readily available method is the detection of antibodies against the virus. This study has investigated the prevalence of anti-SARS-CoV-2 antibodies in outpatients of the Hospital das Clinicas, in Sao Paulo city (Brazil), which is a large university hospital belonging to the public health system that cares for patients with complex diseases who need tertiary or quaternary medical care. Our serological inquiry was carried out for 6 weeks, with once-a-week blood sampling and included 439 patients from several outpatient services. Overall, 61 patients tested positive for anti-SARS-CoV-2 IgG (13.9%); 56.1 % of the patients live in Sao Paulo city, with the remaining living in other towns of the metropolitan area; 32.8% of the patients testing positive for IgG antibodies to SARS-CoV-2 were asymptomatic, 55.7% developed mild or moderate disease and 11.5% had to be hospitalized. The prevalence of SARS-CoV-2 positive serology was lower among patients who had received the seasonal influenza vaccine compared to the ones who did not. These findings may indicate that those individuals care more about health issues, and/or that they have a better access to health care and/or a better quality of health care service. The large proportion of patients who were unaware of having had contact with SARS-CoV-2 deserves attention, reflecting the scarcity of tests performed in the population.
C1 [da Silva Oliveira, Luanda Mara; Tiyo, Bruna Tiaki; da Silva, Lais Teodoro; Marcondes Fonseca, Luiz Augusto; Rocha, Rosana Coura; de Almeida, Alexandre; da Silva Duarte, Alberto Jose; Oshiro, Telma Miyuki] Univ Sao Paulo, Hosp Clin, Fac Med, Lab Invest Med Dermatol & Imunodeficiencias LIM 5, Rua Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [dos Santos, Vera Aparecida; Ceneviva, Carina; Bedin, Anderson Aparecido; da Silva Duarte, Alberto Jose] Univ Sao Paulo, Hosp Clin, Fac Med, Div Lab Cent, Sao Paulo, SP, Brazil.
RP Oliveira, LMD (corresponding author), Univ Sao Paulo, Hosp Clin, Fac Med, Lab Invest Med Dermatol & Imunodeficiencias LIM 5, Rua Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM luandaoliveira@usp.br
OI Fonseca, Luiz/0000-0003-3113-8558; Tiyo, Bruna/0000-0002-8107-9536;
   Bedin, Anderson Aparecido/0000-0002-1854-8002
FU Sao Paulo Foundation Research, FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2016/25212-9]; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2019/07976-0, 2018/12460-0];
   CAPESCAPES [88887.472042/2019-00]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [302945/2019-9]
FX This work was supported by Sao Paulo Foundation Research, FAPESP (grant
   No 2016/25212-9). LMSO and LTS are recipients of fellowship from FAPESP
   (grants No 2019/07976-0 and 2018/12460-0). BTT is recipient of a
   fellowship from CAPES (grant No 88887.472042/2019-00). TMO is recipient
   of a fellowship from CNPq (grant No 302945/2019-9).
CR [Anonymous], SER SOR SURV MON PRE
   Brasil. Ministerio da Saude, COVID 19 BRAS
   Brasil. Ministerio da Saude, COVID 19 PAIN COR
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Garces TS, 2020, J CLIN NURS, V29, P4343, DOI 10.1111/jocn.15472
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Nikolai Lea A, 2020, Int J Infect Dis, V100, P112, DOI 10.1016/j.ijid.2020.08.076
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Sao Paulo, 2020, B DIARIO COVID 19 ED
   Theel ES, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00797-20
   Wang YR, 2020, J INFECT DIS, V221, P1770, DOI 10.1093/infdis/jiaa119
   World Health Organization, WHO COR DIS COVID 19
   Zhao B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002019
NR 17
TC 0
Z9 0
U1 0
U2 0
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2020
VL 62
AR e91
DI 10.1590/S1678-9946202062091
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA OW4TT
UT WOS:000592881800005
PM 33206865
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yuan, J
   Kou, SL
   Liang, YH
   Lan, JF
   Li, XH
   Zeng, LJ
   Zou, RR
   Liu, YX
   Liu, L
   Pan, YC
AF Yuan, Jing
   Kou, Shanglong
   Liang, Yanhua
   Lan, JianFeng
   Li, Xiaohe
   Zeng, Lijiao
   Zou, Rongrong
   Liu, Yingxia
   Liu, Lei
   Pan, Yanchao
TI Immunological Evaluation on Potential Treatment Window for Hospitalized
   COVID-19 Patients
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE COVID-19; critical illness; potential window; length of hospital stay
AB Purpose: Novel coronavirus disease has become such an escalating epidemic that the exponential growth of infected patients has overloaded the health-care systems in many countries. Determination of early assessments for patients with a risk of clinical deterioration would benefit the management of COVID-19 outbreaks.
   Patients and Methods: A total of 214 confirmed COVID-19 patients were enrolled from January 11th to February 11th 2020. Medical records including laboratory parameters, clinical outcomes and other characteristics of the admitted patients were analyzed retrospectively.
   Results: The critical patients experienced a significantly prolonged onset-admission interval and presented with lymphopenia (r=-0.547, p=0.015) and lower albumin level (p<0.001) 6 days after symptom onset. Early admission of critical patients significantly reduced the duration of hormone therapy. Starting from 9 days of hospital stay, the reduced lymphocyte counts exhibited linear growth. Furthermore, on days 9 and 12, significant correlations were demonstrated between immunological manifestations and duration of hormone therapy in critical patients, and length of hospital stay in severe patients. In addition, the virus negative conversion rate was more significantly correlated with increased lymphocytes in critical patients.
   Conclusion: Early intervention, within 6 days of symptom onset, benefited patients' recovery from critical illness. The 9-12 days of hospital care represented a valuable window during which to evaluate the therapeutic effects on physical recovery and virus clearance.
C1 [Yuan, Jing; Liang, Yanhua; Lan, JianFeng; Li, Xiaohe; Zeng, Lijiao; Zou, Rongrong; Liu, Yingxia; Liu, Lei; Pan, Yanchao] Shenzhen Third Peoples Hosp, Diag & Treatment Infect Dis Res Ctr, Shenzhen, Guangdong, Peoples R China.
   [Kou, Shanglong] South China Univ Technol, Coll Chem & Chem Engn, Guangzhou, Guangdong, Peoples R China.
RP Pan, YC (corresponding author), Shenzhen Third Peoples Hosp, Diag & Treatment Infect Dis Res Lab, Shenzhen 518112, Guangdong, Peoples R China.
EM panychao@126.com
FU Sanming Project of Medicine in Shenzhen [SZSM201512005]
FX This work was supported by Sanming Project of Medicine in Shenzhen
   (SZSM201512005).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Basu A, 2020, HEALTH AFFAIR, V39, P1229, DOI 10.1377/hlthaff.2020.00455
   Chen G, 2020, CLIN INVEST
   Danis K, 2020, CLIN INFECT DIS, V71, P825, DOI 10.1093/cid/ciaa424
   Erikstrup C, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa84914., DOI 10.1093/CID/CIAA84914]
   Escalera-Antezana JP, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101653
   Ghisolfi S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003094
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kenyon C, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9060128
   Li H, 2020, J INFECT, V18
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Meyerowitz-Katz Gideon, 2020, Int J Infect Dis, V101, P138, DOI 10.1016/j.ijid.2020.09.1464
   Onder G, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.46839., DOI 10.1001/JAMA.2020.46839]
   Qin C, 2020, CLIN INFECT DIS
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2020
VL 13
BP 985
EP 993
DI 10.2147/JIR.S280331
PG 9
WC Immunology
SC Immunology
GA OW0JB
UT WOS:000592583500001
PM 33262634
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Carvalho, HD
   Vasconcelos, KGMC
   Gomes, HC
   Salvajoli, JV
AF Carvalho, Heloisa de Andrade
   Vasconcelos, Karina Gondim Moutinho C.
   Gomes, Herbeni Cardoso
   Salvajoli, Joao Victor
TI Impact of COVID-19 pandemic on a daily-based outpatient treatment
   routine: experience of a radio-therapy department of a tertiary
   public/university hospital in Brazil
SO CLINICS
LA English
DT Article
DE Radiotherapy; Coronavirus Pandemic; Treatment Policy
ID CANCER
AB OBJECTIVES: To report the impact of the COVID-19 pandemic on patient attendance at a radiotherapy department two months after the implementation of specific policies regarding the pandemic.
   METHODS: The proposed treatment schemes, favoring hypofractionated schedules, and COVID-19 management strategies regarding irradiation are presented. Attendance after two months of implementation of these policies was measured and compared with that during the same period in 2019.
   RESULTS: A 10% reduction in the number of treated patients and a 26% reduction in the number of sessions was observed. The main impact was a decrease in the treatment of benign diseases and gastrointestinal tumors, with a general increase in breast cancer treatments. Eighteen (1.7%) patients were confirmed as having COVID-19 during radiotherapy in April and May 2020, three of whom were hospitalized, and one patient died because of COVID-19. Among the 18 patients, 12 had their treatments interrupted for at least 15 days from symptom appearance.
   CONCLUSION: There was a decrease in the number of treated patients in our radiotherapy department, with a greater decrease in the total number of sessions. This indicated, overall, a smaller number of fractions/patients treated, despite our efforts to maintain the treatment routine. We had several patients who were infected with COVID-19 and one related death during treatment in the first few months of the pandemic in Sao Paulo Brazil.
C1 [Carvalho, Heloisa de Andrade; Vasconcelos, Karina Gondim Moutinho C.; Gomes, Herbeni Cardoso; Salvajoli, Joao Victor] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Serv Radioterapia,Inst Radiol InRad,Inst Canc Est, Sao Paulo, SP, Brazil.
RP Carvalho, HD (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Serv Radioterapia,Inst Radiol InRad,Inst Canc Est, Sao Paulo, SP, Brazil.
EM heloisa.carvalho@hc.fm.usp.br
CR Akladios C, 2020, J GYNECOL OBSTET HUM, V49, DOI 10.1016/j.jogoh.2020.101729
   Baldotto C, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2060
   Chaves ALF, 2020, ORAL ONCOL, V107, DOI 10.1016/j.oraloncology.2020.104734
   Chen ATC, 2018, RADIOTHER ONCOL, V127, P299, DOI 10.1016/j.radonc.2018.03.021
   Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006
   Gay HA, 2019, PRACT RADIAT ONCOL, V9, P305, DOI 10.1016/j.prro.2019.03.007
   Governo do Estado de Sao Paulo-Secretaria de Estado da Saude, B DIAR COVID 19
   Guckenberger M, 2020, RADIOTHER ONCOL, V146, P223, DOI 10.1016/j.radonc.2020.04.001
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Thomson DJ, 2020, INT J RADIAT ONCOL, V107, P618, DOI 10.1016/j.ijrobp.2020.04.016
   Tuech JJ, 2020, J VISC SURG, V157, pS7, DOI 10.1016/j.jviscsurg.2020.03.008
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
NR 14
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2020
VL 75
AR e2298
DI 10.6061/clinics/2020/e2298
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OV5PD
UT WOS:000592260700001
PM 33174949
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rathnasinghe, R
   Strohmeier, S
   Amanat, F
   Gillespie, VL
   Krammer, F
   Garcia-Sastre, A
   Coughlan, L
   Schotsaert, M
   Uccellini, MB
AF Rathnasinghe, Raveen
   Strohmeier, Shirin
   Amanat, Fatima
   Gillespie, Virginia L.
   Krammer, Florian
   Garcia-Sastre, Adolfo
   Coughlan, Lynda
   Schotsaert, Michael
   Uccellini, Melissa B.
TI Comparison of transgenic and adenovirus hACE2 mouse models for
   SARS-CoV-2 infection
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE2; adenovirus; mouse models
ID RESPIRATORY SYNDROME CORONAVIRUS; DENDRITIC CELLS; IN-VIVO; MICE; SARS;
   RECEPTOR; TOXICITY; ACE2
AB Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is currently causing a worldwide pandemic with high morbidity and mortality. Development of animal models that recapitulate important aspects of coronavirus disease 2019 (COVID-19) is critical for the evaluation of vaccines and antivirals, and understanding disease pathogenesis. SARS-CoV-2 has been shown to use the same entry receptor as SARS-CoV-1, human angiotensin-converting enzyme 2 (hACE2) [1-3]. Due to amino acid differences between murine and hACE2, inbred mouse strains fail to support high titer viral replication of SARS-CoV-2 virus. Therefore, a number of transgenic and knock-in mouse models, as well as viral vector-mediated hACE2 delivery systems have been developed. Here we compared the K18-hACE2 transgenic model to adenovirus-mediated delivery of hACE2 to the mouse lung. We show that K18-hACE2 mice replicate virus to high titers in the nasal turbinates, lung and brain, with high lethality, and cytokine/chemokine production. In contrast, adenovirus-mediated delivery results in viral replication to lower titers limited to the nasal turbinates and lung, and no clinical signs of infection. The K18-hACE2 model provides a stringent model for testing vaccines and antivirals, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.
C1 [Rathnasinghe, Raveen; Strohmeier, Shirin; Amanat, Fatima; Krammer, Florian; Garcia-Sastre, Adolfo; Coughlan, Lynda; Schotsaert, Michael; Uccellini, Melissa B.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Rathnasinghe, Raveen; Garcia-Sastre, Adolfo; Schotsaert, Michael; Uccellini, Melissa B.] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [Rathnasinghe, Raveen; Strohmeier, Shirin; Amanat, Fatima] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Gillespie, Virginia L.] Icahn Sch Med Mt Sinai, Ctr Comparat Med & Surg CCMS, Comparat Pathol Lab, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Coughlan, Lynda] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Coughlan, Lynda] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth CVD, Baltimore, MD 21201 USA.
RP Coughlan, L; Schotsaert, M (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Schotsaert, M (corresponding author), Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
EM Lcoughlan@som.umaryland.edu; Michael.Schotsaert@mssm.edu
OI Rathnasinghe, Raveen/0000-0002-1260-2493; Coughlan,
   Lynda/0000-0001-9880-6560
FU National Institute of Allergy and Infectious Diseases (NIAID) Centers of
   Excellence for Influenza Research and Surveillance (CEIRS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201400008C]; NIAIDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI135972, R21AI157606];
   DoDUnited States Department of Defense [W81XWH-20-1-0270]; Defense
   Advanced Research Projects Agency grant [HR0011-19-2-0020]; JPB
   Foundation; Open Philanthropy Project [2020-215611 (5384)]
FX This work was partially supported by the National Institute of Allergy
   and Infectious Diseases (NIAID) Centers of Excellence for Influenza
   Research and Surveillance (CEIRS) contract HHSN272201400008C (F.K.,
   A.G.-S.), by supplements to NIAID grant U19AI135972 and DoD grant
   W81XWH-20-1-0270 (A.G.-S.), by the Defense Advanced Research Projects
   Agency grant HR0011-19-2-0020 (A.G.-S.), by the generous support of the
   JPB Foundation (A.G.-S.), the Open Philanthropy Project (research grant
   2020-215611 (5384)) and other philanthropic donations to A.G.-S and F.K,
   and by NIAID R21AI157606 (L.C).
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   BONI MF, 2020, NAT MICROBIOL 0728, DOI DOI 10.1101/2020.03.30.015008:2020.2003.2030.015008
   Case J.B., 2020, CELL HOST MICROBE
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Coughlan L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00909
   Coughlan L, 2012, MOL THER, V20, P2268, DOI 10.1038/mt.2012.162
   Coughlan L, 2012, HUM GENE THER, V23, P960, DOI 10.1089/hum.2011.218
   Coughlan L, 2010, VIRUSES-BASEL, V2, P2290, DOI 10.3390/v2102290
   Coughlan L, 2009, J VIROL, V83, P6416, DOI 10.1128/JVI.00445-09
   DINNON KH, 2020, NATURE 0827, DOI DOI 10.1101/2020.05.06.081497
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Israelow Benjamin, 2020, bioRxiv, DOI 10.1101/2020.05.27.118893
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   McInnes E., 2013, PRACTICAL GUIDE HIST, P179
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Mercier S, 2002, J VIROL, V76, P2899, DOI 10.1128/JVI.76.6.2899-2911.2002
   MULLIGAN MJ, 2020, NATURE 0812, DOI DOI 10.1101/2020.06.30.20142570:2020.2006.2030.20142570
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Tseng CTK, 2007, J VIROL, V81, P1162, DOI 10.1128/JVI.01702-06
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yinda Claude Kwe, 2020, bioRxiv, DOI 10.1101/2020.08.11.246314
   Yoshikawa N, 2009, J VIROL, V83, P5451, DOI 10.1128/JVI.02272-08
   Zhang Q, 2020, SCIENCE, V370, P422, DOI 10.1126/science.abd4570
   Zhang Y, 2001, MOL THER, V3, P697, DOI 10.1006/mthe.2001.0329
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   ZOST SJ, 2020, NATURE 0715, DOI DOI 10.1101/2020.05.22.111005
   Zsengeller Z, 2000, J VIROL, V74, P9655, DOI 10.1128/JVI.74.20.9655-9667.2000
NR 59
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2433
EP 2445
DI 10.1080/22221751.2020.1838955
PG 13
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OU5PE
UT WOS:000591579900001
PM 33073694
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Mohaithef, M
   Padhi, BK
AF Al-Mohaithef, Mohammed
   Padhi, Bijaya Kumar
TI Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based
   National Survey
SO JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
LA English
DT Article
DE coronavirus; COVID-19 vaccine; vaccine hesitancy; trust; perceived risk;
   Saudi Arabia
ID INFLUENZA VACCINE; WILLINGNESS; INTENTIONS; HESITANCY; TRUST
AB Background: Vaccine hesitancy is a potential threat to global public health. Since there is an unprecedented global effort to develop a vaccine against the COVID-19 pandemic, much less is known about its acceptance in the community. Understanding key determinants that influence the preferences and demands of a future vaccine by the community may help to develop strategies for improving the global vaccination program. The aim of this study was to assess the prevalence of the acceptance of COVID-19 vaccine and their determinants among people in Saudi Arabia.
   Methods: A web-based, cross-sectional study was conducted using snowball sampling strategy under a highly restricted environment. A bilingual, self-administered anonymous questionnaire was designed and sent to the study participants through social media plat-forms and email. Study participants were recruited across the country, including the four major cities (Riyadh, Dammam, Jeddah, and Abha) in Saudi Arabia. Key determinants that predict vaccine acceptance among respondents were modelled using logistic regression analysis. Of the 1000 survey invitees, 992 responded to the survey.
   Results: Of the 992 respondents, 642 showed interest to accept the COVID-19 vaccine if it is available. Willingness to accept the future COVID-19 vaccine is relatively high among older age groups, being married participants with education level postgraduate degree or higher (68.8%), non-Saudi (69.1%), employed in government sector (68.9%). In multivariate model, respondents who were above 45 years (aOR: 2.15; 95% CI: 1.08-3.21) and married (aOR: 1.79; 95% CI: 1.28-2.50) were significantly associated with vaccine acceptance (p < 0.05).
   Conclusion: Addressing sociodemographic determinants relating to the COVID-19 vaccination may help to increase uptake of the global vaccination program to tackle future pandemics. Targeted health education interventions are needed to increase the uptake of the future COVID-19 vaccine.
C1 [Al-Mohaithef, Mohammed] Saudi Elect Univ, Coll Hlth Sci, Dept Publ Hlth, Riyadh, Saudi Arabia.
   [Padhi, Bijaya Kumar] Post Grad Inst Med Educ & Res PGIMER, Dept Community Med, Chandigarh, India.
   [Padhi, Bijaya Kumar] Post Grad Inst Med Educ & Res PGIMER, Sch Publ Hlth, Chandigarh, India.
RP Al-Mohaithef, M (corresponding author), Saudi Elect Univ, Coll Hlth Sci, Dept Publ Hlth, Riyadh, Saudi Arabia.
EM m.almohaithef@seu.edu.sa
CR Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171
   Alsuwaidi AR, 2020, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2020.1753439
   Barry M, 2020, J NAT SCI MED, V2
   Barry M, 2020, J EPIDEMIOL GLOB HEA, V10, P1, DOI 10.2991/jegh.k.200218.003
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty Chiranjib, 2020, Arch Med Res, V51, P728, DOI 10.1016/j.arcmed.2020.05.021
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chan EYY, 2015, VACCINE, V33, P4737, DOI 10.1016/j.vaccine.2015.07.046
   Cooper S, 2019, COCHRANE DATABASE SY
   Eilers R, 2017, VACCINE, V35, P2823, DOI 10.1016/j.vaccine.2017.04.014
   Fu C, 2020, ACCEPTANCE PREFERENC
   Gidengil CA, 2012, AM J PUBLIC HEALTH, V102, P672, DOI 10.2105/AJPH.2011.300407
   Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0
   Halpin Carmel, 2019, Nurs Older People, V31, P32, DOI 10.7748/nop.2019.e1154
   Harris KM, 2010, NEW ENGL J MED, V363, P2183, DOI 10.1056/NEJMp1012333
   Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154
   Horney JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011226
   Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330
   Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Musa D, 2009, AM J PUBLIC HEALTH, V99, P1293, DOI 10.2105/AJPH.2007.123927
   Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033
   Rubin G, 2010, HEALTH TECHNOL ASSES, V14, DOI 10.3310/hta14340- 0330.
   Saha RP, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01258
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Thunstrom L, 2020, HESITANCY COVID 19 V
   WILSON K, 2011, INFECT DRUG RESIST, V4, P197, DOI DOI 10.1016/J.BJMSU.2011.01.002
   Wu SS, 2018, VACCINE, V36, P491, DOI 10.1016/j.vaccine.2017.12.008
   Xiao XZ, 2020, VACCINE, V38, P5131, DOI 10.1016/j.vaccine.2020.04.076
NR 31
TC 0
Z9 0
U1 2
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2390
J9 J MULTIDISCIP HEALTH
JI J. Multidiscip. Healthc.
PY 2020
VL 13
BP 1657
EP 1663
DI 10.2147/JMDH.S276771
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA OV5ND
UT WOS:000592255500001
PM 33262600
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Matos, CCDA
   Barbieri, CLA
   Couto, MT
AF de Souza Amorim Matos, Camila Carvalho
   Alves Barbieri, Carolina Luisa
   Couto, Marcia Thereza
TI Covid-19 and its impact on immunization programs: reflections from
   Brazil
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE Coronavirus Infections; Immunization; Immunization Programs; Unified
   Health System; Health Care Systems
ID VACCINATION; PROGRESS; MEASLES
AB Due to social distancing guidelines and the displacement of both human and material resources to fight the covid-19 pandemic, individuals seeking healthcare services face certain challenges. Immunization programs have already been a worrisome topic for health authorities due to declines in vaccine uptake rates and are now especially affected by the covid-19 pandemic. Disbelief in science, dissemination of fake news about vaccines, socioeconomic vulnerability and social inequality are some of the challenges faced. This commentary article discusses the impacts of the covid-19 pandemic on immunization programs in Brazil. In light of advances (and notability) of Brazil's national immunization program, established in the 1970s, the programs face challenges, such as the recent drop in vaccine uptake rates. In addition to this health crisis, there is also Brazil's current political crisis, which will undoubtedly require assistance from researchers, policymakers and society to be fixed.
C1 [de Souza Amorim Matos, Camila Carvalho; Couto, Marcia Thereza] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, SP, Brazil.
   [de Souza Amorim Matos, Camila Carvalho] Univ Fed Santa Catarina, Dept Ciencias Saude, Ararangua, SC, Brazil.
   [Alves Barbieri, Carolina Luisa] Univ Catolica Santos, Santos, SP, Brazil.
RP Matos, CCDA (corresponding author), Univ Fed Santa Catarina, Av Governador Jorge Lacerda 3201, BR-88906072 Ararangua, SC, Brazil.
EM camilacarvalhoamorim@gmail.com
RI COUTO, Marcia Thereza/C-1156-2012
OI COUTO, Marcia Thereza/0000-0001-5233-4190
CR Domingues CMAS, 2019, EPIDEMIOL SERV SAUDE, V28, DOI [10.5123/S1679-49742019000200024, 10.5123/s1679-49742019000200024]
   [Anonymous], 2020, LANCET, V395, P1461, DOI 10.1016/S0140-6736(20)31095-3
   Barra RP, 2020, APS REV, V2, P38
   Brasil. Constituicao, 1988, CONSTITUICAO REPUBLI
   Buntin MB, 2020, JAMA HLTH FORUM, V1
   Cancian N, 2020, FOLHA SAO PAULO
   Chandir S, 2020, VACCINE, V38, P7146, DOI 10.1016/j.vaccine.2020.08.019
   Cojean A, 2020, MONDE AFRIQUE
   Domingues CMAS, 2013, EPIDEMIOL SERV SAUDE, V22, P9, DOI 10.5123/S1679-49742013000100002
   Ducomble T, 2020, LANCET INFECT DIS, V20, P542, DOI 10.1016/S1473-3099(20)30265-6
   Haas ARN, 2020, CONVERSATION
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   Hochman G, 2011, CIENC SAUDE COLETIVA, V16, P375, DOI 10.1590/S1413-81232011000200002
   Horton R, 2020, LANCET, V395, P1022, DOI 10.1016/S0140-6736(20)30727-3
   Kennedy J, 2020, PEDIATR DRUGS, V22, P105, DOI 10.1007/s40272-020-00385-4
   Kenyon C, 2020, J INFECTION, V81, pE98, DOI 10.1016/j.jinf.2020.04.007
   Litvoc MN, 2019, REV ASSOC MED BRAS, V65, P1229, DOI 10.1590/1806-9282.65.10.1129
   Mello-Thery NA, 2020, ESPACO EC, V9, DOI [10.4000/espacoeconomia.11224, DOI 10.4000/ESPACOECONOMIA.11224]
   Mendonca CS, 2020, APS REV, V2, P33, DOI [10.14295/aps.v2i1.63, DOI 10.14295/APS.V2I1.63]
   Ministerio da Saude (BR) Secretaria de Vigilancia em Saude, 2020, B EPIDEMIOL
   Monie F., 2020, ESPACO EC, V9, DOI [10.4000/espacoeconomia.13629, DOI 10.4000/ESPACOECONOMIA.13629]
   Ortega F, 2020, GLOB PUBLIC HEALTH, V15, P1257, DOI [10.1080/17441692.2020.1795223CrossMarkLogoCrossMark, 10.1080/17441692.2020.1795223]
   Pinho SB, 2020, HU REV, V46, P1, DOI DOI 10.34019/1982-8047.2020.V46.30077
   Roberts L, 2020, NATURE, V580, P446, DOI 10.1038/d41586-020-01011-6
   Rosa Walisete de Almeida Godinho, 2005, Rev. Latino-Am. Enfermagem, V13, P1027, DOI 10.1590/S0104-11692005000600016
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Sun XJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4242-7
   Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organization, 2020, GLOBAL MEASLES RUBEL
   World Health Organization, 2014, REPORT SAGE WORKING
NR 32
TC 0
Z9 0
U1 0
U2 0
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PY 2020
VL 54
AR 114
DI 10.11606/s1518-8787.2020054003042
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OV5SN
UT WOS:000592269500001
PM 33175028
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sato, APS
AF Sayuri Sato, Ana Paula
TI Pandemic and vaccine coverage: challenges of returning to schools
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE Coronavirus Infections; prevention & control; Vaccine-Preventable
   Diseases; Immunization Coverage; Immunization Programs
ID UNITED-STATES; COVID-19; HEALTH; IMPACT; BRAZIL; DIPHTHERIA; DISEASES;
   SYSTEM
AB Since March 2020, Brazil has faced the pandemic of the coronavirus disease 2019 (Covid-19), which has severely modified the way in which the population lives and uses health services. As such, face-to-face attendance has dropped dramatically, even for child vaccination, due to measures of social distancing to mitigate the transmission of the virus. Several countries have recorded a substantial drop in vaccination coverage in children, especially of those under two years of age. In Brazil, administrative data indicate the impact of the covid-19 pandemic on this downward trend, which was already an important challenge of the National Immunization Program in recent years. Many children will be susceptible to immunopreventable diseases, which reinforces the need to assess the vaccine status of schoolchildren before returning to face-to-face classes.
C1 [Sayuri Sato, Ana Paula] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, SP, Brazil.
RP Sato, APS (corresponding author), Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, SP, Brazil.
EM sah@usp.br
CR Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/52214-109X(20)30308-9, 10.1016/S2214-109X(20)30308-9]
   American Academy of Pediatrics, 2020, COVID 19 PLANNING CO
   Antunes JLF, 2007, INT J EPIDEMIOL, V36, P1319, DOI 10.1093/ije/dym208
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Barnes M, 2020, NEW ENGL J MED, V383, P779, DOI 10.1056/NEJMsr2019953
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Betz CL, 2020, J PEDIATR NURS, V54, pA7, DOI 10.1016/j.pedn.2020.07.015
   Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1
   Brown AL, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00011618, 10.1590/0102-311x00011618]
   Cesare N, 2020, INT J INFECT DIS, V98, P275, DOI 10.1016/j.ijid.2020.06.092
   Chen RT, 1996, EPIDEMIOL REV, V18, P99, DOI 10.1093/oxfordjournals.epirev.a017931
   Clarke KEN, 2019, EMERG INFECT DIS, V25, P1834, DOI 10.3201/eid2510.190271
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   de Camargo KR, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311x00037620, 10.1590/0102-311X00037620]
   Domingues CMAS, 2013, EPIDEMIOL SERV SAUDE, V22, P9, DOI 10.5123/S1679-49742013000100002
   Elston JWT, 2017, PUBLIC HEALTH, V143, P60, DOI 10.1016/j.puhe.2016.10.020
   Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Hartnett KP, 2020, MMWR-MORBID MORTAL W, V69, P699, DOI 10.15585/mmwr.mm6923e1
   Hirabayashi K., 2020, IMPACT COVID 19 ROUT
   Levinson M, 2020, NEW ENGL J MED, V383, P981, DOI 10.1056/NEJMms2024920
   Luhm KR, 2009, EPIDEMIOL SERV SAUDE, V18, P65
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Massarani L, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311x00148319, 10.1590/0102-311X00148319]
   McAteer J, 2020, CLIN INFECT DIS, V71, P703, DOI 10.1093/cid/ciaa433
   McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848
   Ministerio da Saude Secretaria de Vigilancia em Saude, 2020, B EPIDEMIOL, Vcited 2020 Sep 10 51, P1
   Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2
   Pacheco FC, 2019, VACCINE, V37, P2651, DOI 10.1016/j.vaccine.2019.04.019
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   Pan American Health Organization, 2020, IMMUNIZATION PROGRAM
   Pan American Health Organization, 2020, VACCINATION NEWBORNS
   de Souza LEPF, 2019, CIENC SAUDE COLETIVA, V24, P2783, DOI 10.1590/1413-81232018248.34462018
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   SAXENA S, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2392
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Sato APS, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005925
   Silveira MF, 2020, VACCINE, V38, P482, DOI 10.1016/j.vaccine.2019.10.070
   Sociedade Brasileira de Pediatria, 2020, CALENDARIO VACINAL C
   Suwantika AA, 2020, EXPERT REV VACCINES, V19, P687, DOI 10.1080/14760584.2020.1800461
   Takahashi S, 2015, SCIENCE, V347, P1240, DOI 10.1126/science.aaa3438
   Truelove SA, 2020, CLIN INFECT DIS, V71, P89, DOI 10.1093/cid/ciz808
   Vitek CR, 1998, EMERG INFECT DIS, V4, P539, DOI 10.3201/eid0404.980404
   Waldman EA, 2015, VELHOS NOVOS MALES S, V1, P234
   Waldman Eliseu Alves, 2008, Rev. bras. epidemiol., V11, P129, DOI 10.1590/S1415-790X2008000500013
   World Health Organization, 2019, GLOBAL VACCINE ACTIO
   World Health Organization, 2020, GUIDING PRINCIPLES I
   World Health Organization Regional Office for Europe, 2020, GUIDANCE ROUTINE IMM
NR 48
TC 0
Z9 0
U1 1
U2 1
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PY 2020
VL 54
AR 115
DI 10.11606/s1518-8787.2020054003142
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OV5SN
UT WOS:000592269500002
PM 33175029
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Samad, N
   Sodunke, TE
   Al Banna, H
   Sapkota, A
   Fatema, AN
   Iskandar, K
   Jahan, D
   Hardcastle, TC
   Nusrat, T
   Chowdhury, TS
   Haque, M
AF Samad, Nandeeta
   Sodunke, Temitayo Eniola
   Al Banna, Hasan
   Sapkota, Ashmita
   Fatema, Aneeka Nawar
   Iskandar, Katia
   Jahan, Dilshad
   Hardcastle, Timothy Craig
   Nusrat, Tanzina
   Chowdhury, Tajkera Sultana
   Haque, Mainul
TI Convalescent Plasma Therapy for Management of COVID-19: Perspectives and
   Deployment in the Current Global Pandemic
SO RISK MANAGEMENT AND HEALTHCARE POLICY
LA English
DT Article
DE convalescent plasma therapy; safety; risk; availability; accessibility;
   COVID-19; global pandemic
ID EBOLA-VIRUS DISEASE; ACUTE RESPIRATORY SYNDROME; BLOOD-PRODUCTS;
   INTRAVENOUS IMMUNOGLOBULIN; INFECTIOUS-DISEASES; PATHOGEN REDUCTION;
   TRANSFUSION; ANTIBODY; SAFETY; VACCINE
AB The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy's efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy's availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT's effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.
C1 [Samad, Nandeeta] North South Univ, Dept Publ Hlth, Dhaka 1229, Bangladesh.
   [Sodunke, Temitayo Eniola] Univ Ilorin, Ilorin, Kwara State, Nigeria.
   [Al Banna, Hasan] Univ Dhaka, Inst Social Welf & Res, Dhaka 1000, Bangladesh.
   [Sapkota, Ashmita] Mahidol Univ, Dept Microbiol, Bangkok 10400, Thailand.
   [Fatema, Aneeka Nawar] Prima Asia Univ, Dept Microbiol, Dhaka 1213, Bangladesh.
   [Iskandar, Katia] Lebanese Univ, Sch Pharm, Lebanon, NH USA.
   [Jahan, Dilshad] Asgar Ali Hosp, Dept Hematol, Dhaka 1204, Bangladesh.
   [Hardcastle, Timothy Craig] Univ KwaZulu Natal, Nelson R Mandela Sch Clin Med, Dept Surg, ZA-4001 Berea, South Africa.
   [Nusrat, Tanzina] Chittagong Med Coll, Dept Microbiol, Chattogram 4203, Bangladesh.
   [Chowdhury, Tajkera Sultana] Shaheed Suhrawardy Med Coll Hosp, Dept Urol, Dhaka 1207, Bangladesh.
   [Haque, Mainul] Natl Def Univ Malaysia, Fac Med & Def Hlth, Unit Pharmacol, Kuala Lumpur 57000, Malaysia.
RP Haque, M (corresponding author), Natl Def Univ Malaysia, Fac Med & Def Hlth, Unit Pharmacol, Kem Perdana Sungai Besi, Kuala Lumpur 57000, Malaysia.
EM runurono@gmail.com
CR Accorsi P, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102817
   Accorsi P, 2020, BLOOD TRANSFUS-ITALY, V18, P163, DOI 10.2450/2020.0124-20
   Adriana T, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20264
   AGARWAL A, 2020, BMJ-BRIT MED J, V371, DOI DOI 10.1136/BMJ.M3939
   Aggarwal M, 2020, INDIAN J HEMATOL BLO, V36, P616, DOI 10.1007/s12288-020-01328-2
   Ahmed S, 2020, CLIN RHEUMATOL, V39, P2529, DOI 10.1007/s10067-020-05275-1
   Ahmed W, 2020, FINANCIAL EXPRESS
   Ahn JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e149
   Alabdulmonem W, 2020, INT J HEALTH SCI-IJH, V14, P7
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Ali S, 2020, CAN J PUBLIC HEALTH, V111, P415, DOI 10.17269/s41997-020-00351-0
   Allain JP, 2017, TRANSFUSION MED, V27, P320, DOI 10.1111/tme.12456
   ALRIYAMI AZ, 2020, VOX SANG, DOI DOI 10.1111/V0X.12973
   Anand SP, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030103
   Annamaria P, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102850
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, REC INV COVID 19 CON
   [Anonymous], 2020, IN DEPTH AN MED TOUR
   [Anonymous], 2020, THE TIME
   [Anonymous], 2020, IN DEPTH AN LAT TOUR
   [Anonymous], 2020, FINANCIAL TIMES
   Anudeep T C, 2020, J CLIN TRIALS, V10, P409, DOI DOI 10.35248/2167-0870.20.10.409
   Anwar S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00154
   Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
   Barelli S, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00091
   Barone P, 2020, TRANSFUSION, V60, P1123, DOI 10.1111/trf.15843
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI 10.1055/s-0029-120758938
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   Beigel JH, 2012, CRIT CARE MED, V40, P1027, DOI 10.1097/CCM.0b013e31823d77c3
   Benjamin RJ, 2016, ROSSIS PRINCIPLES TR, P608
   Berry CM, 2018, HUM VACC IMMUNOTHER, V14, P796, DOI 10.1080/21645515.2017.1363135
   Bilgin YM, 2008, VOX SANG, V95, P261, DOI 10.1111/j.1423-0410.2008.01100.x
   Bloch EM, 2020, VOX SANG, DOI [10.1111/vox.12970215, DOI 10.1111/V0X.12970]
   Bloch Evan M, 2020, Transfus Apher Sci, P102957, DOI 10.1016/j.transci.2020.102957
   Bloch EM, 2020, BLOOD, V136, P654, DOI 10.1182/blood.2020007714
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Bracha A, 2011, SINGAP MED J, V52, P1
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Cai XH, 2020, BLOOD TRANSFUS-ITALY, V18, P79, DOI 10.2450/2020.0076-20
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Casadevall A, 2003, TRENDS IMMUNOL, V24, P474, DOI 10.1016/S1471-4906(03)00228-X
   CASADEVALL A, 1995, CLIN INFECT DIS, V21, P150, DOI 10.1093/clinids/21.1.150
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cascella M, 2020, STATPEARLS
   Center for Policy Dialogue (CPD), 2020, 133 CPD
   Chang Brian Bih-Jeng, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101068
   Chang CM, 2020, PEERJ, V8, DOI 10.7717/peerj.9360
   Chaurasia Rahul, 2014, J Blood Transfus, V2014, P412105, DOI 10.1155/2014/412105
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Long KCV, 2020, THER ADV INFECT DIS, V7, DOI 10.1177/2049936120960646
   Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   Crookston KP, 2015, J INFUS MURS, V38, P104, DOI 10.1097/NAN.0000000000000097
   Crookston KP, 2016, ROSSIS PRINCIPLES TR, P30
   Dan YY, 2009, EMERG INFECT DIS, V15, P1909, DOI 10.3201/eid1512.090902
   Desborough J, 2020, MED J AUSTRALIA, V213, P104, DOI 10.5694/mja2.50693
   Desborough J, 2020, AUST J GEN PRACT, V49, P369, DOI 10.31128/AJGP-04-20-5374
   Devasenapathy N, 2020, CAN MED ASSOC J, V192, pE745, DOI 10.1503/cmaj.200642
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Diep BA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1153
   Drexler M, 2010, WHAT YOU NEED KNOW I
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eastridge BJ, 2019, TRANSFUSION, V59, P1423, DOI 10.1111/trf.15161
   Eckhardt CM, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04504-x
   Eder A, 2009, TRANSFUS MED REV, V23, P205, DOI 10.1016/j.tmrv.2009.03.003
   Epstein J, 2020, VOX SANG, DOI [10.1111/vox.12964220., DOI 10.1111/V0X.12964]
   Epstein J, 2020, VOX SANG, DOI [10.1111/vox.12939100., DOI 10.1111/V0X.12939]
   Escalera-Antezana JP, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101653
   Estcourt LJ, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3516
   Eyler JM, 2010, PUBLIC HEALTH REP, V125, P27, DOI 10.1177/00333549101250S306
   Ferreira LMR, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0209-2
   Flesland O, 2016, ROSSIS PRINCIPLES TR, P58
   Fleurant-Ceelen A, 2018, Can Commun Dis Rep, V44, P331, DOI 10.14745/ccdr.v44i12a06
   Forthal DN, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0019-2014
   Franchini M, 2020, EUR J INTERN MED, V77, P150, DOI 10.1016/j.ejim.2020.05.019
   Frazier SK, 2017, CRIT CARE NURS CLIN, V29, P271, DOI 10.1016/j.cnc.2017.04.002
   Garraud O, 2016, TRANSFUS CLIN BIOL, V23, P39, DOI 10.1016/j.tracli.2015.12.003
   Gayatri R, 2020, ASIAN J BIOL, V9, P1, DOI [10.9734/AJOB/2020/v9i33008.15., 10.9734/AJOB/2020/v9i33008.15, DOI 10.9734/AJ0B/2020/V9I33008]
   Gehrie EA, ROSSIS PRINCIPLES TR, p2016 23
   Gholipour C, 2016, WORLD J EMERG MED, V7, P135, DOI 10.5847/wjem.j.1920-8642.2016.02.009
   Gokhale SG, 2016, J ROY ARMY MED CORPS, V162, P63, DOI 10.1136/jramc-2014-000361
   Gonzalez-Garcia J, 2019, FARM HOSP, V43, P50, DOI 10.7399/fh.11110
   Graham BS, 2015, CURR OPIN HIV AIDS, V10, P129, DOI 10.1097/COH.0000000000000154
   Hachfi Wissem, 2020, Tunis Med, V98, P299
   Haley M, 2003, CLIN INFECT DIS, V37, pE88, DOI 10.1086/377172
   Haque M, 2020, BANG J MED SCI, V19, pS366, DOI [10.3329/bjms.v19i0.48106147., DOI 10.3329/BJMS.V19I0.48106]
   Haque M, 2020, PESQUISA BRASILEI S1, V20, DOI 10.1590/pboci.2020.137204.
   Haque M, 2020, HIGH COST COVID 19 T
   Haque MA, 2020, BANG J INFECT DIS, V7, pS51, DOI [10.3329/bjid.v7i0.468033, DOI 10.3329/BJID.V7I0.468033]
   Haque M, 2020, RISK MANAG HEALTHC P, V13, P409, DOI 10.2147/RMHP.S239074
   Hardcastle TC, 2006, ISBT SCI SER, V1, P180, DOI 10.1111/j.1751-2824.2006.00027.x
   Health Information Division Ministry of Health, 2014, SING PRIM CAR SURV
   Hey A, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.AID-0026-2014
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa20214364., DOI 10.1056/NEJM0A20214364]
   Hossain MI, 2020, COVID 19 BANGLADESH
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang Wan-Tsuei, 2020, Hu Li Za Zhi, V67, P75, DOI 10.6224/JN.202006_67(3).10
   Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975
   Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458
   Ilona B, 2020, ORVOSI HETILAP, V161, P1111, DOI 10.1556/650.2020.31901
   Inaba K, 2011, J TRAUMA, V70, pS57, DOI 10.1097/TA.0b013e31821a6057
   InformedHealth.org, 2006, DOES IMM SYST WORK
   Jan CF, 2018, FAM PRACT, V35, P352, DOI 10.1093/fampra/cmx111
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Khadka S, 2020, ALTERN THER HEALTH M
   Khoo Hwee Sing, 2014, Asia Pac Fam Med, V13, P8, DOI 10.1186/s12930-014-0008-x
   Klimpel GR, 1996, MED MICROBIOLOGY
   Koh Y, 2012, INT J NURS PRACT, V18, P195, DOI 10.1111/j.1440-172X.2012.02018.x
   Kong YJ, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102820
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Kreil TR, 2012, TRANSFUSION, V52, P803, DOI 10.1111/j.1537-2995.2011.03347.x
   Kumar GV, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100682
   Kumar Pratyush, 2016, J Family Med Prim Care, V5, P543, DOI 10.4103/2249-4863.197263
   Kunin M, 2015, ISR J HEALTH POLICY, V4, DOI 10.1186/s13584-015-0028-5
   Kunin M, 2013, DISASTER MED PUBLIC, V7, P522, DOI 10.1017/dmp.2013.82
   Langhi DM, 2020, HEMATOL TRANSF CELL, V42, P113, DOI 10.1016/j.htct.2020.04.003
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Legido-Quigley H, 2020, LANCET, V395, P848, DOI 10.1016/S0140-6736(20)30551-1
   Leider JP, 2010, TRANSFUSION, V50, P1384, DOI 10.1111/j.1537-2995.2010.02590.x
   Levi M, 2020, BLOOD ADV, V4, P2850, DOI 10.1182/bloodadvances.2020002197
   Lewis GK, 2017, AIDS RES HUM RETROV, V33, P760, DOI [10.1089/aid.2016.0299, 10.1089/AID.2016.0299]
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li L, 2020, TRANSFUSION, DOI 10.1111/trf.15921
   Li Yang HSU, WHAT SINGAPORE CAN T
   Lim WH, 2020, ANN FAM MED, V18, P259, DOI 10.1370/afm.2539
   Lin C, 2020, EMERG INFECT DIS, V26, P1506, DOI 10.3201/eid2607.200574
   Lin RJH, 2020, MED J AUSTRALIA, DOI 10.5694/mja2.50623
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Luczkowiak J, 2018, J INFECT DIS, V218, pS574, DOI 10.1093/infdis/jiy302
   Luczkowiak J, 2016, VIRUS RES, V213, P224, DOI 10.1016/j.virusres.2015.12.019
   Lunemann JD, 2015, NAT REV NEUROL, V11, P80, DOI 10.1038/nrneurol.2014.253
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Luke TC, 2010, CRIT CARE MED, V38, pE66, DOI 10.1097/CCM.0b013e3181d44c1e
   MacLennan S, 2006, BEST PRACT RES CL HA, V19, P169, DOI 10.1016/j.beha.2005.01.033
   Mahase E, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1327, 10.1136/bmj.m3327]
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Malani AN, 2020, JAMA-J AM MED ASSOC, V324, P524, DOI 10.1001/jama.2020.10699
   Mansourabadi AH, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118185
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mas-Coma S, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100132
   Maskens C, 2014, TRANSFUSION, V54, P66, DOI 10.1111/trf.12240
   Mayo Clinic, 2020, COVID 19 EXP ACC PRO
   McGreal C, 2020, GUARDIAN
   Mehta N, 2020, AM J EMERG MED, V38, P1488, DOI [10.1016/j.ajem.2020.03.011, 10.1016/j.ajem.2020.04.035]
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149
   Milne A, 2020, REUTERS
   Ministry of Health Singapore, 2020, CONF IMP CAS NOV COR
   MONTELONGOJAUREGUI, 2020, PLOS PATHOG, V16
   Montravers P, 2020, ANAESTH CRIT CARE PA, V39, P383, DOI 10.1016/j.accpm.2020.05.004
   Mortimer P, 2005, REV MED VIROL, V15, P407, DOI 10.1002/rmv.480
   Nair PM, 2020, SEMIN HEMATOL, V57, P73, DOI 10.1053/j.seminhematol.2020.07.006
   Nakamura K, 2020, J INFECT CHEMOTHER, V26, P756, DOI 10.1016/j.jiac.2020.03.018
   Nelson NP, 2018, MMWR-MORBID MORTAL W, V67, P1216, DOI 10.15585/mmwr.mm6743a5
   Nicholson LB, 2016, ESSAYS BIOCHEM, V60, P275, DOI 10.1042/EBC20160017
   Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
   Organization WH, 2012, BLOOD DON SEL GUID A
   Pei S., 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.04.07.20056440, DOI 10.1101/2020.04.07.20056440]
   Perez-Cameo Cristina, 2020, EClinicalMedicine, V23, P100370, DOI 10.1016/j.eclinm.2020.100370
   Pham TD, 2016, ROSSIS PRINC TRANSFU, P626
   Piechotta V, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600.pub2
   Piyush R, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200174
   Planitzer CB, 2009, EMERG INFECT DIS, V15, P1668, DOI [10.3201/eid1510.080711, 10.3201/eid1510.081668]
   Pruett CR, 2015, TRANSFUS MED REV, V29, P35, DOI 10.1016/j.tmrv.2014.09.003
   Psaltopoulou T, 2020, HEMASPHERE, V4, DOI 10.1097/HS9.0000000000000409
   Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01598
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   Pulia MS, 2020, ANN MED, V52, P207, DOI 10.1080/07853890.2020.1763449
   Raab CP, 2011, PRIMARY CARE, V38, P681, DOI 10.1016/j.pop.2011.07.006
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Ramirez-Valles J, 2020, HEALTH EDUC BEHAV, V47, P501, DOI 10.1177/1090198120935067
   Refaai MA, 2013, EXPERT REV HEMATOL, V6, P653, DOI 10.1586/17474086.2013.850026
   Ritchie H, 2020, CORONAVIRUS PANDEMIC
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rojas M, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102375
   Rust G, 2009, AM J PUBLIC HEALTH, V99, pS316, DOI 10.2105/AJPH.2009.161125
   Saadah NH, 2017, TRANSFUSION, V57, P2104, DOI 10.1111/trf.14245
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sanyaolu Adekunle, 2020, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00363-4
   Sarti TD, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/S1679-49742020000200024, 10.5123/s1679-49742020000200024]
   Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X
   Schaefer GO, 2020, VACCINE, V38, P5085, DOI 10.1016/j.vaccine.2020.06.007
   Seghatchian J, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102794
   Seifried E, 2016, ROSSIS PRINCIPLES TR, P581
   Shadmi E, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01218-z
   Shamim S, 2020, ARCH VIROL, V165, P2419, DOI 10.1007/s00705-020-04768-3
   Shammi M, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04063
   Sharma A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106054
   Sharun K, 2020, EXPERT OPIN BIOL TH, V20, P1033, DOI 10.1080/14712598.2020.1796963
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shimoni Z, 2001, EMERG INFECT DIS, V7, P759
   Simmons Jeffrey W, 2014, Curr Anesthesiol Rep, V4, P189
   Skrip L, 2020, CLIN MANAGEMENT MORT, DOI [10.1101/2020.06.04.20119784149, DOI 10.1101/2020.06.04.20119784]
   Slifka MK, 2018, PLOTKINS VACCINES, P84, DOI 10.1016/B978-0-323-35761-6.00008-031
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Spenser BR, 2016, ROSSIS PRINCIPLES TR, P599
   Sridevi K, 2020, ANN CLIN LAB RES, V8
   Stadlbauer D, 2020, TRANSFUSION, V60, P2457, DOI 10.1111/trf.16047
   Syal K, 2020, J MED VIROL, V92, P1380, DOI 10.1002/jmv.25870
   Tajmim T, 2020, BUSINESS STANDARD
   Tan ZH, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010357
   Tanne JH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1256
   Taylor Vinters, 2016, SING WHY IS CIT GLOB
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   The American Society for Microbiology, 2019, TOX BAS DIS COMM N A
   The World Bank, 2020, GLOB EC OUTL COVID 1
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Tonn Torsten, 2020, Lancet Microbe, V1, pe63, DOI 10.1016/S2666-5247(20)30037-9
   Tracker Corona, 2020, BANGLADESH OVERVIEW
   Triulzi DJ, 2016, ROSSIS PRINCIPLES TR, P11
   U.S. Food and Drug Administration, 2020, REC INV COVID 19 CON
   U.S. Food and Drug Administration, 2020, INV COVID 19 CONV PL
   US Food and Drug Administration, 2020, DON COVID 19 PLASM
   US National Library of Medicine. ClinicalTrails.gov, 2020, COVID 19 STUD WHO DA
   Uyeki TM, 2016, NEW ENGL J MED, V374, P636, DOI 10.1056/NEJMoa1504874
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   van Griensven J, 2016, NEW ENGL J MED, V375, P2307, DOI 10.1056/NEJMc1609116
   van Griensven J, 2016, NEW ENGL J MED, V374, P2500, DOI 10.1056/NEJMc1602284
   Vanderwerf JD, 2017, HAND CLINIC, V141, P743, DOI 10.1016/B978-0-444-63599-0.00040-5
   Verhagen LM, 2020, INT J INFECT DIS, V99, P334, DOI 10.1016/j.ijid.2020.07.069
   Verma HK, 2020, BIOMED J, V43, P424, DOI 10.1016/j.bj.2020.07.008
   Verma HK, 2020, ANTIBODY THER, V3, P115, DOI [10.1093/abt/tbaa010226., DOI 10.1093/ABT/TBAA010]
   Vieillard V., 2017, ANNALES PHARMACEUTIQUES FRANCAISES, V75, P17, DOI 10.1016/j.pharma.2016.08.002
   Wang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00966
   Wang ZC, 2020, NAT MED, P19, DOI 10.1038/s41591-020-0823-6
   Ware AD, 2018, VOX SANG, V113, P3, DOI 10.1111/vox.12620
   Weimer A, 2019, TRANSFUSION, V59, P412, DOI 10.1111/trf.14949
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2014, US CONV WHOL BLOOD P
   Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
   WHO World Health Organization, 2020, WHO STAT CAS COVID 1
   Winau F, 2002, MICROBES INFECT, V4, P185, DOI 10.1016/S1286-4579(01)01526-X
   Wong HK, 2020, VOX SANG, V115, P545, DOI 10.1111/vox.12927
   Wooding DJ, 2020, CLIN MICROBIOL INFEC, V26, P1436, DOI 10.1016/j.cmi.2020.08.005
   World Health Organization, 2015, ETH US CONV WHOL BLO
   World Health Organization, 2020, WHO COR DIS COVID 19
   World O Meter, 2020, COVID 19 COR PAND
   WORLDOMETER, 2020, COVID 19 COR PAND
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079
   Yang Y, 2020, J MED VIROL, V92, P536, DOI 10.1002/jmv.25720
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Young MK, 2019, HUM VACC IMMUNOTHER, V15, P2060, DOI 10.1080/21645515.2019.1621148
   Young MK, 2014, COCHRANE DB SYST REV, V4, DOI 10.1002/14651858
   Yu HH, 2020, THROMB RES, V195, P219, DOI 10.1016/j.thromres.2020.07.047
   Zeng H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00329-x
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zeng YC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2840-8
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   Zhao Q, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104358
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   2014, HLTH PEOPL WHAT, P1
NR 269
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1179-1594
J9 RISK MANAG HEALTHC P
JI RISK MANAG. HEALTHC. POLICY
PY 2020
VL 13
BP 2707
EP 2728
DI 10.2147/RMHP.S281388
PG 22
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OU9WZ
UT WOS:000591874900001
PM 33262668
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Namal, E
   Dinc, N
   Saglam, S
   Ozturk, AV
   Demir, SK
   Yir, A
   Cevik, E
   Sabet, S
   Sokmen, BK
   Gurcan, NI
   Tokat, Y
   Ciftci, C
AF Namal, Esat
   Dinc, Nur
   Saglam, Sezer
   Ozturk, Ali Vefa
   Demir, Safiye Koculu
   Yir, Asiye
   Cevik, Esin
   Sabet, Soheyl
   Sokmen, Bedriye Koyuncu
   Gurcan, Nagihan Inan
   Tokat, Yaman
   Ciftci, Cavlan
TI Single Center Experience on Screening Oncology Patients for Covid-19
   Before Anti-Cancer Treatment
SO UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
LA English
DT Article
DE COVID-19; Pandemic; Chemotherapy; Oncology
AB The most important factor in the transmission of the COVID-19 is asymptomatic carriers. We've tested all oncology patients , that receive anti-cancer therapy, for COVID-19. We aimed to determine the rate of asymptomatic carriers, and analyze the clinical and radiological findings of infected patients. Oncology patients who have indications of receiving anti-cancer treatment in the hospital were tested for COVID-19, two day prior to their treatment even if they were asymptomatic by collecting nasopharyngeal and oropharyngeal swab specimens for RT-PCR for viral RNA detection. Positive patients, underwent inspiratory phase of chest computed tomography examination. Infected patients were given the recommended treatment for COVID-19. PCR test was positive in 28 of 312 patients that we tested, and the positivity rate was 8.9%. Three patients (10.7%) had symptoms, 25 patients (89.3%) had no symptoms. Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.
C1 [Namal, Esat; Dinc, Nur; Saglam, Sezer] Demiroglu Bilim Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey.
   [Ozturk, Ali Vefa] Demiroglu Bilim Univ, Fac Med, Dept Pulm Dis, Istanbul, Turkey.
   [Demir, Safiye Koculu; Yir, Asiye; Cevik, Esin] Demiroglu Bilim Univ, Fac Med, Dept Infect Dis, Istanbul, Turkey.
   [Sabet, Soheyl; Sokmen, Bedriye Koyuncu; Gurcan, Nagihan Inan] Demiroglu Bilim Univ, Fac Med, Dept Radiol, Istanbul, Turkey.
   [Tokat, Yaman] Demiroglu Bilim Univ, Fac Med, Dept Liver Transplantat, Istanbul, Turkey.
   [Ciftci, Cavlan] Demiroglu Bilim Univ, Fac Med, Dept Cardiol, Istanbul, Turkey.
RP Namal, E (corresponding author), Abide I Hurriyet Caddesi 164, TR-34387 Istanbul, Turkey.
EM esatnamal2000@yahoo.com
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   European Society of Medical Oncology, 2020, CANC PAT MAN COVID 1
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Perrotta F, 2020, AGING CLIN EXP RES, V32, P1599, DOI 10.1007/s40520-020-01631-y
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   WHO, COR DIS COVID 19 PAN
   World Health Organization, DIR GEN REM MED BRIE
   World Health Organization, MOD TRANSM VIR CAUS
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AKAD DOKTORLAR YAYINEVI
PI HILAL CANKAYA
PA 4 CADDE 56, SOKAK, NO 49-E, HILAL CANKAYA, ANKARA 06550, TURKEY
SN 1306-133X
J9 UHOD-ULUSLAR HEMATOL
JI UHOD-Uluslar. Hematol.-Onkol. De.
PY 2020
VL 30
IS 4
BP 207
EP 212
DI 10.4999/uhod.204716
PG 6
WC Oncology
SC Oncology
GA OU6TR
UT WOS:000591659400003
OA Bronze
DA 2021-01-01
ER

PT J
AU Graham, NR
   Whitaker, AN
   Strother, CA
   Miles, AK
   Grier, D
   McElvany, BD
   Bruce, EA
   Poynter, ME
   Pierce, KK
   Kirkpatrick, BD
   Stapleton, RD
   An, G
   denBroek-Altenburg, E
   Botten, JW
   Crothers, JW
   Diehl, SA
AF Graham, Nancy R.
   Whitaker, Annalis N.
   Strother, Camilla A.
   Miles, Ashley K.
   Grier, Dore
   McElvany, Benjamin D.
   Bruce, Emily A.
   Poynter, Matthew E.
   Pierce, Kristen K.
   Kirkpatrick, Beth D.
   Stapleton, Renee D.
   An, Gary
   denBroek-Altenburg, Eline
   Botten, Jason W.
   Crothers, Jessica W.
   Diehl, Sean A.
TI Kinetics and isotype assessment of antibodies targeting the spike
   protein receptor-binding domain of severe acute respiratory
   syndrome-coronavirus-2 in COVID-19 patients as a function of age,
   biological sex and disease severity
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; humoral immune response; isotypes; neutralising antibody;
   SARS-CoV-2; spike protein
ID CORONAVIRUS; SARS-COV-2; INFECTION; PNEUMONIA; REVEALS; ENTRY
AB ObjectivesThere is an incomplete understanding of the host humoral immune response to severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2, which underlies COVID-19, during acute infection. Host factors such as age and sex as well as the kinetics and functionality of antibody responses are important factors to consider as vaccine development proceeds. The receptor-binding domain of the CoV spike (RBD-S) protein mediates host cell binding and infection and is a major target for vaccine design to elicit neutralising antibodies.
   MethodsWe assessed serum anti-SARS-CoV-2 RBD-S IgG, IgM and IgA antibodies by a two-step ELISA and neutralising antibodies in a cross-sectional study of hospitalised COVID-19 patients of varying disease severities. Anti-RBD-S IgG levels were also determined in asymptomatic seropositives.
   ResultsWe found equivalent levels of anti-RBD-S antibodies in male and female patients and no age-related deficiencies even out to 93 years of age. The anti-RBD-S response was evident as little as 6 days after onset of symptoms and for at least 5 weeks after symptom onset. Anti-RBD-S IgG, IgM and IgA responses were simultaneously induced within 10 days after onset, with anti-RBD-S IgG sustained over a 5-week period. Anti-RBD-S antibodies strongly correlated with neutralising activity. Lastly, anti-RBD-S IgG responses were higher in symptomatic COVID-19 patients during acute infection compared with asymptomatic seropositive donors.
   ConclusionOur results suggest that anti-RBD-S IgG reflect functional immune responses to SARS-CoV-2, but do not completely explain age- and sex-related disparities in COVID-19 fatalities.
C1 [Graham, Nancy R.; Strother, Camilla A.; Miles, Ashley K.; McElvany, Benjamin D.; Pierce, Kristen K.; Kirkpatrick, Beth D.; Botten, Jason W.; Diehl, Sean A.] Univ Vermont, Larner Coll Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
   [Graham, Nancy R.; Miles, Ashley K.; McElvany, Benjamin D.; Pierce, Kristen K.; Kirkpatrick, Beth D.; Botten, Jason W.; Diehl, Sean A.] Univ Vermont, Larner Coll Med, Vaccine Testing Ctr, Burlington, VT 05405 USA.
   [Whitaker, Annalis N.; Bruce, Emily A.; Botten, Jason W.] Univ Vermont, Larner Coll Med, Dept Med Immunobiol, Burlington, VT 05405 USA.
   [Whitaker, Annalis N.; Strother, Camilla A.; Poynter, Matthew E.; Botten, Jason W.; Diehl, Sean A.] Univ Vermont, Cellular Mol & Biomed Sci Grad Program, Burlington, VT 05405 USA.
   [Whitaker, Annalis N.; Bruce, Emily A.; Poynter, Matthew E.; Kirkpatrick, Beth D.; Botten, Jason W.; Crothers, Jessica W.; Diehl, Sean A.] Univ Vermont, Larner Coll Med, Vermont Ctr Immunol & Infect Dis, Burlington, VT 05405 USA.
   [Grier, Dore] Univ Vermont, Larner Coll Med, Dept Pathol & Lab Med, Burlington, VT 05405 USA.
   [Bruce, Emily A.; Poynter, Matthew E.; Pierce, Kristen K.; Kirkpatrick, Beth D.; An, Gary; Botten, Jason W.; Crothers, Jessica W.; Diehl, Sean A.] Univ Vermont, Translat Global Infect Dis Res Ctr, Burlington, VT 05405 USA.
   [Poynter, Matthew E.; Stapleton, Renee D.] Univ Vermont, Larner Coll Med, Vermont Lung Ctr, Burlington, VT 05405 USA.
   [Poynter, Matthew E.; Stapleton, Renee D.] Univ Vermont, Larner Coll Med, Dept Med Pulm & Crit Care, Burlington, VT 05405 USA.
   [Pierce, Kristen K.; Kirkpatrick, Beth D.; Crothers, Jessica W.] Univ Vermont, Dept Med Infect Dis, Larner Coll Med, Burlington, VT 05405 USA.
   [An, Gary] Univ Vermont, Larner Coll Med, Dept Surg, Burlington, VT 05405 USA.
   [denBroek-Altenburg, Eline] Univ Vermont, Larner Coll Med, Dept Radiol, Burlington, VT 05405 USA.
RP Diehl, SA (corresponding author), Univ Vermont, Larner Coll Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
EM sean.diehl@med.uvm.edu
FU UVM Translational Global Infectious Disease Research Center (National
   Institute of Health) [P20GM125498]; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U01AI141997]; Office of the Vice President for Research at the
   University of Vermont; University of Vermont Larner College of Medicine
   Departments of Surgery and Radiology; UVM Cancer Center; Lake Champlain
   Cancer Research Organization; UVM College of Agriculture and Life
   Sciences; UVM Larner College of Medicine
FX We thank all healthcare workers and laboratory personnel who contributed
   to treatment and diagnosis of these and other COVID-19 patients. We
   thank the clinical research staff at the University of Vermont (UVM)
   Medical Center Pathology and Laboratory Medicine and the Vaccine Testing
   Center. We also thank the UVM Research Protections Office, Institutional
   Review Board, and Institutional Biosafety Committee for rapid turnaround
   of COVID-19-related projects. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. This work was funded by a pilot grant to SAD and EB from the
   UVM Translational Global Infectious Disease Research Center (National
   Institute of Health grant P20GM125498). Additional funding was from NIH
   grant U01AI141997 to SAD, JWB, and BDK, the Office of the Vice President
   for Research at the University of Vermont to JWB, and the University of
   Vermont Larner College of Medicine Departments of Surgery and Radiology.
   Sequencing confirmation of reagents was performed in the Vermont
   Integrative Genomics Resource Sequencing Facility and was supported by
   the UVM Cancer Center, Lake Champlain Cancer Research Organization, UVM
   College of Agriculture and Life Sciences, and the UVM Larner College of
   Medicine.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fafi-Kremer S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102915
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Jaimes JA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101212
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3
   Smith SA, 2014, J VIROL, V88, P12233, DOI 10.1128/JVI.00247-14
   Stadlbauer D, 2020, TRANSFUSION, V60, P2457, DOI 10.1111/trf.16047
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Suthar MS, 2020, CELL REP MED, DOI 10.1101/2020.05.03.20084442
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, JAMA INTERN MED, P4616
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 42
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2020
VL 9
IS 10
AR e1189
DI 10.1002/cti2.1189
PG 12
WC Immunology
SC Immunology
GA OU2QB
UT WOS:000591377000010
PM 33072323
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shao, ZY
   Feng, YW
   Zhong, L
   Xie, QF
   Lei, M
   Liu, ZY
   Wang, CL
   Ji, JJ
   Liu, HH
   Gu, ZT
   Hu, ZW
   Su, L
   Wu, M
   Liu, ZF
AF Shao, Ziyun
   Feng, Yongwen
   Zhong, Li
   Xie, Qifeng
   Lei, Ming
   Liu, Zheying
   Wang, Conglin
   Ji, Jingjing
   Liu, Huiheng
   Gu, Zhengtao
   Hu, Zhongwei
   Su, Lei
   Wu, Ming
   Liu, Zhifeng
TI Clinical efficacy of intravenous immunoglobulin therapy in critical ill
   patients with COVID-19: a multicenter retrospective cohort study
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; IVIG; clinical efficacy; mortality
ID CYTOKINE; OUTCOMES
AB ObjectiveCoronavirus disease 2019 (COVID-19) outbreak is a major challenge all over the world, without acknowledged treatment. Intravenous immunoglobulin (IVIG) has been recommended to treat critical coronavirus disease 2019 (COVID-19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID-19 patients was lacking.
   Methods325 patients with laboratory-confirmed critical COVID-19 were enrolled from 4 government-designated COVID-19 treatment centres in southern China from December 2019 to March 2020. The primary outcomes were 28- and 60-day mortality, and the secondary outcomes were the total length of in-hospital and the total duration of the disease. Subgroup analysis was carried out according to clinical classification of COVID-19, IVIG dosage and timing.
   ResultsIn the enrolled 325 patients, 174 cases used IVIG and 151 cases did not. The 28-day mortality was improved with IVIG after adjusting confounding in overall cohort (P = 0.0014), and the in-hospital and the total duration of disease were longer in the IVIG group (P < 0.001). Subgroup analysis showed that only in patients with critical type, IVIG could significantly reduce the 28-day mortality, decrease the inflammatory response and improve some organ functions (all P < 0.05); the application of IVIG in the early stage (admission <= 7 days) with a high dose (> 15 g per day) exhibited significant reduction in 60-day mortality in the critical-type patients.
   ConclusionEarly administration of IVIG with high dose improves the prognosis of critical-type patients with COVID-19. This study provides important information on clinical application of IVIG in the treatment of SARS-CoV-2 infection, including patient selection and administration dosage and timing.
C1 [Shao, Ziyun] Gen Hosp Cent Theater Command PLA, Dept Nephrol, Wuhan 430070, Peoples R China.
   [Feng, Yongwen; Wu, Ming] Second Peoples Hosp Shenzhen, Dept Crit Care Med & Hosp Infect Prevent & Contro, Shenzhen 518035, Peoples R China.
   [Feng, Yongwen; Wu, Ming] Shenzhen Univ, Hlth Sci Ctr, Affiliated Hosp 1, Shenzhen 518035, Peoples R China.
   [Feng, Yongwen] Third Peoples Hosp Shenzhen, Dept Crit Care Med, Shenzhen 518035, Peoples R China.
   [Zhong, Li] Guizhou Univ Chinese Med, Affiliated Hosp 1, Dept Crit Care Med, Guiyang 550001, Peoples R China.
   [Xie, Qifeng; Liu, Zheying; Wang, Conglin; Ji, Jingjing; Su, Lei; Wu, Ming; Liu, Zhifeng] Gen Hosp Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.
   [Lei, Ming; Hu, Zhongwei] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Nephrol, Guangzhou 510060, Peoples R China.
   [Liu, Huiheng] Xiamen Univ, Dept Emergency, Zhongshan Hosp, Xiamen 361000, Peoples R China.
   [Gu, Zhengtao] Southern Med Univ, Affiliated Hosp 3, Acad Orthoped Guangdong Prov, Dept Treatment Ctr Traumat Injuries, Guangzhou 515630, Guangdong, Peoples R China.
   [Liu, Zhifeng] Gen Hosp Southern Theater Command PLA, Key Lab Hot Zone Trauma Care & Tissue Repair PLA, Guangzhou 510010, Peoples R China.
RP Wu, M (corresponding author), Second Peoples Hosp Shenzhen, Dept Crit Care Med & Hosp Infect Prevent & Contro, Shenzhen 518035, Peoples R China.; Wu, M (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Affiliated Hosp 1, Shenzhen 518035, Peoples R China.; Su, L; Liu, ZF (corresponding author), Gen Hosp Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.; Hu, ZW (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Dept Nephrol, Guangzhou 510060, Peoples R China.
EM gz8hhzw@126.com; slei_icu@163.com; boshiyy@126.com;
   Zhifengliu7797@163.com
FU PLA Logistics Research Project of China [18CXZ030, CWH17L020, 17CXZ008];
   Sanming Project of Medicine in Shenzhen [SZSM20162011]; Clinical
   Research Project of Shenzhen Municipal Health Commission [SZLY2017007]
FX This work was supported by grants from the PLA Logistics Research
   Project of China [18CXZ030, CWH17L020 and 17CXZ008], Sanming Project of
   Medicine in Shenzhen (SZSM20162011) and Clinical Research Project of
   Shenzhen Municipal Health Commission (SZLY2017007).
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bozza S, 2019, EUR J IMMUNOL, V49, P195, DOI 10.1002/eji.201847774
   Busani S, 2016, MINERVA ANESTESIOL, V82, P559
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Clarivate analytics, 2020, CURR STAT RES COR, V40, P1
   Galeotti C, 2017, INT IMMUNOL, V29, P491, DOI 10.1093/intimm/dxx039
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo MMH, 2015, ALLERGY, V70, P310, DOI 10.1111/all.12558
   Hagiwara Jun, 2020, J Nippon Med Sch, V87, P129, DOI 10.1272/jnms.JNMS.2020_87-303
   Hartung HP, 2008, J NEUROL, V255, P3, DOI 10.1007/s00415-008-3002-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khanna N, 2008, CLIN INFECT DIS, V46, P402, DOI 10.1086/525263
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Linner A, 2014, CLIN INFECT DIS, V59, P851, DOI 10.1093/cid/ciu449
   Liu XS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01660
   Maddur MS, 2017, TRENDS IMMUNOL, V38, P789, DOI 10.1016/j.it.2017.08.008
   Maddur MS, 2011, J ALLERGY CLIN IMMUN, V127, P823, DOI 10.1016/j.jaci.2010.12.1102
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   National Health Commission of the People`s Republic of China, 2020, CHIN REC DIAGN TREAT
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ran Li, 2020, Clin Infect Dis, V71, P2218, DOI 10.1093/cid/ciaa287
   Schijns V, 2020, EUR J IMMUNOL, V50, P932, DOI 10.1002/eji.202048693
   Si M, 2019, DRUGS CLIN, V16, P34
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2019, CLIN THER, V41, P1823, DOI 10.1016/j.clinthera.2019.06.010
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2020
VL 9
IS 10
AR e1192
DI 10.1002/cti2.1192
PG 10
WC Immunology
SC Immunology
GA OU2QB
UT WOS:000591377000016
PM 33082954
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Adejoro, IA
   Babatunde, DD
   Tolufashe, GF
AF Adejoro, Isaiah A.
   Babatunde, Damilare D.
   Tolufashe, Gideon F.
TI Molecular docking and dynamic simulations of some medicinal plants
   compounds against SARS-CoV-2: an in silico study
SO JOURNAL OF TAIBAH UNIVERSITY FOR SCIENCE
LA English
DT Article
DE SARS-CoV-2; ACE2 human; protease; molecular docking; molecular dynamics;
   medicinal plants
ID PHYLLANTHUS-AMARUS; DRUG DISCOVERY; CORONAVIRUS; STABILITY
AB COVID-19 pandemic has poses urgent health challenge, and this project aims to identify potential inhibitors to combat this virus. We screened 198 bioactive compounds from five selected medicinal plants previously reported to be antiviral against SARS-CoV-2 protease and two co-receptors followed by molecular dynamics simulations. From the screened compounds, Astragalin demonstrated very strong molecular interactions with the molecular docking binding energies -8.5, -8.0, -7.6 kcal/mol for 6LU7, 6LZG, and 6VXX proteins of SARS-CoV-2, respectively. Hydrogen bonding interaction with the active site catalytic residue HIS-41 or CYS-145 of the main protease SARS-CoV-2 was observed. Binding free energies (Delta G(bind)) from MM-GBSA after 50 ns MD simulations showed that Astragalin has the highest energy of -33.00 and -34.89 kcal/mol in complex with the main protease and spike glycoprotein of SARS-CoV-2, respectively. The study identifies Astragalin as a better inhibitor for the inactivation of COVID-19 and should be pursued as a potential drug candidate for this virus.
C1 [Adejoro, Isaiah A.; Babatunde, Damilare D.] Univ Ibadan, Dept Chem, Ibadan, Nigeria.
   [Tolufashe, Gideon F.] Univ Porto, Dept Chem & Biochem, Fac Sci, Porto, Portugal.
RP Babatunde, DD (corresponding author), Univ Ibadan, Dept Chem, Ibadan, Nigeria.
EM damilarebabatunde21@gmail.com
CR Ahmad A, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1469-2
   Aier I, 2016, SCI REP-UK, V6, DOI 10.1038/srep34984
   Ali I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138861
   Allouche AR, 2011, J COMPUT CHEM, V32, P174, DOI 10.1002/jcc.21600
   [Anonymous], 2019, PROTEIN DATA BANK RC, P1
   BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5
   Benoy G.K., 2012, INT J RES AYUR PHAR, V3, P752
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cho IH, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-122
   Cournia Z, 2017, J CHEM INF MODEL, V57, P2911, DOI 10.1021/acs.jcim.7b00564
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dubey S., 2014, J PHARM SCI, V4, P39
   Emmanuel O, 2015, NIGERIAN J SCI, V49, P1
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gimenez BG, 2010, PHARMAZIE, V65, P148, DOI 10.1691/ph.2010.9733
   Gohlke H, 2004, J COMPUT CHEM, V25, P238, DOI 10.1022/jcc.10379
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Lipinski CA, 2012, ADV DRUG DELIVER REV, V64, P4, DOI 10.1016/j.addr.2012.09.019
   Liu K, 2017, J COMPUT AID MOL DES, V31, P201, DOI 10.1007/s10822-016-0005-2
   Londhe JS, 2008, REDOX REP, V13, P199, DOI 10.1179/135100008X308984
   Moore N, 2020, DRUG SAFETY, V43, P393, DOI 10.1007/s40264-020-00933-4
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Niranjani Iyer, 2020, DECODING SARS COV 2
   Okereke S. C., 2017, African Journal of Pharmacy and Pharmacology, V11, P25, DOI 10.5897/AJPP2016.4712
   Okunade AL, 2002, FITOTERAPIA, V73, P1, DOI 10.1016/S0367-326X(01)00364-1
   Patel JR, 2011, J ETHNOPHARMACOL, V138, P286, DOI 10.1016/j.jep.2011.09.040
   Pongthanapisith V, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/729081
   Quarcoo R., 2014, SEARCH LIST, P2013
   Rofaani E, 2015, HAYATI J BIOSCI, V22, P67, DOI 10.4308/hjb.22.2.67
   Sabe VT, 2019, J MOL MODEL, V25, DOI 10.1007/s00894-019-4196-z
   Salehi B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051459
   Sarin B, 2014, SCI WORLD J, DOI 10.1155/2014/839172
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+
   Strodel B, 2020, HIGH THROUGHPUT VIRT, DOI [10.20944/preprints202004.0161.v1, DOI 10.20944/PREPRINTS202004.0161.V1]
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Tallei T. E., 2020, POTENTIAL PLANT BIOA, DOI [10.20944/preprints202004.0102.v1, DOI 10.20944/PREPRINTS202004.0102.V2]
   Tang LIC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-3
   Tang LIC, 2014, BIOTECH WORLD, P1
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   WHO, COR COVID 19 EV THEY
   Wintachai P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14179
   World Health Organisation, COR COVID 19 EV HAPP
   YEH SF, 1993, ANTIVIR RES, V20, P185, DOI 10.1016/0166-3542(93)90019-F
   Yeo SG, 2015, ARCH PHARM RES, V38, P193, DOI 10.1007/s12272-014-0390-9
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 53
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1658-3655
J9 J TAIBAH UNIV SCI
JI J. Taibah Univ. Sci.
PD JAN 1
PY 2020
VL 14
IS 1
BP 1563
EP 1570
DI 10.1080/16583655.2020.1848049
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OU2VQ
UT WOS:000591391800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wei, J
   Zhao, JP
   Han, MF
   Meng, FK
   Zhou, JF
AF Wei, Jia
   Zhao, Jianping
   Han, Meifang
   Meng, Fankai
   Zhou, Jianfeng
TI SARS-CoV-2 infection in immunocompromised patients: humoral versus
   cell-mediated immunity
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE immunotherapy; adoptive; immunity; humoral; immunity; cellular;
   receptors; chimeric antigen
ID COVID-19
AB Background
   The coronavirus disease 2019 (COVID-19) pandemic placed unprecedented pressure on various healthcare systems, including departments that use immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy and immunosuppression therapy in organ transplantation units. The true impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on immunocompromised CAR T-cell therapy recipients and kidney transplant recipients (KTRs) has not yet been established.
   Case presentation
   In this report, we compare two patients with severe COVID-19 pneumonia in either the humoral or cell-mediated immunodeficient states. The first patient was a man in his early 30s who was diagnosed with refractory multiple myeloma. He received fully humanized, anti-B-cell maturation antigen, CAR T-cell therapy before 4 months and achieved strict complete remission. He was infected with SARS-CoV-2 starting on January 26, 2019 and gradually progressed to severe pneumonia. Throughout the clinical progression of the disease, SARS-CoV-2 could not be cleared due to his humoral immunodeficient state. During this period of his severe COVID-19 pneumonia, elevated cytotoxic T-cells were observed in this patient's peripheral blood while elevated plasma levels of interleukin (IL)-2R, IL-6, tumor necrosis factor alpha, and ferritin were observed in his cytokine profiles. This patient eventually progressed into acute respiratory distress syndrome and recieved non-invasive ventilatory support. He failed to generate specific SARS-CoV-2 antibodies and died of respiratory failure on day 33 (d33). The second patient was a 52-year-old kidney transplant recipient (KTR) who took ciclosporin after renal transplantation for more than 7 years. He confirmed SARS-CoV-2 infection on January 20, 2019 and gradually progressed into severe pneumonia on d16 with a slightly elevated B-cell percentage and normal T-lymphocyte subsets. Viral clearance occurred together with the generation of specific anti-immunoglobulin G-SARS-CoV-2 antibodies after 2 weeks of treatment. He was symptom-free and discharged from the hospital on d42.
   Conclusion
   We report a CAR T-cell therapy recipient diagnosed with COVID-19 for the first time. His virus clearance failure and life-threating cytokine storm during SARS-CoV-2 infection suggested that any decision to proceed CAR T-cell therapy during COVID-19 pandemics will require extensive discussion of potential risks and benefits. Immunosuppressant treatment based on ciclosporin could be relatively safe for KTRs diagnosed with COVID-19.
C1 [Wei, Jia; Meng, Fankai; Zhou, Jianfeng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Zhao, Jianping] Huazhong Univ Sci & Technol, Key Cite Natl Clin Res Ctr Resp Dis, Dept Resp & Crit Care Med,Key Lab Pulm Dis, Hlth Minist,Tongji Hosp,Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Han, Meifang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan, Hubei, Peoples R China.
RP Meng, FK (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM doctormeng@163.com
OI WEI, JIA/0000-0002-6435-9368
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873427]
FX This work is supported by the National Natural Science Foundation of
   China (81873427, to Dr. JW).
CR Bachanova V, 2020, BIOL BLOOD MARROW TR, V26, P1239, DOI 10.1016/j.bbmt.2020.04.008
   Bataille S, 2020, KIDNEY INT, V98, P235, DOI 10.1016/j.kint.2020.04.017
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   China National Health Commission, 2020, DIAGN TREATM PNEUM C
   Lalueza A, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.02.018
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Nakamura K, 2018, INT IMMUNOPHARMACOL, V64, P201, DOI 10.1016/j.intimp.2018.08.029
   Perez-Amill Lorena, 2020, Haematologica, DOI 10.3324/haematol.2019.228577
   Rezzani R, 2004, PROG HISTOCHEM CYTO, V39, P85, DOI 10.1016/j.proghi.2004.04.001
   Rodriguez-Cubillo B, 2020, AM J TRANSPLANT, V20, P3173, DOI 10.1111/ajt.16141
   Roex G, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020194
   Shah N, 2020, LEUKEMIA, V34, P985, DOI 10.1038/s41375-020-0734-z
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0790-y
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e000862
DI 10.1136/jitc-2020-000862
PG 6
WC Oncology; Immunology
SC Oncology; Immunology
GA OT3CG
UT WOS:000590727000004
PM 32727811
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, R
   Wood, J
   Baskaran, A
   Neumann, S
   Graham, E
   Levenstein, M
   Sim, I
AF Li, Rebecca
   Wood, Julie
   Baskaran, Amrutha
   Neumann, Stanley
   Graham, Elizabeth
   Levenstein, Marcia
   Sim, Ida
TI Timely access to trial data in the context of a pandemic: the time is
   now
SO BMJ OPEN
LA English
DT Article
DE information management; information technology; public health;
   statistics &amp; research methods; public health
AB Objective Clinical trial data sharing has the potential to accelerate scientific progress, answer new lines of scientific inquiry, support reproducibility and prevent redundancy. Vivli, a non-profit organisation, operates a global platform for sharing of individual participant-level trial data and associated documents. Sharing of these data collected from each trial participant enables combining of these data to drive new scientific insights or assess reproducibility-not possible with the aggregate or summary data tables historically made available. We report on our initial experience including key metrics, lessons learned and how we see our role in the data sharing ecosystem. We also describe how Vivli is addressing the needs of the COVID-19 challenge through a new dedicated portal that provides a direct search function for COVID-19 studies, availability for fast-tracked request review and data sharing. Data summary The Vivli platform was established in 2018 and has partnered with 28 diverse members from industry, academic institutions, government platforms and non-profit foundations. Currently, 5400 trials representing 3.6 million participants are shared on the platform. From July 2018 to September 2020, Vivli received 201 requests. To date, 106 of 201 requests received approval, 5 have been declined, 27 withdrew and 27 are in the revision stage. Conclusions The pandemic has only magnified the necessity for data sharing. If most data are shared and in a manner that allows interoperability, then we have hope of moving towards a cohesive scientific understanding more quickly not only for COVID-19 but also for all diseases. Conversely, if only isolated pockets of data are shared then society loses the opportunity to close vital gaps in our understanding of this rapidly evolving epidemic. This current challenge serves to highlight the value of data sharing platforms-critical enablers that help researchers build on prior knowledge.
C1 [Li, Rebecca; Wood, Julie; Baskaran, Amrutha; Neumann, Stanley; Graham, Elizabeth; Levenstein, Marcia] Vivli, Cambridge, MA 02138 USA.
   [Li, Rebecca] Harvard Med Sch, Ctr Bioeth, Boston, MA 02115 USA.
   [Sim, Ida] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Li, R (corresponding author), Vivli, Cambridge, MA 02138 USA.; Li, R (corresponding author), Harvard Med Sch, Ctr Bioeth, Boston, MA 02115 USA.
EM rli@vivli.org
CR Bauchner H, 2019, JAMA-J AM MED ASSOC, V322, P2290, DOI 10.1001/jama.2019.19786
   Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1
   Giffen CA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178141
   Humphreys GS, 2019, AM J TROP MED HYG, V100, P13, DOI 10.4269/ajtmh.18-0649
   Institute of Medicine of the National Academies of Science, 2015, SHAR CLIN TRIAL DAT
   Kaiser J, 2018, SCIENCE, V361, P212, DOI 10.1126/science.361.6399.212
   Kiley R, 2017, DATA SHARING CLIN TR, P1990
   Kochhar S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032334
   Li R, 2018, NAM PERSPECT, V8, DOI [10.31478/201811b, DOI 10.31478/201811B]
   Ross JS, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.268
   Taichman DB, 2016, ANN INTERN MED, V164, P505, DOI 10.7326/M15-2928
   Tudur Smith C, 2016, COCHRANE DATABASE SY, V9
NR 12
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 10
AR e039326
DI 10.1136/bmjopen-2020-039326
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OR8FU
UT WOS:000589703800017
PM 33122319
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arutiunov, GP
   Tarlovskaia, EI
   Koziolova, NA
   Boldina, MV
   Batiushin, MM
   Ametov, AS
   Arutiunov, AG
   Belevskii, AS
   Galstian, GR
   Grigor'eva, NI
   Dzhunusbekova, GA
   Esaian, AM
   Mal'chikova, SV
   Mit'kovskaia, NP
   Mkrtumian, AM
   Orlova, IA
   Petrova, MM
   Rebrov, AP
   Ruzanov, DI
   Salukhov, VV
   Sisakian, AS
   Skibitskii, VV
   Sugraliev, AB
   Fomin, IV
   Khalimov, IS
   Chesnikove, AI
   Shaposhnik, II
   Shestakova, MV
AF Arutiunov, G. P.
   Tarlovskaia, E., I
   Koziolova, N. A.
   Boldina, M., V
   Batiushin, M. M.
   Ametov, A. S.
   Arutiunov, A. G.
   Belevskii, A. S.
   Galstian, G. R.
   Grigor'eva, N. Iu
   Dzhunusbekova, G. A.
   Esaian, A. M.
   Mal'chikova, S., V
   Mit'kovskaia, N. P.
   Mkrtumian, A. M.
   Orlova, Ia A.
   Petrova, M. M.
   Rebrov, A. P.
   Ruzanov, D. Iu
   Salukhov, V. V.
   Sisakian, A. S.
   Skibitskii, V. V.
   Sugraliev, A. B.
   Fomin, I., V
   Khalimov, Iu Sh
   Chesnikove, A., I
   Shaposhnik, I. I.
   Shestakova, M., V
TI The agreed experts' position of the Eurasian Association of Therapists
   on tactics of management of patients with comorbid pathology infected
   with SARS-Cov-2
SO TERAPEVTICHESKII ARKHIV
LA Russian
DT Article
DE COVID-19; SARS-Cov-2; coagulopathy; QT interval; diabetes mellitus;
   chronic obstructive pulmonary disease; bronchial asthma; chronic kidney
   disease
ID RESPIRATORY SYNDROME CORONAVIRUS; CARDIOVASCULAR OUTCOMES; SARS
   CORONAVIRUS; RISK; RECEPTOR; LIRAGLUTIDE; MORTALITY; INFLUENZA; SAFETY;
   ACE2
AB The agreement of experts of the Eurasian Association of Therapists (EAT) discusses pathogenesis and treatment of COVID-19. Modern data on the characteristics of cardiovascular, kidney, respiratory damage in SARS-infected CoV-2 are presented. The tactics of managing patients initially having cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, bronchial asthma, chronic kidney disease are discussed in detail. The article presents data on drug interaction of drugs.
C1 [Arutiunov, G. P.; Arutiunov, A. G.; Belevskii, A. S.] Pirogov Russian Natl Res Med Univ, Moscow, Russia.
   [Tarlovskaia, E., I; Boldina, M., V; Grigor'eva, N. Iu; Fomin, I., V] Volga Res Med Univ, Nizhnii Novgorod, Russia.
   [Koziolova, N. A.] Wagner Perm State Med Univ, Perm, Russia.
   [Batiushin, M. M.; Chesnikove, A., I] Rostov State Med Univ, Rostov Na Donu, Russia.
   [Ametov, A. S.] Russian Med Acad Continuous Profess Educ, Moscow, Russia.
   [Galstian, G. R.; Shestakova, M., V] Endocrinol Res Ctr, Moscow, Russia.
   [Dzhunusbekova, G. A.] Kazakh Med Univ Continuing Educ, Alma Ata, Kazakhstan.
   [Esaian, A. M.] Pavlov First St Petersburg State Med Univ, St Petersburg, Russia.
   [Mal'chikova, S., V] Kirov State Med Univ, Kirov, Russia.
   [Mit'kovskaia, N. P.] Belarusian State Med Univ, Minsk, BELARUS.
   [Mkrtumian, A. M.] Yevdokimov Moscow State Univ Med & Dent, Moscow, Russia.
   [Orlova, Ia A.] Lomonosov Moscow State Univ, Moscow, Russia.
   [Petrova, M. M.] Voino Yasenetski Krasnoyarsk State Med Univ, Krasnoyarsk, Russia.
   [Rebrov, A. P.] Razumovsky Saratov State Med Univ, Saratov, Russia.
   [Ruzanov, D. Iu] Gomel State Med Univ, Gomel, BELARUS.
   [Salukhov, V. V.; Khalimov, Iu Sh] Kirov Mil Med Acad, St Petersburg, Russia.
   [Sisakian, A. S.] Yerevan State Med Univ, Yerevan, Armenia.
   [Skibitskii, V. V.] Kuban State Med Univ, Krasnodar, Russia.
   [Sugraliev, A. B.] Asfendiyarov Kazakh Natl Med Univ, Alma Ata, Kazakhstan.
   [Shaposhnik, I. I.] South Ural State Med Univ, Chelyabinsk, Russia.
RP Tarlovskaia, EI (corresponding author), Volga Res Med Univ, Nizhnii Novgorod, Russia.
EM etarlovskaya@mail.ru
RI Ametov, Alexander/ABI-5129-2020
CR Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Allard R, 2010, DIABETES CARE, V33, P1491, DOI 10.2337/dc09-2215
   Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340
   [Anonymous], 2020, REPORT CARATTERISTIC
   [Anonymous], 2020, TREAT GUID VERS 1 36
   [Anonymous], 2020, PREV DIAGN TREATM NE
   [Anonymous], 2020, PREL EST PREV SEL UN
   [Anonymous], 2020, COVID 19 SITUATION 1
   [Anonymous], 2020, INF COVID 19 COR INF
   [Anonymous], 2020, BARNS ROLLE I SPREDN
   Badawi A, 2016, J PUBLIC HEALTH RES, V5, P130, DOI 10.4081/jphr.2016.733
   Bethel MA, 2018, LANCET DIABETES ENDO, V6, P105, DOI 10.1016/S2213-8587(17)30412-6
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Cahn A, 2020, DIABETES CARE, V43, P468, DOI 10.2337/dc19-1476
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Eurich DT, 2013, CIRC-HEART FAIL, V6, P395, DOI 10.1161/CIRCHEARTFAILURE.112.000162
   Fadini GP, 2020, J ENDOCRINOL INVEST, V43, P867, DOI 10.1007/s40618-020-01236-2
   Fang L, 2020, ARE PATIENTS HYPERTE, DOI [10.1016/S2213-2600(20)30116-8, DOI 10.1016/S2213-2600(20)30116-8]
   Fedson DS, 2013, ANTIVIR RES, V99, P417, DOI 10.1016/j.antiviral.2013.06.018
   Fralick M, 2017, NEW ENGL J MED, V376, P2300, DOI 10.1056/NEJMc1701990
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gorricho J, 2017, BRIT J CLIN PHARMACO, V83, P2034, DOI 10.1111/bcp.13288
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hallow KM, 2018, AM J PHYSIOL-RENAL, V315, pF1295, DOI 10.1152/ajprenal.00202.2018
   Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunt B, 2020, PRACTICAL GUIDANCE P
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Izzedine H, 2020, KIDNEY INT, V97, P1297, DOI 10.1016/j.kint.2020.03.015
   Ki M, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020007
   Knapp S, 2013, GERONTOLOGY, V59, P99, DOI 10.1159/000345107
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu W, 2020, COVID 19 ATTACKS 1 B, DOI [DOI 10.26434/CHEMRXIV.11938173.V7, 10.26434/chemrxiv.11938173.v7]
   Liu Y, 2020, ANTIHYPERTENSIVE ANG, DOI [10.1101/2020.03.20.20039586, DOI 10.1101/2020.03.20.20039586]
   LOWE DA, 2020, JAMA INTERN MED, DOI DOI 10.1001/JAMAINTERNMED.2020.0994
   Ma Wan-Xia, 2020, Sichuan Da Xue Xue Bao Yi Xue Ban, V51, P146, DOI 10.12182/20200360606
   Ma Y, 2019, 2019 NOVEL CORONAVIR, DOI [10.1101/2020.02.24.20027201, DOI 10.1101/2020.02.24.20027201]
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
   Mitchel L., 2020, ZOLER EVIDENCE SUGGE
   Moghissi ES, 2009, DIABETES CARE, V32, P1119, DOI 10.2337/dc09-9029
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Nassif ME, 2019, AM J CARDIOL, V124, pS12, DOI 10.1016/j.amjcard.2019.10.025
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pal R, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108146
   Palmieri L, CHARACTERISTICS COVI
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Salpeter SR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002967.pub3
   Seferovic PM, 2018, EUR J HEART FAIL, V20, P853, DOI 10.1002/ejhf.1170
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shlyakhto EV, 2020, RUSSIAN J CARDIOLOGY, V25, P3801, DOI [10.15829/1560-4071-2020-3-3801, DOI 10.15829/1560-4071-2020-3-3801]
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tancredi M, 2015, NEW ENGL J MED, V373, P1720, DOI 10.1056/NEJMoa1504347
   Thachil Jecko, ISTH INTERIM GUIDANC, DOI DOI 10.1111/JTH.14810
   Tisdale JE, 2016, CAN PHARM J, V149, P139, DOI 10.1177/1715163516641136
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Verma Subodh, 2017, CMAJ Open, V5, pE152, DOI 10.9778/cmajo.20160058
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao RQ, 2020, INT J BIOL SCI, V16, P1658, DOI 10.7150/ijbs.43447
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou D, 2020, J ANTIMICROB CHEMOTH
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
NR 84
TC 0
Z9 0
U1 1
U2 1
PU CJSC CONSILIUM MEDICUM
PI MOSCOW
PA NOVIY ZIKOVSKIY PROEZD, D 3, 40, MOSCOW, 125167, RUSSIA
SN 0040-3660
EI 2309-5342
J9 TERAPEVT ARKH
JI Ter. Arkhiv
PY 2020
VL 92
IS 9
BP 108
EP 124
DI 10.26442/00403660.2020.09.000703
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA OJ4TM
UT WOS:000583955900016
PM 33346439
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hipolito, J
   Diele-Viegas, LM
   Cordeiro, TEF
   Sales, LP
   Medeiros, A
   Deegan, KR
   Leite, L
AF Hipolito, Juliana
   Diele-Viegas, Luisa M.
   Cordeiro, Tabata E. F.
   Sales, Lilian P.
   Medeiros, Adriana
   Deegan, Kathleen R.
   Leite, Luciana
TI Unwrapping the tong-term impacts of COVID-19 pandemic on Brazilian
   academic mothers: the urgency of short, medium, and long-term measures
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE coronavirus; gender; pandemic; mothers in science
AB Since the beginning of the COVID-19 pandemic, publications have highlighted the disproportionate impact of the COVID-19 pandemic on academic mothers, mostly focusing on the impact of social distancing and quarantine. A few months later, despite the lack of effective vaccines or therapeutics in sight, many economic activities are being resumed. Nurseries and schools are expected to be among the latest to reopen, which will amplify the impacts of the pandemic on academic mothers. In this letter, we unwrap the pandemic impacts on academic mothers and describe a set of specific short-, medium- and long-term policies that, if implemented, could reduce setbacks for gender equality during the pandemic and can help to level the playing field for academic mothers.
C1 [Hipolito, Juliana; Diele-Viegas, Luisa M.; Cordeiro, Tabata E. F.; Sales, Lilian P.; Medeiros, Adriana; Deegan, Kathleen R.; Leite, Luciana] Kunha Ase Network Women Sci, Adhemar de Barros Ave, BR-40170110 Salvador, BA, Brazil.
   [Hipolito, Juliana] Natl Inst Res Amazon INPA, Coordinat Res Biodivers COBIO, 2936 Andre Araujo Ave, BR-69067375 Manaus, Amazonas, Brazil.
   [Diele-Viegas, Luisa M.] Univ Maryland, Biol Dept, 4094 Campus Dr, College Pk, MD 20742 USA.
   [Cordeiro, Tabata E. F.] Univ Sao Paulo, Sch Philosophy Sci & Literature, 717 Lago St, BR-05508080 Sao Paulo, SP, Brazil.
   [Sales, Lilian P.] Univ Estadual Campinas, Dept Anim Biol, Inst Biol, 255 Monteiro Lobato St, BR-13083862 Campinas, SP, Brazil.
   [Medeiros, Adriana] Univ Fed Bahia, Environm Microbiol Lab, Biol Inst, Adhemar de Barros Ave, BR-40170110 Salvador, BA, Brazil.
   [Deegan, Kathleen R.] Univ Fed Bahia, Veterinarian Med Hosp, Adhemar de Barros Ave, BR-40170110 Salvador, BA, Brazil.
   [Leite, Luciana] Univ Fed Bahia, Post Grad Program Ecol, Biol Inst, Adhemar de Barros Ave, BR-40170110 Salvador, BA, Brazil.
RP Hipolito, J (corresponding author), Kunha Ase Network Women Sci, Adhemar de Barros Ave, BR-40170110 Salvador, BA, Brazil.; Hipolito, J (corresponding author), Natl Inst Res Amazon INPA, Coordinat Res Biodivers COBIO, 2936 Andre Araujo Ave, BR-69067375 Manaus, Amazonas, Brazil.
EM jhdsousa@yahoo.com
RI Diele-Viegas, Luisa M./D-8930-2018; Diele-Viegas, Luisa
   Maria/ABI-2494-2020
OI Diele-Viegas, Luisa M./0000-0002-9225-4678; Diele-Viegas, Luisa
   Maria/0000-0002-9225-4678; Sales, Lilian/0000-0003-1159-6412; Ferreira
   Cordeiro, Tabata Elise/0000-0002-1299-0270; Deegan,
   Kathleen/0000-0002-5466-3040
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil
   (CAPES)CAPES [001]
FX We thank the Kunha Ase Network of Woman in Science for promoting the
   discussion that originated the idea of this manuscript and Dr. Ben
   Phalan for English review. This study was financed in part by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil
   (CAPES) -Finance Code 001.
CR Alon TM, 2020, NBER WORKING PAPER S, DOI [10.3386/w26947, DOI 10.3386/W26947]
   Blithe SJ, 2020, J GENDER STUD, V29, P751, DOI 10.1080/09589236.2019.1657004
   Melnick H, 2020, REOPENING SCH CONTEX
   Myers KR, 2020, NAT HUM BEHAV, V4, P880, DOI 10.1038/s41562-020-0921-y
   STANISCUASKI F, 2020, GENDER RACE PARENTHO, DOI [10.1126/science.abc2740, DOI 10.1126/SCIENCE.ABC2740]
   Staniscuaski F, 2020, SCIENCE, V368, P724, DOI 10.1126/science.abc2740
   STOCK JH, 2020, 60 BOOK I
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PY 2020
VL 92
IS 4
AR e20201292
DI 10.1590/0001-3765202020201292
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OR1YA
UT WOS:000589270600001
PM 33146238
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Tian, J
   Sun, DL
   Xie, YK
   Liu, K
   Ma, YS
AF Tian, Jing
   Sun, Daolei
   Xie, Yuke
   Liu, Kun
   Ma, Yunshu
TI Network pharmacology-based study of the molecular mechanisms of
   Qixuekang in treating COVID-19 during the recovery period
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Network pharmacology; COVID-19; Qixuekang; mechanism
ID ANTIVIRAL ACTIVITIES; ETHYL LINOLEATE; ISORHAMNETIN; INFLAMMATION
AB Objective: In this research, the analytical method of network pharmacology was used to explore Qixuekang molecular mechanism in treating Coronavirus 2019 (COVID-19) during the recovery period. Methods: Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was used to collect the active components and corresponding targets of Qixuekang. Disease targets, related to COVID-19 during the recovery period, were collected from the GeneCards database. Protein-Protein interaction (PPI) network was built by usingthe String database, and analyzing and using Cytoscape 3.7.0 software to screen out hub genes. GO enrichment and KEGG pathway enrichment analysis were analyzed by R 3.6.1 software. Results: 34 active components of Qixuekang were screened out, and 161 common targets of drug and disease were identified. GO enrichment suggested 141 biologic processes, mainly involving nuclear receptor activity, transcription factor activity, and direct ligand regulated sequence-specific DNA binding. KEGG pathway enrichment suggests 96 signaling pathways, mainly including TNF signaling pathway, IL-17 signal pathway, and C-type lectin receptor signal pathway. The hub genes, screened in the PPI network, were mainly inclusive of CXCL8, CXCL2, CXCL10, ADRA2A, and ADRA2C. Conclusion: Qixuekang has numerous components and targets in treating COVID-19 during the recovery period. It is mainly applied in anti-inflammatory action and regulating immune defense, which may guide clinical trials in the later stage.
C1 [Tian, Jing; Ma, Yunshu] Yunnan Univ Chinese Med, Coll Tradit Chinese Med, Kunming 650500, Yunnan, Peoples R China.
   [Tian, Jing; Xie, Yuke; Liu, Kun] Yunnan Baiyao Grp Co Ltd, Pharmaceut Dept, Kunming 650500, Yunnan, Peoples R China.
   [Sun, Daolei] Yunnan Baiyao Grp Tradit Chinese Med Resources Co, Plant Extract Dept, Kunming 650500, Yunnan, Peoples R China.
RP Ma, YS (corresponding author), Yunnan Univ Chinese Med, Coll Tradit Chinese Med, Kunming 650500, Yunnan, Peoples R China.
EM mayunshu_987@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673682]
FX We acknowledge with thanks support by a grant from the National Natural
   Science Foundation of China (Grant No. 81673682).
CR Bao M, 2006, EUR J PHARMACOL, V547, P22, DOI 10.1016/j.ejphar.2006.07.021
   Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610
   BUONGIORNO J, 2020, ACTA CHIN MED, V35, P1, DOI DOI 10.1561/112.00000515
   Chen LY, 2011, J PHARMACEUT BIOMED, V56, P382, DOI 10.1016/j.jpba.2011.05.033
   Chen TL, 2015, INT J CLIN EXP PATHO, V8, P2311
   Cherubini E, 2016, J CELL PHYSIOL, V231, P1745, DOI 10.1002/jcp.25277
   Choi JN, 2012, NAT PROD RES, V26, P2340, DOI 10.1080/14786419.2012.654608
   Clancy DM, 2017, FEBS J, V284, P1712, DOI 10.1111/febs.14075
   Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234
   Fu X, 2018, EXP THER MED, V16, P4553, DOI 10.3892/etm.2018.6785
   Gao Q., 2020, PEOPLES DAILY OVERSE
   Gombar S, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104477
   Hua JS, 2020, TRADIT CHIN MED RES, V33, P67
   Hyun SK, 2006, ARCH PHARM RES, V29, P287, DOI 10.1007/BF02968572
   Ko GA, 2018, KOREAN J PHYSIOL PHA, V22, P53, DOI 10.4196/kjpp.2018.22.1.53
   Lang S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169100
   [李嘉丽 Li Jiali], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P2345
   Li SY, 1995, J YUNNAN U TRADIT CH, V18, P7
   [李晓东 Li Xiaodong], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P928
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Majewska Monika, 2006, Postepy Hig Med Dosw (Online), V60, P52
   Manu KA, 2015, CANCER LETT, V363, P28, DOI 10.1016/j.canlet.2015.03.033
   Park SY, 2014, INT IMMUNOPHARMACOL, V19, P253, DOI 10.1016/j.intimp.2014.01.017
   QIAN Y, 2018, HER MED, V37, P1446, DOI DOI 10.3870/j.issn.1004-0781.2018.12.003
   Tominaga M, 2017, RESPIR INVESTIG, V55, P293, DOI 10.1016/j.resinv.2017.06.001
   Wu T, 2014, CHIN J INFECT CHEMOT, V14, P257
   Yang JH, 2013, FOOD CHEM TOXICOL, V59, P362, DOI 10.1016/j.fct.2013.05.049
   Yang Y, 2017, J MED VIROL, V89, P908, DOI 10.1002/jmv.24705
   Yuan CW, 2020, MOD ONCOL, V28, P1062
   Zhu HY, 2009, BIOL PHARM BULL, V32, P68, DOI 10.1248/bpb.32.68
NR 30
TC 0
Z9 0
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2020
VL 13
IS 10
BP 2677
EP 2690
PG 14
WC Oncology; Pathology
SC Oncology; Pathology
GA OJ3IH
UT WOS:000583858100026
PM 33165417
DA 2021-01-01
ER

PT J
AU Sun, YS
   Xu, F
   An, Q
   Chen, C
   Yang, ZN
   Lu, HJ
   Chen, JC
   Yao, PP
   Jiang, JM
   Zhu, HP
AF Sun, Yi-Sheng
   Xu, Fang
   An, Qi
   Chen, Chen
   Yang, Zhang-Nv
   Lu, Hang-Jing
   Chen, Jian-Cai
   Yao, Ping-Ping
   Jiang, Jian-Min
   Zhu, Han-Ping
TI A SARS-CoV-2 variant with the 12-bp deletion at E gene
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; E gene mutant; virus replication; immunogenicity
ID RESPIRATORY SYNDROME CORONAVIRUS
AB The coronavirus disease 2019 (COVID-19) pandemic is still ongoing and has become an important public health threat. This disease is caused by a new coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and so far, little is known about this virus. In this study, by using plaque purification, we purified two SARS-CoV-2 virus strains from the same specimen, one named F8 containing a 12-bp deletion in the E gene and the other named 8X containing the wild-type E gene. There was no significant difference in the viral titer and infectivity of these two strains. The S protein content of the F8 viral culture was 0.39 mu g/ml, much higher than that of 8X. An inactivated vaccine made from the F8 strain could trigger high levels of the IgG titer and neutralizing antibody titer, which could last for at least 6 weeks and were significantly higher than those from the 8X strain at 1 and 3 weeks post vaccination, respectively. In conclusion, we reported that both the E gene mutant and wild-type SARS-CoV-2 strains were isolated from the same clinical sample by plaque purification. A 12-bp deletion in the E gene was important for SARS-CoV-2 replication and immunogenicity.
C1 [Sun, Yi-Sheng; Xu, Fang; Chen, Chen; Yang, Zhang-Nv; Lu, Hang-Jing; Chen, Jian-Cai; Yao, Ping-Ping; Jiang, Jian-Min; Zhu, Han-Ping] Zhejiang Prov Ctr Dis Control & Prevent, Key Lab Vaccine Prevent & Control Infect Dis Zhej, Hangzhou 310015, Peoples R China.
   [An, Qi] Shanghai King Cell Biotechnol Co Ltd, Shanghai, Peoples R China.
RP Yao, PP; Jiang, JM; Zhu, HP (corresponding author), Zhejiang Prov Ctr Dis Control & Prevent, Key Lab Vaccine Prevent & Control Infect Dis Zhej, Hangzhou 310015, Peoples R China.
EM ppyao@cdc.zj.cn; jmjiang@cdc.zj.cn; hpzhu@cdc.zj.cn
OI Sun, Yisheng/0000-0002-6854-7630
FU Major Science and Technology Project of the Science and Technology
   Department of Zhejiang Province [2018C03070]
FX This work was supported by the Major Science and Technology Project of
   the Science and Technology Department of Zhejiang Province (2018C03070).
CR Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   De Diego ML, 2014, VIRUS RES, V194, P124, DOI 10.1016/j.virusres.2014.07.024
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Okamaoto Kiyoko, 2020, Jpn J Infect Dis, V73, P366, DOI 10.7883/yoken.JJID.2020.108
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sun YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34299
   World Health Organization, 2020, WHO COR DIS COVID 19
   Yao PP, 2020, VIROL SIN, V35, P348, DOI 10.1007/s12250-020-00241-2
   Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 17
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2361
EP 2367
DI 10.1080/22221751.2020.1837017
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OR9EC
UT WOS:000589767700001
PM 33118859
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arun, PVPS
   Hussain, R
   Akhter, Y
   Rao, MVB
   Shyam, P
   Yellaboina, S
AF Arun, P. V. Parvati Sai
   Hussain, Razak
   Akhter, Yusuf
   Rao, Mandava Venkata Basaveswara
   Shyam, Perugu
   Yellaboina, Sailu
TI Drug Re-purposing from SARS-CoV Led the Identification of Potential
   Candidate Drug Target and Alternate Drug Molecules Against SARS-CoV-2
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Drugs; repurposing; SARS-CoV; SARS-CoV-2; 3CL(pro); Benzyl(2-oxopropyl)
   carbamate
AB Background: SARS-CoV-2 causes COVID-19 disease where there are no suitable drugs available.
   Objective: The objective of the work is to rcpurpose the drugs prescribed for SARS-CoV as the drugs for the control of SARS-CoV-2.
   Methods: In this work, we have used homology searches and docking methods for understanding the mechanism of the drugs prescribed for the control of SARS-CoV on SARS-CoV-2.
   Results: In our analysis, we found that the drugs Benzyl (2-Oxopropyl)carbamate, 2-[(2,4-Dichloro-5-methyl phenyl)sulfonyl]-1,3-dinitro-5-(trifluoromethyl)benzene, S-[5-(Trifluoromethyl)-4H-1,2,4-triazol-3-YL] 5-(phenylethynyl)furan-2-carbothioate, 4-(Dimethylamino)benzoic acid, which are capable of inhibition of the activity of 3CL(pro) and prevent the progression of SARS-CoV.
   Conclusion: In this letter, we describe the findings of the protein ligand interactions between 3CL(pro) of SARS-CoV, SARS-CoV-2 with Benzyl (2-oxopropyl) carbamatc.
C1 [Arun, P. V. Parvati Sai] Chaitanya Bharathi Inst Technol, Dept Biotechnol, Hyderabad, Telangana, India.
   [Hussain, Razak] Aligarh Muslim Univ, Dept Bot, Aligarh, Uttar Pradesh, India.
   [Akhter, Yusuf] Babasaheb Bhimrao Ambedkar Univ, Dept Biotechnol, Raebareli Rd, Lucknow, Uttar Pradesh, India.
   [Rao, Mandava Venkata Basaveswara] Krishna Univ, Dept Chem, Machilipatnam, Andhra Pradesh, India.
   [Shyam, Perugu] Natl Inst Technol, Dept Biotechnol, Warangal, Telangana, India.
   [Yellaboina, Sailu] Jamia Hamdard, Dept Med Elementol & Toxicol, New Delhi, India.
RP Arun, PVPS (corresponding author), Chaitanya Bharathi Inst Technol, Dept Biotechnol, Hyderabad, Telangana, India.
EM arun.uoh@gmail.com
RI Arun, PV Parvati Sai/ABI-6028-2020
OI Arun, PV Parvati Sai/0000-0002-9175-7900
CR Bacha U, 2008, CHEM BIOL DRUG DES, V72, P34, DOI 10.1111/j.1747-0285.2008.00679.x
   Baden L.R., 2020, MASS MED SOC, DOI [DOI 10.1056/NEJME2005477, 10.1056/NEJMe2005477]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Zhou P., 2020, BIORXIV, V1
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2020
VL 17
IS 10
BP 1325
EP 1327
DI 10.2174/1570180417999200730190600
PG 3
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA OF2HI
UT WOS:000581035300013
DA 2021-01-01
ER

PT J
AU Cunniffe, NG
   Gunter, SJ
   Brown, M
   Burge, SW
   Coyle, C
   De Soyza, A
   Dymond, T
   Esmail, H
   Francis, DP
   Galloway, J
   Galloway, JB
   Gkrania-Klotsas, E
   Greenaway, J
   Katritsis, G
   Kanagaratnam, P
   Knolle, MD
   Leonard, K
   McIntyre, ZC
   Prudon, B
   Rampling, T
   Torok, ME
   Warne, B
   Yates, M
   Matheson, NJ
   Su, L
   Villar, S
   Stewart, GD
   Toshner, M
AF Cunniffe, Nick G.
   Gunter, Simon J.
   Brown, Michael
   Burge, Sarah W.
   Coyle, Clare
   De Soyza, Anthony
   Dymond, Tom
   Esmail, Hanif
   Francis, Darrel P.
   Galloway, Jacqui
   Galloway, James B.
   Gkrania-Klotsas, Effrossyni
   Greenaway, Jane
   Katritsis, George
   Kanagaratnam, Prapa
   Knolle, Martin D.
   Leonard, Kelly
   McIntyre, Zoe C.
   Prudon, Ben
   Rampling, Tommy
   Torok, Mili Estee
   Warne, Ben
   Yates, Mark
   Matheson, Nicholas J.
   Su, Li
   Villar, Sofia
   Stewart, Grant D.
   Toshner, Mark
TI How achievable are COVID-19 clinical trial recruitment targets? A UK
   observational cohort study and trials registry analysis
SO BMJ OPEN
LA English
DT Article
DE COVID-19; clinical trials; infectious diseases
AB Objectives To analyse enrolment to interventional trials during the first wave of the COVID-19 pandemic in England and describe the barriers to successful recruitment in the circumstance of a further wave or future pandemics. Design We analysed registered interventional COVID-19 trial data and concurrently did a prospective observational study of hospitalised patients with COVID-19 who were being assessed for eligibility to one of the RECOVERY, C19-ACS or SIMPLE trials. Setting Interventional COVID-19 trial data were analysed from the clinicaltrials.gov and International Standard Randomized Controlled Trial Number databases on 12 July 2020. The patient cohort was taken from five centres in a respiratory National Institute for Health Research network. Population and modelling data were taken from published reports from the UK government and Medical Research Council Biostatistics Unit. Participants 2082 consecutive admitted patients with laboratory-confirmed SARS-CoV-2 infection from 27 March 2020 were included. Main outcome measures Proportions enrolled, and reasons for exclusion from the aforementioned trials. Comparisons of trial recruitment targets with estimated feasible recruitment numbers. Results Analysis of trial registration data for COVID-19 treatment studies enrolling in England showed that by 12 July 2020, 29 142 participants were needed. In the observational study, 430 (20.7%) proceeded to randomisation. 82 (3.9%) declined participation, 699 (33.6%) were excluded on clinical grounds, 363 (17.4%) were medically fit for discharge and 153 (7.3%) were receiving palliative care. With 111 037 people hospitalised with COVID-19 in England by 12 July 2020, we determine that 22 985 people were potentially suitable for trial enrolment. We estimate a UK hospitalisation rate of 2.38%, and that another 1.25 million infections would be required to meet recruitment targets of ongoing trials. Conclusions Feasible recruitment rates, study design and proliferation of trials can limit the number, and size, that will successfully complete recruitment. We consider that fewer, more appropriately designed trials, prioritising cooperation between centres would maximise productivity in a further wave.
C1 [Cunniffe, Nick G.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
   [Gunter, Simon J.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA.
   [Brown, Michael] Univ Coll London Hosp NHS Trust, Div Infect, London, England.
   [Burge, Sarah W.] Univ Cambridge, Dept Oncol, Canc Res UK Urol Malignancies Programme, Cambridge, England.
   [Coyle, Clare] Hammersmith Hosp NHS Trust, Dept Cardiol, London, England.
   [De Soyza, Anthony] Freeman Rd Hosp, Resp Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Dymond, Tom] Cambridge Univ Hosp NHS Fdn Trust, Dept Infect & Inflammat Res, Cambridge, England.
   [Esmail, Hanif] Univ Coll London Hosp NHS Fdn Trust, Hosp Trop Dis, London, England.
   [Esmail, Hanif] UCL, MRC Clin Trials Unit, London, England.
   [Esmail, Hanif] UCL, Inst Global Hlth, London, England.
   [Francis, Darrel P.] Imperial Coll London, Natl Heart & Lung Inst, Fac Med, London, England.
   [Galloway, Jacqui; Knolle, Martin D.] Cambridge Univ Hosp NHS Fdn Trust, Dept Resp Med, Cambridge, England.
   [Galloway, James B.; Yates, Mark] Kings Coll London, Ctr Rheumat Dis, London, England.
   [Gkrania-Klotsas, Effrossyni] Cambridge Univ Hosp NHS Fdn Trust, Dept Infect Dis, Cambridge, England.
   [Greenaway, Jane] North Tees Hosp, Res & Dev, Stockton On Tees, England.
   [Katritsis, George] Imperial Coll London, Natl Heart & Lung Inst, London, England.
   [Kanagaratnam, Prapa] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Cardiol, London, England.
   [Leonard, Kelly] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Urol Translat Res & Clin Trials Dept, Cambridge, England.
   [McIntyre, Zoe C.] Univ Cambridge, Sch Clin Med, Off Translat Res, Cambridge, England.
   [Prudon, Ben] North Tees Hosp, Dept Resp Med, Stockton On Tees, England.
   [Rampling, Tommy] Univ Coll London Hosp NHS Trust, Div Pathol, London, England.
   [Torok, Mili Estee] Univ Cambridge, Cambridge, England.
   [Warne, Ben; Matheson, Nicholas J.] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge, England.
   [Matheson, Nicholas J.] NHS Blood & Transplant, Cambridge, England.
   [Matheson, Nicholas J.; Toshner, Mark] Univ Cambridge, Dept Med, Cambridge, England.
   [Su, Li; Villar, Sofia] Univ Cambridge, Sch Clin Med, Cambridge Inst Publ Hlth, MRC Biostat Unit, Cambridge, England.
   [Stewart, Grant D.] Univ Cambridge, Dept Surg, Cambridge, England.
   [Toshner, Mark] NIHR Resp Translat Res Collaborat, Cambridge, England.
RP Toshner, M (corresponding author), Univ Cambridge, Dept Med, Cambridge, England.; Toshner, M (corresponding author), NIHR Resp Translat Res Collaborat, Cambridge, England.
EM mrt34@medschl.cam.ac.uk
FU Cancer Research UK Major Centre award [C9685/A25117]; British Heart
   FoundationBritish Heart Foundation; NIHR Greenshoots personal Award from
   the Clinical Research Network; Imperial College COVID-19 Research Fund;
   MRC CARP; Clinician Scientist Fellowship (Academy of Medical); Clinician
   Scientist Fellowship (Health Foundation); NIHR Cambridge Biomedical
   Research CentreNational Institute for Health Research (NIHR); National
   Institute for Health Research Cambridge Biomedical Research Centre at
   the Cambridge University Hospitals NHS Foundation Trust; British Society
   for Rheumatology; Versus ArthritisVersus Arthritis; MRCMedical Research
   Council UK (MRC) [CSF MR/P008801/1]; NHSBT [WPA15-02]; Medical Research
   Council programmeMedical Research Council UK (MRC) [MRC_MC_UU_00002/10];
   Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_00002/15]
FX SB and GDS declare funding from a Cancer Research UK Major Centre award
   (C9685/A25117). CC declares funding from the British Heart Foundation.
   EG-K is supported by an NIHR Greenshoots personal Award from the
   Clinical Research Network. PK declares funding from the Imperial College
   COVID-19 Research Fund. MDK declares funding from MRC CARP. MET declares
   support from a Clinician Scientist Fellowship (Academy of Medical and
   the Health Foundation) and the NIHR Cambridge Biomedical Research
   Centre. BW receives funding from the National Institute for Health
   Research Cambridge Biomedical Research Centre at the Cambridge
   University Hospitals NHS Foundation Trust. MY's salary is funded by The
   British Society for Rheumatology and Versus Arthritis. NJM declares
   funding from MRC (CSF MR/P008801/1) and NHSBT (WPA15-02). LS declares
   funding from the Medical Research Council programme MRC_MC_UU_00002/10.
   SV declares funding from the Medical Research Council (grant number:
   MC_UU_00002/15). MT is funded by the NIHR Cambridge Biomedical Research
   Centre. This work was enabled by co-operation of the NIHR Respiratory
   Translational Research Collaboration.
CR Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Beigel J. H., 2020, N ENGL J MED
   Brueckner M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203387
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   MRC Biostatistics Unit, 2020, COVID 19 NOWC FOR
   National Academies of Sciences Engineering and Medicine Health and Medicine Division; Board on Health Sciences Policy Board on Global Health, 2017, INT CLIN RES EP RESP
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   Office of national statistics, 2018, OLD AG STRUCT VAR UK
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Petkova E, 2020, JAMA-J AM MED ASSOC, V324, P543, DOI 10.1001/jama.2020.13042
   Public Health England, 2020, COR COVID 19 UK 2020
   Rojek A, 2017, LANCET INFECT DIS, V17, pE280, DOI 10.1016/S1473-3099(17)30234-7
   The RECOVERY Collaborative Group, 2020, N ENGL J MED
   Thoma A, 2010, CAN J SURG, V53, P205
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wilkinson E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1626
   World Health Organisation, 2015, REP EB INT ASS PAN 2
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 24
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 10
AR e044566
DI 10.1136/bmjopen-2020-044566
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OH0IA
UT WOS:000582255500004
PM 33020111
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, Q
   Zhang, T
   Li, F
   Mao, Z
   Kang, H
   Tao, L
   Zhou, F
   Cai, Y
AF Li, Q.
   Zhang, T.
   Li, F.
   Mao, Z.
   Kang, H.
   Tao, L.
   Zhou, F.
   Cai, Y.
TI Acute Kidney Injury Can Predict In-Hospital Mortality in Elderly
   Patients with COVID-19 in the ICU: A Single-Center Study
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE coronavirus disease 2019; acute kidney injury; diagnosis; nomogram;
   in-hospital mortality
ID WUHAN
AB Objective: Severe or critical patients with coronavirus disease 2019 (COVID-19) are at increased risk for developing acute kidney injury (AKI). However, the rate of AKI in patients of different severities and independent predictive factors associated with AKI are not well understood.
   Patients and Methods: We enrolled 107 severely or critically ill elderly patients with COVID-19 who were admitted to the intensive care unit (ICU) in Wuhan, China. AKI was defined according to the 2012 KDIGO criteria. We explored the association between AKI and in-hospital mortality using logistic regression. A predictive nomogram was formulated to predict the AKI development of patients with COVID-19 based on multivariate logistic regression.
   Results: A total of 107 elderly patients were enrolled during the study period. The mean age was 70 (64- 78) years, and 69 (64.5%) were men. For the 107 patients, the degree of severity of COVID-19 was categorized as 37 patients with the severe type (34.6%) and 70 patients with the critical type (65.4%). Overall, 48 of the 107 patients (44.9%) developed AKI during their hospitalization, while AKI occurred in 7 (18.9%) out of the 37 severe patients and 41 (44.9%) out of the 70 critical patients. Of the AKI patients, 35.4% (17/48) required continuous renal replacement therapy, including 14.3% of AKI patients in severe cases and 39.0% of AKI patients in critical cases. Kaplan-Meier analysis demonstrated that patients with AKI had a significantly higher risk for in-hospital mortality than severely and critically ill patients without AKI. Multivariate logistic regression analysis showed that AKI (OR = 33.74; 95% CI = 3.34- 341.29; P = 0.003), septic shock (OR = 15.58; 95% CI = 2.08- 116.78; P = 0.008), invasive mechanical ventilation (OR = 18.44; 95% CI = 2.35- 144.69; P = 0.006), and oxygenation index (OR = 0.99; 95% CI = 0.98- 1.000; P = 0.014) were independent risk factors for in-hospital mortality. A nomogram was established based on the multivariate analysis results. The C-index for the developed AKI model was 0.935 (95% CI, 0.892- 0.978); when 10-fold cross validation was used to validate the model, the corrected C-index was 0.825.
   Conclusion: AKI is common among COVID-19 patients admitted to the ICU and is recognized as a marker of disease severity. The proposed nomogram accurately predicted AKI development in ICU patients with COVID-19 based on individual characteristics. Therefore, the strategy for kidney protection against severe or critical pneumonia is appropriate.
C1 [Li, Q.; Mao, Z.; Kang, H.; Zhou, F.; Cai, Y.] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Crit Care Med, Beijing 100853, Peoples R China.
   [Zhang, T.] Chinese Peoples Liberat Army Gen Hosp, Inst Hosp Management, Med Innovat Res Div, Beijing 100853, Peoples R China.
   [Li, F.; Tao, L.; Zhou, F.; Cai, Y.] Xijing Hosp, Dept Cardiol, Xian 710032, Peoples R China.
   [Li, F.; Cai, Y.] Huo Shen Shan Hosp, Dept Infect Dis, Wuhan, Peoples R China.
RP Zhou, F; Cai, Y (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Crit Care Med, Beijing 100853, Peoples R China.; Zhou, F; Cai, Y (corresponding author), Xijing Hosp, Dept Cardiol, Xian 710032, Peoples R China.; Cai, Y (corresponding author), Huo Shen Shan Hosp, Dept Infect Dis, Wuhan, Peoples R China.
EM feihuzhou301@126.com; caiyueclear1981@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81871587, 81970383]; China National Defense
   Technology Innovation Project [20-163-12-ZD-027-003-06]; Military
   Medical Innovation Project [18CXZ026]; Special Scientific Research
   Project of Military Health Care [20BJZ27]
FX This study was funded by grants from the National Natural Science
   Foundation of China (grant 81871587 to Dr FHZ; grant 81970383 to Dr YC),
   China National Defense Technology Innovation Project (grant
   20-163-12-ZD-027-003-06 to Dr FHZ), the Military Medical Innovation
   Project (grant 18CXZ026 to Dr FHZ), and the Special Scientific Research
   Project of Military Health Care (grant 20BJZ27 to Dr FHZ).
CR Alkindi F., 2020, KIDNEY INT REP, V5, pS13, DOI [10.1016/j.ekir.2020.02.033, DOI 10.1016/J.EKIR.2020.02.033]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chan L, 2020, ACUTE KIDNEY INJURY
   Chao CT, 2015, SCI REP-UK, V5, DOI 10.1038/srep13925
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng XY, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0622-6
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   D Wang, 2020, JAMA
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Wang YF, 2017, AM J KIDNEY DIS, V69, P647, DOI 10.1053/j.ajkd.2016.10.034
   Wei JF, 2020, HEART, V106, P1154, DOI 10.1136/heartjnl-2020-317007
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02939-x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2020
VL 15
BP 2095
EP +
DI 10.2147/CIA.S273720
PG 16
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA OO8XO
UT WOS:000587657800001
PM 33204075
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lopez-Iranzo, FJ
   Lopez-Rodas, AM
   Franco, L
   Lopez-Rodas, G
AF Lopez-Iranzo, Francisco J.
   Lopez-Rodas, Ana M.
   Franco, Luis
   Lopez-Rodas, Gerardo
TI Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine
   Release (Storm) Syndrome" Caused by SARS-CoV-2?
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Pentoxifylline; oxypurinol; SARS-CoV-2; COVID-19; pro-inflammatory
   cytokines; systemic inflammatory response; serine/tbreonine phosphatase
   PP2A; cytokine release syndrome
ID EXPERIMENTAL ACUTE-PANCREATITIS; PRO-INFLAMMATORY CYTOKINES; ACUTE LUNG
   INJURY; OXIDATIVE STRESS; ALVEOLAR MACROPHAGES; HISTONE ACETYLATION;
   XANTHINE-OXIDASE; COVID-19; ACTIVATION; DISEASE
AB Background: COVID-19, caused by SARS-CoV-2, is a potentially lethal, rapidly-expanding pandemic and many efforts are being carried out worldwide to understand and control the disease. COVID-19 patients may display a cytokine release syndrome, which causes severe lung inflammation, leading, in many instances, to death.
   Objective: This paper is intended to explore the possibilities of controlling the COVID-19-associated hyperin- flammation by using licensed drugs with anti-inflammatory effects.
   Hypothesis: We have previously described that pentoxifylline alone, or in combination with oxypurinol, reduces the systemic inflammation caused by experimentally-induced pancreatitis in rats. Pentoxifylline is an inhibitor of TNF-alpha production and oxypurinol inhibits xanthine oxidase. TNF-alpha, in turn, activates other inflammatory genes such as Nos2, Icam or IL-6, which regulate migration and infiltration of neutrophils into the pulmonary interstitial tissue, causing injury to the lung parenchyma. In acute pancreatitis, the anti-inflammatory action of pentoxifylline seems to be mediated by the prevention of the rapid and presumably transient loss of PP2A activity. This may also occur in the hyperinflammatory -cytokinc releasing phase- of SARS-CoV-2 infection. Therefore, it may be hypothesized that early treatment of COVID-19 patients with pentoxifylline, alone or in combination with oxypurinol, would prevent the potentially lethal acute respiratory distress syndrome.
   Conclusion: Pentoxifylline and oxypurinol are licensed drugs used for diseases other than COVID-19 and, therefore, phase I clinical trials would not be necessary for the administration to SARS-CoV-2- infected people. it would be worth investigating their potential effects against the hyperinflammatory response to SARS-CoV-2 infection.
C1 [Lopez-Iranzo, Francisco J.; Franco, Luis; Lopez-Rodas, Gerardo] Univ Valencia, Dept Biochem & Mol Biol, Valencia 46100, Spain.
   [Lopez-Iranzo, Francisco J.] Residential Ctr Elderly People, Savia Requena, Spain.
   [Lopez-Rodas, Ana M.] Hosp Sagunto, SAMU Serv, Med Specialist Family & Community Med, Valencia, Spain.
   [Lopez-Rodas, Ana M.; Franco, Luis; Lopez-Rodas, Gerardo] Royal Acad Med, Valencian Community, Madrid, Spain.
   [Franco, Luis; Lopez-Rodas, Gerardo] Univ Clin Hosp INCLIVA, Inst Hlth Res, Valencia, Spain.
   [Franco, Luis] Spanish Royal Acad Sci, Madrid, Spain.
RP Lopez-Rodas, G (corresponding author), Univ Valencia, Dept Biochem & Mol Biol, Valencia 46100, Spain.
EM Gerardo.lopez@uv.es
OI Franco, Luis/0000-0001-9610-6448
CR Bhatia M, 2005, PANCREATOLOGY, V5, P132, DOI 10.1159/000085265
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chiappelli F, 2020, BIOINFORMATION, V16, P219, DOI [10.6026/97320630016222, 10.6026/97320630016219]
   Closa D, 1999, ANN SURG, V229, P230, DOI 10.1097/00000658-199902000-00011
   deProst D, 1995, J CARDIOVASC PHARM, V25, pS114, DOI 10.1097/00005344-199500252-00024
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Eisendle K, 2016, J AM ACAD DERMATOL, V74, P760, DOI [10.1016/jjaad.2015.09.009, DOI 10.1016/JJAAD.2015.09.009]
   Escobar J, 2012, FREE RADICAL BIO MED, V52, P819, DOI 10.1016/j.freeradbiomed.2011.11.009
   Escobar J, 2012, BIOCHEM PHARMACOL, V83, P122, DOI 10.1016/j.bcp.2011.09.028
   Escobar Javier, 2010, World J Gastrointest Pharmacol Ther, V1, P75, DOI 10.4292/wjgpt.v1.i3.75
   Escobar Javier, 2010, Inflammation & Allergy Drug Targets, V9, P97
   Escobar J, 2009, CURR PHARM DESIGN, V15, P3027, DOI 10.2174/138161209789058075
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Feily A, 2020, INT J CLIN PHARM TH, V58, P406, DOI 10.5414/CP203782
   Fernandes JL, 2008, ATHEROSCLEROSIS, V196, P434, DOI 10.1016/j.atherosclerosis.2006.11.032
   Goicoechea M, 2012, J NEPHROL, V25, P969, DOI 10.5301/jn.5000077
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Irrera N, 2014, WORLD J GASTROENTERO, V20, P16535, DOI 10.3748/wjg.v20.i44.16535
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5
   Lentsch AB, 1998, AM J PATHOL, V152, P1327
   Lentsch AB, 1999, AM J RESP CELL MOL, V20, P692, DOI 10.1165/ajrcmb.20.4.3414
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Maiti R, 2007, VASC PHARMACOL, V47, P118, DOI 10.1016/j.vph.2007.05.004
   Maldonado Valente, 2020, Med Hypotheses, V144, P109988, DOI 10.1016/j.mehy.2020.109988
   Manohar M, 2017, MOJ IMMUNOL, V5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7
   Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pereda J, 2004, ANN SURG, V240, P108, DOI 10.1097/01.sla.0000129343.47774.89
   Pereda J, 2006, CURR MED CHEM, V13, P2775, DOI 10.2174/092986706778522011
   Perez S, 2015, REDOX BIOL, V5, P1, DOI 10.1016/j.redox.2015.01.014
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Sandoval J, 2010, CELL MOL LIFE SCI, V67, P1687, DOI 10.1007/s00018-010-0272-3
   Sandoval J, 2016, J IMMUNOL, V197, P4137, DOI 10.4049/jimmunol.1502378
   Sandoval J, 2009, J PHARMACOL EXP THER, V331, P609, DOI 10.1124/jpet.109.157537
   SARZIPUTTINI P, 2020, NLM MEDLINE, V38, P337
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Seirafianpour F, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13733
   Sunil VR, 2014, EXP MOL PATHOL, V97, P89, DOI 10.1016/j.yexmp.2014.05.009
   Szatmary P, 2020, GASTROENTEROLOGY
   Szatmary P, 2016, ROLE CYTOKINES INFLA
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang D, 2012, APMIS, V120, P572, DOI 10.1111/j.1600-0463.2011.02868.x
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 53
TC 1
Z9 1
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2020
VL 26
IS 35
BP 4515
EP 4521
DI 10.2174/1381612826666200811180232
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OH3WJ
UT WOS:000582502300014
PM 32787748
DA 2021-01-01
ER

PT J
AU Nichetti, F
   Bini, M
   Ambrosini, M
   Ottini, A
   Rametta, A
   Leporati, R
   Polastri, D
   Pircher, C
   Dotti, K
   Ferrari, L
   de Braud, F
AF Nichetti, Federico
   Bini, Marta
   Ambrosini, Margherita
   Ottini, Arianna
   Rametta, Alessandro
   Leporati, Rita
   Polastri, Daniela
   Pircher, Chiara
   Dotti, Katia
   Ferrari, Laura
   de Braud, Filippo
TI COVID-19 risk for patients undergoing anticancer treatment at the
   outpatient clinic of the National Cancer Institute of Milan: the COVINT
   study
SO ESMO OPEN
LA English
DT Article
DE COVID-19; anticancer treatment; chemotherapy; cancer care; pandemic
ID MORTALITY
AB Background In the midst of the COVID-19 pandemic, patients with cancer are regarded as a highly vulnerable population. Overall, those requiring hospital admission for treatment administration are potentially exposed to a higher risk of infection and worse outcome given the multiple in-hospital exposures and the treatment immunosuppressive effects. Methods COVINT is an observational study assessing COVID-19 incidence among patients receiving anticancer treatment in the outpatient clinic of the Istituto Nazionale dei Tumori di Milano. All consecutive patients with non-haematological malignancies treated with intravenous or subcutaneous/intramuscular anticancer therapy in the outpatient clinic were enrolled. The primary endpoint is the rate of occurrence of COVID-19. Secondary endpoints included the rate of COVID-19-related deaths and treatment interruptions. The association between clinical and biological characteristics and COVID-19 occurrence is also evaluated. COVID-19 diagnosis is defined as (1) certain if confirmed by reverse transcriptase PCR assay of nasopharyngeal swabs (NPS); (2) suspected in case of new symptoms or CT scan evidence of interstitial pneumonia with negative/not performed NPS; (3) negative in case of neither symptoms nor radiological evidence. Results In the first 2 months (16 February-10 April 2020) of observation, 1081 patients were included. Of these, 11 (1%) were confirmed and 73 (6.7%) suspected for COVID-19. No significant differences in terms of cancer and treatment type emerged between the three subgroups. Prophylactic use of myeloid growth factors was adopted in 5.3%, 2.7% and 0% of COVID-19-free, COVID-19-suspected and COVID-19-confirmed patients (p=0.003). Overall, 96 (8.9%) patients delayed treatment as a precaution for the pandemic. Among the 11 confirmed cases, 6 (55%) died of COVID-19 complications, and anticancer treatment was restarted in only one. Conclusions During the pandemic peak, accurate protective measures successfully resulted in low rates of COVID-19 diagnosis, although with high lethality. Prospective patients' surveillance will continue with NPS and serology testing to provide a more comprehensive epidemiological picture, a biological insight on the impact of cytotoxic treatments on the immune response, and to protect patients and healthcare workers.
C1 [Nichetti, Federico; Bini, Marta; Ambrosini, Margherita; Ottini, Arianna; Rametta, Alessandro; Leporati, Rita; Polastri, Daniela; Pircher, Chiara; Dotti, Katia; Ferrari, Laura; de Braud, Filippo] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Lombardia, Italy.
RP Nichetti, F (corresponding author), Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Lombardia, Italy.
EM federico.nichetti@istitutotumori.mi.it
OI Leporati, Rita/0000-0001-6671-9809
CR [Anonymous], 2020, INDAGINE SIEROLOGICA
   Cook G, 2020, BRIT J HAEMATOL, V190, pE83, DOI 10.1111/bjh.16874
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   de Azambuja E, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000947
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Onesti CE, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000853
   Pietrantonio F, 2020, CLIN COLORECTAL CANC, V19, P156, DOI 10.1016/j.clcc.2020.05.004
   Poggio Francesca, 2020, JCO Oncol Pract, V16, pe1304, DOI 10.1200/OP.20.00297
   Saini KS, 2020, EUR J CANCER, V139, P43, DOI 10.1016/j.ejca.2020.08.011
   Spicer J, 2020, NAT REV CLIN ONCOL, DOI 10.1038/s41571-020-0370-6
   Tagliamento M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000783
   Urun Y, 2020, JCO GLOB ONCOL, V6, P1248, DOI 10.1200/GO.20.00300
   Valenza F, 2020, TUMORI J, V106, P193, DOI 10.1177/0300891620923790
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 23
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PY 2020
VL 5
IS SUPPL_3
SU 3
AR e000883
DI 10.1136/esmoopen-2020-000883
PG 9
WC Oncology
SC Oncology
GA OP2GW
UT WOS:000587898700001
PM 33158968
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sigorski, D
   Sobczuk, P
   Osmola, M
   Kuc, K
   Walerzak, A
   Wilk, M
   Ciszewski, T
   Kopec, S
   Hryn, K
   Rutkowski, P
   Stec, R
   Szczylik, C
   Bodnar, L
AF Sigorski, Dawid
   Sobczuk, Pawel
   Osmola, Malgorzata
   Kuc, Kamil
   Walerzak, Anna
   Wilk, Michal
   Ciszewski, Tomasz
   Kopec, Sylwia
   Hryn, Karolina
   Rutkowski, Piotr
   Stec, Rafal
   Szczylik, Cezary
   Bodnar, Lubomir
TI Impact of COVID-19 on anxiety levels among patients with cancer actively
   treated with systemic therapy
SO ESMO OPEN
LA English
DT Article
DE SARS-CoV-2; pandemic; anxiety; cancer; treatment
ID TRAIT ANXIETY; VALIDATION; SUPPORT; SCALE
AB Background Life-threatening diseases have a negative impact on emotional well-being and psychosocial functioning. This study aimed to assess the relationship between the level of anxiety caused by a neoplasm and the threat of coronavirus infection among patients with cancer actively treated with systemic therapy during the COVID-19 pandemic. Additionally, we searched for clinical factors associated with a higher level of anxiety. Methods In this multicentre, prospective, non-interventional study conducted in Poland, we enrolled 306 actively treated patients with cancer and collected their clinical data, including age, gender, cancer type and treatment intention. The fear/anxiety of SARS-CoV-2 were rated in Fear of COVID-19 Scale (SRA-FCV-19S) and Numerical Anxiety Scale (SRA-NAS). The fear and anxiety associated with cancer (CRA) were rated with the NAS (CRA-NAS). Results The mean level of SRA-FCV-19S was 18.5 +/- 7.44, which was correlated with the SRA-NAS (r=0.741, p<0.001). SRA-FCV-19S was significantly higher in women versus men (20.18 +/- 7.56 vs 16.54 +/- 6.83; p<0.001) and was tumour type-dependent (p=0.037), with the highest anxiety observed in patients with breast cancer (17.63 +/- 8.75). In the multivariate analysis, only the female gender was significantly associated with higher SRA. CRA-NAS was higher in women versus men (7.07 +/- 2.99 vs 5.47 +/- 3.01; p<0.001), in patients treated with curative versus palliative intention (7.14 +/- 3.06 vs 5.99 +/- 3.06; p=0.01) and in individuals aged <= 65 years versus >65 years (6.73 +/- 2.96 vs 5.66 +/- 3.24; p=0.007). Conclusions For an actively treated patient with cancer, cancer remains the main life-threatening disease during the COVID-19 pandemic. The need for more attentive psychological care should be provided especially to female patients, patients with breast cancer, those under 65 years of age and treated with curative intention, as these factors are associated with a higher level of anxiety.
C1 [Sigorski, Dawid] Univ Warmia & Mazury, Dept Oncol, Olsztyn, Poland.
   [Sobczuk, Pawel; Kopec, Sylwia; Rutkowski, Piotr] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
   [Osmola, Malgorzata] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, Univ Clin Ctr, Warsaw, Poland.
   [Kuc, Kamil; Ciszewski, Tomasz; Hryn, Karolina] St Pios Prov Hosp, Dept Oncol, Przemysl, Poland.
   [Walerzak, Anna] Minist Interior & Adm Hosp, Warmian Masurian Canc Ctr, Clin Dept Oncol Surg, Olsztyn, Poland.
   [Wilk, Michal; Szczylik, Cezary] European Hlth Ctr, Ctr Postgrad Med Educ, Dept Oncol, Otwock, Poland.
   [Stec, Rafal] Med Univ Warsaw, Dept Oncol, Warsaw, Poland.
   [Bodnar, Lubomir] Minist Interior & Adm Hosp, Warmian Masurian Canc Ctr, Clin Dept Oncol & Immunooncol, Olsztyn, Poland.
RP Sigorski, D (corresponding author), Univ Warmia & Mazury, Dept Oncol, Olsztyn, Poland.
EM dawidsigorski@wp.pl
RI Wilk, Michal/V-6527-2017
OI Wilk, Michal/0000-0002-0261-8133; Sigorski, Dawid/0000-0002-4799-9611
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Bakioglu F, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00331-y
   Baqutayan Shadiya Mohamed Saleh, 2012, Indian J Psychol Med, V34, P119, DOI 10.4103/0253-7176.101774
   Bendau A, 2020, EUR ARCH PSY CLIN N, DOI 10.1007/s00406-020-01171-6
   Bitan DT, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113100
   Bodas M, 2015, PSYCHIATRY, V78, P265, DOI 10.1080/00332747.2015.1069658
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Cameron LD, 1998, HEALTH PSYCHOL, V17, P459, DOI 10.1037/0278-6133.17.5.459
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Cattell RB, 1963, BR J SOC CLIN PSYCHO, V2, P224, DOI [10.1111/j.2044-8260.1963.tb00394.x, DOI 10.1111/J.2044-8260.1963.TB00394.X]
   Cg N, 2010, JUMMEC, V13, P12, DOI 10.22452/jummec.vol13no1.3
   Chabowski M, 2018, CANCER MANAG RES, V10, P4085, DOI 10.2147/CMAR.S175210
   Classen C, 1996, HEALTH PSYCHOL, V15, P434, DOI 10.1037/0278-6133.15.6.434
   Crandall M, 2007, ANESTH ANALG, V105, P1250, DOI 10.1213/01.ane.0000284700.59088.8b
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Czerw AI, 2015, WSPOLCZESNA ONKOL, V19, P414, DOI 10.5114/wo.2015.54900
   de Hoog N, 2020, BRIT J PSYCHOL, V111, P157, DOI 10.1111/bjop.12389
   de Pablo GS, 2020, J AFFECT DISORDERS, V275, P48, DOI 10.1016/j.jad.2020.06.022
   Elkins Gary, 2004, Clin Nurs Res, V13, P237, DOI 10.1177/1054773803262222
   Evren C, 2020, DEATH STUD, DOI 10.1080/07481187.2020.1774969
   Fu WN, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00913-3
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Greer JA, 2008, J PSYCHOSOM RES, V65, P549, DOI 10.1016/j.jpsychores.2008.03.005
   Holland Jimmie C, 2007, J Natl Compr Canc Netw, V5, P3
   Juczyski Z, 2009, NARZDZIA POMIARU PRO, P167
   Julian LJ, 2011, ARTHRIT CARE RES, V63, pS467, DOI 10.1002/acr.20561
   Karacin C, 2020, FUTURE ONCOL, V16, P2283, DOI 10.2217/fon-2020-0592
   Karvounides DM, 2016, PEDIAT DIMENS, P1, DOI [10.15761/PD.1000124, DOI 10.15761/PD.1000124]
   Martinez-Lorca Manuela, 2020, Psychiatry Res, V293, P113350, DOI 10.1016/j.psychres.2020.113350
   MILLAR K, 1995, BRIT J ANAESTH, V74, P180, DOI 10.1093/bja/74.2.180
   Fioravanti-Bastos ACM, 2011, PSICOL-REFLEX CRIT, V24, P485, DOI 10.1590/S0102-79722011000300009
   Nikbakhsh N, 2014, CASP J INTERN MED, V5, P167
   Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007
   Poggio Francesca, 2020, JCO Oncol Pract, V16, pe1304, DOI 10.1200/OP.20.00297
   Reznik A, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00283-3
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Schmidt SD, 2012, J HEALTH PSYCHOL, V17, P1033, DOI 10.1177/1359105311429203
   Soraci P, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00277-1
   Stark DPH, 2000, BRIT J CANCER, V83, P1261, DOI 10.1054/bjoc.2000.1405
   Tagliamento M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13315
   Tluczek A, 2009, J NURS MEAS, V17, P19, DOI 10.1891/1061-3749.17.1.19
   Urun Y, 2020, JCO GLOB ONCOL, V6, P1248, DOI 10.1200/GO.20.00300
   Wysocki PJ, 2020, ONCOL CLIN PRACT, V16, P41, DOI 10.5603/OCP.2020.0012
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 44
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PY 2020
VL 5
IS 5
AR e000970
DI 10.1136/esmoopen-2020-000970
PG 8
WC Oncology
SC Oncology
GA OP4PY
UT WOS:000588065300001
PM 33097653
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lai, YM
   Li, GM
   Wu, DM
   Lian, WM
   Li, C
   Tian, JZ
   Ma, XF
   Chen, H
   Xu, W
   Wei, J
   Zhang, YQ
   Jiang, GH
AF Lai, Yaoming
   Li, Guangming
   Wu, Dongmei
   Lian, Wanmin
   Li, Cheng
   Tian, Junzhang
   Ma, Xiaofen
   Chen, Hui
   Xu, Wen
   Wei, Jun
   Zhang, Yaqin
   Jiang, Guihua
TI 2019 Novel Coronavirus-Infected Pneumonia on CT: A Feasibility Study of
   Few-Shot Learning for Computerized Diagnosis of Emergency Diseases
SO IEEE ACCESS
LA English
DT Article
DE Lung; COVID-19; Training; Lesions; Hospitals; Computed tomography;
   COVID-19; chest CT; 2019 novel coronavirus-infected pneumonia; few-shot
   learning
AB COVID-19 is an emerging disease with transmissibility and severity. So far, there are no effective therapeutic drugs or vaccines for COVID-19. The most serious complication of COVID-19 is a type of pneumonia called 2019 novel coronavirus-infected pneumonia (NCIP) with about 4.3% mortality rate. Comparing to chest Digital Radiography (DR), it is recently reported that chest Computed Tomography (CT) is more useful to serve as the early screening and diagnosis tool for NCIP. In this study, aimed to help physicians make the diagnostic decision, we develop a machine learning (ML) approach for automated diagnosis of NCIP on chest CT. Different from most ML approaches which often require training on thousands or millions of samples, we design a few-shot learning approach, in which we combine few-shot learning with weakly supervised model training, for computerized NCIP diagnosis. A total of 824 patients are retrospectively collected from two Hospitals with IRB approval. We first use 9 patients with clinically confirmed NCIP and 20 patients without known lung diseases for training a location detector which is a multitask deep convolutional neural network (DCNN) designed to output a probability of NCIP and the segmentation of targeted lesion area. An experienced radiologist manually localizes the potential locations of NCIPs on chest CTs of 9 COVID-19 patients and interactively segments the area of the NCIP lesions as the reference standard. Then, the multitask DCNN is furtherly fine-tuned by a weakly supervised learning scheme with 291 case-level labeled samples without lesion labels. A test set of 293 patients is independently collected for evaluation. With our NCIP-Net, the test AUC is 0.91. Our system has potential to serve as the NCIP screening and diagnosis tools for the fight of COVID-19S endemic and pandemic.
C1 [Lai, Yaoming; Wei, Jun] Guangzhou Percept Vis Med Technol Inc, Guangzhou 510000, Peoples R China.
   [Li, Guangming; Chen, Hui; Xu, Wen] Hubei Univ Arts & Sci, Affiliated Hosp, Xiangyang Cent Hosp, Xiangyang 441000, Peoples R China.
   [Wu, Dongmei] Nanxishan Hosp Guangxi Zhuang Autonomous Reg, Guilin 541000, Peoples R China.
   [Lian, Wanmin; Li, Cheng; Tian, Junzhang; Ma, Xiaofen; Jiang, Guihua] Guangdong Second Prov Gen Hosp, Dept Med Imaging, Guangzhou 510000, Peoples R China.
   [Zhang, Yaqin] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai 519000, Peoples R China.
RP Wei, J (corresponding author), Guangzhou Percept Vis Med Technol Inc, Guangzhou 510000, Peoples R China.; Jiang, GH (corresponding author), Guangdong Second Prov Gen Hosp, Dept Med Imaging, Guangzhou 510000, Peoples R China.; Zhang, YQ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai 519000, Peoples R China.
EM weijun@pvmedtech.com; zhyaqin@mail.sysu.edu.cn; jianggh@gd2h.org.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81860523, 81801809]; Guangdong Basic and
   Applied Basic Research Foundation [2020A1515010572]; Guangzhou Red
   Cotton Planning Venture Project [HMJH-2019-0010]; Guangzhou Economic and
   Technological Development Zone Science and Technology Innovation Leader
   Project; Guangzhou Science and Technology Planning Project
   [201906010014]; Hospital Basic Foundation of Nanxishan Hospital of
   Guangxi Zhuang Autonomous Region
FX This work was supported in part by the National Natural Science
   Foundation of China under Grant 81860523, Grant 81801809; in part by
   Guangdong Basic and Applied Basic Research Foundation under Grant
   2020A1515010572, in part by the Guangzhou Red Cotton Planning Venture
   Project under Key Grant HMJH-2019-0010, in part by Guangzhou Economic
   and Technological Development Zone Science and Technology Innovation
   Leader Project, in part by the Guangzhou Science and Technology Planning
   Project under Key Grant 201906010014, and in part by the Hospital Basic
   Foundation of Nanxishan Hospital of Guangxi Zhuang Autonomous Region.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cubuk ED, 2019, PROC CVPR IEEE, P113, DOI 10.1109/CVPR.2019.00020
   Gu YC, 2019, I S BIOMED IMAGING, P438, DOI 10.1109/ISBI.2019.8759207
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He KM, 2017, IEEE I CONF COMP VIS, P2980, DOI 10.1109/ICCV.2017.322
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kooraki S, 2020, J AM COLL RADIOL, V17, P447, DOI 10.1016/j.jacr.2020.02.008
   Li FF, 2006, IEEE T PATTERN ANAL, V28, P594, DOI 10.1109/TPAMI.2006.79
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhao DH, 2020, CLIN INFECT DIS, V71, P756, DOI 10.1093/cid/ciaa247
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 0
Z9 0
U1 2
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 194158
EP 194165
DI 10.1109/ACCESS.2020.3033069
PG 8
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA OP1RI
UT WOS:000587857500001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Tarolli, CG
   Andrzejewski, K
   Zimmerman, GA
   Bull, M
   Goldenthal, S
   Auinger, P
   O'Brien, M
   Dorsey, ER
   Biglan, K
   Simuni, T
AF Tarolli, Christopher G.
   Andrzejewski, Kelly
   Zimmerman, Grace A.
   Bull, Michael
   Goldenthal, Steven
   Auinger, Peggy
   O'Brien, Michael
   Dorsey, E. Ray
   Biglan, Kevin
   Simuni, Tanya
TI Feasibility, Reliability, and Value of Remote Video-Based Trial Visits
   in Parkinson's Disease
SO JOURNAL OF PARKINSONS DISEASE
LA English
DT Article
DE Clinical trial protocol; Parkinson's disease; phase III clinical trial;
   technology; telemedicine
ID RATING-SCALE; CLINICAL-TRIALS; VALIDATION; AGREEMENT; VALIDITY
AB Background: There is rising interest in remote clinical trial assessments, particularly in the setting of the COVID-19 pandemic.
   Objective: To demonstrate the feasibility, reliability, and value of remote visits in a phase III clinical trial of individuals with Parkinson's disease.
   Methods: We invited individuals with Parkinson's disease enrolled in a phase III clinical trial (STEADY-PD III) to enroll in a sub-study of remote video-based visits. Participants completed three remote visits over one year within four weeks of an in-person visit and completed assessments performed during the remote visit. We evaluated the ability to complete scheduled assessments remotely; agreement between remote and in-person outcome measures; and opinions of remote visits.
   Results: We enrolled 40 participants (mean (SD) age 64.3 (10.4), 29% women), and 38 (95%) completed all remote visits. There was excellent correlation (ICC 0.81-0.87) between remote and in-person patient-reported outcomes, and moderate correlation (ICC 0.43-0.51) between remote and in-person motor assessments. On average, remote visits took around one quarter of the time of in-person visits (54 vs 190 minutes). Nearly all participants liked remote visits, and three-quarters said they would be more likely to participate in future trials if some visits could be conducted remotely.
   Conclusion: Remote visits are feasible and reliable in a phase III clinical trial of individuals with early, untreated Parkinson's disease. These visits are shorter, reduce participant burden, and enable safe conduct of research visits, which is especially important in the COVID-19 pandemic.
C1 [Tarolli, Christopher G.; Zimmerman, Grace A.; Bull, Michael; Dorsey, E. Ray] Univ Rochester, Dept Neurol, Rochester, NY USA.
   [Tarolli, Christopher G.; Goldenthal, Steven; Auinger, Peggy; Dorsey, E. Ray] Univ Rochester, Ctr Hlth Technol, Rochester, NY USA.
   [Andrzejewski, Kelly] Univ Buffalo, Dept Neurol, Buffalo, NY USA.
   [Goldenthal, Steven] Univ Michigan, Sch Med, Ann Arbor, MI USA.
   [O'Brien, Michael] AMC Hlth, New York, NY USA.
   [Biglan, Kevin] Eli Lilly & Co, Early Phase Clin Dev, Indianapolis, IN 46285 USA.
   [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA.
RP Tarolli, CG (corresponding author), 601 Elmwood Ave,Box MIND, Rochester, NY 14642 USA.
EM christopher_tarolli@urmc.rochester.edu
FU AMC Health, National Parkinson Foundation; NINDSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS) [U01
   NS080840, U01 NS080818, P20 NS092529-02, P50 NS108676]
FX AMC Health, National Parkinson Foundation, and NINDS (U01 NS080840, U01
   NS080818, P20 NS092529-02, P50 NS108676).
CR Abdolahi A, 2013, PARKINSONISM RELAT D, V19, P218, DOI 10.1016/j.parkreldis.2012.10.008
   Beck CA, 2017, NEUROLOGY, V89, P1152, DOI 10.1212/WNL.0000000000004357
   Biglan KM, 2017, ANN CLIN TRANSL NEUR, V4, P360, DOI 10.1002/acn3.412
   Bull MT, 2014, J HUNTINGTONS DIS, V3, P189, DOI 10.3233/JHD-140102
   Dorsey ER, 2016, TELEMED E-HEALTH, V22, P590, DOI 10.1089/tmj.2015.0191
   Dorsey ER, 2015, J PARKINSON DIS, V5, P505, DOI 10.3233/JPD-150549
   Dorsey ER, 2015, JAMA NEUROL, V72, P582, DOI 10.1001/jamaneurol.2014.4524
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   FDA, 2020, FDA GUID COND CLIN T
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   Gallo Yee H, 2020, CLIN LEADER
   Gelfand AA, 2017, JAMA NEUROL, V74, P744, DOI 10.1001/jamaneurol.2017.0285
   Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   Ledford Heidi, 2020, Nature, V580, P15, DOI 10.1038/d41586-020-00889-6
   Martinez-Martin P, 2013, J NEUROL, V260, P228, DOI 10.1007/s00415-012-6624-1
   Muoio D, 2017, MOBI HLTH NEWS
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Norms P., 2001, DIGITAL DIVIDE CIVIC
   Nusca A, 2018, FORTUNE
   Parkinson Study Group STEADY-PD III Investigators, 2020, Ann Intern Med, V172, P591, DOI 10.7326/M19-2534
   Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078
   PETO V, 1995, QUAL LIFE RES, V4, P241, DOI 10.1007/BF02260863
   Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704
   RICHARDS M, 1994, MOVEMENT DISORD, V9, P89, DOI 10.1002/mds.870090114
   Schwab R., 1969, 3 S PARK DIS, P152
   Sommer C, 2018, CONT CLIN TRIAL COMM, V11, P120, DOI 10.1016/j.conctc.2018.06.008
   Stillerova T, 2016, NEUROL RES INT, V2016, DOI 10.1155/2016/4802570
   Tarolli CG, 2020, NEUROL-CLIN PRACT, V10, P7, DOI 10.1212/CPJ.0000000000000680
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   WCG Resource Center, RES CTR COVID 19 CLI
NR 31
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1877-7171
EI 1877-718X
J9 J PARKINSON DIS
JI J. Parkinsons Dis.
PY 2020
VL 10
IS 4
BP 1779
EP 1786
DI 10.3233/JPD-202163
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA OO9WC
UT WOS:000587725300047
PM 32894251
DA 2021-01-01
ER

PT J
AU Selam, MN
AF Selam, Muluken Nigatu
TI Hand Sanitizers Marketed in the Streets of Addis Ababa, Ethiopia, in the
   Era of COVID-19: A Quality Concern
SO RISK MANAGEMENT AND HEALTHCARE POLICY
LA English
DT Article
DE alcohol-based handrubs; quality; COVID-19; Addis Ababa; streets
AB Hand hygiene is one of the least expensive measures proven to be effective in preventing the transmission of coronavirus disease 2019 (COVID-19). When access to handwashing facilities is limited, hand sanitizers offer a viable alternative for hand hygiene. Since the appearance of the first case of COVID-19 in Ethiopia, the demand for hand sanitizers, especially alcohol-based handrubs (ABHRs), was found to be increased. In the country, more than 100 manufacturers are engaged in the production of ABHRs. Besides, there are similar products without labels available for sale in the streets of Addis Ababa for which their nature and source are not clearly known. Generally, hand sanitizers marketed in the streets of the city are against the country's regulatory requirement. The Ethiopian Food and Drug Authority should inspect manufacturers regularly and evaluate the quality of hand sanitizers in the market, especially those obtained from the streets of the city, and take appropriate measures on those products and manufacturers which fail to meet the regulatory requirements.
C1 [Selam, Muluken Nigatu] Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmaceut & Social Pharm, Addis Ababa, Ethiopia.
RP Selam, MN (corresponding author), Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Dept Pharmaceut & Social Pharm, Addis Ababa, Ethiopia.
EM muluken.nigatu@aau.edu.et
CR Arasteh P, 2020, AM J MED SCI, V360, P201, DOI 10.1016/j.amjms.2020.05.019
   Australian Government, 2020, THER GOODS EXCL GOOD
   Bashir MF, 2020, AIR QUAL ATMOS HLTH, DOI [10.1007/s11869-020-00894-8, DOI 10.1007/S11869-020-00894-88]
   Budd A., 2016, Journal of Service Science and Management, V9, P150, DOI 10.4236/jssm.2016.92019
   Canadian Paediatric Society Hand sanitizers, 2020, PROM SAF US CHILDR
   Center for Disease Control, 2020, PROT YOURS OTH
   Centers for disease control and prevention (CDC), 2020, HAND SAN US OUT
   Dear K, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00788-5
   Ethiopian Food and Drug Authority, 2020, LIST SAN MAN
   Ethiopian Food and Drug Authority, 2020, COVID 19 PUBL
   Ethiopian Food and Drug Authority, 2020, GUID REG LOW RISK ME
   Ethiopian Food and Drug Authority, 2020, CERT COR VIR INP MAN
   Ethiopian Standards Agency, 2020, SAMPL SAN TEST WER B
   Fofana NK, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113230
   Gov.UK, 2020, PROD HAND SAN GEL CO
   Mahmood A, 2020, SCI TOTAL ENVIRON, V742, DOI 10.1016/j.scitotenv.2020.140561
   Ministry of Health-Ethiopia, 2020, ETH CONF 1 CAS COVID
   Neufeld M, 2020, ALCOHOL CLIN EXP RES, V44, P1906, DOI 10.1111/acer.14417
   Soltaninejad K, 2020, INT J OCCUP ENV MED, V11, P148, DOI 10.34172/ijoem.2020.1983
   Suthivarakom G, 2020, NY TIMES
   U.S Food and Drug Administration, 2020, GUID IND TEMP POL PR
   U.S. Food and Drug administration, 2020, FDA UPD HAND SAN CON
   USP, 2019, 795 USP
   World Health Organization, 2009, WHO GUID HAND HYG HL
   World Health Organization, 2010, GUID LOC PROD WHO RE
   World Health Organization, 2020, COR DIS COVID 19 ADV
   World Health Organization, 2013, LOC PROD ALC BAS HAN
   Yip L, 2020, MMWR-MORBID MORTAL W, V69, P1070, DOI 10.15585/mmwr.mm6932e1
NR 28
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1179-1594
J9 RISK MANAG HEALTHC P
JI RISK MANAG. HEALTHC. POLICY
PY 2020
VL 13
BP 2483
EP 2487
DI 10.2147/RMHP.S284007
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OP8LA
UT WOS:000588340600001
PM 33177903
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Homma, A
   Freire, MD
   Possas, C
AF Homma, Akira
   Freire, Marcos da Silva
   Possas, Cristina
TI Vaccines for neglected and emerging diseases in Brazil by 2030: the
   "valley of death" and opportunities for RD&I in Vaccinology 4.0
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE Vaccines; Scientific Research and Technological Development; Governance
AB We examine the implications of the very low competitiveness of the Brazilian vaccine RD&I system, which precludes the development of all the important vaccines required by the National Immunization Program (NIP), severely impacting the healthcare of the population. In a country dramatically affected by COVID-19 pandemic and by an exponential increase in emerging and neglected diseases, particularly the poor, these RD&I constraints for vaccines become crucial governance issues. Such constraints are aggravated by a global scenario of limited commercial interest from multinational companies in vaccines for neglected and emerging diseases, which are falling into a "valley of death," with only two vaccines produced in a pipeline of 240 vaccines. We stress that these constraints in the global pipeline are a window of opportunity for vaccine manufacturers in Brazil and other developing countries in the current paradigm transition towards Vaccinology 4.0. We conclude with recommendations for a new governance strategy supporting Brazilian public vaccine manufacturers in international collaborations for a sustainable national vaccine development and production plan by 2030.
C1 [Homma, Akira; Freire, Marcos da Silva; Possas, Cristina] Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol, Av Brasil 4365, BR-21045904 Rio De Janeiro, RJ, Brazil.
RP Possas, C (corresponding author), Fundacao Oswaldo Cruz, Inst Tecnol Imunobiol, Av Brasil 4365, BR-21045904 Rio De Janeiro, RJ, Brazil.
EM cristina.possas@bio.fiocruz.br
OI Freire, Marcos/0000-0002-4723-8994; Possas, Cristina/0000-0002-2886-2812
CR Barbano D, 2019, 4 INT S IMM 7 SEM AN
   Belluck P, 2019, NY TIMES
   Bloom DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00549
   Bragazzi NL, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00062
   Brende B, 2017, LANCET, V389, P233, DOI 10.1016/S0140-6736(17)30131-9
   Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y
   Clemens R., 2019, 4 INT S IMM 7 SEM AN
   Hochman G, 2011, CIENC SAUDE COLETIVA, V16, P375, DOI 10.1590/S1413-81232011000200002
   Homma A., 2003, MANGUINHOS, V10, P671
   Homma A, 2013, VACCINE, V31, pB54, DOI 10.1016/j.vaccine.2012.11.084
   Hong MS, 2018, COMPUT CHEM ENG, V110, P106, DOI 10.1016/j.compchemeng.2017.12.007
   Jodar L, 2003, LANCET, V361, P1902, DOI 10.1016/S0140-6736(03)13494-0
   Jouanguy E., 2019, 4 INT S IMM 7 SEM AN
   Kaslow DC, 2018, NATURE, V564, P337, DOI 10.1038/d41586-018-07758-3
   Kuhn T., 1962, STRUCTURE SCI REVOLU
   LaForce FM, 2007, VACCINE, V25, pA97, DOI 10.1016/j.vaccine.2007.04.049
   MarketsandMarkets, 2019, VACC MARK DIS TECHN
   Martins RM, 2011, ATUALIZACOES ORIENTA, P113
   Mazzucato M., 2018, PEOPLES PRESCRIPTION
   Mazzucato M, 2015, MISSION ORIENTED FIN
   Mesquita EC, 2019, 4 INT S IMM 7 SEM AN
   Ministerio da Saude, 100 DIAS GOV AC BUSC
   Netscribes, 2019, TOP 10 TOP PLAYERS B
   Plotkin AS, 2011, HIST VACCINE DEV
   Poland GA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002344
   Ponte Carlos Fidelis, 2003, Hist. cienc. saude-Manguinhos, V10, P619, DOI 10.1590/S0104-59702003000500009
   Possas C, 2020, SCI TECHNOLOGY INNOV, P219
   Possas C, 2019, VACINAS VACINACOES B
   Possas C, 2019, INTELLECTUAL PROPERT, P337
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760180278
   Possas C, 2016, INTELLECTUAL PROPERTY ISSUES IN BIOTECHNOLOGY, P181, DOI 10.1079/9781780646534.0181
   Possas C, 2015, NAT BIOTECHNOL, V33, P599, DOI 10.1038/nbt.3244
   Rappuoli R, 2011, LANCET, V378, P360, DOI 10.1016/S0140-6736(11)60440-6
   Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017
   Soto C, 2019, NATURE, V566, P398, DOI 10.1038/s41586-019-0934-8
   Stamm B, 2009, FUTURE INNOVATION
   Statista, GLOB PHARM IND STAT
   Stokes DE, 2009, QUADRANTE PASTEUR CI
   Telarolli JR, 1999, REV CIENC FARM, V20, P461
   Wilder-Smith Annelies, 2017, Lancet Infect Dis, V17, pe101, DOI 10.1016/S1473-3099(16)30518-7
   World Health Organization, 2018, EP REP
NR 41
TC 0
Z9 0
U1 0
U2 0
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2020
VL 36
SU 2
AR e00128819
DI 10.1590/0102-311X00128819
PG 17
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA ON5RR
UT WOS:000586758400001
PM 33111747
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Neiva, MB
   Carvalho, I
   Costa, ED
   Barbosa, F
   Bernardi, FA
   Sanches, TLM
   de Oliveira, LL
   Lima, VC
   Miyoshi, NSB
   Alves, D
AF Neiva, Mariane Barros
   Carvalho, Isabelle
   Costa Filho, Etevaldo dos Santos
   Barbosa-Junior, Francisco
   Bernardi, Filipe Andrade
   Michelin Sanches, Tiago Lara
   de Oliveira, Lariza Laura
   Lima, Vinicius Costa
   Brandao Miyoshi, Newton Shydeo
   Alves, Domingos
TI Brazil: the emerging epicenter of COVID-19 pandemic
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE COVID-19; Sars-Cov-2; Pandemic; Brazil
AB Introduction: Five months after the first confirmed case of COVID-19 in Brazil, the county has the second highest number of cases in the world. Without any scientifically proven drug or vaccine available combined with COVID-19's high transmissivity, slowing down the spread of the infection is a challenge. In an attempt to save the economy, the Brazilian government is slowly beginning to allow nonessential services to reopen for in-person customers. Methods: In this study, we analyze, based on data analysis and statistics, how other countries evolve and under which conditions they decided to resume normal activity. In addition, due to the heterogeneity of Brazil, we explore Brazilian data of COVID-19 from the State Health Secretaries to evaluate the situation of the pandemic within the states. Results: Results show that while other countries have flattened their curves and present low numbers of active cases, Brazil continues to see an increase in COVID-19 patients. Furthermore. a number of important states are easing restrictions despite a high percentage of confirmed cases. Conclusions: All analyses show that Brazil is not ready for reopening, and the premature easing of restrictions may increase the number of COVID-19-related deaths and cause the collapse of the public health system.
C1 [Neiva, Mariane Barros; Carvalho, Isabelle] Univ Sao Paulo, Inst Ciencias Matemat & Comp, Sao Carlos, SP, Brazil.
   [Costa Filho, Etevaldo dos Santos] Univ Sao Paulo, Inst Fis Sao Carlos, Sao Carlos, SP, Brazil.
   [Barbosa-Junior, Francisco; Michelin Sanches, Tiago Lara; de Oliveira, Lariza Laura; Brandao Miyoshi, Newton Shydeo; Alves, Domingos] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Med Social, Ribeirao Preto, SP, Brazil.
   [Bernardi, Filipe Andrade; Lima, Vinicius Costa] Univ Sao Paulo, Programa Posgrad Bioengn, Sao Carlos, SP, Brazil.
RP Neiva, MB (corresponding author), Univ Sao Paulo, Inst Ciencias Matemat & Comp, Sao Carlos, SP, Brazil.
EM marianeneiva@usp.br
OI dos Santos Costa Filho, Etevaldo/0000-0003-3639-1181
CR [Anonymous], 2020, BBC NEWS
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Behnke E, 2020, ESTADAO POLITICA
   Brazilian Government, 2020, COR BRAS
   Carvalho ACC, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0199-2020
   Campbell Charlie, 2020, TIME
   Castro MC, 2020, DEMAND HOSPITALIZATI
   Chazan G., 2020, FINANCIAL TIMES
   Cruz EP, 2020, DORIA ANUNCIA FLEXIB
   de Melo Maria Luisa, 2020, COM NECROTERIO LOTAD
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fletcher RH, 1996, EPIDEMIOLOGIA CLIN E, P296
   Friedman Uri, 2020, ATLANTIC
   Griffiths J., 2020, CNN
   Holmes A., 2020, BUSINESS INSIDER
   Keogh B., 2020, STUFF
   Liang L.-H., 2020, BBC WORKLIFE
   McCann A, 2020, NEW YORK TIMES
   Mercer P., 2020, VOICE AM
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Phillips D, 2020, GUARDIAN
   Pontes N., 2020, DTSCH WELLE
   Roser M, 2020, CORONAVIRUS DIS COVI
   Rosiene Carvalho, 2020, ESTADAO
   Spahn J., 2020, GERMANY CONTAINED CO
   Taylor C., 2020, CNBC
   The State Council Information Office-The People's Republic of China, 2020, FULL TEXT FIGHT COVI
   UOL Noticias, 2020, GOV AM ESCR ONU PED
   Winterburn T., 2020, EURO WEEKLY NEWS
   Worldometer, 2020, COR CAS
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
NR 31
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2020
VL 53
AR e20200550
DI 10.1590/0037-8682-0550-2020
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA ON5YZ
UT WOS:000586777400001
PM 33111917
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mehta, HB
   Ehrhardt, S
   Moore, TJ
   Segal, JB
   Alexander, GC
AF Mehta, Hemalkumar B.
   Ehrhardt, Stephan
   Moore, Thomas J.
   Segal, Jodi B.
   Alexander, G. Caleb
TI Characteristics of registered clinical trials assessing treatments for
   COVID-19: a cross-sectional analysis
SO BMJ OPEN
LA English
DT Article
DE epidemiology; public health; infectious diseases
AB Objectives The coronavirus disease 2019 (COVID-19) pandemic has prompted many initiatives to identify safe and efficacious treatments, yet little is known regarding where early efforts have focused. We aimed to characterise registered clinical trials assessing drugs or plasma treatments for COVID-19.
   Design, setting and participants Cross-sectional analysis of clinical trials for the treatment of COVID-19 that were registered in the USA or in countries contributing to the WHO's International Clinical Trials Registry Platform. Relevant trial entries of drugs or plasma were downloaded on 26 March 2020, deduplicated, verified with reviews of major medical journals and WHO websites and independently analysed by two reviewers.
   Main outcome(s) Trial intervention, sponsorship, critical design elements and specified outcomes
   Results Overall, 201 clinical trials were registered for testing the therapeutic benefits of 92 drugs or plasma, including 64 in monotherapy and 28 different combinations. Only eight (5.1%) products or combinations involved new molecular entities. The other test therapies had a wide range of prior medical uses, including as antivirals, antimalarials, immunosuppressants and oncology treatments. In 152 trials (75.7%), patients were randomised to treatment or comparator, including 55 trials with some form of blinding and 97 open-label studies. The 49 (24.4%) of trials without a randomised design included 29 single armed studies and 20 trials with some comparison group. Most trial designs featured multiple endpoints. Clinical endpoints were identified in 134 (66.7%) of trials and included COVID-19 symptoms, death, recovery, required intensive care and hospital discharge. Clinical scales were being used in 33 (16.4%) trials, most often measures of oxygenation and critical illness. Surrogate endpoints or biomarkers were studied in 88 (42.3%) of trials, primarily assays of viral load. Although the trials were initiated in more than 17 countries or regions, 100 (49.8%) were registered in China and 78 (37.8%) in the USA. Registered trials increased rapidly, with the number of registered trials doubling from 1 March to 26 March 2020.
   Conclusions While accelerating morbidity and mortality from the COVID-19 pandemic has been paralleled by early and rapid clinical investigation, many trials lack features to optimise their scientific value. Global coordination and increased funding of high-quality research may help to maximise scientific progress in rapidly discovering safe and effective treatments.
C1 [Mehta, Hemalkumar B.; Ehrhardt, Stephan; Segal, Jodi B.; Alexander, G. Caleb] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.
   [Mehta, Hemalkumar B.; Segal, Jodi B.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.
   [Moore, Thomas J.] Inst Safe Medicat Practices, Alexandria, VA USA.
   [Segal, Jodi B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
RP Alexander, GC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.; Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.
EM galexan9@jhmi.edu
OI Moore, Thomas/0000-0003-0994-836X
CR [Anonymous], COR DIS COVID 19 DAS
   Apuzzo M, 2020, NY TIMES
   Califf RM, 2012, JAMA-J AM MED ASSOC, V307, P1838, DOI 10.1001/jama.2012.3424
   ClinicalTrials.gov, NAT LIB MED
   ClinicalTrials.gov, 2019, PROT REG DAT EL DEF
   ClinicalTrials.gov, PROT REG DAT EL DEF
   Coronavirus Resource Center, COR COVID 19 GLOB CA
   European Medicines Agency, EUR MED REG NETW FUL
   Garde D, UPDATED GUIDE CORONA
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Kupferschmidt K., 2020, SCIENCE, DOI [10.11 26/science.abb8497, DOI 10.1126/SCIENCE.ABB8497, 10.1126/science.abb8497]
   Milken Institute, COVID 19 TREATM VACC
   Pletcher MJ, 2011, CIRCULATION, V123, P1116, DOI 10.1161/CIRCULATIONAHA.110.943860
   Selleck MJ, 2017, BIOMARK INSIGHTS, V12, DOI 10.1177/1177271917715236
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Staff writer, 2020, UN NEWS
   Tse T, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1452
   U.S. Food and Drug Administration, 2020, COR DIS 2019 COVID 1
   Viergever RF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084727
   World Health Organization, WHO DAT COVID 19 TRI
   World Health Organization, INT CLIN TRIALS REG
   World Health Organization, INT STAND CLIN TRIAL
   Zimmer C., 2020, NY TIMES
NR 23
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 6
AR e039978
DI 10.1136/bmjopen-2020-039978
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC7ZO
UT WOS:000561433300058
PM 32518212
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, WL
   Paudel, R
   Shi, R
   Liang, J
   Liu, JW
   Zeng, XS
   Zhou, YF
   Zhang, B
AF Zhang, Wanling
   Paudel, Dhirendra
   Shi, Rui
   Liang, Jie
   Liu, Jingwen
   Zeng, Xiansheng
   Zhou, Yunfei
   Zhang, Bin
TI Virtual Reality Exposure Therapy (VRET) for Anxiety Due to Fear of
   COVID-19 Infection: A Case Series
SO NEUROPSYCHIATRIC DISEASE AND TREATMENT
LA English
DT Article
DE VRET; COVID-19; phobia; telemedicine; telehealth; exposure therapy
ID DISORDERS
AB Virtual reality exposure therapy (VRET) is becoming popular for treating phobia and anxiety disorder. The recent pandemic of COVID-19 not only causes infection per se but also has an impact on mental health. This case series aimed to explore the role of VRET in the intervention of psychiatric illnesses with chief complaints of fear of COVID-19 infection. In vivo exposure therapy for fear of COVID-19 infection is not possible due to the risk of virus infection; in this scenario, the VRET provides an immersive experience and can act as adjunctive therapy for treating phobias and anxiety disorders arising due to novel coronavirus pandemic. Clinical presentation and findings as well as management and procedures of VRET are discussed. Medical record of three patients (two male and one female) at the Shenzhen Mental Health Center (Shenzhen Kangning Hospital), China, was included in the present case series. Patients were assessed with the Hamilton Anxiety Rating Scale and Fear of COVID-19 Scale to measure anxiety and fear, respectively. Throughout VRET sessions, we gradually and systematically exposed the patient to virtual COVID-19 scenarios (for example, touching stained door handle which may have viruses, watching pandemic news, watching frontline health care workers, etc.). In our study, VRET intervention significantly reduced the related symptoms caused by fear of COVID-19 infection. Furthermore, virtual reality can provide relevant theoretical and practical support for exploring the remote psychological counseling of patients in isolation wards.
C1 [Zhang, Wanling; Shi, Rui; Liang, Jie; Liu, Jingwen; Zeng, Xiansheng; Zhou, Yunfei] Shenzhen Kangning Hosp, Shenzhen Mental Hlth Ctr, Shenzhen 518118, Peoples R China.
   [Zhang, Wanling; Paudel, Dhirendra; Zhang, Bin] Southern Med Univ, Ctr Brain Sci & Brain Inspired Intelligence, Guangdong Hong Kong Macao Greater Bay Area, Guangzhou 510515, Peoples R China.
   [Paudel, Dhirendra] Dhaulagiri Hosp, Dept Psychiat, Baglung 33300, Gandaki, Nepal.
   [Zhang, Bin] Southern Med Univ, Nanfang Hosp, Dept Psychiat, Guangzhou 510515, Peoples R China.
RP Zhou, YF (corresponding author), Shenzhen Kangning Hosp, Shenzhen Mental Hlth Ctr, Shenzhen 518118, Peoples R China.; Zhang, B (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Psychiat, Guangzhou 510515, Peoples R China.
EM drzyf2007@163.com; zhang73bin@hotmail.com
RI Paudel, Dhirendra/AAA-9513-2019
OI Paudel, Dhirendra/0000-0003-3619-9798
FU Shenzhen Key Medical Discipline Construction Fund [SZXK041]; Shenzhen
   Fund for Guangdong Provincial High-level Clinical Key Specialties
   [SZGSP013]
FX This research was funded by Shenzhen Key Medical Discipline Construction
   Fund (grant number. SZXK041) and Shenzhen Fund for Guangdong Provincial
   High-level Clinical Key Specialties (grant number. SZGSP013).
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   Anthony B, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01596-5
   Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Bokolo AJ, 2020, IRISH J MED SCI, DOI 10.1007/s11845-020-02299-z
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Carl E, 2019, J ANXIETY DISORD, V61, P27, DOI 10.1016/j.janxdis.2018.08.003
   Difede J, 2002, CYBERPSYCHOL BEHAV, V5, P529, DOI 10.1089/109493102321018169
   Dubey S, 2020, DIABETES METAB SYND, V14, P779, DOI 10.1016/j.dsx.2020.05.035
   Hamilton M, 1959, BR J MED PSYCHOL, V32, P50, DOI [10.1111/j.2044-8341.1959.tb00467.x17, DOI 10.1111/J.2044-8341.1959.TB00467.X17]
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Klinger E, 2004, ST HEAL T, V99, P91
   Krijn M, 2004, CLIN PSYCHOL REV, V24, P259, DOI 10.1016/j.cpr.2004.04.001
   Lee SA, 2020, J ANXIETY DISORD, V74, DOI 10.1016/j.janxdis.2020.102268
   Lin C-Y, 2020, SOCIAL HLTH BEHAV, V3, P1, DOI [10.4103/SHB.SHB_11_20, DOI 10.4103/SHB.SHB_11_20]
   McCabe RE, 2015, PHOBIAS PSYCHOL IRRA, V18, P361
   Meyerbroker K, 2010, DEPRESS ANXIETY, V27, P933, DOI 10.1002/da.20734
   Opris D, 2012, DEPRESS ANXIETY, V29, P85, DOI 10.1002/da.20910
   Singh RP, 2020, DIABETES METAB SYND, V14, P661, DOI 10.1016/j.dsx.2020.05.011
   WHO, 2020, 209 WHO
   World Health Organization, 1992, ICD 10 CLASS MENT BE
NR 20
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-2021
J9 NEUROPSYCH DIS TREAT
JI Neuropsychiatr. Dis. Treat.
PY 2020
VL 16
BP 2669
EP 2675
DI 10.2147/NDT.S276203
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA OM4EQ
UT WOS:000585979600002
PM 33192065
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, HY
   Zhao, CY
   Zhang, YH
   Yuan, F
   Zhang, Q
   Shi, XL
   Zhang, LQ
   Qin, CF
   Zheng, AH
AF Li, Hongyue
   Zhao, Chaoyue
   Zhang, Yuhang
   Yuan, Fei
   Zhang, Qi
   Shi, Xuanling
   Zhang, Linqi
   Qin, Chengfeng
   Zheng, Aihua
TI Establishment of replication-competent vesicular stomatitis virus-based
   recombinant viruses suitable for SARS-CoV-2 entry and neutralization
   assays
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; VSV; replication-competent; neutralization assay; entry
ID PSEUDOTYPED VIRUS; DIARRHEA-VIRUS; CORONAVIRUS; GLYCOPROTEIN; PROTEIN
AB Replication-competent vesicular stomatitis virus (VSV)-based recombinant viruses are useful tools for studying emerging and highly pathogenic enveloped viruses in level 2 biosafety facilities. Here, we used a replication-competent recombinant VSVs (rVSVs) encoding the spike (S) protein of SARS-CoV-2 in place of the original G glycoprotein (rVSV-eGFP-SARS-CoV-2) to develop a high-throughput entry assay for SARS-CoV-2. The S protein was incorporated into the recovered rVSV-eGFP-SARS-CoV-2 particles, which could be neutralized by sera from convalescent COVID-19 patients. The recombinant SARS-CoV-2 also displayed entry characteristics similar to the wild type virus, such as cell tropism and pH-dependence. The neutralizing titers of antibodies and sera measured by rVSV-eGFP-SARS-CoV-2 were highly correlated with those measured by wild-type viruses or pseudoviruses. Therefore, this is a safe and convenient screening tool for SARS-CoV-2, and it may promote the development of COVID-19 vaccines and therapeutics.
C1 [Li, Hongyue; Zhao, Chaoyue; Zhang, Yuhang; Zheng, Aihua] Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing, Peoples R China.
   [Li, Hongyue; Zhao, Chaoyue; Zhang, Yuhang; Zheng, Aihua] Univ Chinese Acad Sci, CAS Ctr Excellence Biot Interact, Beijing, Peoples R China.
   [Yuan, Fei] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
   [Zhang, Qi; Shi, Xuanling; Zhang, Linqi] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Ctr Global Hlth & Infect Dis, Beijing, Peoples R China.
   [Zhang, Qi; Shi, Xuanling; Zhang, Linqi] Tsinghua Univ, Sch Med, Beijing Adv Innovat Ctr Struct Biol, Beijing, Peoples R China.
   [Qin, Chengfeng] Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Dept Virol, Beijing, Peoples R China.
   [Zheng, Aihua] Hainan Med Univ, Sch Trop Med & Lab Med, Minist Educ, Key Lab Trop Translat Med, Haikou, Hainan, Peoples R China.
RP Zheng, AH (corresponding author), Chinese Acad Sci, Inst Zool, State Key Lab Integrated Management Pest Insects, Beijing, Peoples R China.; Zheng, AH (corresponding author), Univ Chinese Acad Sci, CAS Ctr Excellence Biot Interact, Beijing, Peoples R China.; Zheng, AH (corresponding author), Hainan Med Univ, Sch Trop Med & Lab Med, Minist Educ, Key Lab Trop Translat Med, Haikou, Hainan, Peoples R China.
EM zhengaihua@ioz.ac.cn
OI Zheng, Aihua/0000-0002-2184-227X
FU National Key Plan for Scientific Research and Development of China
   [2016YFD0500303]; National Science and Technology Major Project
   [2018ZX10101004]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81871687]
FX This project was supported by the National Key Plan for Scientific
   Research and Development of China (Grant no. 2016YFD0500303); the
   National Science and Technology Major Project (Grant no.
   2018ZX10101004); and National Natural Science Foundation of China,
   General Program (Grant no. 81871687).
CR Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348
   Chan SY, 2000, J VIROL, V74, P4933, DOI 10.1128/JVI.74.10.4933-4937.2000
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Conceicao C, 2020, BIORXIV PREPRINT
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Fukushi S, 2006, J MED VIROL, V78, P1509, DOI 10.1002/jmv.20732
   Fukushi Shuetsu, 2008, V454, P331, DOI 10.1007/978-1-59745-181-9_23
   Haglund K, 2000, VIROLOGY, V268, P112, DOI 10.1006/viro.1999.0120
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Ke Y, 2019, VIROLOGY, V533, P77, DOI 10.1016/j.virol.2019.05.009
   Kohl W, 2007, J GEN VIROL, V88, P157, DOI 10.1099/vir.0.81972-0
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764
   WHELAN SP, 2018, P NATL ACAD SCI USA, V92, P8388
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Wicht O, 2014, J VIROL, V88, P7952, DOI 10.1128/JVI.00297-14
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2269
EP 2277
DI 10.1080/22221751.2020.1830715
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OM0US
UT WOS:000585746200001
PM 32990161
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Meekins, DA
   Morozov, I
   Trujillo, JD
   Gaudreault, NN
   Bold, D
   Carossino, M
   Artiaga, BL
   Indran, SV
   Kwon, T
   Balaraman, V
   Madden, DW
   Feldmann, H
   Henningson, J
   Ma, WJ
   Balasuriya, UBR
   Richt, JA
AF Meekins, David A.
   Morozov, Igor
   Trujillo, Jessie D.
   Gaudreault, Natasha N.
   Bold, Dashzeveg
   Carossino, Mariano
   Artiaga, Bianca L.
   Indran, Sabarish V.
   Kwon, Taeyong
   Balaraman, Velmurugan
   Madden, Daniel W.
   Feldmann, Heinz
   Henningson, Jamie
   Ma, Wenjun
   Balasuriya, Udeni B. R.
   Richt, Juergen A.
TI Susceptibility of swine cells and domestic pigs to SARS-CoV-2
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; swine; coronavirus; pigs; infection models;
   zoonotic disease
ID ANTIGENIC CROSS-REACTIVITY; RESPIRATORY-SYNDROME SARS; CORONAVIRUS;
   IMMUNITY; COV
AB The emergence of SARS-CoV-2 has resulted in an ongoing global pandemic with significant morbidity, mortality, and economic consequences. The susceptibility of different animal species to SARS-CoV-2 is of concern due to the potential for interspecies transmission, and the requirement for pre-clinical animal models to develop effective countermeasures. In the current study, we determined the ability of SARS-CoV-2 to (i) replicate in porcine cell lines, (ii) establish infection in domestic pigs via experimental oral/intranasal/intratracheal inoculation, and (iii) transmit to co-housed naive sentinel pigs. SARS-CoV-2 was able to replicate in two different porcine cell lines with cytopathic effects. Interestingly, none of the SARS-CoV-2-inoculated pigs showed evidence of clinical signs, viral replication or SARS-CoV-2-specific antibody responses. Moreover, none of the sentinel pigs displayed markers of SARS-CoV-2 infection. These data indicate that although different porcine cell lines are permissive to SARS-CoV-2, five-week old pigs are not susceptible to infection via oral/intranasal/intratracheal challenge. Pigs are therefore unlikely to be significant carriers of SARS-CoV-2 and are not a suitable pre-clinical animal model to study SARS-CoV-2 pathogenesis or efficacy of respective vaccines or therapeutics.
C1 [Meekins, David A.; Morozov, Igor; Trujillo, Jessie D.; Gaudreault, Natasha N.; Bold, Dashzeveg; Artiaga, Bianca L.; Indran, Sabarish V.; Kwon, Taeyong; Balaraman, Velmurugan; Madden, Daniel W.; Henningson, Jamie; Ma, Wenjun; Richt, Juergen A.] Kansas State Univ, Dept Diagnost Med Pathobiol, Coll Vet Med, Ctr Excellence Emerging & Zoonot Anim Dis, Manhattan, KS 66506 USA.
   [Carossino, Mariano; Balasuriya, Udeni B. R.] Louisiana State Univ, Sch Vet Med, Louisiana Anim Dis Diagnost Lab, Baton Rouge, LA 70803 USA.
   [Carossino, Mariano; Balasuriya, Udeni B. R.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.
   [Feldmann, Heinz] NIAID, Lab Virol, Div Intramural Res, NIH, Hamilton, MT USA.
   [Ma, Wenjun] Univ Missouri, Dept Vet Pathobiol, Columbia, MO USA.
   [Ma, Wenjun] Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO USA.
RP Richt, JA (corresponding author), Kansas State Univ, Dept Diagnost Med Pathobiol, Coll Vet Med, Ctr Excellence Emerging & Zoonot Anim Dis, Manhattan, KS 66506 USA.
EM jricht@ksu.edu
FU National Bio and Agro-Defense Facility (NBAF) Transition Funds from the
   State of Kansas; Kansas State University; NIAID Centers of Excellence
   for Influenza Research and Surveillance [HHSN 272201400006C]; Department
   of Homeland Security Center of Excellence for Emerging and Zoonotic
   Animal DiseasesUnited States Department of Homeland Security (DHS)
   [HSHQDC-16-A-B0006]; NIAID, NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID)
FX Funding for this study was provided through grants from the National Bio
   and Agro-Defense Facility (NBAF) Transition Funds from the State of
   Kansas. Kansas State University internal funds, the NIAID Centers of
   Excellence for Influenza Research and Surveillance under contract number
   HHSN 272201400006C, and the Department of Homeland Security Center of
   Excellence for Emerging and Zoonotic Animal Diseases [grant number
   HSHQDC-16-A-B0006] to J.A.R. H.R. is funded through the Intramural
   Research Program, NIAID, NIH.
CR Abdel-Moneim AS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070529
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Carossino M, 2020, ARCH VIROL, V165, P2373, DOI 10.1007/s00705-020-04737-w
   Centers for Disease Control and Prevention RVB Division of Viral Diseases, 2020, REAL TIME RT PCR PAN
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chen D, 2020, SINGLE CELL SCREENIN
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen WJ, 2005, EMERG INFECT DIS, V11, P446, DOI 10.3201/eid1103.040824
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Gaudreault NN, 2020, EMERG MICROBES INFEC, P1
   Gollakner R., 2020, VET ITAL, V56, P7, DOI 10.12834/VetIt.2246.12523.1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Hernandez M, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060480
   Kim Y, 2020, CARDIOL J, V27, P1, DOI 10.5603/CJ.2020.0012
   Langel SN, 2016, VIRUS RES, V226, P93, DOI 10.1016/j.virusres.2016.05.016
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Lee J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100905
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Macera M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17145062
   McNamara T, 2020, VECTOR-BORNE ZOONOT, V20, P393, DOI 10.1089/vbz.2020.2650
   Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Organization WH, 2020, CORONAVIRUS DIS COVI
   Quick J., 2020, NCOV 2019 SEQUENCING, DOI [10.17504/protocols.io.bdp7i5rn, DOI 10.17504/PR0T0C0LS.I0.BDP7I5RN]
   Ramadan N, 2019, GERMS, V9, P35, DOI 10.18683/germs.2019.1155
   Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17367-2
   Richt JA, 2003, J CLIN MICROBIOL, V41, P3198, DOI 10.1128/JCM.41.7.3198-3205.2003
   Sarkar J, 2020, VET RES COMMUN, V44, P101, DOI 10.1007/s11259-020-09778-9
   Schlottau Kore, 2020, Lancet Microbe, V1, pe218, DOI 10.1016/S2666-5247(20)30089-6
   Sestak K, 1996, AM J VET RES, V57, P664
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sun ZF, 2004, J CLIN MICROBIOL, V42, P2351, DOI 10.1128/JCM.42.5.2351-2352.2004
   Vergara-Alert J, 2020, PIGS ARE NOT SUSCEPT
   Vijayanand P, 2004, CLIN MED, V4, P152, DOI 10.7861/clinmedicine.4-2-152
   Vlasova AN, 2007, J VIROL, V81, P13365, DOI 10.1128/JVI.01169-07
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang QH, 2019, CURR OPIN VIROL, V34, P39, DOI 10.1016/j.coviro.2018.12.001
   Weingartl HM, 2004, EMERG INFECT DIS, V10, P179, DOI 10.3201/eid1002.030677
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Yoo HS, 2020, J VET SCI, V21, DOI 10.4142/jvs.2020.21.e51
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 48
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2278
EP 2288
DI 10.1080/22221751.2020.1831405
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OM0UL
UT WOS:000585745500001
PM 33003988
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guo, T
   Shen, QX
   Zhou, ZG
   Li, JH
   Guo, W
   He, WL
   Wang, YN
   Xiang, Z
   Huang, P
   Zeng, NY
   Qin, QW
   Chen, P
   Luo, H
   Peng, H
AF Guo, Ting
   Shen, Qinxue
   Zhou, Zhiguo
   Li, Jinhua
   Guo, Wei
   He, Wenlong
   Wang, Yunnian
   Xiang, Zhi
   Huang, Peng
   Zeng, Nanyang
   Qin, Qingwu
   Chen, Ping
   Luo, Hong
   Peng, Hong
TI Combined Interventions for Severe Novel Coronavirus Disease (COVID-19):
   Experience from 350 Patients
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE coronavirus disease 2019; SARS-CoV-2; severe disease; corticosteroid;
   immunoglobulin
AB Purpose: To summarize the clinical features and effective therapy of severe COVID-19 patients.
   Patients and Methods: In this retrospective, multicenter study, the medical records of COVID-19 patients in Hunan, from January 21, 2020 to February 19, 2020 were reviewed.
   Results: Of the 350 COVID-19 patients, 13.7% were severe cases. On admission, compared with non-severe patients, more severe patients had a neutrophil/lymphocyte ratio > 3 (58.3% vs 33.8%, P=0.001), D-dimer > 1 mg/L (41.7% vs 13.6%, P<0.0001), higher level of CRP (39.1 mg/L, IQR18.1-75.9 vs 13.4 mg/L, IQR5.0-32.8, P0.0001), and multiple pneumonia on CT (77.1% vs 18.2%, P0.0001). All severe patients received oxygen support. 95.8% of them received antivirals, and the most frequent therapy was lopinavir and ritonavir plus human interferon-alpha 2b. Moxifloxacin was used in 70.8% severe patients. The total dosage of methyl-prednisolone sodium succinate was 640 mg (IQR 360-960) in severe patients, and the duration of use was 8.5 days (IQR 6.8-11.3). The total dosage of immunoglobulin was 80 g (IQR, 60-140) in severe patients, and the duration was 8.0 days (IQR, 6.0-11.5). As of March 15, 2020, 95.8% of the severe patients had been discharged and only two deaths occurred.
   Conclusion: The rate of severe cases and mortality of COVID-19 in Hunan are lower than those in Wuhan. In addition to antivirals and oxygen support, timely interventions including corticosteroids, immunoglobulin, and antibiotics, contribute to improving the prognosis of severe COVID-19 patients.
C1 [Guo, Ting; Shen, Qinxue; Li, Jinhua; Guo, Wei; He, Wenlong; Qin, Qingwu; Chen, Ping; Luo, Hong; Peng, Hong] Cent South Univ, Dept Resp & Crit Care Med, Xiangya Hosp 2, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
   [Guo, Ting; Shen, Qinxue; Li, Jinhua; Guo, Wei; He, Wenlong; Qin, Qingwu; Chen, Ping; Luo, Hong; Peng, Hong] Cent South Univ, Res Unit Resp Dis, Changsha, Hunan, Peoples R China.
   [Guo, Ting; Shen, Qinxue; Li, Jinhua; Guo, Wei; He, Wenlong; Qin, Qingwu; Chen, Ping; Luo, Hong; Peng, Hong] Resp Dis Diag & Treatment Ctr Hunan Prov, Changsha, Hunan, Peoples R China.
   [Zhou, Zhiguo] First Hosp Changsha, Dept Resp & Crit Care Med, Changsha, Hunan, Peoples R China.
   [Wang, Yunnian] Tradit Chinese Med Hosp Liling, Dept Resp & Crit Care Med, Zhuzhou, Hunan, Peoples R China.
   [Xiang, Zhi] First Peoples Hosp Huaihua, Dept Resp & Crit Care Med, Huaihua, Hunan, Peoples R China.
   [Huang, Peng] Cent Hosp Zhuzhou, Dept Resp & Crit Care Med, Zhuzhou, Hunan, Peoples R China.
   [Zeng, Nanyang] Lvkou Peoples Hosp Zhuzhou, Dept Infect Dis, Zhuzhou, Hunan, Peoples R China.
RP Peng, H (corresponding author), Cent South Univ, Dept Resp & Crit Care Med, Xiangya Hosp 2, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
EM penghong66@csu.edu.cn
OI Peng, Hong/0000-0003-3235-3348
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81370164, 81670062]; National Natural
   Science Foundation of Hunan ProvinceNatural Science Foundation of Hunan
   Province [2015JJ4087, 2020JJ8070]; National key clinical specialist
   construction Programs of China; Innovative Major Emergent Project
   against the Outbreak of New Coronavirus Pneumonia in Hunan Province
   [2020SK3014]; Fundamental Research Funds for the Central Universities of
   Central South University [2020zzts880]; China Scholarship CouncilChina
   Scholarship Council [201906370230]
FX This study was funded by the National Natural Science Foundation of
   China (No. 81370164 and No. 81670062), the National Natural Science
   Foundation of Hunan Province (No. 2015JJ4087 and No. 2020JJ8070), the
   National key clinical specialist construction Programs of China, the
   Innovative Major Emergent Project against the Outbreak of New
   Coronavirus Pneumonia in Hunan Province (No. 2020SK3014), the
   Fundamental Research Funds for the Central Universities of Central South
   University (No. 2020zzts880), and the China Scholarship Council (No.
   201906370230). These first authors contributed equally to this work:
   Ting Guo, Qinxue Shen.
CR Aining Z, 2020, INT J INFECT DIS
   Aliye B, 2020, INT IMMUNOPHARMACOL, V88
   Chang C, 2020, MEDRXIV
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese National Health Committee, DIAGN TREATM GUID NO
   Dawei W, 2020, JAMA-J AM MED ASSOC
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jian W, 2020, CLIN INFECT DIS
   Jinjin Z, 2020, ALLERGY
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   National Health Commission of the People's Republic of China, LAT SIT NEW COR PNEU
   Qin L, 2016, AGING-US, V8, P848, DOI 10.18632/aging.100894
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sepulchre E, 2020, ACTA CLIN BELG, DOI 10.1080/17843286.2020.1822078
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Simiao C, 2020, LANCET
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Wang C, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361-6528/ab8326
   Wang DC, 2020, SURG INFECT, DOI 10.1089/sur.2020.133
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, GEN OP REM MISS BRIE
   World Health Organization, WHO COR DIS COVID 19
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Xiaolei L, 2020, INT J ADV MANUF TECH, P1
   Xiaowei F, 2020, J INFECT
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 33
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 3907
EP 3918
DI 10.2147/IDR.S279255
PG 12
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA OJ4SS
UT WOS:000583953900002
PM 33154656
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Florencio, FKZ
   Tenorio, MD
   Macedo, ARA
   de Lima, SG
AF Zacarias Florencio, Francisco Kleyton
   Tenorio, Maiza de Oliveira
   Andrade Macedo Junior, Aluisio Roberto
   de Lima, Sandro Goncalves
TI Aspirin with or without statin in the treatment of endotheliitis,
   thrombosis, and ischemia in coronavirus disease
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE COVID-19; Aspirin; Thrombosis; Endothelium; Hydroxymethylglutaryl-CoA
   Reductase Inhibitors
AB Introduction: In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach. Statins could potentiate the ASA therapy.
   Methods: This is a series of 14 cases with a laboratory-confirmed diagnosis of COVID-19. All patients underwent the ASA therapy. Those who had risk factors forvascular disease also underwent the high-potency statin therapy. When symptoms were totally or practically resolved, patients were discharged and advised to continue medications for a complementary time, according to the clinical evolution of each patient.
   Results: The mean age of monitored patients was 48.6 years. A total of 78.6% patients presented with at least one comothidity, which could have contributed as a risk factor for a poor prognosis in the evolution of COVID-19. Four patients had secondary bacterial infections; three patients needed hospitalization. None of the cases progress to stage III, and all patients had remission of symptoms, with 100% survival.
   Conclusions: the process of endothelial dysfunction in COVID-19 involves disseminated thrombosis, initially microvascular and later expansion into larger vessels. ASA could act as a secondary prophylaxis and prevent thrombosis from developing and reaching stage III of the disease. As this was a case series, we cannot provide definitive conclusions: however, this study allows us to formulate hypotheses and support clinical trials to evaluate benefits of the ASA therapy in the treatment of COVID-19.
C1 [Zacarias Florencio, Francisco Kleyton; Andrade Macedo Junior, Aluisio Roberto] Hosp Metropolitano Sul Dom Helder Camara, Cabo De Santo Agostinho, PE, Brazil.
   [Tenorio, Maiza de Oliveira; de Lima, Sandro Goncalves] Univ Fed Pernambuco, Ctr Ciencias Med, Recife, PE, Brazil.
   [Zacarias Florencio, Francisco Kleyton; Andrade Macedo Junior, Aluisio Roberto; de Lima, Sandro Goncalves] Univ Fed Pernambuco, Hosp Clin, Serv Cardiol, Recife, PE, Brazil.
   [de Lima, Sandro Goncalves] Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
RP Tenorio, MD (corresponding author), Univ Fed Pernambuco, Ctr Ciencias Med, Recife, PE, Brazil.
EM maizatenorio@hotmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Avogaro A, 2011, DIABETES CARE, V34, pS285, DOI 10.2337/dc11-s239
   Baigent C, 1998, BMJ-BRIT MED J, V316, P1337, DOI 10.1136/bmj.316.7141.1337
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Denilson A, 2015, REV SOCERJ, V17, P88
   Esmon CT, 2009, BLOOD REV, V23, P225, DOI 10.1016/j.blre.2009.07.002
   Figueiredo VN, 2013, REV SOC CARDIOL ESTA, V23, P40
   Flammer AJ, 2012, CIRCULATION, V126, P753, DOI 10.1161/CIRCULATIONAHA.112.093245
   Gurbel PA, 2020, CIRCULATION, V142, P315, DOI 10.1161/CIRCULATIONAHA.120.047830
   Jourde-Chiche N, 2019, NAT REV NEPHROL, V15, P87, DOI 10.1038/s41581-018-0098-z
   Krishna SM, 2015, INT J MOL SCI, V16, P11294, DOI 10.3390/ijms160511294
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Liu XY, 2020, ACTA PHARMACOL SIN B, V10, P1205, DOI 10.1016/j.apsb.2020.04.008
   Massachusetts General Hospital (MGH), 2020, MASS GEN HOSP MGH CO
   Mekaj YH, 2015, THER CLIN RISK MANAG, V11, DOI [10.2147/TCRM.S84210, 10.2147/TCRM.S92222]
   Morinaga LK, 2020, HEPARIN THERAPY IMPR, V2, P1
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pittilo RM, 2000, INT J EXP PATHOL, V81, P219
   Salamanna F, 2020, PLATELETS, V31, P627, DOI 10.1080/09537104.2020.1762852
   SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603
   Spieker L E, 2006, Handb Exp Pharmacol, P249
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   WINTHER K, 1994, PHARMACOL TOXICOL, V74, P141, DOI 10.1111/j.1600-0773.1994.tb01089.x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 2
U2 2
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2020
VL 53
AR e20200472
DI 10.1590/0037-8682-0472-2020
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA OL2FC
UT WOS:000585155600001
PM 32965455
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hedayatipour, A
   Mcfarlane, N
AF Hedayatipour, Ava
   Mcfarlane, Nicole
TI Wearables for the Next Pandemic
SO IEEE ACCESS
LA English
DT Article
DE Diseases; Vaccines; Viruses (medical); Temperature sensors; Lung;
   Biomedical monitoring; Bioimpedance; circuits and systems; COVID-19;
   influenza; pandemic; pulse oximetry; sensors; temperature sensor;
   wearable devices
ID CMOS TEMPERATURE SENSOR; ULTRA-LOW-POWER; PULSE OXIMETRY; HEALTH-CARE;
   ENERGY; INFLUENZA; IOT; DEVICE; SOC; NETWORKS
AB This paper reviews the current state of the art in wearable sensors, including current challenges, that can alleviate the loads on hospitals and medical centers. During the COVID-19 Pandemic in 2020, healthcare systems were overwhelmed by people with mild to severe symptoms needing care. A careful study of pandemics and their symptoms in the past 100 years reveals common traits that should be monitored for managing the health and economic costs. Cheap, low power, and portable multi-modal-sensors that detect the common symptoms can be stockpiled and ready for the next pandemic. These sensors include temperature sensors for fever monitoring, pulse oximetry sensors for blood oxygen levels, impedance sensors for thoracic impedance, and other state sensors that can be integrated into a single system and connected to a smartphone or data center. Both research and commercial medically approved devices are reviewed with an emphasis on the electronics required to realize the sensing. The performance characteristics, such as accuracy, power, resolution, and size of each sensor modality are critically examined. A discussion of the characteristics, research challenges, and features of an ideal integrated wearable system is also presented.
C1 [Hedayatipour, Ava] Calif State Univ Long Beach, Dept Elect Engn, Long Beach, CA 90840 USA.
   [Hedayatipour, Ava; Mcfarlane, Nicole] Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN 37996 USA.
RP Hedayatipour, A (corresponding author), Calif State Univ Long Beach, Dept Elect Engn, Long Beach, CA 90840 USA.; Hedayatipour, A; Mcfarlane, N (corresponding author), Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN 37996 USA.
EM ahedaya1@vols.utk.edu; mcfarlane@utk.edu
OI Hedayatipour, Ava/0000-0003-1034-3616
FU National Science FoundationNational Science Foundation (NSF) [1816703]
FX This material is based upon work supported by the National Science
   Foundation under Grant No. 1816703.
CR Ajami S, 2015, J RES MED SCI, V20, P1007, DOI 10.4103/1735-1995.172797
   Alexander JC, 2017, J CLIN MONIT COMPUT, V31, P825, DOI 10.1007/s10877-016-9889-6
   Allegri D, 2018, IEEE T BIOMED CIRC S, V12, P1301, DOI 10.1109/TBCAS.2018.2867172
   [Anonymous], 2019, 1968 PANDEMIC H3N2 V
   [Anonymous], 2019, 2014 2016 EBOLA OUTB
   [Anonymous], 2019, WEARABLE TECHNOLOGY
   [Anonymous], 2018, HIST 1918 FLU PANDEM
   [Anonymous], 2020, 2009 SWINE FLU PANDE
   [Anonymous], 2019, MIDDLE E RESP SYNDRO
   [Anonymous], 2020, CORONAVIRUS COVID 19
   [Anonymous], 2019, 2009 H1N1 PANDEMIC H
   [Anonymous], 2015, CORVENTIS LAUNCHES A
   [Anonymous], 2010, SPANISH FLU
   [Anonymous], 2020, FACEBOOK AMAZON GOOG
   [Anonymous], 2017, LOOK MUCH HUMANITY H
   [Anonymous], 2019, 1957 1958 PANDEMIC H
   Bashir M, 2019, ANALOG INTEGR CIRC S, V99, P311, DOI 10.1007/s10470-018-1278-2
   Bodo M., 2018, J ELECT BIOIMPEDANCE, V9, P123
   Bonomi A. G., 2018, U.S. Patent, Patent No. [9 955 916, 9955916]
   Braun M, 2017, 2017 INTERNATIONAL CONFERENCE ON FPGA RECONFIGURATION FOR GENERAL-PURPOSE COMPUTING (FPGA4GPC), P1
   Caizzone A, 2019, IEEE T BIOMED CIRC S, V13, P1243, DOI 10.1109/TBCAS.2019.2944393
   Chamola V, 2020, IEEE ACCESS, V8, P90225, DOI 10.1109/ACCESS.2020.2992341
   Chiou AYC, 2016, IEEE ASIAN SOLID STA, P197, DOI 10.1109/ASSCC.2016.7844169
   Cho N, 2005, PROC EUR SOLID-STATE, P279, DOI 10.1109/ESSCIR.2005.1541614
   Choi A, 2015, SENSORS-BASEL, V15, P22151, DOI 10.3390/s150922151
   Chong YW, 2019, IEEE SENS J, V19, P9047, DOI 10.1109/JSEN.2019.2925638
   Ciui B, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701264
   Coffey L., 2020, USF IS USING WEARABL
   Coltart CEM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0297
   Elgendi M, 2012, CURR CARDIOL REV, V8, P14, DOI 10.2174/157340312801215782
   Ensworth JF, 2017, IEEE T MICROW THEORY, V65, P3360, DOI 10.1109/TMTT.2017.2687866
   Environ, 2012, TECH REP
   Ferreira J, 2013, IEEE ENG MED BIO, P559, DOI 10.1109/EMBC.2013.6609561
   Ferreira J., 2017, THESIS
   Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999
   Fortino G., 2013, P 8 INT C BOD AR NET, P363
   Ghanad MA, 2017, IEEE T BIOMED CIRC S, V11, P54, DOI 10.1109/TBCAS.2016.2574895
   Glaros KN, 2013, IEEE T BIOMED CIRC S, V7, P363, DOI 10.1109/TBCAS.2012.2200677
   Gubbi SV, 2015, IEEE T BIOMED CIRC S, V9, P272, DOI 10.1109/TBCAS.2014.2326712
   Hafid A, 2018, IEEE J BIOMED HEALTH, V22, P1883, DOI 10.1109/JBHI.2017.2783949
   Hay WW., 2005, NEOREVIEWS, V6, pe533
   He C, 2009, SIXTH INTERNATIONAL WORKSHOP ON WEARABLE AND IMPLANTABLE BODY SENSOR NETWORKS, PROCEEDINGS, P207, DOI 10.1109/P3644.27
   Hedayatipour A., 2020, P IEEE INT S CIRC SY, P1
   Hedayatipour A, 2019, MIDWEST SYMP CIRCUIT, P152, DOI 10.1109/MWSCAS.2019.8884994
   Hedayatipour A, 2017, MIDWEST SYMP CIRCUIT, P253, DOI 10.1109/MWSCAS.2017.8052908
   Hughes Mark D, 2009, J Diabetes Sci Technol, V3, P1219
   Ibrahem H, 2019, NAT RADIO SCI CO, P360, DOI 10.1109/NRSC.2019.8734533
   Islam SMR, 2015, IEEE ACCESS, V3, P678, DOI 10.1109/ACCESS.2015.2437951
   Jayathilaka WADM, 2019, ADV MATER, V31, DOI 10.1002/adma.201805921
   Jeong S, 2014, IEEE J SOLID-ST CIRC, V49, P1682, DOI 10.1109/JSSC.2014.2325574
   Jia WZ, 2013, ANGEW CHEM INT EDIT, V52, P7233, DOI 10.1002/anie.201302922
   Jordan TB, 2020, AM J EMERG MED, V38, P925, DOI 10.1016/j.ajem.2019.07.020
   Karkani MRG, 2016, 2016 8TH INTERNATIONAL SYMPOSIUM ON TELECOMMUNICATIONS (IST), P12, DOI 10.1109/ISTEL.2016.7881772
   Kaushalya SADS, 2019, ADV INTELL SYST, V924, P485, DOI 10.1007/978-981-13-6861-5_42
   Kawata M., 1999, US Patent, Patent No. [5 889 735, 5889735]
   Khandwalla RM, 2016, J AM COLL CARDIOL, V67, P1296, DOI 10.1016/S0735-1097(16)31297-9
   Kim S, 2014, P IEEE, V102, P1649, DOI 10.1109/JPROC.2014.2357031
   Korcyl G, 2018, IEEE T MED IMAGING, V37, P2526, DOI 10.1109/TMI.2018.2837741
   Krikidis I, 2014, IEEE COMMUN MAG, V52, P104, DOI 10.1109/MCOM.2014.6957150
   Kyriacou PA, 2006, PHYSIOL MEAS, V27, pR1, DOI 10.1088/0967-3334/27/1/R01
   Lansbury LE, 2017, INFLUENZA OTHER RESP, V11, P356, DOI 10.1111/irv.12464
   Law MK, 2010, IEEE J SOLID-ST CIRC, V45, P1246, DOI 10.1109/JSSC.2010.2047456
   Law MK, 2009, IEEE T CIRCUITS-II, V56, P891, DOI 10.1109/TCSII.2009.2034201
   Lee H, 2016, IEEE T CIRCUITS-II, V63, P553, DOI 10.1109/TCSII.2016.2530803
   Lee R, 2019, OLD NEW PERSPECTIVES, P167
   Lee S, 2015, IEEE ENG MED BIO, P438, DOI 10.1109/EMBC.2015.7318393
   Lee S, 2013, J PHYS CONF SER, V434, DOI 10.1088/1742-6596/434/1/012013
   Leonov V, 2013, IEEE SENS J, V13, P2284, DOI 10.1109/JSEN.2013.2252526
   LePan N, 2020, VISUALIZING HIST PAN
   Lin BH, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19030512
   Lin TH, 2017, IEEE MTT S INT MICR, P1030
   Lin YS, 2008, IEEE CUST INTEGR CIR, P507, DOI 10.1109/CICC.2008.4672133
   Lu X, 2015, IEEE COMMUN SURV TUT, V17, P757, DOI 10.1109/COMST.2014.2368999
   Mahbub I., 2017, US NAT COMM URSI NAT, P1
   Makinwa KAA, 2010, PROCEDIA ENGINEER, V5, P930, DOI 10.1016/j.proeng.2010.09.262
   Marquez JC, 2013, EUR J CLIN NUTR, V67, pS22, DOI 10.1038/ejcn.2012.161
   Mateu Loreto, 2007, 2007 International Conference on Sensor Technologies and Applications - SensorComm 2007, P366, DOI 10.1109/SENSORCOMM.2007.4394949
   Mazhab-Jafari H, 2012, IEEE T BIOMED CIRC S, V6, P468, DOI 10.1109/TBCAS.2012.2226334
   Merrett GV, 2015, IEEE SENS J, V15, P434, DOI 10.1109/JSEN.2014.2346019
   Mody L, 2007, J AM GERIATR SOC, V55, P1431, DOI 10.1111/j.1532-5415.2007.01299.x
   Mucha Andreas, 2011, 2011 IEEE Sensors Applications Symposium (SAS), P12, DOI 10.1109/SAS.2011.5739770
   Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186
   O'Malley P, 2009, B WORLD HEALTH ORGAN, V87, P614, DOI 10.2471/BLT.08.056689
   Opasjumruskit K, 2006, IEEE PERVAS COMPUT, V5, P54, DOI 10.1109/MPRV.2006.15
   Orlik T., 2020, CORONAVIRUS COULD CO
   Ostfeld AE, 2017, FLEX PRINT ELECTRON, V2, DOI 10.1088/2058-8585/aa5750
   Ostfeld AE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26122
   Ott M, 2007, PUBLIC HEALTH REP, V122, P803, DOI 10.1177/003335490712200612
   Perkins R., 2016, HERES WAY PRODUCE NA
   Potter S. J., 2020, WIRELESS INTERNATION
   Pourmousavian N, 2018, IEEE J SOLID-ST CIRC, V53, P2572, DOI 10.1109/JSSC.2018.2843337
   Prasad D, 2019, MICROSYST TECHNOL, V25, P2301, DOI 10.1007/s00542-018-4115-8
   Prasad D, 2018, MICROSYST TECHNOL, V24, P1553, DOI 10.1007/s00542-017-3564-9
   Pullini A, 2019, IEEE J SOLID-ST CIRC, V54, P1970, DOI 10.1109/JSSC.2019.2912307
   Qi ZW, 2014, MICROELECTRON J, V45, P126, DOI 10.1016/j.mejo.2013.10.010
   Qian K, 2016, ADV ELECTRON MATER, V2, DOI 10.1002/aelm.201500370
   Radin JM, 2020, LANCET DIGIT HEALTH, V2, pE85, DOI 10.1016/S2589-7500(19)30222-5
   Rajesh PV, 2016, ISSCC DIG TECH PAP I, V59, P386, DOI 10.1109/ISSCC.2016.7418069
   Rapoport BI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038436
   Rhee S, 2001, IEEE T BIO-MED ENG, V48, P795, DOI 10.1109/10.930904
   Roser M., 2019, MORTALITY HALF DIED
   Rossi S, 2015, SENSOR ACTUAT A-PHYS, V232, P359, DOI 10.1016/j.sna.2015.05.004
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rusci M, 2016, IEEE SENS J, V16, P5344, DOI 10.1109/JSEN.2016.2556421
   Sangeeta B., 2011, INT J COMPUT APPL, V36, P45, DOI DOI 10.5120/4537-6461
   Schlebusch Thomas, 2010, 2010 International Conference on Body Sensor Networks (BSN), P302, DOI 10.1109/BSN.2010.21
   Sever C., 2020, CUE HLTH AWARDED 13
   Sharma A, 2017, IEEE J SOLID-ST CIRC, V52, P1021, DOI 10.1109/JSSC.2016.2642205
   Shi Y, 2019, ISSCC DIG TECH PAP I, V62, P442
   Someya T, 2019, IEEE J SOLID-ST CIRC, V54, P613, DOI 10.1109/JSSC.2019.2891718
   Song K, 2016, ADV HEALTHC MATER, V5, P1572, DOI 10.1002/adhm.201600222
   Sood SK, 2017, COMPUT IND, V91, P33, DOI 10.1016/j.compind.2017.05.006
   Souri K, 2014, ISSCC DIG TECH PAP I, V57, P222, DOI 10.1109/ISSCC.2014.6757409
   Sperling E., 2014, MUCH WILL CHIP COST
   Tholl MV, 2020, APPL ENERG, V269, DOI 10.1016/j.apenergy.2020.114948
   Thometz K., 2020, LOCAL RESEARCHERS DE
   Tomlinson S, 2018, TELEMED E-HEALTH, V24, P527, DOI 10.1089/tmj.2017.0166
   Ulbrich M, 2014, PHYSIOL MEAS, V35, P1181, DOI 10.1088/0967-3334/35/6/1181
   Vaz A, 2010, IEEE T CIRCUITS-II, V57, P95, DOI 10.1109/TCSII.2010.2040314
   Villa F, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16050673
   Vooka P, 2015, IEEE T INSTRUM MEAS, V64, P902, DOI 10.1109/TIM.2014.2361552
   Wang B, 2014, IEEE T CIRCUITS-I, V61, P337, DOI 10.1109/TCSI.2013.2278388
   Wang IJ, 2010, TENCON IEEE REGION, P379, DOI 10.1109/TENCON.2010.5686658
   Winokur ES, 2015, IEEE T BIOMED CIRC S, V9, P581, DOI 10.1109/TBCAS.2014.2358673
   Wu TY, 2018, IEEE ACCESS, V6, P35801, DOI 10.1109/ACCESS.2018.2851940
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
   Yan L, 2011, IEEE J SOLID-ST CIRC, V46, P353, DOI 10.1109/JSSC.2010.2074350
   Yang WD, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19081777
   Yedavalli PS, 2017, IEEE ACCESS, V5, P1743, DOI 10.1109/ACCESS.2017.2666299
   Yener SC, 2016, ANALOG INTEGR CIRC S, V89, P719, DOI 10.1007/s10470-016-0795-0
   Yu Y, 2020, SCI ROBOT, V5, DOI 10.1126/scirobotics.aaz7946
   Zhang H, 2019, IEEE SENS J, V19, P8387, DOI 10.1109/JSEN.2018.2872083
   Zhang X, 2019, MICROSYST TECHNOL, V25, P3105, DOI 10.1007/s00542-018-4268-5
   Zhao YS, 2017, IEEE ACCESS, V5, P1340, DOI 10.1109/ACCESS.2017.2667678
   Zhong LH, 2020, IEEE ACCESS, V8, P51761, DOI 10.1109/ACCESS.2020.2979599
   Zhong NS, 2003, AM J RESP CRIT CARE, V168, P7, DOI 10.1164/rccm.200305-707OE
   Zhou SH, 2007, IEEE ASIAN SOLID STA, P464, DOI 10.1109/ASSCC.2007.4425731
NR 137
TC 0
Z9 0
U1 2
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 184457
EP 184474
DI 10.1109/ACCESS.2020.3029130
PG 18
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA OI9CC
UT WOS:000583566300001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Vedaei, SS
   Fotovvat, A
   Mohebbian, MR
   Rahman, GME
   Wahid, KA
   Babyn, P
   Marateb, HR
   Mansourian, M
   Sami, R
AF Vedaei, Seyed Shahim
   Fotovvat, Amir
   Mohebbian, Mohammad Reza
   Rahman, Gazi M. E.
   Wahid, Khan A.
   Babyn, Paul
   Marateb, Hamid Reza
   Mansourian, Marjan
   Sami, Ramin
TI COVID-SAFE: An IoT-Based System for Automated Health Monitoring and
   Surveillance in Post-Pandemic Life
SO IEEE ACCESS
LA English
DT Article
DE COVID-19; Servers; Internet of Things; Bluetooth; Temperature sensors;
   IoT; health monitoring; smart healthcare; pandemic; COVID-19
ID INTERNET; THINGS
AB In the early months of the COVID-19 pandemic with no designated cure or vaccine, the only way to break the infection chain is self-isolation and maintaining the physical distancing. In this article, we present a potential application of the Internet of Things (IoT) in healthcare and physical distance monitoring for pandemic situations. The proposed framework consists of three parts: a lightweight and low-cost IoT node, a smartphone application (app), and fog-based Machine Learning (ML) tools for data analysis and diagnosis. The IoT node tracks health parameters, including body temperature, cough rate, respiratory rate, and blood oxygen saturation, then updates the smartphone app to display the user health conditions. The app notifies the user to maintain a physical distance of 2 m (or 6 ft), which is a key factor in controlling virus spread. In addition, a Fuzzy Mamdani system (running at the fog server) considers the environmental risk and user health conditions to predict the risk of spreading infection in real time. The environmental risk conveys from the virtual zone concept and provides updated information for different places. Two scenarios are considered for the communication between the IoT node and fog server, 4G/5G/WiFi, or LoRa, which can be selected based on environmental constraints. The required energy usage and bandwidth (BW) are compared for various event scenarios. The COVID-SAFE framework can assist in minimizing the coronavirus exposure risk.
C1 [Vedaei, Seyed Shahim; Fotovvat, Amir; Mohebbian, Mohammad Reza; Rahman, Gazi M. E.; Wahid, Khan A.] Univ Saskatchewan, Dept Elect & Comp Engn, Saskatoon, SK S7N 5A9, Canada.
   [Babyn, Paul] Saskatchewan Hlth Author, Coll Med, Saskatoon, SK S7K 0M7, Canada.
   [Marateb, Hamid Reza] Univ Isfahan, Engn Fac, Biomed Engn Dept, Esfahan 8415683111, Iran.
   [Mansourian, Marjan] Isfahan Univ Med Sci, Sch Hlth, Dept Epidemiol & Biostat, Esfahan 8174673461, Iran.
   [Sami, Ramin] Isfahan Univ Med Sci, Sch Med, Dept Internal Med, Esfahan 8174673461, Iran.
RP Vedaei, SS (corresponding author), Univ Saskatchewan, Dept Elect & Comp Engn, Saskatoon, SK S7N 5A9, Canada.
EM shahim.vedaei@usask.ca
RI Marateb, Hamid Reza/G-5556-2013
OI Marateb, Hamid Reza/0000-0003-4408-2397; Fotovvat,
   Amir/0000-0002-5971-6009; Mohebbian, MohammadReza/0000-0003-2645-4425;
   Mansourian, Marjan/0000-0002-7217-0282
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX This work was supported by the Natural Sciences and Engineering Research
   Council of Canada (NSERC).
CR Al Qathrady M, 2017, PROCEEDINGS OF THE 20TH ACM INTERNATIONAL CONFERENCE ON MODELLING, ANALYSIS AND SIMULATION OF WIRELESS AND MOBILE SYSTEMS (MSWIM'17), P79, DOI 10.1145/3127540.3127577
   ALLAM Z, 2020, HEALTHCARE-J DEL SCI, V8, DOI DOI 10.3390/HEALTH-CARE8010046
   Aly H, 2017, ACM TRANS SPAT ALGOR, V3, DOI 10.1145/3085575
   Bai L, 2020, CLIN EHEALTH, V3, P7, DOI DOI 10.1016/j.ceh.2020.03.001
   Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555
   Calvo RA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1373
   Castillejo P, 2013, IEEE WIREL COMMUN, V20, DOI 10.1109/MWC.2013.6590049
   Chang SH, 2016, IT PROF, V18, P14, DOI 10.1109/MITP.2016.48
   Chawathe SS, 2018, 2018 9TH IEEE ANNUAL UBIQUITOUS COMPUTING, ELECTRONICS & MOBILE COMMUNICATION CONFERENCE (UEMCON), P262, DOI 10.1109/UEMCON.2018.8796600
   Christaki E, 2015, VIRULENCE, V6, P554, DOI 10.1080/21505594.2015.1040975
   Deshpande G., 2020, ARXIV200508579
   Farid DM, 2014, EXPERT SYST APPL, V41, P1937, DOI 10.1016/j.eswa.2013.08.089
   Hernandez-Orallo E, 2020, IEEE ACCESS, V8, P99083, DOI 10.1109/ACCESS.2020.2998042
   Imran Ali, 2020, Inform Med Unlocked, V20, P100378, DOI 10.1016/j.imu.2020.100378
   Kang S, 2019, APPL NURS RES, V47, P18, DOI 10.1016/j.apnr.2019.03.005
   Karaboga D, 2019, ARTIF INTELL REV, V52, P2263, DOI 10.1007/s10462-017-9610-2
   Korpas J., 2003, Acta Physiologica Hungarica, V90, P27, DOI 10.1556/APhysiol.90.2003.1.4
   Kotronis C., 2017, UB WIR BROADB ICUWB, P1, DOI [10.1109/ICUWB.2017.8251004, DOI 10.1109/ICUWB.2017.8251004]
   Lam CCV, 2018, PUBLIC HEALTH NUTR, V21, P3462, DOI 10.1017/S1368980018002501
   Laplante PA, 2016, IT PROF, V18, P2, DOI 10.1109/MITP.2016.42
   Laput G, 2018, UIST 2018: PROCEEDINGS OF THE 31ST ANNUAL ACM SYMPOSIUM ON USER INTERFACE SOFTWARE AND TECHNOLOGY, P213, DOI 10.1145/3242587.3242609
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Mackey A, 2020, IEEE INTERNET THINGS, V7, P3160, DOI 10.1109/JIOT.2020.2965583
   Mamdani EH, 1999, INT J HUM-COMPUT ST, V51, P135, DOI 10.1006/ijhc.1973.0303
   Matos S, 2006, IEEE T BIO-MED ENG, V53, P1078, DOI 10.1109/TBME.2006.873548
   Mei XY, 2020, NAT MED, V26, P1224, DOI 10.1038/s41591-020-0931-3
   Ng JKY, 2013, J COMPUT SYST SCI, V79, P1005, DOI 10.1016/j.jcss.2013.01.016
   Painuli D., 2020, INT J MANAGE HUMANIT, V4, P78, DOI [10.35940/ijmh.H0781.044820, DOI 10.35940/IJMH.H0781.044820]
   Pandey P, 2020, IBM J RES DEV, V64, DOI 10.1147/JRD.2019.2947018
   Park C, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-170
   Pasluosta CF, 2015, IEEE J BIOMED HEALTH, V19, P1873, DOI 10.1109/JBHI.2015.2461555
   Penang Institude, 2020, SMART CIT TECHN TAK
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Sami R., 2020, ONE YEAR HOSP BASED, DOI [10.1101/2020.05.11.20096727v2, DOI 10.1101/2020.05.11.20096727V2]
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Setti L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082932
   Sharon T, 2020, ETHICS INF TECHNOL, DOI 10.1007/s10676-020-09547-x
   Ting DSW, 2020, NAT MED, DOI 10.1038/s41591-020-0824-5
   Winning A., REFERENCE DESIGN SMA
   Woolhandler S, 2020, ANN INTERN MED, V173, P63, DOI 10.7326/M20-1491
   Yin YH, 2016, J IND INF INTEGR, V1, P3, DOI 10.1016/j.jii.2016.03.004
   Yoneki E., 2011, P 1 INT C WIR TECHN, P233, DOI [10.1145/2185216.2185282, DOI 10.1145/2185216.2185282]
   Yoneki E, 2011, PROCEEDINGS OF THE 6TH ACM WORKSHOP ON CHALLENGED NETWORKS (CHANTS '11), P61
   Yoon G, 2002, P SOC PHOTO-OPT INS, V4916, P185, DOI 10.1117/12.482947
   Zhang L., 2012, P IEEE SENS TAIP CHI, P1, DOI 10.1109/ICSENS.2012.6411521
NR 45
TC 0
Z9 0
U1 1
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 188538
EP 188551
DI 10.1109/ACCESS.2020.3030194
PG 14
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA OI8TU
UT WOS:000583544700001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ghosh, N
   Tirpack, A
   Chan, KK
   Bass, AR
AF Ghosh, Nilasha
   Tirpack, Aidan
   Chan, Karmela K.
   Bass, Anne R.
TI Impact of COVID-19 on patients with rheumatic complications of cancer
   immunotherapy: results of a registry survey
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE immunotherapy; autoimmunity; programmed cell death 1 receptor
AB Immune checkpoint inhibitors (ICI) block negative regulatory molecules, such as CTLA-4, PD-1 and PD-L1, in order to mount an antitumor response. T cells are important for antiviral defense, but it is not known whether patients with cancer treated with ICI are more or less vulnerable to viral infections such as COVID-19. Furthermore, immunosuppressive treatment of immune-related adverse events (irAE) may also impact infection risk. Rheumatic irAEs are often persistent, and can require long-term treatment with immunosuppressive agents. The aim of this study was to determine the incidence of COVID-19 infection and assess changes in ICI and immunosuppressive medication use among patients enrolled in a prospective rheumatic irAE registry during the height of the COVID-19 pandemic. On April 16 2020, following the 'surge' of COVID-19 infections in the New York Tri-State area, we sent a 23-question survey to 88 living patients enrolled in a single institutional registry of patients with rheumatic irAE. Questions addressed current cancer and rheumatic irAE status, ICI and immunosuppressant medication use, history of COVID-19 symptoms and/or diagnosed infection. A follow-up survey was sent out 6 weeks later. Sixty-five (74%) patients completed the survey. Mean age was 63 years, 59% were female, 70% had received anti-PD-(L)1 monotherapy and 80% had had an irAE affecting their joints. Six patients (10%) had definite or probable COVID-19, but all recovered uneventfully, including two still on ICI and on low-to-moderate dose prednisone. Of the 25 on ICI within the last 6 months, seven (28%) had their ICI held due to the pandemic. In patients on immunosuppression for irAE, none had changes made to those medications as a result of the pandemic. The incidence of COVID-19 was no higher in patients still on ICI. Ten percent of rheumatic irAE patients developed COVID-19 during the NY Tri-state 'surge' of March-April 2020. Oncologists held ICI in a quarter of the patients still on them, particularly women, those on anti-PD-(L)1 monotherapy, and those who had had a good cancer response. The incidence of COVID-19 was no higher on patients still on ICI. None of the patients on disease-modifying antirheumatic drugs or biological immunosuppressive medications developed COVID-19.
C1 [Ghosh, Nilasha; Tirpack, Aidan; Chan, Karmela K.; Bass, Anne R.] Hosp Special Surg, Div Rheumatol, 535 E 70th St, New York, NY 10021 USA.
   [Ghosh, Nilasha; Chan, Karmela K.; Bass, Anne R.] Weill Cornell Med, New York, NY 10065 USA.
RP Ghosh, N (corresponding author), Hosp Special Surg, Div Rheumatol, 535 E 70th St, New York, NY 10021 USA.; Ghosh, N (corresponding author), Weill Cornell Med, New York, NY 10065 USA.
EM ghoshn@hss.edu
FU NIH/NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1-TR-0023849]
FX NG is being supported by NIH/NCATS UL1-TR-0023849, as a Master's student
   for Clinical and Translational research.
CR Braaten TJ, 2020, ANN RHEUM DIS, V79, P332, DOI 10.1136/annrheumdis-2019-216109
   Chan KK, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m736
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487
   Lombardi A, 2019, ALIMENT PHARM THER, V50, P872, DOI 10.1111/apt.15449
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Stadlbauer D, 2020, SEROCONVERSION CITY
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
NR 10
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001550
DI 10.1136/jitc-2020-001550
PG 6
WC Oncology; Immunology
SC Oncology; Immunology
GA OK3MO
UT WOS:000584558000005
PM 33067320
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, YJ
   Li, YB
   Wang, XT
   Qu, RD
   Li, J
   Li, TT
   He, T
   Wang, ZY
   Liu, YS
   Shao, XM
   Lu, T
AF Zhang, Yuejian
   Li, Yibo
   Wang, Xiting
   Qu, Rendong
   Li, Juan
   Li, Tengteng
   He, Tian
   Wang, Zheyi
   Liu, Yansong
   Shao, Xiangming
   Lu, Tao
TI Herbal plants coordinate COVID-19 in multiple dimensions - An insight
   analysis for clinically applied remedies
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE COVID-19 pandemic; Ttraditional Chinese Medicine; anti-coronavirus;
   functional assessment; mechanistic insight
AB The use of multipronged measures, including traditional Chinese medicine (TCM), has greatly increased in response to the COVID-19 pandemic, and we found the use of TCM and is positively correlated with the regional cure rate in China (R=0.77, P<10(-5)). We analyzed 185 commonly administered TCM recipes comprised of 210 herbs nationwide to reveal mechanistic insight. Eight out of the 10 most commonly used herbs showed anti-coronavirus potential by intersecting with COVID-19 targets. Intriguingly, 17 compounds from the 5 most commonly used herbs were revealed to have direct anti-SARS-CoV-2 potential by docking with the two core structures [CoV spike (S) glycoprotein (6SVB) and CoV 3CL hydrolase (6LU7)]. Seven reported COVID-19 drugs served as positive controls; among them, retionavir (-7.828 kcal/mol) and remdesivir (-8.738 kcal/mol) performed best with 6VSB and 6LU7, respectively. The top candidate was madreselvin B (6SVB: -8.588 kcal/mol and 6LU7: -9.017 kcal/mol), an appreciable component of Flos Lonicerae. Eighty-six compounds from 22 unlisted herbs were further identified among 2,042 natural compounds, completing our arsenal for TCM formulations. The mechanisms have been implicated as multifactorial, including activation of immunoregulation (Th2, PPAR and IL10), suppression of acute inflammatory responses (IL-6, IL-1 alpha/beta, TNF, COX2/1, etc.), enhancement of antioxidative activity (CAT and SOD1), and modulation of apoptosis (inhibited CASP3). It is of interest to understand the biological mechanisms of TCM recipes. We then analyzed 18 representative remedies based on molecular targets associated with 14 medical conditions over the disease course, e.g., pyrexia, coughing, asthenia, lymphopenia, cytokine storm, etc. The significant level of coherence (SLC) revealed, in part, the potential uses and properties of corresponding TCMs. Thus, herbal plants coordinate to combat COVID-19 in multiple dimensions, casting a light of hope before effective vaccines are developed.
C1 [Zhang, Yuejian; Li, Yibo; Wang, Xiting; Qu, Rendong; Li, Juan; Li, Tengteng; He, Tian; Wang, Zheyi; Liu, Yansong; Shao, Xiangming; Lu, Tao] Beijing Univ Chinese Med, Sch Life Sci, 11 BeisanhuangDongLu, Beijing 100029, Peoples R China.
   [Wang, Zheyi] Beijing Univ Chinese Med, Affiliated Dongzhimen Hosp, Beijing 100700, Peoples R China.
RP Lu, T (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, 11 BeisanhuangDongLu, Beijing 100029, Peoples R China.
EM taolu@bucm.edu.cn
FU Beijing Research Fund for Double First-class and High-level Talent
   [1000041510053]
FX This work was supported by the Beijing Research Fund for Double
   First-class and High-level Talent to Tao Lu (No. 1000041510053).
   Competing interests: no competing interests in this work.
CR [Anonymous], 2020, SCIENCE
   [Anonymous], 2020, PHARM RES, V156
   [Anonymous], 2020, KNOWL CTR CHIN EXP R
   Bing Gong, 2019, S CHINA FORESTRY SCI, V47, P40
   Can DDT, 2020, J NEUROSURG-PEDIATR, V25, P445, DOI 10.3171/2019.11.PEDS19291
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang XJ, 2014, CHIN HERB MED, V46, P236
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Cheng Fugang JL, 2011, J TCM, V52, P257
   Daniels C, 2020, HIST ANTH CHIN SOC, P1
   Deng YH, 2013, INT IMMUNOPHARMACOL, V17, P561, DOI 10.1016/j.intimp.2013.06.028
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fenghong Zhao, 2020, PHARM CLIN CHINESE M, P1
   Flamini G, 1997, J NAT PROD, V60, P449, DOI 10.1021/np9605551
   GC Q, 2020, CHINESE J INTEGRATIV
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He J HZ, 2016, EVIDENCE BASED RES M, P187
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang H, 2020, J HUNAN U CHIN MED, V40, P255
   Huang RongRong, 2019, Chinese Journal of Immunology, V35, P2936, DOI 10.3969/j.issn.1000-484X.2019.23.025
   HY T., 2020, ZHONGHUA YU FANG YI, V54, pE001
   Jiangrui D., 2017, J CLIN MED, V4, P11352
   JL R, 2020, PHARM RES, V155
   Jun Chen, 2020, CHIN J INFECT DIS, V38, pE008, DOI DOI 10.3760/cma.j.issn.1000-6680.2020.02.006
   JZ W, 2020, INT J CARDIOLOGY
   Kaitao YAO, 2020, CHINESE J EXPT TRADI
   Ko WC, 2020, INT J ANTIMICROBIAL, V55
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li ZG, 2017, ARCH VIROL, V162, P603, DOI 10.1007/s00705-016-3130-2
   Longgang Shao, 2015, GLOBAL TRADITIONAL C, V8, P153
   Luo ED, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00317-x
   Min L., 2019, STUDY CHEM CONSTITUE
   Ren JL, 2020, PHARM RES, V155
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Runfeng L, 2020, PHARM RES
   Shuangbo C., 2019, CHINESE J CLIN RATIO, V12, P113
   Su Lisheng CJ, 2015, CLIN J CHINESE MED, V7, P74
   Sun Q, 2020, GEOTECH SP, P1
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2009, ACTA MED U SCI TECHN, V1, P15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YN, 2020, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2020.1746817
   Wei L., 2019, NAN JING U TRADIT CH, V35, P606
   Weng L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2004794
   Wenxiao H., 2019, OBSERVATION CLIN EFF
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiaojie C., 2017, NEI MONGOL J TRADITI, V36, P11
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yang Yong RC, 2014, WORLD CHINESE MED, V9, P1286
   YAO Weiguang CQ, 2015, CHINESE ARCH TRADITI, V33, P1501
   Ye Q, 2012, GLOBALCHIN MED, V12, P921
   Zhang Guangchao SX, 2019, HENAN MED RES, V28, P4527
   Zhang H, 2020, J SPINAL CORD MED, DOI 10.1080/10790268.2020.1778353
   Zhang JW HX, 2020, CHINESE PHARM J, V96, P1
   Zhang SL, 2009, JILIN J TRADITIONAL, V29, P585
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao Q, 2020, MICRO NANO TECHNOL, P1, DOI 10.1016/C2017-0-02305-4
   Zou HM, 2019, INT IMMUNOPHARMACOL, V69, P307, DOI 10.1016/j.intimp.2019.01.040
   Zou Q, 2020, J 3 MILITARY MED U, V42, P1
NR 65
TC 0
Z9 0
U1 0
U2 0
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2020
VL 17
IS 18
BP 3125
EP 3145
DI 10.7150/ijms.50260
PG 21
WC Medicine, General & Internal
SC General & Internal Medicine
GA OH7SP
UT WOS:000582794100025
PM 33173434
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU SeyedAlinaghi, S
   Ghadimi, M
   Hajiabdolbaghi, M
   Rasoolinejad, M
   Abbasian, L
   Nezhad, MH
   Manshadi, SD
   Ghadimi, F
   Ahmadinejad, Z
AF SeyedAlinaghi, SeyedAhmad
   Ghadimi, Maryam
   Hajiabdolbaghi, Mahboubeh
   Rasoolinejad, Mehrnaz
   Abbasian, Ladan
   Nezhad, Malihe Hassan
   Manshadi, SeyedAli Dehghan
   Ghadimi, Fatemeh
   Ahmadinejad, Zahra
TI Prevalence of COVID-19-like Symptoms among People Living with HIV, and
   Using Antiretroviral Therapy for Prevention and Treatment
SO CURRENT HIV RESEARCH
LA English
DT Article
DE COVID-19; coronavirus; SARS-CoV-2; pneumonia; HIV; antiretroviral
   treatment (ART)
AB Background: COVID-19 has spread globally with remarkable speed, and currently, there is limited data available exploring any aspect of the intersection between HIV and SARSCoV-2 co-infection.
   Objective: To estimate the prevalence of clinical symptoms associated with COVID-19 among people living with HIV (PLWH) in Tehran, Iran.
   Design: Cross-sectional study.
   Methods: A total of 200 PLWH were recruited through the positive club via sampling, and completed the symptom-based questionnaire for COVID-19, which was delivered by trained peers.
   Results: Of 200 participants, respiratory symptoms, including cough, sputum, and shortness of breath, were the most prevalent among participants, but only one person developed symptoms collectively suggested COVID-19 and sought treatments.
   Conclusion: It appears that existing infection with HIV or receiving anti-retroviral treatment (ART) might reduce the susceptibility to the infection with SARS-CoV-2 or decrease the severity of the infection acquired. Further research is needed to understand causal mechanisms.
C1 [SeyedAlinaghi, SeyedAhmad; Hajiabdolbaghi, Mahboubeh; Rasoolinejad, Mehrnaz; Abbasian, Ladan; Manshadi, SeyedAli Dehghan; Ghadimi, Fatemeh] Univ Tehran Med Sci, Iranian Inst Reduct High Risk Behav, Iranian Res Ctr HIV AIDS, Tehran, Iran.
   [Ghadimi, Maryam] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St,Room 143, Baltimore, MD 21287 USA.
   [Nezhad, Malihe Hassan] Univ Tehran Med Sci, Dept Infect Dis, Tehran, Iran.
   [Ahmadinejad, Zahra] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Dept Infect Dis, Liver Transplantat Res Ctr, Tehran, Iran.
RP Ahmadinejad, Z (corresponding author), Imam Khomeini Hosp Complex, Dept Infect Dis, Keshavarz Blvd, Tehran, Iran.
EM ahmadiz@tums.ac.ir
RI SeyedAlinaghi, SeyedAhmad/M-2938-2017; Ghadimi, Fatemeh/V-2659-2019
OI SeyedAlinaghi, SeyedAhmad/0000-0003-3210-7905; Ahmadinejad,
   Zahra/0000-0002-0753-7084
FU Tehran University of Medical SciencesTehran University of Medical
   Sciences [99-1-101-47301]
FX This study was supported by Tehran University of Medical Sciences (Grant
   No. 99-1-101-47301).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Asadollahi-Amin A, 2020, TROP MED INFECT DIS, V5, pE56
   Autenrieth CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207005
   Azadmanesh K, 2020, NATL INTERIM GUIDELI
   Brown J, 2017, THORAX, V72, P355, DOI 10.1136/thoraxjnl-2016-208657
   Cao B, 2020, NEW ENGL J MED, V20, P282, DOI [10.1056/NETMoa2001282, DOI 10.1056/NETMOA2001282]
   Cao J, 2020, CLIN INFECT DIS
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Ghiasvand F, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00815
   Ghiasvand Fereshteh, 2020, Infectious Disorders - Drug Targets, V20, P559, DOI 10.2174/1871526520666200429115535
   Ghosn J, 2018, LANCET, V392, P685, DOI 10.1016/S0140-6736(18)31311-4
   Head BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226347
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Mehraeen E, 2020, EUR ARCH OTO-RHINO-L, DOI 10.1007/s00405-020-06120-6
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Najafi Z, 2020, CURR HIV RES, V18, P228, DOI 10.2174/1570162X18666200605152317
   Razai MS, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m800
   Romanelli A, 2020, AM J TRANSPLANT, V20, P1947, DOI 10.1111/ajt.15905
   Sadr S, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00820
   SeyedAlinaghi S., 2019, AIDS
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Wang CS, 2020, ANN INTERN MED, V173, P499, DOI 10.7326/L20-0354
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CHRON COM COINF PEOP
   WHO, 2020, PEOPL WHO AR HIGH RI
   WHO, 2020, Q A COV 19 HIV ANT W
   WHO, 2020, WHO EM COV 19 DASHB
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhou LH, 2020, TRADIT MED RES, V5, P22, DOI 10.12032/TMR20191102146
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 33
TC 0
Z9 0
U1 0
U2 0
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
EI 1873-4251
J9 CURR HIV RES
JI Curr. HIV Res.
PY 2020
VL 18
IS 5
BP 373
EP 380
DI 10.2174/1570162X18666200712175535
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA OG1UH
UT WOS:000581677500008
PM 32652912
DA 2021-01-01
ER

PT J
AU Acharya, S
   Singh, B
   Godhi, B
   Pandey, S
AF Acharya, S.
   Singh, B.
   Godhi, B.
   Pandey, S.
TI How to deal and learn from the threat of COVID-19 in paediatric
   dentistry
SO EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY
LA English
DT Article
DE Coronavirus; COVID-19; Dentists; Oral Health; Paediatric; Precautions
ID CORONAVIRUS; VIRUSES
AB COVID-19, acronym of coronavirus disease 2019, is a viral infectious disease which rapidly developed as a pandemic. The aetiologic agent of COVID-19 is SARS-CoV-2, or severe acute respiratory syndrome coronavirus 2. The 2019 coronavirus is different from SARS-CoV, but it has the same host receptor: human angiotensin-converting enzyme 2 (ACE2). SARS-CoV-2 was first discovered in 2019 in Wuhan, China, unfortunately spreading globally, resulting in the 2019-2020 pandemic, as declared by the World Health Organization (WHO). This disease started in Asia and has spread worldwide with 1,330,240 cases and 73,868 deaths at the time of writing (6th April, 2020) and many more if this disease is not contained fast. The only effective prevention methods, until a vaccine for this disease will be produced, is active testing and containment measures. This is how China, South Korea and to some extent India have been able to reduce new cases and mortality. The health care workers, especially dentists are the most vulnerable groups of people when facing this virus.
C1 [Acharya, S.; Singh, B.] SOA Deemed Be Univ, Inst Dent Sci, Bhubaneswar, India.
   [Godhi, B.] JSS Acad Higher Educ & Res, JSS Dent Coll & Hosp, Mysore, Karnataka, India.
   [Pandey, S.] Govt Dent Coll, Raipur, Madhya Pradesh, India.
RP Acharya, S (corresponding author), SOA Deemed Be Univ, Inst Dent Sci, Bhubaneswar, India.
EM sonu_ain@yahoo.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Alharbi A, 2020, SAUDI DENT J, V32, P181, DOI 10.1016/j.sdentj.2020.04.001
   Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175
   American Dental Association Commission on Dental Accreditation, 2018, ACCR STAND ADV SPEC
   Ather A, 2020, J ENDODONT, V46, P584, DOI 10.1016/j.joen.2020.03.008
   Coulthard P., 2020, ORAL SURG
   Dave M, 2020, LANCET, V395, P1257, DOI 10.1016/S0140-6736(20)30806-0
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Gamio L, 2020, NY TIMES
   Ge ZY, 2020, J ZHEJIANG UNIV-SC B, V21, P361, DOI 10.1631/jzus.B2010010
   Ghai S, 2020, DIABETES METAB SYND, V14, P933, DOI 10.1016/j.dsx.2020.06.029
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Meng L, 2020, J DENT RES
   Pappas S., 2020, LIVE SCI
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P139, DOI 10.3760/cma.j.issn.0254-6450.2020.02.002
   Stevens H., WHY OUTBREAKS CORONA
   TYRRELL DA, 1966, LANCET, V1, P76
   TYRRELL DAJ, 1975, INTERVIROLOGY, V5, P76, DOI 10.1159/000149883
   World Health Organization, 2020, QUEST ANSW COR
   Zhou P, PREPRINT, DOI DOI 10.1101/2020.01.22.914952V2.FULL.PDF
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ARIESDUE SRL
PI CARIMATE
PA VIA AIROLDI, CARIMATE, 11-22060, ITALY
SN 1591-996X
EI 2035-648X
J9 EUR J PAEDIATR DENT
JI Eur. J. Paediatr. Dent.
PY 2020
VL 21
IS 3
BP 173
EP 175
DI 10.23804/ejpd.2020.21.03.02
PG 3
WC Dentistry, Oral Surgery & Medicine; Pediatrics
SC Dentistry, Oral Surgery & Medicine; Pediatrics
GA OH4TT
UT WOS:000582569000002
PM 32893646
DA 2021-01-01
ER

PT J
AU Jiang, B
   Liang, S
   Liang, G
   Wei, H
AF Jiang, B.
   Liang, S.
   Liang, G.
   Wei, H.
TI Could dantrolene be explored as a repurposed drug to treat COVID-19
   patients by restoring intracellular calcium homeostasis?
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Infection; Replication; Dantrolene
ID RETICULUM CA2+ RELEASE; METHYL-D-ASPARTATE; SARCOPLASMIC-RETICULUM;
   RYANODINE RECEPTOR; ENDOPLASMIC-RETICULUM; CELL-DEATH; INFLAMMATORY
   CYTOKINES; MALIGNANT HYPERTHERMIA; INDUCED NEUROTOXICITY; GLUCOSE
   DEPRIVATION
AB Dantrolene, an FDA approved drug to treat malignant hyperthermia and muscle spasm, has been demonstrated to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mediated toxicity of host cells. Ryanodine receptor overactivation and associated disruption of intracellular Ca2+ homeostasis play important roles in SARS-CoV-2 infection and replication of host cells. Dantrolene, as an inhibitor of RyRs, is expected to ameliorate these detrimental effects of SARS-CoV-2 in host cells. Additionally, dantrolene has also been shown to inhibit multiple cell or organ damage induced by hypoxia/ischemia, mitochondria damage, oxidative stresses, inflammation, impairment of autophagy and apoptosis, etc., which are often the causes of severity and mortality of COVID-19 patients. We have repurposed that dantrolene has a high potential at treating COVID-19 patients and reducing its morbidity and mortality.
C1 [Jiang, B.; Liang, S.; Liang, G.; Wei, H.] Univ Penn, Dept Anaesthesiol & Crit Care, Philadelphia, PA 19104 USA.
   [Jiang, B.] Peking Univ Peoples Hosp, Dept Anaesthesiol, Beijing, Peoples R China.
   [Liang, S.] Jinan Univ, Dept Anesthesiol, Affiliated Hosp 1, Guangzhou, Peoples R China.
RP Wei, H (corresponding author), Univ Penn, Dept Anaesthesiol & Crit Care, Philadelphia, PA 19104 USA.
EM Huafeng.wei@pennmedicine.upenn.edu
RI Jiang, Bailin/Y-8865-2018
OI Jiang, Bailin/0000-0002-9012-7472
FU National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG061447]
FX This work was supported by grants to HW from the National Institute on
   Aging (R01AG061447). The funding paid a partial salary to HW and GL and
   full salary to SL.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   BECKER S, 2006, NOVART FDN SYMP, V272, P68
   Becker Silke, 2006, Novartis Found Symp, V272, P259
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Boissier F, 2013, INTENS CARE MED, V39, P1725, DOI 10.1007/s00134-013-2941-9
   Boys JA, 2010, J INVEST MED, V58, P875, DOI 10.231/JIM.0b013e3181e5d719
   Bull TM, 2010, AM J RESP CRIT CARE, V182, P1123, DOI 10.1164/rccm.201002-0250OC
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen WN, 1998, CIRC RES, V83, P898
   Chen XJ, 2014, PROTEIN CELL, V5, P912, DOI 10.1007/s13238-014-0104-6
   CHEN Y, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa325
   Chung KM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00116
   Clark AL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05935-4
   Cottam EM, 2014, AUTOPHAGY, V10, P1426, DOI 10.4161/auto.29309
   Dahan D, 2012, AM J PHYSIOL-LUNG C, V303, pL824, DOI 10.1152/ajplung.00244.2011
   Delano MJ, 2016, IMMUNOL REV, V274, P330, DOI 10.1111/imr.12499
   Deng Q, 2020, INT J CARDIOL, V311, P116, DOI 10.1016/j.ijcard.2020.03.087
   Du WL, 2005, CHEST, V128, p556S, DOI 10.1378/chest.128.6_suppl.556S
   Du WL, 2005, J BIOL CHEM, V280, P26287, DOI 10.1074/jbc.M502905200
   Ducreux S, 2004, J BIOL CHEM, V279, P43838, DOI 10.1074/jbc.M403612200
   Duzenli S, 2005, TOXICOL IN VITRO, V19, P589, DOI 10.1016/j.tiv.2005.03.007
   EAGLE PHARMACEUTICALS INC, EAGL PHARM ANN LAB T
   Eefting F, 2004, CARDIOVASC RES, V61, P414, DOI 10.1016/j.cardiores.2003.12.023
   Elliott EB, 2013, CARDIOVASC RES, V100, P325, DOI 10.1093/cvr/cvt187
   Fischer DR, 2001, SHOCK, V15, P200, DOI 10.1097/00024382-200115030-00007
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Godai K, 2019, ANESTH ANALG, V129, P276, DOI 10.1213/ANE.0000000000003916
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gwak M, 2008, ANESTH ANALG, V106, P227, DOI 10.1213/01.ane.0000287663.81050.38
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hisatsune J, 2008, J IMMUNOL, V180, P5017, DOI 10.4049/jimmunol.180.7.5017
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   HOTCHKISS RS, 1995, SHOCK, V3, P337
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inan S, 2010, ANESTH ANALG, V111, P1400, DOI 10.1213/ANE.0b013e3181f7181c
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Keles I, 2019, ADV CLIN EXP MED, V28, P1697, DOI 10.17219/acem/110326
   Khomich OA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080392
   Kobayashi S, 2010, CIRC J, V74, P2579, DOI 10.1253/circj.CJ-10-0680
   Kurum T, 2007, TEX HEART I J, V34, P52
   Lai AL, 2017, J MOL BIOL, V429, P3875, DOI 10.1016/j.jmb.2017.10.017
   LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A
   Li F, 2005, BRAIN RES, V1048, P59, DOI 10.1016/j.brainres.2005.04.058
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu TX, 2020, PHARMACOL THERAPEUT, V213, DOI 10.1016/j.pharmthera.2020.107587
   Lopez-Neblina F, 2007, J SURG RES, V140, P121, DOI 10.1016/j.jss.2006.12.003
   Lu YC, 2016, ANTICANCER RES, V36, P697
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Martins BD, 2018, SPINE J, V18, P532, DOI 10.1016/j.spinee.2017.10.067
   Massote PD, 2008, CELL MOL NEUROBIOL, V28, P847, DOI 10.1007/s10571-007-9243-0
   Mattson MP, 2000, J NEUROSCI, V20, P1358
   Maxwell JT, 2012, AM J PHYSIOL-HEART C, V302, pH953, DOI 10.1152/ajpheart.00936.2011
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   MITANI A, 1993, BRAIN RES, V601, P103, DOI 10.1016/0006-8993(93)91700-3
   MITCHELL MB, 1993, J SURG RES, V54, P411, DOI 10.1006/jsre.1993.1065
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Muehlschlegel S, 2015, J NEUROL NEUROSUR PS, V86, P1029, DOI 10.1136/jnnp-2014-308778
   Muehlschlegel S, 2009, NEUROCRIT CARE, V10, P103, DOI 10.1007/s12028-008-9133-4
   Nakayama R, 2002, ANESTHESIOLOGY, V96, P705, DOI 10.1097/00000542-200203000-00029
   Nemeth ZH, 1998, BRAIN RES BULL, V46, P257, DOI 10.1016/S0361-9230(98)00005-7
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Park HW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5834
   Penttinen K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125366
   Phillis JW, 2002, BRAIN RES, V957, P12, DOI 10.1016/S0006-8993(02)03578-3
   Pourmahram GE, 2008, FREE RADICAL BIO MED, V45, P1468, DOI 10.1016/j.freeradbiomed.2008.08.020
   Preckel B, 2000, ACTA ANAESTH SCAND, V44, P194, DOI 10.1034/j.1399-6576.2000.440211.x
   Price LC, 2017, THORAX, V72, P396, DOI 10.1136/thoraxjnl-2016-209199
   Said M, 2008, AM J PHYSIOL-HEART C, V295, pH1669, DOI 10.1152/ajpheart.00010.2008
   SAVVALHA AH, 2020, CLIN IMMUNOL, V215, P108410
   SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063
   Shao HW, 2006, J CLIN IMMUNOL, V26, P546, DOI 10.1007/s10875-006-9046-y
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shin DH, 2018, J GINSENG RES, V42, P165, DOI 10.1016/j.jgr.2017.01.015
   Shneider A, 2020, INT REV IMMUNOL, V39, P153, DOI 10.1080/08830185.2020.1756284
   SIMPSON PB, 1993, J NEUROCHEM, V61, P760
   Skayem C, 2020, AM J MED SCI, V360, P300, DOI 10.1016/j.amjms.2020.05.030
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.8069
   Song Tengyao, 2017, Adv Exp Med Biol, V967, P289, DOI 10.1007/978-3-319-63245-2_17
   Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC
   Straus MR, 2020, J VIROL, V94, DOI 10.1128/JVI.00426-20
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Tang JW, 2006, J INFECT DIS, V194, P808, DOI 10.1086/507044
   TANG W, 2020, HYDROXYCHLO ROQUINE
   Tasker RC, 1998, J CEREBR BLOOD F MET, V18, P1346, DOI 10.1097/00004647-199812000-00009
   Todorova VK, 2020, TRANSL ONCOL, V13, P471, DOI 10.1016/j.tranon.2019.12.006
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wadman M, 2020, SCIENCE, V368, P356, DOI 10.1126/science.368.6489.356
   Walweel K, 2017, CLIN EXP PHARMACOL P, V44, P135, DOI 10.1111/1440-1681.12669
   Wang C, 2002, J CEREBR BLOOD F MET, V22, P206, DOI 10.1097/00004647-200202000-00008
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang Y, 2020, ANESTHESIOLOGY, V132, P1062, DOI 10.1097/ALN.0000000000003224
   Wei HF, 2005, BRAIN RES, V1037, P139, DOI 10.1016/j.brainres.2005.01.009
   Wei HF, 1996, J NEUROCHEM, V67, P2390
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu D, 2008, AM J NEPHROL, V28, P487, DOI 10.1159/000113107
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu SY, 2015, NEURAL REGEN RES, V10, P1279, DOI 10.4103/1673-5374.162761
   Xu X, 2020, P NATL ACAD SCI USA, V117, P10970
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yano T, 2001, RESUSCITATION, V50, P117, DOI 10.1016/S0300-9572(00)00369-5
   Yano T, 2009, ANTIMICROB AGENTS CH, V53, P1420, DOI 10.1128/AAC.01137-08
   Yao WL, 2020, BRIT J ANAESTH, V125, pE28, DOI 10.1016/j.bja.2020.03.026
   Yoon KW, 1996, STROKE, V27, P122, DOI 10.1161/01.STR.27.1.122
   Yu GY, 2000, BASIC RES CARDIOL, V95, P137, DOI 10.1007/s003950050175
   ZAGER EL, 1988, J NEUROSURG, V69, P568, DOI 10.3171/jns.1988.69.4.0568
   Zamiri N, 2014, CIRCULATION, V129, P875, DOI 10.1161/CIRCULATIONAHA.113.005443
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   ZHANG L, 1993, NEUROSCI LETT, V158, P105, DOI 10.1016/0304-3940(93)90623-S
   Zheng YM, 2005, J GEN PHYSIOL, V125, P427, DOI 10.1085/jgp.200409232
   Zhou A, 2016, VIRULENCE, V7, P98, DOI 10.1080/21505594.2015.1131381
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zucchi R, 2001, CARDIOVASC RES, V50, P56, DOI 10.1016/S0008-6363(00)00318-7
NR 119
TC 0
Z9 0
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 19
BP 10228
EP 10238
DI 10.26355/eurrev_202010_23247
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG0EP
UT WOS:000581569100065
PM 33090434
DA 2021-01-01
ER

PT J
AU Jiang, B
   Wei, H
AF Jiang, B.
   Wei, H.
TI Oxygen therapy strategies and techniques to treat hypoxia in COVID-19
   patients
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Oxygen therapy; High flow nasal oxygen (HFNO); High frequency
   jet ventilation (HFJV); Supraglottic jet oxygenation and ventilation
   (SJOV)
ID SUPRAGLOTTIC JET OXYGENATION; HIGH-FLOW OXYGEN; UPPER GASTROINTESTINAL
   ENDOSCOPY; ACUTE RESPIRATORY-FAILURE; NONINVASIVE VENTILATION; NASAL
   CANNULA; PROPOFOL; SUPPORT
AB OBJECTIVE: Hypoxia is one of the primary causes that leads to multiple organ injuries and death in COVID-19 patients. Aggressive oxygen therapy for the treatment of hypoxia is important in saving these patients. We have summarized the mechanisms, efficacy, and side effects of various oxygen therapy techniques and their status or the potential to treat hypoxia in COVID-19 patients. The benefit to risk ratio of each oxygen therapy technique and strategy to use them in COVID-19 patients are discussed. High flow nasal cannula oxygen (HFNO) should be considered a better choice as an early stage oxygen therapy. Supraglottic jet oxygenation and ventilation (SJOV) is a promising alternative for HFNO with potential benefits.
C1 [Jiang, B.; Wei, H.] Univ Penn, Dept Anaesthesiol & Crit Care, Philadelphia, PA 19104 USA.
   [Jiang, B.] Peking Univ Peoples Hosp, Dept Anaesthesiol, Beijing, Peoples R China.
RP Wei, H (corresponding author), Univ Penn, Dept Anaesthesiol & Crit Care, Philadelphia, PA 19104 USA.
EM Huafeng.wei@pennmedicine.upenn.edu
RI Jiang, Bailin/Y-8865-2018
OI Jiang, Bailin/0000-0002-9012-7472
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   Angus DC, 1997, CHEST, V112, P1600, DOI 10.1378/chest.112.6.1600
   Auriant I, 2001, AM J RESP CRIT CARE, V164, P1231, DOI 10.1164/ajrccm.164.7.2101089
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bingold TM, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-7
   Brewster DJ, 2020, MED J AUSTRALIA, V212, P472, DOI 10.5694/mja2.50598
   Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   CRAFT TM, 1990, BRIT J ANAESTH, V64, P524, DOI 10.1093/bja/64.4.524
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dzieciatkowski T, 2020, CARDIOL J, V27, P175, DOI 10.5603/CJ.a2020.0055
   Dziewit JA, 2011, J CLIN ANESTH, V23, P407, DOI 10.1016/j.jclinane.2010.08.018
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Garcia-de-Acilu M, 2019, CURR OPIN CRIT CARE, V25, P54, DOI 10.1097/MCC.0000000000000570
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta S, 2020, INDIAN J ANAESTH, V64, P11, DOI 10.4103/ija.IJA_597_19
   Hasani A, 2008, Chron Respir Dis, V5, P81, DOI 10.1177/1479972307087190
   He Guojun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P232, DOI 10.3785/j.issn.1008-9292.2020.03.13
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang HB, 2018, J CRIT CARE, V43, P300, DOI 10.1016/j.jcrc.2017.09.176
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Ihra G, 2000, EUR J ANAESTH, V17, P418, DOI 10.1046/j.1365-2346.2000.00692.x
   Koga Y, 2020, ACUTE MED SURG, V7, DOI 10.1002/ams2.461
   LEAN K, 2012, PLOS ONE, V7
   Leone M, 2020, EUR J ANAESTH, V37, P265, DOI 10.1097/EJA.0000000000001166
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Levitt C, 2014, J CLIN ANESTH, V26, P157, DOI 10.1016/j.jclinane.2013.09.010
   Levy SD, 2016, LANCET, V387, P1867, DOI 10.1016/S0140-6736(16)30245-8
   Li QY, 2017, J ANESTH, V31, P144, DOI 10.1007/s00540-016-2279-x
   Li TS, 2020, EMERG MICROBES INFEC, V9, P582, DOI 10.1080/22221751.2020.1735265
   Liang HS, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0821-8
   Liang HS, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0709-7
   Loh NHW, 2020, CAN J ANESTH, V67, P893, DOI 10.1007/s12630-020-01634-3
   Lucchini A, 2020, INTENS CRIT CARE NUR, V58, DOI 10.1016/j.iccn.2020.102859
   Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Meselson M, 2020, NEW ENGL J MED, V382, P2063, DOI 10.1056/NEJMc2009324
   Nakano I L, 1997, Kyobu Geka, V50, P754
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Patel BK, 2018, CRIT CARE MED, V46, P1078, DOI 10.1097/CCM.0000000000003124
   Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338
   Peng J, 2012, J EMERG MED, V43, P382, DOI 10.1016/j.jemermed.2011.06.145
   Placidi G, 2006, RESP CARE, V51, P1145
   Qin Y, 2017, BRIT J ANAESTH, V119, P158, DOI 10.1093/bja/aex091
   Respiratory Care Committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P288, DOI 10.3760/cma.j.cn112147-20200304-00239
   Santarpia JL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69286-3
   Simes D C, 2005, Crit Care Resusc, V7, P111
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Stephan F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI 10.1001/jama.2015.5213
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei H F, 1992, J Tongji Med Univ, V12, P183
   Wei H F, 1991, J Tongji Med Univ, V11, P174
   WEI HF, 1992, CRIT CARE MED, V20, P420, DOI 10.1097/00003246-199203000-00020
   Weingart SD, 2012, ANN EMERG MED, V59, P165, DOI 10.1016/j.annemergmed.2011.10.002
   Wu CN, 2017, INTERN EMERG MED, V12, P667, DOI 10.1007/s11739-016-1531-6
   Xis J, 2020, JAMA NETW OPEN, V3
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao WL, 2020, BRIT J ANAESTH, V125, pE28, DOI 10.1016/j.bja.2020.03.026
   Zareifopoulos N, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu YF, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2465-y
NR 68
TC 0
Z9 0
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 19
BP 10239
EP 10246
DI 10.26355/eurrev_202010_23248
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG0EP
UT WOS:000581569100066
PM 33090435
DA 2021-01-01
ER

PT J
AU Doganci, S
   Ince, ME
   Ors, N
   Yildirim, AK
   Sir, E
   Karabacak, K
   Eksert, S
   Ozgurtas, T
   Tasci, C
   Dogan, D
   Ozkan, G
   Cosar, A
   Gulcelik, MA
   Aydin, K
   Yildirim, V
   Erdol, C
AF Doganci, S.
   Ince, M. E.
   Ors, N.
   Yildirim, A. K.
   Sir, E.
   Karabacak, K.
   Eksert, S.
   Ozgurtas, T.
   Tasci, C.
   Dogan, D.
   Ozkan, G.
   Cosar, A.
   Gulcelik, M. A.
   Aydin, K.
   Yildirim, V.
   Erdol, C.
TI A new COVID-19 prediction scoring model for in-hospital mortality:
   experiences from Turkey, single center retrospective cohort analysis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Prognostic Nutritional Index; Hospital Mortality;
   Neutrophil-to-Lymphocyte ratio; Prognosis; Mortality Prediction Model;
   High Sensitive-Modified Glasgow Prognostic Score
ID PROGNOSTIC NUTRITIONAL INDEX; IMMUNE-INFLAMMATION INDEX; POSTOPERATIVE
   COMPLICATIONS; CANCER; SURVIVAL; OUTCOMES; DISEASE
AB OBJECTIVE: Although many studies reported prognostic factors proceeding to severity of COVID-19 patients, in none of the article a prediction scoring model has been proposed. In this article a new prediction tool is presented in combination of Turkish experience during pandemic.
   MATERIALS AND METHODS: Laboratory and clinical data of 397 over 798 confirmed COVID-19 patients from Gulhane Training and Research Hospital electronic medical record system were included into this retrospective cohort study between the dates of 23 March to 18 May 2020. Patient demographics, peripheral venous blood parameters, symptoms at admission, in hospital mortality data were collected. Non-survivor and survivor patients were compared to find out a prediction scoring model for mortality.
   RESULTS: There was 34 [8.56% (95% CI:0.06-0.11)] mortality during study period. Mean age of patients was 57.1 16.7 years. Older age, co morbid diseases, symptoms, such as fever, dyspnea, fatigue and gastrointestinal and WBC, neutrophil, lymphocyte count, C-reactive pro-tein, neutrophil-to-lymphocyte ratio of patients in non-survivors were significantly higher. Univariate analysis demonstrated that OR for prognostic nutritional index (PNI) tertile 1 was 18.57 (95% Cl: 4.39-78.65, p<0.05) compared to tertile 2. Performance statistics of prediction scoring method showed 98% positive predictive value for criteria 1.
   CONCLUSIONS: It is crucial to constitute prognostic clinical and laboratory parameters for faster delineation of patients who are prone to worse prognosis. Suggested prediction scoring method may guide healthcare professional to discriminate severe COVID-19 patients and provide prompt intensive therapies which is highly important due to rapid progression leading to mortality.
C1 [Doganci, S.; Karabacak, K.] Hlth Sci Univ, Gulhane Sch Med, Dept Cardiovasc Surg, Ankara, Turkey.
   [Ince, M. E.; Ors, N.; Eksert, S.; Ozkan, G.; Cosar, A.; Yildirim, V.] Hlth Sci Univ, Gulhane Sch Med, Dept Anesthesiol Reanimat & Intens Care Med, Ankara, Turkey.
   [Yildirim, A. K.] Gazi Univ, Gazi Sch Med, Dept Cardiovasc Surg, Ankara, Turkey.
   [Sir, E.] Hlth Sci Univ, Gulhane Sch Med, Dept Algol & Pain Med, Ankara, Turkey.
   [Ozgurtas, T.] Hlth Sci Univ, Gulhane Sch Med, Dept Biochem, Ankara, Turkey.
   [Tasci, C.; Dogan, D.] Hlth Sci Univ, Gulhane Sch Med, Dept Pulm Dis, Ankara, Turkey.
   [Gulcelik, M. A.] Hlth Sci Univ, Gulhane Sch Med, Dept Gen Surg, Ankara, Turkey.
   [Aydin, K.] Hlth Sci Univ, Gulhane Sch Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkey.
   [Erdol, C.] Hlth Sci Univ, Gulhane Sch Med, Dept Cardiol, Ankara, Turkey.
RP Doganci, S (corresponding author), Hlth Sci Univ, Gulhane Sch Med, Dept Cardiovasc Surg, Ankara, Turkey.
EM suat_doganci@yahoo.com
RI OZKAN, Gokhan/AAQ-6905-2020; sir, ender/AAB-9058-2019
OI OZKAN, Gokhan/0000-0002-7329-2492; sir, ender/0000-0003-2628-135X
CR Chen JH, 2017, WORLD J GASTROENTERO, V23, P6261, DOI 10.3748/wjg.v23.i34.6261
   Dirajlal-Fargo S, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy291
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018
   Fu HY, 2018, CELL PHYSIOL BIOCHEM, V47, P293, DOI 10.1159/000489807
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gandhi RT, 2020, NEW ENGL J MED, DOI [10.1056/NE-JMcp2009249, DOI 10.1056/NE-JMCP2009249]
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang JF, 2020, J MED VIROL, V92, P2152, DOI 10.1002/jmv.26003
   Jiang N, 2014, WORLD J GASTROENTERO, V20, P10537, DOI 10.3748/wjg.v20.i30.10537
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   McMillan DC, 2013, CANCER TREAT REV, V39, P534, DOI 10.1016/j.ctrv.2012.08.003
   Mirili C, 2019, INT J CLIN ONCOL, V24, P1301, DOI 10.1007/s10147-019-01461-7
   Mishra PM, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109790
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y
   Proctor MJ, 2013, CANCER-AM CANCER SOC, V119, P2325, DOI 10.1002/cncr.28018
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Singh AK, 2020, DIABETES METAB SYND, V14, P303, DOI 10.1016/j.dsx.2020.04.004
   Soeters PB, 2019, JPEN-PARENTER ENTER, V43, P181, DOI 10.1002/jpen.1451
   Sun KY, 2014, J CANCER RES CLIN, V140, P1537, DOI 10.1007/s00432-014-1714-3
   Takeno S, 2014, ONCOLOGY-BASEL, V87, P205, DOI 10.1159/000362601
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050
   Wan DY, 2020, EUR REV MED PHARMACO, V24, P4548, DOI 10.26355/eurrev_202004_21039
   Wang Kun, 2020, Clin Infect Dis, V71, P2079, DOI 10.1093/cid/ciaa538
   WHO, 2020, COR VIR DIS COVID 19
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xie HS, 2020, LIVER INT, V40, P1321, DOI 10.1111/liv.14449
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Yang Y, 2016, EJSO-EUR J SURG ONC, V42, P1176, DOI 10.1016/j.ejso.2016.05.029
   Zhang WT, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.09.02
   Zhang YF, 2020, LIVER INT, V40, P2095, DOI 10.1111/liv.14455
   Zhao N, 2020, EUR REV MED PHARMACO, V24, P4597, DOI 10.26355/eurrev_202004_21046
   Zheng C, 2020, CANCER MANAG RES, V12, P2415, DOI 10.2147/CMAR.S245622
   Zhong JH, 2017, ONCOTARGET, V8, P75381, DOI 10.18632/oncotarget.18856
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 0
Z9 0
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 19
BP 10247
EP 10257
DI 10.26355/eurrev_202010_23249
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG0EP
UT WOS:000581569100067
PM 33090436
DA 2021-01-01
ER

PT J
AU Akhter, N
   Ahmad, S
   Alzahrani, FA
   Dar, SA
   Wahid, M
   Haque, S
   Bhatia, K
   Almalki, SS
   Alharbi, RA
   Sindi, AAA
AF Akhter, N.
   Ahmad, S.
   Alzahrani, F. A.
   Dar, S. A.
   Wahid, M.
   Haque, S.
   Bhatia, K.
   Almalki, S. Sr
   Alharbi, R. A.
   Sindi, A. A-A
TI Impact of COVID-19 on the cerebrovascular system and the prevention of
   RBC lysis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-CoV2; Cerebrovascular system; RBC lysis
ID MERS-COV INFECTION; N-ACETYLCYSTEINE; SARS CORONAVIRUS; ANGIOTENSIN-I;
   SEPSIS; BLOOD; ACE2; PENTOXIFYLLINE; THERAPY; HYDROXYCHLOROQUINE
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) uses Angiotensin-converting enzyme 2 (ACE2) receptors to infect host cells which may lead to coronavirus disease (COVID-19). Given the presence of ACE2 receptors in the brain and the critical role of the renin-angiotensin system (RAS) in brain functions, special attention to brain microcirculation and neuronal inflammation is warranted during COVID-19 treatment.
   Neurological complications reported among COVID-19 patients range from mild dizziness, headache, hypogeusia, hyposmia to severe like encephalopathy, stroke, Guillain-Barre Syndrome (GBS), CNS demyelination, infarcts, microhemorrhages and nerve root enhancement.
   The pathophysiology of these complications is likely via direct viral infection of the CNS and PNS tissue or through indirect effects including post-viral autoimmune response, neurological consequences of sepsis, hyperpyrexia, hypoxia and hypercoagulability among critically ill COVID-19 patients.
   Further, decreased deformability of red blood cells (RBC) may be contributing to inflammatory conditions and hypoxia in COVID-19 patients. Haptoglobin, hemopexin, heme oxygenase-1 and acetaminophen may be used to maintain the integrity of the RBC membrane.
C1 [Akhter, N.; Almalki, S. Sr; Alharbi, R. A.; Sindi, A. A-A] Albaha Univ, Fac Appl Med Sci, Dept Lab Med, Albaha, Saudi Arabia.
   [Ahmad, S.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Alzahrani, F. A.] King Abdulaziz Univ, Dept Biol Sci, Jeddah, Saudi Arabia.
   [Dar, S. A.; Wahid, M.; Haque, S.] Jazan Univ, Coll Nursing & Allied Hlth Sci, Res & Sci Studies Unit, Jazan, Saudi Arabia.
   [Bhatia, K.] Arizona State Univ, Sch Math & Nat Sci, Phoenix, AZ USA.
RP Akhter, N (corresponding author), Albaha Univ, Fac Appl Med Sci, Dept Lab Med, Albaha, Saudi Arabia.
EM nakhter@bu.edu.sa
OI Dar, Sajad/0000-0003-2499-8701
CR Abdennour L, 2012, Ann Fr Anesth Reanim, V31, pe101, DOI 10.1016/j.annfar.2012.04.013
   Alanazi KH, 2020, EMERG INFECT DIS, V26, P166, DOI 10.3201/eid2601.190952
   Alqahtani FY, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818002923
   Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Beauverd Y, 2020, EUR J HAEMATOL, V105, P357, DOI 10.1111/ejh.13432
   Bermejo-Martin JF, 2009, CRIT CARE, V13, DOI 10.1186/cc8208
   Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164
   Beyrouti R, 2020, J NEUROL NEUROSUR PS, V91, P889, DOI 10.1136/jnnp-2020-323586
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bischoff SC, 2008, CURR OPIN CLIN NUTR, V11, P733, DOI 10.1097/MCO.0b013e32831394b8
   Brann DH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc5801
   BROWN E, 2020, SCHIZOPHR RES
   Camini FC, 2017, ARCH VIROL, V162, P907, DOI 10.1007/s00705-016-3187-y
   Capes A, 2020, ANN HEMATOL, V99, P1679, DOI 10.1007/s00277-020-04137-9
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Choi HJ, 2009, EUR J PHARM SCI, V37, P329, DOI 10.1016/j.ejps.2009.03.002
   Choi HJ, 2009, ANTIVIR RES, V81, P77, DOI 10.1016/j.antiviral.2008.10.002
   COLUNE LAPINA MR, 2020, POTENTIAL GENETIC NE
   Dar SA, 2020, EUR REV MED PHARMACO, V24, P7923, DOI 10.26355/eurrev_202008_22473
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
   Franceschi AM, 2020, AM J NEURORADIOL, V41, P1173, DOI 10.3174/ajnr.A6595
   Fraternale A, 2009, MOL ASPECTS MED, V30, P99, DOI 10.1016/j.mam.2008.09.001
   Fredenburgh LE, 2007, AM J RESP CELL MOL, V36, P158, DOI 10.1165/rcmb.2006-0331TR
   Garcia JJ, 1997, FEBS LETT, V408, P297, DOI 10.1016/S0014-5793(97)00447-X
   Gong J, 2020, CLIN INFECT DIS, V71, P833, DOI 10.1093/cid/ciaa443
   Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harris Emma, 2010, Paediatr Drugs, V12, P301, DOI 10.2165/11532600-000000000-00000
   Havens Joaquim Michael, 2018, Trauma Surg Acute Care Open, V3, pe000147, DOI 10.1136/tsaco-2017-000147
   He Y, 2016, INT J MOL MED, V37, P631, DOI 10.3892/ijmm.2016.2478
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hinshaw LB, 1996, CRIT CARE MED, V24, P1072, DOI 10.1097/00003246-199606000-00031
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ivanov AV, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8910396
   Janz DR, 2013, CRIT CARE, V17, DOI 10.1186/cc13108
   Janz DR, 2013, CRIT CARE MED, V41, P784, DOI 10.1097/CCM.0b013e3182741a54
   Jin M, 2020, EMERG INFECT DIS, V26, P1618, DOI 10.3201/eid2607.200445
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   Kabbani N, 2020, MOL PHARMACOL, V97, P351, DOI 10.1124/molpharm.120.000014
   KANDEIL A, 2017, EURO SURVEILL, P22
   KANG ZHAO JH, 2020, ACUTE MYELITIS SARS
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Karsten E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21387-w
   Keidar S, 2007, CARDIOVASC RES, V73, P463, DOI 10.1016/j.cardiores.2006.09.006
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Li WL, 2016, J NEUROCHEM, V136, P651, DOI 10.1111/jnc.13436
   Li Y, 2004, J VIROL, V78, P3398, DOI 10.1128/JVI.78.7.3398-3406.2004
   Lopez C, 2020, BRIT J HAEMATOL, V190, P31, DOI 10.1111/bjh.16786
   Ma Q, 2020, EUR REV MED PHARMACO, V24, P8194, DOI 10.26355/eurrev_202008_22508
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Maillart E, 2020, INFECT DIS-NOR, V52, P659, DOI 10.1080/23744235.2020.1774644
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Mumby S, 2014, AM J PHYSIOL-LUNG C, V306, pL88, DOI 10.1152/ajplung.00066.2013
   Nathens AB, 2002, ANN SURG, V236, P814, DOI 10.1097/00000658-200212000-00014
   No Y., 2019, AM J RESP CRIT CARE, V199, pA1465
   Orru B, 2020, EUR REV MED PHARMACO, V24, P8187, DOI 10.26355/eurrev_202008_22507
   Paterson RL, 2003, CRIT CARE MED, V31, P2574, DOI 10.1097/01.CCM.0000089945.69588.18
   Paterson Ross W, 2020, Brain, V143, P3104, DOI 10.1093/brain/awaa240
   Piagnerelli M, 2003, INTENS CARE MED, V29, P1052, DOI 10.1007/s00134-003-1783-2
   Pontes-Arruda A, 2006, CRIT CARE MED, V34, P2325, DOI 10.1097/01.CCM.0000234033.65657.B6
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rabano-Suarez P, 2020, NEUROLOGY, V95, pE767, DOI 10.1212/WNL.0000000000009829
   Rank N, 2000, CRIT CARE MED, V28, P3799, DOI 10.1097/00003246-200012000-00006
   Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Sarkar M, 2015, LUNG INDIA, V32, P142, DOI 10.4103/0970-2113.152626
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Seiden AM, 2004, OTOLARYNG CLIN N AM, V37, P1159, DOI 10.1016/j.otc.2004.06.007
   Shabaan A, 2015, PEDIATR INFECT DIS J, V34, pE143, DOI 10.1097/INF.0000000000000698
   Sharma K, 2019, SAGE OPEN MED CASE R, V7, DOI 10.1177/2050313X19838750
   Simpson SA, 2014, PEDIATR CRIT CARE ME, V15, P503, DOI 10.1097/PCC.0000000000000149
   Song Juhyun, 2014, Exp Neurobiol, V23, P93, DOI 10.5607/en.2014.23.1.93
   Speer EM, 2017, PEDIATR RES, V81, P806, DOI 10.1038/pr.2017.6
   Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443
   Tornabene E, 2016, J PHARM SCI-US, V105, P398, DOI 10.1016/j.xphs.2015.11.041
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Traber MG, 2007, FREE RADICAL BIO MED, V43, P4, DOI 10.1016/j.freeradbiomed.2007.03.024
   Tsai HY, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6384759
   Tsai Li-Kai, 2005, Acta Neurol Taiwan, V14, P113
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Umapathi T, 2004, J NEUROL, V251, P1227, DOI 10.1007/s00415-004-0519-8
   Urata Y, 1999, FREE RADICAL BIO MED, V27, P838, DOI 10.1016/S0891-5849(99)00131-8
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang BJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1942078
   Wang W, 2016, HYPERTENSION, V68, P365, DOI 10.1161/HYPERTENSIONAHA.115.06892
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   World Health Organization (WHO), 2020, MERS SIT UPD
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yeh EA, 2004, PEDIATRICS, V113, pE73, DOI 10.1542/peds.113.1.e73
   Yin Cheng-hong, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P646
   Yu J, 1998, J APPL PHYSIOL, V84, P837
   Zanin L, 2020, ACTA NEUROCHIR, V162, P1491, DOI 10.1007/s00701-020-04374-x
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhang Y, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00079
   Zhang ZZ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1409582
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 117
TC 0
Z9 0
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 19
BP 10267
EP 10278
DI 10.26355/eurrev_202010_23251
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG0EP
UT WOS:000581569100069
PM 33090438
DA 2021-01-01
ER

PT J
AU Abdelnour, C
   de Antonio, EE
   Perez-Cordon, A
   Lafuente, A
   Buendia, M
   Pancho, A
   Jofresa, S
   Aguilera, N
   Ibarria, M
   Cuevas, R
   Canada, L
   Calvet, A
   Diego, S
   Gonzalez-Perez, A
   Orellana, A
   Montrreal, L
   de Jorge, L
   Marqui, M
   Benaque, A
   Gurruchaga, M
   Tarraga, L
   Ruiz, A
   Boada, M
AF Abdelnour, Carla
   Esteban de Antonio, Ester
   Perez-Cordon, Alba
   Lafuente, Asuncion
   Buendia, Mar
   Pancho, Ana
   Jofresa, Sara
   Aguilera, Nuria
   Ibarria, Marta
   Cuevas, Rosario
   Canada, Laia
   Calvet, Anna
   Diego, Susana
   Gonzalez-Perez, Antonio
   Orellana, Adela
   Montrreal, Laura
   de Jorge, Laura
   Marqui, Marta
   Benaque, Alba
   Gurruchaga, Miren
   Tarraga, Lluis
   Ruiz, Agustin
   Boada, Merce
CA Res Ctr Memory Clinic
   Fundacio ACE
TI Managing Clinical Trials for Alzheimer's Disease During the COVID-19
   Crisis: Experience at Fundacio ACE in Barcelona, Spain
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; clinical trials; coronavirus; pandemics;
   telemedicine
AB Background: The COVID-19 pandemic has brought great disruption to health systems worldwide. This affected ongoing clinical research, particularly among those most vulnerable to the pandemic, like dementia patients. Fundacio ACE is a research center and memory clinic based in Barcelona, Spain, one of the hardest-hit countries.
   Objective: To describe the ad-hoc strategic plan developed to cope with this crisis and to share its outcomes.
   Methods: We describe participants' clinical and demographic features. Additionally, we explain our strategic plan aimed at minimizing the impact on clinical trial research activities, which included SARS-CoV-2 RT-PCR and IgG serological tests to all participants and personnel. The outcomes of the plan are described in terms of observed safety events and drop-outs during the study period.
   Results: A total of 130 patients were participating in 16 active clinical trials in Fundacio ACE when the lockdown was established. During the confinement, we performed 1018 calls to the participants, which led to identify adverse events in 26 and COVID-19 symptoms in 6. A total of 83 patients (64%) could restart on-site visits as early as May 11, 2020. All SARS-CoV-2 RT-PCR diagnostic tests performed before on-site visits were negative and only three IgG serological tests were positive. Throughout the study period, we only observed one drop-out, due to an adverse event unrelated to COVID-19.
   Discussion: The plan implemented by Fundacio ACE was able to preserve safety and integrity of ongoing clinical trials. We must use the lessons learned from the pandemic and design crisis-proof protocols for clinical trials.
C1 [Abdelnour, Carla; Esteban de Antonio, Ester; Perez-Cordon, Alba; Lafuente, Asuncion; Buendia, Mar; Pancho, Ana; Jofresa, Sara; Aguilera, Nuria; Ibarria, Marta; Cuevas, Rosario; Canada, Laia; Calvet, Anna; Diego, Susana; Gonzalez-Perez, Antonio; Orellana, Adela; Montrreal, Laura; Marqui, Marta; Benaque, Alba; Gurruchaga, Miren; Tarraga, Lluis; Ruiz, Agustin; Boada, Merce] Univ Int Catalunya, Res Ctr, Fdn ACE, Inst Catala Neurociencies Aplicades, Barcelona, Spain.
   [Abdelnour, Carla; Esteban de Antonio, Ester; Perez-Cordon, Alba; Lafuente, Asuncion; Buendia, Mar; Pancho, Ana; Jofresa, Sara; Aguilera, Nuria; Ibarria, Marta; Cuevas, Rosario; Canada, Laia; Calvet, Anna; Diego, Susana; Gonzalez-Perez, Antonio; Orellana, Adela; Montrreal, Laura; Marqui, Marta; Benaque, Alba; Gurruchaga, Miren; Tarraga, Lluis; Ruiz, Agustin; Boada, Merce] Univ Int Catalunya, Memory Clin, Fdn ACE, Inst Catala Neurociencies Aplicades, Barcelona, Spain.
   [Abdelnour, Carla; Orellana, Adela; Marqui, Marta; Tarraga, Lluis; Ruiz, Agustin; Boada, Merce] Inst Salud Carlos III, Networking Res Ctr Neurodegenerat Dis CIBERNED, Madrid, Spain.
   [de Jorge, Laura] SYNLAB Diagnost Globales SA, Madrid, Spain.
RP Boada, M (corresponding author), Inst Catala Neurociencies Aplicades, Res Ctr, Fdn ACE, Gran Via Carles 3,85 BIS, Barcelona 08028, Spain.; Boada, M (corresponding author), Inst Catala Neurociencies Aplicades, Memory Clin, Fdn ACE, Gran Via Carles 3,85 BIS, Barcelona 08028, Spain.
EM mboada@fundacioace.org
RI Marquie Sayagues, Marta/M-1364-2017
OI Marquie Sayagues, Marta/0000-0002-0660-0950
CR Agencia Espanola~ de Medicamentos y Productos Sanitarios (AEMPS), 2020, MED EXC APL LOS ENS
   [Anonymous], 2020, ALZHEIMERS DEMENT, V16, P587, DOI 10.1002/alz.12093
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], PAIS
   Benaque A, 2020, J ALZHEIMERS DIS, V76, P33, DOI 10.3233/JAD-200547
   Boada M, 2014, ALZHEIMERS DEMENT, V10, P409, DOI 10.1016/j.jalz.2013.03.006
   Brown EE, 2020, AM J GERIAT PSYCHIAT, V28, P712, DOI 10.1016/j.jagp.2020.04.010
   EMA, 2020, GUID MAN CLIN TRIALS
   FDA, 2020, FDA GUID COND CLIN T
   Geerts H, 2020, CPT-PHARMACOMET SYST, V9, P367, DOI 10.1002/psp4.12535
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Insituto de Salud Carlos III, 2020, EST ENE COVID19 PRIM
   McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689
   Ousset PJ, 2020, JPAD-J PREV ALZHEIM, V7, P197, DOI 10.14283/jpad.2020.17
   Singh AG, 2020, HEAD NECK-J SCI SPEC, V42, P1516, DOI 10.1002/hed.26223
   Takeda C, 2020, JPAD-J PREV ALZHEIM, V7, P301, DOI 10.14283/jpad.2020.32
   United Nations, 2020, POL BRIEF IMP COVID
   Wang HK, 2020, EUR UROL, V78, P120, DOI 10.1016/j.eururo.2020.04.026
   Weinberg MS, 2020, AM J GERIAT PSYCHIAT, V28, P913, DOI 10.1016/j.jagp.2020.05.016
NR 19
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2020
VL 77
IS 4
BP 1805
EP 1813
DI 10.3233/JAD-200750
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA OH6TA
UT WOS:000582727100036
PM 32986671
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Carlucci, PM
   Ahuja, T
   Petrilli, C
   Rajagopalan, H
   Jones, S
   Rahimian, J
AF Carlucci, Philip M.
   Ahuja, Tania
   Petrilli, Christopher
   Rajagopalan, Harish
   Jones, Simon
   Rahimian, Joseph
TI Zinc sulfate in combination with a zinc ionophore may improve outcomes
   in hospitalized COVID-19 patients
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE covid 19; coronavirus; hydroxychloroquine; ionophore; mortality; zinc
AB Introduction. COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and prophylaxis against COVID-19 are urgently needed to combat this novel infection. As a result of in vitro evidence suggesting zinc sulphate may be efficacious against COVID-19, our hospitals began using zinc sulphate as add--on therapy to hydroxychloroquine and azithromycin.
   Aim. To compare outcomes among hospitalized COVID-19 patients ordered to receive hydroxychloroquine and azithromycin plus zinc sulphate versus hydroxychloroquine and azithromycin alone.
   Methodology. This was a retrospective observational study. Data was collected from medical records for all patients with admission dates ranging from 2 March 2020 through to 11 April 2020. Initial clinical characteristics on presentation, medications given during the hospitalization, and hospital outcomes were recorded. The study included patients admitted to any of four acute care NYU Langone Health Hospitals in New York City. Patients included were admitted to the hospital with at least one positive COVID-19 test and had completed their hospitalization. Patients were excluded from the study if they were never admitted to the hospital or if there was an order for other investigational therapies for COVID-19.
   Results. Patients taking zinc sulphate in addition to hydroxychloroquine and azithromycin (n=411) and patients taking hydroxychloroquine and azithromycin alone (n=521) did not differ in age, race, sex, tobacco use or relevant comorbidities. The addition of zinc sulphate did not impact the length of hospitalization, duration of ventilation or intensive care unit (ICU) duration. In univariate analyses, zinc sulphate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulphate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09) and reduction in mortality or transfer to hospice among patients who did not require ICU level of care remained significant (OR 0.449, 95 % CI 0.271-0.744).
   Conclusion. This study provides the first in vivo evidence that zinc sulphate may play a role in therapeutic management for COVID-19.
C1 [Carlucci, Philip M.; Petrilli, Christopher; Rahimian, Joseph] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Ahuja, Tania] New York Univ Langone Hlth, Dept Pharm, New York, NY USA.
   [Petrilli, Christopher; Rajagopalan, Harish] NYU Langone Hlth, New York, NY USA.
   [Jones, Simon] NYU Grossman Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA.
   [Jones, Simon] NYU Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA.
RP Rahimian, J (corresponding author), NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
EM Joseph.Rahimian@nyulangone.org
OI Jones, Simon/0000-0002-8267-5647; Carlucci, Philip/0000-0002-9729-4572
CR Acevedo-Murillo JA, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00431
   Barnett JB, 2010, NUTR REV, V68, P30, DOI 10.1111/j.1753-4887.2009.00253.x
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Faber C, 2004, BONE MARROW TRANSPL, V33, P1241, DOI 10.1038/sj.bmt.1704509
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hemila Harri, 2011, Open Respir Med J, V5, P51, DOI 10.2174/1874306401105010051
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Krenn BM, 2009, J VIROL, V83, P58, DOI 10.1128/JVI.01543-08
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Maares M, 2016, ARCH BIOCHEM BIOPHYS, V611, P58, DOI 10.1016/j.abb.2016.03.022
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Prasad AS, 2008, MOL MED, V14, P353, DOI 10.2119/2008-00033.Prasad
   Read SA, 2019, ADV NUTR, V10, P696, DOI 10.1093/advances/nmz013
   Science M, 2012, CAN MED ASSOC J, V184, pE551, DOI 10.1503/cmaj.111990
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   WHO, 2020, COR DIS 2019 COVID 1, P46
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 23
TC 1
Z9 1
U1 3
U2 3
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PY 2020
VL 69
IS 10
BP 1228
EP 1234
DI 10.1099/jmm.0.001250
PG 7
WC Microbiology
SC Microbiology
GA OH3XK
UT WOS:000582505300003
PM 32930657
OA Green Published
DA 2021-01-01
ER

PT J
AU Mareev, VY
   Orlova, YA
   Pavlikova, EP
   Matskeplishvili, ST
   Akopyan, ZA
   Plisyk, AG
AF Mareev, V. Yu
   Orlova, Ya A.
   Pavlikova, E. P.
   Matskeplishvili, S. T.
   Akopyan, Z. A.
   Plisyk, A. G.
TI COMBINATION THERAPY AT AN EARLY STAGE OF THE NOVEL CORONAVIRUS INFECTION
   (COVID-19). CASE SERIES AND DESIGN OF THE CLINICAL TRIAL "BROMHEXINE AND
   SPIRONOLACTONE FOR CORONAVIRUS INFECTION REQUIRING HOSPITALIZATION
   (BISCUIT)"
SO KARDIOLOGIYA
LA Russian
DT Article
ID COVID-19; DRUG
EM julia.begrambekova@ossn.ru
RI ; Matskeplishvili, Simon/C-8420-2016; Orlova, Iana/O-3105-2017
OI Pavlikova, Elena/0000-0001-7693-5281; Matskeplishvili,
   Simon/0000-0002-5670-167X; Orlova, Iana/0000-0002-8160-5612
CR Alfano G, 2020, HYPOKALEMIA PATIENTS, DOI [10.1101/2020.06.14.20131169, DOI 10.1101/2020.06.14.20131169]
   Asselta R, 2020, ACE2 TMPRSS2 VARIANT, DOI [10.1101/2020.03.30.20047878, DOI 10.1101/2020.03.30.20047878]
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432v4, DOI 10.1101/2020.03.17.20037432V4]
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   DAY M, 2020, BMJ-BRIT MED J, V370, DOI DOI 10.1136/BMJ.M2839
   Fani M, 2020, FUTURE VIROL, V15, P317, DOI 10.2217/fvl-2020-0050
   FDA, 2020, COR COVID 19 UPD FDA
   Ferrario CM, 2015, CIRC RES, V116, P206, DOI 10.1161/CIRCRESAHA.116.302706
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Habtemariam S, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104853
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Lechowicz K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061917
   Liaudet L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03055-6
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mareev VY, 2020, KARDIOLOGIYA, V60, P15, DOI 10.18087/cardio.2020.6.n1226
   Mareev YV, 2020, KARDIOLOGIYA, V60, P4, DOI 10.18087/cardio.2020.4.n1122
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Ministry of Health of Russian Federation, 2020, TEMP METH REC PREV D
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sinha Neeraj, 2020, Postgrad Med J, V96, P550, DOI 10.1136/postgradmedj-2020-137785
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Sonawane K, 2020, HOMOLOGY MODELING DO
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   Stubnova V, 2017, CARDIORENAL MED, V7, P128, DOI 10.1159/000454933
   University of Oxford, 2020, RAND EV COVID 19 THE
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wambier CG, 2020, J AM ACAD DERMATOL, V83, P308, DOI 10.1016/j.jaad.2020.04.032
   Wang SF, 2020, DIABETOLOGIA, V63, P2102, DOI 10.1007/s00125-020-05209-1
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, WHO DISC HYDR LOP RI
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zanasi A, 2017, MULTIDISCIP RESP MED, V12, DOI 10.1186/s40248-017-0088-1
NR 55
TC 1
Z9 1
U1 0
U2 0
PU RUSSIAN HEART FAILURE SOC
PI MOSCOW
PA 215, 5, BEREGOVOY PROEZD, MOSCOW, 121087, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2020
VL 60
IS 8
BP 4
EP 15
DI 10.18087/cardio.2020.8.n1307
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH4WQ
UT WOS:000582577300001
PM 33155953
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mareyev, VY
   Orlova, YA
   Pavlikova, EP
   Akopyan, ZA
   Matskeplishvili, ST
   Plisyuk, AG
   Seredenina, EM
   Potapenko, AV
   Malakhov, PS
   Samokhodskaya, LM
   Mershina, EA
   Mareyev, YV
   Begrambekova, YL
   Shatokhina, EA
   Kamalov, AA
   Sinitsin, VE
   Asratyan, DA
   Zhdanova, EA
AF Mareyev, V. Y.
   Orlova, Y. A.
   Pavlikova, E. P.
   Akopyan, Z. A.
   Matskeplishvili, S. T.
   Plisyuk, A. G.
   Seredenina, E. M.
   Potapenko, A., V
   Malakhov, P. S.
   Samokhodskaya, L. M.
   Mershina, E. A.
   Mareyev, Y., V
   Begrambekova, Y. L.
   Shatokhina, E. A.
   Kamalov, A. A.
   Sinitsin, V. E.
   Asratyan, D. A.
   Zhdanova, E. A.
TI PROACTIVE ANTI-INFLAMMATORY AND ANTICOAGULANT THERAPY IN THE TREATMENT
   OF ADVANCED STAGES OF NOVEL CORONAVIRUS INFECTION (COVID-19). CASE STUDY
   AND STUDY DESIGN: COLCHICINE VERSUS RUXOLITINIB AND SECUKINUMAB IN AN
   OPEN, PROSPECTIVE, RANDOMIZED TRIAL IN PATIENTS WITH COVID-19 (COLORIT)
SO KARDIOLOGIYA
LA Russian
DT Article
ID THROMBOEMBOLIC COMPLICATIONS; INFLAMMASOME; EPIDEMIOLOGY; PNEUMONIA;
   MORTALITY; OUTCOMES
C1 [Mareyev, V. Y.; Orlova, Y. A.; Pavlikova, E. P.; Akopyan, Z. A.; Matskeplishvili, S. T.; Plisyuk, A. G.; Seredenina, E. M.; Potapenko, A., V; Malakhov, P. S.; Samokhodskaya, L. M.; Mershina, E. A.; Mareyev, Y., V; Begrambekova, Y. L.; Shatokhina, E. A.; Sinitsin, V. E.; Asratyan, D. A.; Zhdanova, E. A.] Lomonosov Moscow State Univ Med Res & Educ Ctr, Moscow, Russia.
   [Mareyev, V. Y.; Orlova, Y. A.; Pavlikova, E. P.; Akopyan, Z. A.; Plisyuk, A. G.; Seredenina, E. M.; Potapenko, A., V; Samokhodskaya, L. M.; Mershina, E. A.; Mareyev, Y., V; Shatokhina, E. A.; Sinitsin, V. E.; Zhdanova, E. A.] Lomonosov Moscow State Univ, Fac Fundamental Med, Moscow, Russia.
   [Kamalov, A. A.] Natl Med Res Ctr Therapy & Prevent Med, Moscow, Russia.
   [Kamalov, A. A.] Univ Glasgow, Robertsonian Ctr Biostat, Glasgow, Lanark, Scotland.
RP Sinitsin, VE (corresponding author), Lomonosov Moscow State Univ Med Res & Educ Ctr, Moscow, Russia.; Sinitsin, VE (corresponding author), Lomonosov Moscow State Univ, Fac Fundamental Med, Moscow, Russia.
EM julia.begrambekova@ossn.ru
OI Pavlikova, Elena/0000-0001-7693-5281
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Antinori S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102564
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Beringer A, 2019, NAT REV RHEUMATOL, V15, P491, DOI 10.1038/s41584-019-0243-5
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bode Bruce, 2020, J Diabetes Sci Technol, V14, P813, DOI 10.1177/1932296820924469
   Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Bryce C, 2020, PATHOLOGY, DOI DOI 10.1101/2020.05.18.20099960V1
   Bulat V, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14437
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Carugno A, 2020, J AM ACAD DERMATOL, V83, P292, DOI 10.1016/j.jaad.2020.04.165
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Criel M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01201-2020
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dagenais M, 2012, CELL DEATH DIFFER, V19, P5, DOI 10.1038/cdd.2011.159
   De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Di Lernia V, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13580
   Dorward DA, 2020, INFECT DIS HIV AIDS, DOI DOI 10.1101/2020.07.02.20145003V1
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   FitzGerald JD, 2020, ARTHRIT CARE RES, V72, P744, DOI 10.1002/acr.24180
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433
   Gavioli EM, 2020, J CARDIOVASC PHARM, V76, P146, DOI 10.1097/FJC.0000000000000861
   Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   HETHERINGTON E, 2020, EPIDEMIOLOGY, DOI DOI 10.1101/2020.05.06.20092999
   Hoffmann-La Roche, 2020, PHASE 2 OPEN LABEL R
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2020, SEMIN THROMB HEMOST, V46, P89, DOI 10.1055/s-0039-1694995
   Imtiaz Fauzia, 2012, Int Arch Med, V5, P2, DOI 10.1186/1755-7682-5-2
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Lu Y, 2012, PHARM RES-DORDR, V29, P2943, DOI 10.1007/s11095-012-0828-z
   Mangalmurti N, 2020, IMMUNITY, V53, P19, DOI 10.1016/j.immuni.2020.06.017
   Mareev VY, 2020, KARDIOLOGIYA, V60, P15, DOI 10.18087/cardio.2020.6.n1226
   Mareev VY, 2020, KARDIOLOGIYA, V60, P4, DOI 10.18087/cardio.2020.8.n1307
   Marfella R, 2020, DIABETES METAB, DOI [10.1016/j.di- abet.2020.05.005, DOI 10.1016/J.DI-ABET.2020.05.005]
   Martinez GJ, 2018, ATHEROSCLEROSIS, V269, P262, DOI 10.1016/j.atherosclerosis.2017.12.027
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Ministry of Health of Russian Federation, 2020, TEMP GUID MIN HLTH R
   Ministry of Health of Russian Federation, 2020, TEMP METH REC MED RE
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020
   Mohan Vinuta, 2020, BMJ Case Rep, V13, DOI 10.1136/bcr-2020-236519
   Muus C, 2020, BIORXIV, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254]
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Parodi E, 2020, TOCILIZUMAB FAILS HE
   Pericas JM, 2020, EUR HEART J, V41, P2092, DOI 10.1093/eurheartj/ehaa462
   Price LC, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01608-2020
   Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rizzo P, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0791-5
   Roche HL, STUDY EVALUATE EFFIC
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Soylu K, 2016, ARCH MED SCI, V12, P95, DOI 10.5114/aoms.2016.57585
   Spyropoulos AC, 2020, LANCET, V395, pE75, DOI 10.1016/S0140-6736(20)30926-0
   Tan Li, 2020, Med (N Y), V1, P128, DOI 10.1016/j.medj.2020.05.002
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Ucciferri C, 2020, LANCET RHEUMATOL, V2, pE457, DOI 10.1016/S2665-9913(20)30167-3
   Ullah Waqas, 2020, J Clin Med Res, V12, P415, DOI 10.14740/jocmr4227
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Velazquez-Salinas L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01057
   Vernadsky R.Yu., 2019, RUSSIAN ELECT J RADI, V9, P82, DOI [10.21569/2222-7415-2019-9-4-82-96, DOI 10.21569/2222-7415-2019-9-4-82-96]
   WANG K, 2020, INT J TUBERC LUNG D, V24, P564, DOI DOI 10.5588/IJTLD.20.0197
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2058
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wunsch H, 2020, AM J RESP CRIT CARE, V202, P1, DOI 10.1164/rccm.202004-1385ED
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Zayratyants O.V., 2020, PATHOLOGICAL ANATOMY
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang XL, 2020, INT J INFECT DIS, V94, P81, DOI 10.1016/j.ijid.2020.03.040
   Zhang Y, 2020, NEUTROPHIL TO LYMPHO, DOI DOI 10.21203/RS.3.RS-23201/V1.2020
   Zhou CY, 2020, LANCET INFECT DIS, V20, P510, DOI 10.1016/S1473-3099(20)30156-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 108
TC 0
Z9 0
U1 1
U2 1
PU RUSSIAN HEART FAILURE SOC
PI MOSCOW
PA 215, 5, BEREGOVOY PROEZD, MOSCOW, 121087, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2020
VL 60
IS 9
BP 4
EP 21
DI 10.18087/cardio.2020.9.n1338
PG 17
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH4WR
UT WOS:000582577400001
PM 33131470
DA 2021-01-01
ER

PT J
AU Shlyakhto, EV
   Arutyunov, GP
   Belenkov, YN
   Tarlovskaya, EI
   Konradi, AO
   Panchenko, EP
   Yavelov, IS
   Tereshchenko, SN
   Ardashev, AV
   Arutyunov, AG
   Grigor'yeva, NY
   Dzhunusbekova, GA
   Drapkina, OM
   Zhelyakov, EG
   Kanorskiy, SG
   Kolotsey, LV
   Koziolova, NA
   Komarov, AL
   Kropacheva, ES
   Mal'chikova, SV
   Mit'kovskaya, NP
   Orlova, YA
   Petrova, MM
   Rebrov, AP
   Sisakyan, AS
   Skibitskiy, VV
   Snezhitskiy, VA
   Sugraliyev, AB
   Fomin, IV
   Chesnikova, AI
   Shaposhnik, II
AF Shlyakhto, E., V
   Arutyunov, G. P.
   Belenkov, Y. N.
   Tarlovskaya, E., I
   Konradi, A. O.
   Panchenko, E. P.
   Yavelov, I. S.
   Tereshchenko, S. N.
   Ardashev, A., V
   Arutyunov, A. G.
   Grigor'yeva, N. Y.
   Dzhunusbekova, G. A.
   Drapkina, O. M.
   Zhelyakov, E. G.
   Kanorskiy, S. G.
   Kolotsey, L., V
   Koziolova, N. A.
   Komarov, A. L.
   Kropacheva, E. S.
   Mal'chikova, S., V
   Mit'kovskaya, N. P.
   Orlova, Y. A.
   Petrova, M. M.
   Rebrov, A. P.
   Sisakyan, A. S.
   Skibitskiy, V. V.
   Snezhitskiy, V. A.
   Sugraliyev, A. B.
   Fomin, I., V
   Chesnikova, A., I
   Shaposhnik, I. I.
TI USE OF STATINS, ANTICOAGULANTS, ANTIAGGREGANTS AND ANTIARRHYTHMIC DRUGS
   IN PATIENTS WITH COVID-19. THE AGREED EXPERTS POSITION OF RUSSIAN
   SOCIETY OF CARDIOLOGY, EURASIAN ASSOCIATION OF THERAPISTS, NATIONAL
   SOCIETY ON ATHEROTHROMBOSIS, SOCIETIES OF EXPERTS IN URGENT CARDIOLOGY,
   EURASIAN ARRHYTHMOLOGY ASSOCIATION
SO KARDIOLOGIYA
LA Russian
DT Article
ID VENOUS THROMBOEMBOLISM; ACUTELY ILL; MEDICAL PATIENTS;
   THROMBOPROPHYLAXIS; PREVENTION; MANAGEMENT; INFLUENZA
C1 [Shlyakhto, E., V; Konradi, A. O.] FSBI Natl Med Res Ctr, St Petersburg, Russia.
   [Arutyunov, G. P.; Arutyunov, A. G.] FSBEI HE Pirogov Russian Natl Res Med Univ, Minist Hlth Russia, Moscow, Russia.
   [Belenkov, Y. N.] FGAOU VO M First Moscow State Med Univ Sechenov M, Moscow, Russia.
   [Tarlovskaya, E., I; Grigor'yeva, N. Y.; Fomin, I., V] FSBEI HE Privolzhsky Res Med Univ, Minist Hlth Russia, Nizhnii Novgorod, Russia.
   [Panchenko, E. P.; Tereshchenko, S. N.; Kanorskiy, S. G.; Komarov, A. L.; Kropacheva, E. S.] Minist Hlth Russia, FSBI Natl Med Res Ctr Cardiol, Moscow, Russia.
   [Yavelov, I. S.; Drapkina, O. M.] Minist Hlth Russia, FSBI Natl Med Res Ctr Therapy & Prevent Med, Moscow, Russia.
   [Ardashev, A., V] FSBEI HE Lomonosov Moscow State Univ, Moscow, Russia.
   [Dzhunusbekova, G. A.; Orlova, Y. A.] Kazakh Med Univ Postgrad Educ, Alma Ata, Kazakhstan.
   [Kanorskiy, S. G.; Skibitskiy, V. V.] FSBEI HE Kuban State Med Univ, Minist Hlth Russia, Krasnodar, Russia.
   [Kolotsey, L., V; Snezhitskiy, V. A.] EE Grodno State Med Univ, Grodno, BELARUS.
   [Koziolova, N. A.] FSBEI HE Perm State Med Univ, Perm, Russia.
   [Mal'chikova, S., V] FSBEI HE Kirov State Med Univ, Minist Hlth Russia, Kirov, Russia.
   [Mit'kovskaya, N. P.] Belarusian State Med Univ, Minsk, BELARUS.
   [Petrova, M. M.] FSBEI HE Krasnoyarsk State Med Univ, Krasnoyarsk, Russia.
   [Rebrov, A. P.] FSBEI HE Saratov State Med Univ, Saratov, Russia.
   [Sisakyan, A. S.] Yerevan State Med Univ, Yerevan, Armenia.
   [Fomin, I., V] Kazakh Natl Med Univ, Alma Ata, Kazakhstan.
   [Chesnikova, A., I] FSBEI HE Rostov State Med Univ, Minist Hlth Russia, Rostov Na Donu, Russia.
   [Shaposhnik, I. I.] FSBEI HE South Ural State Med Univ, Minist Hlth Russia, Chelyabinsk, Russia.
RP Tarlovskaya, EI (corresponding author), FSBEI HE Privolzhsky Res Med Univ, Minist Hlth Russia, Nizhnii Novgorod, Russia.
EM etarlovskaya@mail.ru
RI Konradi, Alexandra/P-1547-2014; Arutyunov, Gregory/K-9721-2018;
   Bockeria, Leo/E-8336-2014; Yavelov, Igor/G-6689-2013
OI Konradi, Alexandra/0000-0001-8169-7812; Tereshchenko,
   Sergey/0000-0001-9234-6129; Arutyunov, Gregory/0000-0002-6645-2515;
   Tarlovskaya, Ekaterina/0000-0002-9659-7010; Bockeria,
   Leo/0000-0002-6180-2619; Yavelov, Igor/0000-0003-2816-1183
CR Arutiunov G.P., 2020, THERAPEUTIC ARCH, V92
   Arutyunov GP, 2020, KARDIOLOGIYA, V60, P9, DOI 10.18087/cardio.2020.5.n1132
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cohen AT, 2014, J THROMB HAEMOST, V12, P479, DOI 10.1111/jth.12515
   Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747
   Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   European Society of Cardiology, 2020, ESC GUID DIAGN MAN C
   Fedson DS, 2013, ANTIVIR RES, V99, P417, DOI 10.1016/j.antiviral.2013.06.018
   Gibson C Michael, 2017, TH Open, V1, pe56, DOI 10.1055/s-0037-1603929
   Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899
   Gorabi AM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122051
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   HRS, 2020, HRS COVID 19 TASK FO
   Hu TR, 2018, INT J CLIN EXP PATHO, V11, P3925
   Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210
   Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405
   Kunutsor SK, 2017, EUR HEART J, V38, P1608, DOI 10.1093/eurheartj/ehx107
   Kunutsor SK, 2017, LANCET HAEMATOL, V4, pE83, DOI 10.1016/S2352-3026(16)30184-3
   Kushakovsky M.S., 2014, HEART ARRHYTHMIAS HE
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Massachusetts General Hospital, HEM REC DOS GUID COV
   Ministry of Health of Russian Federation, 2020, TEMP METH REC PREV D
   Nagashima T, 2006, ARTHRITIS RHEUM-US, V54, P579, DOI 10.1002/art.21564
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Shlyakhto EV, 2020, RUSSIAN J CARDIOLOGY, V25, P3801, DOI [10.15829/1560-4071-2020-3-3801, DOI 10.15829/1560-4071-2020-3-3801]
   Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   The Liverpool Drug Interaction Group, 2020, LIV COVID 19 INT DET
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
NR 40
TC 0
Z9 0
U1 0
U2 0
PU RUSSIAN HEART FAILURE SOC
PI MOSCOW
PA 215, 5, BEREGOVOY PROEZD, MOSCOW, 121087, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2020
VL 60
IS 6
BP 4
EP 14
DI 10.18087/cardio.2020.6.n1180
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH4WO
UT WOS:000582577100001
PM 32720611
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mareev, VY
   Orlova, YA
   Pavlikova, EP
   Matskeplishvili, ST
   Krasnova, TN
   Malahov, PS
   Samokhodskaya, LM
   Mershina, EA
   Sinitsyn, VE
   Mareev, YV
   Kalinkin, AL
   Begrambekova, YL
   Kamalov, AA
AF Mareev, V. Y.
   Orlova, Y. A.
   Pavlikova, E. P.
   Matskeplishvili, S. T.
   Krasnova, T. N.
   Malahov, P. S.
   Samokhodskaya, L. M.
   Mershina, E. A.
   Sinitsyn, V. E.
   Mareev, Y., V
   Kalinkin, A. L.
   Begrambekova, Y. L.
   Kamalov, A. A.
TI STEROID PULSE -THERAPY IN PATIENTS WITH CORONAVIRUS PNEUMONIA
   (COVID-19), SYSTEMIC INFLAMMATION AND RISK OF VENOUS THROMBOSIS AND
   THROMBOEMBOLISM (WAYFARER STUDY)
SO KARDIOLOGIYA
LA Russian
DT Article
ID LYMPHOCYTE RATIO; PULMONARY-EMBOLISM; PROGNOSTIC VALUE; NEUTROPHIL;
   GLUCOCORTICOIDS
C1 [Mareev, V. Y.; Orlova, Y. A.; Pavlikova, E. P.; Matskeplishvili, S. T.; Krasnova, T. N.; Malahov, P. S.; Samokhodskaya, L. M.; Mershina, E. A.; Sinitsyn, V. E.; Kalinkin, A. L.; Begrambekova, Y. L.; Kamalov, A. A.] Moscow MV Lomonosov State Univ, Med Res & Educ Ctr, Moscow, Russia.
   [Mareev, Y., V] Natl Med Res Ctr Therapy & Prevent Med, Moscow, Russia.
   [Mareev, Y., V] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland.
RP Begrambekova, YL (corresponding author), Moscow MV Lomonosov State Univ, Med Res & Educ Ctr, Moscow, Russia.
EM julia.begrambekova@ossn.ru
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Cataudella E, 2017, J AM GERIATR SOC, V65, P1796, DOI 10.1111/jgs.14894
   Clore JN, 2009, ENDOCR PRACT, V15, P469, DOI 10.4158/EP08331.RAR
   Darmon P, 2006, AM J PHYSIOL-ENDOC M, V291, pE995, DOI 10.1152/ajpendo.00654.2005
   Djaballah-Ider F, 2020, INFLAMMOPHARMACOLOGY, V28, P819, DOI 10.1007/s10787-020-00701-x
   HETHERINGTON E, 2020, EPIDEMIOLOGY, DOI DOI 10.1101/2020.05.06.20092999
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Imtiaz Fauzia, 2012, Int Arch Med, V5, P2, DOI 10.1186/1755-7682-5-2
   Johannesdottir SA, 2013, JAMA INTERN MED, V173, P743, DOI 10.1001/jamainternmed.2013.122
   Karatas MB, 2016, ACTA CARDIOL SIN, V32, P313, DOI 10.6515/ACS20151013A
   Kayrak M, 2014, HEART LUNG CIRC, V23, P56, DOI 10.1016/j.hlc.2013.06.004
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Liao XL, 2020, INTENS CARE MED, V46, P357, DOI 10.1007/s00134-020-05954-2
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Lorente D, 2015, ANN ONCOL, V26, P750, DOI 10.1093/annonc/mdu587
   Majoor CJ, 2016, J THROMB HAEMOST, V14, P716, DOI 10.1111/jth.13265
   Mehra N, 2017, CLIN GENITOURIN CANC, V15, P678, DOI 10.1016/j.clgc.2017.05.012
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ministry of Health of Russian Federation, 2020, TEMP METH REC PREV D
   Ronchetti S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124090
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Shono A, 2019, INTERNAL MED, V58, P3093, DOI 10.2169/internalmedicine.3090-19
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Stuijver DJE, 2013, CHEST, V143, P1337, DOI 10.1378/chest.12-1446
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   Ucciferri C, 2020, LANCET RHEUMATOL, V2, pE457, DOI 10.1016/S2665-9913(20)30167-3
   Wan MT, 2020, J AM ACAD DERMATOL, V83, P677, DOI 10.1016/j.jaad.2020.05.035
   World Health Organization, 2020, CLIN MAN COVID 19
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
   Zarkovic M, 2008, J ENDOCRINOL INVEST, V31, P238, DOI 10.1007/BF03345596
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang Y, 2020, NEUTROPHIL LYMPHOCYT, DOI [10.21203/rs.3.rs-23201/v1. 2020., DOI 10.21203/RS.3.RS-23201/V1]
   Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu Z, 2020, INT J INFECT DIS, V95, P332, DOI 10.1016/j.ijid.2020.04.041
NR 46
TC 3
Z9 4
U1 0
U2 0
PU RUSSIAN HEART FAILURE SOC
PI MOSCOW
PA 215, 5, BEREGOVOY PROEZD, MOSCOW, 121087, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2020
VL 60
IS 6
BP 15
EP 29
DI 10.18087/cardio.2020.6.n1226
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OH4WO
UT WOS:000582577100002
PM 32720612
OA Green Accepted, Other Gold
DA 2021-01-01
ER

PT J
AU Ning, RQ
   Meng, SL
   Tang, FX
   Yu, C
   Xu, D
   Luo, XF
   Sun, HY
AF Ning, Ruoqi
   Meng, Silu
   Tang, Fangxu
   Yu, Chong
   Xu, Dong
   Luo, Xiaofang
   Sun, Haiying
TI A case of SLE with COVID-19 and multiple infections
SO OPEN MEDICINE
LA English
DT Article
DE SLE; COVID-19; SARS-CoV-2; hydroxychloroquine; multiple infections
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS
AB The coronavirus disease 2019 (COVID-19) has become a global pandemic, which is induced by infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with systemic lupus erythematosus (SLE) are susceptible to infections due to the chronic use of immunosuppressive drugs and the autoimmune disorders. Now we report a case of SLE infected with SARS-CoV-2, influenza A virus and Mycoplasma pneumoniae concurrently. The patient used hydroxychloroquine and prednisone chronically to control the SLE. After infection of SARS-CoV-2, she was given higher dose of prednisone than before and the same dosage of hydroxychloroquine. Besides, some empirical treatments such as antiviral, antibiotic and immunity regulating therapies were also given. The patient finally recovered from COVID-19. This case indicated that hydroxychloroquine may not be able to fully protect SLE patient form SARS-CoV-2. Intravenous immunoglobulin therapies and increased dose of corticosteroids might be adoptable for patient with both COVID-19 and SLE. Physicians should consider SARS-CoV-2 virus test when SLE patient presented with suspected infection or SLE flare under the epidemic of COVID-19.
C1 [Ning, Ruoqi; Meng, Silu; Tang, Fangxu; Sun, Haiying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430030, Hubei, Peoples R China.
   [Luo, Xiaofang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rheumatol, Wuhan 430030, Hubei, Peoples R China.
   [Yu, Chong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, Wuhan 430030, Hubei, Peoples R China.
   [Xu, Dong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Infect Dis, Wuhan 430030, Hubei, Peoples R China.
RP Sun, HY (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430030, Hubei, Peoples R China.; Luo, XF (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rheumatol, Wuhan 430030, Hubei, Peoples R China.
EM lxf-692@163.com; haiying-sun@tjh.tjmu.edu.cn
CR Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Fei YY, 2014, CLIN RHEUMATOL, V33, P57, DOI 10.1007/s10067-013-2383-3
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heldwein FL, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2020-217501
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852v1, DOI 10.1101/2020.07.15.20151852V1]
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Mok CC, 2004, LUPUS, V13, P549, DOI 10.1191/0961203304lu1044cr
   National Health Commission of People's Republic of China, 2020, DIAGN TREATM GUID CO
   Ospina FE, 2017, RHEUMATOLOGY, V56, P46, DOI 10.1093/rheumatology/kew340
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Wang YS, 2004, CELL MOL IMMUNOL, V1, P304
   Watson RA, 1995, HOSP PRACT, V2020, P1, DOI DOI 10.1080/
   WHO, 2020, COR DIS COVID 19 PAN
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 0
Z9 0
U1 0
U2 0
PU DE GRUYTER POLAND SP Z O O
PI WARSAW
PA BOGUMILA ZUGA 32A STR, 01-811 WARSAW, MAZOVIA, POLAND
SN 2391-5463
J9 OPEN MED-WARSAW
JI Open Med.
PY 2020
VL 15
IS 1
BP 1054
EP 1060
DI 10.1515/med-2020-0238
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OH4FL
UT WOS:000582526200001
PM 33336061
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, SC
   Mulier, S
   Jonscher, C
   Ye, S
   Chen, L
   Feng, YB
   Li, Y
   Ni, YC
AF Wang, Shuncong
   Mulier, Stefaan
   Jonscher, Charles
   Ye, Sheng
   Chen, Lei
   Feng, Yuanbo
   Li, Yue
   Ni, Yicheng
TI Hypothesis: What is the Best We Can Do with Hydroxychloroquine for
   COVID-19?
SO CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE COVID-19; pandemic; early treatment; hydroxychloroquine; lockdown
ID SARS-COV-2; CHLOROQUINE
AB There are widespread anecdotal reports of seemingly successful treatment among the early (three to seven days from symptoms) stage coronavirus disease 2019 (COVID-19) patients with the drug hydroxychloroquine (HCQ), and randomized placebo-controlled trials of HCQ in outpatient settings are underway. In this note, we (1) report observational evidence and present scientific reasoning as to why early treatment with HCQ may succeed while treatment later in the disease progression is likely to fail and (2) hypothesize a public health regime under which HCQ may be used to mitigate the impact of the current pandemic.
C1 [Wang, Shuncong; Mulier, Stefaan; Chen, Lei; Feng, Yuanbo; Ni, Yicheng] KU, Grp Biomed Sci, Campus Gasthuisberg, Leuven, Belgium.
   [Mulier, Stefaan] Delta Hosp, Dept Surg, Brussels, Belgium.
   [Jonscher, Charles] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.
   [Ye, Sheng] Primary Care NJ, Englewood, NJ USA.
   [Li, Yue] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
RP Ni, YC (corresponding author), Univ Hosp, Dept Radiol, Herestr 49, B-3000 Leuven, Belgium.
EM yicheng.ni@kuleuven.be
CR Ahsan W, 2020, DRUG DISCOV THER, V14, P67, DOI 10.5582/ddt.2020.03008
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   Carlucci P, 2020, HYDROXYCHLOROQUINE A
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gandhi M, 2020, NEW ENGL J MED, V382, P2158, DOI 10.1056/NEJMe2009758
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hoffman Tove, 2020, Infection Ecology & Epidemiology, V10, P1754538, DOI 10.1080/20008686.2020.1754538
   Huang MX, 2020, NATL SCI REV, V7, P1428, DOI 10.1093/nsr/nwaa113
   Jakhar D, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0853-0
   Johnson BA, 2020, BIORXIV
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988
   LENZER J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M133529
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magagnoli J, 2020, MED
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Peto J, 2020, LANCET, V395, P1420, DOI 10.1016/S0140-6736(20)30936-3
   Podsiadlo P, 2004, J BIOL CHEM, V279, P36219, DOI 10.1074/jbc.M400338200
   Prodromos CC, 2020, NEW MICROB NEW INFEC, V37, DOI 10.1016/j.nmni.2020.100747
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sacher F, 2020, ARCH CARDIOVASC DIS, V113, P293, DOI 10.1016/j.acvd.2020.04.003
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Sekine T, CELL
   Shittu Mujeeb Olushola, 2020, Infez Med, V28, P192
   Sun XX, 2020, EMERG MICROBES INFEC, V9, P830, DOI 10.1080/22221751.2020.1760145
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Xiao L, 2020, VIRUSES, V12, P5, DOI [10.3390/v1205049126, DOI 10.3390/V1205049126]
   Yang TZ, 2020, GENET EPIDEMIOL, V44, P880, DOI 10.1002/gepi.22348
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 37
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1349
J9 CLIN EPIDEMIOL
JI Clin. Epidemiol.
PY 2020
VL 12
BP 1139
EP 1144
DI 10.2147/CLEP.S277889
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OH1UT
UT WOS:000582357200001
PM 33116907
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tian, XL
   Li, C
   Huang, AL
   Xia, S
   Lu, SC
   Shi, ZL
   Lu, L
   Jiang, SB
   Yang, ZL
   Wu, YL
   Ying, TL
AF Tian, Xiaolong
   Li, Cheng
   Huang, Ailing
   Xia, Shuai
   Lu, Sicong
   Shi, Zhengli
   Lu, Lu
   Jiang, Shibo
   Yang, Zhenlin
   Wu, Yanling
   Ying, Tianlei
TI Potent binding of 2019 novel coronavirus spike protein by a SARS
   coronavirus-specific human monoclonal antibody
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE 2019-nCoV; SARS-CoV; ACE2; monoclonal antibody; RBD
ID NEUTRALIZATION; PNEUMONIA
AB The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.
C1 [Tian, Xiaolong; Li, Cheng; Huang, Ailing; Xia, Shuai; Lu, Sicong; Lu, Lu; Jiang, Shibo; Wu, Yanling; Ying, Tianlei] Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, MOE NHC CAMS Key Lab Med Mol Virol, Shanghai, Peoples R China.
   [Shi, Zhengli] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, CAS Key Lab Special Pathogens, Wuhan, Peoples R China.
   [Yang, Zhenlin] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China.
RP Yang, ZL; Wu, YL; Ying, TL (corresponding author), Room 504,Fosun Bldg,131 Dong An Rd, Shanghai 200032, Peoples R China.
EM yang_zhenlin@fudan.edu.cn; yanlingwu@fudan.edu.cn; tlying@fudan.edu.cn
RI ; ?, ??/A-1013-2013
OI Lu, Lu/0000-0002-2255-0391; ?, ??/0000-0001-8089-163X; LU,
   SICONG/0000-0002-9054-7303
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81822027, 81630090]; National Key Research
   and Development Program of China [2019YFA0904400]; National Megaprojects
   of China for Major Infectious Diseases [2018ZX10301403]; Chinese Academy
   of Medical Sciences [2019PT350002]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81822027, 81630090), National Key Research and
   Development Program of China (2019YFA0904400), National Megaprojects of
   China for Major Infectious Diseases (2018ZX10301403), Chinese Academy of
   Medical Sciences (2019PT350002), and the staff from Core Facility of
   Microbiology and Parasitology, Shanghai Medical College, Fudan
   University.
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 15
TC 312
Z9 323
U1 17
U2 141
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 382
EP 385
DI 10.1080/22221751.2020.1729069
PG 4
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OI6AE
UT WOS:000583358000001
PM 32065055
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Schloer, S
   Brunotte, L
   Goretzko, J
   Mecate-Zambrano, A
   Korthals, N
   Gerke, V
   Ludwig, S
   Rescher, U
AF Schloer, Sebastian
   Brunotte, Linda
   Goretzko, Jonas
   Mecate-Zambrano, Angeles
   Korthals, Nadia
   Gerke, Volker
   Ludwig, Stephan
   Rescher, Ursula
TI Targeting the endolysosomal host-SARS-CoV-2 interface by clinically
   licensed functional inhibitors of acid sphingomyelinase (FIASMA)
   including the antidepressant fluoxetine
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; IAV; FIASMA; fluoxetine; viral entry; endolysosomal
   interference
ID ENTRY; TRAFFICKING; CORONAVIRUS; DRUG
AB The Coronavirus Disease 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2) is a global health emergency. As only very limited therapeutic options are clinically available, there is an urgent need for the rapid development of safe, effective, and globally available pharmaceuticals that inhibit SARS-CoV-2 entry and ameliorate COVID-19 severity. In this study, we explored the use of small compounds acting on the homeostasis of the endolysosomal host-pathogen interface, to fight SARS-CoV-2 infection. We find that fluoxetine, a widely used antidepressant and a functional inhibitor of acid sphingomyelinase (FIASMA), efficiently inhibited the entry and propagation of SARS-CoV-2 in the cell culture model without cytotoxic effects and also exerted potent antiviral activity against two currently circulating influenza A virus subtypes, an effect which was also observed upon treatment with the FIASMAs amiodarone and imipramine. Mechanistically, fluoxetine induced both impaired endolysosomal acidification and the accumulation of cholesterol within the endosomes. As the FIASMA group consists of a large number of small compounds that are well-tolerated and widely used for a broad range of clinical applications, exploring these licensed pharmaceuticals may offer a variety of promising antivirals for host-directed therapy to counteract enveloped viruses, including SARS-CoV-2.
C1 [Schloer, Sebastian; Goretzko, Jonas; Korthals, Nadia; Gerke, Volker; Rescher, Ursula] Univ Munster, Inst Med Biochem, Ctr Mol Biol Inflammat, Von Esmarch Str 56, D-48149 Munster, Germany.
   [Schloer, Sebastian; Brunotte, Linda; Goretzko, Jonas; Mecate-Zambrano, Angeles; Korthals, Nadia; Gerke, Volker; Ludwig, Stephan; Rescher, Ursula] Univ Munster, Cells Mot Interfac Ctr, Von Esmarch Str 56, D-48149 Munster, Germany.
   [Brunotte, Linda; Mecate-Zambrano, Angeles; Ludwig, Stephan] Univ Munster, Inst Virol, Ctr Mol Biol Inflammat, Munster, Germany.
   [Schloer, Sebastian; Brunotte, Linda; Goretzko, Jonas; Mecate-Zambrano, Angeles; Gerke, Volker; Ludwig, Stephan; Rescher, Ursula] Univ Munster, Interdisciplinary Ctr Clin Res, Munster, Germany.
RP Rescher, U (corresponding author), Univ Munster, Inst Med Biochem, Ctr Mol Biol Inflammat, Von Esmarch Str 56, D-48149 Munster, Germany.; Rescher, U (corresponding author), Univ Munster, Cells Mot Interfac Ctr, Von Esmarch Str 56, D-48149 Munster, Germany.
EM rescher@uni-muenster.de
OI Rescher, Ursula/0000-0001-8892-319X; Brunotte,
   Linda/0000-0001-8074-7400; Ludwig, Stephan/0000-0003-4490-3052
FU German Research Foundation (DFG)German Research Foundation (DFG)
   [CRC1009, CRC1348, KFO342, Br5189/3-1, Lu477/30-1]; Interdisciplinary
   Center for Clinical Research (IZKF) of the Munster Medical School
   [Re2/022/20]; Innovative Medizinische Forschung (IMF) of the Munster
   Medical School [SC121912]
FX This research was funded by grants from German Research Foundation
   (DFG), CRC1009 "Breaking Barriers," Project A06 (to U.R.) and B02 (to
   S.L.), CRC1348 "Dynamic Cellular Interfaces," Project A11 (to U.R.),
   KFO342 TP6, Br5189/3-1 (to L.B.), Lu477/30-1 (to S.L.),
   Interdisciplinary Center for Clinical Research (IZKF) of the Munster
   Medical School [grant number Re2/022/20] and from the Innovative
   Medizinische Forschung (IMF) of the Munster Medical School [grant number
   SC121912] (to S.S.).
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bissig C, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016816
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Cenedella RJ, 2004, J LIPID RES, V45, P1232, DOI 10.1194/jlr.M300469-JLR200
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Corman VM, 2019, INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5
   Cubells L, 2007, TRAFFIC, V8, P1568, DOI 10.1111/j.1600-0854.2007.00640.x
   Desai TM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004048
   Edinger TO, 2014, J GEN VIROL, V95, P263, DOI 10.1099/vir.0.059477-0
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Johnson DE, 2016, J CELL BIOL, V212, P677, DOI 10.1083/jcb.201507112
   Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101
   Kuhnl A, 2018, MBIO, V9, DOI 10.1128/mBio.01345-18
   Lafourcade C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002758
   Lloyd-Evans E, 2008, NAT MED, V14, P1247, DOI 10.1038/nm.1876
   Lozach PY, 2011, CURR OPIN VIROL, V1, P35, DOI 10.1016/j.coviro.2011.05.004
   Lu F C, 2015, ECS J SOLID STATE SC, V4, pR27, DOI DOI 10.7554/eLife.12177
   Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015
   Maxfield FR, 2012, METHOD CELL BIOL, V108, P367, DOI 10.1016/B978-0-12-386487-1.00017-1
   Mazzon Michela, 2019, F1000Res, V8, DOI 10.12688/f1000research.19694.1
   Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Musiol A, 2013, MBIO, V4, DOI 10.1128/mBio.00608-13
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Poeter M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4738
   Pope S, 2016, ANN GEN PSYCHIATR, V15, DOI 10.1186/s12991-016-0117-z
   Preskorn SH, 1991, ANN CLIN PSYCHIATRY, V3, P147
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schloer S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070703
   Schloer S, 2019, EMERG MICROBES INFEC, V8, P80, DOI 10.1080/22221751.2018.1559709
   Staring J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216259
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   White JM, 2016, TRAFFIC, V17, P593, DOI 10.1111/tra.12389
   WONG DT, 1995, LIFE SCI, V57, P411, DOI 10.1016/0024-3205(95)00209-O
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2245
EP 2255
DI 10.1080/22221751.2020.1829082
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA OG8WW
UT WOS:000582158100001
PM 32975484
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zeng, Q
   Tang, CH
   Deng, LS
   Li, S
   Liu, JN
   Wang, SY
   Shan, H
AF Zeng, Qi
   Tang, Caihua
   Deng, Lisi
   Li, Sheng
   Liu, Jiani
   Wang, Siyang
   Shan, Hong
TI Differential Diagnosis of COVID-19 Pneumonia in Cancer Patients Received
   Radiotherapy
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE COVID-19; Pneumonia; Radiation pneumonitis; Multidetector computed
   tomography
ID CORONAVIRUS; WUHAN; CHINA
AB Background: During the outbreak period of COVID-19 pneumonia, cancer patients have been neglected and in greater danger. Furthermore, the differential diagnosis between COVID-19 pneumonia and radiation pneumonitis in cancer patients remains a challenge. This study determined their clinical presentations and radiological features in order to early diagnose and separate COVID-19 pneumonia from radiation pneumonitis patients promptly. Methods and Findings: From January 21, 2020 to February 18, 2020, 112 patients diagnosed with suspected COVID-19 were selected consecutively. A retrospective analysis including all patients' presenting was performed. Four patients from 112 suspected individals were selected, including 2 males and 2 females with a median age of 54 years (range 39-64 years). After repeated pharyngeal swab nucleic acid tests, 1 case was confirmed and 3 cases were excluded from COVID-19 pneumonia. Despite the comparable morphologic characteristics of lung CT imaging, the location, extent, and distribution of lung lesions between COVID-19 pneumonia and radiation pneumonitis differed significantly. Conclusions: Lung CT imaging combined with clinical and laboratory findings can facilitate early diagnosis and appropriate management of COVID-19 pneumonia with a history of malignancy and radiation therapy.
C1 [Zeng, Qi; Tang, Caihua; Deng, Lisi; Liu, Jiani; Wang, Siyang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging & Guangdong, Zhuhai 519000, Guangdong, Peoples R China.
   [Zeng, Qi; Tang, Caihua; Deng, Lisi; Liu, Jiani; Wang, Siyang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai 519000, Guangdong, Peoples R China.
   [Zeng, Qi; Liu, Jiani; Wang, Siyang] Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, 52 Meihua East Rd, Zhuhai 519000, Guangdong, Peoples R China.
   [Tang, Caihua; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, 52 Meihua East Rd, Zhuhai 519000, Guangdong, Peoples R China.
   [Deng, Lisi] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, 52 Meihua East Rd, Zhuhai 519000, Guangdong, Peoples R China.
   [Li, Sheng] Sun Yat Sen Univ, Dept Radiol, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 50060, Guangdong, Peoples R China.
RP Wang, SY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Canc Ctr, 52 Meihua East Rd, Zhuhai 519000, Guangdong, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Guangdong, Peoples R China.
EM 13570608929@163.com; Shanhong@mail.sysu.edu.cn
FU National Key Research and Development Program of China [2020YFC0842400];
   Key Research and Development projects of Guangdong Province
   [2020B111113001]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81701723]
FX I, Dr. Qi Zeng, would like to express my appreciation to my wife, Mrs.
   Shuang Li (Department of Human Resources, the Fifth Affiliated Hospital,
   Sun Yat-Sen University, China) for her hard work of raising our children
   when I worked in the isolation ward. We are also grateful to all of the
   emergency services, doctors, nurses, and other hospital staffs for their
   dedication during the pandemic of COVID-19. This work was funded by the
   National Key Research and Development Program of China (No.
   2020YFC0842400), the Key Research and Development projects of Guangdong
   Province (No. 2020B111113001), and the National Natural Science
   Foundation of China (No. 81701723). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abbasi-Oshaghi E, 2020, INT J SURG, V79, P143, DOI 10.1016/j.ijsu.2020.05.018
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Bledsoe TJ, 2017, CLIN CHEST MED, V38, P201, DOI 10.1016/j.ccm.2016.12.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2
   Ghaye B, 2016, DIAGN INTERV IMAG, V97, P1037, DOI 10.1016/j.diii.2016.06.019
   Hamed Manal A, 2020, Bull Natl Res Cent, V44, P86, DOI 10.1186/s42269-020-00341-9
   Hanania AN, 2019, CHEST, V156, P150, DOI 10.1016/j.chest.2019.03.033
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang PY, 2015, EUR J CANCER, V51, P1760, DOI 10.1016/j.ejca.2015.05.025
   Jain V, 2018, CANCERS, V10, DOI 10.3390/cancers10070222
   Khan S, 2020, CLIN MICROBIOL INFEC, V26, P399, DOI 10.1016/j.cmi.2020.02.005
   Layne SP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb1469
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong AT, 2017, ANN SURG, V265, P1146, DOI 10.1097/SLA.0000000000001825
   Xie XZ, 2020, RADIOLOGY, V296, pE41, DOI 10.1148/radiol.2020200343
   Yu TK, 2004, JNCI-J NATL CANCER I, V96, P1676, DOI 10.1093/jnci/djh315
NR 24
TC 0
Z9 0
U1 0
U2 0
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2020
VL 17
IS 16
BP 2561
EP 2569
DI 10.7150/ijms.46133
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE5DO
UT WOS:000580551000005
PM 33029098
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, E
   Wu, Q
   Crimmins, EM
   Ailshire, JA
AF Zhao, Erfei
   Wu, Qiao
   Crimmins, Eileen M.
   Ailshire, Jennifer A.
TI Media trust and infection mitigating behaviours during the COVID-19
   pandemic in the USA
SO BMJ GLOBAL HEALTH
LA English
DT Article
DE prevention strategies; public health; health education and promotion
ID EMERGENCY RISK COMMUNICATION; CRISIS; INFLUENZA
AB Introduction The COVID-19 pandemic is an unprecedented public health crisis. It is becoming increasingly clear that people's behavioural responses in the USA during this fast-changing pandemic are associated with their preferred media sources. The polarisation of US media has been reflected in politically motivated messaging around the coronavirus by some media outlets, such as Fox News. This resulted in different messaging around the risks of infection and behavioural changes necessary to mitigate that risk. This study determined if COVID-related behaviours differed according to trust in left-leaning or right-leaning media and how differences changed over the first several months of the pandemic. Methods Using the nationally representative Understanding America Study COVID-19 panel, we examine preventive and risky behaviours related to infection from COVID-19 over the period from 10 March to 9 June for people with trust in different media sources: one left-leaning, CNN and another right-leaning, Fox News. People's media preferences are categorised into three groups: (1) those who trust CNN more than Fox News; (2) those who have equal or no preferences and (3) those who trust Fox News more than CNN. Results Results showed that compared with those who trust CNN more than Fox news, people who trust Fox News more than CNN engaged in fewer preventive behaviours and more risky behaviours related to COVID-19. Out of five preventive and five risky behaviours examined, people who trust Fox News more than CNN practised an average of 3.41 preventive behaviours and 1.25 risky behaviours, while those who trust CNN more than Fox News engaged in an average of 3.85 preventive and 0.94 risky behaviours, from late March to June. The difference between these two groups widened in the month of May (p <= 0.01), even after controlling for access to professional information and overall diversity of information sources. Conclusions Our findings indicate that behavioural responses were divided along media bias lines. In such a highly partisan environment, false information can be easily disseminated, and health messaging, which is one of the few effective ways to slowdown the spread of the virus in the absence of a vaccine, is being damaged by politically biased and economically focused narratives. During a public health crisis, media should reduce their partisan stance on health information, and the health messaging from neutral and professional sources based on scientific findings should be better promoted.
C1 [Zhao, Erfei; Wu, Qiao; Crimmins, Eileen M.; Ailshire, Jennifer A.] Univ Calif Los Angeles, Leonard Davis Sch Gerontol, Los Angeles, CA 90095 USA.
RP Zhao, E (corresponding author), Univ Calif Los Angeles, Leonard Davis Sch Gerontol, Los Angeles, CA 90095 USA.
EM erfeizha@usc.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01AG054580];
   National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [P30 AG017265]
FX Support for the preparation of this paper was provided by a grant from
   the National Institutes of Health (U01AG054580) and from the National
   Institute on Aging (P30 AG017265).
CR Ad Fontes Media Inc, INT MED BIAS CHART 5
   Allcott H, 2020, NBER WORKING PAPER, pw26946
   Andersen M., 2020, EARLY EVIDENCE SOCIA
   [Anonymous], 2020, WASHINGTON POST
   Baker AM, 2016, AM J PUBLIC HEALTH, V106, P1181, DOI 10.2105/AJPH.2016.303192
   Baum MA, 2011, J HEALTH POLIT POLIC, V36, P1021, DOI 10.1215/03616878-1460569
   Campbell J, 2020, TUCKER CARLSONS DANG
   Centers for Disease Control and Prevention, 2020, CAS US
   CNN Business, 2020, CNN BUSINESS
   Covello V.T., 1988, 7 CARDINAL RULES RIS
   Frieden TR, 2020, EMERG INFECT DIS, V26, P1061, DOI 10.3201/eid2606.200495
   Glik DC, 2007, ANNU REV PUBL HEALTH, V28, P33, DOI 10.1146/annurev.publhealth.28.021406.144123
   Gollust SE, 2009, AM J PUBLIC HEALTH, V99, P2160, DOI 10.2105/AJPH.2009.161414
   Jurkowitz M, 2020, CABLE TV COVID 19 AM
   Kaiser J, 2019, JOURNALISM, V20, P331, DOI 10.1177/1464884916683548
   Kapteyn A, 2020, SURV RES METHODS-GER, V14, P179, DOI 10.18148/srm/2020.v14i2.7737
   Kim L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0197646
   Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604
   Marier P, 2017, AGEING SOC, V37, P1632, DOI 10.1017/S0144686X16000544
   Olagoke AA, 2020, BRIT J HEALTH PSYCH, V25, P865, DOI 10.1111/bjhp.12427
   Parmer J, 2016, HEALTH COMMUN, V31, P1215, DOI 10.1080/10410236.2015.1049728
   Pei S, 2020, RECONCILING DIVERSE
   Reynolds B, 2005, J HEALTH COMMUN, V10, P43, DOI 10.1080/10810730590904571
   Reynolds B, 2012, CRISIS EMERGENCY RIS
   Reynolds B, 2008, HEALTH PROMOT PRACT, V9, p13S, DOI 10.1177/1524839908325267
   Simonov A, 2020, PERSUASIVE EFFECT FO
   U.S. Department of Health and Human Services, 2002, COMM CRIS RISK COMM
   Vaughan E, 2009, AM J PUBLIC HEALTH, V99, pS324, DOI 10.2105/AJPH.2009.162537
   World Health Organization, 2008, WHO OUTBR COMM PLANN
   Zappal G, 2009, RECENT APPROACHES ME
NR 30
TC 1
Z9 1
U1 7
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2059-7908
J9 BMJ GLOB HEALTH
JI BMJ Glob. Health
PY 2020
VL 5
IS 10
AR e003323
DI 10.1136/bmjgh-2020-003323
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OG7QA
UT WOS:000582072700004
PM 33037063
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yazdani, Z
   Rafiei, A
   Yazdani, M
   Valadan, R
AF Yazdani, Zahra
   Rafiei, Alireza
   Yazdani, Mohammadreza
   Valadan, Reza
TI Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against
   SARS-CoV-2: An in silico Analysis
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE SARS-CoV-2; multi-epitope vaccine; structural proteins; humoral
   immunity; cellular immunity; adjuvant
ID PAN-SPECIFIC PREDICTION; FUSION PROTEIN; BACTERIAL FLAGELLIN; EFFECTIVE
   ADJUVANT; INNATE IMMUNITY; NEURAL-NETWORKS; CORONAVIRUS; BINDING;
   SEQUENCE; RECEPTOR
AB Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2.
   Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensin-converting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli.
   Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli.
C1 [Yazdani, Zahra; Rafiei, Alireza; Valadan, Reza] Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sch Med, Dept Immunol, KM 18 Khazarabad Rd,Khazar Sq, Sari, Iran.
   [Yazdani, Mohammadreza] Isfahan Univ Technol, Dept Chem, Esfahan 8415683111, Iran.
RP Rafiei, A (corresponding author), Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sch Med, Dept Immunol, KM 18 Khazarabad Rd,Khazar Sq, Sari, Iran.
EM rafiei1710@gmail.com
FU Research and Technology deputy of Mazandaran University of Medical
   Sciences [7252]
FX This study received a small grant (Grant no: 7252) from the Research and
   Technology deputy of Mazandaran University of Medical Sciences.
CR Agostini F, 2014, BIOINFORMATICS, V30, P2975, DOI 10.1093/bioinformatics/btu420
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Andreatta M, 2015, IMMUNOGENETICS, V67, P641, DOI 10.1007/s00251-015-0873-y
   Behbahani M, 2020, BIORXIV
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Bhatnager R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1787227
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Buus S, 2003, TISSUE ANTIGENS, V62, P378, DOI 10.1034/j.1399-0039.2003.00112.x
   Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003017
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Chen XY, 2011, MOL PHARMACEUT, V8, P457, DOI 10.1021/mp1003064
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Control ECfDPa, 2020, COVID 19
   Cunningham AF, 2004, EUR J IMMUNOL, V34, P2986, DOI 10.1002/eji.200425403
   DHANDA SK, 2013, BIOL DIRECT, V8, DOI DOI 10.1186/1745-6150-8-3062
   Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Ferris LK, 2013, J INVEST DERMATOL, V133, P460, DOI 10.1038/jid.2012.319
   Funderburg N, 2007, P NATL ACAD SCI USA, V104, P18631, DOI 10.1073/PNAS.0702130104
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hammerbeck DM, 2007, ANTIVIR RES, V73, P1, DOI 10.1016/j.antiviral.2006.07.011
   Han SS, 2003, J IMMUNOL, V170, P1267, DOI 10.4049/jimmunol.170.3.1267
   Honko AN, 2004, INFECT IMMUN, V72, P6676, DOI 10.1128/IAI.72.11.6676-6679.2004
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Joly S, 2005, MOL IMMUNOL, V42, P1073, DOI 10.1016/j.molimm.2004.11.001
   Judge CJ, 2015, CELL IMMUNOL, V297, P61, DOI 10.1016/j.cellimm.2015.06.004
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Kang S, 2020, BIORXIV
   Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   KIM Y, 2009, BMC BIOINFORMATICS, V10, DOI DOI 10.1186/1471-2105-10-39443
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006
   Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   Lopez-Boado YS, 2005, INFECT IMMUN, V73, P7525, DOI 10.1128/IAI.73.11.7525-7534.2005
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lundegaard C, 2008, BIOINFORMATICS, V24, P1397, DOI 10.1093/bioinformatics/btn128
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Lundegaard C, 2006, TRENDS BIOTECHNOL, V24, P537, DOI 10.1016/j.tibtech.2006.10.001
   Magnan CN, 2014, BIOINFORMATICS, V30, P2592, DOI 10.1093/bioinformatics/btu352
   Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101
   Mazaleuskaya L, 2012, VIRUSES-BASEL, V4, P901, DOI 10.3390/v4050901
   McSorley SJ, 2002, J IMMUNOL, V169, P3914, DOI 10.4049/jimmunol.169.7.3914
   Milani A, 2017, IMMUNOL LETT, V191, P16, DOI 10.1016/j.imlet.2017.09.005
   Mizel SB, 2003, J IMMUNOL, V170, P6217, DOI 10.4049/jimmunol.170.12.6217
   Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Negahdaripour M, 2017, INFECT GENET EVOL, V54, P402, DOI 10.1016/j.meegid.2017.08.002
   Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000796
   Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Pino O, 2005, INFECT IMMUN, V73, P6763, DOI 10.1128/IAI.73.10.6763-6770.2005
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rasmussen M, 2016, J IMMUNOL, V197, P1517, DOI 10.4049/jimmunol.1600582
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Rohrl J, 2010, J IMMUNOL, V184, P6688, DOI 10.4049/jimmunol.0903984
   Saenz R, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-211
   Sarwar MA, 2016, INT J COMPUTER SCI I, V14, P317
   Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   Skountzou I, 2010, VACCINE, V28, P4103, DOI 10.1016/j.vaccine.2009.07.058
   Song ZH, 2019, RES VET SCI, V123, P39, DOI 10.1016/j.rvsc.2018.12.005
   Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583
   Srivastava S, 2018, INFECT DRUG RESIST, V11, P2377, DOI 10.2147/IDR.S175114
   Stein RA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13488
   STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Talebi S, 2017, BIOMED PHARMACOTHER, V85, P148, DOI 10.1016/j.biopha.2016.11.115
   Telusma G, 2006, INT IMMUNOL, V18, P1563, DOI 10.1093/intimm/dxl089
   ul Qamar M.T., 2020, J PHARM ANAL
   Ul Qamar MT, 2020, BIORXIV
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang BZ, 2008, J VIROL, V82, P11813, DOI 10.1128/JVI.01076-08
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Westerbeck JW, 2019, J VIROL, V93, DOI [10.1128/JVI.00015-19, 10.1128/jvi.00015-19]
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yazdani Z, 2020, COMPUT BIOL CHEM, V85, DOI 10.1016/j.compbiolchem.2020.107209
   Zhang H, 2009, BIOINFORMATICS, V25, P1293, DOI 10.1093/bioinformatics/btp137
   Zhang Q, 2008, NUCLEIC ACIDS RES, V36, pW513, DOI 10.1093/nar/gkn254
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 108
TC 1
Z9 1
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 3007
EP 3022
DI 10.2147/IDR.S264573
PG 16
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA OF1HE
UT WOS:000580967300001
PM 32943888
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Barros, LM
   Neto, NMG
   Sa, GGD
   Pereira, JDN
   Barbosa, LU
   Neto, JGD
   Henriques, AHB
   Gaetano, JA
AF Barros, Livia Moreira
   Galindo Neto, Nelson Miguel
   de Moura Sa, Guilherme Guarino
   Nunes Pereira, Juliana de Castro
   Barbosa, Luciana Uchoa
   de Oliveira Neto, Joaquim Guerra
   Barros Henriques, Amanda Haissa
   Gaetano, Joselany Afio
TI Experimental studies on COVID-19: overview of the world scientific
   production
SO ACTA PAULISTA DE ENFERMAGEM
LA English
DT Article
DE Coronavirus; Coronavirus infections; COVID-19; Pandemics; Evidence-based
   practice
AB Objective: To describe the world panorama of the production of experimental studies on COVID-19.
   Methods: Descriptive study conducted in April 2020, based on a search for clinical trial records on the Clinical Trials and Brazilian Clinical Trials Records portals. The statistical analysis was descriptive.
   Results: Of the 645 clinical trials in the sample, there was a predominance of 199 (30.9%) from Europe, 213 (33%) performed by hospital institutions, 482 (74.7%) with the objective aimed at the treatment. As for interventions surveyed, 394 (61.1%) were on drugs; 70 (10.8%) investigated biological interventions; 45 (7.0%) interventions with blood and blood products; 40 (6.2%), behavioral interventions; 38 (5.9%), interventions with equipment; 31 (4.8%), care/procedural interventions; 18 (2.8%), diagnostic interventions and nine (1.4%) dietary supplementation interventions. The studied population was composed of adult and elderly subjects in 515 (79.8%) studies, 635 (98.4%) investigated both sexes, the design of 480 (74.4%) included randomization, of 482 (74.7%) parallel allocation of participants and 373 (57.8%) did not have blinding.
   Conclusion: The experimental studies on COVID-19 originated from Europe, were conducted by hospitals, on treatment in adult and elderly subjects, with randomization but without blinding. The findings may direct the performance of studies addressing the identified gaps.
C1 [Barros, Livia Moreira] Univ Integracao Int Lusofonia Afrobrasileira, Redencao, CE, Brazil.
   [Galindo Neto, Nelson Miguel] Inst Fed Educ Ciencia & Tecnol Pernambuco, Pesqueira, PE, Brazil.
   [de Moura Sa, Guilherme Guarino; Nunes Pereira, Juliana de Castro; Barbosa, Luciana Uchoa] Inst Fed Educ Ciencia & Tecnol Pernambuco, Belo Jardim, PE, Brazil.
   [de Oliveira Neto, Joaquim Guerra] Santa Casa Misericordia Sobral, Sobral, CE, Brazil.
   [Barros Henriques, Amanda Haissa] Inst Fed Educ Ciencia & Tecnol Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Gaetano, Joselany Afio] Univ Fed Ceara, Fortaleza, Ceara, Brazil.
RP Sa, GGD (corresponding author), Inst Fed Educ Ciencia & Tecnol Pernambuco, Belo Jardim, PE, Brazil.
EM guilherme_mourasa@hotmail.com
OI Guerra de Oliveira Neto, Joaquim/0000-0002-8068-2026; Henriques,
   Amanda/0000-0001-8735-225X
CR Batagello R, 2018, SAUDE SOC-SAO PAULO, V27, P1033, DOI [10.1590/S0104-12902018180292, 10.1590/s0104-12902018180292]
   Bello S, 2017, J CLIN EPIDEMIOL, V81, P42, DOI 10.1016/j.jclinepi.2016.08.002
   Bouwmeester S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228355
   Braithwaite FA, 2018, PEERJ, V6, DOI 10.7717/peerj.5318
   Caccialanza R, 2020, NUTRITION, V74, DOI 10.1016/j.nut.2020.110835
   Dean CL, 2020, TRANSFUSION, V60, P1024, DOI 10.1111/trf.15739
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gombart AF, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010236
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hong Z, 2020, J MED INTERNET RES, V22, DOI 10.2196/19577
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li Z, 2020, ECOTOX ENVIRON SAFE, V197, DOI 10.1016/j.ecoenv.2020.110614
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Mire CE, 2020, J INFECT DIS, V221, pS471, DOI 10.1093/infdis/jiz515
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
   Sanduzzi A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093289
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Sarti TD, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/S1679-49742020000200024, 10.5123/s1679-49742020000200024]
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, 127 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
NR 28
TC 0
Z9 0
U1 1
U2 1
PU UNIV FED SAO PAULO, DEPT ENFERMAGEN
PI SAO PAULO
PA RUA NAPOLEAO DE BARROS, 754 VILA CLEMENTINO, SAO PAULO, CEP04024-002,
   BRAZIL
SN 0103-2100
EI 1982-0194
J9 ACTA PAUL ENFERM
JI Acta Paul. Enferm.
PY 2020
VL 33
AR eAPE20200121
DI 10.37689/acta-ape/2020AO01215
PG 9
WC Nursing
SC Nursing
GA OE5NH
UT WOS:000580576400001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wang, YC
   Yang, WH
   Yang, CS
   Hou, MH
   Tsai, CL
   Chou, YZ
   Hung, MC
   Chen, Y
AF Wang, Yu-Chuan
   Yang, Wen-Hao
   Yang, Chia-Shin
   Hou, Mei-Hui
   Tsai, Chia-Ling
   Chou, Yi-Zhen
   Hung, Mien-Chie
   Chen, Yeh
TI Structural basis of SARS-CoV-2 main protease inhibition by a
   broad-spectrum anti-coronaviral drug
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus (CoV); drug development; drug action;
   drug screening; protease inhibitor; structural biology
ID PNEUMONIA; TMPRSS2; SARS
AB The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019-nCoV), took tens of thousands of lives and caused tremendous economic losses. The main protease (M-pro) of SARS-CoV-2 is a potential target for treatment of COVID-19 due to its critical role in maturation of viral proteins and subsequent viral replication. Conceptually and technically, targeting therapy against M-pro is similar to target therapy to treat cancer. Previous studies show that GC376, a broad-spectrum dipeptidyl M-pro inhibitor, efficiently blocks the proliferation of many animal and human coronaviruses including SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), porcine epidemic diarrhea virus (PEDV), and feline infectious peritonitis virus (FIPV). Due to the conservation of structure and catalytic mechanism of coronavirus main protease, repurposition of GC376 against SARS-CoV-2 may be an effective way for the treatment of COVID-19 in humans. To validate this conjecture, the binding affinity and IC50 value of M-pro with GC376 was determined by isothermal titration calorimetry (ITC) and fluorescence resonance energy transfer (FRET) assay, respectively. The results showed that GC376 binds to SARS-CoV-2 M-pro tightly (K-D= 1.6 mu M) and efficiently inhibit its proteolytic activity (IC50 = 0.89 mu M). We also elucidate the high resolution structure of dimeric SARS-CoV-2 M-pro in complex with GC376. The cocrystal structure showed that GC376 and the catalytic Cys145 of M-pro covalently linked through forming a hemithioacetal group and releasing a sulfonic acid group. Because GC376 is already known as a broad-spectrum antiviral medication and successfully used in animal, it will be a suitable candidate for anti-COVID-19 treatment.
C1 [Wang, Yu-Chuan; Yang, Chia-Shin; Hou, Mei-Hui; Tsai, Chia-Ling; Chou, Yi-Zhen; Chen, Yeh] China Med Univ, Inst New Drug Dev, Taichung 40402, Taiwan.
   [Yang, Wen-Hao; Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci, Taichung 40402, Taiwan.
   [Hung, Mien-Chie; Chen, Yeh] China Med Univ, Drug Dev Ctr, Res Ctr Canc Biol, Taichung 40402, Taiwan.
   [Hung, Mien-Chie; Chen, Yeh] China Med Univ, Ctr Mol Med, Taichung 40402, Taiwan.
   [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung, Taiwan.
RP Hung, MC; Chen, Y (corresponding author), China Med Univ, Drug Dev Ctr, Res Ctr Canc Biol, Taichung 40402, Taiwan.; Hung, MC; Chen, Y (corresponding author), China Med Univ, Ctr Mol Med, Taichung 40402, Taiwan.
EM mhung@cmu.edu.tw; bluecrystalprotein@gmail.com
FU Ministry of Science and Technology in TaiwanMinistry of Science and
   Technology, Taiwan [108-2311-B241-001]; Drug Development Center, China
   Medical University from the Ministry of Education in Taiwan
FX We would like to thank the National Synchrotron Radiation Research
   Center (NSRRC, Taiwan) for assistance during the data collection. This
   research was supported by the Ministry of Science and Technology in
   Taiwan (108-2311-B241-001) and Drug Development Center, China Medical
   University from the Ministry of Education in Taiwan.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang ST, AM J CANC RES
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Lifesciences A., THANKS CATS ONE PROM
   Lifesciences A, ANIVIVE REPURPOSES V
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma C, 2020, CELL RES, P1
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Ye G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020240
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 0
Z9 0
U1 1
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2020
VL 10
IS 8
BP 2535
EP +
PG 13
WC Oncology
SC Oncology
GA OC8CX
UT WOS:000579385400022
PM 32905393
DA 2021-01-01
ER

PT J
AU Abe, K
   Yamamoto, T
   Matsumoto, K
   Kikuchi, K
   Miura, R
   Tachizawa, N
   Asaoka, Y
   Takezawa, T
   Matsunaga, N
   Obi, S
   Tanaka, A
AF Abe, Koichiro
   Yamamoto, Takatsugu
   Matsumoto, Kotaro
   Kikuchi, Kentaro
   Miura, Ryo
   Tachizawa, Naoko
   Asaoka, Yoshinari
   Takezawa, Tomoko
   Matsunaga, Naohisa
   Obi, Shuntaro
   Tanaka, Atsushi
TI Clinical Features and Liver Injury in Patients with COVID-19 in the
   Japanese Population
SO INTERNAL MEDICINE
LA English
DT Article
DE SARS-CoV-2; coronavirus; COVID-19; liver injury; hepatitis; fever
ID CORONAVIRUS
AB Objective Liver injury is a notable complication of coronavirus disease 2019 (COVID-19). This study aimed to clarify the clinical features and liver injury in Japanese patients with COVID-19.
   Methods We conducted a multicenter retrospective cohort study. All consecutive patients with COVID-19 who visited or were admitted to our hospital before May 12, 2020, were enrolled. Their demographics, symptoms, laboratory findings, comorbidities, concomitant drugs, treatment, and clinical course were reviewed. We defined liver injury as alanine aminotransferase (ALT) or gamma-glutamyl transferase (GGT) levels over the upper limit of normal.
   Results Twenty-two patients with COVID-19 (median age, 47 years old; men/women, 13/9) were enrolled. Two patients had underlying liver diseases, and two were diagnosed as having COVID-19 without any symptoms. Elevated ALT and GGT levels were found in 12 and 12 patients, respectively, and liver injury was observed in 15 patients (68.2%). Compared with the patients without liver injury, those with liver injury had a significantly higher fever during the clinical course (median, 37.5 degrees C vs. 38.8 degrees C, p=0.006). A significant correlation was found between the highest serum liver values and the highest body temperature in each patient. Among the 22 patients, 4 required artificial respiratory support, and 2 died thereafter. Liver injury was not associated with the severity or mortality of COVID-19.
   Conclusion Elevated levels of liver enzymes in the Japanese patients with COVID-19 were associated with the highest body temperature during the clinical course but not with the severity or mortality of COVID-19.
C1 [Abe, Koichiro; Yamamoto, Takatsugu; Miura, Ryo; Tachizawa, Naoko; Asaoka, Yoshinari; Tanaka, Atsushi] Teikyo Univ, Dept Med, Sch Med, Tokyo, Japan.
   [Matsumoto, Kotaro] Teikyo Univ, Dept Gastroenterol, Mizonokuchi Hosp, Tokyo, Japan.
   [Kikuchi, Kentaro] Teikyo Univ, Dept Internal Med 4, Mizonokuchi Hosp, Tokyo, Japan.
   [Takezawa, Tomoko; Matsunaga, Naohisa] Teikyo Univ Hosp, Dept Infect Control & Prevent, Tokyo, Japan.
   [Obi, Shuntaro] Teikyo Univ, Dept Internal Med, Chiba Med Ctr, Tokyo, Japan.
RP Abe, K (corresponding author), Teikyo Univ, Dept Med, Sch Med, Tokyo, Japan.
EM abe@med.teikyo-u.ac.jp
CR Boettler T, JHEP REP
   Cai Q, J HEPATOL
   Cai Q, ALLERGY
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Fix OK, HEPATOLOGY
   Garrido I, 2020, ALIMENT PHARM THER, V52, P267, DOI 10.1111/apt.15813
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hu L L, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P97, DOI 10.3760/cma.j.issn.1007-3418.2020.02.001
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji D, J HEPATOL
   Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472
   Parohan M, HEPATOL RES
   Pascarella G, J INTERN MED
   Sultan S, GASTROENTEROLOGY
   Wang F, GASTROENTEROLOGY
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wu J, J INTERN MED
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Youssef M, J MED VIROL
   Zheng Zhang Y, LIVER INT
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 0
Z9 0
U1 1
U2 1
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2020
VL 59
IS 19
BP 2353
EP 2358
DI 10.2169/internalmedicine.5777-20
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE2NU
UT WOS:000580374600002
PM 32999264
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abbott-Gaffney, C
   Jacobs, K
AF Abbott-Gaffney, Cynthia
   Jacobs, Karen
TI Telehealth in school-based practice: Perceived viability to bridge
   global OT practitioner shortages prior to COVID-19 global health
   emergency
SO WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION
LA English
DT Article
DE Pediatrics; telerehabilitation; telemedicine; telepractice; OT; COVID-19
AB BACKGROUND: Prior to the COVID-19 global health emergency, telehealth was an emerging occupational therapy (OT) service delivery model possessing many positive attributes. These include the potential to offset well-documented global occupational therapy practitioner (OTP) shortages. However, wide-spread adoption of telehealth as a delivery model in school-based practice is lacking in the OT evidence literature. While the COVID-19 global health emergency propelled many OTPs into the use of telehealth technologies, in some cases with minimal preparation, an investigation was conducted into the likelihood of telehealth adoption when comprehensive training was provided so that appropriateness of student fit for telehealth could be determined and essential planning could take place.
   OBJECTIVE: Prior to the COVID-19 global health emergency, a comprehensive training program was developed incorporating detailed perceptions of OTPs experienced in and new to telehealth in school-based practice as measured via surveys with the goal of increasing adoption of telehealth technologies for the delivery of OT services. Following the completion of the online New to Telehealth Pre-training Survey, OTPs new to telehealth were invited to complete the OT Telehealth Primer: School-based Practice training program. Analysis of pre- and post-training surveys yielded information about attitudinal changes experienced post-training.
   METHODS: Prior to the COVID-19 global health emergency, school-based occupational therapy practitioners (OTP) experienced in telehealth were invited to complete a survey exploring benefits and barriers encountered in the delivery of OT services using telehealth. OTPs new-to-telehealth were invited to complete a different survey intended to explore attitudes about the potential use of telehealth. Data collected from both surveys were used to develop a comprehensive training program, The OT Telehealth Primer for School-based Practice. OTPs new-to-telehealth were invited to complete the training program and a post-training survey. A descriptive data analysis was completed on responses from pre- to post-training surveys and the chi-square test of independence was used to evaluate difference in reported likelihood of adopting telehealth into practice before and after training.
   RESULTS: Prior to the COVID-19 global health emergency, the top benefits identified by the OTP Experienced Telehealth-User Survey included: 1) service access, 2) collaboration and carry-over with team members, 3) efficiency themes, and 4) student engagement and comfort. Top benefits identified by the OTP New to Telehealth Survey identified the same top benefits after participating in the training program. A significant decrease in perceived barriers was noted in scores from pre- to post-training by OTPs new to telehealth. The perceived barriers that did not significantly decrease post-training suggest the need for future education and future protocol development. These included: unreliable internet, lack of hands-on opportunity and e-helpers' (parent, caregiver or support system available to assist the student in person during a telehealth session) decreased comfort with technology. Of the participants who completed the OT Telehealth Primer: School-based Practice, 80% reported being likely to add telehealth as a delivery model for future OT practice.
   CONCLUSIONS: Prior to the COVID-19 global health emergency, completion of the comprehensive training program OT Telehealth Primer: School-based Practice program yielded improved perceived benefits and an increased likelihood of telehealth adoption into practice by OTPs. However, both OTPs and school administrators require ongoing education for successful widespread adoption to be achieved thus offsetting the global shortage of OTPs and increasing service access. Future research, particularly related to available training and support for the rapid adoption of telehealth technologies during the COVID-19 global health emergency, will yield helpful information about the likelihood of continued use of telehealth in practice.
C1 [Abbott-Gaffney, Cynthia] Temple Univ, Dept Hlth & Rehabil Sci, Occupat Therapy Program, Philadelphia, PA 19122 USA.
   [Abbott-Gaffney, Cynthia; Jacobs, Karen] Boston Univ, Coll Hlth & Rehabil Sci, Sargent Coll, Occupat Therapy Program, Boston, MA 02215 USA.
RP Abbott-Gaffney, C (corresponding author), Temple Univ, Dept Hlth & Rehabil Sci, Occupat Therapy Program, Coll Publ Hlth, 1913 N Broad St,201f, Philadelphia, PA 19122 USA.
EM cynthia.abbott-gaffney@temple.edu
CR American Association for Employment in Education, 2016, ED SUPPL DEM REP 201
   [Anonymous], 2018, Am J Occup Ther, V72, p7212410059p1, DOI 10.5014/ajot.2018.72S219
   Bureau of Labor Statistics, 2018, OCC OUTL HDB
   Cason J, 2015, AM J OCCUP THER, V69, DOI 10.5014/ajot.2015.692003
   Hersch G, 2015, AM J OCCUP THER, V69, P1, DOI [10.5014/ajot.2015.69s1-po1, DOI 10.5014/AJOT.2015.69S1-PO1]
   Lehrer B., 2016, FOLLOW OCCUPATIONAL
   Lin V, 2015, PM&R, V7, P946, DOI 10.1016/j.pmrj.2015.02.012
   Little LM, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.024786
   Rogers E.M., 1983, DIFFUSION INNOVATION
   Rortvedt D, 2019, WORK, V62, P125, DOI 10.3233/WOR-182847
   Tucker JK, 2012, INT J TELEREHABILITA, V4, P47, DOI 10.5195/ijt.2012.6102
   United States Department of Education, SEC 300 34 REL SERV
   World Federation of Occupational Therapy, 2018, WFOT HUM RES PROJ
NR 13
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1051-9815
EI 1875-9270
J9 WORK
JI Work
PY 2020
VL 67
IS 1
BP 29
EP 35
DI 10.3233/WOR-203240
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OE6GJ
UT WOS:000580626800004
PM 32925151
OA Bronze
DA 2021-01-01
ER

PT J
AU Deriba, BS
   Geleta, TA
   Beyane, RS
   Mohammed, A
   Tesema, M
   Jemal, K
AF Deriba, Berhanu Senbeta
   Geleta, Tinsae Abeya
   Beyane, Rebik Shukure
   Mohammed, Ahmed
   Tesema, Mengistu
   Jemal, Kemal
TI Patient Satisfaction and Associated Factors During COVID-19 Pandemic in
   North Shoa Health Care Facilities
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE patient satisfaction; COVID-19; associated factors; Ethiopia
ID EXPERIENCES
AB Background: Patient satisfaction is an indicator of healthcare quality service and involved as an outcome measure. Quality of healthcare service and patient satisfaction has been affected by the current coronavirus disease 2019 (COVID-19) pandemic. It induced uncertainness and shortage of medical supplies due to a limited global movement. Therefore, this study aimed to assess patient satisfaction and associated factors among chronic patients who had a follow-up in North Shoa healthcare facilities.
   Methods: An institutional-based cross-sectional study was used to select 410 study participants through a systematic random sampling technique. Data were collected by a structured interviewer-administered questionnaire, entered into Epi Info version 7, and transported to SPSS version 23 for analysis. Bivariable and multivariable logistic regressions were used to identify the factors associated with satisfaction. The odds ratio with a 95% confidence interval was computed, and p-value <0.05 was considered statistical significance in the multivariable model.
   Results: The overall level of patient satisfaction was 44.6%. The presence of sign and direction indicators (AOR=3.26, 95% CI=1.1, 9.92), obtaining some ordered drugs (AOR=3.7, 95% CI=1.1, 12.54), getting alcohol for hand cleaning (AOR=2.66, 95% CI=1.1,6.65), obtaining sanitizer for hand cleaning (AOR=4.45, 95% CI=1.72,11.52), and maintaining social distancing (AOR=2.63, 95% CI=1.21, 5.70) were factors associated with patient's satisfaction.
   Conclusion: The level of patient satisfaction was very low during a COVID-19 pandemic. The presence of sign and direction indicators, availability of drugs, social distancing, availability of alcohol, and sanitizer were factors associated with patient satisfaction. The intervention targeted at increasing patient satisfaction and improving the quality of service during COVID-19 through maintaining social distancing and availing alcohol or sanitizers is necessary.
C1 [Deriba, Berhanu Senbeta; Geleta, Tinsae Abeya; Beyane, Rebik Shukure; Mohammed, Ahmed; Tesema, Mengistu] Salale Univ, Coll Hlth Sci, Dept Publ Hlth, Fitche, Ethiopia.
   [Jemal, Kemal] Salale Univ, Coll Hlth Sci, Dept Nursing, Fitche, Ethiopia.
RP Jemal, K (corresponding author), Salale Univ, Coll Hlth Sci, Dept Nursing, Fitche, Ethiopia.
EM olifanjemal@gmail.com
OI Senbeta, Berhanu/0000-0002-4282-1427; Jemal, Kemal/0000-0001-8922-1827
CR Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1
   Alemayehu YK, 2009, INT J QUAL HEALTH C, V21, P356, DOI 10.1093/intqhc/mzp030
   Alkureishi MA, 2016, J GEN INTERN MED, V31, P548, DOI 10.1007/s11606-015-3582-1
   AMBELIE YA, 2014, J PUBLIC HLTH, V2, P417
   Andaleeb SS, 2007, HEALTH POLICY PLANN, V22, P263, DOI 10.1093/heapol/czm017
   [Anonymous], 2020, MONITOR 1 COVID 19 W
   Anteneh A, 2014, J PUBLIC HLTH EPIDEM, V6, P101, DOI [10.5897/JPHE2013.0613, DOI 10.5897/JPHE2013.0613]
   Ashry AH, 2020, EGYPT J NEUROL PSYCH, V56, DOI 10.1186/s41983-020-00212-0
   Assefa F, 2011, ETHIOP J HEALTH SCI, V21, P101
   Babure ZK, 2018, J PUBL HLTH EPIDEMIO, V10, P43
   Berehe Tirhas T, 2018, BMC Res Notes, V11, P507, DOI 10.1186/s13104-018-3603-3
   Berkowitz Bobbie, 2016, Online J Issues Nurs, V21, P1, DOI 10.3912/OJIN.Vol21No01Man01
   Bjertnaes OA, 2012, BMJ QUAL SAF, V21, P39, DOI 10.1136/bmjqs-2011-000137
   Bragazzi NL, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13508
   Busse R, 2013, HLTH SYSTEM PERFORMA, P255
   Cinelli E, 2020, SUPPORT CARE CANCER, V28, P3991, DOI 10.1007/s00520-020-05563-1
   Cristaudo A, 2020, CONTACT DERMATITIS, V83, P536, DOI 10.1111/cod.13683
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Geberu DM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4685-x
   Gedefaw M, 2014, OPEN J EPIDEMIOL, V4, P217, DOI [10.4236/ojepi.2014.4402828, DOI 10.4236/OJEPI.2014.44028]
   Getenet H, 2008, ETHIOPIAN J HLTH SCI, V18, P2
   Gill R, 2009, J QUANT ANAL SPORTS, V5, DOI 10.2202/1559-0410.1172
   Gillman-Wells CC, 2020, AESTHET PLAST SURG, P1
   Girmay A, 2014, ASSESSMENT CLIENTS S
   Gironi LC, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789044
   Gorbalenya A, 2020, SEVERE CUTE RESP SYN
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kaur D, 2020, CUREUS, V12, DOI 10.7759/cureus.9859
   Kruk ME, 2020, LANCET, V396, P1130, DOI 10.1016/S0140-6736(20)31795-5
   Lozano R, 2020, LANCET
   Makoni M, 2020, LANCET, V395, P483, DOI 10.1016/S0140-6736(20)30355-X
   Maliha N, 2012, PAKISTAN J PUBLIC HL, V2, P56
   Mezemir R, 2014, INT J EC MANAG SCI, V3, P2
   Mohd Athar, 2014, Med J Armed Forces India, V70, P237, DOI 10.1016/j.mjafi.2013.06.010
   Monasta L, 2019, LANCET PUBLIC HEALTH, V4, pE645, DOI 10.1016/S2468-2667(19)30189-6
   Mullan Z, 2016, LANCET GLOB HEALTH, V4, pE1, DOI 10.1016/S2214-109X(15)00300-9
   Olomi GA, 2017, J PATIENT CARE, DOI 10:4172/2573-4598.1000124
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Rajbanshi L, 2014, J CHITWAN MED COLL, V4, P11, DOI DOI 10.3126/JCMC.V4I1.1084139
   Sagaro GG, 2015, SCI J CLIN MED, V4, P109, DOI DOI 10.11648/J.SJCM.20150405.16
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tume SM, 2015, INT J CURR RES, V7, P20245
   Udonwa NE, 2012, INT J FAMILY MED, V2012, P38
   Valentine N, 2015, SOC SCI MED, V138, P152, DOI 10.1016/j.socscimed.2015.04.022
   Webster TR, 2011, INT J QUAL HEALTH C, V23, P258, DOI 10.1093/intqhc/mzr019
   World Health Organization (WHO), 2013, WORLD HLTH STAT 2013
NR 46
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2020
VL 14
BP 1923
EP 1934
DI 10.2147/PPA.S276254
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD0CK
UT WOS:000579522300004
PM 33116436
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Reshetnikov, AV
   Prisyazhnaya, NV
   Pavlov, SV
   Vyatkina, NY
AF Reshetnikov, A. V.
   Prisyazhnaya, N. V.
   Pavlov, S. V.
   Vyatkina, N. Yu.
TI PERCEPTION OF THE COVID-19 PANDEMIC BY MOSCOW RESIDENTS
SO SOTSIOLOGICHESKIE ISSLEDOVANIYA
LA Russian
DT Article
DE COVID-19; coronavirus pandemic; perception of pandemics by Moscow
   residents
ID OUTBREAK
AB The article results from a medical sociological survey aimed at specifics of perception of the coronavirus infection (Covid-19) problem by Moscow residents. According to the data received, the level of respondents' awareness about measures to prevent infection, as well as commitment to their implementation is high, and most of all residents of Moscow city are concerned about rapid spread of infection, lack of effective treatment and vaccine, fear for the health of parents and eventual economic destabilization in the country. At the same time, in a situation of forced staying at home in self-isolation, respondents most often experience discomfort from price increases, reducing (losing) income, limiting personal space and broken holiday plans. The authors note that among the most serious consequences of the pandemic (vision of the "post-pandemic world"), residents of Moscow share most common expectations of a recession, a large-scale crisis in the health care system, growing social tension and risk of an "loneliness epidemic" due to the consolidation of distance social practices.
C1 [Reshetnikov, A. V.; Prisyazhnaya, N. V.; Pavlov, S. V.; Vyatkina, N. Yu.] Sechenov Univ, Moscow, Russia.
RP Reshetnikov, AV (corresponding author), Sechenov Univ, Moscow, Russia.
EM niisocmed@mail.ru; nprusova@yandex.ru; pavlov-sv@list.ru;
   tsetse@inbox.ru
CR Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lupton D., 2015, DIGITAL SOCIOLOGY
   McCartney M, 2020, LANCET, V395, P1248, DOI 10.1016/S0140-6736(20)30756-X
   McFadden SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231808
   Segrin C, 2019, HEALTH COMMUN, V34, P118, DOI 10.1080/10410236.2017.1384434
   Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 8
TC 0
Z9 0
U1 3
U2 3
PU IZDATELSTVO NAUKA
PI MOSCOW
PA 19 DMITRIYA ULYANOVA ST, MOSCOW, 19117036, RUSSIA
SN 0132-1625
J9 SOTSIOL ISSLED+
JI Sotsiologicheskie Issled.
PY 2020
IS 7
BP 138
EP 143
DI 10.31857/S013216250009481-2
PG 6
WC Sociology
SC Sociology
GA OC5QW
UT WOS:000579211700013
DA 2021-01-01
ER

PT J
AU Price, A
   Barlow-Pay, F
   Duffy, S
   Pearce, L
   Vilches-Moraga, A
   Moug, S
   Quinn, T
   Stechman, M
   Braude, P
   Mitchell, E
   Myint, PK
   Verduri, A
   McCarthy, K
   Carter, B
   Hewitt, J
AF Price, Angeline
   Barlow-Pay, Fenella
   Duffy, Siobhan
   Pearce, Lyndsay
   Vilches-Moraga, Arturo
   Moug, Susan
   Quinn, Terry
   Stechman, Michael
   Braude, Philip
   Mitchell, Emma
   Myint, Phyo Kyaw
   Verduri, Alessia
   McCarthy, Kathryn
   Carter, Ben
   Hewitt, Jonathan
CA COPE Study Collaborators
TI Study protocol for the COPE study: COVID-19 in Older PEople: the
   influence of frailty and multimorbidity on survival. A multicentre,
   European observational study
SO BMJ OPEN
LA English
DT Article
DE geriatric medicine; health policy; public health
AB Introduction This protocol describes an observational study which set out to assess whether frailty and/or multimorbidity correlates with short-term and medium-term outcomes in patients diagnosed with COVID-19 in a European, multicentre setting. Methods and analysis Over a 3-month period we aim to recruit a minimum of 500 patients across 10 hospital sites, collecting baseline data including: patient demographics; presence of comorbidities; relevant blood tests on admission; prescription of ACE inhibitors/angiotensin receptor blockers/non-steroidal anti-inflammatory drugs/immunosuppressants; smoking status; Clinical Frailty Score (CFS); length of hospital stay; mortality and readmission. All patients receiving inpatient hospital care >18 years who receive a diagnosis of COVID-19 are eligible for inclusion. Long-term follow-up at 6 and 12 months is planned. This will assess frailty, quality of life and medical complications. Our primary analysis will be short-term and long-term mortality by CFS, adjusted for age (18-64, 65-80 and >80) and gender. We will carry out a secondary analysis of the primary outcome by including additional clinical mediators which are determined statistically important using a likelihood ratio test. All analyses will be presented as crude and adjusted HR and OR with associated 95% CIs and p values. Ethics and dissemination This study has been registered, reviewed and approved by the following: Health Research Authority (20/HRA1898); Ethics Committee of Hospital Policlinico Modena, Italy (369/2020/OSS/AOUMO); Health and Care Research Permissions Service, Wales; and NHS Research Scotland Permissions Co-ordinating Centre, Scotland. All participating units obtained approval from their local Research and Development department consistent with the guidance from their relevant national organisation. Data will be reported as a whole cohort. This project will be submitted for presentation at a national or international surgical and geriatric conference. Manuscript(s) will be prepared following the close of the project.
C1 [Price, Angeline; Vilches-Moraga, Arturo] Salford Royal NHS Trust, Ageing & Complex Med, Salford, Lancs, England.
   [Barlow-Pay, Fenella] Royal Alexandra Hosp, Dept Anaesthet, Paisley, Renfrew, Scotland.
   [Duffy, Siobhan; Moug, Susan] Royal Alexandra Hosp, Gen Surg, Paisley, Renfrew, Scotland.
   [Pearce, Lyndsay] Salford Royal NHS Fdn Trust, Gen Surg, Salford, Lancs, England.
   [Moug, Susan] Univ Glasgow, Glasgow, Lanark, Scotland.
   [Quinn, Terry] Univ Glasgow, Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
   [Stechman, Michael] Univ Hosp Wales, Gen Surg, Cardiff, Wales.
   [Braude, Philip; Mitchell, Emma] North Bristol NHS Trust, Med Older People, Westbury On Trym, England.
   [Myint, Phyo Kyaw] Univ Aberdeen, Aberdeen, Scotland.
   [Verduri, Alessia] Hosp Policlin Modena, Modena, Italy.
   [McCarthy, Kathryn] North Bristol NHS Trust, Gen Surg, Bristol, Avon, England.
   [Carter, Ben] Kings Coll London, Biostat & Hlth Informat, London, England.
   [Carter, Ben] Kings Coll London, London, England.
   [Hewitt, Jonathan] Cardiff Univ, Geriatr Med, Cardiff, Wales.
RP Price, A (corresponding author), Salford Royal NHS Trust, Ageing & Complex Med, Salford, Lancs, England.
EM angeline.price@srtf.nhs.uk
OI price, angeline/0000-0002-4674-270X
CR Bebb O, 2018, EUR HEART J-ACUTE CA, V7, P166, DOI 10.1177/2048872617700873
   British Society of Rheumatologists, 2020, COVID 19 GUIDANCE RH
   Carter B, 2020, BRIT J SURG, DOI 10.1002/bjs.11392
   Cesari M, 2016, J AM MED DIR ASSOC, V17, P448, DOI 10.1016/j.jamda.2016.02.007
   Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9
   Dowswell G, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-94
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Gilbert T, 2018, LANCET, V391, P1775, DOI 10.1016/S0140-6736(18)30668-8
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hewitt J, 2019, AGE AGEING, V48, P388, DOI 10.1093/ageing/afy217
   Hewitt J, 2019, GERIATRICS-BASEL, V4, DOI 10.3390/geriatrics4040057
   Hewitt J, 2015, AM J SURG, V209, P254, DOI 10.1016/j.amjsurg.2014.05.022
   ICNARC, 2020, ICNARC REPORT COVID1
   Ingraham NE, 2020, LANCET RESP MED
   Jelley B, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013031
   Lithander FE, 2020, AGE AGEING, V49, P501, DOI 10.1093/ageing/afaa093
   McDermid RC, 2011, CRIT CARE, V15, DOI 10.1186/cc9297
   Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0
   Myint PK, 2018, GERIATR GERONTOL INT, V18, P1025, DOI 10.1111/ggi.13293
   NICE, 2020, COVID 19 RAPID GUIDE
   O'Hanlon S, 2020, AGE AGEING, V49, P497, DOI 10.1093/ageing/afaa094
   Parmar Kat L, 2019, Ann Surg, DOI 10.1097/SLA.0000000000003402
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   Royal College of General Practitioners, COVID 19 FAQS
   Ticinesi A, 2019, EUR J INTERN MED, V64, P41, DOI 10.1016/j.ejim.2019.02.013
   Vilches-Moraga A, 2020, AGING CLIN EXP RES, V32, P2367, DOI 10.1007/s40520-020-01578-0
   Wagner B, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10071202
   Walker DM, 2018, EUR HEART J-ACUTE CA, V7, P176, DOI 10.1177/2048872618758931
   World Health Organization, CLIN MANAGEMENT SEVE
   World Health Organization, WHO DIRECTOR GENERAL
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 0
Z9 0
U1 3
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e040569
DI 10.1136/bmjopen-2020-040569
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OB4JT
UT WOS:000578438100020
PM 32994260
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU MacIntyre, CR
   Dung, TC
   Chughtai, AA
   Seale, H
   Rahman, B
AF MacIntyre, Chandini Raina
   Tham Chi Dung
   Chughtai, Abrar Ahmad
   Seale, Holly
   Rahman, Bayzidur
TI Contamination and washing of cloth masks and risk of infection among
   hospital health workers in Vietnam: a post hoc analysis of a randomised
   controlled trial
SO BMJ OPEN
LA English
DT Article
DE infectious diseases; infection control; respiratory infections
ID EYE PROTECTION; FACE MASKS
AB Background In a previous randomised controlled trial (RCT) in hospital healthcare workers (HCWs), cloth masks resulted in a higher risk of respiratory infections compared with medical masks. This was the only published RCT of cloth masks at the time of the COVID-19 pandemic. Objective To do a post hoc analysis of unpublished data on mask washing and mask contamination from the original RCT to further understand poor performance of the two-layered cotton cloth mask used by HCWs in that RCT. Setting 14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam. Participants A subgroup of 607 HCWs aged >= 18 years working full time in selected high-risk wards, who used a two-layered cloth mask and were part of a randomised controlled clinical trial comparing medical masks and cloth masks. Intervention Washing method for cloth masks (self-washing or hospital laundry). A substudy of contamination of a sample of 15 cloth and medical masks was also conducted. Outcome measure Infection rate over 4 weeks of follow up and viral contamination of masks tested by multiplex PCR. Results Viral contamination with rhinovirus was identified on both used medical and cloth masks. Most HCW (77% of daily washing) self-washed their masks by hand. The risk of infection was more than double among HCW self-washing their masks compared with the hospital laundry (HR 2.04 (95% CI 1.03 to 4.00); p=0.04). There was no significant difference in infection between HCW who wore cloth masks washed in the hospital laundry compared with medical masks (p=0.5). Conclusions Using self-reported method of washing, we showed double the risk of infection with seasonal respiratory viruses if masks were self-washed by hand by HCWs. The majority of HCWs in the study reported hand-washing their mask themselves. This could explain the poor performance of two layered cloth masks, if the self-washing was inadequate. Cloth masks washed in the hospital laundry were as protective as medical masks. Both cloth and medical masks were contaminated, but only cloth masks were reused in the study, reiterating the importance of daily washing of reusable cloth masks using proper method. A well-washed cloth mask can be as protective as a medical mask. Trial resgistration number ACTRN12610000887077.
C1 [MacIntyre, Chandini Raina] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [MacIntyre, Chandini Raina] Arizona State Univ, Coll Publ Affairs & Community Solut, Tempe, AZ 85287 USA.
   [Tham Chi Dung] Minist Hlth, Hanoi, Vietnam.
   [Chughtai, Abrar Ahmad; Seale, Holly; Rahman, Bayzidur] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
RP MacIntyre, CR (corresponding author), Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.; MacIntyre, CR (corresponding author), Arizona State Univ, Coll Publ Affairs & Community Solut, Tempe, AZ 85287 USA.
EM rainam@protonmail.com
RI Seale, Holly/D-4200-2011
OI Seale, Holly/0000-0002-1877-5395; MacIntyre, C Raina/0000-0002-3060-0555
FU National Health and Medical Research Council (NHMRC) Principal Research
   FellowshipNational Health and Medical Research Council of Australia [1
   137 582]; Australian Research CouncilAustralian Research Council
FX CRM is supported by a National Health and Medical Research Council
   (NHMRC) Principal Research Fellowship, grant number 1 137 582. The
   original randomised controlled trial (RCT) was funded by the Australian
   Research Council.
CR Bhattacharjee S, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000698
   Blachere FM, 2009, CLIN INFECT DIS, V48, P438, DOI 10.1086/596478
   Centers for Disease Control and Prevention, 2020, STRAT OPT SUPPL FAC
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Chughtai Abrar A, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2610.200948
   Greenhalgh T, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1435
   Guo ZG, 2021, MATH METHOD APPL SCI, V44, P2130, DOI 10.1002/mma.6923
   Kleinbaum DGK, 2012, STAT BIOL HLTH, P1431
   Ma Q-X SH, 2020, J MED VIROL
   MacIntyre CR, 2020, LANCET, V395, P1950, DOI 10.1016/S0140-6736(20)31183-1
   MacIntyre CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006577
   MacIntyre CRC, 2020, BMJ
   Organization WH, 2020, WAT SAN HYG WAST MAN
   Santarpia JL, 2020, TRANSMISSION POTENTI
   World Health Organization, 2020, COR DIS COVID 19 ADV
NR 15
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e042045
DI 10.1136/bmjopen-2020-042045
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OB4JQ
UT WOS:000578437800008
PM 32988954
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, S
   Liu, C
   Guo, FY
   Taleb, SJ
   Tong, MY
   Shang, D
AF Li, Shuang
   Liu, Chang
   Guo, Fangyue
   Taleb, Sarah J.
   Tong, Mengying
   Shang, Dong
TI Traditional Chinese Medicine as Potential Therapy for COVID-19
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Traditional Chinese Medicine; SARS-CoV-2; COVID-19; Review
ID CHAI-HU-TANG; SCUTELLARIA-BAICALENSIS; BELAMCANDA-CHINENSIS;
   VIRUS-INFECTION; ANTIVIRAL ACTIVITY; NITRIC-OXIDE; BAICALIN;
   CORONAVIRUS; SARS; GLYCYRRHIZIN
AB In December 2019, a novel coronavirus SARS-CoV-2, causing the disease COVID-19, spread from Wuhan throughout China and has infected people over 200 countries. Thus far, more than 3,400,000 cases and 240,000 deaths have occurred worldwide, and the coronavirus pandemic continues to grip the globe. While numbers of cases in China have been steadying, the number of infections outside China is increasing at a worrying pace. We face an urgent need to control the spread of the COVID-19 epidemic, which is currently expanding to a global pandemic. Efforts have focused on testing antiviral drugs and vaccines, but there is currently no treatment specifically approved. Traditional Chinese medicine (TCM) is grounded in empirical observations and the Chinese people use TCM to overcome these sorts of plagues many times in thousands of years of history. Currently, the Chinese National Health Commission recommended a TCM prescription of Qing-Fei-Pai-Du-Tang (QFPDT) in the latest version of the "Diagnosis and Treatment guidelines of COVID-19" which has been reported to provide reliable effects for COVID-19. While doubts about TCM still exist today, this review paper will describe the rationalities that QFPDT is likely to bring a safe and effective treatment of COVID-19.
C1 [Li, Shuang; Shang, Dong] Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
   [Li, Shuang; Liu, Chang; Guo, Fangyue; Shang, Dong] Dalian Med Univ, Affiliated Hosp 1, Clin Lab Integrat Med, Dalian, Liaoning, Peoples R China.
   [Tong, Mengying] Dalian Med Univ, Affiliated Hosp 1, Dept Ultrasound, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
   [Li, Shuang; Liu, Chang; Guo, Fangyue; Shang, Dong] Dalian Med Univ, Inst Integrat Med, Dalian, Liaoning, Peoples R China.
   [Taleb, Sarah J.] Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA.
   [Shang, Dong] Leishenshan Hosp, Wuhan, Hubei, Peoples R China.
RP Shang, D (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.; Tong, MY (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Dept Ultrasound, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
EM mengyingtong@dmu.edu.cn; shangdong@dmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873156]; Liaoning Province Education
   Foundation [LZ2019051]; Natural Science Foundation of Liaoning
   ProvinceNatural Science Foundation of Liaoning Province [2020-BS-195]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81873156), Liaoning Province Education Foundation (No.
   LZ2019051), and Natural Science Foundation of Liaoning Province (No.
   2020-BS-195).
CR Ahn KS, 2006, LIFE SCI, V78, P2336, DOI 10.1016/j.lfs.2005.09.041
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567
   Biggioggero M, 2019, DRUG DES DEV THER, V13, P57, DOI 10.2147/DDDT.S150580
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   Chang JS, 2007, AM J CHINESE MED, V35, P341, DOI 10.1142/S0192415X07004862
   Chen DQ, 2014, J ETHNOPHARMACOL, V157, P114, DOI 10.1016/j.jep.2014.09.022
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen HJ, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.152997
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YC, 2007, AM J CHINESE MED, V35, P533, DOI 10.1142/S0192415X07005041
   Cheng CS, 2018, AM J CHINESE MED, V46, P25, DOI 10.1142/S0192415X18500027
   Cheng KB, 2014, CELL BIOCHEM BIOPHYS, V70, P1305, DOI 10.1007/s12013-014-0055-9
   Cheng PW, 2006, INT IMMUNOPHARMACOL, V6, P1003, DOI 10.1016/j.intimp.2006.01.011
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/263630
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Ding Y, 2014, ARCH VIROL, V159, P3269, DOI 10.1007/s00705-014-2192-2
   Fang YN, 2002, PHYTOMEDICINE, V9, P734, DOI 10.1078/094471102321621359
   Gao JF, 2014, 2014 8TH INTERNATIONAL CONFERENCE ON FUTURE GENERATION COMMUNICATION AND NETWORKING (FGCN), P72, DOI 10.1109/FGCN.2014.25
   Han CW, 2013, J ETHNOPHARMACOL, V146, P402, DOI 10.1016/j.jep.2013.01.010
   Harada S, 2005, BIOCHEM J, V392, P191, DOI 10.1042/BJ20051069
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hsieh CF, 2012, J ETHNOPHARMACOL, V143, P57, DOI 10.1016/j.jep.2012.05.061
   Hsu WL, 2018, AM J CHINESE MED, V46, P769, DOI [10.1142/s0192415x18500404, 10.1142/S0192415X18500404]
   Hu JQ, 2012, STAT MED, V31, P602, DOI 10.1002/sim.4409
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang H, 2017, TOXICOL APPL PHARM, V323, P36, DOI 10.1016/j.taap.2017.03.016
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jiao JY, 2018, PHARM BIOL, V56, P580, DOI 10.1080/13880209.2018.1517184
   Kasote DM, 2017, J ETHNOPHARMACOL, V203, P55, DOI 10.1016/j.jep.2017.03.038
   Kim HI, 2019, AM J CHINESE MED, V47, P691, DOI [10.1142/S0192415X19500368, 10.1142/s0192415x19500368]
   Kim YP, 1999, BBA-MOL CELL BIOL L, V1438, P399, DOI 10.1016/S1388-1981(99)00067-0
   Kong Z., COCHRANE DB SYST REV, DOI [10.1002/14651858.cd013090, DOI 10.1002/14651858.CD013090]
   Lai YS, 2018, AM J CHINESE MED, V46, P1899, DOI [10.1142/S0192415X18500957, 10.1142/s0192415x18500957]
   Lee JW, 2015, ARCH PHARM RES, V38, P991, DOI 10.1007/s12272-014-0529-8
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Li LR, 2019, AM J CHINESE MED, V47, P495, DOI 10.1142/S0192415X19500253
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li X, 2015, VIRUSES-BASEL, V7, P4756, DOI 10.3390/v7082841
   Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005
   Lin CC, 2020, J ETHNOPHARMACOL, V253, DOI 10.1016/j.jep.2020.112656
   Lin LL, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/6082729
   Lin LT, 2015, J HEPATOL, V62, P541, DOI 10.1016/j.jhep.2014.10.040
   Lin LL, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0229-x
   Lin SK, 2017, J ETHNOPHARMACOL, V203, P120, DOI 10.1016/j.jep.2017.03.040
   Liu SS, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103226
   Liu SH, 2015, DRUG SAFETY, V38, P117, DOI 10.1007/s40264-014-0250-z
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luo ED, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00317-x
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Ma CH, 2014, CHIN J NAT MEDICINES, V12, P361, DOI 10.1016/S1875-5364(14)60044-3
   Ma QH, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040079
   Makimoto F, 2013, AM J CHINESE MED, V41, P293, DOI 10.1142/S0192415X13500213
   Makino T, 2008, J NAT MED, V62, P294, DOI 10.1007/s11418-008-0230-7
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nagai T, 2010, INT IMMUNOPHARMACOL, V10, P655, DOI 10.1016/j.intimp.2010.03.004
   Nayak MK, 2014, J ANTIMICROB CHEMOTH, V69, P1298, DOI 10.1093/jac/dkt534
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Pan YC, 2019, INFLAMM RES, V68, P1025, DOI 10.1007/s00011-019-01284-2
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pollicino T, 2018, INFLAMM RES, V67, P89, DOI 10.1007/s00011-017-1099-2
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Saha RK, 2010, ANTIVIR RES, V88, P10, DOI 10.1016/j.antiviral.2010.06.008
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Teschke R, 2014, ALIMENT PHARM THER, V40, P32, DOI 10.1111/apt.12798
   Tong Xiaolin, 2004, J Tradit Chin Med, V24, P266
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang SM, 2018, AM J CHINESE MED, V46, P953, DOI 10.1142/S0192415X18500507
   Wang Y, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4083
   Wolkerstorfer A, 2009, ANTIVIR RES, V83, P171, DOI 10.1016/j.antiviral.2009.04.012
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu ZH, 2018, AM J CHINESE MED, V46, P1421, DOI 10.1142/S0192415X1850074X
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yang Y, 2015, J ETHNOPHARMACOL, V169, P49, DOI 10.1016/j.jep.2015.04.011
   Yang Y, 2017, J MED VIROL, V89, P908, DOI 10.1002/jmv.24705
   Yen MH, 2014, J ETHNOPHARMACOL, V151, P1056, DOI 10.1016/j.jep.2013.11.049
   Zhang L, 2016, J ETHNOPHARMACOL, V186, P1, DOI 10.1016/j.jep.2016.03.046
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao Q, 2016, SCI BULL, V61, P1391, DOI 10.1007/s11434-016-1136-5
   Zheng NN, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/529458
   Zhi HJ, 2019, PHYTOMEDICINE, V57, P105, DOI 10.1016/j.phymed.2018.12.009
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu HY, 2015, ANTIVIR RES, V113, P62, DOI 10.1016/j.antiviral.2014.11.003
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 89
TC 0
Z9 0
U1 6
U2 6
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2020
VL 48
IS 6
BP 1263
EP 1277
DI 10.1142/S0192415X20500627
PG 15
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA NZ8EI
UT WOS:000577334500001
PM 32907358
DA 2021-01-01
ER

PT J
AU Aktas, A
   Tuzun, B
   Kafa, AHT
   Sayin, K
   Ataseven, H
AF Aktas, A.
   Tuzun, B.
   Kafa, Taskin A. H.
   Sayin, K.
   Ataseven, H.
TI How do arbidol and its analogs inhibit the SARS-CoV-2?
SO BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
LA English
DT Article
DE SARS-CoV-2; spike glycoprotein; hemagglutinin esterase; arbidol; in
   silico
ID VIRUS; SPIKE; DOCKING; PROTEIN; GLIDE
AB BACKGROUND: COVID-19 is not fully known and causes severe inflammation and cytokine storm. It has many symptoms, such as: fever, sore throat, headache, dyspnoea, and diarrhoea. Arbidol was used in the treatment of COVID19, which was the most critical health problem in the world. However, the desired recovery was not achieved with Arbidol. Many countries still use this drug in the treatment of COVID19.
   AIM: We aimed to determine whether Arbidol, the hemagglutinin esterase inhibitor used in the treatment of COVID-19, was effective against SARS Cov-2 in silico.
   RESULTS AND CONCLUSION: The similarity between hemagglutinin and spike proteins were reported due to the fact that inhibition properties of Arbidol and its 39 analogues were examined in detail against hemagglutinin esterase and spike glycoproteins. CID 1070884 and CID 1207786 were found to be more active against hemagglutinin esterase than in Arbidol, while these compounds were inactive against spike glycoproteins. The interaction mechanism was clarified between arbidol and spike proteins. Phenylalanine, tyrosine, glycine, lysine, and aspartic acid were found to be the headliner amino acids in the interactions between Arbidol and binding domains of spike glycoproteins in the SARS-CoV2 (Tab. 3, Fig. 8, Ref. 28). Text in PDF www.elis.sk
C1 [Aktas, A.; Tuzun, B.; Kafa, Taskin A. H.; Sayin, K.; Ataseven, H.] Sivas Cumhuriyet Univ, Fac Sci, Dept Chem, TR-58140 Sivas, Turkey.
   [Aktas, A.] Sivas Cumhuriyet Univ, Fac Med, Dept Internal Med, Sivas, Turkey.
   [Tuzun, B.; Sayin, K.] Sivas Cumhuriyet Univ, Fac Sci, Dept Biochem, Sivas, Turkey.
   [Kafa, Taskin A. H.] Sivas Cumhuriyet Univ, Dept Med Microbiol, Fac Med, Sivas, Turkey.
   [Sayin, K.] Sivas Cumhuriyet Univ, Adv Technol Res & Applicat Ctr, Sivas, Turkey.
   [Ataseven, H.] Sivas Cumhuriyet Univ, Fac Med, Dept Gastroenterol, Sivas, Turkey.
   [Ataseven, H.] Minist Hlth Republ Turkey, Gen Directorate Publ Hosp, Ankara, Turkey.
RP Sayin, K (corresponding author), Sivas Cumhuriyet Univ, Fac Sci, Dept Chem, TR-58140 Sivas, Turkey.
EM krysayin@gmail.com
FU Scientific Research Project Fund of Sivas Cumhuriyet
   UniversityCumhuriyet University [RGD-020]
FX This work is supported by the Scientific Research Project Fund of Sivas
   Cumhuriyet University under the project number RGD-020.
CR [Anonymous], 2019, SCHROD REL 2019 4 SI
   [Anonymous], 2019, SCHROD REL 2019 4 LI
   [Anonymous], 2019, SCHROD REL 2019 4 MA
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Devaux CA, 2020, INTERNAT J ANTIMICRO, DOI [10.1016/j.ijantimi- cag.2020.105938., DOI 10.1016/J.IJANTIMI-CAG.2020.105938]
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Song H, 2017, CELL REP, V20, P1201, DOI 10.1016/j.celrep.2017.07.028
   Song Y, 2020, COVID 19 TREATMENT C
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang H, 2015, J VIROL, V89, P4612, DOI 10.1128/JVI.03456-14
NR 28
TC 1
Z9 1
U1 0
U2 0
PU COMENIUS UNIV
PI BRATISLAVA I
PA SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA
SN 0006-9248
EI 1336-0345
J9 BRATISL MED J
JI Bratisl. Med. J.
PY 2020
VL 121
IS 10
BP 705
EP 711
DI 10.4149/BLL_2020_115
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OA1LG
UT WOS:000577555500003
PM 32955901
OA Bronze
DA 2021-01-01
ER

PT J
AU Bahrami, R
   Hashemi, D
   Aziziraftar, SK
   Rahimi, P
AF Bahrami, R.
   Hashemi, D.
   Aziziraftar, Keshavarz S.
   Rahimi, P.
TI Coronaviruses as the emerging threats for human health: should we be
   prepared for the future outbreaks of new coronaviruses?
SO BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
LA English
DT Article
DE SARS-CoV-2; COVID-19; pandemic; zoonosis; SARS; MERS
ID ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; HUMAN
   MONOCLONAL-ANTIBODIES; CONVERTING ENZYME 2; SARS CORONAVIRUS; SPIKE
   PROTEIN; FUNCTIONAL RECEPTOR; SEX-DIFFERENCES; NEUTRALIZING ANTIBODY;
   T-705 FAVIPIRAVIR
AB Recent emergence of SARS-CoV-2 in human communities as the first major zoonotic pandemics of the new millennium following the emergence of SARS-CoV and MERS-CoV has increased our awareness about the future threat of viral zoonosis. Although, several studies have been conducted for better understanding of these viruses' evolution, and designing the effective anti-viral drugs and vaccines, the impact of human beings on occurrence of zoonotic diseases has been less considered and discussed. Improvement in global health resulted in human population growth, increasing demand for animal proteins, more exposures to wildlife, zoonotic and degradation of environment, which have facilitated interspecies transmissions. Since world population is increasing proportionately, the protection of public health against zoonotic diseases is a challenging task. It seems that intensified revision of human lifestyle is the best strategy to prevent the potential devastating future zoonotic pandemics. Herein, the characteristics of SARS-CoV, MERS-CoV, SARS-CoV-2, their transmission routs, their pathogenicity, the therapeutic and prevention approaches including of attempts for designing of effective prophylactic vaccines, anti-viral drugs, and the animal models that have been used for these studies have been reviewed (Ref. 134). Text in PDF www.elis.sk
C1 [Bahrami, R.; Hashemi, D.; Aziziraftar, Keshavarz S.; Rahimi, P.] Pasteur Inst Iran, Dept Hepatitis & AIDS, 12 Farvardin Ave,Enghelab Sq, Tehran, Iran.
   [Bahrami, R.; Hashemi, D.] Shahid Beheshti Univ, Dept Microbiol & Microbial Biotech, Tehran, Iran.
   [Aziziraftar, Keshavarz S.] Pasteur Inst Iran, Dept Mycobacteriol & Pulm Res, Tehran, Iran.
RP Rahimi, P (corresponding author), Pasteur Inst Iran, Dept Hepatitis & AIDS, 12 Farvardin Ave,Enghelab Sq, Tehran, Iran.
EM pooneh5376@yahoo.com
CR Al-Tawfiq JA, 2014, INT J INFECT DIS, V20, P42, DOI 10.1016/j.ijid.2013.12.003
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2012, FAMILY CORONAVIRIDAE, P806, DOI [10.1016/B978-0-12-384684-6.00068-9., DOI 10.1016/B978-0-12-384684-6.00068-9]
   [Anonymous], 2020, REP WHO CHIN JOINT M
   [Anonymous], 2012, 1 GLOBAL ESTIMATES 2
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Breugelmans JG, 2004, EMERG INFECT DIS, V10, P1502, DOI 10.3201/eid1008.040093
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, DOI [10.1056/NEJ- Moa2001282., DOI 10.1056/NEJ-MOA2001282]
   Caroline AL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002790
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Cockrell AS, 2014, J VIROL, V88, P5195, DOI 10.1128/JVI.03764-13
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Coughlin MM, 2012, REV MED VIROL, V22, P2, DOI 10.1002/rmv.706
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drosten C, 2013, LANCET INFECT DIS, V13, P745, DOI 10.1016/S1473-3099(13)70154-3
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Earnest JT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006546
   Elshabrawy HA, 2014, J VIROL, V88, P4353, DOI 10.1128/JVI.03050-13
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Galvani AP, 2004, EMERG INFECT DIS, V10, P1351, DOI 10.3201/eid1007.040166
   Galvani AP, 2003, EMERG INFECT DIS, V9, P991
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao J, 2013, J VIROL, V87, P13134, DOI 10.1128/JVI.02433-13
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GHOSE TK, 1987, PURE APPL CHEM, V59, P257, DOI 10.1351/pac198759020257
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Huaxia, 2020, XINHUANET       0317
   Ishii K, 2009, MICROBIOL IMMUNOL, V53, P75, DOI 10.1111/j.1348-0421.2008.00097.x
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Jin ZN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068347
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kilpatrick AM, 2006, P ROY SOC B-BIOL SCI, V273, P2327, DOI 10.1098/rspb.2006.3575
   Kim UJ, 2016, ANTIVIR THER, V21, P455, DOI 10.3851/IMP3002
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2011, BIOESSAYS, V33, P789, DOI 10.1002/bies.201100128
   Klein SL, 2000, NEUROSCI BIOBEHAV R, V24, P627, DOI 10.1016/S0149-7634(00)00027-0
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu T., 2020, TRANSMISSION DYNAMIC, DOI [10.1101/2020.01.25.919787, DOI 10.1101/2020.01.25.919787]
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Matthews KL, 2014, J GEN VIROL, V95, P874, DOI 10.1099/vir.0.062059-0
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Mizumoto K, 2020, EMERG INFECT DIS, V26, P1251, DOI 10.3201/eid2606.200233
   Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009
   Poon TCW, 2004, CLIN CHEM, V50, P1452, DOI 10.1373/clinchem.2004.035352
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI 10.1517/14712590902763755 
   Rahimi P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142244
   Rahimi P, 2010, EMERG INFECT DIS, V16, P1946, DOI 10.3201/eid1612.100378
   Raj VS, 2014, J VIROL, V88, P1834, DOI 10.1128/JVI.02935-13
   Roberts A, 2006, J INFECT DIS, V193, P685, DOI 10.1086/500143
   Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004
   Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074
   Schmidt M, 2004, TRANSFUSION, V44, P470, DOI 10.1111/j.1537-2995.2004.03269.x
   See RH, 2006, J GEN VIROL, V87, P641, DOI 10.1099/vir.0.81579-0
   Shang GF, 2007, TRANSFUS APHER SCI, V37, P233, DOI 10.1016/j.transci.2007.09.004
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sherbini N, 2017, J EPIDEMIOL GLOB HEA, V7, P29, DOI 10.1016/j.jegh.2016.05.002
   Simani S, 2012, J CLIN VIROL, V54, P251, DOI 10.1016/j.jcv.2012.03.009
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Spanakis N, 2014, INT J ANTIMICROB AG, V44, P528, DOI 10.1016/j.ijantimicag.2014.07.026
   Subbaram Kannan, 2017, Hayati, V24, P53, DOI 10.1016/j.hjb.2017.08.001
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yao YF, 2014, J INFECT DIS, V209, P236, DOI 10.1093/infdis/jit590
   Yoon IK, 2019, LANCET INFECT DIS, V19, P924, DOI 10.1016/S1473-3099(19)30397-4
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JD, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00517
   Zumla A, 2019, LANCET INFECT DIS, V19, P1054, DOI 10.1016/S1473-3099(19)30477-3
NR 121
TC 0
Z9 0
U1 0
U2 0
PU COMENIUS UNIV
PI BRATISLAVA I
PA SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA
SN 0006-9248
EI 1336-0345
J9 BRATISL MED J
JI Bratisl. Med. J.
PY 2020
VL 121
IS 10
BP 733
EP 741
DI 10.4149/BLL_2020_120
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OA1LG
UT WOS:000577555500008
PM 32955906
OA Bronze
DA 2021-01-01
ER

PT J
AU Fernandes, DE
   Ferreira, PRA
   Kirsztajn, GM
AF Fernandes, Danilo Euclides
   Ferreira, Paulo Roberto Abrao
   Mastroianni Kirsztajn, Gianna
TI Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP
   prevent COVID-19-related symptoms?
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE 2019 novel coronavirus disease; flu-like; Influenza; Human; Pandemics;
   Pre-Exposure Prophylaxis (PrEP); Coronavirus; SARS-CoV-2; COVID-19
ID MEN
AB It has been speculated that some drugs can be used against SARS-CoV-2. As for antiretrovirals, the follow-up of pre-exposure prophylaxis (PrEP) users during the coronavirus disease 2019 (COVID-19) outbreak may help to understand the potential protective effect of PrEP against SARS-CoV-2. We aimed to identify associations between oral PrEP use and COVID-19-related symptoms self-reporting. Phone call interviews or digital investigation (through WhatsApp(R)or e-mail) about oral PrEP regular use, social distancing, exposure to suspected or confirmed cases of SARS-CoV-2 infection and COVID-19-related symptoms. Among 108 individuals, the majority were cisgender, white and gay men. Although most of the individuals engaged in social distancing (68.52%), they kept on taking PrEP (75.93%). Few people have had contact with suspected or confirmed cases of COVID-19 (12.04%), but some had COVID-19-related symptoms the month before the interview (27.78%) including rhinorrheoa (56.67%), cough (53.33%), asthaenia (50.00%) and headache (43.33%). Also, oral PrEP was associated with lower self-reporting COVID-19-symptoms (OR 0.26, 95% CI 0.07-0.96,P= 0.04;h= 0.92) even after controlling confounders as social distancing, age, body-mass index and morbidities . In our sample, the regular use of oral PrEP was associated with lower self-reporting of COVID-19-related symptoms during the outbreak in Sao Paulo, Brazil.
C1 [Fernandes, Danilo Euclides; Mastroianni Kirsztajn, Gianna] Univ Fed Sao Paulo UNIFESP, Dept Med Nephrol, Sao Paulo, Brazil.
   [Ferreira, Paulo Roberto Abrao] Univ Fed Sao Paulo, Dept Med Infectol, Sao Paulo, Brazil.
RP Fernandes, DE (corresponding author), Univ Fed Sao Paulo UNIFESP, Dept Med Nephrol, Sao Paulo, Brazil.
EM defernandes@unifesp.br
RI Fernandes, Danilo E/D-8267-2018; Abrao Ferreira, Paulo
   Roberto/A-5703-2016; Mastroianni Kirsztajn, Gianna/D-9596-2013
OI Fernandes, Danilo E/0000-0002-6324-1763; Abrao Ferreira, Paulo
   Roberto/0000-0003-4858-2778; Mastroianni Kirsztajn,
   Gianna/0000-0003-1317-4109
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2019/05266-5];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [001]
FX This study was supported by grant from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP 2019/05266-5) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) finance code 001.
CR [Anonymous], 2020, VIR
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Eakle R, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0408-3
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fernandes D, 2019, RENAL FUNCTION ASSES
   Ge HP, 2020, EUR J CLIN MICROBIOL, V39, P1011, DOI 10.1007/s10096-020-03874-z
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hayes A.F., 2018, INTRO MEDIATION MODE
   Luzi L, 2020, ACTA DIABETOL, V57, P759, DOI 10.1007/s00592-020-01522-8
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175
   Our World in Data, TOT CONF COVID 19 CA
   Rivierez I, 2018, AIDS CARE, V30, P48, DOI 10.1080/09540121.2018.1468014
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Vaira LA, 2020, LARYNGOSCOPE, V130, P1787, DOI 10.1002/lary.28692
   World Health Organization, 2012, GUID OR PREEXP PROPH
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e231
DI 10.1017/S0950268820002253
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NZ1NG
UT WOS:000576857500001
PM 32981567
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, Z
   Hua, S
AF Chen, Zhi
   Hua, Shan
TI Transcription factor-mediated signaling pathways' contribution to the
   pathology of acute lung injury and acute respiratory distress syndrome
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Inflammation; ALI; NF-kappa B; AP-1; Wnt/beta-catenin; transcriptional
   regulation
ID NF-KAPPA-B; INDUCED INFLAMMATION; WNT/BETA-CATENIN; PATHOGENESIS;
   EXPRESSION; INHIBITION; ACTIVATION; EPITHELIUM; CYTOKINES; RECEPTOR
AB The 2019 novel coronavirus (2019-nCoV) is still spreading rapidly around the world, and one cause of lethality for patients infected with 2019-nCoV is acute respiratory distress syndrome (ARDS). ARDS is a severe syndrome of acute lung injury (ALI) that is predominantly triggered by inflammation and results in a sudden loss of, or damage to, kidney function. Emerging studies reveal that multiple transcription factor-associated signaling pathways are activated in the pathology of ALI/ARDS. Of these pathways, the activation of NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells), AP-1 (activator protein 1), IRFs (interferon regulatory factors), STATs (signal transducer and activator of transcription), Wnt/beta-catenin-TCF/LEF (T-cell factor/lymphoid enhancer-binding factor), and CtBP2 (C-Terminal binding protein 2)-associated transcriptional complex contributes to ALI/ARDS pathology through diverse mechanisms, such as inducing proinflammatory cytokine levels and mediating macrophage polarization. In this review, we present an updated summary of the mechanisms underlying these signaling activations and regulations, as well as their contribution to the pathogenesis of ALI/ARDS. We aim to develop a better understanding of how ALI/ARDS occurs and improve ALI/ARDS therapy.
C1 [Chen, Zhi] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Crit Care Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Chen, Zhi] Tongji Univ, Sch Med, Tongji Hosp, Dept Pulm & Crit Care Med, Shanghai 200065, Peoples R China.
   [Hua, Shan] Nanchang Univ, Dept Ultrasonog, Jiangxi Prov Peoples Hosp, Nanchang 330006, Jiangxi, Peoples R China.
RP Hua, S (corresponding author), Nanchang Univ, Dept Ultrasonog, Jiangxi Prov Peoples Hosp, Nanchang 330006, Jiangxi, Peoples R China.
EM shan.hua20@gmail.com
FU Key Research and Development Project of Jiangxi Province
   [20202BB-GL73059]
FX This study was supported by the Key Research and Development Project of
   Jiangxi Province (Social Development Field, No. 20202BB-GL73059).
CR Aggarwal NR, 2013, AM J RESP CELL MOL, V48, P635, DOI 10.1165/rcmb.2012-0351OC
   Bellingan GJ, 2002, THORAX, V57, P540, DOI 10.1136/thorax.57.6.540
   Bhatia M, 2012, AM J RESP CELL MOL, V46, P566, DOI 10.1165/rcmb.2011-0392TR
   Blevins MA, 2017, MOL CANCER THER, V16, P981, DOI 10.1158/1535-7163.MCT-16-0592
   Cai SX, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0060-y
   CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768
   Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200
   Chen Z, 2019, INT J BIOL SCI, V15, P2627, DOI 10.7150/ijbs.37133
   Cheng L, 2018, BIOCHEM BIOPH RES CO, V495, P1890, DOI 10.1016/j.bbrc.2017.12.058
   Coenen T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4250
   Craig VJ, 2015, AM J RESP CELL MOL, V53, P585, DOI 10.1165/rcmb.2015-0020TR
   Crimi Ettore, 2004, Best Pract Res Clin Anaesthesiol, V18, P477, DOI 10.1016/j.bpa.2003.12.007
   Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010
   Dada L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030448
   Darmon M, 2014, CLIN J AM SOC NEPHRO, V9, P1347, DOI 10.2215/CJN.08300813
   Ding XB, 2017, SCI REP-UK, V7, DOI 10.1038/srep34278
   Dotsch A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061266
   Donahoe Michael, 2011, Pulm Circ, V1, P192, DOI 10.4103/2045-8932.83454
   Driessler F, 2004, CLIN EXP IMMUNOL, V135, P64, DOI 10.1111/j.1365-2249.2004.02342.x
   Eckle T, 2014, J IMMUNOL, V192, P1249, DOI 10.4049/jimmunol.1100593
   Fan EKY, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0756-5
   Gao Y, 2017, J IMMUNOL, V199, P2043, DOI 10.4049/jimmunol.1700315
   Goodman RB, 2003, CYTOKINE GROWTH F R, V14, P523, DOI 10.1016/S1359-6101(03)00059-5
   Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Guo RF, 2002, AM J PATHOL, V161, P275, DOI 10.1016/S0002-9440(10)64179-X
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Hoegl S, 2016, CURR OPIN ANESTHESIO, V29, P94, DOI 10.1097/ACO.0000000000000283
   Huang JJ, 2019, MOL MED REP, V20, P3424, DOI 10.3892/mmr.2019.10575
   Huang XF, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1264913
   Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775
   Jones HD, 2014, AM J RESP CELL MOL, V50, P270, DOI 10.1165/rcmb.2013-0087OC
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Li H, 2020, INT J BIOL SCI, V16, P1107, DOI 10.7150/ijbs.42109
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Liu WC, 2009, J BIOL CHEM, V284, P24006, DOI 10.1074/jbc.M109.025528
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   McClendon J, 2017, AM J PATHOL, V187, P1772, DOI 10.1016/j.ajpath.2017.04.012
   Moparthi L, 2019, DIFFERENTIATION, V108, P24, DOI 10.1016/j.diff.2019.01.002
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI [10.1586/ers.10.92, 10.1586/ERS.10.92]
   Platanitis E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02542
   Pooladanda V, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1247-9
   Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168
   Rajaee A, 2018, SURG INFECT, V19, P107, DOI 10.1089/sur.2017.264
   Rajasekaran S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041611
   Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533
   Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161
   Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384
   Sun J, 2005, AM J PHYSIOL-GASTR L, V289, pG129, DOI 10.1152/ajpgi.00515.2004
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Suo T, 2018, BIOMED PHARMACOTHER, V108, P783, DOI 10.1016/j.biopha.2018.09.046
   Suresh MV, 2014, CRIT CARE MED, V42, pE642, DOI 10.1097/CCM.0000000000000488
   Tang B, 2019, INT J CLIN EXP PATHO, V12, P3290
   Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453
   Vaz M, 2012, AM J RESP CELL MOL, V46, P55, DOI 10.1165/rcmb.2011-0169OC
   Villar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023914
   Vohwinkel CU, 2015, J APPL PHYSIOL, V119, P1157, DOI 10.1152/japplphysiol.00226.2015
   Wang AY, 2013, CELL MICROBIOL, V15, P779, DOI 10.1111/cmi.12071
   Wang L, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00593-7
   Wong JJM, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.09.28
   YAMAMOTO R, 1990, J IMMUNOL, V144, P1808
   Yang S. Y., 2017, INT J ADV MANUF TECH, V8, P1
   Yang Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.140
   Yuan XY, 2018, ANESTH ANALG, V126, P308, DOI 10.1213/ANE.0000000000002288
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhou SJ, 2018, EXP THER MED, V15, P3376, DOI 10.3892/etm.2018.5815
NR 74
TC 0
Z9 0
U1 2
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 9
BP 5608
EP 5618
PG 11
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA NZ0TG
UT WOS:000576805000010
PM 33042442
DA 2021-01-01
ER

PT J
AU Cluzel, N
   Lambert, A
   Maday, Y
   Turinici, G
   Danchin, A
AF Cluzel, Nicolas
   Lambert, Amaury
   Maday, Yvon
   Turinici, Gabriel
   Danchin, Antoine
TI Biochemical and statistical lessons from the evolution of the SARS-CoV-2
   virus : paths for novel antiviral warfare
SO COMPTES RENDUS BIOLOGIES
LA French
DT Article
DE ddhCTP; D614G; F1757L; L37F; TN93; tRNA nucleotidyltransferase;
   Non-homothetic growth
ID HUMAN CORONAVIRUS 229E; SARS-COV; PROTEIN; REGION
AB In the fight against the spread of COVID-19 the emphasis is on vaccination or on reactivating existing drugs used for other purposes. The tight links that necessarily exist between the virus as it multiplies and the metabolism of its host are systematically ignored. Here we show that the metabolism of all cells is coordinated by the availability of a core building block of the cell's genome, cytidine triphosphate (CTP). This metabolite is also the key to the synthesis of the viral envelope and to the translation of its genome into proteins. This unique role explains why evolution has led to the early emergence in animals of an antiviral immunity enzyme, viperin, that synthesizes a toxic analogue of CTP. The constraints arising from this dependency guide the evolution of the virus. With this in mind, we explored the real-time experiment taking place before our eyes using probabilistic modelling approaches to the molecular evolution of the virus. We have thus followed, almost on a daily basis, the evolution of the composition of the viral genome to link it to the progeny produced over time, particularly in the form of blooms that sparked a firework of viral mutations. Some of those certainly increase the propagation of the virus. This led us to make out the critical role in this evolution of several proteins of the virus, such as its nucleocapsid N, and more generally to begin to understand how the virus ties up the host metabolism to its own benefit. A way for the virus to escape CTP-dependent control in cells would be to infect cells that are not expected to grow, such as neurons. This may account for unexpected body sites of viral development in the present epidemic.
C1 [Cluzel, Nicolas; Maday, Yvon] Tremplin Carnot SMILES, 4 Pl Jussieu, F-75005 Paris, France.
   [Lambert, Amaury] Univ Paris, Sorbonne Univ, CNRS, Lab Probabilites Stat & Modelisat LPSM,UMR8001, 4 Pl Jussieu, F-75005 Paris, France.
   [Lambert, Amaury] PSL Res Univ, CNRS, INSERM,Coll France, Ctr Interdisciplinaire Rech Biol CIRB,U1050,UMR72, 11 Pl Marcelin Berthelot, F-75005 Paris, France.
   [Maday, Yvon] Sorbonne Univ, F-75005 Paris, France.
   [Maday, Yvon] Univ Paris, CNRS, Lab Jacques Louis Lions LJLL, F-75005 Paris, France.
   [Turinici, Gabriel] Univ Paris Dauphine PSL, CEREMADE, Paris, France.
   [Danchin, Antoine] Inst Cochin, Stellate Therapeut, Kodikos Labs, 24 Rue Faubourg St Jacques, F-75014 Paris, France.
   [Danchin, Antoine] Univ Hong Kong, Li KaShing Fac Med, Sch Biomed Sci, Pokfulam, 21 Sassoon Rd, Hong Kong, Peoples R China.
RP Danchin, A (corresponding author), Inst Cochin, Stellate Therapeut, Kodikos Labs, 24 Rue Faubourg St Jacques, F-75014 Paris, France.; Danchin, A (corresponding author), Univ Hong Kong, Li KaShing Fac Med, Sch Biomed Sci, Pokfulam, 21 Sassoon Rd, Hong Kong, Peoples R China.
EM nicolas.cluzel@upmc.fr; amaury.lambert@upmc.fr; maday@ann.jussieu.fr;
   turinici@ceremade.dauphine.fr; antoine.danchin@normalesup.org
FU Centre Interdisciplinaire de Recherche en Biologie (CIRB, College de
   France); Stellate Therapeutics
FX AL would like to thank the Centre Interdisciplinaire de Recherche en
   Biologie (CIRB, College de France) for its funding, as well as the
   members of the SMILE (Stochastic Models for the Inference of Life
   Evolution) team of the CIRB for many fruitful discussions on the
   modelling of the COVID-19 epidemic. AD thanks Stellate Therapeutics for
   the support of his laboratory.
CR Addetia A, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104523
   Alonso-Carrera J, 2019, ENVIRON RESOUR ECON, V74, P1011, DOI 10.1007/s10640-019-00357-4
   Amann RI, 2019, SCIENCE, V363, P350, DOI 10.1126/science.aaw1280
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Armengaud J, 2020, ENVIRON MICROBIOL, V22, P1997, DOI 10.1111/1462-2920.15039
   Benvenuto D, 2020, J INFECTION, V81, pE24, DOI 10.1016/j.jinf.2020.03.058
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Chen SY, 2020, J INFECT DIS, V222, P223, DOI 10.1093/infdis/jiaa278
   Cong X, 2019, J VIROL, V93, DOI 10.1128/JVI.00723-19
   Corman VM, 2015, J VIROL, V89, P11858, DOI 10.1128/JVI.01755-15
   Danchin A, 2020, ENVIRON MICROBIOL, V22, P2001, DOI 10.1111/1462-2920.15053
   Danchin A, 2020, ENVIRON MICROBIOL, V22, P1977, DOI 10.1111/1462-2920.15025
   Daniloski Z., 2020, BIORXIV, DOI [10.1101/2020.06.14.151357, DOI 10.1101/2020.06.14.151357.]
   Di Giorgio S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5813
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Fisher R. A., 1930, GENETICAL THEORY OFN
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Grosjean H, 2010, FEBS LETT, V584, P252, DOI 10.1016/j.febslet.2009.11.052
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hagemeijer MC, 2014, VIROLOGY, V458, P125, DOI 10.1016/j.virol.2014.04.027
   Iserman Christiane, 2020, bioRxiv, DOI 10.1101/2020.06.11.147199
   Issa E, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00266-20
   Ivanov KA, 2004, J VIROL, V78, P7833, DOI 10.1128/JVI.78.14.7833-7838.2004
   Karsch-Mizrachi I, 2018, NUCLEIC ACIDS RES, V46, pD48, DOI 10.1093/nar/gkx1097
   Kim JH, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00101
   Laha S, 2020, INFECT GENET EVOL, V85, DOI 10.1016/j.meegid.2020.104445
   Lai AL, 2020, J MED VIROL, V92, P675, DOI 10.1002/jmv.25723
   Letko M, 2020, NAT REV MICROBIOL, V18, P461, DOI 10.1038/s41579-020-0394-z
   Liu S., 2020, HEALTH INFO LIBR J
   Lorenzo-Redondo R., 2020, UNIQUE CLADE SARS CO, DOI [10.1101/2020.05.19.20107144, DOI 10.1101/2020.05.19.20107144.]
   Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015
   Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418
   Nelson CA, 2005, STRUCTURE, V13, P75, DOI 10.1016/j.str.2004.10.010
   Ou Z., 2020, BIORXIV, DOI [10.1101/2020.06.20.162933, DOI 10.1101/2020.06.20.162933.]
   Posthuma CC, 2017, VIRUS RES, V234, P58, DOI 10.1016/j.virusres.2017.01.023
   Rivera-Serrano E. E., 2020, ANN REV VIROL, V7
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Rout SS, 2020, J BIOL CHEM, V295, P6926, DOI 10.1074/jbc.RA119.011918
   Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042
   Schaecher SR, 2007, J VIROL, V81, P718, DOI 10.1128/JVI.01691-06
   Selvaraj C, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1778535
   Short B., 2013, J CELL BIOL, V203, P552
   Shridas P, 2006, J BIOL CHEM, V281, P31696, DOI 10.1074/jbc.M604087200
   Simmonds P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00408-20.
   Smith KA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00068
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665
   Ugurel OM, 2020, TURK J BIOL, V44, P157, DOI 10.3906/biy-2005-111
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wellner K, 2018, BBA-GENE REGUL MECH, V1861, P433, DOI 10.1016/j.bbagrm.2018.01.012
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Yamada KD, 2016, BIOINFORMATICS, V32, P3246, DOI 10.1093/bioinformatics/btw412
   Yang XM, 2020, EMERG MICROBES INFEC, V9, P1287, DOI 10.1080/22221751.2020.1773745
   Yang Yiyan, 2020, bioRxiv, DOI 10.1101/2020.06.21.163410
NR 56
TC 0
Z9 0
U1 0
U2 0
PU centre Mersenne pour ldition scientifique ouverte
PI Grenolde Cedex 9
PA Cellule Mathdoc Batiment Ceta, 150 Rue de la Chimie CS 40700, Grenolde
   Cedex 9, FRANCE
SN 1631-0691
EI 1768-3238
J9 CR BIOL
JI C. R. Biol.
PY 2020
VL 343
IS 2
BP 177
EP 209
DI 10.5802/crbiol.16
PG 33
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA NY3PU
UT WOS:000576306700007
PM 33108121
OA Bronze
DA 2021-01-01
ER

PT J
AU Allegra, A
   Tonacci, A
   Pioggia, G
   Musolino, C
   Gangemi, S
AF Allegra, A.
   Tonacci, A.
   Pioggia, G.
   Musolino, C.
   Gangemi, S.
TI Vitamin deficiency as risk factor for SARS-CoV-2 infection: correlation
   with susceptibility and prognosis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-CoV-2 infection; COVID 19; Vitamin D; Vitamin C; Vitamin B; Vitamin
   A; Supplementation; Prognosis; Susceptibility; Clinical trials
ID HUMAN-IMMUNODEFICIENCY-VIRUS; D-BINDING PROTEIN; RETINOIC ACID;
   ASCORBIC-ACID; IN-VITRO; LUNG INFLAMMATION; CELLS; REPLICATION;
   MACROPHAGES; SUPPRESSION
AB OBJECTIVE: In 2019, an infection provoked by SARS-CoV-2 virus arose in Wuhan, China. Currently, there is still no definite and efficacious therapy for SARS-CoV-2 infection. Moreover, our understanding of the physiopathology of the infection, and risk elements for severity and mortality, is incomplete.
   PATIENTS AND METHODS: One largely neglected element that could affect prognosis of SARS-CoV-2 infection is the vitamin status of population. The purpose of this review is to evaluate whether a vitamin insufficiency could provoke an augmented risk of SARS-CoV-2 infection or the appearance of major complications. In particular, we evaluated the presence of studies related to the state and effects of vitamin D, C, B, and A in subjects with SARS-CoV-2 disease.
   RESULTS: Although, actually, the interest in a possible use for vitamin supplementation in SARS-CoV-2 patients is essentially based on indirect data, we tried to examine the evidence about a favorable effect of vitamin supplementation in the therapy of the infection and its complications.
   CONCLUSIONS: Supplements with vitamin A. B, C, D. and E could represent an inexpensive and sufficiently safe approach, and a useful therapeutic complement. However, solid clinical research data are expected to support such claim.
C1 [Allegra, A.; Musolino, C.] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Div Hematol, Messina, Italy.
   [Allegra, A.] AOU Policlin G Martino, COVID Ctr, Messina, Italy.
   [Tonacci, A.] Natl Res Council Italy, IFC, CNR, Clin Physiol Inst, Pisa, Italy.
   [Pioggia, G.] Natl Res Council Italy CNR, Inst Biomed Res & Innovat IRIB, Messina, Italy.
   [Gangemi, S.] Univ Messina, Sch & Operat Unit Allergy & Clin Immunol, Dept Clin & Expt Med, Messina, Italy.
RP Allegra, A (corresponding author), Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano B, Div Hematol, Messina, Italy.; Allegra, A (corresponding author), AOU Policlin G Martino, COVID Ctr, Messina, Italy.
EM aallegra@unime.it
CR Adams JS, 2009, J IMMUNOL, V182, P4289, DOI 10.4049/jimmunol.0803736
   Adams KK, 2020, ANN PHARMACOTHER, V54, P820, DOI 10.1177/1060028020928052
   Agier J, 2015, CENT EUR J IMMUNOL, V40, P225, DOI 10.5114/ceji.2015.51359
   Alberca RW, 2020, CRIT REV FOOD SCI, DOI 10.1080/10408398.2020.1775546
   Ali RM, 2018, EUR J PHARMACOL, V831, P68, DOI 10.1016/j.ejphar.2018.04.032
   Allegra A, 2020, ANN HEMATOL, V99, P1953, DOI 10.1007/s00277-020-04182-4
   Allegra A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134782
   Allegra A, 2020, CANCERS, V12, DOI 10.3390/cancers12061581
   Allegra A, 2018, TOXICOL IN VITRO, V47, P186, DOI 10.1016/j.tiv.2017.12.001
   Alzaman NS, 2016, AM J CLIN NUTR, V104, P205, DOI 10.3945/ajcn.115.129478
   Angulo A, 1998, J VIROL, V72, P4589, DOI 10.1128/JVI.72.6.4589-4600.1998
   Aygun H, 2020, N-S ARCH PHARMACOL, P1
   BANIC S, 1975, NATURE, V258, P153, DOI 10.1038/258153a0
   Beijer MR, 2013, EUR J IMMUNOL, V43, P1608, DOI 10.1002/eji.201343325
   Bendib I, 2019, ANESTHESIOLOGY, V130, P581, DOI 10.1097/ALN.0000000000002619
   Boretti A, 2020, PHARMANUTRITION, V12, DOI 10.1016/j.phanu.2020.100190
   Boucher BJ, 2012, AGING DIS, V3, P313
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211
   Carr AC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1891-y
   Chakhtoura M, 2020, METABOLISM, V109, DOI 10.1016/j.metabol.2020.154276
   Chang HK, 2015, J INTERF CYTOK RES, V35, P200, DOI 10.1089/jir.2014.0098
   Chen KH, 2020, J CHIN MED ASSOC, DOI [10.1097/JC- MA.0000000000000375., DOI 10.1097/JC-MA.0000000000000375]
   Chen SY, 2014, BRIT J NUTR, V111, P1586, DOI 10.1017/S0007114513004133
   Cheng R., 2020, HOSP TREATMENT SERIO
   CINATL J, 1995, ANTIVIR RES, V27, P405, DOI 10.1016/0166-3542(95)00024-G
   Biancatelli RMLC, 2020, EXPERT REV ANTI-INFE, V18, P99, DOI 10.1080/14787210.2020.1706483
   da Silva MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205535
   Darling AL, 2020, VITAMIN D STATUS BOD
   De Smet D, 2020, VITAMIN D DEFICIENCY, DOI [DOI 10.1101/2020.05.01.20079376, 10.1101/2020.05.01.20079376]
   Dey S, 2018, MICROB PATHOGENESIS, V115, P239, DOI 10.1016/j.micpath.2017.12.048
   Dhillon P, 2020, FEBS J, V287, P3612, DOI 10.1111/febs.15442
   Du L, 2012, AM J RESP CELL MOL, V47, P597, DOI 10.1165/rcmb.2012-0094OC
   Duriancik DM, 2010, CELL IMMUNOL, V265, P156, DOI 10.1016/j.cellimm.2010.08.006
   Ettari R, 2019, NAT PROD RES, V33, P3577, DOI 10.1080/14786419.2018.1483927
   Facchiano A, 2020, AM J PHYSIOL-ENDOC M, V318, pE838, DOI 10.1152/ajpendo.00185.2020
   Forrest KYZ, 2011, NUTR RES, V31, P48, DOI 10.1016/j.nutres.2010.12.001
   Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
   Fujii T, 2020, JAMA-J AM MED ASSOC, V323, P423, DOI 10.1001/jama.2019.22176
   Garg M, 2020, ALIMENT PHARM THER, V51, P1438, DOI 10.1111/apt.15796
   Garg M, 2018, CLIN NUTR, V37, P1375, DOI 10.1016/j.clnu.2017.06.011
   Ge LY, 2014, IMMUNOBIOLOGY, V219, P198, DOI 10.1016/j.imbio.2013.10.001
   Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gysin DV, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0162996, 1]
   Harakeh S, 1997, AIDS RES HUM RETROV, V13, P235, DOI 10.1089/aid.1997.13.235
   HARAKEH S, 1990, P NATL ACAD SCI USA, V87, P7245, DOI 10.1073/pnas.87.18.7245
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Hemila H, 2013, COCHRANE DB SYST REV, V1
   Hemila H, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-0432-y
   Hemila H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040708
   Herr C, 2007, EXPERT OPIN BIOL TH, V7, P1449, DOI 10.1517/14712598.7.9.1449
   Herrick KA, 2019, AM J CLIN NUTR, V110, P150, DOI 10.1093/ajcn/nqz037
   Hiemstra IH, 2014, IMMUNOLOGY, V142, P269, DOI 10.1111/imm.12251
   Hong M, 2020, MATERN CHILD NUTR, V16, DOI 10.1111/mcn.12987
   Huang FM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008341
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Islam MA, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102392
   Jimenez-Sousa MA, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030311
   Jolliffe DA, 2018, BRIT J NUTR, V120, P891, DOI 10.1017/S000711451800209X
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Karayigit MO, 2020, BIOTECH HISTOCHEM, V95, P584, DOI [10.1017/S0007114520001749, 10.1080/10520295.2020.1743359]
   Kashiouris MG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020292
   Kast JI, 2017, CLIN EXP IMMUNOL, V190, P351, DOI 10.1111/cei.13042
   KATAOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1213, DOI 10.1136/jnnp.56.11.1213
   Kew RR, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00470
   Kim Yejin, 2013, Immune Netw, V13, P70, DOI 10.4110/in.2013.13.2.70
   Klebanoff CA, 2013, J EXP MED, V210, P1961, DOI 10.1084/jem.20122508
   KLEIN M, 1945, SCIENCE, V101, P587, DOI 10.1126/science.101.2632.587
   Kow CS, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061626
   Laaksi I, 2012, P NUTR SOC, V71, P90, DOI 10.1017/S0029665111003351
   Lallement Aloys, 2015, J Med Case Rep, V9, P1, DOI 10.1186/1752-1947-9-1
   Lanham-New Susan A, 2020, BMJ Nutr Prev Health, V3, P106, DOI 10.1136/bmjnph-2020-000089
   LAU FH, 2020, VITAMIN D INSUFFICIE, DOI [10.1101/2020.04.24.20075838, DOI 10.1101/2020.04.24.20075838.]
   Lee H, 2016, SCI REP-UK, V6, DOI 10.1038/srep25835
   LEIBOVITZ B, 1982, ADV EXP MED BIOL, V135, P1
   Lin M, 2016, MOL BIOL REP, V43, P397, DOI 10.1007/s11033-016-3971-5
   Lips P, 2019, EUR J ENDOCRINOL, V180, pP23, DOI 10.1530/EJE-18-0736
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Maes K, 2020, CALCIFIED TISSUE INT, V106, P76, DOI 10.1007/s00223-019-00591-4
   Mansueto P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/735615
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   May JM, 2013, ANTIOXID REDOX SIGN, V19, P2068, DOI 10.1089/ars.2013.5205
   Meehan Meghan, 2014, J Aging Gerontol, V2, P60
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Moens B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001729
   Murdaca G, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102350
   NATIONAL INSTITUTES OF HEALTH OFFICE OF DIETARY SUPPLEMENTS, VIT C
   PAULING L, 1971, P NATL ACAD SCI USA, V68, P2678, DOI 10.1073/pnas.68.11.2678
   Raverdeau M, 2014, J IMMUNOL, V192, P2953, DOI 10.4049/jimmunol.1303245
   RAWAL BD, 1995, BIOLOGICALS, V23, P75, DOI 10.1016/1045-1056(95)90016-0
   Rondanelli M, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/5813095
   Ross AC, 1996, FASEB J, V10, P979
   Rossi GA, 2020, PEDIATR PULM, V55, P1061, DOI 10.1002/ppul.24699
   Sassi F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111656
   Schwalfenberg GK, 2011, MOL NUTR FOOD RES, V55, P96, DOI 10.1002/mnfr.201000174
   Shrestha S, 2017, IMMUNOL LETT, V182, P24, DOI 10.1016/j.imlet.2017.01.001
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Speeckaert MM, 2020, AGING CLIN EXP RES, V32, P1207, DOI 10.1007/s40520-020-01607-y
   Speeckaert MM, 2014, ADV CLIN CHEM, V63, P1, DOI 10.1016/B978-0-12-800094-6.00001-7
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   Tan SHS, 2020, INT ORTHOP, V44, P1599, DOI 10.1007/s00264-020-04643-5
   Timoneda J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091132
   Trasino SE, 2020, CLIN EXP PHARMACOL P, V47, P1765, DOI 10.1111/1440-1681.13354
   Trottier C, 2008, ANTIVIR RES, V80, P45, DOI 10.1016/j.antiviral.2008.04.003
   Tsujino I, 2019, J CLIN BIOCHEM NUTR, V65, P245, DOI 10.3164/jcbn.19-48
   Uesato S, 2001, CANCER LETT, V166, P143, DOI 10.1016/S0304-3835(01)00444-X
   Valero N, 2015, BRAIN RES, V1622, P368, DOI 10.1016/j.brainres.2015.06.034
   Weir EK, 2020, CLIN MED, V20, pE107, DOI 10.7861/clinmed.2020-0301
   Wen YY, 2017, DESTECH TRANS COMP, P201
   WHITE LA, 1986, J CLIN MICROBIOL, V24, P527, DOI 10.1128/JCM.24.4.527-531.1986
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu J, 2017, MOL MED REP, V16, P7432, DOI 10.3892/mmr.2017.7546
   Xu LH, 2018, INT J CONCR STRUCT M, V12, DOI 10.1186/s40069-018-0302-3
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yuan SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08015-x
   Zhang L, 2020, NAT REV IMMUNOL, V92, P479
   Zhou YF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017252
NR 121
TC 1
Z9 1
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 18
BP 9721
EP 9738
DI 10.26355/eurrev_202009_23064
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY6IW
UT WOS:000576491600064
PM 33015818
DA 2021-01-01
ER

PT J
AU Gomez-Moreno, G
AF Gomez-Moreno, G.
TI Remdesivir-COVID-19: drug interactions in dentistry
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Remdeslyir; COVID-19; Drug interactions; Dentistry; Antibiotics;
   Antifungals; Non-steroidal anti-inflammatories (NAIDS); Acetaminophen
ID COVID-19
AB OBJECTIVE: Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases. It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5). We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19.
   MATERIALS AND METHODS: A literature review was conducted to identify potential drug interactions between remdesivir (used in the treatment of COVID-19) and drugs prescribed in dentistry. The search was made in the databases PubMed and MEDLINE and official web sites using key terms remdesivir, drug interactions and dentistry for articles published up to 31st July 2020.
   RESULTS: According to the articles reviewed, a total of 279 drugs interact with Remdesivir. Two major interactions have been reported, 277 moderate drug interactions, and one with alcohol/food. The drug interactions involving drugs prescribed in dentistry are all moderate drug interactions and are (according to drug group): (1) antibiotics: azithromycin, clavulanate, doxycycline, erythromycin, levofloxacin; (2) antifungals: clotrimazole, fluconazole, itraconazole, ketoconazole; (3) non-steroidal anti-inflammatories (NAIDS): celecoxib diclofenac, etodolac, flurbiprofen, ibuprofen, ketoprofen, ketorolac, mefenamic acid, naproxen, piroxicam.
   CONCLUSIONS: It is clinically necessary for oral health professionals to be aware of possible drug interactions that may occur between remdesivir and drugs commonly prescribed in dentistry in order to prevent adverse reactions that may even endanger the life of a patient with COVID-19.
C1 [Gomez-Moreno, G.] Univ Granada, Sch Dent, Dept Med Compromised Patients Dent, Granada, Spain.
RP Gomez-Moreno, G (corresponding author), Univ Granada, Sch Dent, Dept Med Compromised Patients Dent, Granada, Spain.
EM ggomez@ugr.es
CR Agencia Espanola De Medicamentos Y Productos Sanitarios (AEMPS), REC TRAT CON REMD PA
   [Anonymous], HYDR REMD COMB DANG
   CDC, COR DIS 2019 COVID 1
   Chen J, 2020, EUR REV MED PHARMACO, V24, P5176, DOI 10.26355/eurrev_202005_21213
   Dziedzic A, 2020, ORAL DIS, DOI [10.1111/odi.13359, DOI 10.1111/ODI.13359.DOI:10.1111/ODI.13359]
   European Medicines Agency, INT NONPR NAM REMD P
   Forouzesh M, 2020, EUR REV MED PHARMACO, V24, P4607, DOI 10.26355/eurrev_202004_21047
   Gomez-Moreno G, 2008, MED ORAL PATOL ORAL, V13, pE235
   Gomez-Moreno G, 2009, MED ORAL PATOL ORAL, V14, pE20
   Gomez-Moreno G, 2009, MED ORAL PATOL ORAL, V14, pE81
   Gomez-Moreno G, 2009, MED ORAL PATOL ORAL, V14, pE123
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Herrera D, 2020, CLIN ORAL INVEST, V24, P2925, DOI 10.1007/s00784-020-03413-2
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Li ZY, 2020, DRUG DISCOV THER, V14, P73, DOI 10.5582/ddt.2020.01015
   National Institutes of Health, COVID 19 TREATM GUID
   US Food And Drug Administration, FACT SHEET PAT PAR C
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 20
TC 0
Z9 0
U1 3
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 18
BP 9739
EP 9743
DI 10.26355/eurrev_202009_23065
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY6IW
UT WOS:000576491600065
PM 33015819
DA 2021-01-01
ER

PT J
AU Elmors, R
AF Elmors, R.
TI The therapeutic potential of targeting ACE2 in COVID-19
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronaviridae; ACE 2; Peptidyl-dipeptidase A; COVID-19
ID SARS-COV; SPIKE PROTEIN; PEPTIDES; RECEPTOR; DOMAIN; ENTRY; CELLS
AB OBJECTIVE: ACE2 long served as the human gateway for multiple coronaviruses, including the currently pandemic SARS-CoV-2. This mini-review explores the potential of targeting ACE2 in blocking viral penetrance.
   MATERIALS AND METHODS: PubMed search was conducted using the terms: "coronaviridae", "peptidyl-dipeptidase A", "ACE2", "SARS", and "SARS-CoV-2". References of relevant articles were further screened by the author.
   RESULTS: Four main methods of blocking ACE2-mediated viral penetrance were identified: receptor blockage, receptor decoying, receptor shedding, and co-receptor inhibition.
   CONCLUSIONS: Drugs that inhibit viral binding to ACE2 present a strong choice for the current, and if necessary, future outbreaks. Further research is needed to establish the clinical and pharmacological aspects of the identified candidate molecules.
C1 [Elmors, R.] Mansoura Univ, Fac Med, Mansoura, Egypt.
RP Elmors, R (corresponding author), Mansoura Univ, Fac Med, Mansoura, Egypt.
EM ramiamjad1@gmail.com
OI Elmorsi, Rami/0000-0002-7909-258X
CR Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emori Y, 2005, J GASTROEN HEPATOL, V20, P895, DOI 10.1111/j.1400-1746.2005.03826.x
   Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Lu W, 2005, FEBS LETT, V579, P2130, DOI 10.1016/j.febslet.2005.02.070
   Marchesini N, 2005, J BIOL CHEM, V280, P36841, DOI 10.1074/jbc.M507727200
   Mustafa S, 2018, J INFECT PUBLIC HEAL, V11, P9, DOI 10.1016/j.jiph.2017.08.009
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005
   Sainz B, 2006, VIRUS RES, V120, P146, DOI 10.1016/j.virusres.2006.03.001
   Struck AW, 2012, ANTIVIR RES, V94, P288, DOI 10.1016/j.antiviral.2011.12.012
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200
   Whitton B, 2018, CANCER MED-US, V7, P3800, DOI 10.1002/cam4.1594
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 18
TC 0
Z9 0
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 18
BP 9744
EP 9747
DI 10.26355/eurrev_202009_23067
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY6IW
UT WOS:000576491600066
PM 33015820
DA 2021-01-01
ER

PT J
AU Huang, Q
   Hu, S
   Ran, FM
   Liang, TJ
   Wang, HX
   Chen, CC
   Zhang, J
   Ou, WL
   Dong, S
   Cai, Q
   Luo, CG
   Qian, Y
AF Huang, Q.
   Hu, S.
   Ran, F-M
   Liang, T-J
   Wang, H-X
   Chen, C-C
   Zhang, J.
   Ou, W-L
   Dong, S.
   Cai, Q.
   Luo, C-G
   Qian, Y.
TI Asymptomatic COVID-19 infection in patients with cancer at a
   cancer-specialized hospital in Wuhan, China Preliminary results
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Asymptomatic; Cancer
ID MORTALITY
AB OBJECTIVE: Patients with cancer are usually immunosuppressive and susceptible to COVID-19 infection. Asymptomatic COVID-19 cases are infective and cannot be identified by symptom -based screening. There is an urgent need to control virus spread by asymptomatic carriers at cancer centres. We aim to describe the characteristics, screening methods, and outcomes of cancer patients with asymptomatic COVID-19 infection and to further explore anti -tumour treatment for this population.
   PATIENTS AND METHODS: We reviewed patients with cancer who were admitted to Hubei Cancer Hospital in Wuhan from February 1, 2020, to April 4, 2020. We collected demographic data, laboratory findings, treatment information, nucleic acid and serum test results, chest computed tomography (CT) information and survival status of cancer patients diagnosed with asymptomatic COVID-19 infection.
   RESULTS: A total of 16 cancer patients with asymptomatic COVID-19 infection were confirmed. The most common cancer type was breast cancer. The blood cell counts of most patients were in the normal range. Lymphocytes of 100% of asymptomatic carriers were in the normal range. Thirteen (81.3%) patients were positive for virus-specific IgM antibodies, and three (18.8%) were positive by PCR; only one (6.3%) patient showed novel coronavirus pneumonia features on CT. Three (18.3%) patients died, and the cause of death was considered malignancy caused by delaying anti -tumour treatment.
   CONCLUSIONS: Our study shows that the lymphocytes of 100% of asymptomatic carriers were in the normal range. This result indicates that the host immunity of asymptomatic carriers is not significantly disrupted by COVID-19. Single PCR detection is not sufficient to screen among asymptomatic individuals, and a combination of PCR tests, serological tests and CT is of great importance. Unless the tumour is life-threatening or rapidly progressing, we advise restarting active anti -tumour therapy after PCR tests become negative.
C1 [Huang, Q.; Hu, S.; Ran, F-M; Liang, T-J; Wang, H-X; Chen, C-C; Zhang, J.; Ou, W-L; Dong, S.; Cai, Q.; Luo, C-G; Qian, Y.] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Wuhan, Peoples R China.
RP Luo, CG; Qian, Y (corresponding author), Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Wuhan, Peoples R China.
EM hbchgcp_003@163.com; xdm126@126.com
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bogani G, 2020, GYNECOL ONCOL, V158, P262, DOI 10.1016/j.ygyno.2020.06.161
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Madariaga A, 2020, CLIN CANC RES
   National Health Comm People's Repubission of the China, 2020, 6 VERS PREV CONTR PR
   Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6
   Russano M, 2020, J THORAC ONCOL, V15, pE104, DOI 10.1016/j.jtho.2020.04.001
   Vathiotis I, 2019, J IMMUNOTHER CANCER, V7
   Wang ZJ, 2020, JAMA ONCOL, V6, P631, DOI 10.1001/jamaoncol.2020.1198
   WHO, 2020, COR DIS COVID 19 PAN
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
NR 16
TC 1
Z9 1
U1 2
U2 2
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 18
BP 9760
EP 9764
DI 10.26355/eurrev_202009_23070
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY6IW
UT WOS:000576491600069
PM 33015823
DA 2021-01-01
ER

PT J
AU Cheng, F
   Li, Q
   Han, Y
   Shi, C
   Wu, SL
   Xu, QL
   Zeng, F
   Zhang, Y
AF Cheng, Fang
   Li, Qiang
   Han, Yong
   Shi, Chen
   Wu, Sanlan
   Xu, Qiling
   Zeng, Fang
   Zhang, Yu
TI Analysis of Influencing Factors and Pharmaceutical Care of Patients with
   COVID-19 in Fangcang Shelter Hospital
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE COVID-19; Fangcang shelter hospital; medication; drug-related adverse
   reactions; pharmaceutical care
ID CORONAVIRUS PNEUMONIA; WUHAN; CHINA
AB Purpose: In December 2019, coronavirus disease 2019 (COVID-19) was first identified in Wuhan, and rapidly spread throughout China. Patients with mild symptoms were admitted to Fangcang shelter hospitals for centralized quarantine. We aimed to clarify the medication usage, related adverse reactions, and pharmaceutical interventions in patients with mild COVID-19.
   Patients and Methods: We innovatively carried out targeted pharmacy services. We provided online and off-line pharmaceutical services to patients in the Fangcang shelter hospital. The use of medication, related adverse reactions, and the effects of pharmaceutical intervention were analyzed.
   Results: Lower blood lymphocyte count was proposed as the most significant risk factor in patients with mild illness. All patients received antiviral treatment (arbidol, oseltamivir, and ribavirin); 78.4% of patients received antibiotic therapy (moxifloxacin, levofloxacin, and cefdinir); patients in the moderate disease group received more antibiotic therapy than those in the mild disease group. Most of the patients were treated with traditional Chinese medicine. Patients with moderate disease preferred to receive sedative hypnotic therapy. Diarrhea, nausea and vomiting, insomnia, arrhythmia, and constipation were the most common adverse reactions. The rate of mild-to-moderate illness in the pharmaceutical intervention and non-intervention groups was 20.6% and 31.7%, respectively.
   Conclusion: Most patients with mild illness were treated with antiviral, antibiotic, and Chinese medicine therapy. However, attention should be paid to patients with mild illness presenting with hypertension and low lymphocyte count at the onset; these patients are more likely to develop moderate or severe disease. Moreover, there were many drug-related problems in Fangcang shelter hospital; pharmaceutical care might contribute to alleviate the progress of the patient's condition. Pharmacists should be prepared to provide skilled and effective services to patients, with the aim to ensure medication safety and promote the overall control of the COVID-19 pandemic.
C1 [Cheng, Fang; Li, Qiang; Han, Yong; Shi, Chen; Wu, Sanlan; Xu, Qiling; Zeng, Fang; Zhang, Yu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Peoples R China.
   [Cheng, Fang; Li, Qiang; Han, Yong; Shi, Chen; Wu, Sanlan; Xu, Qiling; Zeng, Fang; Zhang, Yu] Hubei Prov Clin Res Ctr Precis Med Crit Illness, Wuhan 430022, Peoples R China.
RP Zeng, F; Zhang, Y (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430022, Peoples R China.
EM fancyzeng@126.com; zhangwkp@163.com
FU National Key R&D Program of China [2017YFC0909900]
FX This work was supported by the National Key R&D Program of China
   (2017YFC0909900).
CR Cadogan Cathal A, 2021, Res Social Adm Pharm, V17, P2032, DOI 10.1016/j.sapharm.2020.03.015
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3
   Cui YX, 2020, J INFECT DIS, V221, P1775, DOI 10.1093/infdis/jiaa113
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Meng L, 2020, INT J CLIN PHARM-NET, V42, P305, DOI 10.1007/s11096-020-01020-5
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Nguyen HC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040965
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 19
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 3443
EP 3450
DI 10.2147/IDR.S263961
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NY9FI
UT WOS:000576690100003
PM 33116663
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dal Pizzol, JL
   da Hora, VP
   Reis, AJ
   Vianna, J
   Ramis, I
   von Groll, A
   da Silva, PA
AF Dal Pizzol, Juliana Lemos
   da Hora, Vanusa Pousada
   Reis, Ana Julia
   Vianna, Julia
   Ramis, Ivy
   von Groll, Andrea
   da Silva, Pedro Almeida
TI Laboratory diagnosis for Covid-19: A mini-review
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE COVID-19; Diagnostic; Serology; Molecular; Biomarkers
ID CORONAVIRUS
AB Coronavirus disease (COVID-19) is a pandemic caused by a new coronavirus, called SARS-CoV-2. This disease was first identified in December 2019 and rapidly developed into a challenge to the public health systems around the world. In the absence of a vaccine and specific therapies, disease control and promotion of patient health are strongly dependent on a rapid and accurate diagnosis. This review describes the main laboratory approaches to making a diagnosis of COVID-19 and identifying those previously infected with SARS-CoV-2.
C1 [Dal Pizzol, Juliana Lemos; da Hora, Vanusa Pousada; Reis, Ana Julia; Vianna, Julia; Ramis, Ivy; von Groll, Andrea; da Silva, Pedro Almeida] Univ Fed Rio Grande, Nucleo Pesquisa Microbiol Med, Programa Posgrad Ciencias Saude, Rio Grande, RS, Brazil.
RP da Silva, PA (corresponding author), Univ Fed Rio Grande, Nucleo Pesquisa Microbiol Med, Programa Posgrad Ciencias Saude, Rio Grande, RS, Brazil.
EM pedrefurg@gmail.com
OI almeida da silva, pedro/0000-0003-1666-1295; Reis,
   AlessanRSS/0000-0001-8486-7469
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; FAPERGSFoundation for
   Research Support of the State of Rio Grande do Sul (FAPERGS)
FX CAPES, CNPq, NIH, and FAPERGS.
CR ASM, 2020, COVI 19
   Beeching NJ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1403
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Etievant S, 2020, SENSITIVITY ASSESSME
   Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm-2020-0398
   Frater JL, 2020, INT J LAB HEMATOL
   Jia Z, 2020, LANCET INFECT DIS
   Joynt GM, 2020, LANCET INFECT DIS, V20, P635, DOI 10.1016/S1473-3099(20)30237-1
   Kim YJ, 2020, ANN LAB MED, V40, P349, DOI 10.3343/alm.2020.40.5.349
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Li R, 2020, SCIENCE
   Lippi G, 2020, CLIN CHEM LAB MED
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Long Q.-X., 2020, NAT MED
   Lu RF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082826
   Lv DF, 2020, CLIN CHIM ACTA, V506, P172, DOI 10.1016/j.cca.2020.03.032
   Qiu G., 2020, ACS NANO
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sethuraman N, 2020, JAMA
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI [10.1080/14737159.2020.1757437, 10.1080/07435800.2020.1713802]
   Tahmasebi S, 2020, J CELL PHYSIOL
   Tan SS, 2020, J CLIN PATHOL
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Vashist SK, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040202
   Wang W., 2020, JAMA
   WHO, 2020, GENEBRA
   Winter Amy K., 2020, LANCET INFECT DIS
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, LAB BIOS GUID REL NO
   Xiao AT, 2020, J INFECT
   Yan C., 2020, CLIN MICROBIOL INFEC
   Yang X, 2020, J THROMB HAEMOST
   Yong SEF, 2020, LANCET INFECT DIS
   Zeng Z, 2020, J INFECT
   Zhu F, 2020, J MED VIROL
   Zitek T, 2020, ACAD EMERG MED, DOI 10.1111/acem.13995
NR 44
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2020
VL 53
AR e20200451
DI 10.1590/0037-8682-0451-2020
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA NZ1FK
UT WOS:000576837100006
PM 32876316
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, TT
   Zheng, QB
   Yu, H
   Wu, DH
   Xue, WH
   Xiong, HL
   Huang, XF
   Nie, MF
   Yue, MX
   Rong, R
   Zhang, SB
   Zhang, YY
   Wu, YT
   Wang, SJ
   Zha, ZH
   Chen, TT
   Deng, TT
   Wang, YB
   Zhang, TY
   Chen, YX
   Yuan, Q
   Zhao, QJ
   Zhang, J
   Gu, Y
   Li, SW
   Xia, NS
AF Li, Tingting
   Zheng, Qingbing
   Yu, Hai
   Wu, Dinghui
   Xue, Wenhui
   Xiong, Hualong
   Huang, Xiaofen
   Nie, Meifeng
   Yue, Mingxi
   Rong, Rui
   Zhang, Sibo
   Zhang, Yuyun
   Wu, Yangtao
   Wang, Shaojuan
   Zha, Zhenghui
   Chen, Tingting
   Deng, Tingting
   Wang, Yingbin
   Zhang, Tianying
   Chen, Yixin
   Yuan, Quan
   Zhao, Qinjian
   Zhang, Jun
   Gu, Ying
   Li, Shaowei
   Xia, Ningshao
TI SARS-CoV-2 spike produced in insect cells elicits high neutralization
   titres in non-human primates
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; spike; insect cell expression system;
   immunogenicity
ID CRYO-EM STRUCTURE; CORONAVIRUS; VACCINE; DESIGN; SARS; IMMUNOGENICITY;
   ACTIVATION; PROTECTION; PNEUMONIA; PROTEIN
AB The current coronavirus disease 2019 (COVID-19) pandemic was the result of the rapid transmission of a highly pathogenic coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for which there is no efficacious vaccine or therapeutic. Toward the development of a vaccine, here we expressed and evaluated as potential candidates four versions of the spike (S) protein using an insect cell expression system: receptor binding domain (RBD), S1 subunit, the wild-type S ectodomain (S-WT), and the prefusion trimer-stabilized form (S-2P). We showed that RBD appears as a monomer in solution, whereas S1, S-WT, and S-2P associate as homotrimers with substantial glycosylation. Cryo-electron microscopy analyses suggested that S-2P assumes an identical trimer conformation as the similarly engineered S protein expressed in 293 mammalian cells but with reduced glycosylation. Overall, the four proteins confer excellent antigenicity with convalescent COVID-19 patient sera in enzyme-linked immunosorbent assay (ELISA), yet show distinct reactivities in immunoblotting. RBD, S-WT and S-2P, but not S1, induce high neutralization titres (>3-log) in mice after a three-round immunization regimen. The high immunogenicity of S-2P could be maintained at the lowest dose (1 mu g) with the inclusion of an aluminium adjuvant. Higher doses (20 mu g) of S-2P can elicit high neutralization titres in non-human primates that exceed 40-times the mean titres measured in convalescent COVID-19 subjects. Our results suggest that the prefusion trimer-stabilized SARS-CoV-2 S-protein from insect cells may offer a potential candidate strategy for the development of a recombinant COVID-19 vaccine.
C1 [Li, Tingting; Zheng, Qingbing; Yu, Hai; Xue, Wenhui; Xiong, Hualong; Huang, Xiaofen; Nie, Meifeng; Yue, Mingxi; Rong, Rui; Zhang, Sibo; Zhang, Yuyun; Wu, Yangtao; Wang, Shaojuan; Zha, Zhenghui; Chen, Tingting; Deng, Tingting; Wang, Yingbin; Zhang, Tianying; Chen, Yixin; Yuan, Quan; Zhao, Qinjian; Zhang, Jun; Gu, Ying; Li, Shaowei; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Sch Life Sci, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
   [Li, Tingting; Zheng, Qingbing; Yu, Hai; Xue, Wenhui; Xiong, Hualong; Huang, Xiaofen; Nie, Meifeng; Yue, Mingxi; Rong, Rui; Zhang, Sibo; Zhang, Yuyun; Wu, Yangtao; Wang, Shaojuan; Zha, Zhenghui; Chen, Tingting; Deng, Tingting; Wang, Yingbin; Zhang, Tianying; Chen, Yixin; Yuan, Quan; Zhao, Qinjian; Zhang, Jun; Gu, Ying; Li, Shaowei; Xia, Ningshao] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China.
   [Wu, Dinghui] Xiamen Univ, Affiliated Hosp 1, Dept Pulm Med, Xiamen, Peoples R China.
   [Xia, Ningshao] Chinese Acad Med Sci, Res Unit Frontier Technol Struct Vaccinol, Beijing, Peoples R China.
RP Gu, Y; Li, SW; Xia, NS (corresponding author), Xiamen Univ, Sch Publ Hlth, Sch Life Sci, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.; Gu, Y; Li, SW; Xia, NS (corresponding author), Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China.
EM guying@xmu.edu.cn; shaowei@xmu.edu.cn; nsxia@xmu.edu.cn
OI wu, yangtao/0000-0002-9429-266X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [U1705283, 31670935, 81971932, 81991491,
   31730029]; Fujian Provincial Science Foundation for COVID-19 Research
   [2020YZ014001]; Research Unit of Frontier Technology of Structural
   Vaccinology of Chinese Academy of Medical Sciences [2019RU022]
FX This work was supported by grants from the National Natural Science
   Foundation of China [grant numbers U1705283, 31670935, 81971932,
   81991491, 31730029], the Major Project of Fujian Provincial Science
   Foundation for COVID-19 Research [grant number 2020YZ014001], and the
   Research Unit of Frontier Technology of Structural Vaccinology of
   Chinese Academy of Medical Sciences [grant number 2019RU022].
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bloch Magnus, 2020, Methods Mol Biol, V2127, P227, DOI 10.1007/978-1-0716-0373-4_16
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen JR, 2014, P NATL ACAD SCI USA, V111, P2476, DOI 10.1073/pnas.1323954111
   Corbett K.S., 2020, NATURE, P1
   Crank MC, 2019, SCIENCE, V365, P505, DOI 10.1126/science.aav9033
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Drulyte I, 2018, ACTA CRYSTALLOGR D, V74, P560, DOI 10.1107/S2059798318006496
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Go EP, 2017, J VIROL, V91, DOI 10.1128/JVI.02428-16
   Guebre-Xabier M, 2020, BIORXIV, DOI [10.1101/2020.08.18.256578, DOI 10.1101/2020.08.18.256578]
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/NMETH.2727, 10.1038/nmeth.2727]
   Li J, 2013, VIRAL IMMUNOL, V26, P126, DOI 10.1089/vim.2012.0076
   Li TT, 2019, VACCINE, V37, P1418, DOI 10.1016/j.vaccine.2019.01.048
   Li ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07199-6
   Li ZH, 2017, MBIO, V8, DOI 10.1128/mBio.00787-17
   Liu W-CC, 2016, J VIROL, V90, P880
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Medina RA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005996
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Palomares LA, 2018, ADV BIOCHEM ENG BIOT, P1
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sok D, 2016, IMMUNITY, V45, P31, DOI 10.1016/j.immuni.2016.06.026
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Urbanowicz RA, 2019, J VIROL, V93, DOI 10.1128/JVI.01403-18
   Victora GD, 2014, CURR OPIN IMMUNOL, V28, P90, DOI 10.1016/j.coi.2014.02.010
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong H-L, 2020, BIORXIV, DOI [10.1101/2020.04.08.026948, DOI 10.1101/2020.04.08.026948]
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhang XO, 2014, VACCINE, V32, P4039, DOI 10.1016/j.vaccine.2014.05.064
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou TQ, 2017, CELL REP, V19, P719, DOI 10.1016/j.celrep.2017.04.013
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2076
EP 2090
DI 10.1080/22221751.2020.1821583
PG 15
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NY4BC
UT WOS:000576336100001
PM 32897177
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xiong, HL
   Wu, YT
   Cao, JL
   Yang, R
   Liu, YX
   Ma, J
   Qiao, XY
   Yao, XY
   Zhang, BH
   Zhang, YL
   Hou, WH
   Shi, Y
   Xu, JJ
   Zhang, L
   Wang, SJ
   Fu, BR
   Yang, T
   Ge, SX
   Zhang, J
   Yuan, Q
   Huang, BY
   Li, ZY
   Zhang, TY
   Xia, NS
AF Xiong, Hua-Long
   Wu, Yang-Tao
   Cao, Jia-Li
   Yang, Ren
   Liu, Ying-Xia
   Ma, Jian
   Qiao, Xiao-Yang
   Yao, Xiang-Yang
   Zhang, Bao-Hui
   Zhang, Ya-Li
   Hou, Wang-Heng
   Shi, Yang
   Xu, Jing-Jing
   Zhang, Liang
   Wang, Shao-Juan
   Fu, Bao-Rong
   Yang, Ting
   Ge, Sheng-Xiang
   Zhang, Jun
   Yuan, Quan
   Huang, Bao-Ying
   Li, Zhi-Yong
   Zhang, Tian-Ying
   Xia, Ning-Shao
TI Robust neutralization assay based on SARS-CoV-2 S-protein-bearing
   vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing
   BHK21 cells
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; pseudovirus; neutralization assay; vesicular stomatitis
   virus; VSV-SARS-CoV-2
AB The global pandemic of coronavirus disease 2019 (COVID-19) is a disaster for human society. A convenient and reliable neutralization assay is very important for the development of vaccines and novel drugs. In this study, a G protein-deficient vesicular stomatitis virus (VSVdG) bearing a truncated spike protein (S with C-terminal 18 amino acid truncation) was compared to that bearing the full-length spike protein of SARS-CoV-2 and showed much higher efficiency. A neutralization assay was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and hACE2-overexpressing BHK21 cells (BHK21-hACE2 cells). The experimental results can be obtained by automatically counting the number of EGFP-positive cells at 12 h after infection, making the assay convenient and high-throughput. The serum neutralizing titer measured by the VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with that measured by the wild type SARS-CoV-2 assay. Seven neutralizing monoclonal antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 S protein were obtained. This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines.
C1 [Xiong, Hua-Long; Wu, Yang-Tao; Cao, Jia-Li; Ma, Jian; Qiao, Xiao-Yang; Zhang, Bao-Hui; Zhang, Ya-Li; Hou, Wang-Heng; Shi, Yang; Zhang, Liang; Wang, Shao-Juan; Fu, Bao-Rong; Ge, Sheng-Xiang; Zhang, Jun; Yuan, Quan; Zhang, Tian-Ying; Xia, Ning-Shao] Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
   [Xiong, Hua-Long; Wu, Yang-Tao; Cao, Jia-Li; Ma, Jian; Qiao, Xiao-Yang; Zhang, Bao-Hui; Zhang, Ya-Li; Hou, Wang-Heng; Shi, Yang; Zhang, Liang; Wang, Shao-Juan; Fu, Bao-Rong; Ge, Sheng-Xiang; Zhang, Jun; Yuan, Quan; Zhang, Tian-Ying; Xia, Ning-Shao] Xiamen Univ, Sch Life Sci, Xiamen 361102, Peoples R China.
   [Yang, Ren; Huang, Bao-Ying] China Cdc, NHC Key Lab Biosafety, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China.
   [Liu, Ying-Xia] Southern Univ Sci & Technol, State Key Discipline Infect Dis, Shenzhen Peoples Hosp 3, Hosp 2,Natl Clin Res Ctr Infect Dis,Shenzhen Key, Shenzhen, Peoples R China.
   [Yao, Xiang-Yang; Li, Zhi-Yong] Xiamen Univ, Hosp 1, Xiamen 361003, Peoples R China.
   [Xu, Jing-Jing; Yang, Ting] Fujian Med Univ, Dept Hematol, Fujian Inst Hematol, Union Hosp,Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China.
RP Zhang, TY; Xia, NS (corresponding author), Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.; Zhang, TY; Xia, NS (corresponding author), Xiamen Univ, Sch Life Sci, Xiamen 361102, Peoples R China.; Huang, BY (corresponding author), China Cdc, NHC Key Lab Biosafety, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China.; Li, ZY (corresponding author), Xiamen Univ, Hosp 1, Xiamen 361003, Peoples R China.
EM huangby@ivdc.chinacdc.cn; xmlzy_213@163.com; tyzhang1003@163.com;
   nsxia@xmu.edu.cn
OI wu, yangtao/0000-0002-9429-266X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81993149041, 81702006]; Science and
   Technology Major Project of the Fujian Province [2020YZ014001]; Xiamen
   Science and Technology Major Project [3502Z2020YJ02]; National Key
   Research and Development Program of China [2016YFD0500301]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 81993149041, 81702006], Science and Technology Major
   Project of the Fujian Province [grant number 2020YZ014001], Xiamen
   Science and Technology Major Project [grant number 3502Z2020YJ02] and
   National Key Research and Development Program of China [grant number
   2016YFD0500301].
CR Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Dieterle ME, 2020, CELL HOST MICROBE, V28, P486, DOI 10.1016/j.chom.2020.06.020
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   HuiDS IAE, 2020, INT J INFECT DIS, V91, P264, DOI [10.1016/j.ijid.2020.01.009, DOI 10.1016/J.IJID.2020.01.009]
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ogino M, 2003, CLIN DIAGN LAB IMMUN, V10, P154, DOI 10.1128/CDLI.10.1.154-160.2003
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Schwegmann-Wessels C, 2009, J GEN VIROL, V90, P1724, DOI 10.1099/vir.0.009704-0
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 16
TC 2
Z9 2
U1 7
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2105
EP 2113
DI 10.1080/22221751.2020.1815589
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NX9XJ
UT WOS:000576054800001
PM 32893735
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Spoto, S
   Valeriani, E
   Riva, E
   De Cesaris, M
   Tonini, G
   Vincenzi, B
   Locorriere, L
   Anguissola, GB
   Pantano, AL
   Brando, E
   Costantino, S
   Ciccozzi, M
   Angeletti, S
AF Spoto, Silvia
   Valeriani, Emanuele
   Riva, Elisabetta
   De Cesaris, Marina
   Tonini, Giuseppe
   Vincenzi, Bruno
   Locorriere, Luciana
   Anguissola, Giuseppina Beretta
   Pantano, Angelo Lauria
   Brando, Elisa
   Costantino, Sebastiano
   Ciccozzi, Massimo
   Angeletti, Silvia
TI A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast
   Cancer Patient
SO INTERNATIONAL JOURNAL OF GENERAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV2; pneumonia; computed tomography; Staphylococcus
   aureus; cancer patient
ID CRITICALLY-ILL PATIENTS; CORONAVIRUS; INFECTIONS; BACTERIAL
AB Introduction: Coronavirus disease 19 (COVID-19), due to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2), comprises a broad spectrum of clinical presentation ranging from flu-like syndrome to organ failure. The risk of coinfections is high and responsible for a worse prognosis, mainly in the case of bacterial involvement and in the presence of particular comorbidity. We present the clinical, laboratory, radiologic characteristic along with therapeutic management of a patient with COVID-19 and Staphylococcus aureus coinfection.
   Case Presentation: A 55 -year-old Caucasian woman was admitted to our hospital due to a two-day history of fever and acute dyspnea with severe respiratory failure worsened after the administration of atezolizumab and nab-paclitaxel. Her medical history comprehended a triple negative, BRCAJ-related, PD-L1 positive right breast cancer with multiple bone metastasis, causing bone marrow infiltration-related severe pancytopenia. Her physical examination revealed scattered wheezes, rales, and bilateral dry crackles in the middle and lower lung fields and lower limb paresis. The body mass index was 30 kg/m2 and arterial blood gas evaluation revealed a stage III acute respiratory distress syndrome. Microbiological specimens revealed a Staphylococcus aureus positivity from endotracheal aspirate. The chest computed tomography (CT) scan showed the presence of large areas of parenchymal consolidation and aerial bronchogram, bilateral "ground glass" areas reaching the highest extension on the upper and middle zones. The high clinical and radiological suspicion of COVID-19 along with the negative result of nasopharyngeal specimen make necessary an endotracheal aspirate resulting positive for SARS-CoV2. Patient started an antimicrobial treatment and lopinavir-ritonavir plus hydroxychloroquine but, unfortunately, died five days after hospital admission.
   Conclusion: The high risk of mortality of our patient was due to viral-bacterial coinfection, advanced cancer status with active immunotherapy. This case highlights the need for a prompt clinical, laboratory, and radiological evaluation to allow a correct diagnosis and start a specific therapy.
C1 [Spoto, Silvia; Valeriani, Emanuele; Locorriere, Luciana; Anguissola, Giuseppina Beretta; Pantano, Angelo Lauria; Brando, Elisa; Costantino, Sebastiano] Univ Campus Biomed Rome, Diagnost & Therapeut Med Dept, Rome, Italy.
   [Riva, Elisabetta] Univ Campus Biomed Rome, Unit Virol, Rome, Italy.
   [De Cesaris, Marina; Angeletti, Silvia] Univ Campus Biomed Rome, Unit Clin Lab Sci, Rome, Italy.
   [Tonini, Giuseppe] Univ Campus Biomed Rome, Dept Med Oncol, Rome, Italy.
   [Vincenzi, Bruno; Ciccozzi, Massimo] Univ Campus Biomed Rome, Unit Med Stat & Mol Epidemiol, Rome, Italy.
RP Spoto, S (corresponding author), Univ Campus Biomed Rome, Diagnost & Therapeut Med Dept, Rome, Italy.
EM s.spoto@unicampus.it
RI RIVA, ELISABETTA/H-7729-2016
OI RIVA, ELISABETTA/0000-0002-6870-8780
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Cancilleri F, 2018, CLIN CASE REP, V6, P871, DOI 10.1002/ccr3.1442
   Cawcutt K, 2017, CURR OPIN CRIT CARE, V23, P385, DOI 10.1097/MCC.0000000000000435
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Ding Q, 2020, J MED VIROL, V92, P1549, DOI 10.1002/jmv.25781
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Hermann B, 2017, EUR J CLIN MICROBIOL, V36, P565, DOI 10.1007/s10096-016-2833-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ieven M, 2018, CLIN MICROBIOL INFEC, V24, P1158, DOI 10.1016/j.cmi.2018.02.004
   Kim YJ, 2019, INFECT DIS-NOR, V51, P502, DOI 10.1080/23744235.2019.1592217
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Martin-Loeches I, 2017, INTENS CARE MED, V43, P48, DOI 10.1007/s00134-016-4578-y
   Ogimi C, 2017, CLIN INFECT DIS, V64, P1532, DOI 10.1093/cid/cix160
   Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Potere N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03022-1
   Smith AM, 2014, CURR TOP MICROBIOL, V385, P327, DOI 10.1007/82_2014_394
   Torres VBL, 2015, ANN AM THORAC SOC, V12, P1185, DOI 10.1513/AnnalsATS.201501-046OC
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7074
J9 INT J GEN MED
JI Int. J. Gen. Med.
PY 2020
VL 13
BP 729
EP 733
DI 10.2147/IJGM.S261760
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NX8CF
UT WOS:000575931400001
PM 33061542
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Montesarchio, V
   Parrella, R
   Iommelli, C
   Bianco, A
   Manzillo, E
   Fraganza, F
   Palumbo, C
   Rea, G
   Murino, P
   De Rosa, R
   Atripaldi, L
   D'Abbraccio, M
   Curvietto, M
   Mallardo, D
   Celentano, E
   Grimaldi, AM
   Palla, M
   Trojaniello, C
   Vitale, MG
   Million-Weaver, SL
   Ascierto, PA
AF Montesarchio, Vincenzo
   Parrella, Roberto
   Iommelli, Chiara
   Bianco, Antonella
   Manzillo, Elio
   Fraganza, Fiorentino
   Palumbo, Cristiana
   Rea, Gaetano
   Murino, Patrizia
   De Rosa, Rosanna
   Atripaldi, Luigi
   D'Abbraccio, Maurizio
   Curvietto, Marcello
   Mallardo, Domenico
   Celentano, Egidio
   Grimaldi, Antonio Maria
   Palla, Marco
   Trojaniello, Claudia
   Vitale, Maria Grazia
   Million-Weaver, Samuel Lewis
   Ascierto, Paolo Antonio
TI Outcomes and biomarker analyses among patients with COVID-19 treated
   with interleukin 6 (IL-6) receptor antagonist sarilumab at a single
   institution in Italy
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE immunomodulation; case reports; inflammation mediators
ID HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CYTOKINE; TOXICITIES
AB Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing. Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease. Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.
C1 [Montesarchio, Vincenzo; Iommelli, Chiara; Bianco, Antonella] Azienda Osped Colli Monaldi Hosp, Dept Med Oncol, Naples, Italy.
   [Parrella, Roberto; Manzillo, Elio; D'Abbraccio, Maurizio] Azienda Osped Colli Cotugno Hosp, Dept Infect Dis & Infect Dis Emergencies, Naples, Italy.
   [Fraganza, Fiorentino; Murino, Patrizia; De Rosa, Rosanna] Azienda Osped Colli Cotugno & Monaldi Hosp, Crit Area Dept, Naples, Italy.
   [Palumbo, Cristiana; Rea, Gaetano; Atripaldi, Luigi] Azienda Osped Colli Cotugno & Monaldi Hosp, Dept Hlth Serv, Naples, Italy.
   [Curvietto, Marcello; Mallardo, Domenico; Grimaldi, Antonio Maria; Palla, Marco; Trojaniello, Claudia; Vitale, Maria Grazia] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Melanoma Canc Immunotherapy & Dev Therapeut, Naples, Campania, Italy.
   [Celentano, Egidio] Ist Nazl Tumori IRCCS Fdn Pascale, Epidemiol & Biostat Unit, Naples, Campania, Italy.
   [Ascierto, Paolo Antonio] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy.
RP Ascierto, PA (corresponding author), Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy.
EM paolo.ascierto@gmail.com
CR Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Ascierto PA ea, 2020, SITC STAT ANT IL 6 I
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen F, 2016, J IMMUNOL METHODS, V434, P1, DOI 10.1016/j.jim.2016.03.005
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Daniel OG, 2020, EMERGING INFECT DIS, V26
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Eng SS, 2016, CLIN REV ALLERG IMMU, V50, P140, DOI 10.1007/s12016-015-8526-3
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Fu B, 2020, COMMUNICATION
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Horby P, 2020, EFFECT DEXAMETHASONE
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   La Rosee P, 2015, HEMATOL-AM SOC HEMAT, P190, DOI 10.1182/asheducation-2015.1.190
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Liu Y, 2020, J INFECT
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Neelapu SS, 2019, HEMATOL ONCOL, V37, P48, DOI 10.1002/hon.2595
   Oda S, 2005, CYTOKINE, V29, P169, DOI 10.1016/j.cyto.2004.10.010
   @OurWorldInData, 2020, TOT CONF COVID 19 DE
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qian GQ, 2020, QJM-INT J MED, V113, P474, DOI 10.1093/qjmed/hcaa089
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V101623
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537
   Tamamyan GN, 2016, CANCER-AM CANCER SOC, V122, P2857, DOI 10.1002/cncr.30084
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xea X, 2020, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 61
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001089
DI 10.1136/jitc-2020-001089
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA NY2VZ
UT WOS:000576255200005
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, PF
   Liu, LH
   Nair, MS
   Yin, MT
   Luo, Y
   Wang, Q
   Yuan, T
   Mori, K
   Solis, AG
   Yamashita, M
   Garg, A
   Purpura, LJ
   Laracy, JC
   Yu, J
   Joshua-Tor, L
   Sodroski, J
   Huang, YX
   Ho, DD
AF Wang, Pengfei
   Liu, Lihong
   Nair, Manoj S.
   Yin, Michael T.
   Luo, Yang
   Wang, Qian
   Yuan, Ting
   Mori, Kanako
   Solis, Axel Guzman
   Yamashita, Masahiro
   Garg, Ankur
   Purpura, Lawrence J.
   Laracy, Justin C.
   Yu, Jian
   Joshua-Tor, Leemor
   Sodroski, Joseph
   Huang, Yaoxing
   Ho, David D.
TI SARS-CoV-2 neutralizing antibody responses are more robust in patients
   with severe disease
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; antibody; neutralization; severe; non-severe
AB We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by similar to 5-fold and similar to 7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.
C1 [Wang, Pengfei; Liu, Lihong; Nair, Manoj S.; Luo, Yang; Yuan, Ting; Mori, Kanako; Solis, Axel Guzman; Yamashita, Masahiro; Yu, Jian; Huang, Yaoxing; Ho, David D.] Columbia Univ, Vagelos Coll Phys & Surg, Aaron Diamond AIDS Res Ctr, 701 W 168th St, New York, NY 10032 USA.
   [Yin, Michael T.; Purpura, Lawrence J.; Laracy, Justin C.] Columbia Univ, Vagelos Coll Phys & Surg, Dept Internal Med, Div Infect Dis, New York, NY USA.
   [Wang, Qian; Sodroski, Joseph] Harvard Med Sch, Dept Microbiol, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA.
   [Garg, Ankur] Cold Spring Harbor Lab, WM Keck Struct Biol Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
RP Ho, DD (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Aaron Diamond AIDS Res Ctr, 701 W 168th St, New York, NY 10032 USA.
EM dh2994@cumc.columbia.edu
RI ; nair, Manoj/B-4389-2009
OI Garg, Ankur/0000-0003-2397-1670; nair, Manoj/0000-0002-5994-3957
FU JBP Foundation; Wu Family China Center; Jack Ma Foundation; National
   Institute of Allergy and Infectious Diseases of the National Institutes
   of HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32AI114398]
FX This work was supported by The JBP Foundation; the Wu Family China
   Center; and Jack Ma Foundation. For the research reported in this
   publication, LP was supported by the National Institute of Allergy and
   Infectious Diseases of the National Institutes of Health under Award
   Number T32AI114398. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Rusert P, 2016, NAT MED, V22, P1260, DOI 10.1038/nm.4187
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 10
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 2091
EP 2093
DI 10.1080/22221751.2020.1823890
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NY6TX
UT WOS:000576520300001
PM 32930052
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Stankovic, B
   Kotur, N
   Gasic, V
   Klaassen, K
   Ristivojevic, B
   Stojiljkovic, M
   Pavlovic, S
   Zukic, B
AF Stankovic, Biljana
   Kotur, Nikola
   Gasic, Vladimir
   Klaassen, Kristel
   Ristivojevic, Bojan
   Stojiljkovic, Maja
   Pavlovic, Sonja
   Zukic, Branka
TI PHARMACOGENOMICS LANDSCAPE OF COVID-19 THERAPY RESPONSE IN SERBIAN
   POPULATION AND COMPARISON WITH WORLDWIDE POPULATIONS
SO JOURNAL OF MEDICAL BIOCHEMISTRY
LA English
DT Article
DE azithromycin; chloroquine/hydroxychloroquine; COVID-19; lopinavir;
   pharmacogenomics markers; population pharmacogenomics; ritonavir
ID PUBLIC-HEALTH; CHLOROQUINE; POLYMORPHISMS; AZITHROMYCIN; EVOLUTION;
   INFECTION; SINGLE; IL28B; G6PD
AB Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment failure in COVID-19 patients. Aim of our study was to identify pharmacogenes and pharmacogenomics markers associated with drugs recommended for COVID-19 treatment, chloroquine/hydroxychloroquine, azithromycin, lopinavir and ritonavir, in population of Serbia and other world populations.
   Methods: Genotype information of 143 individuals of Serbian origin was extracted from database previously obtained using TruSight One Gene Panel (IIlumina). Genotype data of individuals from different world populations were extracted from the 1000 Genome Project. Fisher's exact test was used for comparison of allele frequencies.
   Results: We have identified 11 potential pharmacogenomics markers in 7 pharmacogenes relevant for COVID-19 treatment. Based on high alterative allele frequencies in population and the functional effect of the variants, ABCB 1 rs1045642 and rs2032582 could be relevant for reduced clearance of azithromycin, lopinavir and ritonavir drugs and UGTIA7 rs17868323 for hyperbilirubinemia in ritonavir treated COVID-19 patients in Serbian population. SLCO/B/ rs4149056 is a potential marker of lopinavir response, especially in Italian population. Our results confirmed that pharmacogenomics profile of African population is different from the rest of the world.
   Conclusions: Considering population specific pharmacogenomics landscape, preemptive testing for pharmacogenes relevant for drugs used in COVID-19 treatment could contribute to better understanding of the inconsistency in therapy response and could be applied to improve the outcome of the COVID-19 patients.
C1 [Stankovic, Biljana; Kotur, Nikola; Gasic, Vladimir; Klaassen, Kristel; Ristivojevic, Bojan; Stojiljkovic, Maja; Pavlovic, Sonja; Zukic, Branka] Univ Belgrade, Inst Mol Genet & Genet Engn, Lab Mol Biomed, Belgrade, Serbia.
RP Zukic, B (corresponding author), Univ Belgrade, Inst Mol Genet & Genet Engn, 444a Vojvode Stepe St, Belgrade 11042, Serbia.
EM branka.zukic@imgge.bg.ac.rs
FU Ministry of Education, Science and Technological Development Republic of
   Serbia [451-0368/2020-14/200042]
FX This work was supported by Ministry of Education, Science and
   Technological Development Republic of Serbia, EB:
   451-0368/2020-14/200042.
CR Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159
   Ahsan T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228000
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   [Anonymous], 2005, JOURNAL
   Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896
   Basco LK, 2003, ANTIMICROB AGENTS CH, V47, P1391, DOI 10.1128/AAC.47.4.1391-1394.2003
   BEUTLER E, 1990, HUM GENET, V85, P9
   BREWER GJ, 1967, B WORLD HEALTH ORGAN, V36, P303
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chary M A, 2020, J MED TOXICOL
   Chen C-C, 2020, Fungal Systematics and Evolution, V5, P119, DOI 10.3114/fuse.2020.05.07
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   Colson P, 2020, INT J ANTIMICROB AG, V55
   Danielson PB, 2002, CURR DRUG METAB, V3, P561, DOI 10.2174/1389200023337054
   Davidson AL, 2008, MICROBIOL MOL BIOL R, V72, P317, DOI 10.1128/MMBR.00031-07
   de Wilde A H, 2014, ANTIMICROBIAL AGENTS, V58, P4875
   Eagling VA, 1997, BRIT J CLIN PHARMACO, V44, P190, DOI 10.1046/j.1365-2125.1997.00644.x
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Feeney Eoin R, 2011, Open Cardiovasc Med J, V5, P49, DOI 10.2174/1874192401105010049
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Graffelman J, 2016, HEREDITY, V116, P558, DOI 10.1038/hdy.2016.20
   Graffelman J, 2018, MOL ECOL RESOUR, V18, P461, DOI 10.1111/1755-0998.12748
   He XJ, 2009, PHARMACOL REP, V61, P843, DOI 10.1016/S1734-1140(09)70140-9
   Jordovic J, 2019, J INFECT DEV COUNTR, V13, P526, DOI 10.3855/jidc.11351
   Jovanovic-Cupic S, 2019, GENETICS APPL, V3, P36
   Kalil A C, 2020, JAMA
   Kassi EN, 2020, J CELL MOL MED, V24, P4913, DOI 10.1111/jcmm.15312
   Khetarpal S, 2017, NATURE MED, V23
   King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171
   Lakiotaki K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182138
   Lazarevic I, 2013, J CLIN VIROL, V58, P254, DOI 10.1016/j.jcv.2013.06.014
   Li G, 2020, NATURE REV DRUG DIS, V19
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mette L, 2012, PHARMACOGENOMICS, V13, P803, DOI [10.2217/PGS.12.52, 10.2217/pgs.12.52]
   Milosevic G, 2018, J MED BIOCHEM, V37, P320, DOI 10.1515/jomb-2017-0060
   Mizzi C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162866
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Montessori V, 2004, CAN MED ASSOC J, V170, P229
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Patrinos GP, 2018, PHARMACOGENOMICS, V19, P3, DOI 10.2217/pgs-2017-0166
   Philippidis A., 2020, JOURNAL
   Phillips MC, 2014, IUBMB LIFE, V66, P616, DOI 10.1002/iub.1314
   Plantone D, 2018, CLIN DRUG INVESTIGAT, V38
   Rock B, 2014, MOL PHARM, V86
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savic B, 2019, MEDICINA, V55, P642
   Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
   Tehrani R., 2009, SEMIN OPHTHALMOL, V23, P201
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Wang L-Y, 2020, GENETIC PROFILES PHA
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966
   Zhou Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/cpt.690
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 61
TC 0
Z9 0
U1 0
U2 0
PU SOC MEDICAL BIOCHEMISTS SERBIA
PI BELGRADE
PA VOJISLAVA ILICA 94B, I SPRAT, STAN 7, BELGRADE, VOZDOVAC, SERBIA
SN 1452-8258
EI 1452-8266
J9 J MED BIOCHEM
JI J. Med. Biochem.
PY 2020
VL 39
IS 4
BP 488
EP 499
DI 10.5937/jomb0-26725
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NW5WZ
UT WOS:000575084800011
PM 33312066
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ader, F
AF Ader, Florence
CA Discovery French Trial Mana
TI Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised
   trial of the safety and efficacy of treatments for COVID-19 in
   hospitalised adults
SO BMJ OPEN
LA English
DT Article
DE clinical trials; infectious diseases; respiratory infections; public
   health; intensive & critical care
ID RESPIRATORY SYNDROME; LOPINAVIR-RITONAVIR; CLINICAL-TRIALS; CORONAVIRUS;
   COMBINATION
AB Introduction To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials. As COVID-19 was spreading in Europe, the French national institute for Health and Medical Research (Inserm) established a transdisciplinary team to develop a multi-arm randomised controlled trial named DisCoVeRy. The objective of the trial is to evaluate the clinical efficacy and safety of different investigational re-purposed therapeutics relative to Standard of Care (SoC) in patients hospitalised with COVID-19.
   Methods and analysis DisCoVeRy is a phase III, open-label, adaptive, controlled, multicentre clinical trial in which hospitalised patients with COVID-19 in need of oxygen therapy are randomised between five arms: (1) a control group managed with SoC and four therapeutic arms with re-purposed antiviral agents: (2) remdesivir + SoC, (3) lopinavir/ritonavir + SoC, (4) lopinavir/ritonavir associated with interferon (IFN)-beta-1a + SoC and (5) hydroxychloroquine + SoC. The primary endpoint is the clinical status at Day 15 on the 7-point ordinal scale of the WHO Master Protocol (V.3.0, 3 March 2020). This trial involves patients hospitalised in conventional departments or intensive care units both from academic or non-academic hospitals throughout Europe. A sample size of 3100 patients (620 patients per arm) is targeted. This trial has begun on 22 March 2020. Since 5 April 2020, DisCoVeRy has been an add-on trial of the Solidarity consortium of trials conducted by the WHO in Europe and worldwide. On 8 June 2020, 754 patients have been included.
   Ethics and dissemination Inserm is the sponsor of DisCoVeRy. Ethical approval has been obtained from the institutional review board on 13 March 2020 (20.03.06.51744) and from the French National Agency for Medicines and Health Products (ANSM) on 9 March 2020. Results will be submitted for publication in peer-reviewed journals.
C1 Ctr Hosp Univ Lyon, Infect & Trop Dis Dept, F-69004 Lyon, France.
   Univ Lyon, Inserm 1111 Ctr Int Rech Infectiol CIRI, Univ Claude Bernard Lyon 1, CNRS,UMR5308,Ecole Normale Super Lyon, F-69007 Lyon, France.
RP Ader, F (corresponding author), Hosp Civils Lyon, Infect & Trop Dis Dept, Hop Croix Rousse, F-69004 Lyon, France.
EM florence.ader@chu-lyon.fr
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Programme Hospitalier de Recherche Clinique -PHRC 2020 (Ministry of
   Health) [PHRC-20-0351]; EACTing, a French multidisciplinary
   collaborative network working on emerging infectious diseases; Institut
   national de la sante et de la recherche medicale (INSERM,
   France)Institut National de la Sante et de la Recherche Medicale
   (Inserm)
FX The trial is funded by a grant from Programme Hospitalier de Recherche
   Clinique -PHRC 2020 (PHRC-20-0351) (Ministry of Health). This study also
   received a financial support from REACTing, a French multidisciplinary
   collaborative network working on emerging infectious diseases. The trial
   is sponsored by Institut national de la sante et de la recherche
   medicale (INSERM, France).
CR Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Etievant S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061871
   Fallah MP, 2019, LANCET, V393, P850, DOI 10.1016/S0140-6736(19)30160-6
   Fragkou PC, 2020, CLIN MICROBIOL INFEC, V26, P988, DOI 10.1016/j.cmi.2020.05.019
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Groneberg DA, 2005, LANCET INFECT DIS, V5, P147, DOI 10.1016/S1473-3099(05)70022-0
   HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Laurent L, 2020, WASHINGTON POST
   Le MP, J ANTIMICROB CHEMOTH
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu X., 2020, BIORXIV
   Lo MK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9242
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lokugamage KG, 2020, BIORXIV
   MILLER DK, 1981, P NATL ACAD SCI-BIOL, V78, P3605, DOI 10.1073/pnas.78.6.3605
   Moustgaard H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6802
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nakkazi E, 2018, LANCET, V392, P2338, DOI 10.1016/S0140-6736(18)33011-3
   Peiffer-Smadja N, J ANTIMICROB CHEMOTH
   Peiffer-Smadja N, 2020, AM J EPIDEMIOL, V189, P1443, DOI 10.1093/aje/kwaa151
   PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Sattui SE, 2020, EXPERT REV CLIN IMMU, V16, P659, DOI 10.1080/1744666X.2020.1792778
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sissoko D, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001967
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WHITEHEAD J, 1993, STAT MED, V12, P2257, DOI 10.1002/sim.4780122404
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   World Health Organization, 2020, WHO R D BLUEPR NOV C
   World Health Organization, 2020, WHO CHAR COVID 19 PA
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
NR 44
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e041437
DI 10.1136/bmjopen-2020-041437
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NW7TC
UT WOS:000575220500015
PM 32958495
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mitrasinovic, PM
AF Mitrasinovic, Petar M.
TI Prediction of Single Point Mutations in Human Coronavirus and Their
   Effects on Binding to 9-O-Acetylated Sialic Acid and Hidroxychloroquine
SO ACTA CHIMICA SLOVENICA
LA English
DT Article
DE CoViD-19; coronavirus; hidroxychloroquine; pandemic; single point
   mutation
ID STRUCTURE-BASED DESIGN; INFLUENZA-VIRUS NEURAMINIDASES; G-QUADRUPLEX
   DNA; PROTEIN; H5N1; OSELTAMIVIR; INHIBITORS; INSIGHTS; PROGRESS; SPIKE
AB Due to the current spreading of the new disease CoViD-19, the World Health Organization formally declared a world pandemic on March 11, 2020. The present trends indicate that the pandemic will have an enormous clinical and economic impact on population health. Infections are initiated by the transmembrane spike (S) glycoproteins of human coronavirus (hCoV) binding to host receptors. Ongoing research and therapeutic product development are of vital importance for the successful treatment of CoViD-19. To contribute somewhat to the overall effort, herein, single point mutations (SPMs) of the binding site residues in hCoV-OC43 S that recognizes cellular surface components containing 9-O-acetylated sialic acid (9-O-Ac-Sia) are explored using an in silico protein engineering approach, while their effects on the binding of 9-O-Ac-Sia and Hidroxychloroquine (Hcq) are evaluated using molecular docking simulations. Thr3lMet and Va184Arg are predicted to be the critical - most likely SPMs in hCoV-OC43 S for the binding of 9-O-AcSia and Hcq, respectively, even though Thr3lMet is a very likely SPM in the case of Hcq too. The corresponding modes of interaction indicate a comparable strength of the Thr31Met/9-O-Ac-Sia and Va184Arg/Hcq (or Thr3lMet/Hcq) complexes. Given that the binding site is conserved in all CoV S glycoproteins that associate with 9-O-acetyl-sialoglycans, the high hydrophobic affinity of Hcq to hCoV-OC43 S speaks in favor of its ability to competitively inhibit rapid S-mediated virion attachment in high-density receptor environments, but its considerably low specificity to hCoV-OC43 S may be one of the key obstacles in considering the potential of Hcq to become a drug candidate.
C1 [Mitrasinovic, Petar M.] Belgrade Inst Sci & Technol, Ctr Biophys & Chem Res, Belgrade 11060, Serbia.
RP Mitrasinovic, PM (corresponding author), Belgrade Inst Sci & Technol, Ctr Biophys & Chem Res, Belgrade 11060, Serbia.
EM pmitrasinovic.ist-belgrade.edu.rs@tech-center.com
OI Mitrasinovic, Petar M./0000-0002-0987-4893
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052
   Baeten L, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000083
   Becke AD, 2002, J CHEM PHYS, V117, P6935, DOI 10.1063/1.1503772
   Cosconati S, 2010, EXPERT OPIN DRUG DIS, V5, P597, DOI 10.1517/17460441.2010.484460
   Deng NJ, 2017, J PHYS CHEM B, V121, P10484, DOI 10.1021/acs.jpcb.7b09406
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4
   HERRLER G, 1991, Behring Institute Mitteilungen, P177
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360
   Mihajlovic ML, 2008, BIOPHYS CHEM, V136, P152, DOI 10.1016/j.bpc.2008.06.003
   Mihajlovic ML, 2009, J SERB CHEM SOC, V74, P1, DOI 10.2298/JSC0901001M
   Mihajlovic ML, 2009, MOL SIMULAT, V35, P311, DOI 10.1080/08927020802430752
   Mitrasinovic PM, 2020, ACTA CHIM SLOV, V67, P386, DOI [10.17344/acsi.2019.5105, 10.17344/acsi.2020.5823, 10.17344/acsi.2020.5847]
   Mitrasinovic PM, 2019, CROAT CHEM ACTA, V92, P43, DOI 10.5562/cca3456
   Mitrasinovic PM, 2018, J BIOMOL STRUCT DYN, V36, P2292, DOI 10.1080/07391102.2017.1358670
   Mitrasinovic PM, 2015, J CHEM INF MODEL, V55, P421, DOI 10.1021/ci5006965
   Mitrasinovic PM, 2014, MED CHEM, V10, P252, DOI 10.2174/157340641003140304143442
   Mitrasinovic PM, 2014, MED CHEM, V10, P46
   Mitrasinovic PM, 2013, CURR DRUG TARGETS, V14, P817, DOI 10.2174/1389450111314070009
   Mitrasinovic PM, 2010, CURR DRUG TARGETS, V11, P315, DOI 10.2174/138945010790711932
   Mitrasinovic PM, 2010, CURR ORG CHEM, V14, P198, DOI 10.2174/138527210790069857
   Mitrasinovic PM, 2009, BIOPHYS CHEM, V140, P35, DOI 10.1016/j.bpc.2008.11.004
   Mitrasinovic PM, 2003, CHEM PHYS, V286, P1, DOI 10.1016/S0301-0104(02)00902-3
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403
   Pavlov A, 2010, CURR ORG CHEM, V14, P129, DOI 10.2174/138527210790069866
   Petukhov M, 1999, PROTEIN SCI, V8, P1982, DOI 10.1110/ps.8.10.1982
   Reguera J, 2014, VIRUS RES, V194, P3, DOI 10.1016/j.virusres.2014.10.005
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Schymkowitz JWH, 2005, P NATL ACAD SCI USA, V102, P10147, DOI 10.1073/pnas.0501980102
   Thompson M.A., 2004, ARGUSLAB 4 0 1
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Van Durme J, 2011, BIOINFORMATICS, V27, P1711, DOI 10.1093/bioinformatics/btr254
   Vanhee P, 2011, NUCLEIC ACIDS RES, V39, pD435, DOI 10.1093/nar/gkq972
   Vijayakumar M, 1998, J MOL BIOL, V278, P1015, DOI 10.1006/jmbi.1998.1747
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
NR 40
TC 0
Z9 0
U1 0
U2 0
PU SLOVENSKO KEMIJSKO DRUSTVO
PI LJUBLJANA
PA HAJDRIHOVA 19, LJUBLJANA 1000, SLOVENIA
SN 1318-0207
EI 1580-3155
J9 ACTA CHIM SLOV
JI Acta Chim. Slov.
PY 2020
VL 67
IS 3
BP 949
EP 956
DI 10.17344/acsi.2020.6009
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA NV7VO
UT WOS:000574524400028
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Jones, CW
   Woodford, AL
   Platts-Mills, TF
AF Jones, Christopher W.
   Woodford, Ashley L.
   Platts-Mills, Timothy F.
TI Characteristics of COVID-19 clinical trials registered with
   ClinicalTrials.gov: cross-sectional analysis
SO BMJ OPEN
LA English
DT Article
DE clinical trials; virology; statistics & research methods
ID REDUCING WASTE; CONDUCT; DESIGN
AB Objectives To characterise current COVID-19-related research activities. Design Cross-sectional analysis.
   Setting Clinical trials registered with ClinicalTrials.gov testing interventions relevant to COVID-19.
   Data sources ClinicalTrials.gov was searched for COVID-19 and related terms to identify trials registered between 1 December 2019 and 1 May 2020 that test interventions related to the COVID-19 pandemic.
   Main outcome measures We classified trials according to intervention type, and report key trial characteristics including recruitment status, location, funder type, target enrolment number, intervention model (single group, randomised or sequential assignment) and projected completion date.
   Results Of the 630 identified clinical trials related to COVID-19, 509 (81%) involved the study of drugs or biological agents. Of these trials of drugs and biologics, 305 (60%) use an open-label design, 43 (8%) are single blinded (participant only) and 161 (32%) are double blinded (participant and investigator). 94 (18%) of the drug/biological trials are non-randomised. Either hydroxychloroquine or chloroquine is administered as part of the study protocol in 152 (30%) of the drug/biological trials. The total planned enrolment for these hydroxychloroquine/chloroquine trials is over 200 000 participants, which represents 65% of the total planned enrolment for all registered trials of drugs or biologics. There are also at least 25 registered trials of azithromycin (n=53), convalescent plasma (n=38), lopinavir/ritonavir (n=30), stem cell treatments (n=29) and tocilizumab (n=25). 142 trials were registered in the first 3 months of 2020, and 488 trials were registered between 1 April and 1 May 2020.
   Conclusions These findings demonstrate a robust research response to the COVID-19 pandemic, though many of the currently planned and ongoing trials focus on a small number of potential therapies, and many also lack essential design features and power necessary to provide accurate treatment effect estimates.
C1 [Jones, Christopher W.; Woodford, Ashley L.] Rowan Univ, Emergency Med, Cooper Med Sch, Camden, NJ 08102 USA.
   [Platts-Mills, Timothy F.] Univ N Carolina, Emergency Med, Chapel Hill, NC 27515 USA.
RP Jones, CW (corresponding author), Rowan Univ, Emergency Med, Cooper Med Sch, Camden, NJ 08102 USA.
EM jones-christopher@cooperhealth.edu
CR Adaptive Platform Trials Coalition, 2019, Nat Rev Drug Discov, V18, P797, DOI 10.1038/s41573-019-0034-3
   ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283
   [Anonymous], TRENDS CHARTS MAPS U
   [Anonymous], 2016, FED REGISTER, V81, P64981
   [Anonymous], SUBM STUD US NAT LIB
   Bangdiwala SI, 2016, TRANSL BEHAV MED, V6, P228, DOI 10.1007/s13142-016-0386-8
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1
   Chavez C, 2020, HERES WHY WHAT WE CA
   Cytel, GLOB COR COVID 19 CL
   da Costa BR, 2014, EUR HEART J, V35, P3336, DOI 10.1093/eurheartj/ehu424
   DeVito Nicholas J, 2019, BMJ Evid Based Med, V24, P53, DOI 10.1136/bmjebm-2018-111107
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X
   Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358
   Huang JH, 2020, DRUG DES DEV THER, V14, P2159, DOI 10.2147/DDDT.S254354
   Hunter KE, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019983
   Ioannidis JPA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7089
   Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8
   ISRCTN Registry, PUBL HLTH EM SOL TRI
   Jones CW, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017719
   Klitzman R, 2015, AM J PUBLIC HEALTH, V105, P1513, DOI 10.2105/AJPH.2015.302757
   Li GW, 2017, INT J EPIDEMIOL, V46, P746, DOI 10.1093/ije/dyw320
   Loder E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020037
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mehta HB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039978
   National Institutes of Health, NIH LAUCH PUBL PRIV
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rodgers F, 2020, MISSING CLIN TRIAL D
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537
   Song SY, 2017, J CLIN EPIDEMIOL, V84, P78, DOI 10.1016/j.jclinepi.2017.02.009
   Tan AC, 2019, J CLIN EPIDEMIOL, V113, P64, DOI 10.1016/j.jclinepi.2019.05.009
   Tse T, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1452
   World Health Organization, INT CLIN TRIALS REG
   World Health Organization, 2020, WHO COR DIS COVID 19
NR 39
TC 1
Z9 1
U1 3
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e041276
DI 10.1136/bmjopen-2020-041276
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NW0KN
UT WOS:000574698500002
PM 32948577
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhu, Y
   Zhu, RJ
   Liu, K
   Li, X
   Chen, DZ
   Bai, DY
   Luo, JL
   Liu, YX
   Zhang, Y
   Li, L
   Hu, JF
   Xu, DY
   Liu, Y
   Zhao, RC
AF Zhu, Yue
   Zhu, Rongjia
   Liu, Kun
   Li, Xin
   Chen, Dezhong
   Bai, Dunyao
   Luo, Jieli
   Liu, Yixun
   Zhang, Yan
   Li, Li
   Hu, Junfang
   Xu, Dayong
   Liu, Yan
   Zhao, Robert Chunhua
TI Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a
   Critically III COVID-19 Patient: A Case Report
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE COVID-19; UC-MSCs; critically ill; cell transplantation; case report
ID STROMAL CELLS
AB Background: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available.
   Case Presentation: We reported the treatment process and clinical outcome of a 48-year-old man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs).
   Conclusions: We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.
C1 [Zhu, Yue; Li, Xin] Wuhan Univ Sci & Technol, Stem Cell Lab, Puren Hosp, Wuhan 430081, Hubei, Peoples R China.
   [Zhu, Rongjia; Zhao, Robert Chunhua] Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China.
   [Liu, Kun] Wuhan Univ Sci & Technol, Otorhinolaryngol, Puren Hosp, Wuhan 430081, Hubei, Peoples R China.
   [Chen, Dezhong] Wuhan Univ Sci & Technol, Puren Hosp, Dept Resp & Crit Care Med, Wuhan 430081, Hubei, Peoples R China.
   [Bai, Dunyao; Luo, Jieli] Wuhan Univ Sci & Technol, Puren Hosp, Mol Lab, Wuhan 430081, Hubei, Peoples R China.
   [Liu, Yixun] Chinese Acad Sci, Inst Zool, Gonadal Biol Res Grp, Beijing 100101, Peoples R China.
   [Zhang, Yan] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Li, Li] Wuhan Univ Sci & Technol, Minist Sci & Educ, Puren Hosp, Wuhan 430081, Hubei, Peoples R China.
   [Hu, Junfang] Wuhan Univ Sci & Technol, Puren Hosp, Dept Pharm, Wuhan 430081, Hubei, Peoples R China.
   [Xu, Dayong; Liu, Yan] Wuhan Univ Sci & Technol, Puren Hosp, Wuhan 430081, Hubei, Peoples R China.
   [Zhao, Robert Chunhua] Shanghai Univ, Sch Life Sci, Shanghai 200444, Peoples R China.
RP Zhao, RC (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China.; Liu, Y (corresponding author), Wuhan Univ Sci & Technol, Puren Hosp, Wuhan 430081, Hubei, Peoples R China.
EM liuyan@wust.edu.cn; zhaochunhua@vip.163.com
FU National Key Research and Development Program of China [2016YFA0101000,
   2016YFA0101003, 2018YFA0109800, 2020YFC0844000]; CAMS Innovation Fund
   for Medical Sciences [2017-I2M -3-007]; 111 ProjectMinistry of
   Education, China - 111 Project [B18007]
FX This work was supported by the National Key Research and Development
   Program of China (2016YFA0101000, 2016YFA0101003, 2018YFA0109800,
   2020YFC0844000), CAMS Innovation Fund for Medical Sciences (2017-I2M
   -3-007) and the 111 Project (B18007). The funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Bari E, 2019, J CONTROL RELEASE, V309, P11, DOI 10.1016/j.jconrel.2019.07.022
   Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006
   Connick P, 2012, LANCET NEUROL, V11, P150, DOI 10.1016/S1474-4422(11)70305-2
   Darwish I, 2011, EXPERT REV ANTI-INFE, V9, P807, DOI [10.1586/ERI.11.56, 10.1586/eri.11.56]
   Esposito M, 2013, IN VIVO, V27, P495
   Hashmi S, 2016, LANCET HAEMATOL, V3, pE45, DOI 10.1016/S2352-3026(15)00224-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Muraca M, 2020, J CONTROL RELEASE, V325, P135, DOI 10.1016/j.jconrel.2020.06.036
   Shu Y, 2018, J CELL BIOCHEM, V119, P8872, DOI 10.1002/jcb.27140
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5
NR 15
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 3295
EP 3300
DI 10.2147/IDR.S272645
PG 6
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NW4ZR
UT WOS:000575019000002
PM 33061476
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Arnaldez, FI
   O'Day, SJ
   Drake, CG
   Fox, BA
   Fu, BQ
   Urba, WJ
   Montesarchio, V
   Weber, JS
   Wei, HM
   Wigginton, JM
   Ascierto, PA
AF Arnaldez, Fernanda, I
   O'Day, Steven J.
   Drake, Charles G.
   Fox, Bernard A.
   Fu, Bingqing
   Urba, Walter J.
   Montesarchio, Vincenzo
   Weber, Jeffrey S.
   Wei, Haiming
   Wigginton, Jon M.
   Ascierto, Paolo Antonio
TI The Society for Immunotherapy of Cancer perspective on regulation of
   interleukin-6 signaling in COVID-19-related systemic inflammatory
   response
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE immunomodulation; inflammation mediators
ID CYTOKINE-RELEASE SYNDROME; TUMOR-NECROSIS-FACTOR; T-CELL THERAPY;
   INTERFERON-GAMMA; RECEPTOR ANTAGONIST; DOUBLE-BLIND; FACTOR-ALPHA;
   IFN-GAMMA; TNF-ALPHA; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
AB The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often accompanied by a pathological immune reaction, sometimes referred to as 'cytokine storm'. One hallmark feature of the profound inflammatory state seen in patients with COVID-19 who succumb to pneumonia and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved outcomes for critically ill patients with COVID-19 with the administration of cytokine-modulatory therapies, especially anti-IL-6 agents. Although ongoing trials are investigating anti-IL-6 therapies, access to these therapies is a concern, especially as the numbers of cases worldwide continue to climb. An immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in patients with COVID-19. Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19.
C1 [Arnaldez, Fernanda, I] MacroGenics Inc, Rockville, MD USA.
   [O'Day, Steven J.] Providence St Johns Hlth Ctr, John Wayne Canc Inst & Canc Clin, Santa Monica, CA USA.
   [O'Day, Steven J.] Providence Los Angeles Metro Hosp, Santa Monica, CA USA.
   [Drake, Charles G.] Columbia Univ, Med Ctr, Herbert Irving Canc Ctr, New York, NY USA.
   [Fox, Bernard A.; Urba, Walter J.] Earle A Chiles Res Inst, Portland, OR USA.
   [Fu, Bingqing; Wei, Haiming] Univ Sci & Technol China, Hefei, Anhui, Peoples R China.
   [Montesarchio, Vincenzo] AORN Colli Monaldi Cotugno CTO Hosp, Naples, Italy.
   [Weber, Jeffrey S.] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA.
   [Ascierto, Paolo Antonio] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy.
RP Ascierto, PA (corresponding author), Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy.
EM paolo.ascierto@gmail.com
OI Weber, Jeffrey/0000-0002-4962-2957
CR Abboud R, 2016, BIOL BLOOD MARROW TR, V22, P1851, DOI 10.1016/j.bbmt.2016.06.010
   ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934
   Abraham E, 1998, LANCET, V351, P929
   Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5
   Alejo A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04098-8
   [Anonymous], 2020, I MAB BIOPHARMA ANNO
   [Anonymous], 2020, NEW YORK TIMES  0313
   [Anonymous], 2020, ROIVANT ANNOUNCES DE
   Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27
   Ascierto PA, 2020, COMMUNICATION
   Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563
   Bai F, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2546161
   Barnes PJ, 2007, AM J RESP CRIT CARE, V175, P866, DOI 10.1164/rccm.200702-253ED
   Bharadwaj U, 2020, PHARMACOL REV, V72, P486, DOI 10.1124/pr.119.018440
   BIONDILLO DE, 1994, AM J PHYSIOL-LUNG C, V267, pL564
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   COmmission CNH, 2020, CHIN CLIN GUID COVID
   Conti P, 2020, J BIOL REGUL HOMEOST, P34
   CRESTANI B, 1994, J CLIN INVEST, V94, P731, DOI 10.1172/JCI117392
   Das R, 2016, BLOOD, V127, P1666, DOI 10.1182/blood-2015-12-684399
   De Andrea Marco, 2002, Eur J Paediatr Neurol, V6 Suppl A, pA41, DOI 10.1053/ejpn.2002.0573
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   FDA U, 2020, COR COVID 19 SUPPL C
   FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836
   FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008
   Flammiger A, 2012, ACTA HAEMATOL-BASEL, V128, P69, DOI 10.1159/000338179
   Fu B, 2020, COMMUNICATION
   Furst DE, 2004, CLIN THER, V26, P1960, DOI 10.1016/j.clinthera.2004.12.019
   Garlanda C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00180
   Goldbach-Mansky R, 2012, CLIN EXP IMMUNOL, V167, P391, DOI 10.1111/j.1365-2249.2011.04533.x
   Hallstrand TS, 2014, CLIN IMMUNOL, V151, P1, DOI 10.1016/j.clim.2013.12.003
   Han SH, 2015, J IMMUNOL, V194, P855, DOI 10.4049/jimmunol.1402513
   Harden JL, 2015, J ALLERGY CLIN IMMUN, V135, P553, DOI 10.1016/j.jaci.2014.05.046
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641
   Kenderian SS, 2017, BIOL BLOOD MARROW TR, V23, pS19, DOI 10.1016/j.bbmt.2016.12.003
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   La Rosee P, 2015, HEMATOL-AM SOC HEMAT, P190, DOI 10.1182/asheducation-2015.1.190
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Liu Bo, 2019, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2019.07.009
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Lotfi N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01265
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Malaviya R, 2017, PHARMACOL THERAPEUT, V180, P90, DOI 10.1016/j.pharmthera.2017.06.008
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Mukhopadhyay S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-125
   Neelapu SS, 2019, HEMATOL ONCOL, V37, P48, DOI 10.1002/hon.2595
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Novartis, 2020, NOV ANN PLAN IN CLIN
   O'Shea JJ, 2013, ANN RHEUM DIS, V72, P111, DOI 10.1136/annrheumdis-2012-202576
   Oda S, 2005, CYTOKINE, V29, P169, DOI 10.1016/j.cyto.2004.10.010
   Opal SM, 1997, CRIT CARE MED, V25, P1115, DOI 10.1097/00003246-199707000-00010
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qian GQ, 2020, QJM-INT J MED, V113, P474, DOI 10.1093/qjmed/hcaa089
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V101623
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sachdeva M, 2019, J BIOL CHEM, V294, P5430, DOI 10.1074/jbc.AC119.007558
   Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907
   Santarlasci V, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00182
   Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691
   Schon MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01323
   Schumacher N, 2019, CANCERS, V11, DOI 10.3390/cancers11111736
   Schumacher N, 2015, J BIOL CHEM, V290, P26059, DOI 10.1074/jbc.M115.649509
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shrestha B, 2008, J VIROL, V82, P8956, DOI 10.1128/JVI.01118-08
   Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5
   Sinha P, 2018, THORAX, V73, P699, DOI 10.1136/thoraxjnl-2017-211443
   Skurkovich B, 2006, E SCHERING RES FDN W, V56, P1
   Skurkovich B, 2003, CURR OPIN MOL THER, V5, P52
   SOBI, 2020, GAM EM IZSG PRESCR I
   Sterner RM, 2019, BLOOD, V133, P697, DOI 10.1182/blood-2018-10-881722
   Tamamyan GN, 2016, CANCER-AM CANCER SOC, V122, P2857, DOI 10.1002/cncr.30084
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xea X, 2020, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang X, 2020, CORRECTION LANCET RE
   Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 107
TC 17
Z9 17
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 1
AR e000930
DI 10.1136/jitc-2020-000930
PG 12
WC Oncology; Immunology
SC Oncology; Immunology
GA NV6TD
UT WOS:000574450400003
PM 32385146
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Araujo, BCL
   Lima, TRCD
   de Gois-Santos, VT
   Santos, VS
   Simoes, SD
   Martins, PR
AF Lima Araujo, Brenda Carla
   Correia de Melo Lima, Thales Rafael
   de Gois-Santos, Vanessa Tavares
   Santos, Victor Santana
   Simoes, Silvia de Magalhaes
   Martins-Filho, Paulo Ricardo
TI Speech therapy practice in hospital settings and COVID-19 pandemic
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Letter
DE Coronavirus infections; Speech therapy; Deglutition Disorders; Primary
   Health Care
ID DYSPHAGIA
C1 [Lima Araujo, Brenda Carla] Univ Fed Sergipe, Dept Fonoaudiol, Aracaju, SE, Brazil.
   [Lima Araujo, Brenda Carla; de Gois-Santos, Vanessa Tavares; Martins-Filho, Paulo Ricardo] Univ Fed Sergipe, Lab Patol Invest, Aracaju, SE, Brazil.
   [Correia de Melo Lima, Thales Rafael] Univ Fed Sergipe, Programa Posgrad Profiss Gestao & Inovacao Tecnol, Aracaju, SE, Brazil.
   [de Gois-Santos, Vanessa Tavares; Simoes, Silvia de Magalhaes; Martins-Filho, Paulo Ricardo] Univ Fed Sergipe, Programa Posgrad Ciencias Saude, Aracaju, SE, Brazil.
   [Santos, Victor Santana] Univ Fed Alagoas, Ctr Epidemiol & Saude Publ, Arapiraca, SE, Brazil.
   [Simoes, Silvia de Magalhaes] Univ Fed Sergipe, Hosp Univ EBSERH, Dept Med, Aracaju, SE, Brazil.
RP Araujo, BCL (corresponding author), Univ Fed Sergipe UFS, Posgrad Ciencias Saude, Rua Claudio Batista S-N, BR-49060100 Aracaju, Sergipe, Brazil.
EM brendaaraujo@yahoo.com.br
RI Santos, Victor S/B-8738-2014; Santos, Victor S/M-5710-2019;
   Martins-Filho, Paulo Ricardo/D-1077-2011
OI Santos, Victor S/0000-0003-0194-7397; Santos, Victor
   S/0000-0003-0194-7397; Gois Santos, Vanessa/0000-0002-1325-139X; Araujo,
   Brenda/0000-0002-4720-1710; Simoes, Silvia de
   Magalhaes/0000-0003-2751-7993; Martins-Filho, Paulo
   Ricardo/0000-0001-8779-0727; Reis, AlessanRSS/0000-0001-8486-7469
CR American Speech-Language-Hearing Association, 2020, SLP SERV DEL CONS HL
   Associacao de Medicina Intensiva Brasileira, 2020, PAR DEP FON AM REF A
   Bolton L, 2020, INT J LANG COMM DIS, V55, P629, DOI 10.1111/1460-6984.12544
   de Lima MS, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2021
   Jotz Geraldo Pereira, 2020, Int. Arch. Otorhinolaryngol., V24, P125, DOI 10.1055/s-0040-1709724
   Kiekens C, 2020, EUR J PHYS REHAB MED, V56, P323, DOI 10.23736/S1973-9087.20.06305-4
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Mayadevi M, 2018, DYSPHAGIA, V33, P474, DOI 10.1007/s00455-018-9876-9
   Morrell K, 2017, CEREBROVASC DIS, V44, P225, DOI 10.1159/000478107
   Nordio S, 2018, ACTA OTORHINOLARYNGO, V38, P79, DOI 10.14639/0392-100X-1816
   Sohrabi C, 2020, INT J SURG, V77, P217, DOI 10.1016/j.ijsu.2020.03.036
   Tedesco Angela, 2018, Recenti Progressi in Medicina, V109, P146, DOI 10.1701/2865.28913
NR 13
TC 0
Z9 0
U1 2
U2 2
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PY 2020
VL 66
SU 2
BP 10
EP 12
DI 10.1590/1806-9282.66.S2.10
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NV4EN
UT WOS:000574277200005
PM 32965347
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Pires, ALR
   Batista, JG
   Aldrighi, JM
   Massaia, IFDS
   Delgado, DM
   Ferreira, ES
   Soares, JM
AF Ribeiro Pires, Andrea Larissa
   Batista, Jose Gomes
   Aldrighi, Jose Mendes
   Delfino Silva Massaia, Irineu Francisco
   Delgado, Diego Medeiros
   Ferreira-Filho, Edson Santos
   Soares-Junior, Jose Maria
TI Risk of venous is thromboembolism in users of contraception and
   menopausal hormone therapy during the COVID-19 pandemic
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE Contraception; Hormone Replacement Therapy; Corona virus Infections;
   Betacoronavirus; Venous Thromboembolism/prevention & control
ID HYPERINFLAMMATION; SYSTEM
AB OBJECTIVES: The outbreak of coronavirus disease (COVID-19) is a public health emergency of international concern. Inflammatory changes are part of COVID-19 pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. We aimed to discuss the main aspects related to this issue and propose management strategies for women affected by COVID-19.
   METHODS: This narrative review collected information from several articles published since the beginning of the outbreak of the new coronavirus disease about the pathophysiology, stage of the disease, the occurrence of thrombotic events, and the risk of thromboembolism in users of contraception and hormonal therapy.
   RESULTS: This article consolidates clinical parameters about the risk o f venous thromboembolism in users of contraception and menopausal hormone therapy emphasizing the probable increase of that risk in women with suspected or confirmed COVID-19 and bringing safer recommendations.
   CONCLUSIONS: In this scenario, apart from the fundamental orientations of preventive measures, like social isolation and hygiene, it is important that all female health professionals have knowledge of the new rules and adopt safety measures, especially on the prescription of hormonal therapy and contraception.
C1 [Ribeiro Pires, Andrea Larissa; Batista, Jose Gomes; Delgado, Diego Medeiros] Univ Fed Paraiba UFPB, Ctr Ciencias Med, Dept Obstet & Ginecol, Joao Pessoa, Paraiba, Brazil.
   [Aldrighi, Jose Mendes; Delfino Silva Massaia, Irineu Francisco] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, SP, Brazil.
   [Aldrighi, Jose Mendes] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, SP, Brazil.
   [Ferreira-Filho, Edson Santos; Soares-Junior, Jose Maria] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
RP Pires, ALR (corresponding author), Univ Fed Paraiba, Campus 1,Lot Cidade Univ, BR-58051900 Joao Pessoa, Paraiba, Brazil.
EM alarissaribeiro@gmail.com
RI ; Ferreira-Filho, Edson Santos/C-6136-2012; Soares-Jr, Jose
   Maria/G-1467-2012
OI Reis, AlessanRSS/0000-0001-8486-7469; Ferreira-Filho, Edson
   Santos/0000-0002-0017-3273; Soares-Jr, Jose Maria/0000-0003-0774-9404
CR Anderson FA, 2003, CIRCULATION, V107, pI9, DOI 10.1161/01.CIR.0000078469.07362.E6
   BASTOS M, 2014, COCHRANE DB SYST REV, P10813
   Black A, 2017, J OBSTET GYNAECOL CA, V39, P229, DOI 10.1016/j.jogc.2016.10.005
   Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Dragoman MV, 2018, INT J GYNECOL OBSTET, V141, P287, DOI 10.1002/ijgo.12455
   Henry BM, 2020, CLIN CHIM ACTA, V507, P167, DOI 10.1016/j.cca.2020.04.027
   Luo W, 2020, PATHOLOGY PATHOBIOLO, V2020
   Mantha S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4944
   Nicin L, 2020, EUR HEART J, V41, P1804, DOI 10.1093/eurheartj/ehaa311
   Pereira MD, 2020, REV ASSOC MED BRAS, V66, P366, DOI 10.1590/1806-9282.66.3.366
   Pinkerton JV, 2018, CLIN OBSTET GYNECOL, V61, P260, DOI 10.1097/GRF.0000000000000358
   Ramirez I, 2020, MATURITAS, V137, P57, DOI 10.1016/j.maturitas.2020.04.019
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PY 2020
VL 66
SU 2
BP 22
EP 26
DI 10.1590/1806-9282.66.S2.22
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NV4EN
UT WOS:000574277200008
PM 32965350
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ogando, NS
   Dalebout, TJ
   Zevenhoven-Dobbe, JC
   Limpens, RWAL
   van der Meer, Y
   Caly, L
   Druce, J
   de Vries, JJC
   Kikkert, M
   Barcena, M
   Sidorov, I
   Snijder, EJ
AF Ogando, Natacha S.
   Dalebout, Tim J.
   Zevenhoven-Dobbe, Jessika C.
   Limpens, Ronald W. A. L.
   van der Meer, Yvonne
   Caly, Leon
   Druce, Julian
   de Vries, Jutte J. C.
   Kikkert, Marjolein
   Barcena, Montserrat
   Sidorov, Igor
   Snijder, Eric J.
TI SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics,
   rapid adaptation and cytopathology
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
DE plaque phenotype; evolution; RNA synthesis; antisera; furin-like
   cleavage site; antiviral drugs
ID RESPIRATORY SYNDROME CORONAVIRUS; DOUBLE-STRANDED-RNA; SARS-CORONAVIRUS;
   NONSTRUCTURAL PROTEINS; MONOCLONAL-ANTIBODIES; CYCLOSPORINE-A;
   CATHEPSIN-L; INTERFERON; SARS-COV-2; INFECTION
AB The sudden emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 from the Chinese province of Hubei and its subsequent pandemic spread highlight the importance of understanding the full molecular details of coronavirus infection and pathogenesis. Here, we compared a variety of replication features of SARS-CoV-2 and SARS-CoV and analysed the cytopathology caused by the two closely related viruses in the commonly used Vero E6 cell line. Compared to SARS-CoV, SARS-CoV-2 generated higher levels of intracellular viral RNA, but strikingly about 50-fold less infectious viral progeny was recovered from the culture medium. lmmunofluorescence microscopy of SARS-CoV-2-infected cells established extensive cross-reactivity of antisera previously raised against a variety of non-structural proteins, membrane and nucleocapsid protein of SARS-CoV. Electron microscopy revealed that the ultrastructural changes induced by the two SARS viruses are very similar and occur within comparable time frames after infection. Furthermore, we determined that the sensitivity of the two viruses to three established inhibitors of coronavirus replication (remdesivir, alisporivir and chloroquine) is very similar, but that SARS-CoV-2 infection was substantially more sensitive to pre-treatment of cells with pegylated interferon alpha. An important difference between the two viruses is the fact that - upon passaging in Vero E6 cells - SARS-CoV-2 apparently is under strong selection pressure to acquire adaptive mutations in its spike protein gene. These mutations change or delete a putative furin-like cleavage site in the region connecting the S1 and S2 domains and result in a very prominent phenotypic change in plaque assays.
C1 [Ogando, Natacha S.; Dalebout, Tim J.; Zevenhoven-Dobbe, Jessika C.; van der Meer, Yvonne; Kikkert, Marjolein; Sidorov, Igor; Snijder, Eric J.] Leiden Univ, Dept Med Microbiol, Mol Virol Lab, Med Ctr, Leiden, Netherlands.
   [Limpens, Ronald W. A. L.; Barcena, Montserrat] Leiden Univ, Dept Cell & Chem Biol, Sect Electron Microscopy, Med Ctr, Leiden, Netherlands.
   [Caly, Leon; Druce, Julian] Peter Doherty Inst Infect & Immun, Royal Melbourne Hosp, Victorian Infect Dis Reference Lab, Virus Identificat Lab, Melbourne, Vic 3000, Australia.
   [de Vries, Jutte J. C.] Leiden Univ, Med Ctr, Dept Med Microbiol, Clin Microbiol Lab, Leiden, Netherlands.
RP Snijder, EJ (corresponding author), Leiden Univ, Dept Med Microbiol, Mol Virol Lab, Med Ctr, Leiden, Netherlands.
EM e.j.snijder@lumc.nl
RI Barcena, Montserrat/B-5823-2012
OI Barcena, Montserrat/0000-0002-7719-4443; Ogando,
   Natacha/0000-0002-3577-4909; Kikkert, Marjolein/0000-0002-5779-7386;
   Limpens, Ronald/0000-0002-6243-6729
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Banerjee A, 2020, ISOLATION SEQUENCE I
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   CHINESE SME, 2004, SCIENCE, V303, P1666, DOI DOI 10.1126/SCIENCE.1092002
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Coelmont L, 2009, ANTIMICROB AGENTS CH, V53, P967, DOI 10.1128/AAC.00939-08
   Corman VM, 2015, J VIROL, V89, P11858, DOI 10.1128/JVI.01755-15
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davidson AD, 2020, CHARACTERISATION TRA
   de Wilde AH, 2018, VIROLOGY, V522, P46, DOI 10.1016/j.virol.2018.06.011
   de Wilde AH, 2017, VIRUS RES, V228, P7, DOI 10.1016/j.virusres.2016.11.011
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   DECLERCQ E, 1973, INFECT IMMUN, V8, P309, DOI 10.1128/IAI.8.3.309-316.1973
   Doyle N, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111030
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247
   Falzarano D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01686
   Fang Y, 2006, ADV EXP MED BIOL, V581, P153
   Follis KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/j.virol.2006.02.003
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gillim-Ross L, 2004, J CLIN MICROBIOL, V42, P3196, DOI 10.1128/JCM.42.7.3196-3206.2004
   Goebel SJ, 2007, J VIROL, V81, P1274, DOI 10.1128/JVI.00803-06
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   HU H, 2020, VIROL SIN, V86, DOI DOI 10.1016/J.INTIMP.2020.106725
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Izaguirre G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090837
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kim AHJ, 2020, ANN INTERN MED
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WT, 2018, P NATL ACAD SCI USA, V115, pE5135, DOI 10.1073/pnas.1802879115
   Li X, 2020, SCI CHINA LIFE SCI, V63, P461, DOI 10.1007/s11427-020-1645-7
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu Z, 2020, IDENTIFICATION COMMO
   Lokugamage KG, 2020, SARS COV 2 SENSITIVE
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maier HJ, 2013, MBIO, V4, DOI 10.1128/mBio.00801-13
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009
   Ogando NS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01813
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Nga PT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002215
   Pyrc K, 2007, EXPERT REV ANTI-INFE, V5, P245, DOI 10.1586/14787210.5.2.245
   Rangan R, 2020, BIORXIV2020032701290
   Reusken CBEM, 2013, LANCET INFECT DIS, V13, P859, DOI 10.1016/S1473-3099(13)70164-6
   Riss T. L., 2004, ASSAY GUIDANCE MANUA
   Rothan HA, 2020, VIROLOGY, V547, P7, DOI 10.1016/j.virol.2020.05.002
   Sawicki S G, 1995, Adv Exp Med Biol, V380, P499
   Schaecher SR, 2007, J VIROL, V81, P718, DOI 10.1128/JVI.01691-06
   SCHONBORN J, 1991, NUCLEIC ACIDS RES, V19, P2993, DOI 10.1093/nar/19.11.2993
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Snijder EJ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000715
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   Stammler SN, 2011, RNA, V17, P1747, DOI 10.1261/rna.2816711
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Sung SC, 2009, VIROLOGY, V387, P402, DOI 10.1016/j.virol.2009.02.021
   Tan YJ, 2004, J VIROL, V78, P14043, DOI 10.1128/JVI.78.24.14043-14047.2004
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   Tseng CTK, 2005, J VIROL, V79, P9470, DOI 10.1128/JVI.79.15.9470-9479.2005
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van den Worm SHE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032857
   van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999
   van Hemert MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000054
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Jing, 2003, Genomics Proteomics & Bioinformatics, V1, P226
   Yao X, 2020, CLIN INFECT DIS, P10
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yuan XL, 2006, VIROLOGY, V346, P74, DOI 10.1016/j.virol.2005.10.015
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 109
TC 20
Z9 19
U1 2
U2 2
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PY 2020
VL 101
IS 9
BP 925
EP 940
DI 10.1099/jgv.0.001453
PG 16
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA NU9NF
UT WOS:000573961800006
PM 32568027
OA Green Published
DA 2021-01-01
ER

PT J
AU Su, Y
   Han, Y
   Liu, J
   Qiu, Y
   Tan, Q
   Zhou, Z
   Yu, YZ
   Chen, J
   Giger, ML
   Lure, FYM
   Luo, Z
AF Su, Ying
   Han, Yi
   Liu, Jie
   Qiu, Yue
   Tan, Qian
   Zhou, Zhen
   Yu, Yi-zhou
   Chen, Jun
   Giger, Maryellen L.
   Lure, Fleming Y. M.
   Luo, Zhe
TI Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT
   scans: three case reports
SO JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Coronavirus; pneumonia; treating COVID-19 patients; steroids;
   computerized tomography; image analysis using artificial intelligence
ID COMMUNITY-ACQUIRED PNEUMONIA; ACUTE RESPIRATORY SYNDROME; CORTICOSTEROID
   TREATMENT; HOSPITALIZED-PATIENTS; INFLUENZA; THERAPY; SARS; INFUSION;
   OUTCOMES; ADULTS
AB In this article, we analyze and report cases of three patients who were admitted to Renmin Hospital, Wuhan University, China, for treating COVID-19 pneumonia in February 2020 and were unresponsive to initial treatment of steroids. They were then received titrated steroids treatment based on the assessment of computed tomography (CT) images augmented and analyzed with the artificial intelligence (AI) tool and output. Three patients were finally recovered and discharged. The result indicated that sufficient steroids may be effective in treating the COVID-19 patients after frequent evaluation and timely adjustment according to the disease severity assessed based on the quantitative analysis of the images of serial CT scans.
C1 [Su, Ying; Qiu, Yue; Luo, Zhe] Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
   [Han, Yi] Fudan Univ, Zhongshan Hosp, Dept Emergency, Shanghai, Peoples R China.
   [Liu, Jie] Fudan Univ, Zhongshan Hosp, Dept Resp Med, Shanghai, Peoples R China.
   [Tan, Qian] Tianjin Med Univ Canc Inst & Hosp, Tianjin Lung Canc Ctr, Dept Lung Canc, Tianjin, Peoples R China.
   [Zhou, Zhen] Peking Univ, Sch Elect Engn & Comp Sci, Beijing, Peoples R China.
   [Yu, Yi-zhou] Univ Hong Kong, Dept Comp Sci, Hong Kong, Peoples R China.
   [Chen, Jun] Wuhan Univ, Dept Radiol, Renmin Hosp, Wuhan, Peoples R China.
   [Giger, Maryellen L.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
   [Lure, Fleming Y. M.] MS Technol Corp, Rockville, MD 20850 USA.
   [Lure, Fleming Y. M.] Shenzhen Smart Imaging Healthcare Co, Shenzhen, Peoples R China.
RP Luo, Z (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
EM luo.zhe@zs-hospital.sh.cn
CR Al-Busaidi Mujahid, 2016, Oman Med J, V31, P290, DOI 10.5001/omj.2016.56
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   BLOM P S, 1959, Ned Tijdschr Geneeskd, V103, P109
   Boudreault AA, 2011, BIOL BLOOD MARROW TR, V17, P979, DOI 10.1016/j.bbmt.2010.09.014
   Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   de Hoop B, 2010, RADIOLOGY, V255, P199, DOI 10.1148/radiol.09090571
   Delaney JW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1230-8
   Delgado-Rodriguez M, 2012, J ANTIMICROB CHEMOTH, V67, P1739, DOI 10.1093/jac/dks098
   Han K, 2011, CLIN INFECT DIS, V53, P326, DOI 10.1093/cid/cir398
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SF, 2017, J MICROBIOL IMMUNOL, V50, P586, DOI 10.1016/j.jmii.2015.08.016
   Lee FEH, 2011, CHEST, V140, P1155, DOI 10.1378/chest.11-0047
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Li ZH, 2019, LECT NOTES COMPUT SC, V11769, P13, DOI 10.1007/978-3-030-32226-7_2
   Linko R, 2011, ACTA ANAESTH SCAND, V55, P971, DOI 10.1111/j.1399-6576.2011.02491.x
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meijvis SCA, 2011, LANCET, V377, P2023, DOI 10.1016/S0140-6736(11)60607-7
   Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4
   Nawab QUA, 2011, INTENS CARE MED, V37, P1553, DOI 10.1007/s00134-011-2274-5
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Song YS, 2014, RADIOLOGY, V273, P276, DOI 10.1148/radiol.14132324
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88
   Yam LYC, 2007, J INFECTION, V54, P28, DOI 10.1016/j.jinf.2006.01.005
   Zhao R, 2017, OSTEOPOROSIS INT, V28, P1027, DOI 10.1007/s00198-016-3824-z
   Zheng QT, 2020, J X-RAY SCI TECHNOL, V28, P391, DOI 10.3233/XST-200687
NR 35
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0895-3996
EI 1095-9114
J9 J X-RAY SCI TECHNOL
JI J. X-Ray Sci. Technol.
PY 2020
VL 28
IS 5
BP 885
EP 892
DI 10.3233/XST-200710
PG 8
WC Instruments & Instrumentation; Optics; Physics, Applied
SC Instruments & Instrumentation; Optics; Physics
GA NV7LS
UT WOS:000574498800006
PM 32675436
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Li, CH
   Zhao, H
   Wang, B
AF Li, Chenghai
   Zhao, Hua
   Wang, Bin
TI Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE COVID-19; mesenchymal stem cell; immunomodulation; tissue regeneration
ID RESPIRATORY-DISTRESS-SYNDROME; STROMAL CELLS; MECHANISMS; MIGRATION;
   IMPROVES; ARDS
AB The coronavirus disease 2019 (COVID-19) global pandemic continues and antiviral agents and vaccines are currently under investigation. Mesenchymal stem cell (MSC)-based therapy can be a suitable option for management of patients with COVID-19 at the urgent time of virus outbreak. Currently, MSCs are being explored against the novel infectious disease due to their therapeutic properties of anti-inflammation, immunomodulation and tissue repair and regeneration, albeit the precise mechanisms of MSC action toward COVID-19 remain unclear. To date, rigorous results from clinical trials using MSCs in human have been weakly positive. The pervasive uncertainty of using MSC therapeutic products as an effective combatant against COVID-19 requires rigorous resolution on several fronts, including MSC fate after infusion, safety issue, homing capability, and MSC resistance to the disease microenvironment. Focusing on these facets, a few important ones will be critically analyzed and addressed in this article for the development of safe and effective MSC-based therapies for COVID-19.
C1 [Li, Chenghai] Zhengzhou Univ, Henan Prov Peoples Hosp, Clin Res Ctr, Stem Cell Program, Zhengzhou 450003, Peoples R China.
   [Li, Chenghai; Zhao, Hua; Wang, Bin] Zhengzhou Univ, Peoples Hosp, Zhengzhou 450003, Peoples R China.
   [Li, Chenghai] Henan Key Lab Stem Cell Differentiat & Modificat, Zhengzhou 450003, Peoples R China.
   [Zhao, Hua] Zhengzhou Univ, Henan Prov Peoples Hosp, Reprod Med Inst, Zhengzhou 450003, Peoples R China.
   [Zhao, Hua] Henan Univ, Peoples Hosp, Zhengzhou 450003, Peoples R China.
   [Wang, Bin] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou 450003, Peoples R China.
RP Li, CH (corresponding author), Zhengzhou Univ, Henan Prov Peoples Hosp, Clin Res Ctr, Stem Cell Program, Zhengzhou 450003, Peoples R China.; Li, CH; Wang, B (corresponding author), Zhengzhou Univ, Peoples Hosp, Zhengzhou 450003, Peoples R China.; Li, CH (corresponding author), Henan Key Lab Stem Cell Differentiat & Modificat, Zhengzhou 450003, Peoples R China.; Wang, B (corresponding author), Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou 450003, Peoples R China.
EM chenghai_li@yahoo.com; bin.wang201166@hotmail.com
FU Henan Key Laboratory of Stem Cell Differentiation
FX The authors are thankful to Dr. A.H. Rezwanuddin Ahmed (City College of
   City University of New York, USA) for his assistance in drafting,
   discussing and editing the manuscript. This work was supported by Henan
   Key Laboratory of Stem Cell Differentiation and Modification.
CR Abraham A, 2020, STEM CELL TRANSL MED, V9, P28, DOI 10.1002/sctm.19-0205
   Bustos ML, 2014, AM J RESP CRIT CARE, V189, P787, DOI 10.1164/rccm.201306-1043OC
   Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374
   Daverey A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13744
   De Becker A, 2007, HAEMATOLOGICA, V92, P440, DOI 10.3324/haematol.10475
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Guo ZN, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03142-8
   Han JB, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1518-0
   He X, 2018, TRANSL RES, V199, P52, DOI 10.1016/j.trsl.2018.04.006
   Islam D, 2019, AM J RESP CRIT CARE, V199, P1214, DOI 10.1164/rccm.201802-0356OC
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Liu S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01678-8
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   McIntyre LA, 2018, AM J RESP CRIT CARE, V197, P337, DOI 10.1164/rccm.201705-1006OC
   Molina ER, 2015, J CONTROL RELEASE, V219, P107, DOI 10.1016/j.jconrel.2015.08.038
   Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z
   Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451
   Schlosser K, 2019, CRIT CARE MED, V47, P918, DOI 10.1097/CCM.0000000000003657
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Spees JL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0363-7
   Sui BD, 2019, BIOMATERIALS, V196, P18, DOI 10.1016/j.biomaterials.2017.10.046
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]
   Zheng CX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23098-8
   Zheng GP, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-39
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2020
VL 14
BP 3995
EP 4001
DI 10.2147/DDDT.S269407
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NU7YP
UT WOS:000573855700001
PM 33061304
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yi, ZG
   Ling, Y
   Zhang, XN
   Chen, JL
   Hu, KY
   Wang, YY
   Song, WH
   Ying, TL
   Zhang, R
   Lu, HZ
   Yuan, ZH
AF Yi, Zhigang
   Ling, Yun
   Zhang, Xiaonan
   Chen, Jieliang
   Hu, Kongying
   Wang, Yuyan
   Song, Wuhui
   Ying, Tianlei
   Zhang, Rong
   Lu, HongZhou
   Yuan, Zhenghong
TI Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19
   convalescent population
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; epitope; neutralizing antibody; vaccine; diagnosis
ID CORONAVIRUS
AB Pandemic SARS-CoV-2 has caused unprecedented mortalities. Vaccine is in urgent need to stop the pandemic. Despite great progresses on SARS-CoV-2 vaccine development, the efficacy of the vaccines remains to be determined. Deciphering the interactions of the viral epitopes with the elicited neutralizing antibodies in convalescent population inspires the vaccine development. In this study, we devised a peptide array composed of 20-mer overlapped peptides of spike (S), membrane (M) and envelope (E) proteins, and performed a screening with 120 COVID-19 convalescent sera and 24 non-COVID-19 sera. We identified five SARS-CoV-2-specific dominant epitopes that reacted with above 40 & percnt; COVID-19 convalescent sera. Of note, two peptides non-specifically interacted with most of the non-COVID-19 sera. Neutralization assay indicated that only five sera completely blocked viral infection at the dilution of 1:200. By using a peptide-compete neutralizing assay, we found that three dominant epitopes partially competed the neutralization activity of several convalescent sera, suggesting antibodies elicited by these epitopes played an important role in neutralizing viral infection. The epitopes we identified in this study may serve as vaccine candidates to elicit neutralizing antibodies in most vaccinated people or specific antigens for SARS-CoV-2 diagnosis.
C1 [Yi, Zhigang; Ling, Yun; Zhang, Xiaonan; Lu, HongZhou] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
   [Yi, Zhigang; Zhang, Xiaonan; Chen, Jieliang; Hu, Kongying; Wang, Yuyan; Song, Wuhui; Ying, Tianlei; Zhang, Rong; Yuan, Zhenghong] Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
RP Yi, ZG; Lu, HZ (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.; Yi, ZG; Yuan, ZH (corresponding author), Fudan Univ, Shanghai Med Coll, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
EM zgyi@fudan.edu.cn; luhongzhou@shphc.org.cn; zhyuan@shmu.edu.cn
OI Reis, AlessanRSS/0000-0001-8486-7469; Ying, Tianlei/0000-0002-9597-2843
FU National Science and Technology Major Project of China [2017ZX10103009];
   Key Emergency Project of Shanghai Science and Technology Committee
   [20411950103]; Development programs for COVID-19 of Shanghai Science and
   Technology Commission [20431900401]
FX This work was supported in part by the National Science and Technology
   Major Project of China (2017ZX10103009), Key Emergency Project of
   Shanghai Science and Technology Committee (20411950103) and Development
   programs for COVID-19 of Shanghai Science and Technology Commission
   (20431900401). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Bonovas S, 2020, NEW ENGL J MED, V382
   Brain D, 2020, BIORXIV
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002
   Forthal DN, 2018, AIDS, V32, P2439, DOI [10.1097/QAD.00000000000002011, 10.1097/QAD.0000000000002011]
   Gao Q, 2020, SCIENCE
   Huang M, 2015, ANAL CHEM, V87, P7085, DOI 10.1021/acs.analchem.5b00694
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Masters PS, FIELDS VIROLOGY, P825
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wong YK, 2020, LANCET RHEUMATOL, V2, pE255, DOI 10.1016/S2665-9913(20)30093-X
   Zhang DD, 2020, INT J COMPUT ASS RAD, V15, P15, DOI 10.1007/s11548-019-02074-1
   Zhang HY, 2018, J CLIN VIROL, V105, P41, DOI 10.1016/j.jcv.2018.06.001
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1988
EP 1996
DI 10.1080/22221751.2020.1815591
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NU0DL
UT WOS:000573310500001
PM 32844713
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saccomanno, S
   Quinzi, V
   Sarhan, S
   Lagana, D
   Marzo, G
AF Saccomanno, S.
   Quinzi, V.
   Sarhan, S.
   Lagana, D.
   Marzo, G.
TI Perspectives of tele-orthodontics in the COVID-19 emergency and as a
   future tool in daily practice
SO EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY
LA English
DT Article
DE COVID-19; Tele-orthodontics; Emoji; Malocclusion; Rapid Palatal Expander
ID TELEDENTISTRY
AB Aim The aim of our study was to explain how tele-orthodontics represents the only way to perform orthodontics during a period of restriction as the one subsequent to COVID-19 emergencies: To do this, we report a case study and explore the proposal of a model of tele-orthodontics, considering the advantages of this modality in the immediate post-emergency phase and in the future daily practice.
   Materials and methods Study design: Our study involves 30 patients, who had undergone different orthodontic therapies in a traditional way, and that the clinician continued to follow by means of tele-orthodontics. Given the obvious limitations of tele-practice, a comparison with patients who did not undergo any follow-up or underwent only in-office follow-ups could not be possible. The communication tools used in our study and proposed in our model of tele-orthodontics are videocalls, dedicated applications, intraoral and extraoral photos taken by the patients and instant messaging.
   Results Tele-orthodontics allowed to perform some orthodontic follow-ups with less chairside time, reduced time spent by the patients in the dental office from up to 45 min, less risk of infection, fewer to no missed appointments, specific troubleshooting solutions, and more follow-ups with odontophobic patients. Overall, tele-orthodontics balanced the disadvantages of less personal contacts and in-office visits.
   Conclusions The need to respect safety distance and the fears patients have about the risk of infection make tele-orthodontics a fundamental tool during a pandemic lockdown and in its immediate post-emergency phase. Tele-orthodontics demonstrated to be a viable tool to continue at least some orthodontic care in times of emergency, but it may be considered an appropriate solution and addition even in normal times to ease therapy demands for both the orthodontist and the patient, while reducing time and money spent, without an excessive decrease in orthodontic quality.
C1 [Saccomanno, S.] Univ Aquila, Orthodont Residency Sch, Laquila, Italy.
   [Quinzi, V.] Univ Aquila, Orthodont Residency, Laquila, Italy.
   [Sarhan, S.; Lagana, D.] Univ Cattolica Sacro Cuore, Sch Dent, Rome, Italy.
   [Marzo, G.] Univ Aquila, Sch Dent, Laquila, Italy.
RP Lagana, D (corresponding author), Univ Cattolica Sacro Cuore, Sch Dent, Rome, Italy.
EM daniele.lagana@outlook.it
CR [Anonymous], 2020, OD INF COVID 19 VERS
   Berndt J, 2008, AM J ORTHOD DENTOFAC, V134, P700, DOI 10.1016/j.ajodo.2007.12.023
   Cook J, 2001, J TELEMED TELECARE, V7, P324, DOI 10.1258/1357633011936958
   Estai M, 2018, J TELEMED TELECARE, V24, P147, DOI 10.1177/1357633X16689433
   Irving M, 2018, J TELEMED TELECARE, V24, P129, DOI 10.1177/1357633X16686776
   Mandall NA, 2005, BRIT DENT J, V199, P659, DOI 10.1038/sj.bdj.4812930
   Paolantonio EG, 2019, EUR J PAEDIATR DENT, V20, P204, DOI 10.23804/ejpd.2019.20.03.07
   Quinzi V, 2019, EUR J PAEDIATR DENT, V20, P164, DOI 10.23804/ejpd.2019.20.02.16
   Stephens Chris, 2002, Dent Clin North Am, V46, P507, DOI 10.1016/S0011-8532(02)00010-1
NR 9
TC 3
Z9 3
U1 0
U2 0
PU ARIESDUE SRL
PI CARIMATE
PA VIA AIROLDI, CARIMATE, 11-22060, ITALY
SN 1591-996X
EI 2035-648X
J9 EUR J PAEDIATR DENT
JI Eur. J. Paediatr. Dent.
PY 2020
VL 21
IS 2
BP 157
EP 162
DI 10.23804/ejpd.2020.21.02.12
PG 6
WC Dentistry, Oral Surgery & Medicine; Pediatrics
SC Dentistry, Oral Surgery & Medicine; Pediatrics
GA NW4VN
UT WOS:000575006500013
PM 32567949
DA 2021-01-01
ER

PT J
AU Hayashi, T
   Abiko, K
   Mandai, M
   Yaegashi, N
   Konishi, I
AF Hayashi, Takuma
   Abiko, Kaoru
   Mandai, Masaki
   Yaegashi, Nobuo
   Konishi, Ikuo
TI Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2
   between humans and mammals
SO VETERINARY QUARTERLY
LA English
DT Article
DE SARS-CoV-2; COVID-19; ACE2; binding region; mink
ID SARS-CORONAVIRUS
AB Several cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection transmitted from human owners to their dogs have recently been reported. The first ever case of SARS-CoV-2 transmission from a human owner to a domestic cat was confirmed on March 27, 2020. A tiger from a zoo in New York, USA, was also reportedly infected with SARS-CoV-2. It is believed that SARS-CoV-2 was transmitted to tigers from their caretakers, who were previously infected with this virus. On May 25, 2020, the Dutch Minister of Agriculture, Nature and Food Quality reported that two employees were infected with SARS-CoV-2 transmitted from minks. These reports have influenced us to perform a comparative analysis among angiotensin-converting enzyme 2 (ACE2) homologous proteins for verifying the conservation of specific protein regions. One of the most conserved peptides is represented by the peptide "353-KGDFR-357 (H. sapiensACE2 residue numbering), which is located on the surface of the ACE2 molecule and participates in the binding of SARS-CoV-2 spike receptor binding domain (RBD). Multiple sequence alignments of the ACE2 proteins by ClustalW, whereas the three-dimensional structure of its binding region for the spike glycoprotein of SARS-CoV-2 was assessed by means of Spanner, a structural homology modeling pipeline method. In addition, evolutionary phylogenetic tree analysis by ETE3 was used. ACE2 works as a receptor for the SARS-CoV-2 spike glycoprotein between humans, dogs, cats, tigers, minks, and other animals, except for snakes. The three-dimensional structure of the KGDFR hosting protein region involved in direct interactions with SARS-CoV-2 spike RBD of the mink ACE2 appears to form a loop structurally related to the human ACE2 corresponding protein loop, despite of the reduced available protein length (401 residues of the mink ACE2 available sequence vs 805 residues of the human ACE2). The multiple sequence alignments of the ACE2 proteins shows high homology and complete conservation of the five amino acid residues: 353-KGDFR-357 with humans, dogs, cats, tigers, minks, and other animals, except for snakes. Where the information revealed from our examinations can support precision vaccine design and the discovery of antiviral therapeutics, which will accelerate the development of medical countermeasures, the World Health Organization recently reported on the possible risks of reciprocal infections regarding SARS-CoV-2 transmission from animals to humans.
C1 [Hayashi, Takuma; Abiko, Kaoru; Konishi, Ikuo] Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan.
   [Hayashi, Takuma] Japan Sci & Technol Agcy JST, START, Tokyo, Japan.
   [Mandai, Masaki; Konishi, Ikuo] Kyoto Univ, Sch Med, Dept Obstet & Gynecol, Kyoto, Japan.
   [Yaegashi, Nobuo] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan.
   [Konishi, Ikuo] Asian Soc Gynecol Oncol, Tokyo, Japan.
RP Hayashi, T (corresponding author), Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan.
EM yoyoyo224@hotmail.com
FU Japan Ministry of Education, Culture, Sports, Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [24592510, 15K1079, 19K09840]; Foundation of
   Osaka Cancer Research; Ichiro Kanehara Foundation for the Promotion of
   Medical Sciences and Medical Care; Foundation for Promotion of Cancer
   Research; Kanzawa Medical Research FoundationKanzawa Medical Research
   Foundation; Shinshu Medical Foundation; Takeda Foundation for Medical
   Science
FX This study was supported in part by grants from the Japan Ministry of
   Education, Culture, Sports, Science and Technology (Nos. 24592510,
   15K1079, and 19K09840); Foundation of Osaka Cancer Research; Ichiro
   Kanehara Foundation for the Promotion of Medical Sciences and Medical
   Care; Foundation for Promotion of Cancer Research; Kanzawa Medical
   Research Foundation; Shinshu Medical Foundation; and Takeda Foundation
   for Medical Science.
CR [Anonymous], 2020, WHO REPORT
   [Anonymous], 2020, AP NEWS         0422
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Cyranoski D, 2020, NATURE, V579, P18, DOI 10.1038/d41586-020-00548-w
   Daly N, 2020, NATL GEOGRAPHIC
   Enserink M, 2020, SCIENCE, V368, P1169, DOI 10.1126/science.368.6496.1169
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mercurio I, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03580-1
   Patterson E I, 2020, bioRxiv, DOI 10.1101/2020.07.21.214346
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Sit THC, 2020, NATURE, DOI 10.1038/s41586-020-2334-5
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   World Health Organization, 2020, COR DIS COVID 2019 S
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 19
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0165-2176
EI 1875-5941
J9 VET QUART
JI Vet. Q.
PD JAN 1
PY 2020
VL 40
IS 1
BP 243
EP 249
DI 10.1080/01652176.2020.1823522
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA NU2WP
UT WOS:000573504100001
PM 32921279
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abdel-Basset, M
   Hawash, H
   Elhoseny, M
   Chakrabortty, RK
   Ryan, M
AF Abdel-Basset, Mohamed
   Hawash, Hossam
   Elhoseny, Mohamed
   Chakrabortty, Ripon K.
   Ryan, Michael
TI DeepH-DTA: Deep Learning for Predicting Drug-Target Interactions: A Case
   Study of COVID-19 Drug Repurposing
SO IEEE ACCESS
LA English
DT Article
DE Drugs; Proteins; Diffusion tensor imaging; Compounds; Machine learning;
   Feature extraction; Inhibitors; Deep learning; drug-target interaction;
   SARS-CoV-2
ID CHLOROQUINE
AB The rapid spread of novel coronavirus pneumonia (COVID-19) has led to a dramatically increased mortality rate worldwide. Despite many efforts, the rapid development of an effective vaccine for this novel virus will take considerable time and relies on the identification of drug-target (DT) interactions utilizing commercially available medication to identify potential inhibitors. Motivated by this, we propose a new framework, called DeepH-DTA, for predicting DT binding affinities for heterogeneous drugs. We propose a heterogeneous graph attention (HGAT) model to learn topological information of compound molecules and bidirectional ConvLSTM layers for modeling spatio-sequential information in simplified molecular-input line-entry system (SMILES) sequences of drug data. For protein sequences, we propose a squeezed-excited dense convolutional network for learning hidden representations within amino acid sequences; while utilizing advanced embedding techniques for encoding both kinds of input sequences. The performance of DeepH-DTA is evaluated through extensive experiments against cutting-edge approaches utilising two public datasets (Davis, and KIBA) which comprise eclectic samples of the kinase protein family and the pertinent inhibitors. DeepH-DTA attains the highest Concordance Index (CI) of 0.924 and 0.927 and also achieved a mean square error (MSE) of 0.195 and 0.111 on the Davis and KIBA datasets respectively. Moreover, a study using FDA-approved drugs from the Drug Bank database is performed using DeepH-DTA to predict the affinity scores of drugs against SARS-CoV-2 amino acid sequences, and the results show that that the model can predict some of the SARS-Cov-2 inhibitors that have been recently approved in many clinical studies.
C1 [Abdel-Basset, Mohamed; Hawash, Hossam] Zagazig Univ, Fac Comp & Informat, Zagazig 44519, Egypt.
   [Elhoseny, Mohamed] Amer Univ Emirates, Dept Comp Sci, Coll Comp Informat Technol, Dubai 503000, U Arab Emirates.
   [Elhoseny, Mohamed] Mansoura Univ, Fac Comp & Informat, Mansoura 35516, Egypt.
   [Chakrabortty, Ripon K.; Ryan, Michael] Univ New South Wales Canberra, Sch Engn & IT, Capabil Syst Ctr, Canberra, ACT 2612, Australia.
RP Abdel-Basset, M (corresponding author), Zagazig Univ, Fac Comp & Informat, Zagazig 44519, Egypt.
EM analyst_mohamed@zu.edu.eg
OI Chakrabortty, Ripon/0000-0002-7373-0149
CR Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gao Kaifu, 2020, bioRxiv, DOI 10.1101/2020.01.30.927889
   Gawehn E, 2018, EXPERT OPIN DRUG DIS, V13, P579, DOI 10.1080/17460441.2018.1465407
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   He T, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0209-z
   Hingorani AD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54849-w
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu F, 2020, ARXIV200300728
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/CVPR.2018.00745, 10.1109/TPAMI.2019.2913372]
   Hu SS, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3263-x
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Jakhar D, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0853-0
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Kipf T. N., 2016, ARXIV160902907
   Lee JB, 2020, AM J SPEECH-LANG PAT, V29, P393, DOI [10.1044/2019_AJSLP-CAC48-18-0220, 10.1093/bioinformatics/btz682]
   Lin X., 2020, ARXIV200313902
   Liu TQ, 2007, NUCLEIC ACIDS RES, V35, pD198, DOI 10.1093/nar/gkl999
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Madhukar NS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12928-6
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mikolov T, 2013, ADV NEURAL INF PROCE, V3111, P3119
   Nguyen T., 2019, GRAPHDTA PREDICTION, DOI [10.1101/684662, DOI 10.1101/684662]
   Ozturk H., 2019, ARXIV190204166
   Ozturk H, 2018, BIOINFORMATICS, V34, P821, DOI 10.1093/bioinformatics/bty593
   Pahikkala T, 2015, BRIEF BIOINFORM, V16, P325, DOI 10.1093/bib/bbu010
   Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228
   Quan Z, 2018, IEEE INT C BIOINFORM, P728, DOI 10.1109/BIBM.2018.8621313
   Rifaioglu AS, 2020, CHEM SCI, V11, P2531, DOI 10.1039/c9sc03414e
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Saraon P, 2020, NAT CHEM BIOL, V16, P577, DOI 10.1038/s41589-020-0484-2
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shin B., 2019, ARXIV190806760
   Song WP, 2019, PROCEEDINGS OF THE TWELFTH ACM INTERNATIONAL CONFERENCE ON WEB SEARCH AND DATA MINING (WSDM'19), P555, DOI 10.1145/3289600.3290989
   Stower Hannah, 2020, Nat Med, V26, P465, DOI 10.1038/s41591-020-0849-9
   Tang Bowen, 2020, bioRxiv, DOI 10.1101/2020.03.03.972133
   Tang J, 2014, J CHEM INF MODEL, V54, P735, DOI 10.1021/ci400709d
   Tsubaki M, 2019, BIOINFORMATICS, V35, P309, DOI 10.1093/bioinformatics/bty535
   Vidmar R.J., 1992, IEEE T PLASMA SCI, V21, P876
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang XF, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00267
   Wang X, 2019, WEB CONFERENCE 2019: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW 2019), P2022, DOI 10.1145/3308558.3313562
   Wang YB, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-1052-0
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   Xingjian S., 2015, ADV NEURAL INFORM PR, P802
   Yang Z., 2019, ADV NEURAL INFORM PR, P5753
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang HP, 2020, INTERDISCIP SCI, V12, P368, DOI 10.1007/s12539-020-00376-6
   Zhao LL, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01243
   Zhao QC, 2019, IEEE INT C BIOINFORM, P64, DOI 10.1109/BIBM47256.2019.8983125
   Zhavoronkov A., 2020, TECH REP, V307, DOI [10.26434/chemrxiv.12301457.v1, DOI 10.26434/CHEMRXIV.12301457.V1]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 64
TC 0
Z9 0
U1 2
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 170433
EP 170451
DI 10.1109/ACCESS.2020.3024238
PG 19
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA NT4LY
UT WOS:000572915600001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Torkos, T
   Macay, J
AF Torkos, T.
   Macay, J.
TI Flavonoids as a potential adjuvant therapy of COVID-19?
SO BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
LA English
DT Letter
C1 [Torkos, T.] Highly Specialized Profess Inst Geriatr, Strojarenska 13, Kosice 04001, Slovakia.
   [Macay, J.] Benfield 8, Grasmere LA22 9RD, Cumbria, England.
RP Macay, J (corresponding author), 3 Market Strand, Padstow PL28 8AH, Cornwall, England.
EM mejcej@gmail.com
CR Bilaloglu Seda, JAMA
   Ginter E, 2012, BRATISL MED J, V113, P476, DOI 10.4149/BLL_2012_105
   Hatala R., PROPOSAL COMPLEMENTA
   Sanders JM, JAMA
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 5
TC 0
Z9 0
U1 1
U2 1
PU COMENIUS UNIV
PI BRATISLAVA I
PA SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA
SN 0006-9248
EI 1336-0345
J9 BRATISL MED J
JI Bratisl. Med. J.
PY 2020
VL 121
IS 9
BP 687
EP 687
DI 10.4149/BLL_2020_112
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR5AX
UT WOS:000571576000013
PM 32990020
OA Bronze
DA 2021-01-01
ER

PT J
AU Penate-Medina, T
   Damoah, C
   Benezra, M
   Will, O
   Kairemo, K
   Humbert, J
   Sebens, S
   Penate-Medina, O
AF Penate-Medina, Tuula
   Damoah, Christabel
   Benezra, Miriam
   Will, Olga
   Kairemo, Kalevi
   Humbert, Jana
   Sebens, Susanne
   Penate-Medina, Oula
TI Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory
   Bowel Disease (IBD)
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE alpha MSH; DSS model; liposomes; fluorescence; targeting; IBD
   inflammation
ID MELANOCYTE-STIMULATING HORMONE; SILICA NANOPARTICLES; DRUG-DELIVERY
AB Background: The purpose of our study was to find a novel targeted imaging and drug delivery vehicle for inflammatory bowel disease (IBD). IBD is a common and troublesome disease that still lacks effective therapy and imaging options. As an attempt to improve the disease treatment, we tested alpha MSH for the targeting of nanoliposomes to IBD sites. alpha MSH, an endogenous tridecapeptide, binds to the melanocortin-1 receptor (MC1-R) and has anti-inflammatory and immunomodulating effects. MC1-R is found on macrophages, neutrophils and the renal tubule system. We formulated and tested a liposomal nanoparticle involving alpha MSH in order to achieve a specific targeting to the inflamed intestines.
   Methods: NDP-alpha MSH peptide conjugated to Alexa Fluor (TM) 680 was linked to the liposomal membrane via N-Succinyl PE and additionally loaded into the lumen of the liposomes. Liposomes without the alpha MSH-conjugate and free NDP-alpha MSH were used as a control. The liposomes were also loaded with ICG to track them. The liposomes were tested in DSS treated mice, which had received DSS via drinking water order to develop a model IBD. Inflammation severity was assessed by the Disease Activity Index (DAI) score and ex vivo histological CD68 staining of samples taken from different parts of the intestine. The liposome targeting was analyzed by analyzing the ICG and ALEXA 680 fluorescence in the intestine compared to the biodistribution.
   Results: NPD-alpha MSH was successfully labeled with Alexa and retained its biological activity. Liposomes were identified in expected regions in the inflamed bowel regions and in the kidneys, where MC1-R is abundant. In vivo liposome targeting correlated with the macrophage concentration at the site of the inflammation supporting the active targeting of the liposomes through aMSH. The liposomal aMSH was well tolerated by animals.
   Conclusion: This study opens up the possibility to further develop an alpha MSH targeted theranostic delivery to different clinically relevant applications in IBD inflammation but also opens possibilities for use in other inflammations like lung inflammation in Covid 19.
C1 [Penate-Medina, Tuula; Will, Olga; Humbert, Jana; Penate-Medina, Oula] Univ Kiel, Univ Med Ctr Schleswig Holstein UKSH, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Kiel, Germany.
   [Penate-Medina, Tuula; Will, Olga; Humbert, Jana; Penate-Medina, Oula] MOIN CC, Bot Garten 14, D-24118 Kiel, Germany.
   [Penate-Medina, Tuula; Damoah, Christabel; Sebens, Susanne; Penate-Medina, Oula] Inst Expt Tumorforsch IET, Arnold Heller Str 3,Bldg U30, D-24105 Kiel, Germany.
   [Benezra, Miriam] Touro Coll, Dept Biol, New York, NY 10006 USA.
   [Benezra, Miriam] Baruch Coll, Dept Nat Sci, New York, NY 10010 USA.
   [Kairemo, Kalevi] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA.
   [Humbert, Jana] Univ Kiel, Univ Med Ctr Schleswig Holstein UKSH, Dept Radiol & Neuroradiol, Kiel, Germany.
RP Penate-Medina, T (corresponding author), Univ Kiel, Univ Med Ctr Schleswig Holstein UKSH, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Kiel, Germany.; Penate-Medina, T (corresponding author), MOIN CC, Bot Garten 14, D-24118 Kiel, Germany.
EM oula.penate@rad.uni-kiel.de
RI penate medina, oula/G-5136-2012
OI penate medina, oula/0000-0001-9878-5309; Kairemo,
   Kalevi/0000-0002-5194-746X
FU Damp Foundation; European Union ERDF-European Regional Development Fund
   [122 09 053]; cluster of Excellence "Inflammation at Interfaces"
   [EXC306]; European Regional Development Fund (ERDF)European Union (EU);
   ZukunftsprogrammWirtschaft of Schleswig-Holstein, Germany [122-09-053];
   state of Schleswig-Holstein; intramural grant for Oula Penate Medina
   (FoFo 2012); intramural grant for Tuula Penate Medina (FoFo 2014)
FX The study was funded in part by the Damp Foundation, a research grant
   from the state of Schleswig-Holstein and the European Union
   ERDF-European Regional Development Fund (122 09 053) (MOIN CC,
   Zukunftsprogramm Wirtschaft), as well as intramural grants for Oula
   Penate Medina (FoFo 2012) and Tuula Penate Medina (FoFo 2014). The
   cluster of Excellence "Inflammation at Interfaces" (EXC306), Kiel
   University and the Medical Faculty are acknowledged for supporting the
   Molecular Imaging North Competence Center (MOIN CC) as a core facility
   for imaging in vivo. MOIN CC was founded by a grant of the European
   Regional Development Fund (ERDF) and the ZukunftsprogrammWirtschaft of
   Schleswig-Holstein (Project no. 122-09-053), Germany.
CR Benezra M, 2011, J CLIN INVEST, V121, P2768, DOI 10.1172/JCI45600
   Brzoska T, 2010, ADV EXP MED BIOL, V681, P107, DOI 10.1007/978-1-4419-6354-3_8
   Burns AA, 2009, NANO LETT, V9, P442, DOI 10.1021/nl803405h
   Chen F, 2018, ACS APPL MATER INTER, V10, P4379, DOI 10.1021/acsami.7b14362
   Ericson MD, 2017, J MED CHEM, V60, P805, DOI 10.1021/acs.jmedchem.6b01707
   Etemad-Moghadam B, 2002, J NEUROIMMUNOL, V125, P23, DOI 10.1016/S0165-5728(02)00015-2
   Heneweer C, 2012, THER DELIV, V3, P645, DOI 10.4155/TDE.12.38
   Hu GR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01998
   Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004
   Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678
   Kohda Y, 1998, CURR OPIN NEPHROL HY, V7, P413, DOI 10.1097/00041552-199807000-00011
   Lee JB, 2012, INT J CANCER, V131, pE781, DOI 10.1002/ijc.27361
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   Mura S, 2012, ADV DRUG DELIVER REV, V64, P1394, DOI 10.1016/j.addr.2012.06.006
   Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4
   Patel HB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00041
   Penate-Medina O, 2014, United States patent application, Patent No. [US 14/162, 494, 14162494]
   Phillips E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009524
   SINGH M, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/874610
   Wei PJ, 2016, J MED MICROBIOL, V65, P160, DOI 10.1099/jmm.0.000197
   Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41
NR 21
TC 1
Z9 1
U1 3
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2020
VL 26
IS 31
BP 3840
EP 3846
DI 10.2174/1381612826666200727002716
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NR2ZA
UT WOS:000571430500009
PM 32718282
DA 2021-01-01
ER

PT J
AU Mohamud, MFY
   Mohamed, YG
   Ali, AM
   Adam, BA
AF Mohamud, Mohamed Farah Yusuf
   Mohamed, Yahye Garad
   Ali, Abdiladhif Mohamed
   Adam, Bakar Ali
TI Loss of Taste and Smell are Common Clinical Characteristics of Patients
   with COVID-19 in Somalia: A Retrospective Double Centre Study
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE anosmia; ageusia; severe acute respiratory syndrome coronavirus 2;
   SARS-CoV-2; pneumonia
ID CORONAVIRUS; PNEUMONIA
AB Purpose: The purpose of this study was to identify the common clinical presentations and the evidence on the presence of ageusia and anosmia as an emerging coronavirus disease 2019 (COVID-19) symptom to better inform in both COVID-19 patients and clinicians.
   Patients and Methods: As part of a double-institutional collaboration coordinated by doctors, this study retrospectively collected and analyzed the clinical characteristics of 60 patients with COVID-19 pneumonia between April 1 and April 20, 2020. Pregnant women and patients taking anti-cancer drugs had been excluded from the study. Data from each institution's electronic medical record had been obtained.
   Results: Sixty patients who had RT-PCR positive for COVID-19 were included in this study; of these patients, all of them had unknown exposure to COVID-19. The mean (SD) age was 45.7 (13.5) years, and 42 were men (70%). Of these patients, 80% had at least ageusia or anosmia. The most common symptoms at the onset of illness were cough (75%), fever (71.3%), myalgia or fatigue (53.3%), anosmia (loss of smell) (40%), ageusia (loss of taste) (28.3%), sore throat (25%), shortness of breath (16.7%), headache (16.7%), and GI symptoms (diarrhea, nausea, vomiting and loss appetite) (16.7%). A total of 68.3% of COVID-19 infected patients had reported either loss of taste or smell, and about 33.3% of them had only loss of smell, while 23.3% of them had impaired taste, and 11.7% of COVID-19 infected patients had both taste and smell loss.
   Conclusion: During the epidemic period of SARS-CoV-2 infection, when presenting patients with ageusia and anosmia, physicians should consider COVID-19 pneumonia as a differential diagnosis to achieve early identification, avoid the delayed diagnosis, and prevention of transmission.
C1 [Mohamud, Mohamed Farah Yusuf; Mohamed, Yahye Garad; Ali, Abdiladhif Mohamed; Adam, Bakar Ali] Mogadishu Somali Turkish Training & Res Hosp, Mogadishu, Somalia.
RP Mohamud, MFY (corresponding author), Turkish Training & Res Hosp, Thirty St Alikamin, Wartanabada Dist, Mogadishu, Somalia.
EM m.qadar59@gmail.com
OI Garad Mohamed, Yahye/0000-0003-3767-1644
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   Beltran-Corbellini A, 2020, EUR J NEUROL, V22
   Cabaraux P, 2020, OBJECTIVE OLFACTORY
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Haro-Licer J, 2013, ACTA OTORRINOLAR ESP, V64, P331, DOI [10.1016/j.otorri.2013.04.003, 10.1016/j.otoeng.2013.10.004]
   Doty Richard L, 2019, Handb Clin Neurol, V164, P3, DOI 10.1016/B978-0-444-63855-7.00001-0
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Hopkins C, 2020, ENT UK, V26, P2020
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Lovato A, 2020, ENT-EAR NOSE THROAT
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Printza A, 2020, EUR ARCH OTO-RHINO-L, V277, P2625, DOI 10.1007/s00405-020-06069-6
   SONNA, 2020, DOWL OO XAQ AY SOOKO
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V42, P1560, DOI 10.1002/hed.26269
   van Riel D, 2015, J PATHOL, V235, P277, DOI 10.1002/path.4461
   Wang P, 2020, EPIDEMIOLOGICAL CHAR
   Wee LE, 2020, EUR ARCH OTO-RHINO-L, V277, P2389, DOI 10.1007/s00405-020-05999-5
   World Health Organization, 2005, 2 M INT HLTH REG EM
   Yamagishi Masuo, 1994, Rhinology (Utrecht), V32, P113
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 20
TC 2
Z9 2
U1 2
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 2631
EP 2635
DI 10.2147/IDR.S263632
PG 5
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NR3WM
UT WOS:000571494000001
PM 32801800
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alonazi, WB
AF Alonazi, Wadi B.
TI The Impact of Emotional Intelligence on Job Performance During COVID-19
   Crisis: A Cross-Sectional Analysis
SO PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT
LA English
DT Article
DE emotional intelligence; nurses; job performance; COVID-19
ID WORK; LEADERSHIP; EMPLOYEES; NURSES; STRESS
AB Background: During a pandemic, healthcare professionals encounter various health hazards that affect their personal life and workplace. Emotional intelligence (EI) has a substantial impact on nurses' success and performance in the healthcare industry. However, previous research studies report inconsistent findings regarding how different levels of EI affect job performance (JP), particularly during pandemics. The present study contributes to the literature on this contemporary topic by investigating the impact of EI on JP among nurses during COVID-19 crisis management in Saudi Arabia (SA).
   Methods: In a convenience sampling, 340 nurses from three tertiary hospitals completed an online survey assessing EI and JP during COVID-19 climax levels in March and April, 2020. Only nurses who had direct contact with patients diagnosed with COVID-19 were eligible. The Wong & Law EI scale (WLEIS) was used in a cross-sectional design to determine participants' EI. Empirically, JP was measured by the Individual Work Performance Questionnaire (IWPQ). Data analysis was performed using SPSS statistical software version 20.0 (IBM Corp).
   Results: Generally, nurses reported, out of a 5 -point Likert scale, moderate to high levels of EI (M = 3.99, SD = 0.434). Nurses in critical care units demonstrated the highest levels of EI, followed by nurses in intensive care, neonatal intensive care, then general nurses. Nurses working in respiratory therapy demonstrated the lowest levels. Across all groups during crisis, nurses reported a significant impact of EI on JP (beta = 0.389, p < 0.01).
   Conclusion: Nurses reported satisfactory levels of EI, and most of their practices were aligned with national standards during COVID-19, but slightly in inverse to EI. However, more research is necessary to understand the greater impact of stressors influencing JP to the extent that levels of EI are no longer satisfactory.
C1 [Alonazi, Wadi B.] King Saud Univ, Hlth & Hosp Adm, Coll Business Adm, POB 71115, Riyadh 11587, Saudi Arabia.
RP Alonazi, WB (corresponding author), King Saud Univ, Hlth & Hosp Adm, Coll Business Adm, POB 71115, Riyadh 11587, Saudi Arabia.
EM waalonazi@ksu.edu.sa
FU Deanship of Scientific Research at King Saud UniversityKing Saud
   University; Research Center at the College of Business Administration
FX The author extends his appreciation to the Deanship of Scientific
   Research at King Saud University and the Research Center at the College
   of Business Administration for supporting this work.
CR Aftab HA, 2012, INT J BUS MANAG SOC, V3, P174
   Akhtar M, 2017, J ACCOUNT MARK, V6, P1, DOI 10.4172/2168-9601.1000259
   Akhtar W, 2017, J ACCOUNT MARK, V6, P2, DOI [10.4172/2168-9601.1000243, DOI 10.4172/2168-9601.1000243]
   Al-Ahmadi H, 2009, INT J HEALTH CARE Q, V22, P40, DOI 10.1108/09526860910927943
   Al-Hamdan Z, 2017, NURS FORUM, V52, P12, DOI 10.1111/nuf.12160
   Alessandri G, 2020, J RES PERS, V85, DOI 10.1016/j.jrp.2020.103913
   Ali SR, 2013, J CAREER ASSESSMENT, V21, P111, DOI 10.1177/1069072712454820
   Almutairi KM, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5999-z
   Alshammari Farhan, 2020, J Prof Nurs, V36, P503, DOI 10.1016/j.profnurs.2020.04.003
   Arora S, 2010, MED EDUC, V44, P749, DOI 10.1111/j.1365-2923.2010.03709.x
   Bailey C, 2011, J CLIN NURS, V20, P3364, DOI 10.1111/j.1365-2702.2011.03860.x
   Birks Y, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-61
   Cadman C, 2001, J Nurs Manag, V9, P321, DOI 10.1046/j.0966-0429.2001.00261.x
   Cheshire MH, 2020, NURS EDUC PERSPECT, V41, P103, DOI 10.1097/01.NEP.0000000000000476
   Coetzee M, 2014, J VOCAT BEHAV, V84, P90, DOI 10.1016/j.jvb.2013.09.001
   Coleman D., 1995, EMOTIONAL INTELLIGEN
   Czabanowska K, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-83
   Deshpande SP, 2009, J BUS ETHICS, V85, P403, DOI 10.1007/s10551-008-9779-z
   Di Fabio A, 2013, J CAREER ASSESSMENT, V21, P42, DOI 10.1177/1069072712454698
   Doherty EM, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-38
   Ebrahim SH, 2020, LANCET, V395, pE48, DOI 10.1016/S0140-6736(20)30466-9
   Ebrahim SH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa029
   Freshman Brenda, 2002, Health Care Manag (Frederick), V20, P1
   Goleman D., 2013, PRIMAL LEADERSHIP UN
   Huang H, 2019, PSYCHOL RES BEHAV MA, V12, P351, DOI 10.2147/PRBM.S207283
   Hulsheger UR, 2013, J APPL PSYCHOL, V98, P310, DOI 10.1037/a0031313
   HUNT SD, 1982, J MARKETING RES, V19, P269, DOI 10.2307/3151627
   Koopmans L, 2011, J OCCUP ENVIRON MED, V53, P856, DOI 10.1097/JOM.0b013e318226a763
   KREJCIE RV, 1970, EDUC PSYCHOL MEAS, V30, P607, DOI 10.1177/001316447003000308
   Landa J. M. A., 2010, PSYCHOLOGY, V1, P50, DOI [10.4236/psych.2010.11008, DOI 10.4236/PSYCH.2010.11008]
   Lucas V, 2008, J NURS MANAGE, V16, P964, DOI 10.1111/j.1365-2834.2008.00856.x
   Mann K, 2011, ACAD MED, V86, P1120, DOI 10.1097/ACM.0b013e318226abdd
   Marcus-Varwijk AE, 2020, J AGING HEALTH, V32, P83, DOI 10.1177/0898264318804946
   McCallin Antoinette, 2007, J Nurs Manag, V15, P386, DOI 10.1111/j.1365-2834.2007.00711.x
   McQueen ACH, 2004, J ADV NURS, V47, P101, DOI 10.1111/j.1365-2648.2004.03069.x
   Mo YY, 2020, J NURS MANAGE, V28, P1002, DOI 10.1111/jonm.13014
   MOGHADAM A. H., 2011, WORLD APPL SCI J, V12, P1017
   Nightingale S, 2017, INT J NURS STUD, V80, P106, DOI 10.1016/j.ijnurstu.2018.01.006
   Nunnally J. C., 1994, PSYCHOMETRIC THEORY
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879
   Ram P., 2013, INT J ACAD RES EC MA, V2, P16
   Restubog SLD, 2020, J VOCAT BEHAV, V119, DOI 10.1016/j.jvb.2020.103440
   Shooshtarian Z, 2013, IRAN J MANAG STUD, V6, P27, DOI 10.22059/ijms.2013.30123
   Sommer SA, 2016, GROUP ORGAN MANAGE, V41, P172, DOI 10.1177/1059601115578027
   Talman K, 2020, NURS EDUC TODAY, V85, DOI 10.1016/j.nedt.2019.104271
   Trivellas P., 2011, ADV INFORM PROCESSIN, V1, P356
   Vahidi M, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/9547038
   Webb CA, 2013, INTELLIGENCE, V41, P149, DOI 10.1016/j.intell.2013.01.004
   Wong CS, 2002, LEADERSHIP QUART, V13, P243, DOI 10.1016/S1048-9843(02)00099-1
   Wu WZ, 2020, J MED VIROL, V92, P1962, DOI 10.1002/jmv.25914
   Wu YC, 2011, SOC BEHAV PERSONAL, V39, P21, DOI 10.2224/sbp.2011.39.1.21
NR 51
TC 0
Z9 0
U1 6
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1578
J9 PSYCHOL RES BEHAV MA
JI Psychol. Res. Behav. Manag.
PY 2020
VL 13
BP 749
EP 757
DI 10.2147/PRBM.S263656
PG 9
WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary
SC Psychology; Psychiatry
GA NR4NZ
UT WOS:000571542400001
PM 33061691
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, XG
   Zhou, YZ
   Zhang, X
   Li, JM
   Zhou, XM
   Zhang, ZW
AF Wang, Xiaogang
   Zhou, Yangzhao
   Zhang, Xia
   Li, Jianming
   Zhou, Xinmin
   Zhang, ZhiWei
TI Management Strategies for Patients After CABG Surgery in the Outbreak of
   the COVID-19 Pandemic
SO RISK MANAGEMENT AND HEALTHCARE POLICY
LA English
DT Article
DE cardiovascular patients; CABG; COVID-19 pandemic
ID THERAPY
AB Background: The novel coronavirus 2019 pandemic (COVID-19) has quickly spread over the world and affected over 100 countries so far. Patients with pre-existing cardiovascular disease may have a higher risk of infection of COVID-19 and worse outcomes than others. To improve the outcome during the pandemic, management strategies for the patients recovering from coronary artery bypass graft (CABG) surgery need to be reconsidered.
   Methods: Some precaution advices including self-protection, blood glucose and blood pressure controlling are recommended for the patients recovering from CABG during the pandemic. They are encouraged to communicate with doctors by telephone or Internet when COVID-19 related symptoms such as cough, fever and dyspnea occur. As a follow-up strategy for patients after CABG surgery, cardiac biomarkers and CTA could also be helpful to the diagnosis of COVID-19. Some medications being investigated for COVID-19 therapy may have side effects relevant to cardiovascular disease. Appropriate personal protection equipment (PPE) is necessary for cardiovascular health-care workers operating in clinical settings.
   Results: There was zero out of over 300 follow-up patients after CABG surgery confirmed to be infected with COVID-19 from January to June 2020. No cardiovascular health-care workers were reported to be infected neither in the Second Xiangya Hospital during the pandemic.
   Conclusion: The management strategy here we proposed could improve the outcome of patients after CABG during the pandemic and benefit both cardiovascular patients and health-care workers.
C1 [Wang, Xiaogang; Zhou, Yangzhao; Zhang, Xia; Li, Jianming; Zhou, Xinmin; Zhang, ZhiWei] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China.
   [Zhou, Yangzhao; Zhang, ZhiWei] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
RP Zhang, ZW (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Surg, Changsha 410011, Hunan, Peoples R China.
EM somebody_zhang@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81500187, 81502710]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81500187, 81502710).
CR Chinese Center of Disease Control and Prevention, 2020, EP UPD RISK ASS 2019
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
   Kernis SJ, 2004, J AM COLL CARDIOL, V43, P1773, DOI 10.1016/j.jacc.2003.09.071
   Luscher TF, 2003, CIRCULATION, V108, P1655, DOI 10.1161/01.CIR.0000089189.70578.E2
   Mavioglu HL, 2020, TURK GOGUS KALP DAMA, V28, P236, DOI 10.5606/tgkdc.dergisi.2020.09294
   Mayumi H, 1997, ANN THORAC SURG, V63, P129
   Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987
   Patel V, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017042
   Sousa-Uva M, 2019, EUR J CARDIO-THORAC, V55, P4, DOI 10.1093/ejcts/ezy289
   Turnbull F, 2005, ARCH INTERN MED, V165, P1410
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1179-1594
J9 RISK MANAG HEALTHC P
JI RISK MANAG. HEALTHC. POLICY
PY 2020
VL 13
BP 1655
EP 1659
DI 10.2147/RMHP.S271133
PG 5
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA NS1XI
UT WOS:000572056900001
PM 33061699
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cao, XQ
   Zhang, XW
   Meng, WH
   Zheng, H
AF Cao, Xueqin
   Zhang, Xianwei
   Meng, Weihua
   Zheng, Hua
TI Herpes Zoster and Postherpetic Neuralgia in an Elderly Patient with
   Critical COVID-19: A Case Report
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; herpes zoster; postherpetic neuralgia; elderly
   patient
ID EXACERBATION; GABAPENTIN; PAIN; CARE
AB Critical patients with COVID-19 are thought to be at high risk of developing chronic pain. However, the exact nature and mechanisms of COVID-19-related chronic pain remain largely unknown. Here, we describe clinical features, treatments and outcome of herpes zoster as well as postherpetic neuralgia in a 70-year-old woman with critical COVID-19. The patient had a history of type 2 diabetes and myasthenia gravis. She developed herpes zoster in the right 10 to 12 lumbar dermatomes in the recovery period of COVID-19. Intravenous (250 mg 3 times a day) and then oral (400 mg 5 times a day) acyclovir was used for antiviral therapy. Pregabalin (75 mg orally twice a day) and ibuprofen was used for analgesia. Her skin lesions resolved 21 days after the onset of rash. However, she continued to have persistent pain in the same dermatomal distribution. After the dosage of pregabalin was increased to 150 mg orally twice a day, her pain was partially relieved. During the telephone follow-up 4 months after herpes zoster eruption, the patient still complained intermittent pain in the right 10 to 12 lumbar dermatomes. Our case draws attention to postherpetic neuralgia in COVID-19 patients and provides a targeted suggestion for this kind of patients.
C1 [Cao, Xueqin; Zhang, Xianwei; Zheng, Hua] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol & Pain Med, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Meng, Weihua] Univ Dundee, Sch Med, Ninewells Hosp & Med Sch, Div Populat Hlth & Genom, Dundee DD2 4BF, Scotland.
RP Zheng, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anesthesiol & Pain Med, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM hzheng@hust.edu.cn
CR Argoff CE, 2011, POSTGRAD MED, V123, P134, DOI 10.3810/pgm.2011.09.2469
   Arvin AM, 2008, J INFECT DIS, V197, pS58, DOI 10.1086/522123
   Boneva N, 2000, MUSCLE NERVE, V23, P1204, DOI 10.1002/1097-4598(200008)23:8<1204::AID-MUS7>3.0.CO;2-H
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Biancatelli RMLC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01451
   Danikowski KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0892-8
   Elsaie ML, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13666
   Ertugrul G, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1789040
   Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Kemp HI, 2020, BRIT J ANAESTH, V125, P436, DOI 10.1016/j.bja.2020.05.021
   Kemp HI, 2019, BRIT J ANAESTH, V123, pE372, DOI 10.1016/j.bja.2019.03.025
   Le P, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5095
   Scheschonka A, 2003, PAIN, V104, P423, DOI 10.1016/S0304-3959(03)00004-6
   Sheen VL, 2010, MUSCLE NERVE, V42, P149, DOI 10.1002/mus.21708
   Weaver BA, 2007, J AM OSTEOPATH ASSOC, V107, pS2
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zheng KI, 2020, J MED VIROL, DOI 10.1002/jmv.26294
NR 19
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
J9 J PAIN RES
JI J. Pain Res.
PY 2020
VL 13
BP 2361
EP 2365
DI 10.2147/JPR.S274199
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA NR4MS
UT WOS:000571538900001
PM 33061551
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fattorini, L
   Creti, R
   Palma, C
   Pantosti, A
AF Fattorini, Lanfranco
   Creti, Roberta
   Palma, Carla
   Pantosti, Annalisa
CA Unit Antibiotic Resistance Specia
TI Bacterial coinfections in COVID-19: an underestimated adversary
SO ANNALI DELL ISTITUTO SUPERIORE DI SANITA
LA English
DT Article
DE COVID-19; bacterial coinfections; superinfections; antibiotics; therapy;
   intensive care units
ID CORONAVIRUS
AB Current literature shows that secondary bacterial infections, although less frequent than in previous influenza pandemics, affect COVID-19 patients. Mycoplasma pneumoniae, Staphylococcus aureus, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus and Klebsiella spp. are the main species isolated. Of note, Mycobacterium tuberculosis-COVID-19 coinfections are also reported. However, bacterial coinfection rates increase in patients admitted in the intensive care units, and those diseases can be due to super-infections by nosocomial antibiotic-resistant bacteria. This highlights the urgency to revise frequent and empiric prescription of broad-spectrum antibiotics in COVID-19 patients, with more attention to evidence-based studies and respect for the antimicrobial stewardship principles.
C1 [Fattorini, Lanfranco; Creti, Roberta; Palma, Carla; Pantosti, Annalisa; Unit Antibiotic Resistance Specia] Ist Super Sanita, Dipartimento Malattie Infett, Viale Regina Elena 299, I-00161 Rome, Italy.
RP Fattorini, L (corresponding author), Ist Super Sanita, Dipartimento Malattie Infett, Viale Regina Elena 299, I-00161 Rome, Italy.
EM lanfranco.fattorini@iss.it
RI errico, giulia/O-8924-2017
OI errico, giulia/0000-0001-9151-0652
CR Ai J.-W., 2020, OPTIMIZING DIAGNOSTI, DOI [10.1101/2020.02.13.20022673., DOI 10.1101/2020.02.13.20022673]
   Alfaraj SH, 2017, INTERVIROLOGY, V60, P53, DOI 10.1159/000477908
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Charalampous T, 2019, NAT BIOTECHNOL, V37, P783, DOI 10.1038/s41587-019-0156-5
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Crotty MP, 2020, INVESTIGATION SUBSEQ, DOI [10.1101/2020.05.29.20117176, DOI 10.1101/2020.05.29.20117176]
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Easom N, 2020, INFLUENZA OTHER RESP, V14, P374, DOI 10.1111/irv.12739
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hughes S, 2020, CLIN MICROBIOL INFEC, V26, P1395, DOI 10.1016/j.cmi.2020.06.025
   Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
   Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002
   Rhee C, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2899
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Stochino C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01708-2020
   Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01398-2020
   Togun T, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00363-1
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wilder-Smith A, 2004, EPIDEMIOL INFECT, V132, P407, DOI 10.1017/S0950268803001869
   Wingfield T, 2020, LANCET RESP MED, V8, P536, DOI 10.1016/S2213-2600(20)30151-X
   Wong Chak-Yen, 2004, J Chin Med Assoc, V67, P579
   World Health Organization, 2020, COVID 19 CONS TUB TB
   Xia W, 2020, PEDIATR PULM, V55, P1169, DOI 10.1002/ppul.24718
   Xing Q, 2020, PRECAUTIONS ARE NEED, DOI [10.1101/2020.02.29.20027698., DOI 10.1101/2020.02.29.20027698]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 1
Z9 1
U1 2
U2 2
PU PENSIERO SCIENTIFICO
PI ROME
PA VIA SAN GIOVANNI VALDARNO 8, ROME, 00198, ITALY
SN 0021-2571
J9 ANN I SUPER SANITA
JI Ann. Ist. Super. Sanita
PY 2020
VL 56
IS 3
BP 359
EP 364
DI 10.4415/ANN_20_03_14
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NO5GG
UT WOS:000569516100013
PM 32959802
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Maraschini, A
   Corsi, E
   Salvatore, MA
   Donati, S
AF Maraschini, Alice
   Corsi, Edoardo
   Salvatore, Michele Antonio
   Donati, Serena
CA ItOSS COVID-19 Working Grp
TI Coronavirus and birth in Italy: results of a national population-based
   cohort study
SO ANNALI DELL ISTITUTO SUPERIORE DI SANITA
LA English
DT Article
DE pregnancy; SARS-CoV-2; pregnancy outcome; COVID-19; cohort studies
ID DISEASE 2019 COVID-19
AB Introduction. The study was implemented to provide guidance to decision-makers and clinicians by describing hospital care offered to women who gave birth with confirmed SARS-CoV-2 infection.
   Materials and methods. National population-based prospective cohort study involving all women with confirmed SARS-CoV-2 infection who gave birth between February 25 and April 22, 2020 in any Italian hospital.
   Results. The incidence rate of confirmed SARS-CoV-2 infection in women who gave birth was 2.1 per 1000 maternities at a national level and 6.9/1000 in the Lombardy Region. Overall one third of the women developed a pneumonia and 49.7% assumed at least one drug against SARS-CoV-2 infection. Caesarean rate was 32.9%, no mothers nor newborns died. Six percent of the infants tested positive for SARS-CoV-2 at birth.
   Conclusions. Clinical features and outcomes of COVID-19 in women who gave birth are similar to those described for the general population, most women developing mild to moderate illness.
C1 [Maraschini, Alice; Salvatore, Michele Antonio; Donati, Serena] Ist Super Sanita, Ctr Nazl Prevenz Malattie & Promoz Salute, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Corsi, Edoardo] Univ Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy.
RP Donati, S (corresponding author), Ist Super Sanita, Ctr Nazl Prevenz Malattie & Promoz Salute, Viale Regina Elena 299, I-00161 Rome, Italy.
EM serena.donati@iss.it
CR [Anonymous], EPIDEMICS COVID 19
   Arabi S, 2020, MEDRXIV, DOI [10.1101/2020.04.05.20053983, DOI 10.1101/2020.04.05.20053983]
   Campi R, 2019, CERTIFICATO ASSISTEN
   Costantine MM, 2020, OBSTET GYNECOL, V136, P26, DOI [10.1097/A0G.0000000000003924, 10.1097/AOG.0000000000003924]
   Della Gatta AN, 2020, AM J OBSTET GYNECOL, V223, P36, DOI 10.1016/j.ajog.2020.04.013
   Dong L, 2020, JAMA-J AM MED ASSOC, V323, P1846, DOI 10.1001/jama.2020.4621
   European Medicines Agency, EMA 275870 2020
   KNIGHT M, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2107
   Patane Luisa, 2020, Am J Obstet Gynecol MFM, V2, P100145, DOI 10.1016/j.ajogmf.2020.100145
   Perrone E, 2019, BIRTH EMILIA ROMAGNA
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P848, DOI 10.1002/uog.22061
   Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194
   World Health Organization, 2020, CLIN MANAGEMENT SEVE
   World Health Organization Collaborating Centre for Women's Health University of Birmingham, COVID 19 PREGNANCY P
   Yan J, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.014
   Yang ZY, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1759541
NR 16
TC 0
Z9 0
U1 0
U2 0
PU PENSIERO SCIENTIFICO
PI ROME
PA VIA SAN GIOVANNI VALDARNO 8, ROME, 00198, ITALY
SN 0021-2571
J9 ANN I SUPER SANITA
JI Ann. Ist. Super. Sanita
PY 2020
VL 56
IS 3
BP 378
EP 389
DI 10.4415/ANN_20_03_17
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NO5GG
UT WOS:000569516100016
PM 32959805
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Di Stadio, A
   Ishai, R
   Gambacorta, V
   Korsch, F
   Ricci, G
   della Volpe, A
   Bernitsas, E
AF Di Stadio, A.
   Ishai, R.
   Gambacorta, V
   Korsch, F.
   Ricci, G.
   della Volpe, A.
   Bernitsas, E.
TI Nutraceuticals as immune-stimulating therapy to fight COVID-19.
   Combination of elements to improve the efficacy
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Immune modulation; Immune stimulation; Oral supplementation
ID SAMBUCUS-NIGRA; VITAMIN-D; RESPIRATORY SYMPTOMS; ELDERBERRY; INFLUENZA;
   ZINC; SUPPLEMENTATION; MODULATOR; SELENIUM; CHILDREN
AB COVID-19 pandemic has underlined that unknown viral infections, which jump from animals to humans, can be extremely dangerous. In case of new viruses as SARS-CoV2, available drugs can fail to contrast the virus aggressiveness leading patients to death. Long time is necessary to create a vaccine, but immediate solutions are necessary to stop the mortality COVID-19 related. We have learned that the immune-system is the key to reduce the severity of COVID-19 and, through its modulation, it has been possible saving people's life. In this short communication, we discuss the use of nutraceuticals to modulate and stimulate the immune answer for reducing the severity of COVID-19 symptoms. The nutraceuticals are safe and can be administered to all ages. In addition, combination of natural anti-viral elements and immune-stimulating molecules already successfully tested against others upper-respiratory tract infections-could be efficient against SARS-CoV2. We believe that these natural molecules could really be a valid ally against COVID-19, especially in this moment in which a SARS-CoV2 vaccine is still not available.
C1 [Di Stadio, A.; Gambacorta, V; Ricci, G.] Univ Perugia, Otolaryngol Dept, Perugia, Italy.
   [Ishai, R.] Bnai Zion Med Ctr, Otol & Neurotol & Head & Neck Surgert, Haifa, Israel.
   [Korsch, F.; della Volpe, A.] Santobono Posilipo Hosp, Otol & Cochlear Implant Unit, Naples, Italy.
   [Bernitsas, E.] Wayne State Univ, Multiple Sclerosis Ctr, Neurol Dept, Detroit, MI USA.
RP Di Stadio, A (corresponding author), Univ Perugia, Otolaryngol Dept, Perugia, Italy.
EM ariannadistadio@hotmail.com
RI Di Stadio, Arianna/Q-2498-2017
OI Di Stadio, Arianna/0000-0001-5510-3814
CR Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Avery JC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091203
   Barak V, 2001, EUR CYTOKINE NETW, V12, P290
   Bartosik-Psujek H, 2019, NEUROL NEUROCHIR POL, V53, P113, DOI 10.5603/PJNNS.a2019.0015
   Bonaventura P, 2015, AUTOIMMUN REV, V14, P277, DOI 10.1016/j.autrev.2014.11.008
   Boretti A, 2020, PHARMANUTRITION, V12, DOI 10.1016/j.phanu.2020.100190
   Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Ceccarelli G, 2019, EXPERT OPIN BIOL TH, V19, P949, DOI 10.1080/14712598.2019.1638907
   Chen C, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-24
   Chong HX, 2019, J DAIRY SCI, V102, P4783, DOI 10.3168/jds.2018-16103
   D'Angelo C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060615
   Della Volpe A, 2019, EUR REV MED PHARMACO, V23, P6360, DOI 10.26355/eurrev_201907_18460
   Di Stadio A, 2020, EUR REV MED PHARMACO, V24, P4066, DOI 10.26355/eurrev_202004_20980
   Di Stadio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061637
   Fabbri A, 2020, EUR REV MED PHARMACO, V24, P4038
   Fonolla J, 2019, EUR J NUTR, V58, P83, DOI 10.1007/s00394-017-1573-1
   Gao H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6872621
   Gombart AF, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010236
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gruber-Bzura BM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082419
   Harvie Michelle, 2014, Am Soc Clin Oncol Educ Book, pe478, DOI 10.14694/EdBook_AM.2014.34.e478
   Hawkins J, 2019, COMPLEMENT THER MED, V42, P361, DOI 10.1016/j.ctim.2018.12.004
   Hemila H, 2003, J ANTIMICROB CHEMOTH, V52, P1049, DOI 10.1093/jac/dkh002
   Ivory K, 2017, CLIN NUTR, V36, P407, DOI 10.1016/j.clnu.2015.12.003
   Jager R, 2020, PROBIOTICS ANTIMICRO, V12, P1330, DOI 10.1007/s12602-020-09656-5
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Kwak JY, 2017, BENEF MICROBES, V8, P657, DOI 10.3920/BM2016.0147
   Mahmoodpoor A, 2019, IMMUNOL INVEST, V48, P147, DOI 10.1080/08820139.2018.1496098
   Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990
   Martens K, 2018, ALLERGY, V73, P1954, DOI 10.1111/all.13495
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Maywald M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102222
   Miller LE, 2019, NUTR RES, V64, P1, DOI 10.1016/j.nutres.2018.12.011
   Mousavizadeh L., 2020, J MICROBIOL IMMUNOL
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   Parameswaran N, 2020, CRIT REV EUKAR GENE, V20, P87
   Pierrot-Deseilligny C, 2017, MULT SCLER RELAT DIS, V14, P35, DOI 10.1016/j.msard.2017.03.014
   Pique N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102534
   Pohanka M, 2012, MINI-REV MED CHEM, V12, P35, DOI 10.2174/138955712798868986
   Porter RS, 2017, PHYTOTHER RES, V31, P533, DOI 10.1002/ptr.5782
   Ralli M, 2020, EUR REV MED PHARMACO, V24, P3440, DOI 10.26355/eurrev_202004_20797
   Rocha-Ramirez LM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4607491
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Serna-Thome G, 2018, REV INVEST CLIN, V70, P136, DOI 10.24875/RIC.18002527
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Smolders J, 2011, VITAM HORM, V86, P401, DOI 10.1016/B978-0-12-386960-9.00018-6
   Steinbrenner H, 2015, ADV NUTR, V6, P73, DOI 10.3945/an.114.007575
   Tanaka Y, 2020, EUR J NUTR, V59, P2641, DOI 10.1007/s00394-019-02112-3
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Ulbricht Catherine, 2014, Journal of Dietary Supplements, V11, P80, DOI 10.3109/19390211.2013.859852
NR 51
TC 0
Z9 0
U1 3
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 17
BP 9182
EP 9187
DI 10.26355/eurrev_202009_22869
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NO2KI
UT WOS:000569313100075
PM 32965012
DA 2021-01-01
ER

PT J
AU Alshaeri, HK
   Natto, ZS
AF Alshaeri, H. K.
   Natto, Z. S.
TI A contemporary look at COVID-19 medications: available an potentially
   effective drugs
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drugs; Management
ID RESPIRATORY SYNDROME CORONAVIRUS; WORK PRODUCTIVITY; FAVIPIRAVIR T-705;
   EFFICACY; VIRUS; LEDIPASVIR/SOFOSBUVIR; COMBINATION; LEDIPASVIR;
   REMDESIVIR; SOFOSBUVIR
AB OBJECTIVE: There have been significant changes to the management of COVID-19 in recent months, including protocols and guidelines designed to prevent, diagnose, and treat the Novel Coronavirus (COVID-19). Several management options have been suggested and have since gained popularity, though we expect additional modifications to be made, as well as more new cases in the coming months, given a lack of definitive treatment and well-controlled experiments. This review highlights the available and potential treatments, along with the challenges associated with each.
   MATERIALS AND METHODS: We conducted a comprehensive overview of all peer-reviewed studies, editorial comments, and letters to the editor based on a search in PubMed, Google Scholar, Web of Science, and Scopus. The following terms were used: "COVID-19," "SARS-CoV-2," "drug," "treatment," "medication," and "management." All searches were done between March and May 20, 2020.
   RESULTS: There are several potential medications available for COVID-19, such as Interferon a (IFN-alpha), Teicoplanin, Ribavirin, Galidesivir, Lopinavir/Ritonavir, Chloroquine phosphate, Arbidol, Velpatasvir, Favipiravir, Ledipasvir, Remdesivir, Sofosbuvir, Darunavir, Qingfei Paidu Decoction (QPD), and lmatinib. However, we do not have a definitive and specific treatment yet.
   CONCLUSIONS: We are expecting to have more cases in the coming weeks/months. Therefore, further research is needed to characterize the disease behavior, to find the absolute drug, and to refine the treatment.
C1 [Alshaeri, H. K.] Fakeeh Coll Med Sci, Dept Pharmaceut Sci, Jeddah, Saudi Arabia.
   [Natto, Z. S.] King Abdulaziz Univ, Fac Dent, Dept Dent Publ Hlth, Jeddah, Saudi Arabia.
   [Natto, Z. S.] Harvard Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA.
RP Natto, ZS (corresponding author), King Abdulaziz Univ, Fac Dent, Dept Dent Publ Hlth, Jeddah, Saudi Arabia.; Natto, ZS (corresponding author), Harvard Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA.
EM znatto@kau.edu.sa
OI Alshaeri, Heba/0000-0003-1960-0092
FU Deanship of Scientific Research (DSR) at King Abdulaziz University,
   Jeddah [GCV 19-32-1441]
FX This project was funded by the Deanship of Scientific Research (DSR) at
   King Abdulaziz University, Jeddah, under Grant no. GCV 19-32-1441. The
   authors, therefore, acknowledge with thanks DSR for technical and
   financial support.
CR Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454
   [Anonymous], 2020, COR DIS COVID 19 DAS
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   Bausch DG, 2010, CLIN INFECT DIS, V51, P1435, DOI 10.1086/657315
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao B, 2020, SEVERE 2019 NCOV REM
   CAO B, 2020, MILD MODERATE 2019 N
   Chen C, 2020, 20037432 MEDRXIV
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   DE MEYER S, 2020, 20052548 MEDRXIV
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Delang L, 2014, J ANTIMICROB CHEMOTH, V69, P2770, DOI 10.1093/jac/dku209
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   DuDou P., 2020, CLIN TRIAL ARENA
   DutrA R, 2020, ACTA SCI MICROBIOL, V3, P215
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Guerrero NAS, 2018, ANTIVIR RES, V160, P137, DOI 10.1016/j.antiviral.2018.10.026
   Harrison C., 2020, NAT BIOTECHNOL
   Hoffmann M, 2020, 929042 BIORXIV
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hung IF-N, 2020, LANCET
   Isakov V, 2018, CLIN DRUG INVEST, V38, P239, DOI 10.1007/s40261-017-0606-0
   Leneva IA, 2009, ANTIVIR RES, V81, P132, DOI 10.1016/j.antiviral.2008.10.009
   Leonis G, 2012, J CHEM INF MODEL, V52, P1542, DOI 10.1021/ci300014z
   Li D, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2122-y
   Lin FC, 2014, CYTOKINE GROWTH F R, V25, P369, DOI 10.1016/j.cytogfr.2014.07.015
   Liu JY, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-186
   Natto ZS, 2017, J CLIN PERIODONTOL, V44, P649, DOI 10.1111/jcpe.12722
   NHC, 2020, GUID PREV DIAGN TREA
   Pasipanodya B, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25214
   REYNOLDS PE, 1989, EUR J CLIN MICROBIOL, V8, P943, DOI 10.1007/BF01967563
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Su B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01472
   SUNG-SUN K., 2020, KOREAN BIOMED REV
   Surendra M, 2018, HEMODIAL INT, V22, P217, DOI 10.1111/hdi.12604
   Venkiteshwaran A, 2009, MABS-AUSTIN, V1, P432, DOI 10.4161/mabs.1.5.9497
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Westover JB, 2018, ANTIVIR RES, V156, P38, DOI 10.1016/j.antiviral.2018.05.013
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   YANG J, 2020, 056762 BIORXIV
   Younossi ZM, 2018, J VIRAL HEPATITIS, V25, P228, DOI 10.1111/jvh.12808
   Younossi ZM, 2015, HEPATOLOGY, V61, P1471, DOI 10.1002/hep.27757
   Yu SW, 2020, ANN PALLIAT MED, V9, P437, DOI 10.21037/apm.2020.03.27
   Zhang K, 2020, AM J EMERG MED
   Zhang WF, 2020, J PHYS CHEM LETT, V11, P4430, DOI 10.1021/acs.jpclett.0c00571
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
NR 58
TC 1
Z9 1
U1 3
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 17
BP 9188
EP 9195
DI 10.26355/eurrev_202009_22870
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NO2KI
UT WOS:000569313100076
PM 32965013
DA 2021-01-01
ER

PT J
AU Wada, S
   Nagasaki, Y
   Arimizu, Y
   Shimo, M
   Matsukuma, Y
   Okamoto, M
   Yoshida, S
   Ohashi, I
   Hashimoto, G
   Kuwashiro, T
   Yasaka, M
   Okada, Y
AF Wada, Shinichi
   Nagasaki, Yoji
   Arimizu, Yoko
   Shimo, Masatoshi
   Matsukuma, Yuta
   Okamoto, Masaki
   Yoshida, Shinichiro
   Ohashi, Ikkei
   Hashimoto, Go
   Kuwashiro, Takahiro
   Yasaka, Masahiro
   Okada, Yasushi
TI Neurological Disorders Identified during Treatment of a SARS-CoV-2
   Infection
SO INTERNAL MEDICINE
LA English
DT Article
DE Guillain-Barre syndrome; acute disseminated encephalomyelitis;
   SARS-CoV-2; glycolipid antibody; intravenous immunoglobulin
ID ANTIBODIES
AB A 69-year-old man was admitted to our hospital under diagnosis of pneumonia due to severe acute respiratory syndrome-corona virus 2 (SARS-CoV-2) (Day 0). He underwent endotracheal intubation from Day 3. Although his respiratory condition improved and anesthetic drugs were discontinued, no cough reflex was observed despite intubation having been performed until Day 17. His tendon reflexes were also diminished. We suspected that he had developed Guillain-Barre syndrome (GBS), and administered intravenous immunoglobulin from Day 18. The absence of cough reflex improved and extubation was successfully performed on Day 23. Neurological disorders including GBS should be considered when intubated SARS-CoV-2 patients present with a loss of cough reflex during the treatment period.
C1 [Wada, Shinichi; Ohashi, Ikkei; Hashimoto, Go; Kuwashiro, Takahiro; Yasaka, Masahiro; Okada, Yasushi] Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Div Cerebrovasc Med & Neurol, Fukuoka, Japan.
   [Nagasaki, Yoji; Arimizu, Yoko] Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Div Infect Dis, Fukuoka, Japan.
   [Shimo, Masatoshi] Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Div Hematol, Fukuoka, Japan.
   [Matsukuma, Yuta] Natl Hospitalizat Org, Kyushu Med Ctr, Dept Nephrol, Fukuoka, Japan.
   [Okamoto, Masaki] Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Dept Resp Med, Fukuoka, Japan.
   [Yoshida, Shinichiro] Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Dept Emergency & Crit Care Med, Fukuoka, Japan.
RP Wada, S (corresponding author), Natl Hospitalizat Org, Kyushu Med Ctr, Clin Res Inst, Div Cerebrovasc Med & Neurol, Fukuoka, Japan.
EM ichi_basstrombone@yahoo.co.jp
CR Ang CW, 2002, J NEUROIMMUNOL, V130, P179, DOI 10.1016/S0165-5728(02)00209-6
   Capers KN, 2011, CASE REP NEUROL, V3, P1, DOI 10.1159/000322573
   Foster P, 2020, J AM COLL SURGEONS, V230, P1102, DOI 10.1016/j.jamcollsurg.2020.04.014
   Granerod J, 2016, CLIN RADIOL, V71, P1050, DOI 10.1016/j.crad.2016.03.015
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ishikura Teruyuki, 2017, Rinsho Shinkeigaku, V57, P33, DOI 10.5692/clinicalneurol.cn-000914
   Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262
   Koike H, 2013, J NEUROL NEUROSUR PS, V84, P98, DOI 10.1136/jnnp-2012-302833
   Kusunoki S, 2003, MUSCLE NERVE, V27, P302, DOI 10.1002/mus.10307
   Kusunoki S, 2001, NEUROLOGY, V57, P736, DOI 10.1212/WNL.57.4.736
   Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9
   Mader I, 1996, AM J NEURORADIOL, V17, P104
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Needham EJ, 2020, NEUROCRIT CARE, V32, P667, DOI 10.1007/s12028-020-00978-4
   Sauteur PMM, 2018, J NEUROIMMUNOL, V314, P13, DOI 10.1016/j.jneuroim.2017.11.011
   Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Virani A, IDCASES
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yousefifard M, 2020, ARCH ACAD EMERG MED, V8
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhou CK, 2014, NEURAL REGEN RES, V9, P101, DOI 10.4103/1673-5374.125337
NR 23
TC 0
Z9 0
U1 0
U2 0
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2020
VL 59
IS 17
BP 2187
EP 2189
DI 10.2169/internalmedicine.5447-20
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NO3PZ
UT WOS:000569399200017
PM 32713924
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, CT
   Xu, JH
   Liu, JW
   Zhou, YC
AF Li, Chentong
   Xu, Jinhu
   Liu, Jiawei
   Zhou, Yicang
TI The within-host viral kinetics of SARS-CoV-2
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article
DE SARS-CoV-2; MERS; di fferential equation model; basic reproductive
   number
ID ADAPTIVE IMMUNE-RESPONSE; DYNAMICS; MODELS
AB In this work, we use a within-host viral dynamic model to describe the SARS-CoV-2 kinetics in the host. Chest radiograph score data are used to estimate the parameters of that model. Our result shows that the basic reproductive number of SARS-CoV-2 in host growth is around 3.79. Using the same method we also estimate the basic reproductive number of MERS virus is 8.16 which is higher than SARS-CoV-2. The PRCC method is used to analyze the sensitivities of model parameters. Moreover, the drug effects on virus growth and immunity effect of patients are also implemented to analyze the model.
C1 [Li, Chentong; Zhou, Yicang] Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Peoples R China.
   [Xu, Jinhu] Xian Univ Technol, Sch Sci, Xian 710048, Peoples R China.
   [Liu, Jiawei] Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.
RP Zhou, YC (corresponding author), Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Peoples R China.
EM zhouyc@xjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [11701445]; Natural Science Basic Research
   Plan in Shaanxi Province of China [2018JQ1057]; Young Talent Fund of
   University Association for Science and Technology in Shaanxi, China
   [20180504]
FX This work is supported by National Natural Science Foundation of China
   (11701445), Natural Science Basic Research Plan in Shaanxi Province of
   China (2018JQ1057), and Young Talent Fund of University Association for
   Science and Technology in Shaanxi, China (20180504).
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971
   Debroy S, 2011, J BIOL SYST, V19, P533, DOI 10.1142/S0218339011004135
   Dieckmann O., 2000, MATH EPIDEMIOLOGY IN
   Elsland H. W., 2020, REPORT 5 PHYLOGENETI
   Kampf G., 2020, J HOSP INFECT
   Lee HY, 2009, J VIROL, V83, P7151, DOI 10.1128/JVI.00098-09
   Liu T., 2020, TRANSMISSION DYNAMIC
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   Miao HY, 2011, SIAM REV, V53, P3, DOI 10.1137/090757009
   Miao HY, 2010, J VIROL, V84, P6687, DOI 10.1128/JVI.00266-10
   NCBI, 2010, INN AD IMM SYST
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Wang WD, 2008, J DYN DIFFER EQU, V20, P699, DOI 10.1007/s10884-008-9111-8
   Wu J. T., 2020, LANCET
   Yang T, 2020, J MT SCI-ENGL, V17, P2108, DOI 10.1007/s11629-019-5772-5
NR 20
TC 3
Z9 3
U1 0
U2 0
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA
SN 1547-1063
EI 1551-0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PY 2020
VL 17
IS 4
BP 2853
EP 2861
DI 10.3934/mbe.2020159
PG 9
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA NP5UG
UT WOS:000570240500009
PM 32987502
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Roccaro, I
   Smirni, D
AF Roccaro, Ilaria
   Smirni, Daniela
TI Fiat Lux: The Light Became Therapy. An Overview on the Bright Light
   Therapy in Alzheimer's Disease Sleep Disorders
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Alzheimer's disease; biological clocks; bright light therapy; circadian
   rhythms; light boxes; retinal ganglion cells; sleep disorder;
   suprachiasmatic nucleus
ID CIRCADIAN-RHYTHM DISTURBANCES; REST-ACTIVITY RHYTHM; SUPRACHIASMATIC
   NUCLEUS; DOUBLE-BLIND; DEMENTIA; AGITATION; MELATONIN; EXPOSURE;
   BEHAVIOR; WOMEN
AB Background: A system of photosensitive retinal ganglion cells provides 'non-visual' information on the circadian sequences of light to the suprachiasmatic nucleus (SCN), which, as the 'master clock', synchronizes the chronobiological mechanisms of all the biological clocks. Damage to SCN structure alters circadian behavioral and hormonal rhythms and interferes with a regular sleep-wake pattern. Several studies have shown that, in aging and in Alzheimer's disease (AD), circadian rhythms change their synchronization with the environment and behavior loses sync with light. Objective: The current overview aims to examine research studies showing the effect of bright light therapy (BLT) on sleep disorders and sleep-wake patterns in AD. Methods: A literature search was conducted, taking into consideration the relevant studies over the last 20 years. Fifteen studies have been thorough: seven followed an environmental-architectural approach and eight followed a treatment devices approach. Results: Studies agree in considering BLT as a promising non-pharmacological intervention to compensate for circadian rhythm alterations and they support the need for standardized protocols that allow a comparison between multicenter studies. Conclusion: Interestingly, in an attempt to contain the spread of the COVID-19 pandemic, health authorities have forced the population to stay home. Therefore, AD people are not currently able to enjoy exposure to sunlight. It is predictable that they may experience an exacerbation of circadian disturbances and that the BLT can be an effective response to prevent such exacerbation.
C1 [Roccaro, Ilaria; Smirni, Daniela] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RP Smirni, D (corresponding author), Viale Sci,Ed 15, I-90128 Palermo, Italy.
EM daniela.smirni@unipa.it
RI Smirni, Daniela/R-3445-2019
OI Smirni, Daniela/0000-0002-4410-2047
CR Ancoli-Israel S, 2002, J AM GERIATR SOC, V50, P282, DOI 10.1046/j.1532-5415.2002.50060.x
   Ancoli-Israel Sonia, 2003, Behav Sleep Med, V1, P22, DOI 10.1207/S15402010BSM0101_4
   Baron KG, 2014, INT REV PSYCHIATR, V26, P139, DOI 10.3109/09540261.2014.911149
   Barrick AL, 2010, INT J GERIATR PSYCH, V25, P1013, DOI 10.1002/gps.2453
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Braun DL, 1999, COMPR PSYCHIAT, V40, P442, DOI 10.1016/S0010-440X(99)90088-3
   Burns A, 2009, INT PSYCHOGERIATR, V21, P711, DOI 10.1017/S1041610209008886
   Corral M, 2007, ARCH WOMEN MENT HLTH, V10, P221, DOI 10.1007/s00737-007-0200-1
   Corral M, 2000, AM J PSYCHIAT, V157, P303, DOI 10.1176/appi.ajp.157.2.303-a
   Figueiro MG, 2015, SLEEP HEALTH, V1, P322, DOI 10.1016/j.sleh.2015.09.003
   Figueiro MG, 2014, CLIN INTERV AGING, V9, P1527, DOI 10.2147/CIA.S68557
   Germain A, 2008, HUM PSYCHOPHARM CLIN, V23, P571, DOI 10.1002/hup.964
   Grandin LD, 2006, CLIN PSYCHOL REV, V26, P679, DOI 10.1016/j.cpr.2006.07.001
   HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331
   Hanger MA, 1992, SLEEP RES, V21, P88
   Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761
   Hickman SE, 2007, J AM GERIATR SOC, V55, P1817, DOI 10.1111/j.1532-5415.2007.01428.x
   Hofman MA, 2000, CHRONOBIOL INT, V17, P245, DOI 10.1081/CBI-100101047
   Lam RW, 1999, PSYCHIAT RES, V86, P185, DOI 10.1016/S0165-1781(99)00043-8
   LAM RW, 1994, AM J PSYCHIAT, V151, P744
   Landry GJ, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00325
   LeGates TA, 2014, NAT REV NEUROSCI, V15, P443, DOI 10.1038/nrn3743
   LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030
   Lin L, 2013, INT J MOL SCI, V14, P14575, DOI 10.3390/ijms140714575
   Lyketsos CG, 1999, INT J GERIATR PSYCH, V14, P520, DOI 10.1002/(SICI)1099-1166(199907)14:7<520::AID-GPS983>3.3.CO;2-D
   McCurry SM, 2011, J AM GERIATR SOC, V59, P1393, DOI 10.1111/j.1532-5415.2011.03519.x
   Most EIS, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-19
   Onega LL, 2018, ISSUES MENT HEALTH N, V39, P370, DOI 10.1080/01612840.2018.1437648
   Onega LL, 2016, ISSUES MENT HEALTH N, V37, P660, DOI 10.1080/01612840.2016.1183736
   Oren DA, 2002, AM J PSYCHIAT, V159, P666, DOI 10.1176/appi.ajp.159.4.666
   PARRY BL, 1993, AM J PSYCHIAT, V150, P1417
   Ramkisoensing A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00128
   Riemersma-van Der Lek RF, 2008, JAMA-J AM MED ASSOC, V299, P2642, DOI 10.1001/jama.299.22.2642
   Sekiguchi H, 2017, PSYCHOGERIATRICS, V17, P275, DOI 10.1111/psyg.12233
   Sloane PD, 2015, LIGHTING RES TECHNOL, V47, P161, DOI 10.1177/1477153513517255
   Smirni D, 2019, NEUROL SCI, V40, P97, DOI 10.1007/s10072-018-3587-8
   Smirni D, 2018, NEUROL SCI, V39, P1391, DOI 10.1007/s10072-018-3433-z
   Srinivasan V, 2011, INT J ALZHEIMERS DIS, V2011
   STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583
   SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2
   SWAAB DF, 1992, BRAIN RES, V590, P239, DOI 10.1016/0006-8993(92)91101-J
   van Lieshout-van Dal E, 2019, BUILD ENVIRON, V150, P245, DOI 10.1016/j.buildenv.2019.01.010
   Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1
   VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3
   Walton JC, 2011, FRONT NEUROENDOCRIN, V32, P303, DOI 10.1016/j.yfrne.2010.12.003
   Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952
   White MD, 2013, HERD-HEALTH ENV RES, V7, P60, DOI 10.1177/193758671300700106
   Wirz-Justice A, 2011, J CLIN PSYCHIAT, V72, P986, DOI 10.4088/JCP.10m06188blu
   WITTING W, 1990, BIOL PSYCHIAT, V27, P563, DOI 10.1016/0006-3223(90)90523-5
   Yamadera H, 2000, PSYCHIAT CLIN NEUROS, V54, P352, DOI 10.1046/j.1440-1819.2000.00711.x
NR 50
TC 0
Z9 0
U1 2
U2 2
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2020
VL 77
IS 1
BP 113
EP 125
DI 10.3233/JAD-200478
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA NN5GI
UT WOS:000568816600009
PM 32804145
DA 2021-01-01
ER

PT J
AU Theuerkauff, O
   Hanak, C
AF Theuerkauff, Olivier
   Hanak, Catherine
TI TOBACCO USE CESSATION IN THREE PATIENTS SUFFERING FROM PSYCHOTIC
   DISORDERS: THE IMPACT OF THE COVID-19 PANDEMIC
SO PSYCHIATRIA DANUBINA
LA English
DT Article; Proceedings Paper
CT Psychiatria Danubina for the Twined Conference on Mental Health
CY SEP 10-12, 2020
CL Mons, BELGIUM
DE tobacco use cessation; COVID-19; Psychotic disorders
ID MENTAL-ILLNESS; ACTIVE SMOKING; CORONAVIRUS; SEVERITY
AB Background: Tobacco use is one of the major causes of morbidity and mortality amoung patients suffering from psychotic disorders. The association between severe COVID-19 and tobacco use is still debated. The aim of this paper is to enhance the importance of providing up to date informations about nicotine and tobacco use in connection with the SARS-CoV-2-related conditions.
   Methods: We present 3 cases of sudden tobacco use cessation in 3 long-term heavy smokers receiving mental health care for chronic psychotic disorders. Fear of severe form of COVID-19 was their principal motivation. Nicotine replacement therapy and quitline counseling were provided and no major withdrawal symptoms were declared.
   Results: As mass media later wrongly presented tobacco use as a protective factor regarding COVID-19, all three patients resumed smoking. Rigorous counseling took advantage of psychotic symptoms to correct false informations and finally promote tobacco use cessation.
   Conclusions: The COVID-19 pandemic might paradoxically represent a great motivational factor to quit smoking, espacially when considering patients suffering from severe mental health disorders. Beyond the terrible suffering it causes, we illustrate with a case serie that this opportunity must be exploited by mental health professionals to improve quality and life expectancy of their patients.
C1 [Theuerkauff, Olivier] Mental Hlth Ctr Antonin Artaud, 10 Rue Grand Hosp, B-1000 Brussels, Belgium.
   [Hanak, Catherine] Ctr Hosp Univ Brugmann, Psychiat Dept, Brussels, Belgium.
RP Theuerkauff, O (corresponding author), Mental Hlth Ctr Antonin Artaud, 10 Rue Grand Hosp, B-1000 Brussels, Belgium.
EM docteur.olivier.theuerkauff@gmail.com
CR Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206
   Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   D'Souza RS, 2020, GLOB PUBLIC HEALTH, V15, P935, DOI 10.1080/17441692.2020.1761426
   de Andrade M, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7473
   Klemperer EM, 2020, NICOTINE TOB RES, V22, P1662, DOI 10.1093/ntr/ntaa072
   Kroon LA, 2007, AM J HEALTH-SYST PH, V64, P1917, DOI 10.2146/ajhp060414
   Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li HO-Y, 2020, SOCIAL SCI RES NETWO
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Lo E, 2020, EUR J INTERN MED, V77, P125, DOI 10.1016/j.ejim.2020.05.003
   Miller J, 2013, STRUCTURES OF LAW AND LITERATURE: DUTY, JUSTICE, AND EVIL IN THE CULTURAL IMAGINATION, P3
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.4, DOI 10.32388/WPP19W.4, 10.32388/WPP19W.4.]
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Pierce JP, 1998, JAMA-J AM MED ASSOC, V279, P511, DOI 10.1001/jama.279.7.511
   Prochaska JJ, 2017, ANNU REV PUBL HEALTH, V38, P165, DOI 10.1146/annurev-publhealth-031816-044618
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Tindle HA, 2020, NICOTINE TOB RES, V22, P1669, DOI 10.1093/ntr/ntaa077
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vif SL, 2020, CORONAVIRUS TABAC PR
   Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889
   Ziedonis D, 2008, NICOTINE TOB RES, V10, P1691, DOI 10.1080/14622200802443569
NR 23
TC 0
Z9 0
U1 1
U2 1
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-5053
J9 PSYCHIAT DANUB
JI Psychiatr. Danub.
PY 2020
VL 32
SU 1
BP 21
EP 23
PG 3
WC Psychiatry
SC Psychiatry
GA NN9EJ
UT WOS:000569090000005
PM 32890356
DA 2021-01-01
ER

PT J
AU Zhang, L
   Huang, B
   Xia, HZ
   Fan, H
   Zhu, MX
   Zhu, LP
   Zhang, H
   Tao, XG
   Cheng, SH
   Chen, J
AF Zhang, Lin
   Huang, Bin
   Xia, Hongzhen
   Fan, Hua
   Zhu, Muxin
   Zhu, Liping
   Zhang, Huan
   Tao, Xiaogen
   Cheng, Shaohui
   Chen, Jian
TI Retrospective analysis of clinical features in 134 coronavirus disease
   2019 cases
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Blood group distribution; coagulation abnormality; COVID-19;
   inflammatory factors; organ function injury
ID BLOOD-GROUP; SUSCEPTIBILITY
AB We aimed to describe the clinical features in coronavirus disease 2019 (COVID-19) cases. We studied 134 critically ill COVID-19 cases from 30 December 2019 to 20 February 2020 in an intensive care unit (ICU) at Wuhan Jinyintan Hospital. Demographics, underlying diseases, therapy strategies and test results were collected and analysed from patients on admission, admission to the ICU and 48 h before death. The non-survivors were older (65.46 (s.d.9.74)vs.46.45 (s.d.11.09)) and were more likely to have underlying diseases. The blood group distribution of the COVID-19 cases differed from that of the Han population in Wuhan, with type A being 43.85%; type B, 26.92%; type AB, 10% and type O, 19.23%. Non-survivors tend to develop more severe lymphopaenia, with higher C-reactive protein, interleukin-6, procalcitonin, D-dimer levels and gradually increased with time. The clinical manifestations were non-specific. Compared with survivors, non-survivors more likely to have organ function injury, and to receive mechanical ventilation, either invasively or noninvasively. Multiple organ failure and secondary bacterial infection in the later period is worthy of attention.
C1 [Zhang, Lin; Fan, Hua; Zhang, Huan; Tao, Xiaogen; Cheng, Shaohui; Chen, Jian] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Intens Care Med, Hefei 230036, Anhui, Peoples R China.
   [Huang, Bin] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Endocrinol, Hefei 230036, Anhui, Peoples R China.
   [Xia, Hongzhen] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Pathol, Hefei 230036, Anhui, Peoples R China.
   [Zhu, Muxin; Zhu, Liping] Wuhan Jinyintan Hosp, Dept Intens Care Med, Wuhan 430023, Hubei, Peoples R China.
RP Chen, J (corresponding author), Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Intens Care Med, Hefei 230036, Anhui, Peoples R China.
EM chenjian214891@163.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [WK9110000037]
FX This study was supported by the Fundamental Research Funds for the
   Central Universities (WK9110000037).
CR [Anonymous], COR DIS COVID 19 SIT
   Anstee DJ, 2010, BLOOD, V115, P4635, DOI 10.1182/blood-2010-01-261859
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YF, 2005, JAMA-J AM MED ASSOC, V293, P1450, DOI 10.1001/jama.293.12.1450-c
   Guillon P, 2008, GLYCOBIOLOGY, V18, P1085, DOI 10.1093/glycob/cwn093
   Langford Bradley J, 2020, Clin Microbiol Infect, V26, P1622, DOI 10.1016/j.cmi.2020.07.016
   National Health Commission of the People's Republic of China, COVID 19S DIAGN TREA
   Rich SM, 2009, P NATL ACAD SCI USA, V106, P14902, DOI 10.1073/pnas.0907740106
   Tregouet DA, 2009, BLOOD, V113, P5298, DOI 10.1182/blood-2008-11-190389
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wuhan Municipal Health Commission, 2019, REP CLUST PNEUM UNKN
   Xu P, 2015, CHINESE J HEMATOLOGY, V28, P835
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 13
TC 0
Z9 0
U1 2
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e199
DI 10.1017/S0950268820002010
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NN4DL
UT WOS:000568740000001
PM 32878654
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ling, C
   Wen, XJ
AF Ling, Chen
   Wen, Xianjie
TI Community grid management is an important measure to contain the spread
   of novel coronavirus pneumonia (COVID-19)
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE COVID-19
AB The outbreak of novel coronavirus pneumonia (coronavirus disease 2019 (COVID-19)), declared as a 'global pandemic' by the World Health Organization (WHO), is a public health emergency of international concern (PHEIC). The outbreak in multiple locations shows a trend of accelerating spread around the world. China has taken a series of powerful measures to contain the spread of the novel coronavirus. In response to the COVID-19 pandemic, in addition to actively finding effective treatment drugs and developing vaccines, it is more important to identify the source of infection at the community level as soon as possible to block the transmission path of the virus to prevent the spread of the pandemic. The implementation of grid management in the community and the adoption of precise management and control measures to reduce unnecessary personnel movement can effectively reduce the risk of pandemic spread. This paper mainly describes that the grid management mode can promote the refinement and comprehensiveness of community management. As a management system with potential to improve the governance ability of community affairs, it may be helpful to strengthen the prevention and control of the epidemic in the community.
C1 [Ling, Chen; Wen, Xianjie] Second Peoples Hosp Foshan City, Dept Anesthesiol, Foshan, Peoples R China.
   [Ling, Chen; Wen, Xianjie] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China.
RP Wen, XJ (corresponding author), Second Peoples Hosp Foshan City, Dept Anesthesiol, Foshan, Peoples R China.; Wen, XJ (corresponding author), Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China.
EM xjwen166@126.com
CR To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   WHO. Statement on the second meeting of the International Health Regulations, 2005, 2 M INT HLTH REG 200
NR 3
TC 0
Z9 0
U1 3
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e167
DI 10.1017/S0950268820001739
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NM4LM
UT WOS:000568069700001
PM 32758318
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ansarin, K
   Tolouian, R
   Ardalan, M
   Taghizadieh, A
   Varshochi, M
   Teimouri, S
   Vaezi, T
   Valizadeh, H
   Saleh, P
   Safiri, S
   Chapman, KR
AF Ansarin, Khalil
   Tolouian, Ramin
   Ardalan, Mohammadreza
   Taghizadieh, Ali
   Varshochi, Mojtaba
   Teimouri, Soheil
   Vaezi, Tahere
   Valizadeh, Hamed
   Saleh, Parviz
   Safiri, Saeid
   Chapman, Kenneth R.
TI Effect of bromhexine on clinical outcomes and mortality in COVID-19
   patients: A randomized clinical trial
SO BIOIMPACTS
LA English
DT Article
DE Bromhexine hydrochloride; COVID-19 disease; SARS-CoV2; TMPRSS2; COVID-19
   pneumonia; COVID-19 treatment
ID CORONAVIRUS; TMPRSS2
AB Introduction: Bromhexine is a potential therapeutic option in COVID-19, but no data from a randomized clinical trial has been available. The present study aimed to evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19.
   Methods: An open-label randomized clinical trial study was performed in Tabriz, North-West of Iran. They were randomized to either the treatment with the bromhexine group or the control group, in a 1:1 ratio with 39 patients in each arm. Standard therapy was used in both groups and those patients in the treatment group received oral bromhexine 8 mg three times a day additionally. The primary outcome was a decrease in the rate of ICU admissions, intubation/mechanical ventilation, and mortality.
   Results: A total of 78 patients with similar demographic and disease characteristics were enrolled. There was a significant reduction in ICU admissions (2 out of 39 vs. 11 out of 39, P = 0.006), intubation (1 out of 39 vs. 9 out of 39, P = 0.007) and death (0 vs. 5, P = 0.027) in the bromhexine treated group compared to the standard group. No patients were withdrawn from the study because of adverse effects.
   Conclusion: The early administration of oral bromhexine reduces the ICU transfer, intubation, and the mortality rate in patients with COVID-19. This affordable medication can easily be administered everywhere with a huge positive impact(s) on public health and the world economy. Altogether, the verification of our results on a larger scale and different medical centers is strongly recommended.
C1 [Ansarin, Khalil] Tabriz Univ Med Sci, Rahat Breath & Sleep Res Ctr, Tabriz, Iran.
   [Ansarin, Khalil; Taghizadieh, Ali; Valizadeh, Hamed] Tabriz Univ Med Sci, TB & Lung Dis Res Ctr, Tabriz, Iran.
   [Tolouian, Ramin] Univ Arizona, Div Nephrol, Tucson, AZ USA.
   [Ardalan, Mohammadreza; Saleh, Parviz] Tabriz Univ Med Sci, Kidney Res Ctr, Tabriz, Iran.
   [Taghizadieh, Ali; Teimouri, Soheil; Vaezi, Tahere; Valizadeh, Hamed] Tabriz Univ Med Sci, Sch Med, Dept Internal Med, Tabriz, Iran.
   [Varshochi, Mojtaba] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran.
   [Safiri, Saeid] Tabriz Univ Med Sci, Sch Med, Dept Community Med, Tabriz, Iran.
   [Safiri, Saeid] Tabriz Univ Med Sci, Phys Med & Rehabil Res Ctr, Aging Res Inst, Tabriz, Iran.
   [Chapman, Kenneth R.] Univ Toronto, Univ Hlth Network, Asthma & Airway Ctr, Toronto, ON, Canada.
RP Ardalan, M (corresponding author), Tabriz Univ Med Sci, Kidney Res Ctr, Tabriz, Iran.
EM ardalan34@yahoo.com
FU Tabriz University of Medical Sciences, Tabriz, Iran
FX This study was supported by Tabriz University of Medical Sciences,
   Tabriz, Iran.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Berger D, 1997, SHOCK, V7, P422, DOI 10.1097/00024382-199706000-00006
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Depfenhart M, 2020, INTERN EMERG MED, V15, P801, DOI 10.1007/s11739-020-02383-3
   Grein J, 2020, NEW ENGL J MED, V382
   Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kashani KB, 2020, MAYO CLIN PROC, V95, P1094, DOI 10.1016/j.mayocp.2020.04.021
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Meng LZ, 2020, ANESTHESIOLOGY, V132, P1317, DOI 10.1097/ALN.0000000000003296
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 21
TC 4
Z9 4
U1 1
U2 1
PU TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICES
PI TABRIZ
PA DANESHGHAH ST, TABRIZ, REPUBLIC ISLAMIC 51664-14766, IRAN
SN 2228-5652
EI 2228-5660
J9 BIOIMPACTS
JI BioImpacts
PY 2020
VL 10
IS 4
BP 209
EP 215
DI 10.34172/bi.2020.27
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NL1MO
UT WOS:000567188200002
PM 32983936
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Genzor, S
   Sova, M
   Mucska, I
   Lnenicka, J
   Nadjarpour, S
   Sonka, K
AF Genzor, S.
   Sova, M.
   Mucska, I
   Lnenicka, J.
   Nadjarpour, S.
   Sonka, K.
TI Impact of the COVID-19 pandemic on sleep medicine in the Czech Republic
   and Slovakia
SO CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE
LA English
DT Article
DE COVID-19; obstructive sleep apnoea; positive airway pressure therapy;
   sleep
AB Aim: The COVID-19 pandemic affected all parts of the healthcare system. The aim of this study was to assess the pandemics effect on sleep medicine in the Czech Republic (CZE) and Slovakia (SVK). Methods: A questionnaire based study, in which where 23 sleep departments (SD) (16 CZE; 7 SVK) were included between May 5, 2020 and May 17, 2020. Results: The service was completely interrupted in 43.5% SD. The sum of estimated missed sleep studies in responding SD was 1,100 and the sum of missed positive airway pressure titrations was 580. When considering the response rate of the questionnaire through extrapolation, it is estimated that about 1,900 sleep studies and 1,000 positive airway pressure titrations were not performed in the region of the CZE and SVK because of COVID-19. The situation is unlikely to improve soon, as 59.1% of SD do not expect to meet the same number of diagnosed/treated patients as in 2019 (53.3% CZE; 71.4% SVK) and about 34.8% of SD will not restart their activity by the end of May 2020 or will run with a very limited capacity (23.5% CZE; 57.1% SVK). Conclusion: Sleep medicine in the CZE and SVK was heavily affected by COVID-19 and the loss of diagnostic and therapeutic procedures may be considered as one of pandemic "collateral damages".
C1 [Genzor, S.; Sova, M.] Palacky Univ Olomouc, Dept Resp Med, Fac Med & Dent, Olomouc, Czech Republic.
   [Genzor, S.; Sova, M.] Univ Hosp Olomouc, Olomouc, Czech Republic.
   [Mucska, I] Univ Hosp Bratislava, Outpatient Dept Resp Med, Bratislava, Slovakia.
   [Lnenicka, J.] Bulovka Hosp, Dept Resp Med, Prague, Czech Republic.
   [Nadjarpour, S.] Palacky Univ Olomouc, Fac Med & Dent, IP Pavlova 6, Olomouc 77900, Czech Republic.
   [Sonka, K.] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic.
   [Sonka, K.] Gen Univ Hosp, Prague, Czech Republic.
RP Sova, M (corresponding author), Palacky Univ Olomouc, Fac Med & Dent, IP Pavlova 6, Olomouc 77900, Czech Republic.; Sova, M (corresponding author), Palacky Univ Olomouc, Dept Resp Med, Univ Hosp Olomouc, IP Pavlova 6, Olomouc 77900, Czech Republic.
EM milan.sova@fnol.cz
RI Sonka, Karel/G-1801-2017
OI Sonka, Karel/0000-0001-5773-9656
CR Grote L, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01323-2020
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
   Sud A, 2020, ANN ONCOL, V31, P1065, DOI 10.1016/j.annonc.2020.05.009
NR 3
TC 0
Z9 0
U1 2
U2 2
PU CZECH MEDICAL SOC
PI PRAGUE 2
PA SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC
SN 1210-7859
EI 1802-4041
J9 CESK SLOV NEUROL N
JI Cesk. Slov. Neurol. Neurochir.
PY 2020
VL 83
IS 4
BP 421
EP 423
DI 10.14735/amcsnn2020421
PG 3
WC Neurosciences; Surgery
SC Neurosciences & Neurology; Surgery
GA NK4PY
UT WOS:000566715200013
DA 2021-01-01
ER

PT J
AU Andres, C
   Garcia-Cehic, D
   Gregori, J
   Pinana, M
   Rodriguez-Frias, F
   Guerrero-Murillo, M
   Esperalba, J
   Rando, A
   Goterris, L
   Codina, MG
   Quer, S
   Martin, MC
   Campins, M
   Ferrer, R
   Almirante, B
   Esteban, JI
   Pumarola, T
   Anton, A
   Quer, J
AF Andres, Cristina
   Garcia-Cehic, Damir
   Gregori, Josep
   Pinana, Maria
   Rodriguez-Frias, Francisco
   Guerrero-Murillo, Mercedes
   Esperalba, Juliana
   Rando, Ariadna
   Goterris, Lidia
   Codina, Maria Gema
   Quer, Susanna
   Martin, Maria Carmen
   Campins, Magda
   Ferrer, Ricard
   Almirante, Benito
   Esteban, Juan Ignacio
   Pumarola, Tomas
   Anton, Andres
   Quer, Josep
TI Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2
   cleavage site in the viral quasispecies of COVID19 patients
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; deletions; quasispecies; NGS; respiratory virus; diversity
ID VIRUS; PROTEIN
AB The SARS-CoV-2 spike (S) protein, the viral mediator for binding and entry into the host cell, has sparked great interest as a target for vaccine development and treatments with neutralizing antibodies. Initial data suggest that the virus has low mutation rates, but its large genome could facilitate recombination, insertions, and deletions, as has been described in other corona viruses. Here, we deep-sequenced the complete SARS-CoV-2Sgene from 18 patients (10 with mild and 8 with severe COVID-19), and found that the virus accumulates deletions upstream and very close to the S1/S2 cleavage site (PRRAR/S), generating a frameshift with appearance of a stop codon. These deletions were found in a small percentage of the viral quasi species (2.2%) in samples from all the mild and only half the severe COVID-19 patients. Our results suggest that the virus may generate free S1 protein released to the circulation. We suggest that natural selection has favoured a "Don't burn down the house" strategy, in which free S1 protein may compete with viral particles for the ACE2 receptor, thus reducing the severity of the infection and tissue damage without losing transmission capability.
C1 [Andres, Cristina; Pinana, Maria; Esperalba, Juliana; Martin, Maria Carmen; Anton, Andres] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Microbiol Dept, Resp Viruses Unit, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain.
   [Garcia-Cehic, Damir; Guerrero-Murillo, Mercedes; Quer, Susanna; Esteban, Juan Ignacio; Quer, Josep] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Liver Dis Viral Hepatitis, Liver Unit, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain.
   [Gregori, Josep; Rodriguez-Frias, Francisco; Esteban, Juan Ignacio; Quer, Josep] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Gregori, Josep] Roche Diagnost SL, Barcelona, Spain.
   [Rodriguez-Frias, Francisco] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Biochem Dept, Barcelona, Spain.
   [Rodriguez-Frias, Francisco] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Microbiol Dept, Barcelona, Spain.
   [Rodriguez-Frias, Francisco; Esteban, Juan Ignacio; Pumarola, Tomas; Anton, Andres] Univ Autonoma Barcelona, Bellaterra, Spain.
   [Rando, Ariadna; Goterris, Lidia; Codina, Maria Gema; Pumarola, Tomas] Vall dHebron Hosp Univ, Microbiol Dept, Barcelona, Spain.
   [Campins, Magda] Hosp Vall dHebron Hosp Univ, Prevent Med, Barcelona, Spain.
   [Ferrer, Ricard] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Shock Disfuncio Organ & Ressuscitacio SODIR, Intens Care Dept, Barcelona, Spain.
   [Almirante, Benito] Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Infect Dis Dept, Barcelona, Spain.
RP Anton, A (corresponding author), Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Microbiol Dept, Resp Viruses Unit, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain.; Quer, J (corresponding author), Vall dHebron Hosp Univ, Vall dHebron Inst Recerca VHIR, Liver Dis Viral Hepatitis, Liver Unit, Vall dHebron Barcelona Hosp Campus, Barcelona 08035, Spain.; Quer, J (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
EM aanton@vhebron.net; josep.quer@vhir.org
RI Caputo, Francesco/G-5539-2018; Anton, Andres/B-3308-2011; BONET, LIDIA
   GOTERRIS/AAO-7289-2020; Casadei gardini, Andrea/F-1830-2016; Gregori
   Font, Josep/J-2586-2015
OI Anton, Andres/0000-0002-1476-0815; BONET, LIDIA
   GOTERRIS/0000-0003-1471-4461; Casadei gardini,
   Andrea/0000-0001-6289-7202; Gregori Font, Josep/0000-0002-4253-8015;
   Esperalba, Juliana/0000-0003-1326-1341; Reis,
   AlessanRSS/0000-0001-8486-7469; Guerrero Murillo,
   Mercedes/0000-0002-5556-2460; Andres Verges,
   Cristina/0000-0002-3200-0895
FU Direccio General de Recerca i Innovacio en Salut (DGRIS) Catalan Health
   Ministry Generalitat de Catalunya through Vall d'Hebron Institut de
   Recerca (VHIR); European Development Regional Fund (ERDF)"A way to
   achieve Europe" by Spanish Network for Research in Infectious
   DiseasesEuropean Union (EU) [REIPI RD16/0016/0003]; Centro para el
   Desarrollo Tecnologico Industrial (CDTI) from the Spanish Ministry of
   Economy and Business [IDI-20200297]
FX This study was partially supported by the Direccio General de Recerca i
   Innovacio en Salut (DGRIS) Catalan Health Ministry Generalitat de
   Catalunya through Vall d'Hebron Institut de Recerca (VHIR); European
   Development Regional Fund (ERDF) "A way to achieve Europe" by Spanish
   Network for Research in Infectious Diseases (REIPI RD16/0016/0003); and
   Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Spanish
   Ministry of Economy and Business, grant number IDI-20200297.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9
   Caballero A, 2018, ANTIVIR RES, V158, P34, DOI 10.1016/j.antiviral.2018.07.019
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Domingo E, 1996, FASEB J, V10, P859
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   HENDRICKS DA, 1988, J VIROL, V62, P2228, DOI 10.1128/JVI.62.7.2228-2233.1988
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holland JJ., 1993, REPLICATION ERROR QU
   Hughes SA, 2011, LANCET, V378, P73, DOI 10.1016/S0140-6736(10)61931-9
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Kramvis A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02521
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Matsushita K, 2020, RELATIONSHIP COVID 1, DOI [10.1101/2020.04.05.20054155, DOI 10.1101/2020.04.05.20054155]
   Muth D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33487-8
   Pages H, 2012, BIOSTRINGS STRING OB
   Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412
   Polack FP, 2005, P NATL ACAD SCI USA, V102, P8996, DOI 10.1073/pnas.0409478102
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Team RC, 2016, R LANG ENV STAT COMP
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Turner A. J., 2015, PROTECTIVE ARM RENIN, P185, DOI DOI 10.1016/B978-0-12-801364-9.00025-0
   Wong Yik Chun, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa953
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
NR 29
TC 5
Z9 6
U1 5
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1900
EP 1911
DI 10.1080/22221751.2020.1806735
PG 12
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NK9YK
UT WOS:000567083700001
PM 32752979
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Mironova, GD
   Belosludtseva, NV
   Ananya, MA
AF Mironova, G. D.
   Belosludtseva, N., V
   Ananya, M. A.
TI Prospects for the use of regulators of oxidative stress in the
   comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19)
   and its complications
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Hemoglobin; Free iron; Oxidative stress; Uridine;
   Mitochondrial ATP-dependent potassium channel; ROS; Antioxidant;
   Dihydroquercetin
ID DEPENDENT POTASSIUM CHANNEL; URIDINE; IRON; MITOCHONDRIA; MYOCARDIUM;
   METABOLISM
AB Some surface proteins of the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can bind to the hemoglobin molecule of an erythrocyte, which leads to the destruction of the structure of the heme and the release of harmful iron ions to the bloodstream. The degradation of hemoglobin results in the impairment of oxygen-carrying capacity of the blood. and the accumulation of free iron enhances the production of reactive oxygen species. Both events can lead to the development of oxidative stress. In this case, oxidative damage to the lungs leads then to the injuries of all other tissues and organs. The use of uridine. which preserves the structure of pulmonary alveoli and the air-blood barrier of the lungs in the course of experimental severe hypoxia, and dihydroquercetin, an effective free radical scavenger, is promising for the treatment of COVID-19. These drugs can also be used for the recovery of the body after the severe disease.
C1 [Mironova, G. D.; Belosludtseva, N., V] RAS, Inst Theoret & Expt Biophys, Pushchino, Moscow Region, Russia.
   [Ananya, M. A.] Adv Technol Ltd, Dev Innovat Technol, Moscow, Russia.
RP Mironova, GD (corresponding author), RAS, Inst Theoret & Expt Biophys, Pushchino, Moscow Region, Russia.
EM mironova40@mail.ru
FU Russian Foundation for Basic ResearchRussian Foundation for Basic
   Research (RFBR) [20-015-00029 A]
FX This work was supported by the Russian Foundation for Basic Research
   (Grant number 20-015-00029 A).
CR Akopova O, 2020, BMC MOL CELL BIOL, V21, DOI 10.1186/s12860-020-00275-0
   Barnes PJ, 2007, AM J RESP CRIT CARE, V176, P532
   Bresgen N, 2015, BIOMOLECULES, V5, P808, DOI 10.3390/biom5020808
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coates TD, 2014, FREE RADICAL BIO MED, V72, P23, DOI 10.1016/j.freeradbiomed.2014.03.039
   Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5
   Danilenko SA, 2010, SIBER MED J, V3, P59
   Dev S, 2017, HEMODIAL INT, V21, pS6, DOI 10.1111/hdi.12542
   Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   GALLAI V, 1992, ACTA NEUROL SCAND, V86, P3, DOI 10.1111/j.1600-0404.1992.tb08045.x
   Gonzalez PM, 2012, LIPID PEROXIDATION, P89, DOI 10.5772/46181
   Hadadi A, 2020, J MED VIROL, V1, P1
   HOANGA VT, 2020, INT J ANTIMICROB AG
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Jaffe S, 2020, LANCET, V395, P1179, DOI 10.1016/S0140-6736(20)30817-5
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Krylova IB, 2012, B EXP BIOL MED+, V153, P644, DOI 10.1007/s10517-012-1787-4
   Krylova IB, 2006, EXP GERONTOL, V41, P697, DOI 10.1016/j.exger.2006.03.005
   LEE MH, 1995, AM J MED, V98, P566, DOI 10.1016/S0002-9343(99)80015-1
   Li J, 2016, MEDCHEMCOMM, V8, P353
   Lin CW, 2006, FEMS IMMUNOL MED MIC, V46, P375, DOI 10.1111/j.1574-695X.2006.00045.x
   Liu W., 2020, COVID 19 ATTACKS 1 B
   McEvilly M, 2011, AM J HEALTH-SYST PH, V68, P1806, DOI 10.2146/ajhp100434
   Mironova GD, 2019, B EXP BIOL MED+, V166, P806, DOI 10.1007/s10517-019-04445-9
   Mironova GD, 2019, J BIOENERG BIOMEMBR, V51, P329, DOI 10.1007/s10863-019-09806-7
   Mironova GD, 2018, ARCH BIOCHEM BIOPHYS, V654, P70, DOI 10.1016/j.abb.2018.07.006
   Mironova GD, 2010, J BIOENERG BIOMEMBR, V42, P473, DOI 10.1007/s10863-010-9316-5
   Mironova GD, 2004, J BIOL CHEM, V279, P32562, DOI 10.1074/jbc.M401115200
   Negrao L, 2014, PAIN MANAG, V4, P191, DOI [10.2217/pmt.14.10, 10.2217/PMT.14.10]
   Novoselova EG, 2009, EUR J PHARMACOL, V615, P234, DOI 10.1016/j.ejphar.2009.05.004
   Pizzorno G, 2002, BBA-MOL BASIS DIS, V1587, P133, DOI 10.1016/S0925-4439(02)00076-5
   Rozova EV, 2015, BIOCHEMISTRY-MOSCOW+, V80, P994, DOI 10.1134/S0006297915080040
   Rozova EV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45979-2
   Ruan XF, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.202000171
   Shoenfeld Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102538
   Szewczyk Adam, 2018, Postepy Biochem, V64, P196, DOI 10.18388/pb.2018_132
   Tarifeno-Saldivia E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01296
   TESELKIN YuO, 1999, ISS BIOL MED PHARM C, V1, P36
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu YH, 2008, J INFECT DIS, V197, P812, DOI 10.1086/528377
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yamamoto T, 2011, CLIN CHIM ACTA, V412, P1712, DOI 10.1016/j.cca.2011.06.006
   Yu J, 2020, J MECH MED BIOL, V20, DOI 10.1142/S0219519419500854
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou B, 2020, BMC INFECT DIS
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 51
TC 1
Z9 1
U1 5
U2 5
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 16
BP 8585
EP 8591
DI 10.26355/eurrev_202008_22658
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NL0QG
UT WOS:000567130100037
PM 32894566
DA 2021-01-01
ER

PT J
AU Turk, C
   Turk, S
   Malkan, UY
   Haznedaroglu, IC
AF Turk, C.
   Turk, S.
   Malkan, U. Y.
   Haznedaroglu, I. C.
TI Three critical clinicobiological phases of the human SARS-associated
   coronavirus infections
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2
ID INNATE IMMUNE-RESPONSES; RECEPTOR; COVID-19; PNEUMONIA; BINDING; CHINA;
   CELLS; WUHAN; COV
AB OBJECTIVE: COVID-19 immune syndrome is a multi-systemic disorder induced by the COVID-19 infection. Pathobiological transitions and clinical stages of the COVID-19 syndrome following the attack of SARS-CoV-2 on the human body have not been fully explored. The aim of this review is to outline the three critical prominent phase regarding the clinicogenomics course of the COVID-19 immune syndrome.
   MATERIALS AND METHODS: In the clinical setting, the COVID-19 process presents as "asymptomatic/pre-symptomatic phase. "respiratory phase with mild/moderate/severe symptoms" and "multi-systemic clinical syndrome with impaired/disproportionate and/or defective immunity". The corresponding three genomic phases include the "ACE2. ANPEP transcripts in the initial phase", "EGFR and IGF2R transcripts in the propagating phase" and the "immune system related critical gene involvements of the complicating phase".
   RESULTS: The separation of the phases is important since the genomic features of each phase are different from each other and these different mechanisms lead to distinct clinical multi-systemic features. Comprehensive genomic profiling with next generation sequencing may play an important role in defining and clarifying these three unique separate phases for COVID-19. From our point of view. it is important to understand these unique phases of the syndrome in order to approach a COVID-19 patient bedside.
   CONCLUSIONS: This three-phase approach may be useful for future studies which will focus on the clinical management and development of the vaccines and/or specific drugs targeting the COVID-19 processes. ANPEP gene pathway may have a potential for the vaccine development. Regarding the specific disease treatments, MAS agonists, TXA127, Angiotensin (1-7) and soluble ACE2 could have therapeutic potential for the COVID-19 course. Moreover, future CRISPR technology can be utilized for the genomic editing and future management of the clinical course of the syndrome.
C1 [Turk, C.] Lokman Hekim Univ, Dept Med Microbiol, Ankara, Turkey.
   [Turk, S.] Hacettepe Univ, Dept Biochem, Ankara, Turkey.
   [Malkan, U. Y.] Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Dept Hematol, Ankara, Turkey.
   [Haznedaroglu, I. C.] Hacettepe Univ, Dept Hematol, Ankara, Turkey.
RP Malkan, UY (corresponding author), Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Dept Hematol, Ankara, Turkey.
EM umitmalkan@hotmail.com
CR Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Cascella M, 2020, FEATURES EVALUATION
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Ciaglia E, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00206
   Ciftciler R, 2020, TURK J HEMATOL, V37, P207, DOI 10.4274/tjh.galenos.2020.2020.0174
   Cinatl J, 2004, CELL MOL LIFE SCI, V61, P2100, DOI 10.1007/s00018-004-4222-9
   Colavita F, 2020, ANN INTERN MED, V173, P242, DOI 10.7326/M20-1176
   Cong F, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-743
   Danesh A, 2011, VIROLOGY, V409, P102, DOI 10.1016/j.virol.2010.10.002
   Desforges M, 2007, VIRUS RES, V130, P228, DOI 10.1016/j.virusres.2007.06.016
   Diamond MS, 2013, NAT REV IMMUNOL, V13, P46, DOI 10.1038/nri3344
   Dong NG, 2020, JACC-HEART FAIL, V8, P515, DOI 10.1016/j.jchf.2020.04.001
   Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Golechha M, 2020, BRAIN BEHAV IMMUN, V87, P130, DOI 10.1016/j.bbi.2020.05.003
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Haznedaroglu IC, 2020, TURK J MED SCI, V50, P1434, DOI 10.3906/sag-2004-94
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kapmaz M, 2020, INFECT DIS CLIN MICR, V2, P48
   Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091
   Koff JL, 2008, AM J PHYSIOL-LUNG C, V294, pL1068, DOI 10.1152/ajplung.00025.2008
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lange C, 2020, J MED VIROL, V92, P2081, DOI 10.1002/jmv.25981
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Libby P, 2018, J AM COLL CARDIOL, V72, P2071, DOI 10.1016/j.jacc.2018.08.1043
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Mitchell HD, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00200
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Paula Gonzaga A, 2020, CURR DRUG TARGETS, DOI [10.2174/138945012166620021012, DOI 10.2174/138945012166620021012]
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Proost P, 2007, BLOOD, V110, P37, DOI 10.1182/blood-2006-10-049072
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rubin DH, 2006, CRIT REV EUKAR GENE, V16, P155
   Santiago C, 2017, SCI REP-UK, V7, DOI 10.1038/srep46045
   Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669
   Shi Shaobo, 2020, JAMA CARDIOL, DOI [10.1001/jamacar-dio.2020.0950, DOI 10.1001/JAMACAR-DIO.2020.0950]
   Singh P., 2017, REFERENCE MODULE LIF
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Turk C, 2020, J RENIN-ANGIO-ALDO S, V21, DOI 10.1177/1470320320928872
   van der Vaart J, 2020, SCIENCE
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Watanabe Y., 2020, SCIENCE
   Whitworth KM, 2019, TRANSGENIC RES, V28, P21, DOI 10.1007/s11248-018-0100-3
   WHO, 2020, WHO DIR GEN REM MED
   Williamson E, 2020, 20092999 MEDRXIV
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu JX, 2017, CIRC RES, V121, P43, DOI 10.1161/CIRCRESAHA.116.310509
   Yang G, 2014, J ALLERGY CLIN IMMUN, V133, P1702, DOI 10.1016/j.jaci.2014.02.019
   YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0
   Zhang B, 2020, 20028191 MEDRXIV
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 81
TC 1
Z9 1
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 16
BP 8606
EP 8620
DI 10.26355/eurrev_202008_22660
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NL0QG
UT WOS:000567130100039
PM 32894568
DA 2021-01-01
ER

PT J
AU Gorenstein, SA
   Castellano, ML
   Slone, ES
   Gillette, B
   Liu, HE
   Alsamarraie, C
   Jacobson, AM
   Wall, SP
   Adhikari, S
   Swartz, JL
   McMullen, JJS
   Osorio, M
   Koziatek, CA
   Lee, DC
AF Gorenstein, Scott A.
   Castellano, Michael L.
   Slone, Eric S.
   Gillette, Brian
   Liu, Helen
   Alsamarraie, Cindy
   Jacobson, Alan M.
   Wall, Stephen P.
   Adhikari, Samrachana
   Swartz, Jordan L.
   McMullen, Jenica J. S.
   Osorio, Marcela
   Koziatek, Christian A.
   Lee, David C.
TI Hyperbaric oxygen therapy for COVID-19 patients with respiratory
   distress: treated cases versus propensity-matched controls
SO UNDERSEA AND HYPERBARIC MEDICINE
LA English
DT Article
DE COVID-19; hyperbaric oxygen therapy; infectious diseases
ID SICKNESS
AB Objective: Given the high mortality and prolonged duration of mechanical ventilation of COVID-19 patients, we evaluated the safety and efficacy of hyperbaric oxygen for COVID-19 patients with respiratory distress.
   Methods: This is a single-center clinical trial of COVID-19 patients at NYU Winthrop Hospital from March 31 to April 28, 2020. Patients in this trial received hyperbaric oxygen therapy at 2.0 atmospheres of pressure in monoplace hyperbaric chambers for 90 minutes daily for a maximum of five total treatments. Controls were identified using propensity score matching among COVID-19 patients admitted during the same time period. Using competing-risks survival regression, we analyzed our primary outcome of inpatient mortality and secondary outcome of mechanical ventilation.
   Results: We treated 20 COVID-19 patients with hyperbaric oxygen. Ages ranged from 30 to 79 years with an oxygen requirement ranging from 2 to 15 liters on hospital days 0 to 14. Of these 20 patients, two (10%) were intubated and died, and none remain hospitalized. Among 60 propensity-matched controls based on age, sex, body mass index, coronary artery disease, troponin, D-dimer, hospital day, and oxygen requirement, 18 (30%) were intubated, 13 (22%) have died, and three (5%) remain hospitalized (with one still requiring mechanical ventilation). Assuming no further deaths among controls, we estimate that the adjusted subdistribution hazard ratios were 0.37 for inpatient mortality (p=0.14) and 0.26 for mechanical ventilation (p=0.046).
   Conclusions: Though limited by its study design, our results demonstrate the safety of hyperbaric oxygen among COVID-19 patients and strongly suggests the need for a well-designed, multi-center randomized control trial.
C1 [Gorenstein, Scott A.; Castellano, Michael L.; Slone, Eric S.; Gillette, Brian; Liu, Helen; Alsamarraie, Cindy] NYU Winthrop Hosp, Dept Surg, Div Wound Care, New York, NY 11501 USA.
   [Gorenstein, Scott A.; Castellano, Michael L.; Slone, Eric S.; Gillette, Brian; Liu, Helen; Alsamarraie, Cindy; Jacobson, Alan M.] NYU Long Isl Sch Med, New York, NY 10003 USA.
   [Jacobson, Alan M.] NYU Winthrop Hosp, Fdn Med Dept, New York, NY USA.
   [Wall, Stephen P.; Swartz, Jordan L.; McMullen, Jenica J. S.; Osorio, Marcela; Koziatek, Christian A.; Lee, David C.] NYU Grossman Sch Med, Dept Emergency Med, New York, NY 10016 USA.
   [Wall, Stephen P.; Adhikari, Samrachana; Lee, David C.] NYU Grossman Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
RP Gorenstein, SA (corresponding author), NYU Winthrop Hosp, Dept Surg, Div Wound Care, New York, NY 11501 USA.; Gorenstein, SA (corresponding author), NYU Long Isl Sch Med, New York, NY 10003 USA.; Lee, DC (corresponding author), NYU Grossman Sch Med, Dept Emergency Med, New York, NY 10016 USA.; Lee, DC (corresponding author), NYU Grossman Sch Med, Dept Populat Hlth, New York, NY 10016 USA.
EM scott.gorenstein@nyulangone.org; david.lee@nyumc.org
OI Wall, Stephen/0000-0003-3965-5074; Swartz, Jordan/0000-0001-6482-9545;
   Adhikari, Samrachana/0000-0001-9954-5999
FU NYU Grossman School of Medicine [K23-DK110316, R01-DK124400]; National
   Institutes of Diabetes and Digestive and Kidney DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK)
FX This study was funded by internal research support from the NYU Grossman
   School of Medicine. Dr. David Lee is also funded by grants K23-DK110316
   and R01-DK124400, both from the National Institutes of Diabetes and
   Digestive and Kidney Diseases for unrelated work. All authors of this
   study have no financial interests in hyperbaric oxygen therapy nor any
   other relevant financial interests to disclose. Dr. Peter Speigler and
   Dr. Sarun Thomas at NYU Winthrop have since joined the study team to
   provide guidance and expertise in pulmonary and critical care medicine.;
   We want to specifically thank Mike Merrow and Glen Butler at Life
   Support Technologies, which is a third-party supplier of the hyperbaric
   chambers at NYU Winthrop and without whom the study would not have been
   possible. In addition, we want to thank our hyperbaric technologists,
   Daniel Hennig, Vanessa Newman, John Reynolds, and Heather Quiroz, who
   bravely volunteered and took on the risk of being exposed to COVID-19 to
   treat the patients in the study. In addition, we also want to thank Dr.
   Alan Katz, whose encouragement helped to make this study possible. The
   above-listed individuals were not involved in the study design, data
   collection, analysis, or review of the drafted manuscript.
CR Abel FL, 2000, UNDERSEA HYPERBAR M, V27, P67
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Austin PC, 2019, STAT MED, V38, P751, DOI 10.1002/sim.8008
   Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x
   Bessereau J, 2017, INT MARIT HEALTH, V68, P46, DOI 10.5603/IMH.2017.0008
   Bosco G, 2018, J ENZYM INHIB MED CH, V33, P1501, DOI 10.1080/14756366.2018.1485149
   BURNAND B, 1990, J CLIN EPIDEMIOL, V43, P1273, DOI 10.1016/0895-4356(90)90093-5
   Butler G. J., 2011, Journal of Medical Engineering & Technology, V35, P197, DOI 10.3109/03091902.2010.497890
   Cascella M, 2020, STATPEARLS
   Chin W, 2016, UNDERSEA HYPERBAR M, V43, P29
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hantoushzadeh S, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.030
   MacKenzie DA, 2000, HUM IMMUNOL, V61, P1320, DOI 10.1016/S0198-8859(00)00214-7
   Mathieu D, 2017, DIVING HYPERB MED, V47, P24, DOI 10.28920/dhm47.1.24-32
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Naval Specialty Medical Center Program Team, DEM REP INCL HYP OX
   Obiagwu C, 2015, OXF MED CASE REP, P183, DOI 10.1093/omcr/omv002
   Onder G, 2020, JAMA
   Prekker ME, 2020, CHEST
   Rossignol DA, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-6
   Shah RD, 2017, CLIN CHEST MED, V38, P113, DOI 10.1016/j.ccm.2016.11.013
   Shi S, 2020, JAMA CARDIOL
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Thibodeaux K, 2020, J WOUND CARE, V29, pS4, DOI 10.12968/jowc.2020.29.Sup5a.S4
   THOM SR, 1989, J TOXICOL-CLIN TOXIC, V27, P141
   Thomas LE, 2020, JAMA CARDIOL
   U. S Food and Drug Administration, 2013, HYP OX THER DONT BE
   Wadhera RK, 2020, JAMA
   Weaver LK, 2018, UNDERSEA HYPERBAR M, V45, P129
   Weaver LK, 2001, CHEST, V120, P1407
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 1
Z9 1
U1 2
U2 2
PU UNDERSEA & HYPERBARIC MEDICAL SOC INC
PI DURHAM
PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA
SN 1066-2936
J9 UNDERSEA HYPERBAR M
JI Undersea Hyperb. Med.
PY 2020
VL 47
IS 3
BP 405
EP 413
PG 9
WC Marine & Freshwater Biology; Medicine, Research & Experimental
SC Marine & Freshwater Biology; Research & Experimental Medicine
GA NL7JJ
UT WOS:000567586900001
PM 32931666
DA 2021-01-01
ER

PT J
AU Hess, MW
AF Hess, Michael W.
TI Nebulized Therapy in the COVID-19 Era: The Right Tool for the Right
   Patient [Letter]
SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Letter
C1 [Hess, Michael W.] Western Michigan Univ, Homer Stryker MD Sch Med, Dept Internal Med, 1000 Oakland Dr, Kalamazoo, MI 49008 USA.
RP Hess, MW (corresponding author), Western Michigan Univ, Homer Stryker MD Sch Med, Dept Internal Med, 1000 Oakland Dr, Kalamazoo, MI 49008 USA.
EM michael.hess@med.wmich.edu
OI Hess, Michael/0000-0003-1367-6977
FU Theravance Biopharma US, Inc. (South San Francisco, CA, USA)
FX Medical writing support was funded by Theravance Biopharma US, Inc.
   (South San Francisco, CA, USA). The authoracknowledges Gautam Bijur,
   PhD, for medical writing and Frederique H. Evans, MBS, for editorial
   assistance (both from Ashfield Healthcare Communications) in the
   preparation of the document.
CR ACAAI, 2020, MESS ASTHM SUFF SHOR
   Ari A, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105987
   CMAJ, 2020, RE TRANSM COR NEB SE
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Russell R, 2020, INT J CHRONIC OBSTR, V15, P883, DOI 10.2147/COPD.S255101
NR 5
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2005
J9 INT J CHRONIC OBSTR
JI Int. J. Chronic Obstr. Pulm. Dis.
PY 2020
VL 15
BP 2101
EP 2102
DI 10.2147/COPD.S272382
PG 2
WC Respiratory System
SC Respiratory System
GA NK8OU
UT WOS:000566990900001
PM 32982202
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pereira, MFB
   Litvinov, N
   Farhat, SCL
   Eisencraft, AP
   Gibelli, MABC
   de Carvalho, WB
   Fernandes, VR
   Fink, TD
   Framil, JVD
   Galleti, KV
   Fante, AL
   Fonseca, MFM
   Watanabe, A
   de Paula, CSY
   Palandri, GG
   Leal, GN
   Diniz, MDR
   Pinho, JRR
   Silva, CA
   Marques, HHD
AF Badue Pereira, Maria Fernanda
   Litvinov, Nadia
   Lima Farhat, Sylvia Costa
   Eisencraft, Adriana Pasmanik
   Bento Cicaroni Gibelli, Maria Augusta
   de Carvalho, Werther Brunow
   Fernandes, Vinicius Rodrigues
   Fink, Thais de Toledo
   de Souza Framil, Juliana Valeria
   Galleti, Karine Vusberg
   Fante, Alice Lima
   Mota Fonseca, Maria Fernanda
   Watanabe, Andreia
   Yoshino de Paula, Camila Sanson
   Palandri, Giovanna Gavros
   Leal, Gabriela Nunes
   Rodrigues Diniz, Maria de Fatima
   Rebello Pinho, Joao Renato
   Silva, Clovis Artur
   de Sousa Marques, Heloisa Helena
CA Pediat Covid HC-FMUSP Study Grp
TI Severe clinical spectrum with high mortality in pediatric patients with
   COVID-19 and multisystem inflammatory syndrome
SO CLINICS
LA English
DT Article
DE COVID-19; Children; Adolescent; Outcome; Immunosuppression; Multisystem
   Inflammatory Syndrome
ID INFECTION; CHILDREN
AB OBJECTIVES: To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C).
   METHODS: This cross-sectional study included 471 samples collected from 371 patients (age<18 years) suspected of having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study group comprised 66/371 (18%) laboratory-confirmed pediatric COVID-19 patients: 61 (92.5%) patients tested positive on real-time reverse transcription-polymerase chain reaction tests for SARS-CoV-2, and 5 (7.5%) patients tested positive on serological tests. MIS-C was diagnosed according to the criteria of the Center for Disease Control.
   RESULTS: MIS-C was diagnosed in 6/66 (9%) patients. The frequencies of diarrhea, vomiting, and/or abdominal pain (67% vs. 22%, p=0.034); pediatric SARS (67% vs. 13%, p=0.008); hypoxemia (83% vs. 23%, p=0.006); and arterial hypotension (50% vs. 3%, p=0.004) were significantly higher in patients with MIS-C than in those without MIS-C. The frequencies of C-reactive protein levels >50 mg/L (83% vs. 25%, p=0.008) and D-dimer levels >1000 ng/mL (100% vs. 40%, p=0.007) and the median D-dimer, troponin T, and ferritin levels (p < 0.05) were significantly higher in patients with MIS-C. The frequencies of pediatric intensive care unit admission (100% vs. 60%, p=0.003), mechanical ventilation (83% vs. 7%, p < 0.001), vasoactive agent use (83% vs. 3%, p <0.001), shock (83% vs. 5%, p<0.001), cardiac abnormalities (100% vs. 2%, p <0.001), and death (67% vs. 3%, p < 0.001) were also significantly higher in patients with MIS-C. Similarly, the frequencies of oxygen therapy (100% vs. 33%, p=0.003), intravenous immunoglobulin therapy (67% vs. 2%, p < 0.001), aspirin therapy (50% vs. 0%, p < 0.001), and current acute renal replacement therapy (50% vs. 2%, p=0.002) were also significantly higher in patients with MIS-C. Logistic regression analysis showed that the presence of MIS-C was significantly associated with gastrointestinal manifestations [odds ratio (OR)=10.98; 95%CI (95% confidence interval)=1.20-100.86; p=0.034] and hypoxemia [OR=16.85; 95%CI=1.34-211.80; p=0.029]. Further univariate analysis showed a positive association between MIS-C and death [OR=58.00; 95%CI=6.39526.79; p <0 .0001].
   CONCLUSIONS: Pediatric patients with laboratory-confirmed COVID-19 with MIS-C had a severe clinical spectrum with a high mortality rate. Our study emphasizes the importance of investigating MIS-C in pediatric patients with COVID-19 presenting with gastrointestinal involvement and hypoxemia.
C1 [Badue Pereira, Maria Fernanda; Litvinov, Nadia; Lima Farhat, Sylvia Costa; Eisencraft, Adriana Pasmanik; Bento Cicaroni Gibelli, Maria Augusta; Fernandes, Vinicius Rodrigues; Fink, Thais de Toledo; de Souza Framil, Juliana Valeria; Watanabe, Andreia; Yoshino de Paula, Camila Sanson; Palandri, Giovanna Gavros; Leal, Gabriela Nunes; Rodrigues Diniz, Maria de Fatima; de Sousa Marques, Heloisa Helena] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente ICr, Sao Paulo, SP, Brazil.
   [de Carvalho, Werther Brunow; Silva, Clovis Artur] Univ Sao Paulo, Fac Med FMUSP, Sao Paulo, SP, Brazil.
   [Galleti, Karine Vusberg; Fante, Alice Lima] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Mota Fonseca, Maria Fernanda] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Tratamento Canc Infantil, Sao Paulo, SP, Brazil.
   [Rebello Pinho, Joao Renato] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Lab Biol Mol, Sao Paulo, SP, Brazil.
RP Pereira, MFB (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente ICr, Sao Paulo, SP, Brazil.
EM maria.badue@hc.fm.usp.br
RI de Carvalho, Werther Brunow/ABC-1028-2020; Sampaio, Magda/AAU-6748-2020
OI Sampaio, Magda/0000-0002-1924-4043
CR Almeida FJ, 2020, PEDIATR INFECT DIS J, V39, pE161, DOI 10.1097/INF.0000000000002737
   Alveno RA, 2018, J PEDIAT-BRAZIL, V94, P539, DOI 10.1016/j.jped.2017.07.014
   Andre N, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28392
   [Anonymous], COR DIS COVID 19 SIT
   Beavis KG, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104468
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Passone CGB, 2020, REV PAUL PEDIATR, V38, DOI 10.1590/1984-0462/2020/38/2018101
   Capone CA, 2020, J PEDIATR-US, V224, P141, DOI [10.1018/j.jpeds.2020.08.044, 10.1016/j.jpeds.2020.06.044]
   Centers for Disease Control and Prevention, INF HEALTHC PROV MUL
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   European Centre for Disease Prevention and Control, 2020, PAED INFL MULT SYNDR
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Garazzino S, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.18.2000600
   Hrusak O, 2020, EUR J CANCER, V132, P11, DOI 10.1016/j.ejca.2020.03.021
   Kaushik S, 2020, J PEDIATR-US, V224, P24, DOI 10.1016/j.jpeds.2020.06.045
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Miethke-Morais A, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2100
   Safadi MAP, 2021, REV PAUL PEDIATR, V39, DOI 10.1590/1984-0462/2020/38/2020192
   Palmeira P, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1947
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   Ramos GF, 2019, J PEDIAT-BRAZIL, V95, P667, DOI 10.1016/j.jped.2018.06.006
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Shen B, 2020, AM J TRANSL RES, V12, P1348
   Silva CA, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1931
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 32
TC 1
Z9 1
U1 2
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2020
VL 75
AR e2209
DI 10.6061/clinics/2020/e2209
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NJ8SE
UT WOS:000566314900001
PM 32844958
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Cao, Y
   Cai, K
   Xiong, L
AF Cao, Y.
   Cai, K.
   Xiong, L.
TI Coronavirus disease 2019: A new severe acute respiratory syndrome from
   Wuhan in China
SO ACTA VIROLOGICA
LA English
DT Article
DE 2019 novel coronavirus; pneumonia; SARS-CoV-2; Coronaviridae; COVID-19
ID PNEUMONIA
AB An outbreak of new severe acute respiratory syndrome coronavirus disease, coronavirus disease 2019 (COVID-19), has emerged during December 2019. The ongoing outbreak in Wuhan City spread rapidly throughout China, where the fatality rate ranged from 2.1 to 4.9%. Due to its high transmissibility, the World Health Organization (WHO) declared a public health emergency of international concern on 30 January 2020. The current outbreak has the potential to become the first pandemic of the new millennium. Most patients who were first diagnosed with COVID-19 worked at or lived in the vicinity of the local Huanan Seafood Wholesale Market, where live animals were also on sale. The concerted efforts of Chinese scientists led to the independent isolation from patients and identification of a novel coronavirus, SARS coronavirus 2 (SARS-CoV-2), on 6 January 2020; this has been an important step in the development of treatment. The purpose of this article is to overview the history, epidemiology, clinical characteristics, diagnosis, and treatment of COVID 2019 reported in recently published studies. Based on the results of virus genome sequencing and a model of the interaction between host cells and the virus, we propose several possible targets for antiviral drugs, which may provide new ideas for epidemic control and vaccine development.
C1 [Cao, Y.; Cai, K.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan 430022, Peoples R China.
   [Cao, Y.; Cai, K.; Xiong, L.] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nosocomial Infect Management, Wuhan 430022, Peoples R China.
RP Xiong, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nosocomial Infect Management, Wuhan 430022, Peoples R China.
EM 993964218@qq.com
FU Medjaden Academy & Research Foundation [MJA nCoV_MJA20200224]; Free
   innovation pre-research fund and platform scientific research fund in
   2019 [02.03.2019-111]
FX This project was supported by the Medjaden Academy & Research Foundation
   for Young Scientists (Grant No. MJA nCoV_MJA20200224) and the Free
   innovation pre-research fund and platform scientific research fund in
   2019 (02.03.2019-111).
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo Q, 2020, 20200121914044 BIORX, DOI [10.1111/j.1600-0854.2007.00603.x, DOI 10.1111/J.1600-0854.2007.00603.X]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Knudsen TB, 2003, SCAND J IMMUNOL, V58, P277, DOI 10.1046/j.1365-3083.2003.01302.x
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Nguyen TM, 2020, CELL RES, V30, P189, DOI 10.1038/s41422-020-0290-0
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Pradhan P, 2020, 20200130927871 BIORX
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 21
TC 4
Z9 4
U1 1
U2 1
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0001-723X
EI 1336-2305
J9 ACTA VIROL
JI Acta Virol.
PY 2020
VL 64
IS 2
BP 245
EP 250
DI 10.4149/av_2020_201
PG 6
WC Virology
SC Virology
GA NI7XB
UT WOS:000565560800013
PM 32551792
OA Bronze
DA 2021-01-01
ER

PT J
AU Bauerle, A
   Graf, J
   Jansen, C
   Musche, V
   Schweda, A
   Hetkamp, M
   Weismuller, B
   Dorrie, N
   Junne, F
   Teufel, M
   Skoda, EM
AF Baeuerle, Alexander
   Graf, Johanna
   Jansen, Christoph
   Musche, Venja
   Schweda, Adam
   Hetkamp, Madeleine
   Weismueller, Benjamin
   Doerrie, Nora
   Junne, Florian
   Teufel, Martin
   Skoda, Eva-Maria
TI E-mental health mindfulness-based and skills-based 'CoPE It'
   intervention to reduce psychological distress in times of COVID-19:
   study protocol for a bicentre longitudinal study
SO BMJ OPEN
LA English
DT Article
DE telemedicine; infectious diseases; public health
ID COGNITIVE-BEHAVIORAL THERAPY; POSTDISASTER DISTRESS; DISORDER; PROGRAM;
   IMPACT; COMBAT; CHINA
AB Introduction The SARS-CoV-2 (COVID-19) pandemic poses immense challenges for national and international healthcare systems. Especially in times of social isolation and governmental restrictions, mental health should not be neglected. Innovative approaches are required to support psychologically burdened people. The e-mental health intervention 'CoPE It' has been developed to offer manualised and evidence-based psychotherapeutic support adapted to COVID-19-related issues in order to overcome psychological distress. In our study, we aim to assess the efficacy of the e-mental health intervention 'CoPE It' in terms of reducing distress (primary outcome), depression and anxiety symptoms as well as improving self-efficacy, quality of life and mindfulness (secondary outcomes). Furthermore, we want to evaluate the programme's usability, feasibility and participants' satisfaction with 'CoPE It' (tertiary outcome). Methods and analysis The e-mental health intervention 'CoPE It' consists of four 30 min modules, conducted every other day, involving psychotherapeutic techniques of mindfulness-based stress reduction and cognitive-behavioural therapy. The widely applied and previously established content has been adapted to the context of the COVID-19 pandemic by experts in psychosomatic medicine and stress prevention. In our longitudinal study, adult participants-with adequate German language and computer skills, and who have provided informed consent-will be recruited via emergency support hotlines in Germany. Flyers will be distributed, and online channels will be used. Participants will complete a baseline assessment (T0), a postintervention assessment (T1) and assessments 1 and 3 months later (T2 and T3, respectively). We will perform repeated measures analysis of covariance, mixed linear models, standard analyses of variance and regression, and correlation coefficients. In case of binary outcome variables, either mixed logistic regression or chi(2) tests will be used. Ethics and dissemination The Ethics Committees of the University of Duisburg-Essen (20-9243-BO) and University of Tubingen (469/2020BO) approved the study. Results will be published in peer-reviewed journals and conference presentations.
C1 [Baeuerle, Alexander; Jansen, Christoph; Musche, Venja; Schweda, Adam; Hetkamp, Madeleine; Weismueller, Benjamin; Doerrie, Nora; Teufel, Martin; Skoda, Eva-Maria] Univ Duisburg Essen, LVR Univ Hosp Essen, Clin Psychosomat Med & Psychotherapy, Essen, Germany.
   [Graf, Johanna; Junne, Florian] Med Univ Hosp Tubingen, Psychosomat Med & Psychotherapy, Tubingen, Germany.
RP Bauerle, A (corresponding author), Univ Duisburg Essen, LVR Univ Hosp Essen, Clin Psychosomat Med & Psychotherapy, Essen, Germany.
EM alexander.baeuerle@uni-due.de
RI Junne, Florian/ABI-7343-2020; Hetkamp, Madeleine/AAZ-1365-2020
OI Hetkamp, Madeleine/0000-0002-1028-0064; Bauerle,
   Alexander/0000-0003-1488-8592
CR Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006
   Andersson G, 2014, WORLD PSYCHIATRY, V13, P288, DOI 10.1002/wps.20151
   Tran BX, 2020, SAFETY SCI, V129, DOI 10.1016/j.ssci.2020.104811
   Bauerle A, 2020, J PUBLIC HEALTH-UK, V42, P647, DOI 10.1093/pubmed/fdaa058
   Bauerle A, 2020, J PUBLIC HEALTH-UK, V42, P649, DOI 10.1093/pubmed/fdaa053
   Behan C, 2020, IRISH J PSYCHOL MED, V37, P256, DOI 10.1017/ipm.2020.38
   Boden MT, 2012, PSYCHIAT RES, V200, P609, DOI 10.1016/j.psychres.2012.07.011
   Boss L, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5952
   Brooke J., 1996, USABILITY EVALUATION, V4, P189, DOI DOI 10.1002/HBM.20701
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen Y, 2014, PSYCHIAT SERV, V65, P259, DOI 10.1176/appi.ps.201200470
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   Christensen H, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1194
   Silva Juliana Amaral Medeiros da, 2015, Trends Psychiatry Psychother., V37, P171, DOI 10.1590/2237-6089-2014-0026
   Daggubati LC, 2020, WORLD NEUROSURG, V139, pE859, DOI 10.1016/j.wneu.2020.05.140
   Dobson D, 2018, EVIDENCE BASED PRACT
   Ellis A, 1991, J RATION-EMOT COGN-B, V9, P139, DOI DOI 10.1007/BF01061227
   Fiorillo A, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.35
   Fliege H, 2001, DIAGNOSTICA, V47, P142, DOI 10.1026//0012-1924.47.3.142
   Ghebreyesus T, 2020, WHO DIRECTOR GEN OPE
   Hamblen JL, 2017, PSYCHOL TRAUMA-US, V9, P130, DOI 10.1037/tra0000221
   Hamblen JL, 2009, ADM POLICY MENT HLTH, V36, P206, DOI 10.1007/s10488-009-0213-3
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Kearney DJ, 2012, J CLIN PSYCHOL, V68, P101, DOI 10.1002/jclp.20853
   King AP, 2013, DEPRESS ANXIETY, V30, P638, DOI 10.1002/da.22104
   Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lopes AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109013
   Mak WWS, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/mental.8597
   Mehrotra A, 2020, NEJM CATALYST
   Mukaino M, 2020, AM J PHYS MED REHAB, V99, P478, DOI 10.1097/PHM.0000000000001441
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Schroder J, 2015, J AFFECT DISORDERS, V187, P136, DOI 10.1016/j.jad.2015.08.044
   Schwarzer R, 1999, DOKUMENTATION PSYCHO
   Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tan WQ, 2020, BRAIN BEHAV IMMUN, V87, P84, DOI 10.1016/j.bbi.2020.04.055
   Thompson RW, 2011, TRAUMA VIOLENCE ABUS, V12, P220, DOI 10.1177/1524838011416375
   Walach H, 2006, PERS INDIV DIFFER, V40, P1543, DOI 10.1016/j.paid.2005.11.025
   Waller R, 2009, PSYCHOL MED, V39, P705, DOI 10.1017/S0033291708004224
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wind TR, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100317
   World Health Organization (WHO), COVID 19 CAS NUMB
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 49
TC 0
Z9 0
U1 3
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 8
AR e039646
DI 10.1136/bmjopen-2020-039646
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH0DY
UT WOS:000564351500111
PM 32792455
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Franco, G
AF Franco, Giuliano
TI The 1711 rinderpest in Bernardino Ramazzini's XIII Oration and the
   COVID-19 public health emergency: facts and common aspects
SO MEDICINA DEL LAVORO
LA English
DT Article
DE Bernardino Ramazzini; rinderpest; COVID-19
ID PRAYER HELD; MEDICINE; 9TH; 5TH
AB Although Bernardino Ramazzini is usually regarded only as the father of occupational medicine, his approach to fight the devastating rinderpest epidemic in 1711 is worth mentioning in the light of the public health emergency represented by Coronavirus Disease-2019 (COVID-19). This commentary (i) focuses on Ramazzini's XIII oration describing that event, (ii) analyses the approach suggested to fight the cattle epidemic and economic threats, (iii) highlights some similar aspects between the 1711 rinderpest epidemic and the current COVID-19 pandemic (team expertise, contagion transmissibility, drug treatment, preventive measures, decision timeliness).
EM giulianofranco.medlav@gmail.com
CR [Anonymous], 2006, ORG MOND SANT AN WOR
   Bianchi T, 2019, SAF HEALTH WORK-KR, V10, P245, DOI 10.1016/j.shaw.2018.11.002
   Carnevale F, 2015, OCCUP ENVIRON MED, V72, P2, DOI 10.1136/oemed-2014-102744
   Cogrossi CF, 1714, NUOVA IDEA MALE CONT
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   De Zan M, 2003, EDIZIONE TESTO SCI E, P55
   Di Pietro P, 1999, EUR J ONCOL, V4, P183
   Fellows of the Collegium Ramazzini, 2020, J Occup Environ Med, V62, pe467, DOI 10.1097/JOM.0000000000001916
   Fontanarosa PB, 2020, JAMA-J AM MED ASSOC, V323, P1907, DOI 10.1001/jama.2020.6582
   Franco G, 2020, PUBLIC HEALTH, V181, P180, DOI 10.1016/j.puhe.2019.12.016
   Franco G, 2001, AM J PUBLIC HEALTH, V91, P1380
   Franco G, 2020, PREVENTION IS FAR BE
   Garrison FH, 1934, B NY ACAD MED, V12, P679
   Morens DM, 2011, J INFECT DIS, V204, P502, DOI 10.1093/infdis/jir327
   Mutti A, 2020, MED LAV, V111, P83, DOI 10.23749/mdl.v111i2.9546
   Normile D, 2008, SCIENCE, V319, P1606, DOI 10.1126/science.319.5870.1606
   Pagel JL, 1891, DEUT MED WOCHENSCHR, V17, P224
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Ramazzini B, 1713, MORBIS ARTIFICUM DIA
   Ramazzini B, 2011, EPISTOLARY DISSERTAT, P435
   Ramazzini B, 2005, MED LAV, V96, P3
   Ramazzini B, 2011, INAUGURAL ORATIONS, P265
   Ramazzini B, 2010, MED LAV, V101, P138
   Ramazzini B, 2010, MED LAV, V101, P84
   Ramazzini B, 2010, MED LAV, V101, P94
   Riva MA, 2019, AM J IND MED, V62, P631, DOI 10.1002/ajim.22993
   Shanks GD, 2016, AM J TROP MED HYG, V95, P269, DOI 10.4269/ajtmh.16-0138
   Tu HL, 2020, J INFECTION, V81, P1, DOI 10.1016/j.jinf.2020.04.011
NR 28
TC 0
Z9 0
U1 1
U2 1
PU MATTIOLI 1885
PI FIDENZA
PA VIA DELLA LODESANA 649-SX, FIDENZA, 43046 PR, ITALY
SN 0025-7818
J9 MED LAV
JI Med. Lav.
PY 2020
VL 111
IS 4
BP 321
EP 325
DI 10.23749/mdl.v111i4.9672
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NG4SN
UT WOS:000563973800007
PM 32869768
DA 2021-01-01
ER

PT J
AU Pfeifer, M
   Ewig, S
   Voshaar, T
   Randerath, WJ
   Bauer, T
   Geiseler, J
   Dellweg, D
   Westhoff, M
   Windisch, W
   Schonhofer, B
   Kluge, S
   Lepper, P
AF Pfeifer, Michael
   Ewig, Santiago
   Voshaar, Thomas
   Randerath, Winfried Johannes
   Bauer, Torsten
   Geiseler, Jens
   Dellweg, Dominic
   Westhoff, Michael
   Windisch, Wolfram
   Schoenhofer, Bernd
   Kluge, Stefan
   Lepper, PhilippM.
TI Position Paper for the State-of-the-Art Application of Respiratory
   Support in Patients with COVID-19
SO RESPIRATION
LA English
DT Article
DE COVID-19; Respiratory support; Acute respiratory failure
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; NONINVASIVE VENTILATION;
   INFLUENZA-VIRUS; MECHANICAL VENTILATION; DISTRESS-SYNDROME; GERMAN
   SOCIETY; PRESSURE VENTILATION; EXHALED BREATH; VIRAL LOAD; FAILURE
AB Against the background of the pandemic caused by infection with the SARS-CoV-2 virus, the German Respiratory Society has appointed experts to develop therapy strategies for COVID-19 patients with acute respiratory failure (ARF). Here we present key position statements including observations about the pathophysiology of (ARF). In terms of the pathophysiology of pulmonary infection with SARS-CoV-2, COVID-19 can be divided into 3 phases. Pulmonary damage in advanced COVID-19 often differs from the known changes in acute respiratory distress syndrome (ARDS). Two types (type L and type H) are differentiated, corresponding to early- and late-stage lung damage. This differentiation should be taken into consideration in the respiratory support of ARF. The assessment of the extent of ARF should be based on arterial or capillary blood gas analysis under room air conditions, and it needs to include the calculation of oxygen supply (measured from the variables of oxygen saturation, hemoglobin level, the corrected values of Hufner's factor, and cardiac output). Aerosols can cause transmission of infectious, virus-laden particles. Open systems or vented systems can increase the release of respirable particles. Procedures in which the invasive ventilation system must be opened and endotracheal intubation carried out are associated with an increased risk of infection. Personal protective equipment (PPE) should have top priority because fear of contagion should not be a primary reason for intubation. Based on the current knowledge, inhalation therapy, nasal high-flow therapy (NHF), continuous positive airway pressure (CPAP), or noninvasive ventilation (NIV) can be performed without an increased risk of infection to staff if PPE is provided. A significant proportion of patients with ARF present with relevant hypoxemia, which often cannot be fully corrected, even with a high inspired oxygen fraction (FiO(2)) under NHF. In this situation, the oxygen therapy can be escalated to CPAP or NIV when the criteria for endotracheal intubation are not met. In ARF, NIV should be carried out in an intensive care unit or a comparable setting by experienced staff. Under CPAP/NIV, a patient can deteriorate rapidly. For this reason, continuous monitoring and readiness for intubation are to be ensured at all times. If the ARF progresses under CPAP/NIV, intubation should be implemented without delay in patients who do not have a "do not intubate" order. (c) 2020 S. Karger AG, Basel
C1 [Pfeifer, Michael] Univ Klin Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany.
   [Pfeifer, Michael] Fachklin Lungenerkrankungen Donaustauf, Abt Pneumol, Donaustauf, Germany.
   [Pfeifer, Michael] Krankenhaus Barmherzige Bruder, Klin Pneumol & Konservat Intens Med, Regensburg, Germany.
   [Ewig, Santiago] EVK Herne & Augusta Krankenanstalt Bochum, Dept Resp & Infect Dis, Thoraxzentrum Ruhrgebiet, Bochum, Germany.
   [Voshaar, Thomas] Krankenhaus Bethanien, Zentrum Schlaf & Beatmungsmed, Schwerpunkt Pneumol, Allergol,Klin Immunol, Moers, Germany.
   [Randerath, Winfried Johannes] Univ Cologne, Inst Pneumol, Cologne, Germany.
   [Randerath, Winfried Johannes] Krankenhaus Bethanien, Klin Pneumol, Solingen, Germany.
   [Bauer, Torsten] Helios Klinikum Emil von Behring GmbH, Lungenklin Heckeshorn, Berlin, Germany.
   [Geiseler, Jens] Klinikum Vest GmbH, Paracelsus Klin, Med Klin 4 Klin Pneumol Beatmungs & Schlafmed, Marl, Germany.
   [Dellweg, Dominic] Philipps Univ Marburg, Akad Lehrkrankenhaus, Fachkrankenhaus Kloster Grafschaft GmbH, Schmallenberg, Germany.
   [Westhoff, Michael] Lungenklin Hemer, Klin Pneumol, Hemer, Germany.
   [Westhoff, Michael; Windisch, Wolfram] Univ Witten Herdecke, Witten, Germany.
   [Windisch, Wolfram] Univ Witten Herdecke, Lehrstuhl Pneumol, Kliniken Stadt Koln, Klin Pneumol,Klinikum Koln Merheim, Cologne, Germany.
   [Schoenhofer, Bernd] Klinikum Reg Hannover, Klinikum Agnes Karll Laatzen, Laatzen, Germany.
   [Kluge, Stefan] Univ Klinikum Hamburg Eppendorf, Klin Intens Med, Hamburg, Germany.
   [Lepper, PhilippM.] Univ Klinikum Saarlandes, Innere Med V Pneumol Allergol Beatmungs & Umweltm, Homburg, Germany.
RP Bauer, T (corresponding author), Helios Klinikum Emil von Behring GmbH, Lungenklin Heckeshorn, Walterhoferstr 11, DE-14165 Berlin, Germany.
EM torsten.bauer@helios-gesundheit.de
RI Windisch, Wolfram/ABI-7381-2020
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   ALFORD RH, 1966, P SOC EXP BIOL MED, V122, P800, DOI 10.3181/00379727-122-31255
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   An der Heiden M., 2020, MODELLIERUNG BEISPIE, DOI [10.25646/6571.2, DOI 10.25646/6571.2]
   Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Baker JG, 2020, THORAX, V75, P368, DOI 10.1136/thoraxjnl-2020-214913
   BARACH A L, 1946, J Aviat Med, V17, P290
   Barach AL, 1938, ANN INTERN MED, V12, P754, DOI 10.7326/0003-4819-12-6-754
   Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI DOI 10.15585/MMWR.MM6912E2
   Bischoff WE, 2013, J INFECT DIS, V207, P1037, DOI 10.1093/infdis/jis773
   Blachere FM, 2009, CLIN INFECT DIS, V48, P438, DOI 10.1086/596478
   Bourke SC, 2018, LANCET RESP MED, V6, P935, DOI 10.1016/S2213-2600(18)30388-6
   Braunlich J, 2017, RESP PHYSIOL NEUROBI, V242, P86, DOI 10.1016/j.resp.2017.03.012
   Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP
   Brown JR, 2015, J HOSP INFECT, V91, P278, DOI 10.1016/j.jhin.2015.08.004
   Canelli R, 2020, NEW ENGL J MED, V382, P1957, DOI 10.1056/NEJMc2007589
   Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Cowling BJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2922
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dembinski R, 2018, ANASTH INTENSIV NOTF, V53, P102, DOI 10.1055/s-0043-107166
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Duan J, 2017, INTENS CARE MED, V43, P192, DOI 10.1007/s00134-016-4601-3
   Duan YN, 2020, RADIOLOGY, V295, P21, DOI 10.1148/radiol.2020200323
   Edwards DA, 2004, P NATL ACAD SCI USA, V101, P17383, DOI 10.1073/pnas.0408159101
   Ewig S, 2016, PNEUMOLOGIE, V70, P151, DOI 10.1055/s-0042-101873
   Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Fang YC, 2020, RADIOLOGY, V295, P208, DOI [10.1148/radiol.2020200280, 10.1148/2020200280]
   Fichtner F, 2018, DTSCH ARZTEBL INT, V115, P840, DOI 10.3238/arztebl.2018.0840
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Frat JP, 2018, CRIT CARE MED, V46, P208, DOI 10.1097/CCM.0000000000002818
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Gao C, 2020, CRIT CARE MED, V48, P451, DOI 10.1097/CCM.0000000000004207
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan LL, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00352-2020
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Han RB, 2020, ANIM BIOTECHNOL, DOI [10.1080/10495398.2020.1832104, 10.2214/AJR.20.22961]
   Harari SA, 2020, MANAGING RESP CARE P
   He G, 2020, ZHEJIANG DA XUE XUE, V49
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Jiang JJ, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012634, 10.1097/md.0000000000012634]
   Jouvet P, 2015, PEDIATR CRIT CARE ME, V16, P428, DOI 10.1097/PCC.0000000000000350
   Karagiannidis C, 2020, PNEUMOLOGIE, V74, P46, DOI 10.1055/a-1065-6230
   Kluge S, 2020, MED KLIN-INTENSIVMED, V115, P175, DOI 10.1007/s00063-020-00674-3
   Kohler D, 1983, Prax Klin Pneumol, V37 Suppl 1, P922
   Kohler D, 2000, INHALATIONSTHERAPIE, DOI [10.1007/978-3-642-59756-5_41, DOI 10.1007/978-3-642-59756-5_41]
   Kotoda M, 2019, J HOSP INFECT, DOI [10.1016/j.jhin.2019.11.010, DOI 10.1016/J.JHIN.2019.11.01]
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Liang T, 2020, HDB COVID 19 PREVENT
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Maiolo G, 2018, AM J RESP CRIT CARE, V197, P1586, DOI 10.1164/rccm.201709-1804OC
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Munsiff SS, 2006, CLIN INFECT DIS, V42, P1702, DOI 10.1086/504325
   Nehls W, 2020, HANDLUNGSEMPFEHLUNG
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   NHS, 2020, GUID ROL US NON RESP
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pan C, 2020, AM J RESP CRIT CARE, V201, P1294, DOI 10.1164/rccm.202003-0527LE
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Papineni RS, 1996, J AEROSOL MED, V10, P105, DOI 10.1089/jam.1997.10.105
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255
   Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC
   RKI, 2020, STAND ARB KOMP BEH K
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schaberg T, 2010, Pneumologie, V64, P124, DOI 10.1055/s-0029-1243862
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Tang JLW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059970
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thompson KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056278
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wallet F, 2010, EUR J ANAESTH, V27, P270, DOI 10.1097/EJA.0b013e32832dbd49
   Wan GH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087088
   Wang B, 2005, J BIOMECH ENG-T ASME, V127, P32, DOI 10.1115/1.1835350
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
   Westhoff M, 2015, PNEUMOLOGIE, V69, P719, DOI 10.1055/s-0034-1393309
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, IMAI DISTR CLIN MAN
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yang W, 2011, J R SOC INTERFACE, V8, P1176, DOI 10.1098/rsif.2010.0686
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 125
TC 5
Z9 5
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0025-7931
EI 1423-0356
J9 RESPIRATION
JI Respiration
PY 2020
VL 99
IS 6
BP 521
EP 541
DI 10.1159/000509104
PG 21
WC Respiratory System
SC Respiratory System
GA NB2RX
UT WOS:000560361200008
PM 32564028
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, JF
   Zhang, J
   Tu, YX
   Zhou, XL
   Huang, HJ
   Shao, LN
   Chen, LG
   Zhao, Y
   Ge, MH
AF Wang, Jiafeng
   Zhang, Jun
   Tu, Yuexing
   Zhou, Xianlong
   Huang, Haijun
   Shao, Lina
   Chen, Legao
   Zhao, Yan
   Ge, Minghua
TI Cancer patients in SARS-CoV-2 infection: a single-center experience from
   Wuhan
SO JOURNAL OF CANCER
LA English
DT Article
DE COVID-19; Coronavirus; Pandemic; Cancer; Therapy
AB Background: The Coronavirus disease 2019 (COVID-19) global pandemic has posed unprecedented challenges to the health-care systems all over the world. Among the booming literatures about COVID-19, there is yet a paucity of study addressing the association between COVID-19 and cancer, which is a rare comorbidity of COVID-19, as well as consensus for treatment of cancer in this pandemic.
   Methods: In this retrospective, single-center cohort study, information of all inpatient cases with laboratory-confirmed COVID-19 who had treatment outcome were collected from the designated departments in Zhongnan Hospital of Wuhan University, Wuhan, China on March 10, 2020. Demographic data, clinical information, and treatment outcomes were extracted from electronic medical records. Severe events were defined as admission to intensive care unit (ICU), the use of mechanical ventilation, or death.
   Result: A total of 716 patients with laboratory-confirmed COVID-19 infection were identified. Among them, a total of 12 cases (1.7%, 95% CI: 0.7%-2.6%) had history of cancer with 4 cases (33%) experienced severe events. Compared with cases without cancer, patients with cancer have higher risks of severe events (33% vs 7.7%, p=0.012) and deaths (25% vs 3.6%, p=0.009). Multivariable logistic regression model showed that cancer was independently associated with increased odds of severe events after adjusting for other risk factors (OR 6.51, 95% CI 1.72-24.64; p=0.006). Among COVID-19 patients with cancer, we found that patients older than 60 years (75%), with other comorbidities (50%), or experiencing anticancer treatment in past month (42.9%) had a numerically higher incidence of severe events.
   Conclusion: Cancer is a rare comorbidity of patients with COVID-19; however, it cannot be overemphasized due to its poorer outcomes. We propose that personalized treatment recommendation for cancer patients should be addressed during COVID-19 pandemic, along with meticulous personal protective protocols for them to mitigate the risk of SARS-CoV-2 infection.
C1 [Wang, Jiafeng] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou 310053, Zhejiang, Peoples R China.
   [Wang, Jiafeng; Zhang, Jun; Tu, Yuexing; Huang, Haijun; Shao, Lina; Chen, Legao; Ge, Minghua] Zhejiang Prov Peoples Hosp, Med Aiding Team COVID Hubei 19, Hangzhou 310014, Zhejiang, Peoples R China.
   [Zhang, Jun; Tu, Yuexing; Huang, Haijun; Shao, Lina; Chen, Legao; Ge, Minghua] Peoples Hosp, Hangzhou Med Sch, Hangzhou 310014, Zhejiang, Peoples R China.
   [Zhou, Xianlong; Zhao, Yan] Wuhan Univ, Emergency Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
   [Zhou, Xianlong; Zhao, Yan] Wuhan Univ, Hubei Clin Res Ctr Emergency & Resuscitat, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China.
RP Ge, MH (corresponding author), 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.; Zhao, Y (corresponding author), 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM doctoryanzhao@whu.edu.cn; geminghua@hmc.edu.cn
FU Emergency Response Project of Hubei Science and Technology Department
   [2020FCA023]; Emergency Diagnostic and Therapeutic Center of Central
   China
FX This study was supported by grants from the Emergency Response Project
   of Hubei Science and Technology Department (2020FCA023 to Yan Zhao) and
   the Emergency Diagnostic and Therapeutic Center of Central China (to
   Xianlong Zhou and Yan Zhao).
CR Amodeo G, 2018, J PAIN RES, V11, P1297, DOI 10.2147/JPR.S158230
   Atkins S, 2019, INFECT DIS CLIN N AM, V33, P289, DOI 10.1016/j.idc.2019.01.001
   Banna G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000765
   Burki TK, 2020, LANCET ONCOL, V21, P628, DOI 10.1016/S1470-2045(20)30201-1
   Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7
   Carreca I, 2005, CANCER TREAT REV, V31, P380, DOI 10.1016/j.ctrv.2005.04.012
   Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Lei S, 2020, ECLINICALMEDICINE
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma XT, 2020, CELL ONCOL, V43, P751, DOI 10.1007/s13402-020-00512-w
   Phelan A.L., 2020, JAMA
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zu Zi Yue, 2020, RADIOLOGY
NR 18
TC 0
Z9 0
U1 0
U2 0
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2020
VL 11
IS 21
BP 6243
EP 6247
DI 10.7150/jca.47065
PG 5
WC Oncology
SC Oncology
GA NF8UE
UT WOS:000563567300007
PM 33033507
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dicke, M
   Eilenberg, J
   Salles, JF
   Jensen, AB
   Lecocq, A
   Pijlman, GP
   van Loon, JJA
   van Oers, MM
AF Dicke, M.
   Eilenberg, J.
   Salles, J. Falcao
   Jensen, A. B.
   Lecocq, A.
   Pijlman, G. P.
   van Loon, J. J. A.
   van Oers, M. M.
TI Edible insects unlikely to contribute to transmission of coronavirus
   SARS-CoV-2
SO JOURNAL OF INSECTS AS FOOD AND FEED
LA English
DT Article
DE coronavirus; SARS-CoV-2; ACE2; vector; food safety
ID RESPIRATORY SYNDROME CORONAVIRUS; DIPTERA; VACCINE; VIRUS
AB In the context of food safety, edible insects are evaluated for biological hazards such as microbial pathogens according to regulations currently in place. When the European Food Safety Authority evaluated the hazards of edible insects as a potential source of pathogenic viruses for humans and livestock, the novel zoonotic coronavirus SARS-CoV-2 had not yet emerged but other pathogenic coronaviruses such as SARS (SARS-CoV) and MERS (MERS-CoV) were known. As a result of the COVID-19 pandemic, animal sources of protein for human consumption are being evaluated for the risks of being a transmission vector of coronaviruses, like SARS-CoV-2. Insects lack a receptor that can bind SARS-CoV-2, thus preventing the virus from replicating in insects, unlike some vertebrate livestock species and companion animals. Despite extensive monitoring, coronaviruses have never been recorded in insect microbiomes. Contamination of insects produced for food or feed may occur during the production process, resulting from rearing substrate or from insect farmers. However, the currently permitted rearing substrates do not include animal products and the farming process is highly automated, thus limiting interactions between farmers and insects. If contamination would still occur, the fact that the insects in production are not hosts to SARS-CoV-2 precludes virus replication and the further processing of the insects will destroy the contamination. We conclude that the hazard of edible insects being a transmission vector of SARS-CoV-2 is extremely low.
C1 [Dicke, M.; van Loon, J. J. A.] Wageningen Univ & Res, Lab Entomol, POB 16, NL-6700 AA Wageningen, Netherlands.
   [Eilenberg, J.; Jensen, A. B.; Lecocq, A.] Univ Copenhagen, Dept Plant & Environm Sci, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.
   [Salles, J. Falcao] Univ Groningen, Groningen Inst Evolutionary Sci GELIFES, Microbial Community Ecol Cluster, GREEN, Groningen, Netherlands.
   [Pijlman, G. P.; van Oers, M. M.] Wageningen Univ & Res, Lab Virol, POB 16, NL-6700 AA Wageningen, Netherlands.
RP Dicke, M (corresponding author), Wageningen Univ & Res, Lab Entomol, POB 16, NL-6700 AA Wageningen, Netherlands.
EM marcel.dicke@wur.nl
RI Dicke, Marcel/B-2300-2010; Salles, Joana Falcao/A-7313-2008; Salles,
   Joana Falcao/AAG-7070-2020; van Loon, Joop J.A./B-3744-2009; Eilenberg,
   Jorgen/F-7444-2014
OI Dicke, Marcel/0000-0001-8565-8896; Salles, Joana
   Falcao/0000-0003-4317-7263; van Loon, Joop J.A./0000-0002-4260-0501;
   Eilenberg, Jorgen/0000-0002-9273-5252
FU Netherlands Organisation for Scientific Research (NWO; NWA programme,
   InsectFeed project)Netherlands Organization for Scientific Research
   (NWO) [NWA.1160.18.144]; EU Horizon 2020 -Research and Innovation
   Framework Programme (Insect Doctors, MSCA-ITN-2019 Project) [859850]
FX We have evaluated the scientific information on SARSCoV-2 until 25 May
   2020. Our research has been supported by the Netherlands Organisation
   for Scientific Research (NWO; NWA programme, InsectFeed project,
   NWA.1160.18.144) and by the EU Horizon 2020 -Research and Innovation
   Framework Programme (Insect Doctors, MSCA-ITN-2019 Project 859850).
CR Arsiwalla T., 2016, US Patent Bureau, Patent No. [US2016066552 (A1), 2016066552A1]
   Boccazzi IV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182533
   Brinker P, 2019, TRENDS MICROBIOL, V27, P480, DOI 10.1016/j.tim.2019.02.002
   Callaway E., 2020, NATURE, V577, P1, DOI [10.1038/d41586-020-00180-8, DOI 10.1038/D41586-020-00180-8]
   Casanova LM, 2010, APPL ENVIRON MICROB, V76, P2712, DOI 10.1128/AEM.02291-09
   Cashman JS, 2019, BIOCHEM J, V476, P3505, DOI 10.1042/BCJ20190635
   Chan K, 2011, ADV OPTOELECTRON, V2011, DOI [10.1155/2011/734690, 10.1155/2011/196707]
   Cory JS, 2015, CURR OPIN INSECT SCI, V8, P130, DOI 10.1016/j.cois.2015.01.007
   Cox MMJ, 2011, J INVERTEBR PATHOL, V107, pS31, DOI 10.1016/j.jip.2011.05.003
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Smet J, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02722-17
   Dehghani R, 2020, ARCH CLIN INFECT DIS, V15, DOI 10.5812/archcid.102863
   EFSA Sci Comm, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4257
   Eilenberg J., 2018, ECOLOGY INVERTEBRATE, P495
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Geden CJ, 2008, J MED ENTOMOL, V45, P42, DOI 10.1603/0022-2585(2008)45[42:SPATOS]2.0.CO;2
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gurung K, 2019, ENTOMOL EXP APPL, V167, P156, DOI 10.1111/eea.12768
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   ICTV, 2011, 9 ICTV
   International Platform of Insects for Food and Feed (IPIFF), 2019, IPIFF GUID GOOD HYG
   Jansen J., 2019, World Intellectual Property Organisation, patent number, Patent No. [WO2019125165 (A1), 2019125165A1]
   Jiang CL, 2019, MICROB BIOTECHNOL, V12, P528, DOI 10.1111/1751-7915.13393
   Larouche J, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9040182
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Li WB, 2020, APPL PHYS EXPRESS, V13, DOI 10.35848/1882-0786/ab998e
   Luk HKH, 2019, INFECT GENET EVOL, V71, P21, DOI 10.1016/j.meegid.2019.03.001
   Maciel-Vergara G, 2017, J INVERTEBR PATHOL, V147, P60, DOI 10.1016/j.jip.2017.01.013
   Mackay IM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0439-5
   Monie A, 2008, BIOL-TARGETS THER, V2, P107
   Qiu Y, 2020, MICROBES INFECT, V22, P221, DOI 10.1016/j.micinf.2020.03.003
   Ryabov EV, 2017, J INVERTEBR PATHOL, V147, P37, DOI 10.1016/j.jip.2016.10.002
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Shi M, 2016, NATURE, V540, P539, DOI 10.1038/nature20167
   Stoffels I, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9020
   Swinscoe I, 2019, J INSECTS FOOD FEED, V5, P15, DOI 10.3920/JIFF2017.0067
   van Huis A, 2020, J INSECTS FOOD FEED, V6, P27, DOI 10.3920/JIFF2019.0017
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Weaver SC, 2013, TRENDS MICROBIOL, V21, P360, DOI 10.1016/j.tim.2013.03.003
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   WHO, 2020, MOD TRANSM VIR CAUS
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang ZJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06844
   Zheng LY, 2013, SCI REP-UK, V3, DOI 10.1038/srep02563
   Zheng LY, 2013, J MED ENTOMOL, V50, P647, DOI 10.1603/ME12199
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou ZM, 2006, VACCINE, V24, P3624, DOI 10.1016/j.vaccine.2006.01.059
NR 49
TC 2
Z9 2
U1 9
U2 9
PU WAGENINGEN ACADEMIC PUBLISHERS
PI WAGENINGEN
PA PO BOX 220, WAGENINGEN, 6700 AE, NETHERLANDS
EI 2352-4588
J9 J INSECTS FOOD FEED
JI J. Insects Food Feed
PY 2020
VL 6
IS 4
BP 333
EP 339
DI 10.3920/JIFF2020.0039
PG 7
WC Agriculture, Multidisciplinary; Entomology; Food Science & Technology
SC Agriculture; Entomology; Food Science & Technology
GA ND7MM
UT WOS:000562087000002
OA Green Published
DA 2021-01-01
ER

PT J
AU Simpson, CR
   Robertson, C
   Vasileiou, E
   McMenamin, J
   Gunson, R
   Ritchie, LD
   Woolhouse, M
   Morrice, L
   Kelly, D
   Stagg, HR
   Marques, D
   Murray, J
   Sheikh, A
AF Simpson, Colin R.
   Robertson, Chris
   Vasileiou, Eleftheria
   McMenamin, Jim
   Gunson, Rory
   Ritchie, Lewis D.
   Woolhouse, Mark
   Morrice, Lynn
   Kelly, Dave
   Stagg, Helen R.
   Marques, Diogo
   Murray, Josie
   Sheikh, Aziz
TI Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE
   II): protocol for an observational study using linked Scottish national
   data
SO BMJ OPEN
LA English
DT Article
DE public health; epidemiology; public health; respiratory medicine (see
   thoracic medicine)
ID INFLUENZA; VACCINE
AB Introduction Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19 pandemic, population-level surveillance and rapid assessment of the effectiveness of existing or new therapeutic or preventive interventions are required to ensure that interventions are targeted to those at highest risk of serious illness or death from COVID-19. We aim to repurpose and expand an existing pandemic reporting platform to determine the attack rate of SARS-CoV-2, the uptake and effectiveness of any new pandemic vaccine (once available) and any protective effect conferred by existing or new antimicrobial drugs and other therapies.
   Methods and analysis A prospective observational cohort will be used to monitor daily/weekly the progress of the COVID-19 epidemic and to evaluate the effectiveness of therapeutic interventions in approximately 5.4million individuals registered in general practices across Scotland. A national linked dataset of patient-level primary care data, out-of-hours, hospitalisation, mortality and laboratory data will be assembled. The primary outcomes will measure association between: (A) laboratory confirmed SARS-CoV-2 infection, morbidity and mortality, and demographic, socioeconomic and clinical population characteristics; and (B) healthcare burden of COVID-19 and demographic, socioeconomic and clinical population characteristics. The secondary outcomes will estimate: (A) the uptake (for vaccines only); (B) effectiveness; and (C) safety of new or existing therapies, vaccines and antimicrobials against SARS-CoV-2 infection. The association between population characteristics and primary outcomes will be assessed via multivariate logistic regression models. The effectiveness of therapies, vaccines and antimicrobials will be assessed from time-dependent Cox models or Poisson regression models. Self-controlled study designs will be explored to estimate the risk of therapeutic and prophylactic-related adverse events.
   Ethics and dissemination We obtained approval from the National Research Ethics Service Committee, Southeast Scotland 02. The study findings will be presented at international conferences and published in peer-reviewed journals.
C1 [Simpson, Colin R.] Victoria Univ Wellington, Fac Hlth, Wellington Sch Hlth, Wellington, New Zealand.
   [Simpson, Colin R.; Vasileiou, Eleftheria; Woolhouse, Mark; Morrice, Lynn; Stagg, Helen R.; Sheikh, Aziz] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.
   [Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland.
   [Robertson, Chris; McMenamin, Jim; Marques, Diogo; Murray, Josie] Publ Hlth Scotland, Glasgow, Lanark, Scotland.
   [Gunson, Rory] West Scotland Specialist Virol Ctr, Glasgow, Lanark, Scotland.
   [Ritchie, Lewis D.] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen, Scotland.
   [Kelly, Dave] Albasoft Ltd, Ctr Hlth Sci, Inverness, Scotland.
RP Vasileiou, E (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.
EM eleftheria.vasileiou@ed.ac.uk
OI Sheikh, Aziz/0000-0001-7022-3056; Stagg, Helen/0000-0003-4022-3447;
   Vasileiou, Eleftheria/0000-0001-6850-7578
FU National Institute for Health Research Health Technology Assessment
   ProgrammeNational Institute for Health Research (NIHR) [13/34/14];
   Medical Research CouncilMedical Research Council UK (MRC)
   [MR/R008345/1]; Scottish Government; HDR UK
FX The EAVE project was funded by the National Institute for Health
   Research Health Technology Assessment Programme (project number
   13/34/14). EAVE II is funded by the Medical Research Council
   (MR/R008345/1) and supported by the Scottish Government. We also
   acknowledge the support of HDR UK. HRS is supported by the Medical
   Research Council (MR/R008345/1).
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Bloom DE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00549
   Centers for Disease Control and Prevention, INFL FLU PAND INFL P
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   Health Protection Scotland, DAT SURV
   Kelly H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021828
   Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254
   LeDuc J.W., 2004, EMERG INFECT DIS, V10, pe26, DOI [10.3201/eid1011.040797_02, DOI 10.3201/EID1011.040797_02]
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   National Services Scotland, INF SERV DIV SMR01 G
   National Services Scotland, INF SERV DIV DAT QUA
   National Services Scotland, INF SERV DIV DEATHS
   National Services Scotland, INF SERV DIV CHI NUM
   National Services Scotland, INF SERV DIV SMR REC
   National Services Scotland, INF SERV DIV SMR02 M
   NHS Scotland, NHS SCOTL EHEALTH
   Scottish Government, COVID 19 COMM HUBS
   Scottish Intensive Care Society Audit Group, SICSAG
   Simpson CR, 2010, HEALTH TECHNOL ASSES, V14, P323, DOI 10.3310/hta14340-05
   Simpson CR, 2019, LANCET INFECT DIS, V19, pE295, DOI 10.1016/S1473-3099(18)30786-2
   Simpson CR, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014200
   Simpson CR, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19790
   Simpson CR, 2012, LANCET INFECT DIS, V12, P696, DOI 10.1016/S1473-3099(12)70133-0
   Simpson CR, 2013, HLTH SERV DELIV RES, V1, P1, DOI DOI 10.3310/HSDR01100
   Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, INFL PAND
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 32
TC 2
Z9 2
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 6
AR e039097
DI 10.1136/bmjopen-2020-039097
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NC8AA
UT WOS:000561434500065
PM 32565483
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Barata, P
   Agarwal, N
   Nussenzveig, R
   Gerendash, B
   Jaeger, E
   Hatton, W
   Ledet, E
   Lewis, B
   Layton, J
   Babiker, H
   Bryce, A
   Garje, R
   Stein, C
   Kiedrowski, L
   Saylor, P
   Sartor, O
AF Barata, Pedro
   Agarwal, Neeraj
   Nussenzveig, Roberto
   Gerendash, Benjamin
   Jaeger, Ellen
   Hatton, Whitley
   Ledet, Elisa
   Lewis, Brian
   Layton, Jodi
   Babiker, Hani
   Bryce, Alan
   Garje, Rohan
   Stein, Cy
   Kiedrowski, Lesli
   Saylor, Philip
   Sartor, Oliver
TI Clinical activity of pembrolizumab in metastatic prostate cancer with
   microsatellite instability high (MSI-H) detected by circulating tumor
   DNA
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE biomarkers; tumor; immunotherapy; programmed cell death 1 receptor;
   prostatic neoplasms
ID BLOCKADE
AB To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated with immune checkpoint inhibitors. Retrospective analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and MSI-H tumor detected by a commercially available cfDNA NGS assay Guardant360 (G360, Guardant Health) at eight different Academic Institutions in the USA, from September 2018 to April 2020. From a total of 14 MSI-H metastatic prostate cancer patients at participating centers, nine patients with mCRPC with 56% bone, 33% nodal, 11% liver and 11% soft-tissue metastases and a median PSA of 29.3 ng/dL, were treated with pembrolizumab after 2 lines of therapy for CRPC. The estimated median time on pembrolizumab was 9.9 (95% CI 1.0 to 18.8) months. Four patients (44%) achieved PSA50 after a median of 4 (3-12) weeks after treatment initiation including three patients with >99% PSA decline. Among the patients evaluable for radiographic response (n=5), the response rate was 60% with one complete response and two partial responses. Best response was observed after a median of 3.3 (1.4-7.6) months. At time of cut-off, four patients were still on pembrolizumab while four patients discontinued therapy due to progressive disease and one due to COVID-19 infection. Half of the patients with PSA50 had both MSI-H and pathogenic alterations inBRCA1andBRCA2in their G360 assays. The use of liquid biopsy to identify metastatic prostate cancer patients with MSI-H is feasible in clinical practice and may overcome some of the obstacles associated with prostate cancer tumor tissue testing. The robust activity of pembrolizumab in selected patients supports the generalized testing for MSI-H.
C1 [Barata, Pedro; Jaeger, Ellen; Hatton, Whitley; Ledet, Elisa; Lewis, Brian; Layton, Jodi; Sartor, Oliver] Tulane Univ, Deming Dept Med, New Orleans, LA 70118 USA.
   [Agarwal, Neeraj; Nussenzveig, Roberto] Univ Utah, Dept Med Oncol, Salt Lake City, UT USA.
   [Gerendash, Benjamin; Stein, Cy] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA.
   [Babiker, Hani] Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ USA.
   [Bryce, Alan] Mayo Clin, Dept Oncol, Scottsdale, AZ USA.
   [Garje, Rohan] Univ Iowa, Div Hematol Oncol & Blood & Marrow Transplant, Iowa City, IA USA.
   [Garje, Rohan] Univ Iowa, Div Hematol Oncol & Blood & Marrow Transplantat, Genitourinary Oncol Program, Iowa City, IA USA.
   [Kiedrowski, Lesli] Guardant Hlth Inc, Redwood City, CA USA.
   [Saylor, Philip] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA.
RP Barata, P (corresponding author), Tulane Univ, Deming Dept Med, New Orleans, LA 70118 USA.
EM pedrobaratamd@gmail.com
RI Garje, Rohan/AAL-9489-2020
OI Garje, Rohan/0000-0002-7244-5602; Agarwal, Neeraj/0000-0003-1076-0428;
   Barata, Pedro/0000-0002-8890-2951
CR Abida W, 2019, JAMA ONCOL, V5, P471, DOI 10.1001/jamaoncol.2018.5801
   Agarwal N, 2020, CABOZANTINIB C COMBI
   [Anonymous], 2020, NATL COMPREHENSIVE C
   Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638
   Cook N, 2015, MOL ONCOL, V9, P997, DOI 10.1016/j.molonc.2014.07.025
   Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1
   Friedlander M, 2019, LANCET ONCOL, V20, P1306, DOI 10.1016/S1470-2045(19)30396-1
   Georgiadis A, 2019, CLIN CANCER RES, V25, P7024, DOI 10.1158/1078-0432.CCR-19-1372
   Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Li K, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1091-8
   Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070
   Mayrhofer M, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0595-5
   Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226
   Murphy KM, 2006, J MOL DIAGN, V8, P305, DOI 10.2353/jmoldx.2006.050092
   Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755
   Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831
   Reichert ZR, 2019, JAMA ONCOL, V5, P478, DOI 10.1001/jamaoncol.2018.5789
   Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053
   Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677
   SHARMA P, 2019, J CLIN ONCOL S, V37
   Shia JR, 2011, AM J SURG PATHOL, V35, P447, DOI 10.1097/PAS.0b013e31820a091d
   Vinayak S, 2019, JAMA ONCOL, V5, P1132, DOI 10.1001/jamaoncol.2019.1029
   Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324
NR 25
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001065
DI 10.1136/jitc-2020-001065
PG 5
WC Oncology; Immunology
SC Oncology; Immunology
GA ND3AE
UT WOS:000561775300005
PM 32788235
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Montesarchio, V
   Parella, R
   Iommelli, C
   Bianco, A
   Manzillo, E
   Fraganza, F
   Palumbo, C
   Rea, G
   Murino, P
   De Rosa, R
   Atripaldi, L
   D'Abbraccio, M
   Curvietto, M
   Mallardo, D
   Celentano, E
   Grimaldi, AM
   Palla, M
   Trojaniello, C
   Vitale, MG
   Million-Weaver, SL
   Ascierto, PA
AF Montesarchio, Vincenzo
   Parella, Roberto
   Iommelli, Chiara
   Bianco, Antonella
   Manzillo, Elio
   Fraganza, Fiorentino
   Palumbo, Cristiana
   Rea, Gaetano
   Murino, Patrizia
   De Rosa, Rosanna
   Atripaldi, Luigi
   D'Abbraccio, Maurizio
   Curvietto, Marcello
   Mallardo, Domenico
   Celentano, Egidio
   Grimaldi, Antonio Maria
   Palla, Marco
   Trojaniello, Claudia
   Vitale, Maria Grazia
   Million-Weaver, Samuel Lewis
   Ascierto, Paolo Antonio
TI Outcomes and biomarker analyses among patients with COVID-19 treated
   with interleukin 6 (IL-6) receptor antagonist sarilumab at a single
   institution in Italy
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE immunomodulation; case reports; inflammation mediators
ID HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CYTOKINE; TOXICITIES
AB Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing. Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease. Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.
C1 [Montesarchio, Vincenzo; Iommelli, Chiara; Bianco, Antonella] Monaldi Hosp, Dept Med Oncol, Azienda Osped Colli, Naples, Italy.
   [Parella, Roberto; Manzillo, Elio; D'Abbraccio, Maurizio] Cotugno Hosp, Dept Infect Dis & Infect Dis Emergencies, Azienda Osped Colli, Naples, Italy.
   [Fraganza, Fiorentino; Murino, Patrizia; De Rosa, Rosanna] Cotugno & Monaldi Hosp, Crit Area Dept, Azienda Osped Colli, Naples, Italy.
   [Palumbo, Cristiana; Rea, Gaetano; Atripaldi, Luigi] Cotugno & Monaldi Hosp, Dept Hlth Serv, Azienda Osped Colli, Naples, Italy.
   [Curvietto, Marcello; Mallardo, Domenico; Grimaldi, Antonio Maria; Palla, Marco; Trojaniello, Claudia; Vitale, Maria Grazia] Ist Nazl Tumori IRCCS Fdn Pascale, Dept Melanoma Canc Immunotherapy & Dev Therapeute, Naples, Campania, Italy.
   [Celentano, Egidio] Ist Nazl Tumori IRCCS Fdn Pascale, Epidemiol & Biostat Unit, Naples, Campania, Italy.
   [Ascierto, Paolo Antonio] Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy.
RP Ascierto, PA (corresponding author), Ist Nazl Tumori IRCCS Fdn Pascale, Naples, Italy.
EM paolo.ascierto@gmail.com
CR Arnaldez FI, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000930
   Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen F, 2016, J IMMUNOL METHODS, V434, P1, DOI 10.1016/j.jim.2016.03.005
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Daniel OG, 2020, EMERGING INFECT DIS, V26
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Eng SS, 2016, CLIN REV ALLERG IMMU, V50, P140, DOI 10.1007/s12016-015-8526-3
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Fu B, 2020, COMMUNICATION
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Horby P, 2020, EFFECT DEXAMETHASONE
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   La Rosee P, 2015, HEMATOL-AM SOC HEMAT, P190, DOI 10.1182/asheducation-2015.1.190
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Neelapu SS, 2019, HEMATOL ONCOL, V37, P48, DOI 10.1002/hon.2595
   Oda S, 2005, CYTOKINE, V29, P169, DOI 10.1016/j.cyto.2004.10.010
   @OurWorldInData, 2020, TOT CONF COVID 19 DE
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qian GQ, 2020, QJM-INT J MED, V113, P474, DOI 10.1093/qjmed/hcaa089
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V101623
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537
   Tamamyan GN, 2016, CANCER-AM CANCER SOC, V122, P2857, DOI 10.1002/cncr.30084
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xea X, 2020, EFFECTIVE TREATMENT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang AP, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106504
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 60
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001089
DI 10.1136/jitc-2020-001089
PG 10
WC Oncology; Immunology
SC Oncology; Immunology
GA ND3AE
UT WOS:000561775300007
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, GQ
   Hong, TP
   Yang, J
AF Liu, Guoqiang
   Hong, Tianpei
   Yang, Jin
TI A Single Large Dose of Vitamin D Could be Used as a Means of Coronavirus
   Disease 2019 Prevention and Treatment
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE vitamin D; large dose; coronavirus disease 2019
ID RESPIRATORY SYNCYTIAL VIRUS; D DEFICIENCY; RISK; SUPPLEMENTATION;
   MODULATION; INFECTION; CHILDREN; THERAPY; ADULTS
AB There is no specific and effective medication for coronavirus disease 2019 (COVID-19), and avaccine is not available in recent months. Here, we hypothesize that a single large dose of vitamin D (Vit D) could be an option for trial in COVID-19. Vit D deficiency or insufficiency is very common in the general population as well as in patients with COVID-19. It has been shown that low Vit D level is associated with viral infection, and Vit D supplementation is beneficial for people infected with viruses, such as HIV and hepatitis C virus. Although COVID-19 is a respiratory disease, the morbidity and mortality of this disease are driven by coagulopathy. Clinical studies have shown that Vit D can exert anticoagulant effects. Vit D, a lipid-soluble vitamin, can be administered as a draught. Vit D supplementation is safe and has rare toxic events. In addition, the cost of Vit D is fairly low. Based on these observations, we speculate that a single dose of 300,000 IU Vit D may have a role in the prevention and treatment of COVID-19.
C1 [Liu, Guoqiang; Hong, Tianpei; Yang, Jin] Peking Univ, Hosp 3, Dept Endocrinol & Metab, Beijing 100191, Peoples R China.
RP Yang, J (corresponding author), Peking Univ, Hosp 3, Dept Endocrinol & Metab, Beijing 100191, Peoples R China.
EM yangjin@bjmu.edu.cn
RI Liu, Guoqiang/ABA-9493-2020
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bergqvist C, 2019, GIORN ITAL DERMAT V, V154, P669, DOI 10.23736/S0392-0488.19.06433-2
   Bivona G, 2019, NEUROL RES, V41, P827, DOI 10.1080/01616412.2019.1622872
   Teixeira NDCCD, 2019, NUTR HOSP, V36, P1205, DOI 10.20960/nh.02647
   Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318
   Chawla D, 2019, J NUTR SCI, V8, DOI 10.1017/jns.2019.4
   Eckard AR, 2018, ANTIVIR THER, V23, P315, DOI 10.3851/IMP3199
   Eltayeb AA, 2015, WORLD J GASTROENTERO, V21, P1284, DOI 10.3748/wjg.v21.i4.1284
   Ezeamama AE, 2016, CLIN NUTR, V35, P1110, DOI 10.1016/j.clnu.2015.08.007
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240
   Halasa N, 2015, VACCINE, V33, P6479, DOI 10.1016/j.vaccine.2015.08.048
   Hathcock JN, 2007, AM J CLIN NUTR, V85, P6
   Hejazi ME, 2017, J CLIN PHARMACOL, V57, P40, DOI 10.1002/jcph.774
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Hurwitz JL, 2017, J PEDIATR-US, V187, P323, DOI 10.1016/j.jpeds.2017.04.061
   Jafarzadeh A, 2020, LIFE SCI, V257, DOI [10.1016/j.lfs.2020.11810228, DOI 10.1016/J.LFS.2020.11810228]
   Kebapcilar AG, 2013, ARCH GYNECOL OBSTET, V288, P207, DOI 10.1007/s00404-013-2735-x
   Keum N, 2014, BRIT J CANCER, V111, P976, DOI 10.1038/bjc.2014.294
   Lachmann R, 2015, AIDS, V29, P1127, DOI 10.1097/QAD.0000000000000666
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Martineau AR, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011511.pub2
   Mattioli AV, 2020, NUTR METAB CARDIOVAS, DOI [10.1016/j.numecd.2020.05.02018., DOI 10.1016/J.NUMECD.2020.05.02018]
   Merzon E, 2020, FEBS J, DOI [10.1111/febs.1549517., DOI 10.1111/FEBS.1549517.]
   Miri M, 2019, IRAN J PHARM RES, V18, P1067, DOI 10.22037/ijpr.2019.1100647
   Mohamed AA, 2013, ACTA GASTRO-ENT BELG, V76, P38
   Murdaca G, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102350
   Pei Y, 2013, CHIN J OSTEOPOROSIS, V6, P308
   Piso RJ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-577
   Ren B, 2020, CIRCULATION, V142, P181, DOI 10.1161/CIRCULATIONAHA.120.047407
   Sacerdote A, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1201-y
   Suaini NHA, 2015, NUTRIENTS, V7, P6088, DOI 10.3390/nu7085271
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   von Restorff C, 2009, BONE, V45, P747, DOI 10.1016/j.bone.2009.06.012
   Yu H, 2019, MATERN CHILD HLTH J, V34, P3664
   [张浩 Zhang Hao], 2011, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V17, P43
   Zhang RH, 2017, AM J CLIN NUTR, V105, P810, DOI 10.3945/ajcn.116.140392
   Zisi D, 2019, HORM-INT J ENDOCRINO, V18, P353, DOI 10.1007/s42000-019-00155-z
NR 39
TC 2
Z9 2
U1 2
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2020
VL 14
BP 3429
EP 3434
DI 10.2147/DDDT.S271754
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NC3GZ
UT WOS:000561104200001
PM 32904593
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Patel, A
   Shah, KJ
   Dharsandiya, M
   Patel, K
   Patel, T
   Patel, M
   Reljic, T
   Kumar, A
AF Patel, Atul
   Shah, Kinjal
   Dharsandiya, Mitkumar
   Patel, Ketan
   Patel, Tushar
   Patel, Mukesh
   Reljic, Tea
   Kumar, Ambuj
TI Safety and efficacy of tocilizumab in the treatment of severe acute
   respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort
   study
SO INDIAN JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; cytokine release storm; severe acute respiratory
   syndrome coronavirus-2; tocilizumab
ID CYTOKINE STORM; OSELTAMIVIR; COVID-19
AB Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is thought to be the cause for organ damage and death which is independent of the actual viral burden. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is approved for the treatment of CRS. We describe the efficacy and safety of TCZ in SARS CoV-2 pneumonia. Methods: This retrospective study was conducted at a tertiary care hospital from April 20 2020 to May 21 2020. The primary endpoint was the cumulative incidence of a composite of either need for admission to the intensive care unit (ICU) with invasive mechanical ventilation or death. Safety outcomes included an increase in liver transaminases and/or evidence of infection. Results: A total of 20 patients received TCZ during the study period. The median age was 54 years (95% confidence interval [CI] 47-63). About 85% of the patients were male. Nearly 70% of the patients had at least one comorbidity. About 55% required ICU admission. The median duration of ICU stay was 11 days (95% CI: 3-13 days). The cumulative incidence of the requirement for mechanical ventilation, clinical improvement and mortality was 11% (95% CI: 0.03%-1%), 74% (95% CI 37%-89%) and 25% (95% CI: 11%-63%), respectively. There was no difference in outcomes according to age, gender or computed tomography severity score. Asymptomatic transaminitis was the most common drug reaction (55%), and one patient developed bacteraemia. Conclusions: TCZ is likely a safe and effective modality of treatment for improving clinical and laboratory parameters of SARS CoV-2 patients with a reduction in ICU stay and ventilatory care need.
C1 [Patel, Atul] Univ S Florida, Morsani Coll Med, Div Infect Dis, Dept Internal Med, Tampa, FL 33620 USA.
   [Reljic, Tea; Kumar, Ambuj] Univ S Florida, Morsani Coll Med, Dept Internal Med, Tampa, FL 33620 USA.
   [Shah, Kinjal; Dharsandiya, Mitkumar; Patel, Ketan] Sterling Hosp, Dept Infect Dis, Ahmadabad 380052, Gujarat, India.
   [Patel, Tushar; Patel, Mukesh] Sterling Hosp, Dept Pulm & Crit Care Med, Ahmadabad, Gujarat, India.
RP Patel, A (corresponding author), Sterling Hosp, Dept Infect Dis, Ahmadabad 380052, Gujarat, India.
EM atulpatel65@gmail.com
CR Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Fadel R, CLIN INFECT DIS, DOI 10.1093/cid/ciaa60l
   Hiba V, 2011, J ANTIMICROB CHEMOTH, V66, P1150, DOI 10.1093/jac/dkr089
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Kumar A, 2011, J ANTIMICROB CHEMOTH, V66, P959, DOI 10.1093/jac/dkr090
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van Kraaij Tom DA, 2020, Eur J Case Rep Intern Med, V7, P001675, DOI 10.12890/2020_001675
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0255-0857
EI 1998-3646
J9 INDIAN J MED MICROBI
JI Indian J. Med. Microbiol.
PD JAN-MAR
PY 2020
VL 38
IS 1
BP 117
EP 123
DI 10.4103/ijmm.IJMM_20_298
PG 7
WC Immunology
SC Immunology
GA NA3WI
UT WOS:000559744600017
PM 32719218
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Miao, XN
   Luo, Y
   Huang, X
   Lee, SMY
   Yuan, ZJ
   Tang, YZ
   Chen, LD
   Wang, C
   Wu, F
   Xu, YF
   Jiang, WC
   Gao, W
   Song, XD
   Yan, Y
   Pang, TL
   Chen, C
   Zou, YF
   Fu, WH
   Wan, LP
   Gilbert-Jaramillo, J
   Knight, M
   Tan, TK
   Rijal, P
   Townsend, A
   Sun, J
   Liu, XL
   James, W
   Tsun, A
   Xu, YD
AF Miao, Xiaoniu
   Luo, Yi
   Huang, Xi
   Lee, Suki M. Y.
   Yuan, Zhijun
   Tang, Yongzhou
   Chen, Liandi
   Wang, Chao
   Wu, Fan
   Xu, Yifeng
   Jiang, Wenchao
   Gao, Wei
   Song, Xuedong
   Yan, Yao
   Pang, Tuling
   Chen, Cheng
   Zou, Yuefeng
   Fu, Weihui
   Wan, Liping
   Gilbert-Jaramillo, Javier
   Knight, Michael
   Tan, Tiong Kit
   Rijal, Pramila
   Townsend, Alain
   Sun, Joanne
   Liu, Xiaolin
   James, William
   Tsun, Andy
   Xu, Yingda
TI A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2
   infection: implications for therapy
SO MABS
LA English
DT Article
DE Biparatopic; neutralizing antibody; antibody-ACE2 fusion; COVID-19;
   SARS-CoV-2
ID SARS; NEUTRALIZATION; RESPONSES; SPIKE
AB In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combines the specificity of a monoclonal antibody (89C8) that recognizes the relatively conserved N-terminal domain of the viral Spike (S) glycoprotein, and the ectodomain of ACE2, which binds to the receptor-binding domain of S. This molecule shows exceptional performancein vitro, inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater than ACE2-Fc itself. Moreover, 89C8-ACE2 was able to neutralize authentic viral infection in a standard 96-h co-incubation assay at low nanomolar concentrations, making this class of molecule a promising lead for therapeutic applications.
C1 [Miao, Xiaoniu; Luo, Yi; Yuan, Zhijun; Tang, Yongzhou; Chen, Liandi; Wang, Chao; Wu, Fan; Xu, Yifeng; Jiang, Wenchao; Gao, Wei; Song, Xuedong; Yan, Yao; Pang, Tuling; Chen, Cheng; Zou, Yuefeng; Fu, Weihui; Wan, Liping; Sun, Joanne; Liu, Xiaolin; Tsun, Andy; Xu, Yingda] Biotheus Inc, New Drug Discovery & Dev, Zhuhai, Peoples R China.
   [Huang, Xi] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China.
   [Lee, Suki M. Y.] Hong Kong Sci & Technol Pk, New Drug Discovery & Dev, Hong Kong, Peoples R China.
   [Gilbert-Jaramillo, Javier; Knight, Michael; James, William] Univ Oxford, Sir William Dunn Sch Pathol, Oxford, England.
   [Tan, Tiong Kit; Rijal, Pramila; Townsend, Alain] Univ Oxford, Chinese Acad Med Sci Oxford Inst, Ctr Translat Immunol, Oxford, England.
RP Tsun, A; Xu, YD (corresponding author), Biotheus Inc, New Drug Discovery & Dev, Zhuhai, Peoples R China.; James, W (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Oxford, England.
EM james@path.ox.ac.uk; tsun.a@biotheus.com; xu.yd@biotheus.com
RI james, william/H-4289-2013
OI james, william/0000-0002-2506-1198; Gilbert, Javier/0000-0003-1268-2304
CR Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Coughlin MM, 2009, VIROLOGY, V394, P39, DOI 10.1016/j.virol.2009.07.028
   DEMADRID AT, 1969, B WORLD HEALTH ORGAN, V40, P113
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   JAMES WS, 1986, J GEN VIROL, V67, P2803, DOI 10.1099/0022-1317-67-12-2803
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Prabakaran P, 2009, EXPERT OPIN BIOL TH, V9, P355, DOI 10.1517/14712590902763755 
   Qian KW, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1782600
   Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sun Z, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051633
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yu Y, 2016, J BIOMOL SCREEN, V21, P88, DOI 10.1177/1087057115609564
NR 24
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PD JAN 1
PY 2020
VL 12
IS 1
AR 1804241
DI 10.1080/19420862.2020.1804241
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NA5TU
UT WOS:000559879500001
PM 32804015
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Appelberg, S
   Gupta, S
   Akusjarvi, SS
   Ambikan, AT
   Mikaeloff, F
   Saccon, E
   Vegvari, A
   Benfeitas, R
   Sperk, M
   Stahlberg, M
   Krishnan, S
   Singh, K
   Penninger, JM
   Mirazimi, A
   Neogi, U
AF Appelberg, Sofia
   Gupta, Soham
   Svensson Akusjarvi, Sara
   Ambikan, Anoop T.
   Mikaeloff, Flora
   Saccon, Elisa
   Vegvari, Akos
   Benfeitas, Rui
   Sperk, Maike
   Stahlberg, Marie
   Krishnan, Shuba
   Singh, Kamal
   Penninger, Josef M.
   Mirazimi, Ali
   Neogi, Ujjwal
TI Dysregulation in Akt/mTOR/HIF-1 signaling identified by
   proteo-transcriptomics of SARS-CoV-2 infected cells
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; transcriptomics; proteomics; Akt; mTOR; HIF-1; MK-2206
ID RESPIRATORY SYNDROME CORONAVIRUS; A VIRUS-REPLICATION; KAPPA-B;
   EXPRESSION; INHIBITOR; TRANSLATION; PNEUMONIA; AUTOPHAGY
AB How severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections engage cellular host pathways and innate immunity in infected cells remains largely elusive. We performed an integrative proteo-transcriptomics analysis in SARS-CoV-2 infected Huh7 cells to map the cellular response to the invading virus over time. We identified four pathways, ErbB, HIF-1, mTOR and TNF signaling, among others that were markedly modulated during the course of the SARS-CoV-2 infectionin vitro. Western blot validation of the downstream effector molecules of these pathways revealed a dose-dependent activation of Akt, mTOR, S6K1 and 4E-BP1 at 24 hours post infection (hpi). However, we found a significant inhibition of HIF-1 alpha through 24hpi and 48hpi of the infection, suggesting a crosstalk between the SARS-CoV-2 and the Akt/mTOR/HIF-1 signaling pathways. Inhibition of the mTOR signaling pathway using Akt inhibitor MK-2206 showed a significant reduction in virus production. Further investigations are required to better understand the molecular sequelae in order to guide potential therapy in the management of severe coronavirus disease 2019 (COVID-19) patients.
C1 [Appelberg, Sofia; Mirazimi, Ali] Publ Hlth Agcy Sweden, Solna, Sweden.
   [Gupta, Soham; Svensson Akusjarvi, Sara; Ambikan, Anoop T.; Mikaeloff, Flora; Saccon, Elisa; Sperk, Maike; Krishnan, Shuba; Singh, Kamal; Mirazimi, Ali; Neogi, Ujjwal] Karolinska Inst, Dept Lab Med, Div Clin MicroBiol, Stockholm, Sweden.
   [Vegvari, Akos; Stahlberg, Marie] Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, Stockholm, Sweden.
   [Benfeitas, Rui] Stockholm Univ, Natl Bioinformat Infrastruct Sweden NBIS, Sci Life Lab, Dept Biochem & Biophys, Stockholm, Sweden.
   [Singh, Kamal; Neogi, Ujjwal] Univ Missouri, Dept Vet Pathobiol, Columbia, MO USA.
   [Singh, Kamal; Neogi, Ujjwal] Univ Missouri, Bond Life Sci Ctr, Columbia, MO 65211 USA.
   [Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, Vienna, Austria.
   [Penninger, Josef M.] Univ British Columbia, Life Sci Inst, Dept Med Genet, Vancouver, BC, Canada.
   [Mirazimi, Ali] Natl Vet Inst, Uppsala, Sweden.
RP Mirazimi, A (corresponding author), Publ Hlth Agcy Sweden, Solna, Sweden.; Neogi, U (corresponding author), Univ Missouri, Bond Life Sci Ctr, Columbia, MO 65211 USA.; Mirazimi, A (corresponding author), Natl Vet Inst, Uppsala, Sweden.; Mirazimi, A; Neogi, U (corresponding author), Karolinska Inst, Div Clin Microbiol, Dept Lab Med, ANA Futura, Campus Flemingsberg, Stockholm, Sweden.; Neogi, U (corresponding author), Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.
EM ali.mirazimi@folkhalsomyndigheten.se; ujjwal.neogi@ki.se
RI Penninger, Josef M/I-6860-2013
OI Penninger, Josef M/0000-0002-8194-3777; Gupta,
   Soham/0000-0003-1136-3010; Reis, AlessanRSS/0000-0001-8486-7469;
   Vegvari, Akos/0000-0002-1287-0906
FU Swedish Research CouncilSwedish Research Council [2017-01330,
   2018-05766, 2017-03126]; Canada 150 Research Chair program; CIHR rapid
   Response COVID-19 grantCanadian Institutes of Health Research (CIHR);
   Office of Research (Early Concept Grant, Bond Life Sciences Center),
   University of Missouri, Columbia, MO
FX The study is funded by the Swedish Research Council [grant number
   2017-01330, UN]. A. M. is supported by the Swedish research Council
   [2018-05766 and 2017-03126]. J.M.P. is supported by the Canada 150
   Research Chair program and CIHR rapid Response COVID-19 grant. K.S.
   acknowledges the funding from the Office of Research (Early Concept
   Grant, Bond Life Sciences Center), University of Missouri, Columbia, MO.
CR Alsuwaidi AR, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0618-6
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Brysbaert G, 2018, CYTOSCAPE
   Chen HH, 2017, CELL MOL IMMUNOL, V14, P736, DOI 10.1038/cmi.2017.44
   Chu H, 2020, LANCET MICROBE, V1, pE14
   Cimmino F, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0767-1
   Csardi G, 2006, INT J COMPLEX SYST, V1695, P1, DOI DOI 10.3724/SP.J.1087.2009.02191
   Denisova OV, 2014, ANTIMICROB AGENTS CH, V58, P3689, DOI 10.1128/AAC.02798-13
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ehrhardt C, 2009, CELL MICROBIOL, V11, P863, DOI 10.1111/j.1462-5822.2009.01309.x
   Erdos P., 1964, ACTA MATH ACAD SCI H, V12, P261, DOI DOI 10.1007/BF02066689
   Gassen N.C., 2020, BIORXIV
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Kawamata N, 2007, BLOOD, V110, P2667, DOI 10.1182/blood-2005-11-026344
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Le Sage V, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060152
   Luo QH, 2018, ISCIENCE, V3, P87, DOI 10.1016/j.isci.2018.04.010
   Mizutani T, 2005, BBA-MOL BASIS DIS, V1741, P4, DOI 10.1016/j.bbadis.2005.04.004
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Murray James L., 2012, Antiviral Chemistry & Chemotherapy, V22, P205, DOI 10.3851/IMP2080
   Pinno J, 2016, CELL SIGNAL, V28, P907, DOI 10.1016/j.cellsig.2016.04.004
   Ranadheera C, 2018, EBIOMEDICINE, V32, P142, DOI 10.1016/j.ebiom.2018.05.027
   Riehmann P, 2005, IEEE S INF VIS INFOV
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rohde C, 2019, EMERG MICROBES INFEC, V8, P1300, DOI 10.1080/22221751.2019.1659552
   Shi G, 2018, P NATL ACAD SCI USA, V115
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Tang BSF, 2005, J VIROL, V79, P6180, DOI 10.1128/JVI.79.10.6180-6193.2005
   TRAAG VA, 2019, SCI REPORTS, V9, P1, DOI DOI 10.1038/S41598-019-41695-Z
   Wang CH, 2014, CRIT CARE MED, V42, P313, DOI 10.1097/CCM.0b013e3182a2727d
   Weinlich R, 2014, MOL CELL, V56, P469, DOI 10.1016/j.molcel.2014.11.001
   Willforss J, 2019, J PROTEOME RES, V18, P732, DOI 10.1021/acs.jproteome.8b00523
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zecha J, 2020, MOL CELL PROTEOMICS, V19, DOI 10.1074/mcp.RA120.002164
   Zhang W, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02358
   Zhao CQ, 2020, EMERG MICROBES INFEC, V9, P691, DOI 10.1080/22221751.2020.1742585
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Zhou J, 2004, CANCER RES, V64, P9041, DOI 10.1158/0008-5472.CAN-04-1437
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2020, CELL DISCOV, V14, P6, DOI DOI 10.1038/S41421-020-0153
   Zwergal A, 2006, J IMMUNOL, V177, P665, DOI 10.4049/jimmunol.177.1.665
NR 45
TC 5
Z9 5
U1 8
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1748
EP 1760
DI 10.1080/22221751.2020.1799723
PG 13
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MY5ZS
UT WOS:000558495700001
PM 32691695
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Feitosa, EL
   Junior, FTDS
   Neto, JADN
   Matos, LFL
   Moura, MHD
   Rosales, TO
   De Freitas, GBL
AF Feitosa, Eduardo L.
   Junior, Francisco Tiago Dos S. S.
   Neto, Jose Arimatea De O. N.
   Matos, Luis F. L.
   Moura, Matheus H. De S.
   Rosales, Thiele Osvaldt
   De Freitas, Guilherme Barroso L.
TI COVID-19: Rational discovery of the therapeutic potential of Melatonin
   as a SARS-CoV-2 main Protease Inhibitor
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Melatonin; COVID-19; Rational Design; Docking; hyper-inflammation
ID EMERGING CORONAVIRUS; OXIDATIVE STRESS; NEONATAL SEPSIS; CALMODULIN;
   CELLS; INFECTION; BINDING; RECEPTOR; DEATH; RISK
AB The SARS-CoV-2 spread quickly across the globe. The World Health Organization (WHO) on March 11 declared COVID-19 a pandemic. The mortality rate, hospital disorders and incalculable economic and social damages, besides the unproven efficacy of the treatments evaluated against COVID-19, raised the need for immediate control of this disease. Therefore, the current study employed in silico tools to rationally identify new possible SARS-CoV-2 main protease (Mpro) inhibitors. That is an enzyme conserved among the coronavirus species; hence, the identification of an Mpro inhibitor is to make it a broad-spectrum drug. Molecular docking studies described the binding sites and the interaction energies of 74 Mpro-ligand complexes deposited in the Protein Data Bank (PDB). A structural similarity screening was carried out in order to identify possible Mpro ligands that show additional pharmacological properties against COVID-19. We identified 59 hit compounds and among them, melatonin stood out due to its prominent immunomodulatory and anti-inflammatory activities; it can reduce oxidative stress, defence cell mobility and efficiently combat the cytokine storm and sepsis. In addition, melatonin is an inhibitor of calmodulin, an essential intracellular component to maintain angiotensin-converting enzyme 2 (ACE-2) on the cell surface. Interestingly, one of the most promising hits in our docking study was melatonin. It revealed better interaction energy with Mpro compared to ligands in complexes from PDB. Consequently, melatonin can have response potential in early stages for its possible effects on ACE-2 and Mpro, although it is also promising in more severe stages of the disease for its action against hyper-inflammation. These results definitely do not confirm antiviral activity, but can rather be used as a basis for further preclinical and clinical trials.
C1 [Feitosa, Eduardo L.; Junior, Francisco Tiago Dos S. S.; Neto, Jose Arimatea De O. N.; Matos, Luis F. L.; Moura, Matheus H. De S.; De Freitas, Guilherme Barroso L.] Univ Fed Piaui, Dept Biochem & Pharmacol, Lab Quim Med & Biotecnol LAQUIMB, Teresina, PI, Brazil.
   [Rosales, Thiele Osvaldt] Univ Fed Santa Catarina, Dept Pharmacol, Florianopolis, SC, Brazil.
RP De Freitas, GBL (corresponding author), Univ Fed Piaui, Dept Biochem & Pharmacol, Lab Quim Med & Biotecnol LAQUIMB, Teresina, PI, Brazil.
EM guilhermebarroso@ufpi.edu.br
RI de Oliveira Nery Neto, Jose Arimatea/AAY-5778-2020
CR Acuna-Castroviejo D, 2017, CELL MOL LIFE SCI, V74, P3965, DOI 10.1007/s00018-017-2610-1
   Ali T, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1157-x
   Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832
   BenitezKing G, 1996, BBA-GEN SUBJECTS, V1290, P191, DOI 10.1016/0304-4165(96)00025-6
   BENITEZKING G, 1993, LIFE SCI, V53, P201, DOI 10.1016/0024-3205(93)90670-X
   Berchtold MW, 2014, BBA-MOL CELL RES, V1843, P398, DOI 10.1016/j.bbamcr.2013.10.021
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Biancatelli RMLC, 2020, J THORAC DIS, V12, pS54, DOI 10.21037/jtd.2019.12.85
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P149, DOI 10.1007/978-1-4939-9752-7_10
   Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Castillo R. R., 2020, MELATONIN RES, V3, P297, DOI [10.32794/mr11250063., DOI 10.32794/MR11250063]
   Chen CL, 2020, HUM-CENT COMPUT INFO, V10, DOI 10.1186/s13673-020-00221-1
   Chen H., 2020, MEDRXIV, DOI [10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen SJ, 2016, INT IMMUNOPHARMACOL, V31, P169, DOI 10.1016/j.intimp.2015.12.020
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Choi EY, 2011, J PINEAL RES, V50, P197, DOI 10.1111/j.1600-079X.2010.00829.x
   Costanzo M, 2020, CURR MED CHEM, DOI [10.2174/0929867327666200416131117., DOI 10.2174/0929867327666200416131117.]
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   D'Angelo G, 2017, AM J PERINAT, V34, P1382, DOI 10.1055/s-0037-1604244
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   do Amaral FG, 2018, ARCH ENDOCRIN METAB, V62, P472, DOI 10.20945/2359-3997000000066
   Fang J, 2018, AGING-US, V10, P2954, DOI 10.18632/aging.101602
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Garofalo M, 2020, MOLECULES, V25, DOI 10.3390/molecules25071756
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Henderson R, 2018, COMPLEMENT THER MED, V39, P131, DOI 10.1016/j.ctim.2018.06.002
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandemir YB, 2018, EURASIAN J MED, V50, P160, DOI 10.5152/eurasianjmed.2018.17361
   Lambert DW, 2008, FEBS LETT, V582, P385, DOI 10.1016/j.febslet.2007.11.085
   Lee S, 2018, INT J MED SCI, V15, P1083, DOI 10.7150/ijms.26314
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Li SW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050678
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   Mandal H, 2020, TURK J MED SCI, V50, P485, DOI 10.3906/sag-2004-180
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Prauchner CA, 2017, BURNS, V43, P471, DOI 10.1016/j.burns.2016.09.023
   Reiter RJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00226
   Rio B.D., 2004, J BIOL CHEM, V279, P38294, DOI [10.1074/jbc.m403140200, DOI 10.1074/JBC.M403140200.]
   Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054
   Romero MP, 1998, FASEB J, V12, P1401
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Seidel T, 2019, PROG CHEM ORG NAT PR, V110, P99, DOI 10.1007/978-3-030-14632-0_4
   Sharma A, 2020, MICROBES INFECT, V22, P154, DOI 10.1016/j.micinf.2020.04.004
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shi DB, 2012, J PINEAL RES, V53, P154, DOI 10.1111/j.1600-079X.2012.00982.x
   Shneider A, 2020, INT REV IMMUNOL, V39, P153, DOI 10.1080/08830185.2020.1756284
   Sinha Neeraj, 2020, Postgrad Med J, V96, P550, DOI 10.1136/postgradmedj-2020-137785
   Srinivasan V, 2012, RECENT PATENTS ENDOC, V6, P30, DOI 10.2174/187221412799015317
   Srinivasan V, 2010, J CRIT CARE, V25
   Sturrock BRH, 2020, CLIN MED, V20, P278, DOI 10.7861/clinmed.2020-0129
   Tan DX, 2020, MELATONIN RES, V3, P120, DOI DOI 10.32794/mr11250052
   Thomson G, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13503
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   Ui-Tei K, 2000, APOPTOSIS, V5, P133, DOI 10.1023/A:1009676528805
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01371
   Yadav S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176403
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhong HZA, 2013, CURR TOP MED CHEM, V13, P1290
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
NR 83
TC 2
Z9 2
U1 1
U2 1
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2020
VL 17
IS 14
BP 2133
EP 2146
DI 10.7150/ijms.48053
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA MZ6GU
UT WOS:000559224600008
PM 32922174
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Naveed, M
   Rafiq, M
   Raza, A
   Ahmed, N
   Khan, I
   Nisar, KS
   Soori, AH
AF Naveed, Muhammad
   Rafiq, Muhammad
   Raza, Ali
   Ahmed, Nauman
   Khan, Ilyas
   Nisar, Kottakkaran Sooppy
   Soori, Atif Hassan
TI Mathematical Analysis of Novel Coronavirus (2019-nCov) Delay Pandemic
   Model
SO CMC-COMPUTERS MATERIALS & CONTINUA
LA English
DT Article
DE 2019-nCov; delay model; reproduction number; stability analysis;
   numerical results
ID TRANSMISSION; COVID-19
AB In this manuscript, the mathematical analysis of corona virus model with time delay effect is studied. Mathematical modelling of infectious diseases has substantial role in the different disciplines such as biological, engineering, physical, social, behavioural problems and many more. Most of infectious diseases are dreadful such as HIV/AIDS, Hepatitis and 2019-nCov. Unfortunately, due to the non-availability of vaccine for 2019-nCov around the world, the delay factors like, social distancing, quarantine, travel restrictions, holidays extension, hospitalization and isolation are used as key tools to control the pandemic of 2019-nCov. We have analysed the reproduction number R-nCov of delayed model. Two key strategies from the reproduction number of 2019-nCov model, may be followed, according to the nature of the disease as if it is diminished or present in the community. The more delaying tactics eventually, led to the control of pandemic. Local and global stability of 2019-nCov model is presented for the strategies. We have also investigated the effect of delay factor on reproduction number R-nCov. Finally, some very useful numerical results are presented to support the theoretical analysis of the model.
C1 [Naveed, Muhammad; Soori, Atif Hassan] Air Univ, Dept Math, Islamabad, Pakistan.
   [Rafiq, Muhammad] Univ Cent Punjab, Fac Engn, Lahore, Pakistan.
   [Raza, Ali] Natl Coll Business Adm & Econ, Dept Math, Lahore, Pakistan.
   [Ahmed, Nauman] Univ Lahore, Dept Math & Stat, Lahore, Pakistan.
   [Khan, Ilyas] Ton Duc Thang Univ, Fac Math & Stat, Ho Chi Minh 72915, Vietnam.
   [Nisar, Kottakkaran Sooppy] Prince Sattam Bin Abdulaziz Univ, Coll Arts & Sci Wadi Aldawaser, Dept Math, Alkharj, Saudi Arabia.
RP Khan, I (corresponding author), Ton Duc Thang Univ, Fac Math & Stat, Ho Chi Minh 72915, Vietnam.
EM ilyaskhan@tdtu.edu.vn
RI Khan, Ilyas/C-8770-2019; Nisar, K.S./F-7559-2015; Ahmed,
   Nauman/ABB-8662-2020
OI Khan, Ilyas/0000-0002-2056-9371; Nisar, K.S./0000-0001-5769-4320; Ahmed,
   Nauman/0000-0003-1742-585X
CR Baleanu D, 2019, IET SYST BIOL, V13, P316, DOI 10.1049/iet-syb.2019.0065
   Diekmann O, 2010, J R SOC INTERFACE, V7, P873, DOI 10.1098/rsif.2009.0386
   Gawanmeh A, 2018, COMPUT SYST SCI ENG, V33, P21
   Khan M. A., 2020, ALEX ENG J, V2, P1
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P1, DOI 10.1016/S1473-3099(19)30711-X
   Li T, 2019, INT J HYPERTENS, V2019, P1, DOI DOI 10.1155/2019/6051262
   Raza A., 2019, INT J BIOMATH, V12, P445
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Tahir M, 2019, FILOMAT, V33, P3947, DOI 10.2298/FIL1912947T
   You J. Y., 2020, MOB INF SYST, V1, P1
   Yu F, 2019, NEUROCOMPUTING, V350, P108, DOI 10.1016/j.neucom.2019.03.053
   Zhang G., 2018, J COMMUN INF NETW, V3, P1, DOI [10.1007/s41650-018-0024-3, DOI 10.1007/s41650-018-0024-3]
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
   Zhou LL, 2019, NEUROCOMPUTING, V359, P264, DOI 10.1016/j.neucom.2019.05.077
NR 15
TC 2
Z9 2
U1 2
U2 2
PU TECH SCIENCE PRESS
PI HENDERSON
PA 871 CORONADO CENTER DR, SUTE 200, HENDERSON, NV 89052 USA
SN 1546-2218
EI 1546-2226
J9 CMC-COMPUT MATER CON
JI CMC-Comput. Mat. Contin.
PY 2020
VL 64
IS 3
BP 1401
EP 1414
DI 10.32604/cmc.2020.011314
PG 14
WC Computer Science, Information Systems; Materials Science,
   Multidisciplinary
SC Computer Science; Materials Science
GA MX6YY
UT WOS:000557868500005
OA Bronze
DA 2021-01-01
ER

PT J
AU Costanzo, M
   De Giglio, MAR
   Roviello, GN
AF Costanzo, Michele
   De Giglio, Maria Anna Rachele
   Roviello, Giovanni Nicola
TI SARS-CoV-2: Recent Reports on Antiviral Therapies Based on
   Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine,
   Remdesivir, Favipiravir and other Drugs for the Treatment of the New
   Coronavirus
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE SARS-CoV-2; Coronavirus; COVID-19; antiviral drugs; hydroxychloroquine;
   remdesivir; favipiravir; lopinavir; ritonavir
AB Here we report on the most recent updates on experimental drugs successfully employed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease-19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir [which is widely used to treat Human Immunodeficiency Virus (HIV) infection] in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experimental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this virus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies.
C1 [Costanzo, Michele] Univ Naples Federico II, Sch Med, Dept Mol Med & Med Biotechnol, Via S Pansini 5, I-80131 Naples, Italy.
   [Costanzo, Michele] CEINGE Biotecnol Avanzate Scarl, Via G Salvatore 486, I-80145 Naples, Italy.
   [De Giglio, Maria Anna Rachele] Univ Naples Federico II, Sch Med & Surg, Via S Pansini 5, I-80131 Naples, Italy.
   [Roviello, Giovanni Nicola] CNR, Inst Biostrutture & Bioimmagini IBB, Via Mezzocannone 16, I-80134 Naples, Italy.
RP Roviello, GN (corresponding author), CNR, Inst Biostrutture & Bioimmagini IBB, Via Mezzocannone 16, I-80134 Naples, Italy.
EM giroviel@unina.it
RI Costanzo, Michele/AAO-5873-2020
OI Costanzo, Michele/0000-0002-6386-2009; de giglio, maria anna
   rachele/0000-0003-3736-9592; Roviello, Giovanni/0000-0002-6978-542X
CR Agence France-Presse, 2020, NEW STRAITS TIMES
   AIFA (Agenzia Italiana del Farmaco), 2020, AZ INTR FAV RIC ACC
   [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, DEV CORONAVIRUS TREA
   [Anonymous], 2020, TRIESTE ALL NEWS
   [Anonymous], 2019, REUTERS
   [Anonymous], 2019, S CHINA MORNING POST
   [Anonymous], 2020, NEWS CORONAVIRUS EXP
   Baron SA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105944
   CHEN Y, 2019, F1000 RES, V9, P129, DOI DOI 10.12688/02FF1000RESEARCH.22457.2
   Chinese Clinical Trial Register (ChiCTR), 2015, HYDR TREAT NOV COR C
   Cui Yan, 2003, Environ Health, V2, P15, DOI 10.1186/1476-069X-2-15
   Dayer MR, 2017, ARCH CLIN INFECT DIS, V12, DOI 10.5812/archcid.13823
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gilead Company News And Press, 2019, GILEAD CO NEWS PRESS
   Hoenen T, 2019, NAT REV MICROBIOL, V17, P593, DOI 10.1038/s41579-019-0233-2
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUB, 2020, BALT MOR US
   Ji S, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109652
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nagata T, 2015, DISASTER MED PUBLIC, V9, P79, DOI 10.1017/dmp.2014.151
   Ramos-Martin V, 2017, J ANTIMICROB CHEMOTH, V72, P3382, DOI 10.1093/jac/dkx289
   Salman S, 2017, INT J ANTIMICROB AG, V50, P542, DOI 10.1016/j.ijantimicag.2017.05.011
   Sciencemag, 2020, WHO LAUNCH GLOB MEG
   Sciensano Epidemiology of Infectious Disease, 2020, INTERIM CLIN GUIDANC
   Venkiteshwaran A, 2009, MABS-AUSTIN, V1, P432, DOI 10.4161/mabs.1.5.9497
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Q., 2020, VIRTUAL SCREENING AP
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang L, 2020, GENOMIC VARIATIONS S, DOI [10.1101/2020.02.25.20027953., DOI 10.1101/2020.02.25.20027953, 10.1101/2020.02.25.20027953]
NR 39
TC 41
Z9 41
U1 8
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2020
VL 27
IS 27
BP 4536
EP 4541
DI 10.2174/0929867327666200416131117
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA MX7HN
UT WOS:000557891800007
PM 32297571
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Anastasiou, IA
   Eleftheriadou, I
   Tentolouris, A
   Tsilingiris, D
   Tentolouris, N
AF Anastasiou, Ioanna A.
   Eleftheriadou, Ioanna
   Tentolouris, Anastasios
   Tsilingiris, Dimitrios
   Tentolouris, Nikolaos
TI In Vitro Data of Current Therapies for SARS-CoV-2
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE SARS-CoV-2 (COVID-19); in vitro studies; VeroE6 Cells; therapies;
   vaccines; ACE2 receptor
ID SARS CORONAVIRUS; PLANT-LECTINS; CHLOROQUINE; INFECTIONS
AB Background: In December 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in the Wuhan region and then spread worldwide. Due to a lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find a therapeutic solution.
   Objectives: The aim of this study was to summarize in vitro data of current agents used for the management of SARS-CoV-2 all over the world.
   Methods: A literature search of articles from January 2000 until April 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2.
   Results: Although in vitro studies are scarce, data regarding chloroquine, hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine, and emetine seem promising.
   Conclusion: Scientists all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat.
C1 [Anastasiou, Ioanna A.; Eleftheriadou, Ioanna; Tentolouris, Anastasios; Tsilingiris, Dimitrios; Tentolouris, Nikolaos] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Dept Propaedeut Internal Med 1, 17 AgiouThoma St, Athens 11527, Greece.
RP Tentolouris, N (corresponding author), Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Dept Propaedeut Internal Med 1, 17 AgiouThoma St, Athens 11527, Greece.
EM ntentol@med.uoa.gr
RI Tentolouris, Nikolaos/AAH-6231-2019
OI Tentolouris, Nikolaos/0000-0003-0615-2534; Eleftheriadou,
   Ioanna/0000-0003-2763-2481; Tsilingiris, Dimitrios/0000-0002-6864-4289
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Aguiar ACC, 2018, INT J PARASITOL-DRUG, V8, P459, DOI 10.1016/j.ijpddr.2018.10.002
   Angeli F, 2020, EUR J INTERN MED, V71, P15, DOI 10.1016/j.ejim.2019.10.031
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ganjhu Rajesh Kumar, 2015, VirusDisease, V26, P225, DOI 10.1007/s13337-015-0276-6
   Golden EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14748
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Keyaerts E, 2007, ANTIVIR RES, V75, P179, DOI 10.1016/j.antiviral.2007.03.003
   Kulcsar KA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131774
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Ma YX, 2019, APMIS, V127, P372, DOI 10.1111/apm.12928
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sohail MN, 2011, ASIAN J ANIM VET ADV, V6, P1125, DOI 10.3923/ajava.2011.1125.1152
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   World Health Organization, 2019, MOD LIST ESS MED 21
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang J, 2020, BIORXIV, DOI [10.1101/2020.02.05.935387., 10.1101/2020.02.05.9353872020.02.05.935387, DOI 10.1101/2020.02.05.935387]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 38
TC 3
Z9 3
U1 4
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2020
VL 27
IS 27
BP 4542
EP 4548
DI 10.2174/0929867327666200513075430
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA MX7HN
UT WOS:000557891800008
PM 32400323
DA 2021-01-01
ER

PT J
AU D'Aurizio, N
   Baldi, TL
   Paolocci, G
   Prattichizzo, D
AF D'Aurizio, Nicole
   Baldi, Tommaso Lisini
   Paolocci, Gianluca
   Prattichizzo, Domenico
TI Preventing Undesired Face-Touches With Wearable Devices and Haptic
   Feedback
SO IEEE ACCESS
LA English
DT Article
DE Face; Magnetometers; Haptic interfaces; Wrist; Magnetic sensors;
   Training; Haptic interfaces; magnetic sensors; wearable sensors
ID HABIT REVERSAL; RHINOVIRUS; THERAPY
AB The alarming morbidity of COVID-19 has drawn the attention to the social role of hygiene rules, with a particular focus on the importance of limiting face-touch occurrences. To deal with this aspect, we present No Face-Touch, a system able to estimate hand proximity to face and notify the user whenever a face-touch movement is detected. In its complete setup, the system consists of an application running on the smartwatch and a wearable accessory. Its ease of implementation allows this solution to be ready-to-use and large-scale deployable. We developed two gesture detection approaches compatible with sensors embedded in recent smartwatches, i.e. inertial and magnetic sensors. After preliminary tests to tune target gesture parameters, we tested the two approaches and compared their accuracy. The final phase of this project consisted in exploiting the most robust approach in a daily living scenario during a 6-days campaign. Experimental results revealed the effectiveness of the proposed system, demonstrating its impact in reducing the number of face-touches and their duration.
C1 [D'Aurizio, Nicole; Baldi, Tommaso Lisini; Paolocci, Gianluca; Prattichizzo, Domenico] Univ Siena, Dept Informat Engn & Math, I-53100 Siena, Italy.
   [D'Aurizio, Nicole; Paolocci, Gianluca; Prattichizzo, Domenico] Ist Italiano Tecnol ADVR, Dept Adv Robot, I-16163 Genoa, Italy.
RP Baldi, TL (corresponding author), Univ Siena, Dept Informat Engn & Math, I-53100 Siena, Italy.
EM lisini@diism.unisi.it
OI PRATTICHIZZO, Domenico/0000-0001-9051-9698; D'Aurizio,
   Nicole/0000-0001-5104-4466
FU IEEE Robotics and Automation Society Special Interest Group on
   Humanitarian Technology (RAS-SIGHT) Humanitarian Project, No Face-Touch:
   an Open Project to Limit the COVID-19 Outbreak
FX This work was supported by the IEEE Robotics and Automation Society
   Special Interest Group on Humanitarian Technology (RAS-SIGHT)
   Humanitarian Project, No Face-Touch: an Open Project to Limit the
   COVID-19 Outbreak.
CR Al Hawsawi K., 2003, DERMATOL PSYCHOSOM, V4, P42
   Baldi TL, 2020, IEEE HAPTICS SYM, P961, DOI 10.1109/HAPTICS45997.2020.ras.HAP20.3.3eea0b25
   Baldi TL, 2020, IEEE SENS J, V20, P492, DOI 10.1109/JSEN.2019.2940612
   Baldi Tommaso Lisini, 2020, IEEE Trans Haptics, V13, P761, DOI 10.1109/TOH.2020.2967049
   Barralon P, 2009, J CLIN MONIT COMPUT, V23, P137, DOI 10.1007/s10877-009-9175-y
   Bartlett R., 2014, INTRO SPORTS BIOMECH
   Bate KS, 2011, CLIN PSYCHOL REV, V31, P865, DOI 10.1016/j.cpr.2011.03.013
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Boughan S, 2002, RES NURS HEALTH, V25, P135, DOI 10.1002/nur.10028
   Bouwer A., 2013, MUSIC HUMAN COMPUTER, P101
   Di Giuseppe G, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-36
   DIMOND S, 1984, NEUROPSYCHOLOGIA, V22, P227, DOI 10.1016/0028-3932(84)90065-4
   Finlay CC, 2010, GEOPHYS J INT, V183, P1216, DOI 10.1111/j.1365-246X.2010.04804.x
   FOA EB, 1984, BEHAV THER, V15, P450, DOI 10.1016/S0005-7894(84)80049-0
   Gu J, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1867, DOI 10.1177/1010539512443699
   GWALTNEY JM, 1982, AM J EPIDEMIOL, V116, P828, DOI 10.1093/oxfordjournals.aje.a113473
   Heesterbeek H, 2015, SCIENCE, V347, P1216, DOI 10.1126/science.aaa4339
   Heo P, 2012, INT J PRECIS ENG MAN, V13, P807, DOI 10.1007/s12541-012-0107-2
   JACKSON WT, 1994, MED ENG PHYS, V16, P123, DOI 10.1016/1350-4533(94)90025-6
   Jones LA, 2008, HUM FACTORS, V50, P90, DOI 10.1518/001872008X250638
   Kopp B, 1997, ARCH PHYS MED REHAB, V78, P615, DOI 10.1016/S0003-9993(97)90427-5
   Kwok YLA, 2015, AM J INFECT CONTROL, V43, P112, DOI 10.1016/j.ajic.2014.10.015
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Macias AE, 2009, J HOSP INFECT, V73, P280, DOI 10.1016/j.jhin.2009.06.017
   Miltenberger RG, 1996, J BEHAV THER EXP PSY, V27, P181, DOI 10.1016/0005-7916(96)00016-X
   Nicas M, 2008, J OCCUP ENVIRON HYG, V5, P347, DOI 10.1080/15459620802003896
   Oikonomidis I, 2011, PROCEEDINGS OF THE BRITISH MACHINE VISION CONFERENCE 2011, DOI 10.5244/C.25.101
   Organization WH, 102 WHO
   Amaro JP, 2016, IEEE IND ELEC, P5171, DOI 10.1109/IECON.2016.7793729
   Rapp JT, 1998, J APPL BEHAV ANAL, V31, P665, DOI 10.1901/jaba.1998.31-665
   Tanaka OM, 2008, AM J ORTHOD DENTOFAC, V134, P305, DOI 10.1016/j.ajodo.2006.06.023
   Winther B, 2007, J MED VIROL, V79, P1606, DOI 10.1002/jmv.20956
   Woods DW, 2006, BEHAV RES THER, V44, P639, DOI 10.1016/j.brat.2005.05.006
   World Health Organization, COR DIS COVID 19 ADV
NR 34
TC 1
Z9 1
U1 1
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 139033
EP 139043
DI 10.1109/ACCESS.2020.3012309
PG 11
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA MX5RH
UT WOS:000557779600001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hlavat, T
   Krajcovicova, A
AF Hlavat, T.
   Krajcovicova, A.
TI Novel unorthodox strategies to reduce the case fatality rate of COVID-19
   in high risk groups
SO BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
LA English
DT Letter
DE COVID-19; coronavirus; distress syndrome; lopinavir/ritonavir;
   ribavirin; chloroquine; interferons
ID CHLOROQUINE; PHARMACOKINETICS; CORONAVIRUS
AB Dear editors: We propose novel strategies to combat the COVID-19 outbreak, that are aimed at high-risk groups and might reduce the progression to severe forms of COVID and thus decrease the very high case fatality rate.
   Following the first reports of the outbreak of several cases of acute respiratory distress syndrome in the Chinese city of Wuhan at the end of December 2019, a novel beta coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) as the main causative agent was identified while the disease associated with was named by WHO as COVID-19 (1, 2).
   The outbreak has rapidly spread globally with more than 150.000 cases detected in over 100 countries as of March 13, 2020. The overall case-fatality rate (CFR) of COVID-19 in China was 2.3 %, but globally it seems to be higher in the range of 3.5 % (3). At present, no specific antivirals or approved vaccines are available to combat COVID-19. Many patients however receive off-label antivirals such as lopinavir/ritonavir, ribavirin and/or chloroquine and /or interferons. Several new antivirals such as remdesivir are studied in ongoing clinical trials.
   Given the alarming global situation and rapidly evolving large scale pandemics, there is an urgent need for effective strategies to prevent the spread of the disease and decrease its high CFR. The gravity of the situation requires to consider even novel unorthodox strategies to control the outbreak and high lethality of COVID-19.
C1 [Hlavat, T.; Krajcovicova, A.] Comenius Univ, Fac Med, Univ Hosp, Dept Internal Med 5, Bratislava, Slovakia.
   [Hlavat, T.] Comenius Univ, Fac Med, Univ Hosp Bratislava, Dept Internal Med 5, Ruzinovska 6, SK-82606 Bratislava, Slovakia.
   [Hlavat, T.; Krajcovicova, A.] Gastroenterol Ctr Ruzinov, Bratislava, Slovakia.
RP Hlavat, T (corresponding author), Comenius Univ, Fac Med, Univ Hosp Bratislava, Dept Internal Med 5, Ruzinovska 6, SK-82606 Bratislava, Slovakia.
EM tibor.hlavaty2@gmail.com
CR [Anonymous], 2020, MED BEH BIJ OPG PAT
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cortegiani A, 2020, J CRIT CARE
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Fang L., 2020, LANCET RESP MED
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GiViTI CdC, 10 MARZ VID COVID 19
   Guan W-J, 2020, NEW ENGL J MED
   Hoffmann M, 2020, CELL
   Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002
   MACKENZIE AH, 1983, AM J MED, V75, P40, DOI 10.1016/0002-9343(83)91269-X
   Park SY, 2019, J HOSP INFECT, V101, P42, DOI 10.1016/j.jhin.2018.09.005
   Pourdowlat G, 2020, ADV J EMERG MED, V4, DOI 10.22114/ajem.v0i0.362
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu Z, 2020, JAMA
   Yao T.T., 2020, J MED VIROL
   Zhou F., 2020, LANCET
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 3
Z9 3
U1 2
U2 2
PU COMENIUS UNIV
PI BRATISLAVA I
PA SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA
SN 0006-9248
EI 1336-0345
J9 BRATISL MED J
JI Bratisl. Med. J.
PY 2020
VL 121
IS 7
BP 462
EP 465
DI 10.4149/BLL_2020_074
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA MX0CK
UT WOS:000557396700002
PM 32989996
DA 2021-01-01
ER

PT J
AU Ong, SWX
   Tan, WYT
   Chan, YH
   Fong, SW
   Renia, L
   Ng, LFP
   Leo, YS
   Lye, DC
   Young, BE
AF Ong, Sean Wei Xiang
   Tan, Wilnard Yeong Tze
   Chan, Yi-Hao
   Fong, Siew-Wai
   Renia, Laurent
   Ng, Lisa F. P.
   Leo, Yee-Sin
   Lye, David Chien
   Young, Barnaby Edward
TI Safety and potential efficacy of cyclooxygenase-2 inhibitors in
   coronavirus disease 2019
SO CLINICAL & TRANSLATIONAL IMMUNOLOGY
LA English
DT Article
DE COVID-19; COX-2 inhibitors; interleukin-6; SARS-CoV-2
ID INFECTION
AB Objectives. While the safety of non-steroidal anti-inflammatory drugs in COVID-19 has been questioned, they may be beneficial given the hyper-inflammatory immune response associated with severe disease. We aimed to assess the safety and potential efficacy of cyclooxygenase-2 (COX-2) selective inhibitors in high-risk patients. Methods.Retrospective study of patients with COVID-19 pneumonia and aged >= 50 years who were admitted to hospital. Adverse outcomes analysed included supplemental oxygen use, intensive care unit admission, mechanical ventilation and mortality, with the primary endpoint a composite of any of these. Plasma levels of inflammatory cytokines and chemokines were measured in a subset. Results. Twenty-two of 168 (13.1%) in the cohort received COX-2 inhibitors [median duration 3 days, interquartile range (IQR) 3-4.25]. Median age was 61 (IQR 55-67.75), 44.6% were female, and 72.6% had at least one comorbidity. A lower proportion of patients receiving COX-2 inhibitors met the primary endpoint: 4 (18.2%) versus 57 (39.0%),P = 0.062. This difference was less pronounced after adjusting for baseline difference in age, gender and comorbidities in a multivariate logistic regression model [adjusted odds ratio (AOR) 0.45, 95% CI 0.14-1.46]. The level of interleukin-6 declined after treatment in five of six (83.3%) treatment group patients [compared to 15 of 28 (53.6%) in the control group] with a greater reduction in absolute IL-6 levels (P-value = 0.025). Conclusion. Treatment with COX-2 inhibitors was not associated with an increase in adverse outcomes. Its potential for therapeutic use as an immune modulator warrants further evaluation in a large randomised controlled trial.
C1 [Ong, Sean Wei Xiang; Tan, Wilnard Yeong Tze; Leo, Yee-Sin; Lye, David Chien; Young, Barnaby Edward] Natl Ctr Infect Dis, 16 Jln Tan Tock Seng, Singapore 308442, Singapore.
   [Ong, Sean Wei Xiang; Tan, Wilnard Yeong Tze; Leo, Yee-Sin; Lye, David Chien; Young, Barnaby Edward] Tan Tock Seng Hosp, Singapore, Singapore.
   [Chan, Yi-Hao; Fong, Siew-Wai; Renia, Laurent; Ng, Lisa F. P.] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore.
   [Fong, Siew-Wai] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   [Ng, Lisa F. P.] Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Ng, Lisa F. P.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
   [Leo, Yee-Sin; Lye, David Chien; Young, Barnaby Edward] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Leo, Yee-Sin; Lye, David Chien] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
RP Young, BE (corresponding author), Natl Ctr Infect Dis, 16 Jln Tan Tock Seng, Singapore 308442, Singapore.
EM barnaby_young@ncid.sg
RI Ong, Sean/AAO-9560-2020
OI Ong, Sean/0000-0002-8570-436X; Lye, David/0000-0003-0324-0205; Ng,
   Lisa/0000-0003-4071-5222; LEO, Yee-Sin/0000-0003-4978-5825
FU NMRC COVID-19 Research Fund [COVID19RF-001]
FX This study was funded by the NMRC COVID-19 Research Fund
   (COVID19RF-001). The funding sources had no role in study design, data
   analysis and collection, interpretation of results or decision to submit
   the paper for publication.
CR Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Darnell MER, 2006, TRANSFUSION, V46, P1770, DOI 10.1111/j.1537-2995.2006.00976.x
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang ZY, 2020, AM J GASTROENTEROL, V115, P473, DOI 10.14309/ajg.0000000000000529
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Lee SMY, 2008, J INFECT DIS, V198, P525, DOI 10.1086/590499
   Lee SMY, 2011, ANTIVIR RES, V91, P330, DOI 10.1016/j.antiviral.2011.07.011
   Lim VW, 2020, INFLUENZA OTHER RESP, V14, P226, DOI 10.1111/irv.12699
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Theodoridou Athina, 2017, Mediterr J Rheumatol, V28, P33, DOI 10.31138/mjr.28.1.33
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   World Health Organization, US NONST ANT INFL DR
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2050-0068
J9 CLIN TRANSL IMMUNOL
JI Clin. Transl. Immunol.
PY 2020
VL 9
IS 7
AR e1159
DI 10.1002/cti2.1159
PG 9
WC Immunology
SC Immunology
GA MW3AO
UT WOS:000556914500002
PM 32728438
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grenga, L
   Gallais, F
   Pible, O
   Gaillard, JC
   Gouveia, D
   Batina, H
   Bazaline, N
   Ruat, S
   Culotta, K
   Miotello, G
   Debroas, S
   Roncato, MA
   Steinmetz, G
   Foissard, C
   Desplan, A
   Alpha-Bazin, B
   Almunia, C
   Gas, F
   Bellanger, L
   Armengaud, J
AF Grenga, Lucia
   Gallais, Fabrice
   Pible, Olivier
   Gaillard, Jean-Charles
   Gouveia, Duarte
   Batina, Helene
   Bazaline, Niza
   Ruat, Sylvie
   Culotta, Karen
   Miotello, Guylaine
   Debroas, Stephanie
   Roncato, Marie-Anne
   Steinmetz, Gerard
   Foissard, Charlotte
   Desplan, Anne
   Alpha-Bazin, Beatrice
   Almunia, Christine
   Gas, Fabienne
   Bellanger, Laurent
   Armengaud, Jean
TI Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can
   optimize whole viral particle antigen production for vaccines
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; proteomics; host response; infection kinetics;
   vaccine; mass spectrometry; viral protein detection
ID PNEUMONIA OUTBREAK; CORONAVIRUS; VIRUS
AB Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and is continuing to spread rapidly around the globe. No effective vaccine is currently available to prevent COVID-19, and intense efforts are being invested worldwide into vaccine development. In this context, all technology platforms must overcome several challenges resulting from the use of an incompletely characterized new virus. These include finding the right conditions for virus amplification for the development of vaccines based on inactivated or attenuated whole viral particles. Here, we describe a shotgun tandem mass spectrometry workflow, the data produced can be used to guide optimization of the conditions for viral amplification. In parallel, we analysed the changes occurring in the host cell proteome following SARS-CoV-2 infection to glean information on the biological processes modulated by the virus that could be further explored as potential drug targets to deal with the pandemic.
C1 [Grenga, Lucia; Gallais, Fabrice; Pible, Olivier; Gaillard, Jean-Charles; Gouveia, Duarte; Batina, Helene; Bazaline, Niza; Ruat, Sylvie; Culotta, Karen; Miotello, Guylaine; Debroas, Stephanie; Roncato, Marie-Anne; Steinmetz, Gerard; Foissard, Charlotte; Desplan, Anne; Alpha-Bazin, Beatrice; Almunia, Christine; Gas, Fabienne; Bellanger, Laurent; Armengaud, Jean] Univ Paris Saclay, Dept Medicaments & Technol Sante DMTS, CEA, INRAE,SPI Bagnols Sur Ceze, St Aubin, France.
RP Armengaud, J (corresponding author), CEA Marcoule, DRF Li2D, Lab Innovat Technol Detect & Diagnost, BP 17171, F-30200 Bagnols Sur Ceze, France.
EM jean.armengaud@cea.fr
OI Gouveia, Duarte/0000-0001-5578-3370; Pible, Olivier/0000-0003-4398-6730;
   ARMENGAUD, Jean/0000-0003-1589-445X; Reis,
   AlessanRSS/0000-0001-8486-7469
FU French Alternative Energies and Atomic Energy Commission; Agence
   Nationale de la RechercheFrench National Research Agency (ANR)
   [ANR-17-CE18-0023-01]; European Virus Archive goes Global (EVAg) project
   from the European Union's Horizon 2020 research and innovation programme
   [653316]; European CommissionEuropean CommissionEuropean Commission
   Joint Research Centre
FX This work was funded in part by the French Alternative Energies and
   Atomic Energy Commission, and the Agence Nationale de la Recherche
   (project "Phylopeptidomics", ANR-17-CE18-0023-01). This publication was
   supported by the European Virus Archive goes Global (EVAg) project that
   has received funding from the European Union's Horizon 2020 research and
   innovation programme under [grant agreement number 653316]; Agence
   Nationale de la Recherche; European Commission.
CR Benam KH, 2016, NAT METHODS, V13, P151, DOI [10.1038/NMETH.3697, 10.1038/nmeth.3697]
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Chew T, 2009, MOL IMMUNOL, V46, P393, DOI 10.1016/j.molimm.2008.10.010
   Choi S, 2019, J MICROBIOL BIOTECHN, V29, P1817, DOI 10.4014/jmb.1908.08013
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Davidson A D, 2020, CHARACTERISATION TRA, DOI [10.1101/2020.03.22.002204v1, DOI 10.1101/2020.03.22.002204V1]
   Gouveia D, ENV MICROBIOL
   Gouveia D, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.202000107
   Grenga L, 2019, CLIN MASS SPECTROM, V14, P9, DOI 10.1016/j.clinms.2019.04.004
   Hartmann EM, 2014, METHODS MOL BIOL, V1197, P275, DOI 10.1007/978-1-4939-1261-2_16
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jiang XS, 2005, MOL CELL PROTEOMICS, V4, P902, DOI 10.1074/mcp.M400112-MCP200
   Karlsson R, 2015, SYST APPL MICROBIOL, V38, P246, DOI 10.1016/j.syapm.2015.03.006
   Lin HX, 2017, J PROTEOME RES, V16, P2113, DOI 10.1021/acs.jproteome.6b00957
   Ortea I, 2020, BIORXIV, DOI [10.1101/2020.03.26.009605v1, DOI 10.1101/2020.03.26.009605V1]
   Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x
   Park WB, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e84
   Pereira S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092974
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Plotkin SA, 2008, B ACAD NATL MED, V192
   Plotkin SA, 2008, B ACAD NAT MED PARIS, V192, P511, DOI 10.1016/S0001-4079(19)32809-2
   Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668
   Rau A, 2018, BRIEF BIOINFORM, V19, P425, DOI 10.1093/bib/bbw128
   Si L, 2020, HUMAN ORGANS CHIPS T, DOI [10.1101/2020.04.13.039917v1, DOI 10.1101/2020.04.13.039917V1]
   Sun JF, 2014, PROTEOMICS, V14, P1403, DOI 10.1002/pmic.201300404
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Weston S, 2020, FDA APPROVED DRUGS B, DOI [10.1101/2020.03.25.008482v1, DOI 10.1101/2020.03.25.008482V1]
   Weston S, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00203-20
   Wickham H, 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]
   Zeng SL, 2015, PROTEOMICS, V15, P1819, DOI 10.1002/pmic.201400458
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 35
TC 3
Z9 3
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1712
EP 1721
DI 10.1080/22221751.2020.1791737
PG 10
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MV7QM
UT WOS:000556547500001
PM 32619390
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pashaki, PA
   Roudkenar, MH
   Rahim, F
   Ebrahimi, A
AF Pashaki, P. Abbasi
   Roudkenar, M. Habibi
   Rahim, F.
   Ebrahimi, A.
TI From SARS-CoV to SARS-CoV2: a potentia guide to better understanding of
   pathophysiology of the disease and potential therapeutic modality
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-CoV; SARS-CoV2; COVID-19; ACE2
ID NUCLEOCAPSID PROTEIN; SPIKE PROTEIN; IN-VITRO; CORONAVIRUS; INFECTION;
   EXPRESSION; PNEUMONIA; REPLICATION; APOPTOSIS; COVID-19
AB Currently, the outbreak and spread of coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), are increasing worldwide. Furthermore, it has been considered as a major challenge, which threatens human beings and affects all aspects of their life. Understanding the cellular and molecular pathophysiology of the disease is currently under the focus of investigations. Accordingly, this turns the human scientific community attention to find a solution for addressing the challenge. The development of vaccines and efficient therapeutic modality is critical. So, both primary and clinical scientists are not only trying to decipher the structure of SARS-CoV-2, but also attempting to understand the underlying molecular mechanisms that cause tissues and cell injuries. SARS-CoV and SARS-CoV2 are highly homologous and share a highly similar function and behavior patterns. Therefore. this might guide us toward decoding the molecular mechanisms that are behind the SARS-CoV2 pathologic effects. It is noteworthy to mention that. the undesired host immune reactions play important roles in the pathophysiology of the disease. and it also seems that, renin-angiotensin signaling (RAS) is a key contributor in this regard. In this review, we provided a vision, highlight as well as discussing on potential therapeutic targets that might be considered to address the COVID-19 challenge.
C1 [Pashaki, P. Abbasi; Roudkenar, M. Habibi; Ebrahimi, A.] Guilan Univ Med Sci, Sch Paramed, Dept Med Biotechnol, Rasht, Iran.
   [Rahim, F.] Ahvaz Jundishapur Univ Med Sci, Thalassemia & Hemoglobinopathy Res Ctr, Ahwaz, Iran.
RP Ebrahimi, A (corresponding author), Guilan Univ Med Sci, Sch Paramed, Dept Med Biotechnol, Rasht, Iran.
EM Ebrahimi.am@outlook.com
RI pashaki, pejman Abbasi/AAW-4311-2020; Roudkenar, Mehryar
   Habibi/ABI-5197-2020; Ebrahimi, Ammar/B-7555-2013
OI pashaki, pejman Abbasi/0000-0001-5173-6550; Roudkenar, Mehryar
   Habibi/0000-0001-8364-7245; Ebrahimi, Ammar/0000-0002-4586-5468
FU Guilan University of Medical Sciences, Iran [IR-96123]
FX This research was supported by the deputy of research, Guilan University
   of Medical Sciences, Iran (grant number: IR-96123).
CR ABBASi PASHAKI RAHiM F, 2020, APPL BIOCHEM BIOTECH, V190, P214
   Ahmad A, 2020, EUR REV MED PHARMACO, V24, P4030, DOI 10.26355/eurrev_202004_20873
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101608
   Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   Arabi YM, 2019, CLIN INFECT DIS, V70, P1837, DOI DOI 10.1093/cid/ciz544
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Biondi Zoccai G, 2020, MINERVA CARDIOANGIOL, V68, P61, DOI 10.23736/S0026-4725.20.05250-0
   Bordi L, 2006, ARCH VIROL, V151, P369, DOI 10.1007/s00705-005-0632-8
   C FAN, 2020, CLIN INFECT DIS
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Castilletti C, 2005, VIROLOGY, V341, P163, DOI 10.1016/j.virol.2005.07.015
   Ceccarelli M, 2020, EUR REV MED PHARMACO, V24, P2781, DOI 10.26355/eurrev_202003_20551
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen C, 2020, HERZ, V45, P230, DOI 10.1007/s00059-020-04909-z
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Crinelli R, 2004, NUCLEIC ACIDS RES, V32, P1874, DOI 10.1093/nar/gkh503
   Day CW, 2009, VIROLOGY, V395, P210, DOI 10.1016/j.virol.2009.09.023
   De Lang A, 2007, PLOS PATHOG, V3, P1129, DOI 10.1371/journal.ppat.0030112
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dube M, 2016, J VIROL, V90, P6303, DOI 10.1128/JVI.00634-16
   EBRAHIMI A, 2020, ANN CANC RES THER, V28, P3
   Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6
   Glass WG, 2004, J IMMUNOL, V173, P4030, DOI 10.4049/jimmunol.173.6.4030
   Haga S, 2010, ANTIVIR RES, V85, P551, DOI 10.1016/j.antiviral.2009.12.001
   Hao Dong, 2005, Zhonghua Nei Ke Za Zhi, V44, P890
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu H, 2009, BIOTECHNOL LETT, V31, P1685, DOI 10.1007/s10529-009-0061-y
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Ji HL, 2009, AM J PHYSIOL-LUNG C, V296, pL372, DOI 10.1152/ajplung.90437.2008
   Kliger Y, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-20
   Koppikar P, 2012, CANCER DISCOV, V2, P670, DOI 10.1158/2159-8290.CD-12-0310
   Ksiezakowska K, 2008, GINEKOL POL, V79, P47
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com
   Liu Y, 2020, J INFECTION, DOI [10.1016/j.jinf.2020.02.028, DOI 10.1016/J.JINF.2020.02.028.EPUB]
   Lu Yuan, 2005, Beijing Da Xue Xue Bao Yi Xue Ban, V37, P453
   Matalon S, 2002, J APPL PHYSIOL, V93, P1852, DOI 10.1152/japplphysiol.01241.2001
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Mizutani T, 2007, ANN NY ACAD SCI, V1102, P86, DOI 10.1196/annals.1408.006
   Mizutani T, 2006, FEMS IMMUNOL MED MIC, V46, P236, DOI 10.1111/j.1574-695X.2005.00028.x
   Mizutani T, 2005, BBA-MOL BASIS DIS, V1741, P4, DOI 10.1016/j.bbadis.2005.04.004
   Mizutani T, 2004, VIROLOGY, V327, P169, DOI 10.1016/j.virol.2004.07.005
   Mossel EC, 2008, VIROLOGY, V372, P127, DOI 10.1016/j.virol.2007.09.045
   Nakaya T, 1997, ANTIMICROB AGENTS CH, V41, P319, DOI 10.1128/AAC.41.2.319
   Nicholls JM, 2006, PLOS MED, V3, P222, DOI 10.1371/journal.pmed.0030027
   Nie YC, 2004, BIOCHEM BIOPH RES CO, V321, P994, DOI 10.1016/j.bbrc.2004.07.060
   Park M, 2020, EUR J IMMUNOL, V50, P308, DOI 10.1002/eji.202070035
   Rahim F, 2014, TRANSPL IMMUNOL, V31, P165, DOI 10.1016/j.trim.2014.08.001
   Reinke LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179177
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   SCHWARTZ DA, 2020, ARCH PATHOL LAB MED, DOI [10.5858/ arpa.2020-0901-SA, DOI 10.5858/ARPA.2020-0901-SA.EPUB]
   SHRESTHA NC, 2020, INT J EPIDEMIOL, DOI DOI 10.1093/IJE/DYAA033.[EPUB
   SIGRIST CJ, 2020, ANTIVIR RES, V177, P104
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Wang K, 2020, BIORXIV
   Wei WY, 2012, ARCH VIROL, V157, P635, DOI 10.1007/s00705-011-1221-7
   Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yap YL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-43
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Yeung YS, 2008, VIROLOGY, V371, P32, DOI 10.1016/j.virol.2007.09.016
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yu YTC, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0234-7
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
   Zheng NY, 2009, VACCINE, V27, P5001, DOI 10.1016/j.vaccine.2009.05.073
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu YG, 2009, INFLAMM RES, V58, P312, DOI 10.1007/s00011-009-8062-9
NR 79
TC 1
Z9 1
U1 2
U2 2
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 14
BP 7816
EP 7825
DI 10.26355/eurrev_202007_22286
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MU7XP
UT WOS:000555882500027
DA 2021-01-01
ER

PT J
AU De Vito, A
   Geremia, N
   Fiore, V
   Princic, E
   Babudieri, S
   Madeddu, G
AF De Vito, A.
   Geremia, N.
   Fiore, V
   Princic, E.
   Babudieri, S.
   Madeddu, G.
TI Clinical features, laboratory findings and predictors of death in
   hospitalized patients with COVID-19 in Sardinia, Italy
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV2; CT scan; Pneumonia; Lymphocytes
ID CORONAVIRUS; PNEUMONIA
AB OBJECTIVE: Since December 2019, when the first SARS-CoV2 infections have been reported, the number of cases has increased exponentially. In our University Hospital Unit, the first patient with COVID-19 was admitted on the 8th of March 2020. We aimed to investigate the predictors of death among inpatients with COVID-19.
   MATERIALS AND METHODS: We performed a retrospective, monocentric study, consecutively enrolling patients with SARS-CoV2 infection. Clinical, laboratory, and radiological data were collected from the 8th of March to the 8th of April 2020. We aimed to describe the most frequent clinical and laboratory features and predictors of death among patients admitted to our Unit.
   RESULTS: 87 patients were enrolled, 56 (64.4%) were male, with a median age of 72 (IQR 62.5-83.5) years. The majority of our population had at least one comorbidity in their medical anamnesis. Hypertension and cardiovascular disease were the most frequent, followed by obesity. Eighty (92%) patients had at least one symptom, whereas 7 (8%) were asymptomatic. The most common symptoms were fever and dyspnoea. Overall, 53 patients had lung disease confirmed at CT scan (60.9%). Twenty-five (28.7%) deaths occurred. Statistically significant predictors of death at multivariate analysis were lymphocytes count <900 cells/mm3, moderate ARDS, and lack of compliance at baseline.
   CONCLUSIONS: This is the first Italian experience available. Our results seem to be in line with international literature. As highlighted by our data, more studies are needed to investigate the role of lymphocytes subsets, CT scan values. Furthermore, therapy choice and timing in this challenging setting should be urgently investigated in randomized clinical trials.
C1 [De Vito, A.; Geremia, N.; Fiore, V; Princic, E.; Babudieri, S.; Madeddu, G.] Univ Sassari, Dept Med Surg & Expt Sci, Unit Infect Dis, Sassari, Italy.
   [Madeddu, G.] Univ Sassari, Mediterranean Ctr Dis Control, Sassari, Italy.
RP De Vito, A (corresponding author), Univ Sassari, Dept Med Surg & Expt Sci, Unit Infect Dis, Sassari, Italy.
EM andreadevitoaho@gmail.com
RI De Vito, Andrea/AAO-3014-2020
OI De Vito, Andrea/0000-0002-8265-5400
CR Ceccarelli M, 2020, EUR REV MED PHARMACO, V24, P2781, DOI 10.26355/eurrev_202003_20551
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Commission WMH, 2019, REP CLUST PNEUM UNKN
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Misra D.P., 2020, CLIN RHEUMATOL, P1, DOI DOI 10.1007/S10067-020-05073-9
   Pan Y, 2020, EUR RADIOL 0213, P1, DOI DOI 10.1007/S00330-020-06731-X
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Vaira LA, 2020, HEAD NECK-J SCI SPEC, V1-7, P1252
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 26
TC 5
Z9 5
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 14
BP 7861
EP 7868
DI 10.26355/eurrev_202007_22291
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MU7XP
UT WOS:000555882500032
PM 32744714
DA 2021-01-01
ER

PT J
AU Deng, W
   Qi, D
   Wang, DX
AF Deng, W.
   Qi, D.
   Wang, D-X
TI An emergency strategy for intensive care unit during COVID-19 outbreak
   in Chongqing, China
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus disease 2019; Intensive care unit; Emergency strategy
AB OBJECTIVE: Since December 2019, a novel coronavirus disease 2019 (COVID-19) broke out in Wuhan, China, which has rapidly spread from China to at least 200 countries abroad. COVID-19 was issued a global outbreak and pandemic by the World Health Organization with more than 3 million confirmed cases by May 31, 2020. So far more than ten thousand severe and critically ill patients and hospital-related infection with COVID-19 have been reported with more than four thousand deaths in China. There is a great challenge for intensive care units (ICUs) in hospitals.
   PATIENTS AND METHODS: The comment mainly focused on admission and discharge criteria, therapy protocol, prevention and control strategies for ICU during COVID-19 outbreak. The emergency strategy for ICU will be helpful for prevention and control of COVID-19 and treatment of critically ill patients with COVID-19.
   CONCLUSIONS: Progress in the management of ICU is crucial for a decrease in the mortality of critically ill patients with COVID-19 with the clinical evidence and experience updated.
C1 [Deng, W.; Qi, D.; Wang, D-X] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Chongqing, Peoples R China.
   [Deng, W.; Qi, D.; Wang, D-X] Chongqing Med Res Ctr Resp & Crit Care Med, Chongqing, Peoples R China.
RP Wang, DX (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Chongqing, Peoples R China.
EM 303528@hospital.cqmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81600058, 81670071]; Clinical Medical Study
   Program of Chongqing Medical University, China [XGFY-2019-040]; Key
   projects of Chongqing Medical University, China [XGFY-2019-06]
FX This work is supported by grant from the National Natural Science
   Foundation of China (81600058 and 81670071), grants from the Clinical
   Medical Study Program of Chongqing Medical University, China
   (XGFY-2019-040) and Key projects of Chongqing Medical University, China
   (XGFY-2019-06).
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Liu LM, 2020, ANN AM THORAC SOC, DOI [10.1513/Annal-sATS.202003-225OC, DOI 10.1513/ANNAL-SATS.202003-225OC]
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhan WQ, 2020, EUR REV MED PHARMACO, V24, P3385, DOI 10.26355/eurrev_202003_20705
NR 9
TC 0
Z9 0
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 14
BP 7886
EP 7888
DI 10.26355/eurrev_202007_22294
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MU7XP
UT WOS:000555882500035
PM 32744717
DA 2021-01-01
ER

PT J
AU Ma, Q
   Qi, D
   Deng, XY
   Yuan, GD
   Tian, WG
   Cui, Y
   Yan, XF
   Wang, DX
AF Ma, Q.
   Qi, D.
   Deng, X-Y
   Yuan, G-D
   Tian, W-G
   Cui, Y.
   Yan, X-F
   Wang, D-X
TI Corticosteroid therapy for patients with severe novel Coronavirus
   disease 2019
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVD-19; Corticosteroid; Therapy
ID CYTOKINE STORM; SARS; STEROIDS
AB OBJECTIVE: To investigate the effect of corticosteroid on hospital mortality, hospital length of stay, and time of viral clearance in patients with severe and critical COVID-19.
   PATIENTS AND METHODS: Patients with severe and critical COVID-19 who had been discharged or expired were enrolled in this study. Patients were divided into corticosteroid group and non-corticosteroid group according to the systemic corticosteroid use or not. Clinical data were collected, and hospital mortality, hospital length of stay, time of viral clearance, time of mechanical ventilation, and duration from illness onset to symptom resolution were compared between the two groups.
   RESULTS: A total of 72 inpatients who were diagnosed with severe and critical COVID-19 were enrolled, in which 47 patients were divided into corticosteroid group and 25 were involved as the non-corticosteroid group. Baseline characteristics were generally similar between the two groups. Four (5.6%) patients died during hospitalization, and 68 (94.4%) were discharged. Among survivors, the mean duration time from admission to discharge was 19.5d (SD 7.05 d). The mean time of viral clearance among survivors was 17.5d (SD 7.67 d), with a maximum of 37 d, and a minimum of 5 d. Hospital mortality (4.3% vs. 8.0%), length of hospital stay (18.7d vs. 21.0d), and time of viral clearance (16.1d vs. 19.4d) had no significant difference between two groups (p>0.05). The duration of symptoms suffering was shorter in the corticosteroid group than non-corticosteroid group, with statistically significant difference (p<0.05).
   CONCLUSIONS: Corticosteroid therapy in patients with severe COVID-19 cannot reduce the hospital mortality, and is not associated with delayed viral clearance, but it could re lieve the inflammatory storm and improve clinical symptoms in brief. Patients with severe COVID-19 could benefit from low-dose corticosteroid treatment.
C1 [Ma, Q.; Qi, D.; Deng, X-Y; Wang, D-X] Chongqing Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Yuan, G-D] Chongqing Publ Hlth Med Ctr, Intens Care Unit, Chongqing, Peoples R China.
   [Tian, W-G] Chongqing Med Univ, Dept Infect Dis, Yongchuan Hosp, Chongqing, Peoples R China.
   [Cui, Y.] Chongqing Three Gorges Cent Hosp, Intens Care Unit, Chongqing, Peoples R China.
   [Yan, X-F] Chongqing Publ Hlth Med Ctr, Dept Resp Med, Chongqing, Peoples R China.
RP Wang, DX (corresponding author), Chongqing Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Chongqing, Peoples R China.
EM 300293@hospital.cqmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670071]; National Natural Science
   Foundation for Young Scholars of ChinaNational Natural Science
   Foundation of China (NSFC)National Science Fund for Distinguished Young
   Scholars [81800083]; Natural Science Foundation of Chongqing,
   ChinaNatural Science Foundation of Chongqing [Cstc2020jscx-fyzx0230];
   Emergency Foundation for Novel Coronavirus Pneumonia of Chongqing Health
   Committee, China [2020NCPZX19]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81670071), the National Natural Science Foundation for
   Young Scholars of China (Grant No. 81800083), the Natural Science
   Foundation of Chongqing, China (Grant No. Cstc2020jscx-fyzx0230) and the
   Emergency Foundation for Novel Coronavirus Pneumonia of Chongqing Health
   Committee, China (Grant No. 2020NCPZX19).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   de Vlas SJ, 2009, TROP MED INT HEALTH, V14, P1, DOI 10.1111/j.1365-3156.2009.02349.x
   Delaney JW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1230-8
   Guo KJ, 2014, BONE JOINT J, V96B, P259, DOI 10.1302/0301-620X.96B2.31935
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Kim ES, 2016, J KOREAN MED SCI, V31, P1717, DOI 10.3346/jkms.2016.31.11.1717
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Marik PE, 2018, J THORAC DIS, V10, pS1070, DOI 10.21037/jtd.2018.04.35
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   National Health Commission of the People's Republic of China, 2020, CHIN MAN GUID COVID
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sehgal Virendra N, 2019, Skinmed, V17, P172
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 28
TC 1
Z9 1
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 15
BP 8194
EP 8201
DI 10.26355/eurrev_202008_22508
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MX0BN
UT WOS:000557394400035
PM 32767349
DA 2021-01-01
ER

PT J
AU De Giorgi, A
   Fabbian, F
   Di Simone, E
   Greco, S
   De Giorgio, R
   Zuliani, G
   Passaro, A
   Caselli, E
   Manfredini, R
AF De Giorgi, A.
   Fabbian, F.
   Di Simone, E.
   Greco, S.
   De Giorgio, R.
   Zuliani, G.
   Passaro, A.
   Caselli, E.
   Manfredini, R.
CA OUTCOME-INTMED-COV19 Study
TI Morning vs. evening administration of ntiviral therapy in COVID-19
   patients. A preliminary retrospective study in Ferrara, Italy
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2);
   Chronobiology; Chronotherapy; Antiviral drugs; Darunavir; Ritonavir;
   C-reactive protein; Inflammation; Hospitalization; Outcome
ID CIRCADIAN-RHYTHMS; LOPINAVIR/RITONAVIR; VACCINATION; INFECTION; INNATE;
   CLOCK
AB OBJECTIVE: At the end of 2019, the Novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), spread rapidly from China to the whole world. Circadian rhythms can play crucial role in the complex interplay between viruses and organisms, and temporized schedules (chronotherapy) have been positively tested in several medical diseases. We aimed to compare the possible effects of a morning vs. evening antiviral administration in COVID patients.
   PATIENTS AND METHODS: We retrospectively evaluated all patients admitted to COVID internal medicine units with confirmed SARSCoV-2 infection, and treated with darunavir-ritonavir (single daily dose, for seven days). Age, sex, length of stay (LOS), pharmacological treatment, and timing of antiviral administration (morning or evening), were recorded. Outcome indicators were death or LOS, and laboratory parameters, e.g., variations in C-reactive protein (CRP) levels, ratio of arterial oxygen partial pressure (PaO2, mmHg) to fractional inspired oxygen (FiO2) (PaO2/FiO(2)), and leucocyte count.
   RESULTS: The total sample consisted of 151 patients, 33 (21.8%) of whom were selected for antiviral treatment. The mean age was 61.8 +/- 18.3 years, 17 (51.5%) were male, and the mean LOS was 13.4 +/- 8.6 days. Nine patients (27.3%) had their antiviral administration in the morning, and 24 (72.7%) had antiviral administration in the evening. No fatalities occurred. Despite the extremely limited sample size, morning group subjects showed a significant difference in CRP variation, compared to that in evening group subjects (-65.82 +/- 33.26 vs. 83.32 +/- 304.89, respectively, p<0.032). No significant differences were found for other parameters.
   CONCLUSIONS: This report is the first study evaluating temporized morning vs. evening antiviral administration in SARS-CoV-2 patients. The morning regimen was associated with a significant reduction in CRP values. Further confirmations with larger and multicenter samples of patients could reveal novel potentially useful insights.
C1 [De Giorgi, A.; Fabbian, F.; Di Simone, E.; Greco, S.; De Giorgio, R.; Zuliani, G.; Passaro, A.; Manfredini, R.] Azienda Osped Univ S Anna, Clin Med, Med Interna Univ, Med Osped 2,COVID Internal Med Units 19, Ferrara, Italy.
   [Fabbian, F.; Greco, S.; De Giorgio, R.; Zuliani, G.; Passaro, A.; Manfredini, R.] Univ Ferrara, Dept Med Sci, Ferrara, Italy.
   [De Giorgio, R.; Zuliani, G.; Passaro, A.] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Caselli, E.] Univ Ferrara, Dept Chem & Pharmaceut Sci, Clin Microbiol, Ferrara, Italy.
RP Fabbian, F (corresponding author), Azienda Osped Univ S Anna, Clin Med, Med Interna Univ, Med Osped 2,COVID Internal Med Units 19, Ferrara, Italy.; Fabbian, F (corresponding author), Univ Ferrara, Dept Med Sci, Ferrara, Italy.
EM f.fabbian@ospfe.it
RI Passaro, Angelina/P-3401-2015
OI Passaro, Angelina/0000-0001-8462-7000
FU University of Ferrara
FX This work has been supported by a research grant from the University of
   Ferrara, (Fondo Attivita Ricerca FAR 2019, Prof. Roberto Manfredini).
CR Buttgereit F, 2015, NAT REV RHEUMATOL, V11, P349, DOI 10.1038/nrrheum.2015.31
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cederroth CR, 2019, CELL METAB, V30, P238, DOI 10.1016/j.cmet.2019.06.019
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chowd D, 2019, CELLS, V8
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   De Giorgi A, 2013, EUR J INTERN MED, V24, P698, DOI 10.1016/j.ejim.2013.03.019
   Druzd D, 2017, IMMUNITY, V46, P120, DOI 10.1016/j.immuni.2016.12.011
   Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8
   Edgar RS, 2016, P NATL ACAD SCI USA, V113, P10085, DOI 10.1073/pnas.1601895113
   Grimaldi B, 2007, NATURE, V447, P386, DOI 10.1038/447386a
   Grimaldi B, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.965626
   Hill RJW, 2020, PLOS COMPUT BIOL, V16, DOI [10.1371/journal.pcbi.1007218, 10.1371/journal.pcbi.1007218.r001, 10.1371/journal.pcbi.1007218.r002, 10.1371/journal.pcbi.1007218.r003, 10.1371/journal.pcbi.1007218.r004, 10.1371/journal.pcbi.1007218.r005, 10.1371/journal.pcbi.1007218.r006]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kaur G, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8020013
   Kirby T, 2016, LANCET RESP MED, V4, P435, DOI [10.1016/S2213-2600(16)30100-X, 10.1016/s2213-2600(16)30100-X]
   Levi F, 2007, ANNU REV PHARMACOL, V47, P593, DOI 10.1146/annurev.pharmtox.47.120505.105208
   Long JE, 2016, VACCINE, V34, P2679, DOI 10.1016/j.vaccine.2016.04.032
   Lou J, 2020, EUR REV MED PHARMACO, V24, P3411, DOI 10.26355/eurrev_202003_20712
   Majumdar T, 2017, INNATE IMMUN-LONDON, V23, P147, DOI 10.1177/1753425916681075
   MANFREDINI R., 2007, ENCY STRESS, V1, P500
   Mazzoccoli G, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020083
   Nguyen KD, 2013, SCIENCE, V341, P1483, DOI 10.1126/science.1240636
   Pick R, 2019, TRENDS IMMUNOL, V40, P524, DOI 10.1016/j.it.2019.03.010
   Ruben MD, 2019, SCIENCE, V365, P547, DOI 10.1126/science.aax7621
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017
   Soares AC, 2020, DRUG DISCOV TODAY, pS1359
   Sulli G, 2018, TRENDS PHARMACOL SCI, V39, P812, DOI 10.1016/j.tips.2018.07.003
   Sundar IK, 2015, SCI REP-UK, V5, DOI 10.1038/srep09927
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Zhao N, 2020, EUR REV MED PHARMACO, V24, P4597, DOI 10.26355/eurrev_202004_21046
   Zhuang XD, 2017, J MOL MED, V95, P1283, DOI 10.1007/s00109-017-1592-7
NR 37
TC 0
Z9 0
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 15
BP 8219
EP 8225
DI 10.26355/eurrev_202008_22511
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MX0BN
UT WOS:000557394400038
PM 32767353
DA 2021-01-01
ER

PT J
AU Fan, Q
   Chen, X
   Lin, Y
   Wang, ZQ
AF Fan, Qian
   Chen, Xin
   Lin, Yan
   Wang, Zhiquan
TI Prevention and Treatment Strategies for the Cardiology Department of a
   Non-COVID-19 Designated Hospital in the Post-Epidemic Period
SO RISK MANAGEMENT AND HEALTHCARE POLICY
LA English
DT Article
DE post-epidemic period; non-COVID-19 designated hospitals; strategy
AB Background: Coronavirus infection disease 2019 (COVID-19) occurred in Wuhan in December 2019. With the spread of the virus, the global epidemic situation has become extremely serious, especially in the United States, Spain and Italy. Due to a series of control measures, the epidemic situation in Wuhan has been alleviated to a certain extent, and this region has entered into a post-epidemic period. The treatment of some acute and worsened cardiovascular diseases has become more complex because of epidemic prevention measures.
   Patients and Methods: We examined cardiovascular patients in the emergency department, as well as outpatient clinics and inpatient units in the Zhongnan Hospital of Wuhan University, from March 20th to April 17th, 2020, as the study subjects, and we performed standard medical activities according to the principles of border treatment and border protection. Additionally, we aimed to minimize the adverse effects of the epidemic on the therapy that was administered to cardiology patients.
   Results: Due to this standard and feasible strategy, the cardiology department admitted a total of 97 patients, with 36 patients being discharged. No patients have been observed to become infected with SARS-CoV-2 in the cardiology department. In addition, we have no outpatient, caregivers or medical staff infected.
   Conclusion: Our study aimed to provide prevention and treatment strategies for the rapid and effective medical recovery of patients in non-COVID-19 designated hospitals in highrisk areas after remission, as well as in low- and medium-risk areas.
C1 [Fan, Qian; Chen, Xin; Lin, Yan; Wang, Zhiquan] Wuhan Univ, Zhongnan Hosp, Dept Cardiol, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
RP Wang, ZQ (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Cardiol, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
EM 2455098577@qq.com
FU Chinese Universities Scientific Fund [2042018kf0136]
FX This work was supported by the Chinese Universities Scientific Fund
   [2042018kf0136].
CR Aggarwal G, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100617
   Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang L, 2020, EUR HEART J, V41, P1788, DOI 10.1093/eurheartj/ehaa266
NR 7
TC 0
Z9 0
U1 2
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1179-1594
J9 RISK MANAG HEALTHC P
JI RISK MANAG. HEALTHC. POLICY
PY 2020
VL 13
BP 979
EP 987
DI 10.2147/RMHP.S261533
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA MU2AR
UT WOS:000555474900001
PM 32801972
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dastan, F
   Saffaei, A
   Mortazavi, SM
   Jamaati, H
   Adnani, N
   Roudi, SS
   Kiani, A
   Abedini, A
   Hashemian, SM
AF Dastan, Farzaneh
   Saffaei, Ali
   Mortazavi, Seyed Mehdi
   Jamaati, Hamidreza
   Adnani, Nadia
   Roudi, Sasan Samiee
   Kiani, Arda
   Abedini, Atefeh
   Hashemian, Seyed MohammadReza
TI Continues renal replacement therapy (CRRT) with disposable hemoperfusion
   cartridge: A promising option for severe COVID-19
SO JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
LA English
DT Article
DE COVID-19; Continues renal replacement therapy; Hemoperfusion; Acute
   respiratory distress syndrome
AB Cytokine release syndrome is prevalent in severe cases of COVID-19. In this syndrome, an uncontrolled response of immune system occurs. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. Here, we reported a successful case to represent our experience of extracorporeal blood purification in a patient with severe COVID-19. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
C1 [Dastan, Farzaneh] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Tehran, Iran.
   [Dastan, Farzaneh; Mortazavi, Seyed Mehdi; Jamaati, Hamidreza; Abedini, Atefeh; Hashemian, Seyed MohammadReza] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr CRDRC, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Saffaei, Ali] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Student Res Comm, Tehran, Iran.
   [Adnani, Nadia] Alborz Univ Med Sci, Nephrol Res Ctr, Sch Med, Dept Nephrol, Karaj, Iran.
   [Roudi, Sasan Samiee] Iran Univ Med Sci, Infect Res Ctr, Sch Med, Dept Infect Dis, Tehran, Iran.
   [Kiani, Arda] Shahid Beheshti Univ Med Sci, Tracheal Dis Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
RP Hashemian, SM (corresponding author), Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr CRDRC, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
EM iran.criticalcare@yahoo.com
OI Saffaei, Ali/0000-0002-9563-924X
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   MacLaren G, 2020, JAMA
   Venkataraman R, 2003, CRIT CARE, V7, P139, DOI 10.1186/cc1889
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
NR 4
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-7165
EI 2213-7173
J9 J GLOB ANTIMICROB RE
JI J. Glob. Antimicrob. Resist.
PY 2020
VL 21
BP 340
EP 341
DI 10.1016/j.jgar.2020.04.024
PG 2
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA MU2JZ
UT WOS:000555500900021
PM 32353526
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wild, J
   Warnock-Parkes, E
   Murray, H
   Kerr, A
   Thew, G
   Grey, N
   Clark, DM
   Ehlers, A
AF Wild, Jennifer
   Warnock-Parkes, Emma
   Murray, Hannah
   Kerr, Alice
   Thew, Graham
   Grey, Nick
   Clark, David M.
   Ehlers, Anke
TI Treating posttraumatic stress disorder remotely with cognitive therapy
   for PTSD
SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY
LA English
DT Article
DE PTSD; cognitive therapy; cognitive behaviour therapy; trauma-focused;
   COVID-19; remote therapy
ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIORAL THERAPY; INTERVENTIONS;
   ADOLESCENTS; MANAGEMENT; MEMORIES; SYMPTOMS; CHILDREN
AB Delivering trauma-focused cognitive behavioural therapy to patients with PTSD during the COVID-19 pandemic poses challenges. The therapist cannot meet with the patient in person to guide them through trauma-focused work and other treatment components, and patients are restricted in carrying out treatment-related activities and behavioural experiments that involve contact with other people. Whilst online trauma-focused CBT treatments for PTSD have been developed, which overcome some of these barriers in that they can be delivered remotely, they are not yet routinely available in clinical services in countries, such as the UK. Cognitive therapy for PTSD (CT-PTSD) is a trauma-focused cognitive behavioural therapy that is acceptable to patients, leads to high rates of recovery and is recommended as a first-line treatment for the disorder by international clinical practice guidelines. Here we describe how to deliver CT-PTSD remotely so that patients presenting with PTSD during the COVID-19 pandemic can still benefit from this evidence-based treatment.
C1 [Wild, Jennifer; Warnock-Parkes, Emma; Murray, Hannah; Thew, Graham; Clark, David M.; Ehlers, Anke] Univ Oxford, Dept Expt Psychol, Oxford, England.
   [Wild, Jennifer; Warnock-Parkes, Emma; Murray, Hannah; Thew, Graham; Clark, David M.; Ehlers, Anke] Oxford Hlth NHS Fdn Trust, Oxford, England.
   [Warnock-Parkes, Emma; Kerr, Alice] Kings Coll London, Dept Psychol, London, England.
   [Grey, Nick] Sussex Partnership NHS Fdn Trust, Worthing, England.
RP Wild, J (corresponding author), Univ Oxford, Dept Expt Psychol, Oxford, England.
EM jennifer.wild@psy.ox.ac.uk
RI ; Ehlers, Anke/G-8713-2014
OI Wild, Jennifer/0000-0001-5463-1711; Thew, Graham/0000-0003-2851-1315;
   Ehlers, Anke/0000-0002-8742-0192
FU Wellcome TrustWellcome Trust [200796]; NIHR Senior Fellowships; Oxford
   Health NIHR Biomedical Research Centre
FX The authors were funded by Wellcome Trust grant 200796 (awarded to AE
   and DMC), NIHR Senior Fellowships to AE and DMC, and the Oxford Health
   NIHR Biomedical Research Centre. The views expressed are those of the
   authors and not necessarily those of the NHS, the NIHR or the Department
   of Health.
CR Acierno R, 2017, BEHAV RES THER, V89, P57, DOI 10.1016/j.brat.2016.11.009
   American Psychological Association, 2017, CLIN PRACT GUID TREA
   Ashwick R, 2019, EUR J PSYCHOTRAUMATO, V10, DOI 10.1080/20008198.2019.1573128
   BBC, 2020, BBC
   Clohessy S, 1999, BRIT J CLIN PSYCHOL, V38, P251, DOI 10.1348/014466599162836
   Duffy M, 2007, BRIT MED J, V334, P1147, DOI 10.1136/bmj.39021.846852.BE
   DuHamel KN, 2010, J CLIN ONCOL, V28, P3754, DOI 10.1200/JCO.2009.26.8722
   Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7
   Ehlers A, 2005, BEHAV RES THER, V43, P413, DOI 10.1016/j.brat.2004.03.006
   Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0
   Ehlers A, 2003, ARCH GEN PSYCHIAT, V60, P1024, DOI 10.1001/archpsyc.60.10.1024
   Ehlers A., 2013, CBT ANXIETY DISORDER, P161, DOI DOI 10.1002/
   Ehlers A., 2020, EFFICIENT USE UNPUB
   Ehlers A., 2020, EFFECTIVENESS UNPUB
   Ehlers A, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4176-8
   Ehlers A, 2014, AM J PSYCHIAT, V171, P294, DOI 10.1176/appi.ajp.2013.13040552
   Ehlers A, 2013, BEHAV RES THER, V51, P742, DOI 10.1016/j.brat.2013.08.006
   Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-3590.11.3.303
   Foa EB, 1998, TREATING TRAUMA RAPE
   International Society for Traumatic Stress Studies, 2019, POSTTR STRESS DIS PR
   Kleim B, 2013, J CONSULT CLIN PSYCH, V81, P383, DOI 10.1037/a0031290
   Knaevelsrud C, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-13
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Kuester A, 2016, CLIN PSYCHOL REV, V43, P1, DOI 10.1016/j.cpr.2015.11.004
   Kuhn E, 2017, J CONSULT CLIN PSYCH, V85, P267, DOI 10.1037/ccp0000163
   Lange Alfred, 2003, Cognitive Behaviour Therapy, V32, P110, DOI 10.1080/16506070302317
   Lewis C, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011710.pub2
   Litz BT, 2007, AM J PSYCHIAT, V164, P1676, DOI 10.1176/appi.ajp.2007.06122057
   Luxton DD, 2014, INT J PSYCHIAT MED, V48, P19, DOI 10.2190/PM.48.1.c
   Meiser-Stedman R, 2017, J CHILD PSYCHOL PSYC, V58, P623, DOI 10.1111/jcpp.12673
   Michael T, 2005, BEHAV RES THER, V43, P613, DOI 10.1016/j.brat.2004.04.006
   Morland LA, 2015, DEPRESS ANXIETY, V32, P811, DOI 10.1002/da.22397
   Murray H, 2020, COGN BEH THER, V13, DOI 10.1017/S1754470X2000015X
   Murray H, 2015, COGN BEH THER, V8, DOI 10.1017/S1754470X15000677
   National Institute of Health and Clinical Excellence, 2018, POSTTRAUMATIC STRESS
   Olff M, 2019, EUR J PSYCHOTRAUMATO, V10, DOI 10.1080/20008198.2019.1672948
   Price M, 2018, EUR J PSYCHOTRAUMATO, V9, DOI 10.1080/20008198.2018.1500822
   Resick P. A., 1993, COGNITIVE PROCESSING
   Sander LB, 2020, EUR J PSYCHOTRAUMATO, V11, DOI 10.1080/20008198.2019.1701788
   Simon N, 2019, EUR J PSYCHOTRAUMATO, V10, DOI 10.1080/20008198.2019.1646092
   Smith P, 2007, J AM ACAD CHILD PSY, V46, P1051, DOI 10.1097/CHI.0b013e318067e288
   van der Meer C. A. I., 2020, EUROPEAN J PSYCHOTRA, V11, P1
   Weathers F. W., 2013, PTSD CHECKLIST DSM 5, P10
   Weiss D. S., 2007, ASSESSING PSYCHOL TR
   Wild J, 2016, EUR J PSYCHOTRAUMATO, V7, DOI 10.3402/ejpt.v7.31019
NR 45
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2000-8198
EI 2000-8066
J9 EUR J PSYCHOTRAUMATO
JI Eur. J. Psychotraumatol.
PY 2020
VL 11
IS 1
AR 1785818
DI 10.1080/20008198.2020.1785818
PG 15
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA MS1DN
UT WOS:000554025400001
PM 33029325
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jo, S
   Kim, S
   Kim, DY
   Kim, MS
   Shin, DH
AF Jo, Seri
   Kim, Suwon
   Kim, Dae Yong
   Kim, Mi-Sun
   Shin, Dong Hae
TI Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE SARS-CoV 3CL protease; antiviral; flavonoid; FRET; inhibitory compounds
ID CORONAVIRUS; PROTEASE; MODEL; SARS; PNEUMONIA
AB Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. Anin silicodocking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2.
C1 [Jo, Seri; Kim, Suwon; Kim, Mi-Sun; Shin, Dong Hae] Ewha W Univ, Graduates Sch Pharmaceut Sci, Coll Pharm, Seoul, South Korea.
   [Kim, Dae Yong] N BIOTEK, Bucheon Si, Gyeong Gi, South Korea.
RP Shin, DH (corresponding author), Ewha W Univ, Dept Pharm, Seoul 03760, South Korea.
EM dhshin55@ewha.ac.kr
OI Reis, AlessanRSS/0000-0001-8486-7469
FU N-Biotek fund; Brain Korea 21 (BK21) ProjectMinistry of Education &
   Human Resources Development (MOEHRD), Republic of Korea
FX This work was supported by the N-Biotek fund. SJ was supported by Brain
   Korea 21 (BK21) Project.
CR Brownson DM, 2002, J NUTR, V132, p3482S, DOI 10.1093/jn/132.11.3482S
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chuck CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027228
   Datla KP, 2001, NEUROREPORT, V12, P3871, DOI 10.1097/00001756-200112040-00053
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gu XH, 2016, BEHAV BRAIN RES, V311, P309, DOI 10.1016/j.bbr.2016.05.052
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Lin H, 2009, SPECTROCHIM ACTA A, V73, P936, DOI 10.1016/j.saa.2009.04.025
   Mesel-Lemoine M, 2012, J VIROL, V86, P7577, DOI 10.1128/JVI.00269-12
   Pohjala L, 2012, MOLECULES, V17, P10774, DOI 10.3390/molecules170910774
   Ren RT, 2016, SCI REP-UK, V6, DOI 10.1038/srep22135
   Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c
   Wu AD, 2015, VIRUS RES, V208, P56, DOI 10.1016/j.virusres.2015.05.018
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Youns M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169335
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 21
TC 4
Z9 4
U1 13
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475-6366
EI 1475-6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD JAN 1
PY 2020
VL 35
IS 1
BP 1539
EP 1544
DI 10.1080/14756366.2020.1801672
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA MT6QF
UT WOS:000555096700001
PM 32746637
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pham, QV
   Nguyen, DC
   Thien, HT
   Hwang, WJ
   Pathirana, PN
AF Pham, Quoc-Viet
   Nguyen, Dinh C.
   Huynh-The, Thien
   Hwang, Won-Joo
   Pathirana, Pubudu N.
TI Artificial Intelligence (AI) and Big Data for Coronavirus (COVID-19)
   Pandemic: A Survey on the State-of-the-Arts
SO IEEE ACCESS
LA English
DT Article
DE Artificial intelligence; Big Data; Drugs; Government; Viruses (medical);
   Computational modeling; COVID-19; Artificial intelligence (AI); big
   data; COVID-19; coronavirus; epidemic outbreak; deep learning; data
   analytics; machine learning
ID MOBILE-HEALTH; DIGITAL TWIN; DEEP; SURVEILLANCE; BLOCKCHAIN; CARE
AB The very first infected novel coronavirus case (COVID-19) was found in Hubei, China in Dec. 2019. The COVID-19 pandemic has spread over 214 countries and areas in the world, and has significantly affected every aspect of our daily lives. At the time of writing this article, the numbers of infected cases and deaths still increase significantly and have no sign of a well-controlled situation, e.g., as of 13 July 2020, from a total number of around 13.1 million positive cases, 571,527 deaths were reported in the world. Motivated by recent advances and applications of artificial intelligence (AI) and big data in various areas, this paper aims at emphasizing their importance in responding to the COVID-19 outbreak and preventing the severe effects of the COVID-19 pandemic. We firstly present an overview of AI and big data, then identify the applications aimed at fighting against COVID-19, next highlight challenges and issues associated with state-of-the-art solutions, and finally come up with recommendations for the communications to effectively control the COVID-19 situation. It is expected that this paper provides researchers and communities with new insights into the ways AI and big data improve the COVID-19 situation, and drives further studies in stopping the COVID-19 outbreak.
C1 [Pham, Quoc-Viet] Pusan Natl Univ, Res Inst Comp Informat & Commun, Busan 46241, South Korea.
   [Nguyen, Dinh C.; Pathirana, Pubudu N.] Deakin Univ, Sch Engn, Waurn Ponds, Vic 3216, Australia.
   [Huynh-The, Thien] Kumoh Natl Inst Technol, ICT Convergence Res Ctr, Gumi 39177, South Korea.
   [Hwang, Won-Joo] Pusan Natl Univ, Dept Biomed Convergence Engn, Busan 46241, South Korea.
   [Hwang, Won-Joo] Pusan Natl Univ, Dept Informat Convergence Engn Artificial Intelli, Busan 46241, South Korea.
RP Hwang, WJ (corresponding author), Pusan Natl Univ, Dept Biomed Convergence Engn, Busan 46241, South Korea.; Hwang, WJ (corresponding author), Pusan Natl Univ, Dept Informat Convergence Engn Artificial Intelli, Busan 46241, South Korea.
EM wjhwang@pusan.ac.kr
RI Pham, Quoc Viet/O-2350-2018; Huynh-The, Thien/X-1291-2018; Pathirana,
   Pubudu/Q-2132-2018
OI Pham, Quoc Viet/0000-0002-9485-9216; Huynh-The,
   Thien/0000-0002-9172-2935; Pathirana, Pubudu/0000-0001-8014-7798; Chi
   Nguyen, Dinh/0000-0002-8092-6756
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT (MSIT), Korea Government [NRF-2019R1C1C1006143,
   NRF-2019R1I1A3A01060518]; Institute of Information AMP; Communications
   Technology Planning AMP; Evaluation (IITP) - Korea Government (MSIT)
   through the Artificial Intelligence Convergence Research Center, Pusan
   National University [2020-0-01450]
FX This work was supported in part by the National Research Foundation of
   Korea (NRF) funded by the Ministry of Science and ICT (MSIT), Korea
   Government under Grant NRF-2019R1C1C1006143 and Grant
   NRF-2019R1I1A3A01060518, and in part by the Institute of Information &
   Communications Technology Planning & Evaluation (IITP) funded by the
   Korea Government (MSIT) through the Arti~cial Intelligence Convergence
   Research Center, Pusan National University under Grant 2020-0-01450.
CR Abbas A, 2020, ARXIV200313815
   Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Adadi A, 2018, IEEE ACCESS, V6, P52138, DOI 10.1109/ACCESS.2018.2870052
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2020, DAMO ACAD AI SYSTEM
   [Anonymous], 2020, SEOUL INTRO COVID 19
   [Anonymous], 2020, IBM RELEASES NOVEL A
   [Anonymous], 2020, ARXIV ANNOUNCES NEW
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   [Anonymous], 2020, CORONAVIRUS COVID 19
   [Anonymous], 2020, CISCO ANN INTERNET R
   [Anonymous], 2020, MIPASA PROJECT IBM B
   [Anonymous], 2020, WHITE HOUSE ANNOUNCE
   [Anonymous], 2020, COVID 19 OPEN RES DA, DOI 10.5281/zenodo.3715506
   [Anonymous], 2020, ALMOST ONE ZETTABYTE
   [Anonymous], 2020, NEXT GENERATION INFO
   Apostolopoulos ID, 2020, PHYS ENG SCI MED, V43, P635, DOI 10.1007/s13246-020-00865-4
   Banerjee A., 2020, ENERGETICS BASED EPI, DOI [10.1101/2020.04.02.021725v1, DOI 10.1101/2020.04.02.021725V1]
   Bansal S, 2016, J INFECT DIS, V214, pS375, DOI 10.1093/infdis/jiw400
   Barricelli BR, 2020, IEEE ACCESS, V8, P26637, DOI 10.1109/ACCESS.2020.2971576
   Barricelli BR, 2019, IEEE ACCESS, V7, P167653, DOI 10.1109/ACCESS.2019.2953499
   Barstugan M., 2020, ARXIV200309424
   Bayes C., 2020, ARXIV200402386
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Berman HM, 2003, PROTEIN STRUCTURE: DETERMINATION, ANALYSIS, AND APPLICATIONS FOR DRUG DISCOVERY, P389
   Biswas K., 2020, ARXIV200303149
   Bragazzi NL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093176
   Brann D, 2020, NONNEURAL EXPRESSION, DOI [DOI 10.1101/2020.03.25.009084V2, 10.1101/2020.03.25.009084v2]
   Brauer F., 2012, MATH MODELS POPULATI, V2
   Buckee C, 2020, LANCET DIGIT HEALTH, V2, pE218, DOI 10.1016/S2589-7500(20)30059-5
   Cao CS, 2018, GENOM PROTEOM BIOINF, V16, P17, DOI 10.1016/j.gpb.2017.07.003
   Castorina P., 2020, ARXIV200300507
   Chae S, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081596
   Chaganti S., 2020, ARXIV200401279
   Chamola V, 2020, IEEE ACCESS, V8, P90225, DOI 10.1109/ACCESS.2020.2992341
   Chen B, 2020, ARXIV200207096
   Chen CM, 2020, J MED INTERNET RES, V22, DOI 10.2196/19540
   Chen Y. C., 2020, ARXIV200300122
   Chenthamarakshan V., 2020, ARXIV200401215
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Crokidakis N, 2020, INT J MOD PHYS C, V31, DOI 10.1142/S0129183120501351
   Dai WC, 2020, CAN ASSOC RADIOL J, V71, P195, DOI 10.1177/0846537120913033
   Dandekar R., 2020, ARXIV200402752
   Dandekar R., 2020, ARXIV200309403
   Nguyen DP, 2020, APPL ACOUST, V166, DOI 10.1016/j.apacoust.2020.107349
   Eden JS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa027
   Eisenstein M, 2018, NATURE, V555, pS2
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Eldeen N., 2020, ARXIV200401184
   Fomsgaard AS, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.14.2000398
   Gaeta G., 2021, MATH ENG, V3, P1
   Ganasegeran K., 2020, HUMAN BEHAV ANAL USI, P141, DOI [10.1007/978-3-030-35139-7_7, DOI 10.1007/978-3-030-35139-7_7]
   Gao H, 2015, IEEE COMMUN SURV TUT, V17, P918, DOI 10.1109/COMST.2014.2387836
   Garattini Chiara, 2019, Philos Technol, V32, P69, DOI 10.1007/s13347-017-0278-y
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836v1, DOI 10.1101/2020.03.11.986836V1]
   Geng ZX, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17112449
   Ghoshal B., 2020, ARXIV200310769
   Giordano G, 2020, NAT MED, V26, P855, DOI 10.1038/s41591-020-0883-7
   Goodfellow I., 2016, DEEP LEARNING
   Gozes O., 2020, ARXIV200402640
   Gozes O., 2020, ARXIV200305037
   Gupta R., 2020, SEIR REGRESSION MODE
   He KM, 2016, LECT NOTES COMPUT SC, V9908, P630, DOI 10.1007/978-3-319-46493-0_38
   Heroy S., 2020, ARXIV200401248
   Hofmarcher M., 2020, TECH REP
   Hou Z, 2020, RISK PERCEPTION EMOT
   Hu F, 2020, ARXIV200300728
   Hu Z., 2020, ARXIV200207112
   Hu Z., 2020, ARXIV200309800
   Huynh-The T, 2020, IEEE COMMUN LETT, V24, P811, DOI 10.1109/LCOMM.2020.2968030
   Ienca M, 2020, NAT MED, DOI 10.1038/s41591-020-0832-5
   Imran A., INFORM MED UNLOCKED
   Ivanov D, 2020, INT J PROD RES, V58, P2904, DOI 10.1080/00207543.2020.1750727
   Ivanov D, 2020, TRANSPORT RES E-LOG, V136, DOI 10.1016/j.tre.2020.101922
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jumper J., 2020, TECH REP
   Kalkreuth R, 2020, ARXIV200404569
   Kuo TT, 2017, J AM MED INFORM ASSN, V24, P1211, DOI 10.1093/jamia/ocx068
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lampos V, 2020, ARXIV200308086
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Li C., 2020, BIORXIV, DOI [10.1101/2020.03.12.988246v1, DOI 10.1101/2020.03.12.988246V1]
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Li Z., 2020, BIORXIV, DOI [10.1101/2020.03.23.004580v1, DOI 10.1101/2020.03.23.004580V1]
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Liu Dianbo, 2020, ARXIV200404019
   Lon J. R., 2020, BIORXIV, DOI [10.1101/2020.04.03.022723v1, DOI 10.1101/2020.04.03.022723V1]
   LONG Y, 2020, ARXIV200312028
   Magar R., 2020, ARXIV200308447
   MAGDONiSMAIL M, 2020, ARXIV200307602
   Maghdid H. S., 2020, ARXIV200307434
   Mamoshina P, 2016, MOL PHARMACEUT, V13, P1445, DOI 10.1021/acs.molpharmaceut.5b00982
   Manogaran G., 2017, INNOVATIVE HEALTHCAR, P263, DOI [10.1007/978-3-319-55774-8_10, DOI 10.1007/978-3-319-55774-8_10]
   Manogaran G, 2017, STUD BIG DATA, V23, P133, DOI 10.1007/978-3-319-49736-5_7
   Mehta N, 2018, INT J MED INFORM, V114, P57, DOI 10.1016/j.ijmedinf.2018.03.013
   Narin A, 2020, ARXIV200310849
   Ndiaye BM, 2020, ARXIV200401574
   Notari A., 2020, ARXIV200312417
   Offermanns S., 2008, IC50 VALUES, P611
   Ong E, 2020, BIORXIV
   Ortea I, 2020, BIORXIV, DOI [10.1101/2020.03.26.009605v1, DOI 10.1101/2020.03.26.009605V1]
   Ozkaya U, 2020, ARXIV200403698
   Ozturk T, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103792
   Pal R, 2020, ARXIV200400959
   Panwar H., 2020, CHAOS SOLITON FRACT, V138
   Peng L, 2020, ARXIV200206563
   Perone Gaetano, 2020, ARXIV200400382
   Pham Q.-V., 2020, IEEE ACCESS, V8
   Priyanka K., 2014, INT J COMPUT SCI INF, V5, P5865
   Rasheed A, 2020, IEEE ACCESS, V8, P21980, DOI 10.1109/ACCESS.2020.2970143
   Rees V., 2020, AI CLOUD COMPUTING U
   Sarkar B., 2020, BIORXIV, DOI [10.1101/2020.02.05.935072v1, DOI 10.1101/2020.02.05.935072V1]
   Savioli N., 2020, ARXIV200402136
   Schuller BW, 2020, ARXIV200311117
   Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7
   Shan F., 2020, ARXIV200304655
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Silva BMC, 2015, J BIOMED INFORM, V56, P265, DOI 10.1016/j.jbi.2015.06.003
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Rao ASRS, 2020, INFECT CONT HOSP EP, V41, P826, DOI 10.1017/ice.2020.61
   Strokach A., 2020, BIORXIV, DOI [10.1101/868935v2, DOI 10.1101/868935V2]
   Strzelecki A, 2020, BRAIN BEHAV IMMUN, V88, P950, DOI 10.1016/j.bbi.2020.04.042
   Tang Z., 2020, ARXIV 2003 11988
   TATRAI D, 2020, ARXIV200314160
   Tsai C-W, 2015, J BIG DATA, V2, P21, DOI [10.1186/s40537-015-0030-3, DOI 10.1186/S40537-015-0030-3]
   Ucar F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109761
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Vinayakumar R, 2020, IEEE T IND APPL, V56, P4436, DOI 10.1109/TIA.2020.2971952
   Wang L. D., 2020, ARXIV200309871
   Wang S., 2020, DEEP LEARNING ALGORI, DOI [10.1101/2020.02.14.20023028v5, DOI 10.1101/2020.02.14.20023028V5]
   Wood CS, 2019, NATURE, V566, P467, DOI 10.1038/s41586-019-0956-2
   Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981
   Ye Y, 2020, ARXIV200312232
   Yoon H, 2015, NUCLEIC ACIDS RES, V43, pW213, DOI 10.1093/nar/gkv404
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
   Zhao X., 2020, TRACKING SPREAD NOVE, DOI [10.1101/2020.02.07.20021196v1, DOI 10.1101/2020.02.07.20021196V1]
   Zhavoronkov A., 2020, INSILICO MED HONG A, V307
   Zheng C., 2020, DEEP LEARNING BASED, DOI [10.1101/2020.03.12.20027185v2, DOI 10.1101/2020.03.12.20027185V2]
   Zhong XJ, 2020, IEEE ACCESS, V8, P29648, DOI 10.1109/ACCESS.2020.2972577
   Zhou C, 2020, GEOGRAPHY SUSTAINABI, V1, P77, DOI DOI 10.1016/J.GEOSUS.2020.03.005
   Zhou X., 2020, FORECASTING WORLDWID, DOI [10.1101/2020.03.26.20044289v2, DOI 10.1101/2020.03.26.20044289V2]
NR 143
TC 6
Z9 6
U1 24
U2 24
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 130820
EP 130839
DI 10.1109/ACCESS.2020.3009328
PG 20
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA MQ6FC
UT WOS:000552987800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Naveed, M
   Baleanu, D
   Rafiq, M
   Raza, A
   Soori, AH
   Ahmed, N
AF Naveed, Muhammad
   Baleanu, Dumitru
   Rafiq, Muhammad
   Raza, Ali
   Soori, Atif Hassan
   Ahmed, Nauman
TI Dynamical Behavior and Sensitivity Analysis of a Delayed Coronavirus
   Epidemic Model
SO CMC-COMPUTERS MATERIALS & CONTINUA
LA English
DT Article
DE Coronavirus (COVID-19); delay mathematical model; reproduction number;
   sensitive analysis; stability analysis
ID MATHEMATICAL-MODEL; NUMERICAL-ANALYSIS; WUHAN
AB Mathematical delay modelling has a significant role in the different disciplines such as behavioural, social, physical, biological engineering, and bio-mathematical sciences. The present work describes mathematical formulation for the transmission mechanism of a novel coronavirus (COVID-19). Due to the unavailability of vaccines for the coronavirus worldwide, delay factors such as social distance, quarantine, travel restrictions, extended holidays, hospitalization, and isolation have contributed to controlling the coronavirus epidemic. We have analysed the reproduction number and its sensitivity to parameters. If, Rcovid 1 then this situation will help to eradicate the disease and if, Rcovid 1 the virus will spread rapidly in the human beings. Well-known theorems such as Routh Hurwitz criteria and Lasalle invariance principle have presented for stability. The local and global stabilizes for both equilibria of the model have also been presented. Also, we have analysed the effect of delay reason on the reproduction number. In the last, some very useful numerical consequences have presented in support of hypothetical analysis.
C1 [Naveed, Muhammad; Soori, Atif Hassan] Air Univ, Dept Math, Islamabad, Pakistan.
   [Baleanu, Dumitru] Cankaya Univ, Dept Math, TR-06530 Ankara, Turkey.
   [Baleanu, Dumitru] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Baleanu, Dumitru] Inst Space Sci, Magurele, Romania.
   [Rafiq, Muhammad] Univ Cent Punjab, Fac Engn, Lahore, Pakistan.
   [Raza, Ali] Natl Coll Business Adm & Econ, Dept Math, Lahore, Pakistan.
   [Ahmed, Nauman] Univ Lahore, Dept Math & Stat, Lahore, Pakistan.
RP Naveed, M (corresponding author), Air Univ, Dept Math, Islamabad, Pakistan.
EM 171437@students.au.edu.pk
RI Ahmed, Nauman/ABB-8662-2020
OI Ahmed, Nauman/0000-0003-1742-585X
CR Abodayeh K., 2020, ADV DIFFER EQU-NY, V2508, P1
   Arif MS, 2019, IRAN J SCI TECHNOL A, V43, P2477, DOI 10.1007/s40995-019-00726-0
   Chen T, 2020, MATH MODEL SIMULATIN, V9, P1, DOI DOI 10.1186/s40249-019-0617-6
   Diekmann O, 2010, J R SOC INTERFACE, V7, P873, DOI 10.1098/rsif.2009.0386
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P1, DOI 10.1016/S1473-3099(19)30711-X
   Li TT, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00001
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Raza A, 2019, IET SYST BIOL, V13, P305, DOI 10.1049/iet-syb.2019.0051
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Tahir M, 2019, FILOMAT, V33, P3947, DOI 10.2298/FIL1912947T
   Yang CY, 2020, MATH BIOSCI ENG, V17, P2708, DOI 10.3934/mbe.2020148
   You J. Y., 2020, MOB INF SYST, V1, P1
   Yu F, 2019, NEUROCOMPUTING, V350, P108, DOI 10.1016/j.neucom.2019.03.053
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
   Zhou LL, 2019, NEUROCOMPUTING, V359, P264, DOI 10.1016/j.neucom.2019.05.077
NR 17
TC 3
Z9 3
U1 1
U2 1
PU TECH SCIENCE PRESS
PI HENDERSON
PA 871 CORONADO CENTER DR, SUTE 200, HENDERSON, NV 89052 USA
SN 1546-2218
EI 1546-2226
J9 CMC-COMPUT MATER CON
JI CMC-Comput. Mat. Contin.
PY 2020
VL 65
IS 1
BP 225
EP 241
DI 10.32604/cmc.2020.011534
PG 17
WC Computer Science, Information Systems; Materials Science,
   Multidisciplinary
SC Computer Science; Materials Science
GA MP5PC
UT WOS:000552255300014
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sternberg, A
   McKee, DL
   Naujokat, C
AF Sternberg, Ariane
   McKee, Dwight L.
   Naujokat, Cord
TI Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Coronavinis SARS-CoV-2; COVID-19; S protein; RNA polymerase; 3Clpro;
   Camostat; Remdesivir; alpha-Ketoamides
ID N,N-DIMETHYLCARBAMOYLMETHYL 4-(4-GUANIDINOBENZOYLOXY)-PHENYLACETATE
   METHANESULFATE; SERINE-PROTEASE INHIBITOR; NAFAMOSTAT MESILATE;
   ACUTE-PANCREATITIS; T-705 FAVIPIRAVIR; IN-VITRO; CORONAVIRUS; VIRUS;
   REPLICATION; PREVENTION
AB Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular machines for viral host cell entry, genome replication and protein processing. Such machinery encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the out-break of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
C1 [Sternberg, Ariane] Ctr & Network Targeted Oncol, Muehlackerweg 8, D-69239 Heidelberg, Germany.
   [McKee, Dwight L.] Integrat Canc Consulting, Aptos, CA USA.
   [Naujokat, Cord] Heidelberg Univ, Inst Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.
RP Naujokat, C (corresponding author), Heidelberg Univ, Inst Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.
EM prof.naujokat@gmx.de
CR ADLER G, 1988, EUR J CLIN INVEST, V18, P98, DOI 10.1111/j.1365-2362.1988.tb01173.x
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   BITTNER AK, 2020, MOL CELL, DOI DOI 10.1016/J.MOLCEL.2020.04.022
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   CLARK BG, 1986, DRUGS, V31, P500, DOI 10.2165/00003495-198631060-00003
   Clark JW, 2006, EXPERT OPIN INV DRUG, V15, P71, DOI 10.1517/13543784.15.1.71
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003
   Du Y.X., 2020, CLIN INFECT THER, DOI 10.1002/cpt.1844
   Elmezayen A.D., 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   GOKE B, 1984, DIGESTION, V30, P171, DOI 10.1159/000199102
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon CJ, 2020, J BIOL CHEM
   Greber UF, 2016, J VIROL, V90, P3802, DOI 10.1128/JVI.02568-15
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Grein J, 2020, NEW ENGL J MED, V382
   HIRAISHI M, 1988, INT J ARTIF ORGANS, V11, P212
   Hirota M, 2020, J GASTROENTEROL, V55, P342, DOI 10.1007/s00535-019-01644-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   IKEDA S, 1988, J AM ACAD DERMATOL, V18, P1246, DOI 10.1016/S0190-9622(88)70130-9
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   IWAKI M, 1986, JPN J PHARMACOL, V41, P155, DOI 10.1254/jjp.41.155
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jin ZN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068347
   Jin ZN, 2012, J BIOL CHEM, V287, P10674, DOI 10.1074/jbc.M111.325530
   JONAS JM, 1992, J CLIN PSYCHIAT, V53, P19
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Liu S., 2020, BIOINFORMATICS, DOI 10.1093/bioinformaticsibtaa224
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Lou ZY, 2014, TRENDS PHARMACOL SCI, V35, P86, DOI 10.1016/j.tips.2013.11.006
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lung J, 2020, J MED VIROL, V92, P2248, DOI 10.1002/jmv.26176
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Menendez-Arias Luis, 2013, Subcell Biochem, V68, P599, DOI 10.1007/978-94-007-6552-8_20
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   OHKOSHI M, 1984, J MAXILLOFAC SURG, V12, P148, DOI 10.1016/S0301-0503(84)80235-0
   OHKOSHI M, 1983, J NATL CANCER I, V71, P1053
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Paul D, 2014, CELL HOST MICROBE, V16, P569, DOI 10.1016/j.chom.2014.10.008
   Pawlotsky JM, 2012, ANTIVIR THER, V17, P1109, DOI 10.3851/IMP2423
   Pellett PE, 2014, HAND CLINIC, V123, P45, DOI 10.1016/B978-0-444-53488-0.00002-X
   Ramsey ML, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3606-y
   Sai JK, 2010, J GASTROENTEROL, V45, P335, DOI 10.1007/s00535-009-0148-1
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sissoko D, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001967
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yamawaki H, 2019, DIGESTION, V99, P283, DOI 10.1159/000492813
   Yamaya M, 2015, PULM PHARMACOL THER, V33, P66, DOI 10.1016/j.pupt.2015.07.001
   Yin J, 2018, MICROBIOL MOL BIOL R, V82, DOI 10.1128/MMBR.00066-17
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 76
TC 4
Z9 4
U1 17
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2020
VL 20
IS 16
BP 1423
EP 1433
DI 10.2174/1568026620999200517043137
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA MP2FP
UT WOS:000552025400001
PM 32416679
DA 2021-01-01
ER

PT J
AU Shen, YZ
   Zheng, F
   Sun, DF
   Ling, Y
   Chen, J
   Li, F
   Li, T
   Qian, ZP
   Zhang, YY
   Xu, QN
   Liu, L
   Huang, Q
   Shan, F
   Xu, L
   Wu, J
   Zhu, ZQ
   Song, ZG
   Li, SY
   Shi, YX
   Zhang, JL
   Wu, XY
   Mendelsohn, JB
   Zhu, TY
   Lu, HZ
AF Shen, Yinzhong
   Zheng, Fang
   Sun, Danfeng
   Ling, Yun
   Chen, Jun
   Li, Feng
   Li, Tao
   Qian, Zhiping
   Zhang, Yuyi
   Xu, Qingnian
   Liu, Li
   Huang, Qin
   Shan, Fei
   Xu, Lie
   Wu, Jun
   Zhu, Zhaoqin
   Song, Zhigang
   Li, Shenyang
   Shi, Yuxin
   Zhang, Jianliang
   Wu, Xueyun
   Mendelsohn, Joshua B.
   Zhu, Tongyu
   Lu, Hongzhou
TI Epidemiology and clinical course of COVID-19 in Shanghai, China
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; epidemiology; clinical characteristics; clinical course; viral
   shedding
AB Background:Novel coronavirus pneumonia (COVID-19) is prevalent around the world. We aimed to describe epidemiological features and clinical course in Shanghai. Methods:We retrospectively analysed 325 cases admitted at Shanghai Public Health Clinical Center, between January 20 and February 29, 2020. Results:47.4% (154/325) had visited Wuhan within 2 weeks of illness onset. 57.2% occurred in 67 clusters; 40% were situated within 53 family clusters. 83.7% developed fever during the disease course. Median times from onset to first medical care, hospitalization and negative detection of nucleic acid by nasopharyngeal swab were 1, 4 and 8 days. Patients with mild disease using glucocorticoid tended to have longer viral shedding in blood and feces. At admission, 69.8% presented with lymphopenia and 38.8% had elevated D-dimers. Pneumonia was identified in 97.5% (314/322) of cases by chest CT scan. Severe-critical patients were 8% with a median time from onset to critical disease of 10.5 days. Half required oxygen therapy and 7.1% high-flow nasal oxygen. The case fatality rate was 0.92% with median time from onset to death of 16 days. Conclusion:COVID-19 cases in Shanghai were imported. Rapid identification, and effective control measures helped to contain the outbreak and prevent community transmission.
C1 [Shen, Yinzhong; Chen, Jun; Liu, Li; Wu, Xueyun; Lu, Hongzhou] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect & Immun, Shanghai, Peoples R China.
   [Zheng, Fang; Sun, Danfeng; Xu, Lie; Wu, Jun] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Med Affairs, Shanghai, Peoples R China.
   [Ling, Yun; Huang, Qin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect, Shanghai, Peoples R China.
   [Li, Feng] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Resp Med, Shanghai, Peoples R China.
   [Li, Tao] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept TB, Shanghai, Peoples R China.
   [Qian, Zhiping; Zhang, Yuyi] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Severe Liver Dis, Shanghai, Peoples R China.
   [Xu, Qingnian] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Tradit Chinese Med, Shanghai, Peoples R China.
   [Shan, Fei; Shi, Yuxin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Radiol, Shanghai, Peoples R China.
   [Zhu, Zhaoqin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Clin Lab, Shanghai, Peoples R China.
   [Song, Zhigang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Lab P3, Shanghai, Peoples R China.
   [Li, Shenyang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Data Management Ctr, Shanghai, Peoples R China.
   [Zhang, Jianliang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol, Shanghai, Peoples R China.
   [Mendelsohn, Joshua B.] Pace Univ, Coll Hlth Profess, New York, NY 10038 USA.
   [Zhu, Tongyu] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Urol, Shanghai, Peoples R China.
RP Lu, HZ (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect & Immun, Shanghai, Peoples R China.; Zhu, TY (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Urol, Shanghai, Peoples R China.
EM luhongzhou@fudan.edu.cn; zhutongyu@shphc.org.cn
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Shanghai Science and Technology CommitteeShanghai Science & Technology
   Committee [20431900403, 20431900400, 20411950200, 17411969600]; Shanghai
   Municipal Health Commission [2020NCP001, shslczdzk01102]; Ministry of
   Science and Technology of the People's Republic of ChinaMinistry of
   Science and Technology, China [2017ZX10202101]; Fudan University
   [RC-QT-2019-01]
FX This work was supported by Shanghai Science and Technology Committee
   under Grant 20431900403, 20431900400, 20411950200 and 17411969600;
   Shanghai Municipal Health Commission under Grant 2020NCP001: Special
   Emergency Project for the Prevention and Treatment of COVID-19 with
   Traditional Chinese Medicine in Shanghai and shslczdzk01102: Shanghai
   Municipal Key Clinical Specialty; Ministry of Science and Technology of
   the People's Republic of China under Grant 2017ZX10202101: National Key
   Project of '13th five-year' Infectious Diseases Program; Fudan
   University under Grant RC-QT-2019-01.
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Ledford H., 2020, CORONAVIRUS BREAKTHR
   Leung C, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2103
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   National Health Comission of the People's Republic of China, NOV COR PNEUM EP SIT
   National Health Commission of the People's Republic of China, NAT COVID 19 DIAGN T
   Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018
   Tong ZD, 2020, EMERG INFECT DIS, V26, P1052, DOI 10.3201/eid2605.200198
   World Health Organization, 2005, 2 M INT HLTH REG EM
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, COR DIS COVID 19 OUT
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   World Health Organization, COR DIS COVID 19 TEC
   World Health Organization, 2020, WHO DIR GEN OLP REM
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 2
Z9 2
U1 7
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1537
EP 1545
DI 10.1080/22221751.2020.1787103
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MO9XW
UT WOS:000551869900001
PM 32573353
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yuen, CK
   Lam, JY
   Wong, WM
   Mak, LF
   Wang, XH
   Chu, H
   Cai, JP
   Jin, DY
   To, KKW
   Chan, JFW
   Yuen, KY
   Kok, KH
AF Yuen, Chun-Kit
   Lam, Joy-Yan
   Wong, Wan-Man
   Mak, Long-Fung
   Wang, Xiaohui
   Chu, Hin
   Cai, Jian-Piao
   Jin, Dong-Yan
   To, Kelvin Kai-Wang
   Chan, Jasper Fuk-Woo
   Yuen, Kwok-Yung
   Kok, Kin-Hang
TI SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon
   antagonists
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; interferon antagonist; PLpro; orf6
ID RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE; I INTERFERON;
   PNEUMONIA; RESPONSES; IMPORT; DOMAIN
AB The Coronavirus disease 2019 (COVID-19), which is caused by the novel SARS-CoV-2 virus, is now causing a tremendous global health concern. Since its first appearance in December 2019, the outbreak has already caused over 5.8 million infections worldwide (till 29 May 2020), with more than 0.35 million deaths. Early virus-mediated immune suppression is believed to be one of the unique characteristics of SARS-CoV-2 infection and contributes at least partially to the viral pathogenesis. In this study, we identified the key viral interferon antagonists of SARS-CoV-2 and compared them with two well-characterized SARS-CoV interferon antagonists, PLpro and orf6. Here we demonstrated that the SARS-CoV-2 nsp13, nsp14, nsp15 and orf6, but not the unique orf8, could potently suppress primary interferon production and interferon signalling. Although SARS-CoV PLpro has been well-characterized for its potent interferon-antagonizing, deubiquitinase and protease activities, SARS-CoV-2 PLpro, despite sharing high amino acid sequence similarity with SARS-CoV, loses both interferon-antagonising and deubiquitinase activities. Among the 27 viral proteins, SARS-CoV-2 orf6 demonstrated the strongest suppression on both primary interferon production and interferon signalling. Orf6-deleted SARS-CoV-2 may be considered for the development of intranasal live-but-attenuated vaccine against COVID-19.
C1 [Yuen, Chun-Kit; Lam, Joy-Yan; Wong, Wan-Man; Mak, Long-Fung; Wang, Xiaohui; Chu, Hin; Cai, Jian-Piao; To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Kok, Kin-Hang] Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
   [Yuen, Chun-Kit; Lam, Joy-Yan; Wong, Wan-Man; Mak, Long-Fung; Wang, Xiaohui; Chu, Hin; Cai, Jian-Piao; To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Kok, Kin-Hang] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
   [Chu, Hin; Cai, Jian-Piao; To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Kok, Kin-Hang] Univ Hong Kong, Carol Yu Ctr Infect, Pokfulam, Hong Kong, Peoples R China.
   [Jin, Dong-Yan] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Pokfulam, Hong Kong, Peoples R China.
   [To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung] Univ Hong Kong, Shenzhen Hosp, Dept Clin & Infect Control, Shenzhen, Peoples R China.
   [To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung] Queen Mary Hosp, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
RP Yuen, KY; Kok, KH (corresponding author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY; Kok, KH (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY; Kok, KH (corresponding author), Univ Hong Kong, Carol Yu Ctr Infect, Pokfulam, Hong Kong, Peoples R China.; Yuen, KY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Clin & Infect Control, Shenzhen, Peoples R China.; Yuen, KY (corresponding author), Queen Mary Hosp, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China.
EM kyyuen@hku.hk; khkok@hku.hk
RI ; Jin, Dong-Yan/C-4287-2009
OI To, Kelvin/0000-0002-1921-5824; Reis, AlessanRSS/0000-0001-8486-7469;
   Jin, Dong-Yan/0000-0002-2778-3530; Wang, Xiaohui/0000-0003-1434-2055;
   Yuen, Chun-Kit/0000-0003-2646-2054
FU Health and Medical Research Fund, Hong Kong Special Administrative
   Region [HMRF 17160652]; Consultancy Service for Enhancing Laboratory
   Surveillance of Emerging Infectious Diseases and Research Capability on
   Antimicrobial Resistance for Department of Health of the Hong Kong
   Special Administrative Region Government; Theme-Based Research Scheme of
   the Research Grants Council, Hong Kong Special Administrative Region
   [T11/707/15]; Sanming Project of Medicine in Shenzhen, China
   [SZSM201911014]; High Level-Hospital Program, Health Commission of
   Guangdong Province, China
FX This study was partly supported by funding from the Health and Medical
   Research Fund (HMRF 17160652), Hong Kong Special Administrative Region;
   the Consultancy Service for Enhancing Laboratory Surveillance of
   Emerging Infectious Diseases and Research Capability on Antimicrobial
   Resistance for Department of Health of the Hong Kong Special
   Administrative Region Government; the Theme-Based Research Scheme
   (T11/707/15) of the Research Grants Council, Hong Kong Special
   Administrative Region; Sanming Project of Medicine in Shenzhen, China
   (No. SZSM201911014); and the High Level-Hospital Program, Health
   Commission of Guangdong Province, China; and the donations of Michael
   Seak-Kan Tong, the Shaw Foundation Hong Kong, Richard Yu and Carol Yu,
   May Tam Mak Mei Yin, Respiratory Viral Research Foundation Limited, Hui
   Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan Yin Chuen
   Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong Kong Hainan
   Commercial Association South China Microbiology Research Fund, the
   Jessie & George Ho Charitable Foundation, and Perfect Shape Medical
   Limited. The funding sources had no role in the study design, data
   collection, analysis, interpretation, or writing of the report.
CR Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   Chu H, 2020, CLIN INFECT DIS
   Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09
   Daffis S, 2010, NATURE, V468, P452, DOI 10.1038/nature09489
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Freundt EC, 2009, J VIROL, V83, P6631, DOI 10.1128/JVI.00367-09
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Huang IC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001258
   Hussain S, 2008, J VIROL, V82, P7212, DOI 10.1128/JVI.02406-07
   Hussain S, 2010, VIRUS RES, V153, P299, DOI 10.1016/j.virusres.2010.08.017
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Kok KH, 2011, CELL HOST MICROBE, V9, P299, DOI 10.1016/j.chom.2011.03.007
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Mielech AM, 2014, VIRUS RES, V194, P184, DOI 10.1016/j.virusres.2014.01.025
   Niemeyer D, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007296
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Qiu CF, 2020, J MED VIROL, V92, P2027, DOI 10.1002/jmv.25975
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Siu KL, 2009, J BIOL CHEM, V284, P16202, DOI 10.1074/jbc.M109.008227
   Sun L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030802
   Thornbrough JM, 2016, MBIO, V7, DOI 10.1128/mBio.00258-16
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
NR 39
TC 17
Z9 18
U1 6
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1418
EP 1428
DI 10.1080/22221751.2020.1780953
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MQ0JN
UT WOS:000552583400001
PM 32529952
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Koti, M
   Morales, A
   Graham, CH
   Siemens, DR
AF Koti, Madhuri
   Morales, Alvaro
   Graham, Charles H.
   Siemens, David Robert
TI BCG vaccine and COVID-19: implications for infection prophylaxis and
   cancer immunotherapy
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE interferon inducers; urinary bladder neoplasms; immunotherapy;
   B-lymphocytes; adjuvants; immunologic
ID B-CELLS; BLADDER
AB The COVID-19 pandemic has killed over 400 000 people globally. Ecological evidence indicates that countries with national universal BCG vaccination programs for tuberculosis (TB) prevention have a much lower incidence of severe COVID-19 and mortality compared with those that do not have such programs. BCG is a century old vaccine used for TB prevention via infant/childhood vaccination in lowto middle-income countries with high infection prevalence rate and is known to reduce all-cause neonatal mortality. BCG remains the standard immunotherapy treatment for patients with high-risk non-muscle invasive bladder cancer globally for more than 44 years. Several trials are, therefore, investigating BCG as a prophylactic against COVID-19 in healthcare workers and the elderly. In this commentary, we discuss the potential mechanisms that may underlie BCG associated heterologous protection with a focus on tertiary lymphoid structure (TLS) organogenesis. Given the significance of TLSs in mucosal immunity, their association with positive prognosis and response to immune checkpoint blockade with a critical role of Type I interferon (IFN-1) in inducing these, we also discuss potentiating TLS formation as a promising approach to enhance anti-tumor immunity. We propose that lessons learned from BCG immunotherapy success could be applied to not only augment such microbe-based therapeutics but also lead to similar adjunctive IFN-1 activating approaches to improve response to immune checkpoint blockade therapy in cancer.
C1 [Koti, Madhuri; Graham, Charles H.; Siemens, David Robert] Queens Univ, Biomed & Mol Sci, Kingston, ON, Canada.
   [Koti, Madhuri; Morales, Alvaro; Graham, Charles H.; Siemens, David Robert] Queens Univ, Dept Urol, Kingston, ON, Canada.
RP Koti, M (corresponding author), Queens Univ, Biomed & Mol Sci, Kingston, ON, Canada.; Koti, M (corresponding author), Queens Univ, Dept Urol, Kingston, ON, Canada.
EM kotim@queensu.ca
FU Queen's University Research Initiation Grant; Ontario Ministry of
   Research Innovation and Science, Early Researcher Award
FX This work was supported by Queen's University Research Initiation Grant
   and the Ontario Ministry of Research Innovation and Science, Early
   Researcher Award to MK.
CR Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hegarty PK, 2020, EUR UROL ONCOL
   Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8
   Jallad S, 2014, BJU INT, V113, pE22, DOI 10.1111/bju.12334
   Koti M, 2019, BLADDER CANCER, V5, P225, DOI 10.3233/BLC-190228
   Koti M, 2017, BLADDER CANCER, V3, P259, DOI 10.3233/BLC-170120
   MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6
   Nieuwenhuizen NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01147
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Phuah JY, 2012, AM J PATHOL, V181, P508, DOI 10.1016/j.ajpath.2012.05.009
   Silva-Sanchez A, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P21, DOI 10.1016/B978-0-12-811924-2.00002-X
   Sorup S, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofv204
   Sorup S, 2014, JAMA-J AM MED ASSOC, V311, P826, DOI 10.1001/jama.2014.470
   Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042
NR 15
TC 2
Z9 2
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PY 2020
VL 8
IS 2
AR e001119
DI 10.1136/jitc-2020-001119
PG 4
WC Oncology; Immunology
SC Oncology; Immunology
GA MQ1SC
UT WOS:000552677200005
PM 32636240
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, P
   Zhao, LW
   Ferrere, G
   Alves-Costa-Silva, C
   Ly, P
   Wu, Q
   Tian, AL
   Derosa, L
   Zitvogel, L
   Kepp, O
   Kroemer, G
AF Liu, Peng
   Zhao, Liwei
   Ferrere, Gladys
   Alves-Costa-Silva, Carolina
   Ly, Pierre
   Wu, Qi
   Tian, Ai-Ling
   Derosa, Lisa
   Zitvogel, Laurence
   Kepp, Oliver
   Kroemer, Guido
TI Combination treatments with hydroxychloroquine and azithromycin are
   compatible with the therapeutic induction of anticancer immune responses
SO ONCOIMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; immune checkpoint; hydroxychloroquine;
   immunotherapy; cancer
ID AUTOPHAGY; CHEMOTHERAPY; MICROBIOME
AB Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
C1 [Liu, Peng; Zhao, Liwei; Wu, Qi; Tian, Ai-Ling; Kepp, Oliver; Kroemer, Guido] Univ Paris, Sorbonne Univ, Equipe Labellisee Ligue Canc, INSERM,UMR1138,Ctr Rech Cordeliers, Paris, France.
   [Liu, Peng; Zhao, Liwei; Wu, Qi; Tian, Ai-Ling; Kepp, Oliver; Kroemer, Guido] Gustave Roussy Canc Campus, Metab & Cell Biol Platforms, Villejuif, France.
   [Ferrere, Gladys; Alves-Costa-Silva, Carolina; Ly, Pierre; Derosa, Lisa; Zitvogel, Laurence] Gustave Roussy Canc Campus, INSERM, U1015, Villejuif, France.
   [Ferrere, Gladys; Alves-Costa-Silva, Carolina; Ly, Pierre; Wu, Qi; Tian, Ai-Ling; Derosa, Lisa; Zitvogel, Laurence] Univ Paris Saclay, St Aubin, France.
   [Kroemer, Guido] Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Peoples R China.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
   [Kroemer, Guido] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
RP Kroemer, G (corresponding author), Univ Paris, Sorbonne Univ, Equipe Labellisee Ligue Canc, INSERM,UMR1138,Ctr Rech Cordeliers, Paris, France.; Kepp, O (corresponding author), Gustave Roussy Canc Campus, Metab & Cell Biol Platforms, Villejuif, France.
EM captain.olsen@gmail.com; kroemer@orange.fr
RI Kepp, Oliver/N-2763-2017; Kroemer, Guido/AAY-9859-2020; Liu,
   Peng/ABI-1773-2020
OI Kepp, Oliver/0000-0002-6081-9558; Liu, Peng/0000-0002-1682-9222
FU Ligue contre le Cancer (equipe labellisee); Agence National de la
   Recherche (ANR) - Projets blancsFrench National Research Agency (ANR);
   ANRFrench National Research Agency (ANR); AMMICa US23/CNRS UMS3655;
   Association pour la recherche sur le cancer (ARC)Fondation ARC pour la
   Recherche sur le Cancer; Association "Le Cancer du Sein, Parlons-en!";
   Canceropole Ile-de-FranceRegion Ile-de-France; Chancelerie des
   universites de Paris (Legs Poix), Fondation pour la Recherche Medicale
   (FRM); Gustave Roussy Odyssea; European Union Horizon 2020 Project
   Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in
   China, Institut National du Cancer (INCa)Institut National du Cancer
   (INCA) France [GDW20171100085]; Inserm (HTE); Institut Universitaire de
   France; LeDucq FoundationLeducq Foundation; LabEx Immuno-Oncology
   [ANR-18-IDEX-0001]; RHU Torino Lumiere; Seerave Foundation; SIRIC
   Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
   (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM);
   European Research Area Network on Cardiovascular Diseases (ERA-CVD,
   MINOTAUR)
FX GK is supported by the Ligue contre le Cancer (equipe labellisee);
   Agence National de la Recherche (ANR) - Projets blancs; ANR under the
   frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa
   US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC);
   Association "Le Cancer du Sein, Parlons-en!"; Canceropole Ile-de-France;
   Chancelerie des universites de Paris (Legs Poix), Fondation pour la
   Recherche Medicale (FRM); a donation by Elior; European Research Area
   Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy
   Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation
   Carrefour; High-end Foreign Expert Program in China (GDW20171100085),
   Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire
   de France; LeDucq Foundation; the LabEx Immuno-Oncology
   (ANR-18-IDEX-0001); the RHU Torino Lumiere; the Seerave Foundation; the
   SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
   (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine
   (CARPEM).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Carmona-Gutierrez D, 2020, MICROB CELL, V7, P119, DOI 10.15698/mic2020.05.715
   Cassidy LD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14187-x
   Chang CL, 2007, CANCER RES, V67, P10047, DOI 10.1158/0008-5472.CAN-07-0523
   Christine MA Chugh S Ramireddy A Chugh H Reinier K Ebinger J Park E Thompson M Cingolani ECheng S et al, 2020, J AM HEART ASSOC, pe017144, DOI [10.1161/JAHA.120.017144, DOI 10.1161/JAHA.120.017144]
   Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044
   Elkrief A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1568812
   Enot DP, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462431
   Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Jacquelot N, 2019, CELL RES, V29, P846, DOI 10.1038/s41422-019-0224-x
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI [10.1038/nrclinonc.2011.82, 10.1038/nrclinonc.2011.71]
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kepp O, 2009, CELL CYCLE, V8, P860, DOI 10.4161/cc.8.6.7939
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levesque S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1657375
   Liu P, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1596652
   Liu P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09415-3
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500
   Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rogado J, 2020, CLIN TRANSL ONCOL, V22, P2364, DOI 10.1007/s12094-020-02381-z
   Rosich L, 2012, CLIN CANCER RES, V18, P5278, DOI 10.1158/1078-0432.CCR-12-0351
   Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706
   Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Wang Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000462
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180
   Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918
   Zitvogel L, 2016, NAT REV CLIN ONCOL, V13, P431, DOI 10.1038/nrclinonc.2016.41
   Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845
NR 44
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2020
VL 9
IS 1
AR 1789284
DI 10.1080/2162402X.2020.1789284
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA MP0CF
UT WOS:000551881200001
PM 32923151
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jung, F
   Krieger, V
   Hufert, FT
   Kupper, JH
AF Jung, F.
   Krieger, V.
   Hufert, F. T.
   Kuepper, J. -H.
TI Herd immunity or suppression strategy to combat COVID-19
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE COVID-19; strategy; Sweden; Taiwan; Germany
AB Some months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Some states, such as the Netherlands, Germany, Great Britain, Sweden and the USA initially focused on keeping the restrictions for economy and society as low as possible. The responsible authorities were of the opinion - and still are e.g. in Sweden - that it is sufficient enough to protect particularly vulnerable persons such as the elderly or people with pre-existing conditions. The idea behind this is that as soon as 60 to 70 percent of the population is infected with a pathogen, a so-called "herd immunity" has developed. However, the increasing numbers of deaths and modelling studies showed the expected overload of the hospitals. Therefore, most countries decided for a temporary lockdown with the exception of Sweden.
   Based on the number of the total population, three times more people died from COVID-19 in Sweden (2679 deaths per 10 million inhabitants) compared to Germany (6848 deaths per 80 million inhabitants). The comparison Sweden versus Taiwan is even worse because 1072 times more people died in Sweden based on the number of the population (6 deaths per 24 million inhabitants).
   In the face of the lack of an antiviral treatment and the lack of a protective vaccine one must state Taiwan has made the best out of the pandemic situation whereas Sweden failed completely.
C1 [Jung, F.; Kuepper, J. -H.] Brandenburg Tech Univ Cottbus, Inst Biotechnol, Mol Cell Biol, Senftenberg, Germany.
   [Krieger, V.] TMM AG Boblingen, Dept Head Lab Planning & Norming Informat Managem, Boblingen, Germany.
   [Hufert, F. T.] Brandenburg Med Sch, Inst Microbiol & Virol, Senftenberg, Germany.
   [Hufert, F. T.; Kuepper, J. -H.] Brandenburg Med Sch Theodor Fontane & Univ Potsda, Joint Fac Brandenburg Univ Technol Cottbus Senfte, Fac Hlth Sci, Potsdam, Germany.
RP Jung, F (corresponding author), Brandenburg Tech Univ Cottbus, Inst Biotechnol, Mol Cell Biol, Senftenberg, Germany.
EM friedrich.jung@b-TU.de
CR Barco S, 2019, CLIN RES CARDIOL, V108, P772, DOI 10.1007/s00392-018-1405-1
   Bernard Stoecklin S, 2020, EURO SURVEILL, P25
   Borgel D, 2019, HEMATOLOGY, V24, P742, DOI 10.1080/16078454.2019.1687144
   Gardner JM, 2020, INTERVENTION STRATEG, DOI [10.1101/2020.04.11.20062133., DOI 10.1101/2020.04.11.20062133, 10.1101/2020.04.11.20062133]
   Johnson HC, 2020, EURO SURVEILL, P25
   Jung EM, 2020, CLIN HEMORHEOL MICRO, V74, P353, DOI 10.3233/CH-209003
   Jung F, 2020, CLIN HEMORHEOL MICRO, DOI [10.3233/CH-170277, DOI 10.3233/CH-170277]
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Spiezia L, 2020, THROMB HAEMOST
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
NR 11
TC 3
Z9 3
U1 7
U2 7
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2020
VL 75
IS 1
BP 13
EP 17
DI 10.3233/CH-209006
PG 5
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA MP7GT
UT WOS:000552370600001
PM 32538831
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bhole, RP
   Sarode, VI
   Bonde, CG
AF Bhole, R. P.
   Sarode, V., I
   Bonde, C. G.
TI Understanding and implementing alternative solutions to address the
   COVID-19 pandemic in the sense of public health emergencies
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Coronavirus; SARS; CoV-2; Pandemic; Vaccine
AB The Coronavirus disease (COVID-19) caused by the novel SARS-CoV-2 coronavirus has spread from China and quickly transmitted to most other countries around the world. The World Health Organization announced COVID-19 as a pandemic that is spreading steadily and soon in most states. Coronavirus genomic characterization showed that it most closely resembled another bat-origin beta-coronavirus. Coronavirus has the largest genome of viruses that have RNA. Spike (S) glycoprotein is present in the virus and is responsible for virus entry into the host cell. COVID-19 can spread through the droplet, direct contact, and aerosol transmission in humans. It can remain in the environment and exists on plastic and steel for the longest time, making it a dangerous and contagious disease that can kill other individuals. The virus has an incubation time of 2 to 14 days. Confirmed cases of COVID-19 have evolved exponentially in the world. Possible preventive steps for disease control include more mask use, hand sanitization, and social distancing. There is no antiviral therapy and only symptomatic care. Many inhibitors of HIV protease and other antimalarial drugs have tested. There is currently no vaccine available for COVID-19 prevention, though others are available in clinical trials. Scientists often use spike proteins for vaccine production. Research is needed to develop a new innovative vaccine and targeted medicine, which will meet people's demands.
C1 [Bhole, R. P.; Sarode, V., I] Dr DY Patil Inst Pharmaceut Sci & Res, Dept Pharmaceut Chem, Pune, Maharashtra, India.
   [Bonde, C. G.] SVKMs NMIMS, Sch Pharm & Technol Management, Dept Pharmaceut Chem, Shirpur Campus, Savalade, Maharashtra, India.
RP Bhole, RP (corresponding author), Dr DY Patil Inst Pharmaceut Sci & Res, Dept Pharmaceut Chem, Pune, Maharashtra, India.
EM ritesh.bhole@dypvp.edu.in
RI Bhole, Ritesh/AAX-4463-2020
OI Bonde, chandrakant/0000-0001-5712-1119
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Alex P., 2020, GENETIC ENG BIOTECHN
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], CORONAVIRUS DIS 2019
   [Anonymous], 2020, IND COVID 19 COR CIT
   [Anonymous], 2020, HINDU BUSINESS LINE
   Aria B, 2020, BUSINESS INSIDER IND
   Cascella M, 2020, FEATURES EVALUATION
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Goothy SS, 2020, INT J RES PHARM SCI, V11, P16
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hemida MG, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100127
   Jackson R., 2020, CNET
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Organization WH, 2020, ADV US MASKS COMM HO
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Sanal MG, 2020, ORAL LIVE ATTENUATED, DOI [10.20944/preprints202004.0153.v1., DOI 10.20944/PREPRINTS202004.0153.V1]
   Sharq IK, 2020, ELECT J GEN MED, V17, P1
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tabish SA, 2020, INT J SCI RES, V9, P175
   Valencia DN, 2020, CUREUS, V12, DOI 10.7759/cureus.7386
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, P1
   W. H. Organization, COR DIS 2019 COVID 1, P72
   WHO, 2020, BAC CALM GUER BCG VA
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   World Health Organization, 2020, RAT US PERS PROT EQ
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie JF, 2020, INTENS CARE MED, V46, P837, DOI 10.1007/s00134-020-05979-7
   Xu SQ, 2020, LANCET, V395, P1321, DOI 10.1016/S0140-6736(20)30845-X
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
NR 43
TC 0
Z9 0
U1 4
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 13
BP 7485
EP 7493
DI 10.26355/eurrev_202007_21920
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MN9OX
UT WOS:000551170100032
PM 32706088
DA 2021-01-01
ER

PT J
AU Gonzalez-Pacheco, H
   Amezcua-Guerra, LM
   Sandoval, J
   Arias-Mendoza, A
AF Gonzalez-Pacheco, H.
   Amezcua-Guerra, L. M.
   Sandoval, J.
   Arias-Mendoza, A.
TI Potential usefulness of pentoxifylline, a non-specific phosphodiesterase
   inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and
   anti-fibrogenic properties, in the treatment of SARS-CoV-2
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Pentoxifylline; COVID-19; SARS-CoV-2; Cytokine storm
ID NECROSIS-FACTOR-ALPHA; IN-VIVO; EXPRESSION; COVID-19; RELEASE; DISEASE;
   BLOOD
AB Although most patients with coronavirus disease 2019 (COVID-19) have a good prognosis, in some cases, the disease progresses rapidly, and the mortality rate is high. Some evidence suggests that infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces a `cytokine storm', which is related to acute respiratory distress syndrome or multi-organ dysfunction leading to physiological deterioration and death. It is important to highlight the state of hypercoagulability that can be triggered, involving microvascular thrombosis and vascular occlusive events, which are relevant to such poor outcomes. At present, no specific antiviral drug or vaccine is available for SARS-CoV-2 infection, and current research is aimed at preventing and mitigating damage to the target organs, mainly the lungs. In seeking therapies for patients with COVID-19, immunomodulators, cytokine antagonists and early anti-coagulation therapies have been tested in attempts to reduce the mortality rate. Pentoxifylline, a non-specific phosphodiesterase inhibitor widely used to improve the rheological properties of blood, has beneficial anti-inflammatory properties and can significantly reduce the serum levels of pro-inflammatory cytokines such as interleukin (IL)-6, IL-1, tumour necrosis factor-alpha, C-reactive protein and other immunoregulators. It has also been found to exert anti-thrombotic, antioxidant and anti-fibrogenic actions. These properties could help to prevent or mitigate the inflammatory response and hypercoagulability that develop with SARS-CoV-2 infection, decreasing multi-organ dysfunction manifesting primarily as acute lung injury.
C1 [Gonzalez-Pacheco, H.; Arias-Mendoza, A.] Natl Inst Cardiol Mexico City, Coronary Care Unit, Mexico City, DF, Mexico.
   [Amezcua-Guerra, L. M.; Sandoval, J.] Natl Inst Cardiol Mexico City, Dept Immunol, Mexico City, DF, Mexico.
RP Gonzalez-Pacheco, H (corresponding author), Natl Inst Cardiol Mexico City, Coronary Care Unit, Mexico City, DF, Mexico.
EM hectorglezp@hotmail.com
OI Arias-Mendoza, Alexandra/0000-0002-5942-4102
CR Adel M, 2010, J CLIN PHARM THER, V35, P257, DOI 10.1111/j.1365-2710.2009.01077.x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   CROUCH SPM, 1992, INFECT IMMUN, V60, P4504, DOI 10.1128/IAI.60.11.4504-4509.1992
   Fernandes JL, 2008, ATHEROSCLEROSIS, V196, P434, DOI 10.1016/j.atherosclerosis.2006.11.032
   Georgiev T, 2020, RHEUMATOL INT, V40, P825, DOI 10.1007/s00296-020-04570-z
   Giridhar Prashanth, 2015, Asian Pac J Cancer Prev, V16, P2613
   Gonzalez-Espinoza L, 2012, NEPHROL DIAL TRANSPL, V27, P2023, DOI 10.1093/ndt/gfr579
   Hanania AN, 2019, CHEST, V156, P150, DOI 10.1016/j.chest.2019.03.033
   HEINKELEIN M, 1995, J ACQ IMMUN DEF SYND, V10, P417, DOI 10.1097/00042560-199512000-00004
   Krakauer T, 2000, IMMUNOPHARMACOLOGY, V46, P253, DOI 10.1016/S0162-3109(99)00186-1
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Mandi Yvette, 1995, Acta Microbiologica et Immunologica Hungarica, V42, P301
   Neuner P, 1997, IMMUNOLOGY, V90, P435, DOI 10.1111/j.1365-2567.1997.00435.x
   NEUNER P, 1994, IMMUNOLOGY, V83, P262
   OTT E, 1983, EUR NEUROL, V22, P105, DOI 10.1159/000115658
   REED WR, 1992, J LAB CLIN MED, V119, P763
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Salhiyyah K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005262.pub3
   Shaw SM, 2009, EUR J HEART FAIL, V11, P113, DOI 10.1093/eurjhf/hfn040
   Windmeier C, 1997, GEN PHARMACOL-VASC S, V29, P181, DOI 10.1016/S0306-3623(96)00314-X
   Ye Q., 2020, J INFECT
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 24
TC 2
Z9 2
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 13
BP 7494
EP 7496
DI 10.26355/eurrev_202007_21921
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MN9OX
UT WOS:000551170100033
PM 32706089
DA 2021-01-01
ER

PT J
AU Papa, A
   Covino, M
   Pizzolante, F
   Miele, L
   Lopetuso, LR
   Bove, V
   Iorio, R
   Simeoni, B
   Vetrone, LM
   Tricoli, L
   Mignini, I
   Schepis, T
   D'Alessandro, A
   Coppola, G
   Nicoletti, T
   Visconti, E
   Rapaccini, G
AF Papa, A.
   Covino, M.
   Pizzolante, F.
   Miele, L.
   Lopetuso, L. R.
   Bove, V
   Iorio, R.
   Simeoni, B.
   Vetrone, L. M.
   Tricoli, L.
   Mignini, I
   Schepis, T.
   D'Alessandro, A.
   Coppola, G.
   Nicoletti, T.
   Visconti, E.
   Rapaccini, G.
TI Gastrointestinal symptoms and digestive comorbidities in an Italian
   cohort of patients with COVID-19
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE SARS-Cov-2; COVID-19; Gastrointestinal symptoms; Diarrhoea; Digestive
   comorbidities
AB OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic mainly involves respiratory symptoms, though gastrointestinal (GI) symptoms are increasingly being recognized. In this context, the presence of comorbidities appears to be associated with adverse outcomes. However, the role of digestive manifestations is not yet well defined. The primary aim of this study was to assess the prevalence of GI symptoms and digestive comorbidities in a cohort of patients with COVID-19 compared to controls. The secondary aim was to determine the association of GI-symptoms and digestive comorbidities with clinical outcomes.
   PATIENTS AND METHODS: Inpatients with COVID-19 and controls with similar symptoms and/or radiological findings were enrolled. Symptoms at admission and throughout hospitalization were collected as they were comorbidities. The measured clinical outcomes were mortality, intensive care unit admission and cumulative endpoint.
   RESULTS: A total of 105 patients were included: 34 with COVID-19 and 71 controls. At admission, the prevalence of GI symptoms among COVID-19 patients was 8.8%. During hospitalization, the frequency of GI symptoms was higher in patients with COVID-19 than in controls (p=0.004). Among patients with COVID-19, the mortality and a cumulative endpoint rates of those with GI symptoms were both lower than for those without GI symptoms (p= 0.016 and p= 0.000, respectively). Finally, we found diges-tive comorbidities to be associated with a milder course of COVID-19 (p= 0.039 for cumulative endpoint).
   CONCLUSIONS: Our results highlighted the non-negligible frequency of GI symptoms in patients with COVID-19, partly attributable to the therapies implemented. In addition, the presence of GI symptoms and digestive comorbidities is associated with better outcomes. Most likely, digestive comorbidities do not hinder the host's immune response against SARS-COV-2, and the occurrence of GI symptoms might be linked to a faster reduction of the viral load via the faecal route.
C1 [Papa, A.; Pizzolante, F.; Miele, L.; Lopetuso, L. R.; Bove, V; Vetrone, L. M.; Mignini, I; Schepis, T.; D'Alessandro, A.; Coppola, G.; Rapaccini, G.] Fdn Policlin Univ A Gemelli, Gastroenterol Dept, IRCCS, Rome, Italy.
   [Papa, A.; Miele, L.; Vetrone, L. M.; Tricoli, L.; Mignini, I; Schepis, T.; D'Alessandro, A.; Coppola, G.; Nicoletti, T.; Visconti, E.; Rapaccini, G.] Univ Cattolica S Cuore, Rome, Italy.
   [Covino, M.; Simeoni, B.] Fdn Policlin Univ A Gemelli, Emergency Dept, IRCCS, Rome, Italy.
   [Lopetuso, L. R.] G dAnnunzio Univ Chieti Pescara, Dept Med & Ageing Sci, Chieti, Italy.
   [Lopetuso, L. R.] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, Chieti, Italy.
   [Iorio, R.; Tricoli, L.; Nicoletti, T.] Fdn Policlin Univ A Gemelli, Neurol Dept, IRCCS, Rome, Italy.
   [Visconti, E.] Fdn Policlin Univ A Gemelli, Infect Dis Dept, IRCCS, Rome, Italy.
RP Papa, A (corresponding author), Fdn Policlin Univ A Gemelli, Gastroenterol Dept, IRCCS, Rome, Italy.; Papa, A (corresponding author), Univ Cattolica S Cuore, Rome, Italy.
EM alfredo.papa@unicatt.it
RI Covino, Marcello/AAR-3596-2020; Covino, Marcello/T-5377-2019; Miele,
   Luca/C-2255-2015
OI Covino, Marcello/0000-0002-6709-2531; Miele, Luca/0000-0003-3464-0068;
   PAPA, Alfredo/0000-0002-4186-7298; Nicoletti,
   Tommaso/0000-0002-9335-1218
CR Aroniadis OC, 2020, CLIN GASTROENTEROL H, V18, P1682, DOI 10.1016/j.cgh.2020.04.039
   Cholankeril G, 2020, GASTROENTEROLOGY, V159, P775, DOI 10.1053/j.gastro.2020.04.008
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guan WJ, 2020, NEW ENGL J MED, DOI [10.1056/NEJ-Moa2002032, DOI 10.1056/NEJ-MOA2002032]
   JIN X, 2020, GUT, DOI [10.1136/gutjnl-2020-320926, DOI 10.1136/GUTJNI-2020-320926]
   NOBEL YR, 2020, GASTROENTEROLOGY, DOI [10.1053/j.gastro.2020.04.017, DOI 10.1053/J.GAS-TRO.2020.04.017]
   Redd WD, 2020, GASTROENTEROLOGY, V159, P765, DOI 10.1053/j.gastro.2020.04.045
   RICHARDSON S.HIRSCHJS, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.6775, DOI 10.1001/JA-MA.2020.6775]
   SINHA N, 2020, POSTGRAD MED J, DOI [10.1136/postgrad- med j-2020 -137785., DOI 10.1136/POSTGRAD-MEDJ-2020-137785]
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wei XS, 2020, CLIN GASTROENTEROL H, V18, P1753, DOI 10.1016/j.cgh.2020.04.030
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   ZHANG X, 2020, CLIN GASTROENTEROL H, DOI [10.10164.cgh.2020.03.043., DOI 10.10164/J.CGH.2020.03.043]
NR 16
TC 3
Z9 3
U1 0
U2 0
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 13
BP 7506
EP 7511
DI 10.26355/eurrev_202007_21923
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MN9OX
UT WOS:000551170100035
PM 32706091
DA 2021-01-01
ER

PT J
AU Tashkandi, E
   BaAbdullah, M
   Zeeneldin, A
   AlAbdulwahab, A
   Elemam, O
   Elsamany, S
   Alfayez, M
   Dabash, Y
   Khayat, E
   Hassanin, F
   Abdulhameed, R
   Jazieh, AR
AF Tashkandi, Emad
   BaAbdullah, M.
   Zeeneldin, Ahmed
   AlAbdulwahab, A.
   Elemam, Omima
   Elsamany, S.
   Alfayez, M.
   Dabash, Y.
   Khayat, E.
   Hassanin, Fayza
   Abdulhameed, Rasha
   Jazieh, Abdul Rahman
TI Optimizing the Communication with Cancer Patients During the COVID-19
   Pandemic: Patient Perspectives
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE patient preference; e-health; patient online access; health disparities;
   cancer; COVID-19
AB Background: During curfew, patients are self-isolated at home and worried. Patient-doctor interactions may be disrupted and therefore need to be replaced by alternative effective communication methods.
   Purpose: To describe the preferences of cancer patients with respect to communication methods and the use of patient-accessible electronic health records (PAEHRs). To record the impact on cancer patients during the COVID-19 pandemic and the knowledge and attitude of the patients towards it.
   Patients and Methods: We created a self-administered electronic survey that was piloted and evaluated for its clinical relevance. Using convenient sampling methods, we surveyed the cancer patients in our Oncology Center.
   Results: We received 385 responses between April 15 and April 30, 2020. The preferred method for communication was a phone call with a 92% response rate followed by the electronic patient portal, mobile application, telemedicine and text message in 75%, 76%, 73%, and 72%, respectively. The majority (97%) preferred the use of PAEHRs for appointments, 95% for drug delivery and to view laboratory tests, and 92% in requesting medical reports. In our survey, 22% of patients with cancer reported that their medical cancer care had not been affected by COVID-19. They reported that trusted sources of information during COVID-19 included the Ministry of Health with 98% and doctors with 94%. Sixty-one percent know that they are more susceptible to COVID-19 infection and 91% of respondents supported the notion of digital transformation in the caring of cancer patients.
   Conclusion: Our study revealed a general acceptance of patients to telecommunication as substitute to in-person interaction with their physicians. Interaction between cancer patients and health care providers should not be disrupted but should be augmented with more effective platforms to improve health care outcomes.
C1 [Tashkandi, Emad; Zeeneldin, Ahmed; AlAbdulwahab, A.; Elemam, Omima; Elsamany, S.; Alfayez, M.] King Abdullah Med City, Oncol Ctr, Mecca, Saudi Arabia.
   [Tashkandi, Emad; Alfayez, M.] Umm AlQura Univ, Coll Med, Mecca, Saudi Arabia.
   [BaAbdullah, M.] King Abdullah Med City, Informat Technol, Mecca, Saudi Arabia.
   [Zeeneldin, Ahmed] Cairo Univ, Dept Oncol, Natl Canc Inst, Cairo, Egypt.
   [Elemam, Omima; Elsamany, S.] Mansoura Univ, Oncol Ctr, Mansoura, Egypt.
   [Dabash, Y.] King Abdullah Med City, Patients Affairs, Mecca, Saudi Arabia.
   [Khayat, E.] King Abdullah Med City, Patients Experience, Mecca, Saudi Arabia.
   [Hassanin, Fayza; Abdulhameed, Rasha] King Abdullah Med City, Nursing Adm, Mecca, Saudi Arabia.
   [Jazieh, Abdul Rahman] King Saud Bin Abdulaziz Univ Hlth Sci, Dept Oncol, King Abdulaziz Med City, Riyadh, Saudi Arabia.
RP Tashkandi, E (corresponding author), Umm AlQura Univ, Coll Med, Oncol Ctr, King Abdullah Med City, Mecca, Saudi Arabia.
EM Tashkandi.e@kamc.med.sa
OI Tashkandi, Emad/0000-0002-0260-8947; KHAYAT, Emad/0000-0002-2480-7736
FU TrakCare, Electronic Medical Record System, InterSystems
FX We thank all patients who participated in this survey. Also, we would
   like to thank Lawrence, Myer who provided language editing and
   proofreading. The publication fee for this article was supported by
   TrakCare, Electronic Medical Record System, InterSystems.
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   Mendez LA, 2017, STUD FUZZ SOFT COMP, V349, P339, DOI 10.1007/978-3-319-48317-7_21
   Barsom EZ, 2020, SURG ENDOSC, DOI 10.1007/s00464-020-07499-3
   Chan B, 2018, J GEN INTERN MED, V33, P2085, DOI 10.1007/s11606-018-4637-x
   Collins D, 2003, QUAL LIFE RES, V12, P229, DOI 10.1023/A:1023254226592
   Hendren S, 2011, J NATL MED ASSOC, V103, P701, DOI 10.1016/S0027-9684(15)30409-0
   Jorgensen Lone, 2019, Cancer Nurs, DOI 10.1097/NCC.0000000000000778
   Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087
   Linde DS, 2020, J MED INTERNET RES, V22, DOI 10.2196/15863
   McKay FH, 2018, J TELEMED TELECARE, V24, P22, DOI 10.1177/1357633X16673538
   McLean S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071238
   Passmore C, 2002, FAM MED, V34, P281
   Potdar R, 2020, SUPPORT CARE CANCER, V28, P5455, DOI 10.1007/s00520-020-05393-1
   Ralston JD, 2009, J GEN INTERN MED, V24, P349, DOI 10.1007/s11606-008-0899-z
   Seyhan AA, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1864-9
   Shankar Abhishek, 2020, Asian Pac J Cancer Prev, V21, P569, DOI 10.31557/APJCP.2020.21.3.569
   Stubbins R, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.18.00054
   WOODWARD CA, 1988, MED EDUC, V22, P345, DOI 10.1111/j.1365-2923.1988.tb00764.x
   Zanaboni P, 2020, J MED INTERNET RES, V22, DOI 10.2196/16144
NR 19
TC 0
Z9 0
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2020
VL 14
BP 1205
EP 1212
DI 10.2147/PPA.S263022
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MN2PW
UT WOS:000550689000001
PM 32764893
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tousi, B
AF Tousi, Babak
TI Dementia Care in the Time of COVID-19 Pandemic
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Article
DE Access; Alzheimer's disease; caregivers; clinical trial; coronavirus;
   COVID-19; dementia; health care; pandemic; telehealth; telemedicine
ID MECHANICAL VENTILATION; AGE
AB Patients with dementia are particularly vulnerable during the COVID-19 pandemic. The initial response to COVID-19 promoted behavioral changes in both society and healthcare, while a long-term solution is sought by prioritizing societal values. In addition, there has been disruption to clinical care and clinical research. This pandemic might have significantly changed the care for our patients with dementia toward increased acceptance of telemedicine by the patients and providers, and its utilization in both clinical care and research.
C1 [Tousi, Babak] Cleveland Clin, Clin Trials Program, Lou Ruvo Ctr Brain Hlth, Neurol Inst, Cleveland, OH 44106 USA.
   [Tousi, Babak] Case Western Reserve Univ, Med & Neurol, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Tousi, Babak] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 9500 Euclid Ave,U-10, Cleveland, OH 44195 USA.
RP Tousi, B (corresponding author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 9500 Euclid Ave,U-10, Cleveland, OH 44195 USA.
EM Batous@ccf.org
CR Alzheimer's Association, 2020, COR COVID 19 TIPS DE
   Anderson M, 2017, IEEE SPECTRUM, V54, P17, DOI 10.1109/MSPEC.2017.8048829
   Arbour N, 2000, J VIROL, V74, P8913, DOI 10.1128/JVI.74.19.8913-8921.2000
   Campbell IH, 2011, IEEE ENG MED BIO, P6793, DOI 10.1109/IEMBS.2011.6091675
   Centers for Medicare & Medicaid, 2020, MED TEL HLTH CAR FAC
   CHEYETTE SR, 1995, J NEUROPSYCH CLIN N, V7, P125
   Cipriani G, 2020, AM J GERIAT PSYCHIAT, V28, P796, DOI 10.1016/j.jagp.2020.04.009
   Cleveland Clinic, 2019, FUT TEL WHATS WAY
   COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Docherty A.B., 2020, FEATURES 16749 HOSP, DOI [10.1101/2020.04.23.20076042thisversion, DOI 10.1101/2020.04.23.20076042]
   Feng Y, 2009, CHEST, V136, P759, DOI 10.1378/chest.09-0515
   Garrett KB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58191-4
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Mao L., 2020, NEUROLOGICAL MANIFES, DOI [10.1101/2020.02.22.20026500., 10.1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]
   Morgan DG, 2011, J APPL GERONTOL, V30, P304, DOI 10.1177/0733464810366564
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pennsylvania Department of Health The Hospital & Healthsystem Association of Pennsylvania, 2020, INT PENNS CRIS STAND
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   The Centers for Medicare and Medicaid Services (CMS), 2020, COVID 19 EM DECL BLA, P1
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   United States Department of Labor, 2020, PAND UN ASS PUA IMPL
   University of Pittsburgh, 2020, ALL SCARC CRIT CAR R
   White D., 2020, ALLOCATION SCARCE CR
   White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 28
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2020
VL 76
IS 2
BP 475
EP 479
DI 10.3233/JAD-200461
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA MN8PO
UT WOS:000551104100006
PM 32651326
OA Bronze
DA 2021-01-01
ER

PT J
AU Weng, CH
   Saal, A
   Butt, WWW
   Bica, N
   Fisher, JQ
   Tao, J
   Chan, PA
AF Weng, C-H.
   Saal, A.
   Butt, W. W-W.
   Bica, N.
   Fisher, J. Q.
   Tao, J.
   Chan, P. A.
TI Bacillus Calmette-Guerin vaccination and clinical characteristics and
   outcomes of COVID-19 in Rhode Island, United States: a cohort study
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Adult; BCG vaccine; COVID-19
AB Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, and there is limited data on effective therapies. Bacillus Calmette-Guerin (BCG) vaccine, a live-attenuated strain derived from an isolate ofMycobacterium bovisand originally designed to prevent tuberculosis, has shown some efficacy against infection with unrelated pathogens. In this study, we reviewed 120 consecutive adult patients (>= 18 years old) with COVID-19 at a major federally qualified health centre in Rhode Island, United States from 19 March to 29 April 2020. Median age was 39.5 years (interquartile range, 27.0-50.0), 30% were male and 87.5% were Latino/Hispanics. Eighty-two (68.3%) patients had BCG vaccination. Individuals with BCG vaccination were less likely to require hospital admission during the disease course (3.7%vs.15.8%,P= 0.019). This association remained unchanged after adjusting for demographics and comorbidities (P= 0.017) using multivariate regression analysis. The finding from our study suggests the potential of BCG in preventing more severe COVID-19.
C1 [Weng, C-H.] Brown Univ, Warren Alpert Med Sch, Dept Family Med, Providence, RI 02903 USA.
   [Weng, C-H.; Saal, A.; Butt, W. W-W.; Bica, N.; Fisher, J. Q.] Providence Community Hlth Ctr, Providence, RI 02905 USA.
   [Tao, J.; Chan, P. A.] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02906 USA.
RP Weng, CH (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Family Med, Providence, RI 02903 USA.; Weng, CH (corresponding author), Providence Community Hlth Ctr, Providence, RI 02905 USA.
EM chien-hsiang_weng@brown.edu
RI Weng, Chien-Hsiang/ABG-7022-2020
OI Weng, Chien-Hsiang/0000-0002-0794-1263
CR Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086
   Berg MK, 2020, MANDATED BACILLUS CA
   Chow EJ, 2020, JAMA
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamiel U, 2020, JAMA
   Miller A, 2020, CORRELATION UNIVERSA, DOI 10.1101/2020.03.24.20042937
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Totsch SK, 2017, MOL PAIN, V13, DOI 10.1177/1744806917724559
NR 10
TC 5
Z9 5
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e140
DI 10.1017/S0950268820001569
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MJ7BC
UT WOS:000548241000001
PM 32641191
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xiang, Z
   Liu, JL
   Shi, DK
   Chen, W
   Li, J
   Yan, RL
   Bi, YF
   Hu, WG
   Zhu, ZG
   Yu, YY
   Yang, ZT
AF Xiang, Zhen
   Liu, Jialin
   Shi, Dake
   Chen, Wei
   Li, Jun
   Yan, Ranlin
   Bi, Yufang
   Hu, Weiguo
   Zhu, Zhenggang
   Yu, Yingyan
   Yang, Zhitao
TI Glucocorticoids improve severe or critical COVID-19 by activating ACE2
   and reducing IL-6 levels
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; ACE2; Glucocorticoids; Drug repurposing
ID RESPIRATORY SYNDROME CORONAVIRUS; CONNECTIVITY MAP; SMALL MOLECULES;
   EXPRESSION
AB COVID-19 is a public health emergency that has rapidly spread to over 200 countries and regions, and no effective treatment has been established to date. Severe and critical cases have been associated with higher mortality due to acute respiratory distress syndrome (ARDS) and cytokine storm. Based on the novelty and recent emergence of COVID-19, no effective treatment regimen has been identified, thus prompting clinicians to engage in drug repurposing to address the immediate therapeutic need. This study focused on the molecular target angiotensin-converting enzyme 2 (ACE2) of SARS-CoV-2 and screened a group of ACE2 agonists by bioinformatics. Glucocorticoids are a type of ACE2 activator. We verified the efficacy of nine chemicals on regulating ACE2 expression in human GES-1, an upper digestive tract epithelial cell line, and THP-1, a human monocyte cell line, and found that several glucocorticoids imparted activating effects on ACE2 in both cell lines. The drugs triciribine and kinetin riboside activate ACE2 expression or inhibit IL-6 production in macrophages to some extent. In addition, we compared the efficacies of several glucocorticoids. Hydrocortisone showed the strongest effect on ACE2 activation, followed by prednisolone, dexamethasone, and methylprednisolone. We retrospectively analyzed the therapeutic efficacy of nine severe or critical patients from a cohort of 90 COVID-19 cases, who received medium to small doses of glucocorticoids from our integrated medical team in Wuhan. Seven out of nine patients revealed significant improvement in clinical parameters and chest CT images. This study provides experimental and clinical evidence that medium-to-low-dose glucocorticoids may play a protective role in the respiratory and digestive systems by activating ACE2 and suppressing cytokine storm.
C1 [Xiang, Zhen; Li, Jun; Yan, Ranlin; Hu, Weiguo; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Shanghai Inst Digest Surg, Ruijin Hosp, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China.
   [Xiang, Zhen; Li, Jun; Yan, Ranlin; Hu, Weiguo; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai 200025, Peoples R China.
   [Liu, Jialin] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Crit Care Med, Sch Med, Shanghai 200025, Peoples R China.
   [Shi, Dake] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Infect Control, Sch Med, Shanghai 200025, Peoples R China.
   [Chen, Wei] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pulm & Crit Care Med, Sch Med, Shanghai 200025, Peoples R China.
   [Bi, Yufang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Endocrinol & Metab Dis, Sch Med, Shanghai 200025, Peoples R China.
   [Yang, Zhitao] Shanghai Jiao Tong Univ, Ruijin Hosp, Emergency Dept, Sch Med, Shanghai 200025, Peoples R China.
RP Zhu, ZG; Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Inst Digest Surg, Ruijin Hosp, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China.; Zhu, ZG; Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai 200025, Peoples R China.; Yang, ZT (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Emergency Dept, Sch Med, Shanghai 200025, Peoples R China.
EM zzg1954@hotmail.com; yingyan3y@sjtu.edu.cn; yangzhitao@hotmail.fr
FU Shanghai Science and Technology CommitteeShanghai Science & Technology
   Committee [18411953100]; Cross-institute Innovation Foundation of
   Shanghai Jiao Tong University [YG2017ZD01]; Innovation Foundation of
   Translational Medicine of Shanghai Jiao Tong University School of
   Medicine [15ZH4001, TM201617, TM201702]; Innovation Foundation for
   Doctor's Degree [BXJ201914]
FX This project was partially supported by the Shanghai Science and
   Technology Committee (18411953100), the Cross-institute Innovation
   Foundation of Shanghai Jiao Tong University (YG2017ZD01), the Innovation
   Foundation of Translational Medicine of Shanghai Jiao Tong University
   School of Medicine (15ZH4001, TM201617 and TM201702), and the Innovation
   Foundation for Doctor's Degree (BXJ201914). We acknowledge the open
   database of CCLE and CMap. We also thank the staff of Ruijin Hospital
   COVID-19 Critical Care Medical Team. We thank LetPub (www.letpub.com)
   for its linguistic assistance during the preparation of this manuscript.
CR Adcock IM, 2017, HANDB EXP PHARMACOL, V237, P171, DOI 10.1007/164_2016_98
   [Anonymous], 2020, Chin Med J (Engl), DOI 10.1097/CM9.0000000000000819
   Arakelyan A, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120677
   Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Czock D, 2005, CLIN PHARMACOKINET, V44, P61, DOI 10.2165/00003088-200544010-00003
   Delavan B, 2018, DRUG DISCOV TODAY, V23, P382, DOI 10.1016/j.drudis.2017.10.009
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Fang Y, 2019, QJM-INT J MED, V112, P914, DOI 10.1093/qjmed/hcz206
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Kapugi M, 2019, ORTHOP NURS, V38, P336, DOI 10.1097/NOR.0000000000000595
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Langedijk J, 2015, DRUG DISCOV TODAY, V20, P1027, DOI 10.1016/j.drudis.2015.05.001
   Liu W, 2018, EXP THER MED, V16, P493, DOI 10.3892/etm.2018.6275
   Manzotti G, 2015, CELL CYCLE, V14, P2578, DOI 10.1080/15384101.2015.1033591
   Ngaosuwan K, 2018, SHOCK, V50, P280, DOI 10.1097/SHK.0000000000001061
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Smalley JL, 2016, J MOL MED, V94, P235, DOI 10.1007/s00109-015-1344-5
   Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Wang C, 2020, AVEOLAR MACROPHAGE A, DOI [10.21203/rs.3.rs-19346/v1., DOI 10.21203/RS.3.RS-19346/V1, 10.21203/rs.3.rs-19346/v1]
   Zheng J, 2014, NEUROSCIENCE, V273, P39, DOI 10.1016/j.neuroscience.2014.04.060
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 2
Z9 2
U1 4
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 13
BP 2382
EP 2391
DI 10.7150/ijbs.47652
PG 10
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA MJ7CO
UT WOS:000548244800012
PM 32760206
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Masoudi-Sobhanzadeh, Y
AF Masoudi-Sobhanzadeh, Yosef
TI Computational-based drug repurposing methods in COVID-19
SO BIOIMPACTS
LA English
DT Letter
DE COVID-19; Drug repurposing; In silico drug discovery
AB COVID-19, as a newly emerging disease, has disrupted human's different activities. Hence, it is essential to develop drugs or vaccines in order to control COVID-19. Since there is not a medication or vaccine for treating the disease and drug development project is a time and cost consuming process, drug repurposing approaches may yield to proper curing plans. However, there are some limitations in this field, which make the process a challenging one. This letter aims to introduce drug repurposing methods and the existing challenges to detect candidate drugs which may be helpful in controlling COVID-19.
C1 [Masoudi-Sobhanzadeh, Yosef] Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
RP Masoudi-Sobhanzadeh, Y (corresponding author), Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
EM masoudi.sobhanzad@ut.ac.ir
OI masoudi-sobhanzadeh, yosef/0000-0002-2472-0980
CR Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Masoudi-Sobhanzadeh Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45814-8
   Masoudi-Sobhanzadeh Y, 2020, GENOMICS, V112, P1087, DOI 10.1016/j.ygeno.2019.06.021
   Masoudi-Sobhanzadeh Y, 2019, COMPUT BIOL MED, V109, P254, DOI 10.1016/j.compbiomed.2019.05.006
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 5
TC 2
Z9 2
U1 2
U2 2
PU TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICES
PI TABRIZ
PA DANESHGHAH ST, TABRIZ, REPUBLIC ISLAMIC 51664-14766, IRAN
SN 2228-5652
EI 2228-5660
J9 BIOIMPACTS
JI BioImpacts
PY 2020
VL 10
IS 3
BP 205
EP 206
DI 10.34172/bi.2020.25
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ML5FB
UT WOS:000549490600010
PM 32793443
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Isik, AT
AF Isik, Ahmet Turan
TI Covid-19 Infection in Older Adults: A Geriatrician's Perspective
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE Covid-19 infection; pandemic; older adults; atypical presentation
ID TERM-CARE FACILITIES; FEVER; TEMPERATURE; SEPSIS; AGE
AB The pandemic of the Covid-19 virus has become the main issue all over the world. In its current form, the disease is more severe in geriatric cases and individuals with chronic disease, even causing death. In older adults and atypical presentations, testing strategies for Covid-19, potential drug interactions of experimental Covid-19 therapies, and ageism are important issues in the course of the disease. Therefore, health-care professionals should be aware of these, and screening policies for Covid-19 should also include atypical presentations with or without classical symptoms of the illness in older adults. Furthermore, evaluation of individuals > 65 years of age from a geriatrician's perspective is very important, because Covid-19 is severe and fatal in seniors.
C1 [Isik, Ahmet Turan] Dokuz Eylul Univ, Fac Med, Dept Geriatr Med, TR-35340 Izmir, Turkey.
RP Isik, AT (corresponding author), Dokuz Eylul Univ, Fac Med, Dept Geriatr Med, TR-35340 Izmir, Turkey.
EM atisik@yahoo.com
OI ISIK, Ahmet Turan/0000-0001-5867-6503
CR [Anonymous], 2020, COVID 19 DRUG INTERA
   Caterino JM, 2019, J AM GERIATR SOC, V67, P484, DOI 10.1111/jgs.15679
   D'Adamo H, 2020, J AM GERIATR SOC, V68, P912, DOI 10.1111/jgs.16445
   Dosa D, 2020, J AM MED DIR ASSOC, V21, P569, DOI 10.1016/j.jamda.2020.03.004
   Girard TD, 2005, CLIN INFECT DIS, V40, P719, DOI 10.1086/427876
   High KP, 2009, CLIN INFECT DIS, V48, P149, DOI 10.1086/595683
   Liang SY, 2016, EMERG MED CLIN N AM, V34, P501, DOI 10.1016/j.emc.2016.04.005
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Norman DC, 2000, CLIN INFECT DIS, V31, P148, DOI 10.1086/313896
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Roghmann MC, 2001, AM J MED SCI, V322, P68, DOI 10.1097/00000441-200108000-00003
   Singler K, 2013, AGE AGEING, V42, P740, DOI 10.1093/ageing/aft121
   Sun Xuelin, 2020, Aging Med (Milton), V3, P98, DOI 10.1002/agm2.12104
   Waalen J, 2011, J GERONTOL A-BIOL, V66, P487, DOI 10.1093/gerona/glr001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2020
VL 15
BP 1067
EP 1069
DI 10.2147/CIA.S260972
PG 3
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA MJ4PV
UT WOS:000548075100001
PM 32753857
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lin, CY
   Yao, CA
AF Lin, Chih-Yin
   Yao, Chun-An
TI Potential Role of Nrf2 Activators with Dual Antiviral and Anti -In
   flammatory Properties in the Management of Viral Pneumonia
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE pneumonia; Keywords; COVID-19; viral pneumonia; Nrf2 activators;
   curcumin; sulforaphane; macrolide
ID ACUTE LUNG INJURY; VIRUS-INFECTION; GRANZYME-B; CURCUMIN; INFLUENZA;
   EXPRESSION; INFLAMMATION; SULFORAPHANE; PROTECTION; INDUCTION
AB The outbreak of coronavirus disease 2019 (COVID-19) pandemic has already caused a huge burden to the global healthcare system, with the death toll reached tens of thousands. Although some antiviral agents were identified and used to inhibit viral replication, the management of cytokine storm is also a critical issue. In this article, we reviewed the literature on drug candidates for severe acute respiratory syndrome (SARS-CoV-1) and provided a brief overview of a class of drugs that exert antiviral and anti-inflammatory effects. These molecules mitigated inflammatory cytokine cascades induced by viral infections via Nrf2 activating capacity and might have additional anti-fibrotic and anti-remodeling properties. Besides, their effects on the regulation of scavenger receptors expression by macrophages may offer some benefits to the pulmonary antibacterial defense system after viral infection. The potential roles of these agents assessed on the basis of the pathophysiology of viral pneumonia and acute respiratory distress syndrome were also discussed. Further research is needed to ascertain whether Nrf2 activators are useful in the management of viral pneumonia.
C1 [Lin, Chih-Yin] Chang Gung Mem Hosp, Dept Neurol, Linkou 333, Taiwan.
   [Yao, Chun-An] Cathay Gen Hosp, Dept Dermatol, 280 Renai Rd Sec 4, Taipei, Taiwan.
RP Yao, CA (corresponding author), Cathay Gen Hosp, Dept Dermatol, 280 Renai Rd Sec 4, Taipei, Taiwan.
EM chunany115@gmail.com
CR Avasarala S, 2013, PLOS ONE, V8, P1, DOI DOI 10.1371/J0URNAL.P0NE.0057285
   Bewley MA, 2018, AM J RESP CRIT CARE, V198, P739, DOI 10.1164/rccm.201705-0903OC
   Bolger GT, 2019, CANCER CHEMOTH PHARM, V83, P265, DOI 10.1007/s00280-018-3730-5
   Chen LW, 2018, INT IMMUNOPHARMACOL, V61, P1, DOI 10.1016/j.intimp.2018.04.041
   Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601
   Chen T, 2015, INT IMMUNOPHARMACOL, V25, P55, DOI 10.1016/j.intimp.2015.01.011
   Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC
   Clemens DL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124078
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Dai JP, 2018, INT IMMUNOPHARMACOL, V54, P177, DOI 10.1016/j.intimp.2017.11.009
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Han SG, 2018, CLIN EXP PHARMACOL P, V45, P84, DOI 10.1111/1440-1681.12848
   Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042
   Houghton CA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2716870
   Hu YZ, 2018, INT J PHARMACEUT, V551, P212, DOI 10.1016/j.ijpharm.2018.09.031
   Inoue D, 2008, RESPIROLOGY, V13, P215, DOI 10.1111/j.1440-1843.2007.01227.x
   Ishimatsu Y, 2018, C60 TRANSLATIONAL BA, pA5479, DOI [10.1164/ajrccm- conference.2018.197.1, DOI 10.1164/AJRCCM-CONFERENCE.2018.197.1_MEETINGABSTRACTS.A5479]
   Iwayama K, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0119-8
   Jamwal R, 2018, J INTEGR MED-JIM, V16, P367, DOI 10.1016/j.joim.2018.07.001
   Kesic MJ, 2011, FREE RADICAL BIO MED, V51, P444, DOI 10.1016/j.freeradbiomed.2011.04.027
   Kuang XH, 2009, BRAIN RES, V1286, P174, DOI 10.1016/j.brainres.2009.06.007
   Kumari A, 2019, INFLAMMOPHARMACOLOGY, V27, P731, DOI 10.1007/s10787-018-0544-3
   Lasoff DR, 2018, CLIN TOXICOL, V56, P384, DOI 10.1080/15563650.2017.1388387
   Lee IC, 2017, AM J CHINESE MED, V45, P1253, DOI [10.1142/S0192415X17500690, 10.1142/s0192415x17500690]
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2010, J INVEST MED, V58, P730, DOI 10.231/JIM.0b013e3181d88fde
   Lin XP, 2018, CHINESE MED J-PEKING, V131, P1686, DOI 10.4103/0366-6999.235863
   Liu QM, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7090534
   McElhaney JE, 2009, VACCINE, V27, P2418, DOI 10.1016/j.vaccine.2009.01.136
   McElhaney JE, 2001, VACCINE, V19, P3744, DOI 10.1016/S0264-410X(01)00087-1
   Min JY, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/649570
   Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864
   Muller L., 2016, PLOS ONE, V11, P1, DOI DOI 10.1371/J0URNAL.P0NE.0147742
   Praditya D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00912
   Qi TJ, 2016, INT J MOL MED, V37, P182, DOI 10.3892/ijmm.2015.2396
   Robledinos-Anton N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Rothan HA, 2019, ANTIVIR RES, V171, DOI 10.1016/j.antiviral.2019.104590
   Shelton LM, 2013, KIDNEY INT, V84, P1090, DOI 10.1038/ki.2013.248
   Simonis FD, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.25
   Sun ZJ, 2018, EXP THER MED, V15, P4911, DOI 10.3892/etm.2018.6036
   Takahashi E, 2018, COMP IMMUNOL MICROB, V56, P6, DOI 10.1016/j.cimid.2017.11.002
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Wise RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163716
   Wu MZ, 2017, AM J PHYSIOL-LUNG C, V313, pL138, DOI 10.1152/ajplung.00075.2017
   Xiao XF, 2012, J SURG RES, V176, pE31, DOI 10.1016/j.jss.2011.11.1032
   Xu YM, 2017, INFLUENZA OTHER RESP, V11, P457, DOI 10.1111/irv.12459
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Yang Y, 2014, FASEB J, V28, DOI 10.1096/fasebj.28.1_supplement.869.11
   Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302
   Zingg JM, 2014, FASEB J, V28
   Zuccotti GV, 2009, J BIOL REG HOMEOS AG, V23, P119
NR 51
TC 1
Z9 1
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 1735
EP 1741
DI 10.2147/IDR.S256773
PG 7
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA MI5OM
UT WOS:000547457000001
PM 32606823
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Akalu, Y
   Ayelign, B
   Molla, MD
AF Akalu, Yonas
   Ayelign, Birhanu
   Molla, Meseret Derbew
TI Knowledge, Attitude and Practice Towards COVID-19 Among Chronic Disease
   Patients at Addis Zemen Hospital, Northwest Ethiopia
SO INFECTION AND DRUG RESISTANCE
LA English
DT Article
DE COVID-19; chronic disease patients; attitude; knowledge; practice;
   Ethiopia
ID HEALTH
AB Purpose: The recent outbreak of coronavirus disease 2019 (COVID-19) is the worst global crisis after the Second World War. Since no successful treatment and vaccine have been reported, efforts to enhance the knowledge, attitudes, and practice of the public, especially the high-risk groups, are critical to manage COVID-19 pandemic. Thus, this study aimed to assess knowledge, attitude, and practice towards COVID-19 among patients with chronic disease.
   Patients and Methods: A cross-sectional study was conducted among 404 chronic disease patients from March 02 to April 10, 2020, at Addis Zemen Hospital, Northwest Ethiopia. Both bivariable and multivariable logistic regression analyses with a 95% confidence interval were fitted to identify factors associated with poor knowledge and practice towards COVID-19. The adjusted odds ratio (AOR) was used to determine the magnitude of the association between the outcome and independent variables. P-value <0.05 was considered statistically significant.
   Results: The mean age of the participants was 56.5 +/- 13.5. The prevalence of poor knowledge and poor practice was 33.9% and 47.3%, respectively. Forty-one percent of the participants perceived that avoiding of attending a crowded population is very difficult. Age (AOR=1.05, (95% CI (1.01-1.08)), educational status of "can't read and write" (AOR=7.1, 95% CI (1.58-31.93)), rural residence (AOR=19.0, 95% CI (6.87-52.66)) and monthly income (AOR=0.8, 95% CI (0.79-0.89)) were significantly associated with poor knowledge. Being unmarried (AOR=3.9, 95% CI (1.47-10.58)), cannot read and write (AOR=2.7, 95% CI (1.03-7.29)), can read and write (AOR=3.5, 95% CI (1.48-8.38)), rural residence (AOR=2.7, 95% CI (1.09-6.70)), income of <7252 Ethiopian birr (AOR=2.3, 95% CI (1.20-4.15)) and poor knowledge (AOR=8.6, 95% CI (3.81-19.45)) were significantly associated with poor practice.
   Conclusion: The prevalence of poor knowledge and poor practice was high. Leaflets prepared in local languages should be administered and health professionals should provide detailed information about COVID-19 to their patients.
C1 [Akalu, Yonas] Univ Gondar, Coll Med & Hlth Sci, Sch Med, Dept Physiol, Gondar, Ethiopia.
   [Ayelign, Birhanu] Univ Gondar, Coll Med & Hlth Sci, Sch Biomed & Lab Sci, Dept Immunol & Mol Biol, Gondar, Ethiopia.
   [Molla, Meseret Derbew] Univ Gondar, Coll Med & Hlth Sci, Sch Med, Dept Biochem, Gondar, Ethiopia.
RP Akalu, Y (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Dept Human Physiol, POB 196, Gondar, Ethiopia.
EM yonasakalu21@gmail.com
RI MOLLA, MESERET DERBEW/ABB-1928-2020
OI MOLLA, MESERET DERBEW/0000-0002-2622-522X; Akalu,
   Yonas/0000-0002-0914-7768; Ayelign, Birhanu/0000-0001-9157-3637
CR Austrian K, 2020, B WORLD HEALTH ORGAN, P1
   Azlan AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233668
   Baloch S, 2020, TOHOKU J EXP MED, V250, P271, DOI 10.1620/tjem.250.271
   Barnes DF, 2016, ELECT ACCESS OUTPUT, P28
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Braveman PA, 2010, AM J PUBLIC HEALTH, V100, pS186, DOI 10.2105/AJPH.2009.166082
   Brunello G, 2016, HEALTH ECON, V25, P314, DOI 10.1002/hec.3141
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Erfani A., 2020, B WHO, P30
   Estacio EV, 2019, J HEALTH PSYCHOL, V24, P1668, DOI 10.1177/1359105317695429
   Geldsetzer P, 2020, ANN INTERN MED, V2020, P1
   Guan WJ, 2019, CLIN CHARACTERISTICS, V2020, P2020, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974]
   Guan WJ, 2020, NEW ENGL J MED, V1, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   He YH, 2020, J BIOMED NANOTECHNOL, V16, P1, DOI 10.1166/jbn.2020.2878
   Hironaka LK, 2008, ARCH DIS CHILD, V93, P428, DOI 10.1136/adc.2007.131516
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kebede Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233744
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941
   Mantwill S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145455
   Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031
   McEachan R, 2016, ANN BEHAV MED, V50, P592, DOI 10.1007/s12160-016-9798-4
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Park CL, 2018, PSYCHOL HEALTH, V33, P1416, DOI 10.1080/08870446.2018.1510932
   Qualls N, 2017, COMMUNITY MITIGATION, V66, P2017
   Ramirez AS, 2018, SOC SCI MED, V219, P11, DOI 10.1016/j.socscimed.2018.10.006
   Seid MA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3199-1
   SHEHAB A, 2020, JMIR PUBLIC HLTH SUR, V9
   Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2
   Taghrir MH, 2020, ARCH IRAN MED, V23, P249, DOI [10.34172/aim.2020.06, 10.34172/aim.2020.06 Abstract View:]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239
   Wolf MS, 2005, ARCH INTERN MED, V165, P1946, DOI 10.1001/archinte.165.17.1946
   World Health Organization, 2020, COR DIS
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhan SY, 2020, EMERG MICROBES INFEC, V9, P534, DOI 10.1080/22221751.2020.1732232
   Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 13
Z9 13
U1 4
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2020
VL 13
BP 1949
EP 1960
DI 10.2147/IDR.S258736
PG 12
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA MI5OM
UT WOS:000547457000021
PM 32612371
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Okba, NMA
   Widjaja, I
   van Dieren, B
   Aebischer, A
   van Amerongen, G
   de Waal, L
   Stittelaar, KJ
   Schipper, D
   Martina, B
   van den Brand, JMA
   Beer, M
   Bosch, BJ
   Haagmans, BL
AF Okba, Nisreen M. A.
   Widjaja, Ivy
   van Dieren, Brenda
   Aebischer, Andrea
   van Amerongen, Geert
   de Waal, Leon
   Stittelaar, Koert J.
   Schipper, Debby
   Martina, Byron
   van den Brand, Judith M. A.
   Beer, Martin
   Bosch, Berend-Jan
   Haagmans, Bart L.
TI Particulate multivalent presentation of the receptor binding domain
   induces protective immune responses against MERS-CoV
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE Vaccine; MERS-coronavirus; spike; i301; lumazine synthase;
   spytag-spycatcher; rabbit; SARS-CoV-2
ID RESPIRATORY SYNDROME-CORONAVIRUS; SPIKE PROTEIN; VACCINES; REGION;
   GLYCOPROTEIN; INFECTION; EPITOPE; HR2
AB Middle East respiratory syndrome coronavirus (MERS-CoV) is a WHO priority pathogen for which vaccines are urgently needed. Using an immune-focusing approach, we created self-assembling particles multivalently displaying critical regions of the MERS-CoV spike protein -fusion peptide, heptad repeat 2, and receptor binding domain (RBD) - and tested their immunogenicity and protective capacity in rabbits. Using a "plug-and-display" SpyTag/SpyCatcher system, we coupled RBD to lumazine synthase (LS) particles producing multimeric RBD-presenting particles (RBD-LS). RBD-LS vaccination induced antibody responses of high magnitude and quality (avidity, MERS-CoV neutralizing capacity, and mucosal immunity) with cross-clade neutralization. The antibody responses were associated with blocking viral replication and upper and lower respiratory tract protection against MERS-CoV infection in rabbits. This arrayed multivalent presentation of the viral RBD using the antigen-SpyTag/LS-SpyCatcher is a promising MERS-CoV vaccine candidate and this platform may be applied for the rapid development of vaccines against other emerging viruses such as SARS-CoV-2.
C1 [Okba, Nisreen M. A.; Schipper, Debby; Martina, Byron; van den Brand, Judith M. A.; Haagmans, Bart L.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Widjaja, Ivy; van Dieren, Brenda; Bosch, Berend-Jan] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Virol Div, Utrecht, Netherlands.
   [Aebischer, Andrea; Beer, Martin] Friedrich Loeffler Inst, Inst Diagnost Virol, Insel Riems, Germany.
   [van Amerongen, Geert; de Waal, Leon; Stittelaar, Koert J.] Viroclin Biosci BV, Rotterdam, Netherlands.
RP Haagmans, BL (corresponding author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.; Bosch, BJ (corresponding author), Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Virol Div, Utrecht, Netherlands.
EM b.j.bosch@uu.nl; b.haagmans@erasmusmc.nl
RI Okba, Nisreen/K-9984-2017
OI Okba, Nisreen/0000-0002-2394-1079; Haagmans, Bart/0000-0001-6221-2015
FU IMI-ZAPI (Zoonotic Anticipation and Preparedness Initiative (ZAPI)
   project; Innovative Medicines Initiative (IMI)) [115760]; IMI; European
   CommissionEuropean CommissionEuropean Commission Joint Research Centre
FX This study was financed by a grant from the IMI-ZAPI (Zoonotic
   Anticipation and Preparedness Initiative (ZAPI) project; Innovative
   Medicines Initiative (IMI)) [grant agreement no. 115760], with the
   assistance and financial support of IMI and the European Commission, and
   in-kind contributions from European Federation of Pharmaceutical
   Industries and Associations partners.
CR Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432
   Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234
   Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805
   Chattopadhyay Saborni, 2017, Nanotheranostics, V1, P244, DOI 10.7150/ntno.19796
   DANIEL C, 1993, J VIROL, V67, P1185, DOI 10.1128/JVI.67.3.1185-1194.1993
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Falzarano D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004250
   Haagmans BL, 2015, J VIROL, V89, P6131, DOI 10.1128/JVI.00661-15
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Houser KV, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006565
   Hsia Y, 2016, NATURE, V535, P136, DOI 10.1038/nature18010
   Huber VC, 2014, EXPERT REV VACCINES, V13, P31, DOI 10.1586/14760584.2014.852476
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Kim YS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01093
   Lai SC, 2005, J BIOMED SCI, V12, P711, DOI 10.1007/s11373-005-9004-3
   Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185
   Leneghan DB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03798-3
   Li L, 2014, J MOL BIOL, V426, P309, DOI 10.1016/j.jmb.2013.10.021
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Lip KM, 2006, J VIROL, V80, P941, DOI 10.1128/JVI.80.2.941-950.2006
   Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Modjarrad K, 2016, NAT MED, V22, P701, DOI 10.1038/nm.4131
   Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13
   Okba NMA, 2017, CURR OPIN VIROL, V23, P49, DOI 10.1016/j.coviro.2017.03.007
   Organization WH, R D BLUEPR LIST BLUE
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   ROUTLEDGE E, 1991, J VIROL, V65, P254, DOI 10.1128/JVI.65.1.254-262.1991
   Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang LS, 2018, J VIROL, V92, DOI 10.1128/JVI.02002-17
   WHO, MIDDL E RESP SYNDR C
   Widagdo W, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040381
   Widjaja I, 2019, EMERG MICROBES INFEC, V8, P516, DOI 10.1080/22221751.2019.1597644
   Wilson JT, 2019, SCIENCE, V363, P584, DOI 10.1126/science.aav9000
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
NR 40
TC 2
Z9 2
U1 3
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1080
EP 1091
DI 10.1080/22221751.2020.1760735
PG 12
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MH6SU
UT WOS:000546857200001
PM 32471334
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Qian, KW
   Hu, S
AF Qian, Kewen
   Hu, Shi
TI Ig-like ACE2 protein therapeutics: A revival in development during the
   COVID-19 pandemic
SO MABS
LA English
DT Article
DE SARS-CoV-2; SARS-CoV; Ig-like proteins; neutralization; diffuse alveolar
   damage
ID CONVERTING ENZYME 2; LUNG INJURY; CORONAVIRUS
AB While the potential therapeutic utility of angiotensin-converting enzyme 2 (ACE2) is well established, the clinical development of ACE2 drugs has been limited, likely due in part to the short half-life of the protein. In contrast, Ig-like ACE2 fusion proteins have exhibited greatly extended plasma half-life in vivo, and they have been shown to have a potent neutralization effect against SARS-CoV-2. Clinical investigation of Ig-like ACE2 fusion proteins as COVID-19 interventions is thus warranted.
C1 [Qian, Kewen; Hu, Shi] Second Mil Med Univ, Coll Basic Med Sci, Dept Biophys, Shanghai, Peoples R China.
RP Hu, S (corresponding author), Second Mil Med Univ, Shanghai 200433, Peoples R China.
EM hus@smmu.edu.cn
RI Hu, Shi/ABF-4231-2020; Hu, Shi/A-2140-2015
OI Hu, Shi/0000-0002-7905-4284
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041012]
FX This work was supported by the National Natural Science Foundation of
   China [82041012].
CR Fu W, 2019, 819243 BIORXIV
   Haschke M, 2013, CLIN PHARMACOKINET, V52, P783, DOI 10.1007/s40262-013-0072-7
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jafari R, 2017, CURR MED CHEM, V24, P1228, DOI 10.2174/0929867324666170113112759
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Liu SW, 2019, CLIN IMMUNOL, V203, P72, DOI 10.1016/j.clim.2019.04.007
   Nicholls J, 2005, NAT MED, V11, P821, DOI 10.1038/nm0805-821
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Treml B, 2010, CRIT CARE MED, V38, P596, DOI 10.1097/CCM.0b013e3181c03009
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zisman LS, 2003, CIRCULATION, V108, P1707, DOI 10.1161/01.CIR.0000094734.67990.99
NR 15
TC 2
Z9 2
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PD JAN 1
PY 2020
VL 12
IS 1
AR e1782600
DI 10.1080/19420862.2020.1782600
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MJ1CS
UT WOS:000547832800001
PM 32546047
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Liu, PC
   Cai, JH
   Jia, R
   Xia, S
   Wang, XS
   Cao, LF
   Zeng, M
   Xu, J
AF Liu, Pengcheng
   Cai, Jiehao
   Jia, Ran
   Xia, Shuai
   Wang, Xiangshi
   Cao, Lingfeng
   Zeng, Mei
   Xu, Jin
TI Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in
   children with COVID-19
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE Children; SARS-CoV-2; COVID-19; viral shedding; neutralizing antibody
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and quickly spread globally. In this study, we investigated the characteristics of viral shedding from different sites and the neutralizing antibody (NAb) response during the acute and convalescent phases of nine children with COVID-19. SARS-CoV-2 was detected in their nasopharyngeal swabs (9/9, 100%), stool samples (8/9, 89%), and oropharyngeal swabs (3/9, 33%) but was not detected in their serum and urine samples. The median duration of viral shedding detected in nasopharyngeal swabs, oropharyngeal swabs, and stools was 13, 4, and 43 days respectively, and the maximum duration of viral shedding detected from stools was 46 days after discharge. In children, nasopharyngeal swabs appear to be a more sensitive specimen type for the diagnosis of COVID-19 compared with oropharyngeal swabs. Three of eight patients produced NAbs in the acute phase, and NAbs were detected in all eight patients with convalescent sera. The results of this study provide valuable information for the diagnosis and surveillance of COVID-19 and development of SARS-CoV-2 vaccines for use in children.
C1 [Liu, Pengcheng; Jia, Ran; Cao, Lingfeng; Xu, Jin] Fudan Univ, Childrens Hosp, Dept Clin Lab, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.
   [Cai, Jiehao; Wang, Xiangshi; Zeng, Mei] Fudan Univ, Childrens Hosp, Dept Infect Dis, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.
   [Xia, Shuai] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai, Peoples R China.
RP Xu, J (corresponding author), Fudan Univ, Childrens Hosp, Dept Clin Lab, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.; Zeng, M (corresponding author), Fudan Univ, Childrens Hosp, Dept Infect Dis, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.
EM zengmeigao@aliyun.com; jinxu_125@163.com
OI Reis, AlessanRSS/0000-0001-8486-7469; Zeng, Mei/0000-0002-3491-5298;
   Liu, Pengcheng/0000-0003-0879-1970
FU Children's Hospital of Fudan University [EKXGZX006]
FX This work was supported by grants specific for Coronavirus disease 2019
   from Children's Hospital of Fudan University (grant number EKXGZX006).
CR Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang X, 2020, INT J INFECT DIS, V94, P107, DOI 10.1016/j.ijid.2020.04.023
   World Health Organization, 109 WHO
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 8
Z9 8
U1 2
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1254
EP 1258
DI 10.1080/22221751.2020.1772677
PG 5
WC Immunology; Microbiology
SC Immunology; Microbiology
GA MH6UF
UT WOS:000546860900001
PM 32515685
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Deftereos, SG
   Siasos, G
   Giannopoulos, G
   Vrachatis, DA
   Angelidis, C
   Giotaki, SG
   Gargalianos, P
   Giamarellou, H
   Gogos, C
   Daikos, G
   Lazanas, M
   Lagiou, P
   Saroglou, G
   Sipsas, N
   Tsiodras, S
   Chatzigeorgiou, D
   Moussas, N
   Kotanidou, A
   Koulouris, N
   Oikonomou, E
   Kaoukis, A
   Kossyvakis, C
   Raisakis, K
   Fountoulaki, K
   Comis, M
   Tsiachris, D
   Sarri, E
   Theodorakis, A
   Martinez-Dolz, L
   Sanz-Sanchez, J
   Reimers, B
   Stefanini, GG
   Cleman, M
   Filippou, D
   Olympios, CD
   Pyrgakis, VN
   Goudevenos, J
   Hahalis, G
   Kolettis, TM
   Iliodromitis, E
   Tousoulis, D
   Stefanadis, C
AF Deftereos, Spyridon G.
   Siasos, Gerasimos
   Giannopoulos, Georgios
   Vrachatis, Dimitrios A.
   Angelidis, Christos
   Giotaki, Sotiria G.
   Gargalianos, Panagiotis
   Giamarellou, Helen
   Gogos, Charalampos
   Daikos, Georgios
   Lazanas, Marios
   Lagiou, Pagona
   Saroglou, Georgios
   Sipsas, Nikolaos
   Tsiodras, Sotirios
   Chatzigeorgiou, Dimitrios
   Moussas, Nikolaos
   Kotanidou, Anastasia
   Koulouris, Nikolaos
   Oikonomou, Evangelos
   Kaoukis, Andreas
   Kossyvakis, Charalampos
   Raisakis, Konstantinos
   Fountoulaki, Katerina
   Comis, Mihalis
   Tsiachris, Dimitrios
   Sarri, Eleni
   Theodorakis, Andreas
   Martinez-Dolz, Luis
   Sanz-Sanchez, Jorge
   Reimers, Bernhard
   Stefanini, Giulio G.
   Cleman, Michael
   Filippou, Dimitrios
   Olympios, Christoforos D.
   Pyrgakis, Vlasios N.
   Goudevenos, John
   Hahalis, George
   Kolettis, Theofilos M.
   Iliodromitis, Efstathios
   Tousoulis, Dimitrios
   Stefanadis, Christodoulos
TI The Greek study in the effects of colchicine in COvid-19 complications
   prevention (GRECCO-19 study): Rationale and study design
SO HELLENIC JOURNAL OF CARDIOLOGY
LA English
DT Article
DE COVID; Cardiac; Troponin; CRP; Complications
ID NLRP3 INFLAMMASOME; MECHANISMS; THERAPY
AB Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention.
   Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group.
   Results: Trial results will be disseminated through peer-reviewed publications and conference presentations.
   Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (C) 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.
C1 [Deftereos, Spyridon G.; Siasos, Gerasimos; Vrachatis, Dimitrios A.; Angelidis, Christos; Giotaki, Sotiria G.; Giamarellou, Helen; Daikos, Georgios; Lagiou, Pagona; Saroglou, Georgios; Sipsas, Nikolaos; Tsiodras, Sotirios; Kotanidou, Anastasia; Koulouris, Nikolaos; Oikonomou, Evangelos; Sarri, Eleni; Filippou, Dimitrios; Iliodromitis, Efstathios; Tousoulis, Dimitrios] Natl Kapodistrian Univ Athens, Sch Med, Athens, Greece.
   [Giannopoulos, Georgios; Kaoukis, Andreas; Kossyvakis, Charalampos; Raisakis, Konstantinos; Pyrgakis, Vlasios N.] Gen Hosp Athens G Gennimatas Hosp, Athens, Greece.
   [Vrachatis, Dimitrios A.; Sanz-Sanchez, Jorge; Reimers, Bernhard; Stefanini, Giulio G.] Humanitas Clin & Res Inst, Milan, Italy.
   [Gargalianos, Panagiotis; Moussas, Nikolaos; Tsiachris, Dimitrios; Stefanadis, Christodoulos] Athens Med Ctr, Athens, Greece.
   [Giamarellou, Helen] Therapeutir Hygeia, Athens, Greece.
   [Gogos, Charalampos; Hahalis, George] Univ Patras, Sch Med, Patras, Greece.
   [Daikos, Georgios] Mitera Hosp, Athens, Greece.
   [Lazanas, Marios] Metropolitan Gen Hosp, Athens, Greece.
   [Saroglou, Georgios] Metropolitan Hosp, Athens, Greece.
   [Chatzigeorgiou, Dimitrios] Hellenic Air Force, Athens, Greece.
   [Comis, Mihalis; Olympios, Christoforos D.] Gen Hosp Elefsina Thriasio, Elefsina, Greece.
   [Theodorakis, Andreas] Missolonghi Gen Hosp Chatzikosta, Missolonghi, Greece.
   [Martinez-Dolz, Luis; Sanz-Sanchez, Jorge] Hosp Univ & Politecn La Fe, Valencia, Spain.
   [Cleman, Michael] Yale Univ, Sch Med, New Haven, CT USA.
   [Goudevenos, John; Kolettis, Theofilos M.] Univ Ioannina, Ioannina, Greece.
RP Deftereos, SG (corresponding author), Natl & Kapodistrian Univ Athens, Attikon Hosp, Rimini 1, Athens, Greece.
EM spdeftereos@gmail.com
RI Siasos, Gerasimos/AAD-7218-2019; Stefanadis, Christodoulos/ABH-2232-2020
OI Siasos, Gerasimos/0000-0001-7601-8870; Stefanadis,
   Christodoulos/0000-0001-5974-6454; Reimers,
   Bernhard/0000-0002-9890-5582; Sanz Sanchez, Jorge/0000-0003-4991-6549;
   KOULOURIS, NIKOLAOS/0000-0002-1719-7220; Vrachatis,
   Dimitrios/0000-0002-2385-5365; Giannopoulos,
   Georgios/0000-0002-7287-3850; Oikonomou, Evangelos/0000-0001-8079-0599
FU Hellenic Society of Cardiology (Athens, Greece); Fundacion Alfonso
   Martin Escudero (Madrid, Spain); ELPEN Pharmaceutical Co. Inc.; Hellenic
   Society of Rhythmology
FX DV is personally supported by a scholarship from Hellenic Society of
   Cardiology (Athens, Greece) JSS is personally supported by a grant from
   the Fundacion Alfonso Martin Escudero (Madrid, Spain) The study is
   funded by ELPEN Pharmaceutical Co. Inc. and sponsored by Hellenic
   Society of Rhythmology.
CR Calkins H, 2017, J ARRYTHM, V33, P369, DOI 10.1016/j.joa.2017.08.001
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Cerquaglia C., 2005, Current Drug Targets - Inflammation and Allergy, V4, P117
   CHAPPEY ON, 1993, CLIN PHARMACOL THER, V54, P360, DOI 10.1038/clpt.1993.161
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Chow S, 2008, SAMPLE SIZE CALCULAT
   Deftereos S, 2015, CIRCULATION, V132, P1395, DOI 10.1161/CIRCULATIONAHA.115.017611
   Deftereos S, 2013, J AM COLL CARDIOL, V62, P1817, DOI 10.1016/j.jacc.2013.08.726
   Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC
   Grailer JJ, 2014, J IMMUNOL, V192, P5974, DOI 10.4049/jimmunol.1400368
   Hemkens LG, 2016, HEART, V102, P590, DOI 10.1136/heartjnl-2015-308542
   Jones HD, 2014, AM J RESP CELL MOL, V50, P270, DOI 10.1165/rcmb.2013-0087OC
   Kaksonen M, 2018, NAT REV MOL CELL BIO, V19, P313, DOI 10.1038/nrm.2017.132
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Li DD, 2018, MOL MED REP, V18, P4399, DOI 10.3892/mmr.2018.9427
   Marques-Da-Silva C, 2011, BRIT J PHARMACOL, V163, P912, DOI 10.1111/j.1476-5381.2011.01254.x
   Martinez GJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002128
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Molad Yair, 2002, Curr Rheumatol Rep, V4, P252, DOI 10.1007/s11926-002-0073-2
   Morales L, 2017, CELL HOST MICROBE, V21, P344, DOI 10.1016/j.chom.2017.01.015
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Robertson S, 2016, CLIN SCI, V130, P1237, DOI 10.1042/CS20160090
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shi CS, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0181-7
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Toldo S, 2018, NAT REV CARDIOL, V15, P203, DOI 10.1038/nrcardio.2017.161
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 33
TC 27
Z9 27
U1 3
U2 4
PU HELLENIC CARDIOLOGICAL SOC
PI ATHENS
PA 6 POTAMIANOU ST, ATHENS, 11528, GREECE
SN 1109-9666
EI 2241-5955
J9 HELL J CARDIOL
JI Hell. J. Cardiol.
PD JAN-FEB
PY 2020
VL 61
IS 1
BP 42
EP 45
DI 10.1016/j.hjc.2020.03.002
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA ML4FZ
UT WOS:000549425200010
PM 32251729
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Pokhrel, R
   Chapagain, P
   Siltberg-Liberles, J
AF Pokhrel, Rudramani
   Chapagain, Prem
   Siltberg-Liberles, Jessica
TI Potential RNA-dependent RNA polymerase inhibitors as prospective
   therapeutics against SARS-CoV-2
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
DE sequence analysis; protein evolution; broadly neutralizing antivirals;
   docking
ID MULTIPLE SEQUENCE ALIGNMENT; CORONAVIRUS; ACCURACY; TARGET; VIRUS;
   MODEL; SARS
AB Introduction. The emergence of SARS-CoV-2 has taken humanity off guard. Following an outbreak of SARS-CoV in 2002, and MERS-CoV about 10 years later, SARS-CoV-2 is the third coronavirus in less than 20 years to cross the species barrier and start spreading by human-to-human transmission. It is the most infectious of the three, currently causing the COVID-19 pandemic. No treatment has been approved for COVID-19. We previously proposed targets that can serve as binding sites for antiviral drugs for multiple coronaviruses, and here we set out to find current drugs that can be repurposed as COVID-19 therapeutics.
   Aim. To identify drugs against COVID-19, we performed an in silico virtual screen with the US Food and Drug Administration (FDA)-approved drugs targeting the RNA-dependent RNA polymerase (RdRP), a critical enzyme for coronavirus replication.
   Methodology. Initially, no RdRP structure of SARS-CoV-2 was available. We performed basic sequence and structural analysis to determine if RdRP from SARS-CoV was a suitable replacement. We performed molecular dynamics simulations to generate multiple starting conformations that were used for the in silico virtual screen. During this work, a structure of RdRP from SARS-CoV-2 became available and was also included in the in silico virtual screen.
   Results. The virtual screen identified several drugs predicted to bind in the conserved RNA tunnel of RdRP, where many of the proposed targets were located. Among these candidates, quinupristin is particularly interesting because it is expected to bind across the RNA tunnel, blocking access from both sides and suggesting that it has the potential to arrest viral replication by preventing viral RNA synthesis. Quinupristin is an antibiotic that has been in clinical use for two decades and is known to cause relatively minor side effects.
   Conclusion. Quinupristin represents a potential anti-SARS-CoV-2 therapeutic. At present, we have no evidence that this drug is effective against SARS-CoV-2 but expect that the biomedical community will expeditiously follow up on our in silico findings.
C1 [Pokhrel, Rudramani; Chapagain, Prem] Florida Int Univ, Dept Phys, 11200 SW 8th St, Miami, FL 33199 USA.
   [Chapagain, Prem; Siltberg-Liberles, Jessica] Florida Int Univ, Biomol Sci Inst, 11200 SW 8th St, Miami, FL 33199 USA.
   [Siltberg-Liberles, Jessica] Florida Int Univ, Dept Biol Sci, 11200 SW 8th St, Miami, FL 33199 USA.
RP Siltberg-Liberles, J (corresponding author), Florida Int Univ, Biomol Sci Inst, 11200 SW 8th St, Miami, FL 33199 USA.; Siltberg-Liberles, J (corresponding author), Florida Int Univ, Dept Biol Sci, 11200 SW 8th St, Miami, FL 33199 USA.
EM jliberle@fiu.edu
OI Pokhrel, Rudramani/0000-0002-7208-0420
CR Asthana S, 2013, BIOCHEMISTRY-US, V52, P3752, DOI 10.1021/bi400107h
   Bhatia HK, 2014, J PHARMACOL PHARMACO, V5, P278, DOI 10.4103/0976-500X.142464
   Brown J, 2004, ANN PHARMACOTHER, V38, P677, DOI 10.1345/aph.1D323
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0
   Campbell EA, 2005, EMBO J, V24, P674, DOI 10.1038/sj.emboj.7600499
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020, NAT MICROBIOL, P1
   Darden T, 1999, STRUCT FOLD DES, V7, pR55, DOI 10.1016/S0969-2126(99)80033-1
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DeLano W.L, PYMOL MOL GRAPHICS S
   Dong E, 2020, LANCET INFECT DIS
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Elber R, 2011, EUR PHYS J-SPEC TOP, V200, P211, DOI 10.1140/epjst/e2011-01525-9
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Graifer D, 2015, BIOCHIMIE, V109, P1, DOI 10.1016/j.biochi.2014.11.016
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Harms JM, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-4
   Holmes NE, 2015, SEMIN RESP CRIT CARE, V36, P17, DOI 10.1055/s-0034-1397040
   Huang J, 2016, NAT METHODS
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jiang W, 2011, J PHYS CHEM LETT, V2, P87, DOI 10.1021/jz101461d
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kupferschmidt K., 2020, SCIENCE
   Lee CY, 2017, J INFECTION, V75, P395, DOI 10.1016/j.jinf.2017.08.013
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Lefort V, 2017, MOL BIOL EVOL, V34, P2422, DOI 10.1093/molbev/msx149
   Li YC, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100984
   Ma C, 2016, MICROBIOL MOL BIOL R, V80, P139, DOI 10.1128/MMBR.00055-15
   Ma YY, 2015, P NATL ACAD SCI USA, V112, P9436, DOI 10.1073/pnas.1508686112
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maximova T, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004619
   OBoyle NM, 2011, J CHEM INFORM, V3
   Pfizer, SYN QUIN DALF INJ PO
   Pihan E, 2012, BIOINFORMATICS, V28, P1540, DOI 10.1093/bioinformatics/bts186
   Pushpakom S, 2018, NAT PUBL GR
   Rahaman J, 2016, GENOME BIOL EVOL, V8, P3471, DOI 10.1093/gbe/evw246
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Sandhaus S, 2018, SCI REP, V8, P1
   Stein GE, 2005, CLIN INFECT DIS, V41, pS293, DOI 10.1086/431671
   Tchesnokov E, VIRUSES, V11, P326
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Velkov T, 2014, CURR DRUG TARGETS, V15, P103, DOI 10.2174/1389450114888131204163210
   Vertrees J., FINDSURFACERESIDUES
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 52
TC 2
Z9 2
U1 5
U2 7
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PY 2020
VL 69
IS 6
BP 864
EP 873
DI 10.1099/jmm.0.001203
PG 10
WC Microbiology
SC Microbiology
GA MH8CX
UT WOS:000546951100013
PM 32469301
OA Green Published
DA 2021-01-01
ER

PT J
AU Martinez, A
AF Martinez, Ana
TI Cloroquine and Hydroxychloroquine: The Yin-yang of these Drugs from a
   Theoretical Study
SO JOURNAL OF THE MEXICAN CHEMICAL SOCIETY
LA English
DT Article
DE COVID-19; SARS-CoV2; coronavirus; oxidation; electroaccepting power
ID DENSITY-FUNCTIONAL THEORY; DONATOR ACCEPTOR MAP; SET MODEL CHEMISTRY;
   TOTAL ENERGIES; CHLOROQUINE; CORONAVIRUS; SOLUTES; ATOMS
AB On November 12, 2019 the first case of infection of a novel coronavirus (COVID-19) was identified at Wuhan, the capital of Hubei province in China Regardless of the origin of this virus, which is uncertain, it has produced a pandemic that has been the cause of human deaths worldwide. Two drugs are being used as antiviral against this virus; cloroquine and hydroxychloroquine, although controversy exists concerning their effectiveness. The main objective of this report is to present the electronic properties of cloroquine and hydroxychloroquine that might help explain the action mechanisms against virus. The idea that emerges from this study is that acid-base equilibrium is not the only criteria of importance to explain the action mechanism, but that the oxide-reduction balance may also help explain the toxicity or effectiveness of these drugs. Being molecules able to oxidize other molecules is similar to yin-yang; a dualism that describes contrary forces, as oxidation may produce dysfunction and affect the conditions needed for viral infection, replication and propagation of the virus, but also contribute to increasing oxidative stress. These results offer a further step along the path of understanding these action mechanisms.
C1 [Martinez, Ana] Univ Nacl Autonoma Mexico, Dept Mat Baja Dimensionalidad, Inst Invest Mat, Circuito Exterior SN,Ciudad Univ, Cdmx 04510, Mexico.
RP Martinez, A (corresponding author), Univ Nacl Autonoma Mexico, Dept Mat Baja Dimensionalidad, Inst Invest Mat, Circuito Exterior SN,Ciudad Univ, Cdmx 04510, Mexico.
EM martina@unam.mx
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Benjamin N., NEW ENGL J MED, DOI [10.1056/NEJMp2009457, DOI 10.1056/NEJMP2009457]
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Ceron-Carrasco JP, 2010, J PHYS CHEM B, V114, P4366, DOI 10.1021/jp911846h
   Chermette H, 1999, J COMPUT CHEM, V20, P129, DOI 10.1002/(SICI)1096-987X(19990115)20:1<129::AID-JCC13>3.3.CO;2-1
   Alfaro RAD, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2337-y
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Garcia-Hernandez E, 2017, J MEX CHEM SOC, V61, P222
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gazquez JL, 2007, J PHYS CHEM A, V111, P1966, DOI 10.1021/jp065459f
   Gazquez JL, 2008, J MEX CHEM SOC, V52, P3
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   Geerlings P, 2020, THEOR CHEM ACC, V139, DOI 10.1007/s00214-020-2546-7
   KRISHNAN R, 1980, J CHEM PHYS, V72, P650, DOI 10.1063/1.438955
   Liu SB, 2009, ACTA PHYS-CHIM SIN, V25, P590, DOI 10.3866/PKU.WHXB20090332
   Martinez A, 2008, J PHYS CHEM A, V112, P9037, DOI 10.1021/jp803218e
   Martinez A, 2009, J PHYS CHEM B, V113, P4915, DOI 10.1021/jp8102436
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   MCLEAN AD, 1980, J CHEM PHYS, V72, P5639, DOI 10.1063/1.438980
   Mennucci B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558
   PETERSSON GA, 1988, J CHEM PHYS, V89, P2193, DOI 10.1063/1.455064
   PETERSSON GA, 1991, J CHEM PHYS, V94, P6081, DOI 10.1063/1.460447
   Semeniuk A, 2008, J CHEM CRYSTALLOGR, V38, P333, DOI 10.1007/s10870-008-9327-9
   Taccone FS, 2020, LANCET RESP MED, V8, P539, DOI 10.1016/S2213-2600(20)30172-7
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   Tomasi J, 1999, J MOL STRUC-THEOCHEM, V464, P211, DOI 10.1016/S0166-1280(98)00553-3
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang B, 2019, THEOR CHEM ACC, V138, DOI 10.1007/s00214-019-2515-1
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   WHO, 2005, INT HLHT REG WHA58 3
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
NR 35
TC 0
Z9 0
U1 4
U2 4
PU SOC QUIMICA MEXICO
PI MEXICO D F
PA BARRANCA DEL MUERTO 26, COL CREDITO CONSTRUCTOR, DEL BENITO JUAREZ,
   MEXICO D F, C P 03940, MEXICO
SN 1870-249X
EI 1665-9686
J9 J MEX CHEM SOC
JI J. Mex. Chem. Soc.
PY 2020
VL 64
IS 3
BP 230
EP 237
DI 10.29356/jmcs.v64i3.1213
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA MH5FR
UT WOS:000546755300006
OA Other Gold
DA 2021-01-01
ER

PT J
AU Emerson, KG
AF Emerson, Kerstin Gerst
TI Coping with being cooped up: Social distancing during COVID-19 among
   60+in the United States
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Article
DE Aging; coronavirus infections; United States
ID LONELINESS; HEALTH
AB Objectives. This study examined the impact of sheltering in place and social distancing among adults aged 60 and older during the 2020 outbreak of COVID-19 in the United States.
   Methods. Using convenience sampling respondents were asked to complete a web-administered survey to explore impact of social distancing on loneliness, stress, and behavioral changes. The analytic sample consisted of 833 responses of persons aged 60 and older.
   Results. A large portion reported being stressed (36%), and/or being lonely (42.5%). Nearly 1/3 stated that their sense of loneliness increased during the time of social distancing. Respondents reported engaging in more solitary activity (and fewer in-person activities), using email and text messages more than usual, and spending more time on computers/tablet than usual. Approximately 2/3 reported using more social media than usual. These differed significantly by younger (age 60-70) and older (71+) respondents. Additionally, changes in physical activity, drinking, recreational drug use and sleeping pattern changes differed by age.
   Conclusions. Social distancing has significant consequences on loneliness and health behaviors among adults in the United States, many of which differ by age group. Results have implications for continued shelter in place practices, but also for any older adult that may be homebound for other reasons.
C1 [Emerson, Kerstin Gerst] Univ Georgia, Athens, GA 30602 USA.
RP Emerson, KG (corresponding author), Univ Georgia, Athens, GA 30602 USA.
EM emerson@uga.edu
CR CDC, 2020, PEOPL WHO AR HIGH RI
   Connolly S, 2020, BIOMICROFLUIDICS, V14, DOI 10.1063/5.0005154
   Dykstra PA, 2009, EUR J AGEING, V6, P91, DOI 10.1007/s10433-009-0110-3
   Gerst-Emerson K, 2015, AM J PUBLIC HEALTH, V105, P1013, DOI 10.2105/AJPH.2014.302427
   Girdhar R, 2020, J GERIATRIC CARE RES, V7, P29, DOI DOI 10.1056/NEJMP2008017
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   Institute on Aging, 2020, FRIENDSH LIN
   Klinenberg E, 2016, AM J PUBLIC HEALTH, V106, P786, DOI 10.2105/AJPH.2016.303166
   Ong AD, 2016, GERONTOLOGY, V62, P443, DOI 10.1159/000441651
   Pearce K., 2020, WHAT IS SOCIAL DISTA
   Peplau LA, 1985, LONELINESS SOURCEBOO, P1
   Rijal B., 2020, SOCIAL DISTANCING TI
   U.S. Census Bureau, 2020, HISP OR
NR 14
TC 3
Z9 3
U1 8
U2 8
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PY 2020
VL 44
AR e81
DI 10.26633/RPSP.2020.81
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MI6BF
UT WOS:000547490100001
PM 32612645
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU de Souza, CTV
   de Santana, CS
   Ferreira, P
   Nunes, JA
   Teixeira, MDB
   Gouvea, MIFD
AF Vieira de Souza, Claudia Teresa
   de Santana, Clarke Silva
   Ferreira, Patricia
   Nunes, Joao Arriscado
   Benamor Teixeira, Maria de Lourdes
   Fragoso da Silveira Gouvea, Maria Isabel
TI Caring in the age of COVID-19: lessons from science and society
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
DE Citizen Participation in Science and Technology; Health Promotion;
   Social Isolation; COVID-19
AB This paper focuses on our research and intervention in health promotion with patients and communities affected by various infectious diseases, in the project Knowledge-Sharing Platform. This project is developed at the National Institute of Infectious Diseases Evandro Chagas in the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, and promotes the continuing involvement of health researchers and professionals in the collaborative production of knowledge on health with patients and community groups and in their training as community health promoters. The new epidemic scenario created the demand for a space of dialogue and knowledge-sharing on the prevention of COVID-19 transmission. Due to the interruption of regular activities in the Knowledge-Sharing Platform, a strategy was launched to serve as a link between science and society and help overcome the social isolation imposed by the COVID-19 pandemic. The WhatsApp group allowed project members to participate by addressing questions (audio) on COVID-19 through mediation by community group leaders. The main questions by participants related to risk factors, transmission, immunity to the novel coronavirus, care related to prevention, symptoms, and treatment; and COVID-19 and influenza vaccine. The educational material Caring in the Age of COVID-19 was produced and shared with community leaders and distributed to the respective groups and was eventually shared in their communities as a response to a demand for knowledge that responds to the concerns of people already exposed to structural vulnerability.
C1 [Vieira de Souza, Claudia Teresa; de Santana, Clarke Silva; Benamor Teixeira, Maria de Lourdes; Fragoso da Silveira Gouvea, Maria Isabel] Fundacao Oswaldo Cruz, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Ferreira, Patricia; Nunes, Joao Arriscado] Univ Coimbra, Ctr Estudos Sociais, Coimbra, Portugal.
RP de Souza, CTV (corresponding author), Fundacao Oswaldo Cruz, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM claudiateresa.souza@fiocruz.br
CR Barros S, 2007, REV ESC ENFERM USP, V41, P815, DOI 10.1590/S0080-62342007000500013
   Bourgois P, 2017, ACAD MED, V92, P299, DOI 10.1097/ACM.0000000000001294
   Ferreira P, 2020, SOMATO SPHERE SCI ME
   Lima Fabiana Araújo, 2016, Physis, V26, P157, DOI 10.1590/S0103-73312016000100010
   Lima ICV, 2018, ESC ANNA NERY, V22
   Queiroz AG, 2015, PESQUI PRAT PSICOSSO, V10, P171
   SANTOS B. S., 2019, FIM IMPERIO COGNITIV
   Secretaria de Atencao Primaria a Saude Ministerio da Saude, 2020, PROT MAN CLIN COR CO
   Silva RC, 2002, METODOLOGIAS PARTICI
   WALDOW VR, 2015, INVESTIG ENFERM IMAG, V17, P13, DOI DOI 10.11144/JAVERIANA.IE17-1.EPDC
   Waldow VR, 2012, CUIDAR EXPRESSAO HUM
   WHO, COR DIS COVID 19 PAN
NR 12
TC 0
Z9 0
U1 14
U2 14
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2020
VL 36
IS 6
AR e00115020
DI 10.1590/0102-311X00115020
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MH3RC
UT WOS:000546649700001
PM 32609168
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Pachiega, J
   Afonso, AJD
   Sinhorin, GT
   de Alencar, BT
   de Araujo, MDM
   Longhi, FG
   Zanetti, AD
   Espinosa, OA
AF Pachiega, Julianne
   dos Santos Afonso, Alexandre Jose
   Sinhorin, Gessica Thais
   de Alencar, Bianca Teshima
   Miranda de Araujo, Marta dos Santos
   Longhi, Fabiana Gulin
   dos Santos Zanetti, Andernice
   Espinosa, Omar Ariel
TI Chronic heart diseases as the most prevalent comorbidities among deaths
   by COVID-19 in Brazil
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE COVID-19; Prevalence; Deaths; Comorbidities; Brazil; Heart disease;
   Diabetes
AB Age, sex and presence of comorbidities are risk factors associated with COVID-19. Hypertension, diabetes and heart disease are the most common comorbidities in patients with COVID-19. The objective of this study was to estimate the prevalence of patients with comorbidities who died of COVID-19 in Brazil. Searches of data were carried out on the official pages of the 26 State health departments and the federal district. The random-effect method was used to calculate the prevalence of patients with comorbidities who died. From the beginning of the pandemic in Brazil until May 20, 2020, 276,703 cases of COVID-19 were notified in Brazil, 6.4% died, 58.6% of whom were male. The prevalence of comorbidities among deaths was 83% (95% CI: 79 - 87), with heart disease and diabetes being the most prevalent. To our knowledge, this study represents the first large analysis of cases of patients with confirmed COVID-19 in Brazil. There is a high prevalence of comorbidities (83%) among patients who died from COVID-19 in Brazil, with heart disease being the most prevalent. This is important considering the possible secondary effects produced by drugs such as hydroxychloroquine.
C1 [Pachiega, Julianne; dos Santos Afonso, Alexandre Jose; Sinhorin, Gessica Thais] Univ Estado Mato Grosso, Fac Ciencias Saude, Dept Med, Caceres, MG, Brazil.
   [de Alencar, Bianca Teshima] Univ Estado Mato Grosso, Fac Ciencias Saude, Dept Enfermagem, Caceres, MG, Brazil.
   [Miranda de Araujo, Marta dos Santos; dos Santos Zanetti, Andernice] Univ Estado Mato Grosso, Fac Ciencias Agr & Biol, Programa Posgrad Ciencias Ambientais, Caceres, MG, Brazil.
   [Longhi, Fabiana Gulin] Ctr Brasileiro Para Cuidado Saude Informado Evide, Ctr Excelencia Inst Joanna Briggs, Sao Paulo, SP, Brazil.
   [Espinosa, Omar Ariel] Fac Pantanal, Caceres, MG, Brazil.
RP Espinosa, OA (corresponding author), Fac Pantanal, Av Sao Luiz 2522, BR-78200000 Caceres, MT, Brazil.
EM omer.espinosa@fapan.edu.br
RI ; Espinosa, Omar Ariel/L-8549-2018
OI Alencar, Bianca Teshima de/0000-0001-6812-3494; Espinosa, Omar
   Ariel/0000-0002-0912-9527
CR Boulware D.R., 2020, N ENGL J MED
   Brasil. Ministerio da Saude, 2020, B EP ESP COE COVID 1
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, J GERONTOL A-BIOL
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Du RH, 2020, ANN AM THORAC SOC
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Espinosa OA, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062043, 10.1590/s1678-9946202062043]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e132
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
NR 17
TC 1
Z9 1
U1 1
U2 1
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2020
VL 62
AR e45
DI 10.1590/S1678-9946202062045
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA MH3WL
UT WOS:000546663600002
PM 32609257
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fawad, M
   Mubarik, S
   Malik, SS
   Hao, YY
   Yu, CH
   Ren, JL
AF Fawad, Muhammad
   Mubarik, Sumaira
   Malik, Saima Shakil
   Hao, Yangyang
   Yu, Chuanhua
   Ren, Jingli
TI Trend Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2
   (SARS-CoV-2) Transmission in 16 Cities of Hubei Province, China
SO CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE SARS-CoV-2; death; trends; cities; Wuhan; China
ID MIDDLE-EAST; OUTBREAK; PNEUMONIA; IMPACT; WUHAN; DRUGS
AB Objective: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected by researchers from a patient in Wuhan, Hubei province, China, in December 2019, and broke out in January 2020. Then, the pandemic was detected in countries around the world. Therefore, precise estimates of its current and future trends are highly required for future policy implications.
   Methods: We retrieved data from the Health Commission of Hubei, China. Logistic-S curve model was used to estimate the current and future trends of SARS-CoV-2-infected cases among 16 cities of Hubei, China from Jan-11 to Feb-24, 2020.
   Results: Out of 64,287 confirmed cases of SARS-CoV-2 infection in Hubei, higher percentage of cases were in Wuhan and Xiaogan. The highest death percentage was found in Wuhan and Qianjiang. A significant percentage of cures were found in Enshi Prefecture and Huanggang, while Wuhan showed the lowest percentage of cures. Rising trends in infected cases were observed throughout the study period, particularly in Wuhan, and a higher trend was observed after 12-Feb. Gradual decline trend of SARS-CoV-2 cases was observed during Feb-25 to Mar-15 in Hubei Province. Future forecast showed that the average number of SARS-CoV-2-infected cases might be decreased or stable in Hubei in the coming 20 days.
   Conclusion: The public must take precautionary measures in order to control and prevent disease spread and avoid extra travelling.
C1 [Fawad, Muhammad; Ren, Jingli] Zhengzhou Univ, Henan Acad Big Data, Zhengzhou 450052, Peoples R China.
   [Fawad, Muhammad; Hao, Yangyang] Zhengzhou Univ, Sch Math & Stat, Zhengzhou 450001, Peoples R China.
   [Mubarik, Sumaira; Yu, Chuanhua] Wuhan Univ, Sch Hlth Sci, Dept Epidemiol & Biostat, Wuhan 430071, Hubei, Peoples R China.
   [Malik, Saima Shakil] Univ Gujrat, Dept Zool, Gujrat 50700, Pakistan.
RP Ren, JL (corresponding author), Zhengzhou Univ, Henan Acad Big Data, Zhengzhou 450052, Peoples R China.
EM renjl@zzu.edu.cn
RI Fawad, Muhammad/AAH-6558-2020
OI Fawad, Muhammad/0000-0001-8921-4248
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [11771407]; CAE Advisory Project [2020-ZD-16]
FX This research is supported by the National Natural Science Foundation of
   China (Grant No. 11771407) and CAE Advisory Project (No. 2020-ZD-16).
   The funders had no role in the study design, data collection, analysis,
   decision to publish, or preparation of the manuscript. The APC was
   funded by Jingli Ren.
CR [Anonymous], 2020, COVID 19 GLOBAL PAND
   Arshad U, 2020, PRIORITISATION POTEN
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15
   DEBECKER A, 1994, TECHNOL FORECAST SOC, V46, P153, DOI 10.1016/0040-1625(94)90023-X
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Haynes B, 2020, CDC CONFIRMS ADDITIO, V26, P2020
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kucharavy D, 2007, CURRENT SCI IND REAL
   Kyurkchiev N., 2016, BIOMATH COMMUNICATIO, V3, P2, DOI [10.11 145/bmc.2016.12.171, DOI 10.11145/BMC.2016.12.171]
   Lau SKP, 2015, J VIROL, V89, P10532, DOI 10.1128/JVI.01048-15
   Li G, 2020, THERAPEUTIC OPTIONS
   Li J-PO, 2020, BMJ
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   Matsuda T, 2020, 200208802 ARXIV
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Momattin H, 2019, TRAVEL MED INFECT DI, V30, P9, DOI 10.1016/j.tmaid.2019.06.012
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Ryu S, 2020, ESTIMATE INFECT INDI
   Shen Z, 2004, EMERG INFECT DIS, V10, P256, DOI 10.3201/eid1002.030732
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Sookaromdee P, 2020, ASIAN PAC J TROP MED, V13, P139, DOI 10.4103/1995-7645.277516
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tao Y, 2017, J VIROL, V91, DOI 10.1128/JVI.01953-16
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang W, J MED VIROL
   Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yasri S, 2020, INT J PREVENTIVE MED, V11, DOI 10.4103/ijpvm.IJPVM_39_20
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 0
Z9 0
U1 1
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1349
J9 CLIN EPIDEMIOL
JI Clin. Epidemiol.
PY 2020
VL 12
BP 699
EP 709
DI 10.2147/CLEP.S254806
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MF6DV
UT WOS:000545431400001
PM 32669878
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Haeryfar, SMM
AF Haeryfar, S. M. Mansour
TI MAIT Cells in COVID-19: Heroes, Villains, or Both?
SO CRITICAL REVIEWS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; coronaviruses; pandemic; innate-like T cells; antiviral
   immunity; cytokine; inflammation; toxic shock; immunotherapy;
   vaccination
ID INVARIANT T-CELLS; RECEPTOR-ALPHA-CHAIN; TISSUE-REPAIR; ACTIVATION; MR1;
   TCR; IMMUNITY; DEFICIENCY; EXPRESSION; METASTASES
AB Mucosa-associated invariant T cells (MAIT cells) are unconventional, innate-like T lymphocytes with remarkable effector and immunoregulatory functions. They are abundant in the human peripheral blood and also enriched in mucosal layers and in the lungs, SARS-CoV-2's main ports of entry. Once activated, MAIT cells produce inflammatory cytokines and cytolytic effector molecules quickly and copiously. MAIT cells are best known for their antibacterial and antifungal properties. However, they are also activated during viral infections, typically in a cytokine-dependent manner, which may promote antiviral immunity. On the other hand, it is plausible to assume active roles for MAIT cells in infection-provoked cytokine storms and tissue damage. SARS-CoV-2 infection may be asymptomatic, mild, severe, or even fatal, depending on sex, age, the presence of preexisting morbidities, and the individual's immunological competence, or lack thereof, among other factors. Based on the available literature, I propose that MAIT cells regulate the host response to SARS-CoV-2 and constitute attractive targets in the prevention or clinical management of coronavirus disease 19 (COVID-19) and some of its complications. Unlike mainstream T cells, MAIT cells are restricted by a monomorphic antigen-presenting molecule called MHC-related protein 1 (MR1). Therefore, MR1 ligands should modify MAIT cell functions relatively uniformly in genetically diverse subjects and may be tested as immunotherapeutic agents or vaccine adjuvants in future studies.
C1 [Haeryfar, S. M. Mansour] Western Univ, Dept Microbiol & Immunol, 1151 Richmond St, London, ON N6A 5C1, Canada.
   [Haeryfar, S. M. Mansour] Western Univ, Dept Med, Div Clin Immunol & Allergy, London, ON, Canada.
   [Haeryfar, S. M. Mansour] Western Univ, Dept Surg, Div Gen Surg, London, ON, Canada.
   [Haeryfar, S. M. Mansour] Western Univ, Ctr Human Immunol, London, ON, Canada.
   [Haeryfar, S. M. Mansour] Lawson Hlth Res Inst, London, ON, Canada.
RP Haeryfar, SMM (corresponding author), Western Univ, Dept Microbiol & Immunol, 1151 Richmond St, London, ON N6A 5C1, Canada.
EM mansour.haeryfar@schulich.uwo.ca
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR)
FX I thank Patrick Rudak for critical discussions and for his expert
   assistance in generating Figure 1. Our work on COVID-19 is supported by
   the Canadian Institutes of Health Research.
CR Angele MK, 2014, VIRULENCE, V5, P12, DOI 10.4161/viru.26982
   Barathan M, 2016, EUR J CLIN INVEST, V46, P170, DOI 10.1111/eci.12581
   Boccardi V, 2020, GERIATRICS, V5, pE24
   Bolte FJ, 2017, GASTROENTEROLOGY, V153, P1392, DOI 10.1053/j.gastro.2017.07.043
   Boudinot P, 2016, P NATL ACAD SCI USA, V113, pE2983, DOI 10.1073/pnas.1600674113
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   CHEN QQ, 2020, J INFECTION, DOI DOI 10.1016/JTIN12020.04.021
   Chiba A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01333
   Clay CC, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-4
   Constantinides MG, 2019, SCIENCE, V366, P445, DOI 10.1126/science.aax6624
   Cooper AM, 2009, EUR J IMMUNOL, V39, P649, DOI 10.1002/eji.200839090
   Corbett AJ, 2014, NATURE, V509, P361, DOI 10.1038/nature13160
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   Cui Y, 2015, J CLIN INVEST, V125, P4171, DOI 10.1172/JCI82424
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Duployez C, 2020, EMERG INFECT DIS, V26, P1939, DOI 10.3201/eid2608.201413
   Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339
   Fernandez CS, 2015, IMMUNOL CELL BIOL, V93, P177, DOI 10.1038/icb.2014.91
   Finer N, 2020, CLIN OBES, V10, DOI 10.1111/cob.12365
   Franciszkiewicz K, 2016, IMMUNOL REV, V272, P120, DOI 10.1111/imr.12423
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Gu H., 2020, BIORXIV, DOI [10.1101/2020.05.02.073411, DOI 10.1101/2020.05.02.073411]
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo TX, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00247
   Haeryfar SMM, 2018, CANCER IMMUNOL IMMUN, V67, P1885, DOI 10.1007/s00262-018-2132-1
   Haeryfar SMM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00611
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hegde P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04450-y
   Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447
   Hinks TSC, 2019, CELL REP, V28, P3249, DOI 10.1016/j.celrep.2019.07.039
   Hinks TSC, 2016, AM J RESP CRIT CARE, V194, P1208, DOI 10.1164/rccm.201601-0002OC
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Howson LJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00303
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Jouan Y, 2020, FUNCTIONAL ALTERATIO, DOI [10.1101/2020.05.03.20089300, DOI 10.1101/2020.05.03.20089300]
   Keller AN, 2017, NAT IMMUNOL, V18, P402, DOI 10.1038/ni.3679
   Kelly J, 2019, IMMUNOL CELL BIOL, V97, P689, DOI 10.1111/imcb.12281
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Koff WC, 2020, NEW ENGL J MED, DOI [10.1056/NE1Mp2006761, DOI 10.1056/NE1MP2006761]
   Kwon YS, 2016, COPD, V13, P196, DOI 10.3109/15412555.2015.1069806
   Lamichhane R, 2019, CELL REP, V28, P3061, DOI 10.1016/j.celrep.2019.08.054
   LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097
   Law BMP, 2019, J AM SOC NEPHROL, V30, P1322, DOI 10.1681/ASN.2018101064
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Lee OJ, 2014, EXP GERONTOL, V49, P47, DOI 10.1016/j.exger.2013.11.003
   Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Legoux F, 2019, SCIENCE, V366, P494, DOI 10.1126/science.aaw2719
   Leng TQ, 2019, CELL REP, V28, P3077, DOI 10.1016/j.celrep.2019.08.050
   Lepore M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4866
   Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113
   Macedo A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109816
   Magalhaes I, 2015, J CLIN INVEST, V125, P1752, DOI 10.1172/JCI78941
   Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520
   Metcalf CJE, 2015, TRENDS IMMUNOL, V36, P753, DOI 10.1016/j.it.2015.10.004
   Miyazaki Y, 2011, INT IMMUNOL, V23, P529, DOI 10.1093/intimm/dxr047
   Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Paquin-Proulx D, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006154
   Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345
   Peckham H, 2020, SEX BIAS COVID 19 ME, DOI [10.21203/rs.3.rs-23651/v2, DOI 10.21203/RS.3.RS-23651/V2]
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1
   Rahimpour A, 2015, J EXP MED, V212, P1095, DOI 10.1084/jem.20142110
   Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958
   Rha MS, 2020, J HEPATOL, V73, P640, DOI 10.1016/j.jhep.2020.03.033
   Rudak PT, 2018, J LEUKOCYTE BIOL, V104, P473, DOI 10.1002/JLB.4RI0118-023R
   Salio M, 2020, P NATL ACAD SCI USA, V117, P10465, DOI 10.1073/pnas.2003136117
   Salio M, 2017, J IMMUNOL, V199, P2631, DOI 10.4049/jimmunol.1700615
   Salou M, 2019, TRENDS IMMUNOL, V40, P975, DOI 10.1016/j.it.2019.09.001
   Shaler CR, 2017, CANCER IMMUNOL IMMUN, V66, P1563, DOI 10.1007/s00262-017-2050-7
   Shaler CR, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001930
   Shivakumar P, 2009, J CLIN INVEST, V119, P2281, DOI 10.1172/JCI38879
   Soudais C, 2015, J IMMUNOL, V194, P4641, DOI 10.4049/jimmunol.1403224
   Suliman S, 2019, J IMMUNOL, V203, P2917, DOI 10.4049/jimmunol.1900674
   Szabo M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0671-1
   Szabo PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00401
   Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218
   Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907
   Touch S, 2018, FASEB J, V32, P5078, DOI 10.1096/fj.201800052RR
   Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van der Geest KSM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00752
   van Wilgenburg B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07207-9
   van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653
   Victor JR, 2020, CLIN REV ALLERG IMMU, V59, P371, DOI 10.1007/s12016-020-08784-8
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, CHEM RES CHINESE U, V36, P68, DOI 10.1007/s40242-019-0040-3
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Yamaguchi H, 1997, BIOCHEM BIOPH RES CO, V238, P697, DOI 10.1006/bbrc.1997.7379
   Yan JM, 2020, CANCER DISCOV, V10, P124, DOI 10.1158/2159-8290.CD-19-0569
   Ye LY, 2020, J ALLERGY CLIN IMMUN, V145, P1469, DOI 10.1016/j.jaci.2019.12.891
   Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953
   Zhao B, 2020, PROTEIN CELL, V11, P771, DOI 10.1007/s13238-020-00718-6
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
NR 100
TC 0
Z9 0
U1 7
U2 7
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1040-8401
EI 2162-6472
J9 CRIT REV IMMUNOL
JI Crit. Rev. Immunol.
PY 2020
VL 40
IS 2
BP 173
EP 184
DI 10.1615/CritRevImmunol.2020034943
PG 12
WC Immunology
SC Immunology
GA MG8VS
UT WOS:000546311900005
PM 32749095
OA Bronze
DA 2021-01-01
ER

PT J
AU Sedokani, A
   Feizollahzadeh, S
AF Sedokani, Amin
   Feizollahzadeh, Sadegh
TI Plasmapheresis, Anti-ACE2 and Anti-Fc gamma RII Monoclonal Antibodies: A
   Possible Treatment for Severe Cases of COVID-19
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; antibody-dependent enhancement; plasmapheresis;
   monoclonal antibodies
ID DEPENDENT ENHANCEMENT; CORONAVIRUS; INFECTION; RECEPTOR; OUTBREAK
AB In March 2020, the WHO declared the COVID-19 disease as a pandemic disease. There have been studies on the COVID-19 to find a certain treatment, but yet, there is no certain cure. In this article, we present a possible way to treat severe cases of COVID-19. Based on the previous studies, there are similarities between the spike antigens of SARS-CoV and SARS-CoV-2 viruses. It is expected that these similarities (structural and affinity to the receptor of ACE2) can lead to the same pathophysiological activity of the virus by the use of ACE2 and Fc gamma RII (the antibody-dependent enhancement mechanism). Therefore, we propose a way of washing out (by plasmapheresis) the possible antibodies against the spike protein of the virus out of patients' plasma to stop the antibody-dependent enhancement (ADE)-mediated infection of the immune system cells at the first phase of the treatment and simultaneous use of the anti-ACE2 with anti-Fc gamma RII monoclonal antibodies at the second phase. We propose these procedures for the patients that have no significant response for typical anti-viral, ARDS and conservative therapies, and the disease persists or progresses despite sufficient therapies.
C1 [Sedokani, Amin] Urmia Univ Med Sci, Med Fac, Cardiol Dept, 17 Sharivar St, Orumiyeh 571478334, Iran.
   [Feizollahzadeh, Sadegh] Urmia Univ Med Sci, Sch Allied Med Sci, Lab Sci, Med Immunol, Orumiyeh, Iran.
RP Sedokani, A (corresponding author), Urmia Univ Med Sci, Med Fac, Cardiol Dept, 17 Sharivar St, Orumiyeh 571478334, Iran.
EM A.sedokani@gmail.com
RI Sedokani, Amin/AAM-6004-2020
OI Sedokani, Amin/0000-0003-1325-3309
CR [Anonymous], 2020, WHO DIR GEN OP REM M
   [Anonymous], 2020, UNIPROTKB Q9BYF1 AC
   Cheung C. Y., 2010, Hong Kong Medical Journal, V16, P378
   DOUZINAS EE, 1992, CRIT CARE MED, V20, P57, DOI 10.1097/00003246-199201000-00017
   Geller C, 2012, VIRUSES-BASEL, V4, P3044, DOI 10.3390/v4113044
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gorbalenya A. E., 2020, SEVERE ACUTE RESP SY
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Kohli RS, 2006, DIGEST DIS SCI, V51, P2287, DOI 10.1007/s10620-006-9315-x
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Lu H, 2020, J VIROL, V94, DOI 10.1128/JVI.01894-19
   Malik YA, 2020, MALAYS J PATHOL, V42, P3
   MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500
   Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004
   Sullivan NJ, 2001, CURR TOP MICROBIOL, V260, P145
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang K, 2020, SARS COV 2 INVADES H
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zemans RL, 2017, THORAX, V72, P1, DOI 10.1136/thoraxjnl-2016-209170
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 1
Z9 1
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2020
VL 14
BP 2607
EP 2611
DI 10.2147/DDDT.S262491
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MH3TX
UT WOS:000546657000001
PM 32753842
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wei, ZX
   Tang, TT
   Jiang, SP
AF Wei, Z-X
   Tang, T-T
   Jiang, S-P
TI The antiviral mechanisms, effects, safety and adverse effects of
   chloroquine
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Chloroquine; Antiviral mechanisms; Antiviral effects; Safety; Adverse
   effects; COVID-19
ID RESPIRATORY SYNDROME CORONAVIRUS; ANTIRETROVIRAL THERAPY; IMMUNE
   ACTIVATION; VIRAL-INFECTIONS; HYDROXYCHLOROQUINE; INHIBITION;
   REPLICATION; DRUG; SARS
AB Chloroquine, a 4-aminoquinoline derivative, was initially used to treat malaria. It was later found to have immunomodulating, anti-infective, anti-thrombotic, anti-tumor, and metabolic effects. Recently, many studies have focused on the application of chloroquine in viral infections. Most in vitro studies suggested that chloroquine exerted some benefit in infections from viruses. However, animal experiment and clinical trials that attempted to use chloroquine in prevention or treatment of viral infections have reported disappointing results. It might be attributable to inadequate steadystate whole blood chloroquine concentration necessary for exerting its antiviral effects. A 16 pM/L steady-state whole blood concentration of chloroquine should suffice in antiviral treatment with minimal toxicity. Furthermore, chloroquine has both acute and cumulative toxicity. Hence, not only the appropriate treatment dose is crucial, the occurrence of adverse reactions should also be closely monitored and treated in time. Herein, we report the antiviral mechanisms, effects, safety and adverse effects of chloroquine.
C1 [Jiang, S-P] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pulm & Crit Care Med, Guangzhou, Guangdong, Peoples R China.
   Sun Yat Sen Univ, Inst Pulm Dis, Guangzhou, Guangdong, Peoples R China.
RP Jiang, SP (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pulm & Crit Care Med, Guangzhou, Guangdong, Peoples R China.
EM jiangshp@mail.sysu.edu.cn
FU Emergency Program for Major Public Health Event of Ministry of Science
   and Technology, Department of Science and Technology of Guangdong
   Province of China [2020B111113001]; Emergency Program for Guangzhou
   Regenerative Medicine and Health Guangdong Laboratory of China
   [2020GZR110106003]; Tencent Charity Foundation of China
FX This study was funded by the Emergency Program for Major Public Health
   Event of Ministry of Science and Technology, Department of Science and
   Technology of Guangdong Province of China (2020B111113001), the
   Emergency Program for Guangzhou Regenerative Medicine and Health
   Guangdong Laboratory of China (2020GZR110106003) and Tencent Charity
   Foundation of China.
CR Akpovwa H, 2016, CELL BIOCHEM FUNCT, V34, P191, DOI 10.1002/cbf.3182
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bergholz R, 2010, BRIT J OPHTHALMOL, V94, P1637, DOI 10.1136/bjo.2009.174458
   Borges MC, 2013, MEM I OSWALDO CRUZ, V108, P596, DOI 10.1590/S0074-02762013000500010
   Di Trani L, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-39
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   FISCHER VW, 1976, EXP MOL PATHOL, V25, P242, DOI 10.1016/0014-4800(76)90035-6
   FOX RI, 1993, LUPUS, V2, pS9, DOI 10.1177/096120339300200103
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   FRISKHOLMBERG M, 1979, CLIN PHARMACOL THER, V25, P345
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   Hwang DM, 2005, MOL PATHOL, V18, P1
   Jiang MC, 1996, BIOCHEM BIOPH RES CO, V226, P1, DOI 10.1006/bbrc.1996.1302
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Krafts K, 2012, PARASITOL RES, V111, P1, DOI 10.1007/s00436-012-2886-x
   KRZYSTYNIAK K, 1984, J GEN VIROL, V65, P227, DOI 10.1099/0022-1317-65-1-227
   LADIPO GOA, 1983, INT J CARDIOL, V4, P198, DOI 10.1016/0167-5273(83)90136-5
   Legssyer R, 2003, J INORG BIOCHEM, V94, P36, DOI 10.1016/S0162-0134(02)00633-5
   Long Jason, 2015, F1000Res, V4, P30, DOI 10.12688/f1000research.6085.1
   MacInty AC, 1988, J PHARM SCI, V77, P196
   MARKS JS, 1982, ANN RHEUM DIS, V41, P52, DOI 10.1136/ard.41.1.52
   Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5
   Martinson JA, 2010, ANTIMICROB AGENTS CH, V54, P871, DOI 10.1128/AAC.01246-09
   Megarbane B, 2010, CLIN TOXICOL, V48, P904, DOI 10.3109/15563650.2010.518969
   Multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0019
   Murray SM, 2010, J VIROL, V84, P12082, DOI 10.1128/JVI.01466-10
   Naarding MA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-6
   Neely Michael, 2003, Afr Health Sci, V3, P61
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Paton NI, 2012, JAMA-J AM MED ASSOC, V308, P353, DOI 10.1001/jama.2012.6936
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Piconi S, 2011, BLOOD, V118, P3263, DOI 10.1182/blood-2011-01-329060
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Shivanna V, 2014, VIROLOGY, V464, P287, DOI 10.1016/j.virol.2014.07.025
   Farias KJS, 2015, VIRAL IMMUNOL, V28, P161, DOI 10.1089/vim.2014.0090
   Farias KJS, 2014, MICROBIOL IMMUNOL, V58, P318, DOI 10.1111/1348-0421.12154
   Farias KJS, 2013, SCI WORLD J, DOI 10.1155/2013/282734
   Singh SK, 2016, SEMIN RESP CRIT CARE, V37, P572, DOI 10.1055/s-0036-1584796
   SPERBER K, 1995, CLIN THER, V17, P622, DOI 10.1016/0149-2918(95)80039-5
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91
   Sperber K, 1997, CLIN THER, V19, P913, DOI 10.1016/S0149-2918(97)80045-8
   THE GENERAL OFFICE OF THE NATIONAL HEALTH COMMIS- SION OF THE PEOPLE'S REPUBLIC OF CHINA THE OFFICE OF THE NATIONAL ADMINISTRATION OF TRADITIONAL CHINESE MEDICINE, 2020, NOT ADJ US DOS CHLOR
   THE GENERAL OFFICE OF THE NATIONAL HEALTH COMMIS- SION OF THE PEOPLE'S REPUBLIC OF CHINA THE OFFICE OF THE NATIONAL ADMINISTRATION OF TRADITIONAL CHINESE MEDICINE, 2020, NOT PUBL DIAGN TREAT
   van Loosdregt J, 2013, J ALLERGY CLIN IMMUN, V131, P1443, DOI 10.1016/j.jaci.2013.02.026
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weber GF, 2017, SEMIN IMMUNOPATHOL, V39, P517
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2016, CELL MOL IMMUNOL, V13, P432, DOI 10.1038/cmi.2016.1
NR 59
TC 0
Z9 0
U1 5
U2 5
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 12
BP 7164
EP 7172
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MD5SR
UT WOS:000544032800083
PM 32633413
DA 2021-01-01
ER

PT J
AU Sun, ZH
   Chen, C
   Li, W
   Martinez, DR
   Drelich, A
   Baek, DS
   Liu, XL
   Mellors, JW
   Tseng, CT
   Baric, RS
   Dimitrov, DS
AF Sun, Zehua
   Chen, Chuan
   Li, Wei
   Martinez, David R.
   Drelich, Aleksandra
   Baek, Du-San
   Liu, Xianglei
   Mellors, John W.
   Tseng, Chien-Te
   Baric, Ralph S.
   Dimitrov, Dimiter S.
TI Potent neutralization of SARS-CoV-2 by human antibody heavy-chain
   variable domains isolated from a large library with a new stable
   scaffold
SO MABS
LA English
DT Article
DE Therapeutic antibodies; coronaviruses; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; MONOCLONAL-ANTIBODIES; VIRUSES;
   HENDRA; NIPAH
AB Effective therapies are urgently needed for COVID-19. Here we describe the identification of a new stable human immunoglobulin G1 heavy-chain variable (VH) domain scaffold that was used for the construction of a large library, lCAT6, of engineered human VHs. This library was panned against the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. Two VH domains (VH ab6 and VH m397) were selected and fused to Fc for increased half-life in circulation. The VH-Fc ab6 and m397 specifically neutralized SARS-CoV-2 with high potencies (50% neutralization at 0.35 mu g/ml and 1.5 mu g/ml, respectively) as measured by two independent replication-competent virus neutralization assays. Ab6 and m397 competed with ACE2 for binding to RBD, suggesting a competitive mechanism of virus neutralization. These VH domains may have potential applications for prophylaxis and therapy of COVID-19 alone or in combination, as well as for diagnosis and as tools for research.
C1 [Sun, Zehua; Chen, Chuan; Li, Wei; Baek, Du-San; Liu, Xianglei; Mellors, John W.; Dimitrov, Dimiter S.] Univ Pittsburgh, Sch Med, Dept Med, Ctr Antibody Therapeut,Div Infect Dis, S848 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.
   [Martinez, David R.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Drelich, Aleksandra; Tseng, Chien-Te] Galveston Natl Lab, Dept Microbiol & Immunol, Ctr Biodef & Emerging Dis, Galveston, TX USA.
   [Mellors, John W.; Dimitrov, Dimiter S.] Abound Bio, Pittsburgh, PA USA.
RP Sun, ZH (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Ctr Antibody Therapeut,Div Infect Dis, S848 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.; Dimitrov, DS (corresponding author), Univ Pittsburgh, Dept Med, ScD Ctr Antibody Therapeut, Div Infect Dis,Sch Med, 930 Scaife Hall, Pittsburgh, PA 15261 USA.
EM zes20@pitt.edu; mit666666@pitt.edu
OI Baek, Du-San/0000-0002-5356-6716
FU University of Pittsburgh Medical Center; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI132178, AI108197]
FX This work was supported by the University of Pittsburgh Medical Center.
   [University of Pittsburgh Medical Center.]; NIH [AI132178 and AI108197].
CR Agrawal AS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31629
   BHARDWAJ D, 1995, J IMMUNOL METHODS, V179, P165, DOI 10.1016/0022-1759(94)00280-A
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105
   Dudgeon K, 2012, P NATL ACAD SCI USA, V109, P10879, DOI 10.1073/pnas.1202866109
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   IYER S, 1986, J BIOL RESP MODIF, V5, P548
   Kumar R, 2019, INT J BIOL MACROMOL, V135, P907, DOI 10.1016/j.ijbiomac.2019.06.006
   KUNG PC, 1983, INT J DERMATOL, V22, P67, DOI 10.1111/j.1365-4362.1983.tb03318.x
   Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Schuklenk U, 2020, BIOETHICS, V34, P325, DOI 10.1111/bioe.12744
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Tiller T, 2013, MABS-AUSTIN, V5, P445, DOI 10.4161/mabs.24218
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Ubah O, 2017, ADV EXP MED BIOL, V1053, P99, DOI 10.1007/978-3-319-72077-7_6
   Van Blarcom T, 2018, MABS-AUSTIN, V10, P256, DOI 10.1080/19420862.2017.1406570
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Ying TL, 2014, J VIROL, V88, P7796, DOI 10.1128/JVI.00912-14
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu Z, 2008, J INFECT DIS, V197, P846, DOI 10.1086/528801
   Zhu ZY, 2006, J VIROL, V80, P891, DOI 10.1128/JVI.80.2.891-899.2006
NR 23
TC 5
Z9 5
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PD JAN 1
PY 2020
VL 12
IS 1
AR UNSP 1778435
DI 10.1080/19420862.2020.1778435
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA ME2GX
UT WOS:000544478900001
PM 32544372
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Trindade, GG
   Caxito, SMC
   Xavier, AREO
   Xavier, MAS
   Brandao, F
AF Trindade, Guilherme G.
   Caxito, Samyra M. C.
   Xavier, Alessandra Rejane E. O.
   Xavier, Mauro A. S.
   Brandao, Fabiana
TI COVID-19: therapeutic approaches description and discussion
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE antivirals; antiparasitic; COVID-19; SARS-CoV-2; therapeutic approaches
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HIV PROTEASE INHIBITORS; SARS-CORONAVIRUS;
   RHEUMATOID-ARTHRITIS; ANTIMALARIAL ACTION; FAVIPIRAVIR T-705;
   EBOLA-VIRUS; CHLOROQUINE; HYDROXYCHLOROQUINE; PNEUMONIA
AB COVID-19 emerged in December 2019 in China, and since then, has disrupted global public health and changed economic paradigms. In dealing with the new Coronavirus, SARS-CoV-2, the world has not faced such extreme global fragility since the "Spanish flu" pandemic in 1918. Researchers globally are dedicating efforts to the search for an effective treatment for COVID-19. Drugs already used in a clinical setting for other pathologies have been tested as a new therapeutic approach against SARS-CoV-2, setting off a frenzy over the preliminary data of different studies. This work aims to compile and discuss the data published thus far. Despite the potential effects of some antivirals and antiparasitic against COVID-19, clinical studies must confirm real effectiveness. However, non-pharmacological approaches have proven to be the most efficient strategy to date.
C1 [Trindade, Guilherme G.] Univ Brasilia, Lab Clin Microbiol & Immunol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
   [Caxito, Samyra M. C.] AMIL United Hlth Grp UHG, 6580,SMAS Trecho 1, BR-70211970 Brasilia, DF, Brazil.
   [Caxito, Samyra M. C.] Inst Management & Hlth Fed Dist IGES DF, Dept Nursing, Quadra 400-600 S-N, BR-72630250 Brasilia, DF, Brazil.
   [Xavier, Alessandra Rejane E. O.; Xavier, Mauro A. S.] Univ Estadual Montes Claros, Ctr Biol & Hlth Sci, Microbiol Lab, Av Prof Rui Braga, BR-39401089 Montes Claros, MG, Brazil.
   [Brandao, Fabiana] Univ Brasilia, Dept Pharm, Lab Clin Microbiol & Immunol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
   [Brandao, Fabiana] Univ Brasilia, Nucleus Trop Med, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
RP Brandao, F (corresponding author), Univ Brasilia, Dept Pharm, Lab Clin Microbiol & Immunol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.; Brandao, F (corresponding author), Univ Brasilia, Nucleus Trop Med, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
EM fabianabrandao@unb.br
RI de Oliveira Xavier, Alessandra Rejane Ericsson/AAU-3361-2020
OI Guedes Trindade, Guilherme/0000-0003-3657-8368; Caxito, Samyra Mara
   Coelho/0000-0002-4266-2964; Brandao, Fabiana/0000-0001-8358-8062;
   Xavier, Mauro/0000-0002-0512-1616
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   AL HASAN SM, 2020, B WHO
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   ANVISA-AGENCIA NACIONAL DE VIGILANCIA SANITARIA, 2020, NOT TECN CLOR HIDR
   ANVISA-AGENCIA NACIONAL DE VIGILANCIA SANITARIA, 2020, COV 19 LIB PESQ COM
   Arakawa M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092336
   Atkeson A., 2020, WHAT WILL BE EC IMPA
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   BULKLEY DP, 2010, STRUCTURE THERMUS TH, DOI [10.2312/molva.20181103, DOI 10.2312/MOLVA.20181103]
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, 2020, INT GUID COLL HANDL
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cortegiani A, 2020, J CRIT CARE
   De Clercq E, 2019, CHEM-ASIAN J, V14, P3962, DOI 10.1002/asia.201900841
   Ferguson N., 2020, IMPACT NONPHARMACEUT
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham Dukes MN, 2016, MEYLERS SIDE EFFECTS, P253
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   HARDMAN JG, 2005, GOODMAN GILMAN BASES
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ison MG, 2017, CLIN CHEST MED, V38, P139, DOI 10.1016/j.ccm.2016.11.008
   Kelleni MT, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104874
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kirby BJ, 2011, DRUG METAB DISPOS, V39, P1070, DOI 10.1124/dmd.110.037523
   KROGSTAD DJ, 1987, AM J TROP MED HYG, V36, P213, DOI 10.4269/ajtmh.1987.36.213
   KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830
   LAAKSONEN AL, 1974, SCAND J RHEUMATOL, V3, P103, DOI 10.3109/03009747409115809
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lv ZT, 2015, HIV AIDS-RES PALLIAT, V7, P95, DOI 10.2147/HIV.S79956
   MADRID PB, ACS INFECT DIS, V1
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Midde NM, 2016, EXPERT OPIN INV DRUG, V25, P1189, DOI 10.1080/13543784.2016.1212837
   Millán-Oñate José, 2020, Infect., V24, P187, DOI 10.22354/in.v24i3.848
   Mitsuyasu RT, 1998, AIDS, V12, pF103, DOI 10.1097/00002030-199811000-00001
   Modrow S., 2013, MOL VIROLOGY, P185, DOI DOI 10.1007/978-3-642-20718-1_14
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Nagy PD, 2012, NAT REV MICROBIOL, V10, P137, DOI 10.1038/nrmicro2692
   Ng ML, 2003, J MED VIROL, V71, P323, DOI 10.1002/jmv.10499
   NIH, 2020, AD COVID 19 TREATM T
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Ornstein MH, 1996, ARTHRITIS RHEUM, V39, P157, DOI 10.1002/art.1780390122
   Paul David, 2013, World J Virol, V2, P32, DOI 10.5501/wjv.v2.i2.32
   PERTER DH, 1992, DRUGS, V44, P750, DOI DOI 10.2165/00003495-199244050-00007
   Pokorna J, 2009, VIRUSES-BASEL, V1, P1209, DOI 10.3390/v1031209
   Popert A J, 1976, Rheumatol Rehabil, V15, P235, DOI 10.1093/rheumatology/15.3.235
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Rang HP, 2007, RANG DALES PHARM
   REID C, 2015, VIRUSES, V7
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Romero-Brey I, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060160
   Romero-Brey I, 2014, VIRUSES-BASEL, V6, P2826, DOI 10.3390/v6072826
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   RUIZ ESTRADA MA, 2020, EC WAVES EFFECT WUHA
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Siegel D, 2017, J MED CHEM, V60, P1648, DOI 10.1021/acs.jmedchem.6b01594
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Simsek Yavuz S, 2020, TURK J MED SCI, V50, P611, DOI 10.3906/sag-2004-145
   Smith T., 2020, COVID 19 DRUG THERAP
   Tenore SB, 2009, BRAZ J INFECT DIS, V13, P371, DOI 10.1590/S1413-86702009000500012
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   WHO-WORLD HEALTH ORGANIZATION, 2020, WHO NAM COR DIS COVI
   WHO-WORLD HEALTH ORGANIZATION, 2020, EM PREP RESP DIS OUT
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   ZAND M, 2020, POTENTIAL MECH AGE R, DOI [10.31219/osf.io/f3pze, DOI 10.31219/OSF.IO/F3PZE]
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 97
TC 1
Z9 1
U1 3
U2 3
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PY 2020
VL 92
IS 2
AR e20200466
DI 10.1590/0001-3765202020200466
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA MA8YU
UT WOS:000542197700001
PM 32556054
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hrenak, J
   Zorad, S
   Simko, F
AF Hrenak, Jaroslav
   Zorad, Stefan
   Simko, Fedor
TI Renin-angiotensin system and SARS-CoV-2 interaction: underlying
   mechanisms and potential clinical implications
SO GENERAL PHYSIOLOGY AND BIOPHYSICS
LA English
DT Article
DE SARS-CoV-2; COVID-19; Angiotensin II; ACE 2; ACE-inhibitor; AT1R blocker
AB Renin-angiotensin system (RAS) inhibition supposedly increases the expression of angiotensin converting enzyme 2, serving as a binding site for SARS-CoV-2. Concerns arose regarding therapy with RAS inhibition during the COVID- 19 pandemic. However, the pharmacological restraining the classical RAS axis might be beneficial due to the reduction of deleterious effects of angiotensin II and enhancement of the anti-inflammatory angiotensin 1-7 pathway. Unless large controlled studies are performed, RAS inhibition remains the cornerstone therapy in populations with cardiovascular disorders.
C1 [Hrenak, Jaroslav] Univ Hosp Bern, Dept Cardiovasc Surg, Inselspital, Bern, Switzerland.
   [Hrenak, Jaroslav; Simko, Fedor] Comenius Univ, Fac Med, Inst Pathophysiol, Sasinkova 4, Bratislava 81372, Slovakia.
   [Zorad, Stefan; Simko, Fedor] Slovak Acad Sci, Biomed Res Ctr, Inst Expt Endocrinol, Bratislava, Slovakia.
   [Simko, Fedor] Comenius Univ, Fac Med, Dept Internal Med 3, Bratislava, Slovakia.
RP Simko, F (corresponding author), Comenius Univ, Fac Med, Inst Pathophysiol, Sasinkova 4, Bratislava 81372, Slovakia.
EM fedor.simko@fmed.uniba.sk
RI Zorad, Stefan/E-8740-2018
OI Zorad, Stefan/0000-0003-2082-4659
FU Scientific Grant Agency VEGAVedecka grantova agentura MSVVaS SR a SAV
   (VEGA) [1/0035/19, 2/0112/19]
FX This work was supported by Scientific Grant Agency VEGA (No. 1/0035/19
   and No. 2/0112/19).
CR Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hanff TC, 2020, CLIN INFECT DIS, V71, P870, DOI 10.1093/cid/ciaa329
   Imai Yumiko, 2008, Masui, V57, P302
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
NR 8
TC 1
Z9 1
U1 0
U2 0
PU GENERAL PHYSIOL AND BIOPHYSICS
PI BRATISLAVA
PA INST OF MOLEC PHYSIOL GENETICS SLOVAK ACAD OF SCI VLARSKA 5, 83334
   BRATISLAVA, SLOVAKIA
SN 0231-5882
EI 1338-4325
J9 GEN PHYSIOL BIOPHYS
JI Gen. Physiol. Biophys.
PY 2020
VL 39
IS 3
BP 203
EP 204
DI 10.4149/gpb_2020019
PG 2
WC Biochemistry & Molecular Biology; Biophysics; Physiology
SC Biochemistry & Molecular Biology; Biophysics; Physiology
GA MA8XI
UT WOS:000542193700001
PM 32525813
OA Bronze
DA 2021-01-01
ER

PT J
AU Guo, DZ
   Pan, SY
   Wang, MM
   Guo, YF
AF Guo, Dazhi
   Pan, Shuyi
   Wang, MaoMao
   Guo, Yufeng
TI Hyperbaric oxygen therapy may be effective to improve hypoxemia in
   patients with severe COVID-2019 pneumonia: two case reports
SO UNDERSEA AND HYPERBARIC MEDICINE
LA English
DT Article
DE COVID-2019 pneumonia; hyperbaric oxygen therapy; hypoxemia
AB Objectives: To determine whether hyperbaric oxygen (HBO2) therapy be effective to improve hypoxemia for severe COVID-19 pneumonia patients.
   Methods: Two male patients ages 57 and 64 years old were treated. Each met at least one of the following criteria: shortness of breath; respiratory rate (RR) >= 30 breaths/minute; finger pulse oxygen saturation (SpO(2)) <= 93% at rest; and oxygen index (P/F ratio: PaO2/FiO(2) <= 300 mmHg). Each case excluded any combination with pneumothorax, pulmonary bullae or other absolute contraindications to HBO2. Patients were treated with 1.5 atmospheres absolute HBO2 with an oxygen concentration of more than 95% for 60 minutes per treatment, once a day for one week. Patients' self-reported symptoms, daily mean SpO(2) (SO2), arterial blood gas analysis, D-dimer, lymphocyte, cholinesterase (che) and chest CT were conducted and measured.
   Results: For both patients, dyspnea and shortness of breath were immediately alleviated after the first HBO2 treatment and remarkably relieved after seven days of HBO2 therapy. The RR also decreased daily. Neither patient became critically ill. The decreasing trend of SO2 and P/F ratio was immediately reversed and increased day by day. The lymphocyte count and ratio corresponding to immune function gradually recovered. D-dimer corresponding to peripheral circulation disorders and serum cholinesterase, reflecting liver function had improved. Follow-up chest CT showed that the pulmonary inflammation had clearly subsided.
   Conclusion: Our preliminary uncontrolled case reports suggest that HBO2 therapy may promptly improve the progressive hypoxemia of patients with COVID-2019 pneumonia. However, the limited sample size and study design preclude a definitive statement about the potential effectiveness of HBO2 therapy to COVID-2019 pneumonia. It requires evaluation in randomized clinical trials in future.
C1 [Guo, Dazhi; Pan, Shuyi] Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hyperbar Oxygen, Beijing, Peoples R China.
   [Wang, MaoMao; Guo, Yufeng] Navy Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, MaoMao; Guo, Yufeng] Wuhan Huoshenshan Hosp, Wuhan, Hubei, Peoples R China.
RP Guo, DZ; Pan, SY (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hyperbar Oxygen, Beijing, Peoples R China.
EM guodazhigod1983@163.com; psy9992011@163.com
CR Al-Waili NS, 2006, THESCIENTIFICWORLDJO, V6, P425, DOI 10.1100/tsw.2006.78
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   CLARK JM, 1971, J APPL PHYSIOL, V30, P753
   FRACICA PJ, 1991, J APPL PHYSIOL, V71, P2352
   Goldfrank LR, 1994, GOLDFRANKS TOXICOLOG, P1211
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   National Health Commission of the People's Republic of China, 2020, CHIN COVID 19 DIAGN
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
   World Health Organization, 2020, COR DIS COVID 2019 S
   Zhong X, 2020, ZHONGHUA HANGHAI YIX, DOI [10.3760/cma.j.is sn.1009-6906.2020.0001., DOI 10.3760/CMA.J.ISSN.1009-6906.2020.0001, 10.3760/cma.j.issn.1009-6906.2020.0001]
   Zhong XL, 2020, 1 CASE HBOT CRITICAL
NR 15
TC 4
Z9 4
U1 4
U2 4
PU UNDERSEA & HYPERBARIC MEDICAL SOC INC
PI DURHAM
PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA
SN 1066-2936
J9 UNDERSEA HYPERBAR M
JI Undersea Hyperb. Med.
PY 2020
VL 47
IS 2
BP 181
EP 187
PG 7
WC Marine & Freshwater Biology; Medicine, Research & Experimental
SC Marine & Freshwater Biology; Research & Experimental Medicine
GA MA4LK
UT WOS:000541886500002
PM 32574433
DA 2021-01-01
ER

PT J
AU Zhang, LY
   Yu, JR
   Zhou, YW
   Shen, MH
   Sun, LT
AF Zhang, Leyin
   Yu, Jieru
   Zhou, Yiwen
   Shen, Minhe
   Sun, Leitao
TI Becoming a Faithful Defender: Traditional Chinese Medicine against
   Coronavirus Disease 2019 (COVID-19)
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Coronaviruses; Traditional Chinese Medicine; Intervention Effect; Review
AB The outbreak caused by COVID-19 is causing a major challenge to clinical management and a worldwide threat to public health. So far, there is no specific anticoronavirus therapy approved for the treatment of COVID-19. Recently, as the efficacy and safety of traditional Chinese medicine (TCM) is widely acknowledged, it has been brought to a crucial status by the public, governments, and World Health Organization (WHO). For a better popularization of TCM, governments have made several advances in regulations and policies for treatment and measures of novel coronavirus pneumonia (NCP). Therefore, on the basis of epidemiology and virology information, we reviewed relevant meta-analysis and clinical studies of anti-coronavirus therapeutics by TCM, in the aspect of mortality, symptom improvement, duration and dosage of corticosteroid, incidence of complications and the like. In addition, we also summarized preclinical rationale for anti-coronavirus activity by TCM in terms of virion assembly and release, as well as viral entry and replication, which could be a useful contribution for figuring out effective Chinese herbal medicine (CHM) for coronavirus, including ingredients from single monomeric compounds, Chinese herbs, Chinese herb extracts and Chinese herb formulas, or potential targets for medicine. We would like to see these relevant studies, ranging from basic researches to clinical application, could provide some idea on effects of CHM to combat COVID-19 or other coronaviruses, and also offer new thinking for the exploration of therapeutic strategies under the guidance of TCM.
C1 [Zhang, Leyin; Sun, Leitao] Zhejiang Chinese Med Univ, Clin Med Coll 1, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Yu, Jieru] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhou, Yiwen] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou 310053, Zhejiang, Peoples R China.
   [Shen, Minhe; Sun, Leitao] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Med Oncol, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
RP Sun, LT (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 1, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.; Sun, LT (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Med Oncol, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM sunnylt@zcmu.edu.cn
OI Sun, Leitao/0000-0002-1441-3899
CR Bauch CT, 2013, LANCET, V382, P662, DOI 10.1016/S0140-6736(13)61504-4
   Bian Yong-jun, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P658
   Chen CJ, 2008, J ETHNOPHARMACOL, V120, P108, DOI 10.1016/j.jep.2008.07.048
   Chen ZM, 2020, WORLD J PEDIATR, V16, P240, DOI 10.1007/s12519-020-00345-5
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   Ho TY, 2007, ANTIVIR RES, V74, P92, DOI 10.1016/j.antiviral.2006.04.014
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Kim JY, 2018, INT J ANTIMICROB AG, V52, P730, DOI 10.1016/j.ijantimicag.2018.05.003
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Lau KM, 2008, J ETHNOPHARMACOL, V118, P79, DOI 10.1016/j.jep.2008.03.018
   Li Jun, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P28
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li Zhijun, 2003, CHIN J INTEGR TRAD W, P214
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin SC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2253-8
   Liu XM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004882.pub3
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Luo WS, 2009, BIOSCI TRENDS, V3, P124
   NHC, 2020, NOT NOV COR INF DIAG
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Ren Ai-min, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P112
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008
   Wen Chih-Chun, 2011, J Tradit Complement Med, V1, P41
   Weng JR, 2019, VIRUS RES, V273, DOI 10.1016/j.virusres.2019.197767
   WHO, 2004, CAS DEF SURV SEV AC
   World Health Organization, 2019, MERS SIT UPD
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yi W.L., 2006, EXPT STUDY EFFECT SH
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu S.Y, 2003, LETT BIOTECHNOL, P390
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 36
TC 8
Z9 8
U1 22
U2 24
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2020
VL 48
IS 4
BP 763
EP 777
DI 10.1142/S0192415X2050038X
PG 15
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA MA3GI
UT WOS:000541805400001
PM 32349517
DA 2021-01-01
ER

PT J
AU Zhang, HT
   Huang, MX
   Liu, X
   Zheng, XC
   Li, XH
   Chen, GQ
   Xia, JY
   Hong, ZS
AF Zhang, Hai-Tao
   Huang, Ming-Xing
   Liu, Xi
   Zheng, Xin-Chun
   Li, Xing-Hua
   Chen, Gong-Qi
   Xia, Jin-Yu
   Hong, Zhong-Si
TI Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on
   COVID-19: A Retrospective Matched Case-Control Study
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Nature Herbal Medicine (NHM); Traditional Chinese Medicine; Corona Virus
   Disease 2019 (COVID-19); Treatment Approach; Clinical Study
ID PNEUMONIA; WUHAN; CHINA
AB Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group (3.4 +/- 2.4 days) was significantly shorter than that in the control group (5.6 +/- 2.2 days) (p = 0:03). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) (p = 0:03). Compared with the control group (7:5 +/- 1:6), the duration for improvement (DI) of chest CT in the NHM group (5.6 +/- 2.3) was significantly shorter (p = 0: 04). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19.
C1 [Zhang, Hai-Tao; Huang, Ming-Xing; Liu, Xi; Zheng, Xin-Chun; Li, Xing-Hua; Chen, Gong-Qi; Xia, Jin-Yu; Hong, Zhong-Si] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 5, Zhuhai, Guangdong, Peoples R China.
RP Xia, JY; Hong, ZS (corresponding author), Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 5, 52 MeiHua East Rd, Zhuhai City, Guangdong, Peoples R China.
EM xiajinyu@mail.sysu.edu.cn; hongzhs@sysu.edu.cn
FU special research project on infectious disease emergency response of the
   Guangdong administration of traditional Chinese medicine
FX We thank the imaging center of our hospital, The Fifth Affiliated
   Hospital of Sun Yat-sen University, for providing the imaging technical
   support. We also thank the Chinese medicine pharmacy of our hospital for
   its professional preparation of NHM, as well as all our colleagues and
   study volunteers working in the COVID-19 isolation ward. Additionally,
   we thank Katie Oakley, Ph.D., from Liwen Bianji, Edanz Editing China
   (www.liwenbianji.cn/ac), for editing the English text of a draft of this
   manuscript. This work was supported by the special research project on
   infectious disease emergency response of the Guangdong administration of
   traditional Chinese medicine.
CR Ahn M, 2020, ADV TRADIT MED, DOI 10.1007/s13596-020-00452-8
   [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   [Anonymous], 2020, 51 WHO
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gale J., 2020, BLOOMBERG
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Kwon SH, 2015, J MED FOOD, V18, P762, DOI 10.1089/jmf.2014.3341
   Lee YR, 2017, J ETHNOPHARMACOL, V198, P109, DOI 10.1016/j.jep.2016.12.049
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   National Center for Clinical Medicine Research in Children's Health and Disease, 2020, GUID PNEUM DIAGN TRE
   National Health Commission of China, 2020, NOT PREV CONTR PNEUM
   National Health Commission of China, 2020, NOT ISS PNEUM DIAGN
   National Health Commission of China and Tongji Hospital of Huazhong University of Science and Technology, 2020, CONS DIAGN MAN SEV N
   Niu M. R., 2020, J TRADIT CHIN MED, DOI [10.19540/j.cnki.cjcmm.20200206.501, DOI 10.19540/J.CNKI.CJCMM.20200206.501]
   Niu PH, 2018, SCI CHINA LIFE SCI, V61, P1280, DOI 10.1007/s11427-018-9343-8
   Peng J, 2020, CHIN J CONT PEDIAT, V22, P1
   Pi Jian-hui, 2015, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V31, P89
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu B, CHIN J EXP TRADIT ME, DOI [10.13422/j.cnki.syfjx.20201029, DOI 10.13422/J.CNKI.SYFJX.20201029]
   Xu X, 2020, CRIT REV BIOCHEM MOL, V55, P1, DOI 10.1080/10409238.2020.1726279
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou P. X.L., 2020, NATURE, V578, P7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   姜毅, 2020, [中华实用儿科临床杂志, Chinese Journal of Applied Clinical Pediatrics], V35, P81
NR 31
TC 2
Z9 2
U1 14
U2 14
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2020
VL 48
IS 4
BP 779
EP 792
DI 10.1142/S0192415X20500391
PG 14
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA MA3GI
UT WOS:000541805400002
PM 32420751
DA 2021-01-01
ER

PT J
AU Staszkiewicz, P
   Chomiak-Orsa, I
   Staszkiewicz, I
AF Staszkiewicz, Piotr
   Chomiak-Orsa, Iwona
   Staszkiewicz, Igor
TI Dynamics of the COVID-19 Contagion and Mortality: Country Factors,
   Social Media, and Market Response Evidence From a Global Panel Analysis
SO IEEE ACCESS
LA English
DT Article
DE Pandemics; Economics; Viruses (medical); Social networking (online);
   Education; Crisis management; economic recession; financial markets;
   SARS-CoV-2; social media
ID CORONAVIRUS; CHALLENGES; EPIDEMIC; HEALTH
AB This research asks how an epidemic affects human behaviour. Probably the COVID-19 contagion is the most adverse global public health, economic, social, and technological stress since the Second World War. It affects almost all countries and challenges the globalisation particularly the global supply chain. The research community struggles with the multidimensional consequences of the SARS-CoV-2 virus infections. The critical goal is to quickly implement an efficient vaccine, as the society faces a tradeoff between death exposure and the size of the economic downturn. With this paper, we search for factors affecting contagion, mortality, and the time span between the country virus inception and first death. Additionally, we analyse the development of social media and financial markets. We applied a panel data set on all of the countries across the globe from 31 December 2019 until 31 March 2020 to investigate the patterns of epidemic development. We examined 7,642 country-daily data. We constructed classification tree regression, panel, and cross-sectional regression models. Our results support the conclusion that: 1) the speed of severity and contagion is different between themselves and across continents, 2) financial markets and social media respond differently to factors affecting contagion and severity, and 3) the time span between the first contagion in the economy and first death case cannot be plausibly explained with time-invariant variables. This research supports the policymakers with robust data for the informative allocation of scarce resources.
C1 [Staszkiewicz, Piotr] SGH Warsaw Sch Econ, PL-02554 Warsaw, Poland.
   [Chomiak-Orsa, Iwona] Wroclaw Univ Econ, Chair Business Intelligence Management, PL-53345 Warsaw, Poland.
   [Staszkiewicz, Igor] XIV High Sch Stanislaw Stasz Warsaw, PL-02010 Warsaw, Poland.
RP Staszkiewicz, P (corresponding author), SGH Warsaw Sch Econ, PL-02554 Warsaw, Poland.
EM piotr.staszkiewicz@mail.com
RI Staszkiewicz, Piotr/AAD-7991-2019; Staszkiewicz, Piotr/F-2923-2011
OI Staszkiewicz, Piotr/0000-0002-2251-2360
FU Ministry of Science and Higher Education in PolandMinistry of Science
   and Higher Education, Poland [015/RID/2018/192, SGH-KNOP/DB/20]
FX This work was supported in part by the Ministry of Science and Higher
   Education in Poland under Project 015/RID/2018/192, and in part by
   SGH-KNOP/DB/20.
CR Almarzooq ZI, 2020, J AM COLL CARDIOL, V75, P2635, DOI 10.1016/j.jacc.2020.04.015
   [Anonymous], 2018, R LANG ENV STAT COMP
   Betsch C, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0866-1
   Bwire GM, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00201-2
   Calda P, 2020, AKTUALNI GYNEKOL POR, V12, P17
   Catton H, 2020, INT NURS REV, V67, P4, DOI 10.1111/inr.12578
   Chater N, 2020, NAT HUM BEHAV, V4, P439, DOI 10.1038/s41562-020-0865-2
   Chatterjee P, 2020, LANCET, V395, P675, DOI 10.1016/S0140-6736(20)30459-1
   Emma H. B., 2020, SWISS MED WKLY, V150, P1
   Fitch Ratings, 2020, DEEP GLOB REC 2020 C
   Gao PC, 2020, ENVIRON PLANN A, V52, P698, DOI 10.1177/0308518X20910162
   Godlewska-Majkowska H., 2019, EUR RES STUD J, V22, P290, DOI [10.35808/ersj/1510, DOI 10.35808/ERSJ/1510]
   Govindarajan V., 2020, HARVARD BUS REV  MAR
   Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000424
   Hu ZL, 2020, SCI CHINA LIFE SCI, V63, P706, DOI 10.1007/s11427-020-1661-4
   Ji LN, 2020, WORLD J PEDIATR, V16, P267, DOI 10.1007/s12519-020-00356-2
   Johann M, 2016, BENCHMARKING, V23, P1860, DOI 10.1108/BIJ-04-2015-0038
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e88
   Kolesnik J, 2020, J BANK REGUL, DOI 10.1057/s41261-020-00125-1
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   Krajewski P, 2017, COMP ECON RES, V20, P21, DOI 10.1515/cer-2017-0002
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li HJ, 2020, IEEE T IND INFORM, V16, P5327, DOI 10.1109/TII.2019.2960835
   Li HJ, 2020, PHYSICA A, V542, DOI 10.1016/j.physa.2019.123514
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   MacKenzie D, 2020, NEW SCI, V245, P10, DOI 10.1016/S0262-4079(20)30525-X
   MOBERLY T, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M806
   Nocon A, 2019, J BUS ECON MANAG, V20, P424, DOI 10.3846/jbem.2019.9606
   Oke J., 2020, GLOBAL COVID 19 CASE
   Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600
   Rauliajtys-Grzybek M, 2017, J HEALTH MANAG, V19, P275, DOI 10.1177/0972063417699690
   Ritchie H., 2020, CAUSES DEATH
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Shi Y, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.22
   Staszkiewicz P, 2018, PRZEM CHEM, V97, P1769, DOI 10.15199/62.2018.10.27
   Staszkiewicz P, 2018, SPR PROC BUS ECON, P219, DOI 10.1007/978-3-319-76228-9_21
   StataCorp, 2015, STAT STAT SOFTW REL
   Strzelecki A, 2020, BRAIN BEHAV IMMUN, V88, P950, DOI 10.1016/j.bbi.2020.04.042
   Thackeray D., 2020, COVID 19 COMPARES SE
   Turek D., 2017, INT J CONT MANAGE, V16, P267, DOI [10.4467/24498939IJCM.17.018.7531, DOI 10.4467/24498939IJCM.17.018.7531]
   van Staden C, 2020, NAT HUM BEHAV, V4, P443, DOI 10.1038/s41562-020-0852-7
   Wang CY, 2020, J RISK FINANC MANAG, V13, DOI 10.3390/jrfm13020036
   Wang X, 2020, BIOSCI TRENDS, V14, P3, DOI 10.5582/bst.2020.01043
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Xiao CF, 2020, PSYCHIAT INVEST, V17, P175, DOI 10.30773/pi.2020.0047
   Yang CY, 2020, MATH BIOSCI ENG, V17, P2708, DOI 10.3934/mbe.2020148
   Yang S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.66
   Zhang HW, 2020, ACAD RADIOL, V27, P463, DOI 10.1016/j.acra.2020.02.003
   Zhou WK, 2020, MATH BIOSCI ENG, V17, P2693, DOI 10.3934/mbe.2020147
NR 49
TC 7
Z9 7
U1 12
U2 12
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 106009
EP 106022
DI 10.1109/ACCESS.2020.2999614
PG 14
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA MD5RS
UT WOS:000544030000001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Celik, O
   Celik, N
   Aydin, S
   Baysal, B
   Aydin, S
   Saglam, A
   Gursu, Y
   Dalkilic, S
   Ulas, M
   Ozcil, MD
   Tayyar, AT
   Cengiz, F
   Ugur, K
   Akkoc, RF
   Ersahin, AA
AF Celik, Onder
   Celik, Nilufer
   Aydin, Suleyman
   Baysal, Bora
   Aydin, Suna
   Saglam, Aylin
   Gursu, Yagmur
   Dalkilic, Semih
   Ulas, Mustafa
   Ozcil, Mustafa D.
   Tayyar, Ahter T.
   Cengiz, Ferhat
   Ugur, Kader
   Akkoc, Ramazan Fazil
   Ersahin, Aynur A.
TI Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear
   factor-kappa b pathways in non-pregnant and pregnant populations
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE SARS-CoV-2; ACE2; Viral entry pathways; Nuclear factor-kappa B;
   Proteasome; Lipoxin; Off label drugs; Serine protease
ID ACUTE-RESPIRATORY-SYNDROME; ACUTE LUNG INJURY; CONVERTING ENZYME 2;
   SYNDROME CORONAVIRUS; SARS CORONAVIRUS; LIPID MEDIATORS; RECEPTOR;
   PROTEIN; ENTRY; RESOLUTION
AB It can be misleading to think that the new severe acute respiratory-syndrome coronavirus (SARS-COV2) which has a very strong mutation and adaptation capabilities, uses only the angiotensin-converting enzyme II (ACE2) pathway to reach target cells. Despite all the precautions taken, the pandemic attack continues and the rapid increase in the number of deaths suggest that this virus has entered the cell through different pathways and caused damage through different mechanisms. The main reason why the ACE2 pathway comes to the fore in all scientific studies is that this receptor is located at the entry point of basic mechanisms that provide alveolo-capillary homeostasis. SARS-CoV-2 has to use nuclear factor-kappa B (NF-kappa B), caveloae, clathrin, lipoxin, senile protease and pro-teasome pathways in addition to ACE2 to enter the target cell and initiate damage. For this reason, while new drug development studies are continuing, in order to be beneficial to patients in their acute period, it is imperative that we are able to come up with drugs that activate or inhibit these pathways and are currently in clinical use. It is also critical that we adopt these new pathways to the treatment of pregnant women affected by SARS-CoV-2, based on the scientific data we use to treat the general population.
C1 [Celik, Onder] Private Clin Obstet & Gynecol, Usak, Turkey.
   [Celik, Nilufer] Dr Behcet Uz Childrens Res & Training Hosp, Dept Biochem, Izmir, Turkey.
   [Aydin, Suleyman] Firat Univ, Dept Med Biochem, Sch Med, Elazig, Turkey.
   [Baysal, Bora] Usak Univ, Fac Med, Dept Neonatol, Usak, Turkey.
   [Aydin, Suna] Fethi Sekin City Hosp, Dept Cardiovasc Surg, Elazig, Turkey.
   [Saglam, Aylin] Aksaray Univ, Dept Obstet & Gynecol, Sch Med, Aksaray, Turkey.
   [Gursu, Yagmur] Bezm I Alem Univ, Fac Med, Dept Family Med, Istanbul, Turkey.
   [Dalkilic, Semih] Firat Univ, Dept Mol Biol & Genet, Fac Sci Elazig, Elazig, Turkey.
   [Ulas, Mustafa] Firat Univ, Dept Physiol, Sch Med, Elazig, Turkey.
   [Ozcil, Mustafa D.] Mustafa Kemal Univ, Dept Obstet & Gynecol, Sch Med, Antakya, Turkey.
   [Tayyar, Ahter T.; Cengiz, Ferhat; Ersahin, Aynur A.] Bahcesehir Univ, Dept Obstet & Gynecol, IVF Clin, Sch Med, Istanbul, Turkey.
   [Ugur, Kader] Firat Univ, Sch Med, Dept Internal Med, Elazig, Turkey.
   [Akkoc, Ramazan Fazil] Firat Univ, Dept Anat, Sch Med, Elazig, Turkey.
RP Aydin, S (corresponding author), Firat Univ, Dept Med Biochem, Sch Med, Elazig, Turkey.
EM saydin1@hotmail.com
RI Ugur, Kader/W-7053-2018
CR Adams J, 1999, CANCER RES, V59, P2615
   Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Berger A, 2000, BRIT MED J, V321, P424, DOI 10.1136/bmj.321.7258.424
   BUCKLEY S, 1998, AM J PHYSIOL, V274, pL71
   Cai QC, 2003, ACTA PHARMACOL SIN, V24, P1051
   Celik O, 2008, HUM REPROD, V23, P2458, DOI 10.1093/humrep/den246
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen QF, 2018, INNATE IMMUN-LONDON, V24, P285, DOI 10.1177/1753425918785008
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cheng JPX, 2016, TRENDS CELL BIOL, V26, P177, DOI 10.1016/j.tcb.2015.10.010
   Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220
   Chopra M, 2009, EXP BIOL MED, V234, P361, DOI 10.3181/0811-MR-318
   Cortjens B, 2018, THORAX, V73, P578, DOI 10.1136/thoraxjnl-2017-210289
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Eulitz D, 2007, APOPTOSIS, V12, P1511, DOI 10.1007/s10495-007-0078-4
   Filep JG, 2013, P NATL ACAD SCI USA, V110, P18033, DOI 10.1073/pnas.1317798110
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853
   Gien Jason, 2020, Neoreviews, V21, pe157, DOI 10.1542/neo.21-3-e157
   Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo SW, 2007, GYNECOL OBSTET INVES, V63, P71, DOI 10.1159/000096047
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P777, DOI 10.1002/ddr.21689
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoeltzenbein M, 2018, CLIN RES CARDIOL, V107, P679, DOI 10.1007/s00392-018-1234-2
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horie S, 2005, FERTIL STERIL, V83, P1530, DOI 10.1016/j.fertnstert.2004.11.042
   Huentelman MJ, 2004, HYPERTENSION, V44, P903, DOI 10.1161/01.HYP.0000146120.29648.36
   Imai Y, 2008, EXP PHYSIOL, V93, P543, DOI 10.1113/expphysiol.2007.040048
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Joki-Korpela P, 2001, J VIROL, V75, P1958, DOI 10.1128/JVI.75.4.1958-1967.2001
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P419, DOI 10.1001/jama.2019.22438
   Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x
   Kogo H, 2004, J BIOL CHEM, V279, P25574, DOI 10.1074/jbc.M310807200
   Krishna A, 2019, BIOPHYS J, V116, P69, DOI 10.1016/j.bpj.2018.11.3127
   Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y
   Levy A, 2008, AM J PHYSIOL-REG I, V295, pR1953, DOI 10.1152/ajpregu.90592.2008
   Linton EA, 2003, PLACENTA, V24, P745, DOI 10.1016/S0143-4004(03)00106-1
   Liu F., 2020, INT J INFECT DIS
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu W, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165431
   Lyden TW, 2002, PLACENTA, V23, P640, DOI 10.1053/plac.2002.0847
   Magagnoli J, 2020, OUTCOMES HYDROXYCHLO
   Mahey R, 2013, BMJ CASE REP, V2013
   Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875
   Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626
   Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109
   Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133
   Ortiz-Munoz G, 2014, BLOOD, V124, P2625, DOI 10.1182/blood-2014-03-562876
   Padhan K, 2007, J GEN VIROL, V88, P3067, DOI 10.1099/vir.0.82856-0
   Papait A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010127
   Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645
   ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931
   Sekheri M, 2020, P NATL ACAD SCI USA, V117, P7971, DOI 10.1073/pnas.1920193117
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002
   Seval GC, 2018, EXPERT OPIN DRUG SAF, V17, P953, DOI 10.1080/14740338.2018.1513487
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Skeggs L., 1980, ADV EXP MED BIOL, V130, P1, DOI DOI 10.1007/978-1-4615-9173-3_16250339
   Supe S, 2016, BRIT J PHARMACOL, V173, P1618, DOI 10.1111/bph.13462
   Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366
   Thomas BJ, 2014, SCI REP, V4, P1
   Tsubosaka M, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-03231-3
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Wang H, 2019, VIROLOGY, V528, P118, DOI 10.1016/j.virol.2018.12.012
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang YX, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4938-7
   Weber-Schoendorfer C, 2020, J HYPERTENS, V38, P133, DOI 10.1097/HJH.0000000000002233
   Wong SF, 2003, BJOG-INT J OBSTET GY, V110, P641, DOI 10.1046/j.1471-0528.2003.03008.x
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Xia J, 2013, INFLAMMATION, V36, P1431, DOI 10.1007/s10753-013-9683-2
   Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022
   Xiao HL, 2016, N-S ARCH PHARMACOL, V389, P1159, DOI 10.1007/s00210-016-1278-7
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 88
TC 0
Z9 1
U1 6
U2 6
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2020
VL 66
IS 3
BP 221
EP 229
DI 10.14715/cmb/2020.66.3.36
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA LY3EW
UT WOS:000540410000036
PM 32538775
DA 2021-01-01
ER

PT J
AU Ugurel, OM
   Ata, O
   Turgut-Balik, D
AF Ugurel, Osman Mutluhan
   Ata, Oguz
   Turgut-Balik, Dilek
TI An updated analysis of variations in SARS-CoV-2 genome
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; genomic diversity; codon bias; multiple sequence
   alignment
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; CODON USAGE;
   FUNCTIONAL RECEPTOR; RNA; VIRUS; PROTEINS; MERS; RECOMBINATION;
   EPIDEMIOLOGY
AB A novel pathogen, named SARS-CoV-2, has caused an unprecedented worldwide pandemic in the first half of 2020. As the SARS-CoV-2 genome sequences have become available, one of the important focus of scientists has become tracking variations in the viral genome. In this study, 30366 SARS-CoV-2 isolate genomes were aligned using the software developed by our group (ODOTool) and 11 variations in SARS-CoV-2 genome over 10% of whole isolates were discussed. Results indicated that, frequency rates of these 11 variations change between 3.56%-88.44 % and these rates differ greatly depending on the continents they have been reported. Despite some variations being in low frequency rate in some continents, C14408T and A23403G variations on Nsp12 and S protein, respectively, observed to be the most prominent variations all over the world, in general, and both cause missense mutations. It is also notable that most of isolates carry C14408T and A23403 variations simultaneously and also nearly all isolates carrying the G25563T variation on ORF3a, also carry C14408T and A23403 variations, although their location distributions are not similar. All these data should be considered towards development of vaccine and antiviral treatment strategies as well as tracing diversity of virus in all over the world.
C1 [Ugurel, Osman Mutluhan; Turgut-Balik, Dilek] Yildiz Tech Univ, Fac Chem & Met Engn, Dept Bioengn, Istanbul, Turkey.
   [Ugurel, Osman Mutluhan] Altinbas Univ, Sch Engn & Nat Sci, Dept Basic Sci, Istanbul, Turkey.
   [Ata, Oguz] Altinbas Univ, Sch Engn & Nat Sci, Dept Software Engn, Istanbul, Turkey.
RP Turgut-Balik, D (corresponding author), Yildiz Tech Univ, Fac Chem & Met Engn, Dept Bioengn, Istanbul, Turkey.
EM dilekbalik@gmail.com
RI Turgut-Balik, Dilek/AAZ-5212-2020; Ata, Oguz/O-2961-2016
OI Ata, Oguz/0000-0003-4511-7694
CR Angelini MM, 2013, MBIO, V4, DOI 10.1128/mBio.00524-13
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293
   Belalov IS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056642
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Briguglio I, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/213135
   BULMER M, 1987, NATURE, V325, P728, DOI 10.1038/325728a0
   CARNEIRO JS, 1995, J GEN VIROL, V76, P1189, DOI 10.1099/0022-1317-76-5-1189
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chew Suok Kai, 2007, Bull World Health Organ, V85, P324
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   De Lorenzo G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166719
   de-Dios T, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104209
   DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Fang SG, 2007, VIROLOGY, V358, P136, DOI 10.1016/j.virol.2006.08.020
   Frick DN, 2006, CURR PHARM DESIGN, V12, P1315, DOI 10.2174/138161206776361147
   Gadlage MJ, 2008, J VIROL, V82, P11964, DOI 10.1128/JVI.01126-07
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Issa E, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00266-20
   Jang KJ, 2008, BIOCHEM BIOPH RES CO, V366, P738, DOI 10.1016/j.bbrc.2007.12.020
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   KIMURA M, 1977, NATURE, V267, P275, DOI 10.1038/267275a0
   Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5
   Kocherhans R, 2001, VIRUS GENES, V23, P137, DOI 10.1023/A:1011831902219
   Kuraku S, 2013, NUCLEIC ACIDS RES, V41, pW22, DOI 10.1093/nar/gkt389
   Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Lu W, 2010, MOL BIOL SARS CORONA
   Madhugiri R, 2016, ADV VIRUS RES, V96, P127, DOI 10.1016/bs.aivir.2016.08.007
   Ng WC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060137
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   PEABODY DS, 1989, J BIOL CHEM, V264, P5031
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pyrc K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Sanchez CM, 1999, J VIROL, V73, P7607
   SHARP PM, 1993, BIOCHEM SOC T, V21, P835, DOI 10.1042/bst0210835
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang Z, 2011, FEBS J, V278, P383, DOI 10.1111/j.1742-4658.2010.07961.x
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 71
TC 4
Z9 4
U1 1
U2 1
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2020
VL 44
IS 3
SI SI
BP 157
EP 167
DI 10.3906/biy-2005-111
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9EP
UT WOS:000541522100005
PM 32595352
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Durdagi, S
AF Durdagi, Serdar
TI Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE Drug repurposing; TMPRSS2; COVID19; SARS-CoV-2
ID DISCOVERY
AB Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. Therefore, there is a need for the urgent development of novel drugs and vaccines for COVID-19. Since it can take years to develop new drugs against this disease, here we used a hybrid combined molecular modeling approach in virtual drug screening repurposing study to identify new compounds against this disease. One of the important SARS-CoV-2 targets namely type 2 transmembrane serine protease (TMPRSS2) was screened with NPC's NIH small molecule library which includes approved drugs by FDA and compounds in clinical investigation. We used 6654 small molecules in molecular docking and top-50 docking scored compounds were initially used in short (10-ns) molecular dynamics (MD) simulations. Based on average MM/GBSA binding free energy results, long (100-ns) MD simulations were employed for the identified hits. Both binding energy results as well as crucial residues in ligand binding were also compared with a positive control TMPRSS2 inhibitor, Camostat mesylate. Based on these numerical calculations we proposed a compound (benzquercin) as strong TMPRSS2 inhibitor. If these results can be validated by in vitro and in vivo studies, benzquercin can be considered to be used as inhibitor of TMPRSS2 at the clinical studies.
C1 [Durdagi, Serdar] Bahcesehir Univ, Sch Med, Dept Biophys, Computat Biol & Mol Simulat Lab, Istanbul, Turkey.
RP Durdagi, S (corresponding author), Bahcesehir Univ, Sch Med, Dept Biophys, Computat Biol & Mol Simulat Lab, Istanbul, Turkey.
EM serdar.durdagi@med.bau.edu.tr
RI Durdagi, Serdar/J-1904-2018
OI Durdagi, Serdar/0000-0002-0426-0905
FU Bahcesehir University, Scientific Research Projects UnitBahcesehir
   University [BAP.2020-01.01]
FX This study was supported by Bahcesehir University, Scientific Research
   Projects Unit, Project No: BAP.2020-01.01
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v2., DOI 10.26434/CHEMRXIV.12032712.V2]
   Durdagi S, 2018, EUR J MED CHEM, V145, P273, DOI 10.1016/j.ejmech.2017.12.021
   EVANS DJ, 1985, J CHEM PHYS, V83, P4069, DOI 10.1063/1.449071
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Is YS, 2018, ACS CHEM NEUROSCI, V9, P1768, DOI 10.1021/acschemneuro.8b00095
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Sanders JM, 2020, PHARM TREATMENTS COR, DOI [10.1001/jama.2020.6019, DOI 10.1001/JAMA.2020.6019]
   Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3
   Tutumlu G, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00167
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
NR 14
TC 0
Z9 0
U1 3
U2 3
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2020
VL 44
IS 3
SI SI
BP 185
EP +
DI 10.3906/biy-2005-112
PG 10
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9EP
UT WOS:000541522100008
PM 32595355
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tastan, C
   Yurtsever, B
   Karakus, GS
   Kancagi, DD
   Demir, S
   Abanuz, S
   Seyis, U
   Yildirim, M
   Kuzay, R
   Elibol, O
   Arbak, S
   Elmas, MA
   Birdogan, S
   Sezerman, OU
   Kocagoz, AS
   Yalcin, K
   Ovali, E
AF Tastan, Cihan
   Yurtsever, Bulut
   Karakus, Gozde Sir
   Kancagi, Derya Dilek
   Demir, Sevda
   Abanuz, Selen
   Seyis, Utku
   Yildirim, Mulazim
   Kuzay, Recai
   Elibol, Omer
   Arbak, Serap
   Elmas, Merve Acikel
   Birdogan, Selcuk
   Sezerman, Osman Ugur
   Kocagoz, Aye Sesin
   Yalcin, Koray
   Ovali, Ercument
TI SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus
ID SARS CORONAVIRUS; RESPONSES; OUTBREAK
AB The novel coronavirus pneumonia, which was named later as coronavirus disease 2019 (COVID-19), is caused by the severe acute respiratory syndrome coronavirus 2, namely SARS-CoV-2. It is a positive-strand RNA virus that is the seventh coronavirus known to infect humans. The COVID-19 outbreak presents enormous challenges for global health behind the pandemic outbreak. The first diagnosed patient in Turkey has been reported by the Republic of Turkey Ministry of Health on March 11, 2020. In May, over 150,000 cases in Turkey, and 5.5 million cases around the world have been declared. Due to the urgent need for a vaccine and antiviral drug, isolation of the virus is crucial. Here, we report 1 of the first isolation and characterization studies of SARS-CoV-2 from nasopharyngeal and oropharyngeal specimens of diagnosed patients in Turkey. This study provides an isolation and replication methodology,and cell culture tropism of the virus that will be available to the research communities.
C1 [Tastan, Cihan; Yurtsever, Bulut; Karakus, Gozde Sir; Kancagi, Derya Dilek; Abanuz, Selen; Seyis, Utku; Yildirim, Mulazim; Kuzay, Recai; Yalcin, Koray; Ovali, Ercument] Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkey.
   [Demir, Sevda] Yeditepe Univ, Fac Engn, Genet & Bioengn Dept, Istanbul, Turkey.
   [Elibol, Omer] Acibadem Altunizade Hosp, Istanbul, Turkey.
   [Arbak, Serap; Elmas, Merve Acikel] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkey.
   [Birdogan, Selcuk] Acibadem Mehmet Ali Aydinlar Univ, Electron Microscopy Lab, Istanbul, Turkey.
   [Sezerman, Osman Ugur] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Biostat & Med Informat, Istanbul, Turkey.
   [Sezerman, Osman Ugur] Epigenetiks Genet Bioinformat Software Inc, Istanbul, Turkey.
   [Kocagoz, Aye Sesin] Acibadem Altunizade Hosp, Infect Dis Unit, Istanbul, Turkey.
   [Yalcin, Koray] Med Pk Goztepe Hosp, Pediat Bone Marrow Transplantat Unit, Istanbul, Turkey.
RP Ovali, E (corresponding author), Acibadem Labcell Cellular Therapy Lab, Istanbul, Turkey.
EM ercument.ovali@acibadem.com
RI Tastan, Cihan/AAF-8070-2019
OI Tastan, Cihan/0000-0002-4173-6634; KANCAGI, Derya/0000-0003-4725-3200;
   Demir, Sevda/0000-0003-0427-3519
FU Acibadem Healthcare Group, Istanbul, Turkey
FX The authors would like to thank Prof. Fikrettin Sahin and Prof. Dilek
   Telci from Genetic and Bioengineering Department, Faculty of
   Engineering, Yeditepe University, Istanbul, Turkey for their comments
   and their insightful suggestions for the study. All funding in the work
   was supported by Acibadem Healthcare Group, Istanbul, Turkey.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baer A, 2014, JOVE-J VIS EXP, DOI 10.3791/52065
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Guallart N, 2015, AXIOMATHES, V25, P61, DOI 10.1007/s10516-014-9260-9
   Harcourt Jennifer, 2020, bioRxiv, DOI 10.1101/2020.03.02.972935
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Libraty DH, 2007, VIROLOGY, V368, P317, DOI 10.1016/j.virol.2007.07.015
   Liu W, 2020, ATTACKS 1 BETA CHAIN, DOI [10.26434/chemrxiv, DOI 10.26434/CHEMRXIV]
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Matsumoto Mitsuyo, 2005, Animal Science Journal, V76, P507, DOI 10.1111/j.1740-0929.2005.00297.x
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   STOHL W, 1987, CLIN EXP IMMUNOL, V70, P649
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 21
TC 4
Z9 4
U1 2
U2 2
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2020
VL 44
IS 3
SI SI
BP 192
EP 202
DI 10.3906/biy-2004-113
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9EP
UT WOS:000541522100009
PM 32595356
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Istifli, ES
   Tepe, AS
   Sarikurkcu, C
   Tepe, B
AF Istifli, Erman Salih
   Tepe, Arzuhan Sihoglu
   Sarikurkcu, Cengiz
   Tepe, Bektas
TI Interaction of certain monoterpenoid hydrocarbons with the receptor
   binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane
   serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and
   their pharmacokinetic properties
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE 2019-nCoV; ACE2; TMPRSS2; cathepsin; monoterpene; docking;
   pharmacokinetic
ID SARS CORONAVIRUS; DOCKING; ANTIOXIDANT
AB As of June 2020, the coronavirus disease 19 (COVID-19) caused by the 2019 new type coronavirus (2019-nCoV) infected more than 7,000,000 people worldwide and caused the death of more than 400,000 people. The aim of this study was to investigate the molecular interactions between monoterpenoids and spike protein of 2019-nCoV together with the cellular proteases [transmembrane serine protease 2 (TMPRSS2), cathepsin B (CatB), and cathepsin L (CatL)]. As a result of the relative binding capacity index (RBCI) analysis, carvone was found to be the most effective molecule against all targets when binding energy and predicted (theoretical) IC50 data were evaluated together. It was found to exhibit drug-likeness property according to the Lipinski's rule-of-five. Carvone has also been determined to be able to cross the blood-brain barrier (BBB) effectively, not a substrate for P-glycoprotein (P-gp), not to inhibit any of the cytochrome P molecules, and to have no toxic effects even on liver cells. In addition, the LD50 dose of carvone in rats was 1.707 mol/kg. Due to its interaction profile with target proteins and excellent pharmacokinetic properties, it has been concluded that carvone can be considered as an alternative agent in drug development studies against 2019-nCoV.
C1 [Istifli, Erman Salih] Cukurova Univ, Fac Sci & Literature, Dept Biol, Adana, Turkey.
   [Tepe, Arzuhan Sihoglu] Gaziantep Univ, Fac Sci & Literature, Dept Biol, Gaziantep, Turkey.
   [Sarikurkcu, Cengiz] Afyonkarahisar Hlth Sci Univ, Fac Pharm, Dept Analyt Chem, Afyon, Turkey.
   [Tepe, Bektas] Kilis 7 Aralik Univ, Dept Mol Biol & Genet, Fac Sci & Literature, Kilis, Turkey.
RP Tepe, B (corresponding author), Kilis 7 Aralik Univ, Dept Mol Biol & Genet, Fac Sci & Literature, Kilis, Turkey.
EM bektastepe@yahoo.com
RI ; TEPE, Bektas/N-2987-2013
OI SIHOGLU TEPE, Arzuhan/0000-0001-8290-9880; TEPE,
   Bektas/0000-0001-8982-5188; Istifli, Erman Salih/0000-0003-2189-0703;
   Sarikurkcu, Cengiz/0000-0001-5094-2520
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Corman VM, 2019, INTERNIST, V60, P1136, DOI 10.1007/s00108-019-00671-5
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Greenspan PD, 2001, J MED CHEM, V44, P4524, DOI 10.1021/jm010206q
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Hardegger LA, 2011, CHEMMEDCHEM, V6, P2048, DOI 10.1002/cmdc.201100353
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Meneguzzo F, 2020, ACCELERATED PRODUCTI, DOI [10.20944/preprints202003.0386.v1, DOI 10.20944/PREPRINTS202003.0386.V1]
   Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Nasab RR, 2017, RES PHARM SCI, V12, P425, DOI 10.4103/1735-5362.213988
   Nguyen PH, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113813
   Pedretti A, 2004, J COMPUT AID MOL DES, V18, P167, DOI 10.1023/B:JCAM.0000035186.90683.f2
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Prakash D, 2007, INT J FOOD SCI NUTR, V58, P18, DOI 10.1080/09637480601093269
   Rac A, 2020, DATA BRIEF, V28, DOI 10.1016/j.dib.2019.105038
   Ramirez D, 2018, MOLECULES, V23, DOI 10.3390/molecules23051038
   Remmert M, 2012, NAT METHODS, V9, P173, DOI [10.1038/NMETH.1818, 10.1038/nmeth.1818]
   Rettie AE, 2005, ANNU REV PHARMACOL, V45, P477, DOI 10.1146/annurev.pharmtox.45.120403.095821
   Ricci CG, 2009, J CHEM INF MODEL, V49, P1925, DOI 10.1021/ci9001537
   Sampangi-Ramaiah MH, 2020, CURR SCI INDIA, V118, P1087, DOI 10.18520/cs/v118/i7/1087-1092
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sharma S., 1996, 2 GROUP DISCRIMINATN
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Singh BN, 2009, FOOD CHEM TOXICOL, V47, P1161, DOI 10.1016/j.fct.2009.02.004
   Singh BN, 2009, FOOD CHEM TOXICOL, V47, P1109, DOI 10.1016/j.fct.2009.01.034
   Singh BN, 2009, FOOD CHEM TOXICOL, V47, P778, DOI 10.1016/j.fct.2009.01.009
   Singh HB, 2010, BIORESOURCE TECHNOL, V101, P6444, DOI 10.1016/j.biortech.2010.03.057
   Smith M, 2020, REPURPOSING THEREPEU, DOI [10.26434/chemrxiv.11871402, DOI 10.26434/CHEMRXIV.11871402]
   Spector AA, 2015, BBA-MOL CELL BIOL L, V1851, P356, DOI 10.1016/j.bbalip.2014.07.020
   Studer G, 2020, BIOINFORMATICS, V36, P1765, DOI 10.1093/bioinformatics/btz828
   Tallei T. E., 2020, POTENTIAL PLANT BIOA, DOI [10.20944/preprints202004.0102.v1, DOI 10.20944/PREPRINTS202004.0102.V2]
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066
   Xiang ZX, 2006, CURR PROTEIN PEPT SC, V7, P217, DOI 10.2174/138920306777452312
   Zar JH., 1996, BIOSTATISTICAL ANAL
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 1
Z9 1
U1 1
U2 1
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2020
VL 44
IS 3
SI SI
BP 242
EP 264
DI 10.3906/biy-2005-46
PG 23
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LZ9EP
UT WOS:000541522100013
PM 32595360
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Benjamin, GC
AF Benjamin, Georges C.
TI Ensuring health equity during the COVID-19 pandemic: the role of public
   health infrastructure
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Article
DE Health policy; planning and management; communicable disease control;
   vulnerable populations; health equity
AB The COVID-19 pandemic has significantly stressed public health systems around the world and exposed the gaps in health care for underserved and vulnerable populations. In the context of the social determinants of health, focusing on health system preparedness is paramount for protecting the health of all of society. Faced with old threats (e.g., re-emergence of measles), disruptive new technologies (e.g., electronic cigarettes), increased challenges (e.g. drug-resistant organisms), and new threats (e.g., the current pandemic, climate change, politicized misinformation), our health systems must be robust and resilient. The response must include those who now suffer disproportionately-the poor and the vulnerable. Current World Health Organization priorities call for infrastructures capable of detecting, monitoring, and responding to health emergencies, such as COVID-19, and the health impacts of climate change in the context of health for all. Health care infrastructure can be better prepared and more equitable if systems are strengthened by building on core competencies and following the recommendations made for leadership, stakeholder involvement, accreditation, data collection, and funding resources. Ensuring health equity in a pandemic requires robust and resilient public health infrastructure during normal times.
C1 [Benjamin, Georges C.] Amer Publ Hlth Assoc, Washington, DC 20001 USA.
RP Benjamin, GC (corresponding author), Amer Publ Hlth Assoc, Washington, DC 20001 USA.
EM georges.benjamin@apha.org
CR Buckley GJ, 2014, COMMITTEE INVESTING
   DeSalvo KB, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.170017
   Institute of Medicine (US) Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH
   Kronstadt J, 2016, MMWR-MORBID MORTAL W, V65, P803, DOI 10.15585/mmwr.mm6531a3
NR 4
TC 1
Z9 1
U1 3
U2 3
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PY 2020
VL 44
AR e70
DI 10.26633/RPSP.2020.70
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LY1DW
UT WOS:000540263700001
PM 32523608
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, BM
   Yang, QQ
   Zhao, LY
   Xie, W
   Si, XY
AF Liu, B. M.
   Yang, Q. Q.
   Zhao, L. Y.
   Xie, W.
   Si, X. Y.
TI Epidemiological characteristics of COVID-19 patients in convalescence
   period
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Convalescence period; COVID-19; epidemiological characteristics;
   SARS-CoV-2
ID VIRAL-RNA
AB This study aimed to investigate the clinical characteristics and to analyse the epidemiological features of coronavirus disease 2019 (COVID-19) patients during convalescence. In this study, we enrolled 71 confirmed cases of COVID-19 who were discharged from hospital and transferred to isolation wards from 6 February to 26 March 2020. They were all employees of Zhongnan Hospital of Wuhan University or their family members of which three cases were <18 years of age. Clinical data were collected and analysed statistically. Forty-one cases (41/71, 57.7%) comprised medical faculty, young and middle-aged patients (aged <= 60 years) accounted for 81.7% (58/71). The average isolation time period for all adult patients was 13.8 +/- 6.1 days. During convalescence, RNA detection results of 35.2% patients (25/71) turned from negative to positive. The longest RNA reversed phase time was 7 days. In all, 52.9% of adult patients (36/68) had no obvious clinical symptoms, and the remaining ones had mild and non-specific clinical symptoms (e.g. cough, sputum, sore throat, disorders of the gastrointestinal tract etc.). Chest CT signs in 89.7% of adult patients (61/68) gradually improved, and in the others, the lesions were eventually absorbed and improved after short-term repeated progression. The main chest CT manifestations of adult patients were normal, GGO or fibre streak shadow, and six patients (8.8%) had extrapulmonary manifestations, but there was no significant correlation with RNA detection results (r= -0.008,P> 0.05). The drug treatment was mainly symptomatic support therapy, and antibiotics and antiviral drugs were ineffective. It is necessary to re-evaluate the isolation time and standard to terminate isolation for discharged COVID-19 patients.
C1 [Liu, B. M.; Yang, Q. Q.; Zhao, L. Y.; Si, X. Y.] Wuhan Univ, Zhongnan Hosp, Dept Nephrol, Wuhan, Hubei, Peoples R China.
   [Xie, W.] Wuhan Univ, Zhongnan Hosp, Dept Lab Med, Wuhan, Hubei, Peoples R China.
RP Si, XY (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Nephrol, Wuhan, Hubei, Peoples R China.
EM lzgk.lxm@163.com
OI Liu, Bingman/0000-0003-2226-9249; Xie, Wen/0000-0002-1033-4720; Yang,
   Qingqing/0000-0001-9717-3503
CR Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Gao Y., 2020, EVALUATION AUXILIARY, DOI [10.1101/2020.03.26.20042044, DOI 10.1101/2020.03.26.20042044]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li Youjiang, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P270, DOI 10.3785/j.issn.1008-9292.2020.03.11
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   National Health Commission of the PRC and National Administration of Traditional Chinese Medicine, 2020, JIANGSU J TRADITIONA, V52, P1
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Peng L, 2020, J MED VIROL, V92, P1676, DOI 10.1002/jmv.25936
   Tan W, 2020, VIRAL KINETICS ANTIB, DOI [10.1101/2020.03.24.20042382, DOI 10.1101/2020.03.24.20042382]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xing Y, 2020, EURO SURVEILLANCE, V25
   Xing YH, 2020, J MICROBIOL IMMUNOL, V53, P473, DOI 10.1016/j.jmii.2020.03.021
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 18
TC 2
Z9 2
U1 2
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PY 2020
VL 148
AR e108
DI 10.1017/S0950268820001181
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA LW6VL
UT WOS:000539281700001
PM 32487271
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sear, RF
   Velasquez, N
   Leahy, R
   Restrepo, NJ
   El Oud, S
   Gabriel, N
   Lupu, Y
   Johnson, NF
AF Sear, Richard F.
   Velasquez, Nicolas
   Leahy, Rhys
   Restrepo, Nicholas Johnson
   El Oud, Sara
   Gabriel, Nicholas
   Lupu, Yonatan
   Johnson, Neil F.
TI Quantifying COVID-19 Content in the Online Health Opinion War Using
   Machine Learning
SO IEEE ACCESS
LA English
DT Article
DE Vaccines; Machine learning; Facebook; Coherence; Public healthcare;
   Immune system; COVID-19; machine learning; topic modeling; mechanistic
   model; social computing
AB A huge amount of potentially dangerous COVID-19 misinformation is appearing online. Here we use machine learning to quantify COVID-19 content among online opponents of establishment health guidance, in particular vaccinations (& x201C;anti-vax & x201D;). We find that the anti-vax community is developing a less focused debate around COVID-19 than its counterpart, the pro-vaccination (& x201C;pro-vax & x201D;) community. However, the anti-vax community exhibits a broader range of & x201C;flavors & x201D; of COVID-19 topics, and hence can appeal to a broader cross-section of individuals seeking COVID-19 guidance online, e.g. individuals wary of a mandatory fast-tracked COVID-19 vaccine or those seeking alternative remedies. Hence the anti-vax community looks better positioned to attract fresh support going forward than the pro-vax community. This is concerning since a widespread lack of adoption of a COVID-19 vaccine will mean the world falls short of providing herd immunity, leaving countries open to future COVID-19 resurgences. We provide a mechanistic model that interprets these results and could help in assessing the likely efficacy of intervention strategies. Our approach is scalable and hence tackles the urgent problem facing social media platforms of having to analyze huge volumes of online health misinformation and disinformation.
C1 [Sear, Richard F.] George Washington Univ, Dept Comp Sci, Washington, DC 20052 USA.
   [Velasquez, Nicolas; Leahy, Rhys; Restrepo, Nicholas Johnson; Johnson, Neil F.] George Washington Univ, Inst Data Democracy & Polit, Washington, DC 20052 USA.
   [Velasquez, Nicolas] George Washington Univ, Elliott Sch Int Affairs, Washington, DC 20052 USA.
   [Leahy, Rhys; Restrepo, Nicholas Johnson] ClustrX LLC, Washington, DC 20007 USA.
   [El Oud, Sara; Gabriel, Nicholas; Johnson, Neil F.] George Washington Univ, Dept Phys, Washington, DC 20052 USA.
   [Lupu, Yonatan] George Washington Univ, Dept Polit Sci, Washington, DC 20052 USA.
RP Johnson, NF (corresponding author), George Washington Univ, Inst Data Democracy & Polit, Washington, DC 20052 USA.; Johnson, NF (corresponding author), George Washington Univ, Dept Phys, Washington, DC 20052 USA.
EM neiljohnson@gwu.edu
OI Sear, Richard/0000-0002-1871-7478; Johnson, Neil F./0000-0002-3224-3213;
   Lupu, Yonatan/0000-0002-1735-7511; Leahy, Rhys/0000-0001-5363-630X;
   Velasquez, Nicolas/0000-0002-0170-5294
CR Almasy S, 2020, CNN HLTH
   Ammari T, 2016, ACM CONFERENCE ON COMPUTER-SUPPORTED COOPERATIVE WORK AND SOCIAL COMPUTING (CSCW 2016), P1363, DOI 10.1145/2818048.2819927
   [Anonymous], 2020, LATENT DIRICHLET ALL
   Benner K., 2020, THE NEW YORK TIMES
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   CDC, 2020, CDC WASH STAT REP 1
   Frenkel S., 2020, SURGE VIRUS MISINFOR
   Givetash L., 2019, NBC NEWS
   Guy J., 2020, E ASIAN STUDENT ASSA
   Iyengar R., 2020, CNN BUSINESS
   Johnson NF, 2019, NATURE, V573, P261, DOI 10.1038/s41586-019-1494-7
   Johnson NF, 2016, SCIENCE, V352, P1459, DOI 10.1126/science.aaf0675
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Lama Y, 2018, J MED INTERNET RES, V20, DOI 10.2196/10244
   Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w
   Ma LL, 2020, BMC BIOTECHNOL, V20, DOI 10.1186/s12896-019-0593-8
   Manrique PD, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.048301
   Maqbool A., 2020, BBC NEWS
   Martin B., 2020, TEXAS MONTHLY
   Rajagopalan M, 2020, BUZZFEED NEWS
   Roder M, 2015, WSDM'15: PROCEEDINGS OF THE EIGHTH ACM INTERNATIONAL CONFERENCE ON WEB SEARCH AND DATA MINING, P399, DOI 10.1145/2684822.2685324
   Schaeffer K., 2020, PEW FACT TANK
   Schraer R., 2020, BBC NEWS
   Sievert C., 2014, P WORKSH INT LANG LE, P63, DOI DOI 10.3115/V1/W14-3110
   Syed S, 2017, PR INT CONF DATA SC, P165, DOI 10.1109/DSAA.2017.61
   World Health Organization, 2020, COR DIS COVID 19 ADV
NR 26
TC 3
Z9 3
U1 14
U2 17
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2169-3536
J9 IEEE ACCESS
JI IEEE Access
PY 2020
VL 8
BP 91886
EP 91893
DI 10.1109/ACCESS.2020.2993967
PG 8
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA LV9BZ
UT WOS:000538738800019
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Biembengut, IV
   de Souza, TDCB
AF Biembengut, Isis Venturi
   Campos Brasil de Souza, Tatiana de Arruda
TI Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for
   COVID-19 treatment: an in silico approach
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE structure; ligand binding; in silico approach; COVID-19; SARS-CoV-2 Mpro
ID THROMBIN
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results.
C1 [Biembengut, Isis Venturi; Campos Brasil de Souza, Tatiana de Arruda] Fundacao Oswaldo Cruz Fiocruz, Lab Proteom Estrutural & Computac, Inst Carlos Chagas, Curitiba, Parana, Brazil.
RP de Souza, TDCB (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Lab Proteom Estrutural & Computac, Inst Carlos Chagas, Curitiba, Parana, Brazil.
EM tatiana.brasil@fiocruz.br
OI Souza, Tatiana/0000-0002-1850-6080
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bachli E, 2012, THER UMSCH, V69, P635, DOI 10.1024/0040-5930/a000341
   Beck DL, 2020, CARDIOLOGY MAGAZINE
   BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x
   Chu CM, 2004, CAN MED ASSOC J, V171, P1349, DOI 10.1503/cmaj.1040398
   Connolly SJ, 2013, EUR HEART J, V34, P1498, DOI 10.1093/eurheartj/eht039
   Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440
   Cervantes CE, 2019, EXPERT REV CARDIOVAS, V17, P319, DOI 10.1080/14779072.2019.1598263
   Ezihe-Ejiofor JA, 2013, BJA EDUC, V13, P87, DOI 10.1093/bjaceaccp/mks061
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hinsen K, 2000, J COMPUT CHEM, V21, P79, DOI 10.1002/(SICI)1096-987X(20000130)21:2<79::AID-JCC1>3.0.CO;2-B
   Kawano N, 2020, THROMB J, V18, DOI 10.1186/s12959-020-0216-6
   Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Skelley Jessica W, 2018, P T, V43, P85
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Venugopal A, 2014, INDIAN J ANAESTH, V58, P603, DOI 10.4103/0019-5049.144666
   Watkins J, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m810
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yang HT, 2005, PLOS BIOL, V3, P2044, DOI 10.1371/journal.pbio.0030428
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang PL, 2009, BIOORG MED CHEM LETT, V19, P2179, DOI 10.1016/j.bmcl.2009.02.111
NR 25
TC 1
Z9 1
U1 1
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2020
VL 115
AR e200179
DI 10.1590/0074-02760200179
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA LV4UJ
UT WOS:000538431900001
PM 32490889
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Momekov, G
   Momekova, D
AF Momekov, Georgi
   Momekova, Denitsa
TI Ivermectin as a potential COVID-19 treatment from the pharmacokinetic
   point of view: antiviral levels are not likely attainable with known
   dosing regimens
SO BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT
LA English
DT Article
DE Ivermectin; SARS-CoV-2; COVID-19; drug repurposing
ID PLASMA; CHLOROQUINE; SAFETY
AB The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.
C1 [Momekov, Georgi] Med Univ Sofia, Fac Pharm, Dept Pharmacol Pharmacotherapy & Toxicol, Lab Expt Chemotherapy & Mol Pharmacol, 2 Dunav Str, Sofia 1000, Bulgaria.
   [Momekova, Denitsa] Med Univ Sofia, Fac Pharm, Dept Pharmaceut Technol & Biopharmaceut, Sofia, Bulgaria.
RP Momekov, G (corresponding author), Med Univ Sofia, Fac Pharm, Dept Pharmacol Pharmacotherapy & Toxicol, Lab Expt Chemotherapy & Mol Pharmacol, 2 Dunav Str, Sofia 1000, Bulgaria.
EM gmomekov@gmail.com
RI Momekov, Georgi/H-4178-2019
CR Agencia Espanola de Medicamentos y Productos Sanitarios-AEMPS, 2020, TRAT DISP MAN INF RE
   [Anonymous], 2020, VET WARN DO NOT BUY
   [Anonymous], 2020, NIGERIA RECORDS CHLO
   [Anonymous], 2020, THAIL JOINS WHO SOL
   [Anonymous], 2010, BRIT NAT FORM 60
   [Anonymous], 1992, IV INCHEM MON
   [Anonymous], 2020, MED BEH BIJ PAT MET
   Baraka OZ, 1996, EUR J CLIN PHARMACOL, V50, P407, DOI 10.1007/s002280050131
   Bray M, 2020, ANTIVIR RES, V178
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chaccour C, 2020, AM J TROP MED HYG, V102, P1156, DOI 10.4269/ajtmh.20-0271
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Critical Care, 2020, BRIGHAM WOMENS HOSP
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   EDWARDS G, 1988, EUR J CLIN PHARMACOL, V35, P681, DOI 10.1007/BF00637608
   ELKASSABY MH, 1991, TROP MED PARASITOL, V42, P79
   European Medicines Agency/178637/2020/Human Medicines Division, 2020, SUMM COMP US REM GIL
   Fawcett RS, 2003, AM FAM PHYSICIAN, V68, P1089
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   Guzzo CA, 2002, J CLIN PHARMACOL, V42, P1122, DOI 10.1177/009127002401382731
   Jakhar D, 2020, NAT MED, V26, P632, DOI 10.1038/s41591-020-0853-0
   KRISHNA DR, 1993, ARZNEIMITTEL-FORSCH, V43-1, P609
   Lespine A, 2006, CHEM-BIOL INTERACT, V159, P169, DOI 10.1016/j.cbi.2005.11.002
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liang T., 2020, HDB COVID 19 PREVENT
   Long Q, 2001, CHIN J CLIN PHARM, V17, P203
   Loukas A, 2006, GOODMAN GILMANS PHAR, P1073
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Munoz J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006020
   Navarro M, 2020, J ANTIMICROB CHEMOTH, V75, P827, DOI 10.1093/jac/dkz524
   NJOO FL, 1995, AM J TROP MED HYG, V52, P94, DOI 10.4269/ajtmh.1995.52.94
   OGBUOKIRI JE, 1993, EUR J CLIN PHARMACOL, V45, P389, DOI 10.1007/BF00265962
   OKONKWO PO, 1993, CLIN PHARMACOL THER, V53, P426, DOI 10.1038/clpt.1993.46
   Patel A, 2020, USEFULNESS IVERMECTI
   Schmith VD, 2020, CLIN PHARMACOL THER, V108, P762, DOI 10.1002/cpt.1889
   Sciensano Epidemiology of Infectious Disease, 2020, INTERIM CLIN GUIDANC
   Shapiro T. A., 2006, GOODMAN GILMANS PHAR, V11, P1021
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Societa Italiana di Malattie Infettive e Tropicali, 2020, VAD CUR PERS CON MAL
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   THUMMEL KE, 2006, GOODMAN GILMANS PHAR, P1787
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 44
TC 7
Z9 7
U1 3
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1310-2818
EI 1314-3530
J9 BIOTECHNOL BIOTEC EQ
JI Biotechnol. Biotechnol. Equip.
PD JAN 1
PY 2020
VL 34
IS 1
BP 469
EP 474
DI 10.1080/13102818.2020.1775118
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA LW1SM
UT WOS:000538925200001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Paumgartten, FJR
   Delgado, IF
   Pitta, LD
   de Oliveira, ACAX
AF Roma Paumgartten, Francisco Jose
   Delgado, Isabella Fernandes
   Pitta, Luciana da Rocha
   Amado Xavier de Oliveira, Ana Cecilia
TI Chloroquine and hydroxychloroquine repositioning in times of COVID-19
   pandemics, all that glitters is not gold
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article
ID DRUG
C1 [Roma Paumgartten, Francisco Jose; Amado Xavier de Oliveira, Ana Cecilia] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, Brazil.
   [Delgado, Isabella Fernandes] Fundacao Oswaldo Cruz, Educ Informacao & Comunicacao, Rio De Janeiro, Brazil.
   [Pitta, Luciana da Rocha] Fundacao Oswaldo Cruz, Inst Nacl Controle Qualidade Saude, Rio De Janeiro, Brazil.
RP Paumgartten, FJR (corresponding author), Fundacao Oswaldo Cruz, Lab Toxicol Ambiental, Escola Nacl Saude Publ Sergio Arouca, Av Brasil 4034, BR-21040361 Rio De Janeiro, RJ, Brazil.
EM paum@ensp.fiocruz.br
OI Delgado, Isabella/0000-0003-0610-5324; Paumgartten, Francisco Jose
   Roma/0000-0002-6207-0149
CR Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Mak KK, 2019, DRUG DISCOV TODAY, V24, P773, DOI 10.1016/j.drudis.2018.11.014
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Naylor S., 2015, DRUG DISCOV WORLD, V16, P57
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roos JM, 2002, CARDIOVASC PATHOL, V11, P277, DOI 10.1016/S1054-8807(02)00118-7
   Sanders JM, 2020, JAMA
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Taherian E, 2013, CURR RHEUMATOL REV, V9, P45, DOI 10.2174/1573397111309010010
   Talevi A, 2020, EXPERT OPIN DRUG DIS, V15, P397, DOI 10.1080/17460441.2020.1704729
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yella JK, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11020057
NR 16
TC 2
Z9 2
U1 1
U2 1
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PY 2020
VL 36
IS 5
AR e00088520
DI 10.1590/0102-311X00088520
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LT4SL
UT WOS:000537062100001
PM 32428074
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Bardazzi, F
   Loi, C
   Sacchelli, L
   Di Altobrando, A
AF Bardazzi, Federico
   Loi, Camilla
   Sacchelli, Lidia
   Di Altobrando, Ambra
TI Biologic therapy for psoriasis during the covid-19 outbreak is not a
   choice
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Letter
ID INFECTION; PATIENT
C1 [Bardazzi, Federico; Loi, Camilla; Sacchelli, Lidia; Di Altobrando, Ambra] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
RP Di Altobrando, A (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
EM ambra.dialtobrando@studio.unibo.it
OI Di Altobrando, Ambra/0000-0003-3236-8822
CR American Academy of Dermatology Association, GUID US BIOL AG COVI
   [Anonymous], 2020, COMMUNICATION
   Bardazzi F, 2017, ACTA DERM-VENEREOL, V97, P989, DOI 10.2340/00015555-2698
   Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Deodhar A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1882-2
   Italian Group for the study of Inflammatory Bowel Disease, AVV PAZ CON MICI
   Kaushik SB, 2019, J AM ACAD DERMATOL, V80, P43, DOI 10.1016/j.jaad.2018.06.056
   Kling MC, 2010, ARCH DERMATOL, V146, P651, DOI 10.1001/archdermatol.2010.96
   Magnano M, 2017, DERMATOL THER, V30, DOI 10.1111/dth.12476
   Menter A, 2019, J AM ACAD DERMATOL, V80, P1029, DOI 10.1016/j.jaad.2018.11.057
   Odorici G, 2019, J EUR ACAD DERMATOL, V33, pE453, DOI 10.1111/jdv.15775
   Serrato VA, 2013, CLIN RHEUMATOL, V32, pS21, DOI 10.1007/s10067-010-1415-5
   SIDeMaST, 2020, INF COR VAD PAZ AFF
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 16
TC 10
Z9 11
U1 2
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
PY 2020
VL 31
IS 4
BP 320
EP 321
DI 10.1080/09546634.2020.1749545
PG 2
WC Dermatology
SC Dermatology
GA LU9GB
UT WOS:000538054000001
PM 32248724
DA 2021-01-01
ER

PT J
AU Dong, JB
   Huang, B
   Jia, ZJ
   Wang, B
   Kankanamalage, SG
   Titong, A
   Liu, Y
AF Dong, Jianbo
   Huang, Betty
   Jia, Zhejun
   Wang, Bo
   Kankanamalage, Sachith Gallolu
   Titong, Allison
   Liu, Yue
TI Development of multi-specific humanized llama antibodies blocking
   SARS-CoV-2/ACE2 interaction with high affinity and avidity
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; bi-specific antibody; tri-specific antibody; llama
   antibody; humanized antibody; nanobody
AB Coronaviruses cause severe human viral diseases including SARS, MERS and COVID-19. Most recently SARS-CoV-2 virus (causing COVID-19) has led to a pandemic with no successful therapeutics. The SARS-CoV-2 infection relies on trimeric spike (S) proteins to facilitate virus entry into host cells by binding to ACE2 receptor on host cell membranes. Therefore, blocking this interaction with antibodies are promising agents against SARS-CoV-2. Here we describe using humanized llama antibody VHHs against SARS-CoV-2 that would overcome the limitations associated with polyclonal and monoclonal combination therapies. From two llama VHH libraries, unique humanized VHHs that bind to S protein and block the S/ACE2 interaction were identified. Furthermore, pairwise combination of VHHs showed synergistic blocking. Multi-specific antibodies with enhanced affinity and avidity, and improved S/ACE2 blocking are currently being developed using an in-silico approach that also fuses VHHs to Fc domains. Importantly, our current bi-specific antibody shows potent S/ACE2 blocking (KD - 0.25 nM, IC100 similar to 36.7 nM, IC95 similar to 12.2 nM, IC50 similar to 1 nM) which is significantly better than individual monoclonal VHH-Fcs. Overall, this design would equip the VHH-Fcs multiple mechanisms of actions against SARS-CoV-2. Thus, we aim to contribute to the battle against COVID-19 by developing therapeutic antibodies as well as diagnostics.
C1 [Dong, Jianbo; Huang, Betty; Jia, Zhejun; Wang, Bo; Kankanamalage, Sachith Gallolu; Titong, Allison; Liu, Yue] Ab Studio Inc, 3541 Investment Blvd Suite 3, Hayward, CA 94545 USA.
   [Liu, Yue] Ab Therapeut Inc, Hayward, CA USA.
RP Dong, JB (corresponding author), Ab Studio Inc, 3541 Investment Blvd Suite 3, Hayward, CA 94545 USA.
EM jianbo.dong@antibodystudio.com
OI Gallolu Kankanamalage, Sachith/0000-0001-6559-686X
CR Centers for Disease Control and Prevention (CDC), 2020, HUM COR TYP
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Klasse PJ, 2014, ADV BIOL, V2014, P1, DOI DOI 10.1155/2014/157895
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pascal KE, 2018, J INFECT DIS, V218, pS612, DOI 10.1093/infdis/jiy285
   WHO, 2020, COR DIS COVID 19 PAN
   Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 8
TC 7
Z9 8
U1 6
U2 37
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 1034
EP 1036
DI 10.1080/22221751.2020.1768806
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LT2DG
UT WOS:000536882400001
PM 32403995
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU El Taguri, A
   Nasef, A
AF El Taguri, Adel
   Nasef, Aisha
TI The world is waiting, use sequential analysis and get us the
   evidence-based treatment we need for COVID-19
SO LIBYAN JOURNAL OF MEDICINE
LA English
DT Article
DE Sequential analysis; COVID-19; clinical trials; treatment
ID AUDITORY RESPONSE DETECTION; CLINICAL-TRIALS; IMPROVEMENT; SIZE; DRUG
AB In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease.
C1 [El Taguri, Adel] Natl Ctr Accreditat Hlth Estab, Sabaa St, Tripoli, Libya.
   [El Taguri, Adel] Univ Tripoli, Commun Med Dept, Fac Med, Tripoli, Libya.
   [Nasef, Aisha] Author Nat Sci Res & Technol, Tripoli, Libya.
   [Nasef, Aisha] Med Specialty Council, Sci Council Lab Med, Tripoli, Libya.
RP El Taguri, A (corresponding author), Natl Ctr Accreditat Hlth Estab, Sabaa St, Tripoli, Libya.
EM tajoury@cahel.org.ly
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Armitage P, 1975, SEQUENTIAL MED TRIAL
   Baiardi P, 2011, EUR J CLIN PHARMACOL, V67, pS109, DOI 10.1007/s00228-011-0990-y
   Balachandar V, 2020, SCITOTAL ENV, V725, P138277
   Bhatt DL, 2016, NEW ENGL J MED, V375, P65, DOI 10.1056/NEJMra1510061
   Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007
   Caldwell PHY, 2004, LANCET, V364, P803, DOI 10.1016/S0140-6736(04)16942-0
   Cebulla M, 2015, INT J AUDIOL, V54, P568, DOI 10.3109/14992027.2015.1017659
   DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914
   Eggen TJHM, 1999, APPL PSYCH MEAS, V23, P249, DOI 10.1177/01466219922031365
   Harrington D, 2016, NEW ENGL J MED, V375, P7, DOI 10.1056/NEJMp1602256
   Hemmingsen B, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6898
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Institute of Medicine, 2001, SMALL CLIN TRIALS IS
   Kulldorff M, 2011, SEQUENTIAL ANAL, V30, P58, DOI 10.1080/07474946.2011.539924
   Lava SAG, 2018, EUR J PEDIATR, V177, P733, DOI 10.1007/s00431-018-3110-5
   Live Science Staff, 2020, TREATM COVID 19 DRUG
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   NIH, 2020, COVID 19
   Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170
   Pica N, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0223
   Pocock SJ, 1983, CLIN TRIALS PRACTICA
   Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3
   Sebille V, 2000, CLIN SCI, V98, P569, DOI 10.1042/CS19990336
   Selma OA, 2014, CIRCULATION, V129, P224
   Sibanda N, 2007, J PEDIATR SURG, V42, P1919, DOI 10.1016/j.jpedsurg.2007.07.023
   Soares C, 2020, HERE ARE DRUGS VACCI
   Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7
   Sturzebecher E, 2013, INT J AUDIOL, V52, P861, DOI 10.3109/14992027.2013.822995
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Todd S, 2007, STAT MED, V26, P237, DOI 10.1002/sim.2763
   van der Lee JH, 2008, J CLIN EPIDEMIOL, V61, P324, DOI 10.1016/j.jclinepi.2007.07.008
   van der Lee JH, 2010, J CLIN EPIDEMIOL, V63, P19, DOI 10.1016/j.jclinepi.2009.07.005
   WALD A, 1945, ANN MATH STAT, V16, P117, DOI 10.1214/aoms/1177731118
   Whitehead J., 1990, SEQUENTIAL ANAL, V9, P117, DOI DOI 10.1080/07474949008836200
NR 34
TC 1
Z9 1
U1 0
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1993-2820
EI 1819-6357
J9 LIBYAN J MED
JI Libyan J. Med.
PD JAN 1
PY 2020
VL 15
IS 1
AR 1770518
DI 10.1080/19932820.2020.1770518
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA LT0KM
UT WOS:000536765900001
PM 32459574
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Novara, E
   Molinaro, E
   Benedetti, I
   Bonometti, R
   Lauritano, EC
   Boverio, R
AF Novara, E.
   Molinaro, E.
   Benedetti, I.
   Bonometti, R.
   Lauritano, E. C.
   Boverio, R.
TI Severe acute dried gangrene in COVID-19 infection: a case report
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; DIC; Coagulopathy; Septic shock
AB OBJECTIVE: Coronavirus disease 2019 (COVID-19) related coagulopathy may be the first clinical manifestation even in non-vasculopathic patients and is often associated with worse clinical outcomes.
   CASE PRESENTATION: A 78 years old woman was admitted to the Emergency Unit with respiratory symptoms, confusion and cyanosis at the extremity, in particular at the nose area, hands and feet fingers. A nasal swab for COVID-19 was performed, which resulted positive, and so therapy with doxycycline, hydroxychloroquine and antiviral agents was started. At admission, the patient was hemodynamically unstable requiring circulatory support with liquids and norepinephrine; laboratory tests showed disseminated intravascular coagulation (DIC). During hospitalization, the clinical condition worsened and the cyanosis of the nose, fingers, and toes rapidly increased and became dried gangrene in three days. Subsequently, the neurological state deteriorated into a coma and the patient died.
   DISCUSSION: In severe cases, COVID-19 could be complicated by acute respiratory disease syndrome, septic shock, and multi-organ failure. This case report shows the quick development of dried gangrene in a non-vasculopathic patient, as a consequence of COVID-19's coagulopathy and DIC.
   CONCLUSIONS: In our patient, COVID-19 related coagulopathy was associated with poor prognosis.
C1 [Novara, E.; Molinaro, E.] IRCCS San Matteo Hosp Fdn Univ Pavia, Dept Emergency Med, Pavia, Italy.
   [Benedetti, I.] IRCCS San Matteo Hosp Fdn Univ Pavia, Dept Internal Med, Pavia, Italy.
   [Bonometti, R.; Lauritano, E. C.; Boverio, R.] Santi Antonio & Biagio & Cesare Arrigo Hosp, Dept Emergency Med, Alessandria, Italy.
RP Novara, E (corresponding author), IRCCS San Matteo Hosp Fdn Univ Pavia, Dept Emergency Med, Pavia, Italy.
EM elena.novara01@ateneopv.it
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jung KJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009800
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 6
TC 1
Z9 1
U1 1
U2 2
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5769
EP 5771
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300067
PM 32495913
DA 2021-01-01
ER

PT J
AU Zou, J
   Song, DW
   Niu, JJ
   Shi, JW
   Yang, HL
AF Zou, J.
   Song, D. -W.
   Niu, J. -J.
   Shi, J. -W.
   Yang, H. -L.
TI Standardized out-patient diagnosis and treatment process for
   osteoporosis clinics during the COVID-19 pandemic
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Novel coronavirus pneumonia; COVID-19; Osteoporosis; Diagnosis and
   treatment process; Home prevention
AB Since the end of 2019, China and other regions around the world have been facing a pandemic of novel coronavirus pneumonia (COVID-19). The virus is highly transmissible, and the human population is generally susceptible. Most patients with osteoporosis are postmenopausal women or elderly people with hypoimmunity, so the osteoporosis clinic has become a new hotspot for corona virus infection. During the COVID-19 pandemic, it is necessary to establish standardized out-patient protocols to provide safe and effective treatment for osteoporosis patients and medical staff. In an osteoporosis clinic, we advocate the following suggestions to prevent and control osteoporosis during the pandemic period: (1) specialized diagnosis and treatment techniques for osteoporosis patients in the outpatient care, including enhancing the prevention for outpatient medical staff, strengthening awareness of COVID-19 prevention, strictly screening outpatients with COVID-19 infection, and insistent administration of anti-osteoporosis drugs during outbreaks; (2) home prevention for osteoporosis patients including keeping windows open, exposing them to sunlight, supplementing them with enough protein, exercising regularly, and administrating calcium supplements; and (3) simplifying the follow-up and evaluation of osteoporosis using online platforms.
C1 [Zou, J.; Song, D. -W.; Niu, J. -J.; Shi, J. -W.; Yang, H. -L.] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Jiangsu, Peoples R China.
RP Yang, HL (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Jiangsu, Peoples R China.
EM hlyang@suda.edu.cn
CR General office of National Healt h Comm ission of the Peopl e's Republic of China Office of State Adm inis- tration of traditional Chinese Medicine, COVID 19 TREATM PLAN
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Ma YZ, 2019, CHINESE J GERONTOLOG, V39, P2561, DOI DOI 10.3969/j.issn.1005-9202.2019.11.001
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   office of the First Affiliated Hospital of Novel coronavirus pneumonia Soochow University, NOV COR PNEUM PREV C
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15-1361
   Rosenbaum L., 2020, NEW ENGL J MED, DOI [10.1056/ NE- JMp2005492, DOI 10.1056/NE-JMP2005492]
   Taubenberger JK, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038695
   Taubenberger JK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5485
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 13
TC 1
Z9 1
U1 2
U2 2
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5778
EP 5782
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300069
PM 32495915
DA 2021-01-01
ER

PT J
AU Wang, L
   Peng, X
   Wang, ZH
   Cai, J
   Zhou, FC
AF Wang, L.
   Peng, X.
   Wang, Z. -H.
   Cai, J.
   Zhou, F. -C.
TI Tocilizumab in the treatment of a critical COVID-19 patient: a case
   report
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; Tocilizumab; Interleukin-6; Cytokine storm
AB In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.
C1 [Wang, L.] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.
   [Peng, X.] Chongqing Med Univ, Dept Neurol, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Wang, Z. -H.] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Cai, J.] Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Zhou, F. -C.] Chongqing Med Univ, Dept Crit Care Med, Affiliated Hosp 1, Chongqing, Peoples R China.
RP Zhou, FC (corresponding author), Chongqing Med Univ, Dept Crit Care Med, Affiliated Hosp 1, Chongqing, Peoples R China.
EM zfc88@126.com
FU Medical Research Project of Chongqing Health Committee [2017MSXM013];
   Chongqing Entrepreneurship and Innovation Support Program for Overseas
   Returnees [cx2018145]; Kuanren Outstanding Young Talent Program
   [KY2019Y006]
FX This work was supported by the Medical Research Project of Chongqing
   Health Committee (2017MSXM013), Chongqing Entrepreneurship and
   Innovation Support Program for Overseas Returnees (cx2018145) and
   Kuanren Outstanding Young Talent Program (KY2019Y006). We thank the
   Wuhan No. 1 Hospital and all members of our Medical Team supported Wuhan
   No. 1 Hospital. We thank AJE (www.aje.cn) for linguistic assistance
   during the preparation of this manuscript.
CR Bannwarth B, 2011, EXPERT OPIN DRUG SAF, V10, P123, DOI 10.1517/14740338.2011.537256
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gupta KK, 2020, J INTERF CYTOK RES, V40, P19, DOI 10.1089/jir.2019.0085
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0
   Li Y, 2013, MICROBES INFECT, V15, P88, DOI 10.1016/j.micinf.2012.10.008
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   National Healt h Comm iss ion of the Peopl e's Republ ic of China, 2020, DIAGN TREATM COVID 7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu X, 2020, EFFECTIVE TREATMENT, DOI [10.12074/202003.00026, DOI 10.12074/202003.00026]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang Xiaoping, 2011, Expert Rev Clin Pharmacol, V4, P539, DOI 10.1586/ecp.11.33
NR 14
TC 3
Z9 3
U1 2
U2 2
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5783
EP 5787
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300070
PM 32495916
DA 2021-01-01
ER

PT J
AU Ding, JG
   Li, J
   Hong, L
   Yu, XQ
   Ye, EL
   Sun, GQ
   Zhang, XX
   Chen, L
   Sun, QF
AF Ding, J. -G.
   Li, J.
   Hong, L.
   Yu, X. -Q.
   Ye, E. -L.
   Sun, G. -Q.
   Zhang, X. -X.
   Chen, L.
   Sun, Q. -F.
TI Viral kinetics and factors associated with rapid viral clearance during
   lopinavir/ritonavir-based combination therapy in non-severe COVID-19
   patients
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Antiviral therapy; Viral kinetics; Viral clearance
ID VIRUS CLEARANCE; CORONAVIRUS; INFECTION
AB OBJECTIVE: Lopinavir/ritonavir has modest antiviral activity against severe acute respiratory syndrome coronavirus 2. The aim was to investigate the viral kinetics and factors associated with viral clearance during lopinavir/ritonavir-based combination treatment in non-severe patients.
   PATIENTS AND METHODS: Sixty-four patients were retrospectively enrolled. Viral RNA was detected by real-time RT-PCR assay from sputum or throat swab samples at different time points. The patterns of viral kinetics were characterized, and factors associated with rapid viral clearance, which was defined as viral RNA undetectable within two weeks, were analyzed using multivariate logistic regression analyses.
   RESULTS: All patients achieved viral RNA negativity and were discharged from the hospital. Furthermore, 48 (75%) and 16 (25%) patients achieved rapid and delayed viral clearance, respectively. The lymphocyte counts of rapid viral clearance patients (1.40 [1.20-1.80] x 10(9)/L) were higher, when compared to delayed viral clearance patients (1.00 [0.70-1.47] x 10(9)/L) (p=0.024). The multivariate logistic analysis revealed that high lymphocyte count (=1.3x10(9)/L) is an independent factor associated with rapid viral clearance (OR=7.62, 95% CI=1.15-50.34, p=0.035).
   CONCLUSIONS: The viral shedding exhibited different patterns during treatment. Immune insufficiency is responsible for the delayed viral clearance, suggesting that an immunomodulator should be considered to promote viral clearance in patients with low lymphocyte counts.
C1 [Ding, J. -G.; Hong, L.; Sun, Q. -F.] Ruian Peoples Hosp, Dept Infect Dis, Ruian, Zhejiang, Peoples R China.
   [Li, J.; Yu, X. -Q.; Zhang, X. -X.] Shanghai Jiao Tong Univ, Ruijin Hosp, Res Lab Clin Virol, Sch Med, Shanghai, Peoples R China.
   [Ye, E. -L.] Ruian Peoples Hosp, Dept Endocrinol, Ruian, Zhejiang, Peoples R China.
   [Sun, G. -Q.] Gordon Coll, Dept Biol, Wenham, MA USA.
   [Chen, L.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Dept Gastroenterol, Shanghai, Peoples R China.
   [Zhang, X. -X.; Chen, L.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Clin Res Ctr, Shanghai, Peoples R China.
RP Sun, QF (corresponding author), Ruian Peoples Hosp, Dept Infect Dis, Ruian, Zhejiang, Peoples R China.; Chen, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Dept Gastroenterol, Shanghai, Peoples R China.; Chen, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Clin Res Ctr, Shanghai, Peoples R China.
EM drchenli@163.com; sunxue0806@126.com
OI chen, li/0000-0001-8492-1963; sun, qingfeng/0000-0001-8562-5189
FU Ruian Science and Technology Bureau [MS2020023]
FX The study was supported by a Grant from the Ruian Science and Technology
   Bureau (MS2020023).
CR Canini L, 2014, J PHARMACOKINET PHAR, V41, P431, DOI 10.1007/s10928-014-9363-3
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Giannella M, 2011, CLIN MICROBIOL INFEC, V17, P1160, DOI 10.1111/j.1469-0691.2010.03399.x
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   National Health Comm China, 2020, GUID ISS DIAGN TREAT
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Ogimi C, 2017, J INFECT DIS, V216, P203, DOI 10.1093/infdis/jix264
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao4966
NR 23
TC 2
Z9 2
U1 2
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5788
EP 5796
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300071
PM 32495917
DA 2021-01-01
ER

PT J
AU Prajapati, S
   Sharma, M
   Kumar, A
   Gupta, P
   Kumar, GVN
AF Prajapati, S.
   Sharma, M.
   Kumar, A.
   Gupta, P.
   Kumar, G. V. Narasimha
TI An update on novel COVID-19 pandemic: a battle between humans and virus
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Coronavirus; Virus; COVID-19; Novel; nCov; Vaccine; Chloroquine
ID CORONAVIRUS OUTBREAK; PNEUMONIA; WUHAN; CHINA; REMDESIVIR; EFFICACY;
   HEALTH; SARS; MERS
AB In the 21st century, human civilization has witnessed three major epidemics caused by Coronaviruses namely severe acute respiratory syndrome coronavirus (SARS CoV) in 2003, Middle East respiratory syndrome coronavirus (MERS CoV) in 2012 and 2019 novel coronavirus (2019 nCoV) or coronavirus disease (COVID 19) in 2019. Among these, COVID-19 has greater transmission and mortality rate. 2019 nCoV belongs to a large family of positive sense single-stranded RNA viruses (+ssRNA) that can be isolated in different animal species. The most communal symptoms of COVID-19 include fever, cough, and shortness of breath during the incubation period (2-14 days) of infection. COVID-19 transmission is occurring from infected humans to close contact with one another through respiratory droplets, coughs, and sneezes of infected person. Moreover, the virus containing surfaces may also transmit the infection. Diagnosis is being carried out by collecting a nasopharyngeal swab or sputum specimen for detection of SARS-CoV-2 RNA by reverse-transcription polymerase chain reaction (RT-PCR). Rapid diagnosing methods are also under development which can diagnose COVID 19 in few minutes to hours. Currently, there is no specific cure or preventive therapeutics available. Hence, based upon limited in-vitro and anecdotal data, Chloroquine, or Hydroxychloroquine, Remdesivir, Lopinavir and Ritonavir are being employed in the management. Search for new specific anti-viral drugs from natural/synthetic origins is under full swing and many of them are currently used as chemotherapeutic drugs under clinical investigation. Yet, there is a strong need for development of vaccine, which may take several months to few years for the development.
C1 [Prajapati, S.; Sharma, M.; Kumar, A.; Gupta, P.] Dr DP Rastogi Cent Res Inst Homeopathy, Noida, Uttar Pradesh, India.
   [Kumar, G. V. Narasimha] Dr Anjali Chatterjee Reg Res Inst Homeopathy, Kolkata, India.
RP Prajapati, S (corresponding author), Dr DP Rastogi Cent Res Inst Homeopathy, Noida, Uttar Pradesh, India.
EM saimpj@gmail.com
OI G V, Narasimha Kumar/0000-0003-4991-1932; Gupta, Dr.
   Pankaj/0000-0003-3896-7869
CR [Anonymous], 2020, SCI DAILY
   [Anonymous], LAB TEST 2019 NOV CO
   [Anonymous], 2020, AFGH DAIL BRIEF COVI
   [Anonymous], 2020, REUTERS         0222
   [Anonymous], 2020, RAPID EXPERT CONSULT, DOI [10.17226/25769, DOI 10.17226/25769]
   [Anonymous], 2020, REUTERS
   [Anonymous], 2020, REPORT WHO CHINA JOI
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Bai Y, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/ja-ma.2020.2565, DOI 10.1001/JA-MA.2020.2565]
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cai J, 2020, EMERG INFECT DIS, V26, P1343, DOI 10.3201/eid2606.200412
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cascella M, 2020, FEATURES EVALUATION
   Centers for Disease Control and Prevention, 2020, INT INF PREV CONTR R
   Centers for Disease Control and Prevention, INT GUID PERS WHO MA
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, STRAT PREV SPREAD CO
   Centers for Disease Control and Prevention, 2020, INT GUID COLL HANDL
   CENTERS FOR DISEASE CONTROL AND PREVENTION, 2020, SEV OUTC PAT COR DIS
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Giovanetti M, 2020, J MED VIROL, V92, P518, DOI 10.1002/jmv.25699
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Z, 2020, J MED VIROL, DOI [10.1002/jmv.25727, DOI 10.1002/JMV.25727.[EPUB]
   Lu JING, GENOMIC EPIDEMIOLOGY
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MARCO C, 2020, STAT PEARLS
   National Health Commission of the People's Republic of China, GUID DIAGN TREATM CO
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Parvez MK, 2017, INTERVIROLOGY, V60, P1, DOI 10.1159/000478729
   Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang V, 2020, NY TIMES
   WANG YM, 2020, CHIN MED J, DOI [10.3760/ cma.j.issn.0366-6999.2020.00.E001, DOI 10.3760/CMA.J.ISSN.0366-6999.2020.00.E001]
   Wee Sui-Lee, 2020, NY TIMES
   World Health Organization, Q A COR COVID 19
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, HOM CAR PAT SUSP NOV
   World Health Organization, 2020, INF PREV CONTR HLTH
   World Health Organization, 2020, ROLL UPD COR DIS COV
   World Health Organization, COR DIS COVID 19 TEC
   Wu C., 2020, JAMA INTERN MED, DOI [10.1001/jamainternmed.2020.0994, 10. 1001, DOI 10.1001/JAMAINTERNMED.2020.0994]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 61
TC 2
Z9 2
U1 4
U2 6
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5819
EP 5829
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300075
PM 32495921
DA 2021-01-01
ER

PT J
AU Deshmukh, V
   Tripathi, SC
   Pandey, A
   Deshmukh, V
   Vykoukal, J
   Patil, A
   Sontakke, B
AF Deshmukh, V.
   Tripathi, S. C.
   Pandey, A.
   Deshmukh, V.
   Vykoukal, J.
   Patil, A.
   Sontakke, B.
TI COVID-19: a conundrum to decipher
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; 2019-nCoV SARS
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FUNCTIONAL RECEPTOR; CORONAVIRUS;
   SARS; PNEUMONIA; WUHAN; CHINA
AB OBJECTIVE: Recent worldwide outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of respiratory coronavirus disease 2019 (COVID-19), is a current, ongoing life-threatening crisis, and international public health emergency. The early diagnosis and management of the disease remains a major challenge. In this review, we aim to summarize the updated epidemiology, causes, clinical manifestation and diagnosis, as well as prevention and control of the novel coronavirus SARS-CoV-2.
   MATERIALS AND METHODS: A broad search of the literature was performed in "PubMed" "Medline" "Web of Science", " Google Scholar" and "World Health Organization-WHO" using the keywords "severe acute respiratory syndrome coronavirus", "2019-nCoV", "COVID-19, "SARS", "SARS-CoV-2" "Epidemiology" "Transmission" "Pathogenesis" "Clinical Characteristics". We reviewed and documented the information obtained from literature on epidemiology, pathogenesis and clinical appearances of SARS-CoV-2 infection.
   RESULTS: The global cases of COVID-19 as of April 2, 2020, have risen to more than 900,000 and morbidity has reached more than 47,000. The incidence rate for COVID-19 has been predicted to be higher than the previous outbreaks of other coronavirus family members, including those of SARS-CoV and the Middle East Respiratory Syndrome Coronavirus ( MERS-CoV). The main clinical presentation of SARS-CoV-2 infection ranges from asymptomatic stages to severe lower respiratory infection in the form of pneumonia. Most of the patients also presented with fever, cough, sore throat, headache, fatigue, myalgia and breathlessness. Individuals at higher risk for severe illness include elderly people and patients with a weakened immune system or that are suffering from an underlying chronic medical condition like hypertension, diabetes mellitus, cancer, respiratory illness or cardiovascular diseases.
   CONCLUSIONS: SARS-Cov-2 has emerged as a worldwide threat, currently affecting 170 countries and territories across the globe. There is still much to be understood regarding SARS-CoV-2 about its virology, epidemiology and clinical management strategies; this knowledge will be essential to both manage the current pandemic and to conceive comprehensive measures to prevent such outbreaks in the future.
C1 [Deshmukh, V.; Sontakke, B.] All India Inst Med Sci, Dept Anat, Nagpur, Maharashtra, India.
   [Tripathi, S. C.] All India Inst Med Sci, Biochem, Nagpur, Maharashtra, India.
   [Pandey, A.] Houston Methodist Ctr, Dept Neurosurg Res, Houston, TX USA.
   [Deshmukh, V.] All India Inst Med Sci, Dept Microbiol, Bhubaneswar, Orrisa, India.
   [Vykoukal, J.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Res, Houston, TX 77030 USA.
   [Patil, A.] All India Inst Med Sci, Dept Physiol, Nagpur, Maharashtra, India.
RP Tripathi, SC (corresponding author), All India Inst Med Sci, Biochem, Nagpur, Maharashtra, India.
EM sctripathi@aiimsnagpur.edu.in
RI Tripathi, Satyendra Chandra/L-9352-2017; Pandey, Arvind/J-9091-2019
OI Tripathi, Satyendra Chandra/0000-0003-3917-9645; Pandey,
   Arvind/0000-0002-9942-5468
CR ALTHAUS N, 2014, PLOS CURRENTS, V6, DOI DOI 10.1109/TAMD.2014.2310061
   [Anonymous], 2020, TRANSPL INFECT DIS
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Biggerstaff M, 2014, EPIDEMIOL INFECT, V142, P114, DOI 10.1017/S0950268813000654
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC, 2020, COR DIS 2019 COVID 1
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen DJ, 2020, INT J GYNECOL OBSTET, V149, P130, DOI 10.1002/ijgo.13146
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y H, 2020, Zhonghua Wei Chang Wai Ke Za Zhi, V23, pI, DOI 10.3760/cma.j.issn.1671-0274.2020.02.001
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Epidemic IPaCo, 2014, INF PREV CONTR EP PA
   Fournier JP, 2012, EUR J CLIN PHARMACOL, V68, P1533, DOI 10.1007/s00228-012-1283-9
   Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a
   Gislason GH, 2009, ARCH INTERN MED, V169, P141, DOI 10.1001/archinternmed.2008.525
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   He X W, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P456, DOI 10.3760/cma.j.cn112148-20200228-00137
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kucharski AJ, 2015, EUROSURVEILLANCE, V20, P14, DOI 10.2807/1560-7917.ES2015.20.25.21167
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li Y, 2020, EMERG INFECT DIS, V26, P1335, DOI 10.3201/eid2606.200287
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu B L, 2020, Zhonghua Zhong Liu Za Zhi, V42, P288, DOI 10.3760/cma.j.cn112152-20200221-00110
   Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239
   Long Youlin, 2020, J Evid Based Med, V13, P93, DOI 10.1111/jebm.12381
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma FH, 2020, ZHONGHUA ZHONG LIU Z, V42, pE001
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Ng PC, 2004, BIOL NEONATE, V85, P293, DOI 10.1159/000078174
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477
   Qian GQ, 2020, CLIN INFECT DIS, V71, P861, DOI 10.1093/cid/ciaa316
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schwartz David A, 2020, Arch Pathol Lab Med, DOI 10.5858/arpa.2020-0901-SA
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   van der Hoek L, 2007, ANTIVIR THER, V12, P651
   van Doremalen N, 2020, NEW ENGL J MED, DOI [10.1056/NE- JMc2004973, DOI 10.1056/NE-JMC2004973]
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Working Group for the Prevention and Control of Neonatal 2019-nCoV Infection in the Perinatal Period of the Editorial Committee of Chinese Journal of Contemporary Pediatrics, 2020, Zhongguo Dang Dai Er Ke Za Zhi, V22, P87
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   Wu F, 2020, ZHONGHUA ZHONG LIU Z, V42, pE004, DOI [10.3760/cma.j.cn112152-20200227-00137, DOI 10.3760/CMA.J.CN112152-20200227-00137]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Yan, 2020, Zhongguo Fei Ai Za Zhi, V23, P136, DOI 10.3779/j.issn.1009-3419.2020.03.02
   Yang H, 2020, ULTRASOUND OBST GYN, V55, P435, DOI 10.1002/uog.22006
   Yang L., 2020, ZHONGHUA ZHONG LIU Z, V42, pE006
   Yu GY, 2020, CHIN J DENT RES, V23, P9, DOI 10.3290/j.cjdr.a44348
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeng L K, 2020, Zhonghua Er Ke Za Zhi, V58, pE009, DOI 10.3760/cma.j.issn.0578-1310.2020.0009
   Zhang H, 2020, J THORAC ONCOL, DOI [10.1016/j. jtho.2020.02.025, DOI 10.1016/J.JTH0.2020.02.025]
   Zhang J., 2020, ZHONGHUA FU CHAN KE, V55
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang Y, 2020, ZHONGHUA ZHONG LIU Z, V42, DOI DOI 10.3760/CMA.J.CN112152-20200227-00141
   Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0
   Zhao Z, 2020, Zhonghua Zhong Liu Za Zhi, V42, pE007, DOI 10.3760/cma.j.cn112152-20200228-00146
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 72
TC 1
Z9 1
U1 4
U2 5
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 10
BP 5830
EP 5841
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA LS3PG
UT WOS:000536299300076
PM 32495923
DA 2021-01-01
ER

PT J
AU Sivaraman, D
   Pradeep, PS
   Manoharan, SS
   Bhat, CR
   Leela, KV
   Venugopal, V
AF Sivaraman, D.
   Pradeep, P. S.
   Manoharan, S. Sundar
   Bhat, C. Ramachandra
   Leela, K., V
   Venugopal, V.
TI Current Strategies and Approaches in Combating SARS-CoV-2 Virus that
   Causes COVID-19
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE SARS-CoV-2; COVID-19; enzyme inhibitors; liposomes; electrospun
   nanofiber technology; nano mask
ID FUNCTIONAL RECEPTOR
AB The pandemic spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) that causes COVID-19 calls for global health emergency with wide prevalence across 94 countries, and around 3073 deaths reported in china on 7th March 2020 which created red alert zone in the country. It was further noticed other than China, countries like the republic of Korea ranked first with 6767 cases, Italy with 4747 and Iran with 3513 cases. The spread of COVID-19 made a historical transition between December 2019 to March 2020 by extending the paradigm to a newer territory every day with the highest predicted reproductive number <2. Hence, while combating the epidemic spread, there are spectra of strategies that require crucial validation, some of which include drug repurposing, enzyme inhibition, target drug delivery etc. Among these, the category of drugs called enzyme inhibitors has a unique opportunity in the process of new drug discovery as these enzymes possess structural versatility starting from the host viral interface and up to the release of a new virus. Drugs entrapped within liposomes are highly effective against intracellular microorganisms as per published observations. Regulatory authorities like World Health Organization (WHO) and Centre for disease control and prevention (CDC) strongly recommend the need for the PPE's like N95 respirator to avoid person to person contact. In this context, Electrospun Nanofiber Technology (ENT) offers ultrathin fibres (20-200 nm) with close proximity of 99.97% of high efficient air filtration. Fabrication of ultrafine nano mask by utilizing electospun technology will surely benefit millions of people in a time-dependent manner.
C1 [Sivaraman, D.; Pradeep, P. S.] Sathyabama Inst Sci & Technol, Ctr Lab Anim Technol & Res, Dept Pharmacol & Toxicol, Chennai 600119, Tamil Nadu, India.
   [Manoharan, S. Sundar] Pandit Deendayal Petr Univ, Sch Technol, Gandhinagar 382007, Gujarat, India.
   [Bhat, C. Ramachandra] Govt Kilpauk Med Coll, Dept Pharmacol, Chennai 600010, Tamil Nadu, India.
   [Leela, K., V] SRM Med Coll Hosp & Res Ctr, Dept Microbiol, Chennai 603211, Tamil Nadu, India.
   [Venugopal, V.] Sundaram Hlth Ctr, Dept Internal Med, Sholinghur 632102, Tamil Nadu, India.
RP Sivaraman, D (corresponding author), Sathyabama Inst Sci & Technol, Ctr Lab Anim Technol & Res, Dept Pharmacol & Toxicol, Chennai 600119, Tamil Nadu, India.
EM sivaraman.clatr@sathyabama.ac.in
RI DHANASEKARAN, SIVARAMAN/D-1764-2015
OI DHANASEKARAN, SIVARAMAN/0000-0002-6889-2434
CR Arasa J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00536
   Balazy A, 2006, AM J INFECT CONTROL, V34, P51, DOI 10.1016/j.ajic.2005.08.018
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   OMRI A, 1994, ANTIMICROB AGENTS CH, V38, P1090, DOI 10.1128/AAC.38.5.1090
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Selvadoss PP, 2018, ARTIF CELL NANOMED B, V46, P2043, DOI 10.1080/21691401.2017.1408119
   Shu A.L., 2008, ANN OCCUP HYG, V52, P177
   U.S. Food and Drug administration, 2020, MASKS N95 RESP PERS
   Wold KA, 2012, ACS APPL MATER INTER, V4, P3022, DOI 10.1021/am300383w
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 16
TC 0
Z9 0
U1 14
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2020
VL 17
IS 5
BP 672
EP 674
DI 10.2174/157018081705200403092546
PG 3
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA LP8ZR
UT WOS:000534606200016
DA 2021-01-01
ER

PT J
AU Sun, XX
   Ni, YC
   Zhang, MJ
AF Sun, Xiaoxuan
   Ni, Yicheng
   Zhang, Miaojia
TI Rheumotologitsts' view on the use of hydroxychloroquine to treat
   COVID-19
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; therapy; hydroxychloroquine (HCQ); Chloroquine
   (CQ)
ID RHEUMATOID-ARTHRITIS; CHLOROQUINE; CORONAVIRUS; RISK
AB The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.
C1 [Sun, Xiaoxuan; Zhang, Miaojia] Nanjing Med Univ, Affiliated Hosp 1, Dept Rheumatol, Nanjing, Peoples R China.
   [Ni, Yicheng] Katholieke Univ Leuven, Fac Med, Dept Imaging & Pathol, Leuven, Belgium.
RP Zhang, MJ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Rheumatol, Nanjing, Peoples R China.
EM miaojia_zhang@163.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81671615]; 13th Five-Year National Science
   and Technology Major Project for New Drugs of the Ministry of Science
   and Technology of China of the Ministry of Science and Technology of
   China of the Ministry of Science and Technology of China
   [2019ZX09734001-002-004]
FX This work was supported by National Natural Science Foundation of China:
   [Grant Number 81671615]; 13th Five-Year National Science and Technology
   Major Project for New Drugs of the Ministry of Science and Technology of
   China of the Ministry of Science and Technology of China of the Ministry
   of Science and Technology of China: [Grant Number
   2019ZX09734001-002-004].
CR Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   LAAKSONEN AL, 1974, SCAND J RHEUMATOL, V3, P103, DOI 10.3109/03009747409115809
   Lisney AR, 2017, ANN RHEUM DIS, V76, P1476, DOI 10.1136/annrheumdis-2016-210927
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 15
TC 3
Z9 3
U1 3
U2 47
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 830
EP 832
DI 10.1080/22221751.2020.1760145
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LO4UC
UT WOS:000533623800001
PM 32338155
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, YC
   Han, S
   Wang, XN
   Shi, XD
   Yang, L
   Yan, JW
   Chen, YX
   Bing, G
AF Zhang Yongchen
   Han Shen
   Wang, Xinning
   Shi, Xudong
   Yang Li
   Yan, Jiawei
   Chen, Yuxin
   Bing Gu
TI Different longitudinal patterns of nucleic acid and serology testing
   results based on disease severity of COVID-19 patients
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; serology testing; antibody responses; viral
   nucleic acid
ID RESPONSES
AB Effective strategy to mitigate the ongoing pandemic of 2019 novel coronavirus (COVID-19) require a comprehensive understanding of humoral responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emerging virus causing COVID-19. The dynamic profile of viral replication and shedding along with viral antigen specific antibody responses among COVID-19 patients started to be reported but there is no consensus on their patterns. Here, we conducted a serial investigation on 21 individuals infected with SARS-CoV-2 in two medical centres from Jiangsu Province, including 11 non-severe COVID-19 patients, and 5 severe COVID-19 patients and 5 asymptomatic carriers based on nucleic acid test and clinical symptoms. The longitudinal swab samples and sera were collected from these people for viral RNA testing and antibody responses, respectively. Our data revealed different pattern of seroconversion among these groups. All 11 non-severe COVID-19 patients and 5 severe COVID-19 patients were seroconverted during hospitalization or follow-up period, suggesting that serological testing is a complementary assay to nucleic acid test for those symptomatic COVID-19 patients. Of note, immediate antibody responses were identified among severe cases, compared to non-severe cases. On the other hand, only one were seroconverted for asymptomatic carriers. The SARS-CoV-2 specific antibody responses were well-maintained during the observation period. Such information is of immediate relevance and would assist COVID-19 clinical diagnosis, prognosis and vaccine design.
C1 [Zhang Yongchen; Wang, Xinning; Shi, Xudong] Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Lab Med, Nanjing, Peoples R China.
   [Han Shen; Yang Li; Chen, Yuxin] Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Yan, Jiawei] Xuzhou Med Univ, Xuzhou Infect Dis Hosp, Dept Lab Med, Xuzhou, Jiangsu, Peoples R China.
   [Bing Gu] Xuzhou Med Univ, Med Technol Sch, Xuzhou Key Lab Lab Diagnost, Xuzhou 221004, Jiangsu, Peoples R China.
   [Bing Gu] Xuzhou Med Univ, Affiliated Hosp, Dept Lab Med, Xuzhou 221006, Jiangsu, Peoples R China.
RP Chen, YX (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Med Sch, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China.; Bing, G (corresponding author), Xuzhou Med Univ, Med Technol Sch, Xuzhou Key Lab Lab Diagnost, Xuzhou 221004, Jiangsu, Peoples R China.; Bing, G (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Lab Med, Xuzhou 221006, Jiangsu, Peoples R China.
EM yuxin_chen2015@163.com; binggu2015@xzhmu.edu.cn
OI Reis, AlessanRSS/0000-0001-8486-7469
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81471994,81600201,81871734]
FX This work was supported by National Natural Science Foundation of China:
   [Grant Number 81471994,81600201,81871734].
CR Baumgarth N, 2013, IMMUNOL REV, V255, P82, DOI 10.1111/imr.12094
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   Lam JH, 2019, J IMMUNOL, V202, P351, DOI 10.4049/jimmunol.1801208
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   National Health Commission of the People's Republic of China, CHIN MAN GUID COVID
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   World Health Organization, CLIN MAN SEV AC RESP
   Wu Y, 2020, LANCET GASTROENTEROL
   Zhang LQ, 2006, J MED VIROL, V78, P1, DOI 10.1002/jmv.20499
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 15
TC 53
Z9 53
U1 5
U2 43
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 833
EP 836
DI 10.1080/22221751.2020.1756699
PG 4
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LO4UR
UT WOS:000533625300001
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lau, SY
   Wang, P
   Mok, BWY
   Zhang, ANJX
   Chu, H
   Lee, ACY
   Deng, SF
   Chen, P
   Chan, KH
   Song, WJ
   Chen, ZW
   To, KKW
   Chan, JFW
   Yuen, KY
   Chen, HL
AF Lau, Siu-Ying
   Wang, Pui
   Mok, Bobo Wing-Yee
   Zhang, Anna Jinxia
   Chu, Hin
   Lee, Andrew Chak-Yiu
   Deng, Shaofeng
   Chen, Pin
   Chan, Kwok-Hung
   Song, Wenjun
   Chen, Zhiwei
   To, Kelvin Kai-Wang
   Chan, Jasper Fuk-Woo
   Yuen, Kwok-Yung
   Chen, Honglin
TI Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE Coronavirus; COVID-19; SARS-CoV-2; Spike mutant; Spike S1; S2 mutant
ID CORONAVIRUS; PNEUMONIA
AB The emergence of SARS-CoV-2 has led to the current global coronavirus pandemic and more than one million infections since December 2019. The exact origin of SARS-CoV-2 remains elusive, but the presence of a distinct motif in the S1/S2 junction region suggests the possible acquisition of cleavage site(s) in the spike protein that promoted cross-species transmission. Through plaque purification of Vero-E6 cultured SARS-CoV-2, we found a series of variants which contain 15-30-bp deletions (Del-mut) or point mutations respectively at the S1/S2 junction. Examination of the original clinical specimen from which the isolate was derived, and 26 additional SARS-CoV-2 positive clinical specimens, failed to detect these variants. Infection of hamsters shows that one of the variants (Del-mut-1) which carries deletion of 10 amino acids (30bp) does not cause the body weight loss or more severe pathological changes in the lungs that is associated with wild type virus infection. We suggest that the unique cleavage motif promoting SARS-CoV-2 infection in humans may be under strong selective pressure, given that replication in permissive Vero-E6 cells leads to the loss of this adaptive function. It would be important to screen the prevalence of these variants in asymptomatic infected cases. The potential of the Del-mut variants as an attenuated vaccine or laboratory tool should be evaluated.
C1 [Lau, Siu-Ying; Wang, Pui; Mok, Bobo Wing-Yee; Zhang, Anna Jinxia; Chu, Hin; Lee, Andrew Chak-Yiu; Deng, Shaofeng; Chen, Pin; Chan, Kwok-Hung; Song, Wenjun; Chen, Zhiwei; To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Chen, Honglin] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China.
   [Lau, Siu-Ying; Wang, Pui; Mok, Bobo Wing-Yee; Zhang, Anna Jinxia; Chu, Hin; Lee, Andrew Chak-Yiu; Deng, Shaofeng; Chen, Pin; Chan, Kwok-Hung; Song, Wenjun; Chen, Zhiwei; To, Kelvin Kai-Wang; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; Chen, Honglin] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   [Song, Wenjun] Guangzhou Med Univ, Affiliated Hosp 1, Inst Integrat Tradit & Western Med, State Key Lab Resp Dis, Guangzhou, Peoples R China.
RP Chen, HL (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Peoples R China.; Chen, HL (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
EM hlchen@hku.hk
RI To, Kelvin/AAV-7007-2020
OI To, Kelvin/0000-0002-1921-5824; Reis, AlessanRSS/0000-0001-8486-7469
FU Theme-Based Research Scheme of the University Grant Committee, Hong Kong
   Special Administrative Region [T11/707/15]; Sanming Project of Medicine
   in Shenzhen [SZSM201911014]; High-Level Hospital Program, Health
   Commission of Guangdong Province; Coalition for Epidemic Preparedness
   Innovations (CEPI)
FX This study is partly supported by the Theme-Based Research Scheme
   (T11/707/15) of the University Grant Committee, Hong Kong Special
   Administrative Region; the Sanming Project of Medicine in Shenzhen
   [grant number SZSM201911014), and the High-Level Hospital Program,
   Health Commission of Guangdong Province as well as Coalition for
   Epidemic Preparedness Innovations (CEPI) seed funding for the Outbreak
   Response to Novel Coronavirus (COVID-19).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Matsuyama S, 2005, P NATL ACAD SCI USA, V102, P12543, DOI 10.1073/pnas.0503203102
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Song WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6509
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 31
Z9 35
U1 3
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 837
EP 842
DI 10.1080/22221751.2020.1756700
PG 6
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LO4UU
UT WOS:000533625600001
PM 32301390
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Chan, KW
   Wong, VT
   Tang, SCW
AF Chan, Kam Wa
   Wong, Vivian Taam
   Tang, Sydney Chi Wai
TI COVID-19: An Update on the Epidemiological, Clinical, Preventive and
   Therapeutic Evidence and Guidelines of Integrative Chinese-Western
   Medicine for the Management of 2019 Novel Coronavirus Disease
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE COVID-19; 2019-nCoV; Chinese Medicine; Integrative Medicine; Guideline;
   Review
ID ACUTE RESPIRATORY SYNDROME; CORTICOSTEROID-THERAPY; SARS; TRANSMISSION;
   PNEUMONIA; OUTCOMES; RIBAVIRIN; SYMPTOMS; CLUSTER; ADULTS
AB As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.
C1 [Chan, Kam Wa; Tang, Sydney Chi Wai] Univ Hong Kong, Dept Med, 4-F Professorial Block,102 Pokfulam Rd, Hong Kong, Peoples R China.
   [Wong, Vivian Taam] Univ Hong Kong, Sch Chinese Med, 10 Sasson Rd, Hong Kong, Peoples R China.
RP Tang, SCW (corresponding author), Univ Hong Kong, Dept Med, 4-F Professorial Block,102 Pokfulam Rd, Hong Kong, Peoples R China.; Wong, VT (corresponding author), Univ Hong Kong, Sch Chinese Med, 10 Sasson Rd, Hong Kong, Peoples R China.
EM vcwwong@hku.hk; scwtang@hku.hk
RI CHAN, Kam Wa/J-5939-2015; Chand, Kishore/AAJ-9566-2020; Lakhan, Muhammad
   Nazim/AAV-5494-2020; chand, kishore/AAV-3533-2020
OI CHAN, Kam Wa/0000-0002-3175-1574; Chand, Kishore/0000-0001-6199-7041;
   Cao, Dianxue/0000-0003-2197-3859; Fouad, Diaa Eldin/0000-0002-0004-3700
FU Health and Medical Research Fund [14151731]
FX We thank Ms. Kam Yan Yu for clerical support on the translation of
   herbs. This work was made possible in part through Health and Medical
   Research Fund (Ref.: 14151731). The funding organizations had no role in
   the design and conduct of the study; collection, management, analysis,
   and interpretation of the data; preparation, review, or approval of the
   manuscript; and decision to submit the manuscript for publication.
CR [Anonymous], 2020, ACAD J SHANGHAI U TR, P1
   [Anonymous], 2020, TIME DATE AS WEATHER
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bernheim A, 2020, RADIOLOGY, V395, P514
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chan JWM, 2003, THORAX, V58, P686, DOI 10.1136/thorax.58.8.686
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Z, 2020, HERALD MED
   Cheng D., 2020, WORLD CHIN MED, V15, P150, DOI DOI 10.3969/j.issn.1673-7202.2020.02.006
   Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Dai M, 2020, TIANJIN J TRADIT CHI, V37, P132
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Fan Y., 2020, J TRADIT CHIN MED
   Gao SM, 2020, TIANJIN J TRADIT CHI, V37, P121
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   GISAID, 2020, GEN EP BETACOV 2019
   GitHub, 2020, 2019 NOV COR COVID 1
   Guan W.-J, 2020, MEDRXIV
   Guangdong Medical Products Administration, 2020, NOT CLIN US TONGJ QU
   Guo Z., 2020, ACTA PHARM SINICA
   Healthmap, 2020, HEALTHMAP COR OUTBR
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hu M, 2020, CHIN J INTEGR TRADIT, DOI [10.7661/j.cjim.20200204.065., DOI 10.7661/J.CJIM.20200204.065]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Idborg H, 2019, LANCET RHEUMATOL, V1, pE76, DOI 10.1016/S2665-9913(19)30047-5
   Jiang Q, 2020, W CHINA J PHARM SCI
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jun Chen, 2020, CHIN J INFECT DIS, V38, pE008, DOI DOI 10.3760/cma.j.issn.1000-6680.2020.02.006
   Knowles SR, 2003, CLIN INFECT DIS, V37, P1139, DOI 10.1086/378304
   Koren G, 2003, CAN MED ASSOC J, V168, P1289
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Lau JTF, 2005, J ALTERN COMPLEM MED, V11, P49, DOI 10.1089/acm.2005.11.49
   Lau TF, 2005, AM J CHINESE MED, V33, P345, DOI 10.1142/S0192415X05002965
   Van Cuong L, 2020, LANCET INFECT DIS, V20, P408, DOI 10.1016/S1473-3099(20)30111-0
   Le W., 2020, XINHUA NET
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Leung PC, 2007, AM J CHINESE MED, V35, P575, DOI 10.1142/S0192415X07005077
   Li C, 2020, MODERNIZATION TRADIT, V22, P1, DOI DOI 10.1080/15376494.2019.1709674
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Li J, 2020, CHIN TRADIT HERB DRU
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu XM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004882.pub3
   Liu YC, 2020, NEW ENGL J MED, V382, P1070, DOI 10.1056/NEJMc2001573
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lu R, 2020, J TRADIT CHIN MED
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Ma J, 2020, BEIJING J TRADIT CHI
   Ma J, 2020, CHINA J CHIN MAT MED, DOI [10.19540/j.cnki.cjcmm.20200216.401., DOI 10.19540/J.CNKI.CJCMM.20200216.401]
   Ma PL, 2019, ENERGY SCI ENG, V7, P431, DOI 10.1002/ese3.286
   Marano G, BLOOD TRANSFUSION, V14, P152
   Miao Q. X., 2020, J TRADIT CHIN MED
   National Administration of Traditional Chinese Medicine, 2020, PROGR SCREEN EFF PRE
   National Administration of Traditional Chinese Medicine, 2020, BEIJ 1 CONF CAS NEW
   National Health Commission and National Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PENUM C
   Niu M, 2020, CHINA J CHIN MAT MED, DOI [10.19540/j.cnki.cjcmm.20200206.501, DOI 10.19540/J.CNKI.CJCMM.20200206.501]
   Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6
   Pang W.T., 2020, CHINA J CHIN MAT MED, DOI [10.19540/j.cnki.cjcmm.20200218.502, DOI 10.19540/J.CNKI.CJCMM.20200218.502]
   Pongpirul WA, 2020, NEW ENGL J MED, V382, P1067, DOI 10.1056/NEJMc2001621
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Scagnolari C, 2004, ANTIVIR THER, V9, P1003
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Sood R, 2014, NAT REV GASTRO HEPAT, V11, P683, DOI 10.1038/nrgastro.2014.127
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Sun KY, 2020, LANCET DIGIT HEALTH, V2, pE201, DOI 10.1016/S2589-7500(20)30026-1
   Sun Z, 2020, J SHAANXI U CHIN MED, V2, p2020b
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   The State Council The People's Republic of China, 2020, LAT DEV EP CONTR 17
   The State Council The People's Republic of China, 2020, LAT DEV EP CONTR 21
   Tong X, 2020, J TRADIT CHIN MED
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M, 2020, CELL RES, V30, P269
   Wang X, 2020, J TROP MED
   Wang XM, 2020, POTENTIAL ANAL, DOI 10.1007/s11118-019-09821-8
   Wang Z., 2020, XINHUA NET
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organisation, 2004, CLIN MAN AC DIARRH W, P1
   World Health Organization, 2020, 31 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xia W, 2020, J TRADIT CHIN MED
   Xu X, 2020, CRIT REV BIOCHEM MOL, V55, P1, DOI 10.1080/10409238.2020.1726279
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Xu Z, 2020, LANCET, V395, P947, DOI 10.1016/S0140-6736(20)30308-1
   Yang H, 2020, BEIJING J TRADIT CHI
   Yang W., 2020, CHIN J BASIC MED TRA
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao K.T., 2020, CHIN J EXP TRADIT ME, DOI [10.13422/j.cnki.syfjx.20201099, DOI 10.13422/J.CNKI.SYFJX.20201099]
   Yeo C, 2020, LANCET GASTROENTEROL, V5, P335, DOI 10.1016/S2468-1253(20)30048-0
   Yong W, 2020, SHANGHAI J TRADIT CH, V54, P21
   Yu M, 2020, J TRADIT CHIN MED
   Yu SM, 2020, BEIJING J TRADIT CHI
   Yu WC, 2004, THORAX, V59, P643, DOI 10.1136/thx.2003.017665
   Yuan Q., 2020, XINHUA NET
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang X, 2020, J NANJING U TRADIT C
   Zhao J, 2020, CHIN TRADIT HERB DRU
   Zhaori G, 2003, CAN MED ASSOC J, V169, P1165
   Zheng W, 2020, J TRADIT CHIN MED
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zong Y, 2020, CHIN TRADIT HERB DRU
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 120
TC 78
Z9 82
U1 28
U2 61
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2020
VL 48
IS 3
BP 737
EP 762
DI 10.1142/S0192415X20500378
PG 26
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA LL9NZ
UT WOS:000531883000013
PM 32164424
OA DOAJ Gold
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Anderson, DE
   Tan, CW
   Chia, WN
   Young, BE
   Linster, M
   Low, JH
   Tan, YJ
   Chen, MIC
   Smith, GJD
   Leo, YS
   Lye, DC
   Wang, LF
AF Anderson, Danielle E.
   Tan, Chee Wah
   Chia, Wan Ni
   Young, Barnaby E.
   Linster, Martin
   Low, JennyG H.
   Tan, Yee-Joo
   Chen, Mark I-C
   Smith, Gavin J. D.
   Leo, Yee Sin
   Lye, David C.
   Wang, Lin-Fa
TI Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS; COVID-19; antibody; cross-neutralization; SARS-CoV-2
ID CORONAVIRUS
AB Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9-17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.
C1 [Anderson, Danielle E.; Tan, Chee Wah; Chia, Wan Ni; Linster, Martin; Smith, Gavin J. D.; Wang, Lin-Fa] Duke NUS Med Sch, Singapore, Singapore.
   [Young, Barnaby E.; Chen, Mark I-C; Leo, Yee Sin; Lye, David C.] Natl Ctr Infect Dis, Singapore, Singapore.
   [Low, JennyG H.] Singapore Gen Hosp, Singapore, Singapore.
   [Tan, Yee-Joo] Natl Univ Singapore, Singapore, Singapore.
RP Anderson, DE; Wang, LF (corresponding author), Duke NUS Med Sch, Singapore, Singapore.
EM danielle.anderson@duke-nus.edu.sg; linfa.wang@duke-nus.edu.sg
RI Linster, Martin/AAY-9088-2020
OI Chen, Mark/0000-0001-9369-5830; Reis, AlessanRSS/0000-0001-8486-7469;
   Tan, Yee-Joo/0000-0002-2278-4497; Lye, David/0000-0003-0324-0205
FU Singapore National Research FoundationSingapore National Research
   Foundation [NRF-2016NRFNSFC002-013]; National Medical Research Council
   of the Ministry of Health Singapore [CCGSFPOR20001, STPRG-FY19-001,
   COVID19RF-003]
FX This study was jointly supported by grants from the Singapore National
   Research Foundation (NRF-2016NRFNSFC002-013), and the National Medical
   Research Council of the Ministry of Health Singapore (CCGSFPOR20001,
   STPRG-FY19-001 and COVID19RF-003).
CR Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu LY, 2003, EMERG INFECT DIS, V9, P713
   Kaku Y, 2012, J VIROL METHODS, V179, P226, DOI 10.1016/j.jviromet.2011.11.003
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yu M, 2008, J IMMUNOL METHODS, V331, P1, DOI 10.1016/j.jim.2007.11.009
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 8
TC 9
Z9 9
U1 2
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 900
EP 902
DI 10.1080/22221751.2020.1761267
PG 3
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LO4TU
UT WOS:000533623000001
PM 32380903
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Urzua, A
   Vera-Villarroel, P
   Caqueo-Urizar, A
   Polanco-Carrasco, R
AF Urzua, Alfonso
   Vera-Villarroel, Pablo
   Caqueo-Urizar, Alejandra
   Polanco-Carrasco, Roberto
TI Psychology in the prevention and management of COVID-19. Contributions
   from the initial evidence
SO TERAPIA PSICOLOGICA
LA Spanish
DT Article
DE Corona-Virus; COVID-19; Health Psychology; Public Health
ID FEBRUARY 27; CORONAVIRUS; EARTHQUAKE; PNEUMONIA; STUDENTS; STRESS;
   IMPACT; RISK
AB In December 2019, highly lethal cases of pneumonia were reported in Wuhan, Hubei Province, China (COVID-19). This disease has spread rapidly around the world with thousands of confirmed cases and deaths, becoming a pandemic and challenging public health systems. There is no vaccine or scientifically proven treatment yet, but the exact behaviours that can prevent transmission and spread have been identified. This article systematizes initial available information on psychology and COVID-19. It is discussed that much of the problem of the disease can be avoided by changing people's behaviors and that psychology can help explain, prevent and intervene to solve it. Psychology has scientific evidence available that explains all these phenomena, evidence that should be highlighted by the same actors in the disciplines available to other areas of knowledge and especially for decision makers.
C1 [Urzua, Alfonso] Univ Catolica Norte, Escuela Psicol, Antofagasta, Chile.
   [Vera-Villarroel, Pablo] Ctr Anal I D, Antofagasta, Chile.
   [Caqueo-Urizar, Alejandra] Univ Tarapaca, Inst Alta Invest, Arica, Chile.
RP Urzua, A (corresponding author), Avda Angamos 0610, Antofagasta, Chile.
EM alurzua@ucn.cl
RI Urzua, Alfonso/A-1208-2012; Vera-Villarroel, Pablo/AAQ-8476-2020
OI Urzua, Alfonso/0000-0002-0882-2194; 
CR BAYES R, 1992, PSICOLOGIA SALUD APO, P1
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Dai Y, 2020, PSYCHOL IMPACT CORON, DOI [10.1101/2020.03.03.20030874, DOI 10.1101/2020.03.03.20030874]
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Jeong H., 2016, RESP SYNDROME, V38, P103
   Jiang XX, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112903
   Lee A.M., 2020, J BEHAV PUBLIC ADM, V3, DOI [10.30636/jbpa.31.147, DOI 10.30636/JBPA.31.147]
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Lopez SV, 2020, AM J SEX EDUC, V15, P201, DOI 10.1080/15546128.2020.1734131
   Main A, 2011, J COUNS PSYCHOL, V58, P410, DOI 10.1037/a0023632
   Murphy D. J., 2020, FRAMEWORK CONTRIBUTI
   National Health Commission, 2020, PRINC EM PSYCH CRIS
   Park JS, 2018, ARCH PSYCHIAT NURS, V32, P2, DOI 10.1016/j.apnu.2017.09.006
   Poudel Adhikari S., 2020, LITERATURE REVIEW 20, DOI [10.20944/preprints202002.0060.v1, DOI 10.20944/PREPRINTS202002.0060.V1]
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   TORRES-SALAZAR CRISTINA, 2020, Rev. colomb. psicol., V29, P61, DOI 10.15446/rcp.v29n1.75853
   Vera-Villarroel P., 2015, MANUAL ESCALAS CUEST
   Vera-Villarroel P, 2011, PSYCHOL REP, V109, P47, DOI 10.2466/02.13.15.17.PR0.109.4.47-58
   Vogel EH, 2010, TER PSICOL, V28, P143, DOI 10.4067/S0718-48082010000200001
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Yang S, 2017, AM J INFECT CONTROL, V45, pE53, DOI 10.1016/j.ajic.2017.02.013
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang J, 2020, PRECISION CLIN MED, V3, P3, DOI [10.1093/pcmedi/pbaa006, DOI 10.1093/pcmedi/pbaa006]
   Zhu YH, 2020, NEUROSCI BULL, V36, P299, DOI 10.1007/s12264-020-00476-9
NR 28
TC 3
Z9 4
U1 9
U2 15
PU SOCIEDAD CHILENA PSICOLOGIA CLINICA
PI SANTIAGO
PA RICARDO MATTE PEREZ 492 PROVIDENCIA, SANTIAGO, 00000, CHILE
SN 0718-4808
J9 TER PSICOL
JI Ter. Psicol.
PY 2020
VL 38
IS 1
BP 103
EP 118
PG 16
WC Psychology, Clinical
SC Psychology
GA LK1AT
UT WOS:000530592100007
DA 2021-01-01
ER

PT J
AU Weng, YH
AF Weng, Yanghui
TI ANALYSIS OF PREVENTION AND CONTROL STRATEGY OF COVID-19 EPIDEMIC IN
   CHINA BASED ON THE CONCEPT OF "ONE HEALTH": AN OPINION PAPER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE One Health; COVID-19; Public health events; outbreaks; Public policy
AB Background: In December 2019, new coronavirus pneumonia (COVID - 19) was found in Wuhan, China. The current epidemic is spreading in China and even the world. The virus has the characteristics of strong infectivity, long incubation period, mainly spread by droplets, close contact. So far there is no specific drug treatment. There are nearly 100,000 confirmed cases worldwide.
   Methods: In the current severe situation of the epidemic, this paper uses the methods of literature, investigation and logical and so on.
   Results: According to the special environment of China, the concept of One Health is proposed for prevention and control. Under the leadership of the government, multiple functional departments and disciplines cooperate to exchange information, forming a working mechanism of efficient coordination, seamless connection, a combination of prevention and control, and coordination among the masses.
   Conclusion: The government should set up a department of "One Health" to promote the coordination and cooperation between multiple departments and disciplines. It is suggested: 1. Strengthening infectious disease medical personnel training and public health research; 2. To intervene in the psychological crisis of different groups;3. Provide security and logistic support for medical staff; 4. Guarantee the reserve of protective and medical materials; 5. Vigilance and prevention and control of the "weak period" of the epidemic;6. International opinion dominates.
C1 [Weng, Yanghui] China Univ Petr East China, Dept Phys Educ, Dongying, Peoples R China.
RP Weng, YH (corresponding author), 66 Changjiang Rd Huangdao Dist, Qingdao 266580, Peoples R China.
EM weng007@upc.edu.cn
FU China university of Petroleum (East China)
FX Thanks for the support from China university of Petroleum (East China),
CR [Anonymous], CHINA DAILY NET
   [Anonymous], EP PREV CONTR TRENDS
   Chinese people's Government, COVID 19 DIAGN TREAT
   Chinese people's Government-Xi Jinping, COMMUNICATION
   Guan WJ, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.06.20020974, DOI 10.1101/2020.02.06.20020974, 10.1101/2020.02.06.20020974.]
   Huang C, 2020, LANCET, V395, P497
   Kock R, 2013, J EMERG INFECT DIS, V19
   Sufen Pang, 2015, ANIMAL QUARANTINE CH, P32
   Tan Zai-xiang, 2020, HLTH EC RES, V2, P11
   Zhihui Li, 2020, J JINAN U NATURAL SC
   Zinsstag J, 2011, PREV VET MED, V101, P148, DOI 10.1016/j.prevetmed.2010.07.003
NR 11
TC 1
Z9 1
U1 5
U2 16
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2020
VL 36
IS 2
BP 1167
EP 1174
DI 10.19193/0393-6384_2020_2_183
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA LD6DV
UT WOS:000526121600068
DA 2021-01-01
ER

PT J
AU Ghosh, S
   Firdous, SM
   Nath, A
AF Ghosh, Sanhita
   Firdous, Sayeed Mohammad
   Nath, Anirban
TI siRNA COULD BE A POTENTIAL THERAPY FOR COVID-19
SO EXCLI JOURNAL
LA English
DT Letter
C1 [Ghosh, Sanhita; Nath, Anirban] Univ Calcutta, Dept Genet & Plant Breeding, Inst Agr Sci, 51-2 Hazra Rd, Kolkata 700073, W Bengal, India.
   [Firdous, Sayeed Mohammad] Calcutta Inst Pharmaceut Technol & AHS, Dept Pharmacol, Howrah 711316, W Bengal, India.
RP Firdous, SM (corresponding author), Calcutta Inst Pharmaceut Technol & AHS, Dept Pharmacol, Howrah 711316, W Bengal, India.
EM firdous.cology@gmail.com
CR Conti DS, 2014, MOL PHARMACEUT, V11, P1808, DOI 10.1021/mp4006358
   Elmen J, 2014, SHORT INTERFERING RN
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lv W, 2006, SARS CORONAVIRUS DIS
   Tang QQ, 2004, RNAI AGENTS ANTISARS
   Wang Y, 2006, SMALL INTERFERING RN
   Weimin H, 2003, MED PREVENTING TREAT
   WHO, 2020, WHO COR DIS COVID 20
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang Y, 2006, SIRNA DISTURBING RDR
NR 12
TC 5
Z9 5
U1 0
U2 2
PU EXCLI JOURNAL MANAGING OFFICE
PI DORTMUND
PA LEIBNIZ RESEARCH CENTRE WORKING ENVIRONMENT & HUMAN FACTORS EXCLI
   JOURNAL, ARDEYSTR 67, DORTMUND, D-44139, GERMANY
SN 1611-2156
J9 EXCLI J
JI EXCLI J.
PY 2020
VL 19
BP 528
EP 531
DI 10.17179/excli2020-1328
PG 4
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA LG3TH
UT WOS:000528026800001
PM 32398976
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Askanase, AD
   Khalili, L
   Buyon, JP
AF Askanase, Anca D.
   Khalili, Leila
   Buyon, Jill P.
TI Thoughts on COVID-19 and autoimmune diseases
SO LUPUS SCIENCE & MEDICINE
LA English
DT Letter
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERFERON-ALPHA; PNEUMONIA
AB Over the 2 months since coronavirus first appeared in China, cases have emerged on every continent, and it is clear that patients with autoimmune diseases might also be affected. Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness with a mortality rate approaching 2%. Here we discuss the challenges that patients with autoimmune diseases might face and the information on using immunomodulatory therapies like chloroquine, tocilizumab and baricitinib to quench the cytokine storm in patients with very severe COVID-19 pneumonia.
C1 [Askanase, Anca D.; Khalili, Leila] Columbia Univ, Med Ctr, Dept Rheumatol, New York, NY 10027 USA.
   [Buyon, Jill P.] NYU Langone Hlth, Dept Rheumatol, New York, NY USA.
RP Askanase, AD (corresponding author), Columbia Univ, Med Ctr, Dept Rheumatol, New York, NY 10027 USA.
EM ada20@cumc.columbia.edu
OI Buyon, Jill/0000-0002-3852-7129
CR Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen J, PILOT STUDY HYDROXYC
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Niewold TB, 2011, J INTERF CYTOK RES, V31, P887, DOI 10.1089/jir.2011.0071
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Pene F, 2003, CLIN INFECT DIS, V37, P929, DOI 10.1086/377612
   PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao Bai Y, 2020, JAMA
   Yao X, 2020, CLIN INFECT DIS
   YEE AMF, 1989, J EXP MED, V169, P987, DOI 10.1084/jem.169.3.987
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 23
TC 13
Z9 13
U1 3
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2053-8790
J9 LUPUS SCI MED
JI Lupus Sci. Med.
PD JAN
PY 2020
VL 7
IS 1
AR UNSP e000396
DI 10.1136/lupus-2020-000396
PG 3
WC Rheumatology
SC Rheumatology
GA LF9VM
UT WOS:000527760600013
PM 32341791
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, LZ
   Duan, YT
   Zhang, WM
   Liang, J
   Xu, JX
   Zhang, YQ
   Wu, CG
   Xu, YL
   Li, H
AF Wang, Lizhen
   Duan, Yueting
   Zhang, Wenming
   Liang, Juan
   Xu, Jianxiang
   Zhang, Yongqing
   Wu, Changgang
   Xu, Yangling
   Li, Hua
TI Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19
   Arising from Patient-to-Patient Transmission in Liaocheng, China
SO CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE coronavirus disease 2019; human-to-human transmission; epidemiologic
   characteristics; clinical characteristics
AB Introduction: Over 40,000 cases of coronavirus (CoV) disease 2019 (COVID-19) have been confirmed in China. The causative agent, 2019 novel CoV (2019-nCoV), has spread rapidly to more than 25 countries worldwide. Human-to-human transmission has accounted for most of the infections outside Wuhan. Most studies to date on COVID-19 have focused on disease etiology and the genomics of 2019-nCoV, with few reports on the epidemiologic and clinical characteristics of infected patients.
   Methods: We report early clinical features of 26 patients with confirmed COVID-19 who were admitted to Liaocheng Infectious Disease Hospital in Shandong Province.
   Results: The median age of the 26 patients with COVID-19 in this study was 42 years. The most common occupation was retail staff (16 patients, 61.54%), with 11 patients or their family members working at the same supermarket. Only 2 patients had visited Wuhan since December 2019; the other cases of 2019-nCoV infection arose from patient-to-patient transmission. Twelve patients had more than one sign or symptom; however, seven patients had no sign or symptom. The average time from symptom onset to admission was 4.5 days. CT revealed signs of bronchitis in 2 patients and unilateral and bilateral pneumonia in 9 and 15 patients, respectively. The patients received the following treatments: antiviral therapy (100%), Chinese medicine (76.92%), antibiotics (50%), gastric mucosal protection (19.23%), immunotherapy (7.69%), and glucocorticoids (3.85%). Most patients (25/26) required >= 1 treatment.
   Discussion: In contrast to previous reports, most patients (24/26) had not been in close contact with individuals from Wuhan. Additionally, 11 patients or their family members worked at the same supermarket, suggesting active viral transmission in a location frequented by a large number of people. Close monitoring is essential for preventing the large-scale spread of the virus in such places.
C1 [Wang, Lizhen; Duan, Yueting] Liaocheng Infect Dis Hosp, Dept TB, Liaocheng, Shandong, Peoples R China.
   [Zhang, Wenming; Liang, Juan; Li, Hua] Liaocheng Infect Dis Hosp, Intens Care Unit, Liaocheng, Shandong, Peoples R China.
   [Xu, Jianxiang; Zhang, Yongqing; Wu, Changgang; Xu, Yangling] Liaocheng Infect Dis Hosp, Dept Respirat, 45 Jianshe Eastern Rd, Liaocheng 252000, Shandong, Peoples R China.
RP Li, H (corresponding author), Liaocheng Infect Dis Hosp, Dept Respirat, 45 Jianshe Eastern Rd, Liaocheng 252000, Shandong, Peoples R China.
EM weiyichunguang@163.com
CR Benvenuto D, 2020, J MED VIROL, V29
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen N, 2020, LANCET, V395
   Guan WJ, 2002, CLIN CHARACTERISTICS
   Huang C, 2020, LANCET
   National Health Commission of the People's Republic of China, 2020, REP NOV COR INF PNEU
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou P, 2020, BIORXIV, DOI [10.1101/2020.01.24.919183, DOI 10.1101/2020.01.24.919183]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 13
TC 13
Z9 13
U1 1
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1349
J9 CLIN EPIDEMIOL
JI Clin. Epidemiol.
PY 2020
VL 12
BP 387
EP 391
DI 10.2147/CLEP.S249903
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LB4EP
UT WOS:000524589100001
PM 32308494
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Xiong, Y
   Liu, Y
   Cao, L
   Wang, DH
   Guo, M
   Jiang, A
   Guo, D
   Hu, WJ
   Yang, JY
   Tang, ZD
   Wu, HL
   Lin, YQ
   Zhang, MY
   Zhang, Q
   Shi, M
   Liu, YL
   Zhou, Y
   Lan, K
   Chen, Y
AF Xiong, Yong
   Liu, Yuan
   Cao, Liu
   Wang, Dehe
   Guo, Ming
   Jiang, Ao
   Guo, Dong
   Hu, Wenjia
   Yang, Jiayi
   Tang, Zhidong
   Wu, Honglong
   Lin, Yongquan
   Zhang, Meiyuan
   Zhang, Qi
   Shi, Mang
   Liu, Yingle
   Zhou, Yu
   Lan, Ke
   Chen, Yu
TI Transcriptomic characteristics of bronchoalveolar lavage fluid and
   peripheral blood mononuclear cells in COVID-19 patients
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; transcriptome profiling; inflammation; cytokine; lymphopenia
ID SARS; CORONAVIRUS; PNEUMONIA; LYMPHOPENIA; CYTOKINES; WUHAN
AB Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health. However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease. To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients. Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the association between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B. Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia. The transcriptome dataset of COVID-19 patients would be a valuable resource for clinical guidance on anti-inflammatory medication and understanding the molecular mechansims of host response.
C1 [Xiong, Yong; Hu, Wenjia] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, State Key Lab Virol, Wuhan, Peoples R China.
   [Liu, Yuan; Wang, Dehe; Guo, Ming; Jiang, Ao; Guo, Dong; Yang, Jiayi; Tang, Zhidong; Zhang, Qi; Liu, Yingle; Zhou, Yu; Lan, Ke; Chen, Yu] Wuhan Univ, Coll Life Sci, Modern Virol Res Ctr, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Cao, Liu; Shi, Mang] Sun Yat Sen Univ, Ctr Infect & Immun Studies, Sch Med, Guangzhou, Peoples R China.
   [Wu, Honglong; Lin, Yongquan; Zhang, Meiyuan] BGI PathoGenesis Pharmaceut Technol, Shenzhen, Peoples R China.
RP Zhou, Y; Lan, K; Chen, Y (corresponding author), Wuhan Univ, Coll Life Sci, Modern Virol Res Ctr, State Key Lab Virol, Wuhan 430072, Peoples R China.
EM yu.zhou@whu.edu.cn; klan@whu.edu.cn; chenyu@whu.edu.cn
OI Zhou, Yu/0000-0002-2102-9377; xiong, yong/0000-0003-0678-4064; Wang,
   Dehe/0000-0002-9465-0957; Lan, Ke/0000-0002-0384-8598; Shi,
   Mang/0000-0002-6154-4437; Lin, Yongquan/0000-0001-6663-731X; Reis,
   AlessanRSS/0000-0001-8486-7469; Chen, Yu/0000-0003-1300-4652
FU National Science and Technology Major Project [2018ZX10733403]; China
   NSFCNational Natural Science Foundation of China (NSFC) [81672008,
   31871316]; Hubei Natural Science FoundationNatural Science Foundation of
   Hubei Province [2018CFA035]; Basic Scientific Research Foundation of
   Central Universities [2042019gf0026]; Ministry of Science and Technology
   of ChinaMinistry of Science and Technology, China; National Key Research
   and Development Program of China [2018YFE0204500]; National Mega Project
   on Major Infectious Disease Prevention [2017ZX10103005]; Special Fund
   for COVID-19 Research of Wuhan University
FX This study was supported by Special Fund for COVID-19 Research of Wuhan
   University, National Science and Technology Major Project
   (#2018ZX10733403), China NSFC grants (#81672008, 31871316), Hubei
   Natural Science Foundation (#2018CFA035), Basic Scientific Research
   Foundation of Central Universities (#2042019gf0026), Ministry of Science
   and Technology of China, the National Mega Project on Major Infectious
   Disease Prevention (#2017ZX10103005) and National Key Research and
   Development Program of China (#2018YFE0204500).
CR Bordon J, 2013, INT J INFECT DIS, V17, pE76, DOI 10.1016/j.ijid.2012.06.006
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Institute B, 2019, PIC TOOLK
   Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC
   Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Lee CM, 2020, NUCLEIC ACIDS RES, V48, pD756, DOI 10.1093/nar/gkz1012
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Michalovich D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13751-9
   Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7
   O'Donnell R, 2003, BRIT MED J, V327, P620, DOI 10.1136/bmj.327.7415.620-b
   Okabayashi T, 2006, J MED VIROL, V78, P417, DOI 10.1002/jmv.20556
   PANESAR N, 2006, NAT REV IMMUNOL, V6, P334, DOI DOI 10.1038/nri1835-c1
   Panesar NS, 2008, MED HYPOTHESES, V71, P298, DOI 10.1016/j.mehy.2008.03.019
   Panesar NS, 2003, LANCET, V361, P1985, DOI 10.1016/S0140-6736(03)13557-X
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Saxena V, 2008, J IMMUNOL, V180, P1903, DOI 10.4049/jimmunol.180.3.1903
   Sheahan T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000240
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Teijaro JR, 2014, P NATL ACAD SCI USA, V111, P3799, DOI 10.1073/pnas.1400593111
   Thaker SK, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0678-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356
   Wang YQ, 2017, GENOM PROTEOM BIOINF, V15, P14, DOI 10.1016/j.gpb.2017.01.001
   Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu XY, 2017, IMMUNITY, V47, P903, DOI 10.1016/j.immuni.2017.10.007
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhang Z, 2020, NUCLEIC ACIDS RES, V48, pD24, DOI 10.1093/nar/gkz913
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 51
TC 154
Z9 161
U1 11
U2 77
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 761
EP 770
DI 10.1080/22221751.2020.1747363
PG 10
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LA9QH
UT WOS:000524274400001
PM 32228226
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Meng, J
   Xiao, GH
   Zhang, JJ
   He, X
   Ou, M
   Bi, J
   Yang, RQ
   Di, WC
   Wang, ZQ
   Li, ZG
   Gao, H
   Liu, L
   Zhang, GL
AF Meng, Juan
   Xiao, Guohui
   Zhang, Juanjuan
   He, Xing
   Ou, Min
   Bi, Jing
   Yang, Rongqing
   Di, Wencheng
   Wang, Zhaoqin
   Li, Zigang
   Gao, Hong
   Liu, Lei
   Zhang, Guoliang
TI Renin-angiotensin system inhibitors improve the clinical outcomes of
   COVID-19 patients with hypertension
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE COVID-19; hypertension; Renin-angiotensin system; angiotensin-converting
   enzyme inhibitors; angiotensin II type1 receptor blockers
AB The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
C1 [Meng, Juan; Xiao, Guohui; Zhang, Juanjuan; He, Xing; Ou, Min; Bi, Jing; Yang, Rongqing; Di, Wencheng; Wang, Zhaoqin; Gao, Hong; Liu, Lei; Zhang, Guoliang] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.
   [Meng, Juan; Xiao, Guohui; Li, Zigang; Zhang, Guoliang] Shenzhen Bay Lab, Shenzhen, Peoples R China.
RP Gao, H; Liu, L; Zhang, GL (corresponding author), Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China.; Zhang, GL (corresponding author), Shenzhen Bay Lab, Shenzhen, Peoples R China.
EM gaoh0508@163.com; liulei3322@aliyun.com; szdsyy@aliyun.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873958]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2019M653108]; National
   Science and Technology Major Project for Control and Prevention of Major
   Infectious Diseases of China [2017ZX10103004]; State Key Laboratory of
   Respiratory Diseases Open Project [SKLRD-OP-201919]; Sanming Project of
   Medicine in Shenzhen [SZSM201911009]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81873958), the China Postdoctoral Science Foundation (No.
   2019M653108), the National Science and Technology Major Project for
   Control and Prevention of Major Infectious Diseases of China (No.
   2017ZX10103004), the State Key Laboratory of Respiratory Diseases Open
   Project (No. SKLRD-OP-201919), and the Sanming Project of Medicine in
   Shenzhen (No. SZSM201911009).
CR Gage JR, 2004, NEUROIMMUNOMODULAT, V11, P173, DOI 10.1159/000076766
   Hampl V, 2015, PHYSIOL RES, V64, P25, DOI 10.33549/physiolres.932861
   Hsu WT, 2020, HYPERTENSION, V75, P483, DOI 10.1161/HYPERTENSIONAHA.119.13197
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Moon Ju-Young, 2013, Electrolyte Blood Press, V11, P41, DOI 10.5049/EBP.2013.11.2.41
   Wang XW, 2012, EXP BIOL MED, V237, P1394, DOI 10.1258/ebm.2012.012212
   Wang Z, CIRCULATION
   Wu Z, 2020, JAMA
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Ye RS, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2019.104350
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 12
TC 166
Z9 168
U1 11
U2 67
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 757
EP 760
DI 10.1080/22221751.2020.1746200
PG 4
WC Immunology; Microbiology
SC Immunology; Microbiology
GA LA9PW
UT WOS:000524273300001
PM 32228222
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Lo, IL
   Lio, CF
   Cheong, HH
   Lei, CI
   Cheong, TH
   Zhong, X
   Tian, YK
   Sin, NN
AF Lo, Iek Long
   Lio, Chon Fu
   Cheong, Hou Hon
   Lei, Chin Ion
   Cheong, Tak Hong
   Zhong, Xu
   Tian, Yakun
   Sin, Nin Ngan
TI Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical
   characteristics of 10 patients with COVID-19 in Macau
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE novel coronavirus; SARS-CoV-2; COVID-19; qRT-PCR; Macau; nasopharyngeal
   swab; stool; urine; sputum
AB As a city famous for tourism, the public healthcare system of Macau SAR has been under great pressure during the outbreak of the Coronavirus Disease 2019 (COVID-19). In this study, we report clinical and microbiological features of ten COVID-19 patients enrolled in the Centro Hospitalar Conde de Sao Januario (CHCSJ) between January 21 to February 16, 2020. Clinical samples from all patients including nasopharyngeal swab (NPS)/sputum, urine, and feces were collected for serial virus RNA testing by standard qRT-PCR assay. In total, seven were imported cases and three were local cases. The median duration from Macau arrival to admission in imported cases was 3 days. Four patients required oxygen therapy but none of them needed machinal ventilation. No fatal cases were noted. The most common symptoms were fever (80%) and diarrhea (80%). In the "Severe" group, there was significantly more elderly patients (p=0.045), higher lactate dehydrogenase levels (p=0.002), and elevated C-Reactive protein levels compared to the "Mild to Moderate" group (p<0.001). There were positive SARS-CoV-2 RNA signals in all patients' NPS and stool specimens but negative in all urine specimens. Based on our data on SARS-CoV-2 RNA shedding in stool and the possibility of a lag in viral detection in NPS specimens, the assessment of both fecal and respiratory specimen is recommended to enhance diagnostic sensitivity, and also to aid discharge decision before the role of viral RNA shedding in stool is clarified.
C1 [Lo, Iek Long; Zhong, Xu] Macau Hlth Bur, Dept Resp Med, Ctr Hosp Conde Sao Januario, Macau, Peoples R China.
   [Lio, Chon Fu; Cheong, Hou Hon; Sin, Nin Ngan] Macau Hlth Bur, Macau Acad Med, Ctr Hosp Conde Sao Januario, Macau, Peoples R China.
   [Lei, Chin Ion] Macau Hlth Bur, Dept Med, Chief Serv, Ctr Hosp Conde Sao Januario, Macau Sar, Peoples R China.
   [Cheong, Tak Hong] Macau Hlth Bur, Dept Resp Med, Chief Serv, Ctr Hosp Conde Sao Januario, Macau, Peoples R China.
   [Tian, Yakun] Macau Hlth Bur, Dept Infect Dis, Ctr Hosp Conde Sao Januario, Macau, Peoples R China.
RP Lei, CI (corresponding author), Macau Hlth Bur, Dept Med, Chief Serv, Ctr Hosp Conde Sao Januario, Macau Sar, Peoples R China.
EM cilei@ssm.gov.mo
CR Aldalur I, 2020, BATTERIES SUPERCAPS, V3, P30, DOI 10.1002/batt.201900133
   [Anonymous], GUID MAN COVID 19 VE
   Blom K, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-014-0056-6
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Ho AS, 2003, ANN INTERN MED, V139, P564, DOI 10.7326/0003-4819-139-7-200310070-00008
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Pan F, RADIOLOGY
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO Novel Coronavirus disease, 2020, 3 WHO
   World Health Organization, INF PREV CONTR HLTH
   World Health Organization (WHO), 38 WHO
   Zhang LY, 2020, J PARKINSON DIS, V10, P523, DOI 10.3233/JPD-191768
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou L, 2020, NEW ENGLAND J MED
NR 23
TC 81
Z9 84
U1 13
U2 33
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 10
BP 1698
EP 1707
DI 10.7150/ijbs.45357
PG 10
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA KZ0PJ
UT WOS:000522973800004
PM 32226287
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Rosa, SGV
   Santos, WC
AF Viveiros Rosa, Sandro G.
   Santos, Wilson C.
TI Clinical trials on drug repositioning for COVID-19 treatment
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA English
DT Article
DE Drug repositioning; clinical trials as topic; coronavirus infection;
   virus diseases; pneumonia; viral; pandemics
ID SARS; EPIDEMIOLOGY
AB The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
C1 [Viveiros Rosa, Sandro G.; Santos, Wilson C.] Univ Fed Fluminense, Rio De Janeiro, Brazil.
RP Rosa, SGV (corresponding author), Univ Fed Fluminense, Rio De Janeiro, Brazil.
EM sandrogvr@gmail.com
RI Santos, Wilson C./R-2595-2019
OI Santos, Wilson C./0000-0001-9971-094X
CR Al-Tawfiq JA, 2017, EXPERT REV ANTI-INFE, V15, P269, DOI 10.1080/14787210.2017.1271712
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cao B, 2020, TRIAL LOPINAVIR RITO, P1, DOI [10.1056/NEJMoa2001282, DOI 10.1056/NEJMOA2001282]
   Cherin P, 2016, AUTOIMMUN REV, V15, P71, DOI 10.1016/j.autrev.2015.09.002
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   DYER O, 2019, BMJ-BRIT MED J, V366, DOI DOI 10.1136/BMJ.L5140
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kashiouris MG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020292
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li CC, 2019, DRUG DISCOV TODAY, V24, P726, DOI 10.1016/j.drudis.2019.01.018
   Li G, 2020, NAT REV DRUG DISCOV, P1
   Long Y, 2016, INT J CLIN EXP MED, V9, P8865
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Markham A, 2018, DRUGS, V78, P1271, DOI 10.1007/s40265-018-0960-0
   Mathias AA, 2010, CLIN PHARMACOL THER, V87, P322, DOI 10.1038/clpt.2009.228
   Maxmen A, 2020, NATURE, V78, P37
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Neuberger A, 2019, DRUG DISCOV TODAY, V24, P1, DOI 10.1016/j.drudis.2018.06.012
   Newfield C., 2018, SCI J LANDER COLL AR, V12
   Okubo K, 2019, ANTICANCER RES, V39, P5891, DOI 10.21873/anticanres.13793
   Perrella A, 2020, EUR REV MED PHARMACO, V24, P2162, DOI 10.26355/eurrev_202002_20396
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Santos JR, 2019, AIDS RES HUM RETROV, V35, P513, DOI [10.1089/aid.2018.0178, 10.1089/AID.2018.0178]
   Schneider WM, 2015, INTERFERON STIMULATE, V32, P513, DOI [10.1146/annurev-immunol-032713-120231, DOI 10.1146/ANNUREV-IMMUNOL-032713-120231.]
   Srinivasan SGM, 2016, ANTIBODY TECHNOL J, V6, P1
   Tang T., 2016, J HAINAN MED U, V22, P113
   Uyeki TM, 2018, CLIN INFECT DIS, V66, P1501, DOI 10.1093/cid/cix1150
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Wang Y, 2019, China, Patent No. [US20190001160, 20190001160]
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   World Health Organisation, 2020, 52 WHO
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, P1
NR 38
TC 76
Z9 77
U1 15
U2 56
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PY 2020
VL 44
AR e40
DI 10.26633/RPSP.2020.40
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA KX5US
UT WOS:000521946500001
PM 32256547
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Nie, JH
   Li, QQ
   Wu, JJ
   Zhao, CY
   Hao, H
   Liu, H
   Zhang, L
   Nie, LL
   Qin, HY
   Wang, M
   Lu, Q
   Li, XY
   Sun, QY
   Liu, JK
   Fan, CF
   Huang, WJ
   Xu, M
   Wang, YH
AF Nie, Jianhui
   Li, Qianqian
   Wu, Jiajing
   Zhao, Chenyan
   Hao, Huan
   Liu, Huan
   Zhang, Li
   Nie, Lingling
   Qin, Haiyang
   Wang, Meng
   Lu, Qiong
   Li, Xiaoyu
   Sun, Qiyu
   Liu, Junkai
   Fan, Changfa
   Huang, Weijin
   Xu, Miao
   Wang, Youchun
TI Establishment and validation of a pseudovirus neutralization assay for
   SARS-CoV-2
SO EMERGING MICROBES & INFECTIONS
LA English
DT Article
DE SARS-CoV-2; COVID-19; neutralizing antibody; pseudovirus; neutralization
   assay
ID SYSTEM ENABLES EVALUATION; IMAGING MOUSE MODEL; IN-VITRO; ANTIBODIES;
   VACCINE; PROTEIN
AB Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.
C1 [Nie, Jianhui; Li, Qianqian; Wu, Jiajing; Zhao, Chenyan; Hao, Huan; Liu, Huan; Zhang, Li; Nie, Lingling; Qin, Haiyang; Wang, Meng; Lu, Qiong; Li, Xiaoyu; Sun, Qiyu; Liu, Junkai; Huang, Weijin; Wang, Youchun] NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, 31 Huatuo St, Beijing 102629, Peoples R China.
   [Li, Qianqian; Wang, Youchun] Peking Union Med Coll, Grad Sch, 9 Dongdan Santiao, Beijing 100730, Peoples R China.
   [Wu, Jiajing] Wuhan Inst Biol Prod, Wuhan, Peoples R China.
   [Fan, Changfa] Natl Inst Food & Drug Control, Div Anim Model Res, Inst Lab Anim Resources, Beijing, Peoples R China.
   [Xu, Miao] Natl Inst Food & Drug Control, Inst Biol Prod Control, Beijing 100050, Peoples R China.
RP Huang, WJ; Wang, YH (corresponding author), NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, 31 Huatuo St, Beijing 102629, Peoples R China.; Wang, YH (corresponding author), Peking Union Med Coll, Grad Sch, 9 Dongdan Santiao, Beijing 100730, Peoples R China.; Xu, M (corresponding author), Natl Inst Food & Drug Control, Inst Biol Prod Control, Beijing 100050, Peoples R China.
EM huangweijin@nifdc.org.cn; xumiaobj@126.com; wangyc@nifdc.org.cns
RI huang, weijin/AAY-5028-2020
OI Huang, Weijin/0000-0002-4246-8889; Reis, AlessanRSS/0000-0001-8486-7469
FU National Science and Technology Major Projects of Drug Discovery
   [2018ZX09101001]
FX This work was supported by National Science and Technology Major
   Projects of Drug Discovery [grant number 2018ZX09101001].
CR Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen QQ, 2018, HUM VACC IMMUNOTHER, V14, P199, DOI 10.1080/21645515.2017.1373922
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Fan CF, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090448
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Kuo CC, 2018, CURR OPIN BIOTECH, V51, P64, DOI 10.1016/j.copbio.2017.11.015
   Li QQ, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1963
   Li QQ, 2017, VACCINE, V35, P5172, DOI 10.1016/j.vaccine.2017.07.101
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu Q, 2017, SCI REP-UK, V7, DOI 10.1038/srep45552
   Ma J, 2019, HUM VACC IMMUNOTHER, V15, P2286, DOI 10.1080/21645515.2019.1627820
   Nakamura K, 2019, VACCINE, V37, P6526, DOI 10.1016/j.vaccine.2019.08.064
   Nie JH, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2019.1702479
   Nie JH, 2019, EMERG MICROBES INFEC, V8, P272, DOI 10.1080/22221751.2019.1571871
   Nie JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep42769
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu JJ, 2017, VACCINE, V35, P6387, DOI 10.1016/j.vaccine.2017.10.007
   Zhang L, 2017, HUM VACC IMMUNOTHER, V13, P1811, DOI 10.1080/21645515.2017.1325050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 82
Z9 81
U1 18
U2 58
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
EI 2222-1751
J9 EMERG MICROBES INFEC
JI Emerg. Microbes Infect.
PD JAN 1
PY 2020
VL 9
IS 1
BP 680
EP 686
DI 10.1080/22221751.2020.1743767
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA KX8BN
UT WOS:000522100500001
PM 32207377
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Zhou, WK
   Wang, AL
   Xia, F
   Xiao, YN
   Tang, SY
AF Zhou, Weike
   Wang, Aili
   Xia, Fan
   Xiao, Yanni
   Tang, Sanyi
TI Effects of media reporting on mitigating spread of COVID-19 in the ear y
   phase of the outbreak
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article
DE COVID-19; media reporting; mathematical model; basic reproduction
   number; sensitivity analysis
AB The 2019 novel coronavirus disease (COVID-19) is running rampantly in China and is swiftly spreading to other countries in the world, which causes a great concern on the global public health. The absence of specific therapeutic treatment or effective vaccine against COVID-19 call for other avenues of the prevention and control measures. Media reporting is thought to be effective to curb the spreading of an emergency disease in the early stage. Cross-correlation analysis based on our collected data demonstrated a strong correlation between media data and the infection case data. Thus we proposed a deterministic dynamical model to examine the interaction of the disease progression and the media reports and to investigate the effectiveness of media reporting on mitigating the spread of COVID-19. The basic reproduction number was estimated as 5.3167 through parameterization of the model with the number of cumulative confirmed cases, the number of cumulative deaths and the daily number of media items. Sensitivity analysis suggested that, during the early phase of the COVID-19 outbreak, enhancing the response rate of the media reporting to the severity of COVID-19, and enhancing the response rate of the public awareness to the media reports, both can bring forward the peak time and reduce the peak size of the infection significantly. These findings suggested that besides improving the medical levels, media coverage can be considered as an effective way to mitigate the disease spreading during the initial stage of an outbreak.
C1 [Zhou, Weike; Tang, Sanyi] Shaanxi Normal Univ, Coll Math & Informat Sci, Xian 710062, Peoples R China.
   [Wang, Aili] Baoji Univ Arts & Sci, Sch Math & Informat Sci, Baoji 721013, Peoples R China.
   [Xia, Fan; Xiao, Yanni] Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Peoples R China.
RP Tang, SY (corresponding author), Shaanxi Normal Univ, Coll Math & Informat Sci, Xian 710062, Peoples R China.; Xiao, YN (corresponding author), Xi An Jiao Tong Univ, Sch Math & Stat, Xian 710049, Peoples R China.
EM yxiao@mail.xjtu.edu.cn; sytang@snnu.edu.cn
RI Mukherjee, Sudip/AAC-8152-2020
OI Mukherjee, Sudip/0000-0001-7783-6306
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2019M663611]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [11801013,
   11631012, 61772017]
FX This research was funded by the China Postdoctoral Science Foundation
   (grant number 2019M663611 (WZ)), and by the National Natural Science
   Foundation of China (grant numbers: 11801013(AW), 11631012
   (YX,ST),61772017(ST)).
CR Backer J.A., 2020, INCUBATION PERIOD 20
   Box G. E., 2015, TIME SERIES ANAL FOR
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chinese Center for Disease Control and Prevention, REP 2019 NCOV
   de Silva UC, 2009, EUROSURVEILLANCE, V14, P11
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang F, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-54
   Kristiansen IS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-48
   Liu Y, 2020, J COGNITIVE NEUROSCI, V32, P1455, DOI 10.1162/jocn_a_01569
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Roth D. Z., 2011, SOCIAL DISTANCING PA
   Shen L, 2020, J MED ECON, V23, P456, DOI 10.1080/13696998.2020.1717500
   Shen M, 2020, BIORXIV
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
NR 17
TC 20
Z9 20
U1 11
U2 45
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA
SN 1547-1063
EI 1551-0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PY 2020
VL 17
IS 3
BP 2693
EP 2707
DI 10.3934/mbe.2020147
PG 15
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA KU7DN
UT WOS:000519873900047
PM 32233561
OA DOAJ Gold
HC Y
HP N
DA 2021-01-01
ER

PT J
AU Malik, YS
   Sircar, S
   Bhat, S
   Sharun, K
   Dhama, K
   Dadar, M
   Tiwari, R
   Chaicumpa, W
AF Malik, Yashpal Singh
   Sircar, Shubhankar
   Bhat, Sudipta
   Sharun, Khan
   Dhama, Kuldeep
   Dadar, Maryam
   Tiwari, Ruchi
   Chaicumpa, Wanpen
TI Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary
   perspective based on genome analysis and recent developments
SO VETERINARY QUARTERLY
LA English
DT Article
DE Coronavirus; 2019-nCoV; Severe Acute Respiratory Syndrome CoV; Middle
   East Respiratory Syndrome CoV; Public Health Emergency; genetic
   analyses; zoonoses; reservoir host; therapeutics; vaccines
ID RESPIRATORY SYNDROME CORONAVIRUS; THREAT; VACCINE; VIRUS; COV
AB Coronaviruses are the well-known cause of severe respiratory, enteric and systemic infections in a wide range of hosts including man, mammals, fish, and avian. The scientific interest on coronaviruses increased after the emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) outbreaks in 2002-2003 followed by Middle East Respiratory Syndrome CoV (MERS-CoV). This decade's first CoV, named 2019-nCoV, emerged from Wuhan, China, and declared as 'Public Health Emergency of International Concern' on January 30(th), 2020 by the World Health Organization (WHO). As on February 4, 2020, 425 deaths reported in China only and one death outside China (Philippines). In a short span of time, the virus spread has been noted in 24 countries. The zoonotic transmission (animal-to-human) is suspected as the route of disease origin. The genetic analyses predict bats as the most probable source of 2019-nCoV though further investigations needed to confirm the origin of the novel virus. The ongoing nCoV outbreak highlights the hidden wild animal reservoir of the deadly viruses and possible threat of spillover zoonoses as well. The successful virus isolation attempts have made doors open for developing better diagnostics and effective vaccines helping in combating the spread of the virus to newer areas.
C1 [Malik, Yashpal Singh; Sircar, Shubhankar; Bhat, Sudipta] ICAR Indian Vet Res Inst, Div Biol Standardizat, Bareilly, Uttar Pradesh, India.
   [Sharun, Khan] ICAR Indian Vet Res Inst, Div Surg, Bareilly, Uttar Pradesh, India.
   [Dhama, Kuldeep] ICAR Indian Vet Res Inst, Div Pathol, Bareilly, Uttar Pradesh, India.
   [Dadar, Maryam] AREEO, Razi Vaccine & Serum Res Inst, Karaj, Iran.
   [Tiwari, Ruchi] Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwa, Coll Vet Sci, Dept Vet Microbiol & Immunol, Mathura, India.
   [Chaicumpa, Wanpen] Mahidol Univ, Siriraj Hosp, Ctr Res Excellence Therapeut Proteins & Antibody, Dept Parasitol,Fac Med, Bangkok, Thailand.
RP Malik, YS (corresponding author), ICAR Indian Vet Res Inst, Div Biol Standardizat, Bareilly, Uttar Pradesh, India.; Dhama, K (corresponding author), ICAR Indian Vet Res Inst, Div Pathol, Bareilly, Uttar Pradesh, India.
EM malikyps@gmail.com; kdhama@rediffmail.com; wanpen.cha@mahidol.ac.th
RI Sharun, Khan/A-3084-2019; Dadar, Maryam/D-3660-2017; Ribeiro,
   Nuno/AAH-2299-2020; sircar, Shubhankar/D-3691-2019; Dhama,
   Kuldeep/B-7852-2015
OI Sharun, Khan/0000-0003-1040-3746; Dadar, Maryam/0000-0001-5831-801X;
   sircar, Shubhankar/0000-0002-1947-4463; Reis,
   AlessanRSS/0000-0001-8486-7469; Malik, Yashpal/0000-0002-2832-4854;
   Dhama, Kuldeep/0000-0001-7469-4752
CR Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   Callaway E, 2020, NATURE, V577, P458, DOI 10.1038/d41586-020-00117-1
   Cheng VCC, 2020, J HOSP INFECT, V104, P254, DOI 10.1016/j.jhin.2020.01.010
   Cohen J, 2020, SCIENCE, V367, P492, DOI 10.1126/science.367.6477.492
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Groot R.J., 2012, VIRUS TAXONOMY, P806, DOI DOI 10.1016/B978-0-12-384684-6.00068-9
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gouilh MA, 2018, VIROLOGY, V517, P88, DOI 10.1016/j.virol.2018.01.014
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Letko M. C., 2020, FUNCTIONAL ASSESSMEN, DOI [10.1101/2020.01.22.915660, DOI 10.1101/2020.01.22.915660]
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M308
   Munjal A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01469
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Singh RK, 2017, VET QUART, V37, P98, DOI 10.1080/01652176.2017.1309474
   WHO, 2015, MIDDL E RESP SYNDR C
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   World Health Organization (WHO), 2020, NOV COR 2019 NCOV AD
   Zaher NH, 2020, ACTA PHARMACEUT, V70, P145, DOI 10.2478/acph-2020-0024
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, PREPRINT, DOI [10.1101/2020.01.22.914952v1, DOI 10.1101/2020.01.22.914952V1]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 35
TC 89
Z9 95
U1 11
U2 64
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0165-2176
EI 1875-5941
J9 VET QUART
JI Vet. Q.
PD JAN 1
PY 2020
VL 40
IS 1
BP 68
EP 76
DI 10.1080/01652176.2020.1727993
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA KQ4DI
UT WOS:000516874900001
PM 32036774
OA DOAJ Gold, Green Published
HC Y
HP Y
DA 2021-01-01
ER

PT J
AU Ralph, R
   Lew, J
   Zeng, TS
   Francis, M
   Xue, B
   Roux, M
   Ostadgavahi, AT
   Rubino, S
   Dawe, NJ
   Al-Ahdal, MN
   Kelvin, DJ
   Richardson, CD
   Kindrachuk, J
   Falzarano, D
   Kelvin, AA
AF Ralph, Robyn
   Lew, Jocelyne
   Zeng, Tiansheng
   Francis, Magie
   Xue, Bei
   Roux, Melissa
   Ostadgavahi, Ali Toloue
   Rubino, Salvatore
   Dawe, Nicholas J.
   Al-Ahdal, Mohammed N.
   Kelvin, David J.
   Richardson, Christopher D.
   Kindrachuk, Jason
   Falzarano, Darryl
   Kelvin, Alyson A.
TI 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human
   transmission, travel-related cases, and vaccine readiness
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE 2019-nCoV; coronavirus; Wuhan; human-to-human transmission; vaccine
   readiness
ID RESPIRATORY SYNDROME CORONAVIRUS; MERS-COV INFECTION; SARS-CORONAVIRUS;
   SAUDI-ARABIA; HEALTH-CARE; WEB SERVER; RECEPTOR; PROTEIN; MODEL;
   DETERMINANTS
AB On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan. Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence. While zoonotic transmission appears to be the original source of infections, the most alarming development is that humanto-human transmission is now prevelant. Of particular concern is that many healthcare workers have been infected in the current epidemic. There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission? What is the animal reservoir? Is there an intermediate animal reservoir? Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV? We offer a research perspective on the next steps for the generation of vaccines. We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronaviruglaboratory-diagnostics-for-novel-coronavirus.
C1 [Ralph, Robyn; Lew, Jocelyne; Falzarano, Darryl] Vaccine & Infect Dis Org, Int Vaccine Ctr VIDO InterVac, Saskatoon, SK, Canada.
   [Ralph, Robyn; Falzarano, Darryl] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK, Canada.
   [Zeng, Tiansheng; Xue, Bei; Kelvin, David J.] Shantou Univ, Int Inst Infect & Immun, Med Coll, Shantou, Guangdong, Peoples R China.
   [Francis, Magie; Xue, Bei; Roux, Melissa; Ostadgavahi, Ali Toloue; Dawe, Nicholas J.; Kelvin, David J.; Richardson, Christopher D.; Kelvin, Alyson A.] Dalhousie Univ, Fac Med, Dept Microbiol & Immunol, Halifax, NS, Canada.
   [Rubino, Salvatore] Univ Sassari, Dipartimento Sci Biomed, Sez Microbiol Sperimentale & Clin, Sassari, Italy.
   [Al-Ahdal, Mohammed N.] King Faisal Specialist Hosp & Res Ctr, Dept Infect & Immun, Riyadh, Saudi Arabia.
   [Kelvin, David J.; Richardson, Christopher D.; Kelvin, Alyson A.] IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Kindrachuk, Jason] Univ Manitoba, Dept Med Microbiol, Lab Emerging & Re Emerging Viruses, Winnipeg, MB, Canada.
   [Kelvin, Alyson A.] Dalhousie Univ, Fac Med, Dept Pediat, Div Infect Dis, Halifax, NS, Canada.
RP Kelvin, AA (corresponding author), Dalhousie Univ, Dept Pediat, Fac Med, IWK Hlth Ctr, 5980 Univ Ave,4th Floor,R4020, Halifax, NS B3K 6R8, Canada.; Kelvin, AA (corresponding author), Canadian Ctr Vaccinol, 5980 Univ Ave,4th Floor,R4020, Halifax, NS B3K 6R8, Canada.
EM akelvin@dal.ca
RI Ribeiro, Nuno/AAH-2299-2020
FU Tier 2 Canada Research Chair in the Molecular Pathogenesis of Emerging
   and Re-Emerging Viruses by the Canadian Institutes of Health Research
   [950-231498]; IWK Health Centre [602975]; Nova Scotia Health Research
   Foundation [602932]; LKSF; Canada Foundation for Innovation (JELF)Canada
   Foundation for Innovation; DMRF (Dalhousie Medical Research Foundation);
   Government of Canada through Canada Foundation for Innovation - Major
   Science Initiatives; Government of Saskatchewan through Innovation
   Saskatchewan; Canadian Institutes for Health ResearchCanadian Institutes
   of Health Research (CIHR) [PJT 388665]
FX Research into the novel coronavirus genome (2019-nCoV) was led by Dr.
   Yong-Zhen Zhang at the the Shanghai Public Health Clinical Center &
   School of Public Health, in collaboration with the Central Hospital of
   Wuhan, Huazhong University of Science and Technology, the Wuhan Center
   for Disease Control and Prevention, the National Institute for
   Communicable Disease Control and Prevention, the Chinese Center for
   Disease Control, and the University of Sydney, Sydney, Australia. We
   would like to thank and acknowledge the researchers who were working to
   identify this pathogen and make the data publically available.
   Specifically, we acknowledge the National Institute for Viral Disease
   Control and Prevention, China CDC; Wuhan Institute of Virology, Chinese
   Academy of Sciences; Institute of Pathogen Biology, Chinese Academy of
   Medical Sciences & Peking Union Medical College; and Wuhan Jinyintan
   Hospital. In addition, we acknowledge GISAID (https://www.gisaid.org/)
   for providing a platform that allows data to be freely shared. J.K. is
   funded by a Tier 2 Canada Research Chair in the Molecular Pathogenesis
   of Emerging and Re-Emerging Viruses provided by the Canadian Institutes
   of Health Research (Grant no. 950-231498). A.A.K. is funded by the IWK
   Health Centre (Grant no. 602975) and Nova Scotia Health Research
   Foundation (Grant no. 602932). DJK is a Tier 1 Canada Research Chair in
   Translational Vaccinology and Inflammation. Support for DJK was provided
   by LKSF, Canada Foundation for Innovation (JELF), and DMRF (Dalhousie
   Medical Research Foundation). VIDO-InterVac receives operational funding
   from the Government of Canada through Canada Foundation for Innovation
   -Major Science Initiatives and the Government of Saskatchewan through
   Innovation Saskatchewan. D.F. receives support from Canadian Institutes
   for Health Research (PJT 388665).
CR Agnihothram S, 2014, J INFECT DIS, V209, P995, DOI 10.1093/infdis/jit609
   Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Ajlan AM, 2014, AM J ROENTGENOL, V203, P782, DOI 10.2214/AJR.14.13021
   Al-Ahmadi H, 2005, INT J QUAL HEALTH C, V17, P331, DOI 10.1093/intqhc/mzi046
   Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   AlBarrak AM, 2012, SAUDI MED J, V33, P1265
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490
   [Anonymous], PYMOL MOL GRAPHICS S
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Banner D, 2012, J INFECT DEV COUNTR, V6, P465
   Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336
   Canducci F, 2008, J MED VIROL, V80, P716, DOI 10.1002/jmv.21108
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan PKS, 2013, J THORAC DIS, V5, pS118, DOI 10.3978/j.issn.2072-1439.2013.06.19
   Cowling BJ, 2015, EUROSURVEILLANCE, V20, P7, DOI 10.2807/1560-7917.ES2015.20.25.21163
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hart BJ, 2014, J GEN VIROL, V95, P571, DOI 10.1099/vir.0.061911-0
   Holm L, 2019, BIOINFORMATICS, V35, P5326, DOI 10.1093/bioinformatics/btz536
   Hunter JC, 2016, EMERG INFECT DIS, V22, P647, DOI 10.3201/eid2204.151615
   Jevsnik M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-365
   Jurrus E, 2018, PROTEIN SCI, V27, P112, DOI 10.1002/pro.3280
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lambeir AM, 2003, CRIT REV CL LAB SCI, V40, P209, DOI 10.1080/713609354
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li LF, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5169-3
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Memish ZA, 2014, EMERG INFECT DIS, V20, P1012, DOI 10.3201/eid2006.140402
   Memish ZA, 2013, NEW ENGL J MED, V368, P2487, DOI 10.1056/NEJMoa1303729
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Shi ZL, 2008, VIRUS RES, V133, P74, DOI 10.1016/j.virusres.2007.03.012
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102
   van Doremalen N, 2015, ANTIVIR RES, V122, P28, DOI 10.1016/j.antiviral.2015.07.005
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Walston S, 2008, ANN SAUDI MED, V28, P243
   Weber DS, 2019, ARCH BIOCHEM BIOPHYS, V672, DOI 10.1016/j.abb.2019.07.018
   Wentworth DE, 2004, EMERG INFECT DIS, V10, P1293, DOI 10.3201/eid1007.031119
   Widagdo W, 2016, J VIROL, V90, P4838, DOI 10.1128/JVI.02994-15
   Willman M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121119
   World Health Organization (WHO), 2020, DIAGN NOV COR
   Wu F., 2020, NOVEL CORONAVIRUS AS
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 67
TC 48
Z9 52
U1 5
U2 49
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD JAN
PY 2020
VL 14
IS 1
BP 3
EP +
DI 10.3855/jidc.12425
PG 16
WC Infectious Diseases
SC Infectious Diseases
GA KK7ZU
UT WOS:000512957400002
PM 32088679
OA DOAJ Gold, Green Published
HC Y
HP N
DA 2021-01-01
ER

EF